<SEC-DOCUMENT>0001564590-21-012490.txt : 20210311
<SEC-HEADER>0001564590-21-012490.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311160447
ACCESSION NUMBER:		0001564590-21-012490
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Homology Medicines, Inc.
		CENTRAL INDEX KEY:			0001661998
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473468154
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38433
		FILM NUMBER:		21733258

	BUSINESS ADDRESS:	
		STREET 1:		ONE PATRIOTS PARK
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-301-7277

	MAIL ADDRESS:	
		STREET 1:		ONE PATRIOTS PARK
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fixx-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1664580+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:fixx="http://www.homologymedicines.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
fixx-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001661998_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001661998_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:EntityCentralIndexKey" contextRef="C_0001661998_20200101_20201231">0001661998</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityVoluntaryFilers" contextRef="C_0001661998_20200101_20201231">No</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001661998_20200101_20201231">No</ix:nonNumeric>
			<ix:nonNumeric id="F_000009" name="dei:EntityCurrentReportingStatus" contextRef="C_0001661998_20200101_20201231">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000011" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001661998_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000020" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001661998_20200101_20201231">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000364" name="fixx:InvestmentMaturityTerm" contextRef="C_0001661998_20200101_20201231">Less than one year</ix:nonNumeric>
			<ix:nonNumeric id="F_000426" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160930">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000430" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000521" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">P4Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:PreferredStockValue" contextRef="C_0001661998_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:PreferredStockValue" contextRef="C_0001661998_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000332" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000334" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of the lease term
or estimated useful life</ix:nonNumeric>
			<ix:nonNumeric id="F_000333" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000454" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001661998_20201231">P5Y10M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000544" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001661998_20200101_20201231" decimals="INF">0.632</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000545" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001661998_20190101_20191231" decimals="INF">0.624</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000546" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001661998_20200101_20201231" decimals="INF">0.663</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000547" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001661998_20190101_20191231" decimals="INF">0.647</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000548" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001661998_20200101_20201231" decimals="INF">0.0031</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001661998_20190101_20191231" decimals="INF">0.0136</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000550" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001661998_20200101_20201231" decimals="INF">0.0173</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001661998_20190101_20191231" decimals="INF">0.0260</ix:nonFraction>
			<ix:nonNumeric id="F_000552" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000553" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000554" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y3M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000555" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231" decimals="2">9.82</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000556" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231" decimals="2">12.73</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000557" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231" decimals="2">21.75</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000558" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231" decimals="2">30.34</ix:nonFraction>
			<ix:nonNumeric id="F_000581" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001661998_20190101_20191231">P8Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000582" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001661998_20200101_20201231">P7Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000583" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001661998_20200101_20201231">P7Y9M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000584" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001661998_20200101_20201231">P7Y</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="fixx-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001661998_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_20210308">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_fixxMajorAssetClassOfLeasedAssetsAxis_fixxATMMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="fixx:MajorAssetClassOfLeasedAssetsAxis">fixx:ATMMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-02</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180402">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-02</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20180401_20180402">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-02</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-12</xbrli:startDate>
					<xbrli:endDate>2019-04-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:UnderwritersOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-12</xbrli:startDate>
					<xbrli:endDate>2019-04-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:UnderwritersOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200311_20200312">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-11</xbrli:startDate>
					<xbrli:endDate>2020-03-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190430_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-30</xbrli:startDate>
					<xbrli:endDate>2019-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-10</xbrli:startDate>
					<xbrli:endDate>2020-11-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:NewAccountingPronouncementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxLaboratoryEquipmentAndOfficeFurnitureMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fixx:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapRepurchaseAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxAssetNotYetInServiceMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fixx:AssetNotYetInServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-01</xbrli:startDate>
					<xbrli:endDate>2016-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-12-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fixxPhase">
				<xbrli:measure>fixx:Phase</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171201_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-12-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171201_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-12-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_utrsqft">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>utr:sqft</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">fixx:LettersOfCreditAndSecuredByRestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">fixx:LettersOfCreditAndSecuredByRestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_srtRangeAxis_srtMaximumMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_us-gaapTypeOfArrangementAxis_fixxSponsoredResearchAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CaliforniaInstituteOfTechnologyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:CoExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-01</xbrli:startDate>
					<xbrli:endDate>2016-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CaliforniaInstituteOfTechnologyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:CoExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-01</xbrli:startDate>
					<xbrli:endDate>2016-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fixx:OrphanDrugMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fixx:OrphanDrugMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fixx:FederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fixx:FederalAndStateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180301_20180331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-03-01</xbrli:startDate>
					<xbrli:endDate>2018-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fixx:UnvestedCommonStockFromEarlyExerciseOfOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fixx:UnvestedCommonStockFromEarlyExerciseOfOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-11-01</xbrli:startDate>
					<xbrli:endDate>2017-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-11-01</xbrli:startDate>
					<xbrli:endDate>2017-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20170701_20170731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-07-01</xbrli:startDate>
					<xbrli:endDate>2017-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171101_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-11-01</xbrli:startDate>
					<xbrli:endDate>2017-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_fixxCandidateorProduct">
				<xbrli:measure>fixx:CandidateorProduct</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-11-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:ReimbursableResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:ReimbursableResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-09</xbrli:startDate>
					<xbrli:endDate>2020-11-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001661998</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000319 F_000320"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000319 F_000320 F_000321 F_000322 F_000323 F_000324"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000325 F_000326 F_000327 F_000328"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.25%;margin-right:42.25%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001661998_20200101_20201231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.25%;margin-right:42.25%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.69%;"></td>
<td style="width:95.31%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001661998_20200101_20201231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000004" name="dei:DocumentFiscalYearFocus" contextRef="C_0001661998_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.69%;"></td>
<td style="width:95.31%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number:&#160;<span style="text-decoration:none;"><ix:nonNumeric id="F_000023" name="dei:EntityFileNumber" contextRef="C_0001661998_20200101_20201231">001-38433</ix:nonNumeric></span></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityRegistrantName" contextRef="C_0001661998_20200101_20201231">Homology Medicines, Inc</ix:nonNumeric>. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.25%;margin-right:42.25%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001661998_20200101_20201231">47-3468154</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityAddressAddressLine1" contextRef="C_0001661998_20200101_20201231">One Patriots Park</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressCityOrTown" contextRef="C_0001661998_20200101_20201231">Bedford</ix:nonNumeric>, <ix:nonNumeric id="F_000028" name="dei:EntityAddressStateOrProvince" contextRef="C_0001661998_20200101_20201231">MA</ix:nonNumeric><span style="font-size:9pt;"> </span></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:EntityAddressPostalZipCode" contextRef="C_0001661998_20200101_20201231">01730</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000030" name="dei:CityAreaCode" contextRef="C_0001661998_20200101_20201231">781</ix:nonNumeric>) <ix:nonNumeric id="F_000031" name="dei:LocalPhoneNumber" contextRef="C_0001661998_20200101_20201231">301-7277</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.25%;margin-right:42.25%;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.9%;"></td>
<td style="width:31.74%;"></td>
<td style="width:34.36%;"></td>
</tr>
<tr style="height:12.15pt;">
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:12.15pt;">
<td valign="bottom" style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:Security12bTitle" contextRef="C_0001661998_20200101_20201231">Common Stock, $0.0001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:TradingSymbol" contextRef="C_0001661998_20200101_20201231">FIXX</ix:nonNumeric></p></td>
<td valign="bottom" style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(g) of the Act: <span style="font-weight:bold;">None</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> NO&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small&#160;reporting&#160;company</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityExTransitionPeriod" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;YES&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000017" name="dei:EntityShellCompany" contextRef="C_0001661998_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting stock held by non-affiliates of the registrant, as of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000019" name="dei:EntityPublicFloat" contextRef="C_0001661998_20200630" decimals="-5" scale="6">511.6</ix:nonFraction> million. Solely for purposes of this disclosure, shares of common stock held by executive officers, directors and certain stockholders of the registrant as of such date have been excluded because such holders may be deemed to be affiliates.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;8, 2021, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000018" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001661998_20210308" decimals="INF" format="ixt:numdotdecimal">50,487,649</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding. </p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001661998_20200101_20201231">None.</ix:nonNumeric> </p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:85.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:none;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:none;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:none;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:none;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:none;">Selected Financial Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:none;">Principal Accountant Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits and Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16. </p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:85.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY1"><span style="text-decoration:none;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SPECIAL_NOTE_REGARDING_FORWARD_LOOKING_S">FORWARD-LOOKING STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form&#160;10-K contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Annual Report on Form&#160;10-K, including statements regarding our future results of operations and financial position, the anticipated impact of the COVID-19 pandemic on our business, anticipated use of cash, business strategy, prospective products, product approvals, research and development costs, anticipated timing and likelihood of success of clinical trials, expected timing of the release of clinical trial data, the plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221;, or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report on Form&#160;10-K are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form&#160;10-K and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under &#8220;Summary Risk Factors&#8221; below and the sections in Item&#160;1A., "Risk Factors" of Part&#160;I and Items&#160;7 and 7A., "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk," respectively, of Part&#160;II of this Annual Report on Form&#160;10-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this Annual Report on Form&#160;10-K and the documents that we reference in this Annual Report on Form&#160;10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary Risk Factors</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have a limited operating history and no history of commercializing genetic medicine products, which may make it difficult to evaluate the prospects for our future viability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are heavily dependent on the success of HMI-102, our most advanced product candidate, and if HMI-102 does not receive regulatory approval or is not successfully commercialized, our business may be harmed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We intend to identify and develop product candidates based on our novel genetic medicines platform, which makes it difficult to predict the time and cost of product candidate development. No products that utilize gene editing technology have been approved in the United States or in Europe, and there have only been a limited number of human clinical trials involving a gene editing product candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The clinical trial and regulatory approval processes are lengthy, time consuming and inherently unpredictable, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The COVID-19 pandemic could adversely impact our business, including our preclinical studies and clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our product candidates may cause serious adverse events, side effects, toxicities or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following marketing approval, if any&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">adverse public perception of genetic medicine, and gene editing in particular, may negatively impact regulatory approval of, or demand for, our potential products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we and our contract manufacturers are subject to significant regulation with respect to manufacturing our products, and the manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize its full market potential&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our existing collaborations are important to our business and future licenses may also be important to us, and if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.52%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if we are unable to adequately protect our proprietary technology, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Our proprietary platform is designed to utilize our human hematopoietic stem cell derived adeno-associated virus vectors, or AAVHSCs, to precisely and efficiently deliver single administration genetic medicines <span style="font-style:italic;">in vivo</span> either through gene therapy or nuclease-free gene editing across a broad range of genetic disorders. Our diverse set of AAVHSCs allows us to precisely target, via a single injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, peripheral nervous system, or PNS, bone marrow, muscle and eye. Our genetic medicines platform is designed to provide us the flexibility to choose the method we believe is best suited from either gene therapy or gene editing for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the tissues exhibit. Our product development strategy is to continue to develop in parallel both gene therapy and gene editing, while initially leveraging the experience from our gene therapy product candidates to further advance our gene editing. We believe our dual technology platform will allow us to provide transformative cures using either modality.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unique properties of our proprietary family of 15 novel AAVHSCs enable us to focus on a method of gene editing called gene integration, through the replacement of an entire diseased gene in the genome with a whole functional copy by harnessing the naturally occurring deoxyribonucleic acid, or DNA, repair process of homologous recombination, or HR. We believe our HR-driven gene editing approach will allow us to efficiently perform gene editing at therapeutic levels without unwanted on- and off-target modifications, and to directly measure and confirm those modifications in an unbiased manner to ensure only the intended changes are made. By utilizing the body&#8217;s natural mechanism of correcting gene defects, we also avoid the need for exogenous nucleases, or bacteria-derived enzymes used in other gene editing approaches to cut DNA, that are known to significantly increase the risk of unwanted modifications. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-102 for Treatment of PKU in Adult Patients</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently in Phase 2 of the pheNIX clinical trial with our first and lead product candidate, HMI-102, a gene therapy for the treatment of adults with phenylketonuria, or PKU. In November 2020, we reported positive safety and efficacy clinical data from the dose-escalation phase of the trial. As of the data cutoff date of October 19, 2020, six patients in the dose-escalation phase of the pheNIX trial had received HMI-102 across three dose cohorts (low-dose Cohort 1, n&#61;2&#59; mid-dose Cohort 2, n&#61;2&#59; high-dose Cohort 3, n&#61;2). The results showed that HMI-102 was generally well-tolerated, and resulted in marked reductions in phenylalanine, or Phe, and the Phe-to-tyrosine, or Tyr, ratio, or the Phe-to-Tyr ratio, at two doses. Phe is a registrable endpoint in PKU, and the Phe-to-Tyr ratio is a clinically relevant diagnostic measurement for PKU. Based on the safety and efficacy results observed in the dose-escalation phase, we have selected and advanced two doses to the randomized, concurrently controlled, dose expansion Phase 2 portion of the pheNIX trial, which has the potential to be converted to a registrational trial. We expect to report initial clinical data from this portion of the trial by the end of 2021.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently progressing two gene therapy product development candidates for the treatment of lysosomal storage diseases: HMI-203 for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome, and HMI-202 for the treatment of metachromatic leukodystrophy, or MLD. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in later-stage IND-enabling studies with HMI-203, an <span style="font-style:italic;">in vivo</span> gene therapy product development candidate for the treatment of Hunter syndrome. HMI-203 is a potential one-time AAVHSC treatment designed to deliver functional copies of the <span style="font-style:italic;">IDS</span> gene to multiple target organs, including those in the PNS and CNS, following a single I.V. administration. In preclinical studies, a single I.V. administration of HMI-203 resulted in robust biodistribution and human I2S, or hI2S, enzyme expression, leading to a significant reduction in heparan sulfate glycosaminoglycans, or GAGs, levels in the cerebrospinal fluid, brain, liver, heart, spleen, lung and kidney, compared with the vehicle-treated disease model. HMI-203 also led to significant changes in skeletal deformities compared with vehicle. We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-203 in 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed IND-enabling studies with HMI-202, a gene therapy CNS product development candidate for the treatment of MLD. We have generated preclinical data that have demonstrated that a single I.V. administration of HMI-202 crossed the blood-brain-barrier and blood-nerve-barrier and led to durable reduction of sulfatides in all brain regions of the disease model.<span style="font-size:12pt;"> </span>We are applying the learnings from the IND-enabling studies to further optimize an HMI-202 vector that we believe may lead to a better therapeutic profile.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in later-stage IND-enabling studies with HMI-103, our lead gene editing product development candidate for the treatment of PKU in pediatric patients. We have generated </span><span style="font-style:italic;">in vivo</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> preclinical data </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that have demonstrated</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Phe reduction following a single I.V. administration of the murine surrogate of HMI-103 in the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PKU disease</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mode</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l out to 43 weeks (end of study)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using quantitative molecular methods, we have demonstrated achievement of gene integration efficiencies in a humanized murine liver model that correspond</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with Phe correction in the PKU murine model. These findings were peer-reviewed and published in </span><span style="font-style:italic;">PLOS ONE</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in May 2020.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-103 in 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to name a development candidate in a new therapeutic area in 2021, demonstrating the broader capability of our AAVHSC platform, which we believe may allow us to target diseases with larger patient populations in the future.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have fully integrated process development and Good Manufacturing Practice, or GMP, manufacturing capabilities <span style="Background-color:#FFFFFF;color:#000000;">that support the full breadth and flexibility of our AAVHSC capsid library. Our process development expertise covers all gene therapy and gene editing development functions and incorporates deep characterization and understanding of vector design and their consequences. Our manufacturing process is a versatile system that rapidly delivers high quality vector at scale. The manufacturing capacity within our</span> 25,000 square foot GMP manufacturing facility includes multi-suite and multi-product capabilities to support our clinical development programs in both gene therapy and gene editing and<span style="font-size:12pt;"> </span>we are now producing all of the clinical material for the pheNIX trial in this facility. Our plug and play process and manufacturing platform is a commercial manufacturing process<span style="font-size:12pt;"> </span>that has successfully produced several of our product candidates. We are currently operating three 500-liter bioreactors in our internal manufacturing facility and have successfully produced GMP material at the 500-liter scale for multiple pipeline candidates. Additionally, we have successfully executed our manufacturing platform with multiple product candidates at the 2,000-liter bioreactor scale. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management team has a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases. We have a robust intellectual property portfolio with issued composition of matter patents in the United States for our family of 15 AAVHSCs and we believe the breadth and depth of our intellectual property is a strategic asset that has the potential to provide us with a significant competitive advantage. We continue to build on our intellectual property estate through our ongoing product and platform development efforts.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have raised approximately $539 million in aggregate net proceeds through our initial public offering, or IPO, in April 2018, a follow-on public offering of common stock in April 2019, proceeds from the sale of common stock under an &#8220;at-the-market&#8221; sales agreement, equity investments and preferred stock financings. Included in our net proceeds is $50.0 million from a former collaboration partner, comprised of an up-front payment of $35.0 million and a $15.0 million equity investment and a $60.0 million equity investment from Pfizer Inc., or Pfizer, through a private placement transaction. We will require additional capital in order to advance HMI-102 and our other product candidates through clinical development and commercialization. We believe that our compelling preclinical data, positive clinical data with HMI-102, scientific expertise, product development strategy, manufacturing capabilities, and robust intellectual property position us as a leader in the development of genetic medicines. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Opportunity in Genetic Medicines </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused on monogenic diseases where the genetic abnormality is known to occur in a single gene. The majority of monogenic diseases harbor thousands of individual mutations within the diseased gene, each resulting in a loss of function. Adding a functional gene to the cell where there is a missing or mutated gene or replacing an entire diseased gene with a whole functional gene are the optimal therapeutic approaches for addressing these monogenic disorders. This can be accomplished either through a method of gene therapy called gene transfer in slowly or non-dividing cells, or through a method of gene editing called gene integration in rapidly dividing cells. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current focus of most nuclease-based gene editing companies is gene knockout, or knocking out a diseased gene to prevent the expression of an undesired protein. Since gene knockout does not result in a fully-corrected gene, this method can only potentially address the minority of monogenic diseases where a diseased protein requires knock-down or inactivation. Our HR-driven gene editing approach aims to achieve functional gene integration into the patient&#8217;s genome and potentially address the majority of monogenic diseases by replacing an entire diseased gene with a whole functional gene. Our gene therapy approach, on the other hand, seeks to introduce a functional copy of a defective gene into a patient&#8217;s own cells, but not incorporate such copy into the patient&#8217;s genome. This method results in the expression of the therapeutic protein of interest without changing the genome. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DNA Repair Pathways </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human cells harbor two primary independent pathways to maintain the integrity of DNA: homologous recombination, or HR, and non-homologous end joining, or NHEJ, which are described below: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">HR</span><span style="font-size:10pt;color:#000000;"> is a process in which cells repair DNA through highly precise incorporation of correct DNA sequences that are homologous, or matching, to the site of damage. HR has evolved to repair DNA with high fidelity and avoids the introduction of unwanted mutations at the site of correction. In the late 1990s, researchers discovered that certain AAV vectors delivered long single strands of homologous DNA to specific regions in the genome and induced the HR pathway, but their low efficiency of approximately 1% limited their use as a viable option for </span><span style="font-style:italic;font-size:10pt;color:#000000;">in vivo</span><span style="font-size:10pt;color:#000000;"> therapeutics.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">NHEJ</span><span style="font-size:10pt;color:#000000;"> is a less selective, error-prone process that rapidly joins the ends of broken DNA resulting in a high frequency of insertions or deletions at the break site. The discovery of nuclease-based gene editing technologies provided researchers with novel tools to specifically introduce DNA breaks into the genome. Despite high potential for error, the majority of nuclease-based gene editing approaches primarily utilize the NHEJ pathway. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the major limitation of nuclease-based gene editing is the preferential utilization of the error-prone NHEJ pathway instead of the HR pathway. Because of this preference, the greatest utility of nuclease-based gene editing technologies may lie in their ability to knockout genes rather than replace an entire diseased gene in the genome with a whole functional copy. Furthermore, the use of nuclease-based gene editing technologies for insertion of a corrective sequence carries the risk of unwanted mutations from NHEJ including insertions and deletions or opposite orientation insertion of the template DNA, and also requires the separate delivery of both the nuclease and the DNA template to the same location at the same time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the unique characteristics of our genetic medicines platform will allow us to focus on the HR pathway, enabling precise nuclease-free gene integration with improved efficiency and a broader set of disease targets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Approach </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product development strategy is to continue to develop in parallel both gene therapy and gene editing modalities, and to choose the method we believe is best suited from either gene therapy or gene editing for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the tissues exhibit, all while initially leveraging the experience from our gene therapy modality to further advance our gene editing modality. Refer to Figure 1 below for a graphical depiction of our platform.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000001.jpg" title="" alt="" style="width:682px;height:148px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 1. Our Genetic Medicines Platform. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our novel AAVHSCs are packaged with either a gene therapy or a gene editing construct. Our gene therapy construct includes a functional copy of the gene and a promoter sequence that is designed to enable the gene to be turned on in the cell and ultimately transcribed to express the therapeutic protein of interest without integrating into the genome. Our gene editing construct includes lengthy guide sequences, or homology arms, which are designed to enable the specific alignment to the desired genomic location and then, through the natural process of HR, enable correction of the diseased gene in the genome by replacement with a whole functional copy. While others are working on identifying and testing ways to mitigate the inherent risk in working with nucleases for gene editing, our approach avoids the use of nucleases entirely. By targeting the HR pathway, our proprietary AAVHSCs mitigate the risks of nuclease-based technologies and have the potential to overcome other AAV vector limitations by combining the precision and high fidelity of HR with highly efficient in vivo gene integration, which we believe is capable of providing potential cures for a wide range of rare genetic diseases. Refer to Figure 2 below for a graphical depiction of how our AAVHSCs are designed to enable each therapeutic modality.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000002.jpg" title="" alt="" style="width:598px;height:348px;" /><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 2. How our AAVHSCs are designed to enable each therapeutic modality. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our approach has several key advantages that include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Our proprietary AAVHSC platform enables both gene therapy and gene editing modalities.</span> Our platform provides us the flexibility to deliver genetic medicines through the best suited modality from either gene therapy or gene editing for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the tissues exhibit. Our AAVHSCs are naturally occurring as they were originally isolated from normal human CD34 cells and have the potential to result in an improved safety profile.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Ability to perform nuclease-free gene editing mediated by HR with high gene integration efficiency.</span><span style="font-style:italic;"> </span>Our family of 15 novel AAVHSCs are designed to enable us to take advantage of the precise and high-fidelity process of HR-directed gene insertion for nuclease-free gene editing while achieving gene integration efficiencies that we believe are in therapeutic ranges and significantly higher than both nuclease-based and other AAV-based approaches. While nuclease-based gene editing technologies have achieved high gene knockout efficiencies in preclinical studies, which is only potentially useful for the minority of monogenic diseases, they have shown limited published evidence of gene integration efficiencies to date. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Ability to introduce an entire gene into the genome or the precise repair of individual mutated nucleotides in addition to gene knockout.</span> Our HR-based gene editing approach provides the flexibility to introduce an entire copy of a functional gene into the genome<span style="font-size:12pt;"> </span>also known as gene integration, in addition to repairing single mutations or knocking out entire genes, thus allowing us to potentially address the significant majority of monogenic diseases. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">High precision and lack of unwanted off-target or on-target DNA modifications</span><span style="font-weight:bold;">. </span>Our gene editing approach leverages HR, which makes DNA repairs with high fidelity, and enables us to precisely perform gene integration without unwanted off- and on-target modifications. Furthermore, we are able to directly measure and confirm those modifications throughout the entire genome to ensure only the intended changes are made. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Ability to target multiple tissues. </span>In preclinical studies, intravenous administration of our family of AAVHSCs has demonstrated<span style="font-size:12pt;"> </span>unique biodistribution properties across the serotypes and the ability to target a wide variety of tissues including the liver, CNS, PNS, muscle, bone marrow, eye and heart, enabling us to potentially address a broad range of monogenic diseases. The diversity of our AAVHSC library of capsids can also be expanded through targeted shuffling of the capsid sequences. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">In vivo </span><span style="font-weight:bold;font-style:italic;">administration with a single component delivery system.</span> Our platform is designed to perform gene editing at high efficiency without the use of a nuclease, enabling us to deliver genetic medicines <span style="font-style:italic;">in vivo </span>using a </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">single vector system that contains everything required to edit DNA. These characteristics simplify the manufacturing and delivery of our therapeutic candidates relative to existing nuclease-based gene editing approaches. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Ability to target a broad range of patients given low frequency of pre-existing neutralizing antibodies. </span>We believe our AAVHSCs can target a broad range of patient populations given the low prevalence of pre-existing neutralizing antibodies relative to other AAV vectors. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Pipeline Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our genetic medicines platform can be applied broadly to treat and potentially cure a wide range of genetic diseases, and we have carefully designed and prioritized our pipeline strategy to maximize this opportunity. We are initially pursuing monogenic diseases where we know exactly what we are seeking to correct and exactly which gene to insert into patients&#8217; cells. We are prioritizing monogenic diseases with significant unmet medical needs, validated regulatory pathways, well-accepted biomarkers and significant commercial opportunities. We are currently focused on developing product candidates to treat monogenic diseases in the liver, CNS and peripheral tissues, bone marrow, and the eye, given that our AAVHSCs naturally show a high degree of tropism or ability to enter cells in these organs and organ systems. These tissues are affected in many rare genetic diseases. We also plan to name a development candidate in a new therapeutic area in 2021, demonstrating the broader capability of our AAVHSC platform, which we believe may allow us to target diseases with larger patient populations in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial focus areas include developing product candidates for intracellular, inborn errors of metabolism and other genetic conditions that are especially well-suited to correction by our gene editing or gene therapy methods. In slow- or non-dividing cells (e.g., CNS and adult liver cells), gene therapy can potentially be curative, while rapidly dividing cells (e.g., hematopoietic CD34+ cells and pediatric liver cells) require a gene editing approach to provide a permanent correction in the genome that can be replicated with each cell division. We are purposefully deploying our proprietary AAVHSCs in certain indications first with a gene therapy approach followed by a gene editing approach, in order to maximize the likelihood of translating our platform into widespread clinical and commercial success.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are building a deep pipeline across a wide range of diseases and tissue types to leverage the broad potential of our platform. We believe we have validated our AAVHSC platform in the liver based on the results observed in the dose-escalation portion of our Phase 1/2 trial with HMI-102, and we are also in IND-enabling studies with HMI-103, a gene editing development candidate for pediatric PKU. We have completed a comprehensive <span style="font-style:italic;">in vivo</span> biodistribution study in NHPs in which all 11 of the AAVHSCs tested crossed the blood-brain-barrier and the blood-nerve-barrier, we are in IND-enabling studies with HMI-203, a gene therapy development candidate for MPS II, or Hunter syndrome, and we have recently completed IND-enabling studies with HMI-202, a gene therapy development candidate for MLD, the data from which we are using to further optimize a HMI-202 vector that we believe may lead to a better therapeutic profile. We continue our discovery efforts across multiple targets, including the liver, CNS, human stem cells and ophthalmology. We also may selectively enter into strategic alliances with pharmaceutical or biopharmaceutical companies to expand indications and accelerate development of programs where collaborators can contribute further disease-specific expertise to our platform.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Pipeline </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current status of our programs is summarized in the table below: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:4.79%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000003.jpg" title="" alt="" style="width:638px;height:276px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to transform the lives of patients suffering from severe genetic diseases by using gene therapy and gene editing to cure the underlying cause of the disease. The critical components of our strategy to achieve this goal include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Transform the treatment paradigm for rare genetic diseases with the delivery of single-administration curative therapies.</span> Utilizing our proprietary AAVHSCs, we intend to deliver genetic medicines <span style="font-style:italic;">in vivo</span> via a single administration to address the underlying genetic problem in a given disease. For each of the programs in our pipeline, we have identified the mutations of a specific gene that we believe can potentially be addressed by introducing a functional copy of a defective gene via gene therapy, or by replacing an aberrant gene with a healthy one via HR-driven gene integration, resulting in specific integration into the patient&#8217;s genome. Our genetic medicines platform allows us to choose the best suited modality for each disease we pursue, and we believe our nuclease-free editing approach will provide life-long clinical benefits for patients. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Advance our pipeline programs through clinical proof-of-concept and commercialization.</span> We are continuing to advance the Phase 1/2 pheNIX clinical trial with investigational HMI-102 gene therapy for adults with PKU at multiple sites in the U.S. and reported positive clinical data from the dose-escalation phase of the trial in November 2020. We believe that our approach of initially utilizing one of our AAVHSCs for gene therapy in adult PKU patients while, in parallel, advancing gene editing for pediatric PKU patients will maximize the efficiency of our pipeline development while providing potential solutions for the unique needs of each particular PKU patient population. Given the well-defined nature of PKU and the concentration of treatment centers, we intend to bring HMI-102, if approved, to patients through a small, targeted internal commercial organization. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Continue to expand our pipeline within existing therapeutic areas and expand into new therapeutic areas.</span> We are focused on applying the transformative potential of our genetic medicines platform to develop treatments for patients with monogenic diseases. Initially, we are targeting diseases occurring in the liver, the CNS and PNS, the eye and the hematopoietic system. Given the ability of our AAVHSCs to deliver to a wide range of disease-relevant tissues, we believe there are many additional indications for which our technology may be applicable, including other inborn errors of metabolism, lysosomal storage diseases, hematological diseases, and ophthalmic diseases, as well as for <span style="font-style:italic;">in vivo</span> cell therapy. We may also choose to selectively collaborate to expand the indications we can pursue and accelerate development of programs where collaborators can contribute further disease-specific expertise to our platform. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Strengthen our platform by leveraging our discovery and development capabilities and selectively collaborating. </span>We are committed to investing in our research and development activities to expand the capabilities of our platform, specifically our AAVHSCs as well as HR gene editing technology. We are optimizing our AAVHSC genetic medicines platform with focused efforts on AAVHSC characterization, gene therapy and editing construct design and screening, and genomic assays to characterize and quantify our </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">editing technology. To augment our own efforts, we intend to continue to collaborate with academic institutions to pursue new scientific and therapeutic insights and strengthen our position as a leader in gene integration. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Control manufacturing through our in-house capabilities.</span> We have developed an internal process development platform that accommodates both gene therapy and gene editing technologies. We have constructed a 25,000 square foot GMP manufacturing facility with 1,500 liters of active capacity that is designed to accommodate all pipeline programs, and we are now producing all of the clinical material for the pheNIX trial in this facility. Additionally, we have executed our manufacturing platform with multiple product candidates at the 2,000-liter bioreactor scale. We believe the quality, reliability and scalability of our gene therapy and gene editing manufacturing approach is a core competitive advantage crucial to our long-term success and that internal manufacturing capabilities will further safeguard our intellectual property. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.58%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;">Continue to strengthen and expand our intellectual property portfolio.</span> We have exclusive worldwide rights to our technologies including issued composition of matter patents in the United States for fifteen of our novel AAVHSCs for both gene therapy and gene editing. We exclusively acquired rights to this foundational intellectual property for the AAVHSCs from City of Hope, or COH, for developing and commercializing therapeutics based on these vectors. We continue to focus on strengthening our intellectual property estate through the discovery of new AAVHSCs, further characterization around our existing AAVHSCs as well as the core technology involved in delivering our product candidates to patients. To further advance our leadership in gene therapy and nuclease-free gene editing, we actively explore opportunities to collaborate with other leading scientific institutions in the field. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Genetic Medicines Platform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary genetic medicines platform is built on our novel AAVHSCs, which allow us to choose the best suited modality from either gene integration or gene therapy for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the target tissues exhibit. The unique characteristics of our platform enable nuclease-free gene editing, specifically gene integration, and broad, systemic tissue distribution. Our AAVHSCs are designed to directly integrate corrective DNA through HR with therapeutically relevant efficiencies. Our HR-based gene editing approach utilizes a single component AAV system that contains everything required to selectively edit DNA with no need for exogenous nucleases or editing machinery. This single-component system simplifies the manufacturing and delivery of our therapeutics. We believe our gene editing approach has the potential to be curative as it provides a permanent correction in the genome that is then replicated with each cell division so that new generations of cells will carry the corrected gene. Our AAVHSCs are naturally occurring and have been modified to be non-replicating to minimize potential safety issues. We believe our platform&#8217;s combined attributes will allow us to develop more efficient and safer therapeutics for a wide range of genetic diseases. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Homologous Recombination&#8212;A Powerful Basis for Gene Editing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike other gene editing approaches, our technology is based on the natural DNA repair process of HR and is designed to enable precise and efficient gene integration without an exogenous nuclease. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our genetic medicines platform induces the endogenous HR cellular process using our AAVHSCs to insert replacement or corrective genes into cells that contain mutated or deleterious genes (refer to Figure 3 below). We engineer our AAVHSCs to contain long, single-stranded DNA corrective sequences highly specific to the target region in the genome. These single-stranded DNA molecules are then delivered to cells in our AAVHSC vectors, which we believe results in precise and efficient gene integration via the HR pathway. The design of our long and specific sequences, up to the 4.7 kilobase packaging limit of our AAVHSCs, is intended to significantly reduce the risk of off-target integration. Based on the packaging size of our AAVHSCs, we believe our capsids are capable of accommodating and delivering up to approximately 85% of the genes in the human genome and thus have the ability to address a significant majority of genetic disorders. We typically use homology arms as long as 1,600 base pairs of DNA to target corrective gene sequences into precise regions of the genome, in contrast to the guide sequences used in CRISPR/Cas 9-based gene editing, which are typically less than 30 base pairs in length. We also benefit from the ability of our platform to utilize HR to precisely insert gene sequences into the DNA of cells, similar to how mammalian cells repair their own DNA. In order to bring about the excision and subsequent replacement that some forms of gene editing require, those other approaches must combine multiple additional techniques and deliver into the cell the requisite cellular machinery at the right place at the same time, increasing the complexity of the task, introducing the possibility of integrating the wrong DNA due to non-HR-based repair mechanisms, and reducing the likelihood of success. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000004.jpg" title="" alt="" style="width:342px;height:314px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3. Schematic of homologous recombination. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Proprietary AAVHSCs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our genetic medicines platform is based on a family of 15 proprietary AAVHSCs which we can deploy with either gene therapy or gene editing constructs. We have the opportunity to expand on this family through capsid shuffling. Both applications rely on a unique ability of our AAVHSCs to efficiently target multiple tissues in the body. Our AAVHSCs were isolated from human stem cells and we believe they can direct nuclease-free gene integration with higher efficiency relative to that indicated in published data for other AAV-based gene editing approaches. Our AAVHSCs display the following advantages: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Single AAVHSC Platform for Both Gene Therapy and Gene Editing Modalities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform provides us the flexibility to deliver genetic medicines through the best suited modality from either gene therapy or gene editing for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the tissues exhibit. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ability to Perform <span style="font-style:normal;">In Vivo</span> Nuclease-free Gene Editing Mediated by HR </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To demonstrate the utility of AAVHSC-mediated gene editing <span style="font-style:italic;">in vivo</span>, we conducted a series of experiments at our headquarters. We obtained preclinical proof-of-concept for <span style="font-style:italic;">in vivo</span> editing efficiency and tissue-specific expression through the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">design of a promoter-less luciferase construct targeting the murine Factor 8, or </span><span style="font-style:italic;">F8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, locus using AAVHSC15. </span><span style="font-style:italic;">F8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is a locus in the murine genome that is known to have a strong promoter but is expressed only in the liver. The editing cassette was flanked by 800bp homology arms with sequences homologous to an insertion site within intron 6 of the murine </span><span style="font-style:italic;">F8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene. The expression cassette (hereafter mF8-Luc) also included a canonical splice acceptor sequence for splicing into the endogenous </span><span style="font-style:italic;">F8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> transcript and a ribosomal skipping 2A element for independent translation of the </span><span style="font-style:italic;">F8</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and luciferase proteins. The luciferase transcript was terminated by an SV40pA element.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAVHSC15 packaging the promoter-less F8 targeting cassette (AAVHSC15-mF8-Luc) was administered by a single intravenous injection to albino-B6 mice to evaluate the level of targeted integration and expression from the murine <span style="font-style:italic;">F8</span> locus. Six- to seven-week-old albino-B6 mice were dosed with AAVHSC15-mF8-Luc and reporter expression was followed over time. High levels of luciferase expression in livers of mice transduced under these conditions were observed. Bioluminescence increased within a week post-dosing, reached a maximum within 1-2 months and remained significantly above that observed in vehicle-treated mice until the end of the study at 470 days post-dosing (*&#61; P&#60;0.0001 vs vehicle). <span style="font-style:italic;">Ex vivo</span> imaging of tissues harvested on Day 470 showed highest luciferase expression within liver (*&#61;p&#60;0.008 vs vehicle), greater than 100-fold higher than other tissues assessed (**&#61;P&#60;0.0001 vs other tissues), which demonstrated specificity of tissue targeting by AAVHSC15-mF8-Luc (refer to Figure 4 below). At 470 days post-dosing, vector genome levels within livers of treated mice were on average 4.7 &#177; 2.7 vector genomes/allele. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000005.jpg" title="" alt="" style="width:253px;height:232px;" />&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<img src="gmz2lq4320rk000006.jpg" title="" alt="" style="width:226px;height:238px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 4. <span style="font-style:italic;">In vivo</span> gene editing proof-of-concept at the murine F8 locus. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To molecularly characterize AAVHSC15-mF8-Luc-mediated genome editing, a ddPCR-based quantitative F8 editing assay was established. A combination of a F8 locus specific primer and probe and editing vector specific primer and probe in the FAM and HEX channel, respectively, were used to calculate the fraction of F8 loci that have an inserted luciferase transgene. Editing signal in this assay showed linear detection between 0 and 30% allele frequencies based on a standard curve of known molar ratios of edited/unedited alleles. Assay signal was specific as digestion of input DNA with HindIII prior to the ddPCR assay separated the payload from the genomic reference, causing each target to segregate independently within each droplet eliminating the editing signal. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genomic DNA was isolated from livers of treated mice at termination of the study at 470 days post-dosing and editing of the murine F8 locus was assessed by the ddPCR editing assay. Mice treated with AAVHSC15-mF8-Luc at this initial low dose of 5e12 vg/kg showed a statistically significant increase in genome editing efficiencies with up to 2.8% of alleles edited (mean 0.8% of alleles edited with a range of editing efficiencies 0.2-2.8%&#59; p&#60;0.03 vs. vehicle). These data demonstrate that AAVHSC15 mediated long-term in vivo editing of the targeted locus within the liver of mice at this dose.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To assess whether expression from AAVHSC15-mF8-Luc was episomal, an AAVHSC15-Luc editing vector was prepared with the splice acceptor sequences removed (designated AAVHSC15-</span><span style="font-size:12pt;">&#8710;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2AmF8-Luc) but maintained an intact Met initiator codon. Relative to an IV injection of vehicle alone, injection of AAVHSC15-mF8-Luc increased luciferase expression at Days 3, 7, and 14 post-dosing, similar to the results described above. By contrast, luciferase expression was reduced &#62;95% for mice that received an identical dose of AAVHSC15-</span><span style="font-size:12pt;">&#8710;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2AmF8-Luc (refer to Figure 5 below).</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000007.jpg" title="" alt="" style="width:548px;height:221px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. <span style="font-style:italic;">In vivo</span> gene editing proof-of-concept at the murine F8 locus.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ability to Introduce Entire Gene into the Genome Mediated via HR </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial data supporting the targeted integration of entire genes using AAVHSCs into the genome have been previously published. We have expanded on those initial studies by demonstrating the targeted integration of a full-length luciferase gene into the murine F8 locus, as described above and illustrated in Figures 4 and 5. This preliminary proof of principle led to the discovery and development of a therapeutic program for pediatric PKU focused on the targeted integration of a full-length <span style="font-style:italic;">PAH</span> cDNA into the human <span style="font-style:italic;">PAH</span> locus. We have successfully inserted full-length cDNA encoding luciferase and PAH into two separate genomic regions <span style="font-style:italic;">in vivo</span> reaching levels of efficiency required for therapeutic efficacy. HMI-103, the development candidate for pediatric PKU, is described in detail below.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability to introduce entire genes specifically into the genome at these efficiencies provides an opportunity to target multiple monogenic diseases where the correction of a defective gene would result in therapeutic benefit. Given that a majority of monogenic diseases harbor mutations that render the gene inactive, we believe our gene integration modality can be expanded well beyond our initial focus on liver-based inborn errors of metabolism.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">High Precision and Lack of Unwanted Off-target or On-target DNA Modifications </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using next-generation sequencing technologies, we have developed methodologies to test for on-target mutations at the site of integration. Using these methods, we observed that HR using our AAVHSCs is very precise at the site of correction. We did not detect any co-incident random mutations at or above our lower limit of detection (0.5%) or inverted terminal repeat, or ITR, sequences at the site of integration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We developed a method to enable whole genome unbiased next-generation sequencing for the detection and mapping of off-target integration sites. By leveraging the potential ability of our AAVHSCs to drive HR-based targeted integration, we can utilize next-generation sequencing technologies to identify and quantify where the inserted sequence maps. Using this method, and testing integration into the human AAVS1 locus, we estimate that 99.967% of insertions (&#62;2.2 million reads) are at the targeted site and that the balance is within expected background of the assay. We have expanded on this assay to characterize the on-target precision of integration at the <span style="font-style:italic;">PAH</span> locus in support of HMI-103, described below.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ability to Target Multiple Tissues </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, intravenous administration of our family of AAVHSCs has demonstrated the ability to target a wide variety of tissues including the liver, CNS, PNS, muscle, bone marrow, eye and heart. Specifically, we have generated evidence of our AAVHSCs&#8217; ability to target a number of tissues including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">neurons throughout the brain, spinal cord, and dorsal root ganglion by crossing the blood-brain-barrier and the blood-nerve-barrier&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">retinal ganglion cells and neurons of the retinal outer nuclear layer&#59; we have also demonstrated the ability to target retinal tissue via intravenous injection as well as multiple layers of target cells, including photoreceptors, retinal pigment epithelial cells and horizontal cells, through sub-retinal injection&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">skeletal muscle myocytes in all skeletal muscle tissues examined, including gastrocnemius, soleus, diaphragm, esophagus, and biceps&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">cardiomyocytes throughout the heart&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">extensive liver tropism. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000008.jpg" title="" alt="" style="width:609px;height:316px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 6. Our family of AAVHSCs has demonstrated the ability to target a wide variety of tissues.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Vivo<span style="font-style:italic;"> Administration with a Single Component Delivery System</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform is designed to perform gene integration at higher efficiency without the use of a nuclease, enabling us to deliver genetic medicines <span style="font-style:italic;">in vivo </span>using a single vector system (refer to Figure 7 below). Existing nuclease-based gene editing technologies, when replacing a defective gene with a functional gene through gene editing, require the use of two or more different vector constructs in combination to perform their gene editing functions. One or more vector constructs house the nuclease, and the other vector construct houses the DNA template, and all vectors must reach and penetrate the specific target cell at the same time to edit the DNA. In contrast to these nuclease-based gene editing technologies, our AAVHSC technology is a single component system that contains everything required to selectively integrate DNA with no need for additional exogenous nucleases, template DNA or editing machinery. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our ability to perform gene integration at efficiencies that are greater than both nuclease-based and other AAV-based approaches, coupled with our single component delivery system, enable us to administer genetic medicines </span><span style="font-style:italic;">in vivo.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We believe the advantages of </span><span style="font-style:italic;">in vivo </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">administration of therapeutics via a single component delivery system include the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">simpler and faster manufacturing relative to </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo </span><span style="font-size:10pt;color:#000000;">resulting in reduced manufacturing costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">improved delivery of therapeutic as only a single vector is required to reach a cell instead of multiple vectors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">ease of use for the patient, eliminating the need for mobilization and myeloablation, a common requirement for many </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo </span><span style="font-size:10pt;color:#000000;">gene editing therapies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">improved safety profile, as compared to an </span><span style="font-style:italic;font-size:10pt;color:#000000;">ex vivo</span><span style="font-size:10pt;color:#000000;"> therapy. </span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000009.jpg" title="" alt="" style="width:100px;height:218px;" /><span style="margin-left:36pt;"><img src="gmz2lq4320rk000010.jpg" title="" alt="" style="width:138px;height:218px;" /></span>&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 7. Our nuclease-free AAVHSC single component gene editing construct vs. nuclease-based multiple component gene editing construct for gene editing applications. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ability to Target a Broad Range of Patients Given Low Frequency of Pre-Existing Neutralizing Antibodies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A potential concern for all AAV vectors is the presence of pre-existing neutralizing antibodies that have the potential to reduce their effectiveness. We conducted a study across 100 human serum donors representing different ethnic segments of the U.S. population. Based on the initial results, we believe the findings suggest that approximately 80% of individuals lack antibodies that recognize AAVHSCs, which is comparable to AAV9, a commonly used vector for development of other gene therapies. These findings were published in <span style="font-style:italic;">Human Gene Therapy Clinical Development</span> in March 2018.<span style="font-size:1pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our genetic medicines platform can be applied broadly to treat and cure a wide range of genetic diseases and have carefully designed and prioritized our pipeline strategy to maximize this opportunity. We are initially pursuing diseases where the genetic abnormality is known and is found in a single gene. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">HMI-102 for Treatment of PKU in Adult Patients and HMI-103 for Treatment of PKU in Pediatric Patients</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead program, HMI-102, is an AAVHSC vector gene therapy candidate designed to treat PAH deficiency, the underlying genetic cause of PKU. We have received orphan drug designation from the FDA and the European Medicines Agency, or EMA, for the use of AAVHSC15 expressing <span style="font-style:italic;">PAH</span> for the treatment of PAH deficiency. In June 2019, we commenced enrollment of our Phase 1/2 pheNIX clinical trial with HMI-102 gene therapy for adults with classical PKU at multiple sites in the U.S. and reported positive clinical data in November 2020. We are currently in the dose expansion Phase 2 portion of the pheNIX trial. HMI-102 is intended to treat adult patients with deficiencies in PAH regardless of the specific underlying <span style="font-style:italic;">PAH</span> mutation. We are also developing HMI-103, an AAVHSC vector gene editing candidate, to address the pediatric PKU population. HMI-103 is designed to replace the defective <span style="font-style:italic;">PAH</span> gene through the targeted integration of a normal copy into the <span style="font-style:italic;">PAH</span> genomic region. We are in IND-enabling studies with HMI-103, and we expect to initiate a Phase 1/2 dose-escalation clinical trial in 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PKU Disease Overview </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PKU is an inborn error of metabolism that results from mutations in the <span style="font-style:italic;">PAH</span> gene. PAH is an enzyme that is normally expressed in the liver and is necessary to metabolize dietary phenylalanine, or Phe, to the amino acid tyrosine, or Tyr. Tyr is a product of Phe metabolism and a precursor to neurotransmitters, and its increase indicates increased enzymatic activity. PKU results from mutations in <span style="font-style:italic;">PAH</span> that render its enzymatic activity deficient. If it is not metabolized by PAH, Phe builds up throughout the body, including in the blood and the nervous system. Approximately 75% of all dietary Phe is typically metabolized by PAH, so the absence of PAH leads directly to the pathological excess of Phe as well as a deficiency of Tyr. Excessive blood Phe and low levels of Tyr result in intellectual disability, which is possibly caused by a variety of mechanisms including effects on neuronal development, myelination, and neurotransmitter synthesis. Blood Phe is an easily measurable and translatable biomarker. It is also a validated clinical endpoint in clinical trials for PKU, facilitating both a rapid path to the clinic and characterization of therapeutic response.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Newborns in all 50 states are screened for PKU. It has been estimated that the incidence of PKU in the United States is one in 12,707, which translates to approximately 350 cases per year with an overall prevalence of 16,500. It has also been estimated that the prevalence of PKU in the European Union is 25,000. Worldwide, the estimated prevalence is 50,000 with 1,000 to 1,500 new cases annually. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of patients are identified soon after birth and are primarily treated by dietary restriction of Phe. While Phe-restricted diets have dramatically reduced the intellectual deficiencies associated with this disease, they fail to address the cognitive and behavioral problems that continue throughout a patient&#8217;s life. Lifetime adherence to a Phe-restricted diet is challenging and blood Phe within the recommended range is not achievable for the vast majority of patients. The inability to achieve recommended levels of Phe results in neurological as well as metabolic problems. Long-term studies in adults identify neurocognitive, psychosocial, quality of life, growth, nutrition, bone pathology and maternal PKU outcomes that are suboptimal despite early and continuous treatment with diet. In a retrospective study of PKU patients peer reviewed and published in the journal of <span style="font-style:italic;">Molecular Genetics &#38; Metabolism</span>, young children were adherent to Phe-restricted diet, whereas most adolescents (79%) did not achieve recommended Phe levels, and 88% of adults were no longer on a Phe-restricted diet. Relaxing of dietary restrictions beyond preschool years, or failure to adhere to physician-assigned diets, which is the current guideline for most adolescents and adults, results in loss of metabolic control and wide fluctuations in Phe levels that are both directly associated with progressive neurological damage.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted a five-year retrospective chart review of PKU patients, which confirmed key elements of our proposed Phase 1/2 clinical trial design. Consistent findings from two PKU academic centers of excellence in the U.S. in 152 PKU patients showed that actively monitored patients, including those on restrictive low Phe diet, had Phe levels well-above the recommended threshold of 360 umol/L, based on current U.S. treatment guidelines, underscoring the need for treatments that restore the normal biochemical pathway (refer to Figure 8 below). Furthermore, we confirmed that Phe continues to be higher, even on standard of care, in the classical PKU population, defined as patients with Phe levels greater than 1200 umol/L (66% of the study population) without treatment, and was significantly elevated in the adult population compared to those patients who were less than 18 years of age. These findings were published in <span style="font-style:italic;">Molecular Genetics and Metabolism</span> in December 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000011.jpg" title="" alt="" style="width:677px;height:250px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 8. Retrospective five-year chart review demonstrates actively monitored adult classical PKU patients across two academic centers have Phe levels &#62;700 umol/L.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current Treatments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no available treatments that address the core underlying genetic biochemical defect in PKU, the deficiency of PAH. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Saproterin dihydrochloride, or Kuvan, is an FDA-approved therapy to reduce elevations in serum Phe. Saproterin is a synthetic version of BH4, a cofactor that is required for PAH activity. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients&#59; however, clinical data suggests that saproterin is not fully effective in lowering high serum levels of Phe back to normal levels and must be used in conjunction with a low Phe diet. Worldwide sales of Kuvan were $458&#160;million in 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pegvaliase, or Palynziq, is a pegylated plant-derived enzyme called phenylalanine ammonia lyase that was approved in the U.S. by the FDA in 2018 and in Europe by the EMA in 2019. This approach does not correct the underlying genetic disorder (PAH deficiency) and will not reconstitute the natural pathway. We believe Palynziq to have certain limitations including that it must be administered via daily injections and its label contains a black box warning that it can cause severe allergic reaction (anaphylaxis) that may be life-threatening and can happen at any time during treatment with Palynziq. The label states that patients must carry auto-injectable epinephrine with them at all times during Palynziq treatment. Patients in its Phase&#160;3 trials did not meet the secondary efficacy endpoints for cognitive benefit. Worldwide sales of Palynziq were $171 million in 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our Gene Therapy and Gene Editing Approaches to PKU </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are taking two approaches towards developing a potential therapy for PKU. The first is a gene therapy in which a gene construct encoding human <span style="font-style:italic;">PAH</span> is delivered to liver cells where it directs production of normal PAH via episomal expression driven off a liver specific promoter. The second potential therapy involves gene integration of a normal copy of the <span style="font-style:italic;">PAH</span> gene into the defective gene of affected patients. We believe that the gene therapy approach offers an expedited clinical development path towards delivery of a therapeutic to adult and adolescent patients where the majority of target cells are non-dividing in the liver. We believe the gene integration approach would be more suitable in newborn and pediatric patients due to the higher rate of dividing cells as the child grows. The goal of both approaches is to enable production of functional PAH, thus restoring the normal biochemical pathway of Phe metabolism. This can reduce the abnormally high levels of Phe in the blood, while also increasing Tyr levels, the product of PAH-driven Phe metabolism. Using gene editing to correct the defective <span style="font-style:italic;">PAH</span> gene in young patients has the potential to provide long-term benefit as the corrected gene will persist as cells replicate. Correcting the gene early in disease progression has the potential to normalize not only Phe levels, but also Tyr levels, the product of the Phe metabolism and a precursor to neurotransmitter synthesis. This may allow affected children to avoid many of the serious neurological consequences associated with PKU. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that an effective gene therapy or gene editing treatment for PKU has the potential to eliminate the need for Phe-restricted diet and may lead to significant improvements in the morbidity and quality of life for patients. Published estimates suggest that restoration of PAH activity to 10% or more of normal levels would lead to significant improvements in serum Phe levels and potentially represent a curative therapy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-102: Our Gene Therapy Approach for PKU</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified HMI-102 as our lead product candidate after screening multiple vector constructs. HMI-102 consists of an AAVHSC15 vector containing the coding sequence of human <span style="font-style:italic;">PAH</span> under control of a promoter designed to continuously express <span style="font-style:italic;">PAH</span>, specifically in the liver. We chose AAVHSC15 as the basis of this product candidate because of its tropism for the liver, the normal site for PAH protein expression.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2 pheNIX Clinical Trial with HMI-102</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we commenced enrollment of our Phase 1/2 pheNIX clinical trial with HMI-102, which is designed to evaluate the safety and efficacy of the investigational gene therapy in a randomized, concurrently controlled, dose-escalation study in adult patients aged 18&#8211;55 years old with classical PKU. The dose-escalation phase of the trial was designed to evaluate safety and efficacy of ascending doses of HMI-102 to enable the selection of a dose for the randomized, concurrently controlled Part B phase of the trial, which has the potential to be converted to a registrational trial. We enrolled six patients in the dose-escalation phase<span style="font-size:12pt;"> </span>across three dose cohorts (refer to Figure 9 below). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000012.jpg" title="" alt="" style="width:679px;height:314px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 9. Baseline characteristics for patients in the dose-escalation phase of the pheNIX clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we reported positive clinical data from the dose-escalation phase of the trial. Safety data from the six patients as of the cutoff date</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of October 19, 2020,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> showed HMI-102 was generally well-tolerated, and there were no treatment-related serious adverse events. There were no clinically significant changes in electrocardiogram or vital signs, no clinical signs of complement activation and no adverse events related to bilirubin. Alanine aminotransferase, or ALT, elevations, which are common in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAV</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-based gene therapy trials, were asymptomatic and managed with increased steroids when necessary. Efficacy data showed significant plasma Phe reductions in Cohorts 2 and 3, compared to Cohort 1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (P&#60;0.004 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">post-hoc comparison using repeated measures MANOVA</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or multivariate analysis of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">variance,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regression analysis</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with two patients achieving target Phe levels per treatment guidelines, even while self-liberalizing diet</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compared to baseline, p</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atients in Cohorts 2 and 3 also displayed </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tyr increases and Phe-to-Tyr ratio decreases consistent with PAH enzymatic activity</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000013.jpg" title="" alt="" style="width:673px;height:294px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 10. Data from Cohort 1 (low-dose) as compared to data from Cohort 2 (mid-dose) and Cohort 3 (high-dose) in the dose-escalation phase of the pheNIX clinical trial as of the data cutoff date of October 19, 2020.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efficacy data from the two patients in Cohort 1 did not show any meaningful reductions in plasma Phe throughout the study, which they have completed. We believe this first and lowest dose in this dose-escalation study was insufficient to impact Phe levels. In Cohort 2, one patient experienced a marked Phe reduction from baseline level of 1,010 &#956;mol/L, and recorded five plasma Phe values &#60;360 &#956;mol/L, and many of &#60;600 &#956;mol/L. The mean percentage change from baseline for this patient are reported in three categories: Phe, Tyr, and the Phe-to-Tyr ratio. For patients with PKU, the goal for a therapy is to lower Phe values, increase Tyr values and lower the overall Phe-to-Tyr ratio. As of the cutoff date, this patient&#8217;s mean percentage change from baseline showed a 48.6% reduction in plasma Phe, an 81.1% increase in Tyr and a 70.8% decrease in the Phe-to-Tyr ratio. We believe these results are consistent with an increase in PAH enzymatic activity and increased Phe metabolism. These results were observed even while the patient self-liberalized diet, including a mean percent change from baseline of more than a 100% increase in dietary Phe intake. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The other patient in Cohort 2 did not experience a similar reduction in plasma Phe, but this patient had pre-existing immune conditions and experienced Grade 3 ALT elevation, which we believe may have affected the results. As of the cutoff date, this patient had a mean percentage change from baseline of 13% increase in plasma Phe, with a 131.1% increase in Tyr and a 45.5% decrease in the Phe-to-Tyr ratio. This also occurred while the patient self-liberalized diet with a mean percent change from baseline of 140.5% more dietary intact protein, 289% more dietary Phe intake and 75.6% decreased dietary Tyr intake. We believe the findings in this patient may be suggestive of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAH</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enzymatic activity sufficient to increase the patient&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tyr</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> concentration from its low baseline, but not sufficient to reduce this patient&#8217;s Phe.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000014.jpg" title="" alt="" style="width:682px;height:338px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 11. Data from patients 5 and 6 in Cohort 3 (high-dose) in the dose-escalation phase of the pheNIX clinical trial as of the data cutoff date of October 19, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Cohort 3, Patient 5 had pre-existing underlying immune conditions, which we believe impacted efficacy. As of the data cutoff date, Patient 5 experienced an increase in the mean percentage change from baseline in Tyr of 22.6% and a reduction in the mean percentage change from baseline in the Phe-to-Tyr ratio of 25.4%, but did not experience a similar reduction in plasma Phe. We believe the findings in this patient may also be suggestive of PAH enzymatic activity, which was enough to improve Tyr, but not enough to reduce Phe.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atient 6 showed a marked reduction in Phe from baseline level of 1,060 &#956;mol/L, and recorded one plasma Phe value &#60;360 &#956;mol/L and several plasma Phe values &#60;600 &#956;mol/L through the 13 weeks of observation as of the cutoff date. The mean percentage change from baseline was a 31.4% reduction in plasma Phe, a 40.3% increase in Tyr and a 52.4% decrease in the Phe-to-Tyr ratio. These results were observed while the patient self-liberalized diet, including a mean percent change from baseline of more than 45.4% increase in dietary intact protein and a 41.8% increase in dietary Phe. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This patient had the benefit of increased monitoring, which also allowed for tighter management of steroids, including additional steroids at the first observation of ALT increases</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000015.jpg" title="" alt="" style="width:678px;height:312px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 12. Summary data from the dose-escalation phase of the pheNIX clinical trial as of the data cutoff date of October 19, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the safety and efficacy results observed in the dose-escalation phase as of the cutoff date, in early 2021 we advanced to the randomized, concurrently controlled, expansion phase of the pheNIX trial, which has the potential to be converted to a registrational trial. We selected two doses for the expansion phase: 6E13 vg/kg and 8E13 vg/kg. We expect to share initial clinical data from this portion of the trial by the end of 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies with HMI-102</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential of an AAVHSC15-delivered <span style="font-style:italic;">PAH</span> gene was assessed in a well-established mouse model of PKU called the Pah<sup style="font-size:85%;line-height:120%;vertical-align:top">enu2</sup>, or ENU2, mouse. This model contains a mutation in the murine <span style="font-style:italic;">Pah</span> gene that results in abolished activity and elevated serum Phe levels. Baseline levels of serum Phe in these mice are approximately 1,500 micromoles per liter compared to normal levels of approximately 80 micromoles per liter, levels that are similar to those seen in classical PKU patients and normal controls, respectively. Single intravenous injections of HMI-102 into these PAH-deficient mice resulted in reductions of serum Phe to levels that are within the range for normal mice. As depicted in Figure 13, the reduction in serum Phe levels persisted for 48 weeks in treated mice on a normal protein diet, consistent with the lifespan of the model. In addition to a reduction in serum Phe, the administration of our gene therapy candidate also resulted in elevations of serum Tyr due to the restoration of the normal biochemical pathway.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000016.jpg" title="" alt="" style="width:682px;height:284px;" /></p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 13. A single injection of HMI-102 resulted in rapid and sustained reductions in serum Phe and increased Tyr levels in PAH-deficient mice that are on a regular diet. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A subsequent study was performed to further characterize the effect of HMI-102 on normalizing levels of Phe and neurotransmitter metabolism in the brain. As shown in Figure 14, a single administration of HMI-102 in the ENU2 mouse model reduced levels of Phe in the brain to normal levels as measured at 4 weeks post-dosing. Furthermore, the brain concentrations of 5-HIAA, a metabolite of serotonin, was increased to normal levels. These results indicate that HMI-102 administration directly impacts the metabolic pathway associated with loss of PAH.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000017.jpg" title="" alt="" style="width:360px;height:270px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 14. HMI-102 normalizes key neurological measures underscoring restoration of normal biochemical pathway.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Optimized </span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-103: Our Gene Editing Approach for PKU</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to address the pediatric PKU population, we are developing a gene editing candidate for PKU, optimized HMI-103, that is designed to replace defective <span style="font-style:italic;">PAH</span> genes with normal copies. The gene editing vector transgene is flanked by left and right homology arms, containing sequences that are identical and specific to the genomic target. The arms were designed to integrate by non-nuclease-based, AAV-mediated HR into the target human <span style="font-style:italic;">PAH</span> locus.<span style="font-size:12pt;"> </span>This therapy aims to correct the genetic defect within the treated liver cells then directing the expression of the PAH protein. HR-based integration via AAVHSCs is highly precise, without the introduction of insertions, deletions or viral ITRs. The corrected copy of the <span style="font-style:italic;">PAH</span> gene would be retained as cells divide into daughter cells as the liver grows. Screening for PKU of all newborns in the United States allows the identification of affected individuals before serious neurological complications develop. We believe our HR approach possesses the efficacy and durability characteristics that would be appropriate to treat PKU in newly identified patients. As we further develop our expertise in treating PKU by correcting the defective <span style="font-style:italic;">PAH</span> gene in the liver, we intend to develop treatments for other inborn errors of metabolism in the liver. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted <span style="font-style:italic;">in vivo</span> experiments showing the integration of a human <span style="font-style:italic;">PAH</span> cDNA into the human <span style="font-style:italic;">PAH</span> gene locus using a humanized liver mouse model. In this model, human hepatocytes constitute the majority of the liver cells, providing an <span style="font-style:italic;">in vivo</span> model to test human specific editing constructs. Injection of the human AAVHSC <span style="font-style:italic;">PAH</span> gene editing candidate in this model resulted in the insertion of a codon-optimized human <span style="font-style:italic;">PAH</span> cDNA into the human <span style="font-style:italic;">PAH</span> locus and mRNA expression of the <span style="font-style:italic;">PAH</span> cDNA. The <span style="font-style:italic;">in vivo</span> integration rate at the target locus, shown in Figure 15, was calculated at a frequency of 6%. This level of editing has been shown to be sufficient to normalize Phe levels in the murine model. A second assay was also performed on DNA that was specific for human and murine hepatocytes obtained from this study. The assay provides an orthogonal approach for characterizing the frequency of targeted integration and enables testing the species-selectivity of the targeted integration. The results of this assay showed integration only in the human hepatocytes and not in the murine hepatocytes, demonstrating selectivity for the human locus. Figure 16 below shows data following I.V. administration of the murine surrogate, or the murine version of HMI-103. The human construct is designed with human-specific homology arms, so a murine surrogate is necessary for testing in the PKU murine model. As depicted, we observed that PAH gene integration was durable out to 43 weeks (end of study) and resulted in marked and durable serum Phe reduction. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000018.jpg" title="" alt="" style="width:398px;height:282px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 15. Human-specific AAVHSC <span style="font-style:italic;">PAH</span> gene editing candidate resulted in a targeted integration rate of 6%, as measured by NGS in an <span style="font-style:italic;">in vivo</span> humanized liver murine model.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000019.jpg" title="" alt="" style="width:668px;height:226px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 16. I.V. administration of murine surrogate (with murine homology arms) of HMI-103 showed durable gene integration in Pah<sup style="font-size:85%;line-height:120%;vertical-align:top">enu2</sup> model of PKU.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fidelity of the integration of the cDNA into the target locus was evaluated by NGS and Nanopore sequencing. There were no <span style="font-style:italic;">de novo</span> mutations detected in either homology arm target site. We also evaluated the samples for the presence of ITRs. Viral ITRs are non-homologous sequences that lie beyond the extent of the recombination event and thus should not be integrated into the target site. The integrated alleles were free of ITR sequence, consistent with HR as the main mechanism for integration. Together, these data showed that the targeted integration of the human <span style="font-style:italic;">PAH</span> cDNA into the human <span style="font-style:italic;">PAH</span> locus displayed sequence fidelity with no evidence of mutations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these data, we nominated HMI-103 as a product development candidate consisting of an AAVHSC15 vector and an optimized <span style="font-style:italic;">PAH</span> gene construct with flanking homology arms. We continue to make progress on IND-enabling activities for the HMI-103 development program for the treatment of the pediatric PKU population and expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-103 in 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Product Opportunities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CNS Diseases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CNS programs are designed to take advantage of our AAVHSCs&#8217; natural ability to cross the blood-brain-barrier and blood-nerve-barrier in non-human primates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-203: Our Gene Therapy Approach for Hunter Syndrome</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have nominated a product development candidate, HMI-203, for the treatment of MPS II or Hunter syndrome, a rare, X-linked lysosomal storage disorder caused by mutations in the iduronate-2-sulfatase, or <span style="font-style:italic;">IDS,</span> gene, which is responsible for producing the I2S enzyme that breaks down large sugar molecules, or cellular waste, called glycosaminoglycans, or GAGs. Severe Hunter syndrome results in toxic lysosomal accumulation of GAGs that causes progressive debilitation and decline in intellectual function. Hunter syndrome occurs in approximately 1 in 100,000 to 1 in 170,000 males, and the severe form leads to life expectancy of 10 to 20 years.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard of care for treating Hunter syndrome is enzyme replacement therapy, or ERT, which can delay some complications but does not treat CNS manifestations of Hunter syndrome since the enzyme cannot cross the blood-brain-barrier. In 2006, the recombinant form of human I2S (Elaprase), an ERT for the treatment of Hunter syndrome was approved by the FDA and subsequently approved for use internationally, and in January 2021, the recombinant form of idursulfase-beta (Hunterase), an ERT for the treatment of Hunter syndrome received manufacturing and marketing approval in Japan. However, specific treatment to address the neurological manifestations of Hunter syndrome and prevent or stabilize cognitive decline remains a significant unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development candidate HMI-203 is a potential one-time AAVHSC treatment designed to deliver functional copies of the <span style="font-style:italic;">IDS</span> gene to multiple target organs, including the PNS and CNS, following a single I.V. administration. We have initiated pivotal IND-enabling studies and scaled manufacturing of HMI-203 up to 500L by leveraging our commercial manufacturing platform. We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-203 in 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, a single I.V. administration of HMI-203 l</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed to robust biodistribution and sustained human I2S (hI2S) enzyme expression, which resulted i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ignificant reductions in key Hunter syndrome biomarkers of hepar</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n sulfate GAGs and lysosomal-associated membrane protein 1 (LAMP-1) in the brain, liver, heart, spleen, lung and kidneys compared with vehicle.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant reductions in heparan sulfate GAGs in the cerebrospinal fluid (CSF) compared with vehicle</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were also observed, as well as a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meliorated paw deformities, as shown by significant changes in measurements of ankle depth, paw width, paw depth and ankle width compared with vehicle.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Finally, HMI-203 administration l</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed to uptake of hI2S from the serum of the HMI-203-treated model in human cell lines, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which demonstrated</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential for cell cross-correction</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">presented</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at WORLD</span><span style="font-style:italic;">Symposium</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8482; in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 20</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Figure 17 below.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000020.jpg" title="" alt="" style="width:678px;height:354px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 17. Single IV administration of HMI-203 demonstrated systemic expression, reduction of GAGs, and correction of phenotype in murine model.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-202: Our Gene Therapy Approach for MLD</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed IND-enabling studies with HMI-202, our product development candidate for MLD, and we are using these data to further optimize an HMI-202 vector that we believe may lead to a better therapeutic profile. MLD is a lysosomal storage disease caused by mutation of a gene called arylsulfatase A, or <span style="font-style:italic;">ARSA</span>. The protein ARSA is required for the breakdown of cellular metabolic products that in MLD accumulate in all cells of the body. Cells responsible for the production of myelin are especially sensitive to the toxic build-up of these cellular metabolic products, leading to progressive serious neurological deterioration. The late infantile form of MLD, which is the most common form, includes rapidly progressive motor and cognitive decline and loss of vision. The majority of these patients do not survive past the first decade of life. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, stem cell transplants are currently the only effective treatment for MLD, but have significant drawbacks, including the use of immunosuppression therapy, delayed onset of ARSA expression post-engraftment, conditioning regimens, and the risk of death from the stem cell transplant. In Europe, Libmeldy (autologous CD34+ cells encoding the ARSA gene), a lentiviral vector-based gene therapy for the treatment of MLD, became the first therapy approved for eligible patients with early-onset MLD in December 2020 following receipt of full (standard) market authorization by the European Commission.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have generated preclinical data showing that a single intravenous dose of HMI-202 crossed the blood-brain-barrier and blood-nerve-barrier in a murine model and NHPs, shown in Figure 18, and had broad tissue tropism in physiologically relevant regions of the CNS and PNS, resulting in increased human ARSA enzyme activity to levels well above the therapeutic threshold when compared to average adult human enzyme activity. It is believed that levels of enzyme activity of 10 to 15% of normal could potentially be curative, based on human data from healthy subjects with enzyme activity levels in this range. These data were presented at WORLD<span style="font-style:italic;">Symposium</span>&#8482; in February 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000021.jpg" title="" alt="" style="width:682px;height:198px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 18. Single IV administration of HMI-202 crossed blood-brain-barrier and resulted in broad tissue tropism and therapeutically relevant levels of ARSA activity in the CNS of treated non-human primates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Single IV administration of HMI-202 in the murine <span style="font-style:italic;">Arsa</span> knockout model resulted in a reduction of LAMP-1 accumulation in the spinal cord and a reduction of sulfatide in the brain, both at 52 weeks post-dose (refer to Figure 19 below). </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000022.jpg" title="" alt="" style="width:680px;height:194px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 19. Single IV administration of HMI-202 resulted in reduction of LAMP-1 accumulation (52 weeks post-treatment) and reduction in sulfatide accumulation (52 weeks post-treatment) in murine model. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other CNS Diseases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our gene therapy technology has the potential to address other CNS diseases, including Friedreich&#8217;s ataxia or FA. In FA, mutations in a gene called frataxin, or FXN, lead to progressive deterioration of the spinal cord leading to difficulty walking and eventual complete incapacitation and shortened lifespan. Other CNS diseases include Charcot-Marie-Tooth disease, or CMT,<span style="font-size:12pt;"> </span>a group of disorders that affect the peripheral nerves, the nerves running from outside the brain and spine. The primary clinical features of this disease are slowly progressive distal weakness, muscle atrophy affecting the feet and legs and sensory loss. We also believe our gene therapy technology capable of confronting frontotemporal disorders, or forms of dementia caused by a family of brain diseases known as frontotemporal lobar degeneration. Dementia is a severe loss of thinking abilities that interferes with a person&#8217;s ability to perform daily activities such as working, driving, and preparing meals. Finally, in addition to Hunter syndrome, for which we are currently advancing product development candidate HMI-203, our technology has the potential to address other lysosomal storage disorders.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Liver Diseases and Therapeutics</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to pursue the liver as a target organ given the high tropism of our AAVHSCs and the initial clinical data we have collected via our pheNIX Phase 1/2 gene therapy trial for PKU. We are pursuing potential treatments that target the liver&#8217;s ability to secrete proteins into the serum. We believe that by targeting the liver with genetic medicines that act via gene therapy or gene editing, there is the potential to provide long-lasting secretion of proteins. We plan to name a development program in this therapeutic area in 2021.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hemoglobinopathies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also pursuing treatment of diseases that affect blood cells such as sickle cell disease and beta thalassemia using our AAVHSC vector HR technology. We believe that our potential ability to correct the defective beta globin gene in blood precursor cells may lead to long-term functional cures for affected patients. Sickle cell disease affects over 100,000 individuals and beta thalassemia over 1,000 individuals in the United States.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ophthalmological Diseases </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of serious, but rare diseases of the eye such as Leber&#8217;s congenital amaurosis and Choroideremia, as well as more common diseases such as macular degeneration, have been targeted using gene therapy approaches by academic groups as well as the pharmaceutical industry. We evaluated the ability of our AAVHSCs to transduce retinal cells following subretinal injection in preclinical studies in mice. Expression of green fluorescent protein, or GFP, was seen in all layers of the retina including the retinal pigment epithelium, photoreceptors and the outer nuclear layer, and the AAVHSC subretinal treatment was well-tolerated. In addition, we evaluated the ability of AAVHSC17 to transduce retinal cells in a larger animal model, a mini-pig, and observed significant transduction of all layers of the retina supporting translation across two species. We believe these studies suggest that our AAVHSCs have the potential to be useful as therapeutic vectors for treating retinal diseases in humans based on significant tropism to these target cells. We believe that these vectors have the potential to deliver long-lasting therapeutic benefit to patients that may eliminate the need for the regular and burdensome intravitreal injections that are required for many current treatments.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company committed to curing diseases, the ability to deliver our novel therapeutic vectors to patients is critical. Therefore, we have built strong internal scientific AAV process development and manufacturing capabilities and we have invested in a GMP manufacturing facility to support our clinical development programs. We have established a commercial manufacturing platform and process that supports both gene therapy and gene editing, which is scalable from preclinical to GMP. We view the development of internal manufacturing capacity and expertise as a key competitive advantage as it allows for better control over process development timelines, costs, product quality and intellectual property, and allows us to master our unique technology. Our process development and manufacturing teams are composed of industry veterans in the field of AAV and protein technologies, as well as experts in our novel AAVHSCs, with experience in both early development and commercialization of therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our process development and manufacturing strategy leverages a single platform for both gene therapy and gene editing that is scalable and facilitates rapid development to the clinic. We are executing all development and process steps internally. Our development focus includes design and engineering of plasmid constructs, cell culture, transfection, purification, formulation and analytical development. We leverage our manufacturing platform across our entire pipeline, from our research programs, to our preclinical programs and now to our clinical programs. Our platform was designed from its inception to be our commercial process, allowing us to rapidly transition from research into the clinic and eventually to commercialization.<span style="font-size:12pt;"> </span>Our manufacturing platform has been scaled and tested across more than 450 different constructs with more than 550 unique lots of vector successfully executed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our manufacturing strategy utilizes mammalian cells for our AAVHSC vector-based product candidates. All of our programs, including HMI-102 for PKU, utilize HEK293 transfection in a serum-free suspension bioreactor process. HEK293 is a well-characterized and commonly used system for many clinical-stage AAV vector products. Additionally, HEK293 cells are familiar to regulatory authorities, and commercial raw materials and reagents are readily available. Our purification leverages chromatography-based operations to provide high quality vector and ensure robust commercial-scale operations. In addition to our process development, we also internally developed 45 analytical methods to test, monitor, and characterize our products. Expertise and learnings will be leveraged across gene therapy and gene editing programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a relationship with a contract manufacturing organization, or CMO, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has expertise in the use of HEK293 gene therapy manufacturing so that we have an external manufacturing process alongside our internal GMP manufacturing capability to supply material for our Phase 1/2 pheNIX clinical trial</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as well as our upcoming additional clinical trials</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For gene editing manufacturing, our strategy is to internally control the process development and manufacturing to safeguard the proprietary nature of our technology, and to continue to master all aspects of this technology. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To support clinical expansion, we have constructed a 25,000 square foot GMP manufacturing facility that accommodates both our gene therapy and gene editing pipeline programs. We are currently operating three 500-liter bioreactors and have successfully produced GMP material at the 500-liter scale for multiple pipeline candidates.<span style="font-size:12pt;"> </span>Additionally, we have scaled up our manufacturing platform to a 2,000-liter bioreactor scale, which will give us the ability to produce large scale volumes and support our growing pipeline. Our manufacturing model leverages single use, disposable, closed system operations aligned to the unique characteristics of gene therapy technology to ensure flexibility, robust quality and cost effectiveness. Our internal operations also include quality control labs to facilitate product quality testing and stability.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including in the gene therapy and gene editing fields, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. Not only must we compete with other companies that are focused on gene therapy and/or gene editing technologies, any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We compete in the segments of the pharmaceutical, biotechnology and other related markets that utilize technologies encompassing genomic medicines to create therapies, including gene therapy and gene editing. There are additional companies that are working to develop therapies in areas related to our research programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform and product focus is the development of genetic medicines using our proprietary AAVHSCs <span style="font-style:italic;">in vivo</span> either through the gene therapy or nuclease-free gene editing modality. If our current programs are approved for the indications for which we are currently planning clinical trials, they may compete with other products currently under development, including gene therapy and gene editing products or other types of therapies, such as small molecule, antibody or protein therapies. If our PKU treatments are approved, they may compete with therapies from American Gene Technologies, BioMarin, Generation Bio, Moderna, Nestl&#233; Health Science, PTC Therapeutics, Sangamo Therapeutics and Synlogic. However, we believe that only gene therapy or gene editing approaches have the potential to restore the normal Phe biochemical pathway with a single administration. As such, the major competition in this space may be limited to American Gene Technologies, BioMarin and Sangamo Therapeutics, all of which are behind our development program according to public filings. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of companies developing nuclease-based gene editing technologies using CRISPR/Cas9, TALENs, meganucleases, Mega-TALs and ZFNs, including Beam Therapeutics, bluebird bio, Caribou Biosciences, Cellectis, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences and Sangamo Therapeutics and non-nuclease-based technology, including LogicBio Therapeutics.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our Hunter syndrome treatment is approved, it may compete with investigational product candidates from Avrobio, Denali Therapeutics and REGENXBIO, as well as ERTs from Takeda and/or GC Pharma. However, we believe that only a gene editing approach has the potential to address the neurological manifestations of Hunter syndrome and prevent or stabilize cognitive decline.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our MLD treatment is approved, it may compete with therapies from Orchard Therapeutics and/or Takeda. We believe that our <span style="font-style:italic;">in vivo</span> gene therapy approach for MLD could be used early in the disease progression with the potential for earlier protein expression, offering advantages over Orchard&#8217;s <span style="font-style:italic;">ex vivo</span> approach, as well as advantages over chronic, intrathecal ERTs, such as Takeda&#8217;s approach. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in even more resources being concentrated among a smaller number of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our programs are likely to be their efficacy, safety, convenience and availability of reimbursement. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we rely upon a combination of patents and trade secret protection, as well as license and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product development candidates. Our success depends in large part on our ability to secure and maintain patent protection in the United States and other countries with respect to HMI-102 and any future product development candidates. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. If, therefore, we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained or in-licensed is not sufficiently broad or if the validity of such patent is threatened, we may not be able to compete effectively in our markets, as it could create opportunities for competitors to enter the market or dissuade other companies from collaborating with us to develop products and technology, any of which would hurt our competitive position and could impair our ability to successfully commercialize our product development candidates in any indication for which they are approved. For more information regarding these competitive risks, see Item 1A. &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part upon our ability to secure and maintain proprietary protection for our technologies and products and to operate without infringing the proprietary rights of others. Our policy is to protect our proprietary position by, among other methods, filing, or collaborating with our licensors to file, U.S. and foreign patent applications related to our proprietary technology, inventions, and improvements and trademarks that are important to the development and implementation of our business. We require employees who are inventors on any company-owned patent applications to assign the rights to us. Also, we use other forms of protection, particularly where we do not believe patent protection is appropriate or obtainable.<span style="font-size:12pt;"> </span>We rely on trade secrets, technical know-how, and continuing innovation to develop and maintain our competitive advantage. In addition, we rely on confidentiality agreements with our employees, consultants, and other advisors to protect our proprietary information. Our policy is to require third parties that receive material confidential information to enter into confidentiality agreements with us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio includes a combination of issued patents and pending patent applications that are licensed from third parties. As of December 31, 2020, we have an exclusive license or co-exclusive license under 16 United States issued patents, two European patents and 35 patent applications, pending in the United States and internationally. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For any individual patent, the term depends on the applicable law in the country in which the patent is granted. In most countries where we have filed patent applications or in-licensed patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed non-provisional priority date. In the United States, the patent term is 20 years but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may also be lengthened by a patent term adjustment, in order to address administrative delays by the United States Patent and Trademark Office in granting a patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the term of a patent that covers an FDA-approved drug or biologic may be eligible for patent term extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the natural expiration of the patent. The patent term restoration period is generally equal to the regulatory review period for the approved product which period occurs after the date the patent issued, subject to certain exceptions. Only one patent may be extended for a regulatory review period for any product, and the application for the extension must be submitted prior to the expiration of the patent. In the future, we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant Biologics License Application, or BLA. Similarly, certain foreign jurisdictions also have mechanisms for extending patent term and, to the extent we have granted patents that are eligible, we may decide to apply for patent term extensions in those jurisdictions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Patent Term Restoration and Marketing Exclusivity </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally equal to the regulatory review period for the approved product which period occurs after the date the patent issued, subject to certain exceptions. Only one patent may be extended for a regulatory review period for any product, and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For patents that might expire during the BLA review phase, the patent owner may request an interim patent term extension. If eligible, an interim patent term extension may be granted for a period of not more than one year. The patent owner may apply for not more than four subsequent interim extensions. Any interim extension granted will not be longer than the maximum period of extension allowed post-approval.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Licensed Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our issued patents and pending patent applications are exclusively licensed to us in all fields of use from COH. Certain of our issued patents and pending patent applications are co-exclusively licensed to us in all human therapeutic applications with and from the California Institute of Technology, or Caltech. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The City of Hope Portfolio </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we exclusively licensed two families of patents and patent applications directed to novel AAV capsids and their manufacture and methods of use, including their use in genome editing from COH. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These two families of patents and patent applications together include eleven granted patents in the United States, two foreign granted patents, and 14 pending applications in the United States, Europe, Canada, Australia and other selected countries in Latin America and Asia. The first family of issued patents and patent applications is material to HMI-102 and relates to our novel AAV vectors and their use in cellular transduction. The eight issued U.S. patents in this family are expected to expire in 2031 and may be extended by up to five years in the United States via patent term extension depending on the regulatory pathway of the products covered by such patents. The second family includes two issued U.S. patents relating to our AAV vectors and their use in genome editing. The issued patents in this family are expected to expire in 2035 and may be extended by up to five years in the United States and in certain other countries via patent term extension depending on the regulatory pathway of the products covered by such patents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The Caltech Portfolio </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2016, we co-exclusively licensed, with another commercial third party, two families of patents and patent applications directed to novel AAV capsids and vectors that demonstrate enhanced blood-brain-barrier penetration for the potential treatment of CNS diseases from Caltech. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These families of patents and patent applications include five granted patents in the United States, one granted patent in Europe, one granted patent in South Africa, and 21 pending applications in the United States, Europe, Canada, Australia and other selected countries in Latin America and Asia. The five issued U.S. patents relate to novel AAV capsids and vectors and are expected to expire in 2034. Certain other patent applications directed to novel AAV capsids and vectors, if they were to issue, may have later expirations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trademarks </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks Homology Medicines, HMI, the H logo, and AMENDR, are pending or registered in the United States and certain international countries. We currently own one registered trademark and four pending trademark applications in the United States, 17 registered trademarks around the world, and five pending foreign trademark applications. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Strategic Collaborations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement with the Novartis Institutes for BioMedical Research, Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, we entered into a collaboration and license agreement with Novartis, pursuant to which we agreed to collaborate on researching, developing, and commercializing novel genome editing products that modulate certain gene targets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we and Novartis agreed to collaborate to identify and synthesize gene editing vector candidates that modulate certain ophthalmic gene targets, against which Novartis agreed to develop licensed products. Our obligation to perform research for the targets was to continue for five years from the effective date of the agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Novartis agreed also to collaborate to explore the applicability of our technology with respect to other gene targets. Our obligation to perform such exploratory research was extended pursuant to an amendment to the collaboration agreement and was set to conclude in May 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, Novartis confirmed an ophthalmic target for a therapeutic editing program. Additionally, in accordance with the terms of the Collaboration Agreement, Novartis&#8217; right to substitute other ophthalmic targets expired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to certain limitations pursuant to the terms of the agreement, Novartis was responsible for the internal and external costs incurred by us for the research activities as contemplated under the agreement. Novartis also agreed to pay for the development of gene editing vector candidates and licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the agreement, we were responsible for manufacturing gene editing vector candidates for certain ophthalmic gene targets for research, and gene editing vector candidates and licensed products for development and commercialization, and Novartis agreed to bear all such manufacturing costs that we incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the agreement, taking into account Novartis&#8217; election to discontinue our collaboration on the sickle cell disease program, we had granted Novartis the following licenses: (i)&#160;a worldwide, non-exclusive, sublicensable license under certain of our intellectual property rights to perform Novartis&#8217; responsibilities under the applicable research plan&#59; (ii)&#160;a worldwide, sublicensable license under certain of our intellectual property rights to conduct preclinical development activities, which license is co-exclusive (with us) during the research term, and exclusive for the remainder of the term of the agreement&#59; (iii)&#160;a worldwide, non-exclusive, perpetual, irrevocable license, without the right to grant sublicenses, to use certain reagents generated as a result of our exploratory research activities under the agreement solely for Novartis&#8217; internal research purposes&#59; (iv)&#160;an exclusive, royalty-bearing, sublicensable license under certain of our intellectual property rights to develop and commercialize certain gene editing vector candidates and licensed products directed to certain ophthalmic gene targets&#59; (v)&#160;as of the effective date, a co-exclusive (with us), royalty-bearing, sublicensable, worldwide license under certain of our intellectual property rights to manufacture certain gene editing vector candidates and/or licensed products directed to certain ophthalmic gene targets, which license will be exclusive as of a certain date on which Novartis is permitted to manufacture certain gene editing vector candidates and/or licensed products pursuant to the terms of the agreement&#59; and (vi)&#160;a non-exclusive, royalty-free, fully paid, perpetual, irrevocable, worldwide license under certain of our intellectual property rights in connection with research, development, manufacturing, commercialization or other exploitation of products or services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the agreement, Novartis granted to us the following licenses: (i)&#160;a worldwide, non-exclusive, sublicensable license under certain of Novartis&#8217; intellectual property rights to perform certain research activities during the research term and (ii)&#160;a non-exclusive, royalty-bearing, perpetual, irrevocable, worldwide, sublicensable license under certain of Novartis&#8217; intellectual property rights that may arise under the agreement that relate to our manufacturing know-how for our manufacture of gene editing vector candidates and products created using our platform technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, we received an upfront payment of $35.0&#160;million and Novartis also purchased shares of our Series B preferred stock for an aggregate purchase price of $15.0&#160;million. Taking into consideration Novartis&#8217; election to discontinue our collaboration on the sickle cell disease program<span style="font-size:12pt;"> </span>and the expiration of Novartis&#8217; rights to make substitutions of an ophthalmic target, we were also eligible to receive up to a total of $5.0&#160;million upon completion of certain development candidate selection activities. In addition, we were eligible to receive up to a total of $265.0&#160;million in milestone payments, including up to $90.0 million in development milestone payments, up to $85.0 million in regulatory milestone payments and up to $90.0 million in commercial milestone payments, with respect to the licensed products. We were also eligible to earn tiered royalties on net sales of licensed products by Novartis, its affiliates or sublicensees ranging from mid-single-digit to sub-teen double-digit percentages, which royalties were potentially subject to various reductions and offsets. If any of the exploratory research efforts were advanced into formal research and development programs, the parties agreed to negotiate the economics, including potential milestone payments for such programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the agreement continues on a target-by-target basis until the expiration of all royalty payment obligations for the licensed products that modulate the applicable target on a country-by-country basis. Our royalty obligations under the agreement continue on a country-by-country and licensed product-by-licensed product basis until the later of (a)&#160;10&#160;years after the first commercial sale of such licensed product in a country, (b)&#160;the date on which such licensed product is no longer covered by certain intellectual property rights, and (c)&#160;the date on which certain regulatory exclusivity for such product expires. Either party may terminate the agreement on a target-by-target basis for the other party&#8217;s material breach with respect to such target, or in the event of the other party&#8217;s bankruptcy. Novartis may terminate the agreement for convenience on a target-by-target basis. We may terminate the agreement if Novartis files, or joins a third party in filing or maintaining, a patent challenge against certain of the patent rights we license to Novartis under the terms of the agreement. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 26, 2021, we received notice from Novartis that they had elected to terminate the agreement with respect to the ophthalmic target, which was the only remaining target under the agreement. Accordingly, the notice served as notice of Novartis&#8217; termination of the agreement in its entirety, with an effective date of August 26, 2021, which is six months from the date of the notice. Novartis has agreed to work with us to effect the orderly wind down of activities in accordance with the agreement. As a result of this notice, we have regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize our proprietary nuclease-free gene editing technology platform for the ophthalmic target. We plan to continue to advance the program toward naming a development candidate. The companies believe that results of studies conducted under the agreement provide early proof-of-principle and support a nuclease-independent approach to editing of relevant cell types in the eye after sub-retinal injection, and are the subject of a planned presentation at an upcoming scientific meeting.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License Agreement with the California Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2016, we entered into a license agreement with Caltech, pursuant to which Caltech granted us a co-exclusive (subject to certain reserved non-commercial rights), sublicensable, and worldwide license under certain AAV-related patents owned by Caltech for human therapeutic applications. Under this agreement, Caltech also granted us a non-exclusive, worldwide license under certain patents and other intellectual property controlled by Caltech to develop, manufacture, commercialize, and otherwise exploit products covered by such intellectual property rights for human therapeutic applications. We may grant sublicenses under the non-exclusive license to third parties to the extent necessary or useful for our, or our sublicensees&#8217;, development, manufacturing, or sale of such products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Caltech agreement, we paid Caltech an initial licensing fee of $100,000. We are also required to pay Caltech up to a total of $7.2&#160;million in milestone payments for the first licensed product&#59; royalties, in the low single-digit percentages on net sales of licensed products, subject to a certain annual minimum royalty&#59; and mid to high single-digit percentages of sublicensing revenues.&#160;Subject to certain exceptions, our royalty obligations under the agreement continue on a country-by-country and licensed product-by-licensed product basis until the earliest of (a)&#160;the date on which such licensed product is no longer covered by certain intellectual property rights, (b)&#160;10&#160;years after the first commercial sale of such licensed product, or (c)&#160;15 years after the effective date of the agreement. As partial consideration for the licenses granted under the agreement, we issued 101,405 shares of our common stock to Caltech. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement will expire upon the expiration of the last-to-expire patent that is licensed to us or as long as royalties are due under the agreement, whichever is later. We agreed to use commercially reasonable efforts to introduce commercially, and reasonably fulfill market demand for, licensed products as soon as practicable. Either party may terminate the agreement in the event of the other party&#8217;s uncured material breach and in the event of the other party&#8217;s bankruptcy or insolvency. We may terminate the agreement for convenience. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">City of Hope License Agreement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we entered into a license agreement with COH, pursuant to which COH granted us an exclusive, sublicensable, worldwide license to certain AAV vector-related patents and know-how owned by COH to develop, manufacture, use and commercialize products and services covered by such patents and know-how in any and all fields. COH also granted us a non-exclusive, sublicensable, worldwide license to certain background patents owned by COH to develop, manufacture, use and commercialize licensed products and licensed services in any and all fields. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, we paid COH an initial licensing fee of $75,000, and made a subsequent payment of $4.5&#160;million representing a percentage of sublicensing revenue. We are also required to pay COH an annual license maintenance fee&#59; up to a total of $3.2&#160;million in potential milestone fees&#59; a royalty in the low single-digit percentages on net sales of licensed products or services, subject to certain reductions in certain circumstances, with a certain annual minimum royalty&#59; and low double-digit percentages of sublicensing revenues. As partial consideration for the licenses granted under the agreement, we issued 154,837 shares of our common stock to COH. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COH agreement will expire on a&#160;country-by-country&#160;and on a licensed patent-by-licensed patent basis upon the expiration of the last-to-expire valid claim of such patent in such country. We agreed to use commercially reasonable efforts to develop and commercialize licensed products and licensed services. If we fail to achieve certain diligence milestones, COH may terminate the agreement or convert the exclusive rights under the agreement from exclusive to non-exclusive. Either party may terminate the agreement in the event of the other party&#8217;s material breach, subject to an opportunity to cure, and in the event of the other party&#8217;s bankruptcy or insolvency. We may terminate the agreement for convenience. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governmental authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing, post-approval monitoring and reporting and export and import of products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, are extensive and require the expenditure of substantial time and financial resources. For the purposes of this Section, the term &#8220;gene therapy&#8221; includes both traditional gene therapy products as well as gene editing and our gene integration product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA Approval Process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our future product candidates to be regulated as biologics. Biological products, including gene therapy products, are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FDCA and the PHS Act and their corresponding regulations govern, among other things, the research, development, safety, testing, packaging, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biological products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.<span style="font-size:1pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biological Products Development Process </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA determined that more than minimally manipulated products must be approved by the FDA through the BLA process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of extensive nonclinical, sometimes referred to as preclinical laboratory tests, and preclinical animal trials and applicable requirements for the humane use of laboratory animals and formulation studies in accordance with applicable regulations, including good laboratory practices, or GLP, requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to good clinical practice, or GCP, requirements and any additional requirements needed for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">preparation and submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of an FDA Advisory Committee review, if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with GMP to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential FDA audit of the nonclinical and clinical study sites that generated the data in support of the BLA&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval, or licensure, of the BLA. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including a gene therapy product candidate, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical study sponsor must submit the results of the preclinical tests, together with manufacturing and controls, information about product chemistry, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug to humans. Some preclinical testing, such as reproductive toxicity tests and carcinogenicity in animals, may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, after which human clinical trials may begin unless the FDA places the clinical study on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the IND submission process, under the National Institutes of Health, or NIH, Guidelines for Research Involving Recombinant DNA Molecules, or the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria, the efficacy measurements to be evaluated and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical study must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical study subject or his or her legal representative and must monitor the clinical study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or a data monitoring committee, which provides guidance for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase I.&#160;&#160;&#160;&#160;The biological product candidate is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase II.&#160;&#160;&#160;&#160;The biological product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Phase III.&#160;&#160;&#160;&#160;The biological product candidate is further evaluated for dosage, clinical efficacy, potency, and safety in an expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may also be made a condition to approval of the BLA.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or <span style="font-style:italic;">in vitro</span> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase I, Phase II and Phase III clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or permanently discontinue a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or the clinical study is not being conducted in accordance with FDA regulations. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product candidate has been associated with unexpected serious harm to patients. The FDA and the IRB may also halt, terminate or impose other conditions if either believes the patients are subject to unacceptable risk. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the physical characteristics of the biological product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product candidate, FDA approval of a BLA must be obtained before commercial marketing and distribution of the biological product. The BLA must include results of product development, laboratory and animal trials, human trials, information on the manufacture, pharmacology, chemistry and controls of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for marketed products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first human drug application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews the submitted BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. Under PDUFA, the FDA has agreed to certain performance goals to complete the review of BLAs. For example, the FDA may give a priority review to BLAs submitted for biological products that are designed to treat a serious or life-threatening disease or condition, and if approved, would offer a significant improvement in safety or efficacy compared to marketed products. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for original BLAs, which typically adds approximately two months to the timeline for review and decision from the date of submission. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, or effective, for its intended use, and whether the product is being manufactured in accordance with GMP requirements to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To assure GMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates a BLA, conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced and conducts inspections at select clinical sites, the FDA may issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its potential risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The requirement for a REMS can materially affect the potential market and profitability of the product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. The FDA may require one or more Phase IV post-market studies or surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and marketing the drug or biologic for this type of disease or condition will be recovered from its sales in the United States. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and BLA user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application, including a full BLA, to market the same drug or biologic for the same </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indication for a period of seven&#160;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan-designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product for seven years if a competitor obtains approval of the same biological product as defined by the FDA or if </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rare Pediatric Disease Priority Review Voucher Program</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.28%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents&#59; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until September 30, 2024. Consequently, sponsors of marketing applications approved after that date will not receive the voucher unless Congress reauthorizes the Rare Pediatric Disease Priority Review Voucher program before that time. However, even if the program is not reauthorized, if a drug candidate receives Rare Pediatric Disease Designation before October 1, 2024, the sponsor of the marketing application for such drug will be eligible to receive a voucher if the application for the designated drug is approved by the FDA before October 1, 2026.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a Fast Track product at any time during the clinical development of the product. The FDA must determine if the biologic product candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor&#8217;s request. With regard to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receiving</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accelerated approval perform adequate and well-controlled post-marketing Phase IV clinical studies</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to verify the predicted clinical benefit</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Failure to conduct required post-approval trials, or to confirm a clinical benefit during such post-marketing trials, will allow the FDA to withdraw the approved biologic product from the market on an expedited basis. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the provisions of FDASIA, enacted in 2012, the FDA established a Breakthrough Therapy Designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or conditions. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track designation, as well as more intensive FDA interaction and guidance. The Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same product candidate if the relevant criteria are met. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover In 2017, the FDA established the Regenerative Medicine Advanced Therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. An investigational drug is eligible for RMAT designation if: (1) it meets the definition of a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions&#59; (2) it is intended to treat, modify, reverse, or cure a serious disease or condition&#59; and (3) preliminary clinical evidence indicates that the investigational drug has the potential to address unmet medical needs for such disease or condition. In a February 2019 final guidance, the FDA also stated that certain gene therapies that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review of BLAs and priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval if the relevant statutory conditions are met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, priority review, RMAT designation and Breakthrough Therapy designation do not change the standards for approval but may expedite the development or approval process. Even if we receive one or both of these designations for our product candidates, the FDA may later decide that our product candidates no longer meet the conditions for qualification. In addition, receiving these designations may not provide us with a material commercial advantage. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP requirements,<span style="font-size:12pt;"> </span>record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To help reduce the increased risk of the introduction of adventitious agents, the PHS Act emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHS Act also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA remains subject to significant uncertainty. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims and physician and other healthcare provider payment transparency laws and regulations. If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, exclusion from participation in federal and state healthcare programs and individual imprisonment.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing reimbursements for medical products, drugs and services. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, President Obama signed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the Affordable Care Act, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The Affordable Care Act contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the Affordable Care Act: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">required collection of rebates for drugs paid by Medicaid managed care organizations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70&#160;percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the Affordable Care Act. The U.S. Supreme Court is currently reviewing the constitutionality of the Affordable Care Act in its entirety. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year,<span style="font-size:12pt;"> </span>which was temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Privacy and Security Laws</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, and regulations promulgated thereunder, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition, certain state and non-U.S. laws, such as the California Consumer Privacy Act, or CCPA, the California Privacy Rights Act, or CPRA, and the General Data Protection Regulation, or GDPR, govern the privacy and security of personal data, including health-related data in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation Outside of the United States </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, ethical, social and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. The requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain countries outside of the United States have a similar process that requires the submission of a clinical study application, or CTA, much like the IND prior to the commencement of human clinical studies. In the European Union, or EU, for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant member state(s), in accordance with a country&#8217;s requirements, clinical study development may proceed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products, or ATMPs. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive opinion from an independent ethics committee. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, CTAs must be submitted to the competent authority in each EU member state in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect by early 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement. Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and European Union-wide regulatory requirements may also apply.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a medicinal product, the EMA and national regulators provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Scientific Advice Working Party of the Committee for Medicinal Products for Human Use, or CHMP. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical trials, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future marketing authorization application of the product concerned.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorizations</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, medicinal products can only be placed on the market after obtaining a Marketing Authorization, or MA. To obtain regulatory approval of an investigational biological product in the EU, we must submit a marketing authorization application, or MAA. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements. The process for doing this depends, among other things, on the nature of the medicinal product.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure results in a single MA, issued by the European Commission, based on the opinion of the EMA&#8217;s CHMP, which is valid across the entire territory of the EU. The centralized procedure is compulsory for human medicines that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii) designated orphan medicines and (iv) advanced therapy medicinal products, or ATMPs, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. It is very likely that the centralized procedure would apply to the products we are developing. National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this national MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the national competent authority of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Committee for Advanced Therapies, or CAT, is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CAT is primarily responsible for the scientific evaluation of ATMPs and prepares a draft opinion on the quality, safety and efficacy of each ATMP for which a MAA is submitted. The CAT&#8217;s opinion is then considered by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs&#59; the manufacturing and control information that should be submitted in a marketing authorization application&#59; and post-approval measures required to monitor patients and evaluate the long term efficacy and potenti</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al adverse reactions of ATMPs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the maximum timeframe for the evaluation of a MAA by the EMA is 210 days. This excludes so-called clock stops, during which additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. At the end of the review period, the CHMP provides an opinion to the European Commission. If this opinion is favorable, the Commission may then adopt a decision to grant an MA. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to optimize their product development plans and speed up their evaluation to help them reach patients earlier. Product developers that benefit from PRIME designation can expect to be eligible for accelerated assessment, but this is however not guaranteed. The benefits of a PRIME designation include the appointment of a CHMP rapporteur before submission of a <span style="font-size:12pt;">MAA</span>, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review earlier in the application process. PRIME designation do not however change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data and Marketing Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving a MA, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity. There is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the European Union. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Medicinal Products</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition&#59; (2)&#160;either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. The application for orphan drug designation must be submitted before the MAA. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of an MA, entitled to ten years of market exclusivity for the approved therapeutic indication. During the ten-year market exclusivity period, the EMA cannot accept a MAA, or grant a MA, or accept an application to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extend a MA, for the same indication, in respect of a similar medicinal product. An orphan medicinal product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an MA</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be granted to a similar product for the same indication at any time if</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (1) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the applicant consents to a second orphan medicinal product application&#59; or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the applicant cannot supply enough orphan medicinal product. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Development</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which an MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all Member States and study results are included in the product information, even when negative, the product is eligible for a six-months supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity is granted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the member states. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The advertising and promotion of medicinal products is also subject to laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each member state and can differ from one country to another. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland. With respect to the United Kingdom, following its exit from the European Union on January 31, 2020, the transition period, during which EU pharmaceutical laws continued to apply to the United Kingdom, has expired on December 31, 2020. However, the EU and the United Kingdom have concluded a trade and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cooperation agreement, or TCA, which is provisionally applicable since January 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of Good Manufacturing Practice, or GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 205 full-time employees, including 42 employees with M.D. or&#160;Ph.D. degrees. Of these full-time employees, 185 employees are engaged in research and development activities, including technical operations, clinical and regulatory and research and development. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in March 2015. Our principal executive offices are located at One Patriots Park, Bedford, MA 01730 and our telephone number is (781) 301-7277. Our website address is&#160;www.homologymedicines.com. Information contained on or accessible through our website is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and other information. Our SEC filings are available to the public over the Internet at the SEC's website at http://www.sec.gov. We make available on our website at&#160;www.homologymedicines.com, under &#8220;Investors,&#8221; free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the other information included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business, prospects, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline. We may never achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage genetic medicines company with a limited operating history. We have never been profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses in each year since beginning to develop our product candidates, including net losses of approximately $128.7 million and $103.9&#160;million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of approximately $328.4&#160;million. In addition, we have not commercialized any products and have never generated any revenue from product sales. We have devoted most of our financial resources to research and development, including our preclinical development activities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant additional operating losses for the foreseeable future as we seek to advance product candidates through preclinical and clinical development, expand our research and development activities, develop new product candidates, complete clinical trials, seek regulatory approval and, if we receive FDA approval, commercialize our products. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with genetic medicine</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially if and as we: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">continue our current research programs and our preclinical development of product candidates from our current research programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">seek to identify, assess, acquire and/or develop additional research programs and additional product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">initiate preclinical testing and clinical trials for any product candidates we identify and develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">further develop our genetic medicines platform&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">hire additional clinical, scientific and commercial personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our operations as a public reporting company&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">acquire or in-license other commercial products, product candidates and technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">make royalty, milestone or other payments under current and any future in-license agreements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">further expand our Good Manufacturing Practices, or GMP, manufacturing capacity. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our ability to successfully develop, commercialize and license our products and generate product revenue is subject to substantial additional risks and uncertainties. Each of our programs and product candidates will require additional preclinical and clinical development, potential regulatory approval in multiple jurisdictions, securing manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. These risks are further described under &#8220;&#8212;Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212;Risks Related to Commercialization.&#8221; As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more of our product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we are unable to achieve and then maintain profitability, the value of our equity securities will be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and commercialize our lead product candidate, HMI-102. We will require additional capital, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential commercialization of HMI-102, HMI-103, HMI-202,<span style="font-size:12pt;"> </span>HMI-203 and any other product candidates. In addition, we may not be able to enter into any collaborations that will generate significant cash. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and harm our product candidate development efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2022, including, subject to the impact of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 pandemic on our business, additional development activities related to our Phase 1/2 pheNIX clinical trial with HMI-102, the advancement of our lead gene editing product candidate, HMI-103, and our gene therapy product candidates, HMI-202 and HMI-203, the scale-up of our manufacturing processes and the expansion of our intellectual property portfolio. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of HMI-102, HMI-103, HMI-202, HMI-203 and any other product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the initiation, progress, timing, costs and results of our planned clinical trials for HMI-102 and our other product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or HMI-102, HMI-103, HMI-202, HMI-203 or any of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effect of competing technological and market developments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost and timing of completion of commercial-scale manufacturing activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs of operating as a public company&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which we in-license or acquire other products and technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of establishing sales, marketing and distribution capabilities for HMI-102, HMI-103, HMI-202, HMI-203 or any of our product candidates in regions where we choose to commercialize our products&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the initiation, progress, timing and results of our commercialization of HMI-102, HMI-103, HMI-202, HMI-203 or any of our product candidates, if approved for commercial sale. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Moreover, market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of HMI-102, HMI-103, HMI-202, HMI-203 or other product candidates or potentially discontinue operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, including under our effective Registration Statement on Form S-3, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and no history of commercializing genetic medicine products, which may make it difficult to evaluate the prospects for our future viability. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were established and began operations in 2015. Our operations to date have been limited to financing and staffing our company, developing our technology and identifying and developing our product candidates. We have not yet demonstrated an ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Typically, it takes about six to ten years to develop a new drug from the time it enters Phase 1 clinical trials to when it is approved for treating patients, but in many cases, it may take longer. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing genetic medicine products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as indications of future operating performance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are heavily dependent on the success of HMI-102, our most advanced product candidate, and if HMI-102 does not receive regulatory approval or is not successfully commercialized, our business may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have invested a significant portion of our efforts and financial resources in the development of HMI-102. Our future success and ability to generate product revenue is substantially dependent on our ability to successfully develop, obtain regulatory approval for and successfully commercialize this product candidate. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures over the next few years will be devoted to HMI-102, which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, securing manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we can generate any revenues from any commercial sales. Accordingly, our business currently depends heavily on the successful development, regulatory approval and commercialization of HMI-102, which may never occur if HMI-102 is ultimately shown to not be associated with phenylalanine hydroxylase enzymatic activity and increased Phe metabolism, or if HMI-102 were associated with serious adverse events, or if it were found to not be efficacious. Therefore, we cannot be certain that HMI-102 will be successful in our current Phase 1/2 pheNIX trial or future clinical trials, receive regulatory approval or be successfully commercialized even if we receive regulatory approval. Even if we receive approval to market HMI-102 from the FDA or other regulatory authorities, we cannot be certain that our product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Additionally, the research, testing, manufacturing, labeling, approval, sale, marketing and distribution of genetic medicine products are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries that each have differing regulations. We are not permitted to market HMI-102 in the United States until it receives approval of a Biologics License Application, or BLA, from the FDA, or in any foreign countries until it receives the requisite approval from such countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not submitted a BLA to the FDA or comparable applications to other regulatory authorities and do not expect to be in a position to do so for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HMI-102 is our most advanced product candidate, and because our other product candidates are based on similar technology, if HMI-102 shows unexpected adverse events or a lack of efficacy in the indications we intend to treat, or if we experience other regulatory or developmental issues, our development plans and business could be significantly harmed. Further, competitors may be developing products with similar technology and may experience problems with their products that could identify problems that would potentially harm our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to identify additional product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may not be able to assemble sufficient resources to acquire or discover additional product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential product candidates may not be effective in treating their targeted diseases&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the regulatory pathway for a potential product candidate is too complex and difficult to navigate successfully or economically. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. If we are unable to identify additional suitable product candidates for clinical development, this would adversely impact our business strategy and our financial position and share price and could potentially cause us to cease operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to significantly expand our organization, and we may have difficulty identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be limited. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be required to make significant payments in connection with our license agreements with each of the City of Hope and the California Institute of Technology. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our license agreements with each of City of Hope Medical Center, or COH, and California Institute of Technology, or Caltech, we are subject to significant obligations, including payment obligations upon achievement of specified milestones and royalties on product sales, as well as other material obligations, including potential payments to COH if we were to sublicense the COH technology to additional strategic collaborators. If these payments become due, we may not have sufficient funds available to meet our obligations or we may have to direct funds from other development efforts, and as a result, our development efforts may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to identify and develop product candidates based on our novel genetic medicines platform, which makes it difficult to predict the time and cost of product candidate development. No products that utilize gene editing technology have been approved in the United States or in Europe, and there have only been a limited number of human clinical trials involving a gene editing product candidate. Moreover, none of those trials has involved our nuclease-free gene editing technology. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research and development efforts on our genetic medicines platform, which uses both nuclease-free gene editing and gene therapy technologies. Our future success depends on the successful development of this novel therapeutic approach. To date, no product that utilizes gene editing has been approved in the United States or Europe. There have been a limited number of clinical trials of gene editing technologies, however no product candidates have been approved, and none of these clinical trials involved product candidates that utilize our novel gene correction editing technology. In addition, because our programs are all in the research, preclinical or early-clinical stage, we have not yet been able to fully assess safety in humans, and there may be long-term effects from treatment with any of our future product candidates that we cannot predict at this time. Any gene correction editing product candidates we may develop will act at the level of DNA, and, because animal DNA differs from human DNA, it will be difficult for us to test our future product candidates in animal models for either safety or efficacy. Also, animal models may not exist for some of the diseases we expect to pursue. Our genetic medicines platform is based on a family of 15 proprietary AAVHSCs which we can deploy with either gene editing or gene therapy constructs. Both applications rely on a unique ability of our AAVHSCs to efficiently target multiple tissues in the body. The mechanism of action by which these vectors target particular tissues is still not completely understood. Therefore, it is difficult for us to determine that our vectors will be able to properly integrate corrective DNA in or deliver gene transfer constructs to enough tissue cells to reach therapeutic levels. We cannot be certain that our AAVHSCs will be able to meet safety and efficacy levels needed to be therapeutic in humans or that they will not cause significant adverse events or toxicities. Furthermore, studies conducted by a third party in non-human primates suggests that intravenous delivery of certain AAV vectors at very high doses may result in severe toxicity. To date, we have not observed the severe toxicities described in these publications after intravenous administration in non-human primates with our naturally occurring AAVHSC vectors, and we have not seen these toxicities in our product candidates. However, we cannot be certain that we will be able to avoid triggering toxicities in our future preclinical or clinical studies. Any such results could impact our ability to develop a product candidate. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our genetic medicines platform, or any similar or competitive gene therapy or gene editing platforms, will result in the identification, development, and regulatory approval of any medicines, or that other genetic medicine technologies will not be considered better or more attractive for the development of medicines. There can be no assurance that any development problems we experience in the future related to our genetic medicines platform or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we may develop on a timely or profitable basis, if at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because gene therapy and gene editing are novel and the regulatory landscape that governs any product candidates we may develop is uncertain and continues to change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing products created with genome editing technology or involving gene therapy treatment have changed frequently and will likely continue to change in the future. Approvals by one regulatory authority may not be indicative of what any other regulatory authority may require for approval, and there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy products, cell therapy products and other products created with genome editing technology. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, with responsibility for the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other regulatory review agencies, committees and advisory groups and any requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, under NIH Guidelines supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, or EU, the EMA, has a Committee for Advanced Therapies, or CAT, that, in conjunction with the CHMP, is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products, or ATMPs. ATMPs include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. The CAT&#8217;s opinion is considered by the CHMP when giving its final recommendation regarding the authorization of a product in view of the balance of benefits and risks identified. Although the CAT&#8217;s draft opinion is submitted to the CHMP for final approval, the CHMP may depart from the draft opinion, if it provides detailed scientific justification. In the EU, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The CHMP and CAT are also responsible for providing guidelines on ATMPs and have published numerous guidelines, including specific guidelines on gene therapies and cell therapies. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs&#59; the manufacturing and control information that should be submitted in a marketing authorization application&#59; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. Although these guidelines are not legally binding, we believe that our compliance with them is likely necessary to gain and maintain approval for any of our product candidates. In addition, the EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy or genome editing product candidates, but that remains uncertain at this point.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for product candidates created with novel genome editing technology such as ours can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory authorities may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Regulatory authorities administering existing or future regulations or legislation may not allow production and marketing of products utilizing genome editing technology in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in statute or regulations or the interpretation of new available data by applicable regulatory agencies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in applicable regulatory guidelines may lengthen the regulatory review process for our product candidates, require additional studies or trials, increase development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of such product candidates, or lead to significant post-approval limitations or restrictions. Additionally, adverse developments in clinical trials conducted by others of gene therapy products or products created using genome editing technology, or adverse public perception of the field of genome editing, may cause the FDA, the EMA and other regulatory authorities to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing genome editing technologies, either of which could materially harm our business. Furthermore, regulatory action or private litigation could result in expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we advance product candidates, we will be required to consult with these regulatory and advisory groups and comply with all applicable guidelines, rules and regulations. If we fail to do so, we may be required to delay or terminate development of such product candidates. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient product revenue to maintain our business. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process.&#160;The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biotechnology and genetic medicines industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our current and future clinical trials are completed as planned, we cannot be certain that their results will establish the safety, purity, potency and/or effectiveness of HMI-102 for PKU or any other potential indication to the satisfaction of the FDA or other regulatory authorities, even if we believe that such trials were successful.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not completed any clinical trials required for the approval of HMI-102 or any of our product candidates. Although we have initiated our Phase 1/2 pheNIX trial for HMI-102, we may experience delays in conducting any clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtaining regulatory approval to commence a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtaining institutional review board, or IRB, and ethics committee approval at each site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">recruiting suitable patients to participate in a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developing and validating the companion diagnostic to be used in a clinical trial, if applicable&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">having patients complete a trial or return for post-treatment follow-up&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical sites deviating from trial protocol or dropping out of a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">addressing patient safety concerns that arise during the course of a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">adding a sufficient number of clinical trial sites&#59;&#160;or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">manufacturing sufficient quantities of product candidate for use in clinical trials. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trials of our product candidates may produce negative safety and/or efficacy data or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of clinical trials of our product candidates may be greater than we anticipate, and we may not have funds to cover the costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">incur unplanned costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtain marketing approval in some countries and not in others&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">be subject to additional post-marketing testing requirements&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">have the product removed from the market after obtaining marketing approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. For example, we have experienced, and may continue to experience, delays in enrolling our Phase 1/2 pheNIX trial as a result of the COVID-19 pandemic. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we may rely on CROs and clinical trial sites to ensure the proper and timely conduct of clinical trials, and while we would have agreements governing their committed activities, we would have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced product candidate, HMI-102, will require extensive clinical testing before we are prepared to submit a BLA for regulatory approval. We cannot predict with any certainty if or when we might complete the development of HMI-102 and submit a BLA for regulatory approval of HMI-102 or whether any such BLA will be approved by the FDA. We may seek feedback from the FDA or other regulatory authorities on our clinical development program, and the FDA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of HMI-102 could be harmed, and our ability to generate revenues from HMI-102 may be delayed. In addition, any delays in our clinical trials could increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause, or lead to, a delay in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Adverse public perception of genetic medicine, and gene editing in particular, may negatively impact regulatory approval of, or demand for, our potential products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our potential therapeutic products involve editing the human genome. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene editing and gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene editing are unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, gene editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns relating to the application of gene editing technology to human embryos or the human germline. For example, in April 2015, Chinese scientists reported on their attempts to edit the genome of human embryos to modify the gene for hemoglobin beta. This is the gene in which a mutation occurs in patients with the inherited blood disorder beta thalassemia. Although this research was purposefully conducted in embryos that were not viable, the work prompted calls for a moratorium or other types of restrictions on gene editing of human eggs, sperm, and embryos. The Alliance for Regenerative Medicine in Washington, D.C. has called for a voluntary moratorium on the use of gene editing technologies in research that involved altering human embryos or human germline cells. Similarly, the NIH has announced that it would not fund any use of gene editing technologies in human embryos, noting that there are multiple existing legislative and regulatory prohibitions against such work, including the Dickey-Wicker Amendment, which prohibits the use of appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed. Laws in the United Kingdom prohibit genetically modified embryos from being implanted into women, but embryos can be altered in research labs under license from the Human Fertilisation and Embryology Authority. Research on embryos is more tightly controlled in many other European countries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not use our technologies to edit human embryos or the human germline, such public debate about the use of gene editing technologies in human embryos and heightened regulatory scrutiny could prevent or delay our development of product candidates. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any products we may develop. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing gene therapy or gene editing technologies, even if not ultimately attributable to product candidates we may discover and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, a decrease in demand for any such product candidates and a suspension or withdrawal of approval by regulatory authorities of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Breakthrough Therapy Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Breakthrough Therapy Designation for our product candidates if the clinical data support such a designation for one or more product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, or biologic in our case, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for priority review. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The same principles apply to a possible PRIME designation by the EMA in the EU</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Fast Track Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 1, 2019, we received Fast Track Designation for HMI-102 for the prevention or treatment of neurocognitive defects due to phenylalanine hydroxylase deficiency through normalization of circulating phenylalanine levels, and we intend to seek such designation for some or all of our other product candidates. If a drug or biologic, in our case, is intended for the treatment of a serious or life-threatening condition and the biologic demonstrates the potential to address unmet medical needs for this condition, the biologic sponsor may apply for FDA Fast Track Designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Many biologics that have received Fast Track Designation have failed to obtain approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek accelerated approval for products that have obtained Fast Track Designation. Under the FDA&#8217;s accelerated approval program, the FDA may approve a biologic for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. For biologics granted accelerated approval, post-marketing confirmatory trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed and/or initiated prior to approval. Moreover, the FDA may withdraw approval of any product candidate or indication approved under the accelerated approval pathway in an expedited manner if, for example: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the trial or trials required to verify the predicted clinical benefit of the product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the biologic&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">other evidence demonstrates that the product candidate is not shown to be safe or effective under the conditions of use&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we fail to conduct any required post-approval trial of the product candidate with due diligence. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have received orphan drug designation for HMI-102 and HMI-202, and we intend to seek orphan drug designation for our other product candidates, but any orphan drug designations we receive may not confer marketing exclusivity or other expected benefits. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received orphan drug designation for HMI-102 in the United States and Europe for the use of AAVHSC15 expressing <span style="font-style:italic;">PAH</span> for the treatment of PAH deficiency. In addition, we have received orphan drug designation for HMI-202 in the United States and Europe for the use of AAVHSC15 expressing human arylsulfatase A for the treatment of metachromatic leukodystrophy, or MLD. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approve any other applications, including a full </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BLA</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to market the same drug for the same indication for seven years, except in limited circumstances. The applicable exclusivity period is ten years in Europe. The European exclusivity period can be reduced to six years </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if, at the end of the fifth year </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same indication. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same indication if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process, nor does it prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation. The same principles are valid for the EU as well.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have received rare pediatric disease designation for HMI-202, and we may seek rare pediatric disease designation for our other product candidates, however, there is no guarantee that we will obtain such designation, and even if we do, there is no guarantee that FDA approval will result in a priority review voucher.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received rare pediatric disease designation for HMI-202 for the treatment of MLD, and we may seek rare pediatric disease designation for our other product candidates&#59; however, we may not be able to obtain such designation. If we are able to obtain rare pediatric disease designation for our other product candidates, there is no guarantee that we will be able to obtain a priority review voucher, even if the designated product candidate is approved by the FDA. Moreover, Congress included a sunset provision in the statute authorizing the rare pediatric disease priority review voucher program. Specifically, the FDA may not award the voucher to sponsors of marketing applications unless either (i) the drug has received rare pediatric disease designation as of September 30, 2024, and is then approved by the FDA no later than September 30, 2026&#59; or (ii) Congress reauthorizes the program. Even though we received rare pediatric disease designation for HMI-202 by the current statutory deadline of September 30, 2024, we may not receive the voucher if we do not obtain approval by September 30, 2026. Even if legislation is enacted that extends the date by which approval of the rare pediatric disease-designated drug must obtain approval to receive a priority review voucher, we may not obtain approval by that date, and even if we do, we may not obtain a priority review voucher.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A Regenerative Medicine Advanced Therapy designation by the FDA, or Advanced Therapy Medicinal Product designation by the EMA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a Regenerative Medicine Advanced Therapy, or RMAT, designation for HMI-102 or our other product candidates. In 2017, the FDA established the RMAT designation as part of its implementation of the 21st Century Cures Act. An investigational drug is eligible for RMAT designation if: (1) it meets the definition of a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions&#59; (2) it is intended to treat, modify, reverse, or cure a serious disease or condition&#59; and (3) preliminary clinical evidence indicates that the investigational drug has the potential to address </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unmet medical needs for such disease or condition. In a February 2019 final guidance, the FDA also stated that certain gene therapies that lead to a sustained effect on cells or tissues may meet the definition of a regenerative medicine therapy. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review of BLAs and priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites, as appropriate. RMAT-designated product candidates that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">world evidence (such as electronic health records)&#59; through the collection of larger confirmatory data sets&#59; or via post-approval monitoring of all patients treated with such therapy prior to approval of the therapy.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RMAT designation does not change the standards for product approval, and there is no assurance that such designation or eligibility for such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have relationships with a limited number of suppliers for the manufacturing of our viral vectors and product candidates. We completed the build-out of a GMP manufacturing facility to support our clinical development programs in both gene therapy and gene editing and commenced manufacturing activities in April 2019. However, if we experience delays or are unable to scale our internal manufacturing capabilities, we will need to contract with manufacturers that can produce the preclinical, clinical and commercial supply of our products. Each supplier may require licenses to manufacture such components if such processes are not owned by the supplier or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s current good laboratory practices, or GLP, and GMP regulations enforced by the FDA through its facilities inspection program. Some of our contract manufacturers have not produced a commercially-approved product and therefore have not obtained the requisite FDA approvals to do so. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other regulatory authorities can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. The enrollment of patients depends on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patient eligibility criteria defined in the protocol&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the proximity of patients to study sites&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the design of the trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain and maintain patient consents&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidates, or could render further development impossible. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates may cause serious adverse events or undesirable side effects or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or, result in significant negative consequences following marketing approval, if any. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Serious adverse events or undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death. A significant risk in any gene editing product is that the edit will be &#8220;off-target&#8221; (or &#8220;on-target,&#8221; but unwanted) and cause serious adverse events, undesirable side effects, toxicities or unexpected characteristics. For example, off-target cuts could lead to disruption of a gene or a genetic regulatory sequence at an unintended site in the DNA, or, in those instances where we also provide a segment of DNA to serve as a repair template, it is possible that following off-target cut events, DNA from such repair template could be integrated into </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the genome at an unintended site, potentially disrupting another important gene or genomic element. We cannot be certain that off-target editing will not occur in any of our planned or future clinical studies. There is also the potential risk of delayed adverse events following exposure to gene editing therapy, due to the potential for persistent biological activity of the genetic material or other product components used to carry the genetic material. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs or ethics committees at the institutions in which our studies are conducted or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory authorities may withdraw approvals of such product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may be required to recall a product or change the way such product is administered to patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the product could become less competitive&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we could be sued and held liable for harm caused to patients&#59;&#160;and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our reputation may suffer. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that neither HMI-102, HMI-103, HMI-202, HMI-203, nor any other product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of a BLA from the FDA. It is possible that the FDA may refuse to file for substantive review any BLAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory authorities, that such product candidates are safe and effective, or in the case of biologics, safe, pure, and potent, for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program. Depending on the extent of these or any other FDA-required studies, approval of any BLA or application that we submit may be delayed by several </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years or</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may require us to expend significantly more resources than we have available. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of potential products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, in particular the EMA, following its relocation to Amsterdam and related reorganization, may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the global pandemic of COVID-19, on March 10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain FDA approval for HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full market potential. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. Manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any marketing approvals that we may receive for our product candidates may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">restrictions on manufacturing such products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">restrictions on the labeling or marketing of a product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">restrictions on product distribution or use&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">requirements to conduct post-marketing studies or clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">warning letters or holds on clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">withdrawal of the products from the market&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">recall of products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fines, restitution or disgorgement of profits or revenues&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">suspension or withdrawal of marketing approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refusal to permit the import or export of our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product seizure or detention&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, the results of the 2020 U.S. Presidential Election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these orders will be implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of the new administration are unknown and could materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates, including HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">impairment of our business reputation and significant negative media attention&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">withdrawal of participants from our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant costs to defend the related litigation and related litigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">distraction of management&#8217;s attention from our primary business&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">substantial monetary awards to patients or other claimants&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">inability to commercialize HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">decreased demand for HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, if approved for commercial sale&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">loss of revenue. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, employment practices liability, property, auto, workers&#8217; compensation, umbrella, and directors&#8217; and officers&#8217; insurance. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in the future</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for HMI-102, HMI-103, HMI-202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, HMI-203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other product candidate, we intend to acquire insurance coverage to include the sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect that operating as a public company will continue to make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Misconduct by our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i)&#160;the laws and regulations of the FDA, EMA rules and regulations and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities&#59; (ii)&#160;manufacturing standards&#59; (iii)&#160;data privacy, security, fraud and abuse and other healthcare laws and regulations&#59; or (iv)&#160;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business and operations would suffer in the event of system failures. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate could be delayed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we publicly disclose initial, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the initial, top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Initial, top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the initial, top-line or preliminary data we previously published. As a result, initial, top-line and preliminary data should be viewed with caution until the final data are available. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we also disclose data from our preclinical studies and clinical trials. Initial or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between initial or preliminary data and final data could significantly harm our business prospects. Further, disclosure of initial or preliminary data by us or by our competitors could result in volatility in the price of our common stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Healthcare Laws and Other Legal Compliance Matters </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establishment of a Center for Medicare Innovation at the Centers for Medicare&#160;&#38; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, executive, and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, on December 14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the entire ACA is invalid based primarily on the fact that the Tax Cuts and Jobs Act of 2017 repealed the tax-based shared responsibility payment imposed by the ACA, on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#8220;individual mandate.&#8221; On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will affect or our business or financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services&#59; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder, which also impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product unless a biologics license is in effect for that product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain healthcare professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities&#59; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, California recently enacted legislation, the CCPA, which went into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. Further, the CPRA was also recently voted into law by California residents. The CPRA significantly amends the CCPA and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January 1, 2023, and become enforceable on July 1, 2023&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers. For instance, in the EU, interactions between pharmaceutical companies and healthcare professionals and healthcare organizations, are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and Member States level. The provision of benefits or advantages to physicians to induce or encourage </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. Relationships with healthcare professionals and associations are subject to stringent anti-gift statutes and anti-bribery laws, the scope of which differs across the EU. In addition, national &#8220;Sunshine Acts&#8221; may require pharmaceutical companies to report/publish transfers of value provided to </span><span style="font-size:10pt;color:#000000;">healthcare</span><span style="font-size:10pt;color:#000000;"> professionals and associations on a regular (e.g. annual) basis</span><span style="font-size:10pt;color:#000000;">&#59; </span><span style="font-size:10pt;color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">similar laws governing the privacy and security of certain protected information, in the EU and other jurisdictions including the General Data Protection Regulation, or GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the European Economic Area (including health data). Further, the United Kingdom&#8217;s decision to leave the EU has created uncertainty with regard to the status of the UK as an &#8220;adequate country&#8221; for the purposes of data transfers outside the EEA. From January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, including our development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new genetic medicine products is highly competitive. Moreover, the gene editing field is characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. We will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs, including PKU, MLD, Hunter syndrome, hemoglobinopathies and ophthalmological diseases. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our platform and product focus is the development of genetic medicines using our proprietary AAVHSCs <span style="font-style:italic;">in vivo</span> either through the gene therapy or nuclease-free gene editing modality. If our current programs are approved for the indications for which we are currently planning clinical trials, they may compete with other products currently under development, including gene editing and gene therapy products or other types of therapies, such as small molecule, antibody or protein therapies. If our PKU treatments are approved, they may compete with therapies from American Gene Technologies, BioMarin, Censa Pharmaceuticals, Generation Bio, Nestl&#233; Health Science, Sangamo Therapeutics and Synlogic. However, we believe that only gene therapy or gene editing approaches have the potential to restore the normal Phe biochemical pathway with a single administration. If our Hunter syndrome treatment is approved, it may compete with therapies from Shire and/or<span style="font-size:12pt;"> </span>GC Pharma. If our MLD treatment is approved, it may compete with therapies from Orchard Therapeutics and/or Shire. <span style="font-style:italic;">In vivo</span> gene therapy approaches provide potential advantages over <span style="font-style:italic;">ex vivo</span> approaches. There are a number of companies developing nuclease-based gene editing technologies using CRISPR/Cas9, TALENs, meganucleases, Mega-TALs and ZFNs, including but not limited to Beam Therapeutics, bluebird bio, Caribou Biosciences, Cellectis, CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Precision BioSciences, Prime Therapeutics and Sangamo Therapeutics and non-nuclease-based technology, including LogicBio Therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomic or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Moreover, for drugs and biologics administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially-reasonable revenue and profits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. Governments influence the price of medicinal products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products for human use. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member states may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the safety, efficacy and potential advantages compared to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">effectiveness of sales and marketing efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of treatment in relation to alternative treatments, including any similar generic treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to offer our products for sale at competitive prices&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the convenience and ease of administration compared to alternative treatments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the strength of marketing and distribution support&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing of market introduction of competitive products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the availability of third-party coverage and adequate reimbursement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the prevalence and severity of any side effects&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">any restrictions on the use of our product together with other medications. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we expect sales of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, if approved, to generate substantially all of our product revenues for a substantial period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, if approved. Moreover, provisions in our agreements with Pfizer may inhibit our ability to enter into future collaborations with third parties.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any infrastructure for the sales, marketing or distribution of our products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to build a focused sales, distribution and marketing infrastructure to market HMI-102, HMI-103, HMI-202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, HMI-203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other product candidate in the United States and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of HMI-102, HMI-103, HMI-202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, HMI-203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other product candidate. Additionally, if the commercial launch of HMI-102, HMI-103, HMI-202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, HMI-203</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidates in certain markets overseas. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in the product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, if approved, for certain markets overseas&#59; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, we may be forced to delay the potential commercialization of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate or reduce the scope of our sales or marketing activities for HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we have granted Pfizer a right of first refusal to acquire rights (whether through license, asset sale or otherwise) to develop or commercialize HMI-102 and/or HMI-103. This right of first refusal provision may inhibit our ability to enter into future collaborations with third parties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third parties, we will not be successful in commercializing HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate, and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate is approved for commercialization, we intend to enter into agreements with third parties to market it in certain jurisdictions outside the United States. We expect that we will be subject to additional risks related to international pharmaceutical operations, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic commercialization and country-specific regulations of gene therapies in foreign countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">complex and restrictive import/export regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">reduced protection for intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">foreign reimbursement, pricing and insurance regimes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery and anticorruption laws in other jurisdictions&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the EU and many of the EU member states with which we will need to comply. Many U.S.-based biotechnology companies have found the process of marketing their own products in Europe to be very challenging. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, signed into law on March&#160;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently contract with third parties for the manufacture of certain materials for our research programs, preclinical and clinical studies. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost or in compliance with regulatory requirements, which could delay, prevent, or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely on third-party manufacturers for the manufacture of certain materials for research programs, preclinical and clinical studies. We do not have long-term supply agreements with all of the third-party manufacturers, and we purchase our required supply on a purchase order basis. We recently completed the build-out of a GMP manufacturing facility to support our clinical development programs in both gene therapy and gene editing and commenced manufacturing activities in 2019. However, if we experience delays or are unable to scale our internal manufacturing capabilities, we will need to contract with manufacturers that can produce the clinical and commercial supply of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the possible breach of the manufacturing agreement by the third party&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party manufacturers may not be able to comply with GMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, as a result of the COVID-19 pandemic, third-party manufacturers may be affected, which could disrupt their activities and as a result we could face difficulty sourcing key components necessary to produce supply of our product candidates, which may negatively affect our preclinical and clinical development activities.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under GMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to continue to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to continue to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to continue to rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. Our reliance on CROs for clinical development activities limits our control over these activities, but we will remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with GLP and GCP, which are regulations and guidelines enforced by the FDA and are also required by the competent authorities of the EU member states of the European Economic Area and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under GMP regulations. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other product development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations or fail to meet expected deadlines, including as a result of the impact of the COVID-19 pandemic, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may collaborate with third parties for the development and commercialization of HMI-102, HMI-103, HMI-202</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">, HMI-203 </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">or any other product candidate. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize HMI-102, HMI-103, HMI-202</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">, HMI-203</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> or any other product candidate successfully, if at all. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek collaborative relationships for the development and commercialization of HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate. Failure to obtain a collaborative relationship for HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate may significantly impair the potential for the product candidate. We also will need to enter into collaborative relationships to provide funding to support our other research and development programs. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may shift its priorities and resources away from our product candidates due to a change in business strategies, or a merger, acquisition, sale or downsizing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic collaboration&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may not devote sufficient capital or resources towards our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may change the success criteria for a product candidate thereby delaying or ceasing development of such candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a significant delay in initiation of certain development activities by a collaboration partner will also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner could develop a product that competes, either directly or indirectly, with our product candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources to the marketing, distribution or sale of a product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues and be unable to meet demand requirements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a collaboration partner may terminate a strategic alliance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a dispute may arise between us and a partner concerning the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a partner may use our products or technology in such a way as to invite litigation from a third party. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital. Moreover, any collaborative partners we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate or terminate their relationships with us. For example, in February 2021, we received written notice from Novartis that Novartis elected to terminate our collaboration agreement with Novartis with respect to the only remaining ophthalmic target under the agreement. Accordingly, the notice served to terminate the agreement in its entirety. The termination of the collaboration agreement will be effective on August 26, 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not have multiple sources of supply for all of the components used in HMI-102 and our other product candidates. If we were to lose a supplier, it could have a material adverse effect on our ability to complete the development of HMI-102. If we obtain regulatory approval for HMI-102, we </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">would</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> need to expand the supply of its components in order to commercialize them. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have multiple sources of supply for all of the components used in the manufacturing of HMI-102. We also do not have long-term supply agreements with any of our component suppliers. We are currently evaluating manufacturers that will commercially manufacture HMI-102. It is our expectation that we will only qualify one initial supplier that will need to be approved by the FDA. If for any reason we are unable to obtain product from the manufacturer we select, we would have to qualify new manufacturers. We may not be able to establish additional sources of supply for our product candidates, or may be unable to do so on acceptable terms. Manufacturing suppliers are subject to GMP quality and regulatory requirements, covering manufacturing, testing, quality control and record keeping relating to our product candidates and subject to ongoing inspections by the regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in long delays and interruptions in supply. Manufacturing suppliers are also subject to local, state and federal regulations and licensing requirements. Failure by any of our suppliers to comply with all applicable regulations and requirements may result in long delays and interruptions in supply. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of suppliers of the raw material components of our product candidates is limited. In the event it is necessary or desirable to acquire supplies from alternative suppliers, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of any marketing approval, a manufacturer of HMI-102 is required to be licensed by the FDA prior to commercialization. This licensing process normally includes inspections by regulatory authorities that must be successful prior to them being licensed. Failure of manufacturing suppliers to successfully complete these regulatory inspections will result in delays. If supply from the approved supplier is interrupted, there could be a significant disruption in commercial supply. An alternative vendor would need to be qualified through a BLA amendment or supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new supplier is relied upon for commercial production. Switching vendors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain the supplies we need at a reasonable price or on a timely basis, it could have a material adverse effect on our ability to complete the development of HMI-102 and our other product candidates or, if we obtain regulatory approval for HMI-102 or our other product candidates, to commercialize them. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we in-license or acquire development or commercialization rights to products, technology or data from third parties, including those for HMI-102, we could lose such rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to agreements with Caltech for certain AAV vector-related patents owned by Caltech for human therapeutic applications, or the Caltech License, and COH for certain AAV vector-related patents and know-how, and we may enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines, milestone payments, royalties, insurance and other obligations on us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in exchange for the rights granted to us under the Caltech License, we are obligated to pay Caltech up to a total of $7.2&#160;million in milestone payments for the first licensed product, royalties, in the low single-digit percentages, on net sales of licensed products subject to a certain annual minimum royalty, and mid-single- to high single-digit percentages of sublicensing revenues. If we fail to comply with our obligations under the Caltech License, or any of our other collaborators, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product candidate that is covered by these agreements, which could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product candidates. Our success depends in large part on our ability to secure and maintain patent protection in the United States and other countries with respect to HMI-102, HMI-103, HMI-202, HMI-203 and any future product candidates. We seek to protect our proprietary position by filing or collaborating with our licensors to file patent applications in the United States and abroad related to our proprietary technologies, development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our proprietary products and technology, including HMI-102, HMI-103, HMI-202, HMI-203 or any other product candidate in the United States or in other foreign countries, in whole or in part. Alternately, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. Even if patents do successfully issue and even if such patents cover HMI-102, HMI-103, HMI-202, HMI-203 or any future product candidate, third parties may challenge their validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate and companion diagnostic under patent protection could be reduced. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for HMI-102, HMI-103, HMI-202, HMI-203 or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our ability to commercialize future product candidates. Any such outcome could have a materially adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies is highly uncertain, involves complex legal and factual questions, and is characterized by the existence of large numbers of patents and frequent litigation based on allegations of patent or other intellectual property infringement or violation. In addition, the laws of jurisdictions outside the United States may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Since patent applications in the United States and other jurisdictions are confidential for a period of time after filing, we cannot be certain that we were the first to file for patents covering our inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in the issuance of patents, or may result in the issuance of patents which fail to protect our technology or products, in whole or in part, or which fail to effectively prevent others from commercializing competitive technologies and products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available&#59; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may assert claims against us alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our product candidates, prohibit our use of proprietary technology or sale of products or put our patents and other proprietary rights at risk. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous United States, EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our ability to develop and commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we obtained a license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages if we are found to be infringing a third party&#8217;s patent rights. These damages potentially include increased damages and attorneys&#8217; fees if we are found to have infringed such rights willfully. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or require us to grant a cross-license under our intellectual property rights. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, or forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. We might also be forced to redesign or modify our product candidates so that we no longer infringe the third-party intellectual property rights, which may result in significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because during prosecution of the patent an individual connected with such prosecution withheld relevant information, or made a misleading statement. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could be filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to correctly identify or interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates in a manner that no longer infringes third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and genetic medicines industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biotechnology and genetic medicines patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act, or the AIA, which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regardless of whether another inventor had made the invention earlier. A third party that files&#160;a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or in-licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance with such provisions will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, it can create opportunities for competitors to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than those in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expensive, if</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example, relative to other countries, China has a heightened requirement for patentability and specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put at risk our or our licensors&#8217; patents of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of any individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20&#160;years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, a patent that covers an FDA-approved drug or biologic may be eligible for a term extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. In the EU, our product candidates may be eligible for term extensions based on similar legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our proprietary rights may not adequately protect our technologies and product candidates, and do not necessarily address all potential threats to our competitive advantage. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may be able to make products that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others, including inventors or developers of our owned or in-licensed patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to practice the inventions covered by the patents or patent applications that we own, license or will own or license&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors or our other collaboration partners might not have been the first to file patent applications covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors may fail to meet obligations to the U.S. government with respect to in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that our pending patent applications will not result in issued patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">ownership, validity or enforceability of our or our licensors&#8217; patents or patent applications may be challenged by third parties&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from third parties, we may not be able to continue developing our products<span style="font-style:normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently in-license certain intellectual property from COH and Caltech. In the future we may in-license intellectual property from other licensors. We rely on certain of these licensors to file and prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them. We have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or defense activities may be less vigorous than had we conducted them ourselves. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to license agreements with COH and Caltech, pursuant to which we in-license patents and technology for our product candidates. These existing licenses impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations or otherwise materially breach a license agreement, our licensors may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property. In addition, any claims asserted against us by our licensors may be costly and time-consuming, divert the attention of key personnel from business operations or otherwise have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider proprietary trade secrets, confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. However, trade secrets and confidential know-how are difficult to protect, and we have limited control over the protection of trade secrets and confidential know-how used by our licensors, collaborators and suppliers. Because we expect to rely on third parties to manufacture HMI-102, HMI-103, HMI-202, HMI-203 and any future product candidates, and we expect to collaborate with third parties on the development of HMI-102, HMI-103, HMI-202, HMI-203 and any future product candidates, we may, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development collaborations or similar agreements. Under such circumstances, trade secrets and confidential know-how can be difficult to maintain as confidential. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We currently own one registered trademark and four pending trademark applications in the United States, as well as 17 registered trademarks and five pending trademark applications in other countries around the world. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. For example, our programs may involve product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compositions and pre-existing pharmaceutical compositions. These pharmaceutical products may be covered by intellectual property rights held by others. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies licensed to us. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Employee Matters and Managing Growth and Other Risks Related to Our Business</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The COVID-19 pandemic caused by the novel strain of coronavirus could adversely impact our business, including our preclinical studies and clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, a strain of novel coronavirus disease, COVID-19, was declared a pandemic and spread across the world, including throughout the United States, Europe and Asia. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred, supply chains have been disrupted, and facilities and production have been suspended.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the spread of COVID-19, most office-based employees continue to work from home, and we have limited the number of staff in our research and development laboratories and in our manufacturing facility to key personnel. For those employees on-site, we have developed shift schedules for our laboratories and manufacturing facility and a modified office layout and traffic flow pattern to increase spacing capabilities, reduce inter-office risks and allow for business continuity. We have increased cleaning protocols throughout our entire facility, limited visitors to only those who are critical to our ongoing operations and have cancelled all business travel. In addition, we have developed our own on-site COVID-19 surveillance testing for employees to help promote health and safety. Disruptions caused by the COVID-19 pandemic have resulted, and may continue to result, in delays in enrolling our Phase 1/2 pheNIX clinical trial. In addition, we could experience additional disruptions in conducting or completing the Phase 1/2 pheNIX trial or other planned preclinical and clinical trials and could incur unforeseen costs as a result of preclinical study or clinical trial delays. Many of our clinical sites are not currently accepting new patients for enrollment in clinical trials and have placed limitations on patients already enrolled in clinical trials from visiting the clinical sites for follow-up monitoring visits. While we have entered into arrangements with third parties to provide remote patient visits and monitoring, we may still experience delays with the pheNIX trial. All of our ongoing and planned preclinical studies at external CROs are progressing and we have accelerated shipments of reagents and supplies to avoid any disruption of activities. However, it is possible that the COVID-19 pandemic may have an impact in the future on our CROs&#8217; ability to complete critical studies required for the progression of these programs. Moreover, while we currently do not anticipate any interruptions in our manufacturing process, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our and/or our third-party suppliers and CMOs&#8217; ability to manufacture our product candidates or materials needed for our preclinical studies and clinical trials. If the COVID-19 pandemic continues to spread in the United States and elsewhere, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in enrolling patients in our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facility&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal of the FDA to accept data from clinical trials in affected geographies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic impacts our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the effectiveness of vaccines and vaccine distribution efforts, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the ultimate impact of COVID-19 on financial markets and the global economy, and the effectiveness of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions taken in the United States and other countries to contain and treat the disease. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our liquidity. In addition, the recession or market correction resulting from the spread of COVID-19 could materially affect our business.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of Arthur Tzianabos, Ph.D., our President and Chief Executive Officer, and Albert Seymour, Ph.D., our Chief Scientific Officer, as well as the other principal members of our management, scientific and clinical teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates will be limited. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by natural disasters, public health emergencies and other natural catastrophic events, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, public health emergency, such as the COVID-19 pandemic, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. For example, following Hurricane Maria, shortages in production and delays in a number of medical supplies produced in Puerto Rico resulted, and any similar interruption due to a natural disaster affecting us or any of our third-party manufacturers could materially delay our operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our executive officers and directors and their respective affiliates, if they choose to act together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers and directors and their respective affiliates, in the aggregate, hold shares representing approximately 20.9% of our outstanding voting stock as of December&#160;31, 2020. As a result, if these stockholders choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of any merger, consolidation or sale of all or substantially all of our assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A significant portion of our total outstanding shares are eligible, or will soon become eligible, to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Based on filings with the SEC, as of November 6, 2020, holders of an aggregate of approximately 10.0 million shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until the rights terminate pursuant to the terms of the investors&#8217; rights agreement, as amended, between us and such holders. We have also registered all shares of common stock that we may issue under our equity compensation plans, which can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements, if applicable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on November 9, 2020, we entered into a stock purchase agreement with Pfizer, pursuant to which Pfizer purchased 5.0 million shares of our common stock through a private placement transaction. The shares of common stock sold in the Pfizer private placement are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares. Pfizer also has rights, subject to specified conditions, to require us to file a Registration Statement on Form S-3 to register the shares of common stock sold in the Pfizer private placement. Once any such registration statement is declared effective, these shares can be freely sold on the public market.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the closing of the initial public offering of our common stock. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.07&#160;billion or we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">reduced disclosure obligations regarding executive compensation&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could </span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">make an acquisition of</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our certificate of incorporation designates the Court of Chancery of the State of Delaware, subject to certain exceptions, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders and our bylaws designate the federal district courts of the United States as the exclusive forum for actions arising under the Securities Act of 1933, as amended, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders. In addition, our bylaws provide that the federal district courts of the United States are the exclusive forum for any complaint raising a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated certificate of incorporation and bylaws described above. We believe these choice of forum provisions benefit us by providing increased consistency in the application of Delaware law by </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or bylaws </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> contained in our restated certificate of incorporation </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or bylaws </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use net operating losses and research and development credits to offset future taxable income or income tax liabilities may be subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had federal and state net operating loss carryforwards, or NOLs, of approximately $265.1 million and $271.5 million, respectively. Our state NOLs, and federal NOLs generated in taxable years beginning before January 1, 2018 are subject to expiration and will expire at various dates through 2040. As of December&#160;31, 2020, we also had federal and state research and development and other tax credit carryforwards, or credits, including the orphan drug credit, of approximately $34.2 million and $7.2 million, respectively, available to reduce future income tax liabilities. The federal and state credits expire at various dates through 2040. These NOLs and credits could expire unused and be unavailable to offset future taxable income or income tax liabilities, to the extent subject to expiration. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs or credits to offset future taxable income or income tax liabilities. For these purposes, an ownership change generally occurs where the aggregate change in stock ownership of one or more stockholders or groups of stockholders owning at least 5% of a corporation&#8217;s stock exceeds 50 percentage points over a three-year period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, if any. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change. Our NOLs or credits may also be impaired under state law. Accordingly, even if we attain profitability, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, NOLs generated in periods beginning after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in years beginning after December 31, 2020, which may require us to pay federal income taxes in future years despite generating federal NOLs in prior years.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our common shares for the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price at which you purchased them. The market price for our common stock may be influenced by many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of competitive products or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or expected changes in our growth rate relative to our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">results of clinical trials of our product candidates or those of our competitors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments related to our existing or any future collaborations&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory or legal developments in the United States and other countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">development of new product candidates that may address our markets and make our product candidates less attractive&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">announcements by us, our collaborators or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments or disputes concerning patent applications, issued patents or other proprietary rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the recruitment or departure of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the level of expenses related to any of our product candidates or clinical development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">general economic, industry and market conditions&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.07%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the other factors described in this &#8220;Risk Factors&#8221; section. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We could be subject to securities class action litigation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred and expect to continue to incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have incurred and expect to continue to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased our legal and financial compliance costs and have made some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting, which has been both costly and challenging. We will need to continue to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section&#160;404. If we identify one or more material weaknesses, it could cause us to need to restate our previously issued financial statements and result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently occupy approximately 67,000 square feet of office, research and development laboratory and manufacturing space in Bedford, Massachusetts, under a lease that expires in 2027. We are subletting approximately 23,000 square feet of office and laboratory space at our prior facility in Bedford, Massachusetts to a single tenant, under a lease that expires in 2021. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not subject to any material legal proceedings. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our common stock has been publicly traded</span> on the Nasdaq Global Select Market under the symbol &#8220;FIXX&#8221; since March 28, 2018. Prior to that time, there was no public market for our common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 1, 2021, there were approximately 17 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not expect to pay any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans is incorporated herein by reference to Item 12, <span style="font-style:italic;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span>, of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph set forth below compares the cumulative total stockholder return on our common stock between March 28, 2018 (the date our common stock commenced trading on the Nasdaq Global Select Market) and December&#160;31, 2020, with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period. This graph assumes an initial investment of $100 on March 28, 2018 in our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any. The comparisons in the graph are not intended to forecast or be indicative of possible future performance of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gmz2lq4320rk000023.jpg" title="" alt="" style="width:580px;height:284px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities&#59; Purchases of Equity Securities by the Issuer or Affiliated Purchaser</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not repurchase any of our equity securities during the quarter ended December 31, 2020. Other than as disclosed in our Current Report on Form 8-K filed with the SEC on November 9, 2020, we did not sell any equity securities during the year ended December 31, 2020 that were not registered under the Securities Act.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_SELECTED_FINANCIAL_DATA">Item 6. Selected Financial Data. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selected financial data presented below is derived from our audited consolidated financial statements. The selected financial data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 of Part II to this Annual Report on Form 10-K. The selected financial data in this section are not intended to replace our consolidated financial statements and the related notes. Our historical results are not necessarily indicative of our future results.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(as revised)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Statements of Operations Data:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,702</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,666</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,322</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,392</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,398</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,948</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,378</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,695</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,573</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,211</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,279</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,305</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,965</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,609</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,248</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,657</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,263</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,943</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,926</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,657</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of convertible preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock tranche liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(876</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,929</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,027</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,027</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(334</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,953</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,694</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,916</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,577</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,991</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,047</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share-basic and diluted (1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.80</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.95</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.10</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding-basic and diluted (1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,910,787</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,117,690</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,551,807</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,479,432</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,900,531</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:3pt;margin-top:0pt;margin-right:91.55%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">See Note 13 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for an explanation of the method used to calculate basic and diluted net loss per common share and the weighted average number of shares used in the computation of the per share amounts. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(as revised)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,388</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,737</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,659</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,392</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,737</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,094</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,530</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,219</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,742</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,060</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,739</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,222</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,719</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,995</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258,507</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">196,355</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,454</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,892</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,737</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,567</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">259,094</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,530</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,219</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements, related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties such as our plans, objectives, expectations and intentions. As a result of many important factors, including those set forth in the section captioned &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements. A discussion of the year ended December 31, 2019 compared to the year ended December 31, 2018 has been reported previously in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 12, 2020, under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Our proprietary platform is designed to utilize our human hematopoietic stem cell derived adeno-associated virus vectors, or AAVHSCs, to precisely and efficiently deliver single administration genetic medicines <span style="font-style:italic;">in vivo</span> either through gene therapy or nuclease-free gene editing across a broad range of genetic disorders. Our diverse set of AAVHSCs allows us to precisely target, via a single injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, peripheral nervous system, or PNS, bone marrow, muscle and eye. Our genetic medicines platform is designed to provide us the flexibility to choose the method we believe is best suited from either gene therapy or gene editing for each disease we pursue, based on such factors as the targeted disease biology, the biodistribution of our AAVHSCs to key tissues, and the rate of cell division the tissues exhibit. Our product development strategy is to continue to develop in parallel both gene therapy and gene editing, while initially leveraging the experience from our gene therapy product candidates to further advance our gene editing. We believe our dual technology platform will allow us to provide transformative cures using either modality.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unique properties of our proprietary family of 15 novel AAVHSCs enable us to focus on a method of gene editing called gene integration, through the replacement of an entire diseased gene in the genome with a whole functional copy by harnessing the naturally occurring deoxyribonucleic acid, or DNA, repair process of homologous recombination, or HR. We believe our HR-driven gene editing approach will allow us to efficiently perform gene editing at therapeutic levels without unwanted on- and off-target modifications, and to directly measure and confirm those modifications in an unbiased manner to ensure only the intended changes are made. By utilizing the body&#8217;s natural mechanism of correcting gene defects, we also avoid the need for exogenous nucleases, or bacteria-derived enzymes used in other gene editing approaches to cut DNA, that are known to significantly increase the risk of unwanted modifications.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">HMI-102 for Treatment of PKU in Adult Patients</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently in Phase 2 of the pheNIX clinical trial with our first and lead product candidate, HMI-102, a gene therapy for the treatment of adults with phenylketonuria, or PKU. In November 2020, we reported positive safety and efficacy clinical data from the dose-escalation phase of the trial. As of the data cutoff date of October 19, 2020, six patients in the dose-escalation phase of the pheNIX trial had received HMI-102 across three dose cohorts (low-dose Cohort 1, n&#61;2&#59; mid-dose Cohort 2, n&#61;2&#59; high-dose Cohort 3, n&#61;2). The results showed that HMI-102 was generally well-tolerated, and resulted in marked reductions in phenylalanine, or Phe, and the Phe-to-tyrosine, or Tyr, ratio, or the Phe-to-Tyr ratio, at two doses. Phe is a registrable endpoint in PKU, and the Phe-to-Tyr ratio is a clinically relevant diagnostic measurement for PKU. Based on the safety and efficacy results observed in the dose-escalation phase, we have selected and advanced two doses to the randomized, concurrently controlled, dose expansion Phase 2 portion of the pheNIX trial, which has the potential to be converted to a registrational trial. We expect to report initial clinical data from this portion of the trial by the end of 2021.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently progressing two gene therapy product development candidates for the treatment of lysosomal storage diseases: HMI-203 for the treatment of mucopolysaccharidosis type II (MPS II), or Hunter syndrome, and HMI-202 for the treatment of metachromatic leukodystrophy, or MLD. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in later-stage IND-enabling studies with HMI-203, an <span style="font-style:italic;">in vivo</span> gene therapy product development candidate for the treatment of Hunter syndrome. HMI-203 is a potential one-time AAVHSC treatment designed to deliver functional copies of the <span style="font-style:italic;">IDS</span> gene to multiple target organs, including those in the PNS and CNS, following a single I.V. administration. In preclinical studies, a single I.V. administration of HMI-203 resulted in robust biodistribution and human I2S, or hI2S, enzyme expression, leading to a significant reduction in heparin sulfate glycosaminoglycans, or GAGs, levels in the cerebrospinal fluid, brain, liver, heart, spleen, lung and kidney, compared with the vehicle-treated disease model. HMI-203 also led to significant changes in skeletal deformities compared with vehicle. We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-203 in 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed IND-enabling studies with HMI-202, a gene therapy </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CNS </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product development candidate for the treatment of MLD. We have generated preclinical data that demonstrate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that a single I.V. administration of HMI-202 crossed the blood-brain-barrier and blood-nerve-barrier and led to durable reduction of sulfatides in all brain regions of the disease model.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are applying the learnings from the IND-enabling studies to further optimize an HMI-202 vector that may lead to a better therapeutic profile.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are in later-stage IND-enabling studies with HMI-103, our lead gene editing product development candidate for the treatment of PKU in pediatric patients. We have generated <span style="font-style:italic;">in vivo</span> preclinical data demonstrating Phe reduction following a single I.V. administration of the murine surrogate of HMI-103 in the PKU disease model out to 43 weeks (end of study). In addition, using quantitative molecular methods, we have demonstrated achievement of gene integration efficiencies in a humanized murine liver model that corresponded with Phe correction in the PKU murine model. These findings were peer-reviewed and published in <span style="font-style:italic;">PLOS ONE</span> in May 2020.<span style="font-size:12pt;"> </span>We expect to initiate a Phase 1/2 dose-escalation clinical trial with HMI-103 in 2021.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to name a development candidate in a new therapeutic area in 2021, demonstrating the broader capability of our AAVHSC platform, which we believe may allow us to target diseases with larger patient populations in the future.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020, we entered into a stock purchase agreement, or the Stock Purchase Agreement, with Pfizer Inc., or Pfizer, pursuant to which Pfizer purchased 5,000,000 shares of our common stock through a private placement transaction at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million. For additional information, see &#8220;Liquidity and Capital Resources.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 26, 2021, we received notice from Novartis Institutes of BioMedical Research, Inc., or Novartis, that they had elected to terminate the collaboration and license agreement with respect to the ophthalmic target, which was the only remaining target under the agreement. Accordingly, the notice served as notice of Novartis&#8217; termination of the agreement in its entirety, with an effective date of August 26, 2021, which is six months from the date of the notice. Novartis has agreed to work with us to effect the orderly wind down of activities in accordance with the agreement. As a result of this notice, we have regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize our proprietary nuclease-free gene editing technology platform for the ophthalmic target. We plan to continue to advance the program toward naming a development candidate. The companies believe that results of studies conducted under the agreement provide early proof-of-principle and support a nuclease-independent approach to editing of relevant cell types in the eye after sub-retinal injection, and are the subject of a planned presentation at an upcoming scientific meeting. See Note 15 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding the Novartis collaboration and license agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have fully integrated process development and Good Manufacturing Practice, or GMP, manufacturing capabilities that support the full breadth and flexibility of our AAVHSC capsid library. Our process development expertise covers all gene therapy and gene editing development functions and incorporates deep characterization and understanding of vector design and their consequences. Our manufacturing process is a versatile system that rapidly delivers high quality vector at scale. The manufacturing capacity within our 25,000 square foot GMP manufacturing facility includes multi-suite and multi-product capabilities to support our clinical development programs in both gene therapy and gene editing<span style="font-size:12pt;"> </span>and we are now producing all of the clinical material for the pheNIX trial in this facility. Our plug and play process and manufacturing platform is a commercial manufacturing process that has successfully produced several of our product candidates. We are currently operating three 500-liter bioreactors in our internal manufacturing facility and have successfully produced GMP material at the 500-liter scale for multiple pipeline candidates. Additionally, we have successfully executed our manufacturing platform with multiple product candidates at the 2,000-liter bioreactor scale.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management team has a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases. We have a robust intellectual property portfolio with issued composition of matter patents in the United States for our family of 15 AAVHSCs and we believe the breadth and depth of our intellectual property is a strategic asset that has the potential to provide us with a significant competitive advantage. We continue to build on our intellectual property estate through our ongoing product and platform development efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have raised approximately $539 million in aggregate net proceeds through our initial public offering, or IPO, in April 2018, a follow-on public offering of common stock in April 2019, proceeds from the sale of common stock under an &#8220;at-the-market&#8221; sales agreement, equity investments and preferred stock financings. Included in our net proceeds is $50.0 million from a former collaboration partner, comprised of an up-front payment of $35.0 million and a $15.0 million equity investment and a $60.0 million equity investment from Pfizer Inc., or Pfizer, through a private placement transaction. We will require additional capital in order to advance HMI-102 and our other product candidates through clinical development and commercialization. We believe that our compelling preclinical data, positive clinical data with HMI-102, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scientific expertise, product development strategy, manufacturing capabilities, and robust intellectual property position us as a leader in the development of genetic medicines.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated and commenced operations in 2015. Since our incorporation, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, developing our technology platform, advancing our lead product candidate, HMI-102 for the treatment of PKU, through IND-enabling studies and into a Phase 1/2 clinical trial, advancing HMI-103, HMI-203, and HMI-202 into IND-enabling studies, researching and identifying additional product candidates, developing and implementing manufacturing processes and <span style="color:#000000;">internal manufacturing capabilities</span>, building out our manufacturing and research and development space, enhancing our intellectual property portfolio, and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sale of common stock, through the sale of preferred stock, and through funding from our collaboration partner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future, if at all. We recognized $2.7 million and $1.7 million in collaboration revenue for the years ended December&#160;31, 2020 and 2019, respectively. Since inception, we have incurred significant operating losses. Our net losses for the years ended December&#160;31, 2020 and 2019 were $128.7 million and $103.9 million, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $328.4 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our total operating expenses were $133.0 million and $111.6 million for the years ended December&#160;31, 2020 and 2019, respectively. We expect our operating expenses to continue to increase in connection with our ongoing development activities related to our product candidates. Specifically, we anticipate that our expenses will increase due to costs associated with our Phase 1/2 pheNIX clinical trial with HMI-102, development activities including IND-enabling studies and clinical trials associated with our other product candidates, including HMI-103, our gene editing product candidate for PKU, HMI-203, our gene therapy product candidate for Hunter syndrome, HMI-202, our gene therapy product candidate for MLD, for which we are focusing on optimization of the vector, and research activities in additional therapeutic areas to expand our pipeline, hiring additional personnel in manufacturing, research, clinical and regulatory, quality and other functional areas, increased expenses incurred with contract manufacturing organizations, or CMOs, to supply us with product for our clinical studies, costs to manufacture product for preclinical and clinical studies in our internal manufacturing facility and other costs including the maintenance and expansion of our intellectual property portfolio. In addition, we expect to continue to incur additional costs associated with operating as a public company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant capital expenditures for the buildout of a facility we have leased, including research and development labs, office space and manufacturing suites and the procurement of equipment and furniture for this facility and in support of our product development candidates and research initiatives. We expect to incur additional capital expenditures in support of our research and development activities and our manufacturing facility.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with the development of our current and any future product candidates and our platform and technology and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to predict the timing and amount of increased operating expenses and capital expenditures associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs, timing, and results of our ongoing research and development efforts, including clinical trials, on HMI-102&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs, timing, and results of our ongoing research and development efforts for HMI-103, HMI-202 and HMI-203, all of which are in IND-enabling studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs, timing, and results of our research and development efforts for current and future product candidates in our gene therapy and gene editing pipeline&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs and timing of process development and manufacturing scale-up activities, </span><span style="color:#000000;font-size:10pt;">and the adequacy of supply</span><span style="font-size:10pt;color:#000000;"> of our product candidates for preclinical studies and clinical trials through CMOs and internal manufacturing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs and timing of capital expenditures for potential additional manufacturing capacity and related equipment and furniture&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the effect of competitors and market developments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements for our product candidates. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash and cash equivalents will enable us to fund our current projected operating expenses and capital expenditure requirements into the third quarter of 2022, including, subject to the impact of the COVID-19 pandemic on our business, additional development activities related to our Phase 1/2 pheNIX clinical trial with HMI-102, the advancement of HMI-103, our lead gene editing product candidate for PKU, through IND-enabling studies and into a Phase 1/2 clinical trial, HMI-203, our lead <span style="font-style:italic;">in vivo</span> gene therapy product candidate for Hunter syndrome, through IND-enabling studies and into a Phase 1/2 clinical trial, and HMI-202, an <span style="font-style:italic;">in vivo </span>gene therapy product candidate for MLD, through additional preclinical studies as we focus on optimizing the program&#8217;s vector, the continued scale-up of our manufacturing processes and the expansion of our intellectual property portfolio. We have based these estimates on assumptions that may prove to be imprecise, and we may use our available capital resources sooner than we currently expect. See &#8220;Liquidity and Capital Resources.&#8221; Adequate additional funds may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical companies&#8217; stock have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock and any such sales may be on unfavorable terms. See &#8220;Risk Factors&#8212;The COVID-19 pandemic caused by the novel strain of coronavirus could adversely impact our business, including our preclinical studies and clinical trials.&#8221; in Item 1A of this Annual Report on Form 10-K. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect rights as a shareholder. Any future debt financing or preferred equity or other financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute the ownership interests of our shareholders.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of the COVID-19 Pandemic</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are closely monitoring how the spread of the COVID-19 pandemic is affecting our employees, our Phase 1/2 pheNIX clinical trial, preclinical studies, manufacturing and overall operations. In response to the spread of COVID-19, we have taken steps to minimize the impact on our operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operations &#8211;<span style="font-style:italic;"> </span><span style="font-weight:normal;">To protect the health of our employees and the third parties with whom we interact, most office-based employees continue to work from home, while essential staffing levels in our operations remain in place, including key personnel in our laboratories and manufacturing facility. For those employees on-site, we have developed shift schedules for our laboratories and manufacturing facility and a modified office layout and traffic flow pattern to increase spacing capabilities, reduce inter-office risks and allow for business continuity. We have increased cleaning protocols throughout our entire facility, limited visitors to only those who are critical to our ongoing operations and have cancelled all business travel. In addition, we have developed our own on-site COVID-19 surveillance testing for employees to help promote health and safety.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phase 1/2 pheNIX clinical trial &#8211;<span style="font-style:italic;"> </span><span style="font-weight:normal;">We are currently in Phase 2 of our Phase 1/2 pheNIX clinical trial and are working with trial sites to mitigate potential COVID-19-related disruptions in order to help ensure the safety of patients and healthcare professionals. In addition, we have deployed home-health services which include home visits for patient monitoring and reporting, as well as the utilization of a centralized laboratory for testing enrolled patients. Despite our best efforts, disruptions caused by the COVID-19 pandemic have resulted, and may continue to result, in delays in enrolling</span><span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">our Phase 1/2 pheNIX clinical trial. In addition, we could experience additional disruptions in conducting or completing this trial or other planned clinical trials and the incurrence of unforeseen costs as a result of these delays. We will continue to evaluate the impact of the ongoing global pandemic on the pheNIX trial and will make adjustments, as needed. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies &#8211;</span><span style="font-style:italic;"> </span><span style="font-weight:normal;">IND-enabling studies are continuing in support of our HMI-103</span><span style="font-weight:normal;"> and</span><span style="font-weight:normal;"> HMI-20</span><span style="font-weight:normal;">3</span><span style="font-weight:normal;"> programs and we have made operational changes to mitigate the risk of potential disruptions caused by the COVID-19 pandemic. All of our ongoing and planned preclinical studies at external CROs are progressing and we have accelerated shipments of reagents and supplies to avoid any disruption of activities. However, it is possible that the COVID-19 pandemic may have an impact in the future on our CROs&#8217; ability to complete critical studies required for the progression of these programs. In addition, any planned </span><span style="font-weight:normal;">or potential meetings with the FDA or other regulatory authorities about any of our development programs could be delayed as these regulatory bodies respond to the ongoing pandemic.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing &#8211;<span style="font-style:italic;"> </span><span style="font-weight:normal;">We continue to operate our manufacturing facility at or near normal levels. We have on-hand all of the drug product needed for the expansion phase of the pheNIX clinical trial. In addition, during the first quarter of 2020, we began to accelerate the procurement of raw materials for future manufacturing, research and development needs to minimize potential supply chain interruptions. While we currently do not anticipate any interruptions in our manufacturing process, it is possible that the COVID-19 pandemic and response efforts may have an impact in the future on our and/or our third-party suppliers and CMOs&#8217; ability to manufacture our product candidates or materials needed for our preclinical studies and clinical trials.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and impact of related responses and as a result, we expect that the COVID-19 pandemic may impact our business, revenues, results of operations and financial condition. The impact of COVID-19 on our future results will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, the ultimate impact of COVID-19 on financial markets and the global economy, the effectiveness of vaccines and vaccine distribution efforts and the effectiveness of other actions taken in the United States and other countries to contain and treat the disease. See &#8220;Risk Factors&#8212; The COVID-19 pandemic caused by the novel strain of coronavirus could adversely impact our business, including our preclinical studies and clinical trials.&#8221; in Item 1A of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Our Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. We recorded $2.7 million in collaboration revenue for the year ended December&#160;31, 2020 (see Notes&#160;15 and 16 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding revenue recognition discussions). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, and other third parties that conduct research, preclinical activities and clinical trials on our behalf as well as CMOs and our internal technical operations team that manufacture our product candidates for use in our preclinical testing, </span><span style="color:#000000;font-size:10pt;">our Phase 1/2 pheNIX clinical trial and additional&#160;</span><span style="font-size:10pt;color:#000000;">potential future clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">costs of outside consultants, including their fees and related travel expenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">facility-related expenses, which include direct depreciation costs and </span><span style="color:#000000;font-size:10pt;">allocated expenses for rent and maintenance of facilities and other operating costs</span><span style="font-size:10pt;color:#000000;">. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We typically use our employee and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in other research and development expenses in the table below. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses by product candidate or development program: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HMI-102 external development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,409</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,753</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,656</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other development-stage programs' external</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,625</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,632</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,993</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,373</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,532</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,841</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,985</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,481</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,392</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,398</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we advance clinical trials of HMI-102, <span style="color:#000000;">for the treatment of PKU, including our Phase 1/2 pheNIX clinical trial</span>, continue to advance HMI-103, HMI-203, and HMI-202 through IND-enabling studies and into clinical trials and continue to discover and develop additional product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the duration and costs of future clinical trials of HMI-102 and IND-enabling studies and future clinical trials of our other product candidates in development or any other future product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of HMI-102, our other product candidates in development and any other future product candidate we may develop will depend on a variety of factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope, rate of progress, expense and results of clinical trials of HMI-102, HMI-103, HMI-202, and HMI-203 as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">uncertainties in clinical trial design and patient enrollment rates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">any delays in clinical trials as a result of the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the actual probability of success for our product candidates, including the safety and efficacy results, early clinical data, competition, manufacturing capability and commercial viability&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">significant and changing government regulation and regulatory guidance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing and receipt of any marketing approvals&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, human resources, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters&#59; professional fees for accounting, auditing, tax and consulting services&#59; insurance costs&#59; travel expenses&#59; and facility-related expenses, which include direct depreciation costs, rent expense, maintenance of facilities and other operating costs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to HMI-102, HMI-103, HMI-202, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HMI-203 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and any other product candidate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we may develop. We also have incurred and expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> compliance with the Sarbanes-Oxley Act of 2002, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements&#59; director and officer insurance costs&#59; and investor and public relations costs. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest income earned on our cash, cash equivalents and short-term investments. Our interest income has decreased due to lower yields on invested funds as well as lower invested balances during the year ended December&#160;31, 2020 as compared to the same period in 2019. Market volatility resulting from the COVID-19 pandemic has and may continue to adversely impact our interest income.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in 2015, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December&#160;31, 2020, we had federal and state net operating loss carryforwards of $265.1&#160;million and $271.5&#160;million, respectively, that expire at various dates through 2040. As of December&#160;31, 2020, we also had federal and state research and development tax credit carryforwards of $34.2&#160;million and $7.2&#160;million, respectively, that expire at various dates through 2040. Included in the $34.2 million of federal research and development credit carryforwards is $29.0 million of orphan drug credit carryforwards.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates, assumptions and judgements that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition<span style="font-weight:normal;">&#8212;In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue (Topic 606): </span><span style="font-style:italic;font-weight:normal;">Revenue from Contracts with Customers</span><span style="font-weight:normal;"> (&#8220;ASU 2014-09&#8221;), which amends the guidance for accounting for revenue from contracts with customers. ASU 2014-09 supersedes the revenue recognition requirements in FASB ASC Topic 605, </span><span style="font-style:italic;font-weight:normal;">Revenue Recognition</span><span style="font-weight:normal;"> (&#8220;ASC 605&#8221;), and creates a new Topic 606, </span><span style="font-style:italic;font-weight:normal;">Revenue from Contracts with Customers</span><span style="font-weight:normal;"> (&#8220;ASC 606&#8221;). On January 1, 2019, we adopted ASC 606 using the full retrospective transition method.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations&#59; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that we will collect consideration we are entitled to in exchange for the goods or services we transfer to the customer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangement that includes variable consideration, we evaluate the amount of consideration to which we expect to be entitled to. We utilize either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within our control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of such development and clinical milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). We allocate the transaction price based on the estimated standalone selling price of each performance obligation. We develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress for our over-time arrangements at each reporting period and, if necessary, adjust the measure of performance and related revenue recognition and, if necessary, update the measure or progress and revenue recognized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses<span style="font-weight:normal;">&#8212;As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contract and purchase orders, communicating with our personnel and vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met&#59; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid to: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">CROs and other third parties in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf and CMOs in connection with producing product for our clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">vendors in connection with preclinical development activities&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">vendors related to product manufacturing and development and distribution of preclinical supplies. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We base our expenses related to preclinical and clinical studies on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials and CMOs that manufacture product for our research and development activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation</span><span style="font-weight:normal;">&#8212;We account for stock-based compensation transactions using a grant-date fair-value-based method under FASB Codification Topic 718, </span><span style="font-style:italic;font-weight:normal;">Compensation&#8212;Stock Compensation</span><span style="font-weight:normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure stock options and other stock-based awards granted to employees, directors, consultants or advisors of the company or its affiliates based on their fair value on the date of the grant and recognize compensation expense of those awards, over the requisite service period, which is generally the vesting period of the respective award. We apply the straight-line method of expense recognition to all awards with only service-based vesting conditions and apply the graded-vesting method to all awards with performance-based vesting conditions or to awards with both service-based and performance-based vesting conditions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company,&#8221; which we are, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organizations related to their leasing activities. For additional information regarding our adoption of the new leasing standards, please refer to Notes 2 and 8 to our consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span>: Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. ASU 2016-13 is effective for us beginning January 1, 2023, with early application permitted. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued ASU No. 2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718)</span>: Improvements to Nonemployee Share-Based Payment Accounting (&#8220;ASU 2018-07&#8221;), which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. We adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on our consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued ASU 2020-10, <span style="font-style:italic;">Codification Improvements</span>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. We will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material impact on our consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2020 and 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,702</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,666</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,036</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,392</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,398</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,573</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,211</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,362</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,965</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,609</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,356</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,263</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,943</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,320</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,027</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,458</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,569</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,027</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,458</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(128,694</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(103,916</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,778</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Collaboration Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue for the year ended December&#160;31, 2020 was $2.7 million, compared to $1.7 million for the year ended December&#160;31, 2019. For the year ended December 31, 2020, collaboration revenue consisted primarily of revenue recognized under our collaboration agreement with Novartis. We recognize such revenues consistent with the pattern of performance of our research and development activities under the collaboration, taking into consideration all upfront payments and research funding payments under this arrangement together as a single performance obligation. Collaboration revenue recognized under the collaboration in a given period is based on actual costs incurred during that period as a percentage of total estimated costs to complete the single performance obligation under the arrangement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HMI-102 external development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,409</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,753</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,656</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other development-stage programs' external</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,625</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,632</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,993</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee-related costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,373</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,532</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,841</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,985</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,481</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,392</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,398</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December&#160;31, 2020 were $100.4&#160;million, compared to $89.4 million for the year ended December&#160;31, 2019. The increase of $11.0 million was due to an increase of $3.7 million in direct research expenses for HMI-102 including costs incurred with our CRO to conduct and manage our Phase 1/2 pheNIX clinical trial, as well as costs related to manufacturing clinical trial materials. Additionally, there was a $11.0 million increase in direct research expenses related to our other development-stage programs, including our newly announced HMI-203 program for Hunter syndrome, as well as a $9.8 million increase in employee-related costs due to additional employee headcount to support our ongoing development programs, research initiatives, technology platform and manufacturing capabilities resulting in increases in salaries, payroll taxes, stock-based compensation expense and recruiting costs. Partially offsetting these increases was a $13.5 million decrease in research and development costs related to laboratory supplies and research materials for our early-stage research programs.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the year ended December&#160;31, 2020 were $32.6 million, compared to $22.2&#160;million for the year ended December&#160;31, 2019.<span style="font-size:12pt;"> </span>The increase of $10.4 million was due to an increase in employee-related </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which included $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of increased stock-based compensation expense, an increase in facility </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal costs and other professional fees of $0.9 million, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in insurance and taxes of $0.8 million, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in software expense of $0.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in consulting expense of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an increase in recruiting fees of $0.4 million and an increase in market research of $0.4 million</span><span style="font-size:12pt;">&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income for the year ended December&#160;31, 2020 was $1.6 million, compared to $6.0&#160;million for the year ended December&#160;31, 2019. The decrease was the result of lower invested balances in cash, cash equivalents and short-term investments for the year ended December&#160;31, 2020 compared to the year ended December&#160;31, 2019, <span style="Background-color:#FFFFFF;color:#000000;">as well as significantly lower yields on invested funds</span>.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Net Loss</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss for the year ended December&#160;31, 2020 was $128.7 million, compared to $103.9 million for the year ended December&#160;31, 2019. The increase in net loss was primarily due to the increases in research and development and general and administrative expenses discussed above.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs and our capital expenditures will increase in connection with conducting preclinical studies and clinical trials for our product candidates, contracting with CMOs producing material in our internal manufacturing facility to support preclinical studies and clinical trials, expanding our research and development laboratories and manufacturing facility, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of common stock, the sale of preferred stock and through an up-front payment from a collaboration partner. Since our inception in 2015, we have raised approximately $539 million in aggregate net proceeds through our IPO in April 2018, a follow-on public offering of common stock in April 2019, proceeds from the sale of common stock under an &#8220;at-the-market&#8221; sales agreement, equity investments and preferred stock financings. Included in our net proceeds is $50.0 million from a former collaboration partner, comprised of an up-front payment of $35.0 million and a $15.0 million equity investment and a $60.0 million equity investment from Pfizer through a private placement transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, as sales agent, pursuant to which we may, from time to time, issue and sell common stock with an aggregate value of up to $150.0 million in "at-the-market" offerings, or the ATM, under our Registration Statement on Form S-3 (File No. 333-237131) filed with the SEC on March 12, 2020. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Global Market or on any other existing trading market for our common stock. No securities were issued pursuant to the Sales Agreement during the year ended December&#160;31, 2020. As of December&#160;31, 2020, there was $150.0 million of common stock remaining available for sale under the ATM. Simultaneous with the filing of the registration statement in March 2020, our previous Registration Statement on Form S-3 (File No. 333-230664) filed with the SEC on April 1, 2019 and our prior sales agreement with Cowen providing for the offering, issuance and sale of up to an aggregate $100.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings were terminated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Strategic Collaborations and Investments</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020, we entered into the Stock Purchase Agreement with Pfizer, pursuant to which Pfizer purchased 5,000,000 shares of our common stock through a private placement transaction at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million. Under the Stock Purchase Agreement, Pfizer was granted an exclusive right of first refusal, or ROFR, for a 30-month period beginning on the date of the closing of the private placement to negotiate a potential collaboration on the development and commercialization of HMI-102 and HMI-103. Pfizer may exercise its right of first refusal under the ROFR one time for each of HMI-102 and HMI-103 during the ROFR period. In addition to the ROFR, the Stock Purchase Agreement provided for an information sharing committee comprised of representatives of each company which will serve as a forum for sharing information regarding the development of HMI-102 and HMI-103 during the ROFR </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eriod.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, Pfizer has designated a member to join our Scientific Advisory Board to participate in matters related to the development of these programs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Part I, Item 1. &#8220;Strategic Collaborations&#8212;Collaboration and License Agreement with the Novartis Institutes for BioMedical Research, Inc.&#8221; for additional information about our collaboration and license agreement with Novartis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and<span style="font-size:12pt;"> </span>short-term investments totaled $217.4 million and $262.4 million as of December&#160;31, 2020 and 2019, respectively. We had no indebtedness as of December&#160;31, 2020 and 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for the period presented: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(94,332</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91,358</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204,896</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,799</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,093</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,213</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163,657</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,056</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows for the year ended December&#160;31, 2020 </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2020 was $94.3 million, driven primarily by our net loss of $128.7 million as we incurred expenses associated with research and development activities on HMI-102, HMI-103, HMI-203, and HMI-202, <span style="color:#000000;">including the Phase 1/2 pheNIX trial for our HMI-102 program,</span> and research activities on other applications for our technology, and a decrease in operating lease liabilities of $2.3 million. These items were partially offset by net non-cash expenses of $22.8 million, which includes $13.2 million of stock-based compensation expense and $8.0 million of depreciation expense, and a decrease in working capital of $13.8 million.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities for the year ended December&#160;31, 2020 was $204.9 million, attributable to maturities of short-term investments of $228.6 million, partially offset by purchases of short-term investments of $20.0 million and purchases of property and equipment of $3.7 million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2020 was $53.1 million, primarily due to $52.0 million of net proceeds allocated to the issuance of common stock in a private placement transaction with Pfizer in November 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows for the year ended December&#160;31, 2019 </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities for the year ended December&#160;31, 2019 was $91.4 million, driven primarily by our net loss of $103.9 million as we incurred expenses associated with research and development activities on HMI-102, HMI-103 and HMI-202, <span style="color:#000000;">including the Phase 1/2 pheNIX trial for our HMI-102 program,</span> and research activities on other applications for our technology. The funding of our net loss was partially offset by net non-cash expenses of $12.1 million, including $7.6 million of stock compensation expense and $6.3 million of depreciation expense. Changes to working capital were mostly offsetting, with $4.5 million in decreased accounts payable and $0.6 million in decreased deferred revenue netting against $2.8 million in decreased prepaid expenses and other current assets and $2.3 million in increased accrued expenses and other liabilities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities for the year ended December&#160;31, 2019 was $51.8 million, attributable to $286.4 million in purchases of short-term investments and $21.8 million in purchases of property and equipment, partially offset by maturities of short-term investments of $256.4 million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.79%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities for the year ended December&#160;31, 2019 was $158.2 million, primarily due to $134.5 million of net proceeds from the issuance of common stock in a public offering in April 2019 and $22.5 million of net proceeds from the issuance of common stock under an &#8220;at-the-market&#8221; sales agreement in December 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating expenses increased substantially in 2020 and are expected to increase in future years in connection with our ongoing activities, particularly as we advance our Phase 1/2 pheNIX clinical trial with HMI-102 and our preclinical activities including IND-enabling studies and expected Phase 1/2 clinical trials, continue to scale-up our manufacturing processes, engage with CMOs, manufacture materials for preclinical and clinical activities in our internal manufacturing facility and initiate additional human clinical trials. In addition, we have incurred and expect to continue to incur additional costs associated with operating as a public company. We also expect our capital expenditures to increase as we expand our operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, our expenses will increase as we: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">pursue the preclinical and clinical development of HMI-102, including the ongoing pheNIX Phase 1/2 clinical trial, HMI-103, HMI-203 and HMI-202&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">pursue the preclinical and clinical development of other product candidates based on our gene therapy and gene editing technology&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">further scale up our internal manufacturing processes and capabilities, </span><span style="color:#000000;font-size:10pt;">manufacture materials in our internal manufacturing facility</span><span style="font-size:10pt;color:#000000;"> and contract with CMOs to support our preclinical studies and clinical trials of our product candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">further expand our manufacturing capacity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">operate our business in our facility with expanded research and development labs and manufacturing suites and purchase additional equipment for our operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">in-license or acquire the rights to other products, product candidates or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">maintain, expand and protect our intellectual property portfolio&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">hire additional personnel in research, manufacturing and regulatory and clinical development as well as management personnel&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expand our operational, financial and management systems and increase personnel, including personnel to support our operations as a public company. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash and cash equivalents will enable us to fund our current projected operating expenses and capital expenditure requirements into the third quarter of 2022, including, subject to the impact of the COVID-19 pandemic on our business, additional development activities related to our Phase 1/2 pheNIX clinical trial with HMI-102, the advancement of HMI-103, our lead gene editing product candidate for PKU, through IND-enabling studies and into a Phase 1/2 clinical trial, HMI-203, our lead CNS/PNS gene therapy product candidate for Hunter syndrome, through IND-enabling studies and into a Phase 1/2 clinical trial, and HMI-202, a CNS gene therapy product candidate for MLD, through additional preclinical studies as we focus on optimizing the program&#8217;s vector, the continued scale-up of our manufacturing processes and the expansion of our intellectual property portfolio. We have based these estimates on assumptions that may prove to be imprecise, and we may use our available capital resources sooner than we currently expect. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drugs, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the progress, costs and results of our preclinical development and initial clinical trials for HMI-102, including the pheNIX Phase 1/2 clinical trial, HMI-103, HMI-203, and HMI-202&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the progress, costs and results of our additional research and preclinical development programs in gene therapy and gene editing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs, scope and timing of internal process development and manufacturing scale-up activities, </span><span style="color:#000000;font-size:10pt;">the production of materials in our internal manufacturing facility,&#160;</span><span style="font-size:10pt;color:#000000;">and outsourcing activities with CMOs associated with our lead product development programs and other programs we advance through preclinical and clinical development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial terms of such agreements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the scope, progress, results and costs of any product candidates that we may derive from our platform technology or any other product candidates that we may develop&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which we in-license or acquire rights to other products, product candidates or technologies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against any intellectual property-related claims. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity and future funding requirements is uncertain as of the filing date of this Annual Report on Form 10-K, as the pandemic continues to evolve globally. See &#8220;Impact of the COVID-19 Pandemic&#8221; above and &#8220;Risk Factors&#8212; The COVID-19 pandemic caused by the novel strain of coronavirus could adversely impact our business, including our preclinical studies and clinical trials.&#8221; in Item 1A of this Annual Report on Form 10-K for a further discussion of the possible impact of the COVID-19 pandemic on our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances, licensing arrangements and marketing and distribution arrangements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a summary of our significant contractual obligations as of December&#160;31, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments&#160;Due&#160;by&#160;Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less&#160;Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1&#160;Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More&#160;Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1&#160;Year&#160;and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less&#160;Than&#160;3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More&#160;Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3&#160;years&#160;and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less&#160;Than&#160;5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More&#160;Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5&#160;years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligation (1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,403</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,973</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,064</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,433</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,933</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License obligations (2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">655</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">430</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:3pt;line-height:6pt;margin-top:0pt;margin-right:91.55%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents future minimum lease payments under our operating leases for office and lab space in Bedford, Massachusetts that expire in October 2021 and February 2027. Future minimum lease payments are net of anticipated sublease payments of approximately $0.9 million in 2021.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents minimum annual license fees under our license agreements with Caltech and COH. These amounts do not include any potential contingent payments upon the achievement by us of specified clinical, regulatory and commercial events, as applicable, or patent prosecution or royalty payments we may be required to make under these license agreements. We have excluded these potential payments in the contractual obligations table because the timing and likelihood of these contingent payments are not currently known and would be difficult to predict or estimate. See Part I, Item 1. &#8220;Strategic Collaborations&#8221; for additional information about these license agreements, including with respect to potential payments thereunder. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.59%;text-indent:-4.79%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30 days and, as a result, are not included in the table of contractual obligations above.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, and short-term investments of $217.4 million, or 82.4% of our total assets at December&#160;31, 2020, and $262.4 million, or 84.5% of our total assets at December&#160;31, 2019. Interest income earned on these assets was $1.6 million in 2020 and $6.0 million in 2019. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. If a 10% change in interest rates were to have immediately occurred on December&#160;31, 2020, this change would not have had a material effect on the fair value of our investment portfolio as of that date. At December&#160;31, 2020, our cash equivalents consisted of bank deposits and money market funds. Such interest-earning instruments carry a degree of interest rate risk&#59; however, historical fluctuations in interest income have not been significant for us. We had no debt outstanding as of December&#160;31, 2020 and 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of those financial statements is found in Item 15 of Part IV of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations on effectiveness of controls and procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of disclosure controls and procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December&#160;31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s annual report on internal control over financial reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control - Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Attestation report of the registered public accounting firm</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for "emerging growth companies."</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Changes in internal control over financial reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors and Executive Officers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the name, age and position of each of our executive officers and directors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Executive Officers:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer, Treasurer and Secretary</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tim Kelly</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Technical Operations Officer</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gabriel M. Cohn, M.D.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Directors:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D. (3)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D. (2)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D. (2)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson (1)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton (1)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alise S. Reicin, M.D. (3)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Thistle (1)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the audit committee. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the compensation committee. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Member of the nominating and corporate governance committee. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D. <span style="font-style:normal;">has served as our President, Chief Executive Officer and member of our board of directors since April 2016. Dr.&#160;Tzianabos joined Homology from OvaScience, Inc., a biotechnology company (which has since merged with and into Millendo Therapeutics, Inc.), where he served as President and Chief Scientific Officer from September 2013 to March 2016. Prior to OvaScience, Dr.&#160;Tzianabos spent eight years at Shire plc, a biotechnology company, where he served in positions of increasing responsibility, including Senior Director, Discovery Research, Vice President, Program Management and Senior Vice President and Head, Research and Early Development. From 1992 to 2005, Dr.&#160;Tzianabos was a faculty member at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women&#8217;s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Tzianabos currently serves as a director of Stoke Therapeutics, Inc. and is Chairman of the board of directors of Akouos, Inc. Dr. Tzianabos previously served as a director of BIND Therapeutics, Inc. Dr.&#160;Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire. We believe Dr.&#160;Tzianabos&#8217; extensive academic and clinical experience, as well as his knowledge of the industry, qualifies him to serve on our board of directors. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">W. Bradford Smith <span style="font-style:normal;">has served as our Chief Financial Officer and Treasurer since April 2017 and our Secretary since July 2017. From March 2014 to April 2017, Mr.&#160;Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical platform company. Prior to joining Ocular Therapeutix, Inc., Mr.&#160;Smith served as the Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Mr.&#160;Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D.<span style="font-style:normal;"> has served as our Chief Scientific Officer since April 2016. Prior to joining Homology, Dr.&#160;Seymour was Senior Vice President, Head of Global Research and Nonclinical Development at Shire plc, a biotechnology company, from 2011 to 2016. Dr.&#160;Seymour received his B.A. in Biology from the University of Delaware, an M.S. from Johns Hopkins University School of Medicine and his Ph.D. in Human Genetics from the University of Pittsburgh. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tim Kelly<span style="font-style:normal;"> has served as our Chief Technical Operations Officer since April 2018, and prior to that, he served as our Senior Vice President of Technical Operations from May 2017 to April 2018. From January 2017 to May 2017, Mr. Kelly served as Head of Technical Operations at Sarepta Therapeutics, Inc., a biopharmaceutical company. Prior to that, Mr. Kelly spent eight years, from 2009 to 2017, at Shire plc, a biotechnology company, where he served most recently as Senior Vice President and Head of Biologics Operating Unit from May 2016 to January 2017, and prior to that served in roles of increasing responsibility, including Interim Head of Technical Operations from August 2015 to April 2016 and Head of Product Strategy </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">&#38; Planning from 2014 to July 2015. He was previously the Head of Technical Operations at UCB S.A. in Belgium. Mr. Kelly </span><span style="font-style:normal;">also held roles of increasing responsibility at Biogen Idec, including Senior Director of International Operations. Mr. Kelly holds a B.S. with emphasis in Engineering Mechanics from the United States Air Force Academy and an M.B.A. from Troy University.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Gabriel M. Cohn, M.D.<span style="font-style:normal;"> has served as our Chief Medical Officer since December 2019. Prior to joining Homology, Dr. Cohn was Vice President, Clinical Development Lead at AVROBIO, Inc., a clinical-stage gene therapy company, from November 2017 to November 2019. Prior to AVROBIO, Dr. Cohn served as Vice President and Head of Global Clinical and Medical Affairs at OvaScience, Inc., a biotechnology company, from 2015 to July 2017. Prior to that, Dr. Cohn spent seven years at Shire plc, a biotechnology company, including Shire Human Genetic Therapies (HGT), where he most recently held the position of Senior Medical Director, Clinical Sciences from 2012 to 2015, and prior to that served in roles of increasing responsibility including Interim Global Franchise Medical Lead, Gaucher Disease in 2011 and Medical Director, North America from 2008 to 2011. Prior to joining the biotechnology industry, Dr. Cohn served as the Chief, Division of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He began his academic career as the Director, Reproductive Genetics at SUNY Health Science Center (HSC) at Syracuse (now Upstate). Dr. Cohn has a B.S. in Biology from Brooklyn College, an M.D. from SUNY HSC at Syracuse School of Medicine and an M.B.A. from University of Massachusetts Amherst.</span></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D. <span style="font-style:normal;">has served as a member of our board of directors since 2016. Since 2005, Dr.&#160;Gillis has been a managing director at ARCH Venture Partners, a venture capital firm. From 1994 to 2005, Dr.&#160;Gillis served as Chief Executive Officer and chairman of the board of directors of Corixa Corporation, which he co-founded in October 1994. Previously, Dr.&#160;Gillis served as Director, Head of Research and Development, Chief Scientific Officer and acting Chief Executive Officer of Immunex Corporation, which he co-founded, from 1981 until his departure in 1994. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr.&#160;Gillis led its acquisition by Emergent BioSolutions in the fall 2010. Dr.&#160;Gillis currently serves as a director of Takeda Pharmaceutical Company Limited (and as director of Shire plc prior to its acquisition by Takeda), and serves as a director and chairman of VBI Vaccines Inc. Dr. Gillis also currently serves as a director of several private companies. Dr.&#160;Gillis previously served as a director at and Pulmatrix, Inc. from 2008 to 2020, at PhaseRx, Inc. from 2008 to 2018 and at bluebird bio, Inc. from 2011 to 2015. Dr.&#160;Gillis received his B.A. in Biology and English from Williams College and his Ph.D. in Biological Science from Dartmouth College. We believe that Dr.&#160;Gillis&#8217;s knowledge of immunology and experience in the venture capital industry, particularly with biotechnology and pharmaceutical companies, qualifies him to serve as a member of our board of directors. </span></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D. <span style="font-style:normal;">has served as a member of our board of directors since 2015. Prior to his retirement, Dr.&#160;Gregory served as Executive Vice President and Chief Scientific Officer of ImmunoGen, Inc., a biotechnology company, from 2015 until August 2019. Prior to joining ImmunoGen, Inc., he spent 25 years at Genzyme Corporation, a biotechnology company, in roles of increasing responsibility, including Senior Vice President and Head of Research from 2003 until Genzyme Corporation&#8217;s acquisition by Sanofi in 2011, and Head of Research and Development for Genzyme from 2011 through 2014. Dr. Gregory serves as a director of ProMIS Neurosciences, Inc. Dr.&#160;Gregory received his B.A. in Science from Virginia Tech and holds a Ph.D. from the University of Massachusetts, Amherst, and completed his post-doctoral work at the Worcester Foundation for Experimental Biology. We believe that Dr.&#160;Gregory&#8217;s knowledge of immunology qualifies him to serve as a member of our board of directors. </span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D. <span style="font-style:normal;">has served as a member of our board of directors since 2015 and as Chairman of the Board since March 2018. Dr.&#160;Parmar is a Managing Partner at 5AM Venture Management LLC, an early stage venture capital firm focused on the life sciences, where he has been since 2010. Before joining 5AM, from 2002 to 2010, he was at Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. physician scientist fellow in the joint Harvard-MIT Health Sciences and Technology Program. Dr.&#160;Parmar currently serves on the boards of 5:01 Acquisition Corp. and Akouos, Inc., as well as the boards of numerous private companies. He previously served as a board member or observer for Arvinas, Inc., Achaogen, Inc., Audentes Therapeutics, Inc. (acquired by Astellas Pharma Inc.), Pulmatrix, Inc. and scPharmaceuticals Inc. He is a member of the scientific advisory boards of Penn Medicine, Princeton University&#8217;s Department of Molecular Biology, and the Grace Science Foundation, and is a fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr.&#160;Parmar completed clinical clerkships at the Massachusetts General&#160;&#38; Brigham and Women&#8217;s Hospitals, attended courses at Harvard Business School and consulted for an oncology startup. He also founded a non-profit international development organization, the Cruz Blanca Initiative. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University, and an M.D. from Harvard Medical School. We believe that Dr.&#160;Parmar&#8217;s experience in the life sciences industry, his experience as a venture capitalist and senior executive, as well as his service on the boards of directors of numerous companies provide him with the qualifications to serve as a director of our company. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson </span><span style="font-style:normal;">has served as a member of our board of directors since 2018. Mr. Patterson is the co-founder of Audentes Therapeutics, Inc., a biotechnology company, and has served in the role of Strategic Advisor since January 2020. Previously, he served as its Chief Executive Officer from November 2012 until Audentes&#8217; acquisition by Astellas Pharma Inc. in January 2020. Mr. Patterson also served as Audentes&#8217; Chairman of the board of directors and formerly served as President until May 2018. Prior to that, Mr. Patterson was the Entrepreneur-In-Residence at OrbiMed Advisors LLC. Prior to OrbiMed, Mr. Patterson served in roles at Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc. and Genzyme Corporation. </span><span style="font-style:normal;">Mr. Patterson</span><span style="font-style:normal;"> serves as a director of </span><span style="font-style:normal;">Vor Biopharma, Inc. </span><span style="font-style:normal;">and 5:01 Acquisition Corp., and also serves as a director of several private companies</span><span style="font-style:normal;">. </span><span style="font-style:normal;">Mr. Patterson holds a B.A. from Bowdoin College. We believe that Mr. Patterson&#8217;s experience in the biotechnology and biopharmaceutical industries, as well as his service on the board of directors of a public company provide him with the qualifications to serve as a director of our company.</span><span style="font-style:normal;"> </span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton<span style="font-style:normal;"> has served as a member of our board of directors since July 2020. Mr. Poulton has served as Executive Vice President and Chief Financial Officer at Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, since August 2019. Prior to joining Alnylam, Mr. Poulton served as Chief Financial Officer of Indigo Agriculture, a plant microbiome company, from January 2018 to April 2019, where he supported the initial commercial scale-up of the business, including expansion outside the U.S. Between 2003 and December 2017, Mr. Poulton held various roles of increasing responsibility at Shire plc, most recently as Chief Financial Officer and a member of Shire&#8217;s Executive Committee and Board of Directors from January 2015 to December 2017. During his tenure at Shire, Mr. Poulton also led Shire&#8217;s rare disease U.S., LATAM and Asia Pacific commercial operations, as well as Shire&#8217;s global rare disease business unit. Prior to Shire, Mr. Poulton led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corp. and PPG Industries. Mr. Poulton also served in the United States Navy as a Commissioned Officer. Mr. Poulton holds a B.A. in Economics from Duke University and an M.B.A. from Indiana University. We believe that Mr. Poulton is qualified to serve on our board of directors due to his finance background and industry experience.</span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Alise Reicin, M.D.<span style="font-style:normal;"> has served as a member of our board of directors since July 2019. Dr. Reicin has served as Chief Executive Officer of Tectonic Therapeutic, Inc., a biotechnology company, since August 2020. Prior to Tectonic. Dr. Reicin served as President, Global Clinical Development at Celgene Corporation, a pharmaceutical company, from November 2018 to December 2019. Prior to Celgene, she served as Head of Global Clinical Development at EMD Serono, a pharmaceutical company, from May 2015 through October 2018. Prior to EMD Serono, Dr. Reicin served as VP, Program Leadership Oncology at Merck and Co., a pharmaceutical company. She holds a B.A. in Biochemistry from Barnard College of Columbia University and an M.D. from Harvard Medical School. We believe that Dr. Reicin&#8217;s clinical expertise and leadership roles in the biotechnology and biopharmaceutical industries provide her with the qualifications to serve as a director of our company.</span></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Mary Thistle<span style="font-style:normal;"> has served as a member of our board of directors since 2018. Ms. Thistle has served as Special Advisor to the Bill &#38; Melinda Gates Medical Research Institute, a non-profit biotech organization, since the fall of 2020, and previously served as the organization&#8217;s Chief of Staff from January 2018 until assuming her current role. Prior to that, she held senior leadership positions at Dimension Therapeutics, Inc., a gene therapy company, including Chief Operating Officer from 2016 to 2017 and Chief Business Officer from 2015 to 2016. Prior to joining Dimension Therapeutics, Inc., she spent six years at Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where she held various leadership positions, including Senior Vice President, Business Development from 2014 to 2015, Vice President, Business Development from 2012 to 2013 and Senior Director, Business Development from 2009 to 2012. Prior to that, she held various positions at ViaCell, Inc. and PerkinElmer Inc. Ms. Thistle currently serves on the board of directors of Ziopharm Oncology, Inc., as well as the boards of several private companies. Ms. Thistle holds a B.S. in Accounting from the University of Massachusetts, Boston. We believe that Ms. Thistle is qualified to serve on our board of directors due to her finance background and industry experience.</span></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delinquent Section 16(a) Reports</p>
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 16(a) of the Exchange Act requires our directors, executive officers and stockholders who beneficially own more than 10% of any class of our equity securities registered pursuant to Section 12 of the Exchange Act (collectively, the &#8220;Reporting Persons&#8221;) to file initial statements of beneficial ownership of securities and statements of changes in beneficial ownership of securities with respect to our equity securities with the SEC. Based on our review of the copies of such forms filed with the SEC and upon any written representations of the Reporting Persons received by us, we believe that there has been compliance with all Section 16(a) filing requirements applicable to such Reporting Persons with respect to the year ended December 31, 2020.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Code of Ethics</span></p>
<p style="margin-bottom:18pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a written Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website at <span style="text-decoration:none;">www.homologymedicines.com</span> in the &#8220;Investors&#8221; section under &#8220;Corporate Governance.&#8221; In addition, we intend to post on our website all disclosures that are required by law or the listing standards of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) concerning any amendments to, or waivers from, any provision of the code. The information contained on our website is not incorporated by reference into this Annual Report on Form 10&#8209;K.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee and Audit Committee Financial Expert</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a separately-designated standing audit committee (&#8220;Audit Committee&#8221;). The members of the Audit Committee are Matthew R. Patterson, Jeffrey V. Poulton and Mary Thistle. Ms. Thistle serves as the Chairperson of the Audit Committee. The members of our Audit Committee meet the requirements for financial literacy under the applicable rules of the SEC and Nasdaq. Our board of directors has determined that Ms. Thistle is an &#8220;audit committee financial expert&#8221; as defined by Item 407(d)(5)(ii) of Regulation S-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This section discusses the material components of our 2020 compensation program for our principal executive officer and next three most highly compensated executive officers who are named in the 2020 Summary Compensation Table below. These &#8220;named executive officers&#8221; and their positions are: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Arthur O. Tzianabos, Ph.D., President and Chief Executive Officer&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Albert Seymour, Ph.D., Chief Scientific Officer&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">W. Bradford Smith, Chief Financial Officer.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Summary Compensation Table</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning the compensation of our named executive officers for the years ended December 31, 2019 and 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and principal position</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ (1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incentive Plan</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ (2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">309,760</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885,960</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537,600</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,217,097</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">295,680</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,062,877</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,800</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,720</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,057</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607,577</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Scientific Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,600</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,295,756</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,240</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,231</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,876,827</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">162,680</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582,380</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer, Treasurer and Secretary</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,200</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,307,536</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,680</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,880</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,860,296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Amounts reflect the full grant date fair value of stock options granted during the applicable year computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all option awards in Note 12 to our consolidated financial statements included in this Annual Report on Form 10-K.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Amount shown represents 401(k) matching contributions. For additional information, refer to the discussion below under the heading &#8220;Narrative Disclosure to Summary Compensation Table &#8212;Retirement Plans.&#8221;</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:6pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Narrative Disclosure to Summary Compensation Table</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary elements of compensation for our named executive officers are base salary, annual performance bonuses and long-term equity-based compensation awards. The named executive officers also generally participate in employee benefit plans and programs that we offer to our other full-time employees on the same basis.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">20</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">20</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> Salaries</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The named executive officers receive a base salary to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. The following table shows the annual base salaries for 2020 and 2021 of our named executive officers. The 2021 annual base salaries became effective January 1, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 Annual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">563,200</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583,100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">426,800</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,700</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445,300</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2020 Bonuses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We offer our named executive officers the opportunity to earn annual cash bonuses to compensate them for attaining short-term company and individual goals as approved by our board of directors. For 2020, bonuses were based on attaining corporate goals relating to product development, manufacturing processes, and raising equity capital and individual goals related to each named executive officer&#8217;s area of responsibility within the Company. The 2020 target bonus amounts, expressed as a percentage of annual base salary, of our named executive officers were 55% for Dr. Tzianabos, 40% for Dr. Seymour and 40% for Mr. Smith.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, our board of directors met to review performance against the 2020 bonus goals and, based on its determination that the corporate and individual goals had been achieved at 100% of target level, approved cash bonuses for the named executive officers in the amounts set forth in the Non-Equity Incentive Plan Compensation column of the 2020 &#8220;Summary Compensation Table&#8221; above. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, our board of directors approved maintaining the same target bonus amounts for each of our named executive officers for 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not make any grants of equity awards to our named executive officers in 2020. However, we typically offer stock options to our employees, including our named executive officers, as the long-term incentive component of our compensation program. Stock options allow our employees to purchase shares of our common stock at a price equal to the fair market value of our common stock on the date of grant, as determined by the board of directors. Initial stock option grants to newly hired employees generally vest as to 25% of the underlying shares on either the first anniversary of the date of grant or a specified vesting commencement date and in equal monthly installments over the following 36 months, subject to the holder&#8217;s continued service with us. Since 2017, stock options granted from time to time as periodic awards to existing employees generally vest in 48 equal monthly installments on the first day of each calendar month following the vesting commencement date, subject to the holder&#8217;s continued service with us through the applicable vesting dates. Historically, our stock options have been intended to qualify as &#8220;incentive stock options&#8221; to the extent permitted under Internal Revenue Code of 1986, as amended, and, prior to the completion of our initial public offering, allowed &#8220;early exercise&#8221; of an unvested option in exchange for shares of restricted stock subject to the same vesting schedule as the underlying stock option.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain the 2018 Incentive Award Plan to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of our company and to enable our company to obtain and retain services of these individuals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please refer to our Outstanding Equity Awards at 2020 Fiscal Year End table below for additional information regarding the stock options held by our named executive officers.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Retirement Plans </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) Plan on the same terms as other full-time employees. We provide matching contributions under the plan of 50% of the first 6% of each participant&#8217;s eligible compensation contributed. Employee contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Employees are immediately and fully </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vested in their own contributions. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employer contributions vest over three years according to the employees&#8217; years of service. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that providing a vehicle for tax deferred retirement savings though our 401(k) </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Benefits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our named executive officers are eligible to participate in our employee benefit plans and programs, which include medical, dental, and vision benefits, health spending accounts, and short- and long-term disability, accidental death and dismemberment, and life insurance, to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements of those plans.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Equity Awards at 2020 Fiscal Year-End </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:25.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="17" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commencement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/2016</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462,135</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/22/2026</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,242</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,411</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.63</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/7/2027</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,492</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,884</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,270</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,730</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.28</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/14/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,041</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">275,959</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.92</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/11/2029</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,702</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,715</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.63</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/7/2027</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,176</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,458</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.28</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/14/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,208</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,792</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.92</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/11/2029</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/5/2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,786</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,618</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.63</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/6/2027</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,283</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,213</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.63</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/7/2027</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,155</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,556</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.00</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/27/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,166</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,834</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.28</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/14/2028</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,437</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,563</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/11/2029</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Except as otherwise described below, stock options have a term of ten years from the grant date and vest and become exercisable in 48 equal monthly installments based upon the executive&#8217;s completion of each full month of service following the vesting commencement date, subject to the named executive officer&#8217;s continued employment with the Company through each applicable vesting date and potential accelerated vesting as described under the heading &#8220;Employment Agreements&#8221; below. In addition, stock options granted to our named executive officers prior to 2018 permitted early exercise in exchange for restricted stock. As a result, all of such options were exercisable as of December 31, 2020. The number of shares for which each such option is shown as being exercisable and unexercisable represents, respectively, the number of shares for which each such option was vested and unvested as of December 31, 2020.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Awards vest as to 25% of the underlying shares on the first anniversary of the specified vesting commencement date and in equal monthly installments over the following 36 months, subject to the named executive officer&#8217;s continued employment with the Company through each applicable vesting date and potential accelerated vesting as described under the heading &#8220;Employment Agreements&#8221; below.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into employment agreements with each of our named executive officers. The employment agreements are for unspecified terms. Under their respective employment agreements, if we terminate Dr. Tzianabos, Dr. Seymour or Mr. Smith without &#8220;cause&#8221; or he resigns for &#8220;good reason,&#8221; subject to his timely executing a release of claims and continued compliance with a separate restrictive covenant agreement, he is entitled to receive (i) base salary continuation for a period of nine months (or, for Dr. Tzianabos, 12 months), (ii) payment of all bonuses earned but unpaid as of the date of termination and (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to nine </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months (or, for Dr. Tzianabos, 12 months), less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on his termination date. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we terminate Dr. Tzianabos, Dr. Seymour or Mr. Smith without &#8220;cause&#8221; or he resigns for &#8220;good reason,&#8221; in either case, on or within 12 months following a change in control, then, in lieu of the severance benefits described above, subject to his timely executing a release of claims, he is entitled to receive (i) an amount in cash equal to 1.0 times (or, for Dr. Tzianabos, 1.5 times) the sum of his base salary plus target annual bonus for the year of termination, (ii) payment of all bonuses earned but unpaid as of the date of termination, (iii) direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to 12 months (or, for Dr. Tzianabos, 18 months), less the amount he would have had to pay to receive such coverage as an active employee based on the cost sharing levels in effect on his termination date, and (iv) accelerated vesting of all unvested equity or equity-based awards that vest solely based on the passage of time, with any such awards that vest based on the attainment of performance-vesting conditions being governed by the terms of the applicable award agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our named executive officers has agreed to refrain from competing with us or soliciting our employees, in each case, while employed and following his termination of employment for any reason for a period of 12 months. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the employment agreements, &#8220;cause&#8221; generally means the named executive officer&#8217;s refusal to substantially perform the duties associated with his position with our company or to carry out the reasonable and lawful instructions of the board of directors concerning duties or actions consistent with his position, his breach of a material provision of the employment agreement which remains uncured (to the extent capable of cure) for a period of 30 days following written notice from our company, his conviction, plea of no contest or nolo contendere or imposition of unadjudicated probation for any felony or crime involving moral turpitude, his unlawful use (including being under the influence) or possession of illegal drugs on our premises or while performing his duties and responsibilities under the employment agreement, or his commission of any act of fraud, embezzlement, misappropriation, willful misconduct, or breach of fiduciary duty against us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the employment agreements, &#8220;good reason&#8221; generally means, subject to certain cure rights, the named executive officer&#8217;s termination of employment due to a reduction in salary or target bonus, a material decrease in authority or areas of responsibility, our company&#8217;s breach of any one or more of the material provisions of the employment agreement, or a relocation by our company of the named executive officer&#8217;s primary office to a location more than 25 miles from the named executive officer&#8217;s primary office on the date of the agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth in summary form information concerning the compensation that was earned by or paid to each of our non-employee directors during the year ended December 31, 2020. Dr. Tzianabos, our Chief Executive Officer, received no compensation for his service as a director during the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Director Compensation Table</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees Earned</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or Paid in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,750</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213,509</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,500</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">212,259</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton (3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">342,900</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">366,650</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alise S. Reicin, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,759</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Thistle</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">219,759</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Amounts reflect the grant date fair value of stock options granted during the applicable year computed in accordance with ASC Topic 718, rather than the amounts paid to or realized by the named individual. We provide information regarding the assumptions used to calculate the value of all option awards in Note 12 to our consolidated financial statements included in this Annual Report on Form 10-K.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Represents the grant date fair value of an option to purchase 18,000 shares of our common stock granted to each then-current non-employee director on June 10, 2020 with an exercise price of $16.32 per share.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;">Mr. Poulton was appointed to our board of directors on July 21, 2020. Mr. Poulton&#8217;s fees for his board and committee service were prorated as if he had served during the entire second half of 2020.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Represents the grant date fair value of an initial grant of an option to purchase 36,000 shares of our common stock with an exercise price of $16.48 per share granted to Mr. Poulton upon his appointment as a director on July 21, 2020.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below shows the aggregate numbers of shares subject to option awards held as of December 31, 2020 by each non-employee director. None of our non-employee directors held any other outstanding equity awards as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,145</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,740</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,145</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,740</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,145</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,740</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,411</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,279</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,690</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton (3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,000</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,000</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alise S. Reicin, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,282</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,878</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,160</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Thistle</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,145</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,595</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,740</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a compensation program for our non-employee directors under which each non-employee director receives the following amounts for their service on our board of directors. As amended effective January 1, 2020, our non-employee director compensation program provides for the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an option to purchase 36,000 shares of our common stock upon the director&#8217;s initial election or appointment to our board of directors (the &#8220;Initial Award&#8221;), </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if the director has served on our board of directors for at least six months as of the date of an annual meeting of stockholders, an option to purchase 18,000 shares of our common stock on the date of the annual meeting (the &#8220;Annual Award&#8221;), </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an annual director fee of $40,000, and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if the director serves on a committee of our board of directors or in the other capacities stated below, an additional annual fee as follows: </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">chairman of the board or lead independent director, $35,000, </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">chairman of the audit committee, $15,000, </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">audit committee member other than the chairman, $7,500, </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">chairman of the compensation committee, $10,000, </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compensation committee member other than the chairman, $5,000, </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">chairman of the nominating and corporate governance committee, $8,000, and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.59%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">nominating and corporate governance committee member other than the chairman, $4,000.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted to our non-employee directors under the program have an exercise price equal to the fair market value of our common stock on the date of grant and expire not later than ten years after the date of grant. Stock options granted upon a director&#8217;s initial election or appointment vest in three equal installments on each of the first three anniversaries of the date of grant. Stock options granted annually to directors vest in a single installment on the earlier of the day before the next annual meeting or the first anniversary of the date of grant. In addition, all unvested stock options vest in full upon the occurrence of a change in control. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director fees under the program are payable in arrears in four equal quarterly installments not later than the fifteenth day following the final day of each calendar quarter, provided that the amount of each payment is prorated for any portion of a quarter that a director is not serving on our board.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ers and Management and Related Stockholder Matters. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information on our equity compensation plans as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities&#160;to&#160;be</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued&#160;Upon</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,&#160;Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and&#160;Rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average&#160;Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options,&#160;Warrants</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and Rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities&#160;Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available&#160;for&#160;Future</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issuance&#160;Under&#160;Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation&#160;Plans(4)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by security</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; holders (1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,437,197</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans not approved by security</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; holders</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,437,197</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of the 2015 Stock Incentive Plan, as amended (the &#8220;2015 Plan&#8221;), the 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221;) and the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;).</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 1,661,468 outstanding options to purchase stock under the 2015 Plan and 4,179,356 outstanding options to purchase stock under the 2018 Plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As of December 31, 2020, the weighted-average exercise price of outstanding options under the 2015 Plan was $3.95 and the weighted-average exercise price of outstanding options under the 2018 Plan was $19.65.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes 2,397,547 shares available for future issuance under the 2018 Plan and 1,039,650 shares available for issuance under the 2018 ESPP (of which 48,792 shares were issued with respect to the purchase period in effect as of December 31, 2020, which purchase period ended on February 26, 2021). As of March 26, 2018, in connection with our initial public offering, no further grants are made under the 2015 Plan. The 2018 Plan provides for an annual increase on the first day of each calendar year beginning on January 1, 2019 and ending on and including January 1, 2028, by an amount equal to the lesser of (i) 4% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by our board of directors (but no more than 20,887,347 shares may be issued upon the exercise of incentive stock options), plus any shares that were subject to awards outstanding under the 2015 Plan as of the effective date of the 2018 Plan which are forfeited, expire, lapse for any reason or are settled for cash without the issuance of shares. The 2018 ESPP provides for an annual increase on the first day of each calendar year beginning on January 1, 2019 and ending on and including January 1, 2028, by an amount equal to the lesser of (i) 1% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as is determined by our board of directors, provided that no more than 4,778,738 shares of our common stock may be issued under the 2018 ESPP. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Security Ownership of Certain Beneficial Owners and Management </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth certain information with respect to holdings of our common stock by (i)&#160;stockholders who beneficially owned more than 5% of the outstanding shares of our common stock, and (ii)&#160;each of our directors (which includes all nominees), each of our named executive officers and all directors and executive officers as a group as of March 1, 2021, unless otherwise indicated. The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 50,482,124 shares of common stock outstanding as of March 1, 2021. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of March 1, 2021 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated, the address of each beneficial owner listed below is One Patriots Park, Bedford, MA 01730. We believe, based on information provided to us that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Beneficial Owner</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Beneficially</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Owned</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5% or Greater Stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with ARCH Venture Fund (1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,768,694</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc. (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with 5AM Ventures (3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,535,919</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JPMorgan Chase &#38; Co. (4)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441,712</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TLS Beta Pte. Ltd. (5)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,220,293</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BlackRock, Inc. (6)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,763,142</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Named Executive Officers and Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D. (7)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,255,023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Albert Seymour, Ph.D. (8)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,335</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith (9)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,965</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D. (1)(10)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,815,434</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D. (11)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,546</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D. (3)(12)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,582,659</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson (13)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,234</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alise S. Reicin, M.D. (14)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,282</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Thistle (15)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,740</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">All executive officers and directors as a group (12 persons) (16)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12,650,058</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">24.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Less than 1%</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on a Schedule 13G filed with the SEC on February 13, 2020 and the Company's records. Consists of 4,631,031 shares of common stock held by ARCH Venture Fund VIII, L.P. (&#8220;ARCH Fund VIII&#8221;) and 1,137,663 shares of common stock held by ARCH Venture Fund VIII Overage, L.P. (&#8220;ARCH Fund Overage&#8221;). The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. (&#8220;ARCH Partners VIII&#8221;), which may be deemed to beneficially own the shares held by ARCH Fund VIII. The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC (&#8220;ARCH VIII LLC&#8221;), which has shared voting and dispositive power over the shares of common stock held by each of ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to have shared voting and dispositive power over the shares of common stock held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Steven Gillis, M.D., Ph.D., one of our directors, is a managing director at ARCH Venture Partners. Director Steven Gillis owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares held by ARCH Fund VIII, and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of ARCH Fund VIII and ARCH Fund Overage is 8755 West Higgins Road, Suite 1025, Chicago, Illinois 60631.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on a Schedule 13G filed with the SEC on November 19, 2020, Pfizer Inc. has sole voting and dispositive power over all 5,000,000 shares. The address of Pfizer Inc. is 235 East 42nd Street, New York, NY 10017.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on a Schedule 13G filed with the SEC on February 16, 2021 and the Company's records. Consists of 4,354,484 shares of common stock held by 5AM Ventures IV, L.P. (&#8220;Ventures IV&#8221;), as to which Ventures IV has shared voting and dispositive power, and 181,435 shares of common stock held by 5AM Co-Investors IV, L.P. (&#8220;Co-Investors IV&#8221;), as to which Co-Investors IV has shared voting and dispositive power. 5AM Partners&#160;IV, LLC (&#8220;Partners IV&#8221;) is the sole general partner of Ventures IV and Co-Investors IV. Dr.&#160;John Diekman, Andrew J. Schwab and Dr.&#160;Scott M. Rocklage, are the managing members of Partners&#160;IV and, along with Partners IV, have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Kush M. Parmar, M.D., Ph.D., one of our directors, is an </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affiliate of Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr.&#160;Rocklage disclaim beneficial ownership </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such shares except to the extent of its or their recurring interest therein. The address of all entities affiliated with 5AM Ventures is 501 2nd Street, Suite 350, San Francisco, CA 94107.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based solely on a Schedule 13G filed with the SEC on January 25, 2021, JPMorgan Chase &#38; Co. has sole voting power over 3,054,192 shares and sole dispositive power over 3,441,712 shares. The address of Blackrock, Inc. is 383 Madison Avenue, New York, NY 10179.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based solely on a Schedule 13G filed with the SEC on April 11, 2018, Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Temasek Life Sciences Private Limited each has shared voting and dispositive power over 3,220,293 shares of common stock, V-Sciences Investments Pte Ltd has shared voting and dispositive power over 625,000 shares of common stock, and TLS Beta Pte. Ltd. has shared voting and dispositive power over 2,595,293 shares of common stock. The principal business address of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd, Temasek Life Sciences Private Limited, V-Sciences Investments Pte Ltd and TLS Beta Pte. Ltd. is 60B Orchard Road #06-18 Tower 2, The Atrium&#64;Orchard, Singapore 238891. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based solely on a Schedule 13G filed with the SEC on February 2, 2021, Blackrock, Inc. has sole voting power over 2,724,076 shares and sole dispositive power over 2,763,142 shares. The address of Blackrock, Inc. is 55 East 52nd Street, New York, NY 10055.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 1,177,518 shares of common stock that are or will be immediately exercisable by Dr. Tzianabos within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 189,318 shares of common stock that are or will be immediately exercisable by Dr. Seymour within 60 days of March 1, 2021. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of options to purchase 263,965 shares of common stock that are or will be immediately exercisable by Mr. Smith within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 46,740 shares of common stock that are or will be immediately exercisable by Dr. Gillis within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 46,740 shares of common stock that are or will be immediately exercisable by Dr. Gregory within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 46,740 shares of common stock that are or will be immediately exercisable by Dr. Parmar within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of options to purchase 43,234 shares of common stock that are or will be immediately exercisable by Mr. Patterson within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of options to purchase 10,282 shares of common stock that are or will be immediately exercisable by Ms. Reicin within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of options to purchase 46,740 shares of common stock that are or will be immediately exercisable by Ms. Thistle within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.79%;text-indent:-4.79%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes options to purchase 12,650,058 shares of common stock that are or will be immediately exercisable within 60 days of March 1, 2021.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Related Person Transactions</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has adopted a written Related Person Transaction Policy, setting forth the policies and procedures for the review and approval or ratification of related person transactions. Under the policy, our finance department is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. If </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our finance department determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Financial Officer is required to present to the audit committee all relevant facts and circumstances relating </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the related person transaction. Our audit committee must review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm's length dealings with an unrelated third party and the extent of the related person's interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of our code of business conduct and ethics, and either approve or disapprove the related person transaction. If advance audit committee approval of a related person transaction requiring the audit committee's approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the chair of the audit committee subject to ratification of the transaction by the audit committee at the audit committee's next regularly scheduled meeting&#59; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person, then upon such recognition the transaction will be presented to the audit committee for ratification at the audit committee's next regularly scheduled meeting&#59; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. Our management will update the audit committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are certain transactions, arrangements and relationships with our directors, executive officers and stockholders owning 5% or more of our outstanding common stock since January 1, 2019.</p>
<p style="margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Purchase Agreement with Pfizer</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.28%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020, we entered into a stock purchase agreement, or the Stock Purchase Agreement, with Pfizer Inc., or Pfizer, which holds approximately 9.9% of our common stock as of March 1, 2021, pursuant to which Pfizer purchased 5,000,000 shares of our common stock through a private placement transaction at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million. Under the Stock Purchase Agreement, Pfizer was granted an exclusive right of first refusal, or ROFR, for a 30-month period beginning on the date of the closing of the private placement to negotiate a potential collaboration on the development and commercialization of HMI-102 and HMI-103. Pfizer may exercise its right of first refusal under the ROFR one time for each of HMI-102 and HMI-103 during the ROFR period. Additionally, Pfizer has designated a member to join our Scientific Advisory Board to participate in matters related to the development of these programs. For more information regarding Pfizer and its equity holdings, see Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8212;Security Ownership of Certain Beneficial Owners and Management.&#8221;</p>
<p style="margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2019 Follow-On Offering</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.28%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, we completed a registered public offering pursuant to which we issued and sold an aggregate of 6,388,889 shares of our common stock (including 833,333 shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares) at a public offering price of $22.50 per share for aggregate net proceeds to us of approximately $134.5 million. The following table sets forth the number of shares of common stock purchased in our registered public offering by certain former holders of more than 5% of our common stock:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchased</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Deerfield (affiliate of Cameron Wheeler, Ph.D.,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who resigned from our board of directors in July 2019)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533,333</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,999,993</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with T. Rowe Price Group, Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719,464</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,187,940</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into employment agreements with our named executive officers. For more information regarding these agreements, see Item 11. &#8220;Executive Compensation&#8212;Narrative Disclosure to Compensation Tables&#8212;Employment Agreements.&#8221;</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer.</span></p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Independence</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="OrigSetCursorLoc">Steven Gillis, Ph.D., Richard J. Gregory, Ph.D., Kush M. Parmar, M.D., Ph.D., Matthew R. Patterson, Alise S. Reicin, M.D., Jeffrey V. Poulton and Mary Thistle each qualify as &#8220;independent&#8221; in accordance with the listing requirements of Nasdaq. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#8217;s business and personal activities and relationships as they may relate to us and our management, including that Dr. Gillis and Dr. Parmar are affiliated with certain of our significant stockholders. Arthur O. Tzianabos, Ph.D. is not independent because he is the President and Chief Executive Officer of Homology. There are no family relationships among any of our directors or executive officers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 14. Principal Accoun</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">tant Fees and Services. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the fees of<span style="font-size:12pt;"> </span>Deloitte &#38; Touche LLP, our independent registered public accounting firm, billed to us in each of the last two fiscal years for audit services and billed to us in each of the last two fiscal years for other services: </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fee Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">598</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Other Fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Audit Fees</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees consist of fees for the audit of our consolidated financial statements, the review of the unaudited interim financial statements included in our quarterly reports on Form 10-Q and other professional services provided in connection with statutory and regulatory filings or engagements and services associated with the issuance of comfort letters and the issuance of consents on registration statements. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Fees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax fees consist of fees for tax compliance, tax advice, and tax planning services.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">All Other Fees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other fees consist of an annual license fee for use of accounting research software and in 2019, fees for services performed related to the adoption the Financial Accounting Standards Board issued Accounting Standards Update Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee Pre-Approval Policy and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-family:Tahoma;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#65279;<span style="font-family:Times New Roman;">The Audit Committee has adopted a policy (the &#8220;Pre-Approval Policy&#8221;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage Deloitte &#38; Touche LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the Audit Committee (&#8220;specific pre-approval&#8221;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#8220;general pre-approval&#8221;). Unless a type of service to be provided by Deloitte &#38; Touche LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC&#8217;s rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the most effective and efficient service, for reasons such as its familiarity with the Company&#8217;s business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company&#8217;s ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. On an annual basis, the Audit Committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by Deloitte &#38; Touche LLP without first obtaining specific pre-approval from the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item&#160;15. Exhibits and Financial Statement Schedules </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="N1_FINANCIAL_STATEMENTS">(a)(1) Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are included on pages F-1 through F-26 attached hereto and are filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="INDEX_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:13.8pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr style="height:13pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr style="height:13.8pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr style="height:13.8pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr style="height:13pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr style="height:13.8pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr style="height:13.8pt;">
<td valign="top" style="width:94.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(2) Financial Statement Schedules.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(3) Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="5" valign="top" style="width:41.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="width:8.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:0.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:49.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description&#160;of&#160;Exhibit</p></td>
<td valign="bottom" style="width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:8.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date</p></td>
<td valign="bottom" style="width:7.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518106196/d535307dex31.htm"><span style="text-decoration:none;">Restated Certificate of Incorporation of Homology Medicines, Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="width:8.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle" style="width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/3/18</p></td>
<td valign="middle" style="width:7.16%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518106196/d535307dex32.htm"><span style="text-decoration:none;">Amended and Restated Bylaws of Homology Medicines, Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/18/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex41.htm"><span style="text-decoration:none;">Amended and Restated Investors&#8217; Rights Agreement, dated July&#160;28, 2017, by and among Homology Medicines, Inc. and the investors named therein, as amended</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex42.htm"><span style="text-decoration:none;">Specimen Stock Certificate evidencing the shares of common stock</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000119312519094628/d931999dex43.htm"><span style="text-decoration:none;">Form of Indenture</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230664</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4/1/19</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex44_13.htm"><span style="text-decoration:none;">Description of Securities</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000119312518086586/d503245dex101.htm"><span style="text-decoration:none;">2015 Stock Incentive Plan, as amended, and forms of agreements thereunder</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex102_943.htm"><span style="text-decoration:none;">2018 Incentive Award Plan, and forms of awards thereunder</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex103.htm"><span style="text-decoration:none;">2018 Employee Stock Purchase Plan</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000156459018029297/fixx-ex101_190.htm"><span style="text-decoration:none;">2018 Employee Stock Purchase Plan &#8211; Offering Document</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/13/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000156459020010441/fixx-ex105_902.htm"><span style="text-decoration:none;">Non-Employee Director Compensation Program</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/12/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex105.htm"><span style="text-decoration:none;">Form of Indemnification Agreement for Directors and Officers</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex105.htm"><span style="text-decoration:none;">Lease Agreement, dated August 31, 2016, between Homology Medicines, Inc. and ARE-MA Region No.&#160;24,&#160;LLC</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex106.htm"><span style="text-decoration:none;">Lease Agreement, dated December 21, 2017, between Homology Medicines, Inc. and Bedford Patriots Park, LLC</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9#</span></p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000156459020010441/fixx-ex109_1019.htm"><span style="text-decoration:none;">Employment Agreement, November 12, 2019, by and between Homology Medicines, Inc. and Gabriel M. Cohn, M.D.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/12/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex1012.htm"><span style="text-decoration:none;">Employment Agreement, dated March 18, 2018, by and between Homology Medicines, Inc. and Albert Seymour</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex1013.htm"><span style="text-decoration:none;">Employment Agreement, dated March 18, 2018, by and between Homology Medicines, Inc. and Bradford Smith</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex1014.htm"><span style="text-decoration:none;">Employment Agreement, dated March 18, 2018, by and between Homology Medicines, Inc. and Arthur Tzianabos, Ph.D.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13#</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000156459019007250/fixx-ex1013_866.htm"><span style="text-decoration:none;">Employment Agreement, dated April 2,</span> <span style="text-decoration:none;">2018, by and between Homology Medicines, Inc. and Tim Kelly</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/12/19</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14.1&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518092800/d503245dex1015.htm"><span style="text-decoration:none;">Collaboration and License Agreement, dated November 6, 2017, between Homology Medicines, Inc. and Novartis Institutes for BioMedical Research, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/23/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14.2&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518092800/d503245dex1015.htm">Amendment to<span style="text-decoration:none;"> Collaboration and License Agreement, dated December 17, 2018, between Homology Medicines, Inc. and Novartis Institutes for BioMedical Research, Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">08/10/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14.3&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518092800/d503245dex1015.htm">Second Amendment to C<span style="text-decoration:none;">ollaboration and License Agreement, dated October 30, 2020, between Homology Medicines, Inc. and Novartis Institutes for BioMedical Research, Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex1016.htm"><span style="text-decoration:none;">Exclusive License Agreement, dated April 28, 2016, between Homology Medicines, Inc. and City of Hope</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16.1&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518086586/d503245dex10171.htm"><span style="text-decoration:none;">License Agreement, dated September 14, 2016, between Homology Medicines, Inc. and California Institute of Technology</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/19/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16.2&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex10162.htm"><span style="text-decoration:none;">First Amendment to License Agreement, dated May 16, 2017, between Homology Medicines, Inc. and California Institute of Technology</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16.2</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16.3&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex10163.htm"><span style="text-decoration:none;">Letter Agreement, dated November 14, 2017, between Homology Medicines, Inc. and California Institute of Technology</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16.3</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1661998/000119312520288562/d695053dex101.htm"><span style="text-decoration:none;">Stock Purchase Agreement, dated November 9, 2020, by and between Homology Medicines, Inc. and Pfizer Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001- 38433</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/09/20</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001661998/000119312518068882/d503245dex211.htm"><span style="text-decoration:none;">Subsidiaries of Homology Medicines, Inc.</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-223409</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3/2/18</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex231_6.htm"><span style="text-decoration:none;">Consent of Deloitte &#38; Touche LLP, independent registered public accountant</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex311_12.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex312_10.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex321_11.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="fixx-ex322_7.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</span></p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
<tr>
<td valign="middle" style="width:8.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:49.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="width:7.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
</tr>
</table></div>
<p style="margin-bottom:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:91.55%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:2pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:2pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:2pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-bottom:2pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:2pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-bottom:2pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="margin-bottom:2pt;margin-top:2pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:2pt;margin-top:2pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><span style="font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY1">Item 16. Form 10-K Summary.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Homology Medicines, Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.06%;width:97.02%;">
<tr>
<td valign="top" style="width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="top" style="width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:20.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%; border-top:solid 0.75pt #000000;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;W. Bradford Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chief Financial Officer, Treasurer and Secretary</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial and accounting officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Kush M. Parmar, M.D., Ph.D. </p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kush M. Parmar, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steven Gillis, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steven Gillis, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard J. Gregory, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Richard J. Gregory, Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Matthew R. Patterson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Matthew R. Patterson</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jeffrey V. Poulton</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey V. Poulton</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Alise S. Reicin, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Alise S. Reicin, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Mary Thistle</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mary Thistle</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
<tr>
<td valign="top" style="width:92.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and the Board of Directors of Homology Medicines, Inc.</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Homology Medicines, Inc. and its subsidiary (the "Company") as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change in Accounting Principle</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 2 to the financial statements, the Company changed its method of accounting for leases in 2020 due to the adoption of Accounting Standards update No. 2016-02, <span style="font-style:italic;">Leases</span> (Topic 842), as amended, using the modified retrospective approach.</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &#38; Touche LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">208,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,133</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:AssetsCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">219,564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AssetsCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">266,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:RestrictedCash" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:RestrictedCash" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:Assets" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Assets" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">310,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,608</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="fixx:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="fixx:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,632</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001661998_20191231" decimals="-3" scale="3">809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:Liabilities" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">67,742</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:Liabilities" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000078" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001661998_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000079" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001661998_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001661998_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000065">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000066">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000086" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001661998_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000087" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001661998_20191231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">50,268,666</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">45,138,408</ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued as of December 31, 2020 and 2019, respectively&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and <ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">50,265,575</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">45,116,742</ix:nonFraction> shares outstanding as of December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommonStockValue" contextRef="C_0001661998_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommonStockValue" contextRef="C_0001661998_20191231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">524,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">457,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001661998_20191231" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001661998_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">328,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001661998_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">199,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">258,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">263,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">310,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,702</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,392</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:OperatingExpenses" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:OperatingExpenses" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">130,263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">109,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:InvestmentIncomeNonoperating" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:InvestmentIncomeNonoperating" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share-basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000110" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001661998_20200101_20201231" decimals="2" sign="-">2.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001661998_20190101_20191231" decimals="2" sign="-">2.47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding-basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000112" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001661998_20200101_20201231" decimals="0" format="ixt:numdotdecimal">45,910,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001661998_20190101_20191231" decimals="0" format="ixt:numdotdecimal">42,117,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive gain (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain (loss) on available for sale securities, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive gain (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,877</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$0.0001 Par Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gain (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000122" name="us-gaap:SharesOutstanding" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">37,358,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">292,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">95,758</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">196,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in follow-on offering,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of discounts and issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000128" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">6,388,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to ATM financing,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of discounts and issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,105,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">55,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of common stock from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">94,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; option exercises</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">114,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:SharesOutstanding" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">45,116,742</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">457,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">199,674</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">258,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of common stock from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">18,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; option exercises</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">46,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">83,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock pursuant to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; private placement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,978</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="us-gaap:SharesOutstanding" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">50,265,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">524,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">328,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProfitLoss" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">128,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:ProfitLoss" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">103,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:Depreciation" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:Depreciation" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="fixx:NonCashLeaseExpense" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:ShareBasedCompensation" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:ShareBasedCompensation" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="fixx:AccretionOfShortTermInvestments" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="fixx:AccretionOfShortTermInvestments" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:IncreaseDecreaseInPrepaidRent" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="fixx:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">94,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">91,358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">286,391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">228,620</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,733</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">204,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001661998_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in private placement</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock in follow-on public offering,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;net of discounts and issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock pursuant to ATM financing,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of discounts and issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001661998_fixxMajorAssetClassOfLeasedAssetsAxis_fixxATMMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock from option exercises</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">176</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock pursuant to employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">829</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">158,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">163,657</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001661998_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">218,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of liability for common stock vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment additions included in accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment additions included in accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="fixx:PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on available for sale securities, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001661998_20200101_20201231" decimals="-3" sign="-" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering costs included in accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="fixx:OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" contextRef="C_0001661998_20190101_20191231" decimals="-3" scale="3">100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p><ix:nonNumeric id="F_000234" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000234_dcnt_3e687df1-2372-45a9-ac2f-5f05359b27b8">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Business<span style="font-weight:normal;">&#8212;Homology Medicines, Inc. (the &#8220;Company&#8221;) is a clinical-stage genetic medicines company dedicated to translating proprietary gene therapy and gene editing technology into novel treatments for patients with rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. The Company was founded in March 2015 as a Delaware corporation. Its principal offices are in Bedford, Massachusetts. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its resources to recruiting personnel, developing its technology platform and advancing its pipeline of product candidates, developing and implementing manufacturing processes, building out internal manufacturing and research and development space, and maintaining and building its intellectual property portfolio. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependency on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and manufacturing of its product candidates. The Company&#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, conduct clinical trials, obtain regulatory approval of its products, further expand its manufacturing capacity, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) with the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000290" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402" decimals="INF" format="ixt:numdotdecimal">10,350,000</ix:nonFraction> shares of its common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000291" name="us-gaap:SharePrice" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180402" decimals="INF">16.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402" decimals="-5" scale="6">150.8</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock automatically converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000293" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001661998_20180401_20180402" decimals="INF" format="ixt:numdotdecimal">24,168,656</ix:nonFraction> shares of common stock at the applicable conversion ratio then in effect.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 12, 2019, the Company completed a follow-on public offering of its common stock. The Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000294" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412" decimals="INF" format="ixt:numdotdecimal">5,555,556</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000295" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412" decimals="2">22.50</ix:nonFraction> per share and received net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412" decimals="-5" scale="6">116.9</ix:nonFraction> million, after deducting underwriting discounts and commissions and offering expenses. In addition, on April 26, 2019 and May 7, 2019, in connection with the exercise in full of the underwriters&#8217; option to purchase additional shares, the Company issued an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000297" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412" decimals="INF" format="ixt:numdotdecimal">833,333</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000298" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412" decimals="2">22.50</ix:nonFraction> per share and received net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412" decimals="-5" scale="6">17.6</ix:nonFraction> million, after deducting underwriting discounts and commissions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2020, the Company filed a Registration Statement on Form S-3 (File No. 333-237131)<span style="color:#000000;"> (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for a period up to three years from the date of the filing. The Shelf became effective on </span>March 12, 2020<span style="color:#000000;">. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC </span>(&#8220;Cowen&#8221;)<span style="color:#000000;">, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="fixx:ProceedsFromFutureIssuanceStock" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200311_20200312" decimals="-5" scale="6">150.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). </span>The Company did <ix:nonFraction unitRef="U_xbrlishares" id="F_000302" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t sell any shares of common stock pursuant to the ATM during the year ended <span style="color:#000000;">December&#160;31, 2020</span>. At December&#160;31, 2020, there remained $<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="fixx:ProceedsFromFutureIssuanceStock" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231" decimals="-5" scale="6">150.0</ix:nonFraction> million of common stock available for sale under the ATM. Simultaneous with the filing of the Shelf, the previous Registration Statement on Form S-3 (File No. 333-230664) filed with the SEC on April 1, 2019, and a prior sales agreement with Cowen providing for the offering, issuance and sale by the Company of up to an aggregate $<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="fixx:ProceedsFromFutureIssuanceStock" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190430_20190430" decimals="-5" scale="6">100.0</ix:nonFraction> million of its common stock from time to time in &#8220;at-the-market&#8221; offerings, with $<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:CommonStockSharesSubscriptions" contextRef="C_0001661998_20190430" decimals="-5" scale="6">76.8</ix:nonFraction> million of remaining capacity, were terminated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020,<span style="color:#000000;"> the Company entered into a common stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Pfizer Inc.</span> <span style="color:#000000;">(&#8220;Pfizer&#8221;), pursuant to which the Company agreed to issue and sell to Pfizer <ix:nonFraction unitRef="U_xbrlishares" id="F_000305" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of the Company&#8217;s common stock through a private placement transaction (the &#8220;Private Placement&#8221;) at a purchase price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000306" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109" decimals="2">12.00</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109" decimals="-5" scale="6">60.0</ix:nonFraction> million (see Note 16).</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. Through December&#160;31, 2020, the Company has financed its operations primarily through public offerings of its common stock, the issuance of convertible preferred stock, and with proceeds from its collaboration and license agreement with Novartis Institutes of BioMedical Research, Inc. (&#8220;Novartis&#8221;) (see Note 15) and its private placement with Pfizer. During the year ended December&#160;31, 2020, the Company incurred a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:NetIncomeLoss" contextRef="C_0001661998_20200101_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">128.7</ix:nonFraction>&#160;million and as of December&#160;31, 2020, had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001661998_20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">328.4</ix:nonFraction>&#160;million in accumulated deficit. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000234_dcnt_3e687df1-2372-45a9-ac2f-5f05359b27b8">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on current projections, management believes that existing cash</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash equivalents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will enable the Company to continue its operations into the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter of 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.</span></p><ix:nonNumeric id="F_000251" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation<span style="font-weight:normal;">&#8212;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) </span><span style="Background-color:#FFFFFF;font-weight:normal;">and have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business</span><span style="font-weight:normal;">.</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000235" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000235_dcnt_43508d1e-d2cf-48ca-b625-c85beb4dda7f">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000252" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">Principles of Consolidation<span style="font-weight:normal;">&#8212;The Company&#8217;s consolidated financial statements include the accounts of the Company and its subsidiary, Homology Medicines Securities Corporation, a wholly owned Massachusetts corporation, for the sole purpose of buying, selling, and holding securities on the Company&#8217;s behalf. All intercompany balances and transactions have been eliminated in the consolidated financial statements.</span></ix:nonNumeric> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000253" name="us-gaap:UseOfEstimates" contextRef="C_0001661998_20200101_20201231" escape="true">Use of Estimates<span style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis&#59; however, actual results could materially differ from those estimates.</span></ix:nonNumeric> </p><ix:nonNumeric id="F_000254" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) &#8212;<span style="font-weight:normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale investments. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000255" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents and Restricted Cash<span style="font-weight:normal;">&#8212;Cash and cash equivalents consist of standard checking accounts, money market accounts and certain investments. The Company considers all highly liquid investments with original or remaining maturities at the time of purchase of 90 days or less to be cash equivalents. Restricted cash consists of cash serving as collateral for letters of credit issued for security deposits for the Company&#8217;s facility leases in Bedford, Massachusetts.</span></p><ix:nonNumeric id="F_000271" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:RestrictedCash" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:RestrictedCash" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">218,705</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000256" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001661998_20200101_20201231" escape="true">Short-Term Investments<span style="font-weight:normal;">&#8212;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments have maturities of greater than 90 days at the time of purchase and mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying security. Such amortization and accretion, together with interest on securities, are included in interest income in the Company&#8217;s consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income.</span></ix:nonNumeric> </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000235_dcnt_43508d1e-d2cf-48ca-b625-c85beb4dda7f" continuedAt="F_000235_dcnt_cba27873-f646-44d2-bd44-03518ae8a7e0">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000257" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001661998_20200101_20201231" escape="true"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</span><span style="font-weight:normal;">&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and short-term investments. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. We believe that we are not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. We regularly invest excess cash with major financial institutions in money market funds, U.S. government and corporate debt securities and commercial paper, all of which can be readily purchased and sold using established markets. As of </span><span style="font-weight:normal;">December&#160;31, 2020</span><span style="font-weight:normal;">, the Company&#8217;s cash and cash equivalents were held with two financial institutions. We believe that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are either government</span><span style="font-weight:normal;">-</span><span style="font-weight:normal;">backed or of high credit rating.</span></ix:nonNumeric><span style="font-weight:normal;"> </span></p><ix:nonNumeric id="F_000258" name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering Costs<span style="font-weight:normal;">&#8212;The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with equity financings as other current assets until the transactions are completed. After equity financings are complete, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000259" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000259_dcnt_ba0aad6a-e1e5-4d4b-8179-836a078a6ca6">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="font-weight:normal;">&#8212;</span><span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842) (&#8220;ASU 2016-02&#8221;), which eliminated the tests for lease classification under prior U.S. GAAP and requires lessees to recognize right-of-use assets and related lease liabilities on the balance sheet. The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-weight:normal;">, ASU No. 2018-10 &#8211; </span><span style="font-style:italic;font-weight:normal;">Codification Improvements to Topic </span><span style="font-weight:normal;">842</span><span style="font-style:italic;font-weight:normal;">, Leases</span><span style="font-weight:normal;">, ASU No. 2018-11 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Targeted Improvements</span><span style="font-weight:normal;">, ASU No. 2018-20 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Narrow-Scope Improvements for Lessors</span><span style="font-weight:normal;">, and ASU No. 2019-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Codification Improvements</span><span style="font-weight:normal;">. The Company adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the new leasing standards using the modified retrospective approach, as of January 1, 2020, with no restatement of prior periods or cumulative adjustments to accumulated deficit. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. In addition, the Company elected the practical expedient not to apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights&#59; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset&#59; and (3) the Company has the right to direct the use of the identified asset.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company acts as sublessor related to a sublease of the Company's former headquarters. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Right-of-use assets are periodically evaluated for impairment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected lease term for those leases commencing prior to January 1, 2020 did not change with the adoption of the new leasing standards. The expected lease term for leases commencing after the adoption of the new leasing standards includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.<span style="font-size:12pt;"> </span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000235_dcnt_cba27873-f646-44d2-bd44-03518ae8a7e0" continuedAt="F_000235_dcnt_def0a210-48c7-488d-ab09-da9f1eb0bcde"><ix:continuation id="F_000259_dcnt_ba0aad6a-e1e5-4d4b-8179-836a078a6ca6">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the adoption of the new leasing standards, on January 1, 2020, the Company recorded non-cash transactions to recognize a right-of-use asset of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-5" scale="6">6.8</ix:nonFraction> million, operating lease liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-5" scale="6">17.7</ix:nonFraction> million and the derecognition of deferred rent of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:DeferredRentCredit" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101" decimals="-5" scale="6">10.9</ix:nonFraction> million originally accounted for under legacy guidance. The adoption did not have a material impact on the condensed consolidated statement of operations. For additional information on the adoption of the new leasing standards, refer to Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p><ix:nonNumeric id="F_000272" name="us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets (1)(2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">6,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001661998_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">6,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent (2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:DeferredRentCredit" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">1,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:DeferredRentCredit" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">1,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">9,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">9,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">2,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001661998_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">2,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion (3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">15,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001661998_20200101" decimals="-3" format="ixt:numdotdecimal" scale="3">15,441</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) <ix:footnote id="FNT_000000" xml:lang="en-US">Represents capitalization of operating right-of-use assets</ix:footnote></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) <ix:footnote id="FNT_000001" xml:lang="en-US">Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</ix:footnote></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) <ix:footnote id="FNT_000002" xml:lang="en-US">Represents recognition of operating lease liabilities</ix:footnote></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000260" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" contextRef="C_0001661998_20200101_20201231" escape="true">Guarantees and Indemnifications<span style="font-weight:normal;">&#8212;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and <ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="C_0001661998_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.</span></ix:nonNumeric> </p><ix:nonNumeric id="F_000261" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment<span style="font-weight:normal;">&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000273" name="fixx:PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000330" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and office furniture</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxLaboratoryEquipmentAndOfficeFurnitureMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000332">5 - 7 years</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000334">Shorter of the lease term</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or estimated useful life</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000262" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">Impairment of Long-Lived Assets<span style="font-weight:normal;">&#8212;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, <ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> impairments have been recognized for these assets.</span></ix:nonNumeric> </p><ix:nonNumeric id="F_000263" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000263_dcnt_eb6eacc0-f807-441a-a110-449bca81baab">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs<span style="font-weight:normal;">&#8212;Research and development costs are charged to expense as incurred. Research and development expense consists of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical and clinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000235_dcnt_def0a210-48c7-488d-ab09-da9f1eb0bcde" continuedAt="F_000235_dcnt_43061366-d06f-4657-99d1-6b0f7d05baff"><ix:continuation id="F_000263_dcnt_eb6eacc0-f807-441a-a110-449bca81baab">
</ix:continuation><ix:nonNumeric id="F_000264" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes<span style="font-weight:normal;">&#8212;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. <ix:nonNumeric id="F_000336" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" contextRef="C_0001661998_20200101_20201231">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized.</ix:nonNumeric> The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span> Since inception, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets has not been determined to be more likely than not.</p></ix:nonNumeric><ix:nonNumeric id="F_000265" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information<span style="font-weight:normal;">&#8212;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is dedicated to translating proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. All of the Company&#8217;s tangible assets are held in the United States. </span></p></ix:nonNumeric><ix:nonNumeric id="F_000266" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000266_dcnt_02a765ea-e565-493c-ad65-e17a04f7009b">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212;<span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">Revenue is recognized in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="font-style:italic;font-weight:normal;">Revenue from Contracts with Customers</span><span style="font-weight:normal;"> (&#8220;ASC 606&#8221;). On January 1, 2019, the Company adopted ASC 606 using the full retrospective transition method.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations&#59; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods or services in the Company&#8217;s arrangements would likely consist of a license, rights to the Company&#8217;s intellectual property or research, development and manufacturing services. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of consideration to which the Company expects to be entitled to. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000235_dcnt_43061366-d06f-4657-99d1-6b0f7d05baff" continuedAt="F_000235_dcnt_bc6aebee-45c1-40a5-b559-0b3918b4f41a"><ix:continuation id="F_000266_dcnt_02a765ea-e565-493c-ad65-e17a04f7009b">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from the Company&#8217;s collaboration arrangement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocates the transaction price based on the estimated standalone selling price of each performance obligation. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress for its over-time arrangements at each reporting period and, if necessary, updates the measure of progress and revenue recognized.</p></ix:continuation><ix:nonNumeric id="F_000267" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation<span style="font-weight:normal;">&#8212;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#8217;s estimates of these assumptions are primarily based on the trading price of the Company&#8217;s stock, historical data, peer company data and judgment regarding future trends and factors. Stock-based awards granted to nonemployees are initially recorded at fair value and are re-measured at each reporting period as the awards vest and expense is recognized over the period the services are provided. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price of common stock under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) is equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000337" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" scale="-2">85</ix:nonFraction>% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the look-back provision under the ESPP is calculated using the Black-Scholes option pricing model. The fair value of the look-back provision plus the <ix:nonFraction unitRef="U_xbrlipure" id="F_000338" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" scale="-2">15</ix:nonFraction>% discount is recognized as compensation expense over the <ix:nonNumeric id="F_000339" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" format="ixt-sec:durday">180</ix:nonNumeric>-day purchase period. </p></ix:nonNumeric><ix:nonNumeric id="F_000268" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements<span style="font-weight:normal;">&#8212;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;1&#8212;Quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.79%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div></ix:nonNumeric><ix:nonNumeric id="F_000269" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000269_dcnt_45f1eeeb-6c06-46d0-b469-a22354a7ec03">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share<span style="font-weight:normal;">&#8212;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and unvested shares of common stock.</span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000235_dcnt_bc6aebee-45c1-40a5-b559-0b3918b4f41a"><ix:continuation id="F_000269_dcnt_45f1eeeb-6c06-46d0-b469-a22354a7ec03">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p></ix:continuation><ix:nonNumeric id="F_000270" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements<span style="font-weight:normal;">&#8212;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organization related to their leasing activities. For additional information on the adoption of the new leasing standards, please refer to section titled &#8220;Leases&#8221; above, and Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU 2016-13&#8221;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early application permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued ASU No. 2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span> (&#8220;ASU 2018-07&#8221;)<span style="font-style:italic;">,</span> which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued ASU 2020-10, <span style="font-style:italic;">Codification Improvements</span>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material effect on the Company&#8217;s consolidated financial statements.</p></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000236" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. CASH AND CASH EQUIVALENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may have cash balances in financial institutions in excess of federal deposit insurance limits. The Company has never experienced any losses related to these balances. The Company considers only those investments that are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. </p><ix:nonNumeric id="F_000274" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash and cash equivalents: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapRepurchaseAgreementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000237" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000237_dcnt_a4e23ef6-c6af-4c55-a19f-96313d4f419e">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. SHORT-TERM INVESTMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may invest its excess cash in fixed income instruments denominated and payable in U.S. dollars including U.S. treasury securities, commercial paper, corporate debt securities and asset-backed securities in accordance with the Company&#8217;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000237_dcnt_a4e23ef6-c6af-4c55-a19f-96313d4f419e">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has designated all investments as available-for-sale and therefore such investments are reported at fair value</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and classified as short-term investments on the Company&#8217;s consolidated balance sheets</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Unrealized gains or losses on investments are recorded in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity, on the Company&#8217;s consolidated balance sheets.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> short-term investments as of December 31, 2020.</span></p><ix:nonNumeric id="F_000275" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s short-term investments as of December 31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">208,431</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001661998_20191231" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">208,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">The Company utilizes the specific identification method in computing realized gains and losses. The Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="C_0001661998_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> realized gains and losses on its short-term investments for the years</span> <span style="font-size:10pt;">ended December 31, 2020 and 2019. The contractual maturity dates of all of the Company&#8217;s investments are less than one year.</span></p></ix:continuation><ix:nonNumeric id="F_000238" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000238_dcnt_24aeec9e-635f-495b-b19c-81bf7620c8fd">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. FAIR VALUE MEASUREMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, restricted cash and accounts payable. The carrying amount of cash, restricted cash and accounts payable are each considered a reasonable estimate of fair value due to the short-term maturity. </p><ix:nonNumeric id="F_000276" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets measured at fair value on a recurring basis were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">217,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,508</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">208,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">208,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">262,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">222,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term securities are valued using models or other valuation methodologies that use Level&#160;2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000238_dcnt_24aeec9e-635f-495b-b19c-81bf7620c8fd">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="fixx:FairValueAssetsLiabilitiesTransferBetweenLevels" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="fixx:FairValueAssetsLiabilitiesTransferBetweenLevels" contextRef="C_0001661998_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> transfers between fair value measure levels during the years ended December&#160;31, 2020 and 2019.</p></ix:continuation><ix:nonNumeric id="F_000239" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. PROPERTY AND EQUIPMENT </p><ix:nonNumeric id="F_000277" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,703</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,754</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and purchased software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231" decimals="-3" scale="3">640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxAssetNotYetInServiceMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,377</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,126</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,716</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020 and 2019 was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:Depreciation" contextRef="C_0001661998_20200101_20201231" decimals="-5" scale="6">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:Depreciation" contextRef="C_0001661998_20190101_20191231" decimals="-5" scale="6">6.3</ix:nonFraction> million, respectively. The Company disposed of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_0001661998_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million and less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million of property and equipment, net during the years ended December&#160;31, 2020 and 2019, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000240" name="fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. ACCRUED EXPENSES AND OTHER LIABILITIES </p><ix:nonNumeric id="F_000278" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="fixx:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="fixx:AccruedResearchAndDevelopmentExpensesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001661998_20201231" decimals="-3" scale="3">291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001661998_20191231" decimals="-3" scale="3">542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued unvested common stock subject to repurchase</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" contextRef="C_0001661998_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" contextRef="C_0001661998_20191231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001661998_20201231" decimals="-3" scale="3">204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" scale="3">256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="fixx:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="fixx:AccruedExpensesAndOtherLiabilitiesCurrent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000241" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000241_dcnt_167cbd43-b7b1-4b89-8d40-bc9e667f84ab">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. COMMITMENTS AND CONTINGENCIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases<span style="font-weight:normal;">&#8212;In September 2016, the Company entered into a noncancelable operating lease beginning in <ix:nonNumeric id="F_000424" name="fixx:LeaseBeginningDateYearAndMonth" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930" format="ixt:datemonthyearen">November 2016</ix:nonNumeric> for office, laboratory and manufacturing space in Bedford, Massachusetts, that expires in <ix:nonNumeric id="F_000425" name="fixx:LeaseExpirationDateYearAndMonth" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930" format="ixt:datemonthyearen">October 2021</ix:nonNumeric>, with an option for an additional <span style="-sec-ix-hidden:F_000426">three-year</span> term. In 2018, the Company entered into a sublease agreement for the entire leased premises. The rent commencement date of the sublease was December 2018, and the sublease will terminate on the scheduled termination date of the original lease. Under the terms of the sublease, the subtenant is obligated to pay the Company aggregate base rent of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="fixx:SubleaseAggregateBaseRentObligation" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20201231" decimals="-5" scale="6">2.7</ix:nonFraction> million over the term of the sublease, based on the same level of rent the Company is obligated to pay the landlord, in addition to a passthrough of operating expenses and real estate taxes charged by the landlord. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a noncancelable operating lease for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000428" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231" decimals="0" format="ixt:numdotdecimal">67,000</ix:nonFraction> square feet of research and development, manufacturing and general office space in Bedford, Massachusetts. The lease expires in <ix:nonNumeric id="F_000429" name="fixx:LeaseExpirationDateYearAndMonth" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231" format="ixt:datemonthyearen">February 2027</ix:nonNumeric> with an option for an additional<span style="-sec-ix-hidden:F_000430"> five-year</span> term. Rent became due under the lease in <ix:nonFraction unitRef="U_fixxPhase" id="F_000431" name="fixx:NumberOfPhases" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> phases&#59; rent on the first <ix:nonFraction unitRef="U_utrsqft" id="F_000432" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171231" decimals="INF" format="ixt:numdotdecimal">46,000</ix:nonFraction> square feet started in <ix:nonNumeric id="F_000433" name="fixx:RentStartDateYearAndMonth" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171201_20171231" format="ixt:datemonthyearen">September 2018</ix:nonNumeric> and rent on the remaining <ix:nonFraction unitRef="U_utrsqft" id="F_000434" name="us-gaap:AreaOfRealEstateProperty" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171231" decimals="INF" format="ixt:numdotdecimal">21,000</ix:nonFraction> square feet started in <ix:nonNumeric id="F_000435" name="fixx:RentStartDateYearAndMonth" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171201_20171231" format="ixt:datemonthyearen">March 2019</ix:nonNumeric>. The initial annual base rent was $<ix:nonFraction unitRef="U_iso4217USD_utrsqft" id="F_000436" name="fixx:InitialBaseRentPerSquareFeet" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231" decimals="INF">39.50</ix:nonFraction> per square foot and increases by <ix:nonFraction unitRef="U_xbrlipure" id="F_000437" name="fixx:LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231" decimals="2" format="ixt-sec:numwordsen" scale="-2">three</ix:nonFraction> percent annually. The Company is obligated to pay, on a pro-rata </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000241_dcnt_167cbd43-b7b1-4b89-8d40-bc9e667f84ab" continuedAt="F_000241_dcnt_d4939657-b382-4722-be70-7ad0097e2954">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis, real estate taxes and operating costs related to the premises.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease agreement entered into in December 2017 allowed for a tenant improvement allowance not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="fixx:TenantImprovementsAllowance" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20201231" decimals="INF" scale="6">10.9</ix:nonFraction>&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, which the Company received in full, to be applied to the total cost of tenant improvements to the leased premises. The unamortized balance of the tenant improvement allowance was included in deferred rent incentives and has been recorded as a reduction to operating right-of-use asset upon adoption of the new leasing standards.</span><span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains letters of credit, secured by restricted cash, for security deposits totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:SecurityDepositLiability" contextRef="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:SecurityDepositLiability" contextRef="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20191231" decimals="-5" scale="6">1.3</ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively, in conjunction with its current leases.</p><ix:nonNumeric id="F_000279" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes operating lease costs and variable lease costs, as well as sublease income for the year ended December&#160;31, 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:OperatingLeaseCost" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,492</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:VariableLeaseCost" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:SubleaseIncome" contextRef="C_0001661998_20200101_20201231" decimals="-3" scale="3">913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net lease cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:LeaseCost" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for the year ended December 31, 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="C_0001661998_20190101_20191231" decimals="-5" scale="6">1.4</ix:nonFraction> million.</p><ix:nonNumeric id="F_000280" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of our operating lease liabilities as of December&#160;31, 2020 were as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ending December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="fixx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,442</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000281" name="fixx:ScheduleOfLeaseTermAndDiscountRateTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the lease term and discount rate as of December&#160;31, 2020:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">5.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000455" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001661998_20201231" decimals="3" scale="-2">9.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000282" name="fixx:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the supplemental cash flow information related to the Company's operating leases for the year ended December&#160;31, 2020.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000241_dcnt_d4939657-b382-4722-be70-7ad0097e2954">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000242" name="fixx:LicenseAgreementsTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. LICENSE AGREEMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">City of Hope </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company entered into a license agreement with City of Hope (&#8220;COH&#8221;), an academic research and medical center. The license term extends until the last to expire patent, unless terminated earlier by either party under certain provisions. The Company is required to pay an annual license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="fixx:AnnualLicenseFeePayable" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20160430" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction>, reimburse COH for patent costs incurred, pay amounts up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="fixx:DevelopmentAndCommercializationMilestonePayments" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_srtRangeAxis_srtMaximumMember_20160401_20160430" decimals="INF" scale="6">3.2</ix:nonFraction>&#160;million upon the achievement of certain development and commercialization milestones for each product under the license, pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the low double-digits, if any. During the year ended December 31, 2019, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="fixx:CollaborativeArrangementPaymentForExecutionOfAgreements" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction> to COH upon dosing the first patient in the pheNIX Phase 1/2 clinical trial. During the year ended December 31, 2020, the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="fixx:CollaborativeArrangementPaymentForExecutionOfAgreements" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">75,000</ix:nonFraction> plus interest to COH in connection with achievement of a milestone event. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the execution of the Collaboration Agreement with Novartis (see Note 15), the Company paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="fixx:CollaborativeArrangementPaymentForExecutionOfAgreements" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20170101_20171231" decimals="-5" scale="6">4.5</ix:nonFraction> million to COH in December 2017, under the terms of the license agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, the Company entered into a sponsored research agreement with COH with a goal to identify potential treatments for diseases in humans. Under this agreement, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_us-gaapTypeOfArrangementAxis_fixxSponsoredResearchAgreementMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million in research and development expense for the year ended December 31, 2019. The agreement terminated in September 2019 in accordance with its terms. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">California Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2016, the Company entered into a co-exclusive license agreement with the California Institute of Technology (&#8220;Caltech&#8221;), an academic research institute. The license term extends until the expiration, revocation, invalidation or unenforceability of the licensed patent rights. The Company is required to pay an annual minimal royalty fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:RoyaltyExpense" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930" decimals="INF" format="ixt:numdotdecimal">20,000</ix:nonFraction>, reimburse for patent costs incurred, pay an amount up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="fixx:DevelopmentAndRegulatoryMilestonePayment" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930" decimals="INF" scale="6">7.2</ix:nonFraction>&#160;million upon the achievement of certain development and regulatory milestones and pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the mid to high single-digits, if any. </p></ix:nonNumeric><ix:nonNumeric id="F_000243" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000243_dcnt_497f9a8f-bc25-43dc-b542-9a7b71554ab8">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. INCOME TAXES </p><ix:nonNumeric id="F_000283" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation between the U.S. federal statutory tax rate and the Company&#8217;s effective tax rate is summarized as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended&#160;December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000465" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001661998_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000466" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001661998_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000467" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001661998_20200101_20201231" decimals="INF" scale="-2">10.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000468" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001661998_20190101_20191231" decimals="INF" scale="-2">13.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000469" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001661998_20200101_20201231" decimals="INF" scale="-2">8.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000470" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001661998_20190101_20191231" decimals="INF" scale="-2">6.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000471" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001661998_20200101_20201231" decimals="INF" sign="-" scale="-2">1.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000472" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="C_0001661998_20190101_20191231" decimals="INF" sign="-" scale="-2">1.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000473" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001661998_20200101_20201231" decimals="INF" sign="-" scale="-2">37.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000474" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001661998_20190101_20191231" decimals="INF" sign="-" scale="-2">39.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000243_dcnt_497f9a8f-bc25-43dc-b542-9a7b71554ab8" continuedAt="F_000243_dcnt_3bbb5c3a-c04a-4cd3-b63a-a63981363f0d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000284" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,456</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized R&#38;D costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,207</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001661998_20191231" decimals="-3" scale="3">883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expense and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,914</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" contextRef="C_0001661998_20191231" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,517</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">80,537</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="fixx:DeferredTaxLiabilitiesDepreciation" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,726</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="fixx:DeferredTaxLiabilitiesDepreciation" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001661998_20201231" decimals="-3" scale="3">757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,034</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">77,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has <ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001661998_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> income tax expense due to the operating loss incurred for the years ended December 31, 2020 and 2019. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">265.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">271.5</ix:nonFraction> million of federal and state net operating loss carryforwards, respectively, that expire at various dates through <ix:nonNumeric id="F_000509" name="fixx:NetOperatingLossCarryforwardsExpirationYear" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_20200101_20201231">2040</ix:nonNumeric>. Included in the federal net operating loss carryforwards of $265.1 million is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="fixx:OperatingLossCarryforwardsIndefinitely" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231" decimals="-5" scale="6">233.6</ix:nonFraction> million that can be carried forward indefinitely. At December 31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">34.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">7.2</ix:nonFraction> million of federal and state research and development credit carryforwards, respectively, that expire at various dates through <ix:nonNumeric id="F_000510" name="fixx:TaxCreditCarryforwardsExpirationYear" contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"><ix:nonNumeric id="F_000506" name="fixx:TaxCreditCarryforwardsExpirationYear" contextRef="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20200101_20201231">2040</ix:nonNumeric></ix:nonNumeric>. Included in the $34.2 million of federal research and development credit carryforwards is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20191231" decimals="-5" scale="6">29.0</ix:nonFraction> million of orphan drug credit carryforwards. The valuation allowance increased in 2020 and 2019 by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001661998_20200101_20201231" decimals="-5" scale="6">47.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001661998_20190101_20191231" decimals="-5" scale="6">40.2</ix:nonFraction> million, respectively, due to the increase in the deferred tax assets by the same amounts, primarily due to the net operating loss carryforwards and research and development tax credits not utilized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards. Since a full valuation allowance has been provided against the Company&#8217;s research and development credits, any reduction in the gross deferred tax asset established for the research and development credit carryforwards would not result in any net impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect a change in control would have, if any, on the Company&#8217;s ability to utilize its net operating loss and research and development credit carryforwards in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns in the United States and Massachusetts. All tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000243_dcnt_3bbb5c3a-c04a-4cd3-b63a-a63981363f0d">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> uncertain tax positions. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="C_0001661998_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> interest or penalties were recorded for the years ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></ix:continuation><ix:nonNumeric id="F_000244" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. STOCKHOLDERS&#8217; EQUITY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock<span style="font-weight:normal;">&#8212;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting<span style="font-style:normal;">&#8212;<ix:nonNumeric id="F_000514" name="us-gaap:CommonStockVotingRights" contextRef="C_0001661998_20200101_20201231">Each holder of outstanding shares of common stock are entitled to one vote in respect of each share.</ix:nonNumeric> The holders of outstanding shares of common stock, voting together as a single class, shall be entitled to elect one director. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends<span style="font-style:normal;">&#8212;Subject to the payment in full of any preferential dividends to which the holders of preferred stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available therefore at such times and in such amounts as the Board of Directors may determine in its sole discretion. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Rights<span style="font-style:normal;">&#8212;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and any preferential amounts to which the holders of preferred stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000515" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">50,265,575</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000516" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">45,116,742</ix:nonFraction> shares of common stock outstanding at December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock<span style="font-weight:normal;">&#8212;As of December 31, 2020 and 2019, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000517" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000518" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001661998_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000519" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000520" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock issued and outstanding.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000245" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000245_dcnt_1bb65cca-0d82-4d6d-8faf-f361122ebed1">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. STOCK INCENTIVE PLANS</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2015 Stock Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, the Company&#8217;s Board of Directors adopted the 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of qualified incentive and nonqualified stock options or restricted stock awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants. Stock options generally vest over a <span style="-sec-ix-hidden:F_000521">four-year</span> period and expire <ix:nonNumeric id="F_000522" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2015 Plan. At December&#160;31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000523" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> additional shares available for future grant under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2018 Incentive Award Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company&#8217;s Board of Directors adopted and the Company&#8217;s stockholders approved the Homology Medicines, Inc. 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221; and, together with the 2015 Plan, the &#8220;Plans&#8221;), which became effective on the day prior to the first public trading date of the Company&#8217;s common stock. Upon effectiveness of the 2018 Plan, the Company ceased granting new awards under the 2015 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock or cash-based awards to employees and consultants of the Company and certain affiliates and directors of the Company. The number of shares of common stock initially available for issuance under the 2018 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000524" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">3,186,205</ix:nonFraction> shares of common stock plus the number of shares subject to awards outstanding under the 2015 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2018 Plan. In addition, the number of shares of common stock available for issuance under the 2018 Plan is subject to an annual increase on the first day of each calendar year beginning on January&#160;1, 2019 and ending on and including January&#160;1, 2028 equal to the lesser of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000525" name="fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180301_20180331" decimals="INF" scale="-2">4</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s Board of Directors, provided that not more than <ix:nonFraction unitRef="U_xbrlishares" id="F_000526" name="fixx:MaximumSharesAllowedToBeIssued" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">20,887,347</ix:nonFraction> shares of common stock may be issued under the 2018 Plan upon the exercise of incentive stock options (the &#8220;Evergreen Provision&#8221;). As of December&#160;31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,397,547</ix:nonFraction> shares available for future grant under the 2018 Plan. On January 1, 2021, pursuant to the Evergreen Provision, an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101" decimals="INF" format="ixt:numdotdecimal">2,010,623</ix:nonFraction> shares were added to the 2018 Plan, representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000528" name="fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101" decimals="INF" scale="-2">4</ix:nonFraction>% of total common shares outstanding at December 31, 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000245_dcnt_1bb65cca-0d82-4d6d-8faf-f361122ebed1" continuedAt="F_000245_dcnt_4b1029dd-3b86-44ce-99e7-085c56ffbf9e">

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2018 Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved, the Homology Medicines, Inc. 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;). The 2018 ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The 2018 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code. The number of shares of common stock initially available for issuance under the 2018 ESPP was <ix:nonFraction unitRef="U_xbrlishares" id="F_000530" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">353,980</ix:nonFraction> shares of common stock plus an annual increase on the first day of each calendar year beginning on January 1, 2019 and ending on and including January 1, 2028 equal to the lesser of (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000531" name="fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180301_20180331" decimals="INF" scale="-2">1</ix:nonFraction>% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s Board of Directors, provided that not more than <ix:nonFraction unitRef="U_xbrlishares" id="F_000532" name="fixx:MaximumSharesAllowedToBeIssuedUnderESPP" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331" decimals="INF" format="ixt:numdotdecimal">4,778,738</ix:nonFraction> shares of common stock may be issued under the 2018 ESPP (the &#8220;ESPP Evergreen Provision&#8221;). At December&#160;31, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000537" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,039,650</ix:nonFraction> shares available for future issuance under the 2018 ESPP. On January 1, 2021, pursuant to the ESPP Evergreen Provision, an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000533" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101" decimals="INF" format="ixt:numdotdecimal">502,655</ix:nonFraction> shares were added to the 2018 ESPP, representing <ix:nonFraction unitRef="U_xbrlipure" id="F_000534" name="fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101" decimals="INF" scale="-2">1</ix:nonFraction>% of total common shares outstanding at December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2018 ESPP, employees may purchase common stock through after-tax payroll deductions at a price equal to <ix:nonFraction unitRef="U_xbrlipure" id="F_000535" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value on the first trading day of an offering period or the last trading day of an offering period. The 2018 ESPP generally provides for offering periods of <ix:nonNumeric id="F_000536" name="fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331" format="ixt-sec:durwordsen">six months</ix:nonNumeric> in duration that end on the final trading day of each February and August. In accordance with the Internal Revenue Code, no employee will be permitted to accrue the right to purchase stock under the 2018 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of the Company&#8217;s common stock as of the first day of the offering period).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000538" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">83,848</ix:nonFraction> shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million. During the year ended December&#160;31, 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_000539" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">55,234</ix:nonFraction> shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">0.8</ix:nonFraction> million. Pursuant to the 2018 ESPP, the Company recorded stock-based compensation of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award, which is generally the vesting period. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model, with the assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of a peer group of publicly traded companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the options was used for the expected term of options granted to non-employees. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods commensurate with the expected term of the award. The Company recognizes forfeitures as they occur.</p><ix:nonNumeric id="F_000285" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in the Black-Scholes option pricing model are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.2% &#8212; 66.3%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.4% &#8212; 64.7%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.73%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36% &#8212; 2.60%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.25</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underlying common stock fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.82 - $21.75</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.73 &#8212; $30.34</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000245_dcnt_4b1029dd-3b86-44ce-99e7-085c56ffbf9e">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000286" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense related to stock options and shares purchased under the 2018 ESPP as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,248</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001661998_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20201231" decimals="-5" scale="6">29.2</ix:nonFraction> million of unrecognized compensation expense related to unvested employee and non-employee share-based compensation arrangements granted under the Plans. The unrecognized compensation expense is estimated to be recognized over a period of <ix:nonNumeric id="F_000566" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20200101_20201231" format="ixt-sec:duryear">2.4</ix:nonNumeric> years at December&#160;31, 2020. </p><ix:nonNumeric id="F_000287" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of option activity under the Plans during the year ended December&#160;31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">4,843,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000574" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001661998_20191231" decimals="2">14.78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000581">8.5</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001661998_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000568" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,311,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000575" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001661998_20200101_20201231" decimals="2">17.82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000569" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">46,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000576" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001661998_20200101_20201231" decimals="2">3.79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000570" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">266,984</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000577" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001661998_20200101_20201231" decimals="2">22.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000571" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">5,840,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000578" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001661998_20201231" decimals="2">15.18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000582">7.8</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000572" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">5,840,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001661998_20201231" decimals="2">15.18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000583">7.8</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000573" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">2,869,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000580" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001661998_20201231" decimals="2">12.18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.0</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001661998_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised during the year ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001661998_20200101_20201231" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001661998_20190101_20191231" decimals="-5" scale="6">1.9</ix:nonFraction> million, respectively. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000591" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001661998_20200101_20201231" decimals="2">10.39</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000592" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001661998_20190101_20191231" decimals="2">12.90</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted pursuant to the 2015 Plan permit option holders to elect to exercise unvested options in exchange for unvested common stock. Options granted under the 2015 Plan that are exercised prior to vesting will continue to vest according to the respective option agreement, and such unvested shares are subject to repurchase by the Company at the optionee&#8217;s original exercise price in the event the optionee&#8217;s service with the Company voluntarily or involuntarily terminates. </p><ix:nonNumeric id="F_000288" name="fixx:SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested common stock from early exercises that is subject to repurchase by the Company is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;January 1, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000593" name="fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">21,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000594" name="fixx:UnvestedCommonSharesSubjectToRepurchaseVested" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">18,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000595" name="fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">3,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_000596" name="fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding" contextRef="C_0001661998_20201231" decimals="INF" format="ixt:numdotdecimal">3,091</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000597" name="fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding" contextRef="C_0001661998_20191231" decimals="INF" format="ixt:numdotdecimal">21,666</ix:nonFraction> shares, respectively, remained subject to a repurchase right by the Company, with a related liability included in accrued expenses and other liabilities in the consolidated balance sheets of less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20191231" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million as of each date. </p></ix:continuation><ix:nonNumeric id="F_000246" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000246_dcnt_9dbefda9-04c1-4fa8-9368-b50dc0d1cf4e">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. NET LOSS PER SHARE</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include unvested common stock from the early-exercise of stock options and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000246_dcnt_9dbefda9-04c1-4fa8-9368-b50dc0d1cf4e">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><ix:nonNumeric id="F_000289" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000289_cnt_1"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span></ix:nonNumeric><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p><ix:continuation id="F_000289_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested common stock from early exercise of options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000600" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">3,091</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">21,666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,840,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000603" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,843,018</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000604" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,843,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000605" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001661998_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">4,864,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000247" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. DEFINED CONTRIBUTION PLAN </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for all of its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits, while the Company contributes to the plan at the discretion of the Board of Directors. The Company&#8217;s discretionary match made under the 401(k) Plan for the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001661998_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001661998_20190101_20191231" decimals="-5" scale="6">0.5</ix:nonFraction> million, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000248" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000248_dcnt_caab90ca-797e-4011-aec5-248a12b7bbfd">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. COLLABORATION AND LICENSE AGREEMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a collaboration and license agreement with Novartis (as amended, the &#8220;Collaboration Agreement&#8221;) for the research, development, manufacturing and commercialization of products using the Company&#8217;s gene-editing technology for the treatment of certain ophthalmic targets and sickle cell disease. In February 2019, Novartis elected to discontinue the sickle cell disease program under the Collaboration Agreement effective in August 2019. In May 2020, Novartis confirmed an ophthalmic target for a therapeutic editing program. Additionally, in accordance with the terms of the Collaboration Agreement, Novartis&#8217; right to substitute other ophthalmic targets expired. For additional information on the Collaboration Agreement, please refer to Note 17.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Collaboration Agreement, the Company granted Novartis a research license, a development and commercialization license, and a manufacturing license, under certain of its intellectual property rights to research, develop, manufacture and commercialize ophthalmic targets. Upon entering into the Collaboration Agreement in November 2017, the Company received an upfront, nonrefundable payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000608" name="fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130" decimals="-5" scale="6">35.0</ix:nonFraction>&#160;million and issued additional shares of its Series B preferred stock to Novartis for consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million, in addition to the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20170701_20170731" decimals="-5" scale="6">5.0</ix:nonFraction> million of Series B preferred stock Novartis had purchased in July 2017. The Company recorded the November 2017 issuance of Series B preferred stock at its estimated fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="fixx:PreferredStockEstimatedFairValue" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171130" decimals="-5" scale="6">11.7</ix:nonFraction> million, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130" decimals="-5" scale="6">1.7</ix:nonFraction> million of the upfront payment, and allocated the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="fixx:CollaborativeArrangementAllocatedConsideration" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130" decimals="INF" scale="6">33.3</ix:nonFraction> million of the upfront payment to the Collaboration Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration Agreement consists of a research term, where the Company and Novartis were collaborating to perform research and conduct preclinical development to identify candidates that modulate ophthalmic targets. The Collaboration Agreement also includes exploratory work on the applicability of the gene editing technology with respect to other gene targets. The Company&#8217;s obligation to perform such exploratory research was extended pursuant an amendment to the Collaboration Agreement was set to conclude in May 2021. The Company was responsible for the manufacturing of proprietary research grade human hematopoietic stem cell derived adeno-associated virus vectors (&#8220;AAVHSCs&#8221;) during the research term. Novartis agreed to reimburse research activities performed by the Company at a full-time equivalent rate (&#8220;FTE&#8221;) and manufacturing activities at cost, up to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="fixx:CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171101_20171130" decimals="INF" scale="6">17.0</ix:nonFraction> million during the research term, as specified and defined in the Collaboration Agreement. Novartis agreed to pay the Company a target fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="fixx:CollaborativeAgreementTargetFee" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130" decimals="-5" scale="6">5.0</ix:nonFraction>&#160;million if the target meets certain success criteria during the research term (the &#8220;target fee trigger date&#8221;). The research term was to continue for <ix:nonNumeric id="F_000615" name="fixx:CollaborativeArrangementTermOfAgreement" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the effective date of the Collaboration Agreement. Pursuant to the Collaboration Agreement, the Company also agreed to participate on a joint steering committee and a joint manufacturing subcommittee, with equal representation from both the Company and Novartis. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000248_dcnt_caab90ca-797e-4011-aec5-248a12b7bbfd" continuedAt="F_000248_dcnt_22c1bf37-9043-40f9-aa13-4132fb850207">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Novartis had the exclusive right to develop and commercialize <ix:nonFraction unitRef="U_fixxCandidateorProduct" id="F_000617" name="fixx:CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> ophthalmic candidate or product arising from the research activities. Subject to certain limitations pursuant to the terms of the Collaboration Agreement, Novartis agreed to fund all development and commercialization costs. The Company was responsible for manufacturing candidates and products for Novartis during the development and commercialization terms. The Company&#8217;s manufacturing activities were to be reimbursed at cost during the development term and at cost plus a margin during the commercialization term, as defined in the Collaboration Agreement. If the Company was not able to manufacture candidates or products that met the quality or quantity requirements of Novartis, then Novartis would have had the right to designate a third-party contract manufacturer or manufacture such candidates or products itself. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Collaboration Agreement, taking into consideration Novartis&#8217; election to discontinue the sickle cell disease program, and the expiration of Novartis&#8217; rights to make substitutions of an ophthalmic target, the Company was also eligible to receive up to a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="fixx:CollaborativeArrangementMilestonePaymentsEligibleToReceive" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130" decimals="INF" scale="6">265.0</ix:nonFraction>&#160;million in milestone payments, including up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="fixx:CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130" decimals="INF" scale="6">90.0</ix:nonFraction> million in development milestone payments, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="fixx:CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130" decimals="INF" scale="6">85.0</ix:nonFraction> million in regulatory milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="fixx:CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130" decimals="INF" scale="6">90.0</ix:nonFraction> million in commercial milestone payments, with respect to the licensed products. The Company was also eligible to earn tiered royalties on net sales of licensed products by Novartis, its affiliates or sublicensees, ranging from mid-single-digit, to sub-teen double-digit percentages, and such royalties were potentially subject to various reductions and offsets. If any of the exploratory research efforts were advanced into formal research and development programs, the parties agreed to negotiate the economics including potential milestone payments for such programs at that time.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the (1) research, development and commercialization and manufacturing licenses, (2) the research activities performed by the Company (3) service on the joint committees and (4) manufacturing during the research and development terms represented a single performance obligation under the Collaboration Agreement. Since the option for Novartis to obtain manufacturing during the commercialization term from the Company is at a price that would reflect the standalone selling price, the option does not provide Novartis with a material right and is therefore not a performance obligation under the contract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded that the research, development and commercialization and manufacturing licenses are not distinct from the research activities and manufacturing during the research and development term as Novartis cannot benefit from the licenses without the Company performing the research and manufacturing services. These services are so specialized and rely on the Company&#8217;s expertise in gene editing technologies not available in the marketplace. As a result, these licenses have been combined with the research activities, service on the joint committees and the manufacturing during the research and development terms as a single performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price consists of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="fixx:CollaborativeArrangementTransactionPrice" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231" decimals="-5" scale="6">33.3</ix:nonFraction> million non-refundable upfront payment, net of amounts classified as equity, and projected reimbursable research and manufacturing activities, which have been estimated using the expected value method. None of the target fees or development and regulatory milestone payments have been included in the transaction price, as all are fully constrained. As part of the evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones is outside of the Company&#8217;s control and is contingent upon the success of the Company&#8217;s preclinical studies, clinical trials, Novartis&#8217; efforts and the receipt of regulatory approval. In addition, the Company has determined that the commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominately to the licenses transferred to Novartis, and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified only one performance obligation in the Collaboration Agreement. Therefore, the Company allocated the transaction price at the onset of the contract to the single performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue over time using a cost-to-cost method, which it believes best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded over the performance period as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2020, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231" decimals="-5" scale="6">30.2</ix:nonFraction></ix:nonFraction> million, and the Company will recognize this revenue as the research and manufacturing activities are performed, which was expected to occur over a period of time that was estimated to conclude in 2027. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000248_dcnt_22c1bf37-9043-40f9-aa13-4132fb850207">

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In estimating the total costs to satisfy its single performance obligation pursuant to the Novartis agreement, the Company is required to make significant estimates including the expected time it will take to fulfill the performance obligation, which, as of December 31, 2020, was expected to be approximately <ix:nonNumeric id="F_000625" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000626" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></ix:nonNumeric> from the date the Collaboration Agreement was entered into, and the expected costs associated with manufacturing during the research and development terms for a novel manufacturing process as well as the probability of success of a target to move into the development phase. The Company has made estimates of such costs utilizing its experience with similar product candidates, however not identical to those in the Collaboration Agreement. In making such estimates, significant judgment is required to evaluate those key assumptions related to cost estimates. The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s reported cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue under the Collaboration Agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" scale="6">1.7</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101" decimals="-5" scale="6">0.6</ix:nonFraction> million was included in deferred revenue at the beginning of each such period. As of December&#160;31, 2020 and 2019, there was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">30.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">31.0</ix:nonFraction> million of deferred revenue related to the Collaboration Agreement, respectively. In addition, as of December&#160;31, 2020 and 2019, the Company has recorded accounts receivable of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">0.4</ix:nonFraction></ix:nonFraction> million, related to reimbursable research and development costs under the Collaboration Agreement, which are included in prepaid expenses and other current assets on the consolidated balance sheets.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000249" name="fixx:StockPurchaseAgreementDisclosureTextBlock" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. PFIZER STOCK PURCHASE AGREEMENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020,<span style="color:#000000;"> the Company entered into a common stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Pfizer Inc.</span> <span style="color:#000000;">(&#8220;Pfizer&#8221;), pursuant to which the Company agreed to issue and sell to Pfizer <ix:nonFraction unitRef="U_xbrlishares" id="F_000635" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of the Company&#8217;s common stock through a private placement transaction (the &#8220;Private Placement&#8221;) at a purchase price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000636" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109" decimals="2">12.00</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109" decimals="-5" scale="6">60.0</ix:nonFraction> million. <ix:nonNumeric id="F_000638" name="fixx:CommonStockPurchaseAgreementCondition" contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109">The shares of common stock sold to Pfizer are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares.</ix:nonNumeric></span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Stock Purchase Agreement, Pfizer was granted an exclusive right of first refusal (the &#8220;ROFR&#8221;) <span style="color:#000000;">for a 30-month period (the &#8220;ROFR Period&#8221;) beginning on the date of the closing of the Private Placement (collectively, the &#8220;ROFR Provision&#8221;), to negotiate a potential collaboration on the development and commercialization of HMI-102 and HMI-103.</span> Pfizer may exercise its right of first refusal under the ROFR Provision one time for each of HMI-102 and HMI-103 during the ROFR period. In addition to the ROFR, the Stock Purchase Agreement provides for an information sharing committee (the &#8220;Information Committee&#8221;), comprised of representatives of each company which will serve as a forum for sharing information regarding the development of <span style="color:#000000;">HMI-102 and HMI-103 </span>during the ROFR Period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the issuance of common stock at its estimated fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="fixx:CommonStockEstimatedFairValue" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109" decimals="-5" scale="6">52.0</ix:nonFraction> million, which reflects a discount for the lack of marketability of the shares. The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="fixx:StockPurchaseAgreementRemainingAllocatedValue" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109" decimals="-5" scale="6">8.0</ix:nonFraction> million of aggregate purchase price was allocated to the other elements of the Stock Purchase Agreement, which represent a contract with a customer. The Company concluded that the Information Committee represents the only performance obligation under the contract. The ROFR does not provide Pfizer with a material right and is therefore not a performance obligation. As such, the Company allocated the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109" decimals="-5" scale="6">8.0</ix:nonFraction> million to the Information Committee obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize revenue over time as the measure of progress which it believes best depicts the transfer of control to Pfizer. The Information Committee will meet regularly over the ROFR Period to share information which results in recognition of the transaction price over the 30-month ROFR Period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized collaboration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">0.4</ix:nonFraction> million, and as of December 31, 2020, there was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">7.6</ix:nonFraction> million of deferred revenue related to the Company&#8217;s obligation to Pfizer.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:nonNumeric id="F_000250" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001661998_20200101_20201231" escape="true" continuedAt="F_000250_dcnt_5b07f05e-6e58-4d13-b7ea-3e261ca119dc">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. SUBSEQUENT EVENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 26, 2021, Homology received notice from Novartis that they had elected to terminate the Collaboration Agreement with the Company, with respect to the remaining ophthalmic target under the Collaboration Agreement. Accordingly, the notice served as notice of Novartis&#8217; termination of the Collaboration Agreement in its entirety, which will be effective on August 26, 2021. As a result of the termination of the Collaboration Agreement, Homology regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize Homology&#8217;s proprietary nuclease-free gene editing technology platform for an ophthalmic target (see Note 15). Homology announced its plans to continue to advance the program toward naming a development candidate. The Company and Novartis believe that results of studies conducted </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><ix:continuation id="F_000250_dcnt_5b07f05e-6e58-4d13-b7ea-3e261ca119dc">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> C</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollaboration </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide early proof-of-principle and support a nuclease-independent approach to editing of relevant cell types in the eye after sub-retinal</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">injection, and are the subject of a planned presentation at an upcoming scientific meeting</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;*&#160;*&#160;*&#160;*&#160;*</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>fixx-ex44_13.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex44_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.4</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></a>DESCRIPTION OF CAPITAL STOCK </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following description of the capital stock of Homology Medicines, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our restated certificate of incorporation<font style="font-size:12pt;font-family:Arial;"> </font>and our amended and restated bylaws, each of which has been publicly filed with the Securities and Exchange Commission (&#8220;SEC&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized capital stock consists of: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:2.67%;"></td>
<td style="width:1.69%;"></td>
<td style="width:95.05%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">200,000,000 shares of common stock, par value $0.0001 per share; and </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.6%;width:99.4%;">
<tr>
<td style="width:2.7%;"></td>
<td style="width:1.69%;"></td>
<td style="width:95.02%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000,000 shares of preferred stock, par value $0.0001 per share. </p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Select Market under the symbol <font style="color:#000000;">&#8220;</font>FIXX.<font style="color:#000000;">&#8221;</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights. <font style="font-style:normal;color:#000000;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our restated certificate of incorporation. See below under </font><font style="font-style:normal;">&#8220;&#8212;</font><font style="font-style:normal;color:#000000;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</font><font style="font-style:normal;">&#8212;</font><font style="font-style:normal;color:#000000;">Amendment of Charter Provisions.</font><font style="font-style:normal;">&#8221;</font><font style="font-style:normal;color:#000000;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Rights Upon Liquidation. <font style="font-style:normal;color:#000000;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Rights. <font style="font-style:normal;color:#000000;">Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us under this prospectus will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer Agent </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, LLC. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividend </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. We have never declared or paid any cash dividends on our common stock. We do not intend to declare or pay cash dividends for the foreseeable future. We currently expect to retain all future earnings, if any, for use in the development, operation and expansion of our business. Any determination to pay cash dividends in the future will depend upon, among other things, our results of operations, plans for expansion, tax considerations, available net profits and reserves, limitations under law, financial condition, capital requirements and other factors that our board of directors considers to be relevant. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of our restated certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\114315679.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registration Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock are entitled to rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to an amended and restated investors<font style="color:#000000;">&#8217;</font> rights agreement by and among us and certain of our stockholders, until the rights otherwise terminate pursuant to the terms of the investors<font style="color:#000000;">&#8217;</font> rights agreement. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Form S-1 Registration Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the holders of registrable securities request in writing that we effect a registration with respect to all or part of such registrable securities then outstanding having an anticipated aggregate offering price that would exceed $5,000,000, net of expenses, we may be required to register their shares. We are obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Piggyback Registration Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If at any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Form S-3 Registration Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If, at any time after we become entitled under the Securities Act to register our shares on a registration statement on Form S-3, the holders of the registrable securities request in writing that we effect a registration with respect to registrable securities at an aggregate price to the public in the offering of at least $5,000,000, we will be required to effect such registration; <font style="text-decoration:underline;color:#000000;">provided</font>, <font style="text-decoration:underline;color:#000000;">however</font>, that we will not be required to effect such a registration if, within any 12-month period, we have already effected two registrations on Form S-3 for the holders of registrable securities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expenses and Indemnification </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Termination of Registration Rights </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registration rights terminate upon the earlier of April 2, 2021 and the closing of a deemed liquidation event, as defined in the investors<font style="color:#000000;">&#8217;</font> rights agreement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some provisions of Delaware law, our restated certificate of incorporation and our amended and restated<font style="font-weight:bold;color:#000000;">&#160;</font>bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\114315679.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Undesignated Preferred Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholder Meetings </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated<font style="font-weight:bold;color:#000000;"> </font>bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Requirements for Advance Notification of Stockholder Nominations and Proposals </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Elimination of Stockholder Action by Written Consent </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Staggered Board </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Removal of Directors </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation and amended and restated bylaws provide that, subject to the rights of holders of any series of preferred stock, no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote in the election of directors. Subject to the rights of holders of any series of preferred stock, any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office, unless our board of directors determines by resolution that any such vacancy or newly created directorship shall be filled by our stockholders. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stockholders Not Entitled to Cumulative Voting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\114315679.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Delaware Anti-Takeover Statute </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be <font style="color:#000000;">&#8220;</font>interested stockholders<font style="color:#000000;">&#8221;</font> from engaging in a <font style="color:#000000;">&#8220;</font>business combination<font style="color:#000000;">&#8221;</font> with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an <font style="color:#000000;">&#8220;</font>interested stockholder<font style="color:#000000;">&#8221;</font> is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation<font style="color:#000000;">&#8217;</font>s voting stock. Generally, a <font style="color:#000000;">&#8220;</font>business combination<font style="color:#000000;">&#8221;</font> includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Choice of Forum </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our restated certificate of incorporation or amended and restated bylaws; or (4) any action asserting a claim governed by the internal affairs doctrine. In addition, our bylaws provide that the federal district courts of the United States are the exclusive forum for any complaint raising a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these choice of forum provisions. It is possible that a court of law could find the choice of forum provisions contained in our restated certificate of incorporation or bylaws to be inapplicable or unenforceable if challenged in a proceeding or otherwise. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment of Charter Provisions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions of Delaware law, our restated certificate of incorporation and our amended and restated<font style="font-weight:bold;color:#000000;">&#160;</font>bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\114315679.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>fixx-ex102_943.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex102_943.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.2 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 INCENTIVE AWARD PLAN </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURPOSE </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ELIGIBILITY </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADMINISTRATION AND DELEGATION </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 <font style="text-decoration:underline;">Administration</font>. The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award as it deems necessary or appropriate to administer the Plan and any Awards. The Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Appointment of Committees</font>. To the extent Applicable Laws permit, the Board may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries. The Board may abolish any Committee or re-vest in itself any previously delegated authority at any time. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCK AVAILABLE FOR AWARDS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1 <font style="text-decoration:underline;">Number of Shares</font>. Subject to adjustment under Article VIII and the terms of this Article IV, Awards may be made under the Plan covering up to the Overall Share Limit. As of the Plan&#8217;s effective date under Section 10.3, the Company will cease granting awards under the Prior Plans; however, Prior Plan Awards will remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or treasury Shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 <font style="text-decoration:underline;">Share Recycling</font>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, in any case, in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 </font><font style="text-decoration:underline;">Incentive Stock Option Limitations</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Notwithstanding anything to the contrary herein, no more than 20,887,347 Shares may be issued pursuant to the exercise of Incentive Stock Options. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 <font style="text-decoration:underline;">Substitute Awards</font>. In connection with an entity&#8217;s merger or consolidation with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or stock-based awards granted before such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan. Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, and shall only be made to individuals who were not Employees or Directors prior to such acquisition or combination. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5 <font style="text-decoration:underline;">Non-Employee Director Compensation</font>. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. The Administrator will from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as compensation for services as a non-employee Director during any fiscal year of the Company may not exceed $500,000 increased to $750,000 in the fiscal year of a non-employee Director&#8217;s initial service as a non-employee Director. The Administrator may make exceptions to this limit for individual non-employee Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided that the non-employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee Directors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 <font style="text-decoration:underline;">General</font>. The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 <font style="text-decoration:underline;">Exercise Price</font>. The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement. The exercise price will not be less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 </font><font style="text-decoration:underline;">Duration</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that the term of an Option or Stock Appreciation Right will not exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option) (i) the exercise of the Option or Stock Appreciation Right is prohibited by Applicable Law, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including blackout periods) or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be extended until the date that is thirty (30) days after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the Participant is given notice by the Company or any of its Subsidiaries of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the date of the delivery of such notice, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii) the effective date of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will terminate immediately upon the effective date of such termination of Service). </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4 <font style="text-decoration:underline;">Exercise</font>. Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock Appreciation Right, together with, as applicable, payment in full (i) as specified in Section 5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section 9.5 for any applicable taxes. Unless the Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 <font style="text-decoration:underline;">Payment Upon Exercise</font>. Subject to Section 10.8, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Company may limit the use of one of the foregoing payment forms if one or more of the payment forms below is permitted; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) if there is a public market for Shares at the time of exercise, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to pay the exercise price, or (B) the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) to the extent permitted by the Administrator, delivery (either by actual delivery or attestation) of Shares owned by the Participant valued at their Fair Market Value; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) to the extent permitted by the Administrator, surrendering Shares then issuable upon the Option&#8217;s exercise valued at their Fair Market Value on the exercise date; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) to the extent permitted by the Administrator, delivery of a promissory note or any other property that the Administrator determines is good and valuable consideration; or </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) to the extent permitted by the Company, any combination of the above payment forms approved by the Administrator. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VI. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK; RESTRICTED STOCK UNITS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1 <font style="text-decoration:underline;">General</font>. The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such shares at their issue price or other stated or formula price from the Participant (or to require forfeiture of such shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator establishes for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 <font style="text-decoration:underline;">Restricted Stock</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Dividends</font>. Participants holding shares of Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and forfeitability as the shares of Restricted Stock with respect to which they were paid. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Stock Certificates</font>. The Company may require that the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3 <font style="text-decoration:underline;">Restricted Stock Units.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">Settlement</font>. The Administrator may provide that settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply with Section 409A. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) <font style="text-decoration:underline;">Stockholder Rights</font>. A Participant will have no rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Dividend Equivalents</font>. If the Administrator provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VII. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER STOCK OR CASH BASED AWARDS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Stock or Cash Based Awards may be granted to Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which a Participant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, as the Administrator determines. Subject to the provisions of the Plan, the Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions, which will be set forth in the applicable Award Agreement. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE VIII. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADJUSTMENTS FOR CHANGES IN COMMON STOCK </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND CERTAIN OTHER EVENTS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1 <font style="text-decoration:underline;">Equity Restructuring</font>. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to Participants. The adjustments provided under this Section 8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.2 <font style="text-decoration:underline;">Corporate Transactions</font>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control, issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction or event (except that action to give effect to a change in Applicable Law or accounting principles may be made within a reasonable period of time after such change) and either automatically or upon the Participant&#8217;s request, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to (x) prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any Award granted or issued under the Plan, (y) to facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) To provide for the cancellation of any such Award in exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or less than zero, then the Award may be terminated without payment; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) To provide that such Award shall vest and, to the extent applicable, be exercisable as to all shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) To provide that such Award be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article IV hereof on the maximum number and kind of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price), and the criteria included in, outstanding Awards; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e) To replace such Award with other rights or property selected by the Administrator; and/or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f) To provide that the Award will terminate and cannot vest, be exercised or become payable after the applicable event. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3 <font style="text-decoration:underline;">Administrative Stand Still</font>. In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.4 <font style="text-decoration:underline;">General</font>. Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section 8.1 above or the Administrator&#8217;s action under the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article VIII. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IX. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL PROVISIONS APPLICABLE TO AWARDS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.1 <font style="text-decoration:underline;">Transferability</font>. Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2 <font style="text-decoration:underline;">Documentation</font>. Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3 <font style="text-decoration:underline;">Discretion</font>. Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards (or portions thereof) uniformly. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4 <font style="text-decoration:underline;">Termination of Status</font>. The Administrator will determine how the disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator, guardian or Designated Beneficiary may exercise rights under the Award, if applicable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.5 <font style="text-decoration:underline;">Withholding</font>. Each Participant must pay the Company, or make provision satisfactory to the Administrator for payment of, any taxes required by law to be withheld in connection with such Participant&#8217;s Awards by the date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. Subject to Section 10.8 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted, (ii) to the extent permitted by the Administrator, in whole or in part </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by delivery of Shares, including Shares retained from the Award creating the tax obligation, valued at their Fair Market Value, (iii) if there is a public market for Shares at the time the tax obligations are satisfied, unless the Company otherwise determines, (A) delivery (including telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent permitted by the Company, any combination of the foregoing payment forms approved by the Administrator. If any tax withholding obligation will be satisfied under clause (ii) of the immediately preceding sentence by the Company&#8217;s retention of Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.6 <font style="text-decoration:underline;">Amendment of Award; Repricing</font>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive Stock Option to a Non-Qualified Stock Option. The Participant&#8217;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the Award, or (ii) the change is permitted under Article VIII or pursuant to Section 10.6. Notwithstanding the foregoing or anything in the Plan to the contrary, the Administrator may not except pursuant to Article VIII, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of the original Options or Stock Appreciation Rights. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7 <font style="text-decoration:underline;">Conditions on Delivery of Stock</font>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all Award conditions have been met or removed to the Company&#8217;s satisfaction, (ii) as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#8217;s inability to obtain authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as to which such requisite authority has not been obtained. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8 <font style="text-decoration:underline;">Acceleration</font>. The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9 <font style="text-decoration:underline;">Additional Terms of Incentive Stock Options</font>. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections 424(e) or (f) of the Code, respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than 110% of the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section 422 of the Code. By accepting an Incentive Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i) two years from the grant date of the Option or (ii) one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section 422 of the Code for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any reason, including becoming exercisable with respect to Shares having a fair market value exceeding the $100,000 limitation under Treasury Regulation Section 1.422-4, will be a Non-Qualified Stock Option. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE X. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1 <font style="text-decoration:underline;">No Right to Employment or Other Status</font>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan or any Award, except as expressly provided in an Award Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2 <font style="text-decoration:underline;">No Rights as Stockholder; Certificates</font>. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3 <font style="text-decoration:underline;">Effective Date and Term of Plan</font>. Unless earlier terminated by the Board, the Plan will become effective on the day prior to the Public Trading Date and will remain in effect until the tenth anniversary of the earlier of (i) the date the Board adopted the Plan or (ii) the date the Company&#8217;s stockholders approved the Plan, but Awards previously granted may extend beyond that date in accordance with the Plan. If the Plan is not approved by the Company&#8217;s stockholders, the Plan will not become effective, no Awards will be granted under the Plan and the Prior Plans will continue in full force and effect in accordance with their terms. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4 <font style="text-decoration:underline;">Amendment of Plan</font>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of such amendment without the affected Participant&#8217;s consent. No Awards may be granted under the Plan during any suspension period or after Plan termination. Awards outstanding at the time of any Plan suspension or termination will continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5 <font style="text-decoration:underline;">Provisions for Foreign Participants</font>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws, rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6 <font style="text-decoration:underline;">Section 409A</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) <font style="text-decoration:underline;">General</font>. The Company intends that all Awards be structured to comply with, or be exempt from, Section 409A, such that no adverse tax consequences, interest, or penalties under Section 409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the intended tax treatment of Awards, including any such actions intended to (A) exempt this Plan or any Award from Section 409A, or (B) comply with Section 409A, including regulations, guidance, compliance programs and other interpretative authority that may be issued after an Award&#8217;s grant date. The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section 409A or otherwise. The Company will have no obligation under this Section 10.6 or otherwise to avoid the taxes, penalties or interest under Section 409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section 409A. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) </font><font style="text-decoration:underline;">Separation from Service</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. If an Award constitutes &#8220;nonqualified deferred compensation&#8221; under Section 409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section 409A, be made only upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section 409A), whether such &#8220;separation from service&#8221; occurs upon or after the termination of the Participant&#8217;s Service Provider relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221; </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) <font style="text-decoration:underline;">Payments to Specified Employees</font>. Notwithstanding any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section 409A and as the Administrator determines) due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section 409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until the specified employee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest). Any payments of &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7 <font style="text-decoration:underline;">Limitations on Liability</font>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. The Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8 <font style="text-decoration:underline;">Lock-Up Period</font>. The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly, selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period as determined by the underwriter. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9 <font style="text-decoration:underline;">Data Privacy</font>. As a condition for receiving any Award, each Participant explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of personal data as described in this section by and among the Company and its Subsidiaries and affiliates exclusively for implementing, administering and managing the Participant&#8217;s participation in the Plan. The Company and its Subsidiaries and affiliates may hold certain personal information about a Participant, including the Participant&#8217;s name, address and telephone number; birthdate; social security, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details, to implement, manage and administer the Plan and Awards (the &#8220;<font style="font-weight:bold;font-style:italic;">Data</font>&#8221;). The Company and its Subsidiaries and affiliates may transfer the Data amongst themselves as necessary to implement, administer and manage a Participant&#8217;s participation in the Plan, and the Company and its Subsidiaries and affiliates may transfer the Data to third parties assisting the Company with Plan implementation, administration and management. These recipients may be located in the Participant&#8217;s country, or elsewhere, and the Participant&#8217;s country may have different data privacy laws and protections than the recipients&#8217; country. By accepting an Award, each Participant authorizes such recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, to implement, administer and manage the Participant&#8217;s participation in the Plan, including any required Data transfer to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. A Participant may, at any time, view the Data that the Company holds regarding such Participant, request additional information about the storage and processing of the Data regarding such Participant, recommend any necessary corrections to the Data regarding the Participant or refuse or withdraw the consents in this Section 10.9 in writing, without cost, by contacting the local human resources representative. The Company may cancel Participant&#8217;s ability to participate in the Plan and, in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administrator&#8217;s discretion, the Participant may forfeit any outstanding Awards if the Participant refuses or withdraws the consents in this Section 10.9. For more information on the consequences of refusing or withdrawing consent, Participants may contact their local human resources representative. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10 <font style="text-decoration:underline;">Severability</font>. If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been excluded, and the illegal or invalid action will be null and void. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11 <font style="text-decoration:underline;">Governing Documents</font>. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12 <font style="text-decoration:underline;">Governing Law</font>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the State of Delaware. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13 <font style="text-decoration:underline;">Claw-back Provisions</font>. All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will be subject to any Company claw-back policy, including any claw-back policy adopted to comply with Applicable Laws (including the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder) as set forth in such claw-back policy or the Award Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14 <font style="text-decoration:underline;">Titles and Headings</font>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15 <font style="text-decoration:underline;">Conformity to Securities Laws</font>. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16 <font style="text-decoration:underline;">Relationship to Other Benefits</font>. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in writing in such other plan or an agreement thereunder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17 <font style="text-decoration:underline;">Broker-Assisted Sales</font>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section 9.5: (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan in which all participants receive an average price; (c) the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy the Participant&#8217;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE XI. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in the Plan, the following words and phrases will have the following meanings: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1 &#8220;<font style="font-weight:bold;font-style:italic;">Administrator</font>&#8221; means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2 &#8220;<font style="font-weight:bold;font-style:italic;">Applicable Laws</font>&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3 &#8220;<font style="font-weight:bold;font-style:italic;">Award</font>&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Other Stock or Cash Based Awards. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4 &#8220;<font style="font-weight:bold;font-style:italic;">Award Agreement</font>&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5 &#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221; means the Board of Directors of the Company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.6 &#8220;<font style="font-weight:bold;font-style:italic;">Cause</font>&#8221; means (i) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries or an Award Agreement in which the term &#8220;cause&#8221; is defined (a &#8220;<font style="font-weight:bold;font-style:italic;">Relevant Agreement</font>&#8221;), &#8220;Cause&#8221; as defined in the Relevant Agreement, and (ii) if no Relevant Agreement exists, (A) the Administrator&#8217;s determination that the Participant failed to substantially perform the Participant&#8217;s duties (other than a failure resulting from the Participant&#8217;s Disability); (B) the Administrator&#8217;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#8217;s immediate supervisor; (C) the occurrence of any act or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#8217;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable offense or crime involving moral turpitude; (D) the Participant&#8217;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#8217;s duties and responsibilities for the Company or any of its Subsidiaries; or (E) the Participant&#8217;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its Subsidiaries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.7 &#8220;<font style="font-weight:bold;font-style:italic;">Change in Control</font>&#8221; means and includes each of the following: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c) below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<font style="font-weight:bold;font-style:italic;">Successor Entity</font>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity; <font style="text-decoration:underline;">provided</font>, <font style="text-decoration:underline;">however</font>, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event described in subsection (a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award if such transaction also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(5).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Administrator shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(5) shall be consistent with such regulation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.8 &#8220;<font style="font-weight:bold;font-style:italic;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.9 &#8220;<font style="font-weight:bold;font-style:italic;">Committee</font>&#8221; means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule 16b-3, it is intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule 16b-3, a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3; however, a Committee member&#8217;s failure to qualify as a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.10 &#8220;<font style="font-weight:bold;font-style:italic;">Common Stock</font>&#8221; means the common stock of the Company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.11 &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221; means Homology Medicines, Inc., a Delaware corporation, or any successor. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.12 &#8220;<font style="font-weight:bold;font-style:italic;">Consultant</font>&#8221; means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (i) renders bona fide services to the Company; (ii) renders services not in connection with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#8217;s securities; and (iii) is a natural person. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.13 &#8220;<font style="font-weight:bold;font-style:italic;">Designated Beneficiary</font>&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated. Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.14 &#8220;</font><font style="font-weight:bold;font-style:italic;">Director</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a Board member. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.15 &#8220;<font style="font-weight:bold;font-style:italic;">Disability</font>&#8221; means a permanent and total disability under Section 22(e)(3) of the Code, as amended. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.16 &#8220;<font style="font-weight:bold;font-style:italic;">Dividend Equivalents</font>&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.17 &#8220;<font style="font-weight:bold;font-style:italic;">Employee</font>&#8221; means any employee of the Company or its Subsidiaries. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.18 &#8220;<font style="font-weight:bold;font-style:italic;">Equity Restructuring</font>&#8221; means a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization through a large, nonrecurring cash dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.19 &#8220;<font style="font-weight:bold;font-style:italic;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.20 &#8220;<font style="font-weight:bold;font-style:italic;">Fair Market Value</font>&#8221; means, as of any date, the value of Common Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (ii) if the Common Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; or (iii) without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. Notwithstanding the foregoing, with respect to any Award granted on the pricing date of the Company&#8217;s initial public offering, the Fair Market Value shall mean the initial public offering price of a Share as set forth in the Company&#8217;s final prospectus relating to its initial public offering filed with the Securities and Exchange Commission. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.21 &#8220;<font style="font-weight:bold;font-style:italic;">Greater Than 10% Stockholder</font>&#8221; means an individual then owning (within the meaning of Section 424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary corporation, as defined in Section 424(e) and (f) of the Code, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.22 &#8220;<font style="font-weight:bold;font-style:italic;">Incentive Stock Option</font>&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section 422 of the Code. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.23 &#8220;<font style="font-weight:bold;font-style:italic;">Non-Qualified Stock Option</font>&#8221; means an Option not intended or not qualifying as an Incentive Stock Option. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.24 &#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221; means an option to purchase Shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.25 &#8220;<font style="font-weight:bold;font-style:italic;">Other Stock or Cash Based Awards</font>&#8221; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.26 &#8220;<font style="font-weight:bold;font-style:italic;">Overall Share Limit</font>&#8221; means the sum of (i) 3,186,205 Shares; (ii) any shares of Common Stock which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to Article IV and (iii) an annual increase on the first day of each calendar year beginning January 1, 2019 and ending on and including January 1, 2028, equal to the lesser of (A) 4% of the aggregate number of shares of Common Stock outstanding on the final day of the immediately preceding calendar year and (B) such smaller number of Shares as is determined by the Board. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.27 &#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221; means a Service Provider who has been granted an Award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.28 &#8220;<font style="font-weight:bold;font-style:italic;">Performance Criteria</font>&#8221; mean the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Committee may provide for exclusion of the impact of an event or occurrence which the Committee determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or repurchase of bank loans or debt securities, (j) unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities to Common Stock, (m) any business interruption event (n) the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules affecting reported results. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.29 &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221; means this 2018 Incentive Award Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.30 &#8220;<font style="font-weight:bold;font-style:italic;">Prior Plans</font>&#8221; means, collectively, the Homology Medicines, Inc. 2015 Stock Incentive Plan and any prior equity incentive plans of the Company or its predecessor. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.31 &#8220;<font style="font-weight:bold;font-style:italic;">Prior Plan Award</font>&#8221; means an award outstanding under the Prior Plans as of the Plan&#8217;s effective date in Section 10.3. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.32 &#8220;<font style="font-weight:bold;font-style:italic;">Public Trading Date</font>&#8221; means the first date upon which the Common Stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system, or, if earlier, the date on which the Company becomes a &#8220;publicly held corporation&#8221; for purposes of Treasury Regulation Section 1.162-27(c)(1).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.33 &#8220;<font style="font-weight:bold;font-style:italic;">Restricted Stock</font>&#8221; means Shares awarded to a Participant under Article VI subject to certain vesting conditions and other restrictions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.34 &#8220;<font style="font-weight:bold;font-style:italic;">Restricted Stock Unit</font>&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date, subject to certain vesting conditions and other restrictions. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.35 &#8220;<font style="font-weight:bold;font-style:italic;">Rule 16b-3</font>&#8221; means Rule 16b-3 promulgated under the Exchange Act. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.36 &#8220;<font style="font-weight:bold;font-style:italic;">Section 409A</font>&#8221; means Section 409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.37 &#8220;</font><font style="font-weight:bold;font-style:italic;">Securities Act</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means the Securities Act of 1933, as amended. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.38 &#8220;<font style="font-weight:bold;font-style:italic;">Service Provider</font>&#8221; means an Employee, Consultant or Director. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.39 &#8220;<font style="font-weight:bold;font-style:italic;">Shares</font>&#8221; means shares of Common Stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.40 &#8220;<font style="font-weight:bold;font-style:italic;">Stock Appreciation Right</font>&#8221; means a stock appreciation right granted under Article V. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.41 &#8220;<font style="font-weight:bold;font-style:italic;">Subsidiary</font>&#8221; means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.42 &#8220;<font style="font-weight:bold;font-style:italic;">Substitute Awards</font>&#8221; shall mean Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.43 &#8220;<font style="font-weight:bold;font-style:italic;">Termination of Service</font>&#8221; means the date the Participant ceases to be a Service Provider. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* * * * * </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 INCENTIVE AWARD PLAN </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCK OPTION GRANT NOTICE </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Stock Option Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Homology Medicines, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted to the participant listed below (&#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221;) the stock option described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Option</font>&#8221;), subject to the terms and conditions of the Plan and the Stock Option Agreement attached as <font style="font-weight:bold;">Exhibit A</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;), both of which are incorporated into this Grant Notice by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to the Option:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Final Expiration Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[To be specified in individual award agreements]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Type of Option</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Incentive Stock Option/Non-Qualified Stock Option]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:64.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Participant Name]</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STOCK OPTION AGREEMENT </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 <font style="text-decoration:underline;">Grant of Option</font>. The Company has granted to Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Date</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2 <font style="text-decoration:underline;">Incorporation of Terms of Plan</font>. The Option is subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PERIOD OF EXERCISABILITY </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1 <font style="text-decoration:underline;">Commencement of Exercisability</font>. The Option will vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Vesting Schedule</font>&#8221;) except that any fraction of a Share as to which the Option would be vested or exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise determines, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2 <font style="text-decoration:underline;">Duration of Exercisability</font>. The Vesting Schedule is cumulative. Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 <font style="text-decoration:underline;">Expiration of Option</font>. The Option may not be exercised to any extent by anyone after, and will expire on, the first of the following to occur: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The final expiration date in the Grant Notice; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Except as the Administrator may otherwise approve, the expiration of three (3) months from the date of Participant&#8217;s Termination of Service, unless Participant&#8217;s Termination of Service is for Cause or by reason of Participant&#8217;s death or Disability; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Except as the Administrator may otherwise approve, the expiration of one (1) year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or Disability; and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Except as the Administrator may otherwise approve, Participant&#8217;s Termination of Service for Cause. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXERCISE OF OPTION </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 <font style="text-decoration:underline;">Person Eligible to Exercise</font>. During Participant&#8217;s lifetime, only Participant may exercise the Option. After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#8217;s Designated Beneficiary as provided in the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Partial Exercise</font>. Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be exercised for whole Shares. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3 </font><font style="text-decoration:underline;">Tax Withholding</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Option. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax liability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER PROVISIONS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1 <font style="text-decoration:underline;">Adjustments</font>. Participant acknowledges that the Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 <font style="text-decoration:underline;">Notices</font>. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 <font style="text-decoration:underline;">Titles</font>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 <font style="text-decoration:underline;">Conformity to Securities Laws</font>. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5 <font style="text-decoration:underline;">Successors and Assigns</font>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6 <font style="text-decoration:underline;">Limitations Applicable to Section 16 Persons</font>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7 <font style="text-decoration:underline;">Entire Agreement</font>. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8 </font><font style="text-decoration:underline;">Agreement Severable</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9 <font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font>. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10 <font style="text-decoration:underline;">Not a Contract of Employment</font>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11 <font style="text-decoration:underline;">Counterparts</font>. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12 <font style="text-decoration:underline;">Incentive Stock Options</font>. If the Option is designated as an Incentive Stock Option: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Participant acknowledges that to the extent the aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which stock options intended to qualify as &#8220;incentive stock options&#8221; under Section 422 of the Code, including the Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment as &#8220;incentive stock options&#8221; under Section 422 of the Code, such stock options (including the Option) will be treated as non-qualified stock options. Participant further acknowledges that the rule set forth in the preceding sentence will be applied by taking the Option and other stock options into account in the order in which they were granted, as determined under Section 422(d) of the Code. Participant acknowledges that amendments or modifications made to the Option pursuant to the Plan that would cause the Option to become a Non-Qualified Stock Option will not materially or adversely affect Participant&#8217;s rights under the Option, and that any such amendment or modification shall not require Participant&#8217;s consent. Participant also acknowledges that if the Option is exercised more than three (3) months after Participant&#8217;s Termination of Service as an Employee, other than by reason of death or disability, the Option will be taxed as a Non-Qualified Stock Option. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Participant will give prompt written notice to the Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a) within two (2) years from the Grant Date or (b) within one (1) year after the transfer of such Shares to Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* * * * * </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 INCENTIVE AWARD PLAN </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK GRANT NOTICE </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Homology Medicines, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted to the participant listed below (&#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221;)<font style="font-style:italic;"> </font>the shares of Restricted Stock described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Restricted Shares</font>&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Agreement attached as <font style="font-weight:bold;">Exhibit A</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;), both of which are incorporated into this Grant Notice by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Restricted Shares:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[To be specified in individual award agreements]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:64.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Participant Name]</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK AGREEMENT </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 <font style="text-decoration:underline;">Issuance of Restricted Shares</font>. The Company will issue the Restricted Shares to the Participant effective as of the grant date set forth in the Grant Notice and will cause (a) a stock certificate or certificates representing the Restricted Shares to be registered in Participant&#8217;s name or (b) the Restricted Shares to be held in book-entry form. If a stock certificate is issued, the certificate will be delivered to, and held in accordance with this Agreement by, the Company or its authorized representatives and will bear the restrictive legends required by this Agreement. If the Restricted Shares are held in book-entry form, then the book-entry will indicate that the Restricted Shares are subject to the restrictions of this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2 <font style="text-decoration:underline;">Incorporation of Terms of Plan</font>. The Restricted Shares are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control.<font style="font-weight:bold;"> </font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VESTING, FORFEITURE AND ESCROW </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1 <font style="text-decoration:underline;">Vesting</font>. The Restricted Shares will become vested Shares (the &#8220;<font style="font-weight:bold;font-style:italic;">Vested Shares</font>&#8221;) according to the vesting schedule in the Grant Notice except that any fraction of a Share that would otherwise become a Vested Share will be accumulated and will become a Vested Share only when a whole Vested Share has accumulated. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2 <font style="text-decoration:underline;">Forfeiture</font>. In the event of Participant&#8217;s Termination of Service for any reason, Participant will immediately and automatically forfeit to the Company any Shares that are not Vested Shares (the &#8220;<font style="font-weight:bold;font-style:italic;">Unvested Shares</font>&#8221;) at the time of Participant&#8217;s Termination of Service, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Upon forfeiture of Unvested Shares, the Company will become the legal and beneficial owner of the Unvested Shares and all related interests and Participant will have no further rights with respect to the Unvested Shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 <font style="text-decoration:underline;">Escrow</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Unvested Shares will be held by the Company or its authorized representatives until (i) they are forfeited, (ii) they become Vested Shares or (iii) this Agreement is no longer in effect. By accepting this Award, Participant appoints the Company and its authorized representatives as Participant&#8217;s attorney(s)-in-fact to take all actions necessary to effect any transfer of forfeited Unvested Shares (and Retained Distributions (as defined below), if any, paid on such forfeited Unvested Shares) to the Company as may be required pursuant to the Plan or this Agreement and to execute such representations or other documents or assurances as the Company or such representatives deem necessary or advisable in connection with any such transfer. The Company, or its authorized representative, will not be liable for any good faith act or omission with respect to the holding in escrow or transfer of the Restricted Shares. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) All cash dividends and other distributions made or declared with respect to Unvested Shares (&#8220;<font style="font-weight:bold;font-style:italic;">Retained Distributions</font>&#8221;) will be held by the Company until the time (if ever) when the Unvested Shares to which such Retained Distributions relate become Vested Shares. The Company will establish a separate Retained Distribution bookkeeping account (&#8220;<font style="font-weight:bold;font-style:italic;">Retained Distribution Account</font>&#8221;) for each Unvested Share with respect to which Retained Distributions have been made or declared in cash and credit the Retained Distribution Account (without interest) on the date of payment with the amount of such cash made or declared with respect to the Unvested Share. Retained </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distributions (including any Retained Distribution Account balance) will immediately and automatically be forfeited upon forfeiture of the Unvested Share with respect to which the Retained Distributions were paid or declared. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) As soon as reasonably practicable following the date on which an Unvested Share becomes a Vested Share, the Company will (i) cause the certificate (or a new certificate without the legend required by this Agreement, if Participant so requests) representing the Share to be delivered to Participant or, if the Share is held in book-entry form, cause the notations indicating the Share is subject to the restrictions of this Agreement to be removed and (ii) pay to Participant the Retained Distributions relating to the Share. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4 <font style="text-decoration:underline;">Rights as Stockholder</font>. Except as otherwise provided in this Agreement or the Plan, upon issuance of the Restricted Shares by the Company, Participant will have all the rights of a stockholder with respect to the Restricted Shares, including the right to vote the Restricted Shares and to receive dividends or other distributions paid or made with respect to the Restricted Shares. </p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TAXATION AND TAX WITHHOLDING </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 <font style="text-decoration:underline;">Representation</font>. Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of the Restricted Shares and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Section 83(b) Election</font>. If Participant makes an election under Section 83(b) of the Code with respect to the Restricted Shares, Participant will deliver a copy of the election to the Company promptly after filing the election with the Internal Revenue Service. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">3.3 Tax Withholding</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Restricted Shares as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise deliverable under the Award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the Restricted Shares, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Restricted Shares. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the Restricted Shares or the subsequent sale of the Restricted Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure this Award to reduce or eliminate Participant&#8217;s tax liability. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTIVE LEGENDS AND TRANSFERABILITY </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1 <font style="text-decoration:underline;">Legends</font>. Any certificate representing a Restricted Share will bear the following legend until the Restricted Share becomes a Vested Share: </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO FORFEITURE IN FAVOR OF THE COMPANY AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 <font style="text-decoration:underline;">Transferability</font>. The Restricted Shares and any Retained Distributions are subject to the restrictions on transfer in the Plan and may not be sold, assigned or transferred in any manner unless and until they become Vested Shares. Any attempted transfer or disposition of Unvested Shares or related Retained Distributions prior to the time the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested Shares become Vested Shares will be null and void. The Company will not be required to (a) transfer on its books any Restricted Share that has been sold or otherwise transferred in violation of this Agreement or (b) treat as owner of such Restricted Share or accord the right to vote or pay dividends to any purchaser or other transferee to whom such Restricted Share has been so transferred. The Company may issue appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, or make appropriate notations to the same effect in its records. </font></p>
<p style="text-align:center;margin-top:24pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE V. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER PROVISIONS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1 <font style="text-decoration:underline;">Adjustments</font>. Participant acknowledges that the Restricted Shares are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 <font style="text-decoration:underline;">Notices</font>. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3 <font style="text-decoration:underline;">Titles</font>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.4 <font style="text-decoration:underline;">Conformity to Securities Laws</font>. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 <font style="text-decoration:underline;">Successors and Assigns</font>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6 <font style="text-decoration:underline;">Limitations Applicable to Section 16 Persons</font>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Restricted Shares will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7 <font style="text-decoration:underline;">Entire Agreement</font>. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 <font style="text-decoration:underline;">Agreement Severable</font>. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9 <font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font>. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Award. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.10 <font style="text-decoration:underline;">Not a Contract of Employment</font>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.11 <font style="text-decoration:underline;">Counterparts</font>. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* * * * *</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 INCENTIVE AWARD PLAN </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK UNIT GRANT NOTICE </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Notice</font>&#8221;) have the meanings given to them in the 2018 Incentive Award Plan (as amended from time to time, the &#8220;<font style="font-weight:bold;font-style:italic;">Plan</font>&#8221;) of Homology Medicines, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has granted to the participant listed below (&#8220;<font style="font-weight:bold;font-style:italic;">Participant</font>&#8221;) the Restricted Stock Units described in this Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">RSUs</font>&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Unit Agreement attached as <font style="font-weight:bold;">Exhibit A</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;), both of which are incorporated into this Grant Notice by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Participant:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of RSUs:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10pt;;text-indent:-10pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Schedule:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[To be specified in individual award agreements]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By Participant&#8217;s signature below, Participant agrees to be bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top"  style="width:64.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HOMOLOGY MEDICINES, INC.</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Participant Name]</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:61.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:34.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit A </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTED STOCK UNIT AGREEMENT </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms not specifically defined in this Agreement have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE I. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1 <font style="text-decoration:underline;">Award of RSUs and Dividend Equivalents</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The Company has granted the RSUs to Participant effective as of the grant date set forth in the Grant Notice (the &#8220;<font style="font-weight:bold;font-style:italic;">Grant Date</font>&#8221;). Each RSU represents the right to receive one Share or, at the option of the Company, an amount of cash, in either case, as set forth in this Agreement. Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the RSUs have vested. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) The Company hereby grants to Participant, with respect to each RSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable RSU is settled, forfeited or otherwise expires. Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share. The Company will establish a separate Dividend Equivalent bookkeeping account (a &#8220;<font style="font-weight:bold;font-style:italic;">Dividend Equivalent Account</font>&#8221;) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.2 <font style="text-decoration:underline;">Incorporation of Terms of Plan</font>. The RSUs are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 <font style="text-decoration:underline;">Unsecured Promise</font>. The RSUs and Dividend Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE II. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VESTING; FORFEITURE AND SETTLEMENT </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1 <font style="text-decoration:underline;">Vesting; Forfeiture</font>. The RSUs will vest according to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Dividend Equivalents (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the RSU with respect to which the Dividend Equivalent (including the Dividend Equivalent Account) relates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2 <font style="text-decoration:underline;">Settlement</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) RSUs and Dividend Equivalents (including any Dividend Equivalent Account balance) will be paid in Shares or cash at the Company&#8217;s option as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60) days after the RSU&#8217;s vesting date. Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Law until the earliest date the Company reasonably determines the making of the payment will not cause such a violation (in accordance with Treasury Regulation Section 1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section 409A. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) If an RSU is paid in cash, the amount of cash paid with respect to the RSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date. If a Dividend Equivalent is paid in Shares, the number of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares paid with respect to the Dividend Equivalent will equal the quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE III. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TAXATION AND TAX WITHHOLDING </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1 <font style="text-decoration:underline;">Representation</font>. Participant represents to the Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2 <font style="text-decoration:underline;">Tax Withholding</font>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The Company has the right and option, but not the obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the RSUs or Dividend Equivalents as Participant&#8217;s election to satisfy all or any portion of the withholding tax by requesting the Company retain Shares otherwise issuable under the Award. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Participant acknowledges that Participant is ultimately liable and responsible for all taxes owed in connection with the RSUs and the Dividend Equivalents, regardless of any action the Company or any Subsidiary [or Agent (as defined below)] takes with respect to any tax withholding obligations that arise in connection with the RSUs or Dividend Equivalents. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the Dividend Equivalents or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs or Dividend Equivalents to reduce or eliminate Participant&#8217;s tax liability. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[(c) <font style="font-style:italic;text-decoration:underline;">Mandatory Sell to Cover</font>.<font style="text-decoration:underline;"> </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">By accepting this Award, Participant understands and agrees that as a condition of the grant of the RSUs hereunder, Participant is required to, and hereby affirmatively elects to (the &#8220;<font style="font-weight:bold;font-style:italic;">Sell to Cover Election</font>&#8221;), (1) sell that number of Shares determined in accordance with this Section 3.2(c) as may be necessary to satisfy the minimum statutory withholding obligations with respect to any taxable event arising in connection with the RSUs, and (2) to allow the transfer agent (together with any other party the Company determines necessary to execute the Sell to Cover Election, the &#8220;<font style="font-weight:bold;font-style:italic;">Agent</font>&#8221;) to remit the cash proceeds of such sale(s) to the Company.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Participant hereby appoints the Agent as Participant&#8217;s agent and authorizes the Agent to (1) sell on the open market at the then prevailing market price(s), on the Participant&#8217;s behalf, as soon as practicable on or after the date Shares are issued upon the vesting of the RSUs, that number (rounded up to the next whole number) of the Shares so issued necessary to generate proceeds to cover (x) any tax withholding obligations incurred with respect to such vesting or issuance, based on minimum statutory withholding rates, and (y) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto and (2) remit any remaining funds to Participant. Participant hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Shares that must be sold pursuant to this Section 3.2(c)(ii). Participant understands that the Agent may effect sales as provided in this Section 3.2(c)(ii) in one or more sales and that the average price for executions resulting from bunched orders will be assigned to Participant&#8217;s account. In addition, Participant acknowledges that it may not be possible to sell Shares as provided by this Section 3.2(c)(ii), including due to (1) a legal or contractual restriction applicable to Participant or the Agent, (2) a market disruption, or (3) rules governing order execution priority on the national exchange where the Shares may be traded. Participant further agrees and acknowledges that in the event the sale of Shares would result in material adverse harm to the Company, as determined by the Company in its sole discretion, the Company may instruct the Agent not to sell Shares as provided by this Section 3.2(c)(ii). Participant acknowledges that regardless of any other term or condition of this Section 3.2(c), the Agent will not be liable to Participant for (1) special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any kind, or (2) any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond its reasonable control. Participant hereby agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of this Section 3.2(c). The Agent is a third-party beneficiary of this Section 3.2(c). This Section 3.2(c) shall terminate not later than the date on which all tax withholding obligations arising in connection with the Award have been satisfied. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>Participant has carefully reviewed this Section 3.2(c) and Participant hereby represents and warrants that on the date hereof he or she is not aware of any material, nonpublic information with respect to the Company or any securities of the Company, is not subject to any legal, regulatory or contractual restriction that would prevent the Agent from conducting sales, does not have, and will not attempt to exercise, authority, influence or control over any sales of Shares effected by the Agent pursuant to the Agreement, and is entering into the Agreement and this election to &#8220;sell to cover&#8221; in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1 (regarding trading of the Company&#8217;s securities on the basis of material nonpublic information) under the Exchange Act. It is Participant&#8217;s intent that this election to &#8220;sell to cover&#8221; comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to comply with the requirements of Rule 10b5-1(c) under the Exchange Act<font style="font-weight:normal;">. </font>This Section 3.2(c) shall not be deemed a &#8220;10b5-1 plan&#8221; as used in and for the purposes of the Company&#8217;s 10b5-1 Plan Guidelines, as may be amended from time to time (the &#8220;<font style="text-decoration:underline;">10b5-1 Guidelines</font>&#8221;), and, for the avoidance of doubt, Participant&#8217;s execution of this Agreement shall not impact Participant&#8217;s ability to enter into a 10b5-1 plan under the 10b5-1 Guidelines.]</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARTICLE IV. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER PROVISIONS </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1 <font style="text-decoration:underline;">Adjustments</font>. Participant acknowledges that the RSUs, the Shares subject to the RSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2 <font style="text-decoration:underline;">Notices</font>. Any notice to be given under the terms of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3 <font style="text-decoration:underline;">Titles</font>. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 <font style="text-decoration:underline;">Conformity to Securities Laws</font>. Participant acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable Laws. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5 <font style="text-decoration:underline;">Successors and Assigns</font>. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6 <font style="text-decoration:underline;">Limitations Applicable to Section 16 Persons</font>. Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section 16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the RSUs and the Dividend Equivalents will be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3) that are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7 <font style="text-decoration:underline;">Entire Agreement</font>. The Plan, the Grant Notice and this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8 <font style="text-decoration:underline;">Agreement Severable</font>. In the event that any provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the Grant Notice or this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9 <font style="text-decoration:underline;">Limitation on Participant&#8217;s Rights</font>. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs and Dividend Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the RSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10 <font style="text-decoration:underline;">Not a Contract of Employment</font>. Nothing in the Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11 <font style="text-decoration:underline;">Counterparts</font>. The Grant Notice may be executed in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* * * * *</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-4</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>fixx-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in Registration Statement No. 333-237131 on Form S-3 and No. 333-224030 on Form S-8 of our report dated March 11, 2021, relating to the consolidated financial statements of Homology Medicines, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2020. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Deloitte &amp; Touche LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Boston, Massachusetts</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>fixx-ex311_12.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex311_12.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Arthur O. Tzianabos, Ph.D., certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2020 of Homology Medicines, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk33200165"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;"><a name="_Hlk33200165"></a>The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk33200238"></a><a name="_Hlk33200238"></a>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>fixx-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, W. Bradford Smith, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2020 of Homology Medicines, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;W. Bradford Smith</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>fixx-ex321_11.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex321_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Arthur O. Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines, Inc. (the &#8220;Company&#8221;) hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arthur O. Tzianabos, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>fixx-ex322_7.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
fixx-ex322_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, W. Bradford Smith, Chief Financial Officer of Homology Medicines, Inc. (the &#8220;Company&#8221;) hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the &#8220;Report&#8221;) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;W. Bradford Smith</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">W. Bradford Smith</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmz2lq4320rk000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -?!\H# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#L?&7CS4]
M\0/8VJPF-8U8;ER>:P/^%KZYTV0?]\55^)__ ".<O_7)/ZUQM>[A\+2E3BW$
M\*OB*D:C29WG_"U]<_YYP?\ ?%+_ ,+7US^Y!_WQ7!45K]4H_P IE]:K?S'>
M_P#"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\ *'UJM_,=[_PM?7/[D'_?%'_"
MU]<_N0?]\5P5%'U2C_*'UJM_,=[_ ,+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H
M_P H?6JW\QWO_"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\H?6JW\QWO\ PM?7
M/[D'_?%'_"U]<_N0?]\5P5%'U2C_ "A]:K?S'>_\+7US^Y!_WQ1_PM?7/[D'
M_?%<%11]4H_RA]:K?S'>_P#"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\ *'UJ
MM_,=[_PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_*'UJM_,=[_ ,+7US^Y!_WQ
M1_PM?7/[D'_?%<%11]4H_P H?6JW\QWO_"U]<_N0?]\4?\+7US^Y!_WQ7!44
M?5*/\H?6JW\QWO\ PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_ "A]:K?S'>_\
M+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H_RA]:K?S'>_P#"U]<_N0?]\4?\+7US
M^Y!_WQ7!44?5*/\ *'UJM_,=[_PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_*'
MUJM_,=[_ ,+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H_P H?6JW\QWO_"U]<_N0
M?]\4?\+7US^Y!_WQ7!44?5*/\H?6JW\QWO\ PM?7/[D'_?%'_"U]<_N0?]\5
MP5%'U2C_ "A]:K?S'>_\+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H_RA]:K?S'>
M_P#"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\ *'UJM_,=[_PM?7/[D'_?%'_"
MU]<_N0?]\5P5%'U2C_*'UJM_,=[_ ,+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H
M_P H?6JW\QWO_"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\H?6JW\QWO\ PM?7
M/[D'_?%'_"U]<_N0?]\5P5%'U2C_ "A]:K?S'>_\+7US^Y!_WQ1_PM?7/[D'
M_?%<%11]4H_RA]:K?S'>_P#"U]<_N0?]\4?\+7US^Y!_WQ7!44?5*/\ *'UJ
MM_,=[_PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_*'UJM_,=[_ ,+7US^Y!_WQ
M1_PM?7/[D'_?%<%11]4H_P H?6JW\QWO_"U]<_N0?]\4?\+7US^Y!_WQ7!44
M?5*/\H?6JW\QWO\ PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_ "A]:K?S'>_\
M+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H_RA]:K?S'>_P#"U]<_N0?]\4?\+7US
M^Y!_WQ7!44?5*/\ *'UJM_,=[_PM?7/[D'_?%'_"U]<_N0?]\5P5%'U2C_*'
MUJM_,=[_ ,+7US^Y!_WQ1_PM?7/[D'_?%<%11]4H_P H?6JW\QWO_"U]<_N0
M?]\4?\+7US^Y!_WQ7!44?5*/\H?6JW\QWO\ PM?7/[D'_?%'_"U]<_N0?]\5
MP5%'U2C_ "A]:K?S'>_\+7US^Y!_WQ2?\+7US^Y!_P!\5P=%/ZI0_E#ZU6_F
M/6_"WCS4]:FO4N$AQ#;M*NU>X!-8)^*VN*Q 2#@_W*I_#_\ X^M4_P"O)_Y&
MN0?[[?6L(8:DZDER]C66(J*$6F=W_P +7US^Y!_WQ1_PM?7/[D'_ 'Q7!45M
M]4H_RF7UJM_,=[_PM?7/[D'_ 'Q1_P +7US^Y!_WQ7!44?5*/\H?6JW\QWO_
M  M?7/[D'_?%'_"U]<_N0?\ ?%<%11]4H_RA]:K?S'>_\+7US^Y!_P!\4?\
M"U]<_N0?]\5P5%'U2C_*'UJM_,=[_P +7US^Y!_WQ1_PM?7/[D'_ 'Q7!44?
M5*/\H?6JW\QWO_"U]<_N0?\ ?%'_  M?7/[D'_?%<%11]4H_RA]:K?S'>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU%#^&C2M_$84445J9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@@9P?RI<R'RL2B@ GIS13)"BBBF 5T'@C_D;]._ZZK_.N?KH/!'_ "-^G?\
M75?YUE6_ALTI?&C.UO\ Y#=Y_P!=35"K^M_\AN\_ZZFJ%.G\"%4^)GI6E_\
M)(;[ZG_T.O-L$D"O3_"%]H$G@I]*U?4(8%D8[D:3:V-V:9>:#\/XK.62WU4-
M,%RB_:<Y/Y5P0K>SG)-/5G;.CSPB[]"UHWA^'2?"MM?P:(-7OKE0Q1U!"@_6
MJ/C'PY#)X<CUM=,_LVZ5@)K<  <G' %6M*\3V6J>&8=/DUU]'O+<;?-#8# ?
MB,UE>*M8LH].@L[?7+S59BP:5FG)C(!STK*'M75\_F:2]G[/R-[0+"W&G6<=
MGX;CE1P#+<:@H&?7;US6?XD\(V+>.=.M+>-88;L;I%7@<>E:%_J^A:S9Z;<M
MX@^RQVR+YEH#RY'MGK5#Q+XGT^+Q7H^JV5W%<PPIAT1LLN?45-/VG/=>94U3
MY$GY%JXU/0=-\3P:$NBP>4C*OVD "0-]:P?BF/\ BJ5Q_P ^Z8_6MJ[7PC>^
M(8?$#:W$H)#-;<;B??GBN;^(NHV>I^(EFL;F.>(0*NY&R,\UK0C>K&U_.YG6
M?[M[>1R%%%%>KU/-Z!1110 4444 %%%% !1110 4444 %==X=_Y$?Q%_VS_D
MU<C77>'?^1'\1?\ ;/\ DU<^(^%>J-Z&[.1HHJ:T@^U7L%ONV^;(J9QTR<5M
M>RNS%*[LB&BNPU/P.-.\0Z?I7V[?]K7=YGEXV]>V:J^+?!\_A>>$&4SPRCB7
M9M&?2LHXBFVDGN:NA-)MK8YFBNFU7PG_ &;X<L-6^U^9]K"GR]F-N1ZYKIK7
MX3+<6D4YUC9O4-CR>GZTI8JE%7;''#5).R1YG17:>)?AW>:%9F[@G%W OWRJ
MX*_AS7%UI3JQJ*\61.G*#M(**[;PMX 'B32?MQU#[/\ ,5V^5NZ?C6S)\(TC
MC9O[:!P,X\G_ .RK&6+I1ERMZFBPM5KF2/,**DDC*2.HR0K$9Q3,'&<''KBN
MCF7<PLQ**4 GD D4^*/S)XXB=N]@/IFAR2&HMD=%=%XK\+_\(S<P0BY-QYJE
ML[-N/UK%L[;[7?06Q;9YKA,XZ9-3&I&2YDQRIRB[-%>BNJU;PC;Z/KMII]SJ
MBI#/'YC3NF G7MGVK#U:R@L-2DMK2[6\B7&V5!PW%*%:$]BI4IQW*-%+@^AI
M!S6ET9V844NUB0-IY]J2DFGL#36X44450C2\/_\ (P6'_79:M^,O^1PU/_KK
M_054\/\ _(P6'_79:M^,O^1PU/\ ZZ_T%<__ "^^1M_RZ^9A445W'ACX>CQ%
MI"WYU'R,L1M\K=T/KFKJ584U>1-.G*H[1.'HKT?4OA1/:V4DUGJ(N9$&?+,>
MW/ZFN>TWPG]O\,WNL-=^6;7=F+9G./?-1'%4I+F3+EAZD79HYFBE*D=01]10
M 3T%;<RM<RY7>PE%&*7:W]T_E3;2U8DF]A**.^*7!ZD&AM($FQ**/Q%6M/TZ
MZU.[2VM(FDD8XP!0VDKL$FW9%6BNG\4>$'\,VUI)+="22<99=F-A],YYJIIG
MAXWVA7^J27'DI;+\B[<^8>>/;I62KP<>=/0T=*:ERVU,.BNZMOAY$MG;RZKK
M,-A-<?ZN)ESN].XKG?$7AZZ\.Z@+:<JZN-T<B]&7UI0Q%.<N5,)49QCS-&/1
M116YD%%%% !4]E_Q_P!O_P!=5_F*@J>R_P"/^#_KJO\ .IEL..Z.C^(7_(W3
M_P#7-/Y5RM=5\0O^1NG_ .N:?RKE:SH?PXFE;^(PHKK_  CX('BFTFG^W?9_
M*;;CR]V?U%;MS\(Y$MY'MM56:51D(8L9_'-1+%THRY6]2XX:I*/,D>9T5U.@
M^#7UA=1$MU]GDLB0R[-V2/QKF"A!/!P#C-:1JPDW%,SE2E%7:&T4 $]!GZ4N
M".H(_"M+K8BSM<2BE"D\@4G?%%T%F%%+M.,X-)1=,+,**U_#WA^Y\1:DMI;X
M48W.[=%%;VJ^ /LNFSWFG:G%?BW.)E5<%3^9K*5>$9<K>II&C.4>9+0XJBBB
MM3(****8!1110 4444@/?OAU_P B;9?0_P S75URGPZ_Y$VR^A_F:ZNOFJ_\
M61]+0_AH\(^)_P#R.DO_ %Q3^M<;Z5V7Q/\ ^1TE_P"N2?UKC:]_#.U&)X.(
MUK2/4_A='%-H6JQSOLB8D.V<8&T9.:U+"W\)>&)WU"WUIII I_=M<J^?P%<=
MX0\0:;I/A[5+2[F,<UPK",!"<Y7':N*/4GWKC>%=2K+F=D=*Q"ITXJ*NSUSP
M7?V^H1^(]2>W5HVE#JK#MR16+HE^WCGQ%:V^H6T"VUL&D\N-,!AQ@&J7@WQ#
MIND:%JUK>3F.6XQY:A"<\'N*PO#.NMX>UJ*^">8@RKJ.X/7%"H.\[;] =56B
MGMU.]@\7QW'BO^PWTVV_LYG\E5V?-Z=:=I'A/3[7QIJC2Q"2WM8_-BC/:J0U
M;P3;ZPVO1S7#W6-XM=AV[OKCK^-4_#_C&XE\5WE]-:2S072[9$A0N47MTK+E
MGRMP32M^)IS0;2EJ;WA?Q/'KGB::TNM/MAY6[R'1,%0#CGUJ7PP((KKQ3)+"
MCI'<D[2O^]3?"H\.0^*)VTK[3-<2AB_F(5$/.<<@5E6?B+3=*N?$UM=SE)+B
M=O* 4D'D]Q63CS-J"?0TORI.3*.F:_<^)O$%I'+I$5RL!8I#%^[';!8G/2O0
M+.UFU!;RUU5-/V,GRVT2@N@]SGG\J\H\$>(+;P_KOVB[4F!U*%@,E?>NPTGQ
M+X1T;4+J6"]NI/M0):61&(3V QFM<12E&5HHSP]2#5Y,/ RV]IH>O/+ DJP3
M/A2.P'2K?AK5X/$V@:DVHZ?;&*U.41$QP!D5S>A>(M*T_1-<M9;DB2Z=VA^0
M_,"..U0>#O$.G:1H6J6UY,8YK@8C 0G/'M53I2=VT]T*-6*LO)G3>']4A\6:
M#JL%W8VZ10#]TJ)C P<?C7D9ZFNU\$>(-.T;3M3BO9S&\ZCRQM)SP?2N+/))
MKJP\.2<ET.:O-2@NXE%%%=ARA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9G\!5XF[DHJ.I%!I1;;/.""K%3U!P:2E9B[%FZDY-)7H+8XGN%%%%,04444
M%%%%(#W[X=?\B;9?0_S-=77*?#K_ )$VR^A_F:ZNOFJ_\61]+0_AH\(^)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;E)FDNHV5"B@@9&.>:Y%CEB?4UU8>GR3EIH<U>HI0CW$KKO#O_(C^(O^V?\
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M /(P6'_79?YU;\9?\CAJ?_77^@KG_P"7_P C;_ES\S"HHHKH,0HHHH ****
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M *"=K_WPU;O_  L*]_Y\X/\ OHT?\+"O?^?.#_OHT6QO]6#V^ ,+_A3^I?\
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M^?.#_OHT6QO]6#V^ ,+_ (4_J7_03M?^^&H_X4_J7_03M?\ OAJW?^%A7O\
MSYP?]]&C_A85[_SYP?\ ?1HMC?ZL'M\ 87_"G]2_Z"=K_P!\-1_PI_4O^@G:
M_P#?#5N_\+"O?^?.#_OHT?\ "PKW_GS@_P"^C1;&_P!6#V^ ,+_A3^I?]!.U
M_P"^&H_X4_J7_03M?^^&K=_X6%>_\^<'_?1H_P"%A7O_ #YP?]]&BV-_JP>W
MP!A?\*?U+_H)VO\ WPU'_"G]2_Z"=K_WPU;O_"PKW_GS@_[Z-'_"PKW_ )\X
M/^^C1;&_U8/;X PO^%/ZE_T$[7_OAJ/^%/ZE_P!!.U_[X:MW_A85[_SYP?\
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M]&I4,8GS#>*P+5FS"_X4_J7_ $$[7_OAJ/\ A3^I?]!.U_[X:MW_ (6%>_\
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MPI_4O^@G:_\ ?#4?\*?U+_H)VO\ WPU;O_"PKW_GS@_[Z-'_  L*]_Y\X/\
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MQO\ 5@]O@#"_X4_J7_03M?\ OAJ/^%/ZE_T$[7_OAJW?^%A7O_/G!_WT:/\
MA85[_P ^<'_?1HMC?ZL'M\ 87_"G]2_Z"=K_ -\-1_PI_4O^@G:_]\-6[_PL
M*]_Y\X/^^C1_PL*]_P"?.#_OHT6QO]6#V^ ,+_A3^I?]!.U_[X:C_A3^I?\
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M:_\ ?#4?\*?U+_H)VO\ WPU;O_"PKW_GS@_[Z-'_  L*]_Y\X/\ OHT6QO\
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M_P#/G!_WT:$L:OZ0GB, V87_  I_4O\ H)VO_?#4?\*?U+_H)VO_ 'PU;O\
MPL*]_P"?.#_OHT?\+"O?^?.#_OHT[8W^K"]O@#"_X4_J7_03M?\ OAJ/^%/Z
ME_T$[7_OAJW?^%A7O_/G!_WT:/\ A85[_P ^<'_?1HMC?ZL'M\ 87_"G]2_Z
M"=K_ -\-1_PI_4O^@G:_]\-6[_PL*]_Y\X/^^C1_PL*]_P"?.#_OHT6QO]6#
MV^ ,+_A3^I?]!.U_[X:C_A3^I?\ 03M?^^&K=_X6%>_\^<'_ 'T:/^%A7O\
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M *"=K_WPU;O_  L*]_Y\X/\ OHT?\+"O?^?.#_OHT6QO]6#V^ ,+_A3^I?\
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MV^ ,+_A3^I?]!.U_[X:C_A3^I?\ 03M?^^&K=_X6%>_\^<'_ 'T:/^%A7O\
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M_"PKW_GS@_[Z-)_PL&\Q_P >4'_?1I-8UC^L8%/<B\3?#>]UW6I+Z*^@C1E
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M^?.#_OHT6QO]6#V^ ,'_ (4_J7_03M?^^&H_X5!J/_03MO\ OAJWO^%A7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBBD 4=Z*.] +<]6\'_\ (NV_T/\ .M^L#P?_ ,B[;_0_SK?KYFO_
M !)'VN%_@Q]#RSQM_P C')_US6N=KTG7/"T.JZBUT]ZT3%0-H3/2LW_A!+;_
M *"3_P#?L?XUZM'&4HTXQ?0\#$X"M*K*2[G$45V__""6W_02?_OV/\:/^$$M
MO^@B_P#W['^-;?7J)A_9M<XBBNW_ .$$MO\ H(O_ -^Q_C1_P@EM_P!!%_\
MOV/\:/KU$/[-K]CB**[?_A!+;_H(O_W['^-'_""6W_01?_OV/\:/KU$/[-KG
M$45V_P#P@EM_T$7_ ._8_P :/^$$MO\ H(O_ -^Q_C2^O4@_LVON<117;_\
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MSB**[?\ X02V_P"@B_\ W['^-'_""6W_ $$7_P"_8_QH^O4@_LVN<117;_\
M""6W_01?_OV/\:/^$$MO^@B__?L?XT?7J0?V;7.(HKM_^$$MO^@B_P#W['^-
M'_""6W_01?\ []C_ !H^O4@_LVN<117;_P#""6W_ $$7_P"_8_QH_P"$$MO^
M@B__ '['^-'UZD']FUSB**[?_A!+;_H(O_W['^-'_""6W_01?_OV/\:/KU(/
M[-KG$45V_P#P@EM_T$7_ ._8_P :/^$$MO\ H(O_ -^Q_C1]>I!_9M<XBBNW
M_P"$$MO^@B__ '['^-'_  @EM_T$7_[]C_&CZ]2#^S:YQ%%=O_P@EM_T$7_[
M]C_&C_A!+;_H(O\ ]^Q_C1]>I!_9M<XBBNW_ .$$MO\ H(O_ -^Q_C1_P@EM
M_P!!%_\ OV/\:/KU(/[-KG$45V__  @EM_T$7_[]C_&C_A!+;_H(O_W['^-'
MUZD']FUSB**[?_A!+;_H(O\ ]^Q_C1_P@EM_T$7_ ._8_P :/KU(/[-KG$45
MV_\ P@EM_P!!%_\ OV/\:/\ A!+;_H(O_P!^Q_C1]>I!_9M<XBBNW_X02V_Z
M"+_]^Q_C1_P@EM_T$7_[]C_&CZ]2#^S:YQ%%=O\ \();?]!%_P#OV/\ &C_A
M!+;_ *"+_P#?L?XT?7J0?V;7.(HKM_\ A!+;_H(O_P!^Q_C1_P ();?]!%_^
M_8_QH^O4@_LVN<117;_\();?]!%_^_8_QH_X02V_Z"+_ /?L?XT?7J0?V;7.
M(HKM_P#A!+;_ *"+_P#?L?XT?\();?\ 01?_ +]C_&CZ]2#^S:YQ%%=O_P (
M);?]!%_^_8_QH_X02V_Z"+_]^Q_C2^O4@_LVN<117<IX!@<X747/_;,?XT__
M (5Y'_S_ +_]^Q_C1]?HC668A[(X.BN\_P"%=Q_\_P"__?L?XT?\*\C_ .?]
M_P#OV/\ &CZ_1[C_ ++Q'8X.BN\_X5Y'_P _[_\ ?L?XT?\ "NX_^?\ ?_OV
M/\:/K]'N']EXCL<'17>?\*[C_P"?]_\ OV/\:/\ A7D?_/\ O_W['^-'U^CW
M#^R\1V.#HKO/^%>1_P#/^_\ W['^-'_"NX_^?]_^_8_QH^OT>X?V7B.QP=%=
MY_PKR/\ Y_W_ ._8_P :/^%>1_\ /^__ '['^-'U^CW#^R\1V.#HKO/^%=Q_
M\_[_ /?L?XT?\*\C_P"?]_\ OV/\:/K]'N']EXCL<'17>?\ "O(_^?\ ?_OV
M/\:/^%=Q_P#/^_\ W['^-'U^CW#^R\1V.#HKO/\ A7D?_/\ O_W['^-'_"O(
M_P#G_?\ []C_ !H^OT>X?V7B.QP=%=Y_PKN/_G_?_OV/\:/^%>1_\_[_ /?L
M?XT?7Z/</[+Q'8X.BN\_X5Y'_P _[_\ ?L?XT?\ "O(_^?\ ?_OV/\:/K]'N
M']EXCL<'17>?\*[C_P"?]_\ OV/\:/\ A7D?_/\ O_W['^-'U^CW#^R\1V.#
MHKO/^%>1_P#/^_\ W['^-'_"NX_^?]_^_8_QH^OT>X?V7B.QP=%=Y_PKR/\
MY_W_ ._8_P :/^%>1_\ /^__ '['^-'U^CW#^R\1V.#HKO/^%=Q_\_[_ /?L
M?XT?\*\C_P"?]_\ OV/\:/K]'N']EXCL<'17>?\ "O(_^?\ ?_OV/\:/^%>1
M_P#/^_\ W['^-'U^CW#^R\1V.#HKO/\ A7<?_/\ O_W['^-'_"O(_P#G_?\
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M_P"?]_\ OV/\:/K]'N']EXCL<'17>?\ "O(_^?\ ?_OV/\:/^%>1_P#/^_\
MW['^-'U^CW#^R\1V.#HKO/\ A7<?_/\ O_W['^-'_"O(_P#G_?\ []C_ !H^
MOT>X?V7B.QP=%=Y_PKR/_G_?_OV/\:/^%>1_\_[_ /?L?XT?7Z/</[+Q'8X.
MBN\_X5W'_P _[_\ ?L?XT?\ "O(_^?\ ?_OV/\:/K]'N']EXCL<'17>?\*\B
M_P"?]_\ OV/\:/\ A7D7_/\ O_W['^-'U^CW#^R\1V.#HKO/^%>1_P#/^_\
MW['^-'_"O(_^?]_^_8_QH^OT>X?V7B.QP=%=Y_PKR/\ Y_W_ ._8_P :/^%>
M1_\ /^__ '['^-'U^CW#^R\1V.#HKO/^%>1_\_[_ /?L?XT?\*\C_P"?]_\
MOV/\:/K]'N']EXCL<'17>?\ "O(_^?\ ?_OV/\:/^%>1_P#/^_\ W['^-'U^
MCW#^R\1V.#HKO/\ A7D?_/\ O_W['^-'_"O(_P#G_?\ []C_ !H^OT>X?V7B
M.QP=%=Y_PKR/_G_?_OV/\:/^%>1_\_[_ /?L?XT?7Z/</[+Q'8X.BN\_X5Y'
M_P _[_\ ?L?XT?\ "O(_^?\ ?_OV/\:/K]'N']EXCL<'17>?\*\C_P"?]_\
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MPKR/_G_?_OV/\:/^%>1_\_[_ /?L?XT?7Z/</[+Q'8X.BN\_X5Y'_P _[_\
M?L?XT?\ "O(_^?\ ?_OV/\:/K]'N']EXCL<'17>?\*\C_P"?]_\ OV/\:/\
MA7D?_/\ O_W['^-'U^CW#^R\1V.#HKO/^%>1_P#/^_\ W['^-'_"O(_^?]_^
M_8_QH^OT>X?V7B.QP=%=Y_PKR/\ Y_W_ ._8_P :/^%>1_\ /^__ '['^-'U
M^CW#^R\1V.#HKO/^%>1_\_[_ /?L?XT?\*\C_P"?]_\ OV/\:/K]'N']EXCL
M<'17>?\ "O(_^?\ ?_OV/\:/^%>1_P#/^_\ W['^-'U^CW#^R\1V.#HKO/\
MA7D?_/\ O_W['^-'_"O(_P#G_?\ []C_ !H^OT>X?V7B.QP=%=Y_PKR/_G_?
M_OV/\:/^%>1_\_[_ /?L?XT?7Z/</[+Q'8X.BN\_X5Y'_P _[_\ ?L?XT?\
M"O(_^?\ ?_OV/\:/K]'N']EXCL<'17>?\*\C_P"?]_\ OV/\:/\ A7D?_/\
MO_W['^-'U^CW#^R\1V.#HKO/^%>1_P#/^_\ W['^-'_"O(_^?]_^_8_QH^OT
M>X?V7B.QP=%=Y_PKR/\ Y_W_ ._8_P :/^%>1_\ /^__ '['^-'U^CW#^R\1
MV.#HKO/^%>1_\_[_ /?L?XT?\*\C_P"?]_\ OV/\:/K]'N']EXCL<'17>?\
M"O(_^?\ ?_OV/\:/^%>1_P#/^_\ W['^-'U^CW#^R\1V.#HKO/\ A7D?_/\
MO_W['^-'_"O(_P#G_?\ []C_ !H^OT>X?V7B.QP=%=Y_PKR/_G_?_OV/\:/^
M%>1_\_[_ /?L?XT?7Z/</[+Q'8X.BN\_X5Y'_P _[_\ ?L?XT?\ "O(_^?\
M?_OV/\:/K]'N']EXCL<'17>?\*\C_P"?]_\ OV/\:/\ A7D?_/\ O_W['^-'
MU^CW#^R\1V.#HKO/^%>1_P#/^_\ W['^-'_"O(_^?]_^_8_QH^OT>X?V7B.Q
MP=%=Y_PKR/\ Y_W_ ._8_P :/^%>1_\ /^__ '['^-'U^CW#^R\1V.#HKO/^
M%>1_\_[_ /?L?XT?\*\C_P"?]_\ OV/\:/K]'N']EXCL<'17>?\ "O(_^?\
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M_"C\*** #\*/PHHH /PH_"BB@ _"C\*** #\*/PHHH /PH_"BB@ _"C\***
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M/^?B+_OL4?VA:?\ /Q%_WV*.5]@YX]RS15;^T+3_ )^(O^^Q1_:%I_S\1?\
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M%*Y:TKQ9'H'@WP^UU%/<O=KY88,,@YZG/UKH/$GBFW\-Z?;WD]O+,LS!0J$
MKGUS7FNL_+X&\(2MQ&CY9O09%;'Q-U*RN/#^F107,<DA=2%5L\8%/FT'RW9-
MX^OY7U#PY-!)+$D[J^U7QP><'%9_B?QG?6_CBRB2"]%K;2?- J\S'U7UJ3QK
M]_PG](_Y59\5.L?Q1T!W<*@Y))P!P*6H:(]%T^[^W:?!=>4\7FH'$<@PR^QK
MS+XG"YG\1:;:0WQM!, I?S"JC)ZFO55970,K!E(SD'(->5?$K3TU7Q9I%D\A
M19L(64<C)JI;$PW.>U+2M4\*1)J4'BFWNW1QB.*<N3^!-=#XXUB81>&KUY9(
M@X224*2 >.>!UK1L/A!I%I=I/->W%RJD-Y;* #^55OB7!$-3\/PA0(Q*JA1T
MP#TJ4FB[ILUX/B5I[ZK#9RV%Y!'*VV.XE3:K>XSS6OXB\76'AQ8TE1Y[B49C
M@B&7:N6^*J(EEI>Q NV=0"!T'I6-XJ345^(]J]O<PVKO"HAGN!E ?R/-/FL3
MRIG<:!XZL=;O?L4EM<6-T1E8KA<%A[4S5O']AHVNMI5Q:W#2!<AT&03CI@<U
MR#Z?JEUXNTU]2\2:7->1.K*D"$,RYY&57'YFK\L22?&:+S%#;8R>1GG::5V'
M*C<T7XAV&KZB^GO9W-I<@$I'.,%^_%:GAWQ1;^(9+R*.WDMYK23RW20C)//I
M]*X[741?C!HQ55!8') Z_*:BUJ]_X0OQY<WS*19WT!( _O\ &:?,'*F=G#XL
MM[GQ5)H-O;22R1+F28,-JGTKB/#MU<,WB_?/*VR%]F7/R\'I6S\,=/D;3[K7
M+KFYOY-V2.W^36!X;^_XR_ZXO_(TFV"21I>$?%%OH?@<7>H2R32-*5CCW9=S
MZ#-=>OB:"+P\-9OX)+*(C(CE(+>W KQ+2M(U*WTN+Q&!Y]G:W S"QW<9Z@'B
MNZ^(UX=6\'Z7?66#;M*K,1T7@]?8&FF-Q5S5MOB?82W2)<:;>VMLYPMS*AV'
MT_.L[XG^)[JRM(K*Q%P@E <W"#Y&'IFL74[;6KOP[#'J'B?1A8/MV+Y?(XXZ
M)D5=\=V\EK\.](AEF6=HRH,BYPWN,\TKARJYUUAXRLX_"PU74(9[../";9E.
MYS@=*S[7XH:?+=1QW6G7MG#(VV.XF3Y6STK)^(3"31M!G#B2SCF7SBIW*!\O
M6K7C^_TJX\#Q102PR2R!!;JF"<Y'3TIW8K)G0^)/&=EX:^QF>&69+G[K1D8
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MLB!T974\AE.0:=F@!:*3-!.* %HI*,T +129HS0 M%)GGI2T %%%% !1110
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M%XP>5STR*L=/K[4:#N[F)-X4TF?0HM&FMR]G$NU 6^8?0UECX9^&%MQ"+23
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MZ6DI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2-L(+#=N## XSTKJ%_XF7Q#!)YL;3D=@Y/\ @:$)AK'B76)-5?2_#5E%<SP
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MPJU;6EO90B*VB6*,=%45-15I16I+<VK&9=>'M)O9_/N+"*20_P 1%7/L=O\
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M8K_8[;_GWB_[X%'V.V_Y]XO^^!5BBCF8<D>Q7^QVW_/O%_WP*/L=M_S[Q?\
M? JQ11S,.2/8K_8[;_GWB_[X%'V.V_Y]XO\ O@58HHYF')'L5_L=M_S[Q?\
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MU_\ W8OSHW7_ /=B_.KM%%F%_(I;K_\ NQ?G1NO_ .[%^=7:*+!S>12W7_\
M=B_.C=?_ -V+\ZNT46'S>12W7_\ =B_.C=?_ -V+\ZNT46%S>12W7_\ =B_.
MC=?_ -V+\ZNT46'S>12W7_\ =B_.C=?_ -V+\ZNT46%?R*6Z_P#[L7YT;K_^
M[%^=7:*+!S>12W7_ /=B_.C=?_W8OSJ[119AS>12W7_]V+\Z-U__ '8OSJ[1
M18?-Y%+=?_W8OSHW7_\ =B_.KM%%A<WD4MU__=B_.C=?_P!V+\ZNT46#F\BE
MNO\ ^[%^=&Z__NQ?G5VBBP<WD4MU_P#W8OSHW7_]V+\ZNT46#F\BENO_ .[%
M^=&Z_P#[L7YU=HHL'-Y%+=?_ -V+\Z-U_P#W8OSJ[118.;R*6Z__ +L7YT;K
M_P#NQ?G5VBBS'S>12W7_ /=B_.C=?_W8OSJ[1187-Y%+=?\ ]V+\Z-U__=B_
M.KM%%@YO(I;K_P#NQ?G1NO\ ^[%^=7:*+#YO(I;K_P#NQ?G1NO\ ^[%^=7:*
M+"YO(I;K_P#NQ?G1NO\ ^[%^=7:*+#YO(I;K_P#NQ?G1NO\ ^[%^=7:*+"YO
M(I;K_P#NQ?G1NO\ ^[%^=7:*+!S>12W7_P#=B_.C=?\ ]V+\ZNT46'S>12W7
M_P#=B_.C=?\ ]V+\ZNT46%S>12W7_P#=B_.C=?\ ]V+\ZNT46'S>12W7_P#=
MB_.C=?\ ]V+\ZNT468KKL0VYU+>=B0Y]S5K=K'_/.#_OJI+/_6FM"L9[G13V
M,O=K'_/.#_OJC=K'_/.#_OJM2BI+,O=K'_/.#_OJC=K'_/.#_OJM2B@#+W:Q
M_P \X/\ OJC=K'_/.#_OJM2B@#+W:Q_SS@_[ZHW:Q_SS@_[ZK4HH R]VL?\
M/.#_ +ZHW:Q_SS@_[ZK4HH R]VL?\\X/^^J-VL?\\X/^^JU** ,O=K'_ #S@
M_P"^J-VL?\\X/^^JU** ,O=K'_/.#_OJC=K'_/.#_OJM2B@#+W:Q_P \X/\
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M_P \X/\ OJM2B@#+W:Q_SS@_[ZHW:Q_SS@_[ZK4HH R]VL?\\X/^^J-VL?\
M/.#_ +ZK4HH R]VL?\\X/^^J-VL?\\X/^^JU** ,O=K'_/.#_OJC=K'_ #S@
M_P"^JU** ,O=K'_/.#_OJC=K'_/.#_OJM2B@#+W:Q_SS@_[ZHW:Q_P \X/\
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M0E74;6VU;P[=Z;#=<132-D'\,#BM3Q+X\CT+5(M+L].GU+4)%W>1$<'';L:
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MW?XJ22&2YLO#E[<Z7$3OO%R%4#J2,?UKI+CQA9CP@_B&S3[3 J[MF[:?I]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;90'!Z5ZG6;I.@:7H<;)IUG' &.21DG\SS6E32L3)W"BBBF(**** "BBB@
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MWX7#<_ORV%BC6*-44851@4^B@5Y_F>LM!:***!A1110 4444 %%%% !1110
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M "BBB@ HHHH SKO_ %YX[5!6-X@\::?HFJM9W%M+)(%#;E/'-9?_  LK2?\
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MD?\ /E-_WU_]:C_A96D?\^4W_?7_ -:CV53L'L)'6T5R7_"RM(_Y\IO^^O\
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MM33?^?.;_OK_ .M1_P +4TW_ )\YO^^O_K4?5ZO8.5G?T5P'_"U--_Y\YO\
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M3?\ GSF_[Z_^M1_PM33?^?.;_OK_ .M1]7J]@Y6=_17 ?\+4TW_GSF_[Z_\
MK4?\+4TW_GSF_P"^O_K4?5ZO8.5G?T5P'_"U--_Y\YO^^O\ ZU'_  M33?\
MGSF_[Z_^M1]7J]@Y6=_17 ?\+4TW_GSF_P"^O_K4#XJ::3@VDP_'_P"M1]7J
M]@Y6=_17 ?\ "U--S_QZ3?\ ?7_UJ/\ A:FF_P#/G-_WU_\ 6H^KU>P<K._H
MK@/^%J:;_P ^<W_?7_UJ/^%J:;_SYS?]]?\ UJ/J]7L'*SOZ*X#_ (6IIO\
MSYS?]]?_ %J/^%J:;_SYS?\ ?7_UJ/J]7L'*SOZ*X#_A:FF_\^<W_?7_ -:C
M_A:FF_\ /G-_WU_]:CZO5[!RL[^BN _X6IIO_/G-_P!]?_6H_P"%J:;_ ,^<
MW_?7_P!:CZO5[!RL[^BN _X6IIO_ #YS?]]?_6H_X6IIO_/G-_WU_P#6H^KU
M>P<K._HK@/\ A:FF_P#/G-_WU_\ 6H_X6IIO_/G-_P!]?_6H^KU>P<K._HK@
M/^%J:;_SYS?]]?\ UJ/^%J:;_P ^<W_?7_UJ/J]7L'*SOZ*X#_A:FF_\^<W_
M 'U_]:C_ (6IIO\ SYS?]]?_ %J/J]7L'*SOZ*X#_A:FF_\ /G-_WU_]:C_A
M:FF_\^<W_?7_ -:CZO5[!RL[^BN _P"%J:;_ ,^<W_?7_P!:C_A:FF_\^<W_
M 'U_]:CZO5[!RL[^BN _X6IIW_/G-_WU_P#6I1\5--QS:S ^F?\ ZU'U>KV#
ME9WU%<!_PM33?^?.;_OK_P"M1_PM33O^?.;_ +Z_^M1]7J]@Y6=_17 ?\+4T
MW_GSF_[Z_P#K4?\ "U--_P"?.;_OK_ZU'U>KV#E9W]%<!_PM33?^?.;_ +Z_
M^M1_PM33?^?.;_OK_P"M1]7J]@Y6=_17 ?\ "U--_P"?.;_OK_ZU'_"U--_Y
M\YO^^O\ ZU'U>KV#E9W]%<!_PM33?^?.;_OK_P"M1_PM33?^?.;_ +Z_^M1]
M7J]@Y6=_17 ?\+4TW_GSF_[Z_P#K4?\ "U--_P"?.;_OK_ZU'U>KV#E9W])7
M _\ "U--_P"?.;_OK_ZU'_"U--_Y\YO^^O\ ZU'U>KV#E9W]%<!_PM33?^?.
M;_OK_P"M1_PM33?^?.;_ +Z_^M1]7J]@Y6=_17 ?\+4TW_GSF_[Z_P#K4?\
M"U--_P"?.;_OK_ZU'U>KV#E9W]%<!_PM33?^?.;_ +Z_^M1_PM33?^?.;_OK
M_P"M1]7J]@Y6=_17 ?\ "U--_P"?.;_OK_ZU'_"U--_Y\YO^^O\ ZU'U>KV#
ME9W]%<!_PM33?^?.;_OK_P"M1_PM33?^?.;_ +Z_^M1]7J]@Y6=_17 #XJ::
M3S:3#WW?_6H/Q4TT'BTF(]<__6H^KU>P<K._HK@/^%J:;_SYS?\ ?7_UJ/\
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MJ:;_ ,^DW_?7_P!:C_A:FF_\^<WY_P#UJ/J]7L'*SOZ*X$_%/30>+68_C_\
M6I/^%J:;_P ^<W_?7_UJ/J]7L'*SOZ*X#_A:FF_\^<W_ 'U_]:C_ (6IIO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1^=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1^=%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(****L84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*/[-O_\ GQN?^_3?X47@%T0--*Y4O([$="6)Q2^?,9!(97WXQNW'-3?V;?\
M_/C<_P#?IO\ "C^S;_\ Y\;G_OTW^%%X!=%9F9V+,Q8GG)-2?:9PNT32[?3>
M<5+_ &;?_P#/C<_]^F_PH_LV_P#^?&Y_[]-_A3O +HJ\DY.2>YHJU_9M_P#\
M^-S_ -^F_P */[-O_P#GQN?^_3?X4*45U"Z*M%6O[-O_ /GQN?\ OTW^%']F
MW_\ SXW/_?IO\*?/'N%T5:*M?V;?_P#/C<_]^F_PH_LV_P#^?&Y_[]-_A1SQ
M[A=%6BK7]FW_ /SXW/\ WZ;_  H_LV__ .?&Y_[]-_A1SQ[A=%6BK7]FW_\
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MS_WZ;_"C^S;_ /Y\;G_OTW^%'/'N%T5:*M?V;?\ _/C<_P#?IO\ "C^S;_\
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M-_A1_9M__P ^5S_WZ;_"GSQ[A=%6BK7]FW__ #Y7/_?IO\*/[-O_ /GRN?\
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MQ[A=%6BK7]FW_P#SY7/_ 'Z;_"C^S;__ )\KG_OTW^%'/'N%T5:*M?V;?_\
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MC_OTW^%']FW_ /SY7'_?IO\ "CGCW"Z*M%6O[-O_ /GRN/\ OTW^%']FW_\
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M4<\>X715HJU_9M__ ,^5S_WZ;_"C^S;_ /Y\KG_OTW^%'/'N%T5:*M?V;?\
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M7/\ WZ;_  H_LV__ .?*Y_[]-_A1SQ[A=%6BK7]FW_\ SY7/_?IO\*/[-O\
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MN;^]^E04460$_P!KF_O?I1]KF_O?I4%%%D!/]KF_O?I1]KF_O?I4%%%D!/\
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M!1@4M% "<48%+10 F!1@>E+10 F!1@4M% "8%&!2T4 )@48%+10 F!1Q2T4
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M _*DN+^SLV47-W!"6Z"64+GZ9-%P+%%-1TD17C<.AZ,ISFG4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %O3_\ 7'Z5J5EZ?_KC
M]*U*RGN)A115:YO;6S3?=7,,"^LKA1^M2(LT54M=2L;XD6E[;7!7[WDRJ^/R
M-6A0 M%%% !1110 445')-'#&TDKK'&HR68X _&@"2BLS_A(M$_Z#.G_ /@4
MG^-.37=(D5V35;)E099A<(0/QS0!HT5%%-%<1++#(LD;#*NC @_0U+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT_3-7NKS5+JUFM1'%%G:^#\W/O3/"/\ R+MO^//XU9L=;MK^_GM(DD#P_>+
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M@:&:-9(V&&1AD$>E9J^%M!6U>U72+,6[MN:,0C:3ZD5L44 >:^+O#U[<>.M
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M/N%T<]/;PW,7ESQ))'U*L,BG1QI%&L<:A$7@!>@%;_\ PB>J_P!R/_OL4?\
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MZ M455^T3?\ /N?SH^T3?\^Y_.BZ M455^T3?\^Y_.C[1-_S[G\Z+C-73_\
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M*S/[0O?^?%OS'^-']H7O_/BWYC_&@#3HK,_M"]_Y\6_,?XT?VA>_\^+?F/\
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M*S/[0O?^?%OS'^-']H7O_/BWYC_&@#3HK,_M"]_Y\6_,?XT?VA>_\^+?F/\
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MHS2T4 )FC-+10 F:,TM% "9HS2T4 )FC-+10 F:,TM% "9HS2T4 )FC-+10
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MOJEA#>VKEX)EW(Q&,CZ5;H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0MQ!%*HY D0-C\ZR]"\3Z=X@1OLCLLJ_>AD&'7\*V: *?]D:9_T#K3_OPO\
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M2T4 4SI.FDDG3[0DG))A7_"IH+2VM<_9[>*'/7RT"Y_*IJ*+( HHHH MZ?\
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M"TDM;E-\,HVNN<9%>4_#_2-+N?$YU#2_#MQ:6=N#Y5S<7#[SD8QM/'>O7L4
M>'?$+P;H6B:CH\6GV0A2XD*R#S&.X9'J:Z#QKX.T+P[X(U"YTRR\F1U 8B1C
MD8/J:7XJPR2:MH!CC=@)3G:">XK>^)J/)X!O51&8D#@#)Z&@#B+.\\;6?@*S
MU:RO+6VL;:(8@V9>1<]3D<5TVI?$22T\":;JT4*->WW[M%)^4-G!)_*D:.3_
M (4PL?EMO^R$;=O/?M7+77AF]UGX3Z');P/)):,SR0<AF7<<T 7YO$OB[P[%
M;ZM?ZSIVI6LK#S+6)EW1@\]L=.E7O'GC/5K&709="FVQWZ%RC*#OSC'7IUKB
M8[+PQ>?9K73/">I3:@S!9EFG=$7U((/K74^.-->SU7P?;0V[!+=2A"9<+C;Q
MD]?QH Z)6\:Z-HM]>7ES;ZE<LJ_9X4VQK'UR23CVKB[OQKXH\/7MG+>^(+*^
M\UP)+*)!E 3W8#^1KMOBG9ZA=^"I(]/61R'4RJAY*=_PKRW6FT^\\/V(T?P]
M<P);RC[5</'SGC@'J: .[\;^+M?T_7]$MM'E4"\@5FA900S,3WZU#?:_XQ\'
M:M92:[=6]Y87<@0B- /*)[= :RO'=U+;^*/"MQ:0M,Z6B%8QU;!.:F\2:S=_
M$+4=.TG3M*NX5@F$EP\Z;=I'7\* .EB\2:I8_$P:3>W?FZ;>1;[7Y ,$XXSC
M)ZT:MXFU2\^(EGX>TBX,4,0WW3*JMD9Y!STQ57XGZ6]CI6GZ]9G_ $K2V 4_
M[)__ %"H_A/837@U#Q/>J#<7TF%)';OCZYH ].'0 G-+110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !WK*\1_P#( NO]T?S%:O>LKQ'_ ,@"Z_W1_,54/B0UN><4445Z9H%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444P"KNFZG-IER)8SE
M?XE_O52HZ5+2:LP/4-/U"'4+99H6!R.1W!JV*XGPI:7ANOM",4MQPV>C5VPK
MSJD5&5D9O<6BBBH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% &3??\?)^@JM5F^_X^3]!5:MH[%(Y+Q_,QTJUL4+;KNY
MCC 7TW#/Z5T\2K:V*I_##&!^0KG/&.FZA<-87^GQ+/)92^8T)_B'M[UD7?B7
MQ)K5NVGV7AVYLI91M:>XSL []A1U$:'@9!<2:OJ9!/VBZ;:3_=4D5TFK6(U/
M2KJRW[?/C*[O3-95I"WA3P[:6L%I+=R!@KK$.=QZM],U+XFBUC[+#<:/(1+!
M('>#/$J^AHZ 8.GZS/X5LDTW6=+>.TB&P74"YC;Z^E=)H5AI=I:O/I( ANF\
MPE3P37+S^+M=O86LH_"5TL[@J))CF//J?EZ?C6KI$=YX9T2QM)+.2ZGFD_>>
M5P(\GJ>O I =3WK%\4WUQ8Z,\EK<V]O(S!?-G?:$'K[FMJN'\=:?=2WUA?C3
MGU.SA!66T7.6)Z?RIL#G[;6+G3]6L3:^+7U5IYE22W(RH!Z]ZZ/Q#>ZQ=>*;
M+2](N3"WE&29NP![D?AQ6):6M[?^(])G3PXVF:>DF[;L)8$8^]Z"NHT6SN)/
M%FK:E<0NB_+##O0C(&3D?G2U R],DU;0?%,EE?:S)J%N;8W$AD',>,\ 9/I4
M5M#XD\4"758=6?3K57;[-#&.) /[W(ZXJ]::9=:CK?B&XN(I(EEC^SP,ZXR-
MHY'MDFLBPU7Q-IND2:'%H$K7$*LJW7(C(['IZ>] &IX#^T7EUJNHWFTW#2B$
ME1QE<@U>^(%TUOX1NE7/F3CRE ZG/:G^!=/N;#PU&MXC)<RNTDF\8.2<\UG^
M/9+Q7TO[-IEQ>Q1S^=*D*D_=QQT/6GT H:?XG\26.GP6L?@RZ9(U"@[SS^E=
MIHU[=ZAIJ7%[8M93MUA<Y*URJ^/-5"@#P9JAP.Q/_P 36^-=NCIUC<MH]R);
MI]KP]3#SU8XI("EX\N3%X?\ LRYWW<J1+@=>03^@KH+.!;/3H;<?=BC"C\!6
M!XRTN_OK>SNM/199K.<2^43]_@C^M8]SXJ\2:G"UC9>&[JTN'^4SS'Y!ZGH/
MYT^HR_X/07>L:WJH!*S7!CC/LI/^-=A7-Z?;2>$?"\$*6LM[<*1YBQ#EF/4]
M^.*Z)&+(&*[6(!(-" P?&=Y+9^')O)8K),RQ!AVW,!_6K'AW0K/0]+ABMXP)
M&4&60CYF8\G/XT_Q'I!UK1IK1&"2G#QL>S Y'\JY>'Q1XDTV%;"[\-W-U<(-
MHGASL/H>A_G28BQK$-O8>/M'N+9%CN+@,DVS@LO'6J<3>(/$.NZQ;V6HRV=F
MDHC$H8G;C/"CC\:O:-H^J27L^OZVJF[\LK;VZ#/EK_B<"K_A*"6P\.//=Q-#
M++(\SJXP1G'44 <[:CQ!K&N:E86>K3P6MN!$;@DL<CG(&>O/K6AH&I:G9?VU
MINJ737+V*%XYVZL-H/\ 6L?0]9UG2;2>X@T::_BOYFECDB/*'IR,'CBKHT?5
M+?PSJ5W=1O+J6I2+NCB4DHI(&/P S1J!F:7INOW'AB;4(]5;3H0\DZ+$OS29
M8GDY&.M='_;>HMX!MKXW%O;W4J*#-.^T+Q][Z^U6M:MI[3P5'86D$DDC1QQ;
M40DCIDG%8OBG1;F"+1YETYM2L[./RY;1.K'CG]*-0,B#6;G3]5L7M?%SZJ\\
MZH]L1E0"><<UT?B*]UBY\2Z?I>D7)A8QF28YX .>2/;'%8EK:WM_XATF9/#;
M:98)*&8;27!!'WN.!74:-:3R^+]5U"X@>-%"PPEU(RHYR/7K1J!G:.FL:3XQ
M73;K5Y-1BFA,K^8,>7UZ<GTKN?6N6T6UN9_&&K:C<P2I& (H#(I&5P#D>V<U
MTMPQ6VD90694) 7DDTUL!R>C*NI>.]6U 8Q:JMLIZ_7_ -!I_P 0+>.30XY]
MO^DQSIY+=P<]C7-Z#X@U;0X[I'\*ZE<2SSM*T@4KG))'&VMZUMM7\3ZM;7NJ
M6ALM.MSYD=LQR[/ZM[#Z4@(-5O\ 6KKQ19Z7ID[1[;3=,Q;Y5R",X[GTJ4IJ
M5AK&C:0VJW-S(Q::XE)(++AL#KTSBK^AVEPWBC6+^:W>-21%$67&5'.1[<UE
M:K<:KI?C22]CT:?4(Y81%"T1X3G//![YHU T]9OKG_A+--LX9Y(X8XVGG"-C
M<HXP?SK'BCU_Q=+-J-GJ\NG6,;E;=(A_K .YY'M5G0+#5K_6=7O=6B,4DD0A
MB 7  (' ]<8P:S+/5-?\-:9-HRZ(\AAW>5>9Q&%]3Q_6@#8\$7>K7]UJ4FJ3
M,WE,(=N<H&7.2!^(KK+N<6UG/<-@".-G.?89KG/A_#*OA:*XG.9;F0S,WKG%
M6_&370\,7B6D$LTTB[ D2EC@\'@4P*?@*W"Z++>X^:\G>4_F0/T%5=;BCMO'
MFE7,*A9&C<S$?Q*/7]*H:5XLU6QTZWL8_!^HCRT"!F) SZ_=K7T?1-0NYKO5
M-:"+>7$9CAB4Y$2'M]>E(#EY_$3^(+V>4^+(M&MHY"L,:-\[@=SR*Z'PUKM_
M>Z#J"I,E_=V998IDY$W'%<I#I/\ 9(?3KKP6=0N Y"7B@[2.Q)Q74)H6K:;X
M5!TV&VL]2$@E>*U7:K ?PGDYHU Y_37UK49C-;>*I1J:OEM.GRBCGD=>F/:N
MLU>\O3KVA:>MRT,CYDN!&W# *>/<9KG;J;5?%-S9V_\ PC4UC<PRH[WDO  4
M@G' ZXKH[6TGN/'$]Q/!((;:U$4<K*<,3@D@_B: ,^ZEUCQ5K-U;:7J4FG6-
MFVQI8A\SOW'4<=:9X>N-<7Q3<V6I7KS0V,)4MD@29^Z6'KP:@AN-:\)ZC?VD
M.C2WT%U*TT4L9X7.2=QQ[U'X?DU*70O$&JR1&6]N)"BI$-W*Y&!CMS0 FFP^
M)/$MO>W2:W+8V9F8PNH)8@=AR,"M+2-:U/\ X0B:ZEN8#<QLT:3SOM4CIN)]
M:N):7.D?#\VUO!(]TML0%13N+$>GK6'K6@7D7A31Q'9-=I:OON;4<&3)Z8HU
M QI=9NK&2&\@\9-?W#R*#: 90Y(SWZ5N>*].OM:\2Z1:PZG-;^8GG%%'$9 Q
MGKUY_6LF:VO=3N-/%KX5?3+-9U$F4)?CGTZ5T]S)?6OQ#BD_LR>>UDA\I)U^
M[%T)SQZBEJ!()[R/Q=8::+^9XK6T+W&6_P!8>,%OUK. U_QC?7$]EJLFF:9$
M_EPM"#ND(ZD\CCI6MI-E/<>)M;O+B"2,-MAA=UQN SR/;I6!I^I>(/"L,NCK
MH4][AR8;B$'9STSP:>H&KX?U;4;:+6+'59A/+8 NLY_B&W(S6-9VOBC5?#\N
MIRZ]-91(7EC50274$XR<]*M'1M5LO#&H3W$;S:IJ<JB1(E+;%) [>@YK:URV
MN+;P6MA9P223-''%B-3D<C)Q^=&H%_PK>W5_X<M+F\(:9T^8COZ&MFJFF6HL
MM+M;91@1Q*A^H%6ZI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M MZ?_KC]*U*R]/\ ]<?I6I64]Q,*3%+14B$Q12T4 )1S2T4 )1@TM% "4M%%
M "44M% "8XHI:* $HQ[<TM% "8/K1BEHH X;Q1X4U+5_&FCZK:^3]FM%Q)O?
M#=2>!CWKN,4M% ' >./#_BOQ)>?V?9SVL6BOM+Y;$GO]178:/I<.CZ3;Z?;C
M]W @13ZU?HH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ [UE>(_^0!=?[H_F*U>]97B/_D 7
M7^Z/YBJA\2&MSSBBBBO3- HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBBA@%;.AZ%)J,HDD!6W4\GUHT/0Y-2E$D@*VZGD_WJ[V&&.")8
MXE"HHP *YZU:VB)DQ88$@B6*-0J*, "I!TI:*XB HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,F_P#^/H_056JY
M>('N"3(B\="U5_*7_GM'_P!]"M%*-DKE*+:(Z*D\I?\ GM%_WT*7RE_Y[1?]
M]"GSQ[CY7V(J*E\I?^>T7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\
MI?\ GM%_WT*.>/<.5]B*BI?*7_GM%_WT*/*7_GM%_P!]"CGCW#E?8BHJ7RE_
MY[1?]]"CRE_Y[1?]]"CGCW#E?8BHJ7RE_P">T7_?0H\I?^>T7_?0HYX]PY7V
M(J*E\I?^>T7_ 'T*/*7_ )[1?]]"CG7<.5]B*BI?*7_GM%_WT*/*7_GM%_WT
M*.>/<.5]B*BI?*7_ )[1?]]"CRE_Y[1?]]"CGCW#E?8BHJ7RE_Y[1?\ ?0H\
MI?\ GM%_WT*.==PY7V(J*E\I?^>T7_?0H\I?^>T7_?0HYX]PY7V(JJ:G:RWN
MF7-M#(L<LD957;HI/>M#RE_Y[1?]]"CRA_SVBX_VA1S1[AROL9ND6']EZ5;V
M6X,8EP6 ZU=J7RE_Y[1?]]"CRE_Y[1?]]"CFCW#E?8BHJ7RE_P">T7_?0H\I
M?^>T7_?0HYUW#E?8BHJ7RE_Y[1?]]"CRE_Y[1?\ ?0HYUW#E?8BHJ7RE_P">
MT7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?]]"CRE_Y[1?\ ?0HYX]PY7V(J
M*E\I?^>T7_?0H\I?^>T7_?0HYUW#E?8J7=N+JTEMV9E$BE<J<$5PH\#:\R?8
M9?$LCZ5]TP[?G*^F<=:]%\I?^>T7_?0H\I?^>T?_ 'T*.:/<.5]BI:6L5C9Q
MVL"XCB4*H]JF_K4OE+_SVC_[Z%'E+_SVB_[Z%'/'N'*^Q%14OE+_ ,]HO^^A
M1Y2_\]HO^^A1SQ[AROL145+Y2_\ /:+_ +Z%'E+_ ,]HO^^A1SKN'*^Q%2,N
M]2O/(Q4WE+_SVB_[Z%'E+_SVC]OF%'-'N'*^QY]/X+\0)/-'8>)'AL97+-$Z
M[FY.2 <5UFBZ1!HFEQ6-N24C_B;JQ[DUJ>4/^>T7_?0I?*7_ )[1?]]"CFCW
M#E?8BHJ7RE_Y[1?]]"CRE_Y[1?\ ?0HYX]PY7V(J*E\I?^>T7_?0H\I?^>T7
M_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\I?\ GM%_WT*.==PY7V(J*E\I?^>T7_?0
MH\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\I?\ GM%_WT*.==PY7V(J*E\I
M?^>T7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\I?\ GM%_WT*.==PY
M7V(J*E\I?^>T7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\I?\ GM%_
MWT*.==PY7V(J*E\I?^>T7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[1?\ ?0H\
MI?\ GM%_WT*.==PY7V(J*E\I?^>T7_?0H\I?^>T7_?0HYUW#E?8BHJ7RE_Y[
M1?\ ?0H\I?\ GM%_WT*.>/<.5]B;3_\ 7'Z5IUFVFR*0LTT>,8X85=^U0?\
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M2,#_ (0RR_Y[S_F/\*/^$,LO^>\_YC_"M_[3;_\ /:/_ +Z%'VFW_P">T?\
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M;/N%I=C _P"$,LO^>\_YC_"C_A#++_GO/^8_PK?^TV__ #VC_P"^A1]IM_\
MGM'_ -]"CVS[A:78P/\ A#++_GO/^8_PH_X0RR_Y[S_F/\*W_M-O_P ]H_\
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M4?VF#_GM'_WT*/M,'_/:/_OH470<K[$E%1?:8/\ GM'_ -]"C[3!_P ]H_\
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M<K175?\ "%2_\_ _*C_A"I?^?@?E1]5J=@_M'#]SE:*ZK_A"I?\ GX'Y4?\
M"%2_\_ _*CZK4[!_:.'[G*T5U7_"%2_\_ _*C_A"I?\ GX'Y4?5:G8/[1P_<
MY6BNJ_X0J7_GX'Y4?\(5+_S\#\J/JM3L']HX?^8Y6BNJ_P"$*E_Y^!^5'_"%
M2_\ /P/RH^JU.P?VCA^YRM%=5_PA4O\ S\#\J/\ A"I?^?@?E1]5J=@_M'#]
MSE:*ZK_A"I?^?@?E2_\ "%2_\_ _*CZK4[!_:.'[G*45U7_"%2_\_ _*C_A"
MI?\ GX'Y4?5:G8/[1P_<Y6BNJ_X0J7_GX'Y4H\%29YN1^5'U6IV#^T</_,<I
M175GP5+GBY&/I2?\(5+_ ,_ _*CZK4[!_:.'[G*T5U7_  A4O_/P/RH_X0J7
M_GX'Y4?5:G8/[1P_\QRM%=7_ ,(5+_S\#\J3_A"I?^?@?E1]5J=@_M'#]SE:
M*ZK_ (0J7_GX'Y4?\(5+_P _ _*CZK4[!_:.'[G*T5U7_"%2_P#/P/RH_P"$
M*E_Y^!^5'U6IV#^T</W.5HKJO^$*E_Y^!^5'_"%2_P#/P/RH^JU.P?VCA^YR
MM%=7_P (5+_S\#\J3_A"I?\ GX'Y4?5:G8/[1P_\QRM%=5_PA4O_ #\#\J/^
M$*E_Y^!^5'U6IV#^T</W.5HKJO\ A"I?^?@?E1_PA4O_ #\#\J/JM3L']HX?
MN<K175?\(5+_ ,_ _*C_ (0J7_GX'Y4?5:G8/[1P_<Y6BNJ_X0J7_GX'Y4O_
M  A4O_/P/RH^JU.P?VCA^YRE%=7_ ,(5+_S\#\J4>"I,'-SSVXH^JU.P?VCA
M_P"8Y.BNJ_X0J7_GX'Y4?\(5+_S\#\J/JM3L']HX?N<K175?\(5+_P _ _*C
M_A"I?^?@?E1]5J=@_M'#]SE:*ZK_ (0J7_GX'Y4?\(5+_P _ _*CZK4[!_:.
M'[G*T5U?_"%2_P#/P/RI/^$*E_Y^!^5'U6IV#^T</W.5HKJO^$*E_P"?@?E1
M_P (5+_S\#\J/JM3L']HX?N<K175?\(5+_S\#\J/^$*E_P"?@?E1]5J=@_M'
M#]SE:*ZK_A"I?^?@?E1_PA4O_/P/RH^JU.P?VCA_YCE:*ZO_ (0J7_GX'Y4G
M_"%2_P#/P/RH^JU.P?VCA^YRM%=5_P (5+_S\#\J/^$*E_Y^!^5'U6IV#^T<
M/W.5HKJO^$*E_P"?@?E1_P (5+_S\#\J/JM3L']HX?N<K175?\(5+_S\#\J/
M^$*E_P"?@?E1]5J=@_M'#]SE:*ZK_A"I?^?@?E2_\(5+_P _ _*CZK4[!_:.
M'_F.4HKJQX*DSS<C'TH/@J3/%R,>XH^JU.P?VCA^YRE%=7_PA4O_ #\#\J3_
M (0J7_GX'Y4?5:G8/[1P_<Y6BNJ_X0J7_GX'Y4?\(5+_ ,_ _*CZK4[!_:.'
M[G*T5U?_  A4O_/P/RI/^$*E_P"?@?E1]5J=@_M'#]SE:*ZK_A"I?^?@?E1_
MPA4O_/P/RH^JU.P?VCA_YCE:*ZK_ (0J7_GX'Y4?\(5+_P _ _*CZK4[!_:.
M'[G*T5U7_"%2_P#/P/RH_P"$*E_Y^!^5'U6IV#^T</W.5HKJO^$*E_Y^!^5+
M_P (5+_S\#\J/JM3L']HX?N<I175_P#"%2_\_ _*D_X0J7_GX'Y4?5:G8/[1
MP_<Y6BNJ_P"$*E_Y^!^5'_"%2_\ /P/RH^JU.P?VCA_YCE:*ZK_A"I?^?@?E
M1_PA4O\ S\#\J/JM3L']HX?N<K175?\ "%2_\_ _*E_X0N7/-R,?2CZK4[!_
M:.'_ )CE**ZL^"I,_+<C'N*/^$*E_P"?@?E1]5J=@_M'#]SE**ZK_A"I?^?@
M?E1_PA4O_/P/RH^JU.P?VCA^YRM%=5_PA4O_ #\#\J/^$*E_Y^!^5'U6IV#^
MT</_ #'*T5U7_"%2_P#/P/RH_P"$*E_Y^!^5'U6IV#^T</W.5HKJ_P#A"I?^
M?@?E1_PA4O\ S\#\J/JM3L']HX?^8Y2BNJ_X0J7_ )^!^5'_  A4O_/P/RH^
MJU.P?VCA^YRM%=5_PA4O_/P/RH_X0J7_ )^!^5'U6IV#^T</W.5HKJO^$*E_
MY^!^5'_"%2_\_ _*CZK4[!_:.'_F.5HKJO\ A"I?^?@?E2_\(5+_ ,_ _*CZ
MK4[!_:.'[G*45U?_  A4O_/P/RH_X0J7_GX'Y4?5:G8/[1P_<Y2BNJ_X0J7_
M )^!^5'_  A<O_/P/RIK"U+["_M'#_S&[X6_Y </TK:JAI-B=.L([<MN*]ZO
MUZM--029\U6DI5&T4;G_ %WX5#4US_KOPJ&I>YI#9!1112'8****!V"BBB@
MHHHI %%%%, HHHI""BBBF.P4444 %%%% !1110 4444 %%%% !1110 4444!
M8**** "BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5 \!'HSN,T5DZ7J8F412G#CH?6M85TQDI*Z//G3E"5F%%+15$!1110 4444
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M5^IZ5!X<^)>D>(;P6@22TG;[BRG.[\1Q7.?#W3+/6->UG4-1B2XN$G*J)!N
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MG2Z5K>J7J,V)'N,^6V<<*#_A75?$;4M0_P"$GM+.[O+RPT4Q@M/; @@]\D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAK\DEG%;G) .PD>P%>M447)Y3S?Q?X4OU\1IX@T[3X=24ILFM91G=CIU%/\
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MR(R/#=A/IVBPPW:6Z7)^:46\0C0,?0"M>BBD7:P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 3VO^LJ[5*U_UE7:TCL<]3<9,
M"T+@=2IQ7GGP^\/7UC<:\FJV+QPW4HV>8!AUYKT4T51!XGIG@#5=#^)<<]O9
M2R:6LN])QT ]ZV->TCQ)H7Q D\0Z-I?]HQW(PZ*W3C'/I7JF** /(=.T;Q5>
M_$RUUK5M,,4)&2T9RL8VXP3ZU8NM'\3>#_%E]J>A:;_:EI?99HPV"K$YYKU8
M<4=Z //]!M/%MUHFL2ZV"&NE;R+3&60GMGTZ5E:)X'OK_P"&MYHU] UK=-.T
MD2R>O&/PR*]5HH \5ATWQ/!:)I,?@C3?/3"#4'A1E/N016]XP\&ZI>>$--@L
MHK>2ZM)1-+!%$(T<X.0%''4UZ910!XEK.D^+M=&EW+^&TLX+.0*;6'&X_P"U
MC  ''ZUV/BP^*HKJ.6RTRVU;2V0![&2-=P;ZXZ5W=&.: /*?!OAC6'\9R:Y=
MZ0FC6AB9#:(>#D$=!QWJC-X4UCPKK=]+:>&;77K.Z<N@D4%H\_45[+10!PW@
MC1-1$5Y<ZQIUC8^>"D<%M;JC*AZ@L #5G3_AGX;TB_34+.VF%S%ED+3,PS]#
M78"EH \\^'.BZEI.IZW)?V<END\H,3/_ !#FNRUV&2YT'4((4+RR6TBHHZDE
M2 *T*3J: .,^&FD7VD^%OLNHVSP2F0DHXYQ7)7OA/5?#/B&]N[#P[;:]9W;F
M14D4%HV/)ZCZU[#1]: .!\&:'J;M=WFKZ78:<LRE(K>"V1753URP /I7*IX8
MUKPE?74%OX4M->M97+0R.@+(/?(KVBB@#C_ FDZE8VLUSJEG8VD\Q^6*VMUC
M*KV!( S47Q!\&2^)[."XL)%AU*U.Z)R<9'IFNUHH \+N;;XDWWEV-[I$%TB#
MRUGN+5' 'KN/-=EX=^'3:?X/U'3+V=3<:@/WGECY8SST_.O0J* /$K71?$FB
M6;:0O@JPOY%XCOVB5@/0G(YKK[OP]J2?#:ZL3:V[:C,NYHK.%8USZ8&,UWU%
M '#Z9I&H0_"L:;):R+>_9V7R3][.3Q7.67@/4-1^%MMIMQ;FVU*WF>:.*7O\
MQX/U!KUK'I2XH \8CT_Q-/'#IT?@C3+69"%:^EMT96 Z\;>]>NZ?:_8M.AML
M1CRT"_NT"+^"C@5:HH \;\5Z;XPL_'\NL^']-EE^3:LFQ67ICH:=:ZW\66O(
M%N--80F11(?LR#"YY_2O8ATI: /,/$^@>(--\70>*=#M?MDC(JSVV>3@ ?TK
M+DTSQ?K?C_1=:U+1S!;QR E(VSY('7<:]BHQ0!YUI^B:E%\7+O5)+.1;%XBJ
MS'[I/-9VEZ;XC\-_$34;F#1FN[*_D53.&P$7/)KU;K0* /-?"V@ZK9^+/$EU
M<V,L4%S&RPNP&'/'2K/PUT74M(L=834+.2W::X+1A_XASTKT&B@#ROPUX2OV
MA\66VI6\EK#?/^ZDDX!'S<_K5+1?^$ST?0+G0$TV$VR*^+\R_*JX[<<UZQJ%
MC#J6GSV5RNZ&9"C#U!KSI/A7?6L<MK8>*;NVT^0DM;!"0<]1G=0 [X+AAX?U
M$.<M]L;)]3@5Z;6/X<\/VOAO24L+0L54Y9FZL?6M<4 +1110 4444 %%%% !
M1110 E!Z44'I0!QEW_Q^3?[Y_G4-37?_ !^3?[Y_G4->;+=GOT_A04445)84
M444 %%%% !1110 4444 %%%% !1110 444=J8!WK7TO2C*1-,/EZJ#WHTO2S
M*1-,/D'W5/>NA4 # Z5TTJ5]9'GXG%?8@"H%&!P*=1174>:%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )\?_'A_C1]MO_\ GQ_\>'^- &G169]MO_\ GQ_\>'^-'VV__P"?'_QX?XT
M:=%9GVV__P"?'_QX?XT?;;__ )\?_'A_C0!IT5F?;;__ )\?_'A_C1]MO_\
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M :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\
M_GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_Q
MX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]
MMO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A
M_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV
M_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\
M?_'A_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%
M9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_
M\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT
M?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]MO\
M_GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!
MIT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^
M?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A
M_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV
M_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^
M- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_
M /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_
M\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F
M?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_Q
MX?XT :=%9GVV_P#^?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]
MMO\ _GQ_\>'^- &G169]MO\ _GQ_\>'^-'VV_P#^?'_QX?XT :=%9GVV_P#^
M?'_QX?XT?;;_ /Y\?_'A_C0!IT5F?;;_ /Y\?_'A_C1]MO\ _GQ_\>'^- &G
M169]MO\ _GQ_\>_^O1]NOO\ GR_6@#3HJ*W>22%6D38QZC-2T 4+C_6U%4MQ
M_KJBK)[G3"U@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% $]K_K#5VJ5K_K*NUI'8YZFX44451 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ2BHX94FB#H<@U+6R9RM6>H4444 %%%% !1110 4444 %%%% !1110 4444
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M6*NC5HK%\,>(/^$DTO\ M!;-[:(L50.V=WO6U0 4444#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** )[7_ %E7:I6O^LJ[6D=CGJ;B
M'I29R>#23?ZB3_=/\J^>?#/B>Z\.^.;BXG:5M/DG,4[-DJH)X/UZU1!]#Y]Z
M<*\I\0W+2?%_13%*WE/;JP ;@Y)KKK3QE#=>,[KPV+)UDMQDSEQAN,],4 =1
M17+3^-88/&L7AHV3F209$X<8'&>F*HZ]\1[;2=6;3+'3+K5+J,9E2W_@_0T
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MK/POIUL\_GLD('F;2N[WP>1^-9EM\-O"MI?B]ATQ?.!S\SLRY_W2<5U> HP
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M7_Y!DWT'\ZO=ZHZO_P @R;Z#^=3/X673^-')T445YI[X4444 %%%% !1110
M4444 %%%% !1110 4444 %%%':@ J]I^GO=ON.1&#S1IVGO=R98$1CJ?6NHB
MB2% B# %=%*DY:LX<3B>7W8[B11+%&$084=!4E+178>6][A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %&Y_UWX5#4MP<RY]JBK)[G3"]@HHHI%!1110 4444 %%%% M HHHH#0***
M* "BBB@- HHHHL,****+""BBBBPPHHHH%H%%%% PHHHHL 4444"T"BBB@844
M44 %%%% !1110(**** "BBB@ HHHH&%%%% !1110(****!A1110(****!A11
M10 4444 %%%% !1110(****!A1110(****!A1110 4444""BBB@84444 3VO
M^L-7:I6O^LJ[6D=CGJ;AUHHHJB HHHH 3%+BBB@ HHHH **** $Q2T44 %%%
M% !1110 F*7%%% !1110 4444 %%%% "8I:** $Q2T44 )BEHHH **** "BB
MB@ HHHH *3%+10 48HHH **** "BBB@ HHHH **** "BBB@ HHHH 2JU_ ]S
M9R1)C+#C/UJS12:35AIM.Z.9&A7?K'^=+_8-WZQ_G72T5E[")T_7*IS7]@W?
MK'^=']@W?K'^==+11["(?7*IS7]@W?K'^=']@W?K'^==+11["(?7*IS7]@W?
MK'^=']@W?K'^==+11["(?7*IS7]@W?K'^=']@W?K'^==+11["(?7*IS7]@W?
MK'^=']@W?K'^==+11["(?7*IS7]@W?K'^=']@W?K'^==+11["(?7*IS7]@W?
MK'^=']@W?K'^==+11["(?7*IS7]@W?K'^=/AT*?S1YK($'7!KHJ.:/810/%U
M6B.&)84"*, 5)116RMT.5MMW8M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIO\ T +G_O\ K_A1_P +VTW_ * %S_W_ %_PKQ"BCZK3#ZU5[GM__"]M-_Z
M%S_W_7_"C_A>VF_] "Y_[_K_ (5XA11]5IA]:J]SV_\ X7MIO_0 N?\ O^O^
M%'_"]M-_Z %S_P!_U_PKQ"BCZK3#ZU5[GM__  O;3?\ H 7/_?\ 7_"C_A>V
MF_\ 0 N?^_Z_X5XA11]5IA]:J]SV_P#X7MIO_0 N?^_Z_P"%'_"]M-_Z %S_
M -_U_P *\0HH^JTP^M5>Y[?_ ,+VTW_H 7/_ '_7_"C_ (7MIO\ T +G_O\
MK_A7B%%'U6F'UJKW/;_^%[:;_P! "Y_[_K_A1_PO;3?^@!<_]_U_PKQ"BCZK
M3#ZU5[GM_P#PO;3?^@!<_P#?]?\ "C_A>VF_] "Y_P"_Z_X5XA11]5IA]:J]
MSV__ (7MIO\ T +G_O\ K_A1_P +VTW_ * %S_W_ %_PKQ"BCZK3#ZU5[GM_
M_"]M-_Z %S_W_7_"C_A>VF_] "Y_[_K_ (5XA11]5IA]:J]SV_\ X7MIO_0
MN?\ O^O^%'_"]M-_Z %S_P!_U_PKQ"BCZK3#ZU5[GM__  O;3?\ H 7/_?\
M7_"C_A>VF_\ 0 N?^_Z_X5XA11]5IA]:J]SV_P#X7MIO_0 N?^_Z_P"%'_"]
MM-_Z %S_ -_U_P *\0HH^JTP^M5>Y[?_ ,+VTW_H 7/_ '_7_"C_ (7MIO\
MT +G_O\ K_A7B%%'U6F'UJKW/;_^%[:;_P! "Y_[_K_A1_PO;3?^@!<_]_U_
MPKQ"BCZK3#ZU5[GM_P#PO;3?^@!<_P#?]?\ "C_A>VF_] "Y_P"_Z_X5XA11
M]5IA]:J]SV__ (7MIO\ T +G_O\ K_A1_P +VTW_ * %S_W_ %_PKQ"BCZK3
M#ZU5[GM__"]M-_Z %S_W_7_"C_A>VF_] "Y_[_K_ (5XA11]5IA]:J]SV_\
MX7MIO_0 N?\ O^O^%'_"]M-_Z %S_P!_U_PKQ"BCZK3#ZU5[GM__  O;3?\
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M^%>%T4?5H!]8F>Z?\+]L?^@#<?\ ?]?\*/\ A?MC_P! &X_[_K_A7A=%'U:
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M^%>%T4?5H!]8F>Z?\+]L?^@#<?\ ?]?\*/\ A?MC_P! &X_[_K_A7A=%'U:
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M * -Q_W_ %_PH_X7]8_] &X_[_K_ (5X711]6IA]9F>Z?\+^L?\ H W'_?\
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M%^V/_0!N/^_Z_P"%'_"_;'_H W'_ '_7_"O"Z*/JT ^L3/=/^%^V/_0!N/\
MO^O^%'_"_;'_ * -Q_W_ %_PKPNBCZM /K$SW3_A?MC_ - &X_[_ *_X4?\
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M%^V/_0!N/^_Z_P"%'_"_;'_H W'_ '_7_"O"Z*/JT ^L3/=/^%^V/_0!N/\
MO^O^%'_"_;'_ * -Q_W_ %_PKPNBCZM /K$SW3_A?MC_ - &X_[_ *_X4?\
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M%^V/_0!N/^_Z_P"%'_"_;'_H W'_ '_7_"O"Z*/JT ^L3/=/^%^V/_0!N/\
MO^O^%'_"_;'_ * -Q_W_ %_PKPNBCZM /K$SW3_A?MC_ - &X_[_ *_X4?\
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M%^V/_0!N/^_Z_P"%'_"_;'_H W'_ '_7_"O"Z*/JT ^L3/=/^%^V/_0!N/\
MO^O^%'_"_;'_ * -Q_W_ %_PKPNBCZM /K$SW3_A?MC_ - &X_[_ *_X4?\
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M=2=@E1:5SS2BBBMS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH>
MP'U!\)_^2?:?_NG^9KMZXCX3_P#)/M/_ -T_S-=O7DU/C9ZU/X$> _%3PMK6
MJ^-YKJRL)9H3"@#+TSS7$_\ "!^)O^@3/^5?4-X["XP"V .QJ#S'_OM^=;0Q
M$HQM8PEAXN5[GS+_ ,()XF_Z!,_Y4?\ "!^)O^@3/^5?37F/_?;\Z/,?^^WY
MU7UF782PT>Y\S?\ "!^)O^@3/^5)_P ('XF_Z!,_Y5]->8_]]OSH\Q_[[?G1
M]:EV#ZM'N?,O_"!^)O\ H$S_ )4?\('XF_Z!,_Y5]->8_P#?;\Z/,?\ OM^=
M'UF0?5H]SYE_X0/Q-_T"9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[
M!]6CW/F7_A _$W_0)G_*C_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP
M?5H]SYE_X0/Q-_T"9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6C
MW/F7_A _$W_0)G_*C_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP?5H]
MSYE_X0/Q-_T"9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6CW/F7
M_A _$W_0)G_*C_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP?5H]SYE_
MX0/Q-_T"9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6CW/F7_A _
M$W_0)G_*C_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP?5H]SYE_X0/Q
M-_T"9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6CW/F7_A _$W_0
M)G_*C_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP?5H]SYE_X0/Q-_T"
M9_RH_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6CW/F7_A _$W_0)G_*
MC_A _$W_ $"9_P J^FO,?^^WYT>8_P#?;\Z/K,NP?5H]SYE_X0/Q-_T"9_RH
M_P"$#\3?] F?\J^FO,?^^WYT>8_]]OSH^LR[!]6CW/F7_A _$W_0)G_*C_A
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MSY,_X0/Q-_T"9_RH_P"$#\3?] F?\J^LZ*/K4NP?58]SY,_X0/Q-_P! F?\
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MI=@^JQ[GR9_P@?B;_H$S_E1_P@?B;_H$S_E7UG11]:EV#ZK'N?)G_"!^)O\
MH$S_ )4?\('XF_Z!,_Y5]9T4?6I=@^JQ[GR9_P ('XF_Z!,_Y4?\('XF_P"@
M3/\ E7UG11]:EV#ZK'N?)G_"!^)O^@3/^5'_  @?B;_H$S_E7UG11]:EV#ZK
M'N?)G_"!^)O^@3/^5.3P!XG=@JZ3-D^N!7UC11]:EV#ZK'N?)K> O$ZL5.DS
M9'TI/^$#\3?] F?\J^LZ*/K4NP?58]SY,_X0/Q-_T"9_RH_X0/Q-_P! F?\
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M4?6I=@^JQ[GR9_P@?B;_ *!,_P"5'_"!^)O^@3/^5?6=%'UJ78/JL>Y\F?\
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!**6L_6I9(-'N)8F*.H&&'4<B@"_17G7]LZE_S^S?]]4?V
MSJ7_ #^S?]]57*3S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?V
MSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU
M1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4
M?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?V
MSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU
M1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4
M?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?V
MSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU
M1R!S'HM%>=?VSJ7_ #^S?]]4?VSJ7_/[-_WU1R!S'HM%>=?VSJ7_ #^S?]]4
M?VSJ7_/[-_WU1R!S'HM%>=?VSJ/'^FS?]]5OZ%KYD(MKQ_G/W7/>CE#F.GHI
M,TM24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F7O_ !\GZ"JU6;W_
M (^3]!5:FB0HKR_7O&>NZKK<ND>&(3NA.&E4#)/X\8JG#XK\8^%[V'_A)(6E
MMIFP2P7Y1[%>/SH&>N45C7?BG1[ 69N[L1?:TWPY4X(^O:H[3QGH%]?_ &&W
MU"-KC.-I4@$^Q(Q0!N_A17">+/$%]I?BS2;:*\\FTF8>:"%P1GGDUO6/C'0=
M1OS8VU^CW XV[2/UQ@TQ&[17G.L?$.*U\86MC'<JFGQL1<OL.<X/'YXZ5+JW
MBNX@\<:;%'?B/2IHQ(P( !! .>1FD,]!HK$TSQ=H>L7;6EC?+)..2FTC\L]:
M=J_BK1="D6/4+U8I&'"A2Q'Y4Q&S165:Z[8ZOI4]WIETLJI&Q!'!! ]#7->"
MO$US<:/J=]K-XTD=M.1O*CY5S["@#NJ*YI_'WAJ.**1M33;+]W",?S&.*FOO
M&GA_3UB:YU*,"893:"Q(_#I0!OT5AZWJ:-X9EOK'4H[8%<I<[=X4?3!IVCZD
MB>&+>^OM1CG4(6>YP5#<GG'% &U17/Z?XU\/:G>?9;74$:8] RE0?S%=!0 4
M5Q'C-?&9OXCX<9UM]GS[3'U_X%7$:;K/Q$U>6>*QNY)7@.)!B,;3^(H&>W45
MS;>)[/0=+LU\07JQ7K)^\&-QS_P&M'3/$.EZO:/=6-TLT48.XX((QZCK0(TZ
M*YH>/O#116&HJ0S;0-C9S],5<U7Q5HNB[!?WRQ,XR!@L<?0=* -FBL:U\5:+
M>ZDFGVUZDMS(F]44$Y'UZ4W5O%NAZ),(;Z_2.0_P@%B/KB@#;HK,&OZ=+I$F
MIPW2/;(N6=><?4=17)>$?'\6LZS>6UY<*K22A;2-4.&'.3_*@#T"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M6'^M/
MTK2K-L/]:?I6E4LI!13)B5A<CJ%)%>-^%?B-J/\ PG$VF:Q>&6TEE,<195 0
MYXY H ]FS2UYYKOB'5+7XFZ9I=O>%+&:)6>(*"&R3WQFNLA\2:5/KDNC17.Z
M^B&7BV'CC/7&* -;-+FL>3Q-I,>N)HSW6-0?[L6QO3/7&.E0ZUXPT'P]*L>I
MWZ0R,,[=I8_D.E &]16 _B"SU+PW=ZCI%XL@6(LKKU4XXR#TK(^'.NWNK>%Y
MK[5;OS)(YW4R. H"@#TQ0!VU%<M'\0_"TNH_85U6/S]VW!5@N?\ >QBM^[U"
MTL;)[RYN$CMU7<9">,?UH M45R^F_$'PQJUZMG9ZFCSM]U61ES^)&*OZUXHT
M;P\%.J7J0;N@P6/Y"@#9HK(T7Q)I'B*-I-+O4G"G#  @C\#S5;6?&GA_0)Q#
MJ.H)%(?X0"Q'UQG% '0452TO5;'6+-;JPN4GA;^)3T^H[5:D)6)B.H!Q0 ^B
MO"(=<^(^N:M?Q:)>R2Q6\NTC$0"CMU%=IX,D\:64M]<^,)&%E%#O4ML.,9)/
MR\]* /0Z*Y6/XB^%I3 J:FK-.VV,"-LDYQTQQ5O6?&6@Z!(D>I:@D,C=%"EB
M/J .* -_-)FJ&E:S8:W:"ZT^Y2>$]U/(^H[5F:MXY\.:'=?9K_4DCF[JJE\?
M7 .* .CHS52PU"TU2U2ZLITFA<<,A_SBN8\>^-?^$4LX8K6$3ZA<G$49Z#W-
M '945X?-J7Q6AA.J.LJV@'F&,",X7Z?>KTGP1XGE\3^'UOKFV-O,IVN,$*?<
M9[4 =/FBN6N/B%X7M-0^Q2ZI&)\[<!6(_,#%;5WJ]C9:6VI3W"BT4;C*OS#'
MX4 7Z*Y27XC>%8(H9'U:/;.,IA&/?'( X_&N@&I6;:>+\7,?V4KN\W=\N/K0
M!;I,US%G\0?#%_J LK?5(S.3@!E90?Q(Q73]1G.0: #(I:\=\6Z]XSD\=2Z+
MX=O'&$W+$%3ZGEA2Z;%\61J=L;UY/LWF#S1NA^[WZ4 >PYHK'UGQ)I/A^)9-
M4O$@#=!U)_ <UPVI^.);SQQH$&BZGOTV[<"5%4<].N1D4 >H9%+7#)K<EOXZ
MO(KCQ!&UG#"SM8^2=R 9YW;>?SK'\._$^'4O&%Y:7ETD=FQ6.S58V^=L_3B@
M#U'-%<5X<U:>?Q-K$5QKT=Y# NX6RPE3 !CJ<#/YU;;XB>%E@EF;5$"1/Y;@
MHV<_3&>U '545G:3K>G:W8_;-/NDF@[L.,?4'I65_P )[X9747L#JL0G3)/!
MV_\ ?73]: .FHK+T7Q!IGB&"2?3+GSXXW*,P4C!_&M2@ HHHH **** "BBB@
M HHHH *S/$'_ " KKZ#^8K3K,\0?\@*Z^@_F* //J***U,@HHHH&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4#(((X(Z&BB@#K-!U_>%M;MOFZ(Y[UT^:\M!(((/3I[5U>@Z\'"VE
MTWS=$<]_:H:*3.HHI!TXI:DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,R]
M_P"/D_054<$HP'4C JW>_P#'R?H*K4T2>6?#S4+/3-<U>PO72"Z>8E3)QD>F
M:T_B;J^G-X=:Q6:.:ZG8>4J$,1SUK0\3?#O3/$=P;KS&M;EOO2(N0WU'%4-%
M^%.EZ9>+<W-U)>%#N163: ?IDYH&<OXIM%,7A&UO<JK0 .">G2MKXDZ3IFG:
M+9W5C!%;W44JK&8@%)'?IU[<TSXF6L=UXBT&VDR(WW*=O&!D=*V8OAQ ^HQ7
M%_JUY>P0G,5O,20GMG- '.^+(!J/B3PW'=KD2A X]>>E6/'=C:Z7K_A^2QMX
MK=C,BDQ*%R,^U==JWA.+5=<L-3-TT1LR"L83(;!]<TOB+PG'XAO+"Y>[: V<
M@<*J9W8.?7B@#CM;L[5OBQI$9MH2DBDNNP8;Y3U'>CQ/86UW\4-)M)8U^SE0
M#&%XP .,5U'B+P3'KNIVNHPZC-8W5N,"2)<D_J,5(_@X2>(-/U>34)7EM$"%
M63/F8&,DYH Y?Q':6VF_$?0#901V_F.%81J%!Y'85#=RG5/&>I0Z-H]O-=1C
M;-<W;;U7Z*<@#Z"NSU?PI'JWB#3]6:[:-K-MPC"9#?CGBL[4/A]%<ZU+J5GJ
MMU8M.<S)#_'Z\Y&* .7^'2S17?B**5D.V)MWEC"YQV%1^'?^2?\ B3'_ #V/
M\Z[/0? \/A^ZOY+>^D>*[0H8W3[N>^<\T6'@>*PT+4=+%\[K>ON,AC *<YZ9
MYH Y?1=#TX_"JYN&M(GG=&;S60%ASV/44GAO1-/E^&-W=36T<MP\;_O&4$C
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MORO]3GW]* .OHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJK!K^P@N".AD2M&B@"G8:38:7$8[&TBMU/41K@&KE%% !1110 4444 %%%%
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M5/114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P">T'Y?_6H\O5_^>T'Y?_6H TZ*S/+U?_GM!^7_ -:CR]7_ .>T'Y?_ %J
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M/+U?_GM!^7_UJ -.BLSR]7_Y[0?E_P#6H\O5_P#GM!^7_P!:@#3HK,\O5_\
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>/+U?_GM!^7_UJ -*EJI:)>J[&Z>-ACY=E6Z /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmz2lq4320rk000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" --!&4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V>BBBNDXP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"[8_=?ZBBBQ^Z_P!116$_B.FG\**5%%%;G,%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% @HHHH
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444""BBB@84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!=L?NO]111
M8_=?ZBBL)_$=-/X44J***W.8**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRB91NB?/8U=^&#LWA&)G8D[N]3>[*Y=+G:TF?6LJ\\2:-I\ODW>I6\,G]UW
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M!LX'Y5ZMGFKB9S.*^*?_ ")LO^^*\IFL3'X*TC5D',5R\9(_WB?Z5ZK\4_\
MD3I?]\5RVBZ=_:/P<G0+ET=V4^F&-3):EQ>AF>,]9_MX:%9Q-N)1=P'<G%-M
M;1;#XH6MJHP(=J?DM9WP[L&U/QC:>9EDMP9&SZ#C^M;<_P#R6(?]=!_*E:Y3
M=M#3^*>N79U&VT*UD9%< R8/7/2K,'PIL&T,.\TGVUH]V\'@'%4/BKI-S!K-
MKK<,9>%0 Y Z$=,ULP?%'1UT$%R_VH1X\H>N*?74730Q?AMKEY8ZS<Z#=R%U
MC#%<GH5K(6.7QW\0)HKF8BV5SM / 4&M/X<:1=:GX@NM>GC*12!L$C@ECVK,
MMYV\#?$*9[R-A;EVPWJI-(#0\?\ @FW\/Z*MYILDBPEPDL3'@DYP?YU=T35Y
M-%^$\MW <2EMB'T)%5OB%XVL==T5;#3=TH+B220#@ =OUJ33-+FU?X1R00*6
ME5O,"CJ<"GL] Z:F%X6L/#VIV\]YXBU(+<.W"NX!^M7/!^IC1/'9TZSO/M&G
M32;%.[*GT-5/",WA2*TFMO$-HHN48X9^_M6_X4NO#VJ>)Q#IOA\((FW+<!L[
M1Z]*2N.5BA\7?^1BLS_TR'\Z]@TW_D&6W_7,5X_\7/\ D8[/C'[L?SKU_3/^
M09;?]<Q51W,Y;(MT4459 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %VQ^Z_P!1118_=?ZBBL)_$=-/X44J***W.8**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K-U/0=-UAHVO[5)FC&%W=JTJ*0*Z.=_X0?P[_T#(:?%X,\/P2K+'IT2NARI
M [UOT46'S,S=1T'3=6,37MJDQB&$SVJ_%"D$211KM1!A5]!3Z*8FV9%]X9TC
M4KK[3=V4<DP_B(YK42-8XU1!A5& *?12L%S$U+PEHFK2^;>6$4CGOBHK#P5H
M&FS++;:?&)!R&(KH**+(?,R*:WBN(&AD4-&PP5K"_P"$'\.Y_P"09#714460
M<S.>'@?PX"#_ &9#70*H554< <"EHHL@;;*FHZ9::K;?9[V!9HLAMK#N*9!I
M-C;Z:VGQ6ZK:LI4Q]L&KU%.PKF9IOA_2])D:2QM$A=AABHZTU/#NE1ZDVH)9
MH+HG<9.^:U:*+!=E34-,L]4MS!>0)-&>S"LZQ\(:'IQ<VVGQH7!!./6MRBE8
M=V9NG:%INDO(UE:I"TGW]O>F6GAS2K+4#?V]FD=R2<R#KSUK5HHLA78R6))H
M9(I &1U*L#T(/6J&FZ#IFD.[6-JD+/\ >*]ZTJ*+!<RK;PWI-G?F^@LT2X))
M+CKD]:L:EI-EJ\"Q7UNLR*<@-ZU=HHL%V5K2PMK"U6UMHECA7H@Z5D7O@KP_
MJ$QEN-.B9R<D],UT%%%@NREIVD6.DP^58VZ0I_LBKM%%,+LJ7^FVNIVQMKN$
M2Q'DJU,M-(L;&P:RM[=4MSG*#ISUJ]118+F7IWAW2M*F::RLTAD88)7N*#X>
MTMM2_M VB?:LY\SO6I24K!<CGMXKJ)HIXU=#U4CBN?\ ^$#\-_://_LR+?G-
M=+246'=HBM[:&UB6*"-8XP,!5&!5+5- TS65"W]JDV.A(YK3HIV0KO<Q(?".
MAP6;6D>GQ"%OO#'6M"PTVTTVV%O:0K%%V4=*MT4K(+LP+_P;H.I2F:YT^)G/
M);IFK^F:)IVD1>78VJ0K_LBM"BBR#F9F:CX>TO59UFO;1)I%& S5HQHL<:H@
M 51@ 4ZBF%PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"[8_=?ZBBBQ^Z_U%%83^(Z:?PHI4445N<P4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:3- !11FC-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3R!A;N#LSWX/2NQ7X:>$(W#KHL>X'(_>/_C72PVMO!;?9X84CA VA%&!C\*
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MD#$YS]34%AX3T33'NGL[%8FNE*S$.WS _4T >*1Z7-\1?B!? 730Q1$[9!U
M'I^5;VL?"">'2YY_[;N;AHD+B-VR#BO3M(\+:+H,LDNFV*P/)]]@S$G\S6NZ
M+(C(PRK#!![B@#R'X7^)1:^%=4LKF7$E@&= QYQ_^LUS'A3PG<>/-5U'4FOI
M;;$A(D0\G/\ ]:O8D\!>&HWN&33%4W Q+B1QNYSZUI:/H&F:! T&EVBV\;')
M523G\S0!XYXM^%MQI.BRZB-5N+MH>=LAS@5W_P +M<&L>#X%=P9[;]TXSR,=
M/TKL+JTAO;:2VN8Q)#(,,I[BL_1O#.D>'_-_LNS6W\WEP'8Y_,T :XI:04M
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M HHHH **** $Q1@4M% "8HQ2T4 )@48%+10 F!1BEHH 3%&*6B@!,"C%+10
MF*,4M% "8HP*6B@!,48I:* $P*,"EHH 3%&!2T4 )@4 8I:* "DQ2T4 )BC%
M+10 F*,4M% "8HQ2T4 )BC I:* $Q1BEHH 3%&!2T4 )@48I:* $Q1BEHH 3
M%&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2UM-/GMM/C8;S*,8]: -WQOK4LWPKL'D8B:Y1%//7'_ZJJWV="^"4<6=DER
M!^+9_E4?Q1LVC/A_0[9':.+:#M!(]*/BC'*FC>'](A1VQM8A5)'3% %K1=%L
M(?A#--J,(D0*TJ L1\QX'3ZUF?"KP[IT^EWFMWUL))+8DQ')&T@5TOC&RN[/
MX5V]E:1,_P"[3S0HY X/\ZH_"O58[G09/#_V"XCEV.9)F4!3G./?O0!QFG76
MF^*?&]U>>);W99QEMB.3@C. HQ4]Z^DZ+\0].N/"]SFW=U#*C''/!'/6GV<9
M\!>([Z+6=!-_:RL3&WEA^,Y!&>.E=IX/UBU\0ZR1'X/AMK1?F2X,*AE/O_\
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M1[^^;3/$FGVTC&,*SQXR5P<\BJ&L_$74?$>AIHVG:/=1W<JA)&*\'UQ0!?\
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MACC39'&J+_=4 #\JEHH @CM((23%!%&3U**!FB.SMXG+QP1(YZLJ $U/10!
MMI;I+YJ6\2R'JP09_.B6U@G8-+!'(1T+H#BIZ* &A=HP!@>@IU%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444TG')H =15&35K&
M*41/=Q[R<;<\U;#97(/% #Z*SY=9TZ";R9;R%9/[I:KJN'4,I!4\@B@!]%,=
MU1"[, H'))Z52AUC3[F;R8;R%Y,_=#4 :%%(.E+0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !2&EI&R5P#@^M $%Q=6]K'OGF2-?5CBI$=7164Y5AD$=Z
M\*^-&F7EA-I=XVK74RS7(5H68A!W&!GVKVO2!_Q)[/\ ZXK_ "H MDXYS6>V
MO:6MW]E-_ )\XV;N:XGXL>,+C0M-M],TYRFH7[B-6!Y1>Y'O5Z#X<:/%X5^Q
M26ZO>^5EKMA^\,F/O9ZT =RI!&0>*;++'#&9)'5$'5F. *\U^%'BRXU&*^\/
MZG*7O].?8'8\NGK^GZUF>*M;G\6_$:T\&03.FGI^\O-AP7 /2@#U"UUO3+Z4
MQ6M[#+(/X5;FK_6O-/'WA6ST?PTVKZ!;I97U@-Z/"NW('8XKHO!OBR+Q%X,@
MUECM(0B8?W6 YH Z&\O[6PB\VZN(X4]7.*;9ZC9ZA%YEI<QS+ZH<UY-X2<?$
MCQGJ6J:H//TRQ;R[6W;E,\Y)'KTJ3QLR_#;Q#I^NZ8GD:?</Y5W;IPI'KCUY
MH ]?JC=ZSINGN$NKR*%FZ!FYK'\4^*H=!\'3:VI#?NMT0_O$CBN7^'OARVU_
M03KVOP+>WM^2V9ANV+V STH ]+AFBGC$D4BNA&05.0:EKQ_0-7E\'_$R;PM+
M(3IMT-]J&/\ JR>P]J]>!H =1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -+
M8%>6>(_%^H>(O%(\)^&9?+9?^/RZ'_+->X'OBNU\::O_ &%X1U+4 </' P0_
M[1!Q^M>-_"+3_$5QIU_JVGQPI-=2$FYF.30!Z_HO@S2-(B5O)\^YZO/-\S,?
M6LSXF^+CX1\+-)!@7ERWDP#T)[_@.:Y:W^(FO>&?%\6A^+88_)G($-Q'P#GC
M^=8GQZG-QKGAJW!S"Y60>^6(_E0!W7AKP-IUYX6CFU6+[1?7D?F2S/RP)Z$'
MVXK*^&_B2[M?$FJ>#]2F:1[-S]G=CDE.H'Y&O2M,0)I5FHZ"%!_XZ*\-FD-K
M^T:_E<>9M#8_W!0!TGQ$\2W-_P"+]-\&:;,8_/8-=LIY"]=OY5K>*O UC9^%
MIKG18OLNHV4?FQ31\,2O)SZY&:\]T)FU#]HRX>8Y*.V/P0BO>=6 ;1KY3T-O
M)_Z": .:^&WB\^+O"L-W+@747[N;_>'>NRS7AO[/TK>9KEO_ ,LTE)'YU>\:
M?&2^\+>*;K28M+,R0A</SSD ^E 'LF:,U\^?\-":C_T!3^O^%6=,^/E[?:O:
MV4FE"/SI A);IG\* />Z*0<@4M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$XH \
M=^/7_'AHG_7XO]:]6TC_ ) ]G_UQ7^5>4?'GFPT7_K\7^M>K:0?^)/9_]<5_
ME0!X5\3)6N_C/H-LYS&KC KW\C]V1[5X7\7+)M.^(?A_72I$ D"LW8'BO<FD
M7[.9 1MVYS0!\^>#IVM/V@=7BC.$=9@0/]X59^'#&\^-6MW$G++O49^M2?#'
M37UCXLZ_KH7-O"73=_M,>/Y5)X4@.@_'K4;68;1=([QY[\T >M^,8U?PAJJM
MT-NW\J\1^&VH30?"GQ/&C$"$LR^V0?\ "O9/B!>+9^!M5E8XS RY/N*\Y^%W
MAB67X2:GYB$2:B7*C'5<<?S- %W]GZ$#PC=3?Q/<MD_E4WQ^16\#QD]1+Q^E
M5_@+,8-'U+2Y>)K>Y.Y?3/\ ^JG?'Z8R>&;&PB!:>>?"H._2@#EO'VH32_ O
MPYEC^]5=Q]<&O9? L*Q>"]+0# \D5YQ\1_"\L?P7T^VC0E]/C5B .@ZFO0/A
MU>)>^!=+E0Y BP<>U 'E?Q6D-G\6?#L\7#^;'DCO\]>H>./%D_A+PPNIP6OV
ME\@;,XZXKS7QK:MK_P ;]&LHAO\ LS)))CL V:]QEM(+F$0SQ))&!]UAD4 >
M!_\ #0NJ_P#0 '_?9_PI#^T-JB@LV@J .I+G_"O=/[ TG_H'6W_?L5R7Q*T;
M3;?P!JLL-C CB$X94 (H G^&_CF;QQI,U[+:K;F-]NT-G/ KMA7C7[/'_(JW
MG_7?^@KV:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#D/B9ITNJ?#_5;>$$R"(N!Z[>?
MZ5S_ ,#KF.7P(D*G$D4I5QW%>ER(LD;(XRK#!'K7G5KX,UKPEKMS?>&&@FL[
MMMTMG.^P*?4'G^5 '/\ QXLEG?P^\2YN3=*JXZD9JC\9=(N$T/PSJQ4L;0QQ
MS'^Z.O\ ,UWT'A/4-:UZ#6?$K0DVO_'M:1?,J'U)[G\*Z;6M&M-=TB?3;R,-
M#*NT\=/0T .T.Y2[T*QG0@J\"$?E7B^B6K:]\?=2O8QN@M#@MV!"@5V5AHOC
M;0M/;1=.ELIK,96&ZE<AXE/^SWQ]:W_!_@ZV\*VDNUS/>7+&2YG8<NQY/X4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYR^*__)8]&^J?TKZ-KYR^*_\ R6/1OJG]* /HQ?NCZ4M(OW1]
M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N/^*'_).M7_ZXFNPKC_BA_P DZU?_ *XF@#BOV>/^15O/^N_]
M!7LM>-?L\?\ (JWG_7?^@KV6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 449I,T +129I: "BDS2T %%)FES0
M 44F:* %HHHH *X_XH?\DZU?_KB:["N/^*'_ "3K5_\ KB: .*_9X_Y%6\_Z
M[_T%>RUXU^SQ_P BK>?]=_Z"O9: "BBB@ HHHH **** "BBB@ HHHH ****
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M5["=IF=$<CN"V#7LNJZYI^B:>M[J$ZPP''S&@#4KC_BA_P DZU?_ *XFH_\
MA:O@_P#Z"\5<SX_^(OA?5?!6I6=IJ<<D\L1"(.YH J?L\?\ (JWG_7?^@KV6
MO&OV>/\ D5;S_KO_ $%>RT %%%(: %HIM** %HI** %HI** %HIN32T +12"
MEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)2TE '$_$+Q@_ARQ@M+-0^I7S^5 K=!GN:X7Q1\&I?[*CU?3+N0Z[$
M/-GD&!YK]21CIS72?%3PU?W[:=KNF0F>?3I=[0CDLOM706OC_0[K2A<M+)')
MM^:W>,B0'TV]: .<^$_C:Z\2:7=:5JV1J=B-CEA@N.>?TKD?AU$;'XUZW;R\
M.^]AGTS7:_#OPY-'K>L^)KBV:U_M&7,$##!5.>H]\BL_Q=H-UX<\>V?C6PMW
MFMON7L<8RP7CG H [GQI,(/!NJR,< 6[?RKQCX::7-<?"?Q)*J'_ $@LJ^^
M?\:[;QKXEC\5Z&-!\.K+<W5[A68(0L:]RQ[5UWA7PQ;^'?"EOHJ@,JIB0_WF
M/4T <'\ )5/A"ZA_C2Y;/Z4_]H"4)X)A0GEYL ?E4?A^VD^&GC+4+>]1QHNH
M-O@N%4E8VYX..G44[Q);-\3?$VGV-G%*=&LW\RXN'0JKG/1<]>E ',?$#29X
M/@9X>4J<VZKO'IDU[%X&E67P9I;J>/)%.\2^&K?7O"L^BL JM%L0_P!TXXKC
M/ WB2/PIHTGA_P 1"6VN;%B$8H2)4[%3W[T <I\4(SJ'Q>\/6L7+B6/..PW5
MZYXI\)6GB[05TN]EECBX.Z(@'CZBN*\,>'[KQ+\0+CQC?V[PVL8V6:2##-_M
M8/3K7J^.* /'?^&=O#G_ $$=0_[[7_XFL'QC\$-"\/\ A:^U2WOKUY8$+*KL
MN#^E?0&*X_XH?\D[U<_],30!Q?[/'_(JWG_7?^@KV6O&OV>/^15O/^N_]!7L
MM "'I574+Z+3K":\G)$4*EW/L*MGI6!XS_Y$[5?^O9_Y4F[ <T/C'X:=0R_:
M2IZ$0L0?TIW_  N'PWZ77_?EO\*Y#PE;6[^%-/9H(R2AR2H]36S]CMO^?>+_
M +X%?.UL^5.HX<NQZ4,!S13N:W_"X?#7I=?]^6_PH_X7%X:]+K_ORW^%97V.
MV_Y]XO\ O@4?8[;_ )]XO^^!6?\ K$OY"O[.\S5_X7%X:]+K_ORW^%'_  N+
MPWZ77_?EO\*ROL=M_P ^\7_? H^R6W_/O%_WP*7^L2_E#^SO,U/^%P^&_P"[
M=?\ ?EO\*WO#'C32_%GV@:<SDP$!PZD8S7&BTMLC_1XO^^!4?PG15\3^*%4!
M0)QP!]:]'+\T6,FXI6L<^(POL8WN>M"EI ,4M>N<84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7SE\5_\ DL>C?5/Z5]&U\Y?%?_DL>C?5/Z4 ?1B_='TI:1?NCZ4M !1110 4
M444 %%%% !1110 4444 %%%% 'EOQW!;P1&H.";E,'\17B"Z7>;!B_?IZ5[C
M\=/^1+A_Z^H__0A7DB?ZM?H*]3+Z:DG<\W'U)0M8RO[+O/\ G_?\A1_9=Y_S
M_O\ D*UJ6O2]A$\[V\S)_LN\_P"?]_R%)_9=Y_S_ +_D*UZ*/81#ZQ(R/[+O
M/^?]_P A4-YIUTEG*S7KL IR,#FMVJVH?\>$_P#N&HJ48J++IUY.2N?0GPV_
MY$+2O^N5=;7)_#;_ )$+2_\ KE765\X]&>^A:***!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %34=0MM*L9+R[<I
M!&,LP&<"N6_X6KX1_P"@BW_?EO\ "M7QFMJWA34!>%Q!Y>6V'GV_6O*_!?PL
MT_Q!HPU.\NIECF9O*2,C*@$CGB@#O_\ A:OA'_H(M_WY;_"M_1?$>E>((3+I
MMVDP'5>C#\.M>*^,OAYIGA2\L+AKF:2PN)A$Z9&\<'D<5?TC2X_"'Q(TNVTV
M>62TOH\_.><%=U 'N%%)2T %%%% !1110 W;D56_L^T\SS/LD._^]Y8S5NB@
M!H7 QVI&0.I5@&4]01FGT4 5HK.V@),-O%&3U*(!4^#3J* (9;>*=-LT22+_
M '74$416\<"[8HDC7T48%344 -P:AEL[:=@TUO%(PZ%T!-6** &*H0!54!1T
M %/HHH *X_XH?\DZU?\ ZXFNPKC_ (H?\DZU?_KB: .*_9X_Y%6\_P"N_P#0
M5[+7C7[/'_(JWG_7?^@KV6@ K!\9_P#(G:M_U[/_ "K>K!\9_P#(G:M_U[/_
M "I2V!'F/A#_ )%/3O\ </\ Z$:VZQ/"/_(I:?\ [A_]"-;=?G&,_CR]3Z2C
M_#04445S&H4444  ^\*K_"G_ )&GQ3_UW']:L#[PJO\ "G_D:?%/_7<?UKZ+
MAW^++T/.S'X4>LT445]>>.%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Y?%?_ )+'HWU3^E?1
MM?.7Q7_Y+'HWU3^E 'T8OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%%
M !1110!Y?\<_^1+A_P"OJ/\ ]"%>2)_JU^@KUKXYG_BBXO\ KZC_ /0A7DB%
M?+7YEZ#O7K9:TD[GE9C%MJPZEIN5_O+^=&5_O#\Z]7GB>9RR'44W*_WA^=&5
M_O#\Z.9!RR'56U#_ )!\_P#N&I\K_>'YU7U C[!/\P^X>]9U91Y&:4HRYT?0
MWPV_Y$/2_P#KE765R?PV_P"1#TO_ *Y5UE?,O<^C6PM%%%(84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !32:=3'&Y67.,C
M% %#5K"'7-(NK%I!ME0H2#G!KQ!M-\?>"9WLM,:=K9B2AA02 C/T.*[.]\ ^
M([6\>?1?$4B+)*9&CFY R<X'%5F\0_$+P^LLNHZ0E] IVJ8\,3SUPIS0!S5A
MX9\9>-=3@N==:5+:!P6,RA>GHO'\JZ;0_#FJ:A\06U*\1X[+3QY<&\8R -HQ
M^%7++XO:<;F&UU33[NQF;ARZ'"GZ=:]$@F2X@CFC.Z.10RGU!Y% $M+110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_%#_ ))UJ_\ UQ-=
MA7'_ !0_Y)UJ_P#UQ- '%?L\?\BK>?\ 7?\ H*]EKQK]GC_D5;S_ *[_ -!7
MLM !6#XS_P"1.U;_ *]G_E6]6#XS_P"1.U;_ *]G_E2EL-'F/A'_ )%+3_\
M</\ Z$:VZQ/"'_(IZ?\ [A_F:VZ_.,9_'EZGT='^&@HHHKF-0HHHH !]X57^
M%/\ R-/BG_KN/ZU8'WA5?X4_\C3XI_Z[C^M?1</?Q9>AYV8_"CUFBBBOKSQP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\2>);/PQ8+>7P<QEMORCFM
ML]*X+XKR6D?A)OM5NLQ9\1[F("GUXH J?\+H\.?W+C_OFC_A<_AS^[<?]\TS
MPW\+O"TNAV\UU;?;)I%W-)YK#KVX.*Y6_P#"GAK0O']KIDUM]LL[XJ@C\Q@8
M6)P.A_G0!Z_H7B+3O$-H+BPG60?Q+W7ZUK5Y#X#M%T3XDZMI5H2+-5RJYSCB
MO7J "FEL=>U+FN/\8ZO<NT6@:4Q^WWORLZ]88S]YOKC- %W2O&FDZSX@N]'L
MIO-N+7_6%?NUT+R+&C.[ *HR2>U>"?""R73OB;KUHCLXB&W<QR2<<G\ZZWXU
M^)YM$\-0Z?:.4N=1E$6Y3RJYY_/D4 =!/\1=(CGE6*.XGAB.))HHRR+Z\XKI
M=.U*UU6RCN[.=)H7&0RFL;PAH=KIWA"QM/(0AX 9,C.XMR<_G7G7@/4Y/#OQ
M0UKPJ[G[))(985/121NXH ]=U/5;32+)[N]F6*%1R2?Y5SMM\1-(FN(HYDN+
M:.8[8YIHRJ-^.*\_\::L_B?XN:7X75S]BM6#S(#P[8W<_A7H_C/0+75/!E_9
MB)%\N O$5&"A49&/RH Z9&#*&4@J>00>M.KS3X,>)Y]>\)?9[QR]S9-Y18]2
M!TKTH&@!:^<OBO\ \ECT;ZI_2OHS-?.?Q7_Y+%HW^\G]* /HQ?NCZ4M(OW1]
M*6@ HHHH **** "BBB@ HHHH **** "BBB@#"\4^%;'Q=I8T_4"XB#A\H<'(
MKC?^%'>'/^?F]_[^5Z?134FMA-)[GF'_  HWPY_S\WO_ '\H_P"%&^&_^?F]
M_P"_E>GT4^>7<7)'L>8?\*-\-_\ /S>_]_*/^%&^'/\ GYO?^_AKT^BGSR[A
MR1['F'_"C?#G_/S>_P#?RD/P,\-D$&XO"/\ KI7J%%+GEW#DCV,_1M)M]$TN
M#3[7=Y,*[5W=<5?I:*DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *8Y(1B.H%/I,4 >)ZC\3/%]MJ-S!#I!:*.5E
M4^0_(!XJL?BGXS[Z,?\ OP]>W2K;Q1M+*L85069B!Q7E&O?%U+?4)+;0](BO
M!$V'D=#@_3'- '/2^._$-_*!=>&8)"Y"LS6C;L?7%>Y:4=VDV9*>63"GR?W>
M!Q7G7A7XIVNK7Z6&KZ='8W,APC*ORD^G/->H+@@8QCMB@!]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<?\4/^2=:O_UQ-=A7'_%#_DG6
MK_\ 7$T <5^SQ_R*MY_UW_H*]EKQK]GC_D5;S_KO_05[+0 AZ5A>,_\ D3=6
M_P"O9_Y5NGI6#XS_ .1.U;_KV?\ E2>P'F7A'_D4]/\ ]P_S-;=<!X<D\6KX
M?LQ9Q6A@"G9N/.,FM3S?&O\ SPL?SKX?%8'FK2?.MSWZ56T%H=717*>;XU_Y
MX6/YT>;XU_YXV/YUS_4/[Z-/;>1U=%<IYOC7_GC8_G1YOC7_ )X6/YT?4/[Z
M#VWD=6.HJO\ "K_D:?%/_7<?UKG1+XVS_J+'\ZV?@V;LZYXE-\$%R9EWA.F>
M:]O)<-[*HWS)^AP8ZIS16A["*6D%+7TQY84444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO#OB>R\10N;<E)XCMF@?AD/O6[0 5Q_Q0_Y)UJ__ %Q-=A7'_%#_ ))UJ_\
MUQ- '%?L\?\ (JWG_7?^@KV6O&OV>/\ D5;S_KO_ $%>RT !Z5@>,_\ D3M6
M_P"O9_Y5OU@^,_\ D3M6_P"O9_Y4I;#6YYCX0_Y%/3_]P_S-;6*Q?"'_ "*>
MG_[A_F:VZ_.,9_'GZGT='X$)BC%+17/<U$Q2T447 !]X57^%/_(T^*?^NX_K
M5@?>%5_A3_R-/BG_ *^!_6OH>'OXLO0\[,?A1ZR****^O/'"BBB@ HHHH **
M** "BBB@ HHHH ***,T %)FC-)0 N:6FTM "T4E% "T4E% "T4F:6@ HHHH
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M'WA5?X4_\C5XI_Z[C^M?1</?Q9>AYV8_"CUFBBBOKSQPHHHH **** "BBB@
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M,Y1)A@L!DCO7E%]\,/"&G2B.\\1/$Y&=I _I0!V2^*?A^6 6XTS<3@?Z-_\
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MO^%=K\<$63PYIJ. RF\0$'OR*XQ=#TO8O^@0=!_ *]/ <^O*>-FGLM/:"?\
M"0:1_P _\7Z_X4G_  D&D?\ /_%^O^%/_L/2_P#GQ@_[X%']AZ7_ ,^$'_?
MKTOWQX]\-YC/^$@TC_G_ (OU_P *7_A(=(_Y_P"+]?\ "G?V'I?_ #X0?]\"
MC^P]+_Y\(/\ O@4?O@_V;S&?\)!I'_00B_7_  J"^U_26T^Y5;^(LT3 #GDX
M^E6O[#TK_GP@_P"^!5>^T73%TZY9;& $1,0=@XX-14]KRNY=+ZMSJUSU+X0?
M\DVTSW,G_H9KNJX7X0?\DUTW'J__ *&:[JOGI;GUL=D+1112&%%%% !1110
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M **** "D-+2&@#S'XU0SR^'+!H())C'=JS+&,G (KSY?$)VC_B5:CT _U/\
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MGQ8\/:EJEK906%RLL\JQHS1K@$G [T >D@]*=30>E.H **** "BBB@ HHHH
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M>;:RR+:(^QUA.Q<9[XZU[MIT+VVG6L$A!>.)5;'J!B@"Y1110 4444 %%%%
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MQ_Q0_P"2=:O_ -<30!Q7[/'_ "*MY_UW_H*]EKQK]GC_ )%6\_Z[_P!!7LM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7#?%(WS>%6AL;47#2-M9"F[CVKN:81D\T ?/^F^+OB'IEC':0VC
M/'&,*98-Q_/-;6B^-?']WKEC;WMHJVTDZK*?LV,*3SSFO9P!Z"@@>@H !V-.
MIHZTZ@ HHHH **** "BBB@ HHHH **** "OG+XK_ /)8]&^J?TKZ-KYR^*__
M "6/1OJG]* /HQ?NCZ4M(OW1]*6@!#7C_C3_ )*O8?\ 7JW\UKV UX]XS_Y*
MO8?]>K?S6N3'?[O+T-L/_$1HT4G>EK\[:/H@HHHI#N@HHHH"Z.:\5?\ 'YHG
M_7\G\Q7N4/\ J4_W17AOBG_C\T3_ *_4_F*]RB_U*?[HK[G)?]U1X6._BDE%
M%%>N<84444 %%%% !1110 4444 %%%% "52U:Z>QTJ[NT +0Q,Z@]R!5VLOQ
M'_R+6I?]>S_R-"!GD-E\5?&-_;+<0:7:&-CQE_\ ZU6/^%D>-O\ H%6?_?P_
MX5S7A3_D7;?\?YUM5[-+ 4Y04F?.U\TK0J.*+?\ PLCQM_T"K/\ [^'_  H_
MX61XV_Z!5G_W\/\ A52EK3^SZ9C_ &O7+7_"R/&W_0*L_P#OX?\ "C_A9'C;
M_H%6?_?P_P"%5:3\:/[/IC_M>L6_^%D>-L?\@JS_ ._A_P#B:[#X<^,-2\51
M7PU*WBAEMI-F(SD=_;VKA.U;_P '?^/C7O\ KY_QKBQ>%A25XGHY?C:F(DU(
M]7HI*6O//6"BBB@ HHHH **** "BBB@ HHHH **** "D) '-+4;J61E]1B@#
MEM=^(?A_0]RRW0EF7_EG'R:\]U;XNZU?F9="T[RX4&?.==QV_3M^=8NO> _$
M>D:O=:DVF0WUN\CR8'[Q0"3U&*TK;XCV$6@W6EWNB?89C!Y:O",Y/TXP* ,[
M0?#GB7XB2?VC=ZB7BADVYF<G SDA17O]E;?8[*"V!SY4:IGUP,5YI\&K^T70
M+B%[A%E\XG:3@\UZF"* %HHHH **** "BBB@ J*XN8;6%IIY%CC499F. *D.
M*\9^+VO7VI:;?Z;I#XM+-<WLX/&>R#]?RH ]@M;N"]MUN+:59(7&5=3P:?+/
M'!&9)7"*.22>E<9\)^?AMHY)S^Y')^@KE?$VMS>*_B9:>#H)633XOWEWL/+X
M/2@#U&UUS3+Z7RK6]BE<?PJW-7\UYMX^\,6VD>&'U70XEM+ZP^='C&,@=0:W
MO!?BR+Q%X*M]:D(5@A$X'9@.: .BO-0M+"+S+NXCA3U8TEGJ5GJ";[2YCF4=
M2AS7DW@^0_$;Q?J6J:C^]TZS;R[6 \IGGD^_2G^.''PYU[3M>TQ3%8SR>7=0
MKPK#CGZ\T >P9JA=ZWIMA(([J\BB<_PLW-8OBKQ7#H7@R;6T(.8MT7N2.*YG
MX=>&[?6O#_\ ;NN1B[O=0)8F3G:O8"@#TN&XBN8A)#(LB$<%3D&I,UX_H6K2
M^#OB?-X7DD8Z;=C?;*Q_U9]!7KXH =7'_%#_ ))UJ_\ UQ-=A7'_ !0_Y)UJ
M_P#UQ- '%?L\?\BK>?\ 7?\ H*]EKQK]GC_D5;S_ *[_ -!7LM !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6)XGU^'PYHLU_,-VP?*O]XUMUPWQ2TFYU7PFXMD+O"WF;0.N* .%A\=^,+S5
M[&ZDA>VTRZE"H2GRL,^M==;^-KVU\>_V-J,)2UN,"!V&.3_]>N U3XA6M]IF
MC6LMH\4UC*&D Z$#'3\JU+;5YOB!X]TJ:TM7CM+%E=G(]#F@#V\4M-48IU !
M1110 4444 %%%% !1110 4444 %?.7Q7_P"2QZ-]4_I7T;7SE\5_^2QZ-]4_
MI0!]&+]T?2EI%^Z/I2T -/6O$/B0FHO\3; :;)&D_P!F;E^F,K7N!KQ[QG_R
M5>Q_Z]6_FM<N,ERT)/R-:"O41B?9_&/_ #]6OY4?9_&/_/U:_E7645\.\:[_
M  K[CWO8KN<I]G\8_P#/U:_E2?9_&/\ S]6OY5UE%+ZZ_P"5?<'LO,Y/[/XR
M_P"?JU_*C[/XR_Y^K7\JZRBCZZ_Y5]P>R\SS_4HM?35M&.J3PO#]L3 0=\BO
MHR'_ %*?[HKP[Q3_ ,?FB?\ 7\G\Q7N4/^I3_=%?8954Y\.I6L>/C%:H2444
M5Z9R!1110 4444 %%%% !1110 4444 )65XC_P"1;U+_ *]W_D:U3UK+\1_\
MBWJ7_7N_\C0MQ=#YU\-ZYIEMHD,,][''(I.58\CFM;_A(]'_ .@A#_WU67X;
MT?3KC0X)9K*%Y&R2S+R>:UO[!TG_ *!]O_WS7T%%5>16/E<2\-[5\U[C?^$C
MT?\ Z"$/_?5'_"1Z/_T$(?\ OJG?V#I/_0/M_P#OFC^P=)_Z!]O_ -\UK:MY
M&-\+YC?^$CT?_H(0_P#?5)_PD>C_ /00A_[ZI_\ 8.D_] ^W_P"^:/[!TG_H
M'V__ 'S2_?>07POF,_X231O^@A#_ -]5V'P7GCN&UR6)@T;W.0PZ'K7)'0=)
M_P"@=;_]\UUWP8BC@;7(XD"1K<851T'6N#'^TY5S'JY7[+G?L[GK-%)2UY1[
M@4444 %%%% !1110 4444 %%%% !1110 4TTZF."R,H[@B@!AFBZ&1/3DBL/
M6/#'A_70QOK:!W;K(" WYUYCJ'P?UV[U*YN$OH@LLK. 6/ )S5;_ (4MX@_Y
M_P"'_OLT :VI?"&*"Z2YT/4Q$R-NV,W?/KFO6-/26+3K:.=MTJQ*KG.<MCFO
M$X_@SKZ2*YOX<*0?O&O;-/@:UT^VMW(+QQ*A/K@8H MT444 %%%% !24M(:
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M8?!>EHO3R17G/Q&\+RQ_!C3[6-,R:?&K,!Z=37?_  ZO4OO NF2H<CR@..U
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M^$?!3Z1?W.M:K,MSJ]V<R2*,*@_NBNT HP:6@ KC_BA_R3K5_P#KB:["N/\
MBA_R3K5_^N)H XK]GC_D5;S_ *[_ -!7LM>-?L\?\BK>?]=_Z"O9: "BBB@
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M_"H?"O\ SPF_[['^%3V7PM\-Z??07D$,HEAD#H2XZ@Y':@#M <\BG4T>E.H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3';8K-Z#-/J*?_4R?
M[I_E0!ROASQU!XAU>\L$M'A:U8AG9\@X./2N0\:?%"!+R32].L8[P1-B1I1E
M21Z"N5\.^);3P[XHUD7@=5N'D0,/X<YKH?A$VEW6IZJ)426Y:0M&SC.5S0!:
M\&_%&W:XCTS4;%+/S&Q&T8PH_"O6E8, PY4\@UXE\3M1TN_UFQTW3;<?;X9A
MN=%Q^%>QZ6DD>EVB2_ZQ84#9]<"@"[1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7'_%#_ ))UJ_\ UQ-=A7'_ !0_Y)UJ_P#UQ- '%?L\
M?\BK>?\ 7?\ H*]EKQK]GC_D5;S_ *[_ -!7LM !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8I:** "BBB@!
M,4M%% !1110 4444 &**** $Q1BEHH **** "OG+XK_\ECT;ZI_2OHVOG+XK
M_P#)8]&^J?TH ^C%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *0C(YI:* ,/4O".@ZM()+[3()6'
M0D8_E571?!&C^']4FOM/C>-I5V^7GY5'M734G>@#GH?!FC1:[)K#6_F7;G<&
M?D*?:NA Q2T4 %%%% !1110 4444 %%)FC/UH 6BDS1F@!:*3-)D4 .HI,T9
MH 6BDS1F@!:*3/-+0 5Q_P 4/^2=:O\ ]<3785Q_Q0_Y)UJ__7$T <5^SQ_R
M*MY_UW_H*]EKQK]GC_D5;S_KO_05[+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7SE\5_P#DL>C?5/Z5]&U\Y?%?_DL>C?5/Z4 ?
M1B_='TI:1?NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 <?XR\2:A
MI[PZ5H=N+C5;D$H#TC']X_F*\WUJ[^*?A6'^U[J:*ZME.94C&=H^F:]L&G6P
MU!K[RP;AEV[SV%4_%#P1^&M0:YVF'R6SGI0!F^ O&,'C3P['J$:[)5.R5/[K
M5F>,O&=S9:S9^&]%"/JUX?O-R(E]36/\#M)ET[PC=7DBE$NYB\:G^Z,X/ZUS
M/@Z=M9^/.J7<QW?9U=%SVYH [#7)_$?@>QCUB74&U"U4C[3$ZX('J,5W>D:K
M;:QI-OJ-K(&@F0.K9K-\<VJ7?@O58F (\ACS]*\L^%_B&:W^$VLH7):Q9]A]
M 1P/TH ZM_$^I>+_ !7<Z)H4XMK.R_X^;H#))]!^5#>(]3\&>)K/3-;N?M6G
MWIVQ7+#!5O0_F*QO@#"9-"U&_?F2>Y.6/4_YS4_Q^A!\(6URO$D4V58=1TH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?.7Q7_Y+'HWU3^E?1M?.7Q7_P"2
MQZ-]4_I0!]&+]T?2EI%^Z/I2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28I:
M* &-#&QR44GU(I/L\/\ SR3_ +Y%244 -$:K]T ?04I4,"",@]0>]+10!#%:
MV\!)A@CC)ZE$ S^52X%+10!'+!%.A26-9%/9E!%$<$4*!(HU11V48%244 )@
M5%+:6T[!IH(I".A= <5-10 T*% "C '84ZBB@ KC_BA_R3K5_P#KB:["N/\
MBA_R3K5_^N)H XK]GC_D5;S_ *[_ -!7LM>-?L\?\BK>?]=_Z"O9: "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^<OBO_R6/1OJG]*^C:^<OBO_ ,ECT;ZI
M_2@#Z,7[H^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KC_BA_R3K5_^N)KL*X_XH?\ ).M7_P"N
M)H XK]GC_D5;S_KO_05[+7C7[/'_ "*MY_UW_H*]EH **** "BBB@ HHHH *
M*** "BBB@ HHHH 0]*Y?5/ /A[6=0>^OK%9+A_O-DUU)I* .+_X59X4_Z!J_
M]]'_ !H_X59X3_Z!J_\ ?1_QKM**?,Q<J.+_ .%6>$_^@:O_ 'T?\:/^%6>$
M_P#H&K_WT?\ &NTHHYI!RHXO_A5GA/\ Z!J_]]'_ !H_X5;X3_Z!J_\ ?1_Q
MKM**.:0<J.2L_AQX:L;R&\M]/19H6#HV3P1WKK>P%%%+5C%%%(*6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG+XK_\ECT;ZI_2OHVO
MG+XK_P#)8]&^J?TH ^C%^Z/I2TB_='TI: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_XH?\DZU?_KB:["N/
M^*'_ "3K5_\ KB: .*_9X_Y%6\_Z[_T%>RUXU^SQ_P BK>?]=_Z"O9: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@!*6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,T9H 6B@44 %?.7Q7_Y+
M'HWU3^E?1M?.7Q7_ .2QZ-]4_I0!]&+]T?2EI%^Z/I2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-=U12S'"CDDUQ4WQ
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MX'_Z&"V_[Y?_  H [.BN,_X6OX'_ .A@MO\ OE_\*/\ A:_@?_H8+;_OE_\
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MX'_Z&"V_[Y?_  H [.BN,_X6OX'_ .A@MO\ OE_\*/\ A:_@?_H8+;_OE_\
M"@#LZ*XS_A:_@?\ Z&"V_P"^7_PH_P"%K^!_^A@MO^^7_P * .SI,BN-_P"%
MK^!_^A@MO^^7_P *V-#\5:)XE$IT>_CNA%C>4!&/S% &W12"EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#@/B_X@ET#P-<RP.4FF_=*0>1FK'PKTY-/\!V!"_O)5\R1N[$UR/[1
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M ,_-S_G\:]=HH \B_P"&?/#/_/S<_P"?QH_X9\\,_P#/S<_Y_&O7:* /(O\
MAGSPS_S\W/\ G\:/^&?/#/\ S\W/^?QKUVB@#R+_ (9\\,_\_-S_ )_&C_AG
MSPS_ ,_-S_G\:]=HH ^1_"W@;3]9^*-QX<GDD%I&9 &7K\JDBO6_^&?/#/\
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M-+,\>%1>IK'^"FEWND>##;7]N\$OG$[7'..* /2J*** "BBB@ HHHH ****
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M#4+(C9VL&QUP<UX9X#BE7QA)<3,3)=6S3M_P+!_K75_"9L+KI9N!=#DG_>H
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MJV\QMWESV!QN^N*S[N?7_"&N:,DNN7%^UZP6:WF).WU(YH ]<HI%.5!]:6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YC
MQ[HG]N>$[JV1<S(/-C]=R\X_'%=/2$9H \B\#QZAKWB*VNM2MI$33H/+4N.K
M<_\ UJE^(N@%O$]KJ]S;W4^G>7Y<OV5L.G)Y_6O5A&HZ #Z"E* C!P10!Y3X
M*T?3I?$$VHZ?I6I1001LJ7-W/]XE<$;,>_K5[P':S0KXC\R%DWROMW#KQ7I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[BXLH_/9T5E,R+E$;'<_6@#LLTM<]X-O9]0\,V]S<3--([/EV/)&XXKH!0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmz2lq4320rk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '/"%8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4L1GGIP !UGC;X1IX>\+C5=+N[B[DM5!O8Y$SN7@%XPH^4*<D@D_+D[OE^8
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MB/2 !U)OHO\ XJO!?B[J-W=_$34+6:X>2"R$<=M$3A8@T2.V!ZECDGJ< =
M$D\+^%-4LK%=!\6017_E![Q-8!MTZ#.QMI 8-_!EL@Y#?+R ?2M%<3\,?#VI
M^&_#<EK>ZC97MK-+Y]F;1VD149020QP-K'D #&23D[N.VH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=GC/W>^=O->/^%/&GC75?&,%K9ZN_FZE=AY(9?WL,:@EW"+(V515W?*K*2
M#D"O0?\ A1OAG_G^U?\ [_1__&ZZ_P .>#="\*PA=,LD6<IL>ZD^::3A<Y;L
M"5!*C"YY % 'E_Q/\4^&KC6YM.O_  M<W.IV:/;M<&[%NT88!D*E-X<$-N <
M?+GIRPKF/%'AOP?9Z$-7\/>*#=;BL<=C,@,SMO(8GA2BA03\R8..OS"O=/$G
M@C0/%;++JEGNN4B:*.XC<I(@/TX;!Y 8$ D\<G/)GX&^&2,?;]7'OYL7_P ;
MH Y7X%W>HCQ'J-DCS'2S:&:5-N8UFWH$.?X6*[_]X+WVC'N]9VBZ%IGAW3Q8
M:3:);6X<N54DEF/4DDDD]!R>@ Z 5HT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445RVKZ[XKL]4FM]-\&_VC9IM\NZ_M2*'
MS,J"?D89&"2/PS32;V$VD=317$_\)-XY_P"B>?\ E:@_PH_X2;QS_P!$\_\
M*U!_A5>S?E]Z)]HO/[F=M17$_P#"3>.?^B>?^5J#_"C_ (2;QS_T3S_RM0?X
M4>S?E]Z#VB\_N9VU%<3_ ,)-XY_Z)Y_Y6H/\*/\ A)O'/_1//_*U!_A1[-^7
MWH/:+S^YG;45Q/\ PDWCG_HGG_E:@_PH_P"$F\<_]$\_\K4'^%'LWY?>@]HO
M/[F=M17$_P#"3>.?^B>?^5J#_"C_ (2;QS_T3S_RM0?X4>S?E]Z#VB\_N9VU
M%<3_ ,)-XY_Z)Y_Y6H/\*/\ A)O'/_1//_*U!_A1[-^7WH/:+S^YG;45Q/\
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M^%'_  DWCG_HGG_E:@_PH]F_+[T'M%Y_<SMJ*XG_ (2;QS_T3S_RM0?X4?\
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M*XG_ (2;QS_T3S_RM0?X4?\ "3>.?^B>?^5J#_"CV;\OO0>T7G]S.VHKB?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/_-<
M?^Y;_P#;FNVKB?\ FN/_ '+?_MS5PZ^A$^GJ=M1114%A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7$_#C_F;?^QDO/\ V2NVKB?AQ_S-O_8R7G_LE7'X61+XD=M1114%A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!B>+-<NO#GAVXU:UT[^T/LV&EA$I1O+Z%AA6SCJ<X& 3GCGQ/\
MX7%_Q7'_  DO]A?\PW[!]G^V?]-/,W[MGX8Q^-?0DT,5S!)!/$DL,BE'C=0R
MLI&""#U!':OF?_A6UU_PM+_A%=LWV/S?.^T8.?LG7=NVXW8^3.-N_BNK#\C3
MYCFK\Z:Y3Z \)ZY=>(_#MOJUUIW]G_:<M%"92[>7T#'*KC/48R,$'//&W3(8
M8K:"."")(H8U")&BA550,  #H .U/KF=KZ'0KVU"BBBD,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _Y__P#R#)_\37D]%']FTN[_  _R#^VL1V7X_P"9ZQ_PF6@?\_\ _P"09/\
MXFC_ (3+0/\ G_\ _(,G_P 37D]%']FTN[_#_(/[:Q'9?C_F>L?\)EH'_/\
M_P#D&3_XFC_A,M _Y_\ _P @R?\ Q->3T4?V;2[O\/\ (/[:Q'9?C_F>L?\
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M?_$UY/11_9M+N_P_R#^VL1V7X_YGK'_"9:!_S_\ _D&3_P")H_X3+0/^?_\
M\@R?_$UY/11_9M+N_P /\@_MK$=E^/\ F>L?\)EH'_/_ /\ D&3_ .)H_P"$
MRT#_ )__ /R#)_\ $UY/11_9M+N_P_R#^VL1V7X_YGK'_"9:!_S_ /\ Y!D_
M^)H_X3+0/^?_ /\ (,G_ ,37D]%']FTN[_#_ "#^VL1V7X_YGK'_  F6@?\
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M3_XFC_A,M _Y_P#_ ,@R?_$UY/11_9M+N_P_R#^VL1V7X_YGK'_"9:!_S_\
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MH_X3+0/^?_\ \@R?_$UY/11_9M+N_P /\@_MK$=E^/\ F>L?\)EH'_/_ /\
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M']FTN[_#_(/[:Q'9?C_F>L?\)EH'_/\ _P#D&3_XFC_A,M _Y_\ _P @R?\
MQ->3T4?V;2[O\/\ (/[:Q'9?C_F>L?\ "9:!_P __P#Y!D_^)H_X3+0/^?\
M_P#(,G_Q->3T4?V;2[O\/\@_MK$=E^/^9ZQ_PF6@?\__ /Y!D_\ B:/^$RT#
M_G__ /(,G_Q->3T4?V;2[O\ #_(/[:Q'9?C_ )GK'_"9:!_S_P#_ )!D_P#B
M:/\ A,M _P"?_P#\@R?_ !->3T4?V;2[O\/\@_MK$=E^/^9ZQ_PF6@?\_P#_
M .09/_B:/^$RT#_G_P#_ "#)_P#$UY/11_9M+N_P_P @_MK$=E^/^9ZQ_P )
MEH'_ #__ /D&3_XFC_A,M _Y_P#_ ,@R?_$UY/11_9M+N_P_R#^VL1V7X_YG
MK'_"9:!_S_\ _D&3_P")H_X3+0/^?_\ \@R?_$UY/11_9M+N_P /\@_MK$=E
M^/\ F>L?\)EH'_/_ /\ D&3_ .)H_P"$RT#_ )__ /R#)_\ $UY/11_9M+N_
MP_R#^VL1V7X_YGK'_"9:!_S_ /\ Y!D_^)H_X3+0/^?_ /\ (,G_ ,37D]%'
M]FTN[_#_ "#^VL1V7X_YGK'_  F6@?\ /_\ ^09/_B:/^$RT#_G_ /\ R#)_
M\37D]%']FTN[_#_(/[:Q'9?C_F>L?\)EH'_/_P#^09/_ (FC_A,M _Y__P#R
M#)_\37D]%']FTN[_  _R#^VL1V7X_P"9ZQ_PF6@?\_\ _P"09/\ XFC_ (3+
M0/\ G_\ _(,G_P 37D]%']FTN[_#_(/[:Q'9?C_F>L?\)EH'_/\ _P#D&3_X
MFC_A,M _Y_\ _P @R?\ Q->3T4?V;2[O\/\ (/[:Q'9?C_F>L?\ "9:!_P _
M_P#Y!D_^)H_X3+0/^?\ _P#(,G_Q->3T4?V;2[O\/\@_MK$=E^/^9ZQ_PF6@
M?\__ /Y!D_\ B:/^$RT#_G__ /(,G_Q->3T4?V;2[O\ #_(/[:Q'9?C_ )GK
M'_"9:!_S_P#_ )!D_P#B:/\ A,M _P"?_P#\@R?_ !->3T4?V;2[O\/\@_MK
M$=E^/^9ZQ_PF6@?\_P#_ .09/_B:/^$RT#_G_P#_ "#)_P#$UY/11_9M+N_P
M_P @_MK$=E^/^9ZQ_P )EH'_ #__ /D&3_XFDU'QGX?TIX$O;_RFGA6>,>3(
MVY&S@\*?0\=:\HIGQ#_X_M#_ .P/!_-ZB67TE)*[U_KL=%#-*U2,FTM/7_,]
M._X61X2_Z"W_ )+R_P#Q-'_"R/"7_06_\EY?_B:\ HJ_[-I=W^'^1I_:-7LO
MZ^9[_P#\+(\)?]!;_P EY?\ XFC_ (61X2_Z"W_DO+_\37@%%']FTN[_  _R
M#^T:O9?U\SW_ /X61X2_Z"W_ )+R_P#Q-'_"R/"7_06_\EY?_B:\ HH_LVEW
M?X?Y!_:-7LOZ^9[_ /\ "R/"7_06_P#)>7_XFC_A9'A+_H+?^2\O_P 37@%%
M']FTN[_#_(/[1J]E_7S/?_\ A9'A+_H+?^2\O_Q-'_"R/"7_ $%O_)>7_P")
MKP"BC^S:7=_A_D']HU>R_KYGO_\ PLCPE_T%O_)>7_XFC_A9'A+_ *"W_DO+
M_P#$UX!11_9M+N_P_P @_M&KV7]?,]__ .%D>$O^@M_Y+R__ !-'_"R/"7_0
M6_\ )>7_ .)KP"BC^S:7=_A_D']HU>R_KYGO_P#PLCPE_P!!;_R7E_\ B:/^
M%D>$O^@M_P"2\O\ \37@%%']FTN[_#_(/[1J]E_7S/?_ /A9'A+_ *"W_DO+
M_P#$T?\ "R/"7_06_P#)>7_XFO **/[-I=W^'^0?VC5[+^OF>_\ _"R/"7_0
M6_\ )>7_ .)H_P"%D>$O^@M_Y+R__$UX!11_9M+N_P /\@_M&KV7]?,]_P#^
M%D>$O^@M_P"2\O\ \31_PLCPE_T%O_)>7_XFO **/[-I=W^'^0?VC5[+^OF>
M_P#_  LCPE_T%O\ R7E_^)H_X61X2_Z"W_DO+_\ $UX!11_9M+N_P_R#^T:O
M9?U\SW__ (61X2_Z"W_DO+_\31_PLCPE_P!!;_R7E_\ B:\ HH_LVEW?X?Y!
M_:-7LOZ^9[__ ,+(\)?]!;_R7E_^)H_X61X2_P"@M_Y+R_\ Q-> 44?V;2[O
M\/\ (/[1J]E_7S/?_P#A9'A+_H+?^2\O_P 31_PLCPE_T%O_ "7E_P#B:\ H
MH_LVEW?X?Y!_:-7LOZ^9[_\ \+(\)?\ 06_\EY?_ (FC_A9'A+_H+?\ DO+_
M /$UX!11_9M+N_P_R#^T:O9?U\SW_P#X61X2_P"@M_Y+R_\ Q-'_  LCPE_T
M%O\ R7E_^)KP"BC^S:7=_A_D']HU>R_KYGO_ /PLCPE_T%O_ "7E_P#B:/\
MA9'A+_H+?^2\O_Q-> 44?V;2[O\ #_(/[1J]E_7S/?\ _A9'A+_H+?\ DO+_
M /$T?\+(\)?]!;_R7E_^)KP"BC^S:7=_A_D']HU>R_KYGO\ _P +(\)?]!;_
M ,EY?_B:/^%D>$O^@M_Y+R__ !-> 44?V;2[O\/\@_M&KV7]?,]__P"%D>$O
M^@M_Y+R__$T?\+(\)?\ 06_\EY?_ (FO **/[-I=W^'^0?VC5[+^OF>__P#"
MR/"7_06_\EY?_B:/^%D>$O\ H+?^2\O_ ,37@%%']FTN[_#_ "#^T:O9?U\S
MW_\ X61X2_Z"W_DO+_\ $T?\+(\)?]!;_P EY?\ XFO **/[-I=W^'^0?VC5
M[+^OF>__ /"R/"7_ $%O_)>7_P")H_X61X2_Z"W_ )+R_P#Q-> 44?V;2[O\
M/\@_M&KV7]?,]_\ ^%D>$O\ H+?^2\O_ ,31_P +(\)?]!;_ ,EY?_B:\ HH
M_LVEW?X?Y!_:-7LOZ^9[_P#\+(\)?]!;_P EY?\ XFC_ (61X2_Z"W_DO+_\
M37@%%']FTN[_  _R#^T:O9?U\SW_ /X61X2_Z"W_ )+R_P#Q-'_"R/"7_06_
M\EY?_B:\ HH_LVEW?X?Y!_:-7LOZ^9[_ /\ "R/"7_06_P#)>7_XFC_A9'A+
M_H+?^2\O_P 37@%%']FTN[_#_(/[1J]E_7S/?_\ A9'A+_H+?^2\O_Q-06WC
MSP19^=]EO88/.E,TOE6<B^9(>K-A.6..2>:\'HH_LVEW?X?Y!_:-7LOZ^9[_
M /\ "R/"7_06_P#)>7_XFC_A9'A+_H+?^2\O_P 37@%%']FTN[_#_(/[1J]E
M_7S/?_\ A9'A+_H+?^2\O_Q-'_"R/"7_ $%O_)>7_P")KP"BC^S:7=_A_D']
MHU>R_KYGO_\ PLCPE_T%O_)>7_XFC_A9'A+_ *"W_DO+_P#$UX!11_9M+N_P
M_P @_M&KV7]?,]__ .%D>$O^@M_Y+R__ !-'_"R/"7_06_\ )>7_ .)KP"BC
M^S:7=_A_D']HU>R_KYGO_P#PLCPE_P!!;_R7E_\ B:/^%D>$O^@M_P"2\O\
M\37@%%']FTN[_#_(/[1J]E_7S/?_ /A9'A+_ *"W_DO+_P#$T?\ "R/"7_06
M_P#)>7_XFO **/[-I=W^'^0?VC5[+^OF>_\ _"R/"7_06_\ )>7_ .)H_P"%
MD>$O^@M_Y+R__$UX!11_9M+N_P /\@_M&KV7]?,]_P#^%D>$O^@M_P"2\O\
M\31_PLCPE_T%O_)>7_XFO **/[-I=W^'^0?VC5[+^OF>_P#_  LCPE_T%O\
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M $%O_)>7_P")H_X61X2_Z"W_ )+R_P#Q-> 44?V;2[O\/\@_M&KV7]?,]_\
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MO6/&7_(J7O\ P#_T-:\GKV\M_A/U_1'S.=?[PO3]6%%%%>B>0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M/B'_ ,?VA_\ 8'@_F]/IGQ#_ ./[0_\ L#P?S>L9_P 2/S.W"?#/Y''4445L
M;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%=5\-_\ D?M,_P"VO_HIZY6NJ^&__(_:9_VU_P#13UCB/X4O1_D:T/XL?5'O
M]%%%?,GTH4444 %%%% !1110 4444 %%%% !1110 5A>-O\ D0?$?_8+N?\
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M?9,X_D*)UG&;71*X4\.ITE+JY67]?<4_^$-U_P#Y\/\ R-'_ /%4?\(;K_\
MSX?^1H__ (JI/$&N:@=>O1!?W,422E%2.9E48XZ ^U9G]M:J1@ZG>_\ @0W^
M-1!XB45+37R?^9I4CA(3<;2T?=?Y$=CIUWJ5U]FM(O,F )V[@.![DXK3_P"$
M-U__ )\/_(T?_P 56CX(46_]IZDW M[? )Z<\_\ LM8!US5B<_VI>_\ ?]O\
M:;G5E4<86TMN*-*A&E&I5O>5]K;+Y#[_ ,/ZKID(FN[-XXSQO#!@/J03C\:S
M:[GP]/J$NA:I-JLLTEBT!V-<,3N.#T)YQT_&N,M+66]NXK:%=TDK!5%52JR;
MDIVT[$8BC",83IW][H]_Z9<L- U34[=I[.U,D2G:6WJO/XD9K-KTJWO8-.U_
M3/#]JV8H$;S3_><J2/ZG\:X#5(/LVK7D Z1S.H^F34T:\JDVFM+77H:8G"PI
M4TT[M.S];)Z?D/T[2+[5FD6Q@,IC +?,%QGIU(J__P (;K__ #X?^1H__BJT
M]!9M-\%ZKJ",T<LK"-&!P>P!'XL?RKGO[;U;_H*7O_@0_P#C1SU9SDH6LM-;
MB]E0ITXRJWO+72W?T([_ $R]TN817MNT+D9&<$'Z$<&EO=*O=.CADNH=B3KN
MC8.K!A]03ZBNFUF6XD\"V+:DQ-VTV8R_WRN#R?PQ^E&D8\1^%I](<@W=I^\M
MR>I'8?S'XBI6(DH<[Z.S_P T6\)3=3DBW=JZ]>S.-J]<Z/?V=E%>7$'EP2XV
M%G7+9_V<Y_2MCPOH<<[2:IJ("6%KDG=_&P[8]!^O3UK.U_6Y=;U$S-E84^6*
M//W1_B>]:^U<JG)#9;_Y&'L(QH^TJ;O9?J_+\S*HHHK<Y@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "F?$/_C^T/\ [ \'\WI],^(?_']H
M?_8'@_F]8S_B1^9VX3X9_(XZBBBMC8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K4C\.:M+H;:U'9LVGIG=,'7C!P?ESGK
M[5EU[5IUQ;Z3I/AGPW=(I@U2TD68>A8 C\RQ'XUSXBK*FERJ[?\ E=G1AZ4:
MDGS.R7_#'BM:$NAZC#HL.L26^VPF?9'*9%^8\C&W.>Q[4S5]-ETC5[K3Y_\
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M"> !G@5<JE253DIVT5]?,B-.G&'-.^]M"Q<_#_Q/9VLMS/IFR&%"[M]HB.%
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M.YUS5[V!H+O5;ZXA;&8Y;AV4XZ<$XKN_!5X?#?@/5->"!G>ZCC4'^)01D?\
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MO4CH#_+\Z/&["&33=-0Y6VMQQ[GC_P!EJIX4U>UL);FVU!RMG.H)."V&!XX
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M#^;T^F?$/_C^T/\ [ \'\WK&?\2/S.W"?#/Y''4445L;!1110 4444 %%%%
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M/D_F:NWGQ;UJ.^N([>TT\P+(RQEXW)*@\9PXYQ5?X?Z]I&F2:O<ZUJ+0W%V
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M?VD]FLRQBYCCBWM(5^4L&+84[ JCY2!MS@Y- $7PAT":'3+OQ1J:[M2UB1I
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M'_V!X/YO3Z9\0_\ C^T/_L#P?S>L9_Q(_,[<)\,_D<=1116QL%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_%[_ -]I_P#$T?\ "OM)_P"?B]_[[3_XFC^T*(?V1B>R^\\VHKTG_A7VD_\
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MD_\ /Q>_]]I_\31_PK[2?^?B]_[[3_XFC^T*(?V1B>R^\\VHKTG_ (5]I/\
MS\7O_?:?_$T?\*^TG_GXO?\ OM/_ (FC^T*(?V1B>R^\\VHKTG_A7VD_\_%[
M_P!]I_\ $T?\*^TG_GXO?^^T_P#B:/[0HA_9&)[+[SS:BO2?^%?:3_S\7O\
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MC_\ B*/[0HA]0K'BM%>U?\*A\/\ _/YJ?_?V/_XBC_A4/A__ )_-3_[^Q_\
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M  J'P_\ \_FI_P#?V/\ ^(H_X5#X?_Y_-3_[^Q__ !%']H40^H5CQ6BO:O\
MA4/A_P#Y_-3_ ._L?_Q%'_"H?#__ #^:G_W]C_\ B*/[0HA]0K'BM%>U?\*A
M\/\ _/YJ?_?V/_XBC_A4/A__ )_-3_[^Q_\ Q%']H40^H5CQ6BO:O^%0^'_^
M?S4_^_L?_P 11_PJ'P__ ,_FI_\ ?V/_ .(H_M"B'U"L>*T5[5_PJ'P__P _
MFI_]_8__ (BC_A4/A_\ Y_-3_P"_L?\ \11_:%$/J%8\5HKVK_A4/A__ )_-
M3_[^Q_\ Q%'_  J'P_\ \_FI_P#?V/\ ^(H_M"B'U"L>*T5[5_PJ'P__ ,_F
MI_\ ?V/_ .(H_P"%0^'_ /G\U/\ [^Q__$4?VA1#ZA6/%:*]J_X5#X?_ .?S
M4_\ O['_ /$4?\*A\/\ _/YJ?_?V/_XBC^T*(?4*QXK17M7_  J'P_\ \_FI
M_P#?V/\ ^(H_X5#X?_Y_-3_[^Q__ !%']H40^H5CQ6BO:O\ A4/A_P#Y_-3_
M ._L?_Q%'_"H?#__ #^:G_W]C_\ B*/[0HA]0K'BM%>U?\*A\/\ _/YJ?_?V
M/_XBC_A4/A__ )_-3_[^Q_\ Q%']H40^H5CQ6BO:O^%0^'_^?S4_^_L?_P 1
M1_PJ'P__ ,_FI_\ ?V/_ .(H_M"B'U"L>*T5[5_PJ'P__P _FI_]_8__ (BC
M_A4/A_\ Y_-3_P"_L?\ \11_:%$/J%8\5HKVK_A4/A__ )_-3_[^Q_\ Q%'_
M  J'P_\ \_FI_P#?V/\ ^(H_M"B'U"L>*T5[5_PJ'P__ ,_FI_\ ?V/_ .(H
M_P"%0^'_ /G\U/\ [^Q__$4?VA1#ZA6/%:*]J_X5#X?_ .?S4_\ O['_ /$4
M?\*A\/\ _/YJ?_?V/_XBC^T*(?4*QXK17M7_  J'P_\ \_FI_P#?V/\ ^(H_
MX5#X?_Y_-3_[^Q__ !%']H40^H5CQ6BO:O\ A4/A_P#Y_-3_ ._L?_Q%'_"H
M?#__ #^:G_W]C_\ B*/[0HA]0K'BM%>U?\*A\/\ _/YJ?_?V/_XBC_A4/A__
M )_-3_[^Q_\ Q%']H40^H5CQ6BO:O^%0^'_^?S4_^_L?_P 11_PJ'P__ ,_F
MI_\ ?V/_ .(H_M"B'U"L>*T5[5_PJ'P__P _FI_]_8__ (BC_A4/A_\ Y_-3
M_P"_L?\ \11_:%$/J%8\5HKVK_A4/A__ )_-3_[^Q_\ Q%'_  J'P_\ \_FI
M_P#?V/\ ^(H_M"B'U"L>*T5[5_PJ'P__ ,_FI_\ ?V/_ .(H_P"%0^'_ /G\
MU/\ [^Q__$4?VA1#ZA6/%:*]J_X5#X?_ .?S4_\ O['_ /$4?\*A\/\ _/YJ
M?_?V/_XBC^T*(?4*QXK17M7_  J'P_\ \_FI_P#?V/\ ^(H_X5#X?_Y_-3_[
M^Q__ !%']H40^H5CQ6BO:O\ A4/A_P#Y_-3_ ._L?_Q%'_"H?#__ #^:G_W]
MC_\ B*/[0HA]0K'BM%>U?\*A\/\ _/YJ?_?V/_XBC_A4/A__ )_-3_[^Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\_\ _P"09/\ XFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\
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MHH_LVEW?X?Y!_;6([+\?\SUC_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\
MXFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\
M_P#D&3_XFO)Z*/[-I=W^'^0?VUB.R_'_ #/6/^$RT#_G_P#_ "#)_P#$T?\
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M\_\ _P"09/\ XFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\
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MHH_LVEW?X?Y!_;6([+\?\SUC_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\
MXFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\
M_P#D&3_XFO)Z*/[-I=W^'^0?VUB.R_'_ #/6/^$RT#_G_P#_ "#)_P#$T?\
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M\_\ _P"09/\ XFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\
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MHH_LVEW?X?Y!_;6([+\?\SUC_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\
MXFO)Z*/[-I=W^'^0?VUB.R_'_,]8_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\
M_P#D&3_XFO)Z*/[-I=W^'^0?VUB.R_'_ #/6/^$RT#_G_P#_ "#)_P#$T?\
M"9:!_P __P#Y!D_^)KR>BC^S:7=_A_D']M8CLOQ_S/6/^$RT#_G_ /\ R#)_
M\31_PF6@?\__ /Y!D_\ B:\GHH_LVEW?X?Y!_;6([+\?\SUC_A,M _Y__P#R
M#)_\32:CXS\/Z4\"7M_Y33PK/&/)D;<C9P>%/H>.M>44SXA_\?VA_P#8'@_F
M]1++Z2DE=Z_UV.BAFE:I&3:6GK_F>G?\+(\)?]!;_P EY?\ XFC_ (61X2_Z
M"W_DO+_\37@%%7_9M+N_P_R-/[1J]E_7S/?_ /A9'A+_ *"W_DO+_P#$T?\
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M *"W_DO+_P#$T?\ "R/"7_06_P#)>7_XFO **/[-I=W^'^0?VC5[+^OF>_\
M_"R/"7_06_\ )>7_ .)H_P"%D>$O^@M_Y+R__$UX!11_9M+N_P /\@_M&KV7
M]?,]_P#^%D>$O^@M_P"2\O\ \31_PLCPE_T%O_)>7_XFO **/[-I=W^'^0?V
MC5[+^OF>_P#_  LCPE_T%O\ R7E_^)H_X61X2_Z"W_DO+_\ $UX!11_9M+N_
MP_R#^T:O9?U\SW__ (61X2_Z"W_DO+_\31_PLCPE_P!!;_R7E_\ B:\ HH_L
MVEW?X?Y!_:-7LOZ^9[__ ,+(\)?]!;_R7E_^)H_X61X2_P"@M_Y+R_\ Q->
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MK&?\2/S.W"?#/Y''4445L;!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %=5\-_^1^TS_MK_ .BGKE:ZKX;_ /(_:9_VU_\
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M\ ?R^E<KX8_Y&6P_ZZ_T-8TL0JE-S2VZ'17PDJ-94V]'U,FBM;Q/_P C+?\
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M]H?_ &!X/YO3Z9\0_P#C^T/_ + \'\WK&?\ $C\SMPGPS^1QU%%%;&P4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/8   =@ *T_$MEI/AWX/Z#J-CI-LFI:C:Q6AN]H+J)XB\Q.0=Q959!W4.=I
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M+T_5A1117HGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KK-/30M9T*&RN)H-.OX.3,45?,'N3C/!Z9SD5R=%9U*?.M[6-:-7V<
MFVKIZ69V:/I'A6QNC:ZBE_J%Q&8T,6-J*?7!/\_3CO7&444J=/DNV[ME5JWM
M$HI62V04445J8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7_T4]8XC^%+T?Y&M#^+'U1[_ $445\R?2A1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#Q5']GU@_M?#=W]QZ317FW_"P=6_Y][+_OA_\ XJC_ (6#JW_/O9?]\/\
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M_"P=6_Y][+_OA_\ XJC_ (6#JW_/O9?]\/\ _%4?V?6#^U\-W?W'I-%>;?\
M"P=6_P"?>R_[X?\ ^*H_X6#JW_/O9?\ ?#__ !5']GU@_M?#=W]QZ317FW_"
MP=6_Y][+_OA__BJ/^%@ZM_S[V7_?#_\ Q5']GU@_M?#=W]QZ317FW_"P=6_Y
M][+_ +X?_P"*H_X6#JW_ #[V7_?#_P#Q5']GU@_M?#=W]QZ317FW_"P=6_Y]
M[+_OA_\ XJC_ (6#JW_/O9?]\/\ _%4?V?6#^U\-W?W'I-%>;?\ "P=6_P"?
M>R_[X?\ ^*H_X6#JW_/O9?\ ?#__ !5']GU@_M?#=W]QZ317FW_"P=6_Y][+
M_OA__BJ/^%@ZM_S[V7_?#_\ Q5']GU@_M?#=W]QZ317FW_"P=6_Y][+_ +X?
M_P"*H_X6#JW_ #[V7_?#_P#Q5']GU@_M?#=W]QZ317FW_"P=6_Y][+_OA_\
MXJC_ (6#JW_/O9?]\/\ _%4?V?6#^U\-W?W'I-%>;?\ "P=6_P"?>R_[X?\
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M\/\ _%4?V?6#^U\-W?W'I-%>;?\ "P=6_P"?>R_[X?\ ^*H_X6#JW_/O9?\
M?#__ !5']GU@_M?#=W]QZ317FW_"P=6_Y][+_OA__BJ/^%@ZM_S[V7_?#_\
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M@_Y\],_[]2?_ !='_"WO$'_/GIG_ 'ZD_P#BZ/[/K!]?HGM5%>*_\+>\0?\
M/GIG_?J3_P"+H_X6]X@_Y\],_P"_4G_Q=']GU@^OT3VJBO%?^%O>(/\ GSTS
M_OU)_P#%T?\ "WO$'_/GIG_?J3_XNC^SZP?7Z)[517BO_"WO$'_/GIG_ 'ZD
M_P#BZ/\ A;WB#_GSTS_OU)_\71_9]8/K]$]JHKQ7_A;WB#_GSTS_ +]2?_%T
M?\+>\0?\^>F?]^I/_BZ/[/K!]?HGM5%>*_\ "WO$'_/GIG_?J3_XNC_A;WB#
M_GSTS_OU)_\ %T?V?6#Z_1/:J*\5_P"%O>(/^?/3/^_4G_Q='_"WO$'_ #YZ
M9_WZD_\ BZ/[/K!]?HGM5%>*_P#"WO$'_/GIG_?J3_XNC_A;WB#_ )\],_[]
M2?\ Q=']GU@^OT3VJBO%?^%O>(/^?/3/^_4G_P 71_PM[Q!_SYZ9_P!^I/\
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MF?\ ?J3_ .+H_P"%O>(/^?/3/^_4G_Q=']GU@^OT3VJBO%?^%O>(/^?/3/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#K/A]_P A^?\ Z]6_]"2O
M2:\V^'W_ "'Y_P#KU;_T)*])KP<P_CGU64?[LO5GRM1117O'D!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&><="<U/_P (;K__ #X?^1H__BJR=>DG9R7WFRPU>2NH.WHS"HJUJ&FW>EW
M@O(O*E*A@NX-Q^!/I56M$U)71E*,HNTE9A1113$%%%% !1110 4444 %%%%
M!1110 45L6_A76KNVCN(++?%(NY6\U!D?B:E_P"$-U__ )\/_(T?_P 563KT
MD[.2^\W6%KM74']S,*BM2?PYJMM=V]K+:[9KC/E+YBG=CKSG _&J%S;RVES)
M;SILEC;:RY!P?PJHSC+X7<SG2G#XHM$5%%%60%%%% !1110 4444 %%%% !1
M110 4444 %%336EQ;PQ2S0O&DP)C+#&X<<CVY'-2W6F7EG:V]S<0[(;A=T3;
M@=PX/8\=1UJ>:/<KDEKIL5****HD***T]/\ #^J:I;F>SM?-B#%2WF*O/XD>
MM3*48J\G8J$)3?+%79F45N_\(;K_ /SX?^1H_P#XJL>XMI[29H;B%XI%ZJZX
M-3&K">D6F5.C5IJ\XM>J(J***T,PHHIR(TCJB*6=CA549)/I2 ;14MQ;S6L[
M0SQF.5<;E;J,C-14)WU0--.S"BBK=UIEY9VMO<W$.R&X7=$VX'<.#V/'4=:&
MTG9C49--I;%2BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO6/&7_(J7O\ P#_T-:\GKV\M_A/U_1'S.=?[PO3]6%%%%>B>0%%%% !1110
M4444 %%%% !1110 4444 %20Q/<3QPQC+R,$4>Y.*CJWI<RV^K6<SG"),C,?
M0 BD[I:#5F]3K==U,^%[2#1M)Q%)LWS38!8D_7N?7MQBN9A\0:Q!*LB:E=%E
MZ!Y2X_$'(-:GCJW>/Q"9B#LFC4J>W P1_GUJIH]SX>AM&75K&XGG+DJT;$ +
M@<?>'?-<5&,%14W'F;W/2Q,IO$.DI<JCMNDON)?$FJV.L0V5W&NV_*%;E57
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MW >Y_P#U5O*I4ER)>ZW>YS1HT8.JW[RC:VO=^1RUW%'!=S0Q3":-'*K(HP'
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MHQ5@?7""JWA)H'\9W36QS RRF/C'R[ABE[:HH3WT5TVK#>'HN=.UM79I._\
MP3DI(]D[1YSM8KG'O6UJ7AZ/3=:M;"6_41SJ&:=DVA 21R,^WK63/_Q_2_\
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M^!S:>&9KWQ0^BZ1<Q7^&PMRI C*X!+$@G &?>NF/PRMW9K2V\4:?+JBCFSP
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MVOD$'7-2(/4&[D_QKT+Q3\2=8T3Q+>Z;;6U@\,#*%:2-RQRH/.& [^E<_?\
MQ2US4-/N+*:UT]8YXVC8I&X(!&#CY^M<5#G]G']VGHNO_ .ZOR>UE>;6KZ?\
M$R_"OA*7Q2FH"&Y\J6UB#HGE[O-8YPN<C;TZ^]=!#\+XIBUJ/$U@=5126LT
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M[3/^VO\ Z*>L<1_"EZ/\C6A_%CZH]_HHHKYD^E"BBB@ HHHH **** "BBB@
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M..V:@HIPI*$N:]WL*=5RCRVLKW.N^(FM:?KNO6]SIMQY\*6RQLVQEPP9CC#
M>HKD:**=.FJ<%!=!5*CJ2YF%%%%:&84444 %=5\-_P#D?M,_[:_^BGKE:ZKX
M;_\ (_:9_P!M?_13UCB/X4O1_D:T/XL?5'O]%%%?,GTH4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+IDKK"EQ,VI0*D4=NH.W!.?3K@^OI50>&=(TRWC.OZF\-Q* 1#!R4^O!)^N
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M@Z%=^(M473[(QK*REBTA(50/7 )]NG>NR\3,-;^&&B:J#NELV^SRGTXV\_\
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M!)0X_>1'@<\#OZ@$9'7.:X^KIU(U%=$5*<H.S"BBBM#,**** "BBB@ HHHH
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MI34(QD]Y7?HO^'9HZ4Z:I\03.Q!7SG=<]]H.W^0K$URXDNM<O9)22WG,O/8
MX _(58N=3M+77(K[1('MXX@"$E))8\YSR>"..M;+^(/#-W,+V\T64WA^9@I!
M0D=,_, ??*_G4KFA)346U:WFBVX58RIN:3YKWUL_PZ#)D-G\.8XY^'N9]\2G
MKC.?Y#/XUR-:NN:[<:Y<K)*HCACXBB4Y"C^IK*K:A"48MRW;N<V*J0G)*&JB
MK>IU_AX?8?!^LWYZR#RE_+'\V_2N0KK=.U_0XO#L6EW]I=S ,6D"  $YSU#
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M7T,<9.-2LYQZV_+4****W.4**** "BBB@ HHHH **** "BBB@ HHHH ****
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M3@<YH_>0YH*-[N]^FO<G]W-1DY6LK/OIV)HO^2)S_P#7[_[,*-#_ .2.Z_\
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MEGU;Q9#K5\#A)D81Q\[$5L[1G_.32^,=;MO$/B.;4;1)4A=$4+* &X&.Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %7-,U.XTF^6[MBOF*""&&0P/8U3HI-*2L
MQQDXM26Z.N/C6WC9Y[70;2&[;)\[()R>I.%!/YURUS<S7ES)<3N7ED;<S'N:
MBHK.G1A3=XHVJXFK55IO3[OR"BBBM3 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\
MBJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_
M /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&
MC_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_
MY&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/
MA_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\
M_/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO
M_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PA
MNO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_
MPANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 5
M1_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\
M\51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?
M_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(
MT?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/
M_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP
M_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__
M )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_
M /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$
M-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X
M0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=
M_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"H
MK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S
M"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_
M<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^
M1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8
MC^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^
MJ8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>
M@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9
M?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+
M^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K
M%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ
M/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\
MBJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_
M /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&
MC_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_
MY&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/
MA_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\
M_/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO
M_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 51_PA
MNO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_
MPANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?_P 5
M1_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(T?\
M\51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/_(T?
M_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP_P#(
MT?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__ )\/
M_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_ /GP
M_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$-U__
M )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X0W7_
M /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=_P"$
M-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"HK=_X
M0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S"HK=
M_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_<S"H
MK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^1_<S
M"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8C^1_
M<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^J8C^
M1_<S"HK=_P"$-U__ )\/_(T?_P 51_PANO\ _/A_Y&C_ /BJ/K%+^9?>@^J8
MC^1_<S"HK=_X0W7_ /GP_P#(T?\ \51_PANO_P#/A_Y&C_\ BJ/K%+^9?>@^
MJ8C^1_<R_P##[_D/S_\ 7JW_ *$E>DUQ'@[0-3TK5Y9[VV\J-H"@;S%;G<I[
M$^AKMZ\7'2C*M>+N?2Y7"4,/::L[O<^5J*ZK_A6_BW_H$_\ DQ%_\51_PK?Q
M;_T"?_)B+_XJO:^L4OYE]Z/+]A5_E?W'*T5U7_"M_%O_ $"?_)B+_P"*H_X5
MOXM_Z!/_ ),1?_%4?6*7\R^]!["K_*_N.5HKJO\ A6_BW_H$_P#DQ%_\51_P
MK?Q;_P! G_R8B_\ BJ/K%+^9?>@]A5_E?W'*T5U7_"M_%O\ T"?_ "8B_P#B
MJ/\ A6_BW_H$_P#DQ%_\51]8I?S+[T'L*O\ *_N.5HKJO^%;^+?^@3_Y,1?_
M !5'_"M_%O\ T"?_ "8B_P#BJ/K%+^9?>@]A5_E?W'*T5U7_  K?Q;_T"?\
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MM_Z!/_DQ%_\ %4?\*W\6_P#0)_\ )B+_ .*H^L4OYE]Z#V%7^5_<<K175?\
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M7_Q5'UBE_,OO0>PJ_P K^XY6BNJ_X5OXM_Z!/_DQ%_\ %4?\*W\6_P#0)_\
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M_P"3$7_Q5'UBE_,OO0>PJ_RO[CE:*ZK_ (5OXM_Z!/\ Y,1?_%4?\*W\6_\
M0)_\F(O_ (JCZQ2_F7WH/85?Y7]QRM%=5_PK?Q;_ - G_P F(O\ XJC_ (5O
MXM_Z!/\ Y,1?_%4?6*7\R^]!["K_ "O[CE:*ZK_A6_BW_H$_^3$7_P 51_PK
M?Q;_ - G_P F(O\ XJCZQ2_F7WH/85?Y7]QRM%=5_P *W\6_] G_ ,F(O_BJ
M/^%;^+?^@3_Y,1?_ !5'UBE_,OO0>PJ_RO[CE:*ZK_A6_BW_ *!/_DQ%_P#%
M4?\ "M_%O_0)_P#)B+_XJCZQ2_F7WH/85?Y7]QRM%=5_PK?Q;_T"?_)B+_XJ
MC_A6_BW_ *!/_DQ%_P#%4?6*7\R^]!["K_*_N.5HKJO^%;^+?^@3_P"3$7_Q
M5'_"M_%O_0)_\F(O_BJ/K%+^9?>@]A5_E?W'*T5U7_"M_%O_ $"?_)B+_P"*
MH_X5OXM_Z!/_ ),1?_%4?6*7\R^]!["K_*_N.5HKJO\ A6_BW_H$_P#DQ%_\
M51_PK?Q;_P! G_R8B_\ BJ/K%+^9?>@]A5_E?W'*T5U7_"M_%O\ T"?_ "8B
M_P#BJ/\ A6_BW_H$_P#DQ%_\51]8I?S+[T'L*O\ *_N.5HKJO^%;^+?^@3_Y
M,1?_ !5'_"M_%O\ T"?_ "8B_P#BJ/K%+^9?>@]A5_E?W'*T5U7_  K?Q;_T
M"?\ R8B_^*H_X5OXM_Z!/_DQ%_\ %4?6*7\R^]!["K_*_N.5HKJO^%;^+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmz2lq4320rk000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +5 Q<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***0^U !GG%&>*:S!%W,< =ZY
M]?&6EOK\FCQN7N$ )*<KS0!T.3G^=+G/2FO(D2EW8*O<DX K@M5^+>B:5?2V
MIM;Z=HVVLT$+.OY@4 =_FN;U_P =:)X9F\K4II Y .(TW5;T;Q'9>(-/:XLV
MQQ]QN&'X5PNG_8AX_E.L>7O\IL>?C9CMUXS0!W6@^*=,\26XGT^5F4]G7:?R
MK:KREM0M+7X@O'IC+M8*"(B-F.>F.*]6H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *0Y[4M(: .*\8Q>)[V;['H5U%;
MJRC>TB9&._>O._"7A^YT#XA7$=Y.);@HI9@>.2:]WY(/%>5OD_%>ZS_SS3^9
MH ZCXB7KVOABZCC?:\L9 -5OA]H-M;^&8)I8TDDN8PSEAG)J/XG6S7&@EU.!
M&I)K:\$LK>$M-QVA'/XT <)8QQ^'?B5%9VQ*P7"O(Z9ZGBM3Q'%X1US7/LVN
MQ2V\JQ[A*9=@(';I67J,(N/BUIY0YQ"^?S%=WK7@S0?$11]5L4N'"@9;VH \
M]\,Z-IS>,I8M%5VL8E5EE9MP)R<\UZQ?ZM8:6%-]=Q6X?A?,;&:JZ)X<TOP[
M;"WTRU6"(= M<%\;/"#^(O#0OUN5B&FJ92I'W^V/UH [^V\1Z->7"P6VI6TL
MK_=1'R36I7QU\(<?\+,T@$?\M*^Q!0 M%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 44G/THXZ]<4 +17D?Q(\::Q9:O!I>A
M2R),Z;R4]NM=;X \2R^(M#$MPQ\]&*-D\Y'!H Z^BDKS7XG^+M0T6.ULM(E9
M;N=B@*=0: /2Z*\]^''BF\UVTFM-1D9KVV(1V;J35"W\2:SIOQ$BTK4+MY+6
M=6=0>@'&/YT >HT4S>/+WGIC->9WGB?5=1\=2Z3IURT4, 5W(Z$<\?I0!Z?1
M7GVAZ[J=UXXU6PGNF>W@(V)V%=O>RO':2.G# <&@"U17#> =;O\ 5CJ7VVX,
MGDW!1,]AS4/C/Q/?1:@FB:3O6[?#>:G\(- '?T5Y9/X9^(%I;-=GQ@9%1=YB
M"')]JW? /BR?7(I;&]1EO+51YC,>6H [:BN:\7>*H_#=B76,SW#+F.%3RWTK
MD;;1?'FMQ?;X?$[V,<GS+ RG*@]J /4Z*\CB\3:_X*UB.R\0W,FHQ2$ 7!X4
M%CP/UKTV?5K*TL5O+FX2.%ESN8\4 7Z*\8\0?%.:X\46-AHDA:V,VUYHS\KC
M!KT^?4#;>'OMLLFU@F2QH V**\BTS3?'?B-[JZM_%36D DQ&A4GBNO\ #.@^
M)=,N2^L>(/[0CP?DVD<T ==13>?I4-W>V]C"TUU*L4:C)9N@H L45S]QXV\-
M6RQM-K-LBN,J23S^E2OXLT!+(WC:I;BW!YDR<4 ;=%9&F>)-'UDE=.U"&Y;&
M<1FO-?%6K^)KGQJ^DZ5K+62 +SC(YS0![#17F7_"&>/_ /H=_I\AKH/#6B^)
M-(:1]:U_^T5)R!M(P* .MHKR"YUWQ+XO\3/8Z%J;Z=!"61WQD9%6K#6/$7A7
MQ&FGZ[J+ZE#(HQ)C R>E 'JM%,1@R*PXR,UD>*+R:P\.WUS;2%)HXRRL/6@#
M:HKB_A]K%]K&F/+?3-(XQ@FNSSQZ4 +15!]:T^.^^PM=1BZ(SY>><5-<WEO9
M0&6YF6.,#)9NE %FBJEIJ-G?VBW5K.DL##(=>AK*D\:>&X+MK636+99U.#&2
M<@_E0!T%%1PS1SQ++$X=&&01WJ2@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "D-+10 A^Z:\\;P_J?_"P[C4?L[&U9%"R
M=B1FO0\48YS0!F:YI*ZUI5Q9.=GFIMW#M7FUD_C;PBLUA8:))J5LIQ%(QQ@?
MA7KM)CF@#SWP;X4OH[Y]9UC>EVS$K&_\ /:O00/6EQ2T -SGI6%XSL;C4O!V
MJ65I&9+B: JBCN<BM[%8_BRWN[KPMJ,%@^R[DA(B;=MP<^M 'RW\+[&XTSXN
M:=97<9CN(9MKH>QXKZ\%?)/PXMKNT^,=C!J#[KM)\2-NW9/'>OK<4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E5;^\6P
MLY+A@-J#)JU7GGQ6U1X=!?3[=R)[A#LV]: ,?P=8#Q'K.H:I<1@M%(\:$^AJ
M+PA/)X:\;SZ),NV.0/,"?<DT:!\'T?2XKC_A(-2MI)U#NL9XR?QK"\6> KCP
M?=VVL6>I7=XXE1&:8_PY&: />)IA#;M,?NJNZO*=-C7Q9X_O)I4#06KAX\\B
MM[Q#XEC_ .$'6:.3Y[A#$N#WP*XWPA\*FU+1H=4N-;U"TN+A<NL1_P#KT 74
M\SPE\240Q[+?4)B^>V.G]*T_B3IH4VWB*!RKP[4&.X)_^M7,^-/AE-H>FMK%
MKK%]>3VZ[E$S=*[W2RGB?P*MN^'DCC&[Z@&@#9_M=/\ A%?M1(S]GQ^.VN/^
M'&E&X>Y\03$F2<-'@]L'_P"O7('6[\:'_8@YN/MN,9YV;L?RKV7P_IPTO0H[
M8+@XW'\10!Y,^K:YIWQ&U<Z+H_\ :!+C>,D8K>O?&/CUK219/!>Q,<MO/%/\
M._\ )2M:7IAAG\Z]&U(?Z#(/:@#SGX1333VVIR7$7DS-<Y:/T/-6/'/AG5O[
M5CUW1$DGNUVJ85[CO2?# X;6,=?M1Q^M7+_QW=:1XM73M1MTCLG0;95Y.X]*
M ,6?XEZ]HQB7Q'X<6QM'(0S,Q_&NR\,:AX9UAYKS0C"TCC,CQCDU>U#^Q]0T
M]FN_LTT87< Y!Q7G'@8;?'6KC3DVV((P ,*!GM0 [Q5*;WXEZ):2_P"KW$$'
MOS7K$"+'!'&O 5< 5YE\0[&73=:L/$,:%H;4%I"!R*[C0O$&GZMID4\5P@(4
M;@Y (- %N^T;3M5"_;K..?:0R[QT(Z5!JFAVNJ6D=I+&H@0_<QP1Z5RGC#QW
M)IM_#I^D(MS=NZ;E_A"DC/(KN-/DGFLHWND"2D9(% 'E/C;P]I6AZGH@TZRB
MM\S$'8.O!KL/$EK?7W@1[?3[<SSO%\J#O6'\3.-5T,GH9S_(UNZ]K6H:%X16
M^T^W29XXL[6- '%:1\.?%$]KOD\27VFM_P \$ Q_*NA\/ZW/H.N#PUJ-X]W-
ML\P3R_>/M74:'KL.J:3%<S211RE 77<!@UPLT0UGXGEH!E!;8,B_2@#U,'<!
M^=<=\2P3X/OL'#>4<50U'X7_ -HWC7/_  DFIP[A]Q&X'ZU0\0^%_P#A'/!E
M_'_:5S>[H2,SGD<B@#.\$>"M.U/P@DVJVR3NT8,;2#[GTK,^'OAB*^U34;:^
M_P!(L8YV46[CY?:N^^'^#X*M1U/E"L;X;?\ (3U?_KZ:@#(M[:W\-_%06FG1
M+!;M;YV)P,FL[Q9?:C8?$=YM-L?MDY5/W>?K6OJ^!\7TST^S"H[[!^*;'_8C
M_K0!L?\ "9_$#K_PA''^^:[+1;_4M0L/.U73_L4F.8\YK9JEJB2/ITRQ9WD<
M4 >/P2S:+XIN)_"P.JLTC&6 < -Z5<,\VL^(X;KQ.#I$XVA;0\@^A_&K_P -
MKRP@OM2@N-L=T;@D%QC]34'Q3NK:XNK."U(>\\^,Y3GY<CN* /5X]HB3'W=H
MP:PO&F#X2U'_ *XG'YBLC4/!,GB&P@\W6+VS<*"1"WM7/ZO\.O[%T"_N1K^H
M7.V+.R5N/YT :OPK_P"0-("><"O0?X3GFO.OA;<0)H\@::,, .&8"O0/MELW
MRB>(D]@XH \EU4X^+\; _P#+N!BNQ\?_ /(J2DG_ )9G^5<9XB=;#XK0W5S\
ML+0JH;MDUTWQ$U6RA\+$&96,BD*$.>PH Y32M5DT[X00""0I-) 0C#J#Q6KH
M/P_TW7/",5S<P(NH7,88W)'S@^M8-K8R7'PBMIHU),$!;'K7>>#-=LX?!=G+
M<S*GDPC>N1D?A0!O^'])?1M/%J]TUQMP 6'2M:L_2=9L]9A>6R9F1&VDLN.:
MT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "L7Q99S:AX6U&SMI5AFEA*I(S[0ISZ]JVJR?$
MVF3:SX:O].MY!'-<1%$<]C0!\O?#>SN-/^,5C9W,RS30S[7D5]P8\=^]?6PK
MY,^'NES:-\:+/3KF0236]QL9QW/%?68H 6BBB@ HHHH **** "BBB@ HHHH
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M;B>?2NR'3I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>*;6]O?"^HVVG$B
M\DB*Q$''S9]:V:2@#Y)^'-K>V7QDLK;4B3>1S[923GYN.]?6W2OF'0O^3C)/
M^OT_R%?3OO0 N:;)+'$N9'5 >['%.S7/^*_"]GXIT^."]NKBWCB;?NAE,9_$
M@B@"/Q)X[T#PK'"^IW>U9CA/+PW]:\S\7_'^VLY;<>&D2[1@?-,PV[3[=:\^
M\=6?A+2_$UKIT-]J%U#;RXNV>9I!MP?N')_2N8\5GPH9(/\ A&/M6S'[W[1G
MK[9H ]6T/XT^,_$.JQZ;I^BVC7,JED5V*@@?A7:6^N?%)KB(3>']/6(N Y$Q
MR!GG^&O+=,^(/A^V\;>'M2C@>.&SL_L\VV/!+G'/3GI7TQ97MOJ-I'<6TJ21
MR*&!5@<9&: )HRY12X ;:,_6GTE+0 4E+24 9]]H6E:A-Y][803R8QN=,FO+
M-&T'29/C?K5H^GV[6Z6:,L93Y0<MVKT3Q=XNT_P;I(U'4A(82X3Y%R<FOGJZ
M^*Z6OQ.G\1:4I^QW*)'*)$^;:,YP/QH ^E[#1].TQF:RLX;<O][RUQFKI/&:
MQ_#GB2P\4:5#J.GR@QRC.PGYE^H[5L=\T  Z4M%% !1110 4E+2'- !G(XHS
M7'>)_B+IWA;4A8W5E?32%0VZ"!G7GW K 'QR\/-.T*V&IF51DI]F;('TQ0!Z
MAFN*U#XJ^&=,U":QN9;D3PMM<+ 2,_6KOA3QQ8^+I+B.TM+R PC+&XA9 ?ID
M5N/IFGRR%I+"V=VZLT*DG\<4 <6OQG\'OG;<7+8X.("<?K75>'_$FG^)[ WN
MFM(T(8KF1-IR*X#X3:?93#Q)YMG;R;=0(7?$IP.?:O4(+:"U39;PQQ+UVHH4
M?I0!-13?XN*=0 4444 %%%% !1110 4444 %%%% !1110 4444 <=K'Q-\.:
M'J<NGWLMR)XCAPD)(_.LY?C1X.=B%N;EB.H$!X_6NVETVPN)6>6RMY'/5GB4
MD_CBO,/AII]E+XP\8I)9V[JEX H:)2%^5>G% 'H7ASQ1IOBFTDNM,:5HXVVM
MYB;3FMFHH+:WME*V\$<*GDB- H/Y5+0 4444 %%%% !1110 4444 %%%% !2
M4M-.>GYT +CC%>6ZY_R7G0CV^QR?S6O4NG KR;7;VU_X7KHC?:8=JVDBLWF#
M .5X- 'K(Q1UZ4@(*@J001P10,8XH =1110!')/#$<22HA/9F IGVRU_Y^(O
M^^Q7,>*OA_I_BR^BNKN\O8&C3:!;SL@/Y&O+_P#A7ME_PM'_ (1K^T]3^Q?9
M/.S]I?=NQGKF@#WE+B*0XCE1SZ*P-2UR'A7X?V'A.]DNK2\O9WD7:1<3,X _
M$UU] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 44UN.>U+[XH 6L_6M5BT31KO4YT9X[9-[*O4BM"JU_8V^
MIV,UE=QB2WF7:Z'N* /EKP1JL6N?'.#4X$9(KFYWJK=0.*^IKN]MK& SW4R0
MPKP7<X KY@\)V%OIOQ^6RM(Q';PW95%'0#BOI;6=&T_7]->PU.W6:U<@LC=#
MB@#F?%7B);O2A'X>\1Z=:WF\'?*VX8_.O)?&WBWQCHNB_OO$^FWT=R3$R6R_
M,!^=:7QD\ ^&_#7@Y;W2=.CM[@S*NY?0D5X!^% #RQ<EG9F8]R<FF8K2T#23
MKFO66EK((FN9-@<CI7H>L?!J?2?%>D:&=5CD;4<XD"G"8/TH \JR:]O^ 'B3
M5)-=;0GGW6/EM)L/)W<]ZX'XA>!9/ >K6]C)=K<^=&7W*,8J[X6TW5]%\.P^
M+-)U/[++-="SV@<@,VW/ZT ?7W0^U.KS;3/"OCD3VMS<>,?-ARKO'L/S#TKT
M@>N* %JO=WEO80&XNITAA'!=S@"O._'/QBTOPA?1VD$0OY>1*L;8,9]#FO&+
M[Q!X\^(L%S#;)=7.E23#,:C(3T[T ;7QU\8RZCJRZ/9WL,^E[%DQ'S\W'>O&
MR<\U]&^$?@)::?=1WFMS17T#Q#-N5(*L1].U<]/\+]-U;XO7FC6(CM;&TB29
MHL9# DY'Z4 2_L[ZE;6^H:G!<72QM(BK$COU.1T%?1?0<U\S_$;X;WO@O5T\
M0>'(V%NKEU6(?\>X'<UT_@SX[P7DMAI>L0-$Y&V:]D;Y<^M 'M5U>6]A;F>[
MG2&('EW. *SO^$M\/_\ 08M/^_@J34M,TOQ/H_V:\C2ZL9L.!V;T-<AJ7PE\
M%P:7>2QZ-$KI [*?0A210!U?_"6^'_\ H,6G_?P5IVUW;WENL]M,DL3_ '70
MY!KQKX8_#CPMKG@Z.]U#2XYK@SR*7/H#Q7KNE:59:+IT6GV$ AMH1A$'04 7
MJ*2CI0!$UO#(=SQ1NWJR@UY;HEO"?COKB&&,H+*/"[1CJU>KC':O+=$/_%^M
M=_Z\H_YM0!Z='#%#GRXT3/\ =4"O,_BC\48/"UDUEIDJR:G(IVLIR(S_ +0K
MTJYNH+.VDN;F58X8QEG;H!7Q3XXNH;SQOJ]U;2K)#).61UZ$8% '4?#[XIWW
MAK79&OF\RPNY3).B#!+GOG\Z^IM+U2SU>PCO+*9)8W .5.<$]J^$3SS7JOP[
M^+T/@?PZVER:9)<DRE]ZL!U_&@#ZGXI:X#PW\5_#>M:-'>7M[!82LQ!@E;D5
MVMA?VNI6B7=E.D]O(,HZ=#0!:HIOX\4=>O2@!U%)_*@'CUH 6BJ.K7DNGZ5<
M7<%LUS-$FY84ZN?05YS_ ,+/\28_Y$74?^^E_P : /5**\@L?C%J^I^;]B\&
MWL_DMLDV,ORMZ'FO0?"NMWNOZ4;N^TJ;390Y7R92,X]>* -ZBFCUQ2DCUQ0
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M1110 4444 %%%% !1110 4444 %%%% !1124 +129P,FL9?%.E-K+Z4L^;M
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M#G_(@1#/_+Q+_,5WISG.?PKX?T?Q5K.CW,#6EY/Y<4F\0ACM8_2O4/\ A?\
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M6^)/A71-1EL+_5(X;F(X=#U%>:> OB!X9TGQ/XHN[W4HXH;RZ#PL?XA@?X4
M>\"EK(\/^)M)\3VLESI%VMQ%&VUF7L:UZ "BBB@ HHHH **** "BBB@ HHHH
M *;VIU-Z_2@ SWKRW6\?\+YT+O\ Z')_-:]2P,UY;KG_ "7G0L<?Z')_-: /
M4C]:4>]'%'>@!:*** "O,O\ FX$?]@[_ -EKTVO,O^;@1_V#O_9: /3:***
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M@ HHHH *\R_YN!'_ &#O_9:]-KS+_FX$?]@[_P!EH ]-HHHH **** "BBB@
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MOMZUYF?^2_>O_$N_]EH ].HI!2T %%%% !1110 4444 %%%% !1110 4444
M%%%% #3364M&0&(SWI]'K0!R\?@?2YIY)]4A34)F?<C2CE!Z"NCBAC@B6*%
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M*<_%O4O^VW\VKZ8H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH :#^M(6VJ21TIW3ZTA!(]Z .
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\V_!/\ Y*WJ7_;?^;5],U\S?!/_ )*WJ7_;?^;5],T %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHGBLVGS$CG)5>.M>Y?'#_DF-[_UT3^M &;^SY_R(#_\ 7P_\S7K->3?L^?\
M(@/_ -?#_P S7K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 G>@GWQ1[U%
M-E8F(Z]J .6^(FBSZUX7F@@R7#JV .N*Q/!_CG2+'2A9ZS<QZ?<1-L\N8\D#
MC/%3> =4OM0O]42ZN'E1+DJH8]!Z5TMYX,\-ZC.9[O1[::4_Q,#G^= ''>-?
M&.F:QIZ:=HUQ'J$TS;"(3R@/>NH\":--H?A:SLYFQ(BX;(JW8^#O#VFS>=9:
M3;P2_P!Y <UN4 )WI11G R:4=* "BBB@ HHHH **** "L3Q?/;6OA+4I[RW^
MT6R0DR0_WQD<5MUB>+;N*P\*ZE=SVRW,44)9H7Z.,C@T ?,/PUN+6Z^+]A/9
M6_V:W>?,<.?NCCBO<OCA_P DQO?^NB?UKP[X;7D-_P#&&QNH+5+>*6?<L*=$
M'' KW'XW_P#),;W_ *Z)_6@#-_9\_P"1 ?\ Z^'_ )FO6:\F_9\_Y$!_^OA_
MYFO6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M .28WO\ UT3^M>(?#NPNM)^,UG97K[[F"XVR-NSD\=Z]O^.'_),;W_KHG]:
M,W]GS_D0'_Z^'_F:]9KR;]GS_D0'_P"OA_YFO6: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR*4DXXK@_ /B>345GTZZD222W?RXV0Y! ]37=T +GG%+2=Z6@ HHHH ****
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MSSS[T >HTM<!I?Q&BM98=*\2Q-;:T[8:*!"R#/3YJ[[- "T4F<FEH **2EH
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M&Y&&.:\G^"WBQ]"\.B#4;98-)DG*K>D]9">%_.O?D8/&KH<JPR#[4 /HHHH
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M]1_(?XU]/=1UH P* /G72?BSXK\&B2/QAI]W</.<P&0@8'YUI?\ #25M_P!
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M !H ]YHKP7_AI&V_Z 4W_?8_QI?^&DK;_H!3?]]C_&@#WFBO!O\ AI*VS_R
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MPKU%?BRUS<:(/[ ^T9 (^39Q7T3CG-+0!R__  KWPCG_ ) -H/\ @)_QI?\
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MD'D^<#UR*]W2:.091U;_ '3FG8[T <S_ ,*]\(]/[!M,_P"Z?\:/^%>^$?\
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M?OBUHNFZ5\3+"RL;.*"W?RMT:#@Y(S7U/N%9=WIVAWMTL]W!9RSKC#R8+#%
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MF'3+.*UC= S+&."=PKZ?+JJ[F8 >I-9EYI^BZG.LEW!:7$J\*7P2* )]'_Y
MEAV_T>/_ -!%7.^2:155555 "@8 '0"FM/!$=KS1J?\ :8"@"6BF)(D@RCJP
M_P!DYIV: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "FG/X4ZF\]Z .;\;>()?#OAVXO+< SJN4!&17!Z3\.CXEL'U?4K^
M]CNI?WD:Q7#*O//0&MGXL/*-+51_JV0[N*[#PV!_PC=H /\ EB/Y4 <=X%U;
M4K/5Y/#VILK,@9D;.3M'3FO2!ZFO)XGE'Q=(CX'V?FO5UR0,^E #Z*** "BB
MB@ HHHH *2EHH Y3Q=XUM/#$1$L%Q+,PP@BC+<GIT%>9^$?$.L:[\0+B>]+Q
MQLB[8SE<<GM7M$^F6MQ<_:)8@\@&,D9%>;,B+\5;I44*!&G &.YH [SQ5K#:
M+H-U=Q8\V.,LF1GFO-M%\"MXVMGU?5KZ]BDG^=%@G9!S[ UT_P 4'E31%6/[
MK AOI6[X+"_\(EIV!C]R/YT <-X>UR^\,:G)H=])O7#-"S'<=H]35#3=*N?B
M;J<]WJ-U<06D;-&OV>4QG*D@="/2LSXC33P^-[8VP._R6Z#Z5W'PDY\-2DCY
MC.Y/YF@#$LTOOA]XDCLDGDFTV9A'&9G+MD]>37KRL&4$5Y9\3V9+_2=@Y^U#
M^E>E6#,UFA;KB@"U12>E+0 4444 -]Z@NYOL]NTH!.T< "I^_P!:#@\$9H \
M;L]"O?B+J]U/JTUW:VUO(8E$+M$2/7MFF:SH,OPVO+>_TF\N)HY)$B9;F8OP
MQ /!/O7K=Y>66EV[SSO'"@ZDX&:\OO\ [=\0_$$<-NC0Z9"P?,@ZE3V/X4 ;
M/C3Q7=6^BV<%GCSKQA$W'3(%88^%S0Z.-574+XZHB[]AN6V;OIFCQE$;;Q+I
MMNH_=),@&?6O5I\"QDX_AH X_P $>)KB]L+BVOROGV)",1Z_Y-<G#8WGQ(UZ
MX^W7$\%E;.8O]'D*$^G2J_AV6=;[Q24!XG&./85U'PI)-GJ3$?,;GG]: ,3[
M'>_#?78DM;F6;39"JYGD+MN8^_UKUR"594609^90:\T^+9<6MGMZ_:HO_0A7
MH.C%FTJ MUVC^5 &A1110 4444 %1R.8XRY&0.N*DIO?D9S0!Y)>6E]X_P#$
M\UG<-<VVGVLGEEHRT9(]CQGK52[TL_#KQ#:MIUY<SP./F6>4R')([$FO5M6M
MKQ]/F&E/%!=L/E=EXS[UY-JNF:WHVK1:UXMG34+:,[0MNNW&3QZT =AXZ\5W
M6D:!;M: >?=;$.1T#X']:YJW^%XN=(_M6;4+X:C@R!1<MLSU'&:9X_OA=OIK
M0 BW9X2 >W(KU6)0-)48_P"68_E0!QO@+Q!>2PW6FZDRF:R0;B*YN6.]^(?B
MBYL;B>6&PM)?+)@<HQ'7J/K3=)DF3Q5XG$8.0H_F*U?A:2VH:RS#Y_.&?R%
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M-36--O[U]00 LDMPS)[\$T/<R7?Q*TV1A\ID.S(KTW6AC19O7:?Y4 <_X?\
M%;WWA6:\G(\Z ,G [J#_ (5Q6C^';GXCW,VIZK=W,$)RL8MY63D'T!JGX=FG
M7P9J&T'_ (^I?YFN_P#A?SX0B.,?O'H YK1Y+[P-XF31VF>6QG<1PM*Y=OQ)
M^E>L@[L$=*\H^(;.OC'0=@Y^TG/Y&O4K7+6L>>N.: )Z*04M !1110 4444
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M_.@#FOB';231V.JV"&XCBF#L4]!5J7XE:++X<9X[J(W[)Q:AOGSZ5W"V5O\
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M/_"/6YQ_RR7^58_Q$T"_U_1OL]A$KR;U."<=#70:):2VFDPV\HPZQA2!ZXH
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmz2lq4320rk000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J ; # 2(  A$! Q$!_\0
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M3H.HZ@^GV6KV=Q>1DAX(Y@SK@X.17FGC'6O$8^##ZE>7%N9[V.-P;.(QB)&
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M09B6#2KL(/\ #C;T_&I/^%;Z,GBR;Q%!->07,_\ KHHI (Y/7(QGGZUV=-%
M'$Q?#'2X?%[>)H]1U,:@QR3YJ[<?W<;>E48/@[HUL^I/%JFKJ=14K<_OD^<'
M/'W/>O1:,4 >4>*/!EAX2^%U_I-E-J<UK)(&R7!,6>K'"_='4_SKR]O :6]I
M]IT[XC6=W>HN^&TMV+2N_4*!OZYXZ5]3.B2(4=0RD8(89!JNFFV,;ATL[=6!
MR&6)01^E %3PTE]'X;T]-38M>B$>:3US[UJT44 %%%% !1110 4444 %%%%
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MM4;4L9";Y9:,WZ*8K!ERI!'8BG5S'9N+12=Z6@ HHHH **** "BBB@ HHHH
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M5'0 <5I[6E2_AJ[[F7L*U?6L[+LCF],\'VUOB2Z/FR#^'L*Z2.)(D"1H%4=
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M&ZC,<\:NIZAAFN7U/P;&^7L7V,?X&Z5T^THUE::LSC]E7H.]-W78ZQ75ERK
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M-@^OO7H\<4<2!8U"J.@ KS[PD/\ BHNWW'KT2NK&-\]CAP$5R-^8M%%%<AZ
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MW=27$JF6.S4-(J*=V<$C@D8Z]ZZ*YTFRN[^UOIH0US:DF*3N,@@_S-8H\#V
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M4+X+_P"0]_VQ;^8KT*O/?!?_ "'O^V+?S%>A48[^*&6?P/F+1117&>@%%%%
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M_JF^E/IDO^J;Z4UN3+X6>?>$_P#D8O\ @#UZ)7G?A/\ Y&+_ ( ]>B5TXO\
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M_P#HQJ] KS_X*?\ )*-'_P"VO_HQJ] H **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +7GWQL_Y)1J_UB_\
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ML+I&O1276B.^(W!)"KZK_A7OFC:YI_B'3HK_ $VY2:WD&05/(]B* -.BBB@
MHHHH **** "BHWFCC&7< ?6JKZK:KPK-)_N#- %ZBLIM8'_+.!C_ +W%0MJU
MRW2)%_X%G^E &W16$=3NST*#\*/[1O?[Z?\ ?- &[16$-2O!U*'\*<-5N1UC
M1O\ @6* -NBLE-9;^.#'^Z<U.FK6S'#[X_\ >% %^BHH[B&49216^AJ0=* %
MHI*6@ HHI#0 M,=E1&=V"J!DDFHKJ[M[*VDN;F58H8U+,['  %>!^+OB!K?Q
M$U=O#'@R.5;1CLEN <%QWR1T6@#5^(/Q7NKZ]_X1GP8'GO)3Y<MQ&.A[A?\
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M0Z'GLOO7H/P[^&.G>#+5;F8"YU:0?O9V'W?9: ,7X;_"6+1'76O$.+O6)#O
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M+Y;G$;]/8T ;=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSW @7S.B_*3G]*\WM_B%\5[JWCN+?00\,J!T9;9\%2,@]:Z#]H__ )$G3?\
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MBB@ HHHH *@O$#V<JG^[G\JGJ.<9@D_W#_*@#G$.44^HH;[I^E)'_JU^E.H
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MS;5(V 9UQ]WD@9'OZ5PWA/P]XOTCXEWOB.\\+77V:[=@%2>+<@9L@GY^P]*
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MKP^*M2TZ32K.T5-D4\B,\A Q_"2*]B Q0 M%%% !1110 5XC^T;_ ,@'2?\
MKL__ ++7MU>-_&;0?$WB];33](\/W$L5K(SFX,T85\XZ MGMW% #/$NO:O+\
M)+FU?PM?0P&Q*FZ:>$J!MZX#9Q^%:7P#_P"2=?\ ;T_\EJ?7$\0:A\+VT6+P
MQ>B]F@:V*&:+Y,+PQ.[H<_7BJ7POMO$_@[PK-I>H>%;QY5D:5&BGAP^0..7Z
M\4 >>>!/$,GACQUXFU(:7<W\48)E6W9<H 3SR?Y5V/PVT.'Q;XRNOB ]Y$I=
MR%LHLAHFQCY\^V#Q57X?>%O$^A>-=2OM3\,7)LM2.P_O83Y:DG)8;N1SVJ>S
M\'>*_ 'Q"FOO#FFR:AH=S\TD"S*N >HPQ'(ZT >X=J*C@=Y8$=XFB9ER48@E
M3Z<5)0 4444 %%%% !4<QQ!(?]D_RJ2H;I@MK*3_ '2* .=C^X#Z\TZFH,1J
M/04IZ&@#7T<8T]?]]OYUH52TL;;"/WR:NT %%%% !1110 4444 %%%% !111
M0 4444 %%%% "'&.:YHJ4D=#_"Q%=+6!>IY>H2C^_P#,/\_A0!#6CHS8$T?^
MUNK.JSITGEWP'9QB@#=HHHH **** "D-+7#^//%EQI4^GZ%I6UM5U-_+0_\
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M=AAGZ9]*T: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmz2lq4320rk000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +#""@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHI* %HI*6@ HHHH ***2@!:*3/% - "T444 %%%%
M!1110 4444 %%(:* %HHHH **** "BBB@ HHHH **** "BBB@ HH-(* %HHH
MH **** "BBDS0 M%)1F@!:*04M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 444F: %HI,T T +1110 4444 %%%% !1110 4444 %%
M%)F@!:*3FEH **** "BBD- "T4F: : %HHHH ***3- "T4E+0 4444 %%%%
M!112=Z %HI,T"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M($PFD"N@]@Q_'B@#U^BD0Y4$C!(Z'M2T %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&&E:G9B$V]M_K-\F#U'08KT,4 9GA_2AHF@V6G*<^1'M)]3U-:E%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !63XG_ .16U7_KTD_]!-:U9/B?_D5M5_Z])/\
MT$T .\.?\BY8?]<16I67X<_Y%RP_ZXBM2@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K)\3_ /(K:K_UZ2?^@FM:LGQ/_P BMJO_ %Z2?^@F@!WAS_D7+#_KB*U*
MR_#G_(N6'_7$5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BDHH 6BDHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "%0001P:R[7
MPUHME?&]MM-MHKDG)E2,!C^-:M% %._TG3]41%OK*WN0AROFQAMOTS4\%O#;
M0+#!$D42#"HBA0H]@*EHH CF_P!1)_NG^5>;? ?_ ))LO_7[/_,5Z5-_J)/]
MT_RKS7X#_P#)-E_Z_9_YB@#TVBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\3_\
MBMJO_7I)_P"@FM:LGQ/_ ,BMJO\ UZ2?^@F@!WAS_D7+#_KB*U*R_#G_ "+E
MA_UQ%:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!'-_J)/]T_RKS;X#_\ )-E_Z_9_YBO29O\ 42?[
MI_E7FWP'_P"2;+_U^S_S% 'IM%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!K_<;Z5YW\$_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 9-_J)/]T_RKS7X#_P#)-E_Z_9_YBO2IO]1)_NG^5>:_ ?\ Y)LO_7[/_,4
M>FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4E+10 PC(.>]>;O\#?!TCL[+?Y8Y/^D?\
MUJ]*P*,5K2KU:-_9R:N)I/<\S_X45X-_NW__ ($?_6H_X45X-_NW_P#X$?\
MUJ]-HK;Z_BO^?C^\7*NQYE_PHKP;_=O_ /P(_P#K5VOASP[8>%M'BTK3?-%M
M&S,HD;<<L<GG\:V*3%95<36JJU238[) *6BBL1A1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYDG@22&T9?F@4%LX]CD?E7JHJ\RJJIB&[!!604M%%<!04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <AXM\*^'=?O(9=9N%BEC3:@,VS(S]:YW_A6
MO@3_ )_H_P#P*'^-;_B_P#;^+;R"XFO9[<Q)LQ&<9YS7.?\ "E++_H+WGYC_
M  H D_X5KX$!S]N3_P "A_C7I&GP0VNGV]O;G,,<85#G.0!QS7EEU\(=)L(3
M-=:]<PQKR6=P!_*O3])AB@TFTB@E\Z)(E5),YW #@T 7:*** "BBB@ HHHH
MCF_U$G^Z?Y5YM\!_^2;+_P!?L_\ ,5Z5-_J)/]T_RKS7X#_\DV7_ *_9_P"8
MH ]-HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHII..2>!0 ZBN=OO'/AO3G9
M+C5[7S$.&19 6'X5%:?$'PM>$!-9M4)/ DD"G]: .GHIB2)(BNC!D89!!R#3
MJ %HHHH **** "BBB@ HHHH 2L;Q<,^#]8'K9R_^@FMJLCQ2,^%-6'K:2?\
MH)JH?$@9YG\/)M'TZ+PW=2V,[ZI?1R6D=RF2J*I4X;\^/QKV*O)? LNK+\,;
M.;0[2WNKR*]VE9QTC_BQ[]*]:':NC'*V)FO,F.R%HHHKE*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ&.0_P"M<?*/?I0!T5%)2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPP-1\$+'>;9624NI4D#&=H8#/6L?P]#:Z DLB>$-5FO+F,)=3RF-C+Z]7[T
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M%$J ]=HQ4M !1110 4444 %%%% !1110 4E+10 A%<QX;'_%1>)?^OB/_P!
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M*MTYX!'XT >HTM9>B:_IOB*T>YTVX\Z..0QN=I4JP/(((K4H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBD- "T5PVK?$FVTO5[G3UT35;M[=@KO;
M1!ER1]:T_#/C!?$T\\2Z1J-EY2AMUW%M#9]* .FHHHH **** "BBD- !FEK)
MT_7(-1U74-/CBD62R95D9L8;.>GY5J]J #(I<UG7&K6]MJUIISAC/=!BF!P
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MT0UYQ\1KJ/0K:X:VT;S#JL1CN;R,\J5(*@CO]YJXBCL+G4/[*\+F^\B2Y\F
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M9!H(U.Q&C#Y/M&T^?L],9K??PM+;Z[H$UEL^Q:;$T;;V^;[I H YFY\/7?\
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M^-><?#S6=+@\=^/Y9M2LXXYM0C:)WG4!QA^02>?PJG_PS?X<_P"@QJOYQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI.U
M"]J\R^&W_)0/B+_V$8_Y/7I3LJ*68@ #))[5Y!\,/$&GW'Q$\8QQ2Y;4;D3P
MY'55W _^A"M849U(RE%:+<3:1[%1245D,6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBN-\2_$?2?"^J_P!GWL-RTNP/F-01S^-
M&)XC^*<VGZ]/I>EZ0]Z8#M>0-_%Z8QZU07XI>(L@?\(M(/\ @1_PK&T'XE:-
MH'B+5YTL[F2SOY?.#@+O5CU!YZ9S75CXU>'3Q]GO>?\ 97_&@#T:!B\*.PVL
M5!(J2F12"6)9!G# $9I] !1110 4444 %%%% !1110 5D^)_^16U7_KTD_\
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M_P#K5I67AO3K'6KK6DB;^T+M0)9&8MQZ#T%; H 9'%''GRXU3)R=HQFI***
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M_*O-?@/_ ,DV7_K]G_F* /3:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M2EIK,%!). !DT .HK,T[55O;B:+&"I^7W%:0-5*+B[,49*2NA:***D84444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD/2@
MR!WKSWQ#X9\/>.M8NK=+AH-3LP%ED1>QZ9]:ZCQ/HDNO:-+:07<MK/UCEC<K
M@CUQVKR"Q^&?BQM8OD&IRV[+C-SO8>=U[YYQ0!O1_"[0_"Z_VOJNH2W5O;$/
MY>W SGBO5;*:*YLH)H/]5)&K)]".*\B7X3^([EA'?>(FDMBPWH7=MP].M>MV
M%HEA8P6D>2D,:QKGT Q0!9HHHH **** "BBB@!DW^HD_W3_*O-?@/_R39?\
MK]G_ )BO29O]1)_NG^5>;? ?_DFR_P#7[/\ S% 'IM%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45X[
M?7WCKQ!\4?$.A:%XEBTVUT](G5);9'&&1> =N>I)K0'A/XK=O']G_P" *_\
MQ- 'J5%>7?\ ")_%;_H?[/\ \ 5_^)H_X1/XK_\ 0_V?_@"O_P 30 Z;XU6<
M,\D1\*>)&*,5W+:#!P>WS5'_ ,+NLO\ H4O$W_@&/_BJKW&C_$G3R/M?CR!]
MX.P162 @^IRO2IT\+_%.5%=/']F5(R#]A7_XFJ<6E=B4DW87_A=UE_T*/B;_
M , Q_P#%5#_POG2OM0M?^$9\0_:"NX0_9EW[?7&[.*G_ .$3^*W_ $/UG_X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:* $&>]+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/"^EO_>M8S_XZ*ZI.^&7J_R)6YKT445RE!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*I-&K@-U (S7F>A>._!FL:@EG+H=O9.YPC2P(03Z<"O4HD2.-4C5511A548
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M11$Y\L;EK2=7:YO98I6R&.4_PK>%>>P3-;S+*O#*<BNG/BWP_;X2[UO3K:;
M)CFN41A^!.:Z,514&G'8QP]1R5F;E%87_":>%O\ H9-(_P# V/\ QH_X33PM
M_P!#)I'_ (&Q_P"-<ATG$>.O^2T_#_\ [>/_ $&O5*\>\4ZOINK_ !F\!MIN
MHVMXL9G#FWF60+E>,X->P"@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *R?$_P#R*VJ_]>DG_H)K6K)\
M3_\ (K:K_P!>DG_H)H SE3S/AYL];,_RJM\,'W_#[2SZ1 5HZ>N_P3&I[VA_
MD:Q?A(^_X=Z>?3</R-=L/]TE_B7Y,G[1W-%%%<104444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^)_^16U7_KTD_\
M036M63XG_P"16U7_ *])/_030!#I//A" >MJ?Y&N?^$)_P"*"A7^Y<3+^3&N
MBT49\)VH];?^E<Y\*/E\-747]R^F&?\ @9KMI_[I/UC^I+^([VBDI:XB@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHI#TH 6D^IKG/$'BR/PY>0K>6-
MPUG(N6NHQE4.>A%.OM4BUWPO>R:%=I-,\)\LH>0U &B^OZ/'<?9WU2S6;./+
M,Z[L_3-: (8 J001D$5\[0OX8AT=K6_TK4FUP#:TF3GS/8X]:]F\"07]OX0L
M8]2W_: AR'Z@9. ?PQ0!TE%%% !1110 4444 1S?ZB3_ '3_ "KS;X#_ /)-
ME_Z_9_YBO29O]1)_NG^5>;? ?_DFR_\ 7[/_ #% 'IM%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 )1BEHH 2BBB@ %+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117*7NOZU-J\UIH>
MFVMW!;L$FEENA&0W< 8.<4 =717/ZCKTL&J66C6T*/J-S"96W-\D2CJ3Z\@C
MMTJLGC6SAT34+V]7R9]/E,%Q"&R?,[ ?7- '4UD^)_\ D5M5_P"O23_T$UGV
MWB2>#6++3M6MTMY;^,O;[7SA@,E#ZG&>?:K_ (G_ .15U7_KUD_]!- ":$,^
M%[,?],*YCX7G;9ZS%_SSU&4?^/&NI\/<^&K'WA%<K\-B5U#Q5%V359,?]]-7
M52?[BHO0E[H] HI!2URE!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!SOBGQ3I7AVV4:B&E,W"P(FYF_"O/K&3PWKVL$:#)?:!JKCY-R;$D_ &NI\
M;>&]6OM4L=9T989;JT4KY,V-K#GUX[UE:?X<\4ZSXGL-2UVTL[&*R.Y5@*DN
M?JM %M?$>O\ ANXV>)-*%U; X%]:J#^8KM]+U2TUBPCO;*420/T;&*M-&LB%
M74,I&"",@TRVM8+.+RK:%(HP20J* .?:@":BBB@ HHHH **** &3?ZB3_=/\
MJ\U^ _\ R39?^OV?^8KTJ;_42?[I_E7FOP'_ .2;+_U^S_S% 'IM%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQXL\(6-@
MLOB;P_)]BU=)A(6B?"SDL-RL!USDUZ,0&4@]",&L*S\'Z/97C7,4=PS-(9-D
MMS))&&/<(Q*C\J .:MA<GXM6MS>#!N-'3R^. V6+#]:X[Q!9W4J>,;N)2UH-
M7@+;>A"[MW_H2U[+J&CV6IM$]S&QDA.8W1RC+GKR"#BEM]'L+;3FL([=?LSY
MWHWS;B>I)/)/N: .+\:*U]XS\'):'=(+EYB5[1^6_/TY _&K?B;2_$?]A:K)
M_P )-']G\B0^3_9R?=P>-V[T[UT5AX=TW3;A;BWA;S5C\I7DD9RJ^@W$XZ=J
M3Q./^*6U7_KTD_\ 030 >&P1X:L QR?)'.,9KE/A]\OB3Q@A[:CG\\UUGAW_
M )%RP_ZXBN4\%_N_'/BV,][A7KIHJ]*IZ+\R7NCOQ2T@I:YB@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 3%%+10 4444 %%%% !1110 4444 ,F
M_P!1)_NG^5>:_ ?_ ))LO_7[/_,5Z3-_J)/]T_RKS;X#_P#)-E_Z_9_YB@#T
MVBBB@ HHHH **** "BBB@ HHI* %HKG/%?B_3O#.C7=Y+/#)/ ORVXD&YF[#
M'45)HGB[2-8TBUU!;ZVA\Y QCDF567V(S5^RGR<]M!75[&_15'^V]*_Z"=E_
MX$+_ (TG]MZ3_P!!.R_\"$_QJ!E^DS5'^V])_P"@G9?^!"_XU!>^(](M+*>Y
M;4;1EB0N56923@9P.::3;L@+ UBP;5CI8N$^V"/S?*SSMR1G]*NYKY-@\>W<
M7Q(/B8LS S891WBZ;?RKZIL;R+4+&&[@</%*@=6!X(-=^/R^>$Y7+JOQ)C)2
M+5%)2UYY04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5D^)_\ D5M5_P"O23_T$UK5D^)_^16U7_KT
MD_\ 030 OAW_ )%VP_ZXBN5\,_N_B;XFC]4C?^5=5X<_Y%VP_P"N0KEM&^3X
MQ>((_P"]91-_Z#79A?@J+^[^J)ET.]%+24M<904444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME\5];U75M.L[#P^;C2YA#<AMX 8YQ@[N>AH ]JHKRW[9\:/^@=X:_P"^V_\
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M_=?YHF70[^BD%+7&4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM@QFC%%+4@)1BBBD 44M%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<QX^N[JS\*RR6=U):S&1%$T9P5R:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^GH?_$UUVA:)%H&EI80W%Q.B$D27#[G.3GK0!I"EHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K)\3_ /(K:K_UZ2?^@FM:LGQ/_P BMJO_ %Z2?^@F@!WAS_D7;#_KB*Y#
MXB_N_$'A2;TO]OYHU=?X<_Y%VP_ZXBN0^*7R2^&)1U75D'YJU=F7_P"\)>OY
M$SV/0ATI:04M<904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$.G
M^*X/%G]K>'K6QF5[80O]JDQCD'@ CTKN<TGO0!P-KHWB[7M9L+GQ(+&UMK&4
M3)%:DL9&'3))..E/OM$\5:=XJN[_ ,/M9O:Z@%\X7'6,C/( (SUKN^W2EH X
M72?"VK6?AS7[*YD2:ZOF=DDW !RP//MR:L:AX<U&Y\+:+I\:1_:+2:%Y07XP
MI!.#WKL\44 <-XE\,ZL=936M#CL9[@Q"*:VO$!1\=#GMCG\ZDT/0]>\G4)]6
M6Q@FGMVBBM;2-5121UW=?UKM#UH% &-X5TZXTGPY9V-V%$T0;<%.1RQ/]:VJ
M*3/- "T444 %%%% !1110 4444 %%%% !7(>-%\B_P!!U)A^ZMKP!^>F[O\
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MR>8T07/F$=,GTK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU96A^(;#Q#:RW&GR^8D<K1-]15*$G%R2T071KT4F:,U("T4F:,T +129HS0
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MA7GVM:=/'\-=-#.8KN[OXY7DQR&8-S6WX51O"VNW?AV_D:9KG-Q;W+#YIN[
M^IZ_E0!+?_%#3K._E@33=1N+:%MLMY#"3$F.N3[5J^(+R3^Q8-<TZ=BMN1,5
M4G;+&>H(KSB]-E8W%]/H7C"&P0RN9M.OE7+-W&#V-=]9:@^H_#;[;>PI$7M2
M65!A?J!Z4 =/:745[9PW4#;HI4#HWJ",U/7.^!1(O@G21+][[,A_# Q714 %
M%%% !1110 4444 %%%% !2&EHH 3'.:6BB@ HHHH **** "DQ2T4 %%%% !1
M110 4444 %%%% !1110 4444 %)BEHH **** "BBB@ HHHH **** $Q2T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445A^+=>_X1OP]/J(C\R12$C0_P 3'I0!MYK*\3_\
MBMJO_7I)_P"@FL-=;U'1/$6D:=JTJ3#5$9=RC'E3!2Q _P!G /OTYK<\3_\
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M2#E1XC\0=!OO"_A]KJ3Q5K-U=2MLCA64J#GJ3M/3_&O(-*>YM-4AE;[7%&7
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M4XZ'A17M8K,,OG@XTJ</?7EIYF482YKLH_VW\1_^A:T[_P "?_KT?VU\2/\
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MK<__ %JZJBG*M4F[RDVPLD<J/ MB,$:CJH/8BYZ?I3_^$(L_^@GJ_P#X%?\
MUJZ:EJ&V]V,YC_A";/\ Z">K_P#@5_\ 6K'\4>&(],\/7-Y;:KJHFC:/:3<Y
MZNH/;T)KOZ@O+:WN[1X;I%>$X+!NG!S_ #%(#FH/!=J]O$YU35LLH)_TKV^E
M2_\ "$V?_03U?_P*_P#K5T%I<6]U;K+:RI+"<JK(<C@X_I4] ',?\(39_P#0
M3U?_ ,"O_K4?\(39_P#03U?_ ,"O_K5T]% ',?\ "$V?_03U?_P*_P#K4?\
M"$V?_03U?_P*_P#K5T]% ',?\(19_P#03U?_ ,"O_K5A>)?#$6FQ:>UMJ>J
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M!7_UJZ>B@#F/^$)M/^@GJ_\ X%?_ %J/^$)M/^@GJ_\ X%?_ %JZ>B@#F/\
MA";/_H*:O_X%?_6K!_X1Q/\ A-UTS^U=5^S&S:7'VGG<"H]/>N]NKRVLHQ)=
M7$4"DX!D<+D^G-)]CMS>B]\I?M 38),<[3CC]* ,'_A";/\ Z">K_P#@5_\
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M/^$)M/\ H)ZO_P"!7_UJ/^$)M/\ H)ZO_P"!7_UJZ>D- ',_\(3:?]!/5_\
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M5O:[/.FCCW<*&;!;Z#O0!@?\(3:?]!/5_P#P*_\ K4?\(3:?]!/5_P#P*_\
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M U*:\.BZ1+*25AD;47_=)[+Y77UYJ_?^ M&UMC>ZK8PRZE)$%EE4D L!C\J
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M_EN2#C.WGU&3^=/L/AAIEAXZ_M6&R@2P2VQ$H<[A-N!SCTP#0!Z"*6D YI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@!*6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I#2T4 )2T44 %%%% !1110 4G>EHH 04M%% !1110 4444 %%%% !1110
M4444 %%%% "48I:* $I:** "BBB@ I*6B@!*6BB@ HHHH **** "BBB@!**6
MB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *2EI,9H \^^(_B_6?"=QITMEY!
MM)GVRB1,G.>QSQQ6GXQ\5S:#X+&K6OEFXD5/+#C(RPK.^,&G?;/!,DX!+6TB
MN!C/4@'^=<'K&J'Q+X;\(Z+&[-+,V)5S[X&?RH [WX9^-KWQ9;7J:F8A=0,N
M!&FT%3GWJ#1?&NK:S\2;S1H_(&FVI8-B/+\<=<^M<UIVSP9\5;^U'[NUNK=F
M1>V>H_D:L?"IE!\1^)I5.S,C 'KC.^@#V+-&:\4TG4-3\=7%]?W?BPZ-;QN4
M@ABN!&3]1D<>]=!\/_&5Y<7&IZ/JMRMU-8*6CN$.1(J]>>_:@#TO/YT=NM>+
M:=JVH^/=5O[BX\3G1+&W<K!'%.(V;TSR,\5N?#[Q7?R^(;[PUJ5ZM\;?F"Y4
M[MXZ]>] %OPQXRU75O'^J:+<F#[);;_+V1X;@@<G/O7H5?/UGXGM_"GQ"\17
M\P+N?,2) /O,2,?AQ7<?#NUUK7';Q-JVK7#1S,QAM(YSY:]N5!Q^% 'I-)FO
M#+SQ3<:SXNU"RUGQ)>Z%;0/L@%L",GWQ^?/K77> [S7X]7N+&YO%U72<9AO?
M/5F'U&=W/N.U 'H]>6^._''B31O%MOH^AQ6\IFB4JCQ;F9B2,=17J5>(?$;5
M(M%^*FF:C/&\D5O&CLB8R0&)H EN_'WQ$T-$NM8T>*.UW8),.W/XY.*]4\.Z
M[!XBT.VU.W4JLRY*YSM/<?G7DOBKXJ6OB?09M'TS2KKSKD;3YH4X'L 3S6[9
MWUS\.?A1"\R8OI23'&W168YY'L/Y4 >I9HS7E-GX;\6:GH"Z\_B>[COY(S+'
M;(Q$7L"*O>&/'=_JG@G5+J6,2:KIRD,$7A_0X_ T >D9HKP'2=9F\06DEU=^
M.+VQU<DF.T#,D1QTY' S7HWAU=?\0>$)K+5[A[2YSM2^M9E8NOJ"IZT :^A^
M,-/\0:M>V5AN<6F-\A& 2<\#\JZ'->!_"_0I]0\0Z@4U>\MOLLBEA$V/.Y/W
MORKVZ76-+@E:*;4K2.13@J\Z@CZ@F@#C/%?C+5=&\=Z-H]IY'V6\9!+O3+<O
M@X.?2O0,\"O&_'<T5Q\4_#,L,J2QLT6&1MP/[P]Q3_&FL:[!\4++3]+U&:$2
MQH%C,A\O))Y*]#0![%6%XMO-;L]"DFT"V%Q?AE"QE-V1GGC([5YOXVMO$?@E
M+/68?$M[=F28+)%*V$S@GA>F.*Z/QWK5[_PK&+5+:XDMKB58F+PN5(R1GD4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gmz2lq4320rk000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *S!K$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF /S>_TKZ3\-7LNI>'+&\G_UDL6YOK0!JTM)2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:SVM] L\3QMO7AA[U]J>"_\ D3=+_P"N(_F: -ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIXETKQ-XHL[G2G9HE89W)M[BOI3P7_R)NE_]<1_,T ;U%)2T %%%% !1110
M4444 %%%% !1244 +1244 +124M !1124 +1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+37(49/04 +WH^E<!X
MY^)>F^&K22WMY5GOR"%C0Y(K(^#WB74O$<%Y-J$K,=XV@G[HQ0!ZM1534;^+
M3;&:[G;"1J6.:\1D\2^+_B+K$\'AZ=;2S@8@2\@''N* />>U)]<5X#?7OCWX
M=7,5_J=U_:%D3^\QD@#\:]G\.:];^(M&AOK=A\XY [&@"'Q#XJTWPY:R27<Z
M^8!\L0/S$_2N;^'OCNY\8W5Z9(!%#$^$ZYQCO6WK7A#3-2N9]1NX_-D6-BJM
MR!Q7#?") FN:RB *BS8 '^[0!V_C3QA;^$M+\YU,DS\1Q@9R>U>;/\0?'T,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW(0P/&*](I0* (+NUCO+22WF4,DBE6!KQC4?AMXH\-:U)?\ @ZXRLS9:(L%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BCO10 4444 %%%% !1110 4444 %%%% !1110 4
M4WZ49_.@!U%)CGZT=J %HI/:CK0 9%&1Q[T&D'O0 ZC-)10 M%-QQQQ2T +1
M244 +12?I1^I% "T9I.U)WZ4 .S1FDI.^* '44WZTM "T4E% "T444 %%%%
M!12&@_E0 M&:;^%&?TH =124=: %HI.*.U "T4=J* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]<C- 'JL:JD"J.5 PM2BF(@CB5 ?NC&:>.O]: %HHHH **** "BBB@ HHHH
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M3TKR71OB#X@T;58M/\6V:1BX/[N9&+#TZ_6O26\0:1&?GU*T5CU#2@&@#1+
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MCH>@^.?#'B&#S+]M1L92!*9I!E1Z@ 4 >N9YI:8A)4$CDBGT %%%% !1110
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MLXH#9K(R* 68 DT <5_PT3I/_/E<?]\T?\-$Z3_SY7'_ 'S7>_\ "LO"Y/\
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M=F/$7Q&?4=%L'M-.'^L;;@/UJY=7.H_#'Q;-/]FEGTJZ8$E!G;7LMEIUIIL
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M)H \U\:_$O1-5T"33M-S=W%QA51.2*=H/PQCUGP9:V^K3W$+XSM3MSFNVL/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7S_JYE\=?%A-.N')M+=AE >#_G%?0$6?LL>/[@_E7@W@_;!\9;]9.I(QG\:
M/9)/"FC3:4;(Z=;;"FW(B7/3UQ7BWA\3>!OBS+I$$C?8[@L50G('0?UKZ#'3
MCI7@/BC$GQQM IS][I]5H Z;XN7\OVO3]*EE\FQN742-CU..M3R?"[P7_P (
M]YN.?)SYOG?K7:>)/"NG^)[#[->Q\@?*^>5-><CX'2^?@^(9S;9YBRW3TZT
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MMSS.*OV'P5\2Z\&E\0ZF\$J':@C</D5]$?-[4M 'BFC?L_V-M=L^I7\EW%C
M1P, ^M=!_P *0\)Y&+5>OI_]>O2Z* ,"#P5H%O D2Z=%M0 =*OV.B:=II?[)
M:1Q[_O8'6M&B@!@B13D(H/L*=CU-+10 W'-+2T4 -P*,'UIU% "8I:** $Q[
MTFWG-.HH ;M%+BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!N>#P:YKQ=X+LO&%M'#>3SQ",Y!B.#4'CG2]
M;U.QBCT;48[.0,2S.#R,>U<!_P (+\1^O_"1P8[?*_/ZT :G_"AM"_Z"5_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5E*;P?E(R*QKGQ;HEG,T,U]&LBG!!(H W*2L6U\5Z+>3K!;WL;R-T -;/]*
M%YI:0&CI0 M)FD)'6FNZQH7=@J@9))H ?GMWHK!?QEH,<IC;4(MP.#\PK5M+
M^VOHA+;3)*A[J<T 6:,TQY4CC:1VPJ\DGM56RU:RU$N+6X24H<$*>E %ZBD%
M&: %HHHH 2BHYYX[>)I96"QKR2:Q#XTT!6*G4(L@XZB@#?SS1FN?7QKH#' U
M"+\Q6L-2LS9B\\]! 1D.3@4 6J,^E8,?C'0IIA$FH1%R<#YA6XDBR+N5@RGH
M0<T /I*,\52GU:RM[Q+2695F?[JD\F@"[1WHSF@4 +1129H 6BDS2T %%%%
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M8HGE/W5&37CVAVQ\9_$JYO[C]Y:V)Q&K=,@T =-\+_!@\+:&)923<SC<03G
M/(KM+W3[748O*O(%E3T:K(15  &,<"G4 ?+OQHTVSTSQA91V<"Q*6Y"_45]"
M^"_^1-TO_KB/YFO!/CM_R.EC_O?U%>]^"_\ D3=+_P"N(_F: -VEI!2T %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1129H 6BDS1F@!:*3)HH ,T UQUU\0M,@
M\7+H&X";'S,W !STKKU8%00<@\B@!2>>M(>Y/%+U&,"N;\:MJYT"9-&'^E$?
M*<XQ0!JZQJ/]E:5/>A/,\M<[:XSP%\2V\:W]Q;_84@$1/()YXSWKS";XC>+=
M%MY].U[3Y'AVE3*0QZBN:\%^/)_#KWQTRQ\ZZN'W)A3D#&.U 'UKD= 1GTHR
M,@$\UXS\/-8\;ZQK_P!LU2!X[)A@HY(Q5WXC:CXST_55O-%C=[2%0612?FH
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M"00PX_X#5W2OBO>:AJEO:/H5W&LK[2YA8;:H^+6W?%;16Q]XJ?I\M 'L$?\
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MFM=ZWQA\(KI!N%U2$W!3_4;OFSCZ5P7@2PO/&WCZ?Q/+"\=I&3Y9?G.<'^E
M'NE_;R76FS01,%>2,J">@KF/ _A";PNMT;B59))Y"V5]Z['C\.U'/XT %>)?
M&K4_$FCW$-WIUU/!:#[QC8@=*]NQ7E'QX/\ Q1OXT ?-UWK>H:UJ-O-J%U)<
M2!QAG;)'-?9?@O\ Y$W2_P#KB/YFOB6VYO(<_P#/1?YU]M>"_P#D3=+_ .N(
M_F: -T4M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HIM&<CTH 6@G'>H&N[=#M>901[TW[;;#_ELG/O0!9)]*.?QKF]2\=^&
M='NS;7^KVT$P4':Q/3\JI?\ "T/!G_0>M>/]H_X4 =CGFEKS77/C7X6T=H_L
M\W]H;^I@<#;^=8W_  T/H'_0-NO^_BT >Q4M>&:Q^T%;RV>W1=.E%UN'^L*L
M,=^*P?\ A?'B?_GQ3_OT/\: /I TF:^</^%[^*#TL4]OW0_QJF;CXL7S&YBT
M^\\N7YEVKQ@\^M 'TYVXJG/JMA;2>7/=Q1N.H9J^;]OQ<QC^S[W\O_KU:A^%
M7CS7X_[2O=4>TGFY:&3=E?R- 'T%_;NE_P#/]#S_ +58^J^/_#NCW BNM1@#
MD9 WUXS_ ,*0\8_]# /_ !__ !K8TKX!/<P%]>U)YY\X!5F''XT =Z?BQX3_
M .@E#_WV*RM<^-?AS2X4>WD^ULW58B"16/\ \,]:$/\ EXE_[^&M;0O@CX<T
MF5Y)5><MT#/G'YB@#"_X:*TC_H'W7Y"J&L_M"V\VFRQZ;9S1W+#"M(!@5Z2W
MPS\*HA9K!0J@DD@?X5\\?$S^SVUQ[+1K,"V@)4.BCYOQH Y*7Q!?SZZ-7EE+
M77F>823WKZV^'?BJ+Q/X;@F#J9D4+)M[&OCS[%<C_E@^?I7H?PG\2WGAOQ%#
M;203-;7#!=@/?UH ^L,#--<E8V(&<#@40N)(DD QN4''I3^U '@'C>W\3>+_
M !7'I)T^2"RW\R;,;@#WJMXL^%]]X3:SU3P^CRRI@2(HSDDU]"&*,R"0QJ7'
M0XIS(KKM=0R^XH YCP/?ZG>Z!"VJ61MY\#@+C-7/%E]>V&A3S6-HUS/M.$"Y
MK<"A1A1@>E! 88/(]* /G;PO\/M2\;ZE=ZEXAA:!,D(A&.A-2>&](\3>"?&3
M:=:V+W-BS?>*D@"OH-(HX^(T51WP*/*3S ^P;Q_%B@!L#N\*,ZE"1R#VI9BR
MP.R#+!3CWJ3M0: /*= \(ZEJ?CN[UK6XB(T8B%6'&,Y%>F?8+3_GWC_*K5'T
MH \H^(_@V_:^M];\.0 7L1Y"#KQBF_#KP=J)U*?6_$<7^EN %5QTKUFDQSF@
M"L=/M,8^SQ_E7EWBKPCJ6G>-+/7?#T!P[8G5!Q@GG]*];HH XOQQX?G\1^%P
M8X]M]&N^,8YW5RWPS\(ZQ#J[ZKXA0B>- D6X=,'@UZZ:0#V_.@##\76=Q?\
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MI--C;SW(J77O$^GZ'8S337$7FHF53>.37R+X@\57FH^*Y-61RCQR$ISG&":
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M:3IO_0/M/^_*_P"%6UC15"JB@#H *=10 FU?0?E1BEHH 3%&*6B@!,48I:*
M$*@C!Z&JATG3F;<UA:L3U)A7_"KE% %+^R--_P"@?:?]^5_PI5TK3D8,MA:J
MPZ$0J"/TJY10 @&!@4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z444
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MEHH 3%&*6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :<9%>;?%S7KS3
M-)@LK.0QRW;%-X/2NXU;7=,T.%9=2NX[='.%+^M<QX_\,#QEX=273I0T\8\R
M%ADYZ4 9?A/X6:-!I:7.IQ"]N9@&9I1NZUK:G\+?#-_920)810.>5>-0"#7"
MZ3\5=4\)6_\ 9GBC1KDRQ?*CIM7(JY<_'6&\@:WTK1+LWK\1AF4T 1> IKSP
MKXWNO#$MVT]JN[RPS9(Q@5[4*\F^'7A+6)M8G\3^(D\J\G)*Q%<%0:]9'6@!
M:*** "BBB@ HHR*S+SQ!I5A>QV=U>Q17$OW(V/)H TZ*:&# $=#TJ*ZO;:Q@
M:>YE6*-1DLW04 3TTGBN3_X6=X-\[RO[?M-V<8R>OY5TUM=07L"SVTJR1.,A
MEZ&@"7( )SQZ^E4CJ]@)=AO(@W0C/-<'\3_$5_;&UT726Q=73!21U /&:PD^
M$2S6HDFUZX74'7<?W[X#?2@#V8$'#+R"*YOQIXPMO!NE?;[F%Y5_NIUI/!FF
MZSI6E_8]6NTN3&3Y<BJ1D=NOM6KJ^AV&N6OV>_B\R+TH ^4/'_C2V\:>(K6\
MMX'B5' P_7J*^I/!?_(FZ7_UQ'\S7SE\7M"T_0O%=E!80^7&6Y'KR*^C?!?_
M ")NE_\ 7$?S- &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !129HS0 M%)GUK$UKQ=HGA^/?J6H0P9!*AC][% &UWJG?:G::;$TMW<)$
MJKD[CCBO'-6^-.H:Q=?8?"6E2S2,C L0K9]Q5;3OAKXN\6R0WGB?4I+>)H\&
MW4LA'L<'% '1^(?C3I=FSV^D1/?7!7Y6BP5!]ZY7[)\1OB%,?.D;3+1U'&"H
M9:]2\/\ PX\/^'XT\FT620+@M)AL_F*ZQ(UC 5%55'  &* .#\)?"W1?#MK&
M9X$NKL$LTL@R<FNZBB2$;(U"*.@ I^*4 B@!:.]%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M!Z444 ><?%CPKJGB?2[2'3(XV>.0LV]\<8KM- M);'1+2VF $B1JK 'O@5I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!?%<WA+Q+;7ZM(+<./.C0XWKZ5]2?\*O\*C_ )</U'^%'_"K_"N<_8/U'^%
M'3:7J$&J:?!>6[ADE0-P>F1TJY5'2=)M=&LEM+0,(5)(#-D\U?H 04M%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 44F:,T +1249H 6BDS1F@!:XCXEW.OVN@[_#PS<Y
M],UVV:P?%/BG3O"NG_;-2)$/LNZ@#Y+\47?B*[UJU?Q$")]XV\8[BOK3P5_R
M)NE_]<!_,U\R_$OQ9IGBSQ-9W.F$F)' .4V]Q7TUX*_Y$W2_^N(_F: -X4M)
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^*.CZSK5E;6^E(K$.&).<"N9'@/QW!:Q7*^(I8_*0$1++\OTH ]'\'?V\VE
MZ^J+<[CG8^[(JSXD\,6'BBQ^QWZ[HO3&:P/AUXKN=<MI[._P;NU8J[?WL'&:
M[F@#Y,^*'A73O"GB>SM=.7:C.,C&.XKZ7\%_\B;I?_7$?S->!_';_D=++_>_
MJ*][\%?\B;I?_7$?S- &_124M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*3FC- "T444 %%)G\J,T +129HS0 M%)GIVHH 6BD!S10 M%)FC- "T4E&:
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ME^*?B"-8OX=3AT1;&\B.1*I;FNNL/C_JL-C%'+HHF=1@R9;G]* /HBBOG_\
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M<"OFG_A.?BAZ77_?L_X5*GA+XD^+U_M5YBC/\N'D"GCVH ^D/M=K_P _,/\
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MND:[;ZUH2:G ,QLN<5D^/[6W_P"$*O(_)4*L1&,=.*S/AJ,?#\@'@,P'TXH
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MQX/+-X7L2PP=G2N(UYW/QIT96^X+2;'YB@"35&\=>%K%-6NM:CU&"-@9K=8
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M )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% "8H'M2T4 (,TM%%
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M>%MI##T->PT4 4]-TVVTJQCM+2-4BC& !5NEHH **** "BBB@ HHHH ****
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M4O+"T;8<>A[UT_@;Q3;ZI86^FI8:C;S6\"AS<6Y13CC@FNSQ10!%-"DT+QN
MRL,$'O7C$&D7R>(U\)_9)QIPE,QDV'RSN.[KTKVRB@#"UV_O-#TA9[.S%SY>
MT,@R3CO@#VKR[Q'+8^--7LGT30KVUU59TD>[N+9H\*&RW)XKVZB@#C-=\1ZS
MH6HZ586VFF]2X94FG(8[,GD\5V*DE1QSWIU% 'B>B:TWA/QQK4]_IFIR1SJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***0]: %HI,TF: '44E&?PH 6BDR/44F<DC- #J0TF17G_Q"^)-OX1B
M6*W'G7;'[@[4 >@U6O&M!$?M>S9WWCBJ/AS4Y=7T.WOI0%>502,>PK#^(WAC
M4/%&ABTTZZ-O+_>4G^E 'B7QJ>T;Q=8_9/+*;OX![BOH/P7_ ,B;I?\ UQ'\
MS7R=XM\*ZCX5UNUMM1NFN)&<89B3W'K7UCX+_P"1-TO_ *XC^9H W12T@I:
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M]A52PU6QU9)'L+J.X6-MK%#G!K*LO%.C^)-+OFTF]6<1Q,'P",?*?6N<^$Y
MT[52#Q]I'/\ P&@#T0=*6N7U'X@^&-)NVMK[58XY5ZKM)Q^0KH+.\M[^VCNK
M6420R*&5AW% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"6US_WX-'_  OGP?@YFN?^_!H ]2HKRS_A?7@['^NN>/\ I@:/^%]^#O\
MGM<_]^#0!ZG17EG_  OOP=_SVN?^_!H_X7SX/_YZW'_?@T >IT5Y;_POGP?C
M/G7.?^N!I/\ A??@[_GM<_\ ?@T >IT5Y9_POKP<?^6US_WX- ^/7@_&?.N?
M^_!H ]3HKRT?'GP?_P ]KC_OP:/^%]>#_P#GM<_]^#0!ZE17EO\ POKP=_SV
MN?\ OP:/^%]>#_\ GM<_]^#0!ZE17EO_  OGP>?^6UQ_WX-'_"^?!^,^=<?]
M^#0!ZE17EO\ POKP?_SVN?\ OP:/^%]>#_\ GM<_]^#0!ZE17EG_  OKP?\
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MBLQM TY]5CU(VX%Q$C(A'3!Z\5JT4 1""(1"+RD\L=%VC _"L^/P_IL>J/J
MM@)V3RSG[I7Z=*U:* &JJJ JJ !P .@I>E+1VH \T^+[RQZ1:O%%YD@E4JF<
M9.X5#?3^./$NFIIAT-=,@E #W/G!_E[C'N*Z#Q[X>U#7[2UCL$1FCD5FW/MX
M!!KK(4*0(AZJH!H \X\1:#XC\/>!K32O";;GA4)*QQDKSD\TWX?)X:3".6;6
M0G^D_:LXW=]N[C\J],XQ[5@ZWX1TG72)+FW47*#]W*O!4^M '&?$E&'BSPE(
M,"$7W!!X'R&O1;ET32)&<C;Y)Y/TKDO$?@6YU;PW#9KJ4DM]9N9+:9E (.,
M?@*S+J'XB:II8T>?2K&U@*B-KN.[W/@=]N.] $OP?#?V%</NRC3-MX_VC3/C
M)&[:%I[+]U;ZWSS_ +=;Z>'+S0O!?]EZ#+MO5&4D) Y/)JHWAC5?$'@"'2_$
M,P.J "1I%8-^\4DCG\J .KLV4:9$Y(V[,DUX5)')/HGC22$DQ^;-P![UV4$7
MQ&M]%71%TNR>)$\G[:;OYR/[VW'6M[1? T%CX2NM(GD+R7JDW$F.2QZT 7_
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MHN$N,QK,1MW<9ZU[]$"D"*W4*,BO-_B-\.I/$$L>JZ5(8-1AY##C- 'I._\
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MBCD.70-CU% 'D'AWX+^'KW0K6>\@99WC!<-&,@X%:O\ PHWPK_SS/_? KTT
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M./F0')7V-3+X<TG^S19_8+?9LVY\I<]/7%>)V*/X$^+GV&U9EL[IFPF>!T%
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M+B"^U+0)I"R6SL4R<_Q8KVN@!*6BB@ HHHH *0TM% !1110 4GM2T4 %%%%
M!1110 E%!I* %/2N0\5_$#2_"D\$%P3+/*V/+1@"/SH\<WOB"VLHH/#]N99Y
MB5+8!V<=>:\-\9>#]1T.XL=3U:^-Q>3R98'.%Y'&#0!]+V5T+VSBN4!"NN<&
MJ'B37X/#6CRZA<HTB)_"IP34OA\_\2*T/3]V*\T^.FJ>1I=G8[]JS2*7^F[!
MH A3X_V4B[H_#]^ZGH0ZUO>%/BM!XHU=;!-'N[;=CYY&4C]*Y+2OB/X6\.Z1
M::>FD+=%(P&E\L')_$5Z)X1\5^'/$:;M.BMX;D?>C$8##]* .P%+35SCFG4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG3IW+K;/L0GL *@\1_%JS\0Z3)IGARVO)KR?Y/GMV4 '@\_C73_"[PA-X8T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *,\U%)<0Q'$DJ+[,P%,^UVQ_P"7B+'^^* +%)FH/MEL
M/^7B+'^^*5;J!C\L\1 ]&% $]%1I(D@_=NK#U!S3Z %HI** %HI** %HI,T
MYH 6BBB@ HI,^E->14QN=5SZF@!V: ?:F@@CKD&EH =13&D1%W.P5?4FA'60
M95@P]0: 'T4GO1F@!:*3-% "TF:*3([]J %R*6HEE1SA75B.H!Z5+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ!@:Y;XM>*Y_#^@B"RD9+JY)1".W%8/A+X2:?J>E+J6ON]W=W W'>.F>?ZT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJR@\C  K7U'3+75K*2SNXEDAD&"&&:\DNO@[K%A=RMX=UV2RMY#DIYA&/RH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gmz2lq4320rk000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -X!Q4# 2(  A$! Q$!_\0
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M%_NU/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_#-]%8ROM2Z:1=C>] 'HFMZE)I.E3WD5JURT2%O+4X)KAO!'Q9B\8Z_-I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI#T- %>Q_X]_P#@1HHL
M?^/?_@1HH =9?\><7^[4]067_'G%_NU/0 4444 %%%% !1110 4444 %%%%
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M[T5L,W4>U>C_  _\$Z[X*TB^M+Z[M)K9XV.(U.[A37E/A"SN;SXK70M)?*N
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M;@T@<$YZ=*[3QMX/D\6^&&T]I42Y"@*W\- &3\&!_P 6VM._WZ\KMP!^T!:
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M>#M<-V]_820R9,BA3N_"O9%^Z* %HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D/0TM(>AH KV/_'O_ ,"-%%C_
M ,>__ C10 ZR_P"/.+_=J>H++_CSB_W:GH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***#0!1U6.[ETZ:.R,8G=2J^9TY%>+:+\*_&NC>+1K\-WIQF+$LI)Q@]:
M]UP*4=* (K?SO(03[?-Q\VWIFI!UH^E** %HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
MOF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"
MS15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;
M[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_
M +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_
M 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1
M]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_
MVO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\ OF@"S15;[=#_ +7_ 'S1]NA_VO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *3--=UC0LS!0.I-9IUZR^TB 2!B>^>*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,EA81V\UW+=L@QYD@&3^5 'EMYI=O\2KV^G>4VMY82-'"4ZY7H>:2QO[_6/
MVK:;??O)M.9HA(IW%PHZFNDU3X;?:=4EO=)UV\T<S ^:EJBX<GJ3FN@T'PO9
M:#IDEFG[]IN9Y7&#*>Y- &+H5S"/A;$2X!2Q*MSR#@\4WX76S0^%8YR&Q/M<
M;ABFS_#?S+]GAUZ\@L&DWM8(B^6?;UKM+6VALK6.UMXUCAC&$1>@% $]%%%
M"9J.4R@?NU4_4U+24 5MUY_SSC_[ZHW7G_/./_OJK-+0!5W7G_/./_OJC=>?
M\\X_^^JM44 5=UY_SSC_ .^J-UY_SSC_ .^JM44 5=UY_P \X_\ OJC=>?\
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M_/./_OJK5% %7=>?\\X_^^J-UY_SSC_[ZJU10!5W7G_/./\ [ZHW7G_/./\
M[ZJU10!5W7G_ #SC_P"^J-UY_P \X_\ OJK5% %7=>?\\X_^^J-UY_SSC_[Z
MJU10!5W7G_/./_OJC=>?\\X_^^JM44 5=UY_SSC_ .^J-UY_SSC_ .^JM44
M5=UY_P \X_\ OJC=>?\ /./_ +ZJU10!5W7G_/./_OJC=>?\\X_^^JM44 5=
MUY_SSC_[ZHW7G_/./_OJK5% %7=>?\\X_P#OJC=>?\\X_P#OJK5% %7=>?\
M/./_ +ZHW7G_ #SC_P"^JM44 5=UY_SSC_[ZHW7G_/./_OJK5% %7=>?\\X_
M^^J-UY_SSC_[ZJU10!5W7G_/./\ [ZHW7G_/./\ [ZJU10!5W7G_ #SC_P"^
MJ-UY_P \X_\ OJK5% %7=>?\\X_^^J-UY_SSC_[ZJU10!5W7G_/./_OJC=>?
M\\X_^^JM44 5=UY_SSC_ .^J-UY_SSC_ .^JM44 5=UY_P \X_\ OJC=>?\
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M_/./_OJK5% %7=>?\\X_^^J-UY_SSC_[ZJU10!5W7G_/./\ [ZHW7G_/./\
M[ZJU10!5W7G_ #SC_P"^J-UY_P \X_\ OJK5% %7=>?\\X_^^J-UY_SSC_[Z
MJU10!5W7G_/./_OJC=>?\\X_^^JM44 5=UY_SSC_ .^J-UY_SSC_ .^JM44
M5=UY_P \X_\ OJC=>?\ /./_ +ZJU10!5W7G_/./_OJC=>?\\X_^^JM44 5=
MUY_SSC_[ZHW7G_/./_OJK5% %7=>?\\X_P#OJC=>?\\X_P#OJK5% %7=>?\
M/./_ +ZHW7G_ #SC_P"^JM44 5=UY_SSC_[ZHW7G_/./_OJK5% %7=>?\\X_
M^^J-UY_SSC_[ZJU10!5W7G_/./\ [ZHW7G_/./\ [ZJU10!5W7G_ #SC_P"^
MJ-UY_P \X_\ OJK5% %7=>?\\X_^^J-UY_SSC_[ZJU10!5W7G_/./_OJC=>?
M\\X_^^JM44 5=UY_SSC_ .^J-UY_SSC_ .^JM44 5=UY_P \X_\ OJC=>?\
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M_/./_OJK5% %7=>?\\X_^^J-UY_SSC_[ZJU10!5W7G_/./\ [ZHW7G_/./\
M[ZJU10!5WWG_ #SC_P"^J-]YVCC_ .^JL,5 RQ ^IKGM6\21VNZ&WP\G?VH
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M*]GL5DV-?(R^6/?UKL[6ZAO+:.YMI!)%*-RL.A% %BBD'2EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ &_:H/^>J_G1]J@_P">J_G3O(B_YYK^5'D1?\\U_*@!OVJ#_GJOYT?:H/\
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MJ &_:H/^>J_G1]J@_P">J_G3O(B_YYK^5'D1?\\U_*@!OVJ#_GJOYT?:H/\
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MJ &_:H/^>J_G1]J@_P">J_G3O(B_YYK^5'D1?\\U_*@!OVJ#_GJOYT?:H/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFB@!,48I:* #%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(>AI:0]#0!7L?\ CW_X$:*+'_CW
M_P"!&B@!UE_QYQ?[M3U!9?\ 'G%_NU/0 4444 )FEIC$!22P4#J33AC''- "
MYHIO?VI>: #-+FDI,\=: '44TGC/2E)QR: %HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ/M$_P#SZM^= %JBJOVB?_GU;\Z/M$__ #ZM^= %JBJOVB?_ )]6_.C[1/\
M\^K?G0!:HJK]HG_Y]6_.C[1/_P ^K?G0!:HJK]HG_P"?5OSH^T3_ //JWYT
M6J*J_:)_^?5OSH^T3_\ /JWYT 6J*J_:)_\ GU;\Z/M$_P#SZM^= %JBJOVB
M?_GU;\Z/M$__ #ZM^= %JBJOVB?_ )]6_.C[1/\ \^K?G0!:HJK]HG_Y]6_.
MC[1/_P ^K?G0!:HJK]HG_P"?5OSH^T3_ //JWYT 6J*J_:)_^?5OSH^T3_\
M/JWYT 6J*J_:)_\ GU;\Z/M$_P#SZM^= %JBJOVB?_GU;\Z/M$__ #ZM^= %
MJBJOVB?_ )]6_.C[1/\ \^K?G0!:HJK]HG_Y]6_.C[1/_P ^K?G0!:HJK]HG
M_P"?5OSH^T3_ //JWYT 6J*J_:)_^?5OSH^T3_\ /JWYT 6J*J_:)_\ GU;\
MZ/M$_P#SZM^= %JBJOVB?_GU;\Z/M$__ #ZM^= %JBJOVB?_ )]6_.C[1/\
M\^K?G0!:HJK]HG_Y]6_.C[1/_P ^K?G0!:HJK]HG_P"?5OSH^T3_ //JWYT
M6J*J_:)_^?5OSH^T3_\ /JWYT 6J*J_:)_\ GU;\Z/M$_P#SZM^= %JBJOVB
M?_GU;\Z/M$__ #ZM^= %JBJOVB?_ )]6_.C[1/\ \^K?G0!:HJK]HG_Y]6_.
MC[1/_P ^K?G0!:HJK]HG_P"?5OSH^T3_ //JWYT 6J*J_:)_^?5OSH^T3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E
M"YHS3>](>1S0G<!V1FJFH:C;Z=;M/<R*B =36;KWB:ST2%M[AIL<(#R:\CUG
M7KS7+KS)&8(Q^6,'%=>'PLJCN]C"K64=$:_B;QI/JCM!;$QP9QUY/XU0T#PQ
M>Z[.K;2L&>9".*VO"_@>:\=;J_4K#UV8P37J%K:06<*Q0QJJ@8X%=-7$0HKD
MI;F,*4JCO(HZ-H-IH]LL<$8W8Y8\FM7'-+17FRDY.[.R,5%60E%+14C$I:**
M &D&L_5])@U:P>WG4'(X/H:TJ*<6XNZ$TFK,\#U?2KG0=3:%P1ALHXXSBO1?
M!/BE-1A6SN7 N$&%S_%6QXF\/1:W8LNT"91E6KQUTN]#U0JVZ.:-OI7J1E'$
MT^5[G"TZ,K]#Z SQ17.>%?$D.M6*Y8"=!AEKHOK7F3@X2Y6=L9*2NAU%)2U)
M0444E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO,3%'-+16QD)2T44 )2T44 %%%% !1110 G>EHHH *0]#2TAZ&@"O8_\>_\
MP(T46/\ Q[_\"-% #K+_ (\XO]VIZ@LO^/.+_=J>@ HHHH 3%%+10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_*<8/$^H8QO_6E7Q5J"'D@_C77?\(K8?W/TIK>$K%QP"/PH^K8KN5]:P?\
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M;/M=<CMBH)_A_?\ VIH[?7&ATIY-S68CR"/3-=O964&FV<5I;H$@B7:BCL*
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MY4?V[I__ #W'Y4 3_9Y_^?EORH^SS_\ /RWY5!_;NG_\]Q^5']NZ?_SW'Y4
M3_9Y_P#GY;\J/L\__/RWY5!_;NG_ //<?E1_;FG_ //<?E0!/]GG_P"?EORH
M^SS_ //RWY51N/$=C"A*R;F'05A7OBN>7Y;8>7[YH Z:7=$I+WF .O2L6]\0
M1P<17+.WTKF)KFZO7R[,Q/I5RS\/WMUAF0JA[F@!;CQ%?S959F1?:J CNKR7
MA7D8]R*ZZR\*6\/S3MYGMBMRWM(+9-L48 H XRS\*W,^&G_=@]QS6U;>%K>
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M2/"BVX669\OV!'2M?2M&M].B"H@W=S6H!Z5MAL&E[T]698G'.2Y*>B*@MIE
M N&X]J?Y$Y_Y>6_*K-%>BK+1'FLK?9Y_^?EORH^SS_\ /RWY5:HH J?9Y_\
MGY;\J7[//_S\M^56J*+ 5?L\_P#S\M^5'V>?_GY;\JM44 5?L\__ #\M^5'V
M>?\ Y^6_*K5% %7[//\ \_+?E1]GG_Y^6_*K5% %7[//_P _+?E1]GG_ .?E
MORJU10!5^SS_ //RWY4?9Y_^?EORJU118"K]GG_Y^6_*C[//_P _+?E5JB@"
MK]GG_P"?EORH^SS_ //RWY5:HH J_9Y_^?EORH^SS_\ /RWY5:HH J_9Y_\
MGY;\J/L\_P#S\M^56J* *OV>?_GY;\J/L\__ #\M^56J* *OV>?_ )^6_*C[
M//\ \_+?E5JB@"K]GG_Y^6_*C[//_P _+?E5JB@"K]GG_P"?EORH^SS_ //R
MWY5:HH J_9Y_^?EORH^SS_\ /RWY5:HH J_9Y_\ GY;\J/L\_P#S\M^56J*
M*OV>?_GY;\J/L\__ #\M^56J* *OV>?_ )^6_*C[//\ \_+?E5JB@"K]GG_Y
M^6_*C[//_P _+?E5JB@"K]GG_P"?EORI\<4BG+3%OJ*GHH **** "D/0TM(>
MAH KV/\ Q[_\"-%%C_Q[_P# C10 ZR_X\XO]VIZ@LO\ CSB_W:GH **** $!
MHI:* &\Y)_2C%.HH 3-'?^M+10 F**6B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***2@!:2C\*3F@!:**;G'4T!H.-%9FH:[IVG#_2KE(R.@
M)KDM3^)-O$&2TB,C=G!XK6%"I/9&<JL8[G?LZJ,L0/J:Q]1\3Z7IN1/<J'':
MO)M2\6ZMJ)(DGPA[*,&L^'3[^_(*+)(.Y)S79# V5YLYY8EO2*.YU/XDDEH[
M*+'H^:X^^\1:IJC'SYF(/]WBM&R\+P</=WJ+CK'@YKH+1=$TP P6;22#^(MD
M?E6CJ8>C\*U$H59[G'6/A_5-48>3 [J>K&NMTSX;YQ)>S >J$5>?Q)<*,6Z)
M"/\ <%4IM6O+C)>4\^G%<]3'3>BT-(897UU.IM-%T/1E&%0,.YYJ>3Q#IL'$
M;J?H,5PA>5E)9GQ[M4)F0#KS7GU,3'[3.V&'D](H["X\7J,B.$_7-9LWB>_D
M_P!6VT'VKG3<>U.C\^=ML2$GT%<TL;3VCJSJC@*CU9?FU&YGYDE)/L<55:4]
MV.[W-:%IX:U&Z(+@Q+[BMZT\&01\W#&0^Q(H5:K/:(I4*,-Y'(+F1@D8+L?0
M4Z17A?;(A5NU>F6NFVMJH6.%<#N1FHK_ $FVOT*R1@$=".*M0J+4R<J;T2.)
MT_6[JP88<F/^Z:Z_3]?M;P!6(1_0UR.IZ#=:<Q9%,L/J!TK+27!^5B"/2K59
M-VEH2Z$K7CJCUD$$9!R*,UP>F^([BSPLV98O3N*ZZRU:VOE C<;^ZUM=(QLV
M7Z*3/-*.M" 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HI*/PH 6BDIKNJ+N9@ .M #Z*Q;WQ)9VIVJPD;T!K-D\9+T2W8>^10!
MUE%<3)XNN3]Q=OI55_$^I/TD7'^[0!WY8#N*0NH'+#\Z\X?6[^3[TWZ56:ZN
MI2,ROQZ$T >E/>01_>D4?C5=]:T^/[]P!7GRPW<GW3(WXFIETC4I?NP.U '9
M2>)=.7[LP:JDGBVW7[D>[\:P(_#>HO\ >A9/J*MQ^$KMOO.%^HH0%I_&(;(2
MV(]]U4YO%-Q*C+L^4\&K<?@U^KW"_D:MQ^$K8??;=]*-4] T:. N-/M+BX:9
MHN6.>M7+2XDL8C'"Q5#VS7=CPOIJK@QL3_O5YWXOTF\T>[,D9)M7/R\?=]JZ
M:?-6?(V8NU/5%TW-S*!F1S],T]+>[E^Z';/O4'@KQ+%!,+*^V%6.%9@./:O4
MECBQE8T_ 5%>C*D^5E4ZO.M#SM='U&3I YS[U)_PCVJC_EW;\Z]#50/X1^5.
MK$T/.O\ A'M5_P"?9OSH_P"$>U7_ )]F_.O1:* /.O\ A'M5_P"?9OSH_P"$
M>U7_ )]F_.O1:* /.O\ A'M5_P"?9OSH_P"$>U7_ )]F_.O1:* /.O\ A'M5
M_P"?9OSH_P"$>U7_ )]F_.O1:* /.O\ A'M5_P"?9OSH_P"$>U7_ )]F_.O1
M:* /.O\ A'M5_P"?9OSH_P"$>U7_ )]F_.O1:* /.O\ A']6_P"?9OSH/A[5
M?^?9OSKT6B@#SL>'=4+ &U;'KFM:S\(\!KB3ZKBNNHH H6NDVEFH\N(9]ZNA
M<=  /2G44 )1^-+10 4444 %%%)0 444AXH0:"YHI,U7NKV"T0O+(% ]:EM1
M5V.*<G9(L]*I7FHV]DA:60+7+ZIXQX:.T'/]_M7)75]/<2&2>;.>M<%7'1OR
MP5V>E1R^37-5T1W2^,[0S%"N%_O9K7M-:LKL#RI@2:\C2ZMF?8)E!)P,]_:K
MS07=O&LA1U4]"#63KXFEK4CH;?4\-4TIR/75D5NA!IU>5VFOWUGA4E^4=F&:
MZ"S\:K\J3Q'/=LUO#,*<M'H<U7+JL-8ZG:45EVNO6-U@1SJ6/:M)75AD$&NR
M-2,EHSBE"4=T/I,T9HJKD6"CM12BF!5NK"WNT*RH#[US&H^%&4&2U.?]BNQI
M#0!Y>\=U8R_.&1P:V=/\4SPX2Y^=?7TKKKJQM[M"LT8.>X%<QJ'A0KE[0Y']
MV@#H[+5;:^4&*09]*N]>]>7O'=6,N&#HX]ZV=/\ %,T&$N1O4=,<8H [5V5%
M)8X4=ZY'7?$!;=;6Q^I%0:UXC-VGDV^0AZD&L_2]*GU*<#!"9^9C0 S3M-GU
M*Y 3.W/S-Z5WVGV$-A;B.)1[FG65E%90B.-1P.:L8S1ML&^XN:,XIKL$7+<
M5RFN>*DAW06A#OT+#M6-6M"G&\C:A0G6ERQ-;5M=M],C(+!I,<+7G^H:I<ZG
M/EV.">%':HE6ZU.Z.-TDC'\J[30_"\=JJSW(#2^GI7E2G4Q4K1V/6C&E@HWE
MK(R-#\+R71$]T"L9Y"GO7<6UG%:PK'&H"J,"IE54 "@ "E'6O2H8>%-'F8C$
MSK2NP]Z6BBNDY@HHQ11L)7%HHHH&%%%% !1110 4444 %%%% !1110 4444
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MKF[S5[R^;]Y(1Z!>*NV/AJ\NB&D'E+Z,.M=+8^'[2SP2N]_?D4 <?9Z->WK
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MUGT'V_A^]G;!C:/W85HQ>$9SS),GT%8[>*]0=2#M'TJ!_$6H/TE(QZ&LI9E
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ML=TG3=V%8NK>*);Y/+ARD??L:S]-TFZU2;A6VD\L:SK8MU'RTC6A@HTUSUB
M?:M2N?XI'8].M=GHGA9+95FNL-)UQVK4TG1+?3HUPH,G]XUJCTK3#X)1]^>K
M,L3CG+W*>B$1%10%&![4X=:**]%:'FO46BBBF 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +1110 4AZ&EI#T
M- %>Q_X]_P#@1HHL?^/?_@1HH =9?\><7^[4]067_'G%_NU/0 444AS@XZT
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M#S2#GF@#?HHHH 3C-1RRB(9*L?H*EHH J_;E_P">4G_?-'VU?^>4G_?-6J*
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MT57)'HA.4GNRI]M4?\LY/^^:/MJ@?ZJ3_OFK>*,4R2I]M4_\LY?^^:/MJ_\
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M;%'_ "RD_P"^:M459)4^VK_SSD_[YI?MB_\ /*3_ +YJU10!4^VK_P \I/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M HHQ2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (:*6DQ0 4M%%%@$HI:* $I:** $I*=10 VD*@]:?12:3 B\I
M<[!^5/QCI3J*%%+8+L;2TN** $Q12T4P$HI:* $I:** "BBB@ HHHH ****
M"BBB@ HHHH *3O2T4 )24ZDQ2L GTI" PPPIV**8>IQ/B?P/#J :YLE"3=<#
M^(UYHR7^AWW(:&5#R:^@<5B:[X;L]9@(D0"0#Y6KOP^,<5R3U1S5*"WB<[X8
M\<I=[+6_;;-C <]Z[N-U==RL&![BO#-;\.WNA3DNK>7GY'%;/ACQO/IS);7K
M%X>@)_AJZV%C-<](B%9Q?+(]=HJG9:A;ZA;+-;2!U89&*M#-><TT[,ZTTU=#
MJ*3-%(8M%%% !1244 +124M !12<T4 +1112N 44E%,!:*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %(>AI:0]#0!7L?^/?\ X$:*+'_CW_X$:* '67_'
MG%_NU/4%E_QYQ?[M3T %%%% "<Y]JBN'=+=VB7<X' J7G--=UCC+LP"CJ: /
M X-*C\8ZG!<ZS=W:WSW\D#10SM&%C4D*0!T/O7I4']L:%X,U'SF\V6V5_LYQ
MSL'W<YZFLGQGHRRZCI>I^'YHHKY[C:K$?N]P'<#K6CHWC:.YT"_EU:-6FLMP
MG50 'V\$@>E '!+HMK-X<;Q+#JE[)JHF+"-;I]F_KMV]*]1@UFYMO L>IW@\
MN[%KO*L.K8Z8KRZZT34M-D_X2_2W673G?S9+/&0$Z\#IFN[\07ZZ]\.?MMNG
ME*\.\H?X1CI0!@6OAJ76-#?Q9/>7<=^5^T1HL["/ &<;1QVKNO!^MRZ[X;M+
MR<;;AD'FC'>LW067_A5D!)X%@>?P-5_A9&Z^&/,8Y20JR?3% '=T444 %%)4
M<OFD?NV4?44 2T55VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J
M-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J
M-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J
M-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J
M-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J
M-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_R
MH M455VWG_/2/\J-MY_STC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_
M #TC_*C;>?\ /2/\J +5%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_S
MTC_*@"U157;>?\](_P J-MY_STC_ "H M455VWG_ #TC_*C;>?\ /2/\J +5
M%5=MY_STC_*C;>?\](_RH M455VWG_/2/\J-MY_STC_*@"U256VWG_/2/\J-
MMY_STC_*@"U157;>?\](_P J-MY_STC_ "H M4AJMMO/^>D?Y4;;S_GI'^5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF:U9ZK;K+;R@Y_A)Y_*M'-><XN+LSK336@M%)GTHS2&+11FB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB@
MHHHH *0]#2TAZ&@"O8_\>_\ P(T46/\ Q[_\"-% #K+_ (\XO]VIZ@LO^/.+
M_=J>@ HHHH **** "BDSVHS0 M%)FC- "T4F<GB@G% "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC5HKGI?&NAQ'#7BYQZ51E^(.DH,QRAZM4:CV1+JQ74Z^BN#F^)5I&2$@W_\
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M4D:1($10JCH , 4 /HHHH 3C-1R0K*,-G\ZDHQ0!7^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
MOJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!
M6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V*#_:_P"^JLT4 5OL4'^U
M_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\ OJK-% %;[%!_M?\ ?5'V
M*#_:_P"^JLT4 5OL4'^U_P!]4?8H/]K_ +ZJS10!6^Q0?[7_ 'U1]B@_VO\
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M2'H:6D/0T 5['_CW_P"!&BBQ_P"/?_@1HH =9?\ 'G%_NU/4%E_QYQ?[M3T
M%%%% !1110 44F><4M !129HS0 M%)FEH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MD/0TM(>AH KV/_'O_P "-%%C_P >_P#P(T4 .LO^/.+_ ':GJ"R_X\XO]VIZ
M "BBB@ I/:BHKB4PP-( 3M&<"@!9)HXRH>15+G"ACC/TJ2O"6.K^-=1MK]]=
MN]/S?/;I;PD83:2-X!YR:]6\*3:FVGM#J@S+$YC60G)=1T8^YH W^]'6O.O'
MWB;4;2YL;72G*J;@"656QQW%=A)J)L?#37\K;FC@+G/<@4 :IX'X]J4G'->4
MPP^(=6TU_%$.NWD,8_?)9*1Y;)U^O:N]\,:V/$&A6NH;=CR("Z#HIH VJ***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJM44 5?,O/\ G@G_ 'U1YEY_SP3_ +ZJU10!5\R\_P">"?\ ?5'F7G_/!/\
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M,PBDC5<C/!JR:K."=0C.. AH LTM(*6@ I#T-+2'H: *]C_Q[_\  C118_\
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MI>^*K6+O+90ESEB@)/KQ5D=: %HHHH **** $(!&".*.]%!H 6BBB@ HHHH
M0Y['%)VI>M<OK^J7\EU_9>E*1<.N3+_<![XH Z8$=B*7BO-KC1O&UALF_P"$
M@65=V"GDXS70>'_$=Q<S&PU*$P72_=)_C'K0!U=%%% !1110 4444 (0"02.
ME'>EI* %HHHH **** $/ZTF?P]J4],UQNKWVLZO?3:=HLGV7RFP]R1N /TH
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M1M3_ +2LE=T\JX7B:(G)1O2@#2HI*6@ HHHH *2EHH :  , 4ZBD% "T444
M%(:6D- !CUI,CI5#5[_^SM/:94WMD!1GN:XU](\9ZDQNX]9%FLG(A,6[;^-
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M4A )Y'2E-% "BBBB@ HHHH *3/6@TAH 8\L<2EI'5%]6.*C^WV?_ #]0$_\
M705R>HZ:OBC6KG3[V[(L8" \ .TOGT-1?\*D\)X_X]KG_P "6H [6.6.5=T3
MHX_V6S4F<UQ5CI,/A+5K6TT^X86=PVT0,Q8KW/)KM!TXH 4<TM(*6@ HHHH
M*3 SN(YI:* $%+2=Z6@ I#T-+2'H: *]C_Q[_P# C118_P#'O_P(T4 .LO\
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MHH **** "BBB@ HHHH *I:E:M>6$T"G#,N <5=J"YN8K2WDN)Y D:#+,>@%
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M)'"!5;G)H Z^//EKGKCFG4V-@Z*P[BG4 %%%% !1110 4444 %%%% !1110
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MX]_^!&BBQ_X]_P#@1HH =9?\><7^[4]067_'G%_NU/0 4444 %%%% !1110
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M .Z@@2VA2&,;408 ]JE[U!:SFYM8YC&\1=0VQ^JY[&I^>_Z4 +1110 4444
M%%%% !1110 4444 -)P"2<"N7N?^$9\2:CY,DD$]Q;G)7@D8]>*ZD@&N9UCP
M7IVJC*&2UD+99[=MC'\10!>7P]HC#"Z?:G'_ $R7_"D?PMHSLK"QA1E8,"L8
M!!_*N8;PCKFAKG0=1,A/7[8YDJ:RUOQ)I,Z6^LV9O&E<8DM4PJCWS0!W**$0
M*.@IU-1MR D8SVIU !1110 4444 %%%% !1110 4444 1S2I#"TDC!4498GL
M*YB"V\+>(KYM0B-O<RIPQP".?7BNHD19$*. 588(/>N2U?P%IM^X>.:XL@.H
MMI-@/UQ0!L#P[HSC(T^U/TB7_"B/PUI4-W'<Q6<44D?0H@%<JV@>)=&58-!U
M.%X>YNR7;\ZT='U[6HKZ/3-5L7EF/WKF%,1T =@O2EI!2T %%%% !1110 44
M44 %%%% !1110!5O[VVL+1[BZE6.%!\S-T%8&GZ1X8U"1]2MHK>X\WC<5##C
M\*Z.YM8;N%HIXU>-ARK#(-<=J7P\L+FZ,T5]=VJ'I'#,44?@* .@7PYHW;3[
M4G_KDO\ A3K3P_IUA=M<VMLD4C#!V*!7)/I?C'3F$.EZC9O:K]TSJ6<_C6WX
M?U^^OKEK*]T^:.6)?FFVX1C[4 =+CGFG4G>EH **** "BBB@ HHHH **** "
MD(R:6DH S=9U33-,M-VJW,4$$AV9D/!/I5+3O#GATVYGM;"TGBG/F!VB5LY]
M..E:U[I]KJ$/E75O',F<X=0<5QUQ\,;%[IKFWU75(7SN2)+DB-3Z8]* .H_X
M1_1O^@38_P#@.O\ A3[#1['2WF:RMTA\UMS+&H S]!7'FT^(EBW[J]TR6RA.
M0AB)D91VSZUT?AW79]:BF-QIEU9/"VP^>,;^.H]J -OMZTZFC/X4HZ4 +111
M0 4444 %%%% !1110 4A^M+2&@#G?%$^C20+IVJ7,<1FYC#'!R.GZT_PS9WF
MG6Q@N+N*:(?ZK:#D#WJ_J6C66JIBZA5F PK8Y7Z&N3/P[^R2&YLM4OO/7E%D
MG)3\J .KU?2;?6;&2UN%X<8W#@BJ?A3PZGAK3/L2/N4,2#GU-<VDOCG2V^T7
MC6EU;)UC@C.\BNOT/4Y-5T];B6TEMF)(*2C!H TZ*** "BBB@ HHHH ****
M"BBB@ HHHH Y#Q/_ &/JUQ'ILM['%J:',"LW(8UM:)'=V]@L-[/'-,AX:,8&
M.U0ZQX:L-81_-CV3,,":/AU^AKF?^$(N=*W7&D:O.UT.@NIBZ?E0!T/B?PQ:
M^)=->WG!5L<,#@U?T33AI6F06:ME8D"C\*X^/4?%^C'S]42"^B/ CM(_F_6N
MXL+EKRSCG>)XF=0=C]10!9HHHH **** "BBB@ HHHH **** "D)P*6DQD<T
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M67_'G%_NU/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO!.@0WD-S:V4,4T+;E**!S72*-JA1V% !2TE+0 4444 %%%% !1110 4444
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M5KQ_L"F_\(-X<,D<D.GV\;HP8,B#.10!TT;!XU8="*=3401H$'0"G4 %%%%
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M110 4444 %%%% !1110 4444 %%%% '+>(9;R]O$TJSF$7F+N=\X('?%8_\
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M/&KXWC&X&JFAZ.FBV7V=)6D^8L68<\F@#3HHHH **** "BBB@ HHHH ****
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MV/\ Q[_\"-%%C_Q[_P# C10 ZR_X\XO]VIZ@LO\ CSB_W:GH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3O0!EZMH&F:U 8;^UCF0
MG.&KG+CX>6EM%GP_<-I4O\4D &3^=1>,=0U6YUFUT72KM[.25?,,RC/ /3FL
MC5)O&6E20Z/!<274D_)O#P4 .#Q0!K06'BS0'40WC:O'(PW&X<+L'MBNZB+M
M&ID 5\<@5PUCI/B+1)TO+_Q!+>0YPT+J .?>NYC8/&I]10 \4M(*6@ HHHH
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M0!T7AN\U6[M&;5+>*)@<(8Y-P8>M;HZ5SWAF0*D]K&^^"!]B>P%=#0 4444
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M5L+B2[TZ"XE54>2-7*J<@9&:M"LGPT,>'-/ZY^SI_P"@BM84 +1110 4444
M%%%% !1110 4444 )V.*R-8\.:5K<0CU"TCF4'/S5K>O\JX#Q1>ZOJ7B*/1=
M+O'L\()'D4=O3F@"Q<_#Z&VC \/WKZ22?F: #G\Z;:6GBS0KB.)+HZO"[#>]
MPX4J/8"L74)O&5K>0Z'!<22[\,;WH5'TK;T[2]?T*YCGU#7)+V-B$\MU '-
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M;+X&T'0[8WUO$L-S$-RON.2177Z5.UQIT,CG)*CGUH O4444 %%%% !1110
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M_NU/4%E_QYQ?[M3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS2T@I: "BBB@ HHHH **** "D/0TM(>AH KV/_'O_P "-%%C_P >_P#P(T4
M.LO^/.+_ ':GJ"R_X\XO]VIZ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *:R*XPRAAZ$9IU% !T&!2$!AA@"#U!I:* $  &  *6BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "FJBIG:H7/7 Q3J* "D"J"2% )Z\=:6B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!I1"P8JNX=#CFG444 (55B"
M5!(Z9'2EHHH **** "BBB@ HHHH **** "D/0TM(>AH KV/_ ![_ / C118_
M\>__  (T4 .LO^/.+_=J>H++_CSB_P!VIZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "D/0TM(>AH KV/_'O_P "-%%C_P >_P#P
M(T4 .LO^/.+_ ':GJ"R_X\XO]VIZ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***.U "4444  I:3(HS0 M%)FC-  :**
M*-P"D]Z#TI.?QHV =GM2 G&>]><^//%/B[PO)Y]C9V$UBT@1#(QW\G R*Z?2
MI_$<V@^;>P6::@RY5(V.R@#H.:/ZUY;IWBSQW>>*KG1WL=+!MB/,(D/0],5Z
M>F\QKOP&P-V/6@!_>EIH]:=0 4444 %)VI:JWWVD64S680S[3L#G )H LYY^
MM+7E'PUU77;SQ5KEOK-P6DBN"OE!LHGR]%]J]7H **** "BBB@ I">*6L+Q1
M=ZS9:2UQHL5O),F2PG; Q0!N T9KSSX>_$"[\2W-SI^KV\=M?PDG8F<%<X!&
M:[^>58(7E<X51DT 29I:\MT/QUXE\1>*[JQL+.R^P6\Q4R2,0Q4=Q7J0Z<T
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MAI:0]#0!7L?^/?\ X$:*+'_CW_X$:* '67_'G%_NU/4%E_QYQ?[M3T %%%%
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M$=[<W-]H6J.TEU8R&-9CR9 !U)]:YFPU"3X<>+=1CU*TN7LKQFGC:VA:7D]
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MI)N]7LXK1MGFZ; 9&;ZU8\">,=2CNKZWN_[1N;&(9BN;Z$HYX[C%.N;N_P#
M?CR[U*XMIIM(U%O,9X4+NN!@?**ZNVU\>-;6:"PM)DLV0AI+B-HV!QQ@&@#"
MM].UWQQ9OJ]OK]YIJLQ$4%NPVG!QSFN9\76WB:PMO#<&I&*?4ENY/*8R9##'
M&3VXK7\+^+3X"BF\/^(;*\+P.6CEMK=I@X8YY(XK*\;>,H=8UC1+F&PU#[-;
M3%V/V5\X(],4 :U^=>\)ZUX?NI]9NKB*^F$<ML[#8@VYXQ3OB7K?C"QU'2&T
MPPPVD\H"%9<&1MN2K#TJE\1_$5M->>'(HK74)#:2">4K:L0%*<?C4GQ'UZ":
M'PZL5K?2&WE69]MLQPI3^= $^ICQ#X>NM$U.?6[J7[9.L<EJSCRQD9.*VO$.
MNW>LZ[;^'-/O)+.5XA-)/"?F ]JYOXB>)+6XL=!ABM=0=X9$G?;:L<+C^?M2
M:L9]&US3/%UM:3R64D*0RJ(SY@[D[1S0!L:1J>J^$?&2>']4U"XU&VN4,D=Q
M.<N#G ''%'BK_DK6C_\ 7HW_ *$*?83+XX\9P:O:VTZ6%M%M+7$1C;?G(X/:
MLCQ;KD ^*NFS?9KYHX(C [+;,5#%AW]* .I\9:_<RZW9^&=/N'MKB[C,IG0X
M9 IP<?G6-;7VK^!_&%KI>H:I=:I97RLRRW!RR8X  %)\0+*[TWQ#IGB^SMWG
M@A0Q3(JDM\S#G YZ"I$O4^('BO3[NRM;A+&S1EE:YA:,[CR, ]: -+QWK.H'
M5--T*RN7LUO06>ZC.&3'IVKE9-%\067C6RTF3QAJKV]QG:P*D].];_Q1FM(F
MT^&Y%S"&4D7=I"9)8L?W5K%\':UX?M-<62[U/7-2O'XBFU"P,8C^AZ4 6K6U
MUK1?B3!;ZAXCOY-/D($"2,-LAQR#72FROK_Q^9K?6KM;6V5'>V4CRF%+\1=%
M?5- %]:,%O;4;[=B<8)]ZT/!.GW%EH437S%[Q_ON3DD=J .E%>6WF[_A=;[<
M%A:18S^->FSS"VMWF?<RH,G R:\3N/%]B_Q7?4Q9ZE]E\I(=WV-_O*3G\* )
MM2U7QS+\26TKSH[>"2,82.;A4)^\/]JMO1IM7\/?$(:1>:M<7\,UOYH\]A\I
M)[8K&O/$EM=?%>VO4M=0-N\*1AS:MPV>])JWB6UG^+-M<QVFH>2D8@9_LK8W
M9_E[T =/XJU?4-9\30>%])NY;-F3SI+F(X90#R/2N2M=%OM"^+EE%>ZM<ZBK
M6LC)).1N R..*T?$TE]X3\<V_B=+66XTZ6,QR*B%G4L>NT<UG7_BRRO_ (CZ
M;JL-IJ7V7R&A+-9N"&8C'% $OBKQQ)?^)+W3/M6L6,-E(8Q)ID!D+=_F]#5G
MP7J^MZ\FH:,UWJL<0/\ H]]<1%)2 .^1CK2KJ%[X"\<:A?7=M//I&J2&?S(8
MV=U(  &T5UL?CY;NRFU*UL+DV$2\F2%EDW8XPM 'G<&H:WI>HW_AG4=?U0ZE
M.X%M,1\H ZX;I7K_ (:TV[TO28X;W4)[V;&3)*03^E>6ZO,^O^&)?%,_VZ&_
MC8-!"L!)A&>0O?FN]\!>+3XGT@&:UGM[J( 2+)$RCVP3UH ZW/K3J;SGK3J
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M#>+/^$HT99);6>WN8P!(DD3*,^V>M=2!C SDT .HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D/0TM(>AH KV/_ ![_ / C
M118_\>__  (T4 .LO^/.+_=J>H++_CSB_P!VIZ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !1110 4444
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M4 ($4=% _"@JK=5!^HI:* $  Z#%&U2<E1GZ4M% "%5;J ?J* H'0 ?2EHH
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M#'T)JY1VH \L^'NB>*M&U:].JZ1;16]Q*TGF+-N(W'.,5ZB .E'\7X4=&P*
M#8F<[1^5.P/2BB@!NQ!T5?RI=BDY*C\J6B@!"JGJ ?PHP,8P,>E+10 @10<A
M0#]*,#&*6B@!OEI_<7\J-BYSM'Y4ZB@!NQ?[H_*E*J1@@&EHH ;L3^ZOY4I5
M3U /U%+10 FQ<8VC'THV+C&T8],4M% "!5'0 ?04M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI:0]#0!7L?^/?
M_@1HHL?^/?\ X$:* '67_'G%_NU/4%E_QYQ?[M3T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1BBB@!,4M%% !1110 8HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DP*6B@ HHHH 3&*7%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 8HHHH **** "BBB@ HHHH **** "DQ2T4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ&EI#T- %>Q_X]
M_P#@1HHL?^/?_@1HH B@EGBA5#;.<#%2?:9L?\>K_G110 ?:9O\ GU?\Z/M,
MW_/J_P"=%% !]IF_Y]7_ #H^TS?\^K_G110 ?:9O^?5_SH^TS?\ /J_YT44
M'VF;_GU?\Z/M,W_/J_YT44 'VF;_ )]7_.C[3-_SZO\ G110 ?:9O^?5_P Z
M/M,W_/J_YT44 'VF;_GU?\Z/M,W_ #ZO^=%% !]IF_Y]7_.C[3-_SZO^=%%
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9$Q4_Z,X_&BB@!]HK)!AE*G).#1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gmz2lq4320rk000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0C"%H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_8FJ?\ /A<?]^S1_8FJ?\^%Q_W[->R;1Z4;1Z4?VC4[!_8U/^8\;_L35/\
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MT4E% "T4E&: %HI*6@ HKS;Q!\7=.T#6KC3)=/GDDA;!97P#^E>AP2B>VCF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ,A_IUJGX@\4Z5X9BBDU2X\E93M4X)R?PKP7P/J=WX+^(?\ 9,LC&)I_LTR
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MV-V^^+'A6SG:);WSBIP?+4X_6M#1?B%X;UR58;744\YND;@@_P L5XIX%M?
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MJ-.F[*^I$JE17?0]VL-1M-4M5N;*=)H6Z,IJUVKQ/X#7LS/J5DSDQ*HD"D\
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M30Z4[JXM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHV.\1XX_.HHM*:;*K)N#2,3X2^$=!U[PW-<:GID-S*)V4.^<XX]#7HUM\/\
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MB,7@'20W\4"M^8KJJIZ38KIFDVMBF-L$8C&/:KM8R=VV;P5HH****DH****
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M)NHG8\S\;6KI\1-1MY6*%KD N>  <<UZ!!\&KV>TCN%\1'RW0.""V,$9K?\
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M-/FM?,(V>9CFE&2]DT.2?M4RE\>_^/32/]Z3_P!EK4^%%XNG_#FYO'&1$6?
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MQ$'!)&3_ $KJSX5\?^)9!9ZI'="WA')D;@X]L\FM:D$YIMF5.;46DB/X,?\
M)0(B/^>,G_H)I_QH_P"1T_[9BMGX6^#O$.B^-$O-1TN>WMQ$ZF1P,9(..].^
M*?@_Q#K?BK[3INE3W,/E@;TQC/YTN:/M;CY9>SL>J^"5"^"-& &,V<9_\=%?
M/'B[GXJ7@];Y/_9:^C?"MK/9>$]*M;F,QSQ6L:.C=58*,BO$O$O@CQ+=_$6Z
MO[?1[B2T:\1UE7&"O&3UK.C)*3;-*J;BDCW@8&A@#H+;_P!EKYG\!?\ )1+'
M_KO_ %%?37EO_9/E;3O\C;M]]M>"^#?!'B:P\;V=Y=Z/<16Z2[FD., 9^M*D
MTE*XZJ;<2W\=[61=>TVZP?+-OLS[[B<5Z#\*-0M[WP1:I"Z[X24=<\@UJ^,_
M"5MXOT9K.<[)D^:&0?PM7B)\&>._"5V_]FPW#(QQOMV^0_4'%5%JI3Y;V%).
MG/FM<] ^.%_;Q>%H;(NOG32@JN>0 0:S_@1:2+IFJ73;A&T@501P>.M<M8_#
MOQAXKU19=<$\$1^]).V>/8<U[QH>B6OA_1H=.LTQ'&N,XY8]R:4Y*,.1,()R
MGSGS;>?\E9F_["9_]"KU#XU:F;;PE96*MS=. P]@ ?Z5Q]UX(\2O\1YM071[
M@VAOS()>,;=V<]:W_B5HFM:_XKTFWM]/FDL8A&)' & =W)_*M).+E'R(BI*+
M\SN?AKI9TCP/80,N&D4RG_@7S#^=>/\ QN_Y* /^O./^;5]$6D"VMG!;K]V*
M-4'X#%>(_%GPAXAUOQF+S3=+GN;?[+&GF)C&06R.OO65&2]I=FE6+]G9'IGP
M[_Y$32O^N1_]"-=37S!#X1^(T$2Q0V>KQQK]U$G( _ -3_\ A%_B7_SPUK_P
M)/\ \53=%-WYD*-9I6Y3Z;KYP^,#"3X@; >0$'Y@5Z_\.;35['PK'#K2W"W8
M<DBX?<V,#ODUXOK(?Q;\7&BBRWF7(CSV 08_I105IL==WBCZ$\-1M!X:TZ)O
MO+ H.?I6K3$540*H 4< "GUS/5G0M$%%%% PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "D-+2&@#R#Q+_R,=]_UU_I7J^G_P#(-M?^N*?R%>4>)?\ D8[[_KK_
M $KU?3_^0;:_]<4_D*]+&_P:9XF6?[Q5_KJRS115>XO;6UQ]IN88<]/,D"Y_
M.O-/;)Z,51_MG2_^@E9_]_U_QI?[9TO_ *"5G_W_ %_QIV8N9%W%%4O[9TO_
M *"5G_W_ %_QH_MG2_\ H)6?_?\ 7_&BS"Z+U)BJ7]LZ7_T$K/\ [_K_ (T?
MVSI?_02L_P#O^O\ C19A=%W%&*I?VSI?_02L_P#O^O\ C1_;.E_]!*S_ ._Z
M_P"-%F%T7<4$9JE_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^-%F%T70**I?V
MSI?_ $$K/_O^O^-']LZ7_P!!*S_[_K_C19A=%W%&.*I?VSI?_02L_P#O^O\
MC1_;.E_]!*S_ ._Z_P"-%F%T7<48JE_;.E_]!*S_ ._Z_P"-']LZ7_T$K3_O
M^O\ C19A=%W%&*I?VSI?_02L_P#O^O\ C1_;.E_]!*S_ ._Z_P"-%F%T7<<4
M8]ZI?VSI?_02L_\ O^O^-']LZ7_T$K/_ +_K_C19A=%W&*6J/]LZ7_T$K/\
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MT7<9ZT8JE_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^-%F%T7<48JE_;.E_\
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M/_O^O^-']LZ7_P!!*S_[_K_C2LPNB[BC%4O[9TO_ *"5G_W_ %_QH_MG2_\
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M -_U_P :/[9TO_H)6?\ W_7_ !HLPNB[BBJ7]LZ7_P!!*S_[_K_C1_;.E_\
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MH%&*I?VSI?\ T$K/_O\ K_C1_;.E_P#02L_^_P"O^-%F%T7<<T8JE_;.E_\
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MJ*H_VSI?_02L_P#O^O\ C1_;.E_]!*S_ ._Z_P"-.S"Z+U%4?[9TO_H)6?\
MW_7_ !H_MG2_^@E9_P#?]?\ &BS"Z+U%4?[9TO\ Z"5G_P!_U_QH_MG2_P#H
M)6?_ '_7_&BS"Z+U%4?[9TO_ *"5G_W_ %_QH_MG2_\ H)6?_?\ 7_&BS"Z+
MU%4?[9TO_H)6?_?]?\:/[9TO_H)6?_?]?\:+,+HO451_MG2_^@E9_P#?]?\
M&C^V=+_Z"5G_ -_U_P :+,+HO451_MG2_P#H)6?_ '_7_&C^V=+_ .@E9_\
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M ,!A_P#%4?\ "@+3_H/S_P#@,/\ XJO9:*T]M/N9^QAV/&O^% 6?_0?G_P#
M8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\
MQ5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_
M  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"
MS_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#
M\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\
MX##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_
M .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*K
MV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BC
MVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X
M>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV
M/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^
M% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?
M_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G
M_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P#
M8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\
MQ5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_
M  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"
MS_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#
M\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\
MX##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_
M .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*K
MV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BC
MVT^X>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X
M>PAV/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV
M/&O^% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^
M% 6?_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?
M_0?G_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G
M_P# 8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P#
M8?\ Q5'_  H"S_Z#\_\ X##_ .*KV6BCVT^X>PAV/&O^% 6?_0?G_P# 8?\
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M]!^?_P !A_\ %5[+11[:?</80['C7_"@+/\ Z#\__@,/_BJ/^% 6?_0?G_\
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M]!^?_P !A_\ %5[+11[:?</80['C7_"@+/\ Z#\__@,/_BJ/^% 6G_0?G_\
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M_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\ "@+/_H/S_P#@,/\ XJC_ (4!9_\
M0?G_ / 8?_%5[+11[:?</80['C7_  H"S_Z#\_\ X##_ .*H_P"% 6?_ $'Y
M_P#P&'_Q5>RT4>VGW#V$.QXU_P * L_^@_/_ . P_P#BJ/\ A0%G_P!!^?\
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M_P * L_^@_/_ . P_P#BJ/\ A0%G_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\
M"@+/_H/S_P#@,/\ XJC_ (4!9_\ 0?G_ / 8?_%5[+11[:?</80['C7_  H"
MS_Z#\_\ X##_ .*H_P"% 6?_ $'Y_P#P&'_Q5>RT4>VGW#V$.QXU_P * L_^
M@_/_ . P_P#BJ/\ A0%G_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\ "@+/_H/S
M_P#@,/\ XJC_ (4!9_\ 0?G_ / 8?_%5[+11[:?</80['C7_  H"S_Z#\_\
MX##_ .*H_P"% 6?_ $'Y_P#P&'_Q5>RT4>VGW#V$.QXU_P * L_^@_/_ . P
M_P#BJ/\ A0%G_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\ "@+/_H/S_P#@,/\
MXJC_ (4!9_\ 0?G_ / 8?_%5[+11[:?</80['C7_  H"S_Z#\_\ X##_ .*H
M_P"% 6?_ $'Y_P#P&'_Q5>RT4>VGW#V$.QXU_P * L_^@_/_ . P_P#BJ/\
MA0%G_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\ "@+3_H/S_P#@,/\ XJC_ (4#
M9_\ 0?G_ / 8?_%5[+11[:?</80['C7_  H"S_Z#\_\ X##_ .*H_P"% VG_
M $'Y_P#P&'_Q5>RT4>VGW#V,.QXU_P * M/^@_/_ . P_P#BJ/\ A0-I_P!!
M^?\ \!A_\57LM%'MIKJ'L8/H>-?\* L_^@_/_P" P_\ BJ/^% 6?_0?G_P#
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M_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\ "@+/_H/S_P#@,/\ XJC_ (4!9_\
M0?G_ / 8?_%5[+11[:?</80['C7_  H"S_Z#\_\ X##_ .*H_P"% 6?_ $'Y
M_P#P&'_Q5>RT4>VGW#V$.QXU_P * L_^@_/_ . P_P#BJ/\ A0%G_P!!^?\
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M_P * L_^@_/_ . P_P#BJ/\ A0%G_P!!^?\ \!A_\57LM%'MI]P]A#L>-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(:6D- 'D'B7_D8[[_KK_2O5]/_ .0;:_\ 7%/Y"O*/$O\ R,=]_P!=
M?Z5ZOI__ "#;7_KBG\A7I8W^#3/$RS_>*O\ 75EFBBBO-/;"BBB@ HHHH **
M** "BBB@ HHHH **3-+0 449HH **3-+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q#_ ./:S_WV_D*?\//^
M/*\_ZZ#^5,^(?_'M9_[[?R%/^'G_ !Y7G_70?RKT?^8+YGBK_D8_([2BBBO.
M/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,TM !129%&: %HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: /(/$O
M_(QWW_77^E>KZ?\ \@VU_P"N*?R%>4>)?^1COO\ KK_2O5]/_P"0;:_]<4_D
M*]+&_P &F>)EG^\5?ZZLLT445YI[84444 %%%% !1110 4444 %5K^\6PL9K
MIT>18D+%$7+' Z 59I& (P0"/>@#S?P?XZU;Q#XSU.PN[$VEM!")(H74B3M@
MGZY]*YW5OB7XCMM6OI8I+*.*UNO(73'7]_,,GD<^WI74:7HVHP_%?7M1:W:.
MTGM%2&8XP6PO^%>?:IX8UOS=3TZ3P_-<ZQ<W9DM]5##:BY.#U[?2@#MO$/C'
MQ!<ZZFC>'EMHIX;/[7<-<+NQP3M R/2JK_%"_N_!^GSV,$2ZQ>71M,.,HKJ2
M"<>F5JMJ^DZ]X:\1IK$&FRZG]KT_[+-Y1 *R8/)R1QR*SAX$US2_!>E7L=IY
MVH6M\U[):@C)5BQP.V?F]: .Q\'^,=2EUC5M"\1F'[9IRB1KB(;49#GMDXZ'
MO6JWQ)\(J2&UNURO4>8/\:YKP9H.H:MXGUWQ%JU@]E;ZA&(8[:0C<5^;).#_
M +57;KX.^"A!/+_9*E]K-GS&ZX^M '3Z-XPT+7_-_L[4(I?*(#?,.,UJ_;K7
M_GXBY_VA7B?P/TRS_M#Q' 804BN0B<G@ M7LW]CV'_/N/S- $WVZU_Y^8O\
MOH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU
M_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_
M[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\
M8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X
M_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV
M'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S
M0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7
M_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\
MOH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU
M_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_
M[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\
M8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X
M_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV
M'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S
M0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7
M_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\
MOH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU
M_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_
M[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\
M8]A_S[C\S1_8]A_S[C\S0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X
M_,T?V/8?\^X_,T 3?;K7_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV
M'_/N/S- $WVZU_Y^8O\ OH4?;K7_ )^8O^^A4/\ 8]A_S[C\S1_8]A_S[C\S
M0!-]NM?^?F+_ +Z%'VZU_P"?F+_OH5#_ &/8?\^X_,T?V/8?\^X_,T 3?;K7
M_GYB_P"^A1]NM?\ GYB_[Z%0_P!CV'_/N/S-']CV'_/N/S- $WVZU_Y^8O\
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M;[RMT->9>%+8VOQ0\3B&V\N,0((P$PIPHX% %FY^+<4$L]RNCSR:1!<"VDO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I#2TAH \@\2_\C'??]=?Z5ZOI_\ R#;7_KBG\A7E'B7_
M )&.^_ZZ_P!*]7T__D&VO_7%/Y"O2QO\&F>)EG^\5?ZZLLT445YI[84444 %
M%%% !1110 4444 %%%% "8HQ2T4 )BC%+10 5!>?\>5Q_P!<V_E4]07G_'E<
M?]<V_E0!X[\#O^0QXH_Z^_ZM7M->+? [_D,>*/\ K[_JU>TT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q#_X]K/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@#R#Q+_P C
M'??]=?Z5ZOI__(-M?^N*?R%>4>)?^1COO^NO]*]7T_\ Y!MK_P!<4_D*]+&_
MP:9XF6?[Q5_KJRS1117FGMA1110 4444 %%%% !1110 4444 %%%% !1110
M5!>?\>-Q_P!<V_E4]5-261M-NA$VUS$V#CVII7=@/G+P=XWM?!?_  E$K#S+
MR6Z(@BQP3EN3[5T'@'XRS2ZD;'Q%(-DS_NY_[A/8^U>-:FKC5KP.=SK,P=@.
M"<U6CC>618XU+.QPH Y)K[+#9/AI8;5W;ZG/*H[GW'%-'/$LD3JZ,,AE.013
MLBO(?"'A[Q]#X1@B35TM'8AD2:,.57TYKT#PY9Z[::?)%K>H17=R6.V2.,*
M/H*^1KTU3J.$7>QNG=&]FC(KA;/1O'4>L+/<Z];/9B0DQ"!<E?3I6+\3/'$V
MCZC8V.F:U#:3,<3@QA]H]3FE3I3JOE@KL&TEJ>JYHKG/#7]J2^&P]UJD-[<R
M F.YCC 7!'' K)TO1_'$&M)-?Z];S66\EXE@4$CL,X^E0TT[#.YHKE?%&F^*
MKV>%M U:&RC"D2+)$&R?QJ_IUIK4/AXV]]?1RZEL($XC 7=VXI ;=)D5Q>A:
M3XTM=66;5M<M[FS&=T2PJI/XXKDOBOXWU3PW?1+I&LPJY&&M?+5F'N36U"A.
MO-4X+43:2/8<BEKYG\)?%K6;2:XM-2O<K='Y+AQN\EO7![5Z_P"$K;Q2]TE]
MJ'B"VU#3I(\JL4*C.<8.16^+P-7"RM4%&2EL=S17&>(]*\97>I^9HNMV]K:;
M1^[>%6(/KDBMF>UUI_#GV>*^C75/+ ^T>6"N[UQTKB*-JC-<CX8TSQ;97KOK
MNL0WD!7Y42(+S]15?7=)\:W.KM-I.N6]M9$C9$\*DC\<4 =M16)JEKK<V@+!
M87T<.I;%#3L@*DXYX^M4?"VF^*+&>8Z_JT-Y&P'EJD07![\B@#J:,UPVI:/X
MYFUJ2:QU^WAL2X*Q&!20O<=*W-=L]<N=%2'2K^*WO\C=*Z @\<\4 ;M%<WX7
ML/$=D)QK^IQ7N['E^7$$V_E61=:+XZ?6FF@U^W2Q\S(B,"Y"^G2@#NZ*P?$E
MEKUYI\<>B:C':7 ;YY'C#9'T-1^&;'Q#9VDZZYJ45Y,6_=M'&%V\>U '145P
MB:-X[&M>>VOVQLO-)\KR%SLSTZ5L^*+'Q#>VT*Z#J45G(I_>%XPVX?C0!T5%
M8/AZSUVTTN6+6=0CNKLD[)$C"@<>@K$L=&\<QZW'-=Z_;26(DRT0@4$KGIG%
M '<T5S'BG3_$U[Y/]@:I#9!?]9YD0;=^=6]%L]=M]#:#5-0CN-0.=LRQA0/3
MB@#<HKA]&TCQQ;ZO'-J6O6]Q9@_/$L"@D?7%7O%.G>*;VXA;0-6ALHE7$BR1
M!MQYYR: .JI,BL6QM-;C\.-;W=_')JFT@7"Q@*#VXZ5C:!I/C.UU59=8UNWN
MK/!W1) JD^G(% ':45R/B72_%UY?H^AZS!9VX7#(\*L<_4BM(6FM_P#",FV-
M_'_:WEX%SY8V[L=<=* -RBN/\-Z7XPL]1,FN:S!=VI7'EI"JG/U IOB'2O&5
MWJGFZ-K4%K9X&(WA5CGOSB@#LJ*Q+JTUM_#:V\%]&FJ[ #<&,;2W<XZ5G>&-
M,\665W*VO:Q!>0%<(B0A2#]10!UE%<1K>C^-[G5GFTO7;>WLSC;$\"DC\<5M
MZM::Y/H*P:=?QP:C@9F:,$'UXH W**Y?PMI_B>R>;^W]5AO58?((X@NT_A6=
MJ>C^.9M9EFL=>MX;(OE(C I*C\J .YHK"UZSUVZTE(M(OX[6]&-\KQA@?7@U
M!X7L/$EE#.->U.*]9B/+\N(+M_*@#I**X6;1O'3:VT\/B"V6Q\W*Q&W7.S/3
MI6SXELO$%Y801Z)J,5I<*?WC/&&W<>_2@#H:*P/#-EK]E92QZ[J$=Y.6RCI&
M% 'X5AQ:-X[&LK-)K]LUEYF3$(%R5STZ4 =WFBN;\46'B.]BA&@ZG%9LI_>%
MXPV[\ZG\/V>NVFDO%K&H1W-[D[94C"@>G'>@#=HKA=.T?QU%K*37FOV\MD')
M:(0*"5[#.*TO%.G>)[Z2'^P-5ALE4'S!)$&)/;K0!U%%8FD6FMP:"T&HWT<V
MHD-MG5  #CCBL/1M(\;6^KI-J6NV\]D&):)8%!([<XH [>BN2\3Z9XKO;J)M
M"U>"SA"_,CQ!B3]2*WM(AOH-*@BU*X6>[5<22*N 3]* +](>E*.E% 'CGQI2
MW?4=&2Z<QP,<2,.H&3S7(ZGH_@&#39I=-\0WL]ZBYBC:/ 9O3[HKK_C2;9=1
MT8W:LUN#^\"]2N3G%<M=7?PP-I)]ET[55N-I\LLYX;_OJ@#TOPEJ-YH'PRAO
M;Z&:>1%S'&@+,P/3]:Q+GXE>*=,%O>:EHEG#8RO@?O/WNT_[.[K^%9.GZOK]
MA\(KFYCDG!^T;(I&R6$9P,@]?6N?\01Z WARSN(=7N-2U61U,GF2,WE\<@@G
MUH ]8\4_$#^Q=+T^:RM5FN=0&Z!9#A1TZG\:J:/XW\1#6H+'Q!H0@CN!F.:U
M!=1Z9()%9NNGPVW@_0(-<BNMKP+Y5U"ORQG ZG(K!L]<F\-Z]I]IX?\ $<FM
MVMQ(JRQN-WE@GMG.* .]\5>.+G2]7BT31K 7VJ2+NVL?E7Z\CUJOHGCK4QKT
M>B>)M,2PNYANB:,Y1O09R>:XKQMI[0_$SS[_ %*XTRUN8UV7<(QMP!D$Y%+I
M>DZ->>,M/BM_%&J:Q<0NLJ.(@\8P<X+%LCIZ4 ;5Y_R7&T_W/_936CH>I6\O
MQ0U*T32[6*9(V)N4+;VY[Y./TK.N^/CC9_[G_LIH\._\EEU;_KD_\Z );7XC
M^(M2U?4=,T[1(+FXMV_=D,0,?[636MX,\?W.NWU[IVK626E[:J7<)G;@'!ZF
ML;X8 ?\ "8>(SCYMP&?QJKHD;S?%'Q'%']][1@O'?Y: -5_'_B'6+ZXC\*Z)
M%=VUNQ5I9VP&]QR*Z/P=XO3Q1!.DD!MKVV;;-">Q]1[5XUX=TVUMC=VFK>*[
MS0KB&0J8E)"M^HYKO?A9ING)J&I:AI]_J%X''ER27,(0,00<@[CF@#U&BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "DI:2@#B?B'_Q[6?^^W\A3_AY_P >
M5Y_UT'\J9\0_^/:S_P!]OY"G_#S_ (\KS_KH/Y5Z/_,%\SQ5_P C'Y':4445
MYQ[04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R7_5/_NF
MO$/A+_R5#Q=_UW;^;5[?+_JG_P!TUXA\)?\ DJ'B[_KNW\VH ]RHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM5QYS8$8&?EX/7BJ\GQ4:;P=8ZC96&_4KNX-JMLQX60$@YYZ94T >F5#>?\
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M4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 _%%,\Z+_GHG_?0IP(-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
M \@\2_\ (QWW_77^E>KZ?_R#;7_KBG\A7E'B7_D8[[_KK_2O5]/_ .0;:_\
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MOY"G_#S_ (\KS_KH/Y4SXA_\>UG_ +[?R%/^'G_'E>?]=!_*O1_Y@OF>*O\
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M_P"@I-_G\:/[(N_^@I-_G\:UZ* ,C^R+O_H*3?Y_&C^R+O\ Z"DW^?QK7HH
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M\&F>)EG^\5?ZZLLT445YI[84444 %%%% !1110 4444 %%%% !1110 4444
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M3W</W7*_YS6L% &!VI:*IRDU9L!,4M%%2 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4E+24 <3\0_P#CVL_]]OY"G_#S_CRO/^N@_E3/B'_Q[6?^^W\A3_AY_P >
M5Y_UT'\J]'_F"^9XJ_Y&/R.THHHKSCV@HHHH **** "BBB@ HHHH **** "B
MBB@ I,4M% "8HI:* $Q2T44 ,E_U3_[IKQ#X2_\ )4/%W_7=OYM7M\O^J?\
MW37B'PE_Y*AXN_Z[M_-J /<J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *0TM(: /(/$O_ ",=]_UU_I7J^G_\@VU_ZXI_(5Y1XE_Y&.^_
MZZ_TKU?3_P#D&VO_ %Q3^0KTL;_!IGB99_O%7^NK+-%%%>:>V%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]_UU_I7J^G_\@VU_ZXI_(5Z6-_@TSQ,L_P!XJ_UU99HHHKS3VPHHHH ****
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M$*QVNL_V*;FUW!A&_5A].M?3VK>'M*ULQ'4+..<QMN4L.16C'&D<:QHBJBC
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M10 R7_5/_NFO$/A+_P E0\7?]=V_FU>WR_ZI_P#=->(?"7_DJ'B[_KNW\VH
M]RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )^KC_OH?X4?V!'_ ,_5Q_WT/\* ->BLC^P(_P#GZN/^^A_A1_8$?_/U<?\
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M-3_Z"1_*C[!J?_02/Y4 :]%9'V#4_P#H)'\J/L&I_P#02/Y4 :]%9'V#4_\
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M=YNXDDM@[4445F,**** "BBB@ HHHH ***2@ HI*0=32 =10.:*$ UB%&XD
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MW*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#B?B'_P >UG_OM_(4
M_P"'G_'E>?\ 70?RIGQ#_P"/:S_WV_D*?\//^/*\_P"N@_E7H_\ ,%\SQ5_R
M,?D=I1117G'M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#)?]4_\ NFO$/A+_ ,E0\7?]=V_FU>WR_P"J?_=->(?"7_DJ'B[_ *[M_-J
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M% !1110 4444 %%%% !1110 4444 %)2T4 )012T4 )BDQS[&G44 )BEHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !24M)0!Q/Q#_X]K/\ WV_D*?\ #S_CRO/^
MN@_E3/B'_P >UG_OM_(4_P"'G_'E>?\ 70?RKT?^8+YGBK_D8_([2BBBO./:
M"BBB@ HHHH **** "BBB@ I*6N3\3Z_KMI=KIVA:*]W<.N[SY&VQ)^..?SH
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M?X4>3K?_ #]P_P#? _PK7HH R/)UO_G[A_[X'^%'DZW_ ,_</_? _P *UZ*
M,CR=;_Y^X?\ O@?X4>3K?_/W#_WP/\*UZ* ,CR=;_P"?N'_O@?X5I6XF6%1.
MP:3^(@<5+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5E(SB.X>4 H&R3N&.O- 'I'@4:1_PBMJ=$=VLFRPWG+ GJ#[BNEKE?A]H/\
MPCOA2"R-REQ(SM+(\9RNYCDX]LUU0H **** "BBB@ J"\_X\KC_KFW\JGJ"\
M_P"/*X_ZYM_*@#QWX'?\ACQ1_P!??]6KVFO%O@=_R&/%'_7W_5J]IH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH
M XGXA_\ 'M9_[[?R%/\ AY_QY7G_ %T'\J9\0_\ CVL_]]OY"G_#S_CRO/\
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M4 %%%% !1110 4AI:0T >0>)?^1COO\ KK_2O5]/_P"0;:_]<4_D*\H\2_\
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M_03'_?!_QH_L_5?^@F/^^#_C0!L45C_V?JO_ $$Q_P!\'_&C^S]5_P"@F/\
MO@_XT ;%%8_]GZK_ -!,?]\'_&C^S]5_Z"8_[X/^- &Q16/_ &?JO_03'_?!
M_P :/[/U7_H)C_O@_P"- &Q16/\ V?JO_03'_?!_QH_L_5?^@F/^^#_C0!L4
M5C_V?JO_ $$Q_P!\'_&C^S]5_P"@F/\ O@_XT ;%%8_]GZK_ -!,?]\'_&C^
MS]5_Z"8_[X/^- &Q16/_ &?JO_03'_?!_P :/[/U7_H)C_O@_P"- &Q16/\
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M\_O6W_?!_P :/^)Y_>MO^^#_ (T :U%9/_$\_O6W_?!_QH_XGG]ZV_[X/^-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ I*6DH XGXA_P#'M9_[[?R%/^'G_'E>?]=!_*F?$/\
MX]K/_?;^0I_P\_X\KS_KH/Y5Z/\ S!?,\5?\C'Y':4445YQ[04444 %%%% !
M1110 4444 %)2U2U;48M(TJZU"<$QV\32,!U.!F@"8VEMOW&VAW>NP9J8
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M"YE>QUXZ4M(.E+7*4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: /(/$O_(QWW_77
M^E>KZ?\ \@VU_P"N*?R%>4>)?^1COO\ KK_2O5]/_P"0;:_]<4_D*]+&_P &
MF>)EG^\5?ZZLLT445YI[84444 %%%% !1110!6U 1'3[@3(SQ&,[E7J1BO)-
M'\*VWB#PU')H6N3V\UK<R&!I%P8P<AD(STY)_&O1_%7B+3?#FDM<ZG(\<+@J
M&12>:\%LS\-[FWGO6UC5K2:1F8PHW4Y/HM 'NW@[PXGA?0$T\7+7#[VDDE/\
M3,<G]:Z =*XSX7W5K=^"H'LDNE@$CA3<G+L,]>@XKM!0 44A. 2>@KC[GXF^
M&[75FTZ2YEWH_EO*(F,:MZ%\8'YT =C17,>(/'>A^&G@COKAVDF7>J0QF0[?
M4@9P*GO/&>B67AZ/7)+P&QDQL9!N9CZ #G/M0!T%07G_ !Y7'_7-OY5E>'?%
M>E^*+=Y=.F9C&<21NI1T/NIY%:MY_P >5Q_US;^5 'COP._Y#'BC_K[_ *M7
MM->+? [_ )#'BC_K[_JU>TT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMK4UZ*2EKPC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9]:_Y^X?R_\ K5KT4 9'V?6O^?N'\O\ ZU'V?6O^?N'\O_K5KT4 9'V?6O\
MG[A_+_ZU'V?6O^?N'\O_ *U:]% &1]GUK_G[A_+_ .M1]GUK_G[A_+_ZU:]%
M &1]GUK_ )^X?R_^M1]GUK_G[A_+_P"M6O10!D?9]:_Y^X?R_P#K4?9]:_Y^
MX?R_^M6O10!D?9]:_P"?N'\O_K4?9]:_Y^X?R_\ K5KT4 9'V?6O^?N'\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-
M+2&@#R#Q+_R,=]_UU_I7J^G_ /(-M?\ KBG\A7E'B7_D8[[_ *Z_TKU?3_\
MD&VO_7%/Y"O2QO\ !IGB99_O%7^NK+-%%%>:>V%%%% !1110 444E $%["+F
MRF@+E1(A7<.V:\:LD\:^$]-N_#EMX6COX)6?R[M3A2&)Y;Y?>MSXJWM[+J>@
MZ%%?/86E].5FG4XZ%<#/XUT/C#18[[P8;<:LUJ;:+>EP) -Q4<9/X4 2?#SP
M[<^&?"4%C>,IN&=II%7[JECG ^E=6.E<7\+M9OM<\#VUSJ#%YT=HO,(^^%.
M?QKM: "BBB@ HHHH *@O/^/*X_ZYM_*I\U!>?\>-Q_US;^5 'COP._Y#'BC_
M *^_ZM7M->+? [_D,>*/^OO^K5[30 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4E+24 <3\0_^/:S_ -]OY"G_  \_X\KS_KH/Y4SXA_\
M'M9_[[?R%/\ AY_QY7G_ %T'\J]'_F"^9XJ_Y&/R.THHHKSCV@HHHH ****
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M#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\
MT#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[
M9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C
M[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:
M@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"_
M_P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\
M_P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T
M#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\
MT#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[
M9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C
M[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:
M@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"_
M_P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T#D_[_P#_ -:C[9JO_0.3_O\
M_P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\ T#D_[_\ _P!:@#5HK*^V:K_T
M#D_[_P#_ -:C[9JO_0.3_O\ _P#UJ -6BLK[9JO_ $#D_P"__P#]:C[9JO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKJ:-HY'B&Y6'(-=-2E%4HU8N]]R4];&I^-'XTM%<Q0GXT?C2T4 )^-'XTM%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF(RZO0@IS6C!33T1T5+29I,UPE"TM(*6@ HHHI@%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M*6DH XGXA_\ 'M9_[[?R%/\ AY_QY7G_ %T'\J9\0_\ CVL_]]OY"G_#S_CR
MO/\ KH/Y5Z/_ #!?,\5?\C'Y':4445YQ[04444 %%%% !1110 4444 %%%%
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D-+2&@#R#Q+_R,=]_UU_I7J^G_ /(-M?\ KBG\A7E'B7_D8[[_ *Z_
MTKU?3_\ D&VO_7%/Y"O2QO\ !IGB99_O%7^NK+-%%%>:>V%%%% !1110 444
M4 %%%% !1110 R:588))7^ZBEC^%?-OC'Q7;^)-:M]9FU!H8;2^6*WLRK#Y
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M#[K4OM7B!Q9JTSSAI5S]UOFR.M>Q_;=7_P"@>G_?7_UZ\N^!W_(8\4?]??\
M5J]IH R/MNK_ /0/3_OK_P"O1]MU?_H'I_WU_P#7K7HH R/MNK_] ]/^^O\
MZ]'VW5_^@>G_ 'U_]>M>B@#(^VZO_P! ]/\ OK_Z]'VW5_\ H'I_WU_]>M>B
M@#(^VZO_ - ]/^^O_KT?;=7_ .@>G_?7_P!>M>B@#(^VZO\ ] ]/^^O_ *]'
MVW5_^@>G_?7_ ->M>B@#(^VZO_T#T_[Z_P#KT?;=7_Z!Z?\ ?7_UZUZ* ,C[
M;J__ $#T_P"^O_KT?;=7_P"@>G_?7_UZUZ* ,C[;J_\ T#T_[Z_^O1]MU?\
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MI_WU_P#7K7HH R/MNK_] ]/^^O\ Z]'VW5_^@>G_ 'U_]>M>B@#(^VZO_P!
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M10!D_P!IWW_0)G_[[7_&C^T[[_H$S_\ ?:_XUK44 9/]IWW_ $"9_P#OM?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO12U<I725M@%HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 'COP._Y#'BC_K[_ *M7M->+? [_ )#'BC_K[_JU>TT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q#_P"/:S_WV_D*
M?\//^/*\_P"N@_E3/B'_ ,>UG_OM_(4_X>?\>5Y_UT'\J]'_ )@OF>*O^1C\
MCM****\X]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+
M_JG_ -TUXA\)?^2H>+O^N[?S:O;Y?]4_^Z:\0^$O_)4/%W_7=OYM0![E1110
M 4444 %%%% !1110 4E+24 (16,?"FC-K8U@V$1O0,!]H_/Z^];=%5&<H_"[
M U<;2BBBH 6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG_0,F_*C^U+S_H&3?E0!K45D_P!J7G_0,F_*C^U+S_H&3?E0!K45D_VI>?\
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M3_:EY_T#)ORH_M2\_P"@9-^5 &M163_:EY_T#)ORH_M2\_Z!DWY4 :U%9/\
M:EY_T#)ORH_M2\_Z!DWY4 :U%9/]J7G_ $#)ORH_M2\_Z!DWY4 :U%9/]J7G
M_0,F_*C^U+S_ *!DWY4 :U%9/]J7G_0,F_*C^U+S_H&3?E0!K45D_P!J7G_0
M,F_*C^U+S_H&3?E0!K45D_VI>?\ 0,F_*C^U+S_H&3?E0!K4E97]IWG_ $#)
MA^%:<9+(I*E21R#VH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0T >0>)?^1COO^NO]*]7T_\ Y!MK_P!<4_D*\H\2_P#(QWW_ %U_I7J^G_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I#2TAH \@\2_\C'??]=?Z5ZOI_P#R
M#;7_ *XI_(5Y1XE_Y&.^_P"NO]*]7T__ )!MK_UQ3^0KTL;_  :9XF6?[Q5_
MKJRS1117FGMA1110 4444 %%%% !1110 4444 %%%% !1110 5!>?\>5Q_US
M;^53U!>?\>5Q_P!<V_E0!X[\#O\ D,>*/^OO^K5[37BWP._Y#'BC_K[_ *M7
MM- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+
M24 <3\0_^/:S_P!]OY"G_#S_ (\KS_KH/Y4SXA_\>UG_ +[?R%/^'G_'E>?]
M=!_*O1_Y@OF>*O\ D8_([2BBBO./:"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** &2_ZI_]TUXA\)?^2H>+O^N[?S:O;Y?]4_\ NFO$/A+_
M ,E0\7?]=V_FU 'N5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %(:6D- 'D'B7_D8[[_KK_2O5]/\ ^0;:_P#7%/Y"O*/$O_(QWW_77^E>
MKZ?_ ,@VU_ZXI_(5Z6-_@TSQ,L_WBK_75EFBBBO-/;"BBB@ HHHH **** "B
MBB@ HHHH **** "BBD9@JY8X [T +4%Y_P >5Q_US;^52*ZN-RL"/45'>?\
M'E<?]<V_E0!X[\#O^0QXH_Z^_P"K5[37BWP._P"0QXH_Z^_ZM7M- !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 <3\0_\
MCVL_]]OY"G_#S_CRO/\ KH/Y4SXA_P#'M9_[[?R%/^'G_'E>?]=!_*O1_P"8
M+YGBK_D8_([2BBBO./:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **0F@$'.#0 V7_ %3_ .Z:\0^$O_)4/%W_ %W;^;5[?+_JG_W37B'PE_Y*
MAXN_Z[M_-J /<J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *0TM(: /(/$O_(QWW_77^E>KZ?_ ,@VU_ZXI_(5Y1XE_P"1COO^NO\ 2O5]
M/_Y!MK_UQ3^0KTL;_!IGB99_O%7^NK+-%%%>:>V%%%% !1110 4444 %%%%
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M_P +QU/_ *$S5./^F3?X4_X$V$UM#KXNK8INO6*^8G4<=*]A,,6"?*3I_=%
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M3?X5[-Y$7_/)/^^12>3%_P \D_[Y% 'B9^/\ZW(M3X7O1<D9\D@[S^&,U/\
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M/6O6/LEK_P ^\/\ WP* /(O^%[/_ -"CJO\ WP?\*/\ A>S_ /0HZK_WP?\
M"O7?LEK_ ,^T/_? H^R6O_/M#_WP* /''_:!BCF6!_#6H+,WW8VX9OH,5-_P
MO9_^A1U7_O@_X52\:V+'XY^'FCM/W (W%4^7H.M>U?9+7 _T:'_O@4 >1?\
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M_O@4GV2UQ_Q[0_\ ? H \=B_: BGD>.'PUJ$CI]]4Y*_7BIO^%[2?]"CJO\
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M]C^R6I_Y=H?^_8KQ3XBV+-\8O#+0VO[E5.\JGR]^M %[_A>TG_0HZK_WP?\
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M/_Y!MK_UQ3^0KTL;_!IGB99_O%7^NK+-%%%>:>V%%%% !1110 4444 %%%%
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MNC6QT^0DLPG!=5&>=N/:NQ\:_9CX4OA>03SV^S]Y'!]\COBO%K@Z'!J7AQ_
M[7277FYN8_GPL8!SN!XH [/5?B-XDM1?:I;^'\:+8R%9'E?8[@=2,CVKT?1=
M4BUK1[74805CN$#@-VKQ'Q-XSL?%_B*31[V[?3?#ML_[XK"Q:Y([< \?XU[=
MHK63Z+:'3C_HGE@1$#''XT :%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %(:6D- 'D'B7_D8[[_KK_2O5]/_ .0;:_\ 7%/Y"O*/$O\
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M@!,56BTZR@BEBBM84CE.9%5  Y]_6K5% &=9:#I.FS--9:=:V\C=7BB52?Q
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M;?C/35U/PEJ%NRAB(F<9]5&1_*O$M-U%_$</ASPS\V89V:4@],%L?I0!Z/\
M#+Q=J&MV=_'K-QNNK5LL64+@'/I]*?\ #[Q%JNOZCK%S>W>_3X)#'"I10%QC
MOBN1\1W@\&>-]9$0$4-[9LR>A<@XJQ:I<:'\%KF]A)CGOFWLR]>6"G]* /1W
M\<^&([_[$VL0"XW;=G/7ZXQ6[YT7D^=YB^5C=OSQCUKP#3K>:;PN+6/X?3W+
M2Q_+?*"6)/<';6S>7.N:5\&9(+^&YM9UG\D+(I#>7QQ].30!Z2/'7AEK[[$-
M8M_M&[;LP>OUQBL[XCZ[?:)X2-_IEP(YO.10X 8$'/K7F,%M<7/A=;.'X>3R
M2.GRWR@[B>NX';6KKRZI'\%H8-7@FAN8KE4"S*0=HSCK0!Z3;^)["P\.V%[K
M5_'$\Z#+,.6/T J_>^(-)TZPCOKR]CAMI "COGD'VZUX;X:N9;SQ-HS^*XF^
MQM&%L]XVH3SCCOS7>?$GPGJFLW6GZAIL$=S'9KAK5^C#V'>@#L=)\5:'KDK1
MZ9J,-PZC)5<@_J*V:\<\.W&A0^++1]2T&ZT'56(2%$.R-_J,#K7L?:@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I*6DH XGXA_\>UG_ +[?R%/^'G_'E>?]=!_*
MF?$/_CVL_P#?;^0I_P //^/*\_ZZ#^5>C_S!?,\5?\C'Y':4445YQ[04444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.K^%++3$GBBO;/:8KC:<*0>?>F:WX'OM7LM/E356MM6LXPBSQYV-CN17<44
M><:9\.=4?7K75?$6N?VA+:L&B"KMY'KQ7HPZ4M% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !24M)0!Q/Q#_ ./:S_WV_D*?\//^/*\_ZZ#^5,^(?_'M9_[[?R%/
M^'G_ !Y7G_70?RKT?^8+YGBK_D8_([2BBBO./:"BBB@ HHHH **** "BBB@
MHHHH **** $KS_7=9L_$VI_V+9:Q)87EI,';(V^;@<@9%=\Q"J2Q 4<G->6^
M+H/!WB6^VVNKP6FM1G$<D9*[F'8X_G0!F^(=1L?%UY)H&L+-IE_ Y%K/*?E?
MZ]NW6M+PQXEU/1[V+PMXDLVFC?\ =V]PJ[E=<=\=:YZXN!=NOA[QK;^3=)A;
M;4HUY]LGN*]*\&:!?:3I@BU6ZCOFC;-K(5W,B$?WCS0!L:1H.FZ&)QI]LL/G
MOO?;W/\ DT_6-1?2M/>ZCM);ME(_=1'YC5_MQ7DVH_$G4M \>7]E?0";3(W
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M0Y[;X8V=E#IJ12FX1WM[-&8(2#GU/>J6J^%)/#>CZ)X@T.VF6ZMMHN8D4EI
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M\/-9T/2K'6O#TLD.HQPAKFW)^\>^/\*['P5X]C\1%M.O86M]4A&)8R.#[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !24M)0!Q/Q#_P"/:S_WV_D*?\//
M^/*\_P"N@_E3/B'_ ,>UG_OM_(4_X>?\>5Y_UT'\J]'_ )@OF>*O^1C\CM**
M**\X]H**** "BBB@ HHHH **** *U[%+/93102^5*ZD))C.T^M>'0ZCK'PRU
M+41?V N9+L'R[SKEN<'/I7O-4=5TBSUFP>SO[=)H7ZAAT]Q[T >36'AC0O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:K=-<Z=:'=:H6)!/TZ#J:]7P* %'2BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M045EP0/I5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M? UO?Q7)ML3(DT(C# L) ,Y/OS5W1]1OO#?A\Z'<:5>S7D"F.%X86:-QT&6
MP*AO/#M_9?#R&R,3RW;7"RO'&-VW,@/Z"@#N=*AN+;3(4N;HW,@7_6&,)Q]!
MQ7-P:CK/B+5M033+]+&SLW\I6$*R&5QUSN' Y'2NM@4BVC4\?( 1^%<38S7/
MA#5M2AN+"\N;2ZE,\,MO$9.3Q@@#CIUH J^$I]1T^P\12F#[1?)<CY$Z,<8S
M_6H]7\3ZAX?M8[JZ\1PSW:A9)-.%NF"#U4.!FHH-/UF_\.>(L6<UM/<SJZ1D
M$%TX_7%4-4AAD\&3:?H'AB\MKN:(&XWVK)T'/)'S'F@#5GAU"Z^)-E/'J;1B
M6S655\A257)^3^?/O6A>:MJA-U=7NL+H=O'(8X8FA20R8SR<Y(SC]:AN([FQ
M\4Z3?O9W30M8K;[HH2Y1^?O8Z#GK65I-K!I%]?OJV@7=YJWVAY(+I;=I 02=
MOS <8!% '8>#->D\0:&;B5UDDBE:%I5&!)C'S8[=:O\ B'5QHFB7-]MWM& $
M7U)( _G6'\/;>^MM*O5U&V>"X>\D<J1QSCH>XK6\5Z5+K'AZZM+<XF(#)GH2
M"#C]* ,BVD\5V\=AJ$MQ]NCG9?/LTA53$K<Y!ZG'O5V;6+Q/'5II8<"UDMC(
MR%1G.#W_  K/M=?U:YM++3K+3+F"_7:MQ)<V[")0.&PW /M2ZVMSIGC&PUE[
M2XN+40M%)]FC+LK8/\([<T +J.I:E<^(M3TB*[$$"61D0B-6(/'K]37.^&=4
MO] ^']O<QW'VF2YE6&V@:,*$8\9R.3VK7T]+[4/&6HWYL)X+6>R*0M*A4D\<
M$'H:R;+2M1G\&0Z?%9SIJ.F7"S%)8RJ28_NL>O2@#>O[[Q!X;@M=1OM16^MG
M=5GA\A4\O<<#!'7DCK67J-K?W'Q.T]HM6:/S+1WC/D*=BY7C'?Z^U6=:O;WQ
M996NDV>FWL#F1&N)+B%HT4*03@GKTJ]/I]RGQ%TR989&MXK)XS+M.T'*\9_"
M@#)TVQU'_A:>H!M79F2WB9C]G3YUW-\OMWY'K78^)-9&A:+->!0T@PL:GNQ(
M _G6-I]G<I\2=3NF@D6V>UC59"IVD@OD ^M:7B_2)=:\/S6\'^O0K)&,]2"#
MC]* .0\76OB/_A$OM-[J4=Q&^UIK?R541_1@,G'O71W][JAEM+2UN!I]HMN)
M);YD5\<= &^GZU@^(=;O]9\,?V=#HFHB]('G!X&"KCKAL<T:WIBCQ/:7>LZ5
M<:CIAM0B1QQ&7RG&<Y4?A0!)I_B2YU*^U'1(M;2]_P!%:6.]2!5*XP""N,'K
M6?X9U:]\._#^&Z^U?:7N)!#;0-&JA&/&2>I[5=TV*]N_&LMTFE3VNGMI[0V^
M^,KC&T8([=*SH="N]2\$#1VT^;[;I\ZRM'/$5CE [*QX.<4 ;MYJNM:!%:ZA
M=:O%J%O(ZK/ (T0Q[C@8*\G!(KN4<21JZG*L,@UYB=.TN]^R6^D>#UAO2Z^;
M+=V96.,#DD$]>G%>FQH(XU08  QP,"@#EM2U?4K[Q0- TJ=;0QQ":>Y*!RH.
M< *>.U1VNIZK!K%SX?U"\\R9X3+;7BQ*#CC.5Z>M1ZC#=Z%XT;71:S75E<0+
M#*($+NA!." .O6DTZ"[USQ=)KK6T]M9PVYAA6="CN20<[3R.] %7X=6M\C:G
M+-J+31B\E5HS"HWMG[V1S^%6/B#*\S:/I8;;%=W0$HSC*K@X_2KG@BTN+6#4
MQ<P21%[Z5E#KC<I/!%6/%^@S:U8V\EH0+RSE$T.[HQ!&1^(H U[C3K232WL6
M@C-OY>T1[1C&*\_T/Q%/H?@FZ509YK6\-I;ACQS@+S6^_BRZFLS:Q:+J']I,
M-FUX&$0;H?WF,8]ZS)?!U]!X$6SC*/J2SB[<=F<$$C]* -.!O%%C=6$LUP=2
MMKGB>-840P9!.01U'05E6-G?CXJWQ_M1BJPH[#R%^9<<+_\ 7ZUJ0:_JNHR6
M-IIVGW%NZD?:Y+NW9550.=I.,G-1;)['XDS7,MI</;W<*1QRQQ%E4@<[B/NB
M@#LN2,9Y]:\TUG01I_CS0;Z6]FN[F>[(+2' 5=K?*%Z#M7I@'?UKD?%-G<7'
MBCPY+#;R21PW!,CJI(0;6Z^E %7Q7MB\9>'Y[S_CR#,,D94/\NW-5?$&I6T7
MQ$T$6DBF5E993'W7#8!KI/$]Q'%:QQW6C/J5E*VV98UWLGOM R>]8.D:3;ZA
MKEK<:?I#Z;I=BS.%EA,322$$?=/.,$<T =[574K0W^G7%H)6B\Z-D\Q>JY&,
MBHX-5@GU&>P595FA +;D(4@^A[T:O>2V.ESW4$#SRQH2D:#)8XX% ')^(8]-
M\-^#AHD:+//<#RXH]@+2.3G)_7FLT6UQ!KWA'1[XEC#;EW0\C>NW&?7O2>'K
M^"VN6U76-/UJYU63.6-@Y$2YX5:V?$$$\U[I/B:SM;B1;7/F0&,B0HV"?EZY
MXZ4 1^,S]B\1>'KR+*2M.T)91R5(QC]:NQZ=IO@_3-2O+JX\YKAVDD>11N;)
M.%'MS^E49Y)_%/B#3[A+"[@L=/#3.US"8RS$8 53U[5CQWYU'7YK_P 0Z9J[
M1V\I%I;)9NT:XXW=.2?ZT 47BNK;P#"DR-;Q:AJ*LL.,;8V(X_\ K5UGCJVB
MC\$+(JA6MC$T95>5.Y>GI4FO1/XK\-LVGV]S#<02K+&ES$8BS+SCFL[5K^\\
M3:7;:+:Z9?0S2.GVB2XA9$0*03AB,'.* .UTR4SZ7:3-G=)"K'/N!5NHK>,0
MP1Q+]U%"C\*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;3J* $HQ2
MT4 )1CK2T4 -]J6EHH ;^%+CCBEHH 3VHQ2T4 )1^%+10 F*.]+10 AI.W2G
M44 )^%)BG44 )2=?44ZB@! **6B@!N*4CBEHH 3FC'K2T4 -Y]*6EHH 2C%+
M10 E%+10 VCG-.HH ;BEI:* $I".:=10 VEQ2T4 4K?3XX+VXN]S/+-C);L!
MV%7.U+10 E)SBG44 -I0*6B@!M+S2T4 (*6BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gmz2lq4320rk000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -Z"%8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<QNW08X'\S0![A]LMO\ GXA_[[%'VRV_Y^(?^^Q7A3_ W741F.IZ=A1GJ_\
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MECECF7=%(CKZJP(H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGLU><:CJNJ6?Q%O3832-<&^DCA5F)&YF*CC\:]#^!?\ R!M4_P"NJ?R:N!4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1SU'K7*V>G7%SX]-A]L-G<O<LHG(^Z:]#U3X<:M;V$CZEXP*6IP',J?+S^-
M'3?#_P :RZ[X2N)[K]Y>V0(DP/OC&0?\^E>1V,\GCCQ3*NN:X;*-]S*7?"YS
M]T9X%>I_#KPQ:^%X-1N?[9@O;69%W%%P$QG)/-<OJWPWT77=4N#X7UNW\_EV
MM#T7Z'L/PH @NOACXATN\M[GPOJ9NHB<B19@NW'KV(KN?%WA[5_$/@BVCNKI
M+2^MU,D^TDAL=N/I7DFI:1XO^'TD5S)</"COM62*4LI/IS7LGAOQ#/XE^'DM
M]<J!.(W20CHQ Z_K0!X5X.\-77B?7'T^TO1:2+$SF0@\@$#''UKVCQ;X@G\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M73\?_KUG/X ^(6L;;?4GN#"#@&XN@ZCWQDU]"44 <7X"\ 0>#K>26259[Z8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT;Q#IWB/3I+K3I2Z*,,&&"IQW%>>Z#J_A'_A%9].O6M)]1>:X0VR(#.[&5\
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M9+/3/$DMKIK,2MNUL)&0'J%<MD#^5=#I6EVNC:=%8V:%88A@9.2?<GN:NT4
M%%%% 'F&G?\ )QVK_P#8$3_T)*]/KS#3O^3CM7_[ B?^A)7H]W?V=@BM>74-
MNK'"F60*"?QH L45FCQ#HI.!J]B2>G^D)_C6E0 4444 %%%% !1110 4444
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M<T<]Q+>,GS;&#!4V,V3D#KCC-=O10  8&**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\DDALI
MY(4WRI&S(OJ0.!4U% 'F^CV_A_7M+&H>(-0C.K%F+--,(Y+1@?NQYY7'J.O7
MO4-S+?WW@A;Z8RWJZ7J(FBE*G?/"F/FQU)Y(_"N]N/#^BWD[3W.CZ?/,WWI)
M;9&8_4D5?6-$C$:(JH!@*!@ >F* .6\0>)=+N/"UP+.\AN9KN+RX88FR[%N/
MN]1USS6SX?LFTWP]I]G(,/#;HC#W"C/ZT^WT/2+2Y^TVVE6,,X_Y:QVZ*WY@
M9J_0 5YEXK^$/A2]36=<FBO/MLB37+$7)"[\%NGIGM7IM9WB#_D6M5_Z\Y?_
M $ T <S\(;RYOOA=HL]W.\TI1UWNV3A9& 'X  ?A7;UP/P7_ .23Z)])?_1K
MUWU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M K.\0?\ (M:K_P!><O\ Z :T:SO$'_(M:K_UYR_^@&@#DO@O_P DGT3Z2_\
MHUZ[ZN!^"_\ R2?1/I+_ .C7KOJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \TU/0(]<^*EY%]JN+
M-UL$8S6QVN1D#!/IS7>Z1IW]DZ9%9?:9KGR\_O9VR[9)/)_&N9M/^2N7_P#V
M#E_FM=I0!Q/A7_D?/%G_ %TB_D:[:N)\*_\ (^>+/^ND7\C7;4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'H: +]%8B>+_  ^^IC3EU6W-X7V"+)SN]/2MN@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *SO$'_(M:K_UYR_^@&M&L[Q!_P BUJO_ %YR_P#H!H Y+X+_ /))
M]$^DO_HUZ[ZN!^"__))]$^DO_HUZ[Z@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,NO$.D65R]O<Z
MA!%,GWD9N1WJHQE)VBKDSG&"O)V-.BJ5AJUAJ>_[#=QS^7C=L.<9Z5=I2BXN
MS01E&2O%W0444A. 3Z4BA:*RM UH:Y:7$X@\GR;F6WQNW9V,5ST[XJ&Q\0K>
M7^M6QMRG]F2B,MOSYF45\XQQ]['X4 ;=%<WX/\6IXKL9IC:&TFB;F(ON^4YV
MMG ZX-)XL\6IX82U"6ANYIY%7RQ)MVJ3@L3@\4 =+165;ZT)]>;2_(P19I=>
M9N_O,PVXQ_L]:U: "BN8NO&4<6O6.G6]C+-#<SM;M=$[45U4D@<?-C&#TJWK
M6O36%W#I^G6/V[4IAO6$R>6JI_>9L''Y4 ;E%<]I/B2XN=3ETK5=.%AJ*1^:
MD<<WFK(G<JV!R,CC'>JE]XGUJQ62\E\.A=+B?#S-=8E"9P6\O;T[_>Z4 =91
M3(9DN((YHSE)%#*?8T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .+M/^2N7_ /V#E_FM=I7%VG_)
M7+__ +!R_P UKM* .)\*_P#(^>+/^ND7\C7;5Q/A7_D?/%G_ %TB_D:[:@ K
M'U/Q5HFC7?V74+]()BH?848\'OP/:MBN;\;VEM)X3U2X>WA:9;<[9"@+#Z'K
M0!/8^,?#^I7L=G9ZDDMQ*2$0(PS@9[CT%;M<_P"$["S7PUI-PMI )OLL9\P1
MC=DKUSUKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)U
M[Q!:^'[9)[E)'#G"K&.?UK6J.:WAN%"SPQRJ.@=0P_6J@XJ2<E=$55-P:@[,
MXS_A9VE?\^=Y^2_XT?\ "SM*_P"?.\_)?\:ZS^R]/_Y\+7_ORO\ A1_9>G_\
M^%K_ -^5_P *Z_:87^1_><'L<=_S]7_@)Y!JOBS4KO5+B>SO[R"W=LQQ^:1M
M'T!Q6OX:\=G38;A=5>\O'=@4.X-M'?J:Z2_^'FF7]_-=&XGA\UMWEQA0J_3B
MM#1?".FZ+%,@7[5YA!S<(K%<>G%=E3%825+EY>W]7/-HX',(XCGYK;Z[K[C'
M_P"%G:5_SYWGY+_C1_PL[2O^?.\_)?\ &NL_LO3_ /GPM?\ ORO^%']EZ?\
M\^%K_P!^5_PKC]IA?Y']YZ7L<=_S]7_@)'I^IP:OI0O;<,(W4X##!%<'X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%VG_)7+_\
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M)"X(4O&.GJ2#BO1-)\6Z%K:!K'4H').T*6VMGZ'!H VJ*.M% !1110 4444
M%%%% !1110 5G>(/^1:U7_KSE_\ 0#6C6=X@_P"1:U7_ *\Y?_0#0!R7P7_Y
M)/HGTE_]&O7?5P/P7_Y)/HGTE_\ 1KUWU !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KG]>\9Z#X=)34+U%E&,Q+\S\^W6LWQOXY/@^6Q06(N?M)(SYFW;C'L
M?6J.H?#K3_%FLC7=1GE\NXA0BW3C:<#^+O\ E0!PWB;Q_HFNO]GL?#$-S(9.
M))%(+_\ ?.#6'I_PZ\6W[->VFGM9X;*J[F,CZ9YKW[2O"^BZ*FVPT^&(D#+!
M>3BM>@#QWX=^(->TSQ4WA?7)'?@[1(<E2!G@]Q7L58!\'Z8?%(\0GS3? 8'S
M?+TQT^E;] !1110 4444 %%%% !1110 5G>(/^1:U7_KSE_] -:-9WB#_D6M
M5_Z\Y?\ T T <E\%_P#DD^B?27_T:]=]7 _!?_DD^B?27_T:]=]0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!S>M^"-+\02RO?W&ILDH
MPT,=_*D9_P"  XHDT)]&\/7EKI+7EW-.NQ1=W;2[<\<%SP,$]*Z2B@#GHO!^
MG'PU8Z-<"1EM$4)-'(4D5@.65ARN?;L:=IO@_2]-O5O UY=SI_JWO;I[@Q^Z
M[R=I^E;]% &'JWA/3-8O5O9?M-O=!=AGL[AX'9?1F0@D?6KFD:)8Z):M!91L
M [%I))&+O(?5F/+'ZUH44 <Q/X!T2:>613?6\<S;Y+>WO)(H6)ZYC4A>>_%=
M%;V\-I;QV]O$D4,:[41!@*/0"I:* "H+RTAO[.6UN%+0RJ5< XR*GJCK.I+H
MVC7>HO&95MHS(4!P6QVJH*3DE'<F5N5\VQP7_"+Z0/'$NF-$PLUMA( 9#D'C
MG-<OXY\0R^(]3M_#6BAGM(&6)0ISYC#C\A_2JWB'QG)JLUSJUC$]J9XA!AFR
M0!UYKL_AAX-_LVS76KY,W5PN8@W\"GO]3_6OH)7P\%7KN[2LEY]6>!AHQJ2G
M2HJR;=WY=$>:6FB0Z?X]@TC4?WD4=PJ2[21G@'K7TI7SIXVD:W^(]],IP5N0
M0?P%?0UM.MS;13I]V10P^AKCS*<JM.E5?5?B>C@HJ$ZD%T9+6#XU_P"1,U;_
M *]S6]6#XU_Y$S5O^O<UY)Z!-X4_Y%+2?^O2/_T$5L5C^%/^12TG_KTC_P#0
M16Q0 4444 %%%% !1110 4444 %%%% !1110 4444 <_?>-O#VFWLMG=Z@(Y
MXCM=/+<X/X"I])\5:+KETUMIUX)I53>5V,,#(&>1[U@?$RUMU\,^>+>(3-<Q
MYD"#<>?6NPM[*UM\/!;0Q,5P62,*<?A0!8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *XGPO_P E!\5_[T7\C7;5Q/A?_DH/BO\
MWHOY&@#MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\NU+XBZQ8:A]G5
MM"=6F:-2)\E,'&7PWR_C77^$]7U/6;6>XOO[/:(,%B>REWJ3SN!.3TXJY4YQ
M5VFB5.+=DSHJ***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9;^)+PH$$)SG)8X'3W%>BT %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSCZ>M '9?\+5\'?]! _]^'_PKFK+XD7>J?$>WL-.N_.TB9L!3" >_<C-:/\
MPI+P[_S]7_\ W\7_ .)K;\-?#?0_#%\;RU\Z:?&%:9@=OTP!0!V%%%% !111
M0 4R:,3021'HZE3^(I]% 'GNA:__ ,(A9S:)J]CJ)EMYI#;R6]I),LR,Q9?F
M0$#@@<XZ5$/#>K3>%;R\%L$U.74?[3AMB5X(  4GIDXKT>B@#A;_ ,6C7M)?
M2M-TW4AJ5TGE,D]G)&D6?O$NRA3@9Z&NNTJQ&F:19V((/V>%(\CO@ 9JY10
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4\89"JKCKSG-==<ZC9VFGR7\UQ&MJB[C+NR,>V.M<UI%K=^(M:C\0ZA&8;2
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MTR&RDNVMA%,)=RINSP1CK[UGA)PA7C*>R.S$1E*DXQW/G_PH<>+=(][R(?\
MCPKZ#\:_\B7JW_7N:\U\#> (;S5)K\ZA(K:9J&Q4$8/F;"#SSQFO2O&O_(F:
MM_U[FNS-,32KSBZ;O8Y\#1G2BU-&'?Z=_:?PAA@"Y=;"-U]L '^0->8Z+J.[
MX?ZSIS-RD\4R@^Y _I7MOAN)9_!6FPM]V2R13]"N*^>KP2:7K&I:?C:C3%2/
M8-D483]YA*M+MJ+$>YB(3[Z'TU:_\><'_7-?Y5-4-K_QYP?]<U_E4U>6=X44
M44 %%%% !16;KFLQ:%8"[FM[B=2X39;IN;G/./3BN:'Q.TPRM$-,U4R*,E!
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M5 \;J593T(->$^(-,OOAWXOCU&QW?8Y'W1GL1W4_Y[U[S63XCT&V\1:/-87
M'S#*/CE6[&NS!8GV,[2UB]&<V)H>UC>/Q+8ET/6;77])AU"T;,<@Y7/*GN#6
MC7A7A+6KSP%XIET?4\BUD?8_H#V8>W^->YHZR1K(C!D89!'<48S#>PGIK%[,
M>&K^UCKNMQU%%%<9T!7/>,_$*>'/#L]UD>>XV0J>[&NA) &2< 5X1XMU&X\=
M>-X=*L26MHG\N/T_VF_E7;@<.JU2\OA6K.;%5G3A[N[T1J?"GPZ^H:A-XBOP
M7VL1$6_B<]6_G7L=4M)TR#1]+M["V&(H4"CW]ZNUGB\0Z]5SZ=/0K#T52IJ/
M4****YC<**** "BBB@ H/(P:** /%OB/X3FT+4E\0Z2&CB9PT@3_ )9OZ_0U
MW_@;Q;%XHT=6<JM[" LR?U%=)=VD-]:2VMQ&)(95*NI'!!KPC4K/4/AIXQ2Y
MM=QM'/R-V=,\J?>O7I26-H^QE\<=GW\CSJB>&J>TC\+W/1_A]_Q\^)/^PG)_
M,UVU>6_#[Q;HT<^J+<WB037]^7AB8'+;CP.!ZG%>I5Y<Z4Z;M-6.^,XS5XNX
M4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+>-;F+1?BS9
M:GJD1DL=HQD9 ^7'\Z]IK#\3^']'U_3O)U=4$:G*R%@I0^QH \VN/$VBR?%J
MQU-+^ 62VNTR[OE4\\54MK^W\4_&6VO-)7-O",LX&-V."?UJ9_A'H!D8KXIC
M52>!\AP/^^J[[PGH'AKPU'Y.FW%O)<R<-(9%+M0!UE%%% !1110 4444 %%%
M% !1110 5G>(/^1:U7_KSE_] -:-9WB#_D6M5_Z\Y?\ T T >=_!UOW$B_\
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M %Z1_P#H(KQ/XGVL5GXXN)(G0^:%D958':< 8/H>,_C7MGA3_D4M)_Z](_\
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MW.*NG-PFIKH3.*E%Q?4^;+?P'X@NM6NM,AM$-U:A3*GG*  >G.<&MQM$\?\
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M((8[:!(8E"1HH55'85V8B2PE'ZO#XG\3_0YZ*>(J>UE\*V)****\@] ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7BGQ*EU?Q#XXM_#-G(R1%5
MPN["MD9)/KBNZ\<>/$\&&U#V+77VC=C$FW&,>Q]:\D\0_$:/5-?L-;L=--K>
MVIP6:3<'7TQ@4 ;/_"CM6_Z"UM_WRU:WAKX1ZEHGB&SU*74X)(X'W%%#9/%1
M)\=8Q&H?1'+X^8B< $_]\UJ:!\8(M=URUTT:0\1N'V[S-G'X;: /3J*** "B
MBB@ HHHH **** "BBB@ K.\0?\BUJO\ UYR_^@&M&L[Q!_R+6J_]><O_ * :
M /)/A=IUIJ-S9&ZCWF"%)8OF(PP&0>/I7ME>,_")L7EJ,];4?^@U[-79COXB
M?DCS<L_A27:4OS"BBBN,](*YCXA?\B+J7^ZG_H:UT]<Q\0O^1%U+_=3_ -#6
M@#;TG_D#6/\ U[Q_^@BKE4])_P"0-8_]>\?_ *"*N4 %%%% !1110 4444 %
M<;XR_P"1E\)_]?Q_]EKLJXWQE_R,OA/_ *_C_P"RT =E1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !17G?Q'T&"#3+S7HKJ\2Z+1C8LV(QR%Z8]/>MWP[X1LM)EAU"&ZOI)7AP
M5FFW+R!GC% '3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Q/PX_U&N_\ 83D_D*[:N)^''^HU
MW_L)R?R%=M0 4444 %%%% !7/>.?^1)U7_KC_45T-<]XY_Y$G5?^N/\ 44 7
MO#O_ "+6E_\ 7I%_Z"*TZS/#O_(M:7_UZ1?^@BM.@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y7QCXTC\'/927-G+/:SE@[Q=4(QCKQSD]^U)I/Q'\
M+ZN8(XM32*XF&1#,"I4XS@GI^M='>V%IJ-LUO>6\<\3=5D4$5YUK'P5T.\9Y
M-.GGL6VX2,-N3/J<Y/ZT >@?VQI?_02L_P#O^O\ C5#4O&7AW2!&;W5[:/S,
M[=K;\X_W<UY1_P *)U3_ *#-G_W[:M;2_@9:(@;5-4EDD#9VVX 4CT.1F@#H
MM-^*&G:YXFM]'TJUGF5Y&#W#+A H!.X=^2!U ZUW=9.B^&M'\/0^7IEC%!UR
MV-S'_@1YK6H **** "BBB@ HHHH **** "BBB@ HHHH ^?\ QNN?C7J9]-+B
M/ZK7N&AMNT*Q/_3!!^E>*>,EW?&C6#CII,1_\>6O9O#;;O#MB<Y_= 5V3_W2
M/JSSJ>F/G_A1JT445QGHG$_#K[NO_P#83DK8\:_\B9JW_7N:Q_AU]W7_ /L)
MR5L>-?\ D3-6_P"O<T 3>%/^12TG_KTC_P#017,?$[1=,'AJZU(6%O\ ;6DC
M#7'EC>>0.OTKI_"G_(I:3_UZ1_\ H(K&^)W_ ")%S_UUC_\ 0A51G*+O%V$X
MJ6Z+8\#^&KK3HXVT>U3>BDM'&%;IZUQNL_!N,[I=&O=AZB*;./SKU*U_X\X/
M^N:_RJ:NBEC:])WC(QJ8:E-:Q/!UO/'G@EPDBW#VR\ -^\C(]O2NHT7XQ6<Q
M6+5[1[=^ADC^9?Q[UZ<Z+(A1U#*>H89!KEM;^'GA_6@S-:"WF/22#Y<?AT_2
MNOZWAZW\>%GW1S_5ZU+^%*Z[,V].US2]6C$EC>PS ] &P?R/-:%>*ZC\*-<T
MF0W&AWQEV\@*^QQ^/&:K6?Q \6>&)1;:O;/-&O %Q&5./8\9I/+XU%?#S4O+
M9C6,E#2M&WGT/<ZXW3/^2JZW_P!>47_LM4]-^+?AZZ@+7AEM)%&2A0MGZ8KB
M];\?V\7B36-0T9VD^V6J01R,I7;@#)P?H:YXX#$.?)R/]#9XNBH\W,:'Q.\7
M/J-T/#NEL77<!,4_C;^Z*[+P!X13PSI >90;Z<!I6_N_[-<M\+_!SL__  D6
MIH2[DF!7Z_[QKUFNC&5HTH+"TMEN^[,<-3E.7MZF[V\D%%%%>6=P4444 %%%
M% !1110 4444 %9>N>'[#Q%:QVVH+(T<;^8NQRIS@C^M:E% '&_\*O\ #7_/
M&Y_[_FNIT^P@TS3X;*V#"&%=J!CDX^M6:* "BBB@ J*XM8+N(Q7$*2QGJKC(
M-2T4)M; <;JGPR\-ZD&9+3[+(>C0?*!^%>(^(M GT76KRS2*=[>&8QI,T9 ?
MT]J^H*XWXE?\B_9_]A"'_P!FKT<+F=6C\7O+S9QU\%3J[:,QO@W:W%KH^I+<
M02Q,;A2!(A7/R^]>ET45R8BM[:JZC5KG11I^R@H=@HHHK$T"BBB@ HHHH **
M** "BBB@ HHHH **** "N/\ %7P]TOQ('G51;7Q&1,@^\?\ :]:["BM*56=*
M7-!V9$Z<:BY9*YX%%<>*OAIJ&QU9[,M]TG,3CV]#7JGA?QUI7B6$*D@@NP/F
M@D.#^'K70WEE:ZA;-;W<"31,,%77->3>)_A9<V,K:CX=E?"'=Y ;#+_NFO35
M;#XS2K[L^_1^IQ>SJX;6G[T>Q[#17CGACXI7>FRC3O$<<C!#M\XKAT_WA7HM
M[XRT.PL+>^FO UO<$B-XE+Y(Z@XZ5PXC"5<._?6G?H=-'$0JKW3>KRKXL>*F
MBC70+)\R2X,Y7KCLO\JW-1^*7AZ'3YGM;B22X"GRT,+#)^I%</\ #[09_%GB
M6;7=2R\,4AD.[H[]A]!_2NK 4HQ3Q-3X8_BS'%U)-JC#=_D=U\-O"@T#1%NI
MT'VVZ 9_55[#^OXUV]   P!@"BN&M5E5FYRW9U4Z:IQ48] HHHK(L**** "B
MBB@ HHHH *@O;.#4+.6TN8Q)#*I5E/<&IZ*:;3N@:OHSP*9+_P"&?C4.@9K-
MSD>DB$]/J*@UGQ;O77;33F8IJ=[YN\=2G/'YD5Z)\8(8F\&K,R*9$N4"MCD
MYS_*O$M( .M6((R#<1Y'_ A7TN&A#%1CB9KWH_C8\2O*5"4J,7H_P/=_AKX8
M&@Z MQ,N+R[&]_\ 97L/ZUVU( %  & . !2U\]6JRJU'.6[/8ITU3@HKH%%%
M%9%A1110 4444 %%%% !1110 4444 <3\/O^/GQ)_P!A.3^9KMJXGX??\?/B
M3_L)R?S-=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+
MXCM- >R^V:];VTD$ )#3H&VY]*\P;QC\-1=&(>&T*!]OF"V3;C/7KG%7?C==
M3"VTRR1V5)G8L >#C '\ZLVWPHT)O!BN\3'4&MO,\_>>&QGITQ0!T^F>&_!>
ML6,=Y8Z3I\T+CAEA'^%:5IX2\/V-RES:Z1:13(<JZ1 $&O-_@G<S17.K::SD
MQQ,& SP#DC^E>Q4 %%%% !1110 4444 %%%% !1110 5G>(/^1:U7_KSE_\
M0#6C7E_Q9\1ZKH\EG9V-SY4%W!(LR[%.X<#J1QP36V'H2KU%3CNS*M55*'/(
MP_A(V-2T\>ML?_0:]EFO;2W?9-=0QMC.UY #^M>*_"QA'KE@HQA8W4?3!%>I
M:YX3T76))+V^L_-N%BVA_,8<#)' -=.8P<*D8O=)'!E4E*%1K^9FO'?V<T@C
MBNX'<]%60$G\*L5YU\-/#VERZ)::R]MF_260++O;CJ.F<=#7HM<!Z@5S'Q"_
MY$74O]U/_0UKIZYCXA?\B+J7^ZG_ *&M &WI/_(&L?\ KWC_ /015RJ>D_\
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M$DN5((XXSBMGPMXVU:W\;7/A_7$DVRR'R#)U7VSW% 'JM%%% !1110 4444
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M-YJ5S%I-@[7\_G2!Y^%// ^;IS7H]% $<!E:WB:=568H#(JG@-CD#\:DHHH
M**** "BBB@ HHHH **** "BBB@ K#U^PUZ]> Z-JT=BJ@^8'B#[SQCJ/K6Y1
M0!S?A'P[=>'H;X7EW'<S7<_G,Z+MY/7]:Z2BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBO)?B9XVUJSUR+P_H+/'<,%+/&,N2>0!0
M!ZU17S]N^+?_ %%_R%;/A0_$K_A)[#^U_P"T_L'F?OO- VXP>M 'M%%%% !1
M110 4444 %%%% !1110 5G>(/^1:U7_KSE_] -:-9WB#_D6M5_Z\Y?\ T T
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MHHH **** "BBB@ HHHH **** "BBB@#B?AQ_J-=_["<G\A7;5Q/PX_U&N_\
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MHX!&1G'>K%,BBCAC6.*-8XUZ*@P!^%/H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH XGX<?ZC7?^PG)_(5VU<3\./]1KO_83D_D*[:@ HHILDB11M)(P5%&68G
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B\?\ PX\0^)?%
M$NH6$EJ+9D0*)9BI!  /&#7KM>2^//%WC32/%$UIHL,K6:HA4K9^8,D#/./6
M@#F/^%0^-/\ G[M?_ IO\*V?"GPS\5:1XGL+^]N;=K:&3=(%N&8D8/;%8_\
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M9!-*1W,S#^M:<'P_\,V^-NEQ-C^^-W\ZXN;+X_9DSIY<8^J1PLWQIGDXMM%
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M  FWA;_H8--_\"5_QKS*WUVSE^-<#Z%*&M)QY4QA^XYY)/'!^M6/^%#1?]#
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MHS1VJQIK[*2*P"O!S?5A7B/Q9T;4KCQ.^H0V%Q)9I;('G6,E%P3G)KVZN?\
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MI!Z&O2PF*@X_5Z_PO;R.+$4)*7MJ7Q?F=M'(DT22QL&1P&5@>"#T-<?\3?\
MD4O^WJ+^9KAO ?C>X\/7W]AZX76W#;%9^L39Z?2NW^)3K+X.5T8,C7,1!'0C
M-<V*PL\//E>W1]S:A7C6C=;G9I]Q?I2TB?<7Z4M<QN%%%% !1110 4444 %%
M%>-_%#6]<O\ Q3;^%]'DE0NH)6(X+DC/7T% 'LE%?/W_  K7XA_\_+?^!Y_Q
MK8\+^ O&^G>)K"\U"X+6D4H:4?;"V1],\T >TT444 %%%% !1110 4444 %%
M%% !1110 4444 >6VG/[1&M#_J!)_P"A)6G\/SC5]83TD/\ Z%6=8#/[1FL#
MUT1/_0DJ_P" SCQ-K:>C-_Z&:[</_ J_+\SS<7IBJ+\W^1Z#1117$>D%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_0DJ]X6^3Q[JJ^N[^==N&_A55Y?J>;C?X]!^;_(]!HHHKB/2"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KQKQ_'-XI^)5AX8DN6@M%4,?0G;NS
MCU[5[+7FGQ(\"ZCJ]Y#KFA.1J,( 9 ^TL!W!]: ,32O#5CX8^,%CI]AYGE&U
M+L9&R2>0?Y56L[)O"7QIAL;"Y>2"[.75CR V3@^O2N8DU+QVOB&/5WL;TZA
MGDK)]A)&!_P'!^M=_P##_P $:S_;I\3^(W;[2P/EQR-ELGN?3Z>] 'J]%%%
M!1110 4444 %%%% !1110 5G>(/^1:U7_KSE_P#0#6C6=X@_Y%K5?^O.7_T
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MNUNM1MWDF5 @(E9>,D]C[U0C^&_AB*5)$LI R,&!\]^H_&@#K**** "BBB@
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M-=_["<G\A7;4 %%%% !1110 5SWCG_D2=5_ZX_U%=#7/>.?^1)U7_KC_ %%
M%[P[_P BUI?_ %Z1?^@BM.LSP[_R+6E_]>D7_H(K3H **** "BBB@ KC?B;_
M ,BE_P!O47\S795QOQ-_Y%+_ +>HOYF@#L4^XOTI:1/N+]*6@ HHHH ****
M"BBB@ KS/QK\++CQ7XADU2/58K=615\MH2QX&.N:],KR;Q];^/Y/$\C>'FU
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX_Y$K5?^N']1705Q7C?Q+HQ\/ZMI8OX_MOEE/)P<[LCCI0!T/AK_ )%?2O\
MKTB_]!%:E<WX.UO3;_1;&RM;M);FWM(_-C .5P #^M=)0 4444 %%%% !111
M0 4444 %%%% !1110 5QNI?\E7T7_KQE_P#9J[*N-U+_ )*OHO\ UXR_^S4
M=E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!S/CCPG'XNT)K,.([B-M\+GH#Z'VKR2V^%7C*^N8;+493'8
M1M\KO<AU0#^ZN3C\J^@:* .!\7VVJ>&OA_#8^&Q,9(L1'R8][E3U(XR.IY%9
M'PU^'M_I6H-KNN<7; B.-FW,,_Q$^M>JT4 %%%% !1110 4444 %%%% !111
M0 5G>(/^1:U7_KSE_P#0#6C6=X@_Y%K5?^O.7_T T <'\,EW? FT7UMK@?\
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MAN*#4+V"SO;1##+:3.$EROHAY.1C&!5[P-9SP:/<7=S"T$E_=277EN,%0QR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \R^+/B#4M$ET<65Y/:Q2R,9GB8C(!7@_F:I-\5HU\=06R:E;GP^4&^8Q'(.
MSUZ_>]J[SQ7X4L?%VF"RO6>/:VY)8_O*:\KD^"MT/$Z6Z22G12/FNBZ>8#M_
MN_7CI0!Z/_PLKP=_T';?_OE_\*LV/CSPQJ5[%9V>KPS7$IVHBJV6/XBO.'^%
MO@N.0QOXP574X*FXA!!KH]!^$6E:)K-KJD&IW<KP-O56"[6X]A0!Z-1110 4
M444 %%%% !1110 4444 %9WB#_D6M5_Z\Y?_ $ UHUG>(/\ D6M5_P"O.7_T
M T <9\(UW?!G2U]8IQ_Y$>K7PW;]QJ">DO\ C4/P<7=\(='7U28?^17IWPW;
M][JR>DB_S:NRC_NU3Y?F>=B-,91_[>_([ZBBBN,]$**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K*UW2KO5H(H[35KC3F1MS/",EACH
M>16K10!PD'P]OK:ZGNH?%5]'/<8,LBQX+XZ9.ZNSL;>2UL8+>6X>XDC0*TS_
M 'G([FK%% !1110 4444 %%%% '$_#C_ %&N_P#83D_D*[:N)^''^HUW_L)R
M?R%=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>2_%+7]6N=9M/"NBLZRSX,FPX+9Z#/8=_PKUJO%_B!//X5^)MAXD,#26[*
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M4Y]_2MGX,Z4;'PG)?2+M-W*64G^Z./Y@UR;SQ7WQWA>Q.Y%G <CH<9S_ $H
M]VHHHH **** "BBB@ HHHH **** "BBB@ HHHH \PT[_ )..U?\ [ B?^A)5
M_P <_+XHT1_1D_\ 0ZH:=_R<=J__ &!$_P#0DK0\?_+K&D/Z./\ T*NS ?QE
MZ/\ (\[-?]V?JOS.^7E%/M2TR+F)#_LBGUQL]!;!1110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *H:QHNGZ]8-9:E;+/ QS@\$'V(Y%7Z* /+9/@;H
M;RLZZE?(I.0@VD >G(KO-!\-Z7X:LOLNF6RQ*3EFZLQ]R>:T3<0 X,T>?]X5
M+0 4444 %%%% !1110 4444 %%%% !6=X@_Y%K5?^O.7_P! -:-9WB#_ )%K
M5?\ KSE_] - ')?!?_DD^B?27_T:]1^$?D\:ZJGUJ3X+_P#))]$^DO\ Z->H
M_#OR?$?5$]F_I7;A?X=5>7ZGFX[2M1?][]#T*BBBN(](**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&944LS!5')). *
MCBNK><D0SQ2$=0C@T 2T4R26.%-\KJB^K' I(IXIU+12I(!U*,#0!)14+W=M
M&^R2XB1_[K. :FH **** /,-._Y..U?_ + B?^A)6[\2%SX?C/I**PM._P"3
MCM7_ .P(G_H25T7Q%7/AECZ2+_,5TX/^/#U.+,5?"5/0W=#;=H=F?6(5H5E^
M&VW>'+$^L0K4K&KI.7J=%!WI1?D@HHHJ#4**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YKQCXN_P"$0LHKR339KN!VVL\;@;#VSGUY_*O')OB<TGC^/7UB
MO%L57!L_/X/R;?IUYKZ OK"UU*T>TO8$GMY!AHW&0:\UUCX>>%=(\11ZUJ%W
M:6>E?=^PO'\C';CKGUYZ4 5O^%[Z=_T!+K_OZO\ A6'H7BR\\3?%>TNK+[5#
M:2'Y[=I2R@ ')(Z>E=7_ ,6D_P"H1^M:>B:OX T[4H;?0#9_:KMQ&!;+D]">
M<]N* .YHHHH **** "BBB@ HHHH **** "L[Q!_R+6J_]><O_H!K1K.\0?\
M(M:K_P!><O\ Z : .2^"_P#R2?1/I+_Z->H];^3XHZ8W0%4S^;5)\%_^23Z)
M])?_ $:],\3_ "?$+2I/9?YFNW _')>3/-S/^%%_WH_F>@T445Q'I!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>(^/+";Q3\5[709;EH;?RP$;KM^3<<#UKVZO/_ !QX$O=9U>UUS1KK
MR-0MRH()QN&>H/J!0!YO9_#>UE\?77ANYOYHD1-\,P1<N,>E:OACPY8>%/BA
M'I.HJ;B;B2RN%<K@\\%>AR,_E6]\0O#'B!;[3_$>A>:^H6\*QS>2H9\CG<!C
MGKZ5D^!O"WB?5O&4?B'Q''<1FW.=UPFQG;L ,#CK0![71110 4444 %%%% !
M1110 4444 %9WB#_ )%K5?\ KSE_] -:-9WB#_D6M5_Z\Y?_ $ T <E\%_\
MDD^B?27_ -&O3/&/R>,-)D]Q_.G_  7_ .23Z)])?_1KTWQY\FNZ0_\ M'^8
MKLP'\:WD_P CSLU_W>_9K\ST"BBBN,]$**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :Z+(I5U#*>H(R*9';P0G,4,:'U50*EHH ;)&DJ[9
M$5U]&&121Q1PKMBC1!Z*N*?10!$UM;N^]X(F?^\4!-2T44 %%%% 'F&G?\G'
M:O\ ]@1/_0DKK_&J[O"MX/8']:Y#3O\ DX[5_P#L")_Z$E=IXM7=X8O1_L9K
M;#NU6/JCGQ:O0FO)_D0>"&SX4M/8$5T5<SX".?"L'LQ'\JZ:GB?XTO5DX)WP
MT/1!1116!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .PHK$T'Q/9^(7G2UM[N(P@%OM$6S.<].?:MN@ HHHH **** "BBB@ HHHH
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M"?Q!U/PA:SP6-K:2K,^]C,K$YQ[$>E=UX6^+FMZYXFL=,N+*Q2&XDVLT:ON
MP>F6KU_[-!_SPC_[X%*L$*D%8HP1T(44 24444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \PT[_DX[5_^P(G_ *$E>D7@W64X]8V_
ME7F^G?\ )QVK_P#8$3_T)*[7Q)K;:+9HRZ?=7OG$IMMTW%>.I]J:W%+5,Y_X
M;G]SJ"^DO^-=U7DOA'Q(=(FNU&EWMV9W!(@3=Y?)^]Z?_6KTS5-8LM&MTGOI
M3'&[; 0I;G&>WTKLQL7+$M15W_P#SLMG&.#C*3LE?\R]17/V_C70;JYCMXKP
MM)*P11Y3#)/3M63XF\<3Z)JWV2VM[>=/+#%BQX)SQQ]*RAA*TI<G+9^>AM4Q
M^'A#VCDFO+7\CMJ*X7P]XWU'7-8BM#8VR0\F5_,(*C'8$\\XKL)=2L()&CFO
M;:.1>JO*H(_ FIJ4*E.?)):FE'%4JU/VD'H6J*AM[RUN]WV:YAFV_>\MPV/R
MJ:LFFM&;IIJZ"BD)"C)( ]35>34;&'_67ENG^]*H_K0DWL#DENRS16-/XKT2
MWSOOXCC^[\W\JS)_B'H<>?+DDEQ_=0C^8K:.&K2VB_N.>>,P\/BFOO.IDECB
M7=(ZHN<98X%1_;;7_GYA_P"_@KS;Q-XQT_7])DLUL+CY6#I(3@*PZ'CV)KA:
M[J&5RG&]1\K/+Q6>0I22I+F7W?H?1".LB!T8,IZ%3D&E9E499@![FO-=+L?&
M7]EV]I:!;:S1?W?*YP>>O7O5L>"=>NSNO=;?!ZJLC'_ZU<_U6$7[]1?+4ZUC
MZDU^[HR?KH=K/JEA;#,UW"H_WA63<>-=!M\_Z:)".T8S63!\-=/4[KB[GF;O
MGBM:V\$Z#:X*V8<CN[%OYT<N$CO)OY6#GQ\]HQCZN_Y&7/\ $>QY%G9W,Q]U
MQ_+-4CXT\07IQ8Z*5ST)R?Y@5V\.F6%N!Y-E;QX[K$!5OH,"E[?#Q^&G?U8_
MJV+G\=:WHCP369;R;6+F34(_+NV;,B@8P<5L>%&\0I#<MHBJR[E\P$=^<5J>
M/;W[8;C3K3P[=FZ2=6-Y';9$@'7# 9-=-X8UV"_NY+6#P]=:8!'O9Y(!&K$$
M#' Z\UUSS.,J?(H?Y'!2R6<:WM'4[[;_ 'F/_;_C2V_X^-*##V4#^M \?:K
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MD+=Y/7]^: .SSD9%%5[&SBTZP@LX-WE0H$3<<G ]ZL4 %%%% !1110 4444
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M VS_ ._"_P"%']CZ7_T#;/\ [\+_ (4 <-_PO/P!_P!!>;_P#E_^)H_X7GX
M_P"@O-_X!R__ !-=S_8^E_\ 0-L_^_"_X4?V/I?_ $#;/_OPO^% '#?\+S\
M?]!>;_P#E_\ B:/^%Y^ /^@O-_X!R_\ Q-=S_8^E_P#0-L_^_"_X4?V/I?\
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MPO\ A0!PW_"\_ '_ $%YO_ .7_XFC_A>?@#_ *"\W_@'+_\ $UW/]CZ7_P!
MVS_[\+_A1_8^E_\ 0-L_^_"_X4 <-_PO/P!_T%YO_ .7_P")H_X7GX _Z"\W
M_@'+_P#$UW/]CZ7_ - VS_[\+_A1_8^E_P#0-L_^_"_X4 <-_P +S\ ?]!>;
M_P  Y?\ XFC_ (7GX _Z"\W_ (!R_P#Q-4/B9IEG'XJ\ K#8P*CZP!($A !&
M5ZX'2O2/['TO_H&V?_?A?\* .&_X7GX _P"@O-_X!R__ !-'_"\_ '_07F_\
M Y?_ (FNY_L?2_\ H&V?_?A?\*/['TO_ *!MG_WX7_"@#AO^%Y^ /^@O-_X!
MR_\ Q-'_  O/P!_T%YO_  #E_P#B:[G^Q]+_ .@;9_\ ?A?\*/['TO\ Z!MG
M_P!^%_PH X;_ (7GX _Z"\W_ (!R_P#Q-'_"\_ '_07F_P# .7_XFNY_L?2_
M^@;9_P#?A?\ "C^Q]+_Z!MG_ -^%_P * *OASQ/I'BS3!J.C7:W%ON*DX*LI
M!Z%3R/QK7KRSX-1>3=>-5$>Q1KDNT;<#&3TKU.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML?2_^@;9_P#?A?\ "MJ>682$%'V:=NK2N1+%5I-OF9Y?_P +.^%?_/\ S_\
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ML8'D^W3C,D()QD>HH O_ /"\_ '_ $%YO_ .7_XFC_A>?@#_ *"\W_@'+_\
M$UW/]CZ7_P! VS_[\+_A1_8^E_\ 0-L_^_"_X4 <-_PO/P!_T%YO_ .7_P")
MH_X7GX _Z"\W_@'+_P#$UW/]CZ7_ - VS_[\+_A1_8^E_P#0-L_^_"_X4 <-
M_P +S\ ?]!>;_P  Y?\ XFC_ (7GX _Z"\W_ (!R_P#Q-=S_ &/I?_0-L_\
MOPO^%']CZ7_T#;/_ +\+_A0!PW_"\_ '_07F_P# .7_XFC_A>?@#_H+S?^ <
MO_Q-5?C;I=G#\+M0>VL8$E$L.&CA ;_6+Z"NXTO1],.D61;3K0DP)G,"_P!T
M>U '(_\ "\_ '_07F_\  .7_ .)H_P"%Y^ /^@O-_P" <O\ \37<_P!CZ7_T
M#;/_ +\+_A1_8^E_] VS_P"_"_X4 <-_PO/P!_T%YO\ P#E_^)H_X7GX _Z"
M\W_@'+_\37<_V/I?_0-L_P#OPO\ A1_8^E_] VS_ ._"_P"% '#?\+S\ ?\
M07F_\ Y?_B:/^%Y^ /\ H+S?^ <O_P 37<_V/I?_ $#;/_OPO^%']CZ7_P!
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M\W_@'+_\37<_V/I?_0-L_P#OPO\ A1_8^E_] VS_ ._"_P"% '#?\+S\ ?\
M07F_\ Y?_B:/^%Y^ /\ H+S?^ <O_P 365XZTRT3XM^ $BL8%A>2X\Q5B 4\
M+C/%>G?V/I?_ $#;/_OPO^% '#?\+S\ ?]!>;_P#E_\ B:/^%Y^ /^@O-_X!
MR_\ Q-=S_8^E_P#0-L_^_"_X4?V/I?\ T#;/_OPO^% '#?\ "\_ '_07F_\
M .7_ .)H_P"%Y^ /^@O-_P" <O\ \37<_P!CZ7_T#;/_ +\+_A1_8^E_] VS
M_P"_"_X4 <-_PO/P!_T%YO\ P#E_^)H_X7GX _Z"\W_@'+_\37<_V/I?_0-L
M_P#OPO\ A1_8^E_] VS_ ._"_P"% '#?\+S\ ?\ 07F_\ Y?_B:/^%Y^ /\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $  & ,"EHHH **** "
MBBB@ H(!&",BBB@ Z# HHHH **** "BBB@ I" 2"0#CI2T4 %%%% !1110 4
M444 %)@9S@9]:6B@ HHHH **** "BBB@ I  .@ SUI:* "BBB@ HHHH ****
M "D  &  /I2T4 %%%% !1110 4444 (0",$ CWI:** "BBB@ HHHH **** $
M(!Z@'ZTM%% !1110 4444 %%%% "8!() R.E+110 4444 %%%% !1110 F "
M2 ,GK2T44 %%%% !1110 4444 ( !T 'TI:** "BBB@ HHHH *" 1@C(HHH
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M\?+&!Y;G"KV&0.I/2O120!D\ 5Y]XHU?3&\;^%F74;0K'<2;R)UPO[M^O/%
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MJ#S&9)%=@H/S$\@G-=X#D CO7$^++NVU^?2=(TV>*[D:\BGD,+AA&B,&))'
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M'GN/0UU=<IX-NIY)=4M1>2WVGVTH6UN9269@<Y7<?O8P.:ZN@ HHHH ****
M//?'VGW26L5_<:A*^V]B$$,?R(@+#KW+8XSG'/2NZN[;[9926_G2P^8A7S(B
M ZY'4$@\UQOQ(U.P&C0P&^MA,EY#NC,J[AAAU&:ZN36=-@TN;46O8&M($+22
MI(&50!D]* .*\3^']/\ "]A:ZCHJRV^I"X2-&$K,9L]58$D<X[5Z)7 :5J-E
MXEU2'7M3U.SAM82?L%DUPF1_TT<9^]Z#M^-=\&#*&4@@]".] "T444 %%%%
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M9O>9!'.K;%[1H,]!^O6J9TKQ=:>)-2U6WM]'N1<82%I[J56CB&<+@(1U)[T
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M@"K>:;8ZBJK?65M=*IRHGB5P/ID5!!X?T6UF6:WT?3X95Y5X[9%8?0@5HT4
M%%%% !1110!4O-,T_40HOK&VNMGW?/A5\?3(J2TL;2PB\JSM8+:/.=D,809^
M@J>B@"G>:3INHNKWVGVETRC"F>%7(^F15F**.")8H8TCC085$4  >@ I]% !
M1110 4444 1RV\,Y0S0QR&-MR%U!VGU'H:)X(;F%H9XDEB<89)%#*?J#4E%
M%2STO3M.+&QL+6UW_>\B%4S]<"K=%% !1110 4444 116T$#2-##'&TC;G*(
M 6/3)QU/ I[HLB%'4,K#!5AD&G44 ,BBC@B6*&-8XT&U41<!1Z 4^BB@ HHH
MH *CDMX)GC:6&.1HVW(64$J?4>AJ2B@""ZL[6^@,%Y;0W$1.3'-&'4_@:BL]
M)TW3F9K'3[2U9AAC!"J$_7 JY10 4444 %%%% !1110 4444 %%%% !1110
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M!SYJ6Z!\_4#-7Z* "BBB@ HHHH *BDMH)I(Y)88W>([HV9 2AQC(/;@FI:*
M(KFUM[R!H+J"*>)NL<J!E/X&HK/3;#3E9;&RMK56Y801*@/UP*M44 %%%% !
M1110 5$;:!KA;@PQF=5*K(4&X ]0#UQP*EHH *BBMX(&D:&&.,R-N<HH&X^I
MQU/%2T4 %%%% !1110 5'%;PP%S##''YC;GV*!N/J<=34E% &?<Z%I%[.9[O
M2K&>8]9);=&8_B15V**.")8HHUCC485$& !Z 4^B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%JWF3;IY)<QD\[N,]^>U=_XC\4Z7X7L?M.HS[2V?+C499SZ"O&O!'_):9_\
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MKUS^E><^%M(MM:^*<EK=Q^9 +B1V0]#@]Z[KXR:%IT'A>WO;>SAAFBG$8:-
MN00<CCZ"@#U*VN8;RVCN+>020RJ&1EZ$&I:XKX43R7'P_L6D.2K.H^@8@5VM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\Q7H3>(+?PS\/['5+F&66*.VA!2/&XY '>O/?CK_ ,?^D?\ 7-_YBNA\;_\
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MI?AUX7TI? UK++8PRRW<>^1Y$#$Y';/3\* -CPGXZTGQ?&_V(R13Q\M!*!N
M]>.*Z>OG[P"G]F_%^6SM_EA$L\>W_9 ; _2OH&@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_GFOH/P]:36'AZPM;C_710A7]C4EEHFE:;*9;'3;2VD(P6AA5"1]0*OT %>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J&>UM[I0MQ;Q3*#D"1 P'YU-1
M0!%!;6]JA2W@BA4G)$:!1^E2T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!573+!)?-6QMED!SO$2@Y]<XJU110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gmz2lq4320rk000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /7"$H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDI: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I*** /G[XX-M\7V;==MLIQ_P(TZT^.6HV=C!:KHUL1%&
ML88RMS@8]*3XW 'QC8@]/LZY!_WC7IVC^ O"LVC64TF@V32/ C,QCY)*CFNM
MN"IQNCC49RG*QX;&=7^(OC:*X:W.^1E#;1\L: ^OMS7I_P 5O$]UX<T*QT6P
MD*7%Q&%9U.&"CCC\17H^G:-I^DQ^786<-NAY(C7&:\8^.UK-_:NF71_U!B,>
M<=#DFDIJI)(IP=.+96TOX3-JN@IJEUK@34)H_,2,L#U&1DGG-;'PC\4WPU6X
M\-ZE,TWE@^2S'<01U&?3 K!T?X0OK&BP:E!XFMUADC#M^Z)V<="=W:NG\"?#
M,:+XAAU>W\16U['%N#)"G7((Z[C53E&S39--2NK(Y+XQR21_$"-H3B01IM/O
M@5UOA?X2*TUAKNJZG<O> K*\1'&[K][.:Y/XP_\ )08^GW$X_ 5]!68_T.''
M]P?RJ)R:II(J$4ZCN3 8 'I7SK\9W\OQ\K@ [8(SC\Z^B^E?._QC4-\0H@P!
M4PQ@C'UJ<-\>I6)^#0N0_';48+6.!=%MCL0*&,K=ACTKF=,AU;XA>.H[J2$Y
MD<-*RK@1H/\ "O=;#P#X4>PMI&T&Q+-&I)\OJ<5T%AI5CI4/DV-K%;QDYVQK
M@57MHQORH7L92W9YG\;D\OPIIZ=EEQS]!7*>"?AU/XWT=;_4-3F@MT;9 B+N
M! X/!Z<BNN^.G_(M67_78_TK:^$'_)/+,_[<G_H1IJ7+2NA<JE5LS ^(OB!_
M!'ABR\.:1*PF:/RS(3\RH/ZGFL30O@Y<:]I,>I:MJUQ%<S+O1<;SCMDFF_'"
MVF@U_3[]E)A=-H^J_P#ZZ]=\+ZM9ZMX;L[JVE5HQ$H;G[I P<_E2<G"FG'<.
M52FU+8\8T#6=8^'GCA=$U&Y>:Q=PK!FR I/##/2M'XT^'85$'B%;ERTV(_*V
MC '7.?QK&^(=W'XE^)D%KIO[U@4AW+R"W2NT^,L#+X)L0QYC< C'L!5W]Z+Z
MLC[,ET1D?"7P-;S6MGXJ:]D$L;N/)V#;P<=?PK,\7:]K'CCQO_PC^F7#Q6D;
ME (V(W>K''48KO/A"0?AQ"F1DR2@#_@1KS?PE>1>&?BU.FHD1CS'B+G@ G@?
MSH3;G)OH#TA%+J;6J_!B?2=)DU#3-7GDO85WE"NW/K@CFMSX1>-;K6()M'U*
M0O<0#,;MU*^A^E>@:[JEGINA7-Y<3(D/EG!+?>R.,5XM\&K:6]\8WFH(A$"H
MP8G_ &N@_2H3<Z;YNA;7)-<G4A\4:MJ_CWQX=!LKAHK1)-BC<5! &23CKWJ[
MK7P9U'1[2*[T*_N+J[#C<H&PCW!':L7PO,F@_%PK?-Y8$[JS-P!D''\Q7ONL
M^(--T#3Q?:A<". D $<DY]*<Y2C91%",9-N1BZ7>:IX;\"M=>('C>ZMHR05.
M=W' /OFO(=$TK6?BMKUU<7M_+%9*V6VG(3T 7ITKU;Q;>6OBGX?:@^DW"7"[
M-QV')&.3G\*XSX&ZQ:1P7VERR!+EW#H"?O ?UI1;4'+J.=G)1Z&)XK\#ZG\.
M4AU?1]4GD@5P')&W:>V0."*]8\(^)O\ A*/!GVUL>>L3),!_>P:Q/C%K%G:>
M$'LGD4W$[#9'GG [U6^$5C/:> KN65"JW!9TSW&W']*3]ZFF]QQ]V;2V.+^%
MG_)5;G_<F_F*^A:^>_A9_P E6N?]R7^8KZ$[TL1\16'^$6BBBL#<**** "BB
MB@ HHHH **** "@T5#=2F"TEF5"YC0L%!QNP,XH ER:3//6O/O"WQ3M_$GB)
MM';2Y+250WSM*&!(.,=!72^+/$D/A70I-4FA,RHP41AMI;)QUJG!WL2IJUS=
MS1WKS[P7\4K7Q?JSZ>NG/:,J;U9I@V[GIT%=#XP\4P^$=$;4IH&G&\((U;:3
MGWH<))V8E.+5SH.:,UP5C\25O/!=YXD.DRQQ6SA1"902X..<X]ZT/ _C:+QK
M:7,\=BUJ(6"D-(&W9S[#TH<&M04TW8ZW-+2=Z6I+"BDS2T %)FEK@?&_Q*@\
M%ZG#92:9)=&6+S-ZRA<<D8Z'TIQBY.R)E)15V=[1Z5XU_P +]M?^@!-_X$C_
M .)KI/"WQ:T;Q'?1V+Q26=S)]Q7;<#^.!5NC-*]B%6BW:YZ%129%&:S-1:*3
M-&: %HHS29H *6N9\4>-M(\*0C[=+NF8?)"G+'_"M^TN!=6D-PHP)4#@?49I
MM-*[$FGL3T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)F
MEKG/&?BE/"&B?VG):M=+YHC\M7V]0><X/I0DV[";25V=%17C7_"_+7MH$W_@
M2/\ XFKVF?'32+NZ6*\TZ>T1CC?OW_H!6GL9]C/VT#UBBHK>XBNK=)X'#Q.N
MY6!X(J2LS46BDS1F@!:*3-% "TF:,\5Y5KGQJM]$UJ[TUM%EE:WE:,N)P V#
MUQBJC"4MB934=SU7-)FO&_\ A?MK_P! ";_P)'_Q-=!X/^*L/BW6QID>E26S
M;"^]I@PX([8'K5.E-*[1"JP;LCT:BDS1FLS46DS17GNG_%&&_P#&@\.#2Y$?
MS3'YWG C@9SC%-1;V)<DMST('(I:049%(H6DR<T9%<KK/CW1])UFWTEI#->S
M2K$(T_A)..3VII-[";2W.JS1FJ&L:D-)T:YU$QF00)O* XS7-^!?'T7C?[7Y
M5@]K]GVYW2!\YS[#THY7:XN97L=I129HS2*%HI,TN: "BDS1F@ S1S36X4G'
M05P7A[XG0Z]XJ?0DTR2%E+#S3*".!GIBFHM[$N26YWV>:7-&*\_N_B?!:^-?
M^$;.ER,_G"+SQ, .3C.,4*+>P.21Z#12 \49I%"T4F:,B@ HS1FO/_%7Q/@\
M+>((]*?2Y+AGQ^\68*.<=L>].,6]A2DEN>@9-+44$OG0I(!C<,U)FD,6BDS1
MF@ S1GTHKS[4_BA!IWC-/#C:7)([3+'YPF  R<9QBFHM["<DMST'-+35/&<4
MN12&!HS037GW_"T8/^$WC\-_V7)O>;RA/YHQ]<8IJ+>PG)(]"HI :,TABT4F
M11F@!:*3-&: %HI,TM !1110 4444 %%%% !1110 4444 %(:6D]* /'?C=X
MCN+:"UT6V8JLX+S$'L,8'XYIW@7X2Z1+HL.H:TC74MPFX1%BJI^6*YWXXQ,O
MBFSD(^5XOE./3&:]J\,3)<>&M/DB8,C1#!!KIDW&DN4YHKFJNYYKXV^#UJ]J
MMQX9MS',IPT 8D,/7)[UW'@'2=6T+PS#8:M)&\D9^3:22%XX-;.M:W9:!ISW
M]_(4@3J0,FJ*>);#5?#MYJ.DW23+'$S J<X(&>:S<IRC;H6HPC*YS/C'XK6/
MAR].GV5N;V^ Y"_=4^A[_E7-6GQMU&*X3^V-!$-NQP6C# _^/<5C?"?2K?7?
M&M]?:@OG/!NE0-S\Q;&?UKUGQ_HMGJ_A"^6XB4M#$SQOCE2!6C4(OE:,TYR3
MDF;6CZQ9:YIL5_82B2&09!';V-?/$VJP:+\6Y]0NB?)@NF9L#D\FNN^!5[-O
MU2P+$PI\X!['@5RJV$&I_&;[-<H'A:].]2,@C)XJH04)-,4YN44SIKKXWZE!
M<[UT +9$\-*&#D?RKU+POXCM?%.B1:C; H&X9#U4^E<[\5K"W?X?W"^4@\ED
M,?'W>1TK!^"<C)X2U-@?N29'M\IJ'&,J?,D7&4HSY6S?\:?$W3_"<PLHXC=7
M[#/EKT3TS_\ 6KC8/C;JT4ZOJ.@+':D\L@<'_P >XK!\%6D?BCXISSZD!* S
MS%6Y!(Y KW+Q+H]EJWAZ[M+F%&C$1*Y'W2!QBFU"%HM7$G.?O)CO#WB*P\3:
M8E]82;D/#*>J'T-<#XD^+5UX>\6S:5)8V[6L38,I+;B/Y5SGP4NY[7Q-?:6K
M$P,A9A[KP/YUA^/($NOBNT$@S')=1HP]BP!IQI14VF*563@FCI;KXSZ]+YOV
M;PXC6S9",RR9V^O'%>>>&_$E]H?B@ZM:62W%R0P\DAL<]>G-?4RVT5KI/D0H
M%2.':H [ 5X#\,L?\+6;_=E_E54Y1M*R)J1G=79[OX;U.?6- M;^Y@$$TJY:
M, _+S[UJT@I:XV=:V"BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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M\%1Z@(_,\BU1MF<9X'>JJ->SBDMR::?.VWL;_P!*6O$A\?G_ .@ O7_GY_\
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M'_"%ZGC_ )X?U%>:? /IK'UC_P#9JS23BW8MMJ:5S9\0_%:?0/&,FDSVEO\
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MK_DK<W^])_Z":^@W_P!6WTKYZ^';!?BW+D@$M)CW^4TJ6TAUMT?0]?.^K_\
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M6-U8SR274B@;>-F,CD'ZU]'QOYD:N/XAFLX^']'>?SVTNR,N<[S N<^N<5I
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M:&:69HT :25RS,>_)J9TW%*XX5%)NQH44@I:@T"BBB@ HHHH **** "BBB@
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MTKVOPOKT7B30+;4H<#S5^=?[IJ9T^57'"IS.QMT445!H%%%% !1110 4444
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MK SV_P"ZD_I^F*[:L91Y78UC+F5PHHHI%!1110 4444 %%%% !1110 4444
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MJ^6SSTK-^.-_I?V2UL70/J.=RLIY1?0_F*[7PQIOB#0?#<W]IW;:C>!"8HE
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M8P7D]T-P\Y0P09Z#\JY#XF^&X/!OB.QU+15%LLGSA4XV,,=*Z'X=?$_2=/\
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M?S''?![P9I&LZ?=:CJEFETRN$1)5RH'?^5<U\3]!L]&\<):Z; EM%+&C!8^
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M)Y%\R4^I/3],5U@I ,# '2G5+=W<J,>56"BBBD,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YY?!6C+XF;Q#Y<QU!L_,925&?:NAHIIM
M;":3W.>F\%:-/XEC\0212F_C.5;S#M'&.E=!BEHH;;!)(****0PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 G>BEHH 3%&.<T<44!H%%+
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >*_V3\4O^AA?_P <_P */[)^*7_0PO\ ^.?X5ZE177==
MCAU[GEO]D_%+_H87_P#'/\*/[)^*7_0PO_XY_A7J5%%UV#7N>6_V3\4O^AA?
M_P <_P */[)^*7_0PO\ ^.?X5ZE11==@U[GEO]D_%+_H87_\<_PH_LGXI?\
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M_9/Q2_Z&%_\ QS_"C^R?BE_T,+_^.?X5ZE11==@U[GEO]D_%+_H87_\ '/\
M"C^R?BE_T,+_ /CG^%>I44778->YY;_9/Q2_Z&%__'/\*/[)^*7_ $,+_P#C
MG^%>I44778+/N>6_V3\4O^AA?_QS_"C^R?BE_P!#"_\ XY_A7J5%%UV#7N>6
M_P!D_%+_ *&%_P#QS_"C^R?BE_T,+_\ CG^%>I44778->YY;_9/Q2_Z&%_\
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M_P!#"_\ XY_A7L=%'M/)![)=SQS_ (1[XJ_]#"__ (Y_A1_PCWQ5_P"AA?\
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M^*O_ $,+_P#CG^%'_"/?%7_H87_\<_PKV.BCVGD@]DNYXY_PCWQ6_P"AA?\
M\<_PH_X1[XJ_]#"__CG^%>QT4>T\D'LEW/'/^$>^*O\ T,+_ /CG^%'_  CW
MQ5_Z&%__ !S_  KV.BCVGD@]DNYXY_PCWQ5_Z&%__'/\*/\ A'OBK_T,+_\
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M,+_^.?X5['11[3R0>R7<\<_X1[XJ_P#0PO\ ^.?X4?\ "/?%7_H87_\ '/\
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M[XJ_]#"__CG^%'_"/?%7_H87_P#'/\*]CHH]IY(/9+N>.?\ "/?%7_H87_\
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M?%7_ *&%_P#QS_"C_A'OBK_T,+_^.?X5['11[3R0>R7<\<_X1[XJ_P#0PO\
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MNYXY_P (]\5?^AA?_P <_P */^$>^*O_ $,+_P#CG^%>QT4>T\D'LEW/'/\
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M%% &/11172<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYL_"NBI?I;';)-*V%)]N10!Z(#2UQ_A'QH^N7<^FZG:?8=4@&6A[,.Y%=A0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,>BBBNDXPHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *GM/\ 7CZ5!4]I_KQ]*F6Q4/B-#M2T
MG:EK Z@HHHH **** "BBB@ HHHH *Q/$GA\>([%;-[R:VC#9?RN-X].M;=)0
M!Y5!HUEH?Q5TFSL85CB6V.2.K'GDGN:]6KSC4O\ DLFE\?\ +L?ZUZ-GF@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D[TM(:
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MP:]"[5YC\26AG\1>'[>T\LZ@+@$E2-P3G@UZ:N=HSUH 6BBB@ HHHH ****
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M6Q7!_"/=_P (+#NQCSI-O_?1KO* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "DQ2T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &/11173T.,\[^)GB:ZT^*#2-.8K<W7WF7J!Z?CFLVP^$*7EE'<:G
MJES]JD&Y@F"!GZU1\>D1?$O3Y)?]5E.WTS7L,>#$A'0J,5G:YH_=1Y?H7@GQ
M)X=\41_8[S?IP.69V.UU],>M>G3W$5K"99Y%C0?>9C@5+_G->3?%#4)KW7].
MT .RP.RLX!^]N..?IBJ^$GXCN8_''AN6Y^S1ZK"9<X"X8<_7&*VG=)+9F1@R
ME>&!R,5R&J^!=#/A62&.RB2:.'<LRJ V0,\FLGX4ZO/=Z%>6$SEQ:D;"3G .
M>/THNQM+=&'\-;VUL/$6M3W<Z0QA.68_[5>EV'C#P_J=U]GL]3BDESC;@C/Y
MBO*?A]HEIK/BR_%Y%YL4&6\MONGYNXJU\3]*LM&UC2Y=-@2U9P2WE#;R"/2I
M3=BG%-V/9V954LS *.2<\"L&?QMX;M;G[/-JL*RYQMPQ_4"N8^).M7-CX/LX
MHI&1[SY793@X&,C]:N^&_!&B_P#"*0BXLHI9IXMS2NH+#//![4[LE126IV=M
M=07D*S6\J21GHRG(-9+^,?#\5U/;/J42SPC]XK!AC]*X#X>W4NC>-M0\/I([
M6P9MBD]-O>L6TTJ#5_BO/;72;X?.)9#T.%HYF/DU/1M5^(.APZ)<W5CJ,<LP
M4B(%&PS]ATK$^'WC6*_\^+5M0!OYYCY<94],#I@8K=\5Z%I-MX.U$0Z=:Q^7
M"S+MC P?6N9^$FFV,^F7%S-:0R3QS$)(R E>!WI-NX)*QZG7!^,?%NIVNH?V
M%HUB\EY(F3-CA0>./_KUWG;/:HOL\*SO<")!,R[2X'S$?6KD1!V9XU\*A,/&
M-\+DL9O+.\L>^[FO:J\=^'/_ "4#5?\ @?\ Z'7L5*"'/<****HD**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *GM/]>/I4%3VG^O'TJ9;
M%0^(T.U+24M8'4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!0UC3DU;2+NP<X6XC*$^F:YCX;WI_L-])F^6YTZ0Q,AZXZ@_
MK7:UB)X<C@\3MK5M,86E39/$%XE]"??_  H Y;6O!7B:;Q;<ZUH>LVMB9D5/
MG4EL #/8CM4?_"-?$O\ Z&^S]OW7_P!A7I%% ')6F@^(9?#%_IVM:K!>75P,
M1RJI 4>_ K1\(Z)-X>\.6^FSRI+)$.7CS@_G6Y1@4 <CX;\)7.B^(-8U"XGA
MEBOCE43.1TZY^E9-]X!UFSU>XO?"^MKIZ7)W2Q2+E<]\<&O1*,4 <%X<\ 7>
MB>+1K,NH+<AHBLI?.]G(//3&.17?4G%+0!5O[*#4;*:TN4WPRJ58>H->=KX"
M\5:87MM!\3)!I[$XBF7+*#V'RFO3:.* .8\)>#H/#,<LKSM=7TYW2W#]3[#V
MI(O#%RGCJ37S/%Y+0^6(^=W?\.]=110 AZ5R/BKP+!X@NX]1MKB2RU*( +/&
M?O8Z UU]% 'FO_"'^.[I?LU]XMB-FPVL(H\,1]=M==X>\,67AW1O[/MBS;LF
M25OO.?4UN48% '!>&/!>N>'=8EV:O"^C2NSM;;?F)([G']:IS_#W7K#6;JZ\
M-:ZEC;73EY8Y%R<GKC@CN:])HH X30/ $^A^+$UC[:LR>04E+DF1W.<MZ=Q2
M^(/ U]<:W_;/AW5!IUZXQ)N&4;WQ@UW5% 'FUM\.M5&OZ=K5]JT=U>0ONN78
M$!AQ@* /K73>.X[>7P9J27#!8S'P??(Q^M=&1GO7'^(/!$OB#5X[F?6;E+%2
M"]D,[&Q^/]* *_PLTAM+\'PR2@^=<GS6)]#R/YU>\?ZE]A\+S11C-Q=D01+W
M)8X_K73PPQV\*0Q+M1%"J/0"L>]\.IJ.OVNHW4YDAM5_=6Q7Y0_/S?Y]* '>
M%-)_L3PU966 &6,%A_M'D_K6U24M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4^YJT5E?V[!_SPG_ .^:/[=@_P">$_\ WS1[.78/;4^YJT5E?V[!_P \)_\
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M'_/"?_OFC^W8/^>$_P#WS1[.78/;4^YJT5E?V[!_SPG_ .^:/[=@_P">$_\
MWS1[.78/;4^YJT5E?V[!_P \)_\ OFC^W8/^>$__ 'S1[.78/;4^YJT5E?V[
M!_SPG_[YH_MV#_GA/_WS1[.78/;4^YJT5E?V[!_SPG_[YH_MV#_GA/\ ]\T>
MSEV#VU/N:M%97]NP?\\)_P#OFC^W8/\ GA/_ -\T>SEV#VU/N:M%97]NP?\
M/"?_ +YH_MV#_GA/_P!\T>SEV#VU/N:M%97]NP?\\)_^^:/[=@_YX3_]\T>S
MEV#VU/N:M%97]NP?\\)_^^:/[=@_YX3_ /?-'LY=@]M3[FK165_;L'_/"?\
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M,MBH?$:':EI.U+6!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP.IK@/!T:W?Q+U[4;%0MB/D++]UVYZ4 >G4444 %%%% !1110 4444 %%%%
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MZ!9>&KB^TZU2QNK50Z2QG&3D=:ZCP3?W&I>$=/N;HL9FC 9CU;CK0!T-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56^U*RTR(2W
MMS'!&3@,YP,U:KSSXP@-X4A!Z&Y0'\Z .^@N(;F%9H)%DC895E.0:=+-'!$T
MLKA(U&68] *\[^%]Q+9_VAH-RY+VS+)%G^XR@_S-:GQ!N?-LK/18V*S:C.(S
MCKL_B_F* .HLM3LM21WLKF.=4;:Q0YP?2K=>;?!V/RM U",<[;QA^@KT@4 +
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %13W$-K \\\BQQ("S.
MQX %2UY5\1=9NM<:Y\/Z.YV6T;2WDV. %!.W/X?K0!Z;97UKJ-JES9SI/ _W
M70Y!JMJ>O:5HH4ZE?P6H?[IE;&:YWX=N8OA[:..2B.1^9KEO"/AVW\9ZGJ&N
MZ\OVL><T<4+G*KB@#U#3]5L-6MQ<6%U%<1'H\;9%7*\NUK3X/ ?BC2KW1E-O
M:7DODSVRGY#P>@_*O4>U !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 &:J6>IV6H-,MI<QS- ^R4(<[&]#^5<IXKU/Q#<WK
M:-H=F8PT>9+Q_NJ/;WK*^$,4MO::S#-*998[O:\G]X@MS0!Z1)*D4;22,%11
MEB>PK'MO%_AZ]N_LEMJ]K+<9QY:OS7*_$6>XU+4=*\-6TA1;N4/.0>2@.?Z&
MGZ_\-M#CT"4Z;:BWO8$WI.GWF(]: /0<\9K%N_&'AVQN3;76L6D4P."C/S7,
M:;J.M^(_A<CZ:1)J;KY+,S!>W)R>_-6=*^&>@PZ4D6HV"75XRYDFD.6#'KS0
M!VEO<PW4"S02+)&PRK*<@U7U+6-.T> 3:C>16T9. TC8%>??#SS=*\4ZUH,4
MS36,#YBR<[.3Q4&EZ9%X\\:ZI>:JIGT^R;R8(2?E)[Y_.@#T73-<TO68R^G7
MT-RHZF-LXJ_FO*O$.BVW@;Q)I>L:.#:VLLHAN($^ZV?_ -5>IH0R CN,T /H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!*YS7]8T+3]5T^UU:U\V:=OW$C0AE0\]ST-='6%XH\
M+67BC3Q;W6Y)(SNBE0X9&H T=4>WCTNY>Y91 (R7+'C%<7\*E>#PK<33.1 U
MP[QECP$]O;K5$?#;7[S99ZMXJEN=,4\P*I!QZ9KJ]9\-R7/A(Z'H]PEB-H17
M*DX&>>GKS0!S>I:UJ?C;49-'\/MY6F(=EW?=#[A??\:[30M!L?#VFQV-C'MC
M7DD]6/J:\^T_X<^,-*M5M;#Q@MO IR$2(XR>M=)X:\/>*-+U,SZQXE.HVVT@
M1;".?6@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#'HHHKI.,**** "BBB@ HHHH **** "BBB@ HHHH
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ML1FIZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@#'HHHKI.,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "I[3_7CZ5!4]I_KQ]*F6Q4/B-#M2TE+6!U!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M +Z-']FQ?\]'_P"^C1:(7GV+FX>H_.C</4?G5/\ LV+_ )Z/_P!]&C^S8O\
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MHTG]AP_\]9?^^C1:'<.:IV-/S$_O#\Z/,3^\/SK,_L.'_GK+_P!]&C^PX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@!,4M%% &/11172<84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %3VG^O'TJ"I[3_7CZ5,M
MBH?$:':EI.U+6!U!1110 4444 %%%% !1110 444F: %HHI,\T +1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F>: %HI,T9]J
M %HI,T9H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3- "T
M4F?:C- "T4F:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BDSZT9H 6BC-)F@!:*3-&: %HI,T9H 6BDHS0 M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !129HS0 M%)1F@!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'HHHKI.,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y[\7_ /D5X/\
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M802":>Y"D+QZ9^M>JH-J*/08JK9:98Z9&8[&SAMD)R5B0*#^56_PH 6BBB@
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MA;1?$+1MJMBMR8\[-S,,9^AJ+2/!N@:#=&YTS3DMYB-I8.QX_$UNT4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &/11172<16OKZUTVT>ZNY5BA
M099C_GFN N_C%I,%PT<-A/<(#@2!@H/X&LWXHWL^H:_8:"CLL;D%P.A)Q@_S
MKO-)\):+INFQ6PT^WD(7YGEC#$GZFHNWL:));E/PYX^T?Q%(((G:"Y/2*3J?
MH>AKJN>]<<GPXT:+7EU6'S(V4[EB1B #ZYS6MXE\3V'ABP6XNV+,YQ'&G)8U
M2;6XG9[&W37;8C-@G KSD_$76H(EOKOPU)%IK'(G#$DCZ5VFEZU9Z]HXOK%]
MT3@@@]5/H:+ARZF3X9\<6_B74KJRALY86MQDL[ AN<<8KJJ\(\$:V=&\0ZH8
MK26ZN)LK%%&/O$-FNQC^)5[8ZM'9^(-%;3UD^ZV[)QZTE+0<HGHU%4-3U>ST
MG2WU"ZE"P*N<]V] /K7#K\1=8NT>[TWPY)/IR=9BQ! ^E.Y*BV>CT5S_ (7\
M6V/BBU9[8E)H_P#61-U7_P"M7*W?Q0N;;Q!=:6-*65D;9%Y;DES1?0?*STDD
M!26( [D]JKVU_:WCRK;S))Y;;6V'(!KS[7?$?BN;PK=O<>'3:AU*NRRG=&O]
MZL;X7ZKK$.ZV@TLW%I+-F6Z+GY#Q2YA\NA['7,>)_'&E^&"(KC=-<D9$*=<?
M6NG^O%<==_#RQU#Q*=9N[J28EMQ@905]A3=^A*M?4HZ1\6-'U.\2WFMYK0N<
M(TAW G\.E=\"" 5P1U!'2O'_ (J6>F6UWIL-A;Q17C,,K"H7Y>?3WKU'0HY8
MM"L8YMPD6%0V[KG'>E%LJ44:%%%%40%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %3VG^O'TJ"I[3_ %X^E3+8J'Q&AVI:3M2U@=04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'HHHKIZG$
M'O17(_$/7GT3PW(('(N;@^6A'49[UF&RFTSX52"223[0\7F2,6.=QJ6RN6YZ
M#^=']*^<O"&JWEEXBL;R6>5K<2A'+N2.:]8^)NIM9>%?*@<K-<.%0*<$^O\
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M0$_E7"_$FZD>;1],@=UDN+@!BAQQD47&D>@]_K17CWCF2>W\9Z+"LTB@1(&
M8C)S7K<MS;VT:M//%$#T\QPN?SH3N#5D344R.:*:,212(Z$9#*V0?QJ$:A9-
M)Y:WEN9,XVB49_+-/074LT5!'=VLTICBN(9)!U5'!(_"O-YK^?PI\2_*>1S8
M:AV9LA??\Q2;&ET/3Z***8@HHHH *56F4DP*&DQP":2I[7_7CZ4GHAQ5V0^?
MJV/^/=/^^J//U;_GA'_WU6K^%+67.NQM[-]S)\_5O^>$?_?5'GZM_P \(_\
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M[-]S)\_5O^>$?_?5'GZM_P \(_\ OJM:BCG78/9ON9/GZM_SPC_[ZH\_5O\
MGA'_ -]5K44<Z[![-]S)\_5O^>$?_?5'GZM_SPC_ .^JUJ*.==@]F^YD^?JW
M_/"/_OJCS]6_YX1_]]5K44<Z[![-]S)\_5O^>$?_ 'U1Y^K?\\(_^^JUJ*.=
M=@]F^YD^?JW_ #PC_P"^J//U;_GA'_WU6M11SKL'LWW,GS]6_P">$?\ WU1Y
M^K?\\(_^^JUJ*.==@]F^YD^?JW_/"/\ [ZH\_5O^>$?_ 'U6M11SKL'LWW,G
MS]6_YX1_]]4>?JW_ #PC_P"^JUJ*.==@]F^YD^?JW_/"/_OJCS]6_P">$?\
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M6M11SKL'LWW,GS]6_P">$?\ WU1Y^K?\\(_^^JUJ*.==@]F^YD^?JW_/"/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I,UD^)-=A\.:+-J,R^9Y8^6,'!<Y
MZ"HO"WB&/Q-HR7Z0F!BQ1XB<E2/6@#<HHI* %I*JZE?QZ9IUQ>S F.%"Y ]A
MFLN#Q-'<>$FU]+<^6$+B,MR0#CK0!OT5C^&-='B30H-3$!@$O_+,MNQ^-;%
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M)HM@K#D$0+Q^E &NK!E# Y!&12T@    P!TI: "BBB@ HHHH **** "BBB@
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MGOQ29+I-)TN/:US/=*RIW(&?\:]!A79$B^B@4 24444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** $Q12T4 <WXR\-3>)])CLH;A("DRR%G4G(':M^"(PP1QGG8H7CVJ6B@"
M&YA,]K)$" 74@'TK#\&^')O#&BM837"3L96DWHI'7''Z5T5% !1110 4444
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M2H*GM/\ 7CZ5,MBX?$:':EI*6L#J"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ8_\]A^5')+L'M8=R_15#^V+'_GL/RH_MBQ_Y[#\J.278/:P[E^BJ']L6/\
MSV'Y4?VQ8_\ /8?E1R2[![6'<OT50_MBQ_Y[#\J/[8L?^>P_*CDEV#VL.Y?H
MJA_;%C_SV'Y4?VQ8_P#/8?E1R2[![6'<OT50_MBQ_P">P_*C^V+'_GL/RHY)
M=@]K#N7Z*H?VQ8_\]A^5']L6/_/8?E1R2[![6'<OT50_MBQ_Y[#\J/[8L?\
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MK#N7Z6J,>J6<CA$F!8G@8J[D4FFMT4I1>S,/[/!_SQC_ .^11]G@_P">,?\
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M8K_8;3_GVB_[X%'V&T_Y]HO^^!5BBCF8<D>Q7^PVG_/M%_WP*/L-I_S[1?\
M? JQ11S,.2/8K_8;3_GVB_[X%'V&T_Y]HO\ O@58HHYF')'L5_L-I_S[1?\
M? H^PVG_ #[1?]\"K%%',PY(]BO]AM/^?:+_ +X%'V&T_P"?:+_O@58HHYF'
M)'L5_L-I_P ^T7_? H^PVG_/M%_WP*L44<S#DCV*_P!AM/\ GVB_[X%'V&T_
MY]HO^^!5BBCF8<D>Q7^PVG_/M%_WP*/L-I_S[1?]\"K%%',PY(]BO]AM/^?:
M+_O@4?8;3_GVB_[X%6**.9AR1[%?[#:?\^T7_? H^PVG_/M%_P!\"K%%',PY
M(]BO]AM/^?:+_O@4?8;3_GVB_P"^!5BBCF8<D>Q7^PVG_/M%_P!\"C[#:?\
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M!5BBCF8<D>Q7^PVG_/M%_P!\"C[#:?\ /M%_WP*L44<S#DCV*_V&T_Y]HO\
MO@4?8;3_ )]HO^^!5BBCF8<D>Q7^PVG_ #[1?]\"C[#:?\^T7_? JQ11S,.2
M/8K_ &&T_P"?:+_O@4?8;3_GVB_[X%6**.9AR1[%?[#:?\^T7_? H^PVG_/M
M%_WP*L44<S#DCV*_V&T_Y]HO^^!1]AM/^?:+_O@58HHYF')'L5_L-I_S[1?]
M\"C[#:?\^T7_ 'P*L44<S#DCV*_V&T_Y]HO^^!1]AM/^?:+_ +X%6**.9AR1
M[%?[#:?\^T7_ 'P*/L-I_P ^T7_? JQ11S,.2/8K_8;3_GVB_P"^!1]AM/\
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M@ HHHH ***0T +FJS:C8I)Y;WENKYQM,J@_EFJ7B&+5)M&N(M',8O7&U&D;
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ML/&>DOKNNW4]S=7$C[=LI C&3Q6O\/KFZT[Q-K/AI[E[FULV!B=CDKG/'Z4
M>E4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM=3U_P 8S^*K^U:TM_*\JVC8<LO//ZT >DT444 %%%% !1110 4444 %%%%
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MH 844G.T?B*7 /\ ".*=10 4444 %%%% !1110 4444 %%%% !1110 4444
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MC^,03X/U0 9/V=@,5R7P>(_L.[''^O/\A3ZB33@>DC^O:N?U'PSHKZE_;UY
MSSP+OR3D<<]*Z#Z=:Y"[^(&FVGB0Z+=6\D;;MIE<@+]?H:IVZD1OT.!UF^MO
M'7CJRCTTK#'"0IDD^4M@YXKVQ%V(J^G&>]>/_%"]TMKK33ICPF\5P2\![<^G
MO7J6BR32Z)9/<9\UH5+$]<XYS4QWLBY[:E^BBBK,@HHHH&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5/:?Z\?2H*GM/\ 7CZ5,MBH?$:':EI*
M6L#J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;2/_ !X5ZA'_ ,@@?]<OZ5FC66R/#?"OA&W\6:[J<,]U+;B)F<&-0<_-CO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !1110 444F10 M%)FEH **3-+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129I<T %%%)
MF@!:**3- "T4F:,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FC- "T44F
M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF2Y*#/\ ",#@5W0KSOX1_P#('U3_ *_G_D*]%H **** "BBB@ HHHH ****
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MY_Y"O1:SM*T33]$BDBT^W$"2N9' ).6/?FM 4 +1110 4444 %%%% !1110
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M<_@#BMJPTVSTRV6WLK=(8EZ*HH MT444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHYH]@Y)_S&3_ &Q)_P ^<WZ?XT?VQ)_SY3?I_C6MQ1Q1S1[!R3_F,G^V)/\
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M4WZ?XT?VQ)_SY3?I_C6MQ1Q1S1[!R3_F,G^V)/\ GSF_3_&C^V)/^?*;]/\
M&M;BCBCFCV#DG_,9/]L2?\^<WZ?XT?VQ)_SYS?I_C6MQ1Q1S1[!R3_F,G^V)
M/^?*;]/\:/[8D_Y\YOT_QK6XHXHYH]@Y)_S&3_;$G_/E-^G^-']L2?\ /G-^
MG^-:W%'%'-'L')/^8R?[8D_Y\YOT_P :/[8D_P"?*;]/\:UN*.*.:/8.2?\
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MUK<4<4<T>P<D_P"8R?[8D_Y\IOT_QH_MB3_GSF_3_&M;BCBCFCV#DG_,9/\
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MHYH]@Y)_S&3_ &Q)_P ^4WZ?XT?VQ)_SYS?I_C6MQ1Q1S1[!R3_F,G^V)/\
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MP<D_YC,BU62254-I*H8]3CBM//'2DQ3JEM/9%Q4ENQ**6BI*$HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.1U'K4QA*3LBI3C%79ZEFBO*;#XU6D]C<-=V#VUY''O1&'RR?2NA\!^/O\
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M:TN+)!;),$=@>0N>M>QVEU%>6D5S"P:*50RD>AKY$UJ*2;Q#?)&A8B1F('/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24
MM)0!PGQ>_P"1 N?^NB_R->=?#[PQ#XJ\"ZK92#]ZLA>%L<A@!C\\5Z+\7O\
MD0+G_KHO\C7._ C_ ) U_P#]=?\ "NF$N6E='+./-5LSA? GB2?P9XCN=-U
ME+:4M%,&X"L.-W^?6E\"D'XK(1T,CUU/QF\&D,/$5E%_LW(4?DWZ5Q/PNR?'
M]CW/-;*THN:,6G&2BST/XZ:O/!IUCIT3E4F;?)@_>'/!_&K/PE\':4?#":G=
MVD=Q<SL>9%!V@=,5)\:?#UQJFAV^HVJ&1K1OWB@=$YYQ]37/_#3XF:5H>B?V
M3K+M"(F)24*6!![8%9*[I>Z:NRJ^\0?&;PK8:,;+5-/@6 SN4=(Q@9 SFO0_
MA5J\^K>!K1[F0O-$S1DGT!POZ"O*OB7XTA\:WUGIVDQO)!"Y*-M.78\<"O8O
MA[H,GAWP?9V4V/..9'P.FXYQ^&:52ZII2'3LZCY3J:^8_&=W-XF^)#V\LC>6
M)A"@S]U>]?3AKYK^(^CW7AGQT=16,FWED$T38X/J/KUI8:W,RL1>R/<+7P/X
M>MM*73QIEN\03:69 6/OGUKP&ZCD\&_$]H+&1D6"Z5%.>JMC/Z$UZU:?&;PV
M^DK/<RR1W@7+6X1CSZ9QBO+-(M+SQ_\ $9KY(2L<EP)I&QPH7&/Y"KIJ2YN?
M8SJ.+MRG8?'5Q)!I,BGY65B/TK:^$GA;3!X5CU&>TBFN+@DEW4' ]*R/CPH6
M+25 P & _,5V?PH_Y$&Q^E)MJBFBHQ3JM,\;^)>FVNE?$*2.SB6&-C&P5!@
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M_H0KN/@+(O\ 9FKID;A+'Q^#5P_CO_DK$O\ U^1_^A"E'2JPD[TDSTKXO_\
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MP^U3PY<:?;V4J2&/;"PM0NTCISFH?@7J<R:K?::7)@9 Z*?7G)_05KZOXR\
MVNBM<V%C;SW97*0&-AS[UL?#/6K;7VN+J#08[$1@ 3(" _L.:ANT'H7%7FG<
M\S^+R>9\0I$SC<$'Z"O9?#/@W1K/PM:VS6$#M)"/-=D!+''/->._%K_DI#?]
ML_Y"OH+2?^0/:_\ 7(45&U3C8*:3G*Y\U^&8Q8_%."* E52Z95QZ8-=U\>!B
M#2_^!_S%<1HO_)6H_P#K[;^1KM_CS_Q[Z7_P/^E:/6I$B-E!G1?#[_DD[?\
M7M+_ .@FO(OA_HMMKGCJ*VNTWP([.R=FP>E>O?#[_DDS?]>TG_H)KS3X2?\
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MWC'(![UZ=XX^)>BZCX7N=/TB5[JZNH]H"QM\@]3Q1.+E*+04Y*,6F<U\#/\
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MU[)HN?"GP3I%YX7-_J-E%=27#$H94!VKTXS]*[OQ#X>T&X\,_8=2_P!'TRW
M8[7V!<#K69\)_P#DG^G_ $/\S7.?'.:]30[2.'<+5G_>D?WNP/ZUE*\JEC56
MC3N9MMXK^'GA*UDL]-M&O7+$EW0/GVW>E>:W5]#?^,DO+6U^QQR3JRQ ]/\
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M2RG"DCBG64DN5;!2Y7+F>YY3\5?^2EM_O1_R%>E?$C_DE0_[9Y_(UYM\5?\
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M(AB#R,W89(P*^C:QO#OA?2_"]F;;38!&K8WN>6<CU-;-9U9\TKHTI0Y8ZB$
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M574JR@J1@@CK3J2E=W';2QPVK_"?PMJUQ)<M:O#,YRQC<A?R'%7O#OP]\/\
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M[",BNI5E#*>H(ZUP^L_"GPQK%T]R]JT$K\GRF*K^0XKN:,41E*.PY14MSD=
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MWQBTT8FT72TC+#>RWS$@=R!LYH Z8L I8] ,FN;/CWP]YCHMU,YC;:Q2VD8
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M/&T&B7]Q%<6SPM()UB"%^#Q@=,8]>]=K0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6D- 'G>LW?]D_$
M^WU*XMKM[06;1EX+=Y/F.W'W0?2EUR\7QK=:=9:9:WJB"X6:66>W>$* 0>-P
M&>G:O0B0HR2 /4TB2)(N4=6'JIS0!YIJ=M9VOC*[E\1Z==WMM)&IM&CA>55P
M!D$(.#GUJ3PW->#Q3K^H'2)DAEMD:WB*;=Z@MQDC /M7I-% 'D^J1Z/J)@.A
M:1J%EK9F#!UMY(U4_P 66(VXQFK>K:%;Z=XH?4];TQ[ZQN855I(D:1D<?[*\
M\YKTVD_I0!YSI^GVUQ'K%WI>AK9V8M6BBD>)UFE;'HW('/I45I978'@\&VF'
MEL/,S&?DX[^E>D/-%$0'D1">FY@,T\'(S^M '(>'+>:/QGXAE>&18W9=K,I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU#1/LVFR%<SBY#,JGN4QFNKC97174Y4C(->/>+;*PB\*O>W6M3:M?3H@C.\
M(,?W4P,=.HKUJP.=/MR.?W:_RH S==\0II$MM:10-<WUT<0P!MN[W)["F:/X
MB:_U&XTV^LS9:A"H<Q>9O#*<X(; ST-8WB!A8^/M&O[E<6K1-$93T1B01GTZ
M&MRWUNRO/$4EC;6_G2)$&>Z0 J.N%W?A0 FB>(5UBWOI5MC%]DD:,@MG=@5Q
M_BCQ-?:IX7@N;*P*1M>B)SYX!R#TZ=#5OPE>V]C9>((KF98I5N'.QSACE>,#
MO6%&XE^&T$H!"_VH&)/&T9/)H [6;Q//9K8V"::9=6GC#?95F&U!ZE\8[5-9
M>)9I[JXTZZT_[+J<:;TMS,&60>S8QW%8HN8;'X@6UY<.HM;FQ6.*?.4W DD9
M[4Z>5=3^)MI)9XEAM+5Q+*G*Y)4@9Z4 8WAY;V]U?6M3GT""XO(;APDSW*[H
MR /E''Z^]7OAO:&Z$^IWFE0K<--)B\,H9R=Q&W&.W]*T/!WWO$7_ %^2?R%3
M?#G_ )%M_P#KYFX_[:-0!KZYKZ:0;>"*W:ZO;EML,"G&[W)[#D<UR=QJ-[=_
M$+18[_3FLI8U;CS/,5AAN=P %7O$6+#QSHVIW)Q9['B+G.%8XQGTIFL:G:77
MCS0XK69)G178E#D?=;C- &JWB6]N[RYAT;2A?1VS;))6N!$ W<#(.>AKGO%7
MB>YU'P6UQ86K(ZW*0W"^;@Q-N'R].<YQ^-5K ?V]/J3:SK;6=O;W;!M/B"QA
ME!."3@,<^QK%L_)?P!K'V9&$(U5"JL22%W)R<\T =]_PDT^GZ9IMM+IV[5+E
M (K1)@<@#J6QP/PJWIOB.2XU9M)U&P-C>E-Z+YGF*X[X; KCM8AD?Q3HEVFJ
M2V5M+:>4MU"$<*W'!)! Z&K]M9Q-XVL$?7+_ %6XAC9PP6/RXP?[Q4#KB@#T
M'M7,2>*KJYU"XM=%THW_ -F.V9VG$0!] 2#GH:Z9QF-@.I%<1X-O+?3)M9L;
MV1+>=;R23]X=NY6)P03UH L:CXGDU#PA?76F6V;B-'2>)Y-C0G'/;FD^'FG)
M#H45VVE0VEQ*BL9D<,TP(SDXZ5B::'N-(\6Z@L96VN'<Q'&-PV#G]*[+PCG_
M (133/\ KW3_ -!% &+X@GEUKQ=:^&EE>*U$1FN=AQYB\X4^W!_.F:_X3T_1
MM)DU/08%T^\M0'#0#;O&>0WJ*-8C;1?'MIKLJDV4\/V>1P,[#S@GV^:KOB_7
MK,>'YK:TG6XN;H".)(3O))/MTX]: %_X3*)?#^EWJPF:[U%5\BW5L;F.._8<
MBK%AXCN;B_FTZ^TW['J"Q>;%$9@PD7V;'K7+W&G/X=N/")N5S!:H897[(QV@
M'Z<&NO&N6-QKT=E;0_:9?*WM<1[2L8YX)_I[T <YX OM4NM1U@75F!%]J?=*
M9PQ1@QPH&.1UY]J[FX,RV\C0('E"G8I.,GMS7'^ Y$2ZUV)G42F^D8(3AL;F
MYQ7;4 ><:$NLK\3)#K-PCRO9,5BC'RQC<O YY^M6;N%/$/Q#GTO4@)M/M;=9
M$MG/RNQSR1WQ@5:_YJO_ -N#?^A+4VOV>DW>O0D:L^EZLD>1*@ +)Z$L-IH
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M]TDI$9W;4&<DXZ=17;QC;&J^@ H ?1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gmz2lq4320rk000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )K"%8# 2(  A$! Q$!_\0
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M@ HHHH ***3- "T44F: %HHI,T +129HH 6BDSZT9H 6BDS1F@!:*3-&?44
M+129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +1249H 6BDS1F@
M!:*3-&: %HI,T9H 6BDS1F@!:*2C- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%)FC- "T4F:,T +1110 44E&: %HI,T9H 6BDS[49H 6BDS1F@
M!:*3-&: %HI*,T +129HS0 M%)FC- "T4E+0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !534F9-*O'4E66!RI'4'::MU3U7_D#WO_ %[R?^@F
M@#S3X)ZOJ&J6&M-J-]/<M'>%4,TA;:,G@9JIXUUG4K;XQ:%8V^H7$=K($WPI
M(0K<]Q7F7@[X9ZIXW;5+NPUI+%(;ID96#<Y)]#5RU\%WO@KXKZ'8WVHK?.\B
M.'4-P">G- %_XJ^(?$5E\1KB'3=4OHH( CF**9@N.,\"O0O%_C5H?@Y%K%K=
M/'=WD*(CH<,'8?I7(>([)-2^.-U9N,K+;E<?\ S7):#>76M7FA>!I@?+M+]C
M.<'[H88_+F@#J?A#K.OW&I^)+;5=4O+A[>P+J)9F8(W7(ST-=7\#M7U'5K'6
MVU"^GNFCN@J&:0OM'S<#-<UX C$7Q \=1J.$LRH_ 4[X2ZC=Z3X*\77]A!Y]
MU!+OBCVEMS?-Q@<F@#W+499X--NI;:(RW"1,T48&=S ' _.O$T\.^/\ 6-)O
M_$6J^(-0T>Y@+-%98*(5![\C^5:_@#XD>+_$7B9;'7-$6RLO+=FF^S21XP">
MK'%97C#QEJOQ!UQ_!_A5&^Q[MEW=8.#CJ,^E %S2OBEJ(^#=QKMSM;489#;(
M^.&/0,1]:P+F+QKX<\.V/C:3Q)<W"RR!Y[21B8T0GL,_TK<^(_A*+PK\%5TJ
MS!D$,R-*^.6;/)_2I/&MW;R? >U5)T9IHD2,9Y8[AQ^E &SXRUGQ5K6@Z*/"
MMM.L>I(KSW,2Y,*D#OVZ_I7(ZG+XG^%_B+1C-XDN=7M]0E6.6*Y).W)P< DU
MW-CXDL_ GPGTN]U(_,EK&$B'WF8KP/\ Z]<AX/\ #VL_$;Q/'XP\2J8K*$YM
M+?&.G(X/;- 'M\;"2-6'\0R*YWQ9XZT/P9!')JT[!I#A(HEW.??&:Z0<# Z5
MXUX]U=[GXE6>C:/HEA<:SY.X75X3\B\_=Y XP: .S\*_$_PUXPO'M--N)DN
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M7+75[UKFW_UIF_>&<],DDY%6O%OPHT[Q-K U>UU&[TG4",//:'!<?F*]!HH
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MNV?P'H3^#U\,-:_Z %  S\V1_%GKFNFHZT >1+\";8LL5SXHU6>P5LBS=CL
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MA*;PU?WTNIZ>Y.U9D"E/H17$W'[..BRW;21:U=PQ$Y$0B#8'IDG->U]:0]J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444FY<
MXW#/IF@!:**0L ,DX^M "T4T,",@Y'M2&10<%E!]": 'T4T2*3@,"?K2[A^5
M "T4T.K' 8'Z&ES0 M%-#J> 0<4M "T444 %%%% !1110 44F:6@ HI"0.M
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MQYGZ]J /??#OC#2O%VCS7>FRG<BD21-P\9QT->?_  :O+JZ\1>)EN+F:94E
M022%@O)Z9JA\+])U>T\9:U>7U[I#F6!_/@L)U;;)D<E1T[U8^"7_ ",?BD?]
M-1_,T >UT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUJR_X2*2TNM*^P:FXY"C /Z5ZU0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)GG%+7B7Q3^+.M>%]<;1]+MHH_D!^TOSUXZ8H ]
MFN;VULHS)<W$4* 9)D<*/UKSWQ'\:O"^B%H;:5]0N0<>7 ._U/!KSOPYX/OO
MB0AO=<\9+,K<M:VTI<8]",C%5/AIX;TR#XQZCI,MO'<VUH76-9D##@'!Y[T
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M4_&UGXHDN[A+JU "Q+MV'&.O&>U7O%WA'3_&6B/I>H%D0L&62/&Y2/3-;]%
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M\W^MGD.7<^I-0^%/ 5CX1OM1N[2ZN)FOF#.)=N%//3 ]ZZRB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJEYJ-I
M8*&NITB!Z;C44>M:=+(B)=QLS_= /6@#0HI*6@ HHHH **** "N0G\%>;XVB
M\0_:R/+&/*Q76/(L:%W;:H&23VJ&UO;:]4O;3+(H."5- '+:AX(:]\71ZZMX
M4*+@1XH\/^!(=)U6^U"[E6[DN6R ZYVUV..** ..\1^ [?6KZSO+61;.:V<-
ME%QFDM? S0>*UUQ[S>P3:4QUKLJ* .2\9^"(?%B0NLYMKJ$Y251R*AUGP#;Z
M[H5O9WLY:[@7"7(ZUV=% 'DUG\&G6ZC:_P!<GNK=#GRF/'\JZ35? $>I:O87
M'VG;9V8 6WQP<?A7;4=J ,+5_"^GZKI$MC]GBCWKM#A1E?>F>$?#TOAK1ET^
M2Z-P$/RL?2MZJPU&T:\-H+A//'6,'F@!=0_Y!]S_ -<V_E7B7@CPW=:W-JTM
MGJ$EE,)V7('49/M7NK*'4JPRI&"#WJI8Z79:<9/LEND1D.6VC&30!S>A^!8=
M&T2[M!.9;JZ4B2<]3D5<\'>%?^$5TZ2U^T>?O<ON(]:Z3%% '$>(/A^-2U7^
MU-+OFL+P_?=?XJM^&/!,6@W$M[<W!N[Z7[TS5UM% ' 3?#RX3Q8VM6&IM;B4
MYDC ^]^E&L?#J2XU,ZAI.I-83R+B7:/O?I7?9P.3BJ']M:<;G[,+N,S9QLSS
M0!A:5X,_L[0+K3Y+Z6>:Y!WRN<\FLV+X<>5X/DT+[<3O?=YF.G3VKO,_2F^=
M&690XRO+#/2@#F+OP=]J\&1Z!]J*[%V^9ZUJ^'-'_L'0[?3A+YOE#&[UJ[;7
M]K=LRP3+(R'#8/2K- '/>*O"EMXGLUCD<QSQG,<HZJ:Q-&\ 7UEJD-YJ.MS7
M@A&$CS@?CQ7>XI,4 <;-X':^\5KK%]>F:%%Q';D<+^E16?@AM$UJ]U.SO2EM
M.I+VW;-==/?VMM*D4TRQNYPH8]:G(#*0>01S0!X7X0\.W.M:MK$EG?R6,ZRD
M;U[C\J]&\/\ @6+1-,O(6N3-=78(DG(Y.:VK6+1],OGB@6&&YF.65<9-:U '
M,^#O"?\ PBMG-!]I,_FONR1TK)UOX=M>:L^I:3J+:?<2#$A7^+]*[RC% '+Z
M#X/&E:7<6MU>RW4MQ]^1F_E7-R_#'40LUM!K\BV,K9:%AGC\J]-IK$*I8G '
M6@#E)? ED?#*Z/#*\(49$B'G-8,/PQO9YK=-5UIKNT@8,L1'7]*]!MKZVO"X
MMYEDVG#;3TJ=W5$+L<*.23VH X_6/ JZGKVG:BET8DLP (P.M-\1^ EU;44U
M/3KQK&^48,B]ZZRUO;>\4M;S+( <';5B@#CO#?@5-&NY;^]NVO;^0$><W:GZ
M!X*_L37K[4_M?FFZ).TCIFNOHH X_1/!/]C^)[S6/M9D^T?\LR.E=:PWJR^H
MQ39YH[>)I97"(O))[4VVNH+R(2V\JR(?XEH X_3/ /\ 9]YJ]Q]LW?V@I&,?
M<SG_ !JUX>\&#0M"N]-^U&3[1N^?'3-=;10!R_@[PE_PBMK/#]I,WFONSCI6
M[J%I]NT^>U+%?-0KGTR*?=7=O9IYEQ*L:^K5+'(DL8=&#*>AH Y7PUX-_L#0
M;S3?M1D^T,6W8^[G/^--\,^!X="TN\L)YOM,5R3N!'3-==2T >9M\+KJ-I;>
MTUN2'3I6R]N/3TZ5O:CX&M;CPC_8%I)Y$9ZOCK778HH Y.Z\'?:/!D?A_P"T
MD;%V^;Z\YK4\.:*-!T6#3C)YWE#&XCK6G<3Q6T32RN$1>I--MKF&\A$MO(KQ
MGHPH R/%7AP>)-&?3Q-Y&XYW 50N/!OG^#!H'VHC"A?-Q76T4 <=)X$@G\&1
M>'YIRWE#Y9<=#7/3?">ZO-/CM+O6Y)5A8&/CI^E>I44 <-J?P^_M%](;[:4_
ML\ =/O8Q[>U6-<\$?VQKUAJ?VLQ_9<?)C[V*[&DH Y#5?!']I>*K/6C=E?LX
M \O'7I67>_#6<Z_/J>FZJUHMQ_K4 Z_I7HE)WH X;P[\/O[ DORE\TBW:D'(
MZ$_A5SPOX,_X1W2[VS^U&7[22=V.F:Z6YO;:R"FXE6/<<#<>M3(ZN@9""#T(
MH Y?P=X/_P"$5%Y_I)F^T2%^G2NI;H?I5>YOK:S*"XF6/><*#WJ<$$9&"#TH
M \,T+0Y]:\<ZR+:\DM)XV.UP*]#\,^!$T+[5/<71NKVX!#3'M6VD6C:7J#,J
MPPW4YYZ M6M0!ROA+P<?#%Q=R?:C-]H?=C'2H'\#;O%LVN?;#^\C*>7CI79T
M4 <;X=\#_P!A+J0^V&3[:2>GW<Y]O>F^'_ O]AZ3J-E]L,GVPL=V/NYKLZ#@
M#GIWH X&T^&L$/A2XT2:[,GFN763'W>OM[UFR?"B[NM.6TO-;>5(F!B&.%Q^
M%>C6^H6EU*\<$Z.R'#!3TJW0!QNN>!EUKPU:Z6]T4EMP-DH'<5"/ +77AL:7
MJE\;F6/F*?&"GZ5W%% 'GVE?#R^MM1@N-0UR:YB@/[N(' _E5WQ'X'EU;4H]
M1L-4EL[E.,@Y'Y8KM*3% '%^&O 8T?4I-2O[TWMZW D(Q@?E7:48I: "BBB@
M HHJK<WUM:,@GF2,N<+D]: +5%(I#*".0>E+0 4444 %%%5[J\M[*+S;B58U
M]6H GS2U'#*DT:R1L&1NA%/H 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LK5_#VD:]!Y.J6
M$-RF/XQ6K7FWQ+^*">"WAT^QMA=ZG,H98R>%!.,\4 8VM? BQ,K7?AO4I].N
M0<JA;* ^P%<'#X<\>_#+Q')KRV*ZD6R'E4>87!ZG:IR*];U;XC'PWX M-;U2
MW_T^X4!+?IEB,\^U><I\<O%4*1ZC>Z!&=+E?&[G&WV.* /8? WBJ7Q9H"W\U
ME):3!MKQN,<UU%8OAC5].U[0K;5-,1$MYUW850,'OG'OFMJ@ HHHH **** "
MBBB@ HHHH **P/%_BB#PCX?EU6XC,BH0JH.K,>WZ5S/A_P")=]K>IP6S>'+N
M"*7_ );-C 'YT >BT5YCK/QCL;#5KNSL=,N[Z*R.+B>)057UQSVKH)?B+H<7
M@E?%)D8V3  *!\Y8_P ./6@#KJ*\VT'XO66IZU;:9?Z;=:>]V,V[S* KC\_:
MO2 <T +129I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?%?
MBS3/!^DMJ.IRE4SM1%Y9SZ 5PUC\<M/EO8(M2T'4M,MYV"Q7,ZG8Q/3M67\<
M!Y>N^&;F[&=-CF/GDCY1RO6KGQCU#19_AM#%#+;R32F,6JQX+=1G'IQ0!U?B
MCXB6?AK5M'L6LY+K^U!F.6.0 *..??K4WCGQU;^"+"SN[BRENA<R>6%C<*5Z
M>OUKR#QDD]H?A]-?Y01P*'=_X1\N,UN?'C4[&XT71;>"[BDE,VX(K9./EYH
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MG(VU9E0D?RKH/$GC6R\/V4,K*TDL^/*C Y->32?VMX7L(;NTU"WO=+5@$A8
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M^0SMM_.@#U=W"(68@*!DFN U'XFPQ7TMOI]E-=K"<2NBDA:Z_74E?1+M8?\
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M-(FTS4HC);3## '!'/:L;P[\.M \-:5>:9:Q33V=Y@31W3^8"!GCH/6NMHH
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M(HUPH]JMT4 9.N^'['Q%9_9-00O%G.!6)_PK7P[]JAG^SN?*Y1"PQ_*NQHH
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M<&MRB@#D[7X=^'[35$U!+=FE3[@9L@?I5K7O!>D>(I(I;V%O-C^ZZ'!KHJ*
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MJ,DFL71/$<&LW%Q$@VM$W /<52BVKHI1;3:-REI,TM22%%%% !1110 4444
M%%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 SFEHH ,4
MF*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L;4/"VA:I<FYOM,M;B8C!>2)2?U%;-<'XR^*V@^#;LV
M-UYTU]LW"&-#S_P+&* -<> _"P_Y@=C_ -^5_P *I:CX;\"Z1 UQJ&GZ9;Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "&D+!1EB!]32DX!/I7D&M:AXB\9^);C2M%N3;6EM]Z0'O0!Z\KJPR&!^AI
MV:\G\-VGC+PWXBCL;N5KRRDY:0Y(6NIU[QU;:3??8;:WEO+E?OI$,[: .NS2
MYKF=+\966J:5<74:LDELI,D3?>%8^E_$J#6;I(;2QG92VUWVG:OZ4 =[FD+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK,#_ (6[.<?\L^OYT >FSRB"!Y6Z*,FO.KCXQ:3;W4D!MYF:,X) KO\ 4O\
MD&W/_7,U\[Z;K<NCRWS#P^M]$)26E*Y _2@#VSPOXWTWQ2'%J2DJ]4;K72-(
MJ_><#ZFO(? .GSSZE=>*3#%;6PC.V&(T_3[;6?'EQ?7YU22UAA<K#&A/X=Z
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M67PVUB5)VGCD8GH>>O2O4]1\*Z-JLXGN[*.20=\"K3Z/I[Z=]@-L@ML8\L#
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MXA H X;6--DU7X7V?V)=SPH'VCO@YJGIGQ9TZQT!+>X@D6]A388RIY(XKKO
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M.,XMG\Q5*#\_YU3_ .$5^+@'_(?.,?\ />.CQBOBCQY\2K_2-)U*:TM=/@W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ\4P*9,Q7$8^25>"*YC1OA'%:ZC'=:C>R72QG**QZ&O&_P#A>'C'/_'TG_?
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M ,I*]:KR77?^3C_#G_8.?^4E>M4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9=]>W<$X6"T:5<9W UJ4W JHM)W:*BTGJ89U34O^@<_
MY_\ UJ/[4U/_ *![_G_]:MVL_4M4BTU4\Q2=_3%:QDI.RB:1DF[*)S]A>7<6
MHW,D=JSNWWESTK3_ +4U+_H'-^?_ -:LJQUF&VU"YG9&(EZ"NLMIUN;=)5'R
ML,UM7]UW<3:M[KNXF0=5U+_H'O\ G_\ 6K3L9YI[</-$8WR?E-6J,"N:4TUH
MCFE)/H%%%%9$", P*GI6$WA#1V<L;89)R36_BDJXSE'9E1G*.S,NST2PTOS'
MM80A8<FL+P@P2XU-FX42$DFNOD_U3?2N1\'J&N-25AD&0@BMH2;A)R-8R;A)
MLX_Q/K+:IJ[.K'RHCMC'TKN_!NL#4M*$,C9N(/E8$YX[&M0Z%II.?LD?/M4]
MKI]K9%C;PK&6ZE1UJZM>G.FH);%5*T)4U!+8M4M)2UR',%%%% !113<^M "T
M4F?>E!H 6BBB@ HHHH ***0T %%)FC- "TM(*6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW93CA^<AP1@=ZKNOS''2N@N[P7*'="JD# (K&*<\BIJ0479!*-GH5:*LM#W
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MZXZ4T'Y>330<4 @=13%8=DL>: #ZTF[MBG+\O)IJW4+$Z!43D_-7J'P%V_\
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M:**Q,@I#2T4 )112T ,D^X?I7)>#?^/K4?\ KJ:ZV3_5M]*Y+P;_ ,?6H_\
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M9E%8,ZY&.F:<K-#BRIC'%>I_ #_DH#_]<&_D:\MD8%B5& 37J7[/Y_XK]_\
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M])U"_-R&(-H@;;MQUS]:XFS\$^-?$>NZ1)XM:SCT_2L&-83DR$# )_QKV84
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M4MN; K=K1)&M+DY%8VM'TWY6=9 I]ZI:M*'D,;'#*<<=Z[B]^'FKVNDBZBF
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M4 %%%% !1124 &32$\4$@#G@5BZSK#62QF#:VXG/-73A*;21<(.4K(CT@_\
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M>10!ZC2TE+0 E&:KWZW3V$ZV3JER5/ELXR ?>O-)[7XLVT#S3:_H\<:#<S-
MH _\=H ]3S7E?Q^_Y$"V_P"PC%_)JP].\3>/]4U:YTVV\4Z,;F @.#"F#GTX
MK'^*UGX^A\*0OXCU*PN+(WD85((@K;\'!X ]Z /?M,_Y!=M_UR7^56J\ILM/
M^+1L8#%K6DK&4&T&!>G_ 'S4_P#9WQ>_Z#>D?]^%_P#B: /3Z6O/]&LOB7'J
MT#:MJVFRV(;]ZD<*AB/;BO0* "BBB@ HHHH **** "BBB@ K#\8_\BAJG_7
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M@/&<5&&W8)[4KRA%^M4Y)H+#6/Z52=LL34DSD#CO4'/6L6S2*$Z]37JG[/\
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M'/\ L'/_ "DKUJO)==_Y./\ #G_8.?\ E)7K5 !1110 4444 %%%% !1110
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MRO&,Y!'Y4 ?5"LK@$$$'H0>M/JM9VRV5G#;(2R1*%!8Y)Q5F@ HHHH ****
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MB-H@_+$ C!P,4DWQWN?/"S^$;?SGZ"2$[F_/K22?'2YM1OD\'VT/HS0E?UH
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M!FDQZ@TXD!<4A#0!NP:?O"MQ4?X4E $C2%J:"12=:4?>YH$Q20> .:,<9IS
M#[M-&[TXH 04[) Q24AXZTP%R2:<W& #30?2AB/QH0$K!3@#\:C9 ".:9DYI
MSN5(IH":-0O7O4^55<=:IBYRPXX%65E1T(QBNF$E8D;M+MP:1DQW)-2*P52!
MR:%ZU=D)D>5V\CD4GWOI3GCXW4@"D<G%)]A"MY?EXQS2(/D(Z4^)$=]K&II[
M9(U!5\YJ5:XKE0("I&[I2-@, V<4 8?@\4K<]J"@) 'R]*1, [B,TO!7TIJ#
M'4U+V$=!X)R?&VD-C \\?UK[/[5\7^"&/_";:2.WGC^M?:%<M?<M'R7\;?\
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M\%+J[N_AS9M=,S;2RH[')(W&O1:Y_P 'ZOHNKZ(CZ  +"$^7'A2HX]C70>]
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MD!1110 4444 9GB#_D 7_P#U[O\ ^@FN9^$W_(BVW_71_P"==-X@_P"0!?\
M_7N__H)KF?A-_P B+;?]='_G6R_@OU-E_"9W%+2=Z6L3$**** "BBB@ P*YG
MX@?\B3J?_7%OY5TU<S\0/^1)U/\ ZXM_*JA\2*C\2(?AQ_R(NF_[A_G765R?
MPX_Y$73?]P_SKK*)[A+<****DD**** "BBB@#E_$?@;2O%.J6=WJP>:.T!\N
M#/RDG&<^O2IO"GA"P\'PW5OIK2?9[B7S1&[9V< 8'Y5T./>C'- "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GB\@>$M4)Y_<&
MMNL/QA_R*&J?]<#0!\12$&1L# S2@<"F'EV^M/!XQ6_0!Q &"#2Y)I*52?2A
M##G%*.!2_6@+WI@&2*-U#>U)0*X]I,J!BF;N,4N/ER*,4!<=D;>14?X4Y#M:
MG'EJ8$??BG8)&:;W-.#'&*0"?0T[>P7% .",#.*225I#G %4,0''44O+&D!R
M.:57*'IUI$DD>U0<]:C;.[BC))SF@9Q0,;GFI/++CYN*1>O JX5#**N$;L16
M6W5>3S3MBGO4[1;$Y-1[<GTK=1)&X"D8I^-S9Z"F-QQG-/0';@]ZJ]@!CL.#
MRM."HPRHXJ/:%&6/% 8!L ]>U&G-<5@9=C;ATH)W=^*=G)PPICL?N@4.RU'8
M0@@\&AFPF.YH! '-(<=6Z5-] $&<8ZTWE>#09".@X%+DO\QX^M1N,W_!9)\;
MZ1@8_?BOM#_"OB[P.6;QQI(/_/85]H_X5RU_B&CY,^-O_(]S_2O/+?[]>A_&
MW_D>Y_I7 VVU4+-UJ(%(ES@U/E"J\<BH0I8;ZE5&";QTK:S86;)EC>/#.2 >
M14+X,F13O,8HJL<J.E)L/W_X:39+8WOS3W"J!LYSUIP +8(X-->(AL*:@AO4
M8I.>*E1U#?,,9ZTS8 W.14VV$IM.>>] F5WB)E^49'6I401L">M6 T?E>6GW
MAT-01A^5VEB:=R;V)8KLB?:@!SU&*EEMQ*Q\B0'U!/2H6@6 !B2&-0%=C[XV
MJ&G?0FUW=%P6MS"JG8.M5+@R&9B1TZBA;F="&$A..QJR\?VF(SQ?>'WA57?4
M>JW(8Y!C#X&>E2.!C &:A$3JGFMC%2*Q<?(":TBDV&[.G\"P.=3F53QMY4GK
M737OA_3=4LY0B>3<IDC ZUY]9ZE-ITXF@X<=:WSXVN7A:-(%5V&-PK9TGT,)
MTWS&#/ +>9XF/S*<$55$)=B2>*=+)))*TDG+,<DTV,D/ALXKMITUIS(WC'0=
M&OS\G&*60_-@&D:,[\@]:?) 5C!!!-;I22Y4B[!L;;G.::3QQUH20[=IHRJR
M @YJN@6$5MIVD=:)%:-ACH:=(V6+8XQ42RNYP>U1)K9!8>\K(,J.:LVT:3P,
M_205&V[;EUX[4U)2I(0=?2B2>\F5J.=3$<N<YJ)BC#I23.2N&/(J!<]">M*5
M2-[(3)_+\LJX'%-W9!)]*:<A "QP*;DD;14.5MB6D,ZBOJGX3%3X&M-GI_05
M\L\#=]*^I/A'_P B-:?3^@KBQGPW*CN<'^T=_P >VD_[Q_K7S_QZ5] ?M'_\
M>VD_[Q_K7@"@D5P(MB[E]*<I)8#-,]J ISUK12L*Q;W.ZX(&!3<X['\*B0N#
MUJS"P52#UJ[W(:'QQDKN*\'O3T*Q_-GGM49<@$#I2JN1G@D]JE,S:+9F22VR
M"!)42 <YZFHO)967S%*@]#3YU6W;".&![BBXN4E.U4VJ,GO3E.R,_+\Q[U4#
M,,Y[U*95* ,>E":3%84J5&4.XGJ*NP6Y2,33Q$PGN.U5,+M$D; ,.U/-Q=;,
M%R(S_#25]P3%)4L?+'RYZTQD7=UQ4@;Y?E3;D<U7:3#X/2M5+06XR8M@[3Q4
M5L-\@##O1+N8'!Q2VTOE'YQP:JBTZBYMB[:#;NYDBN-JM@#TJU;S17B[6.V3
MO[U6N;)G8RQ$,IYQ45I;/)(2#MV]:[KU'6Y6KQ93C%Q-$YC.P9S3E20'.XJ/
MYU&3YDP4'&!R:E>9V58&QM'0BN2O3C"HTGH8V'Q8W[2,L>E+(LBDI(Y+=AZ4
MJ_NG20J/EHDN5E9G"<YJ+)O0GJ0FW<=3Q4@B"\$?C3FDW%3G..H%)O5I V3@
MC@5FTTQNX(N25!Z]*>R)&GS/S3&'SC!Q2NJ@$2]ZB[N0K7(E2,');@^E!AC
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M/\ZZRB>X2^(****DD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX@EN.HI :*DD6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,4 Y_P :M$2C<V+F\24  ]*>N[&!QD=?6LA/D!;J>U6(KUMRAN@IV,W"VQ8
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M:/+*R%!@<QR94X(Z8K0BFED7<\C.?<U49-S#L35F -&=@2M:,)1=UL*35A6
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M  _[ZIR? _Q4C!EOP".GS5',!Y]X,MI+3Q_I<,HPZSC(K[3KY\\/_!77M/\
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MBSX!O_&T5BME(JF DG/X_P"->8#]G_7B>;B/\Q62E9"L>28XYIHY..U>N_\
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MX<_[!S_RDKUD#%>3:[_R<?X<_P"P<_\ *2O6J $Q2XHHH *3%+10 F*,4M%
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M)8_Y>/\ OL_XUROC70OB'<^/Y-7T:)T6$;(98R02O'!]>E)]K^-7_/-?R/\
MC0![+X5\+6/A'21IVG[_ "0V[YCDUNURG@%_$4GAX-XF&+_<<_2NKH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /)==_P"3C_#G_8.?^4E>M5Y+KO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *,444 %)@4M% !BC%%% "8%&*6D- %2[TVTO1
MBX@5_J*=:V-M9IL@B5%]A5FC'-.['S.UA<4444A!BC%%% !28%+10 8HHHH
M3 I:** "BBB@ I,"EHH 3 I<444 )BEQ110 8HHHH **** "C%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10
M!YS\0_A18^-IUU"&Y:RU15VB8<JP]QU)X]:XBT^ &JW-U$-:\1>=:)UCC4AC
M]#DXKWRB@"CI&E6NBZ7;Z=9Q[+>!-JC^M7Z2EH **** "BBB@ HHHH ****
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M'W!YKYH^&B^(#'?'1M=T[2U!'F_;$#;^.V5-:_@W3/&VI>-M5F\/:U9)./\
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MGQD_Z&[2O^_(_P#B* /6J*\E_P"$<^,G_0W:5_WY'_Q%'_".?&3_ *&[2O\
MOR/_ (B@#UJBO)?^$<^,G_0W:5_WY'_Q%'_".?&3_H;M*_[\C_XB@#UJBJ]B
MES'I]LEY(LETL2B9U'#/@;B/J<U8H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-P.<<XI:X'Q3X)U>
M\U9M:T'Q%/I]YM ,3X,38/<8- ';W=U'9VDMS,=L<2EF/M7EL?Q4\0ZION=%
M\&W=SIX8^7-N(\P>H&VF77C7Q-HD,MCXN\/&ZL7'E_;+'YMWN1G/Z5SWAW0C
M?1-;>$_B"UK9ASFTF4*Z'N/F6@#U3P5XTMO&-A/*EO):W-M)Y5Q!)U1JZFN4
M\$>"K7P9I\T,4\ES<7,GFSSR8R[?A75T %%%% !1110 4444 %%%% !1110
M56O;"UU*SDM+R%)[>08>-QD$59HH YK1? /AKP_??;--TN"&X_A<*,K]*Z3'
MO2T4 )BEHHH 3%4=5T;3];L7L]1M8[B!^J.N15^B@#AK3X0>"K.=I1H\4N?X
M9@&7\L4V'X/^"H+S[2-)C8YSL?!0?ABN[J*>XAMHC+/*D4:\EG8 #\Z .#/P
M8\%-JS:@=..YO^6&X>5_WSBI[KX0>"KJ[%PVD1H1_!'A5/X8KL+/4;*_4M:7
M4,X'7RW#8_*K5 '#7GPB\%WDD;MI$413'$("@X'?BNHT70M-\/V"V6EVD=O
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ME!\N9&C?:<'!&#6;X8\,:=X2T6/2=,$HM4=G E?<<L<GFI=0UZPTV^LK*XF
MN+QBL*#JQ S_ $K4H **** "BBB@ HHHH 3O4%]9Q:CI]S8SY\FXB:)]IP=K
M#!Q^=.ENK>&5(I9XTDD^XK, 6^GK5.;7+"WURUT=YU^VW*,\<7?"C)- $?AS
MP[8>%M$@TC31(+6'=L$C;FY))Y^IK6HHH **** "BBB@ HHJ!KJW2X6!YXUF
M896,N Q^@H R_%/A?3?%^C'2M4$IMC(LA$3[6R.G-:T$*6]O% F=D:A%R<G
M&*HG7+$:ZNCB8->&,R&,=5 K2H 6BBB@ HHHH **** "L/Q1X5TWQ?I::?J@
MF,"2K,/*?:=PSCG\:W#P,FJ=OJEA=W#V]O=PRRI]Y$<$B@"U&BQQJB_=4 "G
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>)?$;5KB;QY%I.JZ_=:'I"P[XY8
M<CS&YZG(]*]MJAJ.BZ;J\8CU"SBN%'02+F@#PW0=5;3O'NDZ;X?\2W/B"RO"
M1=QS$NJ+ZY)->F:[\,/#>MR_:!:_8KQ3D3VA\ML^IQUKHM,\.Z/HQ)T[3X+<
MGJ47FM+% '+^#_#VJ>'+>XM+_6)M3A+Y@>;[ZCT)R<UU-&** "BBB@ HHHH
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ML[%5-W=P6X8X!ED"9_.O#_B5JL5O\1H)M;M/[1T)[,K91+)B-I3MR2V<=<T
M8_B:/5_ _AZ^L+>1=5\*WP(@EW9\ANWK[5U'@[Q%\1+3PWI[)HMIJMD458VA
ME*LJCCG"]JK>%;6TTK4[?PZBVVI#5U>2\BAD$D-NF.%&"<'@]Z]2\)>#]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\I8=R1@Y->EVMK!9VZ6]M"D4,8PB(H  ^@I\4:0Q+'&H5%&%4= *?0 4444
M%%(:9)(D2-([JB*,LS' % #Z\O\ B%XH_M7PUKVF:)-(;RQV_:0AVL4/7;CG
MC@4?$3QEJ*^&(]5\&ZC:SBVE_P!*5#O8+D#H#Z]?:O.[GQ1JMIXNT?Q+<Z*T
M4US&L5W) -\5TA Z8Z'@<9- #-.?P]>6X\06<2V%OI49"0M,RS74P'1L=LX[
M\Y->J:%X$\/:[:V7B#4-#C@OYHP[QJ2$YY&5Z'MU%:L'P\\(RWB:HNAVZS,1
M( R8 ;KG'K76@*BA5   P!0 D<20QK'$BI&@PJJ, #V%/[T"B@ HHI* %IDL
MT<$;22R*B*,EF. *;-*L,#RO]Q%+' ["O$?B-XSM-=T;1=3@,\OAX7A2^1<J
MQQMP&'XGB@#HOBYK<TO@M)=&NO-M?M"B^:W?#"+O@CD<XK@;+^R=+6;QKHB3
M6UE:KMM[22Y;?=R#NXR>./?.:?8'3=#<Z[96\+1:O*MM;:5!.K8CXRS@=>AX
MXQ^%>KZ?\+?"-CJ":A%I,:2J0RQD@HA'<"@!=$\&Z3+K%KXM2U>SOIH<O#$Q
M5"3GJ!P>O<5V?.::!M 4  #IQ3Z  4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(:6L?Q-JE
M[H^B37NGZ;)J-S']VWCZM^AH GO=9L[2[BL'N(UOIT8P0D\O@$_TKYV$I\4Z
MEJUE=W%X?$LMX\<),QC2VC#$!L9 P!CUK2\=>.--U9].UA89]+\0Z9*K/!,N
MUGCSRH/?O7HC^"?"OQ!M+/Q%Y<D=Q-&K--:R;"3CD''ITH YNPT*P\=VU]X6
MNC<-=:&52/6.-TCYYP1U' Z^M>N:79MI^F6UFTS3&&,(9'ZM@55T#PYIOAK3
MEL=,@\N('<23EF/J3W-:N* %Q1110 4444 5K^[^Q6$]SM+>4A;:.^*XWP#\
M3=-\:P-$0+74(_O6[GJ/4>HZUU^J6/\ :6FW%GYK1><A3>O45YGJ_P (([;0
M+"3P]/\ 9M>TY!Y=RHV^<1V;ZT =[X@\*Z/XGMO)U.T2; PDG(9?H1S7G=O\
M']1TKQEIVK:;KSM:V[Y<7',FW(^4''(X[FNO\ Z_K.M:7)'KNES65Y:OY3-(
MI EQ_$*Z_% $-O:P6X8PPQ1LYRY1 NX^IQ4^*** "BBB@ KG/&7BZU\'Z.+R
MX1I997$5O"O61ST%=&>E<]XI\(:?XMALHM0,@6TG$\>QL'<* .1T+XEZRWBF
MUT3Q1X>_LF2^.+1@V=_3@\GU%==XC\&Z+XHB U"U!F4829"5=?Q%>=_%R]@T
M;QWX&U*[9Q:6D[/,_7 #+75>!?%&N^*]1OKZ?3Q;:']VT9QAW/K[B@# T?X3
MZIH?CFVU>VUYYK)%VR+,,NZ\?*>,$<?I7JL-M!;J5@ACB4G)"*%!/X5)BEH
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M/3(SWKL++SC8P>?_ *WRUW_7%3B@   &!TI:** "BBF2R+%$\CG"(I9CZ 4
M.S574-1M-+LY+R^G6"WCY9V!P/RKR_4OBKK3+>:EHOA\W6B63LDMPSXW[3@D
M<=.*[[2K[3?&GA>VO6@66SO(]QBE7/X$4 >;_$#QGKVGZWI6H>'[ZWN-%N1L
M=>"K,>S<9&<&N;\+7TL/Q'N]*U30)+?3=74--:RIN2.3GE2,C'/Z5UWB;X)6
M=[;2CP_?S:;YCAV@!S$Q^G&*] \-:/<:3H-A:7\XN[NVB"&=AR: ,_1OAUX8
MT*_-[8::J3#[A9V<+] 20*ZNDI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM%
M &/J_A?1->@,.I:;!<(?[RX/YCFKFFZ;::18165C"(;>(;41>@JY10 4444
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M:N_&['..F:?2#K2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !24M% "8YI:** "BBB@ HHHH 2
MJU]I]IJ=HUK>P)/ _P!Y'Z&K5% %#3-%TW18/(TVSAMH_P"[&N*O8I:* $ I
M:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gmz2lq4320rk000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 13"$D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444F>: %HI,T9H 6BBB@ HHHH ***3- "T444 %%%% !1110 4
M4F:6@ HHHH **** "BDHS0 M%%% !1124 +129S1F@!:*** "BBB@ HI*,T
M+129I: "BBB@ HHHH **** "BBB@ HI,T"@!:**3- "T4F>*,T +129HR<T
M+129HS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ H[444 <3XO^(VF^%)A;%3<WFW/E*<!1[GM7+V'QRM9;I4O=*:W
MA/\ &DF\_E@5SWC..;PW\2?[7OK$WEHS!UWC((]/P]ZW+OQ?X(\::9]@U&)]
M+9F&V14&X'/J!_.@#UG3[^WU.RBO+259(95RK"K5>>7)E\ > A/X?D74K>)M
MY:X.["G)XVX[FMK0/%G]K^"?[=D2-9(XF:5$SM#*,D"@#J:*\[\)?$&\UG3-
M4U74;6""QLB0IB!RWIU-9UM\0?%VN0RWN@^'[>6Q0D;I7^88]MU 'JM9U_K5
MAILT,-S<HDL[A(X\_,Q/H*YOP9X[7Q3%=6\EL+?4K8'=$3PQ]OQKRGQ5?^(9
M/B3;R75C''?QNGD6X?*/_=[]Z /HH'(SZTM<B/%-WHOA,ZGXEM8[6Y7@0Q-G
M<>V.37*1_$3QA<V+:O;>'(6TI227)._ ]MW]* /6:*YC0?&%MXA\-3ZI:KMD
MA1B\3?PL!G\JXS1OBCK^M_:[6RT2&XOHV)C"$A H[MD]>E 'K5%>2:5\6M3N
M;B?3;G10^JAML4,)P,^^3VJUI7Q*U=/%<>A^(=*BM))6VJ8B?EXR,\G]* -_
MQWXX/@R*T<6(NOM!88,FW&,>Q]:ZC3KO[=IUO=;=GFQA]N<XS7%_$KQ=/X5A
ML7@L;2Z\YF!^T+G;C'3\ZZ&;Q!;Z;X536+W;&@A#E4'&3V% &[17E,/Q"\7Z
MI;RZCI'AR&334R=\A(; ]MW/X5U?@OQK;^+;.0^5Y%W"<2Q$_J/:@#JOI5+5
M[_\ LO2KF]\O?Y,9?;G&<#.*NBL;Q;_R*FI?]>[_ ,C0!YC_ ,+X?_H K_X$
M?_8T^'XZ/+.D?]A*-S!<_:/7_@-9?PO\3^'-#TJ\BUJ:*.5Y 4WPE^.?8UZ%
M:^._ ]U<Q6]O<6[32.$1?LQ&23@?PT =C:R_:+6&<KM\Q ^/3(S4U<1X]\3Z
MUX4M(;W3[.VGL^DF\-E?R/2L;5OBL(/#NF76G0P3ZE=@;H#DA#QD<'/>@#U"
MBN*UOQ3K&A^!TUBYM;7[<0"8@&V#/XYZ5SNG_$;Q3KVGB71M AG>,?OW8D)G
MT&3F@#U?-%<+X)^("^)KB73[VW%IJ,7WH\'!^F:Q->^*.IZ3XOFT>'38;B-<
M+&%SO9C^.* /5:*Y#1-=\0+97=]XGL+;3[>)-Z>6V2WZFN8B^(WB?7)+B?P[
MH$,]C V"\Q()]QR* /5J*X_P7XY@\5K-!) ;:^M_];$W\Q6+J7Q%U.ZU^;1_
M"^EQ7D\'WS,V <=<<B@#TK-%>:Z/\1]03Q$FB^)M,2QN9" C(?ER>G<UL^-?
M'$7A..WBC@^T7=R?W29X^I]J .QJ"\N/LME/<8W>5&SXSUP,UYA>?$#QCH<<
M=[K?AZWCL&/+0MEO_0C7?VVM0:AX<;5;3:\;0-(JGIP#P?RH P? WCL^,7O%
M-@+7[.0.)-V[.?8>E=IGBO/_ (<>,+CQ1)?K/86=MY# #[.I&[.>OY4>(OB-
M)::X=$T&P^WZ@.&S]T'T[4 >@T5YA'\2M7T;4X+/Q;HRV8F/RRP'*K]>373^
M-/$TWAWPLVK6,<,S;E"B3.T@GVH ZBBO+=.^(?B77]+671M CN)DSYSLVV,?
M3)!J]X,^(TVNZS)HVJV2VM^F?N9VG'4<DT >B44E+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(:6D- '!>+/BAIGAJ[-G%&;NZ3[Z*V OL3ZUAZ5\;[.YNA'J&FM:QL?OI)O
MQ^@KD=5>7P?\2+K4-3TTWD#.65G'# C&1VS737OB'P-X\LX;.]+Z7/O&QU0!
MA[9 QB@#UVVN8;RVCN()!)%(NY64\$5+7G>NZE=_#WP99/H@CU"TC.UI+@Y(
M!Q@Y7%;J>+(Y/ S>(E5#M@WE0>-W0C\Z .GHKSOP]\0;N[\)WGB#6+6&*WB;
M9&L((+D?4^XK-A\?^,]1LGU33/#UK)IHR0[/\V!ZC=0!ZKU&16==ZYI]E?P6
M,UR@N9SA(L_,>_2L#PGXV7Q7H]Q);VXCU"!?F@8]3V_ UX_>:AXB;XH?:&L8
MCJRR_):E_D!V_7TYZT ?2-%<AJ/B^7PYX434M>MDAOFX^S1-G+>@Y-<M_P +
M$\81V"ZO-X<A_LEOFWJ3OV_3=_2@#UBBN8M_&$&I>#)]>T]0QCB+>6_9AV-<
M9I'Q.\1:[I]Q_9^A0SWL!+/M)$:I^)SGK0!ZU25Y/H_Q8U/5$EL(]%$NLABJ
M11G">Y.3_6K_ (9^(VHWGBEM!UW3HK2YY ,9. 1V/)H T_&GCX^$=1L;0:>+
MG[4,[O,V[><>E=G#)YL*28QN&<5Y_P#$+QG<^&=7TVVAT^SN1<+DM.F2OS8X
MKI]<\36GAW0/[3O?NX^5%'WB>PH W:*\I7Q_XSN;!]6M?#D!TL?-O8G?M^F[
M^E=EX0\6VOBW2OM<"F.5#MEB;JI_PH Z2LOQ#JQT/0KO4A%YOV="^S=C/XUJ
M5S/Q!_Y$;5?^N!H \]/QW?\ Z *_^!/_ -C5FP^.5M-<JMYI301$X+I+O(_#
M K,^&7BKPSHF@3VVLSQ).TY90\)<XP.X!J/XE^)O#&O:9;VVBHLUX) =\<17
M YXZ#VH ]ML+ZWU*QAO+60203+N1AW%6:XOP<Y\-_#JTFU-C&(HM[!^H&.E<
M[#\1?%.M?:+K0- AFL(20TDQ(8_3D9H ]6I#7)>"O'$'BR&6-H3;WL'^MB;^
ME8GB/XEW-MX@&A^']/6]O0VUBY^7.,]B* -SQSXS;P=90W LA=>:VW:9-N/T
M-;FAZF=8T6UU Q>5YZ;]F<[>?6O$_B7KVKWNEVEGKNE?8;Q6W#:V48>V":[V
M/79_#GPGL]2MHHY)8X1M63.#EL=J ._I:YCP+XBN?%/AF/4KJ***5G9=L6<#
M!QWK!C\?Z@_Q*D\-?9;;[,KLOF?-OX&?7% 'HM%<AXU\<V_A1(H4B-Q?S_ZJ
M$#]37,7/Q#\6Z)%!>Z[X>AAL)6 #1MEO_0CC\: /4Y)$CC,CL%1>2QZ"J>FZ
MO9:NDKV4ZS)&Y1F4Y&17#^/==U&^\#->:);QSV%Q#FXE+X:(9[<]<\5SOPBO
MO$*6ZV]MI\4FE-,QEN&;YP>.V?Z4 =;=?$0V_CU/#/\ 9P8,X7S_ #?]G/3%
M=W7FMYXXN8/B:GA\:=9-$T@7SV0^9]W/6NB\9>-;/PC9H\L;3W4IQ%"O4^]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[/7.ZM.T^%]W>ZE#>^*=:?5&A/RJ!M!]C73>,?#$GB7PTVDVT\=L2RD,RD@
M'- &3\)HU3P#:,%Y=G+>_P QKB-' 7X[WP''[V7@5ZEX.\/2^&?#=OI<TZ3O
M$6)= 0#DD]_K7/V?P^NK7XA3^)3?0M#*[L(=AW#/O0!WV:6DQ2T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !37)"D@ G' IU)B@#S'2O'NG>)]?N-$U_2;6 QDI$93OW'TY'%9
M?Q!\"^%=*T*XU*W<VUUUC0/D.?0"NB\7_"VR\17K:A9W!L[U_O-_"Q]<#G-<
MY9_!&Y-PO]I:V)X <E8PP)_.@"]X%M)O$?PKNK"\#%062$MST *_K7!0>(WL
M?!&H^%Y6 F%QY2 ]2N3G]:^AM+TRUT?3HK&TC"0Q+@ 5X9K^BVNH_&!+*TVR
M122*T@7HIQD_K0!WD>AZ39_"N#3=9O$LX94#-,YX60]/UQ7"VOA/QCI-M]K\
M/:DM]IQR8Q!*6#CW3I7MNJZ-9ZQI,FG7<>Z!UQ@=O<5P$7PV\2:6'MM$\5-:
M6!/$3(21^- %7X8^)Y+S6[K2K_2[6WOE!+20PK&3CJ&P*Q;W_DO*^\W_ +3K
MT;P?X%MO"[S73SM=7\_^LF;]<5E>*_AO<ZSX@CUK2M4%C>#J[+GGIQB@#F_C
MEYN_2\ ^4 ^3CC/%2SP_$23PS^_U#1(],>$ LV  OUVUVMQX-;6/"BZ3KUX;
MRX!W?:0,$&N5/PM\0O:KIDGB@MI*G'V<H<[<^M %/P?I<VF?#OQ K7EI=1.F
M4:UF+@=<]ABK'P8 _L+5#W,C<GZ5W$?A*VLO",V@Z>1$CQE0[C/)[FL_P-X*
MG\):==VLUY'<&=BP9%(QGZT <#\*HT;XAZQ(PRRF4 ^GST7V/^%YK_OC^==G
MX/\ A_<^&?$=]JDM]#.ER7VQHA!7<V>])<?#ZZF\?CQ(+^$1!L^24.[\Z .4
M^,__ ",FA_[O_L]6OC()_P#A&]*9,^0&._Z\8KI?'/@&Y\6ZI87<-]%;K:C#
M*Z$EN<]JZ/6/#MIKNAG3+Y0R%<!AV/J* (?#4EL_@^R<[/L_V?YB>5QWS1H%
MYX:N&F70'L&88\T6J@?3.*XI/AEXCMK=M/L_%31:6>/LY0YV^F:[+PGX1L?"
M6G&VM=SR.<R2OU8_X4 =#7,?$'_D1=6_ZX-73UE>)-)DUSP_>:;'*L3W$90.
MPR!0!X]\.? .B^*?#ES=7Z3?:1,T:.DA ' QQWZUBVB'X=^.#:ZI917-L7X:
M1 ?E/1AGOBO9? ?A*?PAH\MC/=1W#/,9-Z*1U &.?I3/''@>W\86"('2"\C/
M[N8C.!Z'VH S?B?<B]^'$L]BV^&1HV!3NN:X[P3'X];PO&="NM+2P&[Y9@-X
MY.<\5Z'X9\)76E^&)-#U:[AO;=@54HA! (QCFN9'PNUO37GAT'Q(UG8SG+PL
MI)/M0!F?#O2;Z'QU=7T^I:9<2.',\=K/EE8_[.*I^ "D?Q4U$7FT3DMY>?7/
M^%>E>#O!-IX1M'$;F:ZEYEF/?Z>U9'BCX:G5=976-(O_ .S[_.6?&03TS0!C
M?'![?^Q[%6Q]H+G9ZXXS_2I==S_PH^'C_EBO7_?IFJ_"?5-:M ^H^(3=:B"
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MN93X9\22:?;RG+1LNZM7PQ\/!H^K-K&IWS7^I,,>81@?7'K0!W Z4M(.!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UK3F
MU;29[)+J6U:5<":(X9?<5ROAKX:V.@:L=3FO;C4+SG$EQU&?Q.:[GK10 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8GBGPY%XHT
M9].EN'@5SG>J@FG^&-!C\-:)%ID4[3K&2=[+@G-;%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M3XBT9]=TF2Q2^GLBQ!\Z X88.?6L+PI\.]/\,7SW_P!IFO;QP1YTW7GVS79T
M4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%)FEH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **:[;4+>@S7EFJ?%:XLK;Q)=I8XL]
M.D%O:S$\2RY(/]* /5:*\S^'_CC7M5U:32?$UFEO=20"XMV48WH2.V/>O2QZ
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5&_U?3]-"_;+R&$GH'< G
M\*N$@'K7S?\ $&2QD\7^(CXAGF2YAVG3$9B$*Y;D#\J /HN"\M[K<()HY"N,
MA6!(SZU/7B_P[OK>^^(MQ<:%/--8R6$?VLD_() %''OQ7M% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% #)"NPAB ",'->&77@&]U
MWQ/>6-CJ]O+H(O\ [1<0Y^9&W9*_I7J_B[PZ_B70I+&*_GLIB=R30,00?P->
M!OX'_P"$8U"\BUKQTVF22293RIFWRC^\W2@#TWPMI+6_Q*U"XU'48Y+B.W6&
MTME/*Q#;S^=>FBO*?A?X/TJTU"XUZU\2R:W,Z>7O9L[>GO7JPH 6BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 9FO:C/I.CW-];V;W;PKN\E/O-["O I?B
M/_;^N:@-<\&7&HVZ$>1!Y+>9!R?O8_#\J^CS7A'BSQEXGM?$VN'PY!86UMI\
MBQ7,K0J7<DD9)V\]* -OX;:Q?:AXEN(;'PY)HNB)#GRY(RI+9'.3UKUVO*/
M6L^+KGQ?)8>)[VV*_8Q/ D* !P2.1@#UKU>@ HHHH **AN+NWM%5KB9(PQV@
ML<9-2%T";RP"XSDF@!U%06][:W>[[//')M.#M;.*2>^M;:14GN(XV;H&;!-
M%BBDWKMW;AMZYS4,%[:W3,L%Q'(5.&"MG% $]%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !112<YH 1\^6V#@XX-> Z;#X.?Q[XC3QA-#<7GV@F(S,"@7)Z>A]J]B\0^*
MM/\ #CVL=\)";J3RTV#///7\J\H\07OPMC\0WZ:CI-U)>"=O.<%L%L\]Z (?
M!>L^%=$^(VK3Z5J,=IHWD!=CL K/D?=!KW*QOK;4;2.[M)5EAD&5=3D&O'?"
M^B_"_P 77\EEIVCSB5$WGS&8#&<>M>OZ7I=IHVG0V%C%Y=O"-J+G.!0!<HHH
MH **** "BBB@ HHHH ***#0 54_M"S^W?8?M,7VHKN\K>-V/7'6H]8^W_P!D
M70TPH+[RSY)?[N[MFO%O"FF:EI?QN6+5K\WEY+;M)*XZ*<-P/:@#VN]U73]-
MVB]OK>VW?=\V0+GZ9-6%FB>$3+(C18W;PPQCUS7B*Z9;^.?B?X@CUCS)8+2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]X4 6_@H<_#.QX_Y:./UKT*O/O@M_P DTL?]]_YUZ#0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTKZ*^)'_ "3V\_ZYK_,5\ZCI7WN6.]*YSX)6A8]V^#"@>%9_><_R%>E5YO\
M!C_D5)O^NY_D*](KS,5_&D>=B/XK"BBBN<Q"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /./C1?75GX+6.VD:-;FX6&9U[(>M>
M?ZSI5AJ?B+PWX"TVX:XTVV03W!1L[AQG)_X#7NVMZ+8Z_I<VG:A$)()1@CT]
MZYKPY\,M"\-?:GL_->XGC,?GR-EE!ST_.@#C/!%C9>'?B]JFD:#,6T[[,#+'
MNR$;*_K7M-<KX1\":9X0-U+:F2:ZN6)DGE.6()SCZ5U0Z4 %%%% !129I: "
MBBB@ HHHH Q_$JZJ_AZ\&BE!J'EGRBW3=BOF[QK;_$R/P].WB.1VT[(WC<2.
MO'ZU]3,ZHA9V"J.I8X%>8_&N^LYOAS>)%=P2/E?E20$_>'I0!>^"F?\ A6EC
MGKO?^=>AUY[\%?\ DFEB/]M_YUZ%0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C $<]*\$\4
MQ?#G3O'TMW?ZG=>=%/YLUG"NY/,!R<_-_2O>I!F-AZBOGBS\0^%/#7C;Q'!K
M&FO>[[IBEP8V)')RO2@#L_AUJ'A#4/%^J7FCW=S<ZA<1@GSX\!(Q@;1R>XKU
M45Y[X&\6>$M<U:6#0M/-O<+%N9C$5R,^XKT(4 +1110 4444 %%%% !1110
M4444 %)2T4 >+?&?2=>N].O+Z?4%BT>WV&&W3K(V.=WZU8\:ZG<Z9\#K'[+(
MT<DZ11%AU + ']#77_$_2+W7/!-U8Z?"9;AR"J9 S^=9VO>#+OQ!\*K?0SB*
M^BB1ER?XU.<?I0!P>HZ-:>"O$'@O4-(#0O=1+]IPW$A*Y.?QIMKHUIXQUOQW
MJ&JAII;16%KEO]5C=C%:]CX?\5>*/$>@'6M.6RL=%0(QW@^:0,#&#3=2\/>*
M_#6O>)!HVG+?6>N@A'W@>43GU/O0!S>H>(K^7X.Z+9O<.3/J'V21]QRR9;C/
MX"M_^R;7P1\6- M]'#0P7D0CFC#<-TYQZ\UHZA\+[YOA?I^E0LCZI93?:]I/
M#/DG&?QHT'0_$WB7QW8Z]KVGK86^GQ!%3<"6?UX/3B@#F=,T:U\9WOC75=6W
MS7%JS+;Y8_N]H!&/2JUUK]]J?P7T6TEN)!]IO/L\CACDHIQBM^[\->+/"^L:
M_;:1IR7MEK/W)-X'EDX!SS[&K^H_##4(_A98Z19,K:I9RBX )&"W4C\Z *"Z
M;;^"OBUH$&CJ8;:^M,SQ;N'.&Y_E73:C\7['3]2N+-M(U%VAD*%A#P<'&1S6
M9H.@^(_$OCRP\0:[IZV%OIMOY,<>\$NV#SU]Z]8-M QR88R3W*"@#Y\\;^/+
M;Q=K?A>""PNK<PZ@C$S)MSEEZ5]#1_ZM?H*\D^,D4<>I>$/+C1?^)FN=J@?Q
M+7K:?ZM?H* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRYEC.'2,L#7S/HOC?XG^))[E-(NY;CR#\X!48&>.M 'U'17SI]K^-0_Y[?\
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M/%?B36FU(Z'I]M)':7;6ZM*>&VD@GJ*R]+\9>.=6U34-/M])L/.L)!'/EN^
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M]6OT% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2?ZMOH: /G?X5_\ )<=;_P"WC_T8*^BZ^=/A7_R7'6_^WC_T8*^BZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.L?\ (&O/^N3?RKP_
M]G3_ (__ !!]$_\ 0C7N&L?\@:\_ZY-_*O#_ -G/_C_\0?1/_0C0![]1110
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M@'7TP>E7[[4+N/QO8WL;,UP-$ED5<\,VU>U=]+X6L9_"W_"/.9?L>T)G=\V
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MM?O?^%8P:1Y\AA.K_8SSUCR3C]*ZXZ3:>"?BQH$&C)]G@O(A%-&O1NG)]^:
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M0\+%KB% KR"+.\@=>G>@#UWX?ZGX=U329Y?#EH;>V64JZE-N6P.?Y5V%<?\
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M:17 _"_4O">H:3+_ ,(U;BW=6S/$R@.#[UWPH 6BBB@ HHHH **** "BBB@
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M_'Y!_P!=%_G6[XR_Y#"_[E85M_Q]P?\ 71?YUPXO_?'ZG[%A/]T7H=7\2/\
MDGUY_P!<U_F*^=1TKZ*^)'_)/KS_ *YK_,5\ZCI7Z=E7\$\7!_"SWCX,?\BI
M/_UW/\A7I%>;_!C_ )%2?_KN?Y"O2*\W%?QI'G8C^*PHHHKG,0HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN7DW^8<#G)KOATXH 6BBB@ HHH/2@"*::."%I9G6.-1EF8X KRGXR^(=(O\
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M7I/"]M_:"))K#ZA#-<'<,>6ASUS[FMO0/"3P^)_$-_J=G$\5W.CV[-AB5$:
M_J#7;T4QF!XDTS49M!:#0)TL[R-@\6%&UL?PGV-<=JNF>(_%4-KI]UH$-@\<
MR227OF*2-K G;M.><?K7J%% &=J%K)-HLUI'EW:'8,]SBN*T_P )ZM;VG@Z.
M2)0VF"3[2-PXR,#'K7HU% &?JVD6>M6+6=[&7A)R1DC^5&D:19Z)8BRL8RD
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M:?3)/]6WT-49'SO\*_\ DN.M_P#;Q_Z,%?1=?.GPK_Y+CK?_ &\?^C!7T70
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH BG\SRF\K'F8
M^7=TK#T>^U6ZO[B.Z6 0PL4.P')/YUT#=#6)HG_']J7_ %\'^E2]S:FUR2NC
M:'2EHHJC$6OGOX\_\CEH'U/_ ++7T)7SW\>?^1RT#ZG_ -EH ]\L/^0?;?\
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MQC]HOIH/_75__9:]GT'_ )%_3O\ KVC_ /010!H4444 %%%% !1110 4444
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M2 .YQ@'CK7!>%+>TA\(^(_%-W$AN+XS.LK#^';@#\Q7JHMH1:BV$8$(78$'
MQZ56&BZ>-+_LP6R?8L8\KMUS0!X]HMA##J_A&PU5E33VM9+U$DX1I6967\<,
M:U-=U*T;QU?:AIC1^78:5*MQ/&?E+%'"+GN0?YUZ1?\ A[2M3LX;2[M$>*$
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MPV,29CNR1ASZ=:WS/^*CGQWQHZ"BN?MM:U67Q7<:;)I+QZ?&FY+PD88\^_\
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MJ2]6>\Z3_P @FU_ZY+_*KM4M(_Y!%K_UR7^57:]*.R/BJO\ $?J+7SW\>?\
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M Y ([UX-YTO_  IO59/-?<-3F .XY_UK5[C8D_88/]P<T 633))$BC:21PB
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M(_"TS27Q!9"IP,9]O>OH4G')KS;Q_8ZQ=>,?#$^G.WV2"8FY"RA0!D<D$\T
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MOZ=_U[1_^@BO&/VB^F@_]=7_ /9:]GT'_D7]._Z]H_\ T$4 :%%%% !1110
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MQ;0&1=A)PI'L"*K^#=+EF\3ZOK=EI4FE:7/;>6D#IL,K\DMM[=1^5>GNBO\
M?4$#U&:4  8  'I0!XE_8FJ?\*DU.S^P7'VE]1F=8O+.XJ96(./3%>RV:,MG
M"I!!" $5/M7&,#'I3NU ')P^ --@UL:JMWJ)G$AD"&Y.S)]O2K?CBVFN_!.L
M6]O$TDTEK(J(HR2=IX%=#2$9&.OK0!Y=H'C>XTWPQ9Z?'X<U>2\ABV;3;,%W
M?7%49?!FM_\ ")7.JR6P;6I]074GM@<\*2P3Z\XKUT(@.0J@_2G&@#RK7]1O
M/'$.EZ/I^E7L+)-')=2W$118@I!QD]3Q^M0^)K/3I?$%TVL:)J-O=(!]DO\
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M%=_^N8_I7G=>B>(/^18?_<']*\[K/.?XL?0_5\B_W<[SP9_R")/]ZO _&/\
MR..J?]=V_F:]\\&?\@B3_>KP/QC_ ,CCJG_7=OYFOL>'OX:]#C7^]3-'X;?\
MCWI__ O_ $$U])U\V?#;_D>]/_X%_P"@FOI.NO,OXJ]#DQWQH:X^4UX9KO\
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MR0*\_O+KP?/8R7EE)=:1X@.<6EJY1O-[ H",@FO;<57-C:F7S3;0E_[VP9H
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M ,@6^_ZX/_Z":\0_9_\ ^0YXA_ZZ-_Z$*]OU?_D#7W_7!_\ T$UXA^S_ /\
M(=\0?]=&_P#0A0![Y1110 4444 %%%% '!_$O_D&VW_74?R->:#[P^M>E_$O
M_D&VW_74?R->:#[P^M>9B?XA]SDG^Y+YGO.D_P#()M?^N2_RJ[5+2?\ D$VO
M_7)?Y5>KTH_"CXFK_$85\]_'G_D<M ^I_P#9:^A*^>_CS_R.6@?4_P#LM,@]
M\L/^0?;?]<E_E5BJ]A_R#[;_ *Y+_*K% !1110 4444 -?[IKPC7/^0]>_\
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MY.!D<$9QFO:A7F_PTT/PMH]Y?Q:5=R7>J( +F28_. 0",<=.17I H 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH \%^+GA6X@FBUR^U&>
MX:2]18(,_)$O'OUSG\ZU_BY,[^#]!L-Q$%Q+$),'KQT_6NM^)7A:^\5Z19VM
M@4$D-RLK;CC@4GC;P3+XI\'P:=#,(;ZVVO$YZ;E'2@#B]2LK;P_\8O#']F0)
M;+/98E2)0H?ANH%;6J>,?B);ZG<0V7@OS[9)"L<GF'YE!X/3O3?#?@KQ+=^,
MK;Q#XLEMO,LH/)MHX.A'(R>3ZUZE0!\Y^,O$'BO6-<\,1^(?#W]F1IJ"&)MQ
M.\[ER.@KZ*3_ %:_2O)_C/\ \A+PA_V$U_\ 0EKUE/N+]!0 ZBBD- "T4W-+
M0!@^*M>GT#3_ +5!82W?.&"#[H]35#P5XOF\5Q32O8-;(GW6)R&K#\<_$2+1
M=0GT9K)Y2T0/F!N!D5R7@_XDPZ#I]OIAL))&:7&\,/XC_P#7KNAA9.CS<NIU
MQH2E3O8]VHJ.&3S84D' 90<5)7"]&<ECR7XA?\C$G_7/_"N:M/\ C_M_^NJ_
MSKI?B%_R,2?]<_\ "N:M/^/^W_ZZK_.OF,1_O#]3XS%_[V_4]?\ $'_(L/\
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M"N^K@OAG_P >%U_UT%=[710_AH\3-?\ >Y^HM%%%;'GA1110 444E "T444
M%>;?$[_CXL_H?ZUZ37FWQ._X^++Z'^M88C^&SU<E_P!\C\SA;3_C]M_^NB_S
MKWRU_P"/6+_<'\J\#M/^/VW_ .NB_P Z]\M?^/6+_<'\JQP>S/2XD^*!/3)/
M]6WT-/IDG^K;Z&NT^8/G?X5_\EQUO_MX_P#1@KZ+KYT^%?\ R7'6_P#MX_\
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M#[P^M>E_$O\ Y!MM_P!=1_(UYH/O#ZUYF)_B'W.2?[DOF>\Z3_R";7_KDO\
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MOR"BBBJ,#PC]HOIH/_75_P#V6O9]!_Y%_3O^O:/_ -!%>,?M%]-!_P"NK_\
MLM>SZ#_R+^G?]>T?_H(H T**** "BBB@ HHHH **** "BBB@ HHHH 0U76_M
M#-)"MQ&9(@"Z@\BIVY!!&0>M<A%X1^PZG/J9DMR&$A*"(C;D_*5YX..OJ?2A
M=@+_ /PG7AG)']KPG'HK?X5MVUU!>0)/;2++$XRK*>#7!>&/%=A9^&;6VET_
M4I712I,=B[J>3T8#!K?\&6,UEI,K30^1Y\[RI$>JJS$C/OSTI =(* RDD @X
MZX/2N2\0:IJ,.IQVAE:QL&'SW"0ER1W^<<1X]36[H]K96]GOLIC<+(=S3EPY
MD/J2.M, U/7-,T<*=1O(X-_W=V>?RJY%+'/$LL3!XW&58="*Y6&&*^\>:LER
MHD6.TC501D -N!_/%6? [LWAQ$/(CDD5?IO- &IJ>NZ7HVPZC>QV^_[N[//Y
M5+=:M865A]ON+E([7 /F'I@USUM;Q7_C765ND601V\2*&'0,#G\\5@PR7L_A
MK1;>WLY;Q1<ON13M&%)(R<8'(H [S3-9T[68WDT^Z6X5#ABH(Q^8J_WK(TC5
MWOI;BUN;06=[!M,D(D$@ ;D'('-:_>@ Q2T44 %(12T4 )BBEHH 3&:,4M%
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M>)_A,]K%5M2_Y!MS_P!<F_E5D56U+_D&W/\ UR;^5?-S^%GA3^!G@K?ZQ_\
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M_P#937K<,]/4[\?_ +Y$\6;[IKZ>\"?\B7I?_7+^IKYA;[IKZ>\"?\B7I?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "&O"/'&FVUCXYO;]_'$.EW,X'[@!LA<G .%(]:]WKP#Q
M'X1FU#Q;XM%SI3SW#@75E,4R"H+':/<\4 =!\,[M9?$<R+XQ&M?N,F)5("\C
MGE17K_XUXG\+YK6X\<32:+HSV-H+()=;X]H\T$9QQ7MF* ./\6^'_$%[=0ZC
MX>UDVES$FTPN 8Y!G//!YKE'U_XL6K>2?#MM='IYJOC\>M>MXHQ0!YC8:/\
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M=_\ 2O-O%>JZFOB74K=KV;RUG.$WG QTH=54Z*/FL^KJGB)WZL]_M'0VL(#
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M^)?_ "#;;_KJ/Y&O,Q]Y?K7F8G^(?<Y)_N7S9[:FK6>D^&TN[N94B@@5GYY
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MGGG&>/?A]:>.DL1<7,D!M9"P*#.0<9'Z5UMG;+9V4%LA)6*-4!/< 8J;%+0
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M*\I^'GAO6HO$TVK:_JMM<W$=N+>!('W?(".3^5>K#K0 M%%% !1110 4444
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M..J?]=V_F:]\\&?\@B3_ 'J\#\8_\CCJG_7=OYFOL>'OX:]#C7^]3-'X;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@WQ7XCUZ_F@UCPQ/I<*)N660G!.1QR!3&=Q2TV@4 .HI**0"T444P.#^)?\
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MW_AS_P C!)_USKI/%WCJQT&>339X)7DEA.&7&!G(KF_AS_R,$G_7.L7XL?\
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M_G7R^)_WA^I\9B_][?J>O^(/^18?_<']*\[KT3Q!_P BP_\ N#^E>=5GG/\
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M'\5G,^//^1:G^J_S%>/]J]?\>$?\(U/]5_F*\A[5\QF?\4^1SG^,CU7X=_\
M(NM_UU;^0KE]6_Y"US_OUU'P[_Y%UO\ KJW\A7+ZM_R%KG_?K#,?]UI'W'"W
M\/Y(M^&?^0[#^-5?C=_R"]-_Z[_^RFK7AG_D.P_C57XW<Z7IO_7?_P!E->MP
MST]3OQ_^^1/%F^Z:^GO G_(EZ7_UR_J:^86^Z:^GO G_ ")FE_\ 7+^IKZK-
M/A1R8_X4='7 _$W_ (\[/_KH?Y5WU<!\3?\ CSL_^NA_E7S6._@2/G<R_P!V
MD><'I7LFB?\ (G0_]>Y_E7C9Z5['HG_(G0?]>Y_E7E9?]KT/*R'^,SSY_OM_
MO&NH\$?\?US_ +H_K7+O_K&_WC74>"/^/ZY_W1_6O,P'^]KU/U+'_P"YL\[^
M+_\ R-T?_7'^M<1IO_(4L_\ KNO\Z[?XO_\ (W1_]<?ZUQ&F_P#(5L_^NZ_S
MK]6H?[NO0\NC_"1]8VG_ !YP_P"X/Y5-4-I_QYP_[@_E4U?.O<\5[A1112$%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (:\0NM4M_!'Q3UR_\0:9+<6M]AK:X$9<1C+<=_45[>:\YL=<O?$WQ
M+U/1IK2TDT73%V2K,@9BYR 1D>U &'X!G7Q%\2=2U[2].DL=+^SB/+(5$K9!
MZ5['7F_A/7M6LO'>H^%]3BM1 $\ZU:W0* N0,' 'K7I% !1110 4444 %%%%
M !2'I67X@\0:?X:TN34=3F\JW3C..23T K"\+_$C0O%5\]E:/-#=*-PCG0*6
M'J.30!N^(-:3P_H=UJ<D,DRP(6*1CDU\]>/OC%'XM\,W&DKHUQ;F0C]XY&!@
M@_TKZ6DBCFB:.5%D5AAE89!_"O*_C1HNEV?P\O)K;3K6&4,N'CA53U'<"@#5
M^"C;OAI8]OWCC]:]#KSWX+?\DTL/3>_\Z]!H I:Q_P @JY_W#7@O\1^M>]:O
M_P @JX_W#7@O\1^M<&,W1]7PW\,STGX:_P#(.N_^NE>5>,/^1OU/_KNU>J_#
M7_D&W?\ UT'\J\J\7_\ (WZG_P!=VK*O_!B?(\3?[Q+U.@^%'_(U2_\ 7'^H
MKL?&?_(73_<KCOA1_P C3+_UQ_J*['QG_P A=/\ <KDQG^YOU.CAG^(C(TO_
M )"MM_OU7^/_ /R*]E_UV%6-+_Y"MM_OU7^/W/A>S_Z["NWA;^)\SU,]^.)\
M[K_K$_WA7VEX6_Y%32O^O6/_ -!%?%J_ZQ/]X5]I>%O^15TK_KUC_P#017U^
M;_#$\"D;%%)5/4M7L-(A$U_<I!&3@%S7AI-NR-B[7FOQ._X^++Z'^M=WI>LZ
M?K5N;C3KE)X@<%D.1FN$^)O-Q9?0_P!:PQ2:@TSU,E_WR/S.&M/^/RW_ .NB
M_P Z][M?^/6//3:/Y5X):?\ '[;_ /70?SKU3Q?KUWX>\,Q7EFBL^%!W=*YL
M++DBVST>)I*'(V6K.*,>,]1Q&HQ%%C ''!KHNU>"1_$K68K^>]6*'S954-Q_
M=Z=J];T75[G5?!\6HS86>2(L=O8\UK#$1:;70^0PM:%67+'<=J5H&U6W GE4
M2'D*:WE 50!SBO*FU>_>57:X8LO0XZ5V'A&]N+RVE-Q*7(? -<6$QU.K6<(K
M<]_%X*=.DI-['39Q0,UQ7C;Q-J6CVQGTF:Q=8QB1)7PV<]N#6[X?U&:[L8EO
MI[9KXC+K ^1_(5[;I24>:VAY*:9LT9HJKJ%_;Z992WEU((X(E+.Q["LTG)V0
MS/F\5Z-;W@M);U1.6VA,'.:UI#^Z;'I7E%WXO\'3^+[74%GM&@2$[W,:_>R?
MUKT72=>T[Q#ISW6FSK-""5W#UKMQ6$G2A&7*TNMR823=CQ2[_P"/V?\ ZZ&N
MW^&9Q/>?\!KB+O\ X_9_^NAKM_AG_K[S_@-?/4/XI]]FO^X/T1V7B6*.30KK
M>BMB,XR.G%3:)%'%HUF(T5<PH3@=\"O+?&OCG6+/7+[2HQ%]F'RC*C.#3O!O
MCS6;_7K'2Y1%]F("$!1G &*ZE7C[2Q^:_6J?M;'KLCQQ(7<@*.I-,@N[>=BL
M4B,1UP:HZMK%EI^V*[&?,'3;D5AZ1KVEVFY=A61W/(4=">*BIBXPJ*%T>Q3P
MLYTW-19UTBAXV0L0",9':O.]$T1D^(5ZKZI>216J^8B.XVG..#Q[U+\8;^ZL
M? $MS8W$L$OG)AXV*G&?45\VKXFUQ)7F35;L2N,.XF;)_'->]@\)*M3<HO0X
MIRY78^U <]Z6N2^&MS<7?@739[J5Y97C!+NV2>!WKKJX)QY9.+*3T"BDS1FI
M&<)\2_\ D&VW_74?R->:#[P^M>E_$O\ Y!MM_P!=1_(UYH.H^M>9B?XI]SDG
M^Y?>>\Z3_P @FU_ZY+_*KM4M*(&DVN>/W2_RJLWB;1TO5LS?P_:"VT1YYS7H
MII11\16DE-W[FM@4GEI_=7\J7((R#2YJB1%55^Z /H*6BB@ HHI#0 9I"U07
MEY#86DMS.VV*)2[-Z =:\?UGQII%WKUO+:>)YXK1VS,%Z+C\:Z\)@ZF);4?R
MN3*7*>S-]TUX5KG_ "'KW_KI7K?A[Q+IGB&T=]-N?/6+Y6:O)-<_Y#M[_P!=
M*\O'TY4_=DK-'TG#;O6EZ&_\.?\ D8)/^N=8OQ8_Y&J+_KA_4UM?#K_D8)/^
MN=8OQ9_Y&J+_ *X?U-<L_P#=_F>1Q=_&?R.>\'_\C?I?_7=?YU]'NJ/%M?[I
M'>OG#P?_ ,CAI?\ U\+_ #KVCQE//!:VYAE9,MSM.*FG55&A*;5['D9+2=:7
M(G:[+NCVMO'>73JH#*^ <]JW<"O(Q>W:D[;F09//SFN^O==M?#WA<:GJ3R>3
M&JARHRV3Q59;BXXAN$8VL>]F&$E0M*4KW-_-&:^?T^(&@#Q8+TZ[JIT]09/*
M)/+YZ8W=,9KVKP[X@L?$^D1ZEI[.UNY*@N,'(_\ UU[57#RI)-GF)IFL*6DZ
M4N:P&)7)?$/_ )%MO]\?UKK-P/<5R7Q#_P"1<;_KHO\ 6LZOP,Z\!_O,/4\E
M/2NZU+P9+XO\*6,37LL=K%"2ULF/WK<8R2/K7"G[M>V^%/\ D7;3_<'\JX\)
MNSZ7B+^#'U.,^&?P\O/"D=M>/=2P-)&1=69VE2W.#D#/IWKJ_%^CW6L6EE':
MA2T5TLK9/8 _XUT.X#J>:45Z!\>>?>(/ ][/XKLM4TN79;M*'NH<\!@0=X]_
M\*@U'1O$E_:3Z7>Z7:7K,Q$>HDA2 3D9&0<@<5W]SJ-I9D">94STR:E@GBN(
MQ)$X9#T(J5.+=D]2G&25VM#&?P_+-X2CT1]0G1U@$37,9&\X&,\BO/--^"]O
M;>*+VYWR6]NH5K2XC8>9NXR3]>>W>O8:,U1(R",PP1QERY50"QZFI*2EH **
M** "BBB@ HHHH **** $)P"3T%85OXLTZYU.:Q7SO,CXSY3<^O;C\:W3FLJW
M\.V-MJ!OH_.$[;MS&4G=N.>?7';TH JV7B[3;Z2Y2/S@8"<GRFY &<]./IUI
M++QCIM[9SW*B95@SN'EL> ?8?I5FV\.6%F\KP"96EC\MSYK9;KR??GKUHB\-
MZ?;V]Q!"LT<=PH#A)2.G?V)[GO0!FR^.+,:,FH6UK/<,TB1")?E.YC@?,>#U
MI9/%5_:*)M1\.75I:9 >8SQN$SWPIS6;XQTR/2= A338AN;4(72)W(3=O7CV
M'TJS=P>+=9M?L%W8:;:VTN!)+%<L[ #GA2H]/6@#KXY%E170Y5AD&FS3PVT9
MDGE2-!U9VP*(85@ACA3.Q!@5QVJ:?=1:XU]?0'4[$?\ +-)3E?;RONMZY)H
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M&_C3QQ=:7_97B.W$,,_(!C()P??Z5]:5S?C'P9IGC/2C97Z[6'^KF4?,A]J
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M?9J&N)HP$!.,X(/]*Z2D- 'GWP>\.:CX:\%K9ZG$(IVF9]F<X!/%>@XH%+0
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M"UIR3IIULER^Z<1KYA/=L<U;I,>]+0 4444 %(:,UGZIK>FZ-"LFH7D5NK'
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MMZ[=B[UF] 61^H0<<9_"O0:3%+0 4444 %%%% !1110 4444 %%%% !1110
M4452U35;'1[)KS4+A;>W0@%VZ<T 6G?8C.>BC->'ZYX^\4W[W^J:1>VMIIUI
M<?9X+=QNDN'!Z8R.N170>/K[Q%8SV7BO0+K[=I$:?O[5,$,A[UQMCX<FUC5T
M\7^"9+>XCF8O)IUPQ_<2'KQT_P#U4 >O>#O$CZYIB1W_ )4>K1(#<P(V=A/3
M/IP1735Q?@#P?=>'8[V^U.X6?4[^3S)BOW5]%'Y"NTH 6BBB@ HHHH ****
M"BBDSS0 M<1\1?%]UX:L;.VTY4.H7\WDPM)]U.^3^1K>O-:L+B\GT.#4HX=4
M:(E%_B7/0^E>&:T+^>=_!OC2X:*;S3)IFJ=!D]B1VZCI0!U'AOQMXBTSQ)=V
M>OW]I>:5  );U/E5)#_!G)R>#Q[5[#&XDC5U.589!]17B>B_#KQ-?VMGHFL2
M6L>B6TPG>2'EKDCIS^?YU[9#&L421K]U %'X4 /HHHH **** "BBB@ HHI,T
M +2$X&?2H;J[@LK=[BYE6*%!\SL< 5YY\0-:\1Z4;#Q'H,B7>CPC-S;Q\EU.
M#G_/K0!SGB+QYXDOK[59]&O[6QT_3)/*42#+SOQP.1UR!7?^!_%%SK6FQ0:N
M(H=86,/+ K<A3T)';((->6MX8;Q%JL7C+P9-!.96WSZ=.3\DGTZ>E>C^!/"-
M_I%S>ZSK<Z3:M?$;A&/EC4=%'Z4 =R**0=*6@ HHHH **** "BBB@ IO-+FJ
M%SJ=H+HZ<EY"E^\9,<;-S[&@#'\>>*3X2\-27T:![AV$4(/3>>F:\ZTSQEXP
MTKQ3%;:K?65]:^6);TQ\+;+[MD^_Y55O=6O9KN^\$>/&*+=R%K+4,?*N3D4F
MF_#7Q:MA-X<:XM/[+GEWRWZDM)(GID_YYH ]PM+N&^M8[FW</#(,HP/45..E
M5=-L(],TZWLH?]7#&$'X"K= !1110 4444 %%%% !113))4AC:21@J*,DD\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2 ,D@ 4 <-\0?$V
MK:<D&C>'[*2?5;X$(^/DC7N<^N,UP_PIU.W\.^(+W0_$MN8/$%Q(6^TRG/G
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M0Q(FH;<2!2"#[GWK='2@ Q1BEHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC>&UBB=R[JH!8]SCK4U%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ<U[7;P1VUO';PH$BB4(BCL .* '1PQPKMBC5%ZX4 "GBEHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !44\,=Q"\,T:O&X*LK#@@U+10!Y$GP_UCP?X
M^AU7PJ$;3;QMMU;L>$!Y/\J]9"*#OV*&QUQS4E% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %)WI:* ,7Q/H3>(M$FTY+
MV:S,F/WL) 88.:YCPE\+[70-3_M34+Z;4[Y1MBDG.1&/:O0:* $% I:* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOQ8\(7<6I[5UK396BBOD&#)@#@G\:ZGQ'X*\:ZOK-REKXA$&DW/RLB\-&OH
M*[;PMX8L?">BQ:;8K\J\N[=9&[DT <M\)XM2L]'N=.U/2$LYK23RQ,H_UX&?
MFZ^U>B#K2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 3%&*6B@
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24 <E\0?%<OA/01<V
MPC-U(^R(.,C/7D?@:Y3P#\3=4U[Q NG:NMM&LJ%HS&A3)_$]ZR?BA=OKWCG3
MM"MSN$3 ,H_O'G^1JM\0M*'@_P 4:/JUFA6%%4 +ZIC^>: /=^]%9T6H+=Z
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MD9H LFBJFJZE!I.F7%]<G$<*%C[X'2O+]-\1>.?&[3W6B26^G6<3$*9%SO\
MT- 'K=<1\0O&\OA.VMX[2%9+NX.$W]%^H[UF^%?'FI-XC?PUXCA2.\7A)EX#
MG_Z_:N&^*EKKL.OVK:E>0S1R-FU"+@H,]^/6@#U3P;?>+K]?M'B"WLXK>1 T
M)@ZG/KR:Z^N6\$6NNVVCK_;5Y#<[U4P^4N-BX[\#VKJ,T 1W$AB@=QU4$UY[
M\._'&K>*-8U*TU!;<1VR@IY2$'J1SR:] O#_ *'-D?P&O&O@Q_R,NM_[@_\
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MBJ'B+Q1IGABS^T:A-M)^Y&/O/]*X37?B/I'B#POJ%LD-U:R-'^[^T)@/],4
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MN+>5P\;-TQC;_.O0[+X?V5EXQF\2+>7#3RLS&(A=HW?K6KXB\+Z7XFMEBOX
MS)_JY!PR?2@#)^(^HVD'@6_WRQGSXBD7/WB1QBN-\&6=Q;?"/4Y)00D^YXP>
MFW ']*WK;X0Z3'<*]YJ%]?0J>()W^4?E797NC6]UHDFE)F"W:/RQY8'RCVH
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M:^-/_(9T4=P!_P"A&O1?#7@K2?# 9[2,R7+</<2'+M5;Q9X$LO%UW:SW-W/
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MR^$J@^/-;) R%;!]/G%6OCIP-)]_,_\ 9:[;PSX!LO#&L7FI6]Y/-)= AED
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MMQ]*RI_A[97'C-?$K7MP)U??Y.%V'Y<?6@#SGXFVURGQ+LYFNFLDD$8CNO\
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ME2N"/RH ]&UO5;'_ (02XN_.C,#VI53N&"2N,5YAX'TVZE^&7B1X$;_2 !&
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M** "BBB@ HHHH **** .&^+'_(AWG^\G_H0KROP[\,;OQ)X6_MBVU!%=BP6
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MP9<#"X/?-6_BSX<U?7[;3ETJR>Y,3L7"D#' ]30!TNBZ196W@6.UCMXUBDM
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M\*ZW<_%R#5XM/D?3U="9MRX&%QZYZT 5OCE_J])_WG_I7I%N0/""$]K(<_\
M *Y[XF>#;KQ5I4#63#[5;$E4/\><<?I6)9#XB7NA?V)+IL%BBQ^7]J=LL1]
M3]* ,OX)<ZEJV/1?ZU5N/^2]'_KMT_[9UT7PJ\*ZQX=O]2.I63P1OM$;,RG=
MC/H:K3>%=;;XO_VP+"0Z>9=WG;EQC9CUSUH R_B,HU'XH:9I]R/]'^1>>F&Q
MFN_\=Z39W'@2XA>)%6"(-&?[N/2LSXC>!KO7Y(-5TI]M_;]%_O>F/>L?4+?X
M@>)]"?2[W38K")$^9PX+3XZ#J>XH L_ _P#Y%R^_Z[#^M=7\0F9?!.H%21\F
M.*Q?A1H.J:!HEU!JEH]M(\H*JQ!R.?0UUGB2Q.H^';^U R7A?;]<'% '%_!=
M0/",I P3+S^M<I=2#2_CBTMUE$EE^4N?[QP*Z'X+W073-1TUV_>V\^,=^^:V
M_'W@%?%D4=Q:S+;W\/W9#T8>AQ0!VXP1N&#Z&H([ZUFN7MX[B)YD^_&&&Y?J
M*\3^Q?%BSC^PP&Y:W3Y%8>6<CZGFND\#?#O4M.U7^V];O7>X;YA"'/7U:@#3
M\1:IX.\1:X/#6K+*;Y'VJ?+QM.,\-]*Y?7?@G&B27&DZ@45!E89ADG_@6?Z5
MN_$'X=SZ[>1ZOH\JPW\?WU)(WXZ$>]<C)IWQ6O;=M.N/M*VK#823&!CZCF@#
M<^$OB&^O8-2TB]F:;[*A:-F.<#IBN"T?PD_B_P 9:I9)=BUV2RON*;OXO3(]
M:]A\">!_^$3TJ?SI!+?7"GS&'0>U<]X \+:UI/CG4[Z^L'AMI3)Y<A92&RV1
MT- $6D?!>;3-6M;TZVDGD2*^T0$9P<XZUZ5K\:R:!?(V IA(.:TJY_QM?+I_
M@_4IR<8A('N: . ^!\CF+5(CG8I4@GZFO7Z\W^#6F-:^%6NW'-S(2">Z\8KT
MB@#P.Y(T/XV--=G9'+<;@QZ ,W%>K^,K37-1T-4\.7)ANBP8.LNS(^M9OCSP
M!!XMB6X@D6WU",?+(<X(]#BN#CT[XJZ3&MC9/<26Z?*&7RR,?\"YH SKC4?'
M/A[Q+8V&L:U=$R.I*K<;P1[UWOQ9UXZ;X/CM%8^=>87(/('!-8NA?"[6+[58
M=6\1Z@?,1P_E@Y;(['MCZ4_QUX7\0>(_%]BL.GR'3+?:AE++M(SR<9STH Y3
MP=\1[3PKH,FFMH[7#2,3))YP7=UQQCWJ/X;>(8]-\<$C,%K>$H4+=S]W/KR:
M]]M]%TV"WCB6QMB$4*"85SP/I7FWQ*\$:A=ZI8ZEX?TX22QD;TAVIC!R#VH
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M "BBB@ HHHH **** "BBB@ HQ110 4F*6B@ I,4M% !BBBB@ HHHH *,444
M%%%% !1BBB@ Q1BBB@!,48I:* $Q1BEHH *3%+10 F!1@4M% !BBBB@ HHHH
M 3 HQ2T4 &*,444 %&*** "BBB@ HQ110 F*,4M% !28I:* #%&*** "BBB@
M Q1BBB@!,48%+10 48HHH **** "C%%% "8KEM;^'F@>(=5_M'4(IGN, ?+)
MA2![5U5% %>QL;;3;**TM(EB@B&$11@"L37?!.C>(M1@OK])C/ ,(4DVC\OP
MKHZ* &J@1%0=%&!2XI:* "DQ2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH *
M3 I:* "BBB@ I,4M% !28%+10 F!2T44 )@4N*** #%%%% "8I:** #%&***
M $Q1BEHH ,4F *6B@ HHHH ,<TF*6B@ I,4M% "8I<444 %)@4M% !1@444
M%%%% !BBBB@ Q1110 E<G\0?#]]XD\-M8Z>(S,6!_>-M%=;24 <]X)T>[T'P
MO;:=>A//C)+;&R.?>NAZT8I: #%&*** $Q2XHHH **** $P*,4M% !BBBB@
MHHHH *3%+10 F*,4M% !28%+10 4A Q@]*6B@#@M-\'7VA^/Y]5L/*_LRZ0B
M52^"I)!R!WKO:2EH ,4F*6B@ Q28S2T4 %&*** $/%<?X_T+5_$>GV^GZ?Y(
M@:0&=G?!V^U=ACFC% %/2M/ATK3+>QMUQ%"@1:N44M "8HP*6B@ Q28I:* #
M%)@>E+10 F*6BB@ I,4M% "8I<444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F:/I0
M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FC.!0 M%(*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!O?M7#^%8]9778_MGA"RT^+;S/$X)'Z5Z/QUH 6BBB@ HHHH **** "BBB@
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M;_XN@#TVDKS/_A$/B)_T.T?_ (#M_P#%TR;PI\1(H))#XUC.Q2V/L[=A_OT
M>G]_6EK@_A/K^I^(/"DD^JS+-<Q7+P[P,9 Q7>4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 G-<L?B1X02:: ZW"9(7,<BJCG
M:P."#@5U.*\C^" !O/&F1_S%V_FU '9_\+(\(_\ 09C_ ._4G_Q-'_"R/"/_
M $&8_P#OU)_\374[1Z#\J-H]!^5 '+?\+(\(_P#09C_[]2?_ !-'_"R/"/\
MT&8_^_4G_P 374[1Z#\J-H]!^5 '+?\ "R/"/_09C_[]2?\ Q-'_  LCPC_T
M&8_^_4G_ ,374[1Z#\J-H]!^5 '+?\+(\(_]!F/_ +]2?_$T?\+(\(_]!F/_
M +]2?_$UU.T>@_*C:/0?E0!RW_"R/"/_ $&8_P#OU)_\31_PLCPC_P!!F/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@U2TNM*2&==RJZ#('Y4 >O4E>:_9_BW_ ,_NC_\ ? _PH^S_ !;_ .?W1_\
MO@?X4 =;=>%;.Z:\9Y) ;J19'QC@J<C%5[+P=;V>KQZ@+J9VBSM4X _05S7V
M?XM_\_NC_P#? _PI/LWQ;_Y_='_[X'^% 'IE)FO-?L_Q;_Y_='_[X'^%'V;X
MM_\ /[H__? _PH ]*S1FO&_$WB'XE^#],75=4GTR:U658V2)!N.?PKURQF:X
ML+>=AAI8U<@>XS0!9HHHH ,4F*6B@ HHHH 2O/OBGX4U;Q/HP32I5CDB1RPR
M0S\#Y1VY]ZJ7/Q,UF?Q!?Z9H?AB3419OMD<2$<X'8 ^M._X3CQU_T(4O_?YO
M_B: ,6Q^''B./P-/IKW<7VR4[UE+ON48''7&>,5I_"CP9K7AI))M5E5O,! 1
MF)9/Z<U.?&_CG_H0I?\ O\W_ ,31_P )QXZX_P"*"E_[_-_\30!Z517E_P#P
ML[6[#5=/L]<\*OI\=[*(HY#(3S]"!7J'>@!:*** "BC(I,CUH 6L;7]:ETC[
M&D%L9YKN4Q(N0,':3_2MG(]:K7-E;W<D$DR!F@??&3V.,?UH X^Y\?R6RJ'L
M-K([I*2W *G![UV=O.MQ;QS+C#J",&LJ[\+:3>AA-!P[,S@-C<6ZY]:UH88[
M>)(HE58T& !TH D%+2<>M&1ZT +1110 4F:6DH \H^'O_)4_&/U7^25ZN*Y'
MPYX.;0_%FM:R;C>-0(Q'C[N /\*ZZ@!:*** "B@U#<W,%G;27%Q(L<,8R[L<
M!1[T 2YJ&]/^@W'_ %R;^58.G^._#FI:E+86VHQF:-]@!(PY_P!GUKH)XS+;
MR1YQO4KGZB@#S;X'_P#(H7?_ %_R_P!*].KEO GA-O"&CS6+7'G^9</-NQC&
M[''Z5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=J[76O#FG:\(_M]NDQC!V;QD*3[5G>%_ VE^%H8OLT4;7*+M:=8PA?KUQ]:
M.HHH'2B@ HHHH **** "BBB@ HHHH **** "BBB@#RW]H#_DF+_]?D/]:]'T
MO_D$67_7!/\ T$5YQ^T!_P DQ?\ Z_(?ZUZ/I?\ R"++_K@G_H(H MT444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Q?%-KI]SX?O6U.V%Q;QQ,S(1SP.U;5>;^./B&/">NR6.
MI6+2Z;-:LT95<[WQ]V@#S>#Q5/81V]O;^#M,2 Q&:W:=@I:,,1G);KD'BO>O
M#5Z^I>'+"\>*.%IH5?9']U<@<"O#Y/$/PSU[0;&WU&TU*,P%BBJ[%DR3E=V[
M..3Q[U[AX;-@?#FG_P!F*ZV0@00A_O!<#&?PH UJ*** "BBB@ HHHH ****
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M2_\ D$67_7!/_010!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\L^(&F:I:>*K7Q!INIZ9
M8&.#RF:[8 R<GCEAGK7J=>/_ !1T/4GU]-573#JMB;1H!"'QY3D-A\$@=Q^5
M &WX3NO%MQK,0U+4M&GM3'O*6V/,P<8/WCQCVKT2O$/ &F:MJ'B?2+]].?38
M;"U\F9GD&;@_+C@$^E>WT +1110!RWQ(_P"2=ZU_UP_]F%97P;_Y)IIWX_R%
M:OQ(_P"2=ZU_UP_]F%97P;_Y)IIWX_R% &WX[_Y$G5O^N!JA\*_^2=Z5_P!<
MA_(5N>(],EUCP_?:?"RK)/&45FZ"JW@S1)_#OA6QTRX=7FAC 9EZ9QVH WZ*
M** "BBD) !)Z"@ S2UQMS\3/#5KK:Z7+>@.0VY\<*1V/?-==%(DT22H<JRAE
M/L: /-OCI_R3P_\ 7W%_,UZ!I7_('LO^N"?^@BN<^(WA:Z\8>%SIEG+'%+YR
M2;G)Q@&NGL83;6%O;M@M%&J$CO@8H LT4#I10 4E+24 %%)52[U.RL #=7"1
M@]-QI-I;E1C*3LEJ><_#:.1/''BPO&Z@SC!92,\"O4LUE'4](M4^T^=;QB7D
MR# W_P"-7[:ZANXA+!(KH>A!HYE?0<J<XKFDG8F-+24M,@\K^+D4DFM>$2D;
ML%U $E5SCBO4ZCE@AF9#+%&Y0Y4LH.#[5)0 M%%% 'E'AG_DNOB3_K@G\WKU
M>O*/#/\ R77Q)_UP3^;UZO0 4444 %%%% !4<_\ Q[R?[I_E4E1S_P#'O)_N
MG^5 'EWP4_X]O$O_ &%)/_0FKU6O*O@I_P >WB7_ +"DG_H35ZK0 4444 %%
M%% !24M)0!Y8W_)P,7/_ ##_ /XNO4Z\M8?\9 1'!Q_9_7''\=>I4 +S534Q
M_P 2N[_ZXO\ R-6ZJ:I_R"[O_KB_\C0!Y_\  SGX=(>?^/J3_P!EKTNO-/@8
M,?#I,C!^U2?^RUZ70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB"N<HIX!S_NU[CX;2&+P_9)!>->1")0MP_608ZT :U%)WHH 6BDI: "BBB@
MHHHH \E^$'_(V^/_ /L)_P#LSUZU7DOP@_Y&WQ__ -A/_P!F>O6J "BBB@ K
MS'7/$WB67XN0^$=)O[6SMI+'[1YDMMYI##=GN/05Z=7D5S_R<]:?]@@_R>@#
MKO['\<_]#78?^"O_ .SH_L?QS_T-=A_X*Q_\777T4 <A_8_CG_H:[#_P5C_X
MNC^Q_'/_ $-=A_X*Q_\ %UU]% '(?V/XY_Z&NP_\%8_^+H_L?QS_ -#78?\
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M#*&4Y!Z>]3&:>QK5H5:-O:1M<?1BBC-49$4=K;PS231PHDDGWV5<%OK4U%%
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M_*O*_@#_ ,B;J7_83E_DM>J3?ZB3_=/\J\K^ /\ R)NI?]A.7^2T >KT444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*') YR4 )K'\,^&/AQ<:A;3V=W>6]VCYCAO&\ERP[;6 )H ]D7H,]<<TZFC
M  [4Z@"&XMH+J/R[B&.5.ZR*&'Y&@6\*P>0L,8AQCRPHVX^E34F* (H+:WM8
M_+MX8X4'.V- H_2IJ,44 >2_"#_D;?'_ /V$_P#V9Z]:KR7X0?\ (V^/_P#L
M)_\ LSUZU0 4444 %>17/_)SUI_V"#_)Z]=KR*Y_Y.>M/^P0?Y/0!Z[1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M VZ*** "BBB@ HHHH \M_: _Y)B__7Y#_6O1]+_Y!%E_UP3_ -!%><?M ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M59O>7]S%;6R8W2RL%49X&2:Q?^$_\(_]#)IG_@2O^- 6N='7)^%_^1L\5_\
M7>#_ -%U9_X3_P (_P#0R:9_X$K_ (US/AWQIX9@\3>))IM=T](YYH3$S3J
MX$>#CUYH'9GI-%<Y_P )_P"$?^ADTS_P)7_&E7Q[X2=U1?$6FEF. !<+R?SH
M%9G1449S10 4444 ,F_U$G^Z?Y5Y7\ ?^1-U+_L)R_R6O5)O]1)_NG^5>5_
M'_D3=2_["<O\EH ]7HHHH **** "BBB@#@/C5_R2K6/I'_Z,6ND\'?\ (DZ'
M_P!>$/\ Z *YOXU?\DJUCZ1_^C%KI/!W_(DZ'_UX0_\ H H VZ*** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVC\R%HHHH 9-_J)/]T_RKROX _\ (FZE_P!A.7^2UZI-_J)/]T_RKROX _\
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M5E?!O_DFFG?C_(4 =]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 )36(4%CV'-.I" 1@]#27<#R#QMXZ\+:U>R^'[^&22) 0
M+E0?DD],?E7-Z/\ "XZCJ=G+97TT=N?GD+QE6 !XP<?2O4[CX:^'[GQ(NM26
MP\P<M$/N,?4CI77)&D:A$4*JC  '2O=6:1PU)4\+?5:W[F/LW)WD,M+<6MK%
M '9Q&H7<W4_6IL44M>&W=W9M83%%+10 A%>>:M\,;/4O'EMKIV" ?--$!]YQ
MR#_*O0S15PJ2A\(TVMA%0*H50  , #M2BEHJ!!1110 4444 )BEHHH ****
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M7ZH:C_KK#_KZ3^==&%_BH\?/?]PF?8-%+25[Q^3"T444 ,F_U$G^Z?Y5Y7\
M?^1-U+_L)R_R6O5)O]1)_NG^5>5_ '_D3=2_["<O\EH ]7HHHH **** "BBB
M@#@/C5_R2K6/I'_Z,6ND\'?\B3H?_7A#_P"@"N;^-7_)*M8^D?\ Z,6ND\'?
M\B3H?_7A#_Z * -NBBB@ HHHH **** /+?V@/^28O_U^0_UKT?2_^019?]<$
M_P#017G'[0'_ "3%_P#K\A_K7H^E_P#((LO^N"?^@B@"W1110 4444 %%%%
M!1110 4E+24 %%<W?_$#PEI=_-8WVOV4%U"VV2)WPRGT-5O^%G>"/^AEL/\
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MUP_]F%97P;_Y)IIWX_R% '?4444 %%%% !1110 4444 %%%% !1110 4444
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MWE0L'?'!X/8CBN!TO1]<_P"%9VDDUH66SOS/Y*1E7V[R#P>3USTZ5[P0#UI
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MA5#4?]=8?]?2?SJ_5#4?]=8?]?2?SKHPO\5'CY]_N$S["I*6DKWC\F%HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!F%97P;_Y)IIOX_P A0!WU%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** /)?A!_P C;X__ .PG_P"S/7K5>2_"#_D;?'__ &$__9GKUJ@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB%Z&NUOO OAK4;R2[N])BEN)#EI"S9/ZUJ:9I%CHMF+33K=8+<-N" DC/XT
M>2:Y)\5=<T6ZTRXTJP$5PFQBK<XSG^E5O#,'Q2\,:%!I5GI5BT,.<%WR:]QQ
MQUI* /,KV_\ BK;"$PV>FS[TRX&!L/I53^V?BY_T"-._.O6*!0!Y/_;/Q<_Z
M!&G?G0-9^+G_ $"-._[ZKUJDH \+MOB)\1[GQ--H$>GV!OX5RR8X'X_A6W_;
M/Q<S_P @C3O^^JL:1X:U:W^-FI:W+:,NGRQD)-D8.0?QKU&@#R;^V?BY_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^%VI:/>^)H?(;7!<A2-MPP:+J.X']:]WS0 ZBDHS0 IJAJNHQZ78R7,F2%Z
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M#L+O& B<8'Z&O3/ ]IJ%CX?6UU& Q31.P!W9WC)YK:O3A'WHEU(I*Z.GHHK
M\4>*K?PK9QW-Q:W-PKMMQ!&6(]S@=*Y3$WZ6LG0/$6G>)-/2]TZX61#]Y>C*
M?0CJ*UJ "BBB@ HHHH **** "BFD\]:#F@!U)7(:?XKD76;BRU!0B^9M1QT'
M'0UUB2I)]Q@WK@UI4I2AN8TJ\*B]T>*6DS169L+1110 4444 %%%% !1110
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MFH T;7P;H%E=1W%OIT*31'*D*.*WA_DTM)0 M)WI:2@#S_XU?\DLU7_>B_\
M1BUX/:?\><'_ %S'\J]X^-7_ "2S5?\ >B_]&+7@]I_QYP?]<Q_*O.S#X4?9
M<'_QJGHB:BBBO*/OPJAJ/^NL/^OI/YU?JAJ/^NL/^OI/YUT87^*CQ\^_W"9]
MA4E+25[Q^3'S[^TGS=>'O]R;^:UE0?#SP^]O$[0S99 3^]/I6M^TI_Q]^'?]
MR;^:UJ6O_'I#_P!<U_E7AYWB:M",'3=KW/:R>A3JN7.KV.9_X5UX>_YXS?\
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M:VN7)S_I2"7_ -"S7O5% 'GWA/POXIT;4XVOKS36LE7#);VB1M^8%>@8I:*
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M.589!IQDWH]R<105.TH.\624M)2U9RA3),^6VW[V.*<33!+&[%5=69>H!Z4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&LRW4&
MCWDMDNZY2)FB&,Y;'%7ZJ:C>QZ=I]Q>S F*",NX YP* /FW5=4\16$%IJ-[X
MFU!;>^C=@8%+!)0S#8>1C@?K7T!X.FEN?"&E3S2O++);(S/(/F)*CDUYOJ?Q
M.G>UT]+3P_'-+.C7,D;@86(,PS['Y:]3T+4HM9T*RU&%-D=Q"L@0_P .1G%
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M5?.<0_!#YGOY%O,F[T445\N?1A63X5_Y+[8_]@^3_P!!:M:LGPK_ ,E]L?\
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M_P *]<^$'BO5_%WA>ZOM9ECEN([MH@8XP@VA5/0?4U\]GH:]K_9\_P"1)O\
M_L(/_P"@K7G8[#0HVY.IPXNA"E;E/6Z6DI:\\XPHHHH **** "BBB@ HHHH
M3%&*6B@!*,4M% "8HQ2T4 )BC%+10 F*,4M% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*]S&\^'_ )ZI_P!]"CSX?^>L?O\ ,*C\:?!GPQH/@W5M5LIM2^TVMNTD?F7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BDI* '4E13SQVT323.$1>K,< 50@UVPO&9+:YC>0
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M#4+ZUUI%$TC$B63HR^QKKHT^5MR1YV)K*:48NQ%;12>&;E;V(_:["<$.R\[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(1R=HS5BDQP*=7 W<]A126@4444AA1110 4444 %%%% !1110 4444 %%%%
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M]GLE66Q<2G:<!>H^N:]>\(7D^H^$-)N[K/G36L;N3_$2HYH W:*** "BBB@
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M608N((PFX]ZN8HQ0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPNY<;V/4UUE9RO2DU%FU-1Q%-.:N,10D:JO0# IXHH'2L=SI0M%%% PHHHH
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MLT<8:WBD5% 3>@.!^-<5X)\'Q6=FTTN]M/NU69--NHPWV>0'G&<^G2N]P,8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 F*Q9O"NER^(XM=\G;?1H4++P'!QU'
M?I6W10 @&.E+110 44E1SSI;PO*YPJ*6(H ;=WEM8V[3W<\<$2]7D8*!^)KC
MXO'0M?%;Z3K$"VUO<X:PN@<QRC'0GIGK7#>)O&^@?$GP_?Z*DT]E=1L6@\WY
M1*5Y"\'OBL/PY=^?H]KX?U[S+W2+IC'97XYDM)AGY6/4#(.#GIB@#T75I]8\
M66/BG2[?2OL]DL+PP2R#:TTN"">>W2I_AYX.U/2%.J>(+MIM1DA$*Q!LK"@Q
M@#WXS^-=+X6TW4-)T.*RU.]^V31$JLI')7MGWK:H ,<TM%% !1FBL[6M6M]#
MTBYU"X#-' A8JO)- $U]J%M8JGG3Q1O(=L8D<+N;L!FN3T'QV+J\OM)UBU:S
MU:T!;R>TJCH4/?H>F:\Q\:^)-#^(^BVVIV5Y<6NH:<Q8VKN5+)GD@ XSG%:&
MF"3Q5#9:5?S-'JT4?GZ5K$0_URCD!CWZ<@^M &YKEMXD\9^#IYK?3$L9(;SS
M+*)OE9E&02P]<Y-=AX+\+S^'[&674+M[O4[L^9<S,>"WH/;K6]IT5S!IUO%>
M2B6X5 '<#&YN]6Z $ Q2T44 %(317.^,O%UGX-T-]3NXY)%#A%6,9.3G'\J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %)2T4 -(R,5Y_JUK9Z5K4XN[??:W2[DP.0_\ G->@XK%\1:.=4LU\K"S1
ML&0GUIIG#CL.ZU.\5JCG-+T;6X[<7-I<&!'.1!)SA?>NOL;"*T1G6-%EDYD9
M1C)JQ;1R);HDK N!R1WJ;%#8\+A(44GN_,!THQ2TE([0I:2EH **** "BBB@
M -)2TE !1BBB@",PQM('*@N.AJ2C%&*+!<*6BB@ HHHH **** $HI:* &LH8
M8(R#VJM9:=::>KI:6Z0J[;F"#&3ZU;HH **** "BBB@ HHHH **** "BBB@!
M&^Z:X9?$NL1ZI=(UJ)8H6YC7[P'K7<GI7$>*HI]+U2+4+,A//'E2'M]?TKIP
MW*Y.,CAQSG&*E%VL/N[[2/$\'EM)]GO$&4,GRE3^-7]&ANM0L9;'5[<.L1PL
MAZ..U-L_"&G/8H;@&:9CO:4$@D_A7211K%&J+]U1@4ZE2*7+#_AB:%&<I<]3
M_AQ(84@A6*)0J*,*/2I*,4M<K.]))6$%+110,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4E+10 G>EHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ [53U#3[?4K8P7"!D-7*2FFT[H3BI*S&11K#$L:#"J, 4_O11WI E86
MBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2&EJGJ.I6>E6KW5]<QV\"#EW.!0
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MHH **** "BBD- "T4G- H 6BB@]* "BD[\49H 6BD%+0 44F>:* %HI*/YT
M+12 \44 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %)2T4 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=7U:ST32Y]1O
MYEAM8%W.['I7C7B_78]=O-+\5 '5O!\&/M%HHYA;C+.O.[&#P:LZ[\1M1_X2
M75?#6O:!C2Y$*H5YDVX^]UPW//%<CX,\RRN;P: PO5MSMN=-DX^U0]F .,,
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M3DD#N: '-XLMIM-OY;>WNX[JVC+^1-!MD([$+W'-6O"FL3:WX=M+VXBDCF=
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M%%% #3_GFHHK6*.XDG4'S)/O$FI\4F,4 +1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "'/:L[5=/GU*%(8KTV\);]\%C#&1?[N>U:5)B@!
MD42PQ)%&,*BA5'L*DI,4M &=J>E#4I;-FE*+;S>:5 SOX(Q[=:T![T$9HQ0
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gmz2lq4320rk000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /0"$@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI*
M%HJEJ6HP:5IT]]=%A#"A=RHR<"N'_P"%T^$!UFO./^G<U2C)[(ESBMV>BT5Q
M6E?%+PMK%REO!>O&[G"^>FP$_C78!\IO4Y7&1[TI1<=T$9*6S):*YC0O'6B^
M(]2N-/T^29KB 9</'M'7%=+WH::&FF.HI*0\4ACJ*BCFCEW>6ZMM.#@]#3G8
M1HSGHHR: 'T5P,WQ?\*07C6KRW7FJ^PX@.,UW$%PEQ;1W"',<B!U/L1FFXM;
MDJ47L345P5Q\7?"MK>R6DDUUYJ-M.V D9KM;2ZCO;2&ZA),4J!UR,'!H<6MP
M4D]BQ1124BA:*2B@!:*2B@!:*2B@!:*Y?Q'X\T#PO<1P:C<N)7_@B3>1]?2M
MG2]6L]8L([VQF$L$@R"/Y&GRO<GF6Q?HK(TKQ%8:S=WEM9M([VC[)24PN>>A
M[]*UZ330TTPHI,\4TD#D\ 4#'T5QNK_$[POHMS]GN+UI7'7R$\S'UQ4NA_$;
MPUK\WDVEZ4D)P$G&PM] >M5R2[$<\>YUM%9VKZO:Z)I<VHWC,+>%=SE%R<?2
MJ_AWQ+IWBG3C?Z8\C0!RF9$VG(]OQI6=KE<RO8V:*;WI:0Q:*2C%*^H"T4E%
M%P%HI**8"T4E% "T4E+0 451U75;+1K&2]OIEBA0<L:YK1/B;X<U_5$TZPEN
M6N'SC="0/SIV=KD\RO8[.BD%+2*"BBB@ HI*6@ HHHH ***YSQ/XSTCPFD#:
MH\RB<D)Y<>_I_P#KII-NR$Y)+4Z.BO.O^%T^$,?ZZ\_\!S6UH/Q#\/>(KD6]
MC>$3,/E25=I/TI\DNQ/M(WM<ZNBD[T5)8M%)12N M%)13 6BDJ.XG2UMI9Y,
M[(T+M@=@,T("6BN;\-^-M&\523IICS,T&-_F1[>M13^/=$M_$X\/223B_+!0
M!$=N<9ZU7*[V)YU:YU-%)14E"T4E% "T4E+0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 )WKY[^. SXM@'_ $R'\A7T)7S_ /&=0WC:S5@"#&,@_A6^
M&=IW,,1\!L_!VX.EZUJFARL<!%G4M[A>/UKD/B5,^N>+]7N$;]S8;8<=CR1F
MM?Q!=KX.\?V6I;=D%Q:AFP.ORX_F*H:/:27W@KQ)KD@)DN9%!)Z<')_G70E:
M7.<[=X\AW'P,8+X:OB3_ ,MA_6MK6OBQH.CW[V:I<7DL?#_9E#;37"^ ;R6P
M^%'B"YA8K*@RK+V/-8WP\\40^'H+N9O#EYJ=S,Y!GA7("_W>AK*5/F;D:1J<
MJ43VOPSXWTCQ5&?L4I69?O02<.OUJ;Q)XOTGPM;"74)L.WW(E^\_TKQ72+R]
ME^)]MJUAH=]I]O/($D5H6P,GYB3BNG^(5]X9@\66DUY!>ZEJ46-MK"XVC\,'
M-0Z24K%JJW&YMV7QET"ZNT@FMKVT#G DG0!?YUVNI:U;:;H<NK-NEMXXO-_=
M]67&>*\#^).I:UJUE87=]HZ6%F7(ASCS"<=_;\*],OF9O@O(6;)_LX<_\ HE
M22L^X1JMW%@^+WAZ?36NPMPK!MJP%07;W ':K'AWXHZ'X@U$6*K/:SM]U;@
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M_%%EX4T--1N89GARJ!8P"1GIU->3_%W_ )*)I ]HO_0S75_&#_DGL?7B6/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFW<T2L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT@'44G>D[TP'44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"4M%% !24M% !1110 4E+10 E%+10 4444 %)2T4 )12T4 )2T44 %)2T4 )
M12T4 %)2T46 *2EHH 2BEHH ;1VZ4ZB@!**6B@!**6B@!**6B@ I*6B@ HHH
MH **** "DI:* $HI:* $HI:* $%+110 4444 )2T44 )12T4 )2T44 )2T44
M )VHI:* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *2EHH 2BEHH 2CO2T46 2BEHH 2BEHH **** "DI:* $HI:
M*+ )2T44 %%%% !1110 4444 )12T4 %%%% !1110 E+110 E%+10 E%+10
ME%+10 A&12#-.HH :12BEHH 2BEHH **** "DI:* $I:** $I:** $H[TM%
M!24M% "4M%% "44M% "44M% "44M% !24M% "44M% "4M%% "4M%% !1110
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M#?\ ?N?^_AH_X4AX;_OW/_?PT6I]Q<U3L=K_ ,)3H?\ T$[;_OX*/^$IT/\
MZ"=M_P!_!7%?\*0\-_W[G_OX:/\ A2'AO^_<_P#?PT6I]PYJG8[7_A*=#_Z"
M=M_W\%'_  E.A_\ 03MO^_@KBO\ A2'AO^_<_P#?PT?\*0\-_P!^Y_[^&BU/
MN'-4[':_\)3H?_03MO\ OX*/^$IT/_H)VW_?P5Q7_"D/#?\ ?N?^_AH_X4AX
M;_OW/_?PT6I]PYJG8[7_ (2G0_\ H)VW_?P4?\)3H?\ T$[;_OX*XK_A2'AO
M^_<_]_#1_P *0\-_W[G_ +^&BU/N'-4[':_\)3H?_03MO^_@H_X2G0_^@G;?
M]_!7%?\ "D/#?]^Y_P"_AH_X4AX;_OW/_?PT6I]PYJG8[7_A*=#_ .@G;?\
M?P4?\)3H?_03MO\ OX*XK_A2'AO^_<_]_#1_PI#PW_?N?^_AHM3[AS5.QVO_
M  E.A_\ 03MO^_@H_P"$IT/_ *"=M_W\%<5_PI#PW_?N?^_AH_X4CX;_ +]S
M_P!_#1RT^X<U3L=K_P )3H?_ $$[;_OX*/\ A*=#_P"@G;?]_!7%?\*0\-_W
M[G_OX:/^%(>&_P"_<_\ ?PT<M/N'-4[':_\ "4Z'_P!!.V_[^"C_ (2G0_\
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M@H_X2G0_^@G;?]_!7%?\*0\-_P!^Y_[^&C_A2'AO^_<_]_#1:GW#FJ=CM?\
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M_P"_<_\ ?PT?\*1\-_W[G_OX:+4^X<U3L=K_ ,)3H?\ T$[;_OX*/^$IT/\
MZ"=M_P!_!7%?\*1\-_W[G_OX:/\ A2'AO^_<_P#?PT6I]PO4[':_\)3H?_03
MMO\ OX*/^$IT/_H)VW_?P5Q7_"D/#?\ ?N?^_AH_X4CX;_OW/_?PT6I]PYJG
M8[7_ (2G0_\ H)VW_?P4?\)3H?\ T$[;_OX*XK_A2'AO^_<_]_#1_P *1\-_
MW[G_ +^&BU/N'-4[':_\)3H?_03MO^_@H_X2G0_^@G;?]_!7%?\ "D/#?]^Y
M_P"_AH_X4AX;_OW/_?PT6I]PYJG8[7_A*=#_ .@G;?\ ?P4?\)3H?_03MO\
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M/4:*,YZT9J#0*6FYP:7- !2TE+0 4444 %%%% !1110 4444 %%%% !1110
M444'I0 E+7DWC;QUXOT3Q#)::3I@GM5'RO\ 9'?]17)2_&/QK#<K;2V-M'.Q
M^6-K5PQ].,YK6-&3V,G6BCZ%I:\>\)?$#QIJWB.TLM2TH0VDCXD?[(Z8'U->
MOYJ)1<79EPDI*Z'44F:,U)0M%)DTM !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !110>E '@WCQ67XO:>2IP64Y/TKV'Q'QX7U'_KV?\
M]!->8_&33WM=5TG78P<1N(VQVYS7IK%?$/A=OLS@+>6Q",>@R,5T2:M%G/%:
MR/,_@.0+36<_\]8_Y-7:?$77K31_"=X)9E6:9-D29Y8^WX9KS>/X'>((BWDZ
M[:1[CDA?,&?TJ]8_ ^]>=3J^MB:%3G;$6)_\>%.7(Y<UR8\ZCRV*_P *-,N(
M_!^O:A$IW3PM'&<]U!_QJQ\$#$M]JZ38^V>9WZX[_K7K>EZ59Z1IL5A9Q+'!
M&N H'6N"U?X73KK4FK^&-5.F74ARRD94'OC@TO:*5T]+E>S<;-:F-\<S$?[)
M2/'VKS3C'7';]:N^*M(TC5_!FC6NL:Q#I^HI;J8C*V"QP,C^56M,^%MU<:S'
MJOBC5SJ5Q&0551A3CIG@5T_B_P %V'B[34MIR898CF*5.J^WTHYTK)/87(W=
MVW/(6\/?$+PQ:--#+]NL]N=@8SIL_P!UAC%=7X*\5_\ "0>"M8@6Q@MKN"W<
ML;>((KY4\X '-/\ ^%>^./LW]GCQ>G]G$;/+V?-M],[:['PCX,L?">DM:0DS
M/)GS9'ZM[?2G*<;"C"5SQ7X<)XP8Z@/#,]C$PD'G"Y W$\],@\5>U'1?$E]X
MTLI]:U?11J43J!$D^QB,YZ!>378:A\+-0M-<EU/PMK0TZ28DN'&0,\G'!J[X
M5^&DNF:VVMZ[?C4=2SE7 ^4>_0<TW46XE3E>S/0USM]Z\T^-_P#R)L/_ %\C
M^1KTRN3^(/A.Y\7Z%'86MQ#!(LHD+2@XQ@CM]:PIR2G=F]2+<+(9\,B!X!TO
M/_/(5UDK?NF*\MC@5X:GP0\11(%C\06RKZ!I *Z#P?\ ##7/#WB&+4+S68;B
M% 08U9R3G'KQ6DE!OFN9Q<[6L>?^%%\2MXUU-= FM8KXEM_VH Y&[MD'FM/Q
M=H_BW4+ZR3Q'K&B13QL#"IF$;$GZ+S7=>(_AC+>:[_;>@:E_9VH$[B6'RYQC
M/ J'2?A=?RZ_'J_BG5UU*:(@QA!@9'(SP*OVB>MR/9R6EC3\:>'GUCX;"W;#
M7-M DB%3NRRKCKZ5Y)=^,)+WX?6/AM)#]I$_DNN>2O4?K7TH8U,>S VXQBO)
M[3X/26OC0:K]KMVT]9C(("IW=/ICK4TYI:2*J0?0W[;16T'X43V4*GSC9NS@
M#G<5YKRWX;Q^,G@OE\,SV$6)?WPN0"V<=L@U]%M&CQF-E!1A@@]Q7EUW\+-4
ML-8FU#PKK8TXS9WJXR.>>.#2C433N.=-Z-'(S:)XANO'MI<ZOJ^C'4HY$#0I
M<;&*@Y/ 7KUK4^/(S)H^>H1_YBNL\(_#=]&U=]:UF_\ [0U-B?G ^49[]!S3
MOB/X!O?&DEBUI>06_P!G#!O-!.<XZ8^E5[1<Z8O9OD9UFCX_X1NUS_S[C/Y5
MX]\/58_%[5&A7]TKRY]NN*]=F_XDWA:03,#]GM\%ATSC%>:_!;3I9YM2UZ8'
M%PVU"?49S_.IB[1DQR5Y11[%WI:04M8'0%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4E+10 E%+10 E+110 E%+10 4444 %%%% "4M%% "44M
M% "44M% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?Q=_Y$&\_P"
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MXAH]P064Q G QNYZ]ZYC1?\ DOMQ_P!=I?\ T$UW7Q;T$:OX0EN$7,UI^\7
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M%.[M87*KW#%%+12&)1BEHH 3 HP***0!BBBB@ HHHI@&!1CFEHH 3BC I:*
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M ,]8_P#OH4+-$YPLB'Z-33:=R79JQQ\7@:2+X=MX7^W*7,93S_+XY;/3-7/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA9XBN+7Q3>>'7O3>V>3]GEW;AQSQ[5[743CRNQ<)J2N@HHHJ2PHHHH ****
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M<\U[[IEZ-1TRVO NT31K)CTR*F<.57*A-R=F7:***S- HHHH **** "BBB@
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M=\#.*X[P?_P@2Z')%XELHXM2@)!\UG!E^F#^%>_VMI;V-JEM;0I%"@VHBC
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M.^ZDP"1@@+D5KS)T^;J9\O[SEZ'*?$.$3_%:QB;!4LF0?]ZO?8T5$554*H&
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MSA$(RD$9!\XCID[L9_QIP<59DS4G<Z3X;9/PPBR<_N7Z_C7%?!#_ )&75O\
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ML!P5!S^M5M4O/AO!H,=QIFD076I.!_HI>3*D]<\_RKW-;"U6R%FL""V5=HB
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MY\+S\A1_PNS1?^?"\_(4>RGV#VL>YZ=17F/_  NS1?\ GPO/R%'_  NS1?\
MGPO/TH]E/L'M8=STZBO,?^%V:+_SX7GY"C_A=FB_\^%Y^0I>SEV#VL3TZBO,
M?^%V:+_SX7GY"C_A=FB_\^%Y^0H]G/L'M8GIU%>8_P#"[-%_Y\+S\A1_PNS1
M?^?"\_(4>SGV#VL3TZBO,?\ A=FB_P#/A>?D*/\ A=FB_P#/A>?D*/9S[![6
M)Z=17F/_  NS1?\ GPO/R%'_  NS1?\ GPO/R%'LY]@]K$].HKS'_A=FB_\
M/A>?D*/^%V:+_P ^%Y^0H]G/L'M8GIU%>8_\+LT7_GPO/R%'_"[-%_Y\+S\A
M1[.?8/:Q/3J*\Q_X79HO_/A>?D*/^%V:+_SX7GY"CV<^P>UB>G45YC_PNS1?
M^?"\_(4?\+LT7_GPO/R%'LY]@]K$].HKS'_A=FB_\^%Y^0H_X79HO_/A>?D*
M/9S[![6)Z=17F/\ PNS1?^?"\_(4?\+LT7_GPO/R%'LY]@]K$].HKS'_ (79
MHO\ SX7GY"C_ (79HO\ SX7GY"CV<^P>UB>G45YC_P +LT7_ )\+S\A1_P +
MLT7_ )\+S\A1[.?8/:Q/3J*\Q_X79HO_ #X7GY"C_A=FB_\ /A>?D*/9S[![
M6)Z=17F/_"[-%_Y\+S\A1_PNS1?^?"\_(4>SGV#VL3TZBO,Q\9]',+2BPO-J
MD ]*;_PNS1<X^P7GY"CV<^P>UB>G45YC_P +LT7_ )\+S\A1_P +LT7_ )\+
MS\A1[.?8/:Q/3J*\Q_X79HO_ #X7GY"C_A=FB_\ /A>?D*/9S[![6)Z=17F/
M_"[-%_Y\+S\A1_PNS1?^?"\_(4>SGV#VL3TZBO,?^%V:+_SX7GY"C_A=FB_\
M^%Y^0H]G/L'M8GIU%>8_\+LT7_GPO/R%'_"[-%_Y\+S\A1[.?8/:Q/3J*\Q_
MX79HO_/A>?D*/^%V:+_SX7GY"CV<^P>U@>G45YC_ ,+LT7_GPO/R%'_"[=%_
MY\+S\A1[.78/:1[GIU%>8_\ "[=%_P"?"\_(4?\ "[=%_P"?"\_(4>REV#VL
M>YZ=^%'%>8_\+LT7_GPO/R%'_"[=%_Z!]Y^0H]E+L'M8]STZBO,?^%VZ+_SX
M7GY"C_A=FB_\^%Y^0H]E/L'M8]STZBO,?^%V:+_SX7GY"C_A=FB_\^%Y^0H]
MG/L'M8GIU%>8_P#"[-%_Y\+S\A1_PNS1?^?"\_(4>SGV#VL3TZBO,?\ A=FB
M_P#/A>?D*/\ A=FB_P#/A>?D*/9S[![6)Z=17F/_  NS1?\ GPO/R%'_  NS
M1?\ GPO/R%'LY]@]K$].HKS'_A=FB_\ /A>?D*/^%V:+_P ^%Y^0H]G/L'M8
MGIU%>8_\+LT7_GPO/R%'_"[-%_Y\+S\A1[.?8/:Q/3J*\Q_X79HO_/A>?D*/
M^%V:+_SX7GY"CV<^P>UB>G45YC_PNS1?^?"\_(4?\+LT7_GPO/R%'LY]@]K$
M].HKS'_A=FB_\^%Y^0H_X79HO_/A>?D*/9S[![6)Z=17F/\ PNS1?^?"\_(4
M?\+LT7_GPO/R%'LY]@]K$].Q2'IQ7F7_  NW1?\ GPO/R%'_  NS1?\ GPO/
MR%/V<NP>TCW(?%G@WQIXKU-[6ZO[1=%$I:,(<.%[9&.?SKT/0])AT/1[?3[?
M[D*@9]3W-<#_ ,+KT7_GPO/R%'_"Z]%S_P >%Y^0JG&;7*T0I03YD>GT5YA_
MPNS1<?\ 'A>?D*7_ (79HO\ SX7GY"H]G+L7[6)Z=17F/_"[-%_Y\+S\A1_P
MNS1?^?"\_(4>SGV#VL3TZBO,?^%V:+_SX7GY"C_A=FB_\^%Y^0H]G/L'M8GI
MU%>8_P#"[-%_Y\+S\A1_PNS1?^?"\_(4>SGV#VL3TZBO,?\ A=FB_P#/A>?D
M*/\ A=FB_P#/A>?D*/9S[![6)Z=17F/_  NS1?\ GPO/R%'_  NS1?\ GPO/
MR%'LY]@]K$].HKS'_A=FB_\ /A>?D*/^%V:+_P ^%Y^0H]G/L'M8GIU%>8_\
M+LT7_GPO/R%'_"[-%_Y\+S\A1[.?8/:Q/3J*\Q_X79HO_/A>?D*/^%V:+_SX
M7GY"CV<^P>UB>G45YC_PNS1?^?"\_(4?\+LT7_GPO/R%'LY=@]K$].HKS'_A
M=NB_\^%Y^0H_X79HO_/A>?D*/9R[![6/<].QQ1CFO,?^%V:+_P ^%Y^0H_X7
M9HO_ #X7GY"CV<NP>TCW/3L4>U>8_P#"[-%_Y\+S\A1_PNS1?^?"\_(4>RGV
M#VD.YZ=BC%>8_P#"[=%_Y\+S\A1_PNW1?^?"\_(4>SEV#VD>YZ=17F/_  NS
M1?\ GPO/R%'_  NW1?\ H'WGY"CV4NP>TCW/3J*\Q_X79HO_ #X7GY"C_A=N
MB_\ /A>?D*/9S[![2/<].XHKS'_A=NB_\^%Y^0H_X79HO_/A>?D*/9S[![2!
MZ=17F/\ PNS1?^?"\_(4?\+LT7_GPO/R%'LY]@]K$].HKS'_ (79HO\ SX7G
MY"C_ (79HO\ SX7GY"CV<^P>UB>G45YC_P +LT7_ )\+S\A1_P +LT7_ )\+
MS\A1[.?8/:Q/3J*\Q_X79HO_ #X7GY"C_A=FB_\ /A>?D*/9R[#]K$].HKS'
M_A=FB_\ /A>?D*4_&K1EQFPO.>>@H]G+L+VL3TVBO,?^%V:+_P ^%Y^0H_X7
M9HO_ #X7GY"CV<^P>UB>G45YC_PNS1?^?"\_(4?\+LT7_GPO/R%'LY]@]K ]
M.HKS'_A=FB_\^%Y^0H_X79HO_/A>?D*/9R[![6)Z=1Q7F/\ PNS1?^?"\_(4
M?\+MT7_GPO/R%'LY]@]K ].HX]*\Q_X79HO_ #X7GY"C_A=NB_\ 0/O/R%'L
MI]@]K'N>G45YC_PNW1?^?"\_(4?\+LT7_GPO/R%'LI=@]K'N>G45YC_PNW1?
M^?"\_(4?\+MT7_H'WGY"CV<NP>UCW/3L48KS'_A=NB_\^%Y^0H_X7;HO_/A>
M?D*/92[![6/<].Q17F/_  NS1?\ GPO/R%'_  NW1?\ GPO/R%'LY=@]K'N>
MG?A17F/_  NS1?\ GPO/R%'_  NS1?\ GPO/R%'LI]@]K$].HKS'_A=FB_\
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M^_8K4HKIYGW..R[&7_PC>B?] NU_[]BC_A&]$_Z!=K_W[%:E%',^X678R_\
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M12YF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\
MH$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0
M(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_
M (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_
MPBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:B
MCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@
M19_]^A1_PBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - B
MS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\
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MMH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\
MA%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M
M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_
M $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!
M_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,
M.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+
M/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@
M19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3
M_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT
M*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]
M^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (
MMH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\
MA%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M
M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_
M $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!
M_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,
M.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+
M/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@
M19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3
M_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT
M*/\ A%M!_P"@19_]^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]
M^A6M11S,.5&3_P (MH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&3_P (
MMH/_ $"+/_OT*/\ A%M!_P"@19_]^A6M11S,.5&1_P (KH/_ $"+/_OT*7_A
M%M!/72;3_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^_0K6HHYF
M'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\ H$6?
M_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^
M_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;
M0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@
M_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<
MJ,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]
M^A1_PBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]
M"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!
M_P"@19_]^A1_PBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_
M - BS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARH
MR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_ *!%G_WZ
M%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*
MUJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^_0K6HHYF'*C)_P"$6T'_
M *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\
MT"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^_0K6HHYF'*C)
M_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4
M?\(MH/\ T"+/_OT*UJ*.9ARHR?\ A%M!_P"@19_]^A1_PBV@_P#0(L_^_0K6
MHHYF'*C)_P"$6T'_ *!%G_WZ%'_"+:#_ - BS_[]"M:BCF8<J,G_ (1;0?\
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MS_[]"M:BCF8<J,G_ (1;0?\ H$6?_?H4?\(MH/\ T"+/_OT*UJ*.9ARHR?\
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M@WBZ'P_;J9Y7'SRHXPA]/>@#I\TM)S2T %%%% !1110 4444 %%%% !1110
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MRV#7/AG4H+3/-PRG;CU^[0!Z72U4TS4K75K"*]LY5D@D4%2#^GUJW0 4444
M%%%% !1110 4444 %%%% !1110 44F:,T +253U35+31]/FOKV79!$NYC_A7
M ?\ "W8]YD/A[4!8Y_X^\';CU^[0!Z915/2]3M=7T^&^LY \,JAE(_K[U<H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH>PC3M_\
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M10 4444 %%%% !1110 4G>EHH R-2\.:?JNHVE]=+(9K4[H]KX&?<5K8I:*
M&L"48#N*Y#PAX<U#1=:UNZNUC$=Y-OBVODD9[^E=C10!SOBWPK#XHTSR&D,-
MQ&=T,R]5-<>=(^)OD'3?MED;,_)Y^X>9M]>M>I44 <]X5\,1^%]'-K%(9IW)
M>25OXF-+X>'B5GO1X@%KL,A^S^3C[GO7044 >;:GX,\0Z/KMQJWA&ZA4W)S)
M;3<(/>G:3X.\0ZKKL&K^+KJ)FMCF*VA.4!]?TKT>B@! , #TXI:** "BBB@
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M,=[9FQ V"X)'F[>F>N:[+PCX6A\+Z880_G74K;YYR.7:NAHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB5%L]'HJMJ%]#IMA->7#;8H5W.?:O*+GXM:O+<ROIVE(UFK8RR,Q'U(.*&[
MHMGL%%<[X1\5VWBG3C*B^7/'@2QGL:Z*FM1-6"BBBD 4444Q,***S-?U,Z/H
MMS?+M+1+D!NA-*^@[:FGVS17GM[XYU6U\"PZX;>V^TRRA=A!VX/XUU7AC59M
M;\/VU_<(BR2@DA.G6A-#<6C8HHHIB"BBN<\9ZW?^'](74+.&.54<"57!)VD]
ML470EJ='15#1=5AUG28+Z%LK*N<>A[C\ZOTD-JP4444P"BBB@ HHHH ****
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M'_GNM']M6/\ SW6I_L-M_P \5_*C[#;?\\5_*B\ M4[D']M6/_/9:/[:L?\
MGLM3_8;;_GBOY4?8;;_GBOY47@%JG<@_MJQ_Y[+1_;5C_P ]EJ?[#;?\\5_*
MC[#;?\\5_*B\ M4[D']M6/\ SV6C^VK'_GLM3_8;;_GBOY4?8;;_ )XK^5%X
M!:IW(/[:L?\ GNM']M6/_/=:G^PVW_/%?RH^PVW_ #Q7\J+P"U3N0?VU8_\
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MC_SV6C^VK'_GLM3_ &&V_P">*_E1]AMO^>*_E1> 6J=R#^VK'_GLM']M6/\
MSV6I_L-M_P \5_*C[#;?\\5_*B\ M4[D']M6/_/9:/[:L?\ GLM3_8;;_GBO
MY4?8;;_GBOY47@%JG<@_MJQ_Y[K1_;5C_P ]UJ?[#;?\\5_*C[#;?\\5_*B\
M M4[D']M6/\ SW6C^VK'_GNM3_8;;_GBOY4?8;;_ )XK^5%X!:IW(/[:L?\
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M]AMO^>*_E1> 6J=R#^VK'_GLM']M6/\ SV6I_L-M_P \5_*C[#;?\\5_*B\
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M7@%JG<@_MJQ_Y[K1_;5C_P ]UJ?[#;?\\5_*C[#;?\\5_*B\ M4[D']M6/\
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M^PVW_/%?RHO +5.Y!_;5C_SW6C^VK'_GNM3_ &&V_P">*_E1]AMO^>*_E1>
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M_E1]AMO^>*_E1> 6J=R#^VK'_GNM']M6/_/9:G^PVW_/%?RH^Q6W_/%?RHO
M+5.XVWU&VN9-D4@9O2BI8[:&)MR(%/M14NW0TCS6]XS:***Z#E>QYQ\6M4,.
ME6VFQD[KE\-]/_UBNM\*V26'A>Q@5<?N59OJ1S7 ?%Q3_:6E-CY=PY]\UZ9I
M?_('M?\ KDI_2H6YH]D>2_#W_DHFH_\  _\ T.O9Z\6\ .B?$/42[JH._P"\
M<?Q5[)]JM^\\7_?8HBQ31E>)_$=OX9TE[V==[YQ'&#]XUQ=OX@\?:G9G5;*T
MM4L<;EC=1O(]O6H/C&DSVMA,AS;#.X@\9XQ7?:#/;/X9M)(F7RO)ZCMZT-C2
MT,?P?XT'B:&:VDB^SZA /F1NA]__ *U9OA?QAJEWXMN]%U8QY0MY6Q-I//%<
M[X,!G^*=_-:?\>P:0DKT(.<4OC3/A?XAVFLJ#Y4N'8#N!@4KZ#21>\<?$34M
M%\0_8-,DA$<8 EWQACNS_A74WOBDP>!!K2.GGM"-I(XWD>GUKS'1])_X3&_U
MW49!T0R)GUK+FURXNO#-GX<7<9%G;<#]1@4*3'R(])\.^)/$^J^#]1U1UC>Y
M7_CU5(?O?AW[UN^"M2US4M,DEUVW,,XD(4&+9QQVK2\/V,>D^'[2V!"A(P6/
MH3S6FDJ2<HRMC^Z<TT9R?8<1D>QKGK#P5HNFZJ=2@A<W+9)9WR ?7%=#TKS?
MQOXTF^UKX?T1@UY*=LD@/W/:F[(4;W,#XCSV^L>+++3[!5DN$8+(R>I/0GVK
M6^*D30>%-+B;[R,BG'/(6MCP?X-T_0B+Z\N8KC47Y9F<$+GTK.^,6#H=I@]9
MAQ^!J4:7U2&>'?B7X=TWP_96=Q)<B:*,*X$)(S73:'X]T/Q!J LK%IVF*EOG
MBVC ]ZP?#?@OPI>^';.YN[.%IY(P7)F(.?SKH])\+>&]'OEN=.MXH[C&T,)2
M20?;-$12Y49WBSP?=^*-6MO,O&BT^)/G0'[QSZ?3O7!^']/@TOXM/96P*PPR
M2*@;DXQ7MW:O&M/_ .2TW./^>LG\J;W"#NCUS4M.M]5L9;.Z4M#(,, <9KB]
M=O= \!:#)IL%NV^Y0[%V[MV>.375Z[K=OH&FM?7*.T2D [!DBLNR\0:#XFT:
M6]=(MBJ0RS@;EXINS0HW1S7PDT>2VLKG47D0K<8"HASC&>OYUZ97CGPUNV'C
M:^MK)V.GMO95!RH SBO8_P!*(["GN>>>+?%FM^&_$UI'F)M,G91S'R,GGFNE
M\2Z\-(\+S:G"R[RG[DD9!)'%9/Q,T7^U/#+3(/WUJ=Z8_7]*\TU'Q!+XET;1
M=#B8F0'RY /48"TF[%)75STSP;XAU34/#MQK&MR1^2,M'LCV\#^?-<_:^-/%
M7BC4YU\.6]NEK#R?/'4?7UKJ-:TTZ?\ #JXL;88\NV 'Y@FN?^#LL!T2XB!7
MSQ(2WKCM_6BX65F9]W\0?$=OXCM=,GABM6+!98V3<3[@UO\ Q/O2OAJWM!]Z
M\D5#^AKE/'DD3_$FR$;J64KNQVX%;'C5AJGB_0=)#':NV1@.Q&?\*0[;,9X\
MLQI_PUL;;&TQ^6&^M)9^,H/#/P_L4B*R7TBGRX\].3R16G\6QM\(J >DR_SK
MRY/#VJV6BVOB$@-;B3Y5/)'7G'3'%)[CCK'4]G\(7?B*[T][_7GB2-URD2Q;
M2H]37-77CK7M;\0R:7X7AA'ED@R3+D''!-=;IFLQ^(/!TEW; !VMV!4?PMMZ
M5P?PE>*/6-3AF(^TD\9ZG&<U5R4NH[7O'OBK1;BVLKJV@M[DD;WV[UD&>H]*
M]!O8O[8\(2^> SRVQ8X'?;7G_P 7Y(FU+2XPRF08) ZXR:]'T\C_ (1J'/3[
M-_2D@>R.$^$>HL(K[29'SY,A,8]!SG]:]/[UX_\ "Y';Q;JDB_ZL&0?^/5[!
M51V)GN%%%%42%%%% !1110 4444 %%%%+H"WN:=O_J$^E2U%;_ZA/I4M<[W.
MM;!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$5PD,EO(DX7RB,-NX%>:Q^ ]FLS7'ACQ+#:QR8WQ0N&8#\#TKTN>&.Y@>&4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &/11172<84?7FBB@ HHHH **** "BBB@04444##MZ^U%%% @HHHH
M&%%%% @HHHH&%%%% !1110 4444 %%%% @H_GZT44 '-%%% PHHHH */I110
M 4444""BBB@84444 %%%% !1110 4444 %%%%#V$:=O_ *A/I4M16_\ J$^E
M2US,[%L%%%% PHHHH **** "BBB@ HHHH **** *M]J5GIELUQ>W"01+U9S6
M-9>//#&HW0MK75H7F)P%PP_F*Q_$/A._\2^,;5[]5;0K=,A0XR[\<%?3K5?Q
MIX'\/1>%[JZM;""RN+9 \<L2A><CKZT >A @C(YS2UR_P^O;G4/!>GSW;,TN
MP LW5N!S744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+@XY_P#U5ZAX1S_PB6F9_P"> H VZ*** "BBB@ HHHH **** "BBB@ HHHH
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MT>3P3X=OA]N%W9Q*TT"[<%1C.,YYZ5R?A'1M*U:&Y\3^*9+>5KJ5A"+I@%5
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MMO!N"[V!/)^E7Z\R^*EU#+<:/I5Q*D=O/-OE9^@ /_UZ .@_X6;X._Z#</\
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MC./UJY+X1T-M'.G_ -G0>6(]H;RQN^N>M8GC?PS?7>CV,VCLQO-.V^6N[&\
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M[PY8ZQXH\7Q^)=5MFM+6W7%K$W7\1^= 'IOO7)^(?!%AXDUZROKZY<K;#BV
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH QZ***Z3C"BBB@ HHHH **** "BBB@ HHHH
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M^WVG_/Q%_P!]"C[?:?\ /Q%_WT*+,.:/<LT56^WVG_/Q%_WT*/M]I_S\1?\
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M+-%5OM]I_P _$7_?0H^WVG_/Q%_WT*+,.:/<LT56^WVG_/Q%_P!]"C[?:?\
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MLT56^WVG_/Q%_P!]"C[?:?\ /Q%_WT*+,.:/<LT57^WVG_/Q%_WT*3[?:?\
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M_P#/,5/11S2[AR1(/L=O_P \Q1]CM_\ GF*GHHYI=PY(D'V.W_YYBC[';_\
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MA[.'8@ALK>!]T<85O6BIZ*3;>Y2BEL9%%%%=!R!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%'01IP?ZA/I4E1V_
M^H3Z5+7,SL6PE%+10,2BEHH 2C%+10 F*,4M% "44M% "44M% "44M% "44M
M% "44M% "44M% "8HQ2T4 )BBEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 3
M%&*6B@!,44M% "44M% "44M% "44M% "44M% "44M% "48I:* $Q1BEHH 2B
MEHH 2BEHH 2BEHH 2BEHH 2BEHH 2C%+10 F*,4M% "8HI:* $HI:* $HI:*
M $HI:* $HI:* $HI:* $Q1BEHH 3%%+10 E%+10 E%+10 E%+10 E%+10 E%
M+10 E&*6B@!,48I:* $HI:* $HI:* $HI:* $HI:* $HI:* $HQ2T4 )BC%+
M10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 F*,4M% "8HI:* $HI:* $
MHI:* $HI:* $HI:* $HI:* $HQ2T4 )BC%+10 E%+10 E%+10 E%+10 E%+1
M0 E%+10 E&*6B@!,48I:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $Q
M1BEHH 3%%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E&*6B@!,48I:* $HI
M:* $HI:* $HI:* $HI:* $HI:* $HQ2T4 )BC%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 F*,4M% !1110!CT445TG&%%%% !1110 4444 %%%%
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MQU:W$]A=17,1_BC;(H NT4F:6@ HHHH **** "BBB@ HHHH **** "BDS10
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M%CJRB[:_.(K]OOD^GZ^M 'KM%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ2.M+35[9]*=0 4444 %%%% !1110 4444 %)WI:Q?$O]N_V9_Q3PMS>[O\
MEOC;B@#,\0^*+K1_$6EZ=##$\5VV'9\Y'TKK*\'\1GQW_P )'I7]IBP^W;C]
MF\O&W/O7HGAH^/CJP_X2%=/%CL/^HQNW=J &^*]=UQKXZ)H>GN9I$^>[;[L8
M]JQ/A-;SVNH:[;W,PFGCE"O(/XB">:]0D_U;?0UYU\.O^1D\3?\ 7R?YF@"U
M\3=2N8],MM(LG*SZA((\@\[><T/\+O#W]@^2+4"\$>?M63OW8ZU4\?\ 'B_P
MPYX43XS^->B'_4\_W: .#^'VM3Q^'+ZTOI3++I;LA8]U'3^58_A#PW;>,KK4
M->U^+[4LDQ6&-R=H4<9_2F>&%=O^$W(PREI  /\ @5=+\+3_ ,49"!U#OG_O
MHT <_+IR> O'UD^GL8],U']VT&> W;^8KU6O-OB;N;6/#:*?G^V _J*]('0>
MN* /._B/>WE[J.E^&+&4PM?-NF<'^ 9X_2II/AYX..GFQ7[,MYMVBX\X>9N]
M>O7\*Y[Q]'?W'Q-TBVL9O)EFB*+(.J\MG],UKWOPDTQK-[B&[N_[5"[A<M*3
MEO7% '5>$-&O]!T?[!?7J781CY3J#G;[YKH*XCX::Y=ZIHUQ:WTGF7-C,8&D
MS][!./Y5V] !1110 4444 %%%% !1110 4444 %%(:QO$/B?3?"]FEUJ;R+$
MS;1L3<<T ;5<EXMU_5K*XBTW1M.>>[N <2G[B>YJOIOQ2\,ZKJ$-C:S7)GE.
M%#0D"NT% 'DOPVMKVT\<ZQ%J,XFNQ'F1QZG!Q^%>MUYMX4_Y*EX@_P!P?R6O
M2: .5^(>JW&C^#[RYM6*RL-BL.JY!YK"\+?#;17T2*ZU:W%]>7"[VDE)^4GT
MQ76^*]#7Q#X>N=.+;7D7*-Z-VK@]*\3^+O#]NFC77AR>^DC^2.XC)"X[9.#0
M!=\+--X<\>7GAA9I)+%X_.@#G.SKG^0KT@=*\@\/IJQ^+XEU9T^U/:EW1.0@
M(;"_AS7KXZ4 +1110 4444 %%%% !1110!CT445TG&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% @HHHH&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%#V$:=O_ *A/
MI4M16_\ J$^E2US,[%L%%%% PHHHH **** "BBB@ HHHH **** /._&]KK6E
MZ]:^)=,66YAA&VXME<XV\<XZ=JSK_P")LFNV#Z=HFCWIOIEV'S4 5<]<<UZF
M1D8QQ31$@.0B@^H% '/^!]!E\.^&+>QG;,V=\GLQQD?I724F.:6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 5'
MTO3Y'+R6-L[L<EFA4D_I5#5?"NB:Q9K:WEA&8%;<$C^09_#%;5% '!:A\,/"
M,.G7$D>EXD2,E?WK\'\ZR_A-X9TU-'CUA[4KJ"R.@D)(P,#M^->GD?C0JA>
M ![4 >4W,^H_#WQ9>W[V$EUI%\P=WB&64_YS4&M^*;WXA1QZ/H>EW4=NS@W,
MLZ ;0#GUKUTJK<,H(]Q2+&J?=11]!0!S^HZK:^"O#-N\\4\\4 6+$*Y8]JJ>
M+-(/B_PBOV4%)B!-"''.?0UUA4-PP!]B*,<<<4 >6V7Q0FT:R2PUO1[T:A$N
MS]V@*L>V>:O>!M+U&_U^\\4ZK;?9WN!L@C/4)_G%>A&-"<E%)/?%.QQCI]*
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M** "BBB@"O/86=TX>XM()6' ,D88_K49TRS2&9+>VA@:1"A>*,*>1ZBKE!H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0?\ /5/^^A5'^P;+^X?SH_L&R_N'\Z+1"]3L7OM4'_/5/^^A1]J@_P">J?\
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M0?\ /5/^^A5'^P;+^X?SH_L&R_N'\Z+1"]3L7OM4'_/5/^^A1]J@_P">J?\
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M0?\ /5/^^A5'^P;+^X?SH_L&R_N'\Z+1"]3L7OM4'_/5/^^A1]J@_P">J?\
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MX7N$;&/L_?Z5P/P:D8P7\9)VC:1Z=Z.HMXMGJM%%%69A1110,**** "BBB@
MHHHH ****.@+<TX/]0GTJ6HK?_4)]*EKF9UK8*2EHH&)12T4 )12T4 )12T4
M )12T4 )12T4 %%%% !24M% "44M% "44M% "44M% "44M% "44M% !1110
M4444 )12T4 )12T4 )12T4 )12T4 )12T4 )2T44 %%%% "44M% "44M% "4
M4M% "44M% "44M% "4M%% "4M%% !24M% "44M% "44M% "44M% "44M% "4
M4M% "4M%% !1110 4E+10 E%+10 E%+10 E%+10 E%+10 E%+10 4444 %)2
MT4 )12T4 )12T4 )12T4 )12T4 )12T4 %%%% !1110 E%+10 E%+10 E%+1
M0 E%+10 E%+10 E+110 4444 )12T4 )12T4 )12T4 )12T4 )12T4 )2T44
M %%%% !24M% "44M% "44M% "44M% "44M% "44M% !1110 4E+10 E%+10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CT445TG&%%
M%% !1110 4444 %%%% !1110(**** "BBB@ HHHH&%%%% !1110 4444""BB
MB@84444 %%%% !1110 4444 %&3110 4444 %%%% !1110 4444 %%%% !11
M10 4444/81IV_P#J$^E2U%;_ .H3Z5+7,SL6P4444#"BBB@ HHHH **** "B
MBB@ HHHH 2H+F^M;/9]JN8H=YVIYCA=Q]!FGSSQ6\+S3.J1H,LS= *\'\6ZW
M>^)/$5G>H"NE0W8@@)Z.W7/\Z /?,TM,3[HI] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2=JY?Q!XIFT;7M,TY
M+9)$O&VL[,05KJ.U !FH8KRVGEDBAGC>2(X=58$J?<=JY'Q7XHU*WO#HNB:?
M)/>R)DRD?+&/6L'X3QW<6I:]%?2"2[24"5P<@MDYH ]19PJ%F(  Y).*H)KV
MDR3B!-4LVE)QL$RDY^F:R?&6CZQKFG1V&F7*6\4CCSW+$-M[@5SVI?"WP]9Z
M+-<0":&]BB+BY\YL[@,],T >CYHS7'_#34KS5/!T$MZQ:1':,.>K*.AKKV.U
M2Q[#- $%W?6MA&)+NYA@0]&E<*#^=)::E97ZEK.[@N%'4Q2!OY5YA::4/B)X
MOU*;4WE.E69\J&%'(5R#WQ]:;J^AI\//$.FZIH\DD6G2R"*XA9RP )'K]#0!
MZT#2TR%_,B60='4,*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %)3
M9'V1._7:I-<WX4\3S>(GOUEMHX?LLQB&UB=V#UH Z;-17%S#:PF6XF2*,'!9
MV 'YTV[N%M+26X=6*QKN(7DFO%O&VNZ_XCTO[6MHUGHT<JX#\-+\PH ]N219
M$#HP96&00>"*@N]0M+! ]W=0VZ'H97"@_G4&B?\ (!L/^O=/_017(7'@*Y\1
M>(KF]\23"6RZ6]M#*V /?ISUH [:SU&SU!"]G=P7"@\F*0,!^56<UY'K6BP^
M!/%&C2^'Y)(X[R<12VN\L,9&3S]:])US5X]$TF6_EB>41C[B#))H NSWEM:F
M,7$\41<[5#N!N/H*FKPO7[[Q!JOB#1=0U2#[+92W %O;D\CW->Z4 &:,T5PO
MBGQ/JQO9=#T&P>2[*?/.X^6,>M ':07EO=-(L$\4IC.UPC@[3Z'TJ>O,O@^L
MZVFL+<OOG6YVR-GJV6S7IM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %)FCM45U<16EM)<3N$BC7<S'H!0 VXOK6T:-;FYBA,AVH)'"[CZ#-3
MYXSQ7@>OZQ?>(O%FG:F5*Z6+L0VPS][!!S^M>V:O=_V?HMW=GI#"S_D* &/X
MDT2-RCZO8JRG!!N%X_6K%GJMAJ+,ME>V]P4Y812AL?7%>->'-#\%S:7]N\43
MQ1W5W*SH'F93C)["O2_"GAOP[HZ/>:!&-ERH!<2E@P'U^M '2YJO=ZA9V"*]
MY=0VZL<!I7"@G\:L5Y?\3!#JOB#1=%N"!;EC-*2V,+@_X4 =W_PD^A9_Y#%A
M_P"!"_XUJ(ZR(KHP96&00<@BO,;'PE\,=2O/LUE)#-./X%N7S_.O2[>&.VMX
MX(AB.-0JC/0#I0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 1RS)#&TDKJB+RS,< 54MM;TN\F\FVU&TFD_N1S*Q_(&O/O
M'+WWB'QA9>%H;A[>U=?,F9#@L./\:L:E\,-)TW27NM(:>UU"!=ZS+(WS$>HS
M0!Z/FC-<WX&UR7Q!X6M[R?\ X^!\DAQU88R?UK7U6_CTK2KJ^ESL@C+G% #[
MO5+#3]OVR]M[?=T\V0+G\Z=:7UK?1^9:7,,Z#^*)PP_2O+?#/A&'QC%-K_B:
M1YH[ER;>'S2JJOKUX[UM:5X&NO#GBB.\T&Z7^RW!$UM+*2%^G7- 'H-%%% !
M1110 4444 %%%% !1110 4444 %%%% !117->+O$TOANWM)8K9)C/,L1#,1C
M)QF@#I**9"YD@CD(QN4-CZUS7BSQ1<Z,8;/3["6[OKC(C"CY5]S0!T0O+9KI
MK9;B(SJ,F+<-P'KBIZ\A\ IJB?$?4/[8<->-!N;:<@9P0/PKUWM0 R29(8VD
ME=4C499F. *;;W4%W"LMO+'+&W1XV# _B*\Q^)GB"YOUF\/Z,VYTC:2[=3PJ
M@9Q^AKH_AIQX#LCZ;OYF@#J;N^M;&/S+NXB@0G&Z1PH_6FVFI65^I:SO(+A1
MU,4@;^5>80:;_P +#\9ZD^I/*=*LCY442L0'/OCZTW6M C^'FMZ=JNBRR16$
MD@BN(&<L,$CU_&@#UJFO(L:,[L%11DLQP *2&02PQR#HRAA^(KG_ !UJ']F^
M$+Z7J73RA]6X_K0!>_X2?0@<'6+ '_KX7_&KMGJ%GJ$9>RNH;A%."T3A@#^%
M>0:+X:^'T&DV::]<0KJ,J!V#3L#SR.!]:].\.>'](T"Q:/1H]EO,V\_.6R<=
M>: -JBBB@ HHHH **** "BBB@ I*6DH ,T5R^O\ BF;1M>TW3DMHY5O&VEV8
M@K74<XH K7>H6E@F^[NH8$/0RN%_G26FIV-^";.\@GQU\J0-C\J\ZLO!]YXM
MUW4;_P 50W4=JDFRVM2Q52O'S<'ZUG>)_#T7@'5=+U30)9((I9Q%+;ERRD$@
M=_K0![ 2 ,D@#U-9P\0:.TWDC5+,RYQL$ZYS],UR?Q,U>ZM?",(MI#"UXR(\
M@.-H8<\]JSY/A7H$?AUKA99?MJPF3[4)#G.,],XH ],#9&0<@]*J7>JV&GL%
MO;ZVMR>GFRA<_G7$^ M?NY/ ,]S<DS268=5<G[P7I6'X3\(0^-_M&O>(I9;E
M99"(H0Y"J <=OI0!ZQ;7=O>0B:VFCFC/1HV# _B*FYKRY[3_ (5[XML([&64
MZ5?MY1MW8L$;MC/U%>HT !8 $DX ZFL]->TF2?R$U.S:;./+$R[ORS7(_$O5
M;Q(;'0[!F2;49 C,IP0G?'Y55OOA+HT.C2-:/.NI1QEEN?,;+,!]: /2 <]*
M6N/^'.LW&K>'/+O'WW5HY@D;UP2!^@KL* "BBB@ HHHH **** "BBB@ HHHH
M *9++'#$TDKJD:C+,QP *?FH+RTAO[.6TN%W0RJ5=<XR* *'_"3:$.NL6'_@
M0O\ C3X_$>BS2K'%JUB[L<*JSJ23Z=:YB;X6>#8HY)I-/<*JEF/GOP/SKC?!
M?A'2]:\7S:I8VS0Z39.! -Y.]P>N3]!0!['=W]I81"6\N8K>,G :5PHS]35+
M_A)]"_Z#-A_X$+_C7$?%$I?W^C:(Y BGE\R0DXP!D5%9>$_AA?70M+:2&6Y[
MHMR^<_G0!Z?%*DT2R1.KHPRK*<@BGU!9VL-C9PVMNNV&) B#.< # JIK^IIH
M^A7FH/TACW<>O0?SH EO-6T_3V"WE];6['H)90O\ZFM;RVO8O-M;B*>/^]&X
M8?I7EOA?P3;>*K Z]XH=[B6\/F1Q>:55%/(QS6WH/@J]\->)Q/I-VKZ-(N)(
M))"2AX^[USWH [W-+2#J:6@ HHHH **** "BBB@#'HHHKI.,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH>PC3M
M_P#4)]*EJ*W_ -0GTJ6N9G8M@HHHH&%%%% !1110 4444 %%%% !1110!YIX
MZUT:KJL7A&UN4@\XAKJ9G"A4],GZUF^/5TNPTOP]96%S;-'!=*#Y<BG'!R3B
MNLU?X9>&];U*2_O8K@SR?>*S$#\JX#QY\/M!\/KI?V"*=?M%R(Y-\I;C!H ]
MIMKB"YB#V\T<J=-R,&'Z5/61X>\/:?X:T[[#IRNL.\N=[[CD^_X5KT %%%%
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M0P@7(/Y5A:E\+?#&K7\MY=07!ED^]MF('Y4 <SXY.F6;>&;6QN+<PP7(&(Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444/81IV_P#J$^E2U%;_ .H3Z5+7,SL6P4444#"BBB@ HHHH **** "BBB@
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MAZ4M% $0MX5E,JPH)#P7"C<?QJ6BB@!KHKH5=0RG@@C(--CBCB39'&J(.BJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH>PC3M_P#4)]*EJ*W_ -0GTJ6N9G8M@HHHH&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &/12;AZBC</45TV.*Z%HI-P]11N'J*+!="T4FX>HHW#U%%@NA:*3</44;
MAZBBP70M%)N'J*-P]118+H6BDW#U%&X>HHL%T+12;AZBC</446"Z%HI-P]11
MN'J*+!="T4FX>HHW#U%%@NA:*3</44;AZBBP70M%)N'J*-P]118+H6BDW#U%
M&X>HHL%T+12;AZBC</446"Z%HI-P]11N'J*+!="T4FX>HHW#U%%@NA:*3</4
M4;AZBBP70M%)N'J*-P]118+H6BDW#U%&X>HHL%T+12;AZBC</446"Z%HI-P]
M11N'J*+!="T4FX>HHW#U%%@NA:*3</44;AZBBP70M%)N'J*-P]118+H6BDW#
MU%&X>HHL%T+12;AZC\Z-R^HHL[!<U+?_ %"?2I:@@=1"GS#IZU)YB?WA^=<[
M1UIJP^BF>8G]X?G1YB?WA^=%AW0^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.C
MS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)
M_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA
M]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/
MSHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1
MYB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$
M_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70
M^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'
MYT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH
M\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB
M?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H
M?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#
M\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT
M>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q
M/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T
M/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA
M^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z
M/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8
MG]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z
M'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P
M_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^=
M'F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,
M3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=
M#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X
M?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.
MCS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF
M)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@N
MA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\
M/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G
M1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS
M$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP7
M0^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9YB?WA^='F)_>
M'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+H?13/,3^\/S
MH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O#\Z+!=#Z*9Y
MB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'YT>8G]X?G18+
MH?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\Q/[P_.CS$_O
M#\Z+!=#Z*9YB?WA^='F)_>'YT6"Z'T4SS$_O#\Z/,3^\/SHL%T/HIGF)_>'Y
MT>8G]X?G18+H?13/,3^\/SH\Q/[P_.BP70^BF>8G]X?G1YB?WA^=%@NA]%,\
MQ/[P_.CS$_OC\Z+!=#Z*9YB?WQ^='F)_?'YTK!=#Z*:'4G 8&B@9S?\ 94'J
M_P"=']E0>K_G5ZBNOGD>?[*/8H_V5!ZO^=']E0>K_G5ZBCGD'LH]BC_94'J_
MYT?V5!ZO^=7J*.>0>RCV*/\ 94'J_P"=']E0>K_G5ZBCGD'LH]BC_94'J_YT
M?V5!ZO\ G5ZBCGD'LH]BC_94'J_YT?V5!ZO^=7J*.>0>RCV*/]E0>K_G1_94
M'J_YU>HHYY![*/8H_P!E0>K_ )T?V5!ZO^=7J*.>0>RCV*/]E0>K_G1_94'J
M_P"=7J*.>0>RCV*/]E0>K_G1_94'J_YU>HHYY![*/8H_V5!ZO^=']E0>K_G5
MZBCGD'LH]BC_ &5!ZO\ G1_94'J_YU>HHYY![*/8H_V5!ZO^=']E0>K_ )U>
MHHYY![*/8H_V5!ZO^=']E0>K_G5ZBCGD'LH]BC_94'J_YT?V5!ZO^=7J*.>0
M>RCV*/\ 94'J_P"=']E0>K_G5ZBCGD'LH]BC_94'J_YT?V5!ZO\ G5ZBCGD'
MLH]BC_94'J_YT?V5!ZO^=7J*.>0>RCV*/]E0>K_G1_94'J_YU>HHYY![*/8H
M_P!E0>K_ )T?V5!ZO^=7J*.>0>RCV*/]E0>K_G1_94'J_P"=7J*.>0>RCV*/
M]E0>K_G1_94'J_YU>HHYY![*/8H_V5!ZO^=']E0>K_G5ZBCGD'LH]BC_ &5!
MZO\ G1_94'J_YU>HHYY![*/8H_V5!ZO^=']E0>K?G5ZBCGD'LHVV$BT*U:)2
M6?IZT_\ L"U_O/\ G6C;_P"H3Z5+6#J2[G6J,+;&3_8%K_>?\Z/[ M?[S_G6
MM12]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK
M6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]
MY_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']
M@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/
M^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"
MU_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C
M)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'
ML8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]
MK/N'L8=C)_L"U_O/^=']@6O]Y_SK6HH]K/N'L8=C)_L"U_O/^='_  C]K_>D
M_.M:BCVLNX>QAV*%II4%I*)(RQ('<T5?HJ7)O5EQBHJR,>BBBN@Y HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBC
MH!IV_P#J$^E2U%;_ .H3Z5+7,SL6P4444#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M'HHHKI.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV:Z@C;T>0 U)'*DJ[XW5U/=3D4 244E+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !113'D6-=TCJBCJ6.!0 ^BJT=_:3-MANH)&]$D!-6,T
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M+:W($]Q%$3T#N!G\Z?%-',F^*170]&5@1^E $E%(*6@ HHHH **** "BBB@
MHHHH **** "BBB@ HI*1F"*69@H R23P* '44R.1)4WQNKJ>C*<BD>5(E+R2
M*BCJ6. * )**KPWUI<-MANH9&'9) 34X/M0 M%)54ZE8HQ5[VV5AP095!'ZT
M 6Z*@AO;:Y8K!<PRD#)".&Q^53T %%%% !1110 4444 %%%% !1110 4444
M%%%':@ HJO+>VUN<37,,9]'D /ZU)%-',F^*19%]58$?I0!)129IGG1>;Y1E
M02$9";AN_*@"2B@=** "BJ\UY;6YQ-<Q1D]G<+_.I(Y4F7=%(CJ>ZG(H DHI
M.]+0 4444 %%%% !1110!CT445TG&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444/81IV_\ J$^E2U%;_P"H3Z5+
M7,SL6P4444#"BBB@ HHHH **** "BBB@ HHHH \X^*KF[MM-T7J;RX4GGL#C
M^M4;3X<?#ZXD2V2^,EU@;HTO06SWXK9\9>"+WQ5KVG3BZ6&RM\B3:Q#G..GY
M53UWX8:-;Z3+=:6)K6^@3>LRR,2Q'KDT =YIFG6^DZ;!86H;R($")N.3@>IJ
MY7)?#O6YM=\(VUS<L6N$/ENQ[D ?XUUM !1110 4444 %%%% !1110 4444
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M\0W=O>.NY88#A%] >E7/ FLZG!JUYX8UES+<6PW12?WD]_S% 'H->3ZM#?\
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M+ZX78J+$WR$^O%>CRPQS1M'*BNC##*PR#5.VT/2K.836VFVD,@_CCB53^8%
M&5X%T.3P_P"%;6SG'[\_/(/1B!FNEI*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "CMBBB@#G[GP/X8O+F2YN=%M9)I#
MN=V7DFM+3-'T[1;8V^FVD=M"3DI&,#-7J* .,^)W_(D7O']W_P!"%;7A8_\
M%+:9_P!>Z_RK3N+6"[A,-Q#'-&W5'4$'\Z='"D,2QQHJ(HPJJ, "@#RV]OG\
M!>/KF\N8)#I%^H+2HI.QN.3C\:B\3>*X?'3V>A>'DDN4EE!GE,9"JH.>_P!*
M]4N;.VO8C%=01S1GJDBA@?P-16FE6&GD_8K.WMMWWO*C"Y_*@"C>ZIIOA+0X
M7OYC%;0A8@P4M[#I6+X]L9?$7@WS=.!E*D3HN,;Q7675E;7T/DW=O%/'G.R5
M P_(U*D:1QB.-%1%& JC  H \[TGXK:%!I446I>=:7L:X:!HFR2/PJ'P.MWK
M_C'4/%$ELUO:LGE0JRX+CU_2N[FT#2+F<S3Z79R2$Y+O"I)_'%7XXDAC5(T5
M$7@*HP!0 X?2EI ,4M !1110 4444 %%%% !1110 4444 %%%% !1110 4E+
M24 <7X9T#4=/\7:Q?W,(2WN2/+;<#G@5O>(M;@\/:)<:C.,B,<#U/:M;%0W-
MG;7L!AN[>*>(\[)%##\C0!XGH?BGPWJ.JMKOBK4#)=JW[BV\IF6$=CTZ]*])
MTCX@>&M:OH['3[QI)F^ZOE,H_45J#POH7_0&L/\ P&3_  J6VT+2K.59;;3;
M2&0=&CA4$?B!0!Y;XX\;6]_XA;P]+?M9:; V+F55+%R.J\?3]:W='\?^ =#L
M$L["[,42^D#\GN3Q79R^'=%GE:672;)Y&.6=H%))]SBF?\(QH/\ T!K#_P !
MU_PH 2X\1Z9:Z$-9FG*V)4,'V$G!..G6L?Q591^,_ \G]GD2B51+#D8S@9'6
MNF?3[22S%H]K"UL!@1% 5Q].E20P16\2PPQK'&HPJH, 4 >;Z!\3=,TW2HK#
M75FL[RW7RRK1,=V...*B\+^=XL^($WB;[-)#8P1^7 9!C=UY_6O0KG1-+O9/
M,NM.M)I/[TD2L?S(JW#;Q6\2Q0QK'&HPJH, ?A0!)2TG>EH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JNH:;9ZK:-:WUNEQ _WHW'!JU10!SD?@+P
MK#*LL6AVBR*=RL%Z&N*^(?C5(-23PW!=_8X< 7-P%+%5QT&/:O6#TK.GT#2+
MJ9IKC2[.65OO.\*DG\<4 <%X?\;_  _\.V"VUE>,N>7<P/N<^IXKI-8U"?Q#
MX,FO?#5Y(DI!:*1!M)([<UJ?\(QH/_0&L/\ P'7_  K0M[6"T@$-M#'#$.B1
MJ% _ 4 >=:+\5=,MM*6WUYIX-2B&UT>-B7([]*/!J77B7QG=^*YK9[>U$?E6
MRN,$CG_&NZN-"TJ[F\ZXTVTEE/5WA4D_CBKT<21(L<:*B*,!5& * ,I?$NER
M:\VB+.?MZIO,>P\#Z].]<QJ'PET+4=2FOI;F_669MS;)0!_*NU&G68O#>"UA
M%T1@S!!O(^O6K.* /"O%'P]TO2/$.BV5O<WC1WDNV1I) 2!D=./>O8] T6W\
M/Z1#IUJ\KPQ9VM*V6.3FK4]C:W,T<L]M%+)&<H[H"5/M5@#% "T444 %%%%
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MBO4-+LET[2[>S3[L*!119Z98Z>"+.S@M\]?*C"Y_*K= !1110 4444 %%%%
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M;:=AT:6(,1^=68+:&UB6*WB2*->B(N /PH D'6EI*6@ HHHH **** "BBB@
MHHHH **** "L._\ !WAW5+MKN^TBVGN' #2.O)Q6Y10!FZ5H&DZ&KKIEA#:A
MSEA&,9JGXR_Y%'4O^N#_ ,C6]3)8HYXFBE17C8896&010!ROPX_Y$>P/LW\Z
MYC6;N;P9\0I=:N;6673[Q K2H,^7]:].@MH;6%8;>)(HUZ(B@ ?A1<6T-U$8
MKB%)8SU1U!!H \R\4_$;2];T672] 66^NKH>7M$3#:#QGD5U>B"+PAX)MSJ4
MA1+>/=*V"=N3GH/K6S:Z)I=E+YMIIUK!)_>CB53^8%69[:&ZA:&XB26)QAD=
M00?PH Q+^\DU_P )RW>@7;H\L>^&51M/'/?UKD?#_P 4+*PTW['XF>XM]1A)
M5O,B8F3'?@5Z5!;0VL"PV\*11+PJ(H 'X55NM$TN]E\VZTZUGD_O20JQ_,B@
M#S_PVUQXR\<-XB>VD@L+-/+MC(,%_P#.37I]1Q0QP1+%#&L<:\*JC 'X5)0
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MD,MO<QD*Q4C/Y^XK7F@BN(6AGC22)AAD<9!'N*;;VL%I"(;:".&)>B1J% _
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M0 4444 %%%% !1110]A&G;_ZA/I4M16_^H3Z5+7,SL6P4444#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444/81IV_\ J$^E2U%;_P"H3Z5+7,SL6P4444#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#'HHHKI.,1T61&1U#*PP0>]<GJ/PW\-:C<&>2U>)CU$+[!^E=8S*JEF.
M !DGTJE8ZQIVI&865W'-Y)Q)M_AI.PU<S-&\$Z%H4@DM+3=*#D/*=Q'T-;SQ
MI+&T<BAT8892.#6=8>(=(U.[DM+*_BFN(LEHUSD8.#6A/<16L+S3N(XT&78]
M *$D#N<I=_#/PS=W1G>UDC8G)6*3:OY5T&EZ-8:-;>186R0J>I4<M]:;I>NZ
M7K2R-IMY'<B(@,4SQFHV\2:.FJ?V8U_$+W.WR>=V<9HTN#;*>H^"](U76HM6
MN4F-U$5*E9,#Y3D<5KW]A!J>G36-P&,,R[&VG!Q5KOS^5'Z&BR%<R- \-:=X
M:MW@TY9 CMN82/N.:BUKPAHVOG=?6H,AX,B?*Q_&MSH,_G67;>(]'O-2?3K>
M_BDNTSNB&=PQUH'=LS]&\"Z!H<PFM;7=(#D/*=Q4^QK1UW0+'Q%8BTOUD,.[
M=\C;3^=:?X_A1183D4M*TNVT;3X[&T5A A^7<V3577O#.F>([<0ZC"7"G*NC
M88?C6OTYH_ITHL%S%T#POIGAJ.1-.655D.3YC[JVNHYZ&C_)/I6;;^(=)N]0
M>PM[Z*6Z3[T2DY% :F1JOP]\/:Q=FXN;9UD?EC"^S)]ZU-%\-Z7X?A\NPMPF
M>K'EC]35O4-2L]*M6N;ZX2&$'!=N@K&_X3WPKVUNV_7_  I:7*U:T.CHKGXO
M&_AJ>9(HM8MWD<X51G)/Y5T&1VYIW):?4**S;GQ!I-GJ,>GW%]%'=R'"1$G)
MK2SD9%/<'L%%,FFCMX7FE<)&@W,QZ 51TS7M*U@R#3KZ*X,9PVS/% 6ZFC11
M10 4444""BBB@ HJ"[O+>PMGN;J58H4^\[=!5"?Q-HMM80WT^H0QVLQQ'*<X
M8T7&DV:U%16US#>6T=Q;R"2&095QT(J6@ HHHH"X451OM8T_3)(H[VZ2!I3A
M _\ %5T," 0<@C-%P%HHHH **** "BBB@ HHHH ****!=#3@.($SZ5)N%9?]
MF^> _P!HD7(Z"C^Q_P#IZE_.L;+N="E+HC4W"C<*R_['_P"GJ7\Z/['_ .GJ
M7\Z5H]Q\T^QJ;A1N%9?]C_\ 3U+^=']C_P#3U+^=%H]PYI]C4W"C<*R_['_Z
M>I?SH_L?_IZE_.BT>XN:?8U-PHW"LO\ L?\ Z>I?SH_L?_IZE_.BT>X<T^QJ
M;A1N%9?]C_\ 3U+^=']C_P#3U+^=%H]Q\T^QJ;A1N%9?]C_]/4OYT?V/_P!/
M4OYT6CW#FGV-3<*-PK+_ +'_ .GJ7\Z/['_Z>I?SHM'N'-/L:FX4;A67_8__
M $]2_G1_8_\ T]2_G1:/<.:?8U-PHW"LO^Q_^GJ7\Z/['_Z>I?SHM'N'-/L:
MFX4;A67_ &/_ -/4OYT?V/\ ]/4OYT6CW#FGV-3<*-PK+_L?_IZE_.C^Q_\
MIZE_.BT>XN:?8U-PHW"LO^Q_^GJ7\Z/['_Z>I?SHM'N/FGV-3<*-PK+_ +'_
M .GJ7\Z/['_Z>I?SHM'N'-/L:FX4;A67_8__ $]2_G1_8_\ T]2_G1:/<.:?
M8U-PHW"LO^Q_^GJ7\Z/['_Z>I?SHM'N'-/L:FX4;A67_ &/_ -/4OYT?V/\
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M *>I?SHM'N'-/L:FX4;A67_8_P#T]2_G1_8__3U+^=%H]Q\T^QJ;A1N%9?\
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MJ7\Z+1[AS3[&IN%&X5E_V/\ ]/4OYT?V/_T]2_G1:/<.:?8U-PHW"LO^Q_\
MIZE_.C^Q_P#IZE_.BT>X<T^QJ;A1N%9?]C_]/4OYT?V/_P!/4OYT6CW#FGV-
M3<*-PK+_ +'_ .GJ7\Z/['_Z>I?SHM'N'-/L:FX4;A67_8__ $]2_G1_8_\
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M:* $I:** "BBB@ HHHH **** $HI:* $HI:* $HI:* $HI:* "BBB@ HHHH
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M;!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,>BBBNDXPHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ****!!1110,**** "BBB@ HHHH **** "BBB@ HHHH>PC3M_\ 4)]*
MEJ*W_P!0GTJ6N9G8M@HHHH&%%%% !1110 4444 %%%% !1110 E-\U"<!U/X
MUY]XYUC4K[6[3PIHLQAN+@;IY1UC3C].:H77PHEL;3[9I&L7G]J)\P\QP58_
ME0!ZE2UD>&WU.30[?^V(3%?*NV4%@<D=^*UZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]**S=>EU"+1KAM*@\
MZ]VD1+N Y]>: +QD0'!=0?0FG9[@_C7F%M\+)=3M!?:WJUZ-3DRQ$<@VJ>PZ
M5H?#S5=1.HZKX?U&<W)TY]J3GJPR1C]* ._SS2!AG&X''85R_BGQE#H#K96]
MO+=:E*O[J%%/YGVKEOA?=:C=>)-=DU/<+HX,B%LA3QQ^5 'JE!Z4=J0T (3C
MDG H#!@,,"/:O/OB7XGFL[%M'TK+WTZ,7V'E$ R<_AFKWPL+/X&M6=BS;WR2
M<]Z .T%+2"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK T
MGQ5!JVN7VEQVTD<EH?F=F!#?2M[.: #\:16#=&!^AKDO'?B5M$TO[+9?/J5U
M^[A1>H)[_P JQ?@[)/)H=^;EF:7[3\VXYYQ0!Z/D 9)Q[T@D1CA74GV->;>*
M[J_\3^,(_"=C<M:VT:>9=2IU(Y^7]/UK,UKPG=_#Z"+7-$U&YFBA<&XAG;(9
M>_X4 >O"EJIIMZFH:=!=Q\K*@85#K4M]%I-P=,@,UWL(C7('/;K0!=\Q <,Z
M@^YIV<\C%>7VOPOGU:V-]K^JWJZD^6*QR *OH.E7_A]J>HIJ^J^'-0N#=?V<
M0(YCUQTQ0!Z%2TG>EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD
MS0 &FLX49+ ?4T[->;_%-VO6TG18W9&NIPQ96P0HR* /1?.C_P">B_\ ?0IV
M>,@Y'K7ET/PJ\-3,(X]?O'EQRJW2$_E75>([J;PKX+*Z<DT\T,:PQ8!9LXP"
M<?2@#I3(B\-(N?<TX-G/->76?PO?6;%+_6=8OCJ$J[_W;X5<]!C%6? .I:G8
M>(]1\*ZC/]I%KS#*>I'/Z<4 >DTM)TIDT\=O \TK!8T4LQ)Z"@!Q95/+ 9Z9
M-**\.U'Q)>^(/B'IEQ'YB::MR(X#G ?!&3_*O<5Z#Z4 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 44A.*P8_%4$GBQ] %M()4C
MW^;N&TCGM^% &]32ZKPS ?4TDCB.-G(Z#->0:7H=S\2M3U"_U/49X;2"8PPQ
M0M@C% 'L*L&Y!S]#3J\JT'[=X+\?1^'FO9;O3KF+=&)#EDZ__6KU6@!"<4SS
M4)P'7/L17$_$S6[W3M-M+&PD\J>_F$/F?W17/7WPO?2-&EU2UUN[&I01F5G+
M_(2!DX&* /6<FG"N8\!ZW/KOA>WNKGF9<HY]<'&?TKIQTH **** "BBB@ HH
MHH **** "BBB@ HHHH ***3- "T56O[Q;"PFNV4NL2[B!U-4?#>OQ>)-'CU&
M&%X4<X".03^E &O36( Y('UI<UY%\4_%%Q<A]'THL\< #WDB'A1G &?KB@#U
MW((X.?>F-*BG!=0?<UD>$R3X3TMF))-NF2?I7F1T6T\:^--8N=0OYK2SMV$8
M9)@GS 8[_0T >RB5&. ZD^@-./3K7">&_AWHVD:I#JEAJMW<M%D -,KH<C'.
M/K7=T (2 ,DX [FF^='_ ,]$_P"^A7(?$V^-IX0FA0L)+HB%2IP<YS_2N6T_
MX8:!-96_VO7KI+MU!>-;E1AO8=: /6E(894@CVIU9/AS0K?PYI":=;3331HQ
M8/,V6.3FM:@ HHHH **** "BBB@ HHHH **** "BBLOQ!K4?A_19]2EA>5(1
MDHA )_.@#4I#532]135-,M[U$9%F7<%8\BK3%0NYC@#DYH "P Y8#ZTZO#_B
M'XHNM9U>*VL"_P#9MI.J22*<!G_SFO:+=PMC$S'@1@G\J )R<#).,4@((R#D
M5Y3XX\<W>I:??:?H%M,T<2L+FY(V@*.H&:[/P$Q?P5IKLQ+%#DGOR: .EI&.
M!DT9KSSXBZE?W&I:7X:T^?[,VH-B27T&0,?K0!Z")48X#J?H:=7D.M_#Z7PE
MH[ZWI6LW8NK8!Y1(^0XST''O7HWA?5GUKPW9:A(,231AF^N* -FBD%+0 444
M4 %%%% !1110 4444 %%%% !114%W<K:6DMPREA&I8@=Z )Z0GFL?PUXAA\2
M:9]NA@>%=Q7:Y!/'TJKXQ_MR72/L^@Q$W4K!3+N \M>YYH W_-CSCS%SZ9I^
M:\ND^%(BL3?C6;T:HJ>9N+C9O^F*Z'X<:[=Z[X;\R^.Z>"0PM)_?QCG]: .Q
M'2BDJEJNJ6^DZ;->W,@2.-<\GK0!;W#?C<,^F>:?7BO@S6-0UOXI?;KQ7B2X
M@9XHR>B8..*]J'2@ HHHH **** "BBB@ HHHH QZ***Z3C"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****'L(T[?_
M %"?2I:BM_\ 4)]*EKF9V+8****!A1110 4444 %%%% !1110 4444 >+ZS=
M:M_PMVXATE$^V2VZHLDG1!@9-:6I^%/%^B6[:O:^);B]FB^=[:3(3'?N<U+X
ML\WPO\0;7Q,;5I;*2/RIF09V]/\ "M'7OB5H#Z%,FGW0N[N=-B01@[@3ZT =
M#X0U[_A)/#MMJ)7;(PVR = PQG^=;]<A\-M'GT7P;:PW*LDTA,KH>JD@<?I7
M7T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4F<4O:D(R/TH QY_%6@6TSPSZQ9QRH<,C3 $'WJ[8ZE9:G 9K&ZBN(P<%H
MF##-8-Y\._"U_=RW5SI:R3RMN=C(PR?P-1ZIH4OA_P (W4'A*,VMPO[Q57YB
MQYX&[- $GB^+Q7/$L?AR2V12A\PRD9)]O2N=^&MQ#I^H7FBZA;R0ZYG?-)(^
MXS>X)[<&KN@_$W19-)1=9O5M+^,;98Y%(+,/3 K-\+S3>)_B/=>(H+=X]/AA
M\E)'&/,Z]/SH ](:RMFNA=&WC-PHP)2HW ?6O/O G_(]^*/^N@_I7I'\)KSC
MP)_R/GBC_KH/Z4 >D=JQ?%'B&V\-Z/)>3G+?=C0=6;L*NZGJUAHUI]JU&Y2W
M@R%WOG&36#XI\)V7CJPM=U_-#$IWHT(!W?G]: .?T70)T\-ZKX@U5=VJ7L$C
MG</]6I4\#T[UK_"O_D1K;_KH_P#.N:U7X3Q6.D75POB/5'\J)F",PP<#I4GP
MF\+K#8PZZ-0NF9@\?V8G]V.>OZ4 >K44@ZTM !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Q_B?Q7K&AWZV]AX;N=2C*Y,L9. ?3@&NPI* /!_#WB[6
M++Q1JMW;^&;FXFG(WP+G,?3KQ7ING>,)3X<N=7UK3)-+\DD"*4G+>G4#J>*H
M^%M'U"Q\9ZU>7-J\5O.1Y;MC#<"MSQ5X9A\5:0=.GN98$+ EHP"?UH Y7PGI
M<^O7USXLU:,EI,BSB<?<3L<?3'-/^$W_ "#]6/\ T^M5-O@[!! =GB350JKP
MH8 5D?"[PFLU[+JG]I72FRNBOD@_))QU:@#?\+\_%?Q(2,D  'TY:NA^(&#X
M%U7(S^Y/!%<IK-V?!GQ);5[F%SIM_&$DE ^ZW/\ C1XU\:6'B#25T/P_)]ON
M;UA&?+!PH/K0!U_@(LW@C2RXP?)]?<UT=8MH]GX7\,VZWLZP06T85I&Z#_.:
MAUV[O+_PK-=^';H&8IOAD09W#&>,CO0!!XMB\531+'X<>V0%2)#+C/X5S'PX
MN$TW5;S1]3MY(M<<[Y97?=YWN">W!J_X>^)FD/I2QZY>K::C%\LJ2J06([C
MK-\.W$GBOXD2Z];0,FGVT7E)(PQOZ_XT >H]Z6D[TM !1110 4444 %%%% !
M1110 4444 %%%% !1110 56O+VUT^!KB\GC@A7J\C;0/QJS5'5=)LM:LGL[^
M$30/]Y"2,_E0!2C\7>'I9%CCUJQ9V. !,IR:Y?QAX-U3Q/XITZZAG6&P@0AI
M4DP_// K5A^&OA*WFCFBTE5DC8,I\Q^"/QK)\3>(M5\*^*[.:=Y'T&5-K*B
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MB)-TYR1D#@>U %?QG:6]IX*U46\$<0:%RP10N3@U)X _Y$G3?]P_S-.\=_\
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M)!D9J[10!S7_  K_ ,)X_P"0!8_]^ZNZ;X5T+2+K[3IVEVUM-C&^-,'%;%%
M% :)IJZHVIK9PB^*[3/M^;'IG\*O4M% %*[TC3[ZXAN+JTBFF@;=$[KDH?:K
M@&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#N$@3D&MVB@! H!XI:** "BBB@ HHHH **** "BBB@ HHHH **** $HQ2T4
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MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M%HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F
M@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T
M9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@
M!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9
MH 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-
M&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BD
MS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %H
MI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!
M:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI.]% &+_ &)/_P _S?\ ?/\ ]>C^
MQ)_^?YO^^?\ Z];5%:>VF8_5Z?8Q?[$G_P"?YO\ OG_Z]']B3_\ /\W_ 'S_
M /7K:HH]M,/J]/L8O]B3_P#/\W_?/_UZ/[$G_P"?YO\ OG_Z];5%'MIA]7I]
MC%_L2?\ Y_F_[Y_^O1_8D_\ S_-_WS_]>MJBCVTP^KT^QB_V)/\ \_S?]\__
M %Z/[$G_ .?YO^^?_KUM44>VF'U>GV,7^Q)_^?YO^^?_ *]']B3_ //\W_?/
M_P!>MJBCVTP^KT^QB_V)/_S_ #?]\_\ UZ/[$G_Y_F_[Y_\ KUM44>VF'U>G
MV,7^Q)_^?YO^^?\ Z]']B3_\_P W_?/_ ->MJBCVTP^KT^QB_P!B3_\ /\W_
M 'S_ /7H_L2?_G^;_OG_ .O6U11[:8?5Z?8Q?[$G_P"?YO\ OG_Z]']B3_\
M/\W_ 'S_ /7K:HH]M,/J]/L8O]B3_P#/\W_?/_UZ/[$G_P"?YO\ OG_Z];5%
M'MIA]7I]C%_L2?\ Y_F_[Y_^O1_8D_\ S_-_WS_]>MJBCVTP^KT^QB_V)/\
M\_S?]\__ %Z/[$G_ .?YO^^?_KUM44>VF'U>GV,7^Q)_^?YO^^?_ *]']B3_
M //\W_?/_P!>MJBCVTP^KT^QB_V)/_S_ #?]\_\ UZ/[$G_Y_F_[Y_\ KUM4
M4>VF'U>GV,7^Q)_^?YO^^?\ Z]']B3_\_P W_?/_ ->MJBCVTP^KT^QB_P!B
M3_\ /\W_ 'S_ /7H_L2?_G^;_OG_ .O6U11[:8?5Z?8Q?[$G_P"?YO\ OG_Z
M]']B3_\ /\W_ 'S_ /7K:HH]M,/J]/L8O]B3_P#/\W_?/_UZ/[$G_P"?YO\
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M[20>P@9']DW?_01?\O\ Z]']DW?_ $$7_+_Z]:]%'M)!["!D?V3=_P#01?\
M+_Z]']DW?_01?\O_ *]:]%'M)!["!D?V3=_]!%_R_P#KT?V3=_\ 01?\O_KU
MKT4>TD'L(&1_9-W_ -!%_P O_KT?V3=_]!%_R_\ KUKT4>TD'L(&1_9-W_T$
M7_+_ .O1_9-W_P!!%_R_^O6O11[20>P@9']DW?\ T$7_ "_^O1_9-W_T$7_+
M_P"O6O11[20>P@9']DW?_01?\O\ Z]']DW?_ $$7_+_Z]:]%'M)!["!D?V3=
M_P#01?\ +_Z]']DW?_01?\O_ *]:]%'M)!["!D?V3=_]!%_R_P#KT?V3=_\
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M?\O_ *]']DW?_01?\O\ Z]:]%'M)!["!D?V3=_\ 01?\O_KT?V3=_P#01?\
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M!["!D?V3=_\ 01?\O_KT?V3=_P#01?\ +_Z]:]%'M)!["!D?V3=_]!%_R_\
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M_P#KT?V3=_\ 01?\O_KUKT4>TD'L(&1_9-W_ -!%_P O_KT?V3=_]!%_R_\
MKUKT4>TD'L(&1_9-W_T$7_+_ .O1_9-W_P!!%_R_^O6O11[20>P@9']DW?\
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M1:CJND6\&E.1F6.8M(BGH64@ <=>:L^(/%T^F:AIMG862W<E^N8LN1SR>W;
MH ZNBL_29M4FMBVJVMM;S[B-MO*9%Q]2!7/7GBW5#XFNM#TO2XKB>$*P>64J
MFT@$Y(!P>: .QHKF](\32WCWME?VJVVI6B%WB5BRL/4'N/PK/T3Q7KNODS6F
MD6JV:3&.226=E/!Y(&.: .TIDCI&FZ1PBCN3@5R \5ZQJ<UPV@Z5!<VMNVV2
M2XF,99AUV@ YK%\7^)+K5_!(N+"%$9;A([E'D*M&X8?+@=1SS0!Z4"& 92"#
MR"#P:=7&#Q-?Z;I6FV<MC"^LW2 06\<I*%>,%FQD=L\=ZM67B>_@U:'3?$%E
M!9S7 S;M!*9$<^F2!SP: .IHKD;OQ5J5SJMU8^'].@O#:#]^\\IC // P#D\
M5>LO%EG<>'9M6G!A%OD3Q]T8'!'YT =!4+W$*3+"\T:RORJ%@&;Z"N/_ .$M
MUY;,:K)HD(TDD'<)F\X)ZE,8_6J^I7D&H>./#=U;.'AEAD96'<';0!WG>G4F
M,5'<7,5K;27$K!8HU+LWH!R: ):*XH>+==N;634[+1(9-*0G#O,1,ZCN$Q@^
MW-:-YXOM8M&M+VT0SS7IVV\73<W<'TZ&@#I**Y >)]9TW4+6'7].L[>WN7\M
M)+:X,A#G@ @@=S4^J>)KP:R=(T2RAO+Q$WR^=(41!]0#SR* .G9@JEF("@9)
M/:HXIHKB/?#*DJ'@,C!A^8KGK'7CK&B:E'<PBWOK:-XYX0<@';V/<5R?A;6M
M>L?"33V&E6TUE;O(SO-,4<X/.T '/YT >I=J*HZ1J<6KZ5;WT2E4E7.".0>A
MKGM6\6ZC;>*3H.G:9'<W#0K*C22%5YSG. <=* .OHKF](\2W$VHRZ7K%K'::
M@B>8%B<NCIW() ]1VJD/$^N:B)[G1=*M)K&,D"2YN&C9\=<  T ==)+'$F^1
MU11U+' J-KF!'C1YHU>3[@9QEOIZUYOXM\17VL>#[:ZL;>)5-TD=P&E*E) ?
MN].1FMT:U<VMUH%IJ&F6GVFZ &]7W^5P<$$CTH [*BN4N_$^HW.KSZ=X?L(+
MQ[8?OWGE,:J?0$ Y-/M/%K3Z-J4\MH(K_3U)FMRW&><8/H<=: .HJ.26.,@2
M2*A8X7)QFN*'C'7)=&76H-&MSIX7<Y>=A)C.#A<<_G65XMU75+[5_#MSIUM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWJ[/X4^W^-+K4-0L[>XT^2%$59,-\P'I72V>GV>GVWV:SMHH(/\ GG&N!^5
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M8;F.1IRFQ4.2..X[?C7<K;PI;"W6)5A"[=@'&/3%9D?A70(G=X](LU9_O$1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *3%+10 4444 )BC%+10 F*,4M% "8HQ2T4 )BC%+1
M0 4F*6B@ I,4M% "8HQ2T4 )BC%+10 4F*6B@!,>M%+10 4F*6B@ Q28I:*
M"DQ2T4 )@48I:* $Q1BEHH 3%&*6B@!,48I:* "BBB@!,4M%% "8XQ1BEHH
M3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,4M%% "8HQS2T4 )BC%+10 8I,4M%
M "8HQ2T4 )BC%+10 4F*6B@!,48I:* $Q0!BEHH 3%&*6B@!,48I:* $Q1BE
MHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q2XHHH 3%&*6B@!,4M
M%% !28I:* $Q1BEHH 3%&*6B@!,48I:* $HQ2T4 %%%% "8HQ2T4 %)BEHH
M,4F.*6B@!,48I:* $Q2XHHH 3%&.,4M% "8I:** $Q1CBEHH 3%&*6B@!,48
MI:* "DI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gmz2lq4320rk000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1 !TT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I*6FY]: '4E&:.] "T444 %%%%
M !1110 4444 (:*6B@ HI,T=: %HI** %I*** "BBDS0 M%)G\*7M0 M)1F@
M&D M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HS25SOBS66T
MO3]L1_?2_*OMZU<(.<N5&=6K&E!S9?U'7M.TTC[1<*">,+\Q'X"JD'B_2+B9
M8DN"&/\ >4@?G7%Z+X;N]>)N99BD)S^\/+$_2K^H>!)+:T:6VN#,ZC)5EQ7:
MZ%"+Y)2U/+^MXJ:YX0T/0(Y$E4/&P93T(.14E<)X'N+X2/!+'(UMV<]%([5V
M%Y?V]A!YMU*L:]LGK7)5I.$^5:GH4,0JE/GEH6Z*Y=/'.DO(J?OE!.-S(,#]
M:Z*&:.XA$L3AT;D,#4SISA\2L73K4ZGP.Y-16)+XFL(=2-@_F"9>IV_*/QJK
M<^-=)MYS$6ED(_BC4$?SIJC4?0EXJC'>1TM%4['4+;48!-;2!U/7VJ/4=5M-
M+A\RZE"\9"]V^E3RRORVU-/:04>:^AH45S,'C;29YUBW2Q[CC<ZX ^O-="CK
M+&'0AE(R"*<Z<X?$K$TZT*GP.X]C@$UA3>+](MYWA>=@Z'!'EFMPC*D'N,5R
M%UX$BNKN6<WKJ7.X@(/\:NBJ3?OLSQ+K)+V2N7_^$UT;_GNW_?LTJ>,]&=PH
MG;).!^[-<!JVDKINK?8EE9QQ\Q&,9KJ+?P#%^[E^W/P0V/+'^-==2A0A%2ON
M>=2Q>*J2<4MCI;[7+'3HHY+F0JL@RN%)S5RUNHKRW2>%B8W&5.,9KBO',?DV
MUFF<[1CZU=T_Q)8:3H=FEP[%ROW$&2.36#P]Z:E'6YU+&6JN%31(["BLC2_$
M6GZNQ2W=@XYV.,$UHS3QV\32RN$1>22>E<[A*+LT=L:L)1YHO0FHKF)?'&DQ
M2LF9GVG&Y$!!^G-;=C?VVHVXFMI1(I'8]/K3E2G%7:(A7IS=HN[+E%8VJ>(;
M+2;B."Y$A9^FU<U3G\:Z5!+Y>97..J+G^M.-&I)72%+$THNSEJ=+16=>:M:6
M%HMQ<R%%894'J:QQX[TDL!B<9]4'^-$:4Y?"@GB:4':4DCJ:*K6MW#>0+/;R
M!XVZ$&LR3Q/I\.I/8R&02+G<Q7Y1CWI*G)NR1<JL(J[9N45S$OCC28Y3'F5@
M#C<JY'\ZU3K%H=.-]&YEA R=@R:;I5([HB.)I2ORR6AI45E:1KEIK*R-:[QY
M9P0XQUJ35=6MM(M_/N2VW. %&2:GDES<MM2U6IN'/?0T:*HZ9J4.JVHN(%<1
MDX&]<9J]2::=F7&2DKH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!#TKEO$'CO2= 9HF?[1<@?ZJ,_S/058\9ZVVA^'9[B(_OF&Q
M!]>*\K\&^$7\5WDMY>RN+9&S(W>0GM770H1E%U*C]U''7KR4E3I[LZD?&&S+
M@'2IP">3YHX_2NUT/Q)INOP^98SAL?>1N&'X5SUQ\+O#KV[K#'-'*1\KF5C@
M_3-<QX7\(^(=&\6&2*/;;1/M>60E5D3/;U.*N4</.+<-+$1EB(22GK<]@HK/
MU75K31;![R\DVQKZ=3["O.+GXO2BZ<6VE)) &.QVD()'TQ7-3H3J:Q1U5*\(
M:29ZO16!X<\56'B6UWVS%9E \R,]0:R?%OC>7PSJ5O;+9QRI* 2S2%=HS]*2
MI3<N2VHW5@H\]]#M:*\RU7XL16\L:Z=9"Z&WYV9BH!]L=:WO"/CFV\2L8'C\
MB[49\O.01[&KEAZD8\S6A$<33E+E3.OHK)UW7['P_9?:;UR%)PJJ,DGV%>>?
M\+>N//XTF/R=WWO,.<>N,5-.A.I\*'.O"'Q,]8H[5E:'X@L/$%D+FQDW#^)3
MU7ZUJ5G*+3LS2,E)71Q_B?Q];^&=06TEL99V9 ^Y7 '/_P"JL3_A<5G_ - F
M?_OZ/\*P_BJ ?%-NIZ&%<_F:ZO3OASX8N--MII8)=\D2LW[]NI /K7H*GAX4
MHRFF[G ZE>=248-*Q4@^+MG/<1Q#2IP7<+GS1QD_2O18W\R,/CJ,UR,7PW\,
M0S))'!+N5@R_OV/(_&NDO[ZUTC3WN;A]D,2\FN:M[*32I)G32]K%-U&7/H:Y
M/Q1XY@\,7<=O)923EQNRK@?SKF+GXO.MY(EKI:26X.%=I""1],5R_C?Q#:^(
MKFVNK<,I"X=&X*FM:.$DY^^C*MBHJ/N,]J;5D30_[4\IBHB$FS//TK&\*>-8
M?%-S<0Q64EOY*AB6<'.:MV]R+3P9'.T23".V4E&Z-P*Y_P $>*8=8FOQ%I%K
M9&&,,3#C+=>#P*R]FK2TV+=1WCKN=%X@\5Z;X>4+<R;KAAE(EY+?X5K_ &@?
M8S<8X";\?AFOGWQ7KLFM:_)=26ZQ&-B@4,3D*<9_2O4_!WB^7Q!9722V21"V
MBR,.3NX^E:5<)R4XR^\BGBN>I*)+H/CV#7=>?2X[&6)U#'>S@@[:[&O.O"GB
MJ#5/%4EBFBVELRJY,\0&[@_3O6IXP\:2^%[JUB2TCF6899F<KMY^E9SHR<U&
M*-*=9*#E)G945YGJGQ7BM_*6QLQ<MC]Z2Q"J?8]ZV?"7CVV\22&VEB%O=CD(
M#D$>QI2P]2,>9HJ.)IR?*F=G167K6N66@V)NKV3:@X '4GVKSU/BZYO-K:8!
M:[O]8'.[;ZXQUJ84*DU>*'.O"#LSU:BO-KSXI1C5+6WT^UCN(9MN7:0AE).,
M$8KT:-M\:MC&1FE.E*'Q(J%6,_A'T445F:!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV;7_ #9E8PS$,<'MTK=0IQQ%H]CFE.M+"W;ZEN\'A1M-:.&4"X"\.%;)-6?
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M!N2;PB[_ ('>Z7:+8Z?# HQM4 _6KM-%.KRI-MW9]!"*A%170****104444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2=Z6DH X'XK1NWAN-ARJ2?
M-^E'PIDC/AIXU(,BR'=^).*ZKQ#I":YHUQ8OQO7Y3[CI7B5G?:UX#UETV%/F
MPR./ED4=Q_C7H44JM!TT]3SZS=*LIM:'<?$;5M?T_4[5-*FNHXFBRPA3<,Y/
MM7':=XN\3?VQ:P7.I7.&E4,CJ!D9Z=*Z"3XP3-$P72E5MN QES@_3%<_H]KK
M/B_Q/#J#0A@KJTDH7:H /\ZVI4N2#56*1A4J<\U[.5S>^*U[*7TZU+'88][
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MM)2U@= 4444 )11FDS0(6EI,TM PHHHH **** "BBB@ HHHH **** "BBB@
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MRM;FQJQNETZ4V8+3X^4 <UP-UJGBNPB\VY\R-,XRR+BO2P>*Y?QU_P @,?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "5Y_P"/]5N)+_3]$LI726=PTFPX.W/K^%=^:\L8?;?B^JN<K"2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@PJ@ #TJ2L)RYI-G1"/+%(****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,TK@%%%%,
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M/HKCNRQ,48]J6BD F*,4M% "8HQ2T4 )BEHHH *3%+10 F*,4M% "8HQ2T4
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M0>,E\):3=-;0@@3R1G# CD\]>E4=6BUGX8:I:7J:M<ZEI\S;9A<')^@SGWH
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MOB/XO:1H=^UG;V\E_(A*R&-PH4^QP<U8\+?%32/$EY]CDA>QN6.(TD?<'_'
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M-%&QE. !N4<\5B>$_&>IS>'=6U_6IE>T@<^0HC"\=N10!Z5DT9KQZW\2^/\
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M_$?[?X5_L*#3+HZQ+']G:,I\N3P<&H]>\/7&@?":VLYU)N3,'=1SC.3_ %H
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M(-?+%T9Q9."0!GC!S5?1]7\3:I\.=0U!-7NOMUK<DAM_)7C(^G6IM(\=2_\
M"(2Z FEW3:K#$R,NSY% .,DUH_""W%YX.U.WE'$MPZ-^*B@#=@\:(OPV777D
M#3+#MR3]Z0#_ !IWPWDU>\T$ZCJUY/.UTY>)9&SL7IQ^5>1S6NH_VU_P@JG%
MJUYN7V!)P?IS7T18VB65C!;1J%6) H H LT444 %%%% !1110 4444 %%%%
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MU'SJ/?U_.OH'1=>TWQ#8+>Z9=)<0MU*'.#Z'WKS#4TZ*2E[4 %%%% !1110
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MZ7;>7O/S.QW,?;/7% &T.E+2"EH **** "BBB@ HHHH **** "BBB@ HHHH
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M !KW3PYXQT3Q3:K/IEY'(2.8R<,/P/->>^+_ (#Z1JBR76BNUG='D1GE&/\
M2O#M2T7Q1\.]75IEGLYE;*2QDA'^A[T: ?7?B/5X]&T:>Y=OFVX0=R37@-Q/
M)<SO-(=TCG))K,;XJWGB6"VM-994:(;0Z]'/J?2MG2K&35K^&VMQN,A'([#U
MKZ'+(TX4G-O4Y:UW*QW'PU\/BXN7U2=/DCXCSW;U_G7J_:J.DZ=%I>F0VD0
M"+@X'4]ZO5XV*KNM5<GL;PCRQ%HI*6N<L**** "BBB@ HHHH **** "BBB@
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M9V\PJW"ECC/?TKN:* /-O!/A#6(_$5UXB\1*B7DF0D:L"%!^E>DT44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4E+44LRPPO*YPJ@DT6N!S7CK6ETO09423$
M\PV* >>:\/)+/DDEB?UK?\7ZXVN:U)("?)0[4 [CUJ'PQHSZWK,5N!\@.Z0^
M@KZC!TEA:#E/U.*<N>6AZ'\-]!%IIIU&5/WLWW">H7_)KM[BT@NX6AN(DEC8
M8*N,BEMX$MK>."(;4C&U1[5-7SE>JZM1S9UQC9'BWCSX&66IK+?^'2MK=<L;
M<_<;Z>_XUXQI>M>)OAMKY4>=;R1M^\@D^ZX_SZ5]GFN3\:^ -)\:Z>T5W$$N
MP/W5PH^93_4>U9%%;P%\1M,\:Z>OEN(;Y!^\@8\_45VM?&6LZ+K_ ,,_$ZG=
M)!)&^Z&=,A9!]:^C/AI\2;7QMIHAF98M4A'[V//WO]H4 >A44@I: "BBB@ H
MHHH **** "BBB@ I,TM(?Y4 &>.>*\K^)?Q<L_"L+Z=I;+<:HPQD'*Q?7WJC
M\7/BLOA^*31=&E5M1<;99 <B(?XUY%X!^'VI_$#5VN;AG6QW[I[E^K'/('J>
MM &?I6C>)OB1KQ(,US)(V9)Y/NH/\^E?1?@;X2:+X2A2:9%O=0[S2#A3["NN
M\/\ AW3?#6F1V.FVZQ1H.2!RQ]2?6M8=* ,3Q'HL6J:3)&$7S4&8SCI7CDL3
MP2M'(NUU."#UKWX_SKS?QYH)AG_M*!,1OQ)CL:ZL-5L^5FM.6MAW@37O*D_L
MZ<DAS^[)/ KT:O X)GMYUEC)5D.0:]D\.:NNKZ7'-G]X!AQ[TL13L^9!4C9W
M1LT445S&04444 (11BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&/>EHH 3%&*6B
M@!,48I:* $Q1BEHH 3%%+10 4444 )BC%+10 F**6B@!,48I:* $Q1BEHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "DI:* .>O/\ C[?ZUN6__'NGTK.N-.EEG9P1@FM.)2D2J>PH ?11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4&BD- '+?$'7%T+PC=S9_>2KY2 'GYN,_K7@P
M\1:5_P (8=):RF.H&;SC<9&TGG'OWKV/Q_X7UOQ3?Z=;VR0_V;#(&FW28)&1
MGCOTK?7P3X<6U6+^Q;$D(%W>2N3QUH Q/"NO#7OAK/(SAIX;:2*3ZA3_ (UR
M7PI\):1K.F7=YJ=LMRPFQ&KDX7KZ5N>&/!FN^'[C7+0+ =-NXG6#$G.2"!D=
MNU;'PX\-:CX9T6>UU%(UE:7<OEON&.>] '#7>B6NK?&5[*=3]F'WHP2 1MZ5
M7U_PMI]E\3K'2M.5K.TN @>.)CC!ZUV\'A/5(_B=+KS+%]A8<'S/FZ8Z4:SX
M4U2^^(MAK<"1?8X N\E\-QCM0!R/C+0;#POXQT!M'B^R^81OV,?F.3R:]MK@
M?&_A35-?\0:1>6*1&&U/[TN^#U/2N^H **** "BBB@ HHHH **** $HHHH *
MXKXE2Z=_PC$UK>013/.-BJPY'N*[*:5887D<X50237A'C#7FUS678-F"(E(_
M\:[L!AO;U;O9&56?+$\@UOPS+8EKBUR\.>0.JUTWPM^($/A76UCU6/S+63Y!
M*>L7O]*Z_P .Z+)KFK16@3<A.9#Z+3/BI\'19P-K7AV$F)!F>W4<CW%:YC3A
M0J6INU^@J4G):GO]E>V]_:1W5K,LL,BAE=3D$58KY7^%/Q.G\*WZZ3JDC/ID
MK;?F.?)/M[>U?4L$\5S;QSP2+)$XW*ZG((KS#8DHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I*6B@ JO>VL=Y:R02J"CK@YJQ33WSTH3
M\0UK3)-)U.6VDZ Y5O4>M<]=?%"7PC#<6FG;)KB48R3PA]:T_C9X[L(YUTG2
MV#ZA'E9Y1T0>F?7K7D&@>'[K7KDR,2L&<O*>]=3JN<>0U<W+0N:;I?B7XC:\
M2GG74TC9>5_NH/Y5]"^!O@[HOA=([F]1;[4!SO<?*A]A_C6C\,HM,L-"%A90
M)#)%_K"!\S^Y/>NZ'7-<S3B[,S:MN"HJ*%10JCH ,"EQ2T4A"4M%% !1110
M4444 %%%% !112&@"AK>I1Z5HUW>R,%$4;$$^N./UKYZ_L[[1X9N?%@O%74#
M>&1%WC<%RV>/RKT7XPZKFPL]"@8^?>S*& [#(Q^M8D7P+=[>.1M:VN4#%?(Z
M''3K0!Z3I>MC5?!:ZG;OAS:LV1U5@#_A7FWA*]\=^,+>=;?7OLT<$G,SJ"6S
MGC@>U2_#O4)=.L]>\,W<A\V".1DS_N]*U_@OC^P;W_KL?YF@#-U/7_%<7Q!7
M0]/U'?N4)B0#8#MY;@9JK+K_ (W\*^*4T>[U!-5DN% C+C"@GC/&#5__ )KG
M_G^[2^+_ /DKFC_\ _G0!!=:SXQ\(>)[!-7U-;^VO3GRU7 3)Z= <BO8!RH/
MKS7E'Q6_Y&/0/]_^IKU=?N+]!0 ZBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBDS0 &N(^(NN_V?I2V<+XFGX/J!77WMW%8V<MU,VV.-2S&O O$>L2:U
MK$URS$Q[L1CT%>EEF&]K5YWLC&M/EB96">YS7M/@#01I>CK<RIBXN!DY'(%>
M=>"M";6=;CWC,$)#OG^5>Z(@1%1> HP*Z\VQ.BHKYD4(=1U+28I:\$Z0HHI#
MR,4P.>\7^$=.\8:-)8WT:[R/W<N/F1J^4=1L-<^&/C$!6>*>!]T4@^[(N>*^
MS\5Q'Q+\!VWC70'144:A"I:WE[Y]/H>* +?@'QK:>-?#\=Y$RK<(-L\6>4;_
M #_.NLKXW\%^)M1^'?C+$@=(Q)Y5W">-R_YP:^OM.U"VU33X;VTD$D$R!T8=
MP: +=%)FC/- "T444 %%%% !0:*H2ZSIT-X+26[BCG)VA'< D^E %ZO./BO\
M18_!VCFUM'5M4N5Q&/[@_O5U_B;Q!:>&="N=4O'"I$IVC/WF[#\37R-(^L?$
MSQQU:2XNY<+Z(G;/T&* +W@3P7J/Q#\2,\[O]G5M]S</SGVKZST;1K+0M,AL
M+"!8H8U   Z^YJAX/\*V7A'0(-,LU *C,KXY=NY-;^* %HHHH *K7UG%?VDE
MO,H9'&,59I*+VU \.U?3I-+U*:WD4X#?+].U:/A/6CI.J*)&/DR?*PST-=KX
MUT(:A8_:H4S<1#MW%>5GY3SP<UZ$9*K ZHM35CWV.198U=3E6&0:?7'>"==^
MVV?V.=OWT0PN>ZUV KAG%Q=CGDK,6BDI:DD**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M2EI* *$FII'*8RA)!QFKJ-O0-@C(K NO^/I_K6]!_J4^E $E%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 @HHJEJ=_%INGS74Q
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MN411P)@1H>"W<U[[\&/!,/ASPVNHSA&OKP!V8<[%[#^1KY3ZGC\ *]H^$/\
MPL%;B,6 <:4#EUNP=F/]D<9H ^DQUYI:1,X^;KWIU 'GGCO0]CC48%^5C^\Q
MV/K7$6MS):7*31,5=""#7N5Y:QWEK)!* 5=<?2O&-:TR32]1DMW& #P?4=J[
M*,^9<K.FE*ZLSUO0]4CU;3(YT/S8PX]#6I7DW@_7#IFH"&1CY$IP1Z'UKU<$
M$9!R#7/4ARR,:D.5CJ*2EK,@**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:N+OH1)6U.QTF_&HZ=%<XPQ&''HPZ_K5+Q)HJ:OIS#:/.090U%X,)/A]2?\
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M\UV/W(6.UM4XV.STBR73],@MES\B\Y]:NT"BN&^IQO5BT444""BBB@ HHHH
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M!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNA5:Z=#JI3YXF9=>&](O9#)/8Q.YZL1S3;?POHMM()(M/A##H<=*UZ*X[LU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *2EI* .>\6>'X]=TB2/9^_0$QGOFO!IH7MYWAD7
M:Z'!%?31Z5Y/\2/#/V>?^U;9?DD/[T =#ZU[.4XODE[*6SV.;$4[KF0OPV\2
M>1<?V3<O^[?F-F/0^E>KCI7S-!,]O,LL;;70[@P[5[QX1U]-=TA')'G1C;(N
M:>;83EE[6.S##SNN5G144@I:\4Z0HHHH **** "BBB@ HHHH **** "BBB@
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M"DC\: -"BJME?6FHP^?9W,5Q'G&^)PPSZ9%6J "BBB@ HHHH **** "BBB@
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MUUW2)=%U66UD5@JL=C$?>%:'@_Q!)H.KH^<P2G8ZY[5Z/X_\.#5M+-W$I-Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQA< B&2"#/I&K?S%<MJ'CSQ5K1(N-4NCNZB)B@_2OI6T^#/@NV(+:6DV/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@(/:Z*^;O)^/!Y\R_P#^^H*]DL=?_P"$:\&:?=>,;S[/=E-LSRC)+Y[[1]*
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MXE^$-7OQ8V6MP27#' 0JR_J0!75CGD=* '4444 %%%% !1110 4444 %%%%
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M)/CI;&\U[PS;.Q4R,JL1UZG-4?B]X(T;PIH6G:GHT!M;Q) KRJQ)D/')R>M
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M-+9PR.,,R D>^*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO7KEC91Z?8PVL18I"H5=S$G\2: +-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)2T4 4FU*%7*'.0<=*N*<@$=#7.3_\ 'P_^\:Z)
M/N+]* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^$-\,27L:AKJ0^7;J>A?_\ 5FO%[;P+\3O%]F=??6&@:Y!<1-<O$6'7(5>
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MGJ L+DW%S= ?/':H&*?7D4 =U17)>#_B%HGC591ISRI-$?FAF4*X]\9Z5UM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E '.3_\?#_[U=$G
MW%^E4FTR)Y"Y8\G-7@, "@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I*6B@ KS7XX?\ (A+_ -?D?\FKTJO-?CA_R(:_]?D?\FJZ
M7QHSJ_ SC_@)_P A_5O^O5?_ $*O>:\%^ ?_ "']6_Z]5_\ 0J][J\1_$9&'
M7[M"4M%%8FXE+110 4444 %%%% !7GGQ4\?3^#M-AM].C$NJ7AVP*1D+[X[U
MZ'7AGQA==/\ B/X7U.\'^@Q@AV(R!R: .>EL?C1!IW]MOJ-V+=1YQB^T\X'.
M"G7\*]<^&?B^\\6^&/M>I6S07$+;)'9"JOUY&?IS717&O:3%HC:E)=PM9>47
MW;@0RXKA=;\::3K7PJUN]\-/Y?DQLI2- I0YZX'KUH T]1^,/@S2]4?3[C4G
M:96VEHHBZ9_WAQ6_J>K177A"\U+2[M77[.SQRQ,.#CU]:^?O!UWX@7P@UM8_
M#R#5;><-NO7&68D8SGM78?#G3M=TKP)XFM=7T^:R@VEK>.1LX!#$@?I0!)X.
M\3:W>_"OQ!J%SJES+>02D13N^60<=#6-<^*O$Y^!UMJT6KWGV\WGEO<"0[]N
M1QFG^!/^2,^)O^NS?TKLO@K;07?PQMH[F".9#.YV2H&';L: .@G\9:9X6\*:
M?>^(;TI))"A/\;N2.N!R:C\-?$_PKXKOVL=+OG:X W!9HC'GZ9ZUQWQ@\':U
MJ>I:;K&AQQ7$EDFT6A )//93P:Y/3-=M;?Q[I<7B_P 'C2M2PB)/;N8BQS\I
M*+A<$]: /=_%5S/:>%]1N+:1HYHX24=3@J?6O&_@Y\2=2O-=FTCQ!?W%S]HR
M;:6=B>1U&?H*]>\8$-X,U0@\&W.*\$T#PO-J?PL76M.#+J6F7K3H5ZL!M)!/
MI@&@#O;_ ,1:Q'\?K?1TU&X733"C&V#_ "$D+VKNK;QMHEWXHN/#D,TIU*W_
M -8AB.T=^O2O#_#7B-/%/QLTO4E_UC6T:2C'\8"AOUS70:"0/VB]9SQN/&?]
MT4 >GZCXXT/2_$EMX?NII5U"Y*B-!$2#GISTI?%'C?0?!\$4FL7?E>:<*B*7
M8^^T<X]Z\J\<D'X]Z#@@X:+/YBBTC@UG]H*^@U55N(X%'D1S#*C@= >.YH ]
M1\,>/?#WC#S!H]Z9'3K'(I1OP!YKB/ ?B'6=0^*>NZ?>:C<36<"L8X7?*KR.
M@KH=,\'^%[#XB7FI6ETJZGY2G[%%\@B!SS@=<_TK@?!,CP_%+Q9)'G>L#D8^
MHH ](\1?%'PIX6O_ +%J6H'SP.5AC,FWV..A]JW=$\1Z7XBTT7^F72SP$<X/
MS+]1VKYM\"ZEKRW&IW=EX+C\0RS2D2S3_,5]L&NR^%VF^);#QMJ4UWH$NDZ9
M=1/(\6[*+)D=/S- 'JGASQIHOBN2YCTJ:61K9MLH>(K@_C3-/\<:'J?B6?P_
M:SRG4+?/F(T1"C'7GI7FWP(.+[Q$"<'SS_,52\%@/\>=;&[&Y9>0?>@#T'6_
MBYX/T#47L+[4':=/O>3$9 /Q%=)H/B'3/$VF1ZAI=PL]N_3C!'U'8UX"?#/B
M_P '>(=0DM_#]MK^GSL\DF8U<8/^T1E3]*[?X):OH-]9W\&F::^G7B,#/!YS
M2)CG!&X]>M 'KG>EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%(2 ,DXH ,T5$;J!>LJY^M,-[;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 444A( R2 * %ICR+&N6(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^ON/^35I1^-&=7X&<I\$O\ D-ZI_P!>Z_\ H5>UUXI\$O\ D-ZI_P!>Z_\
MH5>UU>(_B$8?^&%%%%8&X4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !3&C5NV*?10!&KRPD8.Y?2K,5TC\'@^]14QH@W/>@"_VHZU02:6'KRM6X
MYDE'!Y]* (Y;96.Y#L;MBG0WTD!"3C(_O5-3717&&&10!>219%W(<@T^L;;-
M:OOB.5_NUH6UZDXQ]U^X- %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BD.,5GW-\=
MQB@Y;N: )KJ]2#Y1\S^@JBL4D[>9.?H*=# %^>0[F/K5B@   & .*.U-9@BY
M8U3EN'E.(QA?6@"::Z5/E7EJK;7E.Z0_A3EC"]>33Z $  &!2T44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 R;_4R?[IKY8L/^1EM?\ K\7_
M -#%?4\W^JD_W37RQ8?\C+:_]?B_^ABNS#?"SDQ.Z/JJBBBN1G4@HHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:5##!%.HH B4R0'*'*^
ME6XKA)!C@-4-1O'GE?E(H T*:RAQAAQ56*Y9#MD'XU;!##*G(H K8EM&WQ'*
M=Q6A;7:7"\'#=Q4)Z56E@(;S(B58=AWH V**HVE\)?DE^5Q^M7: %HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH SVTM&=FWG
MDYQ6@!@8K);4Y1,4VC ;%:RG(!/>@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "F2RI"FYR *BN+E+=,L<MV K-Q)=R;Y"0
MG9: 'RW$MXVU/EB]?6I(H5B' Y]33U55&%&!2T %,DE6-<L?PJ&:Y"?*GS-5
M<(SG<YS[4 .>:2<X7Y5H6,+]?6G# '%+0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLV4C7JQZ"O-?BSK^G:GX/6"UN$DD%RC;5/.,-6M%/G1E6:Y68'P31WUO5-A
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MX%VH @#E3M<8-2=:L,D<R<X(/<54>*2#G[R4 /HIJNK $&G4 %%%% !1110
M4444 %%%% !1110 4444 %1O'G#+]X5)10!);S[QL;AA5BL^1.=R\,*LV\XD
M&UN&% #IX1*O'WAT-/LKLY\F7AAT-.JO/#N^=.'6@#7HJI978F3:W$@ZU:H
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M';VIDDBQ)N)H 2641)DGFJ0W2OO?\!1\TS[VZ=A4O2@ HHHH **** "BBB@
MHHIK.$&2: '5&7R=L8+'UI4CDG.?NI5M$C@7C '<F@"&.U)PTIW'TJ9Y(X5Y
MP!Z"HC-),=L X[M4L5FJG?(2[4 1;Y[@XC78GJ:ECLD4[I/G;U-6O844 (
M, "EHHH **** "BBB@ HHHH *J:EI\&JZ=/8W"[H9D*-^-6Z*+ZW#I8YWP;X
M5A\*:/\ 9$(:5V+R.!U/_P"K%=%113;;=Q))*R"BBBD,**** "BBB@ HHHH
M/I44EO'*/F7GUJ6B@"B8)X.8GW+Z&ECN58[7!1O>KM12P1RCYASZB@""2W24
M9Z'L159EEA.&^9?6IC'-:\K\Z?RJ2.:.8<'Z@T 5PP89!I:=+:X.Z+@^E1+)
MSM<884 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0J&&#38I6@?!Y0T
M^D90PQ0!<!#*"#Q05#*0>AJE!*T+[&^Z>]71@C(- %9'>RFR.8V[5K1NLBAE
M/!JBZ!U*L.#4-M.UI-Y;G]V>AH UZ*0$$ ]C2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !113))%C0LQX% $-W<BWB)'WCP!5"WB.3+)RQ]:1=UW<
M&5_N@_+5K\* #M4%Q/Y:X'WC3Y91$F[O5)09&\Q^_2@!8T/WFY)J2BB@ HHH
MH **** "BB@X')- !D#K4?SS-M0<=S2HCW#=PGK5O"01=@H_6@!(H4A7/4]R
M:8\S2-LA&3ZTU1)=G'W(A^M78XDB7:@Q0!##:+&=TAW/[]JLT?YQ10 4444
M%%%% !1110 4444 %%>6ZAXJ\97GC74-$T,V3+;-\HF0#CZUKZ2?B1_:<']J
M+I@LMP\WR\;MO?% '=T5GRZWI=O+)#-J%M'+",R*T@!3ZTZVU6QU&"5]/O;>
MXVCDQR!@#[XH O45S/A+5-4ODU!]5NK";R9BL9M'#;5_VL=#6E%XDT2>=8(M
M5LWE8X"+,I)/TH U**BN+B&T@>:XE2*)!EG<X JK9:UI>I2-'8ZA;7#J,E8I
M Q _"@"_15&;6=,M[A[>:_MXYD7>R/( 0OJ1Z4R/7M)EM9+F/4K5X(CAY%E!
M5?J: -&BJ]G?6FH0>=9W,4\6<;XV##/X56;7](6[^R-J=H+C./*,HW9^E &C
M115>[OK6PA\Z[N(H(\XWR,%% %BBJD^J6%M;I<3WD$4,G"2.X ;Z&EN-2L;2
M!)[F[ABBDQL=W #9Z8H M45ROB;7[RQU31['36C,MY+^\+)NRF">/RKJOK0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVU%9MSX@T>RN#;W6IVD,PZI)* 1^%5/$OB:U\/Z%)J!DBD;9NB0R >9Z8]:
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M2T;G+Q?RH @)>%MLG3L:DZ_2K!\N>/\ O#^55'1[<YZH>_I0 ^BD!!&0:6@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TG6@#FW_P"/A_\ ?/\
M.ND7[H^E9QTL&4MYG4YK1' Q0 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
MUV"(68X H KWER((N.6/ %4K:(J/,;EFIH+7=P9#]U3Q5KZ4 %5;J;'[M.IZ
MU--*(D)/4]*IQJ6)=NIH <B[5]Z=1FB@ HHHH **** "BBHV8L?+3ECUH &8
MNVR,<GO5J&%85R>6[FB&%85_VCU-1EGNG\N/(0?>;UH 5G>XD\N+A>[5:A@2
M%<+U[FG11+"FQ1]:?0 =J*** "BBB@ HHHH **** . ^+_\ R)!_Z^$_D:Y<
M77]BQZE"05^W6D;Q\]26"_TKT7QGX;D\5:"=.BN4MV,JOO9<CC/&/QK&UGX>
M'5KG2)OMB*;!55LQD[\'/K0!RGA:U%E\4;:WQC9IP!_[YK4^%A'V_P 1#.#]
MH;\JZ6+P=)%X];Q']L0QF'RQ $Y'XYK"F^&6HP:U=7>D>('L;:Y;+Q(I)(/4
M9!H R_"%C:ZGXD\86]R@E@=^F>O+>E1?##1M,,NM7TL6V6RN&6*3<?D'-==X
M/\!?\(K?ZE)]M\^"[ ")M(9!SU/<\U2TOX=7^EZS<S0ZV1IMS(7FM A^;/J<
M_P!* /.]0@LK[3KV]T[2KS4V$K>=?W;!1'_N[6Y_$5N064.I_!5KN]5II[;S
M/)=F.5P3BMVV^%5Y MU9_P!OS#2IBS"UC!'S8X)/?G%;>F>")+7P1/X;N[U9
MEDW!940KC)- '$BWBT/X1QZAIT1AO+V,">56.3\WZ5SRZ+KSZ;:W5AX6-O,-
MKK?I<'<_ORV.:]-T7X?W=GHUUI&JZM]NL9(]L,00CRN<C&2:S[;X7ZB9(;;4
M?$$EUI,3AEM-I' Z#.: ,?Q4)]:\6^'=&U61XK>2$&:,-WYZU%XL\.:=X?\
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M110 4444 %%%% !1110!&ZE3O7J*N0RB5 >_>J]1HQMY?]DT :'7Z55;=:7
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M+5#3IR\?E.?F7BK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5+J$IEE6!>G>GJH1 H[4 .JK=R<"->IZU9=@B%CT K/7+N7- #T7:N*=110
M4444 %%%% !3)'VC'<T\G R:2WC,K^8WW1TH FMHO+3<?OGK3&S=3!%_U:_>
M-/N9#Q&G+,>W:K$$(AC"CJ>IH D50BA1T%+110 4444 %%%% !1110 4444
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M 4444 5[F#S4RO$B\BHX)?,4@\,."*N=JI749CD$Z#ZB@""9/)EWC[K=?:G
M_E5CY9XO]EA5-,QN8V[=* )**** "BBB@ HHHH **** "BBB@ HHHH *9(NY
M:?10!):R[TVG[R]:L5GY,,P8=">:T <X(H JR$VUPLR?=/6M='#H&7H:SY4$
MD;*:739CAH6ZKTH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_>2KU "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4A/RFEI#]TT <^9I?M!'F'&X]ZZ!>@^E<
MX?\ CY/^_71C[H^E "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY_\ CX@3[Y[<#\J@E\3>,/%&IVEMI&DW&DHC[YGN0<,![X&1[=Z]2H^N>.E
M'FOCC1-8@UO3?$]A#]KELT FC3J>N=H_&LZ?^V?B)X@T\RZ/-IMC8N)'^T Y
M;D<#(&>E>M_C10!YJNG74?Q;6X%K-]E6(*)=AV\ =^E6?BG97=[9Z4MM;33L
MET&81H6P,KUQ7H/UH_G0!SOB#19=<\&/IR?+,\"A<\?-CH:\JLK:X2SAT=?
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M L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4A^Z:6D[4 8)MIO/)\LXW9K>'057^W6^[;Y@R.
M*L"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***1F"@D] ,T 9NI2%G2!3U.33D4*@4=!5>
M,^?=O-V'2K7O0 UV"(6]*H1C<S.>I-3WC\",=Z8HPH% "T444 %%%% !111Z
M4 -=MJ$]^U3VL92/+?>;DU7VF6=4[#DU9N'\N(XZG@4 ,0?:+O\ V$_4U?J&
MUC\J!?4\FIJ "BBB@ HHHH **** "BBB@"KJ-F-0L);5F*B08R.W-4M,\.V.
MF/YB)OFQ]]N2*UZ*I3:5D.X?SI"H(*D94]J6BI%8YK4_!EC>EG@_<.QR0/ND
M_2L<?#HC(%U;@'_IB?\ &N]HK:.(J)63.>6&I-W:.!/PY)7;]JM\?]<#_C7
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MHM3].E5;7+N\K=2:M4 0W+[(3ZGBJT2XC!]:==MNE5!T%+VH **** "BBB@
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M2^B\T[M1:#,LC_A0!)=_ZK:.K'%7(U"QJ!V%4Y!OO(5].35Z@ HHHH ****
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M<)D*WX;>*Z3PGXSL/%<$GDHT%U$<2P.>5_QH Z2BBB@ HHHH **** "BBB@
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MB@ HHHH **** "BBB@ HHHH *:WW6^E.I&^XWTH YQ?^/G_@5=&.@^E<XO\
MQ\_\"KHQT% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-]UOI0!!]D@W;M@S4XK!6YF^T8\QL;NF:WAT% "T444 %%%% !1110 4444
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M8[U QFE\->$H/#5SJ$\-U),;V7S&#J!LZ\#\ZZ+Z\T4 %%%% !1110 4444
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MHH !^M%%% !1]/SHHH .G2BBB@ H_"BB@ HHHH **** "BBB@ HHHH ****
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M7UNS,>@5JRO^$%D_Y[P_D:<:%>:NHFE7-\JA+EE+\S0^U>'/^@=%1]J\.?\
M0.B_.J'_  @TG_/>'\C2?\(+(#_KX/\ OEJOZMB?Y3-YSD_22_$V;74/"T:N
M)M+B8G@=ZS;K4;*UGAN=)B6VD253\C?>Y'%7-,^%EQJ6XK=VZ!>I*M71:-\)
M!8ZE%/=W<<B1L&VQ@C)'(ZUFU53Y9(U6-RYPE.F[W.DT;QDM[<1V]W$L3O@
MJV1D],UUG;BN$\;VHMKNUNX%"DHRDJ,9/&*[&TNHGL[=V=0708!/-=-2$>52
M1\Y+NBU16'?Z_% LD1S$3N2.5CP7%8K>+WTB_-K<Q2W4<BATD!&1VQ65C.YV
M4TR6\+2R-M51DU5@U:VF=5RR;ONEQP35:+58+V-4GMBL4GR\L".>@.*S=9BB
MTS"6T81)(^5'KD<TT@;.IHIL9S&OTIU2-!1110 4444 %%%% !1110 4444
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M7YH=1N88 8Y+>4HT9),<ASV)Y!X^E;4Z7.FT<]6O[-J_4])HJGINI0:G:B:
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M7LO\)? KLJ^=Q<4JK2/L<#)NA%LBF_A^M7T^XOTJA-U3ZUH+]P?2N<ZALO\
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MD;"V$(O3>_\ "0SBX(P9,<X_*I7T.QL;63[-XCFQ<G=*H_B^O%87_"%>*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\\W+N?8TX*$%'L0S?>7ZUHK]T?2L^3_6(/>M&H+(Y^(6^E6--&+-?K56Z/\
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M6P4444#"BBB@ HHHH **** "BBB@ J@,RWS-V7BKDK[(F;T%5;0'RRYZN<T
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MN@^U,F&86'J*=&<QK]!0_,;?2@"C"?D_&I*B@^Z:E[T %%%% !1110 4444
M':ELV^]'_=/%)3$/EW0/9N* )B?*O5;'#C!J_5*[!\O>.JG-6HG\R)7'<9H
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MVK(#RIJO*. PZK5Q2)8<GD$4 6$<.@8="*=5.R<J&A/53Q5R@ HHHH ****
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MGZ6F+<MW)H NTM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG[1=%_X$X% $D2B*''IR:J ^9*TGITJQ=R;4"*?F:H47:H H =1110 4444
M%(S!5+$@#UI:QM72<(7,R[.RCBM:5/GE:YAB*KI0YDKBWVM)%E(.6]:Y^:YD
MN&+.Q/XU&23UYI*]BE0C36B/F:^*J5G>0H."*Z[2)?,L5!.2O!KD*WO#\PS)
M%SR,_C6>,AS4KF^65.2M;N;]%%%>,?3!1110 4444 1GYKA%K0]*HVZ[[@M_
M=J]0!!=-B ^_%7K%=MI'GN,UG77+(@[FMA1M4 =!0 M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3
M_5M]#3Z9)_JV^AH Y^+_ (^E_P!ZNB'2N=A_X^U_WJZ(=!0 M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4A&01ZTM)0!CP96YE3W-6NU07 \O4N.C 5/0!2NQB9&]:7W]:?>+F(-Z&
MHD.5% #J*** "BBB@ HHHH **** (R3'*L@^AJY*@FAZ]LBJS+N4BI+20E"A
M^\M $]G+YD.T_>4X-6*H'_1[L/\ P-]ZKXY% !1110 5A>,_^10U/_KB?YBM
MVJFI:?%JFG3V,Y813+M8J><4 >1^#?A^^M^'(+U?$6HVBN3^ZB;"CZ<UN?$V
MR.G> +6U,SS^5.@,CGD\'DUW.A:);>']*CT^T:1HDZ%SDTNMZ)9Z_IDEA?(3
M$_=>JGU% 'GWCN_M6^%]I&LZ%Y538H.=V"*P/&L*S:=X/1AE6MU# ]^%KL4^
M$/AU;:2%I+QRV,,T@)3Z<5KZGX$TS4X=-CEDN!_9R;(<,.<8Z\>U5!I25R*B
M?(['D7BZTM[9M,:&%(B95!*C%+,(Y?'B+=X:+RLJ'^[FNKUWP_!>W$<=RTBF
MW?*[3CI5;5-!LM65?/5E=>DB'#5ZOLI-W1\^L0HI1EYH@AMM#CU640&(7;##
MQJQQCZ=*P_#L,/\ PD&LAHD^0_)E1QR>E=%I7A^RT@NT"L\C]7D.3CTJ!_"M
M@^I-?JTL<K-N(1L TY4Y-*5B(5X1YHW,_P -W4T7@WQ=';,PF+D@KUQSFNH\
M.6/AZ3X6O)/';-(86:1W WB3''/7TJ#0M+M=%EG\O?)'</ND20Y!]JV1\*_#
M=_,+U'NDCD8/Y"2 1CVQCI7!B*+IN_<]G"8J-5670X222Y?X,'SRQC6] B+'
MM\U=+XMT;3K;X66\L-G"DJ(I5P@#<GN>M=SJWA'3-6T!-&=7@M$8,JPD C%2
M:GX8LM5\/C1IWF%N%"AE8;L#\*YCM/-]6U&T32/"=H^G)?7DD2>4)965%.%Z
M@=?QK(LK;4+?XI:='?-:&56)*VB@*HVG@X KT[5?A_HVKZ796%QYP6S0)%*C
M . /?'M4%I\--#L;VRO+8W$<]J#APXR_7EN.>M &#\.O^1Z\4_\ 74<_BU>G
MGH1ZBL/1O"EAH>JW^H6SS-+>MND#L"!UZ<>];M 'DVA3Q^'OBOJL6HN(EO3F
M)WZ-UQBKGCK5?%NB&XU*RUBRCTT8$<6U6<G'T_K78^(O">E>)H/+OH3Y@/RS
M)PZ_0US]I\)?#UK=)-))=W*J<^5/(&0_48H XKQ?J.JZOX5\,W-Q,/,G?,CL
MH"%\G&1^52C0=9C\2Z/-J&L:+%,)5:%(%$;.,C^ZHSVZUZKJGAK2]5T<:7/;
MJMLHPBIQL^E8^@_#G1/#^H+>PFXGF4?*9W#;?IQ0!R5E86U_\9;\7<*3"-0P
M##(SM Z4BVR67QEGCL8EBS9NP2,8&2#VKO[?PG86WB:XUY))S=SC#*6&WMT&
M/:C_ (1.P_X2K_A(?,F^U^68]NX;<?3% 'CF@:?KFI2:PUG>:9$!.WG"]C5F
M'7D$J<5Z/\+K*6QT"6-K^VO(?.)5H&)4'CCD"IM7^&.@ZQJ+WKFX@=SEE@<*
MK'WXKI]*TJTT;3X[*RB$<,8X [T 7?RS1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "$@#)[<U1A_?3O,>@X6I;V0[1$OWVH4"&'T % $%V
M^66(?C2 8&/2HT^>1I#WJ2@ HHHH *9)%%,NV6-'7T9013Z*:;6PFD]RH=+L
M#_RY6X^D8J'^PM-\SS/L<6?]T8K1%%5[27<CV=-]!J11Q*%C147L%&!230QS
MQM'*BNI&""*?WHJ>9WN79-6.4OO 6G7,A>WEEMF//R?X55_X5]@8&LW!_P"V
M:UVM%=$<96CM(YI8&A/5Q.+M_A[:K(&NKR68 ]#QG\JZNRL+73X!%;1*B@8X
M'-6:*B=>I4^)FE/#TJ7PH****Q-@ILAPAIU1S?="^M %FU&( ?7FI^U-10J*
M/042-MC8^@H CL 7O)6["M6J&EK^Z=O4U?H 0],5CQ?NKN2+U.:V.]95ZOE7
MZ/V?K0!/5*\&'1ZNBH+M-T!([<T 144V,Y04Z@ HHHH **** "BBB@ I#R,>
MM+10 MH^TF%CTZ4Z<&*59EXQPU02 @B1>JU<1EFASZ]: +*L'4,.AI:I6[F&
M4P-]T\K5V@ K#\2:VNEVA1#^_<'8/2M>XG2V@>5_NJ,UY/JNH2:C?R3.V1N(
M4>U9U961VX/#^TGKLBK-*\\K2R$L['))IE'2@ G  R>WN:Y'J>]:,="Q8V<M
M]=)!$N68X/M7IVC:-#I5HJJ 9,?,W>J/A?15T^T$TJYFD&?I715U4X65V>)C
M<4YRY8[!1116IYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ;A115/5!=MILXL2HN"I\O=TS32OH*3LKLEO))([.5X%WR!3
MM7U->4P:^=0U2:QUN-8I&)"DC@>Q_P :G\/^,+_1=3DL-;#LC/\ >;^'_P"M
M6[XM\+6_B"Q_M+367[2HW K_ !CTKT:,?82M/KU/-KOZQ%N/3H<1K?AJYTN?
M[1:AMOWN/3VJ.UUA]0@%B8?,NG^10%SGWK6T+Q/.;:31;^T:XN$&V(XY4^AJ
M=-,DT21Q;Q"?5[@$DJ,K"I_R:[E6:7++<\QT%>ZV,Z?3(;::'2[9]S+\]R0.
MA]/UKJ=-U>XT\+&C9C'\)YK'M;+[(A#$M*QW2,>I-6*'%2CRRU.9UI1GS0T.
MWL_$%K<@"1A&W?TK75@ZAE(*GH17F0)!R#5RUU2ZM3\DA ],UQ5,$GK ]&AF
MK6E34]"HKFK7Q2#A9XN3W6M>#5K.X^Y, >X-<4Z%2.Z/4IXRC/:1>HIJNK#*
MLK#V-#L$0LQX%8O3<Z4TRO>2E5\M?OO1&@AB ]LFHH09I&N&'7@"DNY"2(EZ
MGK0,A!,LK2'I_#4E(HVJ!2T %%%!('4C\: 8455FO[>!3ND'T%8]YKKME(1M
M%=%/#3F]CDK8VE25F]37O-0AM%.6R_85R]Y>RW<A9C\O8=J@>5Y&)8Y)IE>E
M1P\:>O4\'%8R5?3H%%&,GBM/3]*DN6#.,)WS6TYQBM3FITIU7RP15M;":Z)\
MM>*OV5M<65ZAD1E3/6NAA@C@C"1C %28!ZBO-J8QRO%;'N4<LC!*3>J"BBBN
M$]8**** "D8X4FEJ.9L)Q0!-9+A6;U-6N:CA39"H]J>3@$^E $"?O=14=DK7
MK,TU=TLLOO@5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4UAE"!W%.IK'"ENN!0!EIILBSK)E<
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MAYF&QLZN(][8WNU%%%>8>\%%%% !1110 4444 '>HP/,N56I#TI+1297?\*
M+M07;[8#[\5/56<>;<1Q>IH TK-/+M8U]N:GI%&% ]!2T %4-3CS K]U-7ZC
MG3S(63U% %&)M\0/K3F 92/457M&^5D/\)JS0!G1?*S(>QJ6FW \NX#=FIU
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MFCSW'45!41W1/O7\10-;GG>N_+K=SZ;NE4*T=>P=8N#ZG-9@X-<4OB/IJ/\
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MH.A1:/;$'#W#\N_]![5$W"BKK<VINI5EY(\TU"WU#2G;3I6'#AGXXDZ?,/\
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MH%MK:.%!A44**Y,53IPLH[G5@ZE2=W+8EHHHKB.X**** "BBB@ HHH)"@DG
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M ']%']EZK_<;_OZ*[:^L);*8HX(]#52O26(E)71X<L.H/E:U.4_LK5>NQO\
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M "BBHY9TA7+G\* )"<#.>*IS719_+A&3Z]A3"TUT>Z1_J:E58X$XX'K0 V*
M1_,QRY[U'-<_P1\MW-,DG>8[8^%[FD1 @XH 1(]O)Y8]Z?110 4444 %%%%
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M]C8[7RC>AJR"#T.: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***.* "BBF/*D8R[ >U #Z:SJ@RQ %56O&<[8$)]S3!;-(=TS;CZ>E #GNWD
M.R!<_P"T:2.WYWR-N;WJ0M'"F#@ 56>X>7B,8']Z@">6=(ACJWH*JG?,=SG
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M$(+9 S]#72VLIGM8IF&"Z!C^->.^-_!]IX;\/6TEC<3['=?-C=\J[>H';O\
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M";4M2DM(WO 7VRE<LN,]#VJWK>Z7X2>'E+X9GQNST.3S0!M/H_Q$&DF_'BN
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M/TJ,WA)_=QD_6F!%'10*=TH :9;ASV44WRLGYV)_&I** $"JO0"EHH)"C).
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MEN7;DU!8VI9O/E')Z UHT +1110 4444 %%%% !1110 4444 %%%% !1110
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M&8(A8G %*3CZ=ZJ@->S[%_U8/)H ?:Q-=3><_P#JU/ K5' IL<:QH%48Q3Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *9+_ *F3_=-/IDW^ID_W3_*@# M/^/R/_>KHATKG;0?Z
M9%_O5T5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9=W:
M-"YGA_$"M2DQGK0!FPS+,OH>XJ2H[NT:)_.@'U%$,RRK_M=Q0!'/;B3YUX?^
M=5T<@['X85H5#/ LH]&'>@"&BH@S1G:X_&I>M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112%@H)- "DX&
M340#3OM7(7N:5(WN&YX6KR(L:[5' H 2.-8E 4?6GT56FF9F\J+ECU]J ":8
MLWE1<L>*NV=H(%W'ESU-%I9K NYN7/.:MT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %131),A5QD=JEHH QG22R
M?!^:,]#Z581U=<@Y%7Y$5T*L 0:RI;:2S;='DQ'K0!8YZ56FM@WSQ\&I8Y5F
M7@U)0!G*Y!VN,&I:GF@64<\-VJHPD@.&&5]: )**16#<J>*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ]Z*** "BBB@ HHHH ****
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M(%F]JGM;'!\V;ECSCTJ>WM([=>!ENY-6>U "=.!2T44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %1S?ZB3_ '3_ "J2D8 J0>AX
MH YZT_X_(O\ >KHJJI8P(X<+\P.:LT +1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 E5[FT2X7T8=#5FB@#&WR6K[)A\O8U95
M@RY'(JY+$DR[7 -9DMM+:,7CRT?<>E %BH)K99.5X:G13I*/0^E2T 9V7B;;
M(./6I 01D&K;H'7#8-5)+5X_FB.1Z4 +148DYPW!J3J.M !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !112%@O)- "TUG"_6F;WD.(Q^-6(K0#YI.30!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR!23ZT 3R2I&,L?H*@59[QL*"L?K5B#3LMYDYW,>U:"J%7:HP!0!7M[2.W'
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M@ HHHH **** "BBB@ I&56&& (]Z6B@"C-IL3\QDHWM59H;NW/ WJ/2M>DH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gmz2lq4320rk000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +H L4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD_?21;H@.] &)X;\1:QKWC*[2.X?^S[2?8Z=B.*]#:[MXWPTRJ?0UY/:W?\
MPAGP]NM9QMNKM!,1T)/^167IENVKZ;)=77BJX@DF^=5P/E]NE 'MTTG^C2.A
MSA"01]*\^\#>)=1U+4+E=0NB\22NHW=@"<5C> _%4RW]QH%S>M>2,KLDCGG
M%<SX7T34]=\27=I;ZA-90^;(WF1XZY- 'T#%<Q3-B.0-]*Y?67UK^W(Q:7;1
MVVX94#@BO.]0CU?P)XG@9]7N+RWE9(]CX R3CT]ZWO$NJWL?BRUCBN'6-V3*
M \<T >H[@J;F;H.34<=U#.2L3A\=<5Y5XJUG4]=\5MX;T^ZDL_L[ R2Q'D@^
MM6+GP5XDT>[L)M.UB[NU1\S)@ ,/?B@"WXA\1:K9>.M'T^WNF6VGF*R(.A'-
M>C.X1=[':HZDUX[K[2O\0/#;3*8Y3,=Z^G6F>,_%5SJ?BRWT2"_>QM]Q26:,
M]* /8([N"9ML<JLWH*G'/45X1KSMX<M5U6P\33W3P#!@X ?Z\5Z[X7U<:UHD
M%T#EB@W?6@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J.=$DB99%#*1T-254U"^AT^T:><X0"@#P77+>.'XSA(XU5?*4X KZ!AX
MAC_W1_*OG'4=;M=0^+RW4+9C**F??-?1L!W6\9']T?RH EHHHH *3%+10 AZ
M9]*^9_B]X]U&36?L-I,T,2@ABC8Y%?3)Y&*^:/C)X$NK2_;5X!FUP2^3DY-
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M7S9><XE;<!^==3&BQHJ* % P !0 ^BBB@ HHHH **** "BBB@ HHHH ****
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M44U30K>X4  J!Q]*V*R] TE-'TF&TCP%4#('KBM0X- "T444 %%%% !1110
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M(R\KA%'4D\5Y/K^I7<7Q*TFW68B)Y\%?SH^)6MZA<^(=-T"QNS;I=@K(>QH
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M#Z&^$_B.37($6;'FJ.<#L*]G%>*_"/P_+H]NC3_ZX]?I7M8H 6BBB@ HHHH
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M  KN!]T5P^A_\?WX5W ^[0 M%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M O\ _CS>O/YO]<_UH 91110!IZ'_ ,?WX5W ^[7#Z'_Q_?A7<#[HH 6BBB@
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,48XQ2T4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:VU&U>!TZ"@!V:6DSTI: "BBB@ HHHH **** "D]J6DY)],4 )U&,?G3?)B
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MKT"__P"/-Z\_F_US_6@!E%%% &GH?_']^%=P/NUP^A_\?WX5W ^Z* %HHHH
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M== P^A% '@GB ?\ %Z5S_P \DKWR'/DQ^FT?RKP/Q ,_&H9_YY)7OL/,$?\
MNB@"2BBB@ HHHH K7_\ QYO7G\W^N?ZUZ!?_ /'F]>?S?ZY_K0 RBBB@#3T/
M_C^_"NX'W17#Z'_Q_?A7<#[M "T444 %%%% !1110 4CG",?04M-D_U;?0T
M>5?$2XNY].N4C8X"'(SVKY:<?.P]Z]_^*GBM]):2VM@ID;Y6W#(P:\#FE,\S
M2, ">N!0!I>&+M++Q#97,C%5CD#$BOJ+0]=_M&6&2"Y9T<\<U\C\[OE./2O4
M?A#JMTFM"V+LZ,P'))Q0!]40G=$N>N.:DJ*#_4(/:I: "BBB@ HHHH ****
M"N.\19^T#ZUV-<5XIFC@;SI6"JG<G% 'G?BWP9;>(8O,!*S*,# ZUQ6G?"J9
MKS%TQ6,'@@YXK6\4?$V*U#P:;S,.,LN1FN5LOB?K,=TIE\K8>ORT >V:;80Z
M9:QV\0 50 >.M>C:3S9*17DWAKQ19Z] CPR 2C 96..?I7K.D\62T :%%%%
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MQ]-PQ7FOC'P/I-IX?U/4&C=KIH22Q?(KT[CI7+^/S_Q1VI9_YX-B@"G\)_\
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MB0RH/W;D<K]*W<4F* .0TKP%INGW*W$B+<RQGY&8<K77* BA0, =!2XH Q0
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MN,26\R[70]Q5D]*!TZYH K:;IMII5E':6<0BAC7:J#L*MTE+0 4444 %%%%
M!1110 4444 %%%% !5#6-,@U:P>VN$#HPZ&K]96OZC/I>F27-O!Y[@<)F@#Y
MYNO#-EI'Q76QMXU6,!9,#US7TM!CR8P.R#^5?+__  D5]JOQ/2\N+ 12G:GE
MY[9ZU]00?ZB,XP2@_E0!+1110 4444 5K_\ X\WKS^;_ %S_ %KT"_\ ^/-Z
M\_F_US_6@!E%%% &GH?_ !_?A7<#[HKA]#_X_OPKN!]V@!:*** "BBB@ HHH
MH *;)_JV^AIU-D_U;?0T <!J?_'\]5*MZG_Q_/52@ JQ8_\ '[%]:KU8L?\
MC]B^M 'H$'^H3Z5)4<'^H3Z5)0 4444 %%%% !1110 5Q_B/_CX'UKL*X_Q'
M_P ? ^M &'0.M% ZT *OWA]:[S2/^/):X-?O#ZUWFD?\>2T 7Z*** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110:
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MO&O/?BGH-EIOA:XUBPMX[>XM$RIC7%4KM/%&O:5H[:7;17%J;8>=YCX^;\J
M*VD:EJUY\7;/[4TB6SPNR(3PR\8->RM]P_2O"))_%<'Q.TL/IELMVEN51 _R
ME>,GI7L&K>(+/0=*6[U5_*! #;1G#$4 >,>(/^2U#_KDE>^P_P"IC_W1_*OF
MV^\0:?JWQ;2]M)2\+(B@D=\U](PG,,?^Z/Y4 24444 %%%% %:__ ./-Z\_F
M_P!<_P!:] O_ /CS>O/YO]<_UH 91110!IZ'_P ?WX5W ^[7#Z'_ ,?WX5W
M^Z* %HHHH **** "BBB@ ILG^K;Z&G4V3_5M]#0!P&I_\?SU4JWJ?_'\]5*
M"K%C_P ?L7UJO5BQ_P"/V+ZT >@0?ZA/I4E1P?ZA/I4E !1110 44E&10 M%
M)S1F@!:X_P 1_P#'P/K77YKD/$?_ !\#ZT 8= ZT4#K0 J_>'UKO-(_X\EK@
MU^\/K7>:1_QY+0!?HHHH **** "BBB@ I#TI:* .=\5PK/ISHXRK<5\^Z_\
M"_?=/<6LK;3R5 Z5]#>).;3\17AGQ.URXL;#[/;L4)8?,#@T >5:MHDFGW1A
M1C(!_%5C1/#.H:E>PB*W8Q[AN8=A6-)=7$CEWD9B?4UZ]\*]2%S;FT>)=T:Y
MWXY- 'MG@.Q&EZ'#:;B=BXS76U@>&Q^Y/TK?H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:0T
M (.F17,>/SGP=J7_ %P:NHYK'\3:5-K6@W5A"ZI)-&4#,.!0!A?"@X^&VD8_
MYY5R&AA;3XH:D)<JTUQ\N[C/ Z5Z+X+T*?PUX3L=*N)%DEMTVLR]#7/>,?!5
M[J&HVVK:1-'!=6Y+989R: '_ !?F0?#O4K?(\R2/Y5SR:TOAY \/A2S# C,2
M]:Y>+P?XF\07T#^(+V&6TCX>-5*EA^=>F6EM'9VD=O$N$C7:!0!1FT*TEUZ+
M67#?:8D*+CI@_P#ZJY_XEZ%;ZUX8DBG:0 -N^0D=*[6L7Q1!+<:+*D=S% W]
M^3I0!\HZ!8BT\;0PIOPLB_>Z]:^PK;!@BZYV#^5?*EI8W-O\2$BEU&VN'W ^
M9%]W&>GUKZLM^+:+/)V#^5 $U%%% !1110!6O_\ CS>O/YO]<_UKT"__ ./-
MZ\_F_P!<_P!: &4444 :>A_\?WX5W ^[7#Z'_P ?WX5W ^Z* %HHHH ****
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MU*6F!5\[\\9KZDM\^1&.VP?RH EHHHH **** *U__P >;UY_-_KG^M>@7_\
MQYO7G\W^N?ZT ,HHHH T]#_X_OPKN!]T5P^A_P#']^%=P/NT +1110 4G>EI
MI&2#Z4 +F@G%(>N*6@ R>]-D/[IOH:7'K36.8FQTP: ."U/_ (_GJI5O4_\
MC^>JE !5BQ_X_8OK5>K%C_Q^Q?6@#T"#_4)]*DJ.#_4)]*DH **** $-07N/
ML4W^X:G.#Q5:_=4L9B[JJ[#R3B@#SSP/_P CCJ&/^>8_F:],_E7EO@>YM_\
MA,+_ /?Q<QC'SCU->I Y':@ %<AXC_X^!]:Z\=37(>(_^/@?6@##H'6B@=:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !56_O(K&V::9@J =2:M50U;3(-5L7MKA0T9'(- 'S]J>L6E_\
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MB@ HHHH **** "BBB@ HHHH ***2@!::WW3]*=FLCQ%;W=WI,D5DQ$QZ8.*
M/%?$'_):1MY_=)7OL/\ J8QC^$?RKY933M7M/B<D-\S&X!5B2V?ES7U);_\
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ME "T444 ==X;_P"/?\*WJP?#?_'O^%;U !1110 4444 %%%% !1110 4444
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M!P'@7_D<=0_ZYC^9I_QD_P"17/\ NFF>!?\ D<=0_P"N8_F:?\9/^17/^Z:
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M&_X0GXB_]#!J/Z?X4?\ "$_$7_H8-1_3_"@#WBO!?"7_ "5V])_Y^S_2G?\
M"$_$7_H8-1_3_"LR#X4^+[:_:]AU"[2Y9MQE &<^O2@#Z+XS[T5X./!7Q$_Z
M#VH_7C_"C_A"?B(!G_A(-1_3_"@!GQN_Y&*Q/_32+^8KV^R_Y!%O_P!>Z_\
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M(_*@#VH=*!4=NCI;HKL2P')-2B@ HHHH **** "BBB@ HHHH **** "BBB@
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M3U_ UF^#_B3;:;X5M+/4=.NI"25:7^'%&M:1)'*OBOPO( C'S)HU^8L/08H
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MCACA7;&@5?0"I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3'&*K1V%
MO'=O<K$HE88+8JU10 F*,8Z4M% "<YXI:** "BBB@ HHHH 3WH^M+10 F!45
MU;17<#0S(&1A@@BIJ* .7\/^"K#0-0N[NW5@UP^_&[@5T^:6B@!**6B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***0\ F@!:*\Y\2^-?$&E:Q);6>G12
MPJ 0S$Y_E7+#XQZX=1>P_LZ#[0GWER?\* /;Z*\ML_B!XBEM+J:?385,2;E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!._P#2N,'@5!XTN?$
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MW7UOXH6W!"IKTVB@"O:6L5G D$"A(T& !5FF\ \GK3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 3%+110 F,48HHH ,48HHH 6DQ110 M&.:** $(I:** $QS2T44 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gmz2lq4320rk000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -R!-P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&NU7D&1[U3TWP=XAN]22;Q+?V]U$@!58EV\CIW->B44 ,1 J*O91@4[K2T4
M)S1M'H*6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!
M-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_
M*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&U?0?E2TA_6@ VKZ
M#\J-J^@_*B@4 &U?0?E1M7T'Y4G/K2^E !M'H/RHVKZ#\J"2!THSQ0 ;1Z#\
MJ-H]!^5 I: $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:*
M$VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#
M\J6B@!-H]!^5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^
M5&T>@_*EHH 3:/0?E1M'H/RI:* $VCT'Y4;1Z#\J6B@!-H]!^5&T>@_*EHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 AZXK%\3N\>CR%/O8/'K6T?2L_6+0
MWFFR1CJ%)&/I0!Y[H'B'Q)8Z+BV\/>="K,?,W&NT\,Z[)K5IOGMQ!,!ED!Z5
MR>F^+++2-)ETF\$JW7S858R0<].:OZ%))H^C7&K.IS)'D)B@#NSTSCFN$\6W
M7]KWT6C6OS._S$CJ,&KNJ>*S%X5^WHC><T>X+M-<SX:\4:!9N]S=2W+74C9^
M:(G;GL* -;6K;RK^S@D.=JQ]?7BMKQ2H_L5!U(&1^58GBF6.[@AU>U,AC5US
M\O88J#4?%MEK\=K8Z?YK2!P)-T9&!0!UGA(EO#=H6Z[:VJIZ7:?8K".W'1!Q
M5R@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $(SSZ5&S@ L0?E]*?SGBE- 'G^H>(/%&L7<D?AB&*-8F*.;M-N3[9[55_X0
M#4_%"^?XKO)(;D<8LIBBX'3H:]("(G*HH)ZX%*2J*2> !DT >:?\*4T3/_(4
MU;_P+?\ QI#\&=*B!>#4]4,J\KNNGQG\ZTM;^)EGI6HO9P:9=:@R=3;<C^55
M;+XL6UQ>PV]QH6H6:R-M\R884?I0!7CM?B/I#>1;M8/I\/$9<AG*^]=CX<U[
M^V;1R\,D<T+;)=Z%06]O:M>&:.Y@66-@Z.,J1T-/6-%^Z@7/7 Q0 ^BDI: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y#QI83/!'=PKN:-U8C&> <UA7GBJ/Q)%;Z?;VEVDBOAV>%
ME&.G7%>DL@<88 CT--6")6R(D'T44 <I)J,_AW^SM-CB>16?8S!"V/QJ76O&
M.GZ5MCO+*YFWCHD!<?RKJ"B$[F521TR*:T,;D%HT;ZJ* .&TUSXEU6.]M[8P
M6D:E"KQ[#^55KRZ7PAXC-U-#<2P-'C]TA?D_2O0UC2,?(BJ/0#%#11M]]%;Z
MC- ' Z5<MXH\1/=I!+';J RB5"IR/K7H5,2)$^ZBK]!BGT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "'VI,#'-+28_*@"NUG:/)DVL!;U,8J7R(O+V&--O]W:,
M?E4GO01G\* *;OIH4PRO: #C8Q7C\*AV:*> MA^ 2O,?&7@W4[:74-;-X/L^
M[?Y8)SC\ZR/#'A34_$=LUU;7HC6*0 AR?\: /<A!"T83RHS'V&T8IB6-I&^Y
M+6!3ZK&!3[6,Q6D,3\LB*I/J0*EH ,44=Z.] "T4@I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $Z4Q@Q! ./0T[H>>]!.%YXH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %)WI:3O0!S?C[_D3;__ '*P?A)_R KO_KL/
MZUO>/O\ D3;_ /W*P?A)_P @*[_Z[#^M 'H=%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_%O2H[V2SAL-0>16VAUMV*'\<5T_ARZU>\M7GU-8U#MNA"C!V>_O0!NTM%%
M"9H!!I/XJ.><_I0 N><4#/>HI+B"$?OIHX_]]@*>K*PW*P8'H0<B@!U+2<9I
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O%]-_Y*XW_7Q_A7M%>+Z;_P E=;_KX_PH ]G(R,48I:* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D[TM)WH YOQ]_R)M_\ [E8/PD_Y
M 5W_ -=A_6M[Q]_R)M__ +E8/PD_Y 5W_P!=A_6@#T.BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $QQGO2>A/6
MG44 1201R_ZV-'_WE!KF];\ :!X@E\V]AEW 8_=/L'Z5U!Z]:3'''% ' _\
M"G/"/3R;O_P(-.C^#_A**0.L-WE3D9G-=[VI >.N30!2L='L=/MHX(+=-B#
MW*"?SJ\!@8  'M2<C/>E% !2T44 -Y'TJ*YF,,#2>E39ZU%,L;0L)L>6>N:
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M\]#1_9(_YZ&M*B@#-_LD?\]#1_9(_P">AK2HH S?[)'_ #T-']DC_GH:TJ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@"QIVH0:I9QW=L6,<@W+N&#5RF)&D2!4144= HP*<* %HHHH **** "BBB@
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M<GI2$\>M #J*3'-+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+8$;1=G[@'K7I.AP00:9$L$BR+M&67O0!I4444 %%%% !1110 4444 %%%%
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M\3:QJ.EV06SLI;B1EYD3^&@#IJ*Y/P3JM[J=I.]](S2+)@!NJ^U=90 4444
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MNRM!$6- B !1T [4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH]LK1EI'9 1C.,XJEXI#JMIJFTE5D#. .@H C_X3'Q':W$"WWAT6\+M@ON/
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M "#A_NUU8O>/J3$S.^*.E':CVKM6Q)Z+\(9I(==NBBY/DCM]:]H_M"Z_N?\
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M+K^Y_P".UK87T'Y487T'Y4 9/]H77]S_ ,=H_M"Z_N?^.UK;5]!^5&%]!^5
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MH%7@1^E:/]H7/]S_ ,=H\-@'P]9' YCK6VKZ#\J^7J:S9[$/A1D_VA=?W/\
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M% !1110 4444 -(KSCXE_P#'Q9?[I_G7I!Z5YO\ $K_CXLO]TUT87^(C"O\
M"><LQW'FDW'U-#?>-)7T<4K'EMNXNX^M&X^M)11HAMLDC8E@,]:]6^&W_()N
M/^N@_K7E$?\ K%KU?X;?\@FY_P"N@_K7!F%O9Z'1AFW,[:CO117A'I"T444P
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6DI:2A
M ?.7Q6_Y'NZ_W%_K7$UVWQ6_Y'NZ_P!Q?ZUQ-?1X7^%$PEN3VG_'ROUJ74/]
M:OTJ*T_X^5^M2ZA_K5^E92_WA#?PE.M/P[_R,6G_ /79:S*T_#O_ ",6G_\
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M9_Y#MA_UT%>YCI7A8_\ B'HX;X1U)2TE<)U"T444 %%%% !1110 E><?$O\
MX^++_=/\Z]'KSCXE_P#'Q9?[I_G71A?XJ,*_P'F[?>/UI*5OO'ZTE?1H\P**
M**?00^/_ %BUZO\ #7_D$W/_ %U']:\HC_UBUZO\-?\ D$W/_74?UKS\P_A'
M3A?C.WHHHKPST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 2BBB@!:2EI*$!\Y?%;_D>[K_<7^M<37;?%;_D>[K_ '%_K7$U]'A?
MX43"6Y/:?\?*_6I=0_UJ_2HK3_CY7ZU+J'^M7Z5E+_>$-_"4ZT_#O_(Q:?\
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M 4444 %%%% !1110 4444 %(:6D- "T444 5-4_Y!=W_ -<7_P#037R7<_\
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M_O&FP!&!WX H ]6L+"VTVTCM;2,1PQ#:JCL*MUGZ/J46K:9;WL.-LR[N*T*
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MR5[<+:'&?+%>'CK<YZ&&V*G]K#_GD?SH_M5?^>9_.KOV6'_GFM)]E@_YYK7
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MSR6H**?]K#_GF?SH_M8?\\S^=7/LL'_/):/LL'_/): *?]K#_GF?SH_M8?\
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M_P"1BO/^N(_K7NU>$_!7_D8[S_KB/ZU[O7S^-_BLVCL%%%%<A04444 %%%%
M!1110 AZ5XKXS_Y&6]_WJ]J/2O%O&?\ R,M[_O5VX'^(<N)^$YFDHHKWD>?T
M"BBBCH);&YX9_P"0[8_]=*]S'2O#/#/_ "';#_KH*]S'2O"Q_P#$/1PWPCJ2
MEI*X3J%HHHH **** "BBB@!*\X^)?^OL_P#=/\Z]'KSCXE_\?%E_NG^==&%_
MBHPK_ >;M]X_6DI6^\?K25]&CS HHHI]!#X_]8M>K_#;_D$W/_70?UKRB/\
MUBUZO\-?^03<_P#74?UKS\P_A'3A?C.VHI:*\,](**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6DI:2A ?.7Q6_Y'NY_P!Q
M?ZUQ-=M\5O\ D>[K_<7^M<37T>%_A1,);D]I_P ?*_6I=0_UJ_2HK3_CY7ZU
M+J'^M7Z5E+_>$-_"4ZT_#O\ R,6G_P#79:S*T_#O_(Q:?_UV6NJI\#$CZP'2
MEI!TI:^7-PHHHH **** "BBB@ HHHH \^^)G^IL_]XUYBY^<FO3OB9_J+/\
MWC7F+_?->[@/X1YF)^,;WHHHKNZ'.@J6'JQJ*I8>K4I;#6Y[MX;_ .1>LO\
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M+U/B9[$/A04E+25)0M%%% !1110 4E+24 8/C'_D5[S_ ':\1F^\*]N\8_\
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MNUXC-]X5[=XQ_P"17O/]VO$9OO"O7RW9GGXO<CHHHKU3D04=J*.U(#K? O\
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M^"O_ ",=Y_UQ']:]WKY_&_Q6;1V"BBBN0H**** "BBB@ HHHH 0]*\6\9_\
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MA[FYK;E]11N7U%9/]GW7]_\ \>H_L^Z_O_\ CU(#6W+ZBC<OJ*R?[/NO[_\
MX]1_9]U_?_\ 'J -;<OJ*-R^HK)_L^Z_O_\ CU']GW7]_P#\>H UMR^HHW+Z
MBLG^S[K^_P#^/4?V?=?W_P#QZ@#E?B7S#9XQ]XUYB_\ K"#7H?Q MI8H+/>V
M<,>]>>/]YJ]W _PCS,1\8WO1117=T.=!4L/\7K452PCYC2EL-;GNOAML>'K'
MD?ZOUK6W#U'YUR^@V5P^B6C*_!3CFM+^S[K^_P#^/5\Q4^-GL0^%&MN'J*-P
M]163_9]U_?\ _'J/[/NO[_\ X]4%&MN7U%&Y?45D_P!GW7]__P >H_L^Z_O_
M /CU &MN7U%&Y?45D_V?=?W_ /QZC^S[K^__ ./4 :VY?44FX>H_.LK^S[K^
M_P#^/4G]GW/]_P#\>H K^,6'_",7G(^[7B<WWA7K?BJTGC\.W6YLC;ZUY'-]
MX5[&7;,\_%;D=%%%>H<B"CM11VI =;X%_P"1EM_3:?Z5[$&&.H_.O&/!D;2>
M(( AP=I[UZB+"Z_O_P#CU>#CE^\/2PVQK;AZBEW+ZBLG[!<X^_\ ^/4?V?=?
MW_\ QZN(Z36W+ZBC</4?G63_ &?=?W__ !Z@6%R&!+_^/4 :U&::@VH :=_%
M0 M%%% !1110 4444 %%)GM2?R% "UYWXS\*:A)K"Z]I,B)/&H# C)91U KJ
M+[QCX>TR?R;W5K>&3^XY.:Y:?XP>'X]?&GI<1- 4W?:0WR_2@#SS7?$>H:AK
MEM=-X?U$F"12Q"=<5O:A>:W\1KR*SMK&XT^QB;]\MRG+J>P->ACXA^$BH/\
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M?C>(C'\V/KFNST'51JNGHY!$@'SY]: -5:6BB@ HHHH **** "BBB@!****
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M,=_%/2PWPA2TE+7&=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 )SF@GMWI/;O1GD9ZT +VH.>U<]KGC#3="($Y:5B?NPC<1^5:N
MGZG:ZE;K-;RJRL,X##(H N9I:3O2T %%%% !1110 4444 %)BEHH AN+2"[3
M9/$LB^C#-5X-&TVU??!90QL.ZKBKU% !1110 4444 %%%% !1110 4AI:0T
M+1110!4U3_D%W?\ UQ?_ -!-?)=S_P ?4W^^W\Z^M-4_Y!=W_P!<7_\ 037R
M7<_\?4W^^W\Z]/+OB9G,BHHHKV3-!0>E%!Z4@/3?@K_R,=Y_UQ']:]WKPCX*
M_P#(QWG_ %Q']:]WKY_&_P 5FT=@HHHKD*"BBB@ HHHH **** $/2O%O&?\
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M%:?AW_D8M/\ ^NRUF5I^'?\ D8M/_P"NRUG5^!C6Y]8#I2T@Z4M?+FX4444
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MQ:3&HGMPZ4M9G]JC_GF?SI?[6'_/,_G7@FII45F_VL/^>9_.C^UA_P \S^=
M&E16;_:P_P">9_.C^U5Y_=DXH TJ*S/[5&/]4:7^U0/^69_.@#2HK-_M8?\
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M8?\ /,US&YI45F_VL/\ GF?SH&JJ3S&<4 :5%1Q2B5-RT_ZT +1110 4444
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M<51U3B!?K0 ZS@B>U5B@R14_V:#_ )YK3+'FT3Z58Q0!%]E@_P">2T?98/\
MGDM34E $7V6#_GDM)]EA_N#Z5/24 0BU@_YY**/LL'_/-:FHR,XI7 B^RP?\
M\UI/LL'_ #R6ILT4P(?LT./]6HH-K#_<%38YHHU#0A^RP?\ /):/LL/_ #R6
MIJ*+A<A^RP?\\EJ.XMXEMW(0<"K5177_ ![2?2D@*&FQ)('W(.#5_P"RP?\
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M_GDM'V6#_GDM2YQUHR* (OLL'_/):/LL'_/):ESQFB@"+[+!_P \EH^RP?\
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M]*8%/2?NR?6M*LW2?NR?6M*@ H/2BB@!F*7V-5-3OTTVPENY$++$NX@5PO\
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MGTL1.)83@MG@UO=:  =*6D&.U+0!'-_J'^E9^E?>D^E:$W^H?Z5GZ5]Z3Z4
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ME^'?^$;\+7UK]I:X)BD8NPYR5-<SX/\ ^207O_;:@"C\--#\22>']*O8M?\
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M""JFH_\ 'HWUJW534?\ CT;ZT ,TO_CV_&KU4=+_ ./;\:O4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0!7OO^/.3Z5#I
M7^H;ZU-??\><GTJ'2O\ 4-]: +]%%% "8Q5#6-)BUC3I;.5V1)!@E>HK0HH
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M*Z^BB@ HHHH *ANO^/:3Z5-4-U_Q[2?2@"GI/W9/K6E6;I/W9/K6E0 4444
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MFG67]GZ=!:><\WE+M\Q_O-]:MT44 %%%% "5D1_\A4_[U:]9$?\ R%3_ +U
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MQ[7_ )"1^IK8H .]%%% !1110 4444 )1@XI:* $ Q2T44 %%%% !1WHH[T
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M:,T +129XHSD9% "T=Z2CO0!2U/_ (]?QI^G?\>:_6F:G_QZ_C3]._X\U^M
M%NBDS2,VT9/2@!U%8>C:\-4GN(L &*38,4>(->71(HG8##R*GYF@#<HJ*&59
MHED7HPS4F: %HI** %HI*0-GGM0 ZBDS03@9H 6BDS1DXH 9-_J'^E9^E?>D
M^E7YVQ V?2J&E?>D^E &I1124 +16%+XACB\0C36Z%-V<<UHZA>BQL9+@]%7
M=0!<HK*T+6$UG2XKM>KC)%:F: %HI-U&: %HI ?6C- "T4A-&: %HI <T9H
M*R(_^0J?]ZM>LB/_ )"I_P!Z@#8HHI,T +16-KFMC2!;< F638<UII.'@\T=
M,9H FHK"T?Q"FJW][;+C=;OLK<S0 M%)FC/- "T4F3FC)H 6BDS2%O2@!U%-
MSD<4N: %JIJ/_'HWUJUSFJE^0;1L>M #=+_X]OQJ]5'2_P#CV_&KU !1110
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MW[2.M=%]:3/M]* !0=N.F*K:A_QZ-]:M#ZU5U#'V1OK0 S2_^/;\:O51TO\
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M 8HHHH *3%+10!CVO_(2/U-;%8]K_P A(_4UL4 %%'>B@!,48I:* "DQ2T4
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M);:/[1+$"9=OS9^M Q/ TRMI^J2QOD-,2I_ US^FZ+K_ (DGN94\2WELJR.
MB8QP3[5M^!+=;;2=4B!)"RD GZ&N:T.]\7P3W::)IUM<0F1_FDDP<Y/M0!N>
M$KW4=(\3W>CZC?RW:Q1!M\GOG_"HM??4_&&O7&D6%[+:V\+8D>/^('UJ[X;\
M-:G'/=ZQK2"*]ECVLBMD#'3^=,\$?\C9K!/M_.@"#0OA5=Z'>^?;^([G!.70
M*/F_2G>+$U6ZU^RTJTU>>T#1'=(F,DC'M7IHQUKRSQQ-J5OXNLWTJ".:Z\H[
M4<X!Z4"*&KZ;K_A.>UN6\1W=ZCR(IC? ')'M7K5G*9[6.1A\Q49_*O)A/?:M
MXB@A\6(+)E561(3N4XZ>E>O0JBQH$^Z%&* )**** "BBB@ HHHH **** "J&
MJ_ZA?K5^J&J_ZA?K0!-8_P#'FGTJS5:Q_P"/-/I5F@ HHHH *;T/7-.I#CDT
M <YK7AJXUB]AE.I2Q6Z?ZRW &U_K7$R6,OACQS:6]G=.EM*A9XEZ,<CFN_\
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MB@ HHHH **** "BBB@ I*6DH KWW_'G)]*ATK_4-]:FOO^/.3Z5#I7^H;ZT
M7Z*** "BBB@ HHHH **** "BBCO0!E:[9/?:5-%'][:2,_2O--%\8GPWI\FC
M7EE>/=9;:T<+,O/3G%>O8&>E,-M 3N,,9;U*B@#QNQT_4M6BUFX:%EE>/(RI
M&3D5<L/')M=%70Q8WGV^-?+#&!MF?KBO61$J]$49ZX%)]F@#9$,>?7:* .#\
M!QW0TG47N(F5WD) *X[&IO 44L(NO-C=<SR8R".YKN BH.% ^@H$:J<JH'T%
M "/&)$9#T(P:\LUA+WP7XGDU2&)Y;2Y?YPBEVP/85ZKC!S37BCD^\BM_O#-
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M4T:YL8].U(2RIM4FV<#/Y5>T;59_#?ABWNY;>5H/+W.BQDO^5>A&U@[01?\
M? IYAB9=IC4KZ8XH \F\1>/;?Q+IG]FZ?I]Z+B1E(,UNP7]17H?AJPET_1HH
MI,;V 8_B*U!:VX.1!&#ZA!4F,?2@!:6DP>]+0 54U'_CT;ZU;JIJ/_'HWUH
M9I?_ ![?C5ZJ.E_\>WXU>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DI:2@"O??\ 'G)]*ATK_4-]:FOO^/.3Z5#I7^H;ZT 7
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0=*IZC&TD2A?6KE!QWH @LU*6R*W4"I^]'':B@!:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q[7_D)'ZFMBL>U_Y"1^IK8H **.]% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ,F!,+ =Q5'38GB9]RD9%:--Y]* '44E+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534?^/1
MOK5NJFH_\>C?6@!FE_\ 'M^-7JHZ7_Q[?C5Z@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *2EI* *]]_P ><GTJ'2O]0WUJ:^_X
M\Y/I4.E?ZAOK0!?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ I <T&@<#B@!:*0=:6@ I.]+2'&<4 &<=:.,TG.:4C
MF@!:*** $Z49H/6D- "T9I.G)HR!^- !DYXZ=Z=33TIPZ4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]K_R$C]3
M6Q6/:_\ (2/U-;% !11WHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110!CVO_ "$C]36Q6/:_\A(_4UL4 '>BBB@
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MB@ HHHH **** "BBB@!.@H/2BB@#*MT<7Y8CC)K5Z"DV '('-+VH 6BD[TM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=04M:,%'.:M4A&>M
M%/3%9;;##G-7,T@'8#%+WH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gmz2lq4320rk000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /6!"X# 2(  A$! Q$!_\0
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M/Y4NQ_[_ .E9_P!IE_O4"ZE_O4 :&U_^>GZ4FQ_^>GZ51^U2_P!ZC[3+_>H
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M T-C?WS^5&QO[Y_*L_[3+_>H^TR_WJ -#8W]\_E1L;^^?RK/^TR_WJ/M,O\
M>H T-C?WS^5+L;^_^E9WVF7^]2_:9?[U &AL;^_^E&QO[_Z5G_:9?[U'VJ7^
M]0!?V/\ WS^5)M?^^?RJC]JE_O4?:9?[U %_:_\ ?_2C:_\ ST_2J'VF7^]1
M]IE_O4 7]K_\]/TI"KCD/D^]4?M,O]Z@74GK0!8%T%E$<V$8G ]ZL@\5AZA(
M982#Z<&K6B7S7MB"Y)=#M8_2@#4HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .=UQC_:=NN>-I./RJ6+[E0:[_R%;?\ W3_2IXON4 24444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %)2TE !17->(/%]OHUTEG&GG
M73C.T'A1[UECQIJ!_P"72+_OJI<TCOHY;B*L>>*T.ZHKA?\ A--0_P"?2+_O
MK_Z]'_"::C_SYP_]]4N=&O\ 9&)['=45PO\ PFFH_P#/G%_WU2_\)GJ'_/I%
M_P!]4>T0?V1B>QW-%<-_PFFH?\^D7_?5'_"::A_SZ1?]]4>T0?V1B>QW-%<-
M_P )IJ'_ #Z1?]]4O_"9W_\ SZ0_]]?_ %Z/:(/[(Q/8[BBN&_X3._\ ^?2'
M_OK_ .O2_P#"9W__ #Z0_P#?7_UZ/:(/[(Q/8[BBN&_X3.__ .?2'\__ *]'
M_"9W_P#SZ1?G_P#7H]H@_L?$]CN:2N'_ .$SO_\ GTB_[Z_^O1_PFFH?\^D7
M_?5'M$']CXGL=Q2UPW_"::C_ ,^<7_?5'_"::A_SZ1?]]4>T0?V1B>QW-%</
M_P )G?\ _/I#_P!]?_7I/^$TO_\ GTB_/_Z]'M$']D8GL=S17"_\)I?_ //I
M%^='_":7_P#SYQ?]]4<Z#^Q\3V.YHKA_^$TU#_GTB_[ZH_X334/^?2'_ +Z_
M^O1[1!_9&)['<T5PW_"::A_SZ0_]]?\ UZ/^$TU#_GTA_P"^O_KT<Z#^R,3V
M.YI*X;_A,]0_Y](O^^O_ *]6M*\;QW&HI97L2PR2'",#P3Z4*:9%3*\13CS-
M'7TM)2U9YU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
M[444 5KS_55%X28YO4S\HDR!^=2WG^JJ'PE_K+[_ *Z#^M '3BEHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .:UW_D*6_P#NG^E6(C\E5M>_Y"EO_NG^E31'
MY* )\T9IF:,T .S1FJMQ=QV\D2NP7S&QD]JL_NO^?J#_ +[% #LBC--_=?\
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M+_>-)_:TO]XUG44:@:7]K2?WC1_:TOJ:S:*-0-+^UI?4TG]K2>IK.HI :/\
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M8H 3-&:/W/\ S]P?]]BC,'_/W!_WV* #-&:,P_\ /W!_WV*,P_\ /W!_WV*
M#-+FDS#_ ,_<'_?8I/W7:[@_[[% "YHS2,80I/VN#C_;%5;.]2\1WC.55BN?
M6@"YFC-,S1F@""\/[HU%X1_UE]_UT']:?>']U3/"/W[[_KH/ZT =11110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <QK__ "%+;_=/]*DB/R5%XA_Y"EM_NG^E
M+$?D% %C-&:CS1F@"GJFG+J4:HS%=O(P:Y?6]"^Q6\3QSOEI I^8^M=IFL/Q
M,?\ 0X/^NR_SH 8_A5%*#SGY0-]X]Q2?\(M'_P ]G_[Z-=),?FB_ZY+_ "%1
MYH Y_P#X1>/_ )[2?]]&D_X1:/\ Y[2?]]&NAS1F@#GO^$5C_P">TG_?1H_X
M16/_ )[2?]]&NAS1F@#G?^$4C_Y[2?\ ?9H_X16/_GM)_P!]FNBS1F@#C]6\
M.K::=+,D\@9<?QFK4/A9'M;60SR9DCW'YSUK2\0'_B33?A_.M&#_ )!]C_UQ
M% &%_P (M'_SWD_[Z-'_  BT?_/>3_OHUT&:,T <]_PBR?\ />3_ +Z-)_PB
MJ=YY/^^C719HS0!SO_"*Q_\ />3_ +Z-'_"*I_SWD_[Z-=%FC- '._\ "*Q_
M\]Y/^^C5:_\ #*PV,TBS2;E0G[QKJ\U3U4_\2NX_ZYG^5 T> 7BE-2F#,6.>
MII14FK(\6JL74@/RI/>J_P V:Y))W/OLOJ16'BKDE%1_/ZT?/4V9V^TCW)**
MC^?UHPWK19A[6/<DHJ/Y_6CY_6C4/:Q[DE%1_/ZT8?U%%F'M8]R2BH\/ZBC#
M^HHLP]K'N245'\_M1\_M19A[6/<DHJ/#^M'S^M%F'M8]R2BH_G]12?/ZT68>
MUCW):*C^?UH^?U%%F'M8]R2BH\/ZT8?UHLP]K'N245'\_J*/G]119A[6/<DH
MJ/YZ/G]:+,/:1[DG:JQ7=>6Z_P!Z5!^HJ7#^M%I&]QJ]I%&I9O.4D#TR*J*=
MSFQ=2/L9:GL]IX:5K6,^<_*@_>-3_P#",+_SWD_[Z-;-G\MK&/10*GS77T/S
MZ7Q,YW_A%8SUFD_[[-'_  BD?_/:3_OLUT6:,T$G._\ "*1?\]I/^^S1_P (
MI'_SVD_[Z-=%FC- '._\(K'_ ,]I/^^C1_PBD?\ SVD_[Z-=%FC- '(0>'0_
MB-;(SOY90M]X^]7%\+1\_OI."?XC6C9?\CG'_P!<C_6M$'K_ +Q_G0!S_P#P
MBT?_ #U?_OHT?\(M'_SV?_OHUT.:,T <\/"R?\]G_P"^C2_\(M'_ ,]G_P"^
MC709HS0!SW_"+I_SV?\ [Z-'_"+)_P ]G_[Z-=#FC- '/?\ "+1_\]I/^^C6
M;<:#Y>M6-L)Y-DK8;YC79YK'NSGQ-I?^_0!6;PI&)77SGPIP/F-;.G62:?:B
M&/..O-6I#BXE_P!ZFYH DS1FH\T9H BO#^ZI/"'WK[_KH/ZTV\/[JG>#NM]_
MUT']: .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0_\ 33\Z3_A!(?\ II^=>E;%]*-B^E'*@^MUOYCS;_A!(?\ II^='_""0_\
M33\Z])V+Z4;%]!1RH/K=;^8\SD\#0K&S?O. >]0Z;X*BNM->=O,W+)MZUZ=.
MB^1)Q_":J^'T'_".3G'_ "\?X4<J#ZY6_F.#'@2'_II^=+_P@L/^W^=>D[%]
M*-B^E'*@^N5OYCS;_A!8?^FGYT?\(+#_ --/SKTG8OI1L7T%'*@^N5OYCS;_
M (06+_;_ #H_X06'T?\ .O2=B^E&Q?2CE0?7*W\QYM_P@D/H_P"=)_P@D/\
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M/%7_ "$K;_=/]*J1'Y* )\T;J9FC- #]U9.O8-O!_P!=E_F*T\UE:Y_J(?\
MKJO\Z .COSB2'_KDO\A53=5G43^\A_ZY+_(53S0 _-&:9FC- #]U&ZF9HS0
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MX_8/^^Q7F_\ :%M_SS6C^T+;_GFM'M0_U?AW/2/[9T[_ )_8/^^Q1_;.G?\
M/[!_WV*\W_M&U_YYK^5']H6O_/,4>U#_ %?AW/2/[:TW_G]@_P"_@H_MK3?^
M?V#_ +^"O-_[1M?^>:TO]HVO_/-:/:B_U?CW/1_[9T[_ )_8/^_@H_MK3O\
MG]@_[^"O./[1M?\ GFM']HVO_/-?RH]J'^K\>YZ/_;6G?\_L'_?P4WP[=P3Z
MWJ312HX,1P5.>U>=?VC:X_U:_E5*U\0266NP2V8**\@1P.X)P::JW9CB,CC3
MIN2>Q[%FC=4,;[XU;U%/S6Q\VTT[,?NHW4S-&:!#]U&ZF9HS0 _=1NIF:,T
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M]<QC[+%_WS0/%FNGK:Q?]\T :WE2_P#/-ORH\J7_ )YM^59?_"5ZU_S[1?\
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M4999D('OD4X[G+C/X,CWBUAF^S)^[;[H[>U3>5+_ ,\V_*L:V\5:PMN@%LF
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M>T7/^S3]-\_R6>X/[QV+&@#0S1FF9HS0!%=']U5_P']R^_ZZ?XUF79_=UI>
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MP5:_LK4/^?8?G1_96H?\^P_.CD8?VI0[E7S!1Y@JU_96H?\ /N/SH_LK4/\
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MZ@"3-&:CW4NX4 /S1FH]U&Z@"3-&:CW4NX4 /S1FF;J-U #\T9J/=07 ')H
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MK^5 'E'FWW_/A<?]\FCS;[_GQG_[Y->K_9H?^>:_E1]FA_YYK^5 'E'FWO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4-PS1V\KKU5"1^5357N_\ CRG_ .N;?RH \\^%'C/5/%S:T-2*'[)*B1[!
MC@[O\*]*'2O$OV?_ +_B?_KXC_\ 9Z]M'2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_S]_I2[I_\ G[_2CV;#ZU$UJ*R-UQ_S]?I1NN/^?K]*/9L/K,#7HK(S<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#7^XWTKQKPC_ ,E!C_ZZS?\ LU>RO]QOI7C?A#_DH,?_ %UF_P#9J /7=14O
MI=VJ@EC"X '?Y37C6A"[T>3[0MM>I.5VDHG:O;J9L7^Z/RH \R_X2/5B,[=2
M_P"^36GX8U75[WQ!Y=P+H6GDL3YP."V1C^M=WL7^Z/RJM?W*V%C-=% 1$N[
MXS0!:'6EKB8OB!#)&'^SJ,C.#,/\*?\ \)[#_P \(_\ O\/\* .SI#TKCO\
MA/(/^>$?_?X?X4W_ (3Z'./LZ?\ ?X?X4 4O&NOSVNJV]O:S%#""[X]:Z/PQ
MK1UK15NI,"1<A\>U>7^(;\:AJTMVQ11(,!5?-=-\.;HIH^J(6R(B2!^% %/6
M?'%Y%KQ^SR%8H&V^7V;L<UZ"NJ(VA#43]TPB0X]<5X)>S^9JDI)R69F'YUZ:
M;X)\+=V3O:,(.>^10!F:)XYNVUU8[B3=;7$N"&YV#VKL_%^L'1M#DEC;$TAV
M1X[$]Z\0M9@MYN!^XX_#FO1/B-?B;3M, /$JF0_AC_&@"[X%\5RZE=-IETY>
M0)OC8\D@=<_I4WCGQ//I3QV=JQC=EW.X/(':N%\ W8A\5V4F<"0&+\\58^(M
MUO\ $5P,G]V G\Z /1?!FNRZYI#2S_ZV)S&S>O _QKDO$/CF]M]8DCMI-D<+
M$!<?>X[T[X97)6+5(<\(@E'X\?TK@M7G\S5GR<[W;K0MP.RMK]]0NVNR<-(
M3CUK92_G50-Q/XURGAT%8,$@X[BNB'2N^G;E/'K7YV6_[1F]:/[0F]:J45=C
M'4M_VA-_>H_M"?\ O54HHL&I;_M";U_6C^T)O4_G52BBP%O^T)O4_G1_:$WK
M52BBP:EO^T)O6C^T)O4U4HHL&I:_M";^\:7^T)O[U5**+!J6_P"T)?6C^T)O
M6JE%%@U+?]H3>M']H3>M5**+!J6_[0F]:/[0F]:J446'<M_VA-ZT?;YO[U5*
M*+!<M_VA/_>-']HS^IJI1181;_M&?^\:/[0G_O&JE%%@+?\ :$^/O5SNL7)B
M*7+DMY;AS[X.:UZY_P 0C-DXSC/%1-*QI2OS(T](\>WO]K0"YDW0RL$*8P%!
M.!_2NZ\4:R^CZ*US#@R-@(3T&:\&BF*3L5.#%A@?I7J/CF\\SPMI@W@^9&KG
MW^6N ]E;#O!?BVYOM2.GW4AD#@LK'J#FM3QOXBET>VCAMWVR2]2.H%>9^#+L
M1^)M/?/#2E2?P-;_ ,3[K.KHF>$CY_'% SJ_ &N2:GITEM<,6FA;J>I!K$\:
M^*;R#57L;2<QK%_=XR:J_#*X5-3N8SU>('\JY?Q3>"7Q)=..C3L![C- 'M/A
M_5EUG1(;T#!88<>C#K7GMQX^NX=>>Y#;K96V^5GC;_C6IX+U#R?!=^=Q'V;<
MV1VX_P#K5YA,X>XD3U4F@#Z U'54L=#?4<;E$>]1GJ2.!7#>'?%=S<^*(UO)
MF,=RI"C. I[ "K&L7YE^&=B2V6F"@GZ&N'L7VZE:S)(J^3(KG)QG!SC\: /?
M!2UQ8\>Q X^SQ_\ ?X?X4[_A/(/^>"?]_A_A0!V5)FN-_P"$]@_Y]X_^_P /
M\*/^$]AQ_P >Z'_ML/\ "@"7QE?ZG8R69L1.8VW>9Y77MBN<_P"$BU;TU+_O
MDUW.@ZQ'K^G?:UBV+N( )S6ML7^Z/RH \?UF\O=7MU2X@OW:,Y3<F0#7=> ;
M>6V\+PQS1M&^XG:PP:Z;8O\ ='Y4N .@XH \S^*?^NM?]P_UKL/!W_(I:=_U
MS/\ ,UQ_Q3_UMK_US/\ 6NP\'?\ (HZ=_P!<S_,T ;M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2O&_"/_)08_\ KK-_
M[-7LC_<;Z5XUX1_Y*#'_ -=9O_9J /9B0%))P!U-5_MUH?\ EXB_[Z%)J1(T
MJ[(X(A?_ -!->.>'YM7U>?[%9^4SQQ[B9#CC\Z /9?MUK_S\1?\ ?0K-U^[M
MFT&] GC+&(@ ,*Y'_A&_%./N6O\ WW_]>D/AGQ.P(9+0@^K?_7H Q?A_I=CJ
MNJ7<=[;K,J(I4-GCK7HH\':!_P! R']?\:Q?!WAC4-&U.[NKQ(E$R@ 1G('7
MWKMQ0!A_\(?H'_0-B_6C_A#] Z?V;%^M;M&* .5U/P;HITRY-OI\23>6Q1AG
M@XKSGPUJJ:0NJ03-@S0&-0>[YQ7MY4%2".",&O--<^'5U-J<EQILD?ERMDJ_
M\'J: ."M]*EO;2\U*/[MFP5_<'_ZYK6;5]W@Z+30?G2<NW^[S_\ 6KTW2/"=
MMIWAR32V.\SJ?-?'4GFN/_X5GJ)O%A-U&+/=DR?Q$>F* .1GTN2TTNROBA"7
M)8Y/U&*O>(-5&JV5@JXS# (R/<XX_2O5-8\+6NI>'5TJ/]WY0'E-Z$5RFD?#
M:XCU2&;49XS;P-N$:?QGW]J .1AA?PWKMHTB -"RR8'%/U"-O$WB@0Q_-Y\F
MX_[HZUZ+XN\%C6Y8KJT98[A!M8'HPIGA'P0=$O)-0O9!)=,NU57[J"@#@_#F
MH-HE_?1.=JRP/&WU4' J[X'T:UUK6+^6]@$T,,? ;IN)_P#KUO:Y\/;BXU*2
MYTZ6-4E.2C_PGUKI/#/AQ/#ND-;AO,F<EI)/4T <3]EALM4N(+>,)&K<*.U7
M/QJMK):QUJ9G!\MSD-BJO]HPY_UR_G7;"2L>36@^=FGQ1FLO^T(/^>R_G1_:
M$'_/9?SK3F1ER,U,T9K+_M"#_GJOYTO]H0_\]5_.CG0<C-.BLS[=%_SU7\Z7
M[=%_SU7\Z.=!R,TN*.*S?MT7_/5?SI/M\/\ SU'YT<Z#D9I\49K,_M"#_GJ/
MSI/[0@_YZK^='.@Y&:F:*R_[0@_YZK^=']H0_P#/5?SI<Z#D9J<45E_VA#_S
MU7\Z7[?#_P ]5_.CG0<C-.C-9GV^'_GJOYTOV^'_ )ZK^='.@Y&:7%'%9G]H
M0_\ /9?SI/[0A_Y[+^='.@Y)&IFBLS[?#_SU7\Z/M\/_ #U7\Z.=!R,T^*,U
MF?VA#_SU7\Z/[0A_YZK^='.@Y&:>:,UE_P!H0?\ /5?SI?[0@_YZC\Z.=!R,
MTZQ]5193%&Z[E>558>H)&:E_M"'_ )[+^=5_-;4-2MK>W&\^:K%@.@!J9R31
MI2@^9%OQOH5IIUG92V=NL,;KA]O<XK&UC6&OO#^G6Q.Z2!"IXZG) 'Y8KUG5
M]#BUS1#92G:VT%'[J:XO3_AO>_VI$U_-']EA<-\G63'2N%[GKK8Y Z8_A_4;
M$N2,B.?Z9P3_ #-7O$$R>*/%BQ6YREPX13]!_P#6KT;Q9X277887MV6*XAX7
M(X(]*S/"?@272]1_M'474S(,1QIR![T <9H=XOASQ%/YP.V,/#P>^?\ ZU4+
M+2Y=9N;R0*SM! TG_ C7H'BCP'<:CJ3WVGO&#)RZ/W/K6QX2\*+X?LI5G=9K
MB<_O& X ]* /-='UC['HFJ69/_'TFU1ZDYK(CTUY+.74P#Y:2",G'6N[U7X<
M7C7\K:;-$MO*Q(#?\LZZFT\'V</A0Z)(=V]27D'7?ZB@#R^ZUGS/"UKIY;)@
M=C^':NY\'>$-,F\.P7&H6,<DTV7W-G.,UC1_#&^>^2*XN(_L2L"SK]YQGIBO
M4;>".WMXX(QB.-0JCV% &./!^@#C^S(?U_QH_P"$/T#_ *!L7ZUNT4 81\'>
M'_\ H&0_K_C7&^/M"TW2]/MY;&T2%V?!*YZ8->GURWC/0KS7+*".SV&2-]Q#
MG - %+X=W,$/AA%DFC1MYX+8KKOMMK_S\1?]]BO/(O"OB2*,*D5H@'0!O_KU
M)_PCGBG^[:_]]_\ UZ .^^W6N/\ CXC_ .^A4L4J3+NC<.OJIR*\EUJ+7="C
MBDO%@V2DJ"K<C]:[3X?RO-X7B=V+,7.2?PH YSXI?ZVU_P"N9_K78>#ACPEI
MP_Z9G^9KC_BG_KK7_KF?ZUV/@_\ Y%/3_P#KG_4T ;E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 -?[C?2O%M D&G>._.N 56.
M:3=QTSG'\Z]JKE->\$0:K=B]MIC:W/\ $5'#?6@"_JNO6"Z3<XF#%XF50HY)
M(Q7 _#*"3^W[J0#Y(X=K'WR*V#X U>7,<VL1^2>/D3G'Y5U6@>';/P]8^1;
MEFYDD8Y+&@#9I,4M% "8H Q2T4 %%%% !28I:* $Q1BEHH 3%&WWI:* $P*,
M<4M% "8I"N1BG44 <[JVAK>'<5!SZUBGPFF?]4OY5W>*-H]!3NQ.*9P?_")I
M_P \E_*C_A$T_P">0_*N\VKZ"C:OI1S,7*C@_P#A$D_YY#\J/^$27_GD/RKO
M-J^E&U?2CF8<J.#_ .$37_GD/RI?^$47_GD/RKN]J^E&U?2CF8^5=CA/^$47
M_GF/RI/^$37_ )Y#\J[S:OI1M7THYF+E1P?_  B:_P#/(?E1_P (FO\ SR7\
MJ[S:OI1M'H*.9ARHX/\ X1-?^>2_E1_PB:_\\A^5=YM'H*-J^E',PY4<'_PB
M:_\ /(?E1_PB:_\ /(?E7>;5]*-J^E',PY4<)_PB:_\ /(?E1_PB:_\ /(?E
M7=[5]*-J^E',PY4<'_PB:_\ /(?E1_PB:_\ /(?E7>;5]*-J^E',PY4<'_PB
M:_\ /(?E1_PB:_\ /(?E7>;5]*-J^E',PY4<'_PB:_\ /(?E1_PB:_\ /(?E
M7>;1Z"C:/04<S#E1P?\ PB:_\\E_*C_A$U_YY+^5=YM'H*-J^E',PY4<'_PB
M:_\ /)?RK6TGP]':2A_+4'Z5TVT>@HP!1=CY4-5 !BG8I:*0Q,48I:* $Q1M
MI:* $Q1BEHH 3 I:** "BBB@ I,4M% !24M% '!_$^-CI-K* 2B2_,?3.*D\
M":G:6GAV.WFE"2!B<$5UU_86^I6<EK=1B2*08(-<2_P^O;:1O[.U01Q$\)*N
M<?I0!C_$?48+V>'R&W*B$%O?FN^\)HT7A?3XW&&$?(_$USEG\.0U]'<ZM?&Z
M$;!EB484GWZ5W4<:QJJ(,*HP !0 ^BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN3UKQU8:+XMTW0YF&^\SEL_=/./SXH ZVBD%+0 4444 %%%% !1110 4444
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M<^"?BG5M3M=0T;5MTLED %E?[P'/RG\J ."\,W_B;5OB]<2+>1/J2EDW2C*
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MQ?;6]M?W5W';P#"11,H&?7D&NOHH Q_#GA^+PWI$.FV]U//;PC;&)B"5'H,
M5RVH_![PUJ7B-M9E6=)G?>Z(^%8_S_6O0:* . G^$/AJ7Q%'K*)-%*A!\N-\
M*2!@>_;UI-8^$FD:WKBZO=ZAJ!ND(,9#KA .@'R^U>@44 <+XF^%NE>*[RVN
MM2O[YGMT"1A64 8QS]WJ<9K6U#P5INK>&5T+4&EN8$4*LDA&\8Z<@8KI*3-
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MC4K;_=/]*AB/R5+XH_Y"5M_NG^E5XC\E $^:,^]1[J-U $F:QO$1_P!'M_\
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M4>ZC=0!)GWHS[U'NHW4 29HS4>ZC=0!)FLR0G_A*--'^U5_=6<QSXITS_>H
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ME6LR1?:!M9W["N?^'G@&]\'Z3>:5=745Q:W'/RC!!_R: /-_@#_R.&L_[O\
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ML_NZO^!/N7W_ %T_QH [*BBB@ HHHH ***I:CJUAI,2RZA=Q6T;':&E; )H
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M,_F:/^$4A_YYG\S1[(/[>AV.1PW]X?G28;^\/SKK_P#A$X?^>9_.C_A$X/\
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M.'EP#ZXS0!VM%(*6@ HHHH *Y+XBZ?J&J^#[O3],M#<W$XVA0X7'/7FNMHH
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MYY)_WS2?\(9IW_/-/^^: .-^VP_WUI/ML/\ >6NS_P"$,T[_ )YK_P!\T?\
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MS1_PA6F_\\8_^^10!QOVV#_GHGYT?;8/[Z?G79?\(5IO_/&/_OD4?\(5IO\
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M:]7T#2DT?2H;5>2!\Q]34UCI-I8+B&)1CT%7J  4M%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %)2T4 %)2T4 )2T44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F:6H;DE
M+69@<$(Q'Y4 2!L]Z<*\E^"WB'5->?Q!_:-V\_V>:-8]QZ [O\*]9'2@!:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ Q1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1244 +1110 4444 %%%% !1110 4444 %5[QE%E/D@?NV_E
M5@UP_P 4=*O]2\'7+Z;<2PW,'[Q?+.,CN* .)_9_<+)XGR<9N(__ &>O;1TK
MY,^#VFZKJOC)8X+B:*UC/FW.TX#8[']:^LD&% ]* '4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%(>E8.I^*+/3IS  9I5'*J0,?C0!O9I:YFW\9V,DZ131M#O. Q8,/TKI
M 00"#D'D$4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* "@56N
MKZVLUW7$\<2^KL!5#_A)]&_Z"%O_ -_!2NC2-*<E>*-FDK'_ .$GT?\ Y_X/
M^_@H_P"$GT?_ )_X/^_@HNBOJ]7^5FQ1S6/_ ,)/HW_/_!_W\%'_  E&C?\
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ML;_A*-'_ .?^#_OX*/\ A)]'_P"?^#_OX*+H/J]7^5FS25C_ /"3Z/\ \_\
M!_W\%'_"3Z/_ ,_\'_?P470?5ZO\K-BBL?\ X2?1L?\ '_!_W\%6[35+*^.+
M:YBD([*X-.Z)E1J15VB[0*2EH,Q:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BD-8>I>)K/3IS;\RS#DJI Q^)XH W:*YFU\96,\Z13(T&\X#%@1G\*Z
M-2& 8'((XQ0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[.'8Z4ZA:X_U:?E5;3O$,UEXELI+0E$>9$8*>""0#6'D^M-M#C6+#_KXC_\
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MF?YF@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:W_S[1_]]?\ UJ^A/[%@_N4?V+!_<H]F@_MBN?/?_"*:W_S[1_\ ?7_UJ/\
MA%-;_P"?:/\ [Z_^M7T)_8L']RC^Q8/[E'LT']KUSY[_ .$4UK_GUC_[Z_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV)7+ZQJOV'25T^'CC,I'4GT% $&EZKJ$NOV4*2'S#(-X0_P@\U["+Y<#Y37
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MA)YP21UZ=*N> /B9/=^&]7.K9EN-*5V#XQYBC./QXH ]8N4DFMW2*8PN1Q(
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MD5[2WP_\+/??;6T:U-SNW>9Y8SGUS3]0\#>&M6NOM5_I%M<3=-\D8)H \?\
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M.0#0 M%%% !1110 4444 %%-8D#BO./^%L1Q>.5\*W&DO'<F3RS()@1UZ]*
M/2:*13D4M !1110 4444 %%%% !12'BO-]<^*\>@^,8O#MUI,AEE=5259AC!
M.,XQ0!Z313$;<BMZC-/H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#E/$O_(3MO]T_TJ.(_)3_ !.<:E;?[I_I4$1_=T 3YHS3,T;J 'YK&\0G
M_1[?_KJ*UMU8WB$_Z/;_ /79?YT =)=G#0_]<E_D*KYJ:].'A_ZY+_(56W4
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M7_EH/7ZC^M>@_"/PY/X<^'Z1W0*S7 :5E/;.2!^M=#X/"2:&ZD!E,S@CKWH
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M 0&*RJ3D'TP17"?'LJ?"&C@$;CM(_(5)X@@N+7]G>QBNL^<(@6W=>7R/T(H
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M2P6DEC>@?/;(5,6?7).:\^^+L5Q'\2M'GER+=A%L)Z#GFMG]H @Z%HJ@\D#
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MZTGVBR'1,9]S1[47^KW]X])_M&TQ_P ?,7_?8I?[1M/^?F+_ +[%>:?:+/\
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M=",T[-;'SS1)NHW5'DT9- B3=1NJ/)HR: )-U(6IF:0F@"#0/^/'5C_TT/\
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MM2NKV/7]0NC=-OE2=8\,?P7-:OBGPW_PE&DR:;)?SVL,@P_DJI+#_@0-;U%
M'FOA/X/6G@[5/MNF:_J0)XDC81[7'H?EKT=HPZ%& *L,$'O3Z* /,KGX.62^
M)GUC2=5N]-\XYEAAQM.>N,@]:AM?@EI=KXC.M)JEZDRR;T52,?B2,UZEFEH
MX7QM\,[;QRUN+_5[V&* ?+'"$QGUY&:W_#GA\^'="ATJ._GN8X4"1R2A=R@=
M.@%;=)F@#S&;X,VDWBAO$+>(-3^WM+YN_;'@'Z;:]&ELTN+%K2X_>QNFQ]W\
M0JS10!SWA+PG9>$=*:RLQD/(TCN>K$UG^./AUI7CFWC%V7@N8O\ 5SQ8W#VY
M[5V-% '!>$?AI%X;E66ZU6\U%HQB)9G^5/H*I:]\'[3Q#XD&N76O:BMTK!HP
MBQX3'0#Y:]*I,T >=^+/A+:>,+ZUNM0UO4%:VC5(U18\# &3]WJ2,UVVDZ<^
MEZ7!9-=2W7DJ%$LH 8@=,X %7LBEH :5)! .,BO-)_@Y:W'BK_A(W\0:E]O\
MSS P6/ /I]VO3:* /-?$?P?M/$WB(:U=Z[J*7"X\L1K'A .F,K70^(O VG^)
M]!BTS4I99)(E 2ZP!(#Z\<5U-% 'GO\ PK!=0N[&37]7N-3@L<"""1553CIN
MV@9K:\7>"H/%NCII<M_<6=JN,K;JO('0<@UU%% 'G^C_  M@T3PS>:#:Z[J
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M_P"@>/R%'_";WW_/@/R% %S#_P!QORHVO_<;\JI_\)M??\^ _(4?\)M??\^
M_(4 69D<POA&^Z>U+I".OA9U*,&\W."/>JI\;7W_ #X#\A31XXO<;1IXQ]!0
M!>"/C[K?E1L?^XWY53_X3:^_Y\%_(4G_  FU_P#] ]?R% %W8_\ <;\J-K_W
M6_*J7_";7_\ T#U_*C_A-K__ *!R_D* +NU_[C?E1M?^XWY51_X3:_\ ^@<O
MY"C_ (3:_P#^@<OY"@"]M?\ N-^5,D5]A^5ORJI_PFM__P! ]/R%-D\:7YC/
M^@)^5 XNS/)_$.?^$CNL]=W]*IAB!U-6=<NWO=?N9Y$V,QY'X55'2N2>Y^A9
M?_N\1=S>I_.EW-ZFDHJ#N%W-_>-&YO[QI**!:B[F_O&C>W]XTE% Q=[>IHWM
MZFDHH%<7<WJ:-S?WC244PN+N;^\:-S?WC28HH 7<WJ:3>WJ:**0Q=[>IHWMZ
MFDHH$+O;U-&]O4TE% "[C_>/YTNYO[WZTVB@-1V]O[QI-[?WC^=)13 -[>I_
M.C<WJ?SHHH -S8ZFH8^-0M?^NR?S%35 )#%?6TBC)29& ]>13CN<N,_@L]VM
ME<VZ?(WW1VJ7:_\ <;\JS+;QK?K;H!8)PH[5+_PF]_\ ] ]?RKL/SN?Q,O;7
M_NM^5&U_[K?E5+_A-[__ *!Z_D*/^$VO_P#H'I^0H)+NU_[C?E1A_P"ZWY51
M_P"$VO\ _H'K^0H_X3:^_P"@>GY4 7L/_=;\J"K_ -UORJC_ ,)K?_\ 0/3\
MJ/\ A-;_ /Z!Z?E0!8\/HZ6&JAD8;G.,CKQ4JA]@^5ORK/\ ^$XOAP-.3\A3
MAXVO_P#H')^0H OX?^ZWY48?^XWY50_X3;4.VG)^0I/^$VU#_H')^0H T,-_
M=;\J-K_W&_*L_P#X3?4/^@:GY"C_ (3?4/\ H&I^5 &AM?\ NM^5&U_[K?E6
M?_PFVH?] Y/RH_X3;4/^@<GY"@#0VO\ W6_*JJQO_P )%IS%'VA^3C@5%_PF
MVH?] Y/R%'_";WHP3IRY'H!0!K7H8WTQ"G!;CBJP;KSSWJF?&M\ZD#3P"?\
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MC_NC\JCB^6("I,UU'Q$M6&Q/[H_*C8G]T?E1FC- @V)_='Y4>6G]T?E1FC-
M!Y<?]T?E1Y<?]T?E1FC- !Y<?]P?E1Y<?]T49HS0 ;$_NBC8G]T49HS0 >7'
M_='Y4>7'_=%&:,T &Q/[HH\N/^Z*,T9H /+C_NC\J/+C_N"C-&: #RX_[HIP
MP!@#%-S1F@!^:,TS-&: (KH_NZU_ /\ JK[_ *Z#^M8MTW[NMCP <PWW_73_
M !H [6BD%+0 4444 %<C\3/^2?ZK_P!<JZZN;\;:3?Z]X9N=,L/+$EP-I:0X
M % 'E?[/6C6=UX?U:YNK>.9GE$7SKGY< X_.N:U*:2U^.L$5K##$L$@2&-OE
M11MQ7JWPK\%:OX&L+JQOG@ECFD\P,C<CC'2LKXC_  IN/$.M1:]H=PMO?IC>
MIX#$="* );OP!KMYX]A\6W-W;121* 8XSU &*X/P7JC-\>[R2^;,DQEB&_L2
MPQ7J_AC1_%T_D-XIOX&AM\;(84P7/JQSS7)>./A'J-WXI'B+PU=+!<LV]T/&
M&]10!VK^!]&T34M2\2Z? ZZE-$W._@$]<#M7DWP+=[CX@ZS-/S,4R2>O4UZQ
MX7TCQ2Q2?Q3J4<IC7:MO NU3[MSR:Y^T^'VI>$_&]SKN@"*>VN5(>W<[2I/I
M0!YWI-Q/:_M"2BV) >YVN!_=.,T[XL!7^,NFJPRI\H8/^_7IG@SX;2:5XEN_
M$VL2))J$[$I&@^5 ?YFL/QC\,?$/B/QQ%K\4MJD<++L0OR0IS0!A_M HJP>'
M % &T#CTYK0^*$:1_!C2@B!0$C/'T%;/Q(^'NO>-O[-6![:%;1!DE\Y-6?%O
M@;7O$7@?3]!C-LCP*HD<OQQTQ0!RRG/[-BY)Z-_Z,K6^!L:/\,+U74$,\F<]
M_O5HV_@'65^%C^%)W@\X-A)%.006SS47ASP=XG\&>'[O1-/^SW<-P,I,6VF,
MGKD<YZT <'\$&FA^).I0Q9,)1PV.GWA4=S_R<;+_ -?9_G7K?P\^'T7@NQN)
MI&6?4[H[I9.P]A[5R4WPQ\1R?$AO%0DM &G,HBW]LYZT <Y\>5#>-](# $&,
M9!^M6_CU&B>&/#P50  P&![+71?$3X;:_P",?$=MJ,$EM%';* H9^34_Q#^'
MNO\ C/3-*LXGMH1:)\Y+YRQP/Z4 2:[I^A:E\(]-_P"$@NGM[>.%6#H>2?2O
M//B)?W5[\-M,\BU,.D1/LMGE;,D@!ZD=OSKT/Q/\.=7\1^ =/T9YXHKNSX^5
MLJXK'O\ X2^(]4\$6^D7FM+)):G]S%C" =>3GF@"'7<_\,\6.3_RS'_H=;GP
M"_Y)_P#]MF_F:O6GP^U"?X:_\(QJMY&TBIB)HUP%YSSSS3/ASX,\1>$-/DT^
MYNH&M5<O&J#!8^Y]* /+_#W_ "<!=?\ 7U)_,U.+FXO/VB&-WG,=P40-V4<#
M]*ZG3/A=XCLOB&_B8RVA#SM(8P_0$FNA\5?#RXO/%UIXJT9HUOHB/-B?A9 !
MZT >>?&R::T^)>CSVO$ZJ"N.N<BNT^.9+?#N-F^]O7/Y59D^']_XE\=0>)-?
M$<45NH$5LAW9(]36K\3/">I>,-"CTS3VAC7=N9I&QB@#SO3XD'[-LY5%!)8D
MXZG K=_9Z)_X1*Z&>EP?Y"K5O\/_ !!#\+I?"9>U\UG.)=_&TBM;X6^#-5\$
MZ=<6-\\,D<C[U:-N<_Y% 'H=%(*6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#CO'-M(;:&[C!/E'YL>E<W9W2R1
MCG.:].N;:.Z@>*10585Y[J7A.\L9V>R^>(G.P]J &^8/6C>/6J)M-64X^R$X
MH^S:M_SZ'\Z +^\>M&\>M4/LVK?\^A_.C[+JO_/J?SH O[QZT;QZU1^RZK_S
MZG\Z/LNJ_P#/J?SH O;QZTGF#UJE]EU7_GU/YT?9=5_Y]3^= %[S!ZT;QZBJ
M/V75?^?4_G2?9=5_Y]3^= %_>/6C>OK5#[+JW_/J?SH^RZM_SZG\Z +^\>M&
M\>M4?LNK?\^Q_.D^RZM_SZG\Z +^\>M&\>M4/LNK?\^I_.C[+JW_ #ZG\Z +
M^\>M&\>M4/LNK?\ /H?SH^RZM_SZ'\Z +^\>M&\>M41:ZKWM3^='V;4_^?5J
M +V\4;AZU1^S:G_SZM1]FU/_ )]6_.@"2>VCF.2*K'2X2>E2?9M3_P"?5OSI
M1;:G_P ^IH'=D7]EP^E']EP>@J7[+J?_ #ZM1]EU/_GU:@+LB_LN#T%)_9<'
MM4WV;5/^?5J/LVJ?\^K4!=D7]EP^U']F0^@J8VFJ]K8_G3?LNK?\^I_.@+LC
M_LR'T%']F0^@J3[+JW_/J?SH^RZM_P ^I_.@+LC_ +,@]!1_9</H*E^RZK_S
MZG\Z/LNJ_P#/J?SH"[(?[,AI?[,A]JE^RZK_ ,^I_.C[+JO_ #ZG\Z N1?V7
M#Z"D_LN'VJ;[-JO_ #Z'\Z/LNJ_\^I_.@+D7]F0^U']F0^U2?9=5_P"?0_G1
M]EU;_GT/YT!=D?\ 9D/I2?V9#Z"IOLNK?\^I_.C[+JW_ #Z'\Z NR'^S(?:E
M_LR'VJ7[+JW_ #Z'\Z/LNK?\^A_.@+D7]F0>@H_LR'T%2_9=5_Y]3^='V75?
M^?4_G0%V1?V7#Z"D_LR'T%3?9=5_Y]3^='V75?\ GU/YT!=D7]F0>@JQ!:Q0
MG(QFF?9M4_Y]3^='V75?^?0_G0*[+N\>HI=X]:H?9=6_Y]3^='V75O\ GU/Y
MT 7]X]:-X]:H_9=5_P"?4_G1]EU7_GU/YT 7MX]:/,%4?LVJ?\^K?G1]FU3_
M )]3^= %[S!ZT;QZU1^S:I_SZG\Z/LVJ?\^I_.@"]O'K1O'K5'[-JG_/JU!M
MM6[6A_.@"]O'K1O'K5#[+JW_ #Z'\Z/LNK?\^A_.@"_O'K1O'K5#[+JW_/H?
MSH^RZK_SZG\Z +_F#UH\P>M4?LNJ_P#/J?SH^RZK_P ^I_.@"]Y@]:/,'K5'
M[+JO_/J?SH^RZI_SZG\Z +WF#U%&]?6J/V75/^?4_G2?9=5_Y]3^= %_>/6D
M,@Q5'[-JW_/H?SI/LFK.,"U(8^] $>HWRQHW/2NP\ 6K0Z&TSJ5,[E^?2L#2
MO!5W>W2SZDQ$:G(C7I^->D00)!$L: !5&.* )!2T44 %%%% !1110 F*,"EH
MH 3%&VEHH 3;1BEHH 3%&VEHH 3%&*6B@!,48I:* $P*-M+10 F!C%&*6B@!
M-HHQ2T4 )BC%+10 FVC%+10 F*,4M% "8H Q2T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9[4M% #/
M*3^X/RH\I/[@_*GT4 ,\J/\ N+^5'E1_W%_*GT4 ,\J/^XOY4>5'_<7\J?10
M SRH_P"XOY4>5'_<7\J?10 SRH_[B_E1Y4?]Q?RI]% #/*C_ +B_E1Y4?]Q?
MRI]% #/*C_N+^5'E1_W%_*GT4 ,\J/\ N+^5'E1_W%_*GT4 ,\J/^XOY4>5'
M_<7\J?10 SRH_P"XOY4>5'_<'Y4^B@"/RH_[@_*E\J/^X/RI]% $?E1_W!^5
M'E1_W!^5244 ,\I/[B_E1Y2?W%_*GT4 1^4G]P?E2^4G]Q?RI]% #/*C_N+^
M5'E1_P!Q?RI]% #/*C_N+^5'E1_W%_*GT4 ,\J/^XOY4>5'_ '!^5/HH 9Y:
M?W!^5'EQ_P!Q?RI]12OY<3R$<*I/Y4 .\N/^XOY4>7'_ '%_*N2\$^.K7QHV
MH"V@:+[$ZHV[OG/^%=>.E #?*C_N#\J/*C_N+^5/HH 9Y4?]Q?RH\J/^X/RI
M]% #/+3^X/RH\M/[@_*GT4 ,\J/^XOY4>5'_ '%_*GT4 ,\J/^XOY4>5'_<7
M\J?10 SR8_[B_E1Y4?\ <7\J?10 SRH_[B_E1Y4?]Q?RI]% #/*C_N+^5'E1
M_P!Q?RI]% #/*C_N+^5'E1_W%_*GT4 ,\J/^XOY4>5'_ '%_*GT4 ,\J/^XO
MY4>4G]Q?RI]% #/*C_N+^5'E1_W%_*GT4 ,\J/\ N+^5'E1_W%_*GT4 ,\J/
M^XOY4>5'_<7\J?10 SRH_P"XOY4>4G]Q?RI]% #/*C_N+^5'E1_W%_*GT4 ,
M\J/^XOY4>4G]Q?RI]% "8]J.U+10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y_QY3_ /7-OY5,:Y'X
M@^)[GPKX<DU"&S-S']R0#^$$'F@#@?V??]9XH_Z^(_\ V>O;:^7O@[XUN-*U
M^ZTVVL3.^J3(V0?N 9_QKZ?3.P9Z]Z '4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WKG_(5M_P#=
M/]*GA^Y4&N_\A6W_ -T_TJ:(_)0!+129HS0 M%)D49H 6BDS1F@!:*;FER/6
M@!:*3(]11D4 +129HS0 M%)D49% "T4F11D4 +129%&10 M%)D49% "TUC@$
M^E+D4R5AY;4 <O)J0;77:1=R1_*!6_'JELR A5%<:>=4N?\ >JWDUVP@G$\B
MM)\[.I_M*W_NK^5']IV_]U?RKE^?6CGUJ^2)ESLZG^T[?^ZOY4G]I6W]Q?RK
ME^?6C)]:.1!SLZC^T;;^XOY4?VE;_P!Q?RKF,GU-)D^IH]F@YV=1_:5M_<7\
MJ/[2MO[B_E7+Y/J:,GU-'LT'/(ZG^TK;^X/RI/[1M?[@_*N7R?>C)]Z/9H.>
M1T_]HVO]P?E2_P!I6W]Q?RKE\GU-&3[T<B#GD=3_ &E;_P!U:/[3M_[B_E7+
M9/J:,GWH]F@YV=3_ &G;?W%I/[2MO[BUR_/K1D^IH]F@YY'4_P!I6W]Q?RH_
MM&U_N#\JY;)]31D^IH]F@YY'4_VE;?W%_*D_M.V_NK^5<OD^IHR?4T>SB'/(
MZC^TK;^XOY4O]I6W]Q?RKELGWI<GU-'LT'/(Z?\ M*V_NK^5']IV_P#=7\JY
MC)]:,GUHY$'.SISJ=MCE5KF-6UC;J$$MNNW$BJ2.XSS2$GUK(U([7A_ZZK_.
MIE!)&E*3YD>CQMYD:MZC-/JO:L/L\?/\(J;</6N)GKK8=13=P]:-P]:0QU%-
MW#UHW#U% #J*;N'K2Y% "T4W-+D4 +129%&10 M%%)0 M%%)0 M%)FC- "T4
MF:0,"..W6@!U'>DS1F@""\_U55_"7^LOO^N@_K4UX?W50^$?]9??]=!_6@#J
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#F=>_Y"EO_ +I_I4T1_=U!X@XU
M2W_W3_2GPGY* +&:3-,S1GWH S-:FNX?(DM!ED8DCUK,NO%NJV<:M+:Q@,0H
M^7O72G:W4 U@^*%3['!\H_UR_P Q0 I\1:T"!]DBY /2C_A(M;_Y](ORK>E1
M,Q?*/]4O;V%-VI_='Y4 87_"0ZU_SZ1?]\T?\)#K?_/I%_WS6[M3^Z/RHVI_
M='Y4 87_  D.M_\ /I#_ -\T?\)#K?\ SZ0_]\UN[4_NC\J-J?W1^5 &%_PD
M6M_\^</Y4A\1:YVLX?\ OFM[:G]T?E1M3^Z/RH YNX\5:S;0--)9Q!5Z\5(G
MB76GC1_L<6'7<ORU<\0HG]BS?*.W;WJ_;(@T^Q^4?ZD=J ,?_A(M;_Y\XO\
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MVK)^K0.-^T7G_/-:7[1=_P#/-:['^RH?[H_*C^RX?[H_*CVK#ZM X[[1=_\
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MHKDO$'Q%T#P]=+9S7#7%ZQXMK==[_P"%1)\0K:&)9M3TK4=.MVY\^>,;,?\
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MG_B7S_[A_E4^:JZB?^)?/_N'^5 %G3_^1;L?]X_UJ3-0Z>?^*9L/]X_UI^:
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MM,^.&EWNFWUU)92QM;<+$OS%S77^*=+L;7PYJ]S!:Q1SR6S!Y%7#-P>]>/\
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M0?E6AFC-(9G_ -C6W]T?E2?V-;^@_*M'-&Z@#._L:W]/TI?[&MO0?E6AFC-
M&:VAVK'.*<-&MNF*T,T9H S_ .QK?TH_L>W]!6AFDS0!0_L:W]*7^Q[?TJ]F
MES0!G_V/;^@_*E_LBW]/TJ_FC- %#^R+?_(IK:+;MUK1S1NH SQHUN!C&?PJ
M]!$EO&$08%.S1F@!^ZC-,S1NH BNF_=UK> ?]5??]=/\:QKH_)6OX _U-]_U
MT']: .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+IMG-,)I;:-Y5Z,1R*MT4 1M"DBA74,H.0"/2HH["UBN&GCMT65NK@<FK-%
M%-M+LGN?M#6L1FS]\KS5L4M% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %)BBB@ Q2T44 %)BBB@ P*6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** #%)BBB@ Q1BBB@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gmz2lq4320rk000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )?"$\# 2(  A$! Q$!_\0
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M6@ HHHH **3-% "T44E "T44A- "T4E+0 4444 %%%% !129YHS0 M%(#2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44F:,F@!:*3-&: %HHI,T +129H!YH 6BBDS0
M M%)FC- "T4F:6@ HHHH **** "BBB@ HHHH **3-&30 M%)FC- "T4F:!0
MM%%)F@!:*3-+0 44AZ49H 6BDS1F@!:*2C/- "T44E "T4F:6@ HHHH ****
M "BBDS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWE6.0H9 "!M)'..?TJT^GK\-OC/IEAH<LB:;J(P]L7+ #'O[]Z /4]&?7O\
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M:XDFB65[8"5@L14GHH..<=_6M3P7:0^*/@CJ4&KA[E;#S&@+2,"I"DCG/8T
M>A_#7QV?&FF7%U=/;PS^>5BMU<;@@ [=377RZMIT$_D37]K',?\ EF\RAORS
M7@WPJTZPTGX>:QXL@MO^)O;),L<V\\#9QQG'?TKB=,FT_5=$O+O4/#OB'4]:
MG9FAU"#>R1-VQ@]C0!];37,%O"9IYHXHAU=V"K^9JNVLZ9&D;OJ-HJ2#*,9U
M ;Z<\UX>^H:M>_L]:@FLPW,=Q;R&)3<H5=E !!.>3U/-9EMX"TRY^![:_=/<
MR:A% 98':9L1@=%"YQC\* /HTRQB/S-Z^7C.[/&/K52'6=+N)?*AU&TDD/\
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MT]POVA_E[<9Z\]>E= -4T_S)$^WVV^(9D7S5RGUYXKQG6O\ DYC2\_\ //\
M]HFL/P]X;M_$_P 9O$%G>R3"T7<TL44A02#L"00<9H ^AK:_L[U2UI=0SJ."
M8I V/RJ?%>"_#RT'AGXVZOX?T^20:<$.(F<D#Y-W\Z][H \(\9?%C7?"OQ/_
M +.:XC;1XG0RP^2N[;GGYL9KK_BEXSU#P_X+M-8T"ZC1YYD D**X*GZ\5YSX
MG\.P>*OCK?:1<,5$ULP5O[K8X-<OK?B*>+P')X,U,.M]IE\HCW?Q)Z?AC]:
M/J'1;]KCP[9WUY*H>2%7D=L*,X_(5;M=2L+UBMI>VUP1U$4JOC\C7@?Q0U^Z
MMO#OA31HFN1:W,(DG2W/SR 8X'YGBL"*X.E>*-*OO!WA;Q%I2HX6YCGC=DE!
M('/7WH ^G)+^SBN4MI+N!)W^[$T@#-]!UHFU"SMYDAGNX(I9/N))(%9OH#UK
MQ/QGD_M >'#W*CC_ (!2_%K_ )*MX2^H_P#0J /:Y-1L8;C[/+>6Z38SY;2J
M&Q],YI;:_L[Q6:UNH)U0X8Q2!@OUQ7@'Q"TG^V_CKIVGF62-)D4,T;;3MVY(
MR/49%;GQ+L[3X<>!AIWAE'LCJ=R$>19"6'3/).>10!Z]'J^FRS^1'J%J\V<>
M6LREORS4US>VED@>ZN88$)P&ED"@_G7AOB'X7Z7H?PZ&O:?<7,.M0Q+</=B9
MLN>I'6LOXAZY/XA^"WA[4+KF=Y")#ZD8&: /H%M5TY9EA:_M1*WW4,R[C]!F
MK$L\4$1EFD2.,=6=@ /QKYV\?^!]/T'X>:;X@@FNCJX:,/<M,Q9L_C@8]J[;
MQ,^D:M\.=$F\3>(+C3;>2-7D6#EISCH0.2/IZT >EVVJZ=>2%+6_M9WQ]V*9
M6/Y UYOK_C77+#XS:3X;M[E%TRY ,L9B4DY4G[V,]:\GN[S1-)\>Z)/X.LM0
MT^W,F'>8N%GZ=-W)%=OXJ_Y..T#Z+_Z : /=,5Y+\2?B-KFD^([;PSX7M5EU
M.9<EF4'!(R  >.GK7K1KR;XA>!SXA\36^J^'==M;3Q!; 9@,PWL ...N<>O&
M* .>T_XF>/O"_B&QL?'&GKY%[(J*X2-2H)QD%.#S7N+ZC90>4)KN"(S8\M9)
M I;/3 /6O![OQCXV\)SVH\>Z%9ZC8F4*EQ+%&Y3GJNW@'ZU;^+5Q%>>+? ]S
M;_ZJ62%TQZ%^* /;KF_L[0+]JNH(-YPOFR!=WTSUKS7QCXUUK2?BAX>T2QND
M33[UHQ,AB5BV6(.&(ST]*P_CS]WPO_U\'^2U6\<_\EC\%?2#_P!"H UO'7Q#
MUJ/QQ9>&?#6IZ?:&109;N?:Z*3V.0<8Q7I.D74]AH%J^OZK92W10>9<HRI&Y
M]5Z#%>#^(?!^B/\ '>ST@V9^PW022:/S&^9B3DYSD5V7Q!TGP7:7FEVVNZQ=
MI:VL6R'2("S"0<==OS?B30!ZM;ZA97JLUK=V\ZK]XQ2!@/RKS^[^)T8^)UMX
M9A>V2R4;I[II%P3MSM!SBO,? EY:6OQB6QT.UO;#2;J,H;2Y+ D'O@\_0U+<
M>"]!?X]C1&LR=/<"1HO,;EBN[.<YZT >RW,FO-XWM3;>(-+31F4%K!MIGD^7
MJIQGKSUZ5T=UJ%E9,HNKR" M]T2RA,_3)KQ+58([7]H[1;>%2L44*H@ST A(
M%4]!TBW^)OQ5UXZ^\TUI8,5BMQ*RJ"IV]CQZ\4 =?8>-]9N?C;<^&_M<;Z0L
M99$6-<G]WN^]C/6O2;G4K&Q(%W>VT!;H)954G\S7@7A72H_#GQ^O+&&666*"
M*0H9'+''E9QD\\=*YB#5[+Q%XDUF\\3:%K6O$RLD*6>[9  <=CQ0!]61RQRH
MKQNKHPR&4Y!_&E;[I(]*\>^!U]K)35-,O[34(;*%A):F]C96 .1M!/I@5["W
MW#]* /,/AYXSUOQ!XT\0Z;J-PDEM92;856)5P,GN!STKU#I7B'PB_P"2E>+O
M^NO]37LFJW366DW5RGWHHF8?4"@!;C5=.M)1%<W]K#(>BR3*I/X$U)->VMM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCS@1#I\(0K%_P(<G\ZR?A/X.UKPK>Z_+JULD*WDR/#ME5\@;L]#QU%>GXHH
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M1\I'W<YZ^E>J44 )7D?Q#^&FM:AXE3Q3X4O!!J:J R%@NX@8!!/'3UKUW%%
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M "BBB@ HHHH **** "BBB@ HHHH ***,T %%)D>O6@NJ_>8#ZF@!:*,C&:*
M"BBB@ HHHH **** "BBB@ HHHH 3%+110 4444 %%%% !1124 <M\1/$Y\)^
M#KS48F NB/+M\]W/2L6QUC6-'^#CZSJE[)/J0M?/\R0#()Q@<>E<W\?G>2VT
M&RRPCFN26].,?XUWOBOPJ/$O@O\ L*&\%FCJH\PKNX Z8R* /./!VC?$CQ3X
M>M=9/CR:U28Y$+VP8D?7CK76>.[_ ,:V5EI>D>'+:6XN9U5+K45B+"/'!;T'
MKS7">,/AQ_PK[PO;:_HVM7OV^R9!(6D^1QZ*O;]:]4M/&=M;?#VT\2:NXA#6
MR2..FYB!P/J: /.KC7_&7PY\6Z39:_KJZS9:@P5BT>TH2<<8]Z]N::..$S.X
M6-5+EB> ,9S7SQX>AU7XO?$6/7[N$Q:+I\G[M3T 'W0/4YP3^-?0[Q))"T3*
M"C*5(]CQ0!3L-=TK5+26[L-0MKFWA)$DL4@94(Y.2*33=>TG68Y)-,U&VNTB
M;;(T$@8*?0XKY[M=:;P-+X\T&0M'O#- ,_Q..WX$51\(:K=^ [+Q+87TFR6Z
MT_SK8YQEB#R/TH ^D+3Q#H]_;3W-IJ=K-# 2LLD<H(0CJ">U,TOQ1H6MS/#I
M>KV=Y(G+)!,'(^N*^;-=BO-&^'7AK3E65UU:XDNKB*)MK2D[0%S^'ZUH7>E:
MXNHZ5?\ AKX=:IHL]JX+R(2PE''7Y1_DT ?1NHZK8:1:FZU&[AM8%X,DSA5'
MXFH]+UO2];@,^EZA;WD*G!>"0. ?J*\#^(VI7>I?%NST^XTFXUBVMH%9=-B?
M;YA/7/!]*M^$M.\0V7Q.M+[3?!NHZ%I$P\NXA?+1J,9SG QR* .F\.>)M:O/
MC5K&C7.H2R:=#$QCMSC:IW#VKT:R\1Z+J&H2Z?9ZK:7%Y"3YD$<H9TP<'([<
MU\T>*]>U/0OBGXB;249KJY5X05&2HSDD?@*]4^$VCZ<_PXN;S2I/,U2^CD$\
M[\L)#GC\Z .[N_&?AFPO#:7>NZ?!< X\J2=0V?I6U%-'-$LL3AXV&593D$5\
MI16L?A+[=9^-O"$]X9Y3MU#<4=!ZJ2#GUKWOX87>A7/A")/#UU=S6<3%<7;@
MO&W4KT]Z .REE2")Y965(T&YF8X  ZFL0^-O#"V9O&U_3A;!S'YIN%V[AVSG
MKS5O7_\ D7=1_P"O:3_T$UX=\&_ FA>)-(U6\U>V%T3<M$J.W"8P<@>O/Z4
M>^6=[:ZA:I=6<\<\$@RDD;;E8>QK.O\ Q9X?TJ[%IJ&LV5K<'I%-,JL?P->(
M> M9O?"J^-],MY7EMM-B:6!6/W2,]/R'Y5H_"[P)HOBOPA=ZUKL)OKZZE<"2
M0Y,>/[OOS0![G%/%/ L\4BO$PW!U.01ZUBGQKX8%[]B.O:>+K=M\K[0N[/IC
M->/^ _[8OO"_C+PE97+NUJ^RTD)Y')R,^^*XJT_LCP_IZZ1XU\'WD-R9"3J4
M3E)0/;(.: /H;Q[XSMO!_AJ>^\Z WA3_ $:&1P#(<]AW]:@^''BV+Q5X:MYI
MK^WGU+#/<11,,Q_-QD=ATKC/&]IX>U;X)_VA8;[R&TA46EQ<G,D?S 8)]<9%
M6O 3:9X.^$B^)K?2DDNS$3,4.UI?GQR>?;M0!ZYGM63<^)]"M-2&FW&KV<5\
MW MWF <Y]NM>9Z)\<#XEEN[*'09;.1;2:996GW %(V8<;1Z5B?"3P;H_B_1=
M7U?7+?[5>37+HDCL<Q# .1[Y)H Z+X1>*-:U[Q!XB@U/49;J&VDQ"KXP@W'I
M@5Z)J/BOP_I%R+;4=8LK6<](YIE5C^!KPKX3W+:!!XXN;?+-9PLR9/)V[L5K
M?"OP/H_C#P[?:YK\)OKRYN'0-*<^7@ Y'OS0![E#<17$"S0R+)$PRKJ<@CZU
MC/XV\+QWOV)]?TY;G=M\HW"[L^F,UX]X"_M>?3/&?@ZPN7<6X*VCMG*DYSS^
M KB[5=,\.:>=(\:^#KM+AY"?[3C<I*H]L@YH ^L#*BQ&5G 0#)8GC%9-CXL\
M/ZG?-8V.LV-S=+G,,4RLPQUX%>/^/M?M(?@]I,7AN[NYM/N)DMPTS_O2@!^4
MGUX%<K>:+J=SH^F-H'PYU73[^W*2?;T<L9@!U/RCKUH ]<^*VM:UX9@TO6]-
MO&2TAN%2\@P-KH>YKO=.O8]1TZWO82/+GC61>>Q&:X3X@1W%]\&+IK^,QW9L
MX7E#CE7RN[\<YJY\(+R2]^&>DR2?>"LG/H&(_I0!W-%%% !1110 4444 %)B
MEHH 3%&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"P R
M> *\O\&^*-6\6?$G6GBO'&A6 \F*%0-KMW)]\UW_ (@E:#PYJ<R9W):R,,=<
MA37F?P!MU'A?4KLG,LU\Y8GZ"@#.U/5/&'BOXKZEH&@^(Y=+M+.,!F6(.H/)
M_7^E=SH^G^*O"^@ZE/J>KR>([P)NMHUAV'(SQQZUS'_"C[.^UG5-1U#7+J1K
MM]ZK:GRRI]SSG]*C^#6M:FFH:UX9O[EKJ+37 BF;J <\?I0!E2+\5)/#]YXJ
MN];?3# 2_P#9;P;1M'UY%>D?#CQ7)XQ\'6VISJJW.3',%'&X=2*\U^*7CZX\
M1ZA_PA'AA3/+,_EW$J<[O]D>U>H^ ?"X\(^$+/2F(,R+OF(/!<]: -:37=*A
MU6/2I-0MDOY!E+9I )&[\#K27'B'1[35(],N-3M8K^7_ %=N\H#MWX'6O+/C
M';OHWB3PWXJA0J8+@0R./?\ ^L#7GOBO4KK6/'\_B^S?-CI]W#$3Z#@$T ?2
M]SKFEV>HPZ?<W]O#>3C,4#R .X]AWJM>^+?#VG7RV5[K5C;W3$ 0R3*K'/3B
MO&#J3>(_B)KOB2UDW0Z3II:W(.<,8\?S-<AX8MY=7\/WTTO@+4-=O+IW(U))
M#^[8_P!WY3T//6@#ZM61&0.K J1D'U%8\'B[P[<ZE_9T&M6$E[G;Y"SJ7SZ8
MKQ&YU+Q3X?\ @7>VNJ6]W8W"W(MXO/!#^2V/\2*Y]M&OK_P?:Q:3\.=4BU'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"&LO7M>LO#NEO?7I8(O"JHRSL>@ K5IDD,4NWS(U;:<C(Z&@#S3X;^,=8\4>
M*=>34HFMH8-ODVK]8P<8)]R#G\:]-KR_P)_R5;QK_O1_^@K7J!H \\\?7VM7
M/B31?#^@ZF=/GG$DLTH&<( ,=Q[U=\+>'_%.G:NMSJOBIM3M!&RF#R\#<>AS
MN/2J_B3X>?\ "3^,8]6EURXM8HK;R#;6YVL1DY.<\9SZ5AV-E>?#[XB:7I-M
MJEU=Z3JJLHMYV+&)QCY@?Q_2@#TF/7-.DUJ;2%N5^W1()&B/7:<]/RI+37-.
MOM3NM.MKE9+JUQYJ+_#G_P#57G'Q-8:AX@T_3_#<3-XMC/F+/'\HAA[[V]#Q
M@>QK9^%,]@FA3:>(GAUJV?;J:2_ZQI>[$]P3G!H C^(_Q"?PY:W6G:1;R7.L
M+%YC[5^6!#_$Q_$?G71^$]3FNO!&G:E?2%Y&LUFE<]2=N2:J_$.&-? 6NRJB
MB1[?YF Y.",56\-@GX06P R3I/'_ 'ZH Y.SO/'GCA+S6]'U.'3M/BE=+.#:
M6\X(2,L<CJ179_#WQ5-XIT!Y+U$34+.9K:[5.@=3_AS5/X0&,_#/2Q%MPN\'
M'9@YS^M97PFW-J7B]U.8CJK >F=HH N^([;55\8Z)<W5^#:-=E8;:-< #:.6
M.>3G-32:=;>)_'&I6FK)]HM+.WC\F!C\JL2V6^O3\JW?$&D7.IZCH]Q 8PEG
M<&23>V#C Z<5GZCH^N6'B.?6=!6TG-W"L4]O=2&,*5)(<, <GGICM0!-X%N)
M)-)O+22223[!>R6JNYR2%"D?^A5U-<Q96-_X7\(7;P6_]I:J%>Y:)#M$TI'W
M0>W0"N0_X6#\1O\ HF4W_@7_ /8T >K45Y!I?Q?UR7QSIWAC6?"@TRXNW56W
MW)9D4@X.-OMZUZ\#0 M%%% !1110 4444 %%%% !1110 4444 %%%% !24M%
M 'E/QWT:6]\(V^HQ*2;"<.^.R'J?T%;NHZ0GQ#^&UK''=F&2XA2:.9.<-CC/
MYUUVI:=;:KIMQ87D8DMYT*2+Z@U5\/Z#9^&M(BTS3S-]EB^X)7WD#TSZ4 >2
MCX>_$/6["R\/^(-3L5T.W9<O"Q:5U7@ ^M7?B9\.?$GB.UTK2= -K'I-C$%"
M33%22!@<8]*]BHH \>\.:)\5] M;+3H(_#D6GPLJNJ9W%<\GIR>M>O+G8N[&
M['S8]:?10!X]\2?A7J/BOQCI^JZ9]F2 *JW?F2;6.&Y(&.>,5'\2/A+J/BK6
M=*N],-NL<,"07&]]IV@]1QR>:]EHH X#QQ\.8_%'AJQLK2<6E[IX!MY ,@'
MR/TK)TCPY\3+W5K/^W]?@L]/M>JZ>YW3CT;_ !KU6B@#S/QW\/-3U/Q%:>*/
M#-Y%;ZQ;*%*S?<D Z9/:K?A+0/')UR35?%FN+L PFGV;'R2?4_X5Z#10!Y?H
M_@#5;7XJ:MX@O%MGTV[B9$ ?+\D=1CTS1X2\!ZWX6\2ZY#;3QIH.H!FB9)2)
M87/((&.W3K7J%% 'CUWX8^*MNEWIMKJ^G:E83Y43WY)F52,8'IQ78?#OP2/
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MQ9_R<_H7T@_DU>_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4F*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+10 4444 %%%%
M !1110 4444 %%%% !1110 4444 )@4M%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)BEHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 > ^+/\ DY_0OI!_)J]^KP'Q9_R<_H7T@_DU>_4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXL_Y.?T+Z0?R:O?J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '@/BS_DY_0OI!_)J]^KP'Q9_R<_H7T@_DU>_4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A( R3VSFEJ.09B
M<!0V0?E/>@#"O/&&E6>IV-D91(UX[(CH<JI4$G/I]TUMVUS!=Q"6WE22,D@,
MAR..M?-_BWP'K=QXRLV%K:6!OKA_)MXF+*<!CECQUQ^M>[^$+&XT[PW:VMW8
M064T8*M% V4Z]1]>M &Q<W=O:(KW$R1*Q"@N<9)Z"L;2O%^EZK-=1QR^4UO<
M?9SYAQN? /'KU%5O'NDW>M>''LK+3[:\FD8 "X?:L?\ M>^.M>-_#GP3K%IX
MGFNS;6NH0VEX(IEF)4QG .].N<9_2@#Z,]ZP=3\6:;I<UK$\HE:YN!;CRSG8
M_O6X.GI7SO\ $3P/K%YXFANUM[73X[N\$,2PL6+G^^W2@#Z$MKNWO%+V\J2J
MI*DJ<X([5/7+> M*O-'\-QV=]I]M9SQL0PMGW*_^U^-=30 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445POQ3\5:AX9\/0+I*@ZC?3K;P$]F)'ZT =UTHKYL\4:MXSOKSP_
MX,;4G75&C#7;K)]YV<D9/LI6O0?A1J^M17^L>%==N3<W>ELI$I.<JPZ9H ]2
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 2D95==K*&4]013J* *RV%HAW+:0*W8B, U/CM3J* (Y88YTV2QI
M(O7:Z@BE6-8T"(H51T"C %/HH @EMK>?F:".0CH70'^=/CBCB7;'&J+Z*,"I
M** (3;0&7SO)C\W^^5&?SI[QI(I61 ZGJ&&13Z* (8K:" _N8(X\]=B@?RJ:
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I".:6B@"N]C:2-ODM8&8]2T8)J5(TC7:BJJCH%&!3Z*
M&D=<BHXK>" DPPQQ[NNQ0,U-10 R2-)$VNBNIZAAD5'%:6T!W16\49/=$ -3
MT4 12P0SKMEB210<X=0<?G3E554*J@*.@ QBGT4 0R6T$KJ\D$;LO1F4$BI1
M2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!X#XL_Y.?T+Z0?R:O?J\!\6?\ )S^A?2#^35[]
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"5POQ2\-:AXA\/6\ND*K:EI\ZW-NC#[S*0<?I6YXRO=6T[PM>76AP>?J*!?*
MCP#GYAGCZ9KQX>._B_\ ]  ?]^%H ;X0\)>,9/$>K^,]?L&AU**V=K:.1/\
M62[,+A<].!WKN?A;X:UJRDU3Q!XC4)JNIN"T>,;4 X^G?BN(_P"$[^+_ /T
M!_WY6NY^&WB#QIK5[?)XIT\6D4:*83Y87<23GI^% 'H]%%% "&BJNJ74EEIE
MQ<Q0M-)$A98UZL?2O%;KQ=\3;30)O%EVMG:V$,V&L'3YPF<'G'TYH ]TS17
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P" 4?\ A7G_ (/M+:Q^/'BZWL[>&W@2Q@VQPH$4<)T XH ]7%+110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X#XL_
MY.?T+Z0?R:O?J\!\6?\ )S^A?2#^35[]0 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 48HHH B6V@60R+#&KGJP4
MU(0",$ @^M+10!''!%""(HDC!ZA% S3\"EHH *\M\,_\G ^,/^O&#^25ZE7E
MOAG_ ).!\8?]>,'\DH ]2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \!\6?\G/Z%](/Y-7OU> ^+/^3G]"^D'\FK
MWZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *2EI#0 45BZUJ4T,]OIUAM-_<Y*EAD(@ZN1[9 _&JP\(6TP\R]O+NXN#R9#
M)C!]L"G85SI**YE9+GPY=PPW-S)<Z;.VQ)92-\+=@3TP>G3N*Z44@N+1110,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!D@?RV$9 ?!VDCC/;-?-?Q'\8>.O[:
ML[+4=)C@6SO@]K);Q2*MPP(*C.?FSQP*^EZYKQGJ7AW1=+34_$*1M#;R!XLK
MEM_;:/6@#R,?%CXH8 '@Y.G_ #Y3?_%5U/PFMO$]WK6N>(?$-I)9&^*!+=T9
M,$=2%;D#I4?_  O_ ,(#@0W9]_*KJO!?Q(T;QS<74&EI,K6RJS^8N.#G'\J
M.RHHHH **** "BBB@ HHHH \#^*/_)>_!_\ V[?^CFKWRO _BC_R7OP?_P!N
MW_HYJ]\H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=K2T )1SWI:* $Q1BEHH \!\6?\ )SVA?2#^35[]7@/BS_DY_0OI!_)J]^H
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MOE>!_%'_ )+WX/\ ^W;_ -'-7OE !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?B__ 'M4_P#!H/\ XNC_ (5[\7_[VJ?^#0?_ != 'U317RM_PKWXO_WM4_\
M!H/_ (NC_A7OQ?\ [VJ?^#0?_%T ?5-%?*W_  KWXO\ ][5/_!H/_BZ/^%>_
M%_\ O:I_X-!_\70!]4T5\K?\*]^+_P#>U3_P:#_XNC_A7OQ?_O:I_P"#0?\
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MTWP!XJ\'7%C?7=RUUJL<;"?;@ ,IXP!7T=7EGQ=_Y#_@+_L,I_-: /4Z***
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M+QV+/()'0<\X ! P/2NEMK2"SA$5O$L48Z*HH;!)DXI:04M26%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 QT61&1P&5A@@]Q7C_B3X$6UYJ,VH>'M4ETN>5BS(
M&.P$]<8Y_6O8'D2-2\C!5'4DX HCD25 T;!E/0@Y% 'A-I\ -4NIE&O>*9;F
MV!SLB9B?_'LBO9= T"P\-:1#IFFPB*WB''JQ]2?6M2B@ HHHH **@O+N"QLY
M;JYD$<,2EW8] !7FG_"\-"8-<0Z=J,FG*VUKT0ML7Z\4 >I9I,BL:3Q3I$7A
MK_A(&NT_L[RQ()?8]OK[5R&F?&70K[4;>VGM;RSBNFVV]Q/&0DASQ@XH ])H
MIJG(R.0>].H \#^*/_)>_!__ &[?^CFKWRO _BC_ ,E[\'_]NW_HYJ]\H **
M** "BBB@ HHHH **** "BBB@"&[_ ./.?_KFW\J^8/V??^2F3_\ 7A+_ .AI
M7T_=_P#'G/\ ]<V_E7S!^SY_R4V?_KPE_P#0DH ^I:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /FC]I#_D<M)_[!_P#[4>OHG1?^0%I__7M'_P"@BOG;]I'_ )'+2?\
ML'_^U'KZ)T7_ ) 6G_\ 7M'_ .@B@"]1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !12'I4<\T5M"\TTB1Q(-S.YP /4F@"6BN8M_B!X5N;
MX6<.MV;3$[5'FC!/H#GFMR^U"STRS>\O;F*WMT'S22N%4?B: +=%8>B^+M!\
M02-%I>IV]Q(HR45QNQZXK;H 6O+?#/\ R<#XP_Z\8/Y)7J5>6^&?^3@?&'_7
MC!_)* /4J*** "BBB@ HHHH **** "BBB@ I,4M% "#I2T44 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <-\7I'B^&6KO&[(P5,%3@CYUKEOA=\0O#>E?#_3K/5-:@BO(]
M^])91N&78C.3Z8KI_C%S\+]8&/X4_P#0UKS_ .&_PC\+^)? ]AJNHQW1NI]^
M\I( .&('&/04 >E?\+3\%_\ 0?L_^_H_QK5T/Q;H?B226/2=1ANGB +B-@<
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MN,< T6.GVFFVPMK*VCMX0<A(UP ?I5J@!:*** "BBB@ HHHH **** "BBB@
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M!O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:X;]FO\ Y%W7/^OM/_0*[GXO?\DIU_\ ZXK_ .C%KAOV:_\ D7=<_P"OM/\
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M.UZU%Q:3C:97B57^4EE)!P#UZ&@#8I,TM8VL^)=-T2.)[J<'S9U@ C^8AF(
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MOE>!_%'_ )+WX/\ ^W;_ -'-7OE !1110 4444 %%%% !1110 4444 %%%%
M!1110 5')(L43R,<*@))]A4E,DC62-D<95A@@^E 'SUI.BWOQD\7ZM=ZM?S0
MZ193&*."-N./;I[YI?&'@J?X2_9?$_AK4;CR(Y56>WD8[6R>,CN#3[:[UGX-
M>+M4$VEW&H:)?2&9'A7.,^_;TY]*;XD\4:Q\89;/0-&T:[L].,JM<3S+VSUS
MTXH ]WT;4%U71[2_3A9X@^*OU3TNP33-+M;&,?)!&$'X5<H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:/VD?\
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M\\?%;PUJ]QK0O;:R&G6\EW'$LGVAF,\A( ;&[ QD=ATKZ'IDD$4P EB20 Y
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M7OE>!_%'_DO?@_\ [=O_ $<U>^4 %%%% !1110 4444 %%%% !1110 4444
M%%<+X^TCQKJ=U9-X4UK^SXHT83KA3O)(QU_&N/\ ^$4^,?\ T-X_[Y3_  H
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MD9P+6+]XRM[L",?E7I?P8\8>)_$\-W'KB;[>!%\FX,9!<DG.3W[4 >MT444
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M!_\ U]Q_^C*]OKQ#XX?\C;X/_P"ON/\ ]&4 >W8I:** "BBB@ HHHH ****
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MZW7+^ K#7],\-16?B*Y2XNXB55U))V=LD]3744 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )
M7G7Q8TFUU[2;2RNM?BTFW6;?,[G)(QQQGUKK?%6M#P[X9O\ 52-Q@B)4'^]T
M'ZUX!X2^'FJ?%>:X\2>(-4EBMY'(BP-[,,]!DC '2@#N?!O@OX86DZ+;WMKJ
MU^ "7G<-SZ@'I^=>MQI'&@6-550. H[5X-K_ .SW%::=)=Z%JDK7< +K%(F-
MQ'/!R<&NF^"GC"_U_2;O2M5D,MYIS;?,8\E>G/OD&@#U>BBB@ HHJG>ZI8Z=
MY?VRZBA\QMJ;VQN- %RBF,X1"S,%4<DDX JA;:]I5Y=-;6VH6\DRG!19 30!
MI44@I: / _BC_P E[\'_ /;M_P"CFKWRO _BC_R7OP?_ -NW_HYJ]\H ****
M "BBB@ HHHH ***2@!:*2EH **** "BBB@ I.M+2<4 > ?$+X<ZQX;EU?7O#
M-V$T^\B<WMLQQA2#NQZ]SVZUB?#[X?ZYXVTO36U2\5/#=M)NC@!)+\\\>_3-
M>Y_$3_D0=:_Z])/_ $$UA?!+_DFEC]6_G0!Z!!#';PQP1+MCC4*H'8"I:3BE
MH **** "BBB@ HHI* %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /FC]I'_D<M)_[!_\ [4>OHG1?^0%I_P#U[1_^@BOG;]I'_D<M)_[!
M_P#[4>OHG1?^0%I__7M'_P"@B@"]1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 45&TT:N$:1%=ONJ6Y-.+!5RQ  ZDT .HJ*.:*7/
ME2H^/[K U)0 M>6^&?\ DX'QA_UXP?R2O4J\M\,_\G ^,/\ KQ@_DE 'J5%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5XA\</\ D;?!_P#U]Q_^
MC*]OKQ#XX?\ (V^#_P#K[C_]&4 >WT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <3\7O^24Z__P!<5_\ 1BUP
MW[-?_(NZY_U]I_Z!7<_%[_DE.O\ _7%?_1BUPW[-?_(NZY_U]I_Z!0![?111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M ^+/^3G]"^D'\FKWZO ?%G_)S^A?2#^35[]0 4444 %%%% !28I:* ,'5/"]
MO?RR303O:32_ZPH,K)_O+T/XUF1?#VPDN$FU.2.]V'(3[.L:D^X'!KL:*=V+
ME12L]'T[3VW6=C;V[8QF*,+Q^%7,4M%(=@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!,48I:* "BBC(H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH *S/$"ZD^@WBZ0RK?F)A 6Z!L<?K6G24 >'?8OC7_S^6__ 'R*3[%\:_\
MG\M_^^17N5+0!X9]B^-?_/Y;_P#?(H^Q?&O_ )_+?_OD5[G10!X9]B^-?_/Y
M;_\ ?(H^Q?&O_G\M_P#OD5[G10!X9]B^-?\ S^6__?(H^Q?&O_G\M_\ OD5[
MG10!\[^);7XM+X<OSJMU UB(6,X &2F.:S_ =M\3I/"UNWARYA33B3Y:L!FO
M4/BQXST32?#.H:3<7:F_NH&1(4Y()!'/I6#\$?&NACPW:^'I;M8=00G$<G ?
M/H>E %+[%\:_^?RW_P"^11]B^-?_ #^6_P#WR*]RS2T >&?8OC7_ ,_EO_WR
M*/L7QK_Y_+?_ +Y%>YT4 >&?8OC7_P _EO\ ]\BC[%\:_P#G\M_^^17N=% '
MAGV+XU_\_EO_ -\BE^Q_&O\ Y^[?_OD5[E10!S_@U->3P]"OB-U?403O*CCV
MKH*2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YH_:1_Y'+2
M?^P?_P"U'KZ)T7_D!:?_ ->T?_H(KYV_:1_Y'+2?^P?_ .U'KZ)T7_D!:?\
M]>T?_H(H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D
M^)->@\-:#=:K<1R2QVZ[BD8RQ^E:U0W%K!=PF&YA2:(]4D4,#^!H ^9[7Q9K
MOB3XT>';G4HYK.&6YC:"V)( C)."1[_TKT/XQ:]?K?:)X9T^ZDM3J4I\Z6-M
MK!1CCCGG/Z5S?C-57]I7PVJ@!0MM@#ZM5WXNQ&W^)GA*\D.V%G8;CT&"O?\
M&@"MJUK)\*?B)X?BTW4KI]-U'<MQ!-(6!P0,\GKDU[U7A/QOMSJ/COP=9PG=
M(Q?@=?O(?Z5Z-\1?#.N>*=#M[30=7_LRYCN!(\WFO'N7:1C*<]2/RH [&O+?
M#/\ R<#XP_Z\8/Y)7*?\*=^)'_0]G_P-N/\ "K?PDT;4M ^*WB73=7O_ +??
M16,?F7&]GWY*D<MSP"!0![E1110 4444 %%%% !1110 4444 %%%% !1110
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MQW$<D>0ZL"I]\U]=:'+)-H&GRS9\U[:-GSZE1F@"_1110!@3>(?L_C*VT&2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'S1^TC_R.6D_]@__ -J/7T3HO_("T_\ Z]H__017SM^TC_R.6D_]@_\ ]J/7
MT3HO_("T_P#Z]H__ $$4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .%UCX;VVK_$33_%[WTL<UF(]L  VML)/]:U_&/@S3?&FD
MBQO]Z%&W131_?C/J*Z.B@#SOPS\*;/0];CU>_P!4O=6O(%VPO=/N\OZ5Z'2T
M4 %>6^&?^3@?&'_7C!_)*]2KRWPS_P G ^,/^O&#^24 >I4444 %%%% !111
M0 4444 %%%% !1110 44AKRC7=%^+$^NWDND>((H=/:4F",I%\J]AR,T >L4
M5XM_PC_QJ_Z&:'_OW#_A1_PC_P :O^AFA_[]P_X4 >NZIIMKK&FSV%Y&)()T
M*.IKY=^(/PZF\(:]I-A::K)):WMP!;*Y.8"6QGVY]*]%_L#XT_\ 0S0_]^XO
M\*QM:^&GQ.\0W=I<ZIK%O<36C!X&(C&Q@<]L9Y]: /1?A_\ #6U\%F:]GN6O
MM4N!B6X?G'TS7>UXM_PC_P :?^AFA_[]Q?X4?\(_\:O^AFA_[]P_X4 >TT5X
MM_PC_P :O^AFA_[]P_X4?V!\:O\ H9H?^_</^% 'M-%8?A.WUNUT&&+Q#="Y
MU$$^9*H !_+BMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH XGXO?\ )*=?_P"N*_\ HQ:X;]FO_D7=<_Z^T_\ 0*[GXO?\DIU_
M_KBO_HQ:X;]FO_D7=<_Z^T_] H ]OHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** / ?%G_)S^A?2#^35[]7@/BS_DY_0O
MI!_)J]]H "<#)Z=Z^7/B)+'-XWU%HIQ.I? 8'(X'3\.E?0GC:]FT[P9JEU;Y
M\V.'C'N0/ZU\ILS.Y=B69CDD]Z $KT#X/6D\WCJ&XC5O*@B<R,!P,J0*\_KW
M3X,:KHXTF2P4QQ:F7)<'AI![4 >L"EI.]+0 4444 %%%% !3)466)HV^ZRE3
M]#3ZY?QGXWT/PA8DZK=*))4^6W5OWCJ3C('7'O0!\[_%>R\)Z-K#Z9HULYNV
M??<7#,2JY.2%]:X#3I+*VNXIKJ,74(DQ)!@@E/4'UK0\2ZE93:O?_P!D2S/I
M]R_F 3CYP>I&?K69IE\FG7\=T]NEQY>2L<@^4GMG\: /L#X=:%HFE>&XKO0X
M98K>^42E9?O ]/Z5V0KQSX6>+]-T[PT9/$'B_3/.N',B6S3JI@']WK[5[#'(
MDL:R1L&1AE6!X(H =1110 4444 %%%% !1110 4444 )FC-9VM:M#HVFO=R\
M\[43."['H!7%?VHVI?Z1=ZCK+J?^@7;Y@0?[V#GZYII$MGHV31FN,L=3EL(/
MMEMJ4FJ:8&VS^<09H#T[8X!XQBNQC=9$61"&5@"I'<4-#3N/HHHI#"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_%?ARW\
M4:%-I\^ S<QN?X6[&OG?5_A]XCTJ^>W_ +-N+E1TE@C+*WY5]24F* / ? OP
MNU&^U"&^UB![6TB;=Y<BD.Y'L>E>^QHL<:H@PJC  ["C%.H **** ,S7](BU
MW1+G3I6*"9"JNO56[$?0U#X8T"'PUX=M=)BD,RP*0TC]7).<FMCFC% '+^$/
M!EKX2-Z;>5I3<R9!;^%>H4>P)/YU>\2Z GB*SM;=Y6C$%TER"O<KGC]:VJ,4
M  X&/2EI,4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKJCJL41_NKWH ]8HHHH **** "BBB@ HHHH \#^*/_)>_!__ &[?^CFKWRO
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M 4444 %%%% !7EOAG_DX'QA_UXP?R2O4J\M\,_\ )P/C#_KQ@_DE 'J5%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YM\<+.[N_AU<FU#%8G5Y0!
MU3I_,BM7X=:]HVH>!M.-A/$BV]LD<R9 *,J@,3^()KK[B"*Z@D@F0/%(I5T;
MH0:\HU3X!Z!=WS3V-Y<V,3-N:%#D?ATQ0!BVEW;:_P#M$Q7>AD/#:Q,+F>/E
M2=A'_P!:O=JYCPAX%T7P7:M%ID+>9)_K)I#EW_'TKIZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ!H=IXET*Z
MT>_,@M;I0LGE-AL @\'GN*R_!O@;2/ UI<VVD&Y,=S()'\^0,<@8XP!73T4
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MI/PPTNQ\0:?XAC,EK>PP*LT41PLC8QD_YYKOATHQ2T %%%% !1110 4449H
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M]R:-9%^A&:RO$6H*E@]A 0]Y=?NHXUY//4GT&,UIZ;:"PTRULP<B"%8@?]T
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MH:A\:V%W=^$-/@MX'DE2ZA9E Y  .35#4?#]YJ?B_P 5((VCBN["&.*4]"P
MX_,4 7+?Q%XKETFWUPZ3;FRF*L+9)291$W1NG7!!(^O-9FFZ[;:%K?C75[D'
MR8G@;;W),: #\20*NV/B+6K/PS::7!H%U_;,*1V^'"^6-N 7SG[N 3TSTXK)
MN_"VJ:S%XSM)(O+ENVMWB;^&1D5"0/J5Q0!K3>,?$&F:7;ZWJ5C8_P!GRLOF
MQ13DR0HQ #?=Y/(R.W-=[!,EQ;QS1G*2*'4^H(R*\EELENM%M=/@\+7K:E(4
MBGCN''E1@8#,3DY&,D5ZQ:0_9[."  +Y<:IA>@P,<4 34444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '/^-/$;^%/"M[K,=LMRUL%(B9]H;+ =<'U
MJIX7\8+K_@2/Q-=6OV9#%)+)#&V_ 0MG!.,\+6?\8O\ DE^L?[J?^AK7#^"O
M&?AVP^"[:7=:M!%??9+A/)8'.YM^!T[Y% '8>%1X#^(*W&LV7AZ!I(9O+>6Y
MM5#EL YX)]:] CB2*-8XT"HHPJ@<"O O@;XNT#0/#>HV^JZG#:RR7A=%?/(V
MJ,\#VKVC1O%6A^(9)8])U**[>( N(\_*#TZB@#8HHHH **** "BBB@ HHHH
M\#^*/_)>_!__ &[?^CFKWRO _BC_ ,E[\'_]NW_HYJ]\H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBDS0 M%&:3- "T4F:,T +1110 4444 %%%% !1110 5
MY;X9_P"3@?&'_7C!_)*]2KRWPS_R<#XP_P"O&#^24 >I4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !129I: "BDS1F@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \!\6?\
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M1F.66UN7C0^ORJ0,^]=#24!8S-+T"PTC<UNDCRL,&:>0R2$>FYLG%:8Z44M
M!1110 GM12T4 )12T4 )1S2T4 )12T4 )2T44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!E^(-"M/$FBW&E7X8VT^-X4X/!![?2O/O^%!>#O[
MES_W^;_&O5:* /*O^% ^#O\ GG=?]_F_QKIO!_PZT3P3<7,^E+,&N%"/O<MP
M,XZGWKKZ* "BBB@ HHHH **** "BBB@#P/XH_P#)>_!__;M_Z.:O?*\#^*/_
M "7OP?\ ]NW_ *.:O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **3\::LB.2%96QUP<XH ?12"EH **** "BBB@ HHHH **** "BBB@
M HHHH *H:KJUCHFGO?:E<"WMD(#2%20/R!J_6'XNTA==\*:EIQ_Y;P,H/H:
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MRU/3M.NUF2$W\*S0Q2. Y!&>!WK4KY"\'^+]/M];L=2\37=W,NG1+%:00Y
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MO-MYDE3)&Y&!'%(MU;O</;I-&TR#+1AAN4>XH FHJ&:[M[9HUGFCC:1MJ!F
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MYUM<13Q$XWQ.&&?J*^#K5V692$,F#]P$\_E7MOA#XJ-X5T"+3+'PMJ4T 9I
M[G));KVZ4 ?1(Z45XBGQ]NG+!/"5ZQ0X;&>/K4!_:*Q((SX;N YSA2_/'6@#
MW6BO$#\?[D1B0^$[P(>C<X-6['XX7EY?VUNWA2]C6:54+D'"@G&: /9:*@M;
MR"\@$T$J2KW*," ?2E%W;M<M;">,SJ-QC##<!ZXH FIK ,I!Z$8J.:ZM[?9Y
M\T<>\[5WL!D^@I[R)&AD=PJ*,EB< 4 >":M<3Z)%XL\)H%W7^I1"TB0X)CE+
ML?\ T$5Z#X]\.1GX:/96T89M,2.2W&.A3'3\,U<O? NB:[XOL?%OVF1Y[<#:
M(G4Q28'!/';Z]ZZ:1K348;FS$T<GRF.558$KD8Y':@#S+P/?#QAX^DUYOGAM
M-,AC3/\ #*ZHS?U%>GW_ /R#KK_KDW\C7-^$/"6C> [>33;*[9GNI/, N'7>
MV,\#&,@"NDO6@2RF^TS+#$5*L[, !GCJ?K0!P7P;_P"12N/^OV;_ -#:O116
M%X5\-V?AC2VM+&>6>&61IMTA!^\2>"!TYK>H **** "BBCO0 44F:,T +7EO
MAG_DX'QA_P!>,'\DKU*O+?#7_)P'C#_KQ@_DE 'J5%-9U7&Y@,G SWI68*I9
MB !R23TH 6BD# C(((]:175L[6!P<'':@!U%-WJ'";AN(R!GFAG51EF 'N:
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MFO:!\2/!77_A)]+_ / A: .JHKEO^%D^"O\ H:-+_P# A:/^%D^"O^AHTO\
M\"%H ZFBN6_X63X*_P"AHTO_ ,"%H_X63X*_Z&C2_P#P(6@#J:*Y;_A9/@K_
M *&C2_\ P(6C_A9/@K_H:-+_ / A: .IHKEO^%D^"O\ H:-+_P# A:/^%D^"
MO^AHTO\ \"%H ZFBN6_X63X*_P"AHTO_ ,"%H_X63X*_Z&C2_P#P(6@#J:*Y
M;_A9/@K_ *&C2_\ P(6C_A9/@K_H:-+_ / A: .IHKEO^%D^"O\ H:-+_P#
MA:/^%D^"O^AHTO\ \"%H ZFBN6_X63X*_P"AHTO_ ,"%H_X63X*_Z&C2_P#P
M(6@#J:*Y;_A9/@K_ *&C2_\ P(6C_A9/@K_H:-+_ / A: .IHKEO^%D^"O\
MH:-+_P# A:/^%D^"O^AHTO\ \"%H ZDU5O["VU.SDM+R%98)!AE:L#_A9/@K
M_H:-+_\  A:/^%D^"O\ H:-+_P# A: .)U'X'6\UXTEAJ9AA)SY<B;B!Z9&*
M[+PAX TOPE'YD(,UVWWIWZCV'H*D_P"%D^"O^AHTO_P(6C_A9/@K_H:-+_\
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M EW/E1C'0=NE+K'A;3];U33]0NO.\^PD\R+8^ 3UYKA?M'QM_P"?/PU^;?\
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M**/3UL5#>2L7E#GG;C'6L_PWX9L?"]B]G8&4Q/(TA\U]QR3G\N:X/[1\;?\
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MNP^T?&W_ )\_#7YM_P#%4?:/C;_SY^&OS;_XJ@#S:3]GOQ26S]JM')/)+?\
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M_P"HG_X$C_XFO+OBW\.]#\%7VAPZ3]JV7K.)O.EW="H&.!C[QKZES7CGQO\
M"^M^(M1\.R:1IL]XMNTAF,0!V9*8S^1_*@"\/V?O!)[ZE_X$C_XFE_X9]\$_
M]1/_ ,"1_P#$UZF.@I<T >5_\,^^"?\ J)_^!(_^)H_X9]\$_P#43_\  D?_
M !->J9I: /*O^&??!/\ U$__  )'_P 31_PS[X)_ZB?_ ($C_P")KU6B@#RK
M_AGWP3_U$_\ P)'_ ,31_P ,^^"?^HG_ .!(_P#B:]5HH \J_P"&??!/_43_
M / D?_$T?\,^^"?^HG_X$C_XFO5:* /*O^&??!/_ %$__ D?_$T?\,^^"?\
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M?^HG_P"!(_\ B:/^&??!/_43_P# D?\ Q->JT4 >5?\ #/O@G_J)_P#@2/\
MXFC_ (9]\$_]1/\ \"1_\37JM% 'E7_#/O@G_J)_^!(_^)H_X9]\$_\ 43_\
M"1_\37JM% 'E7_#/O@G_ *B?_@2/_B:/^&??!/\ U$__  )'_P 37JM% 'E7
M_#/O@G_J)_\ @2/_ (FC_AGWP3_U$_\ P)'_ ,37JM% 'E7_  S[X)_ZB?\
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M_P"!(_\ B:[SPQX:L/"6A0Z/IGF_98F9E\U]S98DGG'J:V** "BBB@ HHHH
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M$]<@].E>O48I: "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 M%)FC-
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MNT=Z '44@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/[S+#^=<!HNE-JGPGU\PJ#<VNHRW,)/\+)*6)_(&O=8X(H;=8(XU2)5VJ@&
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MYNKB^\536]O;R?ZG3XD4F+ZN!S^==K110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gmz2lq4320rk000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J 3D# 2(  A$! Q$!_\0
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MM !1110 4444 %%%% !129HR>U "T444 %%%% !1110 4444 %%%% !1110
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MF?'30X&O[R].Z$^;=.&?[YXR .*]5\8Z%X=\;:H/#6JQE+U+87-O.C@.,DC
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M@'&26#>E=%H\OB&T\92:7J5S'<Z>MGYD$P3#N=V/G/3/T IOPKO8+_X=Z5)
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M]* .)^&GA*?PUHLUQJ"C^U+^0S7'.=N>B_AS7<"C%+0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)1F@!:*3-&<#-
M"TA(K)U'Q#8Z>IW2!Y!_ G)KD[SQ#J>KR>3:HR(>,1]?SKHIX:<]=D<M7%TZ
M>BU9UFI>(++3EPT@DD_N)R:Y.\\0:GJS^3:HR*QQMCZG\:MZ;X/EG(EOY,9Y
MV@\GZUUMGIUK81A+>)5P.N.3^-:\U&C\.K.?EQ&(^)\L3D=.\'2S$2ZA(5SR
M4!Y/U-==9:=:V,82"%5QWQR?QJUBEK"I7G4W.JEAJ=+X4)12T5B= E%+10 U
M@&7! /UK#U+PO97^75?)E_O+P/RK=Q1BJA.4'>+,ZE*%16DCSFXTK5M!F\V!
MG:,'[T9X_$5JZ=XSY6*_CVGH74?SKL"H(((R#6)J?ABQO\LBB&4]"@P/RKK6
M(A4TJKYG%+#5:3O1>G8U;>\M[N,/!*KJ?0U/7G,^EZMH4WFP,S(.=R'C\16I
MIOC+YA%?Q[3T,@'\Q4RPKMS4W=%T\;KRU%9G94M5[:\@NHP\$JNI]#4^:Y6F
MM&=J::NA:*3-+2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E(
M3CO6;JFM6NE)^^8LYZ(.IKD+OQ!J>K2>3:HR(3@*G7\ZWI8>=17Z'+6Q4*;Y
M=WV.LU+Q!8Z<I#2!Y/[B\FN3O/$.IZN_D6J,BMP%CZG\:MZ=X.EF;S;]RH/.
MP')/UKK+/3K:PC"6\2I[XY-;<U&C\/O,Y^7$5_B]V)R>F^#Y9B);^0J#SM!Y
M_&M:\U7PWX1AC6\NX+7>=J@@L['Z $UJZM>_V;H][?;=WV:!Y=OKM4G^E>'_
M  >0>,?&&L>)-8Q<SQ-B 2#/E\\8_ USU*\ZFYU4L-3I;+4]@M/&'A^^C+P:
ME'M#A/G1D)8\  , 3U[5N#D<=ZYSQ9X4MO$L%JS1Q"ZM;B*:.9ARH5PQ /N
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M..N#7J_P\\=)X[T62]^R_99H9-DD0?<!Z8.!GH>U '8T444 ':N,\=_\N7_
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MR +/_KF*TZQJ?&SHH_PX^@4445!H%%%% !1110 4444 %%%% !1110 4444
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M?_"/)Z4?\(\GI72?A10!S?\ PCR>E'_"/+Z5TG'I10!S?_"/*#TK1L--6VY
MK)G^(&B6WB^+PQ,+I-2F.$!@.P\9^]]*ZG.*  # I<4F:6@ JIJ.GV^J63VE
MU'OADZC.*MTE &;I&AV6B12):*X\P@NSG).*TZ3%% !7&^._^7+_ ('_ $KL
MJXWQW_RY?\#_ *5TX3^,CCQ_^[R.@\/?\@"S_P"N8K3K,\/?\@"S_P"N8K3K
M&I\;.BC_  X^@4445!H%%%% !1110 4444 %%%% !1110 4444 >>^-/^0VO
M_7$?S-=Y;?\ 'K%_N#^5<'XT_P"0VO\ UQ'\S7>6V?LT7^X/Y5V8C^#3//PO
M\>H344E%<9Z M(:*K7UXMA9R7+Q32J@R4@C+N?H!R: /G?P!JL>C_%[7YGL[
MVY#,XV6<!E8<GL*/'VJ)J_Q@\/3):7ELJF,;+NW,3'Y_0]JO_#R#5=)^)FI:
MM?Z!K$-I>L5B8V3G&3P3QP*/B%!JNK_$[2]6L- UB:SLF02N+)Q]U\G''(Q0
M!Z+X]\=3^';S3=%TM(FU;4'58VF&4B4G!8CC/?C(JOI7C;5;#QNWA+Q&;66Z
MG7?:7=M&8T8;<D%22?7O61X]T34-2USP_P",M,T^ZGCLRJSVK1$2A=W)"=2>
M>E,MM"O_ !9\6H_$[V%Y::781X3[7"8WD;;V4\XR?TH K6_Q#\:W'C/6?#T:
MZ6?L<;R),86&T#D9&[GCCMUS5.S^+/BS4/ VIZO%;:?%<:7+LGD9"R2Y. JK
MNR.O7)Z54TVVU6W^)WB'59M!U86EU!)#%(+-R&.,>G0XK&T71=;MOAOXITN;
M0-66[O;A7@3[&_S#(/I0!ZC=?%"*Q^&EGXCF@!O+M1'%$. TO?Z#@FJ$GC[Q
M#X8NM$E\2_8;JPU:-=K6L)B,#M@@$EFW#\JP)/!>K:]\&]+M([*X@U+39S-]
MFN(S&SX)X /L:FU_2]6\?S^%]/@TC4+.*P1)+R2[@:)5*@#"[A\WX4 )XJ(/
M[0_AUP1AE!!]?DKHY?'.M>(?&&HZ)X7ELH(M-B=IYKN$R^8X(&U0&7'?GFN<
M\2Z?J1^->CZC;Z+J4NG606-YTMV*_<VYSBK>G:3J/@3QYKUW)IE]>V.J1R20
MS6D#2D.3G:P7IUH VM&^*J77@S5M4O;0+J&D#9<PHW#OTR/09[5RVH?$GQS:
M>"K3Q2KZ4+:[N/*2!K1RR*<X);?ST]*N^$/"EYH'@OQ+J^LZ6]Q-J(,WV!@2
MQ7)."/7G/X5YC9^./#45M9VFH:1J]Q:VTOF_8FO4%N'[X79G'MF@#U'Q9XS\
M>>&_#NFZ[#/I%U8W2KYC_9'4QEAD<;_K75KK/B'4[3P_+I&HZ;(;R(27#/:M
MAEXRRC?QUZ<]:M Z3\0_AZPMH\65W"552O*$#^E87P<\.W^C>'I?[4=GECE:
M*!6_@0>GL>/RH ],&<#)YI:0=** "N-\=_\ +E_P/^E=E7&^._\ ER_X%_2N
MG!_QHG'C_P#=Y'0>'O\ D 6?_7,5IUF>'O\ D 6?_7,5IUC4^-G11_AQ] HH
MHJ#0**** "BBB@ HHHH **** "BBB@ HHHH XGQAIEU+>+>11EXP@4[1G&,_
MXTNE>,?+58;Z/ ' =:[(J&&#R/2L;4_#5E?@LJ>5*?XDKLA6A**IU%HC@J8>
MI&;J4GJ:=K>V]Y%YD$JR*?0]*GKSNYT?5M%D\V!G9!T:/_"M+3?&17$=^G3C
M>H_G4SPK:O3=T.&,2?+55F=G1UJO:WMO>1[X)5<>QZ58S7,TT]3MBTU="T8I
M,TM(848I,UF:UXATWP_%!)J4XA6>40Q\9W,>@H U*,4@8, 1R#T-&<T +129
M%&: %HI,T9H S=?TE=<T2ZTUIY(!.FWS(S@KSFN2M_"7B>&QCL7OO#[0+&(V
M<:<WF%<8SG?U]\5W_6B@#SJX^&EQ:7^B3:#J[6<.G1&*2*52_F@XR>,#/%=]
M9VL5E:16T.?+C4*N>M349&/2@!:0MBLC4O$=CIX*F022#^!37)W>O:GK$AAM
M494/\,8R?Q-=%/#3FK[(Y*N+A#1:LZS4O$=CIP*EQ)(/X$YKC=1U&\\0W2*D
M&0A^55&2,^M:NF^#I)&$M_(1_L*<G\3766FGVUE&$MX50#T'-;*=&A\&K.=T
MZ^)^/2)'H]O)::1;02C#H@!J]117$W=W/1C'EBD%%%%(H**** "BBB@ HHHH
M **** "BBB@ HHHH 2@TM)0 UE##!%8VI>&;+4 6">5*?XEK;HJH3E!WBS.=
M*$U:2/.KG1M5T23S;=G9!_''_A6EIOC(J1'?Q^V]1_.NR*@\$9^M8VI>&K'4
M 65/*E_OI74L1"HK55\SBEA:E)\U&7R-*UO;>\C#P2JX/H>E6*\ZN=&U;1)/
M.MV9D!^]'S^8K2TWQD5Q'?ITX\Q?ZBE/"Z7INZ+AC+/EJJS.RKQ+XTVM[X@L
M+JZL9&\C0G0R*!]Z1L'(^@;]*]-UKQ5:Z9HS7T$-S>N1A([6%I6W=LA0<?C7
M$66@-K/AB_NW\0>([>&?<UQ:-9*IR><!6CW,!TXKE::=F=JDFKIG5_#CQ"GB
M7P1I]VC9D2,129ZAEXY^N*XV/XE^)W\>:EX:CT^QN7MU9H?+5E+<9&26QTKG
MOA!J6H^$]4O])O=*UC^S)Y2;:9K&3 .< D;>,BK7AM;F'XY:EJ,NF:BEI<9B
MBF:SD";A[XX'!YI#+FO?%#QEH.D:->76DV,4U[,T,MO+&ZL"&(!&6X! [^M7
M3\3/$UGXXM_#EWIEC*]Y"KP>22I1F7=\Q+$' SG'6J7QT@O;^\T*"RTV^NC!
M.)I&@MGD55!]0.O-8NH-=7'QBT76H])U4V$$"+))]AEX/E8Z;?6@#NO OQ$U
M#7M5U[3=6MK<3Z87*M;*P#A3@\$GFJ'AGXFZSXDGOWM;>P=(9_+6S&5N%3=C
M>03\P Z@#O6'\,8KZR^('B:ZFTJ^BCNO.>!IK5U5_GR!DCO63XE\/7%QXITN
M_P##NCZEINMS3*UVL<3B 9Y+;R-O/IGBA:@_,^BZ#TS6'=^(;73(%2:437 7
MYA'W/]*Y>[U[5-9E\FU5D0_PQC^9K>GAISUV1R5L93IZ+5G6:EXBL=/!5G$D
M@_A0YKE+O7=4UF7R;565#_#&/YFKNG>#I)");^0C/.P'G\ZZRTT^VLHPEO$J
M >@K;FHT?AU9AR5\1\7NQ.4T[P;+(1+?R$9Y* Y/XFNKM-/M;*,)!"J >@JU
M17/4KSGNSKI8:G36B$Q2T45D;BT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %)2T=Z &D!@01D5BZGX:LK\%@GE2?WDK;HQ51G*#O
M%F<Z4*BM)'G5SH^JZ))YUN[L@/WH^?S%:6F^,RI$5_'R.-ZC^8KL2H(P1D5C
M:GX:LK\%E3RI?[Z5U*O"HK55\SB>%J4G>B_D:=K>V]Y&'@E5P?0]*GKSNYT;
M5M$D\VW9V0'(:/\ J*TM-\9E<17\?/3>H_G2GA7;FINZ*AC4GRUE9G9TA-8E
MYXIT^VA#K)YK,,JJUR]YKVIZQ)Y-LCHAXVQCK]344\-.6KT1I5QE.&BU9UFI
M>(['3@5,@DD_NIS7)W>NZGK,ODVJ.B'C;&/YFKVG>#9)6$M_*1GG8#D_B:ZV
MUT^ULH]EO"J#V'-:\U&E\.K,%#$5]9>ZCDM.\'2R,);^0C/)13R?J:ZVTL+6
MRC"6\*H!Z"K-%<]2O.INSJHX:G26BU"EQ24M9'0%%%% "8I:** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $H-+1
M0 TC(P1D5C:GX:LM0!8)Y4I_B3C]*VZ*J$Y0=XLB=.%16DKGBGAG4;76_'EY
MX=,4B_8]V]R1\VUL5[!::?;6482"%4 ]!7A/PY_Y+OXA_P"VO_HP5] U=2M.
MI\3,Z6&IT_A0E%+161N)12T4 )2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S_\
M./F^.OB(CG'FY(_ZZ"OH"OG_ .%7_);?%/\ VV_]'"OH"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ^?OA5_R6WQ3_ -MO_1PKZ!KY_P#A%^_^
M-'BU^FSS^/\ MN!7T!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?/_ ,&O^2R>,/\ MX_]*!7T!7S_ /!K_DL?C _]?'_I0*^@* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHJG=WJ6PP#ND/11_6@">:>.!-TC "L>YOY9\JA*1_7DU7D=YGWRMEOT'TI*
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MO_S,/_7Q7N@KXW^&&F:KKOB^VL+&YGA@+B6Y:-B/E'K^.!^-?8T:".-8UZ*
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M>\-W=C:WAPMP)TE5>,\[<T >C457LKR'4+."[MI!)!,@=''<$9%6* "BBB@
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MJS0K(IR&&: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JIJ,WE6;8^\_RC\:MUB:E-YMT(QRL?\Z
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MM3A1U;TH +:V:ZEVCB,?>/I6\B+'&%0  # IL,*01A$& *EH **** "BBB@
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M10 4&@;F;8BEF/85I6VE]'N/F/4)V% %6ULGNCN.5B[GN:VXHDB0(B@*/2G
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?,4M% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gmz2lq4320rk000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .9"#<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1B#4(0"R \./45YO\<O^1NM_^O=?YFL;X>NUE\3[1+?+*TYC)7^Z36S\<O\
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M^/5M#YNEW  $Q#J2.XXJHR7M.5(4HOV?-<[+X/\ _)/;3_KI)_.N\K@_@_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7\6/ %U
M'J3:_I%N[I)AITBZJ_3( _#I69I'QIUO2+!+*\L8KEXEVK))E6]@0*^A" >"
M./>LNX\,:)=3>;-I5FS^ODKS]>*WC65N6:.>5%WYH,^<+V[\1_$WQ!$?)=R2
M$4(#Y<0SUST_K7T/X9\-P:!X8@TC"N F)3_?)ZUJVFGV=@I6TM(+=3U$487/
MY59J:E7FT6Q5.ERZO<^9M<T/6OAWXQ&H6L3M"DOF0R@95AG.T^E;VJ_&V_U#
M29+.ST_R;J5=AD4YV^XKW6XM8+J(QW$,<J'JLB!A^1K/A\,Z)#(9(])LE<]_
M(7_"K]M%KWEJ3[&2?NO0\H^$7@>]CU)O$.IPO" O[A&&"Q/4D?E61\<./%UM
M_P!>Z_S-?084*  , = *J7.E:??2>9=V%M<.!@-+"K'\R*E5GS\S&Z*Y.5,S
M?!?_ ")>D_\ 7NM> >-/^2KW?_7W_6OIJ.)(8ECBC5(U&%5!@ >PJI+HVF3S
MFXETVT>8G)D:!2Q/UQFE"IRR;[CG3YHI'-_$3PJ_BKPHT%N!]KA(DB]\#I^-
M>-^$?'&K?#V2XT^\L'>!FRT4@P48>E?2HZ8JC>Z)IFHG-YI]M.W]Z2)2?SQ3
MA5M'EDM G2N^:.Y\\>)_%VL_$F^MK"RL76!6RL2#.3_>)[?_ %Z]D\*^&/\
MA%? DEDYS<- [S'/\14Y%=+9Z1I^GX-G8V\!QC,<04_F!5QE#*58 @C!!Z43
MJW7*M@A2LW)[GS)\)/\ D?[/Z'^5?3F:HV^BZ7:2B6WTVTAD'1XX%4C\0*NU
M-6ISRN52AR1L?,GQ(M[C2/B//<R1MM\U)D..&Z'K7J?A_P ;ZEXX\.ZJ-*C%
ME?VZCRF(#;CP3UR/45W=]I&GZF +VR@GQT,D88CZ9I;'2K'3$*6-G#;J>OEH
M%S]<54JJE%)K8B-)QDVGN>#Z-\3M?\-ZK<1>)()[F-LJT;H%*D'J.@K-\<^+
M;#QJ]K!HVAM!,C[F81+O?C&/E[5]$7NC:;J/_'Y86T['C=)$"?S(IEIH&DV#
M![73;6)QT=(5#?GBJ5:*=TM271DU9O0Y_P"&>@W/A_P=;V]X"L\A,C)G[N3P
M/RKLNU)BE[<UA)\S;.B,>5)'!_%CQ-+X>\*%;5RES=MY2,.H'?\ 2OG?1]5_
MLK5X]0>VCNGC8L$FY!;U/XU]=W>GV=^%6\M+>X"G*B6,/C\Q54>'-$_Z ]A_
MX#)_A6U*LH1M8PJT7.5[GAX^.>N !5T^T '  )KW/0;^35-#L[V50KS1AF"]
M!4?_  CFB?\ 0'T__P !D_PK2BBCAB6.)%1%& JC %1.<9;*Q=.$HO5CC7S;
M\6-,O].\<3:C-"SVTQ#QN1E?I7TD:K7=C:7\7E7=M%/'_=E0,/UHI5.25V.K
M3YU9'CDOQ;?6-"_LC1M%N3J,L?E @ HO&,\&N3^%4IL?B3;I=?NY'5X]K?WC
MCBOHBRT33-/;=::?:P-_>CB53^8%*NC:8ER+E=.M!.&W"00*&SZYQG-:>VBD
MTEN9^QDVFWL>$_'#_D<+?_KW7^9KVCP9_P B;I/_ %[+6A=:3IU[()+NPM;A
MP,!I858X^I%68HTAC6.*-411@*HP!]!6<JEXJ)<86DY'S/XQ_P"2LW7_ %^?
MUKV;XE^%Y/$WA1H[49N[<B6-1_%QTKJ)=%TN:X-Q+IMH\Q.3(T"EB?KC-7<4
MY5;V\A1I6OYGS9X*^(5]X$6?3+VR>2 OGRR,,C=\9]:J^/-<U?Q:D.MW-D]K
MIT;>3 I[D\_CTKZ,N-!TF[G\^XTVTEESG>\*DGZG'-32:5I\UNMO+8VSPH<K
M&T2E1]!C%:*M%2YK:D>QE;EN<=\'S_Q;RS_ZZ2?SKO:AM[6WM(1#;01PQ#HD
M:!5_(5-BN>3YG<WBN56///BSX;O]:T*.ZTV27S[4[FB1B-Z]QQ7G'A3XK7_A
M326TF\L3.8B?++Y#+DYP<U]%$9&*R[KP[HUY+YD^EV<CDY+&%<D^YQS6D*B2
MY9(SG3E?FBSYZTG3-9^)/C7^TI82L3RJTLN,(BKT /?H!7TK!$MO;QPI]V-0
MH^@&*9;6=M91>7:V\4"9^[$@4?D*GI5*G/Z#IT^3U#-?,OQ?_P"2@7G^ZG_H
M(KZ:-4;G1M+NY3-<Z;:3RGJ\D"L3^)%%*?([CJPYU8;H?.@:=_U[1_\ H(K0
MQ3458U5%4*JC 4# %.K-[EK1'FWQGTF^U'PK%)9H\@MY=\B)U(X[5Y_X ^)=
MKX1TF73KK3)IF:0NK0@!LX P<D>E?1#J&!5@"".01UK+'AK1!<&<:39>8><^
M0O\ A6T:JY.1F,J3<^9'S)XVO]3UG6SJU_9R6R7*Y@1UQ\G^<U[KXC1M;^$L
MALQYNZS#*%Y+8':NON=*T^[V_:;"VGV\+YL2MCZ9%3Q00P0K##$D<2C"HB@*
M![ 43JIVLM@A1:O=[GR_X$\;2>![N^?['YQN$52K<8*Y_P :[_XU70O?#.B7
M(7'FLS8].%KT^3PSHDL_GOI%D9,YSY"\_7BKD^FV-W$D5S96\T:?<22(,%^@
M(INK%R4K"5*2BXW. ^%ME'J7PO:RE_U<SR(WT(%>6VK:Q\+?&3336C/&-R]/
MED0GJ#7TM;6MO9Q>5;01P1@Y"1(%'Y"F75C:7RA;NT@G Z"6,-C\Z4:UI.ZT
M8Y4;I:ZH\+\1?&+4M:%O;>'[::UDW98[0S,?0#GBO4_"#Z]+X2,_B&0->2*S
M!0@7:N.,X[UKVOA[1[*3S+;3+2.3J'6%01]#CBM' Q@C.>M*<XM6BBH4Y)^\
MSYE^'O\ R5&S_P"NS5[UX[Y\#ZMC_GA_45IPZ+I=O.)X=-M(Y@<B1(%5A^(%
M6Y88YXFBFC62-AAD=00?J*)U.:5PA3Y8M'@OP*'_ !4=]_U[G^8I?CI83KX@
ML[SRV,+Q%0X' (QP:]QM=+T^Q<O9V%M;L1@M%"J$_D*?=V-K?1>5=VT4\?7;
M*@8?K5>V]_G)]C[G*>7?#GX@3:W%#X=2W$$EO9[(Y^N64 #BN6NO&_C+PGXK
M;^W&EN(8W(*% J2+V((X]#7N-AH6E::Y>ST^W@<_Q)& ?SJQ>:=97ZA;NT@N
M%["6,-C\Z%4@I-VT#V4^5*YX'XS^)&C^*=&>RLM *7LI'[YXTW#GL1S79_!;
MPW>Z3I5U?WL;1&Z.(XV&#@=R/PKO;?PSHEJ^^'2K-6!R&\E<C\<5K  # & *
M4JJY>6*"-)\W-)BT445B;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !113)9%BB:1SA5&2: '45R!^)WA
M)6(.J*".O[MO\*=%\2_"<K[%U9 <9Y4C^E5R2[$\\>YUM%4M/U:PU6'SK&[A
MN$]8W!Q]?2L_6_&&B^'IXX-3O!!)(,J-I.1^%*SO8.96N;O:EJII]_;ZG8Q7
MEI)YD$J[D;&,BK=(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BJNH:
MA;:78RWMW)Y=O$NYVQG KF/^%H>$O^@JO_?MO\*:BWL2Y);G8T5R<'Q(\*7!
M(35H^/[RE?YUTEI>VU]")K6>.:(]'C8,/TH<6MP4HO9D]%<YJ7CKP_I&HFPO
M;\1W*XRFPGK^%=#'(LL:R(<JPR#0TT--,?1112&%%%% !112&@ HK)UOQ)I7
MAV!9M3O$@5ON@\L?H!S570O&F@^)',>F7Z2R 9V,"C'Z \T^5V)YE<Z&BFEL
M#).,5@Z7XST36=6GTNQNFFNH,^8HB8!<>^,4K,=UL=!124M PI.]'-4M1U>Q
MTFW,]_=101CN[8S]/6BS8FTMR[17%#XL>#FF\H:H=WO"X'YXKJ--U:PU>V%Q
M8744\9[HP./KZ4W&2W0E*+T3+U%5-0U&VTNQEO+N3RX(EW.V,X%<S_PM'PE_
MT%5_[]M_A0HR>R!RBMV=A2UQW_"T/"/_ $%5_P"_;?X5L:)XITCQ$LS:7=B<
M08\S"D8SG'7Z&AQDMT"G%]39HKE+OXC>%[&[EM;C4E6:)MKKL8X(_"H?^%H>
M$N!_:J\_[#?X4^2787/'N=C16-IGBG1=9(6QU&"5ST3> Q_ \UL9-)IK<I-/
M86BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ57(S@\?RI3C%PCS,<)24G9'K^GZM8:K#YMA=PW"CKY;AL?6K98 9/ KYD\
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M#@_0U]'^$]3EU?POIU],<RS0*SG'5L<U\SR:N_BGQ1%<>);]HHRP5WV9VCT
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M>+:C\8=3C\836VD0PW=D7$42,#ECZC!KG?\ A6OCZ13:E7\L9X-U\I_6N\\
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M/55Q53QE\-O$FL^.)]4LK>%K5Y%96:90>/:O4]:\/6OB#PX=)O@=K1@97JK
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M?UKV7PCX5M/"6C)86WS/G=))CEV]:4Y1C3Y$[E0C*4^9JQT-%%%<IU!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N&^+_\ R335
M/HO\Z[FN&^+_ /R335/HO\Z -7P#_P B'H__ %[C^9KI*YOP#_R(>C_]>X_F
M:Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D/BA_R3G6/^N7]12_##
M_DG&B_\ 7$_^A&D^*'_).=8_ZY?U%+\,/^2<:+_UQ/\ Z$: .NHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBF[U!P6 ^IH =12;@>A!^E% "T
M4F>*0,#T- #J*** "BBDSQ0 M%-+ <$@>G-.H **** "BBB@ HHHH **** "
MBBB@ HHHH **9++'!$TDKJB*,EF. *A@U"TNK<W$%S')",Y=6X% %FN&^+__
M "335/HO\Z[*UO;:]C\RUGCF3.,HV:XWXO\ _),]4^B_SH U? /_ "(>C_\
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MDH 6BHI94AC+R.$4#))IT;K(H96#*>A%*ZO8=F/HHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC$*"3T')I])C-
M# PKSQ186\4A5RSKQMQU-<[IWB^Y6_8W>6@D/ '\%=O<6-O<1/')&I5Q@\5@
MZ;X1MK/4'N)&\Q0?W2D=*\G$TL9*M&5-Z'I8>IA%3DIQU-6QU>TOY3% ^Y@-
MQ&.U:--6)$^ZH%/KTX*5O?W//ERM^Z<QX_O;G3_!>H75G.\$\:J5DC."/F%<
M#?P>(]$\-0>(5\;7-R^Q)?LLOW3NQ\OWN>OI7<_$I&?P%J:JI8E5X49/WQ6'
MH'PK\,MI^GWTMO</,T22.DDN5+$ GBK)-BZ\?:=I&D:?=:HLYGN85D\N"+<>
M1R<>E4]4^)NEQ>%I-7TX23MO\H1LN"C?[7I53Q?XBO=%U^TTXPW46D/#M#6<
M67+=  <C Z"N5T33[B3P+XL@:WN$G-QY@2498K@$9]Z .DD\:0ZWI6AW:ZC?
MZ?(]ZL4BQ0<2MQ\I^8?+SUKH]=\?:'X<NEM;MYY9\99+>/>5^O(Q7 7VI1ZQ
MX?\ "(M;>X4VNH1Q2B2/;@@KD_2J7B6TO]$\<:E=W.HZII]O=A6BFL8?,+C
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M_P"2::I]%_G0!J^ ?^1#T?\ Z]Q_,UTE<WX!_P"1#T?_ *]Q_,UTE !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!K('4J>XP:X'6/A)H&I6]R%:\CGFR0_VER
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%)F@!:*3-+0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 )BC'%+10!GVNB:=9W\][;V<4=S/_K)%7EJ
MOTM%-R;U86"BBBD 5S5EX;GMO'.H:^T\;0W,"Q+$ =P(QR>W:NEI.: *6KV'
M]J:3=6/F-&)XRF\=1FO.(OAAKGV>RAN==@>*QN%EMXEBPN V3NXR3UKU2C%
M'$WOA'5V\90Z[IVIPVZLBI<1LF2X'4#BJ]I\.<Z!K.EW]S&XO[HW$;Q@_(>,
M9S[BN^Q1B@#SO0O >MV%_"U_J>G2V<)!5(K&,.<=,L4_6MW1_#$^G>,=8UIY
MXFAOE0)&H.Y<>O:NGQ1B@#@;;P!<Q^$]8T:6\A,E[</-&ZJ<+D#&?RKHO"NF
M:GI&BI9:K>QW<T9PCQKM 7L.@]ZW,48H \_UKP'JLVM7MYHFL)90Z@,7<3IN
MW?3CBNOT#1H=!T:WTZ!F=8EP6;JQ]:T<4M !1110 4444 %%%% !1110 444
M4 %%%% !1110 5PWQ?\ ^2::I]%_G7<UPWQ?_P"2::I]%_G0!J^ ?^1#T?\
MZ]Q_,UT=<YX!_P"1#T?_ *]Q_,UT= !FH;N<6UI+,>B*6-2FLF^URUMKV*RX
MDEE8*5[ 'UK*K4C"/O.URZ<)3EHKEK2[B:ZTZ*>=0LCC) J[3% "@  #T%/[
M54$U%)DR:;=@HH[4=JH1F+J!_MMK H -F]6]:U*S[BYMH-1MT=/WTP(1\?2M
M =*SI[M7N7-;.P444'I6I R1]B,WH,U0T>]>_M7F=0O[QE&/0'%7+B58+=Y'
M&549(J+3YHKFRCFA0(D@W!<8ZUD]:BU+2]QZ%DUFZ58S64MV9&RLLI=!GH#6
MD:S+,W7]L7@EW>00ICSTZ#-*HESQ;Z#BWRM&I2TE+6QF%%%(>E !44\\4";Y
M7"+G&2:DK-O+*+5)H3Y^8H7RZ*<Y(Z UG4;2]W<J"3?O;#[+38[:YGNMYDDF
M.=S=AZ#VJ^.M"@!<#H*6G"*@K(4I.3NPI:**L04AI:* $/(Q69I5M<VKW23\
MHTI:,ELD@UIUE/-=)K\<?S&VDC/0<*1_^NL:EE)2-(7::1JBEI!2UL9A1110
M 4444 )113=P'>D(?12#I2TQA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "T444
M %%%% !1110 4444 %%%% !110>E "=ZYCQAJ%S:6BQ6[!5DX8@_-CVK7EU6
M"._2S!+S-U"C.WZ^E,71K<W4US,6F>08&\\*/0"N/$*5:FZ=-Z]SIP\HTIJ=
M1778X_PC=WRZCY,(,D#<R GA?>O01ZUDQ0Z=H,B(D?EFX?;D9/-:PJ,!0E0I
M^SE*[7X%XVLJU3VD8V0ZEI*6N\XPHHHH **** "BBB@ HHHH **** "BBB@
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MDYU?_KE_44[X8?\ ).-%_P"N)_\ 0C0!UU%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !112'K0 M%(.M+0 G:BEHH 05P_Q
M?_Y)IJGT7^==S7#?%_\ Y)IJGT7^= &KX!_Y$/1_^O<?S-='7.> ?^1#T?\
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MM:2G*BD8'8<=<5G:1-=/'+%> ^;%(5W8X8=C6/P3]3364?0TZ***V,Q:***
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M*Q5TS]TBKXIPDI*Z%).+LQ:***H04444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD\.J4H7:(;?6;"YXCN$SZ'BKRR(P^5U/T-4KG1=/N^9;6(MZ[1FJ3>&XH_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDRLW4M70U6LK"&QMD@@4*JC\ZM5UX>G*G249;HY:\XSJ.4=F%%%%;F04444
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MB-1T!/4UI8K&*YI<S6Q<G9<J8ZBBBMB!#THQ2TE !112T )BC%+10!!-:P7
MQ+$CCT89KFM>\*Q36YEL$6.1>2@& U=71CUKGKX:G6BXR6YM1Q%2E)2BSSG1
M=&U5'^W0QE#&<;&.-]=9:^(("XBNXI+6;IB0<'Z&MH#%07-E;W<92>)74]F&
M:YZ&">&C:D_O-Z^+^L2O57W$JR+(NY&# ^AIU8+:)<V3E],NFC_Z92'<I_PH
MBUR6U?R]3MGA.<>:HRA_K6ZK\NE16_(Q=&ZO!W_,WA3)(UDB9&&0PP13(+F"
MX0/#*KJ?0U-FM])(Q::9G:59R:?:FV>0.%8[.>=M:':LV]M+@ZG:75NYVJ2L
MBD\%36GGBHI:7C:R14]=;[@*6D!I:U("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#P&_O+"X\3ZTFO^+-6MIX
MKIUBCM&?RQ'D[0,'KC&:]B\)&U/AJT^QWD]W!M^6:?.]OKGFO+[E-9\->(=3
MAA'AX1WEV\T273_O/F8GD[3ZUZQX>^V'1+<W\5O'<%<LMN<Q_A0!JT444 %%
M&:3(H Y'XH?\DYUC_KE_44OPP_Y)QHO_ %Q/_H1IOQ0/_%NM7_ZY?U%+\,3_
M ,6YT7_KB?\ T(T =?129HS0 M(>E+FHIY/*A9^RC-)NRN)NRN8^C->OJ&I2
M7.\1>=MB5O[N!TJD?#UU<^/4UVXN$:TM[;RK>($Y#DG<3^&/RJU;:I?WGA::
M_AMP]WL<PQ+_ !D9P*3P;87VG^&K>+4Y99+Y\O-YCEBI)Z ^E70O&FY)[F=-
M>Z0^.=;O?#WA_P#M&RC#M',GF C/R?Q5<L-.2#5I=2$H7[9&F8\=QGG]:O:H
M\<.FW$LD'GK&A8QX!W8[<USL%PWBG2M%UO3P8\2!S&S8PN>0<?2E43=-22V8
MJJV=KM'6TUY%C0O(P51U)/2E&<#-><_$75=0B=+%$,=I(,EQ_'[5SXBLJ,'-
MD8K$*A3=1H]$CF25 \;!D/(([TDMQ% F^6147U8XKR[P=K.NQ6\D%I:-=VZ=
M"QQM]A5+QCJVL75TL%]"UM$HW+&#P3ZYKE>8)4?:6.-YI!4/:\K/858,,@Y%
M.KB?A]JU]?64D-TI9(<!96ZG-=FTL:, SJ"> ">M==&JJL%/N=V'KQK4U474
M?5'6'N(]*N&M5+3!/D"]<U=S6-XAU2XTZ.U6V0/)/,(^1]2?Y5<W[K+J-*#+
MND+.FE6JW+,TWE+O+')SCFKU,3[HSUI]4MBHJT4%(>M+2'K3*,3Q%X<MM?L]
MD@"S*/W<@Z@TSPWX9MM MMJ8>X?_ %DI')_^M6]28K+V-/G]I;4Q^KTW4]K;
M4=1116IL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU^BO(/\ A>3?]"?K?_?C_P"O1_PO)O\ H3];_P"_'_UZ /7Z#TKR#_A>3?\
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MH_X7DW_0GZW_ -^/_KT >OT5Y!_PO)O^A/UO_OQ_]>C_ (7DW_0GZW_WX_\
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M\F_Z$_6_^_'_ ->C_A>3?]"?K?\ WX_^O0!Z_17D'_"\F_Z$_6_^_'_UZ/\
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M_H8+;_OE_P#"C_A67A#'_(%M_P#OFC_A67@__H"6_P#WS7C:=30/^%H^"O\
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M?!7_ $,%M_WR_P#A2_\ "L?!_P#T!+;\J/\ A6/@_P#Z EM^5 "?\+1\%?\
M0P6W_?+_ .%'_"T?!7_0P6W_ 'R_^%+_ ,*Q\'_] 2V_*C_A6/@__H"6WY4
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M_?+_ .%+_P *Q\'_ /0$MORH_P"%8^#_ /H"6WY4 )_PM'P5_P!#!;?]\O\
MX4?\+1\%?]#!;?\ ?+_X4O\ PK'P?_T!+;\J/^%8^#_^@);?E0 G_"T?!7_0
MP6W_ 'R_^%'_  M'P5_T,%M_WR_^%+_PK'P?_P! 2V_*C_A6/@__ * EM^5
M"?\ "T?!7_0P6W_?+_X4?\+1\%?]#!;?]\O_ (4O_"L?!_\ T!+;\J/^%8^#
M_P#H"6WY4 )_PM'P5_T,%M_WR_\ A1_PM'P5_P!#!;?]\O\ X4O_  K'P?\
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MK7FXW SJ6]C*R['?A,;"G?VRN^Y;TR87>GPS-!Y99?NL*N;$_NK^5"KM&%X
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MJ* &[$_N+^5&Q/[B_E3J* &[$_N+^5&Q/[B_E3J* &[$_N+^5&Q/[B_E3J*
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MEI_<7\J4  8 Q2T4Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2T4 )12T4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 E%+10 UNAKSS5];:'5)?[/
M#0X;,A(^^1[5Z(>E<_K'ABWU.=)@?*<'YR/XA7GYC1K5*:]B]3MP-6E3J7JK
M0M:#JXU>R\PH5=>'XX_"M8=*K6=G#96ZPP(%51C%61TKKHQG&"4W=G-5<7-N
M"LA:***U,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ I#TI:0]* /$=137_$.H:YJ5I;Z'-;Z=<21HUQ"OF$*3P?ICO70_#WQAK&H
M7UKINJK9O'=67VJW>V&-@!4;2.WWOTKC/$IT34O%6H/INA>(ITCG9+HV#E89
M9 2&R/KFO4?!N@:7"D>N6VES6%S+;K ()F),2* ,?H* .O'2EH'2B@ HHHH
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MD%1MJVFK]Z_M1]9E_P :Y<?"_P -?Q07+?6[E_\ BJ>/AAX3'73G;ZW,I_\
M9JKEPZ^T_N_X(79O2^(=&AC9WU6R"J,G]^O^->3W7QU@C\7K!#;A]&4F-Y<?
M,3G[P]J[QOAGX2,;+_92\C&3*Y_K7EMY\"+M_%7E6MP$T9\OYI(W)_LX[_\
MUJ[L## -R]JWMU)ES=#W:QOK;4K**[M)DE@E4,KJ<@BK?:O,;!/$GPZLUM#9
MC5]%B^[) ,31CW7O^ KL="\6:1XBBWV-TID'#0O\DBGW4\UP5:#B^:&L>Y29
MNT4@HKG&+1110 4444 %%96NZ_I_AS3)+_49UBA0=^K'T ]:DTC6++7=-BOM
M/G66"09!!Z>Q]*KDER\]M OT- UP7C)O[5\7^'-#0@A9S=SIZJA!']:[RN \
M.@ZQ\3==U5AF&R1+.%NV1DM_Z$*VP]TW/LO^ )ECXD6DL&D6NOV<>ZYT:47
M [H,;A^0%==IM]%J.FV]Y"X:.9 P(J2ZMXKNUEMYD#QR*593T(-<3\.KF2Q_
MM+PO<N3-I<V(R?XHF^[C\C3O[2CYQ_)_\$6S.]HI**YBA:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_F:Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "DI:3% !0*,4M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4AZ4M(1D8H \.U>2^\/^)-56P^(&G::EQ<-
M*UKY0;822>>#SS7JWA.ZEO/#=I//J":A(R\W*)M#^^*\JUSPC/I]W?7!CT>X
MO!J$D\27$ZJTT4F\D-EN""5Q]*]*\!6-SIW@ZQM;N2%Y47GR6#(H[*".#CI0
M!TXHI*I:MK%AHE@][J-PD$"=68]?8>IH O45@:?XST'4])N-3M[^/[+;_P"N
M9_E*?4'D5/H/BC2/$L$DVE7:S+&<.,88?@>: ,CXH?\ ).=8_P"N7]12_##_
M ))QHO\ UQ/_ *$:;\4/^2=:O_UR_J*=\,/^2<:+_P!<3_Z$: .N[5PNI:7:
MWGBB[L[MV2&Y@64E6QC:3W^@KNNU<EXAMT7Q%ILK_=G5X&]\@_XUAB%HI=CE
MQ:7*I=F>/^*O@]>1Z['-HLJRZ9<MN,K,#Y('4D]Z]J\%:19Z/X<MH;.5IE(R
MTK?QGH3C\*EL],:V\-/IMU< ;D=!(#T#9QU^M:6F6:6&GPVL;;EC7 /K7=6Q
M]?$1A"IT15.+YDVNA;-<;\3I[Z'P/?\ V&P6\9T*NI&=JD<L!W-=E2,BNI5@
M&4]0144I^SFI-7L;M71\A^!M7UJP\96EQI<+7=XS;#$W.X'J">P]Z^MX\S6R
M^?& S+\R'D#VK%TCP5HFB:M=:E8V:1W%R<L?[OT]*Z#%=^9XV&+J*4(VLB81
MLCE;S3?#?A#S/$/V(6_DQE7>%6/RGKD"L32;E+#XIW<<!!M-8M%N4<=&9<Y_
M]"%=[?64&H64UI=1B2&52KJ>XKRWQ(FF>%;_ ,._9[UF?1Y565'8;O)?N?;Y
M:RH-U;Q;;;7_  WXC>AU/Q$U.6T\/#3[0_Z=J4@MH0.O/4_AC]:Z#0=)AT/1
M+338!^[MXP@/K@=:XNQ=?%_Q,:_C=9=.T:+9$RG(:5NI!Z'&W]:]%%8UE[."
MI_-_UZ#04M%%<XPHHHH **** "BBB@!***6D!\T?$KQ0VF^-;Q/#[W.GLP47
M> 5$C@Y# 'VQ]<5V/P?U)/%&HWNIZJ9[G580%221/W:)C^'C /6NN\>?#;3_
M !I%')N%K>QL/WZCEESR#70>'/#=AX9TF*PL(515'S-CESZFO;JXW#RP:IPC
M[_?_ ()FHOFN:_&:6D I:\4T"BBB@!**6B@!BHB#"J!DYX%.I:*-0"DI:* $
MHI:* $XHX%%%&H 0",$9KEM>\":5K+_:(@]A?CE+JU.Q@?<=#^(KJJ3'-5"<
MH.\6#5SSP:OXL\'*$UBV.LZ<O N[9?WJC_:4=?P%=7H?B?2?$-L)=.O(Y#_%
M&3AU/H5/(K79 PP0"#U!KDM<^'^FZG+]LL7DTS45Y6XM3MY]QT/Y5OSTJGQJ
MS[K_ "%L==FEKSI?$'BCPAB/Q!9'4[!3@7UHI+@>K*,_H*['1O$.EZ]:B?3;
MN*=>ZJPW+[$=0?K6<Z$H*^Z[H+FI249KFO%_BE?#]BD5O&;C4[H^7:VZ\EF/
M&3[#O40@YRY4,\=^.,&H3>((@M\US;B/?]EC&?('/+8_K6K\!]+U=4N-1^V8
MTMB4^SYSN;'7VZBO1/"?A!--L9KG5MMYJ=]\]U)(,@9_@'H *R=*C'A3XDW.
MF*-FGZNGGVZ@85) ,,H_ #\Z]EXU2PKPL5MU[F:BU+F.WU6_32])NKZ7[EO$
MTC?0#-<S\,K%K?PE'=R9,U]*URY/7DX_D*C^)]PY\,II<#8GU.=+51ZAC@_H
M:ZW3K9;/3K>V4!1%&%P/85YGP4/5_D7U+5>?^*4'AWQSI/B1#MM[H_8KPYX
M)^4GZ9:O0*X'XN:OI6G^#+FVU!LS7*E;=5^]O'0CZ9HPB<JJ@E>^@2V.]4AE
MR.AYI:\-^&GQ<EGNTT?7Y-QD8+!<8Q_P%J]R!R![T\7A:F&J<E1"C)26@M%%
M%<Q04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "5XSXOO-&GU[6K"ST#6+^XE$?VF>P!Q$X ((.T_-@8_.O5M:2X
M?1KI;2\2SGV$K<.,B/'<UX_::/XCM[&^\46OQ#LEM)F N+E;;Y&*G9GKZ\4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?S-=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ,4444 %%%% !136<(K,Q 51DDUS=IX]T"\TS4M1CN\6FG2F&>1A@;AV'
MKUQ0!TU<-\7_ /DFFJ?1?YUM^'/%^D^*4F.G2/OA($D<J[6&<$''IR*P_B\0
M?AIJOT7^= &MX!_Y$/1_^O<?S-=)7-^ ?^1#T?\ Z]Q_,UTE !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4AH+  D]!UKG=<\8Z7I6DW%S'=13SI\D<*,"6D)P!^9H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2'.#CK2T4 >6^)I?B-=6-W9II5HUM-+L#6TY\PQ;N<_+QE>/QKSW3;
M;4!X(\464>C2VUM;ZE!,R9W%0K1[EZ<\#.:^DZC6&) P6-1OY; ZT >2^$5;
MQ#XL\37FCSO#;3:=%;1W:C&V7:.GN/Z5SWCWP'XITKP=>WE_XTO+^WC W6\@
M.U^?K7O<$$5NFR&-47.<*,"N+^+_ /R335/HO\Z -7P#_P B'H__ %[C^9KI
M*YOP#_R(>C_]>X_F:Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :Z!U96&588(/<5
MQM_\*O"-^=S:6L3F3S2\!V$MZYKM** /+M-^#]O8:/K=D+Y]]],)8)",^7M8
M,O'<Y YK=\(^#KW2M2OM6UF\2\O[N-8&*1[56-0 !C/? -=I10!PWQ,TZRA^
M'NK/':Q*PBX(7IR*M_##_DG.C?\ 7$_^A&D^*'_).=8_ZY?U%+\,/^2<:+_U
MQ/\ Z$: .NHHHH 2L_6K6VO-*GBNRHB*'+'^'WK1JM?6<-_:26TZAHY!AA4S
M5XM$5%>+1Y/+XIDO$@T>ZD'V)7"23@\LH/\ A7K%FT36D1@(,6T;2/2O,_\
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M HHHH **** "BBB@ KAOB_\ \DTU3Z+_ #KN:X;XO_\ )--4^B_SH U? /\
MR(>C_P#7N/YFNDKF_ /_ "(>C_\ 7N/YFNDH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1HDHI*6M#8**** "BBB@ HHHH *2BB@ -0O=11S+$TBAV^ZN>33;R5H;261
M"RJ2 3@&O$=1UK4KS6OMLLCK<1MA IX7V%<>*Q:H65KMG!C<<L-96O<]S>14
M7<[!0.Y-8]]XJTVS.Q93/-_SSB&XUBZ3HFH:[8I=:W=SC?\ \NZ'8,=LXKIK
M#1M/TU-MK;1Q\<E5 )^M:1G4J*Z5D:PJ5:L4XJR\S#-]XCU0_P"B6:64)/\
MK)CEL?[O_P!>I8_"4=PXDU6[FOFSG:YP@_X#734=ZI4>LG<M8=;R=RM:V-M9
MQB.V@2)!_"HP*LX%%%:I)+0V225D+BC%%%,84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5PWQ?_Y)IJGT7^==S7#?%_\ Y)IJGT7^
M= &KX!_Y$/1_^O<?S-=)7-^ ?^1#T?\ Z]Q_,UTE !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!EC5^6_&O:K2VBM;=(HD"(HP% Z5C0KO%+:R.?#8EXV-TK(@TO2;;2K806Z
M>K'DL?<]ZOC.:**[HQ459'I1BHJR%HHHIC"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;XO\
M_)--4^B_SKN:X;XO_P#)--4^B_SH U? /_(AZ/\ ]>X_F:Z2N;\ _P#(AZ/_
M ->X_F:Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M3%!'I2T4 )7#_%__ ))IJGT7^==S7#?%_P#Y)IJGT7^= &KX!_Y$/1_^O<?S
M-=)7-^ ?^1#T?_KW'\S724 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*,4M%
M ''_ !0_Y)SJ_P#UR_J*=\,/^2<:+_UQ/_H1I/BA_P DYUC_ *Y?U%+\,/\
MDG&B_P#7$_\ H1H ZZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XZOI^9S?'6_P_F34445N=(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<-\7_\ DFFJ?1?YUW-<-\7_ /DFFJ?1?YT
M:O@'_D0]'_Z]Q_,UTE<WX!_Y$/1_^O<?S-=)0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!R'Q0_Y)SK'_7+^HI?AA_R3C1?^N)_]"-)\4/\ DG.L?]<O
MZBE^&'_).-%_ZXG_ -"- '74444 %%%% !1110 4444 %%%% !1110 4444
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MG^\>3^M:W>M*,6HW?4UH1<87>[%HHHK4V"BBB@ HHHH **** "BBB@ HHHH
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M?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"C[1#_P ]H_\ OH4
M245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y[1_]]"C[1#_SVC_[Z% $
ME%1_:(?^>T?_ 'T*/M$/_/:/_OH4 245']HA_P">T?\ WT*/M$/_ #VC_P"^
MA0!)14?VB'_GM'_WT*/M$/\ SVC_ .^A0!)14?VB'_GM'_WT*/M$/_/:/_OH
M4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?0H^T0_\ /:/_
M +Z% $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?_?0H^T0_\]H_
M^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"C[1#_P ]
MH_\ OH4 245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y[1_]]"C[1#_S
MVC_[Z% $E%1_:(?^>T?_ 'T*/M$/_/:/_OH4 245']HA_P">T?\ WT*/M$/_
M #VC_P"^A0!)14?VB'_GM'_WT*/M$/\ SVC_ .^A0!)14?VB'_GM'_WT*/M$
M/_/:/_OH4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?0H^T
M0_\ /:/_ +Z% $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?_?0H
M^T0_\]H_^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"
MC[1#_P ]H_\ OH4 245']HA_Y[1_]]"C[1#_ ,]H_P#OH4 245']HA_Y[1_]
M]"C[1#_SVC_[Z% $E%1_:(?^>T?_ 'T*/M$/_/:/_OH4 245']HA_P">T?\
MWT*/M$/_ #VC_P"^A0!)14?VB'_GM'_WT*/M$/\ SVC_ .^A0!)14?VB'_GM
M'_WT*/M$/_/:/_OH4 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1
M_P#?0H^T0_\ /:/_ +Z% $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?
M^>T?_?0H^T0_\]H_^^A0!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\
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M% &A16?_ &WI7_/_ &__ 'V*/[;TK_G_ +?_ +[% &A16?\ VWI7_/\ V_\
MWV*/[;TK_G_M_P#OL4 :%%9_]MZ5_P _]O\ ]]BC^V]*_P"?^W_[[% &A16?
M_;>E?\_]O_WV*/[;TK_G_M_^^Q0!H45G_P!MZ5_S_P!O_P!]BC^V]*_Y_P"W
M_P"^Q0!H45G_ -MZ5_S_ -O_ -]BC^V]*_Y_[?\ [[% &A16?_;>E?\ /_;_
M /?8H_MO2O\ G_M_^^Q0!H45G_VWI7_/_;_]]BC^V]*_Y_[?_OL4 :%%9_\
M;>E?\_\ ;_\ ?8H_MO2O^?\ M_\ OL4 :%%9_P#;>E?\_P#;_P#?8H_MO2O^
M?^W_ .^Q0!H45G_VWI7_ #_V_P#WV*/[;TK_ )_[?_OL4 :%%9_]MZ5_S_V_
M_?8H_MO2O^?^W_[[% &A16?_ &WI7_/_ &__ 'V*/[;TK_G_ +?_ +[% &A1
M6?\ VWI7_/\ V_\ WV*/[;TK_G_M_P#OL4 :%%9_]MZ5_P _]O\ ]]BC^V]*
M_P"?^W_[[% &A16?_;>E?\_]O_WV*/[;TK_G_M_^^Q0!H45G_P!MZ5_S_P!O
M_P!]BC^V]*_Y_P"W_P"^Q0!H45G_ -MZ5_S_ -O_ -]BC^V]*_Y_[?\ [[%
M&A16?_;>E?\ /_;_ /?8H_MO2O\ G_M_^^Q0!H45G_VWI7_/_;_]]BC^V]*_
MY_[?_OL4 :%%9_\ ;>E?\_\ ;_\ ?8H_MO2O^?\ M_\ OL4 :%%9_P#;>E?\
M_P#;_P#?8H_MO2O^?^W_ .^Q0!H45G_VWI7_ #_V_P#WV*/[;TK_ )_[?_OL
M4 7Z*H?VWI7_ #_V_P#WV*3^W-+_ .?^W_[[% $]Z9%LY6A022!3M4GJ:\*N
M9KM-7>1XS'<"8MY8'1L^E>W'6]*_Y_[?_OL5ES1>&KC4TU%[BV-P@P&WBN'&
M865>W*[6/.Q^#GB>5Q=K&EH4]Y<:1!+?0B*=E^91_.M$5GC6]+ Q]OM\=OG%
M+_;FE?\ /_;_ /?8KLBG%)'="/+%1[&C16?_ &WI7_/_ &__ 'V*/[;TK_G_
M +?_ +[%46:%%9_]MZ5_S_V__?8H_MO2O^?^W_[[% &A16?_ &WI7_/_ &__
M 'V*/[;TK_G_ +?_ +[% &A16?\ VWI7_/\ V_\ WV*/[;TK_G_M_P#OL4 :
M%%9_]MZ5_P _]O\ ]]BC^V]*_P"?^W_[[% &A16?_;>E?\_]O_WV*/[;TK_G
M_M_^^Q0!H45G_P!MZ5_S_P!O_P!]BC^V]*_Y_P"W_P"^Q0!H45G_ -MZ5_S_
M -O_ -]BC^V]*_Y_[?\ [[% &A16?_;>E?\ /_;_ /?8H_MO2O\ G_M_^^Q0
M!H45G_VWI7_/_;_]]BC^V]*_Y_[?_OL4 :%%9_\ ;>E?\_\ ;_\ ?8H_MO2O
M^?\ M_\ OL4 :%%9_P#;>E?\_P#;_P#?8H_MO2O^?^W_ .^Q0!H45G_VWI7_
M #_V_P#WV*/[;TK_ )_[?_OL4 :%%9_]MZ5_S_V__?8H_MO2O^?^W_[[% &A
M16?_ &WI7_/_ &__ 'V*/[;TK_G_ +?_ +[% &A16?\ VWI7_/\ V_\ WV*/
M[;TK_G_M_P#OL4 :%%9_]MZ5_P _]O\ ]]BC^V]*_P"?^W_[[% &A16?_;>E
M?\_]O_WV*/[<TK_H(6__ 'V* -"BHH+F&ZC$D$JR(?XE.14M !1110 4444
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M4;G'!XH \!^'GPVB\7>'Y-0N]9OHY%G:(!&XP/QKK?\ A1EA_P!![4?^^O\
MZ]=YX>\/Z7X3L#8:>2D4DADQ))DDFML&@#RC_A1EA_T'M1_[Z_\ KT?\*,L/
M^@]J/_?7_P!>O6** /)_^%&6'_0>U'_OK_Z]'_"C+#_H/:C_ -]?_7KUBB@#
MR?\ X4;8?]![4?\ OK_Z]<3X7^'T>M^-?$6BS:Q?)#IDP2)E;EASUY]J^BVD
M1/OLJY]3BL'2_#.CZ+K.HZS:LRW&HN'G9I,J3ST].M '$?\ "C;#_H/:C_WU
M_P#7KN?"7AB+PII']GPW4UROF%]\QYYK>!##(((/<4M !1110 4444 %%%%
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MZVZQ_P!JA-@;>,XQCI0!QG_"A/!O]V^_\"#_ (4?\*$\&?W;[_P(/^%>H4M
M'DU]\"O!]OI]U,BWVZ.)F7-P>H!([5Q_PP^%OAWQ9H=W=ZD+HRQ7+1+Y<NT8
M!-?0TT23PR0R#*.I5AZ@UF:#X<TSPU:26VEP>3%)(9&&<Y8T <)_PH3P9_=O
MO_ @_P"%'_"A/!G]V^_\"#_A7J-)F@#YW^*7PN\/>$O#4=]I@NA,TZQGS)MP
MP2 ?YUU^G_ KP?<Z;:SR+>[Y(4=L3]R :]!U_0=)\3VO]GZG&L\:,'V!N01T
M-:%N]M'&EK!+&?*4*$# D #% 'F__"A/!G]V^_\  @_X4?\ "A/!G]V^_P#
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M_P#X4)X,_NWW_@0?\*/^%">#/[M]_P"!!_PKU&B@#R[_ (4)X,_NWW_@0?\
M"C_A0G@S^[??^!!_PKU&D)Q0!\]?%+X5^'?"/@Z34],^U"X65$'F3;A@L ?Y
MUU.E? WPA>:19W,@OC)+ CL1/CD@$UZ'KNC:/XKT]M,U$)<0[@S1JXSD'(K2
M@2WLX8;2,JBH@6-">< 8H \V_P"%">#/[M]_X$'_  H_X4)X,_NWW_@0?\*]
M1HH \N_X4)X,_NWW_@0?\*/^%">#/[M]_P"!!_PKU&B@#R[_ (4)X,_NWW_@
M0?\ "FO\!O!JQL=M]P/^?C_ZU>IU#+/ A\N2:-6;HK, 30!\\?"_X8>'_%NE
M7UQJ?VHR0W+1)Y<NT;17>?\ "A/!G]V^_P# @_X5VNB:%HOA2WD@T]4MDF<R
M,&<?,36V#GH: /+_ /A0G@S^[??^!!_PH_X4)X,_NWW_ ($'_"O4:* /+O\
MA0G@S^[??^!!_P */^%">#?[M]_X$'_"O4:#0!Y=_P *$\&_W;[_ ,"#_A7G
M^J_#/0+/XL:9X<B^T_8+F,LX,N6SC/!KZ.>1(UW2,J*.I8XK$G\/:)>:];^(
MI$1KVW7$<P<8 QB@#C/^%"^#?[M]_P"!!_PH_P"%">#/[M]_X$'_  KTV*:*
M89BD1QZJ013Z /+_ /A0G@S^[??^!!_PH_X4)X,_NWW_ ($'_"O4:* /+O\
MA0G@S^[??^!!_P */^%">#/[M]_X$'_"O4:#TH ^>OBC\*_#GA+P9-JFFBZ%
MPDB*/,FW#E@#_.NFT;X'>$+[1+*ZE%[YDT".V)SU(R>U>C:YHVD>*=/DTS4
MEQ 6!:-7&<@Y%7[46MI%%90N@$2!%3<,@ 4 ><?\*$\&?W;[_P "#_A1_P *
M$\&?W;[_ ,"#_A7J-% 'EW_"A/!G]V^_\"#_ (4?\*$\&?W;[_P(/^%>HT4
M>7?\*$\&?W;[_P "#_A2-\!?!JJ3MON/^G@_X5ZC37D1$+2,JKW+' H ^<_A
MI\,?#_BE-6.I?:B;:X,<?ER[>*[[_A0G@S^[??\ @0?\*[31M!T7PPD_V!4@
M6Z?>Y9Q\QK<!R,CGZ4 >7_\ "A/!G]V^_P# @_X4?\*$\&?W;[_P(/\ A7J-
M% 'EW_"A/!G]V^_\"#_A1_PH3P9_=OO_  (/^%>HT4 >7?\ "A/!O]V^_P#
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M*V:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/2EHH KW<4L]G+%#
M,8)70A9 ,[#V.*\=L-*.E_$/1[#0]6OK^_CD+ZS.\A,;)D<8S@'KQ7L%_!-<
M6%Q!;S&"9T*I*!G:>QK@?"OPYUCPO?++#XD:6W>?SKB-K<9F]06SF@#T<4M(
M*6@#C?'_ (G?1=.BTZPEC75M0)CMO,; 7CEB?0<?G63\%[AY?!<T4UX;J>*]
ME5G9]Q//6NH\0>#=#\3-')JMC'<21*5C9Q]W/_ZJH^!/ ECX'L;F"V;S)+B4
MNTNW!Q_"OX9- '6B@G"D^@H%+0!\\W.KR:MXCU[5-4&L>3IVH>2EU:2X2T0,
M0,KD9S@9KWZRE2>QMY8Y?-1XU99/[P(ZUP&I?#"6YU#4A9:P]KI>JRB6]M?+
M#;V!SP<\9->@V=K%964-K"-L4*"-!Z # H EKE/B/<36O@749+>\^R2[5"R!
MB"<L,@$=R./QKJS6+XH\/0^)]#FTV:1HBQ#)(O5&!!!_2@#S?X63O%XJO+13
M>V=NUE'(+.]D+.[G:3(.V.OYU['7%>&_!5YIVN-K.L:JVH7BP"WB/E[ B#'Z
M\5VM !1110 4444 >9?&5=?_ .$9N)K&_2TTZ*+=-LSYCMD\>PZ4[Q%I-C>>
M'=*U/7M9N;?2;:T4O:0L5,SE>#D'D].*Z_Q=X>'BCPY=:29S )P!Y@7./PKF
M/%'PXO/$#:0L6MM;P:;&H2,Q!U9Q_$03]* +OPM355\&QG57E8M*S6_G$EQ#
M_"#[]:[:L?P[IVH:9IOV?4M1-_-OR)3&$PN!@8%;% !1110 5@>+8-:N=&>'
M1;J&UE8_O)I!DHF#G;[UOU%/%YT$D6<;U*Y^M '@,7B#4;+X):<(KFY,UW?^
M3)+&W[PJ>H'N:[GX:M:66J:GI:'4[2X3:YL+Y]^P'/S*<GKW_"K,7PPMU\ Q
M^&GOY#)#/]HAN57#(_;C-:GA?P?/I&JW>LZIJ)O]4N46-I=FP*@Z "@#K:**
M* "D/2EHH S-?L9]2T2ZL[>_>QDD7'VA!R@SDX_#^=>*_:6\.W&OS^&+^]N-
M.LK#9=3RRED>X+*"5SWY->R^)=)N=<T"ZTVUO7LI)UV><HR5&><?RKC]"^&=
MYIFD2Z+=ZW]ITF6)HVMQ %Y/.[.>N>: .?\ #*3>&O&WA:WMKRZFBUS3OM%V
MLTI<&3;NW#/3I7LXKA/#GP_GTO6[74M3U5K][&#[-9 QA?*C_P <5W8H 6BB
MB@ IDRL\+HC['92%;&<'UI]1SH\MO)''(8W92%<#.TXZT >*W>EMHWC32;?2
M-:O;[6C<^=J<S2GRU@SDAAG ^7/%5M8\67FN_$#0KZ.]6+18]0^SPQB3!D*[
M2SD>G./PKKM&^%EWHMY<S1>*+B5+N;S+I'M5S,.ZEMV<8XJ34?@WX7O+^QNH
M(%M?L\OF2HB B?IP?2@#T0$$ @Y!I:;&BQQJBC"J  /04Z@ HHHH 2O&OB)I
M"65[<7AUJ_N?$%Y,!IEK Y7R1GI@'ITYKV4UYY=?#2^E\77/B.#Q1/#=3?*H
M-JK>6G]U23TH \]\97-\=<U8W4U[=7EI;Q>5/:2E8[)^=V\?E^5>YZ!*TWA^
MPEDNENF:!29UZ2<?>'UKC[[X8RW$VIM;>(9[:/5447T8MU;S2,Y;)/!.37::
M/I<&BZ/::9:Y\BUB6*//7 &* +]%%% !1110!Y]\2- ^VV<FIO<:C.MK"WE6
M-F^SY^SGGG%<S#:0:Q\/M*U?Q!XHN&LK2!UEBA<J99,D $YR6'3\*[[Q!X4O
M=6U(7UAK]UIKF$PR(B>8C@_[)( /O7,7?P<CFL=+L[?7[F&*Q=IMK0AQ)*Q)
M+D$]<DT ;/PL35!X.C;4VG*O*[6PG.9!%N.S/X8KMZRM!TV]TNR,%]JCZC)G
M(E>()@>F 36K0 4444 !KFO&6AG7-*6)KV[A@B)EDAM3A[@ 9V9R.N/UKI:P
M/$WAV?7XK4VNKW.F7%M*)$DAY#>S+D CZT >)'Q%J6G>#I=,BNKT>;JPM_LW
MFDW$$1V?)GU.3W[UZ#\,9K6"_P!4TQ'U*">':[V-ZV[RP?X@<G.:G;X46TUG
M>FYU:>75+JY2Z.H>4 R.N,87./X1WK9\,^"_[!U6^U6[U.74;^\54>61 @"K
MT  )]Z .JI:04M !1110!E>(]=M/#>AW.J7C8BA7('=CV KP^T\2:U:WGBS4
M[W4$%^^G+/#&DNY8BV?E'TKW36M$T_7]/-CJ=NL]L6#%&'&1TKB$^#'AJ/4K
MZYC0I%<P>2L"H,1>K ^IX_*@#G/"8N/#OB_PU%#?74\>LV+27:S2EPT@V_-@
M].IKVH5PWAWX<C1-7L]0N]8FU%K*V-M:H\001KQZ$Y/ KN10 M%%% !45Q-'
M;023RL%CC4LQ/8"I:AN;:*[MY+>=0\4BE74]P: /"Y?%MQKGQ2\/ZM)?)!HQ
MGEB@B\S^%4<%V'N1Q]:?K/BRZ\0>/]#OX+Q8M%COVMH4\S!D(5@SD>F00/J*
MZ^]^"OA6ZU:QNXK=8(+<DRVRH"LV0>">V,_I3[[X->%KF^L;FUMUM!;2^8Z1
MQ@B48. ?3G!_"@#T0,",@Y![TM1QQK%$D:#:J *H'8"I.U !1110 F:\.^)G
MBZXU;4%MM+O%ATW3+R%+EQ)M:60NO ]@"#^=>XUY[XC^$'AS6XV:"U2UNGF6
M5YE4$L,Y(_'I0!YSXROKB?Q'JT@NKV[%M:Q-:RVDQ"61QSO_ )\9ZU[OH$K3
MZ#8RO<+<,T*DRKT8XZUP=S\*)()[V/1-8>PL-1B$5Y (PV1C!V\\9%>@Z3ID
M&C:3:Z=;Y\FW0(N: +M%%% !1110!Y3\3[+6]3\0:7#9Z??W6GP1R/.+6;R]
MQ.,9.?8UGI:Z#K/@RTU2;6]2M-$L_,66S>4[WFXX+9R<?UKNO$GAG5=2U*+4
M-)UZ>PF2,QO$1OC=3WVDXS[URE[\'I9+'3+.TUV6.*RD,[!X@PEE.,LP)]J
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MIUYI>EK;7VHR:A,&),[KM)'IB@#4HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMQH$)U/197:6Z<OYC'<3QSTX/^-9\NB67B #Q-X'NQ:ZE'\TMH#MR>XQ_D4
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MH.G1V-A"(X4'XD^I/>M 57O+ZUT^W\^[G2&/(&YS@<T6M_9WG_'M=0S?]<Y
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M-JSR##'V- '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444AH #TK#UZ#0=7MFTS5IK0EQ@+)(H=3ZCG
M(-:=_))%IMU)",RI"[(/4@'%?/MA;6/B>)8'$TOB2YNF\V5Y"!;J"23UQT%
M'3S6FN_#.X:2$-JGAV4_-&?FV ^W^172>&/"^B7>K6_BO1I9[>"926MAE5+'
M(.1]?PJ;P5JIU"34-!DA\ZST\"(2NWF>9P,Y//J:[:""&V@6&"-(XU&%1!@"
M@"2N+\5?$"W\*^(+/3[VU=K:XCWM,.=O)']*[2N/\2^#1XB\4:=>7.R2PBA>
M.:,]>0<']: )]0\,^&O&.FB98('6096> !6!^H_K7(VMQK'PUUB&TU&>2]T"
MY<+'.YR82>.<U7NM'U_X:7S7^C&2^T5FS+;$Y*#Z?X5Z'+;VWB_PL$NK5HTN
MXL[)!\T9[&@#;C=9(U=#E6&0:=69X?L;G3-#M;*[G$\T*[3(.XSQ^E:= !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM3(X![ D&NJ\(>&H_"NA)IR2F4[R[N>Y/6M^B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,U6U&]CT_
M3[B\E^Y#&7/OBII9%BB:1R BC+$] *\MU;XJVCS302:1/+HDCM ]U@X8]#M/
M2@"E!XYO8)H_$&J:DIM)RPMM)@4%V'(&XXX]>M-TO0="^(=]=7UF+[1+Z-OW
M\<9V[P>_M3X?#>F:9;V^L>%;3^W)IG_=K</E;<$>G'ZUV?@?PS<Z+%=7VI,A
MU*]D\R54^[&.RC'X4 :_AWPW8^&M.%I9*3D[I)&.6<^IK7Z4M4M6N9K+2[JY
MMX#--%$SJ@/4@4 7.M>?^+IO$NI^*=/T?2$EM+52)9;L#@@'GG\.E;G@WQ5%
MXJT?[1M$5U$Q2>'^XPKI![T 1K$3 L<I$GRX8D?>]:D"@  # '&*6B@! ,4M
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4454U/4K72=/FO;R41PQ#+$T 9?BOQ$GAO2/M/E^;<2,(X(
MA_$YZ5P]]XOAMM(N;#QLT4D]T?EM+<!C$ON1T(X[U'JGB30/B.B:0UQ/I=TD
M@DMI9?E#G![_ (UES^'GT._N-&M=,N=7U:[C"OJ%PA,<8.#P3Q0!>T3X:R7=
MD'TOQ$_]AW>':-1AV'H3BO5].T^WTNPALK5 D,*!5 ]JH^%M$'A[P[::;OWM
M$OS-ZL>3^&:US0 9IK,$5F.<*,G KG_%GBN'PI;VL\\#R)/,(V8#A!ZDUNV\
M\=U;QW$+!HY%#(0>H- '"^'/$FN>(O&EZ8H?(T6US$5E3!9AW'O_ $KN)K*U
MN9HIIH(Y)(CF-F4$K]*DCACBW&.-4W'+;5QDT\4 &*,4M% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 AKG/%GC&P\*6T;SJT]Q*<16\?+/70REQ$Q1=S@':/4UX?;Z
M]%I_Q"O+_P :6TJSH&^R*5S&@'3 [\=Z .\T/Q5;>/-(U&Q$4MA=*A1TDZKG
MO7%:]!IWA2^\/Z%K+R2Z3;(\TK>62)7(/H.GS4RQ\,WOC-]4\3S74FE6<H)A
M6([-P7H3^5;WPPC/B#0+B'6HDOH[.XV6\THSD<]#WH =\+O#20FXUV*2XCM;
MB23[/;,2%";SM./I7IV*;'&D,2QQHJ(HP%48 I<C.,\^E #)IXK:)I9I4BC7
MJ[L !^)KSW5=4\<6^I3:AI4=EJ6E,?DCC<, .AZ')-,\<PW6M>*+32;@W$.C
M10/<W,D0P&V@GD_@!7%Z-=^(/!D=KJ^GA[K2K^=TBM#EF(!(Z=<X&: &:?XM
MD\/>.AJ)TNXT^VO"%N[>52JY/&Y<]AUKWR":.>&.:-@T;J&4CN#7&>,=+O?%
M/@I([;2XUO;DQDK*0#$-P/7Z5TV@V#Z7H=G8R/O>&,*S>] &E1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %(:6L3Q5JESH_AV[O+.V>XN$7"(@)/UXH SO$GQ!T/PQ>):7LS-<-R4C4
MMM'OBJWB/3_^$\T#3I=*O$-HTZS.3T90#P1^/2O//#^K>'X?"VIZMJDBZAK=
MTQ1HI1\V3G  _J*9'I?C+PIX-MM735OLUM$V];(J,@-SSG^5 ":V-%UB[\07
M%Q*MK>VDJVUA#'\I^4[<@=^E>J^"-+U/2] B35K]KN=@"NY<>6O9?7\ZI:)X
M;T+7(+'Q+=:5$+^>)96/.-Y&<XS794 +5>]EEAM)7MXQ+,%)CC+ ;CZ5.QPI
M/H*\.U^ZO_%$FLZM)J,]G#IUP+6TMXR5WON _&@#4UGQG?W&GW6E>+?#4T<,
M@($\"$JA[')ST]JF^$OBZ.=9?#T\Y<PDFUD?@LGI]:/#'C34;34(O#7BNP>>
MY(41R"/><$9&0!Z59\1>%)7^(6C3Z+IYMD3Y[BXC&$ZG(/;)'% 'J Z4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3\:^*E\/VD$4%S#%=SR*JM(NX(I."V.];FC32SZ7#-->QWC.,B:*+8K?ADT
M:%%<YK7B[3-/M[R&/4+<:A%&2L1.?F[5+I?B"+_A%[35=5N(H?,0%W/ S]*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_*N >/4(O EOXA;5[YK]2K<3MY9&_&"N<'BIX-/6\^(]G<27-V'DL5F;;<,
M#SQCTXZ4 >D44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&"\L"LWYD5>6-40*BA5 P . !0!S,>G^);V[L_[2N+:VM;=M["SE<M,1T#9
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gmz2lq4320rk000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /=!V\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $S2U%//';6\D
M\SA(HU+,QZ "N%T+XO>%]?U_^Q[6X=9F8K&[J0KD>AQ0!W]%%% $4]S!:Q&6
MXFCAC'5Y&"@?B:>DB2QAXW5T89#*<@UROQ \'R>-?#W]FQ7S6;^8'#CH<=C6
MGX7T-O#GARSTIKE[EK= IE<Y+4 ;-%<5XW^)FB>!WBAOO,FNI1N$,77'J3VJ
M_P"#/'&D^-M.>ZTUV#1G$L3\,AH Z:BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBD- "T4E% !FEI** #-+244 +
M29HHH ,TM)10 9I:2B@!:*3O10 M%)10 4M)10 M%%% !29H-8OB7Q+8>%M*
M:_OF.,[4C7[SGT'^- &UFC->./\ %GQ1<9N-/\+%[(\K(T,C<?4<5UG@KXC6
MGBR9K.2!K6_1=QC;HV.#C_"@#M\TM<%>^.KVW^)47AE+6W-J^/WIW;^4W>N*
M[P4 +1110 F:,U@>,]>G\-^&Y]2MHHY98R %DSC]*3P7K\_B7PU!J=Q%'%)(
M2"L><<?6@#H:*** "DS6?KM^^EZ'>WT2*[P1-(JMT) S7DEI\6_%]_$9;/PU
M%<1@XWPP2N ?J#0![7FEKSSP;XS\3:[K?V35O#YL;?86\TPR+S]6XKT.@ S2
M9KF_''B<^$_#SZA''').7"1H^<$G/I]*YGP%\2[KQ1J\FGZC:6]K)Y?F1>7N
M&[IZGWH ]*S1FBO/_B%\0;GPA<VEK8VT%Q<3#>RR[N!T'0T >@9HS7'^ /&3
M^,-+FFN(HH+J&3:\<>< <<\\UFZ7\0+^7X@3>&]2L[:&,$K'(FX%CVZGO0!Z
M%FC-9GB#5ET/0KO4G (@C+ 'N?2N)T?X@ZOJ'@G5?$,]A:)]EX@5=V'/?.3]
M* /2<T5S7@7Q'<>*O#4>IW4,44K2,A6+.W@^]8OC+Q[?>&O$VFZ7;VEO+%=%
M0SR;LKE@.,'WH [_ #1FN9\8^,K7PAIB7,\9EFE.(HE[GW]JX'_A;7B>,"ZG
M\,%;#J9/)D'R_P"\>* /9<T5A^%_$MIXJT9-0M 5R=KQGJC>E<EXF^*:Z=JD
MFE:'8-J-\AVMM4LN>X ')_"@#TC-+7CL'Q?UFPN4'B#P\UK;OW6-T;_Q[K7J
MVF:C;:MIT%_:2;X)E#J?8T 7**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BL2#Q3IEWXADT6VE\VZB4M+MZ)@XQGUKG/&/CJ^\.>)M+TNWM;>2*\*AWD
MW;AEL<8.* .^HIJDG!]J=0 4444 %)FJ>K7CV&DW5W&JL\,9<*W0US?P]\77
M?C#2KB[N[>&!HI-@$6<'\S0!V-)FEK@F\=7P^)A\,?9;?[+_ ,]?FW_<W>N*
M .]HI!2T %%%% !1110 F:6O/]#\>7VJ>/[KP]+:6R00EL2)NW' SZXKOZ %
MHK@O#OCJ^UCQQ?:#-:VZ0V^[;(F=QQZY-=Y0 M%%% !112'IQ0 N:*XSPMXG
MUW6-?O[+4M'-G;0$^5-Y3KYG)[MP?PKLZ "BBD- "T5Q?Q \8WGA"VLY;2W@
MF,\FQA+GCZ8-=5I]PUYIMK<N K31+(0.V0#0!:HHHH **** "DS2U#=2/%:R
MR1KN=$+*OJ0.E $U%<CX'\1ZUK\=V=8TK[ 86 C'E.FX?\"KKJ "BBB@ HHH
MH **** "BBB@ I,TM<!XV\>7WAG7K#3[:UMI8[D#<TF[(Y[8- '?9HS2*2R*
M3W&:Q]>\3:;X=BB:_FVM*VV.,<EC0!M44R-_,C5P,;AG!I] !1110 4444 %
M%%% !1110 F:6O/_  YX]OM9\<WFA36ELD$!;;(F[<<#W.*[\4 +1110 444
M4 %%%% "9HS61X@\1Z=X:L1=:A-L4DA%')<^PJ/7M<DTSPI<ZQ;1*[1P^:B2
M=#]<4 ;E%<QX#\2W/BOPXNI74,4,AD9-L6=O'U-=/0 4444 %%%% !1110 4
M444 %)FEI,T &:6L+3?%.F:OK-SIME+YTMLH,C ?*,YXSWZ5N4 +1110 49J
MM?3M:V%S<* S11,Z@]#@9KDOA[XSO/&%M>RW=M! 8)-B^3G!&/<F@#MJ*2EH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0T &:,UD
MZ_XBT[PW8&[U&;RT.0@ZESZ"M"UN%N[6.X0$)(H89]#0!/1110 4444 %%%%
M !29K"\7ZOJ.B:!)>Z78F]NE=0(=C-D'J<+S5CPYJ%[JN@VM[?VOV6YE7+P[
M2NT_0\T :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AJCJ6L
MZ=I"HVHWL%LLC;4,KA=Q]J ':K8QZII=U8R,56>,QDCMD5XIX6^!=QH/BJ/5
M=0U2)K&T<RIM&"V.F3FO=8W21%D1@R,,J1WKQWQOK.I^.O%@\$^'9S%:PX;4
M;E.P[C/Z?6@"_P")/C9IEEJ!TS0+5]6ORVP>7]S=_7\*Y37OB!\3=.2&>YL+
M*T^T-M@M@"97^BYR:["[^%_@7POX<GO;RS9_LT1=YWD^=CCL?4GI7-^&O GB
M6U@@\5Z=<Q/=-DP6%\I?$/8 Y&#[X[T ./Q*^('AG3XM0\2>'$>P8C<ZJRLO
MUYXKT'P;\2M!\:)LLI_*O ,M;2G#?AZU07Q!8>.-$U+PYJ-JUCJQA9);.;[P
MX^\OJ*\K\)^"3KW@1M4T5FM/$.EW+JDB''FJ,8!]Z -OXS_#?7==U]-;TB%K
MI6C$;Q+]Y2/05O?!+P%JOA2TO;W5E,,MU@)!GD#U/O71_#/QJWB[0&6\7R]5
MLR(KJ,\'=ZX]\&NX% "UY]\2_B._@%;)EL1=?:21][&,5Z#7@7[2?^IT;_>;
M^M $/_#24O\ T E_[^4#]I*7/.A#'_72N=^$'PZT7QO9ZA+JK7(:!P$\EPO8
M>H->EO\ L^>$&C(2;4%)Z'SE_P#B: &>'_C_ .'M4G2WU&WET^1CC>QW+GZX
MXKUB">&Z@2>WE62)QN5T.00>X-?)WQ*^%-WX&"7UO.;G39&V[]N#&>P/^>U=
MO^S[XQN)9KCPS=RF1%3SK<L?N@<$?J/RH ]8\=^*F\'>&I=66W^T&-@NS..M
M<?\ #[XP/XV\0-I9TP6X$9??OS5WXY_\DVNO^NBUY#^S_P#\C^W_ %[M0!]3
MBEHHH *1B "3QCO17A'QN^)4UE(WAC29BDI7_2Y5/(!_A'IWS^% '6>+/C7X
M;\-S/:V[-J%VA(*0-\JGW;I7G5U^T=K#2DVNDV:1]A)N)_0BN,\ _#35?'ET
MTRDP6"-^]N7&<GT'J:]QL?@+X/MK94N$NKB7'S.T@Y^@Q0!RFC_M' RJFL:0
M I."]NQ&/P.:]@\->+M&\667VG2;Q)MOWX\_,GU'45Y+XL_9\M&MGN/#5U*D
MRC=]GG(8/[ C&/UKQG2=7UOP)XE\R!I+:ZMI-LL3=& Z@CWH ^W12.RHA9B
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M/%7AF&_M]9CL0JG81&&>8CN3T'ITK<^+W_(@W'_71/\ T(5H?#C_ ))]I/\
MUR/_ *$: ,7X9>,M0UY;ZPU4B2XLL?O0,%NO7\JS$\0^)_'/B*\M?#VH+IEA
M9\&?8&+'MP?7%9WPD0R:_P"(HU.&8  _BU<[H.B:+9^(]2TSQ5>W6GR(V8Y(
MYO*5NN<Y!_"@#T/PIXMU>T\5S>%?$4J3W*C,5RHP7^H]^M86K>)O%<OQ*GT'
M2]0*)*=B*Z@K'QG/Z4>"M,\/7?CEFT>VU.9;(D_;I;M61NW39SG/K262@_'F
M3(Z$X_[Y- &CXJB\9>%O#"ZC_P ))+=S0R@S$1*%*D\#&,]<5T&I^,D@^&@U
MZ.4"::#:A'7S#\N1]#74:QIT>K:1=6,BAEFB*X/KCC]:^=8!J5_=6O@EU.R&
M^)Z_P9Y_QH ]6\,:]J6F?#Z;Q#XANY;EV!DC5P!QT"\#N0:R=)F\>>,;%]9L
M]7BTVW)(AMUC!#@?7I74>-/#TE[\/I]+LD^>&-61%_B*\X_&N>^'_CC1--\(
MQV.I7D=I=6F4,<AP6^GK0!I^ O&MWK-S>:-J\:1ZE9G!*]' Z_C_ (UF^%/$
M>L7_ ,4M7TNZOI)+* 2^7"0,+A@!VS6=\-[2;6?'&K^)TB>.RD+K&6&-Q8__
M %JS]&U*V\-_&/5Y=6E6VBF,JK))PHRP(.?3B@#HOB;XDU?1=>T2WTZ^>WBG
M.)54 [OF [BK/Q%\9ZAX?33;*Q=8)+P#?<NN0@Z9KC/B3XAL->\6:/\ V;*+
MB&W=5:5.5)+#H>]=C\1;[2H8-.M=;T62YLI0H%Y'+M,)_(]J ,9=4\9:7+;7
MUEKL?B>V=@)H;:(,4'?A>:];M9C<VL4QC>-G4$HXP5/H17SOXDTG0=%MX[WP
MMXE,TNY=MLLFY_KQC^5>[^&)+V;PU82:CG[6T0,F1S[?IB@#C/B+XSU#2=7L
MM%L+A+(W #27CC(0$XX[<8K,MM5\8Z1?VL\.JKXGT^4XE^RQAM@_X#TK1^)%
MYHK:G9V'B'1Y3:2\)J,<P4QYZ_PGIQ7GNOZ;I.@S6USX4\2FZE:0 01ON9?<
MD?X4 =_XV\1:UX=\7:1=QWDPTBZ($EN4  [8/&>_Z5)\1/$NJVFM:)IFBWK0
M-=MEFC )9<^X/:KOC#1KO7OAPC74?_$S@B68X&,.!S_.N%^'LMQXN\:V5U=H
M673+4 $G.2 %H Z+QGXPU:S\2VOANUU*/30(U\Z_E4'G;G/IBETK5_%VD:Y:
MI+>'Q)I=P0&N+6/<(\G&?EZ8Z\TGCZX\/7?BB'3/$>ERVR.H\O4TF"\8ST*]
M,\5Q&H6=OX?U[3SX1\0F_>650(HFW;>>A(]?I0!T/QJM-15[.[EO]]C*Y$5L
M4QY9P,G-=58WVI^"_ TNIZQJ?]I?(OV= FW;D<+6/\9XYW\,:/+*OSHY,OL2
MH_K5GQ/);^*OA@8='NHKJ:T1'E2-LE<#H1ZT 4K-_B!K.AMXDAUE((R#)%8^
M6"'7ZUM:7XWN->^'6HZDC"#4;5,.4[-V(S^->?Z/:>"3X2%WJ&J:C'J$2D26
M:W80LP_NC;TKJ=!T^RM_A?K=[8V5Y:0W4>0EU.)"V.XPHXYH H:%JWCGQ%X/
MN-0AUI8!9EB93&"\WMZ #Z5)X=\0^,_&.@7!M-2ALC8J3)<>7EY6QG'H/RJY
M\./^25:E])/ZTWX/?\B9K'^\W_H)H V_A?XKU'Q!97MMJKB2YM)-OFXP6'O^
M->@BO(O@Q_Q^Z[_UV/\ .O7J ./^)>K7^B^#IKS3KAK>X61 )% ) )]ZY;5_
M%.M6WPDT[5HM0D2_E= \X"Y;.<]L5N?%_P#Y$&X_Z[1_SKC->_Y(9I7_ %T3
M^M &Q9-X\\0>%X=7M]:CLE6+<B"(,TP ZD] 3]*V/A?XNO?$VFW4>HX:YM6"
MF3IO!]?>M7PA_P DVT_'_/B/_0:XKX(?\QGM^\7^M 'KXI:04M !1110 444
M4 %%%% !1110 4444 %%%% "'WKS3XH?#*X\=3V$]K?_ &=[;*E'&00<<CWX
MKTRFD<4 <V\0\'_#YXO.:4V%EL$C=R%P#^=<E\#]*\OPK/KMPN;S5)WE=CUQ
MN-=7\1(7G^'VM1H,L;?( ]B#6;\(+B*X^&FE-$0=JLI]B&(H J^/U.O>(] \
M)HV(IY?M=T.QC0[@#]2M=]!Y*QK'"4VQ@* IZ =J\^TY7U;XL^)#YA4V=DEK
M$XZH6 .1_P!]5)\._ >J^$=1U6YU#53=QW;YCC!) YSDY[_X4 ;'C+PC;^(+
M/[5#*;/5;8%[:\3AD;W]17!? "^A?3=7LY+E7NUN-SIWQSS7HWCC55T7P7JM
M\6PT=NVSW;' KP_0K6/P3X.T3QG'(J7[SL9X-V&N(7QQCVQ^M '5NH\*?M 1
M+;D):ZW$=Z#IOX)->S5\WR2:MK?QF\-ZK?#RFO',D-L#DPQ ?+GW(->T>._&
MEOX(T1=1GMI+C?((T1!WP3SZ=* .HS7@?[2?^IT;_>;^M>T>'-;B\0Z%::I!
M&\<=PF[8XP0>]>+_ +2?^IT;_>;^M $W[-W_ "#M7_ZZ#^0KW8^W6OBGPIX_
MU[P;#/%H\T4:SG<^^/=FNA?XY>-W0J+V 9'40C(H ]@^/.JV5KX#:QED4W-S
M,OEQYYXSD_AFO*/@):S3?$42H#LBMG+-^*UR3IXH\>:RK.MWJ%U(<*S9( _'
MH*^F/A5\/1X(T1VNMKZG=8:9EZ+_ +(/XT 5_CG_ ,DVNO\ KHM>0_L__P#(
M_M_U[M7KWQS_ .2;77_71:\A_9__ .1_;_KW:@#ZHHHHH @NYUM;2:X?[L:%
MC^%?#VJ75QK_ (HN+B0EIKJX.>?4U]M:O UUH]Y GWI(F4?B*^(+67[#XACE
MD7_57&6'T- 'VIX5T&W\.>&[+2[= JPQ@,<?>;')/O6QCWJ&RN([NRAN(6#1
MR(&5AW%3T )BOG?]HCPY#;7MAKL$85KC]S,0/O,!D'\L5]$UXA^T??Q+H6E6
M.097G,F/08/- &7^SAJ\GG:MI+L3'A9T'OT/Z"NW^-_AZYUWP(\EFADFLW\W
M8.I7O_*O./V<;61_$>J76#Y<<"J3[DFOI$C/!YH ^+/!/C34/ NMF]M8Q(K#
M;-"YP&'^->_:'\>_"VH(JWXFL)CU# ,@_'_ZU6?%?P2\-^(IY+JV#:?=ODLT
M2Y4G_=XKRO6_V?\ Q+8[GT^:WO8QT 8JY_#&/UH ^CM*\1:1KD0ETW4(+E3W
MC:M/O7P[)#K_ (,UA=ZW.G7L9R#G:?S%?3GPB\?S>-=#DCOPHU"T(61A_&.S
M?RH ]'I*6DH R?$]^^F^'+Z[C.)(XF*_7%?/FC69UC7[:W8G]]* Q],FO>/&
M\33>$=0" DB)C@?2O$/"-PEIXJL)).%$HS[5ZN!TI2:W/ILF]W"U9P^(^B+2
MVBM+6."%0D:*  *L4Q"&0$="*?7E/5W9\TVV]1" 00>AKPCXF:1'IGB/S8$"
MQW"[\#H#WKW<UXU\7;I'UFT@7!9(OF]N:[<!)JK8]?(Y26*26S.E^$^HR76@
M2VSG/V>0JGT(!_F:3XM_\B[%_P!=/\*J_!^%UTV]F8$!I<#\A5KXM_\ (NQ?
M]=/\*MI+&67<UM&.:JW<X7P-H$'B&/4[251O$:F)\?=;FL;_ (F/A37^\5S
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MTVT2TLH$@MT&%C08459HH PY_!OARZNC=3Z-:23DY+M'SFME(DBC6.-0JKP
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MO;V-M:626<$*1VR+L6-1P%]*K:9H.E:+YG]FV,-KYIR_E+C=]:T:* "BBB@
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M&/WK>@&#C_Z]+!_R04_]<&_K4WPG\1Z7:^$&L[NZBMYH9&<B5MNX$#D9Z]*
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M>@>&=9'B#P]9ZF(]AG3+)Z&N<^+'_)/+K']^/&/]X5:^&/\ R(.F_P"X?YT
M.^(VO7_ASPJU_ITBQW F5 S(&&#GL:IGQ+J8^%7]O>:G]H?9A)OV#&[CMTJ#
MXQ?\B')_U\)_6L]O^2$#_KS7^E $'AOQ)X[\6:&9[![* Q$AKB9!^]/H% -:
M7P^\;ZGK6KWVBZRB?;+4',J  '#8(P*F^#V!X"A.,9FDS^=<Q\/_ /DK6O\
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M2<M"(\R./4<<9^M0:5XPUB[^*E[H,L\;6$6_:@C /&,<]:ZKP4H7P9I0'_/
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M#&V]<,P;/^]G/ZUMRZ99SZ?]@F@62V"A/+?YN/QJW24 <S:_#WPK9M(T&D1
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M&FV6EVPM[&WC@B'\*#'_ .NK=%% !11FC- !11FC- !1110 444F: %HHHH
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MP*-8T:YU+[)Y-\]OY#AFP/O@5K>8G]X4>8G]X47 R=7T>XU&2S,-]) ('#.
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MPZBBBI*"BBB@ HHHH **** "BBB@ J5/]4]15*G^J>@"*BBB@ HHHH ****
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M4B'@G.,9] 34P@Y2L5.HHQN>V07,%U$);>:.:,]&C<,/S%2UP/PA*KX!@9B
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MM7!R2=CT:BN>\(^+K3Q?ILEY:PO!L?:T;L"5_*J&L_$&STGQ/;Z"EE/=W,I
MS$PPN?7\*7)*]A\\;7.PHKG_ !1XQTOPG:++?N3+)_JX4Y9O\/K7,Z-\8]#U
M2^2VFMY[+S&VK)*003^'2A4Y/4'4BM#T:BL#Q5XIM_"NBC4YH'N(BP4+$PYS
MWYKE)?C/HZS6T4-A=SO,H)"$?(2>GN:%3DU<'4BG8]*HID3^9$CE2NX9P>HI
M]06%%%% !1110 4444 %%%% !1110 4444 2_P#+O^-15+_R[_C45 !1110
M4444 %%%% !1110 4444 %%%% !4%[>VVG6CW5W,L,*#+,QP*GKQ?XS:I<7&
MK:?H<3LL3?-(HZ,21C^M73AS.Q%2?*KF[>_&OP_;7!C@M;NY0?\ +2, #\B1
M75>&O&FC>*(S]@N,3+RT+\,O^/X5'H'@O1=)T6&S.GV\K;!YDDL89F;')R>E
M86G_  O@TOQE_;5C>M;6ZMN2WC]QR#GMS5M4[-$)U+ILT_&'Q!L/!UY;VUW9
MW$[3)O4Q$8 SCN:Z32]2M]7TV"_MFW0S*&!ST]C7C7QOC:;Q#I42#+/#M4>I
M+&K'PE\1S:7J<WAC4R8RQW0AS]TXSM_'^M4Z2=-21*JM5.5['<Z;\0+#5/%L
MWAV.SN5N(RP,C%=IP,\<YK2\2^+M)\+6PEU"?$C [(E&6;'^>]>5^$O^2WWO
MUD_]!%1?%JVNK+QI:ZG<VYN-/V* ISM)!.5..G:G[*/,D+VLN2YU$'QOT*6<
M1R6-[$A/^L;;@>_!S7H.EZK9:S81WEA.LT#C(8?U]*\SM/$_@'Q7IATRZM(=
M-FE&T9A"E?<.!C\S79>"_"MEX7T^6'3]1EO+>=@X9RI ^A7ZU-2,4MK%4YRD
M][G3T445@;A1110 4444 %%%% !1110 4444 %%%% $B_P"I>HZD7_4O4= !
M1110 4444 %%%% !1110 4444 %%%% !VKD-'^(-AK/B>XT*&SN8YX&96=RN
MT[3@XP?:NO/0_2O#O G_ "5_5/\ KK-_Z$:UIQ4HOR,JDG&2\SW&BBO-?BQX
MHUCPY'IQTF\-N968/A%;/Y@U$8N3L7.7*KGI5%<UK&J7EK\/[C4HIMMVEH9%
M? X;'7'2L3X:>(M5U[PU>7>IW1GGCD8*VQ1@8] *KV;M<GVBO8] HKP?0_'W
MC;5KFZTRQ87MXYS&[*JB)1U[ =QUK4\+>/?$MEXP30/$I$KR/L)* %#UXV\$
M<53H21*KQ9[)17G/Q&\>W>@7$&D:1&'OYQDMC.S/0 >O2N:O_%?Q!\-:(\FM
M1?\ 'P!Y-R A,9/J!P/Q%*-&35[[CE6BG8]KHKD/AOK-_KOA2.\U&<S7!<@O
MM _E77U$DXNS-(R4E=!1114C"BBB@ HHHH **** "BBB@ HHHH DBZ/]*CJ2
M+H_TJ.@ HHHH **** "BBB@ HHHH **** "JVH7+6>FW5TJAFAB:0 ]#@9JS
M6?KG_( U'_KVD_\ 0332N[">QY+!\9?$%VSBU\.0S[3@^4)&Q^53I\9=6LY4
M.K^'&MX6.,@.I/TW8KE/ 'CNU\&F]6XLIKCSVR/+8#'YUJ>+_'+>/["/2])T
M.Y,@D#%RN\KSVQT%=GLU>W*<:J.U[GMVEZE;ZOID%_:MNAF7<IJY7!6]Q<?#
M[X71R72JUU!'A48\;ST!KA-*\/\ C3QA82>(/[<E@R28X]Y7?CT X K!4D]3
M=U6M&>\=.:Y.R\=6>I>+Y-!LXF=H0WFRG@ @XP*Y?P%XFU/Q!IFI>'M1F*ZC
M!&0DQX..ASCTXKSG0?#&IZCXTNM)MM4,-W S;[C<PW8;!Z<\U<:*5^8F59NU
MCWCQ#J7B2RO;5-$T:*^@?_72/*%*<_49XK?B+M"C2+M<@%AZ'O7C/Q/GU#2M
M4\.6J7TZE8420QRLHD((!)YY_&M/XN7MW:>%-'DM[J:%V<;FCD*D_(/2I]G>
MR'[2UV>K45X)=Z-XSU+PHOB276)(X8HMZ0)(RML'?CZ=Z[OX8>)-0UOPG,UR
M#<75LY1"2 9!@8!/YU,J*2O<J-9MVL>@45Y2O@_Q)K=S>7_B;6KC2QG]Q';7
M"A0/?''I5+X9>(]3C\5W?AVXOC>VD8<I*S;S\I R&[@YI^RT;3%[75(]CHH]
MJ*Q-@HHHH **** "BBB@ HHHH **** )(/\ 6?A5FJT'^L_"K- !1110 444
M4 %%%% !4<W^K_&I*CF_U?XT 5J*** "BBB@ HHHH **** "BBB@ K#\8_\
M(H:K_P!>S_\ H)K<K(\4V\UUX7U*"WC:2:2!U5%&23@TX_$*7PG@>A:5]O\
MAMK4R ^9;SK(#Z  $UM'6?\ A--1\):5O$GE -.H['."#^ %=-\,_#-_;^$M
M7L-4L)[5[IF4+*A4D%0,\UD_##P=JFF>+[B[U#3I[>&%6$3RH0&R3T/>NUS6
MK.)0>BL9WAZ(P_&Z>/&-L[ #\JM>(/\ DNMGQ_&G\C5_3O#FL0?&2?47TZY%
MD9F87!C.PCCO2_$?PCKW_"5P^(M#MWN&4+E8U)96'MWS2YES;]!\K4=NI?\
MC>P'AFS&1DW([]?E:HM6\-WWB/X3Z3#8#=- BR>7G&\;>E<UXETSX@>+-,BN
MM2TUU6$X2VAB(<GU*\G\:[\67BBW^'VGP:((X+^.%1)',I#=.W/!J':,4KE*
M\I-V.#LOB)J6@Z?'HGB30/,M43R]K(8V8?CQ7H&C>(]%OO!>H7'A^%;=K>!V
M:!5PRL%X^OUK!DU_Q3/HKZ;J/@JZNKUD,1NMGR$D8ST_K6E\./ USH.F7K:H
M%$M\"K0KT5?2B;BU=C@I*5D<W\'-+L]0N-4O[R".><. !(-Q7.<\&O0+?X?Z
M%:^(3K45NRW&[<JJ<*I]0!7FX\.>,_ .NW-SX?M#?6UP2 %C+@CME0>,9K5\
M*Z5XYU7Q4FLZO)+I]OD&2$@KN _A"FB>OO)A#3W6C*\>_P#)8=/[<1?UJM\3
M+I[CXF6\$UK+=0P*FVWCZOD9(%;7C+0-7O?BC8W]MIUS-:((]TR1DJ,=<FM/
MXD^"M2U/4+77=#^:]M^&0=6QT(_P]ZM22Y2'%OF.7\833^(])BMK+P'J=E/"
M1Y<JP'@=,'"UZAX"-]_PAM@FHPRPW*(59)5*L "0,@^V*\]36/BIJ=Q;6XTY
M[3RV ,IMV57_ -XDUZ]8+=K8PK?.CW00>8R+@9K*J_=L:TE[URQ1117.= 44
M44 %%%% !1110 4444 %2I_JGJ*I4_U3T 14444 %%%% !1110 4444 %%%%
M !1110!Y-\<8W.F:;*%8QK(P8]@3BNW\"2Q3>"-):$ *+= 0#T.*L>*?#MOX
MGT.;3;@[=W*/W5AT->56%M\1O B26&GV7]H6A8[-L1D4>XP1BNB-IPY4SGE>
M$^9H]7U7Q/I&BWMO:ZC=K!+<#*;N ?QKA/C:ZR>%].=&#*UQN!'0C:<5D:7X
M'\3>+?$<6L^* UO"C!O*9<$@=% /05TGQ;T6_P!4\.6-OI=C-<M'/DI"A8A0
MI%$5&,TDPDY2@[HZ?P3_ ,B9I?\ UQ_J:\N^,3++XOTN",@S"-<@=>6.*=IG
MB'XF:5IL%A;^&F\J%=BEK-R<>_-7?#7@?7];\41^(O%2^6$8,L+#!W#H,=AF
MKBE&3DV0Y.45%(]/&J6%A;6\5Y>V\$AC7Y9) I/'O7D/COPCJ>BZC)XIFN8=
M0MA/O%O*&P@/X]..U=7\3?!5YK\-OJ&DD?;+;AH\_>7MCW'-<?>0_$;Q99P:
M+?:9);VRD!I7A9-V/[Q/6II63YDRJMVN5HZ;7_B(5^&\&HV,7DW%W^Y 7I&<
M<XKS]-7\.6GP^O+"*YDGUF\PTK-"W7.<;J]FTWP+I$/AJRTC4;6.\6WYR^<;
M^Y&*Y_QM\/='3PM=-H>@H;\8\L0*S/U&>].$X)V%.G-JYF_"W6]/O/"C^&DF
M==1=)?EV' !S@Y_&N:TZ]\4?#&]O(I-*\ZTEDRTKQL5(]0PXZ5W'PX\)MI?A
MC[5+IHM-<(D423H<CDXR,].E5;?6/'6C7US'K.@2ZU#(<QBV7Y4[<<&J<ES-
M(GE?*KDW@KQMX7UK6F$>F)8:I.?O-SYAQV/:O3*\@T'PAJVM>.QXCOM+_LFT
M1PZV[##DCVKU^L*UD]#>C=K4****R-0HHHH **** "BBB@ HHHH *EBZ-]*B
MJ6+HWTH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH \5^+W_ "/&A^R)
M_P"C#7LMK_QZP_[B]_:O)?BSHFMZAXDTV\TK3+F[$$(^:*,LH8.3@XJ*/QA\
M4(XT0>&,A0 /]#D_^*KI<.>"L<T9\M1GHOC?_D2=8_Z]GY_"N)^#,*7'A748
M7 *O+M8'Z&M6&Z\2^(/AWJZZQI;0:@Z.D4"0LI88&, DU'\(M(U'2-#NXM1L
MI[61ILJLJ%<CFEI&#0]933.7\&W9\$^-=;TBZ8);A&D3)X.#\OZ4?#6U?Q/X
MYU'Q)<DM'"S&/(Z$G@?@":O?%OPAJ&I:E:ZGI%C/<2LICF$"$GV)Q77_  X\
M//X>\*00SPF*[F)DF!&"">@/TJI2CRW6[)C&7-9[(\R\?737'Q52.XLYKV*W
MV!+:/JXV@X'XU+XSDN?$NGP16/@74[&XA/RR" XQZ'"UT_Q&\&:K=ZS;>(=
M&Z[B \Q!]XD="/7L*RXM7^*>JWEM#_9S6:QMAG:!D1O]XD\U:E>*:Z$.-I-/
MJ.\9M>'X-:=]OBEBN59%=)5PPPW<5T7PJT2QB\&6UT]I"\\S%R[(">V.M'Q+
MTK5M4\#16T5L]Y?!T,BV\9.3GG K;\ V=SI_@O3[6\@>"=$P\<BX(-92G^[L
MC6,/WEV=+1117.= 4444 %%%% !1110 4444 %%%% !1110!+_R[_C452_\
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M45S+8Z0HHHH **** "BBB@ HHHH **** "BBB@"1?]2]1U(O^I>HZ "BBB@
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M@4444 %%%% !1110 4444 %%%% $D71_I4=21='^E1T %%%% !1110 4444
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MZ?\ :+>5<@1(X\O'IC&<?C5^UC9VZD>RE=7.NHHHKE.H**** "BBB@ HHHH
M**** "BBB@"2#_6?A5FJT'^L_"K- !1110 4444 %%%% !4<W^K_ !J2HYO]
M7^- %:BBB@ HHHH **** "BBB@ HHHH **** "BBBCJ'0*/3_.*** "BBB@
MHHHH **** #_ #UH_P#UT44 %%%% !1110 4444 %%%% !1110 4444 %2I_
MJGJ*I4_U3T 14444 %%%% !1110 4444 %%%% !1110 4?K110 4444 %'Z>
M]%% !_*C^=%% !VHHHH */\ /-%% !]**** "BBB@ HHHH **** "BBB@ HH
MHH *EBZ-]*BJ6+HWTH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** #_ #UHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** )?^7?\ &HJE_P"7?\:BH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH D7_4O4=2+_ *EZCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,3Q!X3T?Q-$J:E;"1DX21>&4>QKGK7X0>%+6X67R;F;:<[)9
M0RG\,5WE%6JDELR'3B]T,BBC@A2&) D: *J@< 4^BBH+"BBB@ HHHH ****
M"BBB@ HHHH **** )(NC_2HZDBZ/]*CH **** "BBB@ HHHH **** "BBB@
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M!%Y _O?I1Y _O?I4M% $7D#^]^E'D#^]^E2T4 1>0/[WZ4>0/[WZ5+10!%Y
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MQ%\1M3UK4SHO@V%I7)VM<*N3[E?0>]6M ^#[W4O]H>*[Q[JX?YC"K<#ZGO\
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M:Q0>";&!44+]GYP.M-**@I-";E*;BF<-IWQE^U:28VTYI-8+A(X8ONOGN/\
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M^E:$7A/QWX&O[A?#0%U:S$_=P?ID-@9KIO!NG^/9-8:^UV^,%LV2]NYW$\=
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M(****6X]@HHH_2C7<--@HH_SS10 4444 %%%% !1110 4444 %%%% !1110
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MPOU&WN=3>YN,[Q,K,"!QQDG-2?!JYGN?"5P]Q/)*XNF :1BQQM7UK:^(K ^
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M^A((JOBBF]R/ADTMCA?!VF^)O&5O-86VL2VUK =[RN['+=AG.>]=OXKU>_\
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M\J\]^#2/+X<UR-#\S8 _)JE^_!MEI<DU8SKS5?$/Q)\67.G:3>M::?"205.
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MKP_\%UM;P$3O.LCIG[F2./TIM)--$INS1N_"7P[II\)"^GLHI;B>0@O(H;@
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M#^7'Q@DD'V[52U/QWX8O?#+Z1#X9>$^7MCF#+E6]<XR:['XM^$KW5/LVL:9
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MGE7B#P;XPT;2FN]7=S:*0&S=[^>W&:]6^%W_ "34?63^53_%S_D0[C_KJO\
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M=8GML,$-O'Y<$4<2?W44*/R%2445R7;9V6LB2#_6?A5FJT/^L_"K-( HHHH
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MOR/EGE"#CD[?_P!JMFFJ;<NIBFO:)1/6JY+XD:R-$\%WTP<+-*OE19/5C_\
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MBNG@A2WMXX8QA(U"J/8"I**;D[6!12=Q&19%VNH8'J",YI$C2-=L:J@SG"C
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M&WI@#!K>%).*DS"I6:ERH][^VVWV-KL3(;<#<9 <C%>'77CLWGQ.MIY=6/\
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M5Z5'86<,;1Q6D"(_#*L8 /UIT%I;6H(M[>*$'J(T"Y_*M)54XV2,XT6I7;/
MO#VOZC\+=8O+#4K&26VD;G:,;B.A4GBJ'Q \47GBUK>_^P26NGQGRXC(.68C
M/T/?I7T7/96ET0;BUAF(Z&2,-_.FMIUB\2Q/9V[1J<JAB4@?08IJM&][:D^Q
ME:U]#SGQ;_R1:'_KA#_-:T/A!_R)$?\ UT:NZ>UMY(/(>")H1QY;("OY4L-O
M#;1^7!#'$G]U%"C]*AU+QY314[24CPV;_DO7_;VG\A7;_&+_ )$.3_KNG]:[
M?[#9_:/M'V2#S\Y\SRQNS]>M236\-S'Y<\,<J9SMD4,/R--U4Y)VV$J346K[
MG!_"?_DGB_[\G\JXOX6?\E*U/_KE)_Z&M>X0V\-O'Y<$,<4?]U%"C\A4<5C:
M6\IEAM8(Y#U=(P"?Q%'M=_,/9/378\1T7_DN4G_7Q)_)JZKXU_\ (JVW_7?^
ME>B+8V:W'GK:0";.?,$8W?GUI\]M!=($N((YE!R%D0,/UH=7WE+L'LO=<>YQ
M_A#_ ))3!_UZ2_S:N!^$,\MK?^(9X;=KB1(@RQ*0"QRW'->WI#%'#Y*1(L0&
M-BJ N/I3(+*UM69K>VAA9OO&.,*3^5"JZ-=P]EJGV/)+KXKVGVF6#Q!X69MI
MPBO&I8?7=_2N5TVQ;Q=X^M[O0]*EL;(.'9L85 .^>F?85]!S:=8W#[Y[.WE;
M^\\2D_J*D@MH+9=L$$<2^D:!1^E/VR2T1+HMO5GE_P ;+&>?2+&ZBB9TBD(<
MJN<9_IQ5OP+XSM]>\-RZ3':RQ265AAG;!5L+CBO1Y(HYD*2QK(AZJRY!J*&P
ML[;=Y%I!%N&&\N,+D>^*2J^[RM%>R][F3/%?@O\ \C;J_P#UQ/\ Z'5OXUVF
MH&_T^\"/)8QIA@ 2JMD]?PKU^"QM+9V>WM8(F;@M'&%)_*I988IXS'-$DB'J
MKJ"#^!H]JN?FL"I/DY;G@VK>,O\ A)/"3:/HOA]H-D8:XE5 % 49/3^M=?\
M!69&\)75N"/,2Y9F'H"!_A7HL5A9P*RQ6D$:N,,$C !^M.@M+:UW?9[>&'=U
M\M N?RIRJIQY4A0I-2NV?/6GZP? OQ(OKN^LYG7+QA$&,Y(Y&>W%=)\7[Y=2
M\/:)>HA19QO"MU&1TKUZ;3[*X??/9V\K_P!YXE8_J*66QM)T5)K6"1$^ZKQ@
M@?3-#K)M.P*B[-7W/+?$WA6Y\0_#/0Y[!-]U:6T;A!U9=G('O_A6=H7Q:ET'
M1XM+U?2;IKN!=B'&W('3(//ITKVE$2-%2-55%& JC  JO+IMC/)YDME;2/\
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MP*/:QBK1!4IM^\SF/&/CVS\&S6\=U9SW!G7(,14 ?G73V5RM[8P72J56:-7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1]:** (%LK5)/,2VA5
M_P"\(QG\ZGHHH]0\D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444:@%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 20
M?ZS\*LU6@_UGX59H **** "BBB@ HHHH *0C((-+10!%Y">]+Y">_P"=244
M1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0G
MO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='
MD)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_
M )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)
M10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'
MY">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_
MYT>0GO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0
MGO\ G4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\
MG4E% $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E%
M $?D)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D
M)[_G1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G
M1Y">_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">
M_P"=244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=
M244 1^0GO^='D)[_ )U)10!'Y">_YT>0GO\ G4E% $?D)[_G1Y">_P"=244
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ JMJ/_ "#+K_KB_P#(U9JKJ/\
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M_@.:HVOC7P[>V<UU;ZK"\,*EI#A@5 ZG!&37C^HV\OCSXL/IUQ.XM(W*A0>
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M&T+'@ 3+G^=<]XBUQ;;X<SZFCC<]K\A!_B(KYTTV*6+6[%I5*^:ZNN>X)ZT
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M'Q&\+:E>"TM]43S2< .C("?J0!74!@P!!R#T- "T444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH *Y'XF?\B'J'T7^8KKJY'XF?\B%J/T7^8H
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M7E^REFR<\[MN,#VKJ/BQIFHZGX2VZ>KOY<@>6-!DLN#V_*O._"WCBY@\._\
M".:?H/GZBX:-9D'J3U&,\9H O?! _P#%0ZJH!5?(!"^GS5'XP_Y+1I__ %\0
M_P#H0IWP=+V/C'4[.[&RY:(J0?[P.33/&'_):-/_ .OB'M_M"@#H?CA_R =-
M_P"NK?R%;'@KPKI \ 6^^R@DDN8-\DCIDDD=L]*Q_CA_R =-_P"NK<?@*[/P
M?_R(FF_]>M 'EGP>1K?QK?VZL=BPL,?0BO=A7AGPG_Y*!J7_ %R?M_M"O<Q0
M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&JR7>IO&^;>6?)#\XPO7TJS\#F7^W-6V\ Q*0/;)H ]PI:** "BBB@ HHHH
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MJ NBRL$*OO6) Y_B"C-!MX6<.T,9<=&*C-,%U&1GG\J3[9#G&318+DLD,4H
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M,MK&,)$R\"H;;PIH-G:36MOI5O'!,,2(%X85I"YB PTJ!NXR*=]I@_Y[1_\
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MS7-A80V\TV?,=!RW.>?QI-3\.:/K./[1TZ"XQT+K6AY\?_/1?SH\^+_GHO\
MWU1=#L96G>$] TB;S;#2K:"3^\J\UL%01@@$>AJ,W$(ZRH/^!"D%S"3@2H2?
M1A1S(+,QKKP1X9O;EKBXT:UDE8Y+%>M;%I96MC L%K D,:]%08%2[USC(_.D
M,BCJP'XTQ&7_ ,(QHG]KC5O[-@^WAMPGP=V?6M&XM8+N%H;B))8V&"K#(-.\
M^+_GHG_?0H\^+_GHG_?5*Z'9F%!X&\+VTXGAT6U20'(8*>M;ZHJ*%10JCH .
ME,^U0?\ /:/_ +Z%'VJ#_GM'_P!]"BZ"S):*B^T1$9$B8_WA1]HA_P">J?\
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MR>.M(ES&\'R8+ XJ38[###''TJKL"%)9;V5/+<;%X?(ZU-Y8#,#TS1&8[(9
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M$T^[!GV$+@?I4MVM<M+>QT4_B.YM&$"Q!_,_=L_4@#_]5;>COI;6<]W>(AD
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M +*D1SGMTKI8AMB9OKQ525D@06_S6P/<GFICG*G/6H8@XB(0X8GBI^0>G05
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M9Y4$P1B%==I]Q57R^PXXJ>=VW+5)7V+DVHW5VV)"-F> *[#P9X;BG":K.X<
MD)'CH:X13Y?]:]/^'P<>'VD<G:TA*Y].*NAK+4SQ"2AH:MY?6>CW+75[<G#C
M"(.P^E9#>(M,U<R6D4L@>4\%EP!7*>(+]M0UB>3)94;:H/05FKE'#+E6'(P:
MTGB'>QG##JUV=+)&8)#&PP14<LFV!RPQ\I[UH6*#6K.&:0 &,;7/<U:GT&![
M>2-"=S# )/2IY9-73!2BG9H\[W#)QUS3P0.PYJ[=:-+:S/"74LI]:B&F2["W
M'YUAJF=*Y6B[9W#"T"AFP#TS3BW&X]:6WTFZBLDF4B1"?F"GD5(;1ASZ]LT[
MLFT2(')YKIK*]C-DDC8#*,5BV.E&]N50RJO<C/-7KVU\M56%'$4>1R.]:PYK
M7,I\M[$,]R\\K,6PO85$QW J.5/!R*$CRO*L#[BI8H\RJ".XJ;ML=DD7K/P_
M %5YF,G&<$=*76;1;:S1H5"JK=!6XH C48Q@"HKNW2XM9(G/#+U]*W<=##G]
MXXY#D8]:Z?P2&&MMUP(F_F*SH])7;M\P?6NH\,6T=M>!8^?W9RWY5-*,N9:E
M59)Q>AUM5[QF2$$>M6*P_%&KKH^G),R%R[[5 ]<$_P!*]!*[L<!8Q*4[ FH]
MLCIR.17$6_BS6-0N52WM#L)[CI791I=&%2259AR*N4.42=R8EAC;^-*0P526
M))]*K"&[C0Y8')Z5.&DQR< =JD8_'^T:<H !.1Q52^O;>P@,EQ(%#=,#DU4B
MU4S(%BA;##//6GRZ :#.-^U6Y/I3CY@4A< ]CZUF?VG,L;%+,EU'!QWKG+CQ
MEKEO(P;3 54]AVIQ@V*YVI>X]1FEW3X_U@W=AZ5S^D^()]30[[0H]:CVLT\+
M*)S$3U(ZT.-GJ!-#>-,77?\ ,IP<=Z<7E<<29'85%9V!LH=L<OF,>I/>K#B<
MGB-:6@ C2#C80.Y-))(J9,C*JCH:8R3MP6*M5&^TB[O;<HTH&[G(H25]0*__
M  D-C+JJV4>2SG&X5NK&Z##<K[5SVC>%[33;G[1*^^8GJ:Z?=@_I3G;H"&[%
MP<>E5;R]73X-[MQVJYALYX KFO&4YMK*,C#-(2 I_"LINR-(*\K#WU2X>W$E
MO*3N.=O?Z4MAK,]P9)&D PF=A[5S%Q=RPHDF2K8&$4CK5FUN#=+)L8(X3GMD
M5S^T9O[-&XFKRFX,;%CN^8,#QBJ\NM7UREU*@:*VA^ZV.7(-8,L5S&D,*R@!
MN<IU JS)->HBV[,JPC"F3/4?2CG8U!%B/5+F2Q$\<SR3,X&TG'?M5^Y=X;QI
MV;=((!G)SM-95LD U<1^>HCC494<Y-6[BQD87*02[<<EFY)'I1=V$TKEC3=4
MN[>W<W/RC&X9[CUJQ'=RZCICF<XD!RGL*Y\ZN9K%;4H3(GRLS#I5&?5[J Q1
M2960#&%Z$>M'.'LSM(KP(N2Y:(C]YCL:!=-V F0Y*N&YKF3&+W3RL5UY)=<N
MH8CFH+;6QI4"6T0=V7@CJ<T^<'3.QA,]Q9--Y;P,IS\QZU2D\3_98U:6,N-V
MTLHXK,L]:U&]MY70%6<;0#4EQ<M!IC@VOF?)\R@9RWK0Y"4#5D\36[E3$TA1
M1N?RQG'UI/M]WJK%]-N$11QM<_>'M7'6"7$>9HR;;S>"H&,C\*F^SS6:"X25
M0P.<JV,TO:,KV2Z':6MJUU$XN+AFD4X#9Z52O8;JULV2>[,Z>@X)%<@^KSE%
MG@DF!5OG(/&:E.MW5PJRS#**?E&>M'M- 5-W-22XM)[BW>X@E&QU6)6;H:]*
M'2O*;1+K4I(?->, R!A'_$%S7JPZ5I2,JRLPKF[@R"YN/W1,8)):ND-84\\O
MDS@1J6#L&4'MG@UO$Q*EA%!-&I*%?FR,GFK#.-[HRE"IPN[^+BJ^F6@*AFGW
M?-N SR/:EN+B*._&\,[\E3_=JWN(9 T\ER5E&57E&[BI?/$UPTXEPB#;MQUJ
MM#-,)7NMQ,;' CQ6A&D;1$[5 /44/1@0V2V=Q),\8&X?>([U!$[)*Z2!<DD\
M<4J6KK<9MP$CZMCO3HK>#[1EW.!G&3UI@36+N%D>7:#GC!J,+#$S(<@R'- 2
M.W!54)5VSR:EA@#NTCD?*,)GUI#!D$@C"R$",\KZBEFMU)7:Q50> *B5FD79
M*0DISE1W%-D:,0H=Y94/8]Z!"Z>FYY;J96C"':%/\ZLS74;1;F&,<YJM K-9
M^697<$DDMUI&BC6$EB3&HYQ1;49:MPD\JE2=J\TQ9#*;@!1$,X#$=:<DL-I#
M'(<A).!Q5.:/R)9DFF)5QE1[46 M;$6TRS[E"_,?6H(3';V1:S11SQNZ=>:6
MWN;9].6(9*Y*G-31Q1?9O+ ^3/&>U+81)&S?:$V!6CQ\Q!Z&B\M4<H?FX.>#
M2%A#Y8ME!S]XFB\6:0QM&<)_%1?49!")=DQEX4=#WJ*)28<H3(6Z$^E63Q)D
M-PPY]*9*P>';"P1F. P[4[@-CC2"/8%"D\D>]-N9KBYM=JJ02<'G'%75B21T
M+C+ 8IMVK12+L V-UI7 JVL?[\-%EQT8$]*NW@=5'DC+$],U =JV<BQ_+(V3
M@=:KQRO]B+N[*Z=1WIO41:CQ;AV56+O][)X%>,^.+W4=0U#4-.D_U$4I:(@8
M_"O71=NTT*>42).2?2O%/B%K\D'BF\M[>$((9"KN1]ZN7$W458ZL+;F.!N-Z
MD%6(8'D>]>HVUWH^N>#K4:G<K%?6RX1@.HKD&T]]=T.35(+0*T'ROM_B]Z@L
M$?[,JNFUE'*MWKC;LM3OLFSL-)LM,N'_ 'UTDB'@J3C'O7+:O9VEK?RI N^(
ML0&]!6DNG.BBZ$$L:LN-Q4J#6SH/AZ'5XWDN8SY:G&\'BA-R2BD2[0;DV-DN
M9=&\$6]BD06.Y^<R#[W7_P"M57P=JDD]Z+%N%9N&Z[?>MK6-+$,!$;>;;QKM
MPQ^Z*S+/4+#1?#<WE6G^F32;5G]!3;=]>A*2<=-;FEXE\.V5E>+/#-YTD@R\
M8Z#WKG-,U66QUQ8%@)2;Y=H'-6[:X>:R,C7/FD_Q9YKHH;2+1_#K>(2JRWBC
M]U&1G%2G=Z!\*LRP\KQ2#Y<,#T/<^E<'XHN)[OQ(H^RQ0.6  C& ?>NFTK5S
MK<?F2;5F!)D(]:YVX\00G52]S912F%B%R2#QWZU3"*:9UMI:0""2&ZO"\@C!
M 'KBN>L8;?4KR:TO=D<1)"F0X!/:M73=8TO53('ADM[GJ)%Y%<YXPT+5K:W2
M\"@V;\HZ'K2=F"YD[%R6*]T&\DLK2,PP,=Q"<Y]P:V-"T.3Q%>R74L[M';D'
M#C&:S/"GB@3:.UCJ)C:YA(\J63^[Z9K0;Q-<I#+;V16*!CR4 RU.Z3NQ--Z)
M'.:]K>J7VIS)<R'[.F5C0C  'I5W3[^/2[>&[MH$E0)NE88)%1^()(+W22XC
MVS@XW ?SK*T*TO1I\PB3?"6Q)WXJ5J[EM:6.GT;5?"WB&\9)I6M[PJ2I(P"?
MY5E^(8+6VBCM(0N?,SST(SUK%BLK2TU,F.-HY2"<]@*DU9HIX$=)3),O7GC%
M.4N9A"'*>@66C6MY86ML+B**7;D>A'UK,\46TJ/;6J%9EB&T;&!YK/M#</;6
M]O"C.63&Y2<BLG3FO)KR6,[QY;XW-G(-%U:PDG>]SL].\.W4;VOF*]K"3ER1
MG=7>3Z-I][I\B>;OE ^9MU8BZW*VF10S#C;@R'J*CT-YENI-L_F1R C'I71'
MEAHCEFY3=V96H+'ID"6\ 7$K;6SVK1FT:'0]-CN8R7$^,MZ=ZS==LI8W7S22
MJ'&36]X>O(M4T.;3-0(*IQ&Y/Y5DK<S1JV^5,YS;IVOI-:S7'EJ@Y<*3@TS1
M/">F1/>+>:C'^[^XZ],$5JV^BIIES<*K(=QZ<'-9FNVIT[3FNI(2D+G&1T)I
M6MN-2[,V?A_X?AL_%OVVWO8)D577:#\V"*]<KQ+X87,5QXKA:-2G[N3CUXKV
MVNB@[QT.;$I\^HC?=J*I6^[47:MSG G )/0519C(Y?\ *IYW!BP#UZBH ,<#
MTJD2Q.:7M2$D$>YQ2F,(2S/DGHHIDE*!2992#R>U#AF*D\,#VJPN!*X!Y/)I
MDZC9R<>AJ;#N.E*M"V6SQVZUG0P/)@(,C_:]*L0[WW;L$8R"*B$YMW4$X0GI
M28(>Z^1.%)4#''O4J(&5D(PA.<52FG,\K>4!)(G8CBM*,@1H<=1T]Z2LRGH1
M! DJE0!V/%-U#&4XR,8HD(C8G<<GDCTJ6=0[*QR>.@%,166[&!&W"KWJ0@-$
M70Y#=:S_ "29Y'D?@]C3XV=#G.$(P#[5"ET*:+T*$1ELD@C(%1&*/!9.&[\]
M:LQC-NI!&!30$+,4_&KM=$7L5H4-N>22&.<5>C(8')%5Y,..3@CIZT0!AD.-
MISP::T!LM%D7:3TSR::=N6(I'X^4C*GK4,C;SMQQBA@B;S $SZ4Y74C/%48V
M(21<?*.].A=M@.<J1QGK24@:+V>>3GT%+SMP#C-0+N"CU]^U2,I;# @'N:LD
MD7/3N.OO1\W>HQ)GK@XIZ[220Q.3TH'<#P>,YI%[DK^-+T''6C _R: $#G!"
MCI3,L'^]P>V*=@@;1C/M0"<?=S1H+4?'DL*OBJ</)';%7!29<1:*2BD4+124
M4 +1244 *.HJ6HAUJ6D =JS&;S&&/N$$XK2/0UFQ%BD;$ L>#30'.7! \0VL
MH."%(;Z<5T;' 8=.:H/IJRW8E!YCR*GBG9[SR' VA <^_%5)W6@BTY**&R,*
M.?RJOIMTUS;NQYVN0*DN\BTN"G)VG JEH2NNDHSJ1O8D\>]))6 T7^>/S%7+
M#H/6GQG<BD@ ]"#7/>*=;;1XH%BSDMN/TK<AE6:V289&]0V*.5VN/J1ZC-/!
M9NUFBO..0A[USND:OXBN-0V:CIIAMR.&6NH^4R'=DGJI]*"\JG)Y3I@4*6@$
M;H)(W#J&C/4-UK*E2'2[.:\C=PB=%-:[^85RH4 CN:Y_Q5#<MI"K&"5!RP%5
M#5V Q-?OWUK3XY[?=Y<9Q+$O8^M96E,8M1B^TQEX<9967BK_ (0C:*^O&E)6
MV*8.X<9Q5N:ZM89O*N"CI(WEH0,')Z5T_#[I!)K&EV7B2S4Z8(HKM!C'3(JE
M8:C=Q:<VG:P56: ?N95;.:9!"+2;R[6X5)N>-U9-_:W44@FF1MA/WL]334>C
M&=%X1OW_ +3ECG/F;Q\C-VK?\3:+%K.F2H%"SIRC]*YWP5"ES-+-*WS1G*8[
MUUVKS_9]*G=S@%>N>E8U-)Z MCC=/_M'PU9Q6[R$-*^!CE>:T[F%II'!EWN4
M.3[XI-/:37M'B9F#>4QVYZ\4MM,T0DCD \P-P<4V[O4$:&BJQM-K'[O!S6^F
M!&H]JQ[7++D8 /7%;"9\M0>N*PEN4APZTW5"5MEP>KC^M. YIFJD"WCRN[,@
MX_ U(UN<EJUS-8M#>)@QJV)!UXJ"\1[M?M]C)A@ RX/4>E/UA)D+N(B]N_RL
MF.GO5#0S):3R0?,\3?ZOT^E/[-RS6MM0_M&P8;0MR!A@/45=T/5_M431,N)(
MFPP/7ZUFR6C65^MU""D;D"1?>L_6@VDZQ;7L+E8W(\W;Z4)(EG8ZE(R2( H8
M., 5;5#Y49/) Z&LS44^U:7;7,#@LA!4YZBM1'\Z(@@J^.0:5A=!NX?,Q'"C
MD'M7 VFJ7FI^,1*L3^2I*9[5W-U+!! [3ML##:QS573?L4D1ALD55C/+ =:T
M@[)NPGN7)62V0>8ZCL23U%)%=0S2R1+AB@!X[5@>([6ZU+48(K<,(X@78]B0
M.E'A\3:=I=Y?7JMYS$_)WXZ4**M<#7U9Q'I%TBL$<H2!GFL[0M'MK:SMI]O[
M_&6QZUAZ,]P)YM5UJ1O*NI/+MXFZD=.E=H R6^+=1]S@-V-#5E9 B3.Z4J2
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M^[7D"I+J!;EXR5P.G/:H8V_T<-'NW'@;J$%P\)\P$D'&0<4NH#93!#<>2D.
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M>%^)F[/=G3M+?3[:)4MY!C(6N61V>;"@?*>M=OHNK2V_A4R200S*XR@=<XK
MAN]/NKIGNK<1JW5H>,?A7 U>R.V+M?0S?$&MZAJ;6\$TH6&W0*FP8'3O6OX0
MU2;3K607!:6W=ML8'J:FN--LYI%AA?\ </@!VZC-7VLM/T%8[.UNUNMPW-[&
MFI.+O<4N5JQ'XI\1)#9BV6S*^:/FESP*S+6Q76=%BB\U84+8#MT%6XH-/O\
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M-V&D'\6.E<Y3:L3\4H% YYHIF8X?>'UJW5-?O#ZU<[T %%%%  >E9NX*A8G
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MU.]ENS=?9YX% ?<>"!QQ4D^K:=<7$*VEP))D3;@=2?6E*M=W!4QFG^%KB/2
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MC+[I, 'CKFDYS@-G'>AE8MUZ=:6@7)VR$R3@4@^\ /N@=:KD%N&<D9XJ<84
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MARW1U=MXC\+R7@33M,\FYD_Y;$<'Z>E<]XE@DGG/RDR*<$8[>M8ZPBVU/Y&
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MPW$D\#VJU49=5=5)^9NE24 &0.N!4>W?*LJO\@&,#O3GQM(/0TJ*J*%3 4=
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M#+!"L4BC*NHK)L2JYBGQYB'ENYKHY)/LL#2.^ !T]:Y>.,W,YD^[N;=4QOU
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M<KT!I^\P-'/R8 )P>3TII.(MRD-(.@K.U>SN+UH$CE:.!6&X \GFKC+#;V^
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M3[PSUI1GHDMPL:>C>#;#3_#LUK;D3>=\RR,._J*\Q\8:--%J"V<SX$"[RP[
M_P#ZJ]D\+2R-X<M$F7:\:XY[US/Q%M PLYX( \LA97;') Q_C7/5J-1DF:TE
M[Z.%\-:=J-YI\\=I/$+'.)=W>IO$=A:Z;8VUI9X-T>9-G.#ZFC2H[N)9S 66
M//SAN,"I)EFD$UY:[)1(V9ACC\*Y%6:1U^S5SG;DWM_?PP2.9)(AY8(_BK7@
MT+4U,K-YD<=LA=B/TI+*&\;=(D7EI)+U;V]*V5BU&:YE6.8M;R+AE0].*M8B
MRT1/LM=3B#;RZC%&QF02.Y^7'6KIT1+*]59%V2^7E3V8]JU=-L&L[YK<(Y?)
M*)CD5H:CX>U:"%);B,OYIP PZ<]JS]O4+Y(G*_8+FYM;I94XC3><?C4<&BKJ
M&FPM#"P7J7_QKI;C0+J*+[-;IF=Q^\P>@]ZO6'AN[L+9I)<>2G#(.YH=9MW%
MRI&='H^G?88$N;@P>7D_NUSFM_0-"L+NR:[$@(481<?-BL^V\.2>1=2&X*2W
M#9A7;P@]ZOZ;IVIZ1#'%+=':[X=E'!H]I*2LQ<J6J,/Q"L=Z/L3RNK1?-&2.
M,56MX[*TL8(Y&:XD!/).%4^E=TWA^21)9CMVLI(+#G-4=/T"VGL6CU"$AMQ9
M0!R12YYVY>@)1O<\]@T_[5?S2I(Q3=PF,X_^M4DNA21^9L$<63DECVKOK+1[
M*SU!XC;N(9,,CGJ/:F7>@+J&IMYDC?90,J".#0YS8THHRO ]I:Z3?O+?RQE9
M(\[6&0:YR\M9KK7[ZZ>-9 )"42,<8KM?^$4WWH@:5E3;\A!_2KGA[1SIT=PE
M\F'1\(0,G%$I2EN$>5.YS%FD*I9VIG*+)(LF9!_%D<5[Z.E>96WA.'5M9CGN
M#)"MN=ZQD=>>]>G#I6M*Z5F<]9IO02N>OE@28[TW!W/'H:Z&N:O2@\Z)-S3!
MRX&?>MX[F(_<WRPQRA"IW<#M2,AEN$9"CLIY(J)9UA@ 9#YDG#>HHTX1PW$Y
MC(V@=QSFM&A$MQ;-)M\J<)M.6V]ZF%RDL *@K'W/2H(D"W63D;SDX]*DFEMY
MHY$)SCJJ]14C'32?NHV1]ON#4%Q,OF"=HT.U?D;N::5>&W6..-73/&3SBFHX
MG$D3PE44X! ZTT!;BNXI+<.Z]>F:@:9I'^0>6$.23T(I7L/.0(HQ$H&!W%3&
M!3'Y1PPQ@TM $N)RH25(@RXZCUJ/"R2K)*BMD8)QR*FCMP82D3X*],U4>TGV
M#S'(8-SBFA$LJ""XQ&N8]N0?>BUEEMY5!)\M\L9&/3VJ!;>0P!/..=V<FENU
MBE5;61LYY4>].P&X"#TQ1WK#AOI$C\VX?RPAVDCI5]]001N8OWKHN[:O>LW'
M49<+!1DD"LHO&\SV]U""#DH>N14D*/.=]PX6-\,J$\CVJIJ<ZF18+?)9& DP
M.@IQ0$DLRM;-! 64H,J[#]*=8PR-+\\2B-ER2#WI[RPQRQ!Y 5( ">]/LT$-
MY<J)MY(!"]EJGHA%9XA'<294#/1C48=1,EPNS:1Q]:FO_+ED17E*$<X]:B2P
M-PZ* HM%&0P/.:?0"2:YE5?,90S'^[4GE/)!N\L8<?,!VJL&CM7F E+<XY[4
MZ.\GMH9&?!8G"@GK18" 9BN8PTA2->BU>F@M[N[A8LAXVE6_B%02_P"D1))A
M58?>7J:=8*GFA<;FP65F'W:'L RXFDD4K"-IC;;^%>+>+=\/B;4IMPSYQP<Y
MS7M-S<1VY(D+,K'G;VKR'6+"#4?%>JQ&=88XW9T9_P"+VKDQ?PHZ\)\;.?L-
M683+'"TL4CL,;#D$UL:O]J:(M]J?S4'7=C=7-^'=8L=/U\/=P%E7*J?0^M=9
M?)::E;S02WZI-*V8Y . />N)WL=FE]CC[^_OI;#R)+EY8R<J&;.*RX!(HY^Z
M.F>]6[ZW97:T2=91"Q&Y.AH@1$M_G;<X''M33TU*LKEC5]&NK#2;>^<H8)UR
M"IY!]"*P[.]>";S'3> -N#V%6?[1FF7R9YF,8/RH3P*C:S;9O'R*>]4K6U)U
M+5GJEREV+RVF:$QGY AY_&O2-+NIGO[6YN71I)5P3&V>M>76LD$49C93_OXK
M9T*=[74(FC#; W0GK3YFM$3RIZGNR7%[;K'86^V16/)D/:MK3K>5;0K+\C;C
MA5Z 5RFC746HP0ZA(/*G49* YQ74V^JK<M$L:[]WWCGI74EU1PRN:0& .IQ0
M1GK1@TM69D<D4<T312HK1L,,".#7#:YX3T^Q@9H[?;:DY.T<J:[SO221I+&R
M2*&5A@@BHE!2*C-QV/'GTO33IT\=OAYC\H9Q7$:S97-FL;QQL@/#%.U>LWMC
M'IFM-!<6ZM;3-F)MO0UTL>AZ+?0JQM8WVK@G%8>S['4JUEKJ>3^!_$^N112+
M<3>=81K@>?SCGH*U]3^(%]IM^\45K&L;*"&'<'K773Z-IAMWCM;%1&&^XH]Z
MYW6?#]O=P"-X7#@X1HQRM/DD"J0;U&VE_:7Z&_6=!%@,82.0U=!HEMITUTUY
MO5&[)T ]ZXN#P->VWESHX9=VYPQQ@5LWNE%--G2'?ND3 8'I4I2W:!VZ,YF]
MTG48=9NY!"LT*,7W@Y&*S=8U^PO;!8(R?-)^;CBM70DO+&::PNYV$-TFS<S5
MSFO>$?[.F62*Y5[<MSGJM9<J;N;J5B]8>&7N;=7ED$2LH921ZUDZS9SZ->>1
M*P9<#8X'#5ZK:W=E=>'HVC1'CMD"[AU8#O7%^,/$%GJMI;VD$2-Y1SO"CCVS
M3E%)!"I*4C#L;:35'2.!%\P]B<5;TZ_A\-:C,\[I]I0$!1S7'O?7<-T#!*\3
MJ?EV'&:U8-*N[N3S[A/-D=<\GO244K,MRO='IGPT\7ZAXA\<QQW,<?E"*3#
M<K@<5[C7S_\ "31=2TCQQ#]MA:%989"%/?BOH"NRC\)YV(^,CG_U+_2LW\:U
M&&5(]:S'&UB#VK>)S,!T/TI,YQQ2*0"?44=O:F(=VH[T GIBCTYH  !^/6DP
M""#WI>^/UHXY!&: ,M]VY@1D= *AC_<R,W'/45;N(]DF0"<G.3VJK+(-A61"
M"3^E9M#1(T>]B"HV,*GM;=80<@ GICL*2&,32; 1PN[-06.H6E[+(;242")S
M&S#/4=N:%%;@VS0C;DCL*D>,2+Z?6FA1O+ #YNOM4@[XZUH252'W"+.!ZT^/
M"K\X&Y>,CO1<LP8*,8^E1NYE&/+/3UZ&I&RQY@ ^M5"@\MXV;!!RM2P*QB8/
MC=Z53=FWE  Q'KVI,":.)795QSZBGW-J&"KS@=2*S[?58)=0FM+:0&XB \Q1
M_#FM1[J)8U5V&\\8'K1H-(5F")Y8/S*O>J49W%8VP?<U9N4# ONSD8&*A9%5
ML < 9S28(NHN%(!.!TS39,D'Y>W6DAY3.3C^5)(2N>>#^E4(C7:XP>' ZU&4
M&W'F88]SWI2HY8X8]N:JR*[R\MP.*ALI(EA64.QE7*X^4BID8Y(QC(ZYJ$K-
MN7G"J/SH4/O/]T_PT)@R6'<Y+NNQAQC/6IP<G/ S5?+,I ;.>!STI V&"@Y&
M.*I,FQ<S]:0CG/.>U+;;2Y#<+C@TA8 MDCV/J*H18M?]9SUQ5X51MN'7],5=
M[4,J(M%%%(H**** #-&:**  =:EJ(=:EI ':LKR_L^=J_*&SFM6J3*&//3/2
M@#S:6UET+XEB_G=5L[LDY/8FO0YY/]!FFB8/^[)0COQ7+^-!::C EE(J[PXV
M..JFK?A,7T%E)87ZEC%PC]B*WE=Q4B5N1>!XIX].N9+H-YLLS-S]:Z"\MH+H
M1B= VTY''2I558QM0*% [4K'Y@?4<5E*5W<H:"W "A0.!5>XD:-9#P0%XJ>2
M,2#&2":Q)=;L[2Y-E,QW$_,QIQ38&3?:[IWAZ[C@>U/F2_ZS;T K.N[Z6UUA
M?((>UF^9>."*@\:^'[NXODU*T821,NU@3]WWJO9ZQ:)I<.GM&6GA'R7&.*ZE
M%6T))M91+B>,V[M'QR@/!-9[M?VZF([S"XPP/2K230R7*/<L,*<G P:W/M]E
M+:M;JKG=T9UXJMA;G/\ A[25U.X,;H41.A[5M7W@<VL,MW;7A:2-=Z(>N15_
MPU-9&_DM1)&DZ\A.F:ZIXUE+JR@,1U-93J24AI*QXEI]W<ZE));S@-Y9+$MV
MKN=$U:5S]C'[J0#Y2O0BJ%EX5EL]4O;A1YD,^0%%:NGZ7:64QG#%I5&-I[5<
MY*2"Q>F9V/[]V?T]*?;1AF4H< ]13&S-C9R>G-7K*T^<&5MI X%8/1#1?@38
M^W':K5,CC">I-2"LFQA1112 .]&HNJ6WS9P3CBE'6FZE&TEMA3A@P(I/8%N8
M9;)RRD>F>]5]JS"<(S!B"#4MQO\ /3GY0<$^]2[5B#$$;NN1WJ%N:Z6,'[++
M:V(N%&;B(G!/<5L1SJ]O%(."XRX]*@EN8$NXXY2<RC(&*AU$_8;.7=@!N!5*
M[%H7+F+-L<98*V[-6[1"9$8\YX^E9UEYTND13Y)5A@CT]ZO:%?07AG5),RQM
M@J?2A1=Q-Z&I<+N&P=&X-<U8:+&-=N+R0',(V(#T4UT[+^\5AT/!%,<#."H
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M()(QQ2XQ35-"YV9<NC1^:EQ$2)>-P_O5/<V4,\.3&1ZJ/6KN*""!Q1R(7.S
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MWDDMXWFC\N0J"R9S@UX9J]UX-NDEN=+.I:7K9!(M8(W!+^AXQ^5>Q>&OMO\
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MQQO7BH=F[L:V-_PC?RZCH4<LBCS%)4G'6H]3M/LMYYRG[_4"J=O+/ID"6UD
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MU*M]X YVFJG2E!7'<T:0]L4Q)X979$E1F7J%8$BJ&JZM'IEQ9I*0$G9@S$]
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MB#TKD;SQ!/XCLY---P!#"/O2,.M5&BG9BN>JS>-+4^%3KMG&SQA@K*PZ5?\
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M9UW^4,Y^N*LT_9[T;/>@H913_+]Z/+]Z &44_P OWH\OWH :.M2TP)SUI](
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MII+ECJ6[595MAN;"N:T(T4+GTJ*6,>6J@?='%,CDD7J>*A#9K66Z=S9CK*N
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MOQ7K%CJ?B.(VUD]I<6X&R1._X5T%KK%]#K5EX:U"'S;61<LI&3SW!K*:"_\
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M-K>AK420#Q1+#NSY@X/I717=A#>1HLJABA#*3U!%5'W7<ILS&CDB>WDD.2$
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M@^E2:C+)9MB($KCH*3 (/.0R-*>#]VFQ+("F[;*G)+GJ*?%,9+8.XPV.AJ9
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MRZDGGEL&%AG%:G@^=5E&FLB%8CO23'2G3=G85575UT.(O?!USI&L+#=8V8W
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M +C--SVI]-- "#CFDC0(6V]SFE!STP<<4H_GTI,#R#Q0,>([[ _Y:GFH]%C
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MAL]>:,[UC<=QFG%"23R#[4K:@BE?2LJ;,[2PP/K7F6HV5V^MYN)@J2/@[CC
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M?>ICOL7."?:@!)B50D+N(/2E1PX/M3Q@CGZBDP%/ Z]: %Q124<YXI &X$D
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M0DA>YZ"G'..:FMU(_>,/84[:DWT+]@%M9!D$Y&"?2NJT$@ZCE>GEGG\JY#<
M,UT/A&=VOFAQE-A(;\JZ:3]Y(YJJ]UL[2JU\@>)?9LU9%17 R@!]:[#C,L0D
MK(F2!USZ4/Y@G@V$=/G]ZLX57*Y]ZC*$R@D_PFF!*S@84'!8?+546Q63<>>.
M3ZU.RE]I P%Z5(ARH]11<"!(3N=CT[5(BE@,L1AL_A4N/2H&&+DD-E<<B@!9
M4)9-HP >OK41B14;=C<S?,?05+ ",D\XI9%W9STR,47 BFB!V;/NC@^]6% P
M&Q@D8-*54XXX'(ILDBHF[(X/- #1(LBMN&5Z8]::6W%?ER6/ /:H3(L+C/\
MJR2V139Y&D9&A(P!T^M %R505&<87H*BAA;8Q=@<ME#[4R.0RM@YP@J6.4#"
M'[Y&30 195&R" #@?G48WL9$B8*1US4D7RG!.<Y)JC:(XNGP3AB6- &BBL(U
M#'+ 8)%9VH,T4D0B4DY.[%:"O^[RW4'&*;L0RX?!8Y*CTI-#3.9LX)UE:/:0
MLJG/J*GN ;2[0.VX^7T'<5N2(@82?=;./;-0W.GQW:;G7$B\ CO[5'*[%<VI
MSZO)-,$ (!'RH!VJ]IELXOVP<(%ZFKMK&JJLN )%&TC':K$NV%E=!@,<FFHL
M;D9=ZL2:M&3P@Q@CO2:E:B*:*>1_]'^Z<]@:T)3&)(_-0%6Z>U+<LLJ>4,,6
M.W:>U%M!7U*EHL,]FT^TE%RO'<4NG1Q7,4R1L4(8$9ZXJQ:1+:F2V&=B+\M.
M18Q(LZL?E&#@=:$@N9SW2)JXCP/*4;"/459OH(Y!$B*<+PN.O-33VEON$ICR
MS Y:B*,26BKNPRG*O_2A('(AN!-)"D9C^ZF"2?3O5=+%HK<2+(2K'!'IGBK<
MAD69HAU7D^X-6[41+;CC(&1@]J?**YG6>G+"KQO)O5P64_W6IX@CAO%<\G9@
M'UJ6 ^3*P_@D;*TMY_J$<GY5;.X4)!<=\AF"?PE< 'UJA?69B,<[K\D:DNWO
MZ58^5HPZG!'(]ZL;ENK8@8VR#!!]:&@V*-FJ,T#HA"R $$]ZZH=*PH"255D
MV8"CTK=IB8E<Y=F0W3>7AE#G.>U='7-NEPUY<JJ#R@2<^IS51$17%Q#&RQ2H
M7D)!55YQ4C7$WVH6Z':FS)]:B=9OL\<V[:1U&,G%6(1%=0^9@J2,%N]6(@6&
M*)1$LQ#.W4U/<[X)(W5@\)7:5[Y]:61551E 2A^4U6AMS-+.N]F5NHS]VA 9
M/BG6KO1/#]S=6I7SE($>X9%3^%-:AUK2%G(V72G%Q$?X7[UC^,G/_"-74,@
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MD#DFN8L+ZPGU.&SNT9%=]K2=@#7H$ME8SM)IX+F1!PS=!7G6H:):_:7\MY%
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M%NY\ZXE!Q\@Z)]3G]*[F!/+0P[0 %PHKP3P!X4\17M_'?6<DEC:AOFF)QO\
M8#O7NG^D!T ^<@8=@,?C5U8*#LB:<W+5DZQ-Y+1KER/6L_7+V?3M-79 LA+
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M);":U&1G*_C@4WDDJ>2.12KQ*R#TSBE(P0P'S4Q O3KT[4K#(IN2F2>I-/)
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MK TV ?X"?6G3ER2NAS7/#ED9F@Z3IN@6PMM+LP5 P\O\3GW-7-2MIKE(G5<
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MS2_,"4A.&/Z&A2UV!Q\SE[F6^U"YMYKC2-,DG(_<M]L&3],-S5G^S]:WRO\
M\(W8YE^_^_Z]_P"]ZU3CT?5R]N);5V>0($D_YXA?7W-;&NQZJ-1F^R0S21S1
M*J&,\(0RDY_ &KOV(L1VP\1V<9CM]!LHT)W%5GXS^=3?:O%7_0%M/^_X_P :
MQSHFL2,TK&Z\P^8W#\9#';V^E=W9B06-N)L^:(UWY]<<U,G8<5<\^UO4==FU
M6QTF_DCT2WN=Q:ZBD4EB/X03D#_Z]+X?U;Q ;F_TZS6+6+>TDVI>2.%W?[.1
M@$C^M=UJ&E6.JV_D7ULD\><@-VI]CIUIIEL+>RMTAB'(511SJU@Y'>]S$T35
M[R^OKVRO[..VGM@A(C?<#NS_ (5K:LF^RQG^(5AZ4?\ BLM='4[8?P^_6UK#
M!;123@%P/T-1(T@8GEI_9LULJG?SM-4])F:^T:X@<XG0$?E2W=XUE<6\P8%.
MA'J*J-+'IVK?:$XM9QN7ZGK3C&Z-&7M+N'OM*VN?WL!*-_2KD#_NQ$W W98U
M4BA6#4OM,#;K>=<D =ZLW ;S ZCY2V,5G):C6IKM%YL4<B<2*/E/K4%RIN;3
M?&2L@."/Z51TK5 ]W)9L3N3H#WK9=%(;!QGDFJL1LS(MSM;^[EL&MKG /M63
M+$EN^6/RAN:U0P**W8BDAL-HW%OXB*;G>21T4]*?^-1G*N#ZGFF2/8!@0>AJ
M-PP8!?F!/.:E_I2$\C.* *>I7T.GVEQ<39*Q)YA4=3CTKGYO$EQ<11R1>']0
M=&&0=O\ ]:L'Q5J5RSWP8G"QLFT>E>CZ2"=(M/\ KDO\JUMRJY#U9R[ZW<R1
MJ!H&I*1_L?\ UJ?!KEU%&5.@ZB<]]O\ ]:NMEC+<JW/UJ!B\"_,"<FES!RLY
M&_UIM1LIK231=3177#%.& _+BL;R8I(K9'T/6'6# 4X^\ <@'"],U+/8:DL]
M^]O#=RPR2"27<A#;=_(7U&*T[0:I:>&;79'<"19PS1A27$6_ICZ5KLM"+7W,
M[3,Z3?RW<&A:KNE_UF1G=^G6MA_$<Z$9\/:CD_['_P!:LF2;Q)<B-EDO(0 #
MMV<\L<YX],5T6@_;GTY5OVD:9964,XP2O&#2?<:[&!J/B74$$,46D7%M/<RB
M**6Z&$4G/7IZ4^VUO5M-UF31M2M/M\Z1>8LEFI'R\?>'.#S77:GIUOJMFUC=
MQ[X3@XZ'/J#VJ#1M!T_0XI6LD?S'Y>21MS-^-3S*P^5W,JVU/^UKQK064]K<
M6^V1EG'5<CIQ[UVM><ZAJ#0_$.2(''FV\8S^*UZ-6<BT+1114C#M6<:T#TK/
M[T 1PNSQY9=ISTJ0C-&:.U ""@@,I!&0>U+10 0J$3"C ]*"<FG#A:90 &D0
MY7.,44ZF 8SQZU@G6;F+4;G3['2WN?(P782 #D _UK>[UC:(?^*IUKG^Y_Z"
MM5%Z$R$_M76?^@ __?T4G]JZU_T+\G_?T5U%%',+E.6.K:P.#H#CZS#FF/J.
MK2J\,OA]G5A@J9EY%)XS9"UI$%G\Z1B!+'DK$/[QQWJE9V]ROBB8*T\HE5@[
MLA4Q#L0>G/-6K6N2[[%=M)9UD0>&I!'(X=D6<8)&?\:UK>^UBVMHX5T*9E0;
M06F&<5+HZ7MCX6N@GFM<1R/L,@RQYK+?6M<NV06HDC5@@+&,\'82WZBGS-BL
MD:G]JZS_ - !_P#O\*R=?\0:U9Z:"-,:R6218VN6<,(@Q +8_&MCPW=:M+=L
MFH.SHT.\$IC:V<8KHIH(KF!HIXUDC<896'!J>:SU*Y;K0\\@O;_1];M;2RU!
M]=6YC+21%ES'_M9 X'UK;;7KVWN;:*\TAX(YY!&',@.":W-/T/3-+=GLK2.%
MGZD=?UK+\5G#Z3[WB8_,4G),%%HXW7(PVMW@/>4T_2KV>R(@,A\HL"I_NFN<
M\27UQ#XKU$1R':)C\IIEOKA;:EPFUB?O=A7E.3C/0]?E4H:GJJ<7*S-)EI!P
MOI3IM,M;F;S'49ZD#O\ 6LW3I?M6C0SJ=[1CC;^5/5)K33+^X9VWM$Q&3T]*
M[=)1YF<-FI61QWB3Q%%<ZG]EAB'D6S; 1W/>JB317"[D?./X?2L'86!8MEB2
M2?K3[0M;W4<H/RAAE?6O-DVV>G&*4=#;<!5"'TS0#@#/3'(J2Y&^X=P.#R!4
M;I@[NM+6X714N+&6-A(JYA;^(=!491L  ]*TGU5K"S> Q+()N@?M64+E1D,,
M9/;M0UV&GW';7P/;M6G8;C!C' /2J"LLI"H?F/ S6U# UO J'[PY-))BDT,=
M=N">@ZU:M[&ROXY&OV$=I%RTA.!]*KK!)<S")3C/WB>P]:P=?U,7+K86N190
MG!(_Y:-ZFM%IJ1;FT(]>\IM3/DMFV7B+;TQ67,P$+8_N\5L>'[2/4+EK:7E0
M,@GM713^#[&6-@C.C%<#FDH-NZ*E-15CH_ O/@[2_P#KD/Y5U63G&:Y70Y%T
M#P_:V;H96MT"EEZ&K*^*[=AD6S_G7>ZBN><H.QT2M@]:BU"0"PG/VG[. I)E
M_NBLB#Q'#,YQ;N% R236;J/B'3]1M9K.ZLY6A?AE5L9%-58I[B=.3Z&6KZS>
MZ%J$MA>N8I) EI),P5F]3S5>UUF\G2TTEKN>"7SG2Y<L"00!T.,=ZM0/H%KI
MTUK%IT_D2#YE,I[>GI64VL^'?L2V9TB<1*^X,)/FSZYQ6GUB!/U>;.PTW6[O
M_A!CJDN))XHR<M_%C'-17/C"YMXLI%&S?8TN.?[QQQ^M5M+\3:3=:=_9L=BR
M0!-GE$]1Z54D?0;1VMTTN<[D"-E_X1C Z>U2JU/=@Z-39%EO%^MQFX\RUM=M
MNL<DA!/W7Q@#GK\PKLQ+YL<<H'#H&P?<5Q)U'16$Q;3I#YRJCC=U"XQV]A6E
M_P );;)&JI:R!5 4#/84I5H/8<:,UN6-;\,6VM7$=UY\]I>1C:+B!L,5]#VI
M='T"UT&*18&DEEE.Z2>4Y=_J:K?\)?;@@?9I/SJ==?-U'F&QD?!YY_\ K4O;
MIJUQ^QL[V,#XF\^'[/)./M2YJG\.$/\ PDS, =HMV!_,5:\7ZAI6IVMI:7-T
ML3QSK(Z#YC@=JZGPO!IB(LNG;6C=3\_>LVN>47V-$W"$HOJ=.*CG^Z/K4E1S
M_='UKI.8KT444 & >HS1110 4444 &!Z#\J*** %K$EUFZ;4[BTL],>X-N0'
M<2!1DCWK;K*TF":'7=6FDC9(Y74HQ'#<"JB2T1_VAJW_ $ I/^_ZT'4=6 R=
M#D _Z[K70;U_O"HY\2P.@899<"GS"Y3C+Z>?57MF:Q<"-SL6.[CPY]/>H6T6
M9U*MHEP1Y@D -PO!'3%6(?"M[&UN/M$2QHQPF?\ 5C/8Y]JT=2TK5+J^D,%X
MJ6[L& SR.,$5?,NA'*/&H:L% _L.0\8R9UK-UO7M7L; .-+-J'D6,W$D@98@
MQ W$#L,UJZ'I%UIET\D]WYL;(1@G/.[(_2MR00S1F.0*Z,,%6&0:ES5]BN5V
M.)T;7M5GGN[5(DU9(& 6\@<*K9 ./0D>U=%I.H_VG8BY\DPD.4*$YP1[UHV\
M%M:1B.WCCB3T48K(\.6L\.G2I+&4<SNV&[@XYI-IE)-,U**D\E_:CR7]OSJ"
MB.BI/)?V_.CR7]OSH A*YZ]J=4GDO[?G1Y+^WYT 0>3$7\PQKNQC=CG%10V5
MO!,TL405WX;%7/)?T'YT>2]%@N87B??_ &0JI*\?F7"J60X.#FG_ /")6O\
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M/F0'(^,%'V*Q"@M)]K1F '08/-=MYJ,,K(,?6HFTVV8?,I/&,DTG]E6WE^6
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M4CDU],[%/\(_*C8H_A'Y5+H*][E+$^[RV/ #J%EI9^PQVLAC5]Q*CM^50/\
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M(8=,5J3K#!=^<J 2O\NZB]]A..NIBZBUY!? +(W7/M6[!<QBVCE*@.PP<T+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BDS1F@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"DS02 ,DX%8&H:Q+),8+%AA#^\ER.* +/B/6?["T::_6 SL@^5!W-8NB>(I;
MTVMS-(O^D ET4@B,?3K69XON+G5=,L[6.[6W9YVR[8#, K=C[XKG]$:VT2Y6
MVNKM7N)U^7*'Y3GI0!Z2WB:P%U+"I+^3_K6'1>]<AX^NE%S::C82R22)B-T3
ME=IYS^M<[J\$UGJ!=I9)8)&P64A>2.A/0UK74!;0#;AWE1P?F1<G)&!C% %R
M:]M=4B^WVMNR( %=R.01UR*CN-?^QS&YTU1=O;?NE0?>P>I []*KZ5)<RI>Z
M9&\ ,2H2[_+SSV-36VCB36X(8TW2+$7GGB( 4\87T]:!E<ZI/>7EOJ=]<1V]
MO-,81%+UC/K[=/UK=FG@TS4K2:&5)O+!:23/RD'@ >^2*X;7)'AMHM,O;/>+
M67<;F%MV5/J!6QOTY-*5(GDMUF(:"-@2<^ASS0(]8AD\V%),$;E!P>V:DKF?
M#6K/_9Z6^H,%N%.T#.21V_2NCCE25-Z,&7ID&@!])FH;F[M[4+Y\J1[CA=S8
MS7+:_P")XFTZ:"S$OG,WE@_=Z]",T :-[XIL;759-.,\*31Q[W,KA0,]*T--
MU*+44D:)D?8<%D;(->8>*K.P01:C'"T[7,Z+/N.63&?3ZUU?AG4M-M)I;6&*
M2+SGSO<8!/I0!V=%(#GG\J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3-+534)I[>PGFMHA+,BDJA/4T 5];O9]/TN6YMX3*
MT?)4#)QWKSZ?XDW=K<1.T,IM96R&:+G'?M5R3Q_-]G\J>':\D)9@L;?)GM]>
M:QM*GTK6X[:*.['VV'.5?&T DYR*+C2;/0] \20:O"NXB.9\E4/5E]:W<UY;
M',8]5FN(Y(_-LADO!T*8Y&/6NNT3Q3;7L*I/*JR]3R#@>^.E CI:@N[C[+:R
M3[&?8N=JC)-1/JEBD;2-=1!5ZG>*YJ_\7RF-%MK1D6=RBS2<*ON: -"+Q7;M
MY3/$PCD_C'(7ZUNQ31SPI+$P9' 96'<5Y)+>BPNYEN(PC._4-^[DSU(_P%3Z
M9XKN!*+6S:><(Q54C3Y5C'<<?2@#U?-&:\[L?&DSZAY<\-U L;#?YJ\!3T[?
M2NE/BS3S=&&(/*H )D094>WUH Z"BLB'Q'ID]QY$<^7QR=IP/J:UA@\CI0 M
M%%(: "EKF9O$L\6H3P+;*T4;%1)VXZU=M=>2X90UNZ G&[M]?I0!LT57-[;+
M.L#7$0E/(0L,G\*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 07-NMS;R0N2%<8R#S7 G=H.KK97!=[:<MLF5A\Q[ ^
M]>B$C'/2O+O$-S;1:A>)+.0&DW0D-PM "7D$.H:C-:S31XCCW1J[88-Z US5
MY'=:;<65\;:X:*)]TGF+U /KC]:MSWNK+J=K<VEF)XY<1EB,GT)%:]UH?]IS
MB>^N7C:W&9(6&!M]"* )+;7+'493,EHIAF8(_P VX1OV/MVK5U$6NG027'FL
M^R+<),@#=Z>]<]?65A9ZA"_A\1.9DW&U+84L/XO;']*F@N[JYTS[-J-Q&\SS
M%&R.!TP* ,W43;:A ^K1P2Q2QH//(/#CG!Q^=6;4M;Z&QM0_ERL%5PWS'/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBL#6=4EMKKRXW"QQQ&23!PW&>E &
M_17"^'O%T]Y;S2R.LP )7)VE<>M2C6=42XAN9"9(I&R(DZX],4 =F[K&A=R
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MOK63::3"=*^SQ(J2D'?,HZ@=1^52*MM<RVL4:H&'!('4>I]J9)TT7BRUE/\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,TM,D=8T+NP55&230
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MYX4^S:;>K"UW<O(J9M_,X5T[CK]*]%219$#*001P17GVG:#)K36DEQ=QPV4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[B![\USUY*-#D;RYYHFO#O1(3D>Y'IUKL?">FK(K7\]G-F10T<ETX=\?F<4
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M110 4444 %%%% !1110 445R>N?$;P]X=U)K#4)IUG4 D)"6'YT =917 _\
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M&0G<@]:?XDBDELSK&F:E;QQN!OCD<$G%2SFVOG9H--$:L@5BJ_<'.1]:FO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 R5UCB:1ONJ,FO*?%.N:U<:B#9X"B,E(P,C9W)]^E>KL 1@]#7#
M^+-.T*R@>7 M[T_,LB=5'O[4 8ECNU.Q4QPF6=(M\CEMH[?K5"Y>WNK:YNH9
M9A-$RNULW0G(R<_G4%WJU["T-T81)8VV%D\L_?7L2/UJY=F#4Y_,TJ1/LLP#
MB()R2>P- #M5E-Q]AO8X/-1%#21J_(7IDGTS59=7M&G;R-D-M-\L\GF;CGT)
MQTZ5JV5DL=VUG=YC")R < #[QSZFJ%U:66IV9MI4EMUDE8JX7/ Z<>^* %AU
M72H9UTFQB,MN$WG;SYC>F:;8QM>(Q@S%IW)DC89$3^U4[&'^SKAI[:Y\FXB3
MRRLB?,%Y]ZU].F+Z ?LH,;7,O[R0<A!ZT 8VHKJ.EWRO:3FXA($FV3Y@?7^E
M:%RUF=-6:VU&*ZO[H@D*N0AZD#VJ&XBTK2[6Z>"]DN;E9<$%\><I[8]*KVNH
MZ2DT,4=JRPS2YEMU0<'!Z&@!D,6JWWF+ PA4MA)0N S#KC]:TH=*M[&_6!$:
MXOYH_G5W^7<?XB>U7[G5;+3[(6_GO:S08-M$!USQU],&ETY&NA,]C<*]P2?/
M<#*=,_G0!EWMS-HEK)!-9K'<!2"JMN#JW4_SK2.K:5=64-U-%(PMX?E:)<_@
M:@EU)-*-W]HC2X-Q&$ )Y3/%+96\^DM'#))BQG3S)8QU ]: )YKBQU'1HC8R
M[4AZAVZYZUR\"7L[2Z7.XANH)QY+$XR#G!Q4E_;VT=T3ILJ0R9,DNX\;?X3C
MUZU<U CQ!8Q:CY#172)CS ."P_BS0!JRQVEK,D-Y>Q)(@VR)"N2W^T>:KW L
MI(9)U>5K>/ @*# +]"3^M57M[AK"";4YI(C@,7!YE'N:V["?,4D2H1 Y#Q!A
ME3[Y]: ,O4WFTVV^U6\A$ODY  X.3C!_$U>@TR=K2U$ER(KJXMF)+GIG/Z5B
MHTUWX@DCU:*9H+>4;I(CE6[J/ITKK;>UDN;F>_=8D51L2,G)P!Q0!DB%4T\1
M*<>60)CTW-Z_3I2:I=QZ7=65Q$BSK A9]J]5]3[\4EQINJIK#WN^"X"+CR';
M&WT^M:=GIC_93OC7:1N2-#CGN30!S]KJ5K>>([E)[@K9S0AHB1^8!_*L_P 2
MO<(UH//C>"2,_9=K?<(Q@-Z\53UF&QL[FUB,IDAAER8?X8\^I_"K.KRL=3MX
MGL($M99>)BN ?8>U $>J:MJ$-MIFH2V*I<8\K:AR,?T/%;\.H3W=JD,.EY@(
M5KB2;[RDX&5JGY<MFUVEO%'=6>59')^Z>F*AT3Q18B2ZM]4MS#(V5$DHR" >
M@H TKJ*"+4[6:UG>"[:01!L\'GO5F\GL);V=)"ZW\"X9@V"_?IZ5S]_>2W<\
M8M8U1+619$VC/FG(X_*NBU-'MGM]0@T^(W*K\\T_."?;VH I:EJ$<%M%9_9Y
M+&ZD^9X\_*ZCH?YUU7A3PWI\=A%?PQS0M*?,92<;CZFN/M-7@BUW.N/#.VW,
M;@8/L,5U_A35C<ZE/ (GBA==\:,, ?2@#L0,4M%% !1110 4444 %%%% !11
M10 G>L34?"/A_5KLW5_I5O<3D8+N#FMRB@#P31?#VD7'QCO=)EL(7L$#[8"/
ME' KNH=9T?PAXRB\.6FA1V:7@7%S')@,><<8_K7,>'_^2\ZA])/_ $$5J_&*
MPDAATS7H,A[27:Q'OC'\C0!M^-OB-;^#KRVM38F[DF4LVV79L'&.Q]:T=3\9
M6VG>#(_$7DB19(U=81)C);^'./Z5Y"\7_"R_&.H7*!A#%:$H">XQC^M99UFY
MU?0=%\* ,98[DB0?C@#\LT >S6OQ"LAX13Q#J=NUE'*Q6*'?O9\''' K*/Q4
MF@B2]O/#-];Z6Y^6[+9!'TQ_6N=^*=D=-?PQ:8QI\.R-O3<#C^6:]"\2M8?\
M(!=&0I]F^Q_)Z$[?EQ^.* -O3-2M=7TZ&^LI!);S+N5A5;Q!K]CX:TI]0OW(
MB7@!>K'T%<9\&!<CPA+YV?*-P?)S_=P/ZYJ7XL:Y:Z5HUM%-IT%[-.Y\H3KN
M5",<X[T 5Y/BO<6T$-Y>^%[RWTV5L)=-)D$'N!M_K72:YXSMM)\)Q>(;> W=
MO+MV+OV$@@GT/I7F7CBQ\2?\(7%>ZUJMNL1=1'96JX0@C@]>WT[UH:Y_R0C3
MOI'_ "- &S/\6MFF0:E!X>NYK)P/-GWX2-NZYQSCFIKOXKQ"P%_INB7E[9H!
MY\^=BQ$]LX.:R;U57X#)@ 9@0_CD4_P_"D?P-N-H^\CEC_P.@#MK'Q'8Z_X0
MGU>*$R6Y@D,D#G!. <J?RK&^&^LZ3JFF7TVE:(FF1QRD.B/NWG YZ5B_#G_D
ME.I_]<IO_034?P4_Y &K?]=S_P"@B@#1L?BS%?W5U9PZ)<R7D;%8H87WF7!Y
M[<5:T;XF17WB!=%U32I]+O'.U%E?=D^AX&*Y;X/1(WBOQ!(RY92 #]6:CQNH
M7XS:,0!DB+_T(T >D>*/%VF^%+1);UF:64XBA099S_A7,CXI/:20OK/AV]TZ
MSF.([AVW _A@5SWQ R/BGHIO?^/'"[=W3W_I78?%)K7_ (0*\\XH2<>5_O9[
M?AF@#L+:XBN[:.X@D62*50R..A!HN[J&RM);F=PD4*EV8]@*Y/X7BY'@.P^U
M$[OFVY_NYX_2M+QKJEMI'A6]N[NT6ZB"A?);HV2 ,T <M)\59Y8KB[T[PS>7
MFFP$A[L/M7CK_":Z[PSXGL?%&D?VA9[D56*R*_56 S_6O,+&'Q'K'@2ZO5O;
M+2=&\F1XX+6/!8#.5/(Z]*F^&8N#\.=?%KDW&9/+Q_>V#% '277Q-$NI366@
M:)=:N8/]8\+;0/T/%;'A/QM8^*EFCCB>VO(#^\MY#DC_ !KE/@J\7]CZ@C;?
MM G)?GG'^<UUVGOX2'B:X6P^PC62&\WRQ^\[9S^E '/Z%K>C7'Q)U+3[?0([
M>_B,GF7HDR9,, >,=ZO^)/B+:Z'JR:39V,NI:BQ'[B)MN,C/7!YKC_"G_);=
M;Q_>F_\ 0Q3?#&Q?C1J?V_ F+2>3N^O'Z4 97Q*\0OK=UI*7.G7&GW<3CS()
MAR!GJ#W%>Z:;_P @JS_ZX)_Z"*\C^-)MO[3T8 J;G(W>NW/^->N:;_R"K/\
MZX)_Z"* ,;Q;XPT_PC9)/=AI))"1'"G5C_05Y_XR\:W.K>"[F&_T&\TT3@&"
M20[DD_' Q3?BI@>.]!:Z_P"/$%-V>GWCG]*ZKXGM:?\ "O)_,*8(7RO]['%
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M++N]M+J\U719M*LX$WB6>3.\=<@8':O/_'D0F^+FCHV,9C/_ (\*[+XKB8>
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M(QVQ^M=CXHT;3;ZW6\O7:)K?G>G<>A'>N'^TZ1837EQ'=^7*5!:"3^+KD T
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MAR,<&F0:3IB6=Q_:URTTDT0,;1CD,>20?K5?2S;Z9;_\3&21;0*?*=SNP?\
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M#9>"9O#(O7>.564SF, C..V?:I_"WA.+POH$FDQW;SJY8^8R;3S[9KHZ,<4
M<CX0\"P^$;N\N(KY[DW7)#1A=O/UIFI> 8-2\90>(FOY$>(J1"(P0<#'7-=C
M]:* ,'Q1X3T[Q98+;7ZD,AS'(O5#7-0?"N*6YMVU?7;[4[:W_P!7;3?=7'XG
MBO0Z,4 <UXN\'P>*M(AT]KIK1(F#*R(&Z=NHK9TNP72]*M;!7,BP1A-Q&,X]
MJN8HQ0!PNJ_#2VNM9DU72]4NM)NYL^:UO_%GKW%:7A3P/8^%I)[E9I+N^GXE
MN91\S#.?YUU%&* .0;P'"WCQ?%/V^3S%_P"7?RQM^[MZYJQXU\&Q>,K&WM9;
MQ[40R%PR(&SQCUKI\48H R+CP[8W_AY-&OD$]NL83)&#QW]C7'_\*H/V<V/_
M  DNH?V7G_CR_@QZ=:]'Q1B@#%M_"VDVWAPZ$EL/L++M93U;W/O7('X2JL+V
M4'B._BTMVRUD!E#]>:])Q1B@#(LO#6EV.@?V)#;C[$4VLA_BSW/O7)K\+7L]
M\6D^)M2T^S<DFWB.1SU[UZ'10!@^&/"6G>%;62*R#-),VZ65^6<UIZI9#4M+
MNK%G*"XB:,N!G;D8S5NC'O0!S/A'P?%X3TFXL([Q[E9G+[V0+C( Z9]J@\'>
M!H?"%Q?2Q7SW/VL@D-&%VXS[^]=;1B@#C]4\!0ZIXTM?$;7\D;P;<0B,$-CW
MS78TF*6@#*\1Z'!XCT2XTRX8HDP W@9*X(.?TKG_  5\/+3P9<7$\=X]U),N
MT,\87:/S-=IBC% &!XO\,1^+=%;39;E[=2P;>J!CP<],U>T/2UT31K735E,J
MVZ; [#!/X5HXHH *\]\3?"72=?U*2_AN9+&:4YD\M P8^N,BO0L48H Y/PAX
M TOPCNE@+3W;C:T[C!Q[#M76T44 <?K/@2'6/%EIKSW\D3VV,0B,$-@^N:ZB
M[M(+^SEM;F,20RJ4=3W!J?%&* /-V^$R1I-;6/B&_M-/F.7LT&4.>N>:Z_2?
M#.F:/H1T>W@!M6!#AN=^>I-;.*,4 >>_\*N-F\BZ+XDU'3+:0Y:"(DC^8KH/
M"W@_3_"L4OV8O-<3G,L\GWF-=%10!P6J_#&UO->;6--U6ZTJZ<EG, Y)/4YR
M,56N/A+9W-_:7[:M=-=0R+)++*-YE(/J3QTKT:B@#EO&7@N+QA86EI+>/;"W
M8L&1 V>,>M7]0\-VNI^&O[$N79H?+";QP>.AK:Q1B@#D/"?@F?PM+@:[=WEJ
M%*I;2#")[@9K?US2UUO1;O37E,2W$90N!DK[XK0Q1B@#F?#GA"+PYX:FT9+Q
MYTEW?O&0 C=[9IG@KP5%X,MKN**]>Z%PX<EHPN,?C74XHQ0!R$W@.&;QTOBC
M[=()%Q^X\L8^[MZYKKZ,48H 6BBB@ HHHH **** "BBB@"&YM8;RVDMYXUDB
M<896'!%<5XA\)Z+::?')#90[HY-Q#8W8KN2Z]"P!/8FO,-=OF34M0@NE+.'W
MPSAS@#T7'>@#*CT:WA<&UD"X)(91]]CVQ5VUT.ST\%Q;R7$ZINF1C^[1B.@
MSGK4<%Y=7$;)9VGR+(N6;&X YYS6_$ATJQD07*K/-)D!7W=?K[4 >>W-K;S6
MD8%JL5T)\$KQD9K?N]:U>RMRLL$?V=X@@AD<DX Z]*FOK6P^U;UN%CN+=MS1
M29^<GG(/U-5)M569XY6TT3!3]TRY=B/;/2@>NYNQV[:E:64EI?1(L8W-"B9
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MC(_AZ\"@#HM42V/VB_MBZM" 8P5+;O6LC7Y]6O;"V32Y8XR5\V6!E!P".?\
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MI_Q]>4WE=/OX..O'7%>"69LK[3TNM-\7WZ:Z &:&[FV1;NX!; KURUN=3E\
M7$VI^6EZMG)EX90P;"G# J: $\$_\)2;*Y_X2D#S_-_=8V?<P/[OOFNIKR?X
M3ZK.GA;6KV[GEF^SRLX,LA;@*#CFLSPQI^K_ !&U"_U2^UJ\M+>)]D*6S[0#
MZ?3I0![917A^BR:Q9?%^/3K_ %*>Y\L[<ESAAV.T<?I3_&5WJW_"VK:RTV_E
M@>5$5 ')5<YYV]#0![;63XD_M;^P+K^Q,?VCM'DYV]<C/WN.F:\H\=:!J?@R
MUM=;M/$.H3S&8+()I!C)!/  QCBNQ\3:I<7GPDDU'S&BN)+6)R\9(()*YQB@
M#9\.SZW;>%C<>(P#?Q*[N!MZ#)'W>.E<-X8\1>,O&FL74MEJ=M9V-M, T30@
MY7/0'!.<5)X=TR3Q)\(P+G4;R-XQ+)YD<GS-@MP2>W%<_P#"+P\NHZE<WIOK
MN(V<P(CC?"R=/O#O0!Z):_\ ":#QU(+C:?#_ /"?W?H/^!=<UVE>/6-[=GXZ
MW5N;F8P MB+S#M^Z.W2I_%&L:GXF\>IX3L+Y[.T0?OI(N&)[\_E0!ZU17F$?
MA#Q3X7UZUGT+4+G4K!O^/B*[G7/ZX_2KWQ &N7-U9VEOJ$&F:4Y_TBX>X2-C
M[#)S^5 'H-%?/-SJZ^&?%EA%X?\ $E[J$+2*D_GOO') P.,$8KLOC-?W5MHN
MF2VT\L+-/DF-RN>,\XH ]4JM?WL.G6$][<'$,"&1R!G  R:\LO?!^K7WA#^W
M+KQ'?B]CMO.2*-PL8 7(' R>!ZU0TV>\\8?"O4&U&_N%DT[S"KQL 9 %!VMZ
MB@#TGPGXIB\665Q>6\+1P1S&--W4XQS^M=%7C'P=\.I<6YU@W]VC0S,GV97_
M '3=.2/6NS^)NG75WX2FN;*>:&YM#YH,3E21W''7M0!VE%>:6'C4?\*D_M26
M7==1Q?9R>[/TS_,T?#BSU6V\#W.I-)+<7]T"T*S2D@8Z=3@>M 'I=%>"WUKM
MTV[U'Q%XPFAU;+%+:RN5=5(Z A<UUOPP\0:AK/A'45OKAII+8LD<C=<;0?ZT
M >FUR7C@^+1%9_\ "*XW[V\_.SIQC[WX]*\N\#Z3J?B_4=2M+C7;^WLX'+GR
MI?F))/<YXXK=^*ZS:%HV@VEG>W2A'=2_FG<_W>I[T >MVWF_9X_._P!;M&[Z
MU-7%^+)M;7PA;C1Y889) OFW,TRH(UQSRQQFO*_$3P>&H+6?3/%]Y>ZL&!E0
M3>9$..<8XZ^M 'O.L:K;Z+I=QJ-T3Y,"[FP,GTJAX5\1)XHT8:E%"8HV=E13
MUP"1_2N*\96K^(OA?;ZU<7EQ'-#:I(R1L LK' .X?CFHOA!X?5-'BUO[==EG
MWI]FW_NAR1G'K0!TWA@^,CXBU#^W0/[,R?LW^K]3C[O/3UKLJ\>^&U[=W'Q
MUZ*:ZFDC0OM5Y"0OS'L>E$NHZK\0O&]WI%MJ4UCI-IPYMR S>^?7- 'L-%>-
M7\^K?#'Q-8*=4N+[1[H[66Y8,P]>?49J;XPZC=VUWHCV5U+%OW'"2%0?NXSC
MK0!Z_17D'B?PAJUMX9E\03^([]]1A02NBN%B]P !6OX?\4ZK>?"FXU4_O=0@
M1E5@.3@XS^7- 'I%%?.FDWECKED\^H>+=2M=:8LRH7VPYSQDXP/SKUWP!/K4
MNA^7K,D$[QMMBN(9ED$B^^T]: .NHKA/B?XIN?#7A^,63!;JZ8HK_P!T=S^M
M<'>6']E>'AK=KXX,NKHOFO +M'4]\*OK0![O17 V4\WQ ^&ZR>;)!?%2-\3E
M2)%'MVYKS2W\3^(7T@>"E6X&HM<[&F+G>!W&>M 'O>L:G;Z-I5QJ%T2(8%W-
M@9/7%9_A/Q&GBC1QJ4<1BC:1E56ZX!(_I7%>,/!PLOAMB34KUIK*,/)^])$K
M$C.[/;FJ?PJT>.R\-MXD:^NB8TES:[_W7RD]O7B@#U^BO"M*NV\>:A?WNM>*
M6TJWC<I!#'<+$?;KU%;WPY\37:^);WPU=WXU"&+)M[@,&R ,_>'6@#U>BO [
M&VU3Q#\2M3TA-8O+:U=V,ACE.0H[+GI73_$#37\+?#N.VL]0O)'%RN9Y)CO;
MKW% 'JM%>0:7X2U;Q'X-@U2]\0W\<P@WP10R;5"@<;CU)_&M'X1>(-2U32KZ
MUOI6N'M& B9CSC!X)H ].I#7C6IVMU?ZKJ%SXL\3G2XHF(M[:SNTWX[9 R>G
MXU-\(O$-[=ZSJ.ERWTMW9QJ6@:7[V-W7/7I0!IQ>+=:;XO2Z"UT/[.4G$7EK
M_<!ZXSUI?%_BO6=*^(FDZ59W02SN!'YD?EJ<Y8@\D9K#A_Y. F^I_P#18IWQ
M Y^+F@_]LO\ T,T >RJ<J#[4M>1:M<W?A?XMV4[W4YT^_&"KR$HI/7 Z<<?G
M3M>N+K6OC#8Z;!=S):VZ!Y%BD('OG'X4 >MT4WM7GOC]=:N]0L[2/4H=+T=O
M]?<-<)&[=^,G/Y4 >B45\]G61X;\:6%OH'B*]U"WDD1)_/;<.6 P#C'3TKKO
MC/?W5IIVDRVMQ+"S2DD1N5SQ[4 >K45Y#J_A#5I?"#Z]=>([\WT5OYPC1]L0
M &<8 S^M:_@3Q9>7'P]NM1U!_.ELBXWGJP &,T >C5YA;>+M:D^++Z&UV#IX
M<@1>6O\ /&:Q?"&CZOX_>ZUO4=<OK55DVPK;.%&?ITP*H>';>]M?C.(+^8SS
MH[ RD %Q@X/'K0![OCO7'>&SXR_X2:_&MA?[*RWV;'E^O'W>>GK79'I7C_P[
MO;N?XD:[#-=321*9-J/(2!\YZ T >PT5X;>3:S>?&&\TW3]3FMQ*=I.XL$78
M,X'3.,]J/&FFZI\/KS3]3L-=OKGSG(=;B3<,C!Z=,<T >Y456L)C<V,$[##2
M(&(JS0 4444 %%%% !1110 4444 %%%% !2'M2TAH \W\0^(H-,\4W&GWLEQ
M''*@D$JAN!SPM41JEM>1+^[\SR'W[@ <+VXZDFNL\:M9QV<(N+=6>5BJS8&Z
M/IT)^M<.-'FTF*,V^)Y)FS"2"&(]_6@!UGXITE+K?=64\*NAQMS^&0._UJ*#
MS-?O5M(#%:JR^;YUQE6'ICUI\UKF"699K?"N//\ -7# ^BBK\VFV<U_%?3.T
M1"*?*#CCCH* ,CQ##J=@ERT*KJ4LL0C#*@RH&.<#Z=:S? EI:ZC-=S23/!+"
M!YK,6W =P/>NVO\ 4K*6%?[/W( G[TH,MD>_:L&UCMK"YVH'CEDW/,P7+%2.
M">U0X7DI'53Q/)1E2MOU +#<W(N8+K,$!(0RG@=OF-7H!;11&.&-;V+:7,<>
M%0'W)QQ56TGL3?":^6.*WBP6A!P9CG@X[UK'6-.FO9H+!X+?SEQM=0% /\C5
MG*5Y4FU2TBMHQ+,P&_RU7 0>F36?)X/AG265"R$)A4>3;@=^_-:&E:K<VT$D
MT4L"K"HM^3]_K\WO5=KKS-0:!K\/&Z[T;:<;AU&?Q_2@"KX?CN=,C=$;]WOW
M-%(.?;&>U/O[S4]3M)FNA+#;L2JA,D1@>H_"I;J[-QJT0@@E+D[8MH_=LX[D
M_3/>IOMZ:7)=:?=Q3//<??<CY4)ZT <U;I<Z?I:O%<6L\,;;T\P\YSG'OFMO
M3-3B&C*T\J03//\ :)8\<Y&. /PI$\.PVF)9S \>POLD8A6[@CFJT,WAYY(Y
M%^T379) 0<XQZ<=* -.P@L[NQOET]L22JSY+X);':LR/2[>>*V_LVYN[>66,
MO(TK[@0.W-7]#@TZ^+-.5B#OM&7V&/Z8QG]:H7.HR"ZNEL[-O(M7\L _W?IU
MI6+C-Q6ALK+:)H,,?E%@JG<G&&']ZN5U'6;_ $\#RH9K4S',;,=^8_?KVK5T
MR&U6US/<+M#?.F_Y@.PQ2:W93Q1QNBR7",=C,$PRKZ#-,@R+!H6U2&-)5NQ,
M-T@!**?]DGBNEU.QA2T^VW5JL<=JP4);YY4GG/KUK'TS3H[J>5)8);:!E B"
M#YE(Z$_E5S4-.U9(BD6KM<VX*@1N%Q)TXX&: N^@^PT:&.\N=0L+Z**QD965
M'Y)8 <8ZXIITT2:K=C4+D*DZB03HN%C/ITXZ51TC4)-)U&9;K2BMTBX6$ABC
M9Z'TJU'JLUWJ4-I/:^9'+(&>"/)+#OSZ4 7#IWAO3EC675)9GVY40J=K'WP/
MYU-'=[6$$T;QQR_-'#SE@/7TK0FCL=/62[M-'9X2AW!ST(]*HQ7#3*UZDY$B
MQ!45D#%AZKQ0! XO9A->68D@N(D=?)E'R,"0,)[T^UO-^A-9,;BUOU $HVD9
M]\]^:=]G\07DBB59HHE!=6*@8_3%4CJ5P=5^P:BOFMM!@DA'^M/UH V)%^U6
M,)=]TC 1.),[N._M4M\\LD-OIMPF-.="@G1<$MZ9J@NO-IJSK-;,)B0HW+G;
MG'3U-:MO<7.L:*8XO)@$;;E:<X8-G/2@# L]*6VL([=KJ3[0)6VAYC\J\8YS
M]:BTQ)P\T-Y#+=*ZDPW#<*WY]*FL(#<>(-1L;N81SLJR)D?*Y]0?PJQ>V=^=
M-:?3I&CMX22J,,^9CK@GM0!;T)+32-*9/M32+)GS&4Y+'L%']:9KVH.VG6NE
MF-]UX=CRD=%'J>@S6++=6K3Z;JVFF66$KLFMD&YEZ9( J/6+^+4Y"=-GF%L6
M\LPL.6/MGD4 ;=M80P(1+/$MI;QA9-TFYF7L!S]*UK 6DPCFTU0(MOR>6Q/3
MJ3_*N0T[2I+/398UO2;PKM6*Y7[OT]:N^$Y;C2H',UJQ99&4M ^3WY*\XH ]
M8MW$D*-D'CGVJ:N4TG4X++][<R2LUTX_A)1,G &>F:ZH'(!'<4 +24M(: /-
M?C'K;6?AZ+2X6Q+>OA@.I4?_ %\5R.AZ/\3M-T-;/3+9([&52P0F$DAO7//>
MO2O$7@&P\3:U;:E>7ETIM\;84V[/U&>U=: %4!1@#@"@#P;X=W-_X1\?2Z3J
M\1ADO%VNN1@,1N!XX]!Q5KXLWEUX@\5V?A[3T\UX@/W8.,R'_P"L17H?B#P!
MI_B#7K76)+JXM[FW*D>3C#8.><BFZ=\/K#3_ !6_B%KRZN;ML_++MVC(QV%
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M[:7EM$UA*ULC!H7(^8?[WH10!Z**6D%+0 4444 %%%% !1110 4444 %%%%
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M *Z_U-.^./\ QZZ+_P!=9/\ V6O6$@BC)\N-$SUVJ!FB2&*7'FQH^.FY0<4
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M:[KEH0LD2C)5@03Q^!KG_AEK6GW7AB3PF[2IJ$BRKM*' SGO7KJ0Q1KMCC1
M>H50*1+:"-MR0QJWJJ@&@#Y^T:T\/^%;Z_L/&NBO(1(3;SE'.X=@,'IWS79?
M#>QCO-8N-6@\.VNG6*96VF"R"1P?JV,?A7I\EM#*<R1(Y]64&GI&J+M10JCH
M ,"@#QGP-@_&#63[/_*NB^,W_(E+_P!?"?UKT(01*Y=8D5SU8*,FE>*.5=LB
M*Z^C#- '+^$L?\*VT\#_ )\!Q_P&N!^$*ROIOB%8,^<1\F.N<'%>SB-%0(J@
M*!C '%-CABBSY4:)GKM4#- 'S_X0O](T35+^/Q3IT\^L&3]P'C9F)],>]:OP
MMD:/XB:LL\#6LLRLRP.NTKD[L8^E>TFU@9][0QEO[Q09IP@B60R") Y_B"C/
MYT >-P_\G 3?4_\ HL4[Q_\ \E<T'Z1?^AFO8?L\/F^9Y2>8?XMHS^=*T$3R
M!WB1G7HQ4$B@#@OBOHQU#PE]NB&)[$^:#CG;W_D*POA#!<:MJ>I^(KT!I&Q&
MCXZYSG^0K?\ '^H>(9[>?0](T&XG2YC"F]7E #G(QC^M;'@/PZ_AKPM!93!1
M<$[Y<=F/44 =-7A_Q!!L_B3;7NO033:'\N!@E3\O/3OFO<:CD@BE&)(T?']Y
M0: /GSQ9J5AJ'B/0[S2]-DM-*BD1(YFB*+)A\D\^G]*Z;XUL'T;164Y#.2"/
MH*]<-M RA3#&57H-@P*5X(I0!)&C@= R@XH YK7?^2:WGOIQ_P#0*XSX8:?_
M &M\-]4L,@>?)(GY@5ZT44KM*@KC&,<8I(X8XEVQHJ#T48H \7\#^*HO <5Y
MH6OVUQ#()2T.V,MO/?\ I5+P_>W&H_&=+RYMGMVE8NL;C#*I'RY_"O<WMH9&
MW/#&S=BR FE%O")/,\I-X_BVC/YT /)X->,?#;_DIWB#_>D_]#->SXIB6\,;
MLZ1(K-U(4 F@#QO3?^3@+GZ-C_OT*N_'3_D%Z5_UU?\ D*]6^SQ"3S/*3?\
MWMHS^=+)!%, )8T<#IN4&@"MH_\ R![3_KDO\JNT@ 48 P*6@ HHHH ****
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M0TT;#)"_7UK4TZTLF A>5[^ZP'5MY*Q+V'/I0!"8[;3;J>YAECM' *;<[G_
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MNISC#.!A1]!0!QEG_P E_N?J?_0!1\9(A/K^BQ''SDJ?S%='K_P_U6X\7?\
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M=O-'#([*0\@..#GM5"T\#0OX"B\-ZG*DFQ<>;$.A[$9H \R-QXS\/Z$=+O\
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M'(C888&F:4-,W3:7K<+,X(=05(!?_.*U]#\(P7NL3W30M!8J04A .US[$]J
MZW'VW@:=A;W+"V,CH%<QD\#U'-=[:6L=E;);PKB-!CZT^-!&JHHPJC %24 )
M2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %<WXE@='2YC^ZZ&*4GH%QG^8%=)
M2$ ]1F@#RBPL)$C^V02LMKN*2J5X<]N?KBJU[9SZI=RW$2S0P(N$1FRKNO\
M#^->L75C;WEJ]O*F8VZ@<4VSL+:PM5MX(PL:] >>?6@#R&W@2'4TP?*::1'?
M ^52#R!6KIRS-XBGVHXB<%WD R)#_2K6NI)8>(KFZN[.0J[+Y%Q'R$7W':LS
M2/,M;NZN;IY@P#,$Z @=/YT 7+JRB:[@MIKJ2&"4L9 3\@]![=_RJ>73;:XT
M&XCL)X"H./E/WL UDSW<NH-+>ZC'']G0;3M.20>^/6@1VMII<\MF2T*2X57X
M+-SRWM0!E6)MU<%BJ26D?S(PRK.>.?S-;FG2Q6*7T]U-')J%Q%MCBB;)C7'!
MK/LU-C!<1'R[B:\RTD3#&.^X-W_*H](B2"*5[J)'?!^9&^8 G]<B@"U:^%[&
M\GB.JR".=B'25FR7&?6KTLEO>7AT>T6,+&PQ,S?O!Z8K#M["UNM39K6V)ABQ
M+L=L9'I]<U8T:ZF_X2V;58K1BFW8JL>$/3)- VQ-4T98!,MTLQM^<E6R4D'?
MZ59A9(I=L=X\UF$YG W!'/0,._?TK6EO-+UR M<3B.624QW"*V 1QSC\ZI/H
M]]HLS"Q5KN"9<@!MI ';OD<_I0(J6US)X=TF<PB.:":?YYR.._3T-2IK>GS7
M%O<R.L"QN1/YARQ!!Y^F<5,]JD]JT&H0Y=/D5D.Y9"*MSZ;H^H6L<%JB0O;P
MAA,!P7X!!]1R: (=3ET5K(HEV958B588NG'.:B@N)M1OK>\M$AAAC(5$N!]]
M@.N/\]*QX((;,R1*D<V\,9)&&!'VXJ":YEOC'IX3;=V[ 6Q4XRIYW'\S0!O7
ME\L^L01ZG^Y8Y==C?*_;K^%1OIMBNG)Y(ENIMQ+R1G. ?7T-065RK17%O=H+
MK6)SY46],* .X_.M[3;6"!46889OE=8SL^;T/J* %L$7P_96\MT6*7(,:A_X
M2>@_G7'/;C3=9N9M1D L9[@!]K9]?SKO==>:6Q@@-M \6=NXG[I]:Y2[T_S;
M""UF@0&U?;YR<HY/][T- %W59H)=4MXK>Q26$ 9F?E5!Z<>M=5H6DV\Z.MXH
M>6-]T>1@@5D6NDQ6=K%9_P!H*';YBOH1VS5O1#<7^I6WGHL2HS<QG)8C(YH
M[9(TC4!$50.!@4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM0(O:1H,&EQN&D>YD8\R38)^G2M< *, 8%':EH **** "BBB@ HHHH ****
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M&.Z0VS#>A;EFP.!^E '#M<:CH^LK-+:N54ATC!W!AT.3Z4C:G=74\VH6=K'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2T 9>AZ.FBV MDE:3G<6;UK4HHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC-A3GIS67-XCT^[A#:=K5@"LP1V?YQS_  \$8- &]BLS5]&AU18V)V319*.
M,C(I+SQ)HNGNZ7FJ6L#(P5P\@&"1G'Y4DOB?0X9H(I-5M%DG ,2F09<$X&*
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MK^WMM_W?-<+F@#2HJJ=2LAI_V\W47V3;O\[=\N/7-5M.U_2=8=TTW4;:Z:,
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MK;RPQ37$:/.=L2LV"Y]J +%%9-WXGT.PO/LEWJMI#<#'[MY &YZ<5JY!&0:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%&*
M6B@!,4M%% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 E&*6B@!,4M%
M% "8HQ2T4 )BC%+10 F*,4M% "8I:** "DQ2T4 )BC I:* $Q1BEHH 3%&*6
MB@!,<YHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% !BDQ2T4 )B
MEHHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q2XHHH *3%+10 F*
M,4M% "8HQ2T4 )BC%+10 F.:7%%% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M)BC%+10 F*,4M% "8I:** "DQ2T4 )BC%+10 8I,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,<4M% "8HQ2T4 )CC%&*6B@!,48I:* $Q1B
MEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%+BBB@ I,
M4M% "8HQ2T4 )BC%+10 F*7%%% "8I<444 )BC%+10 E&*6B@!,4M%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gmz2lq4320rk000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmz2lq4320rk000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,."$0# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH 0T"HYV*6\CK]X*2*\Z\#7.O\
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M5SW]@ZM_T,=U_P!^H_\ "C^P=6_Z&.Z_[]1_X4 =#17/?V#JW_0QW7_?J/\
MPH_L'5O^ACNO^_4?^% '0T5SW]@ZM_T,=U_WZC_PH_L'5O\ H8[K_OU'_A0!
MT-%<]_8.K?\ 0QW7_?J/_"C^P=6_Z&.Z_P"_4?\ A0!T-%<]_8.K?]#'=?\
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M!U;_ *&.Z_[]1_X4 =#17/?V#JW_ $,=U_WZC_PH_L'5O^ACNO\ OU'_ (4
M=#17/?V#JW_0QW7_ 'ZC_P */[!U;_H8[K_OU'_A0!T-%<]_8.K?]#'=?]^H
M_P#"C^P=6_Z&.Z_[]1_X4 =#17/?V#JW_0QW7_?J/_"C^P=6_P"ACNO^_4?^
M% '0T5SW]@ZM_P!#'=?]^H_\*/[!U;_H8[K_ +]1_P"% '0T5SW]@ZM_T,=U
M_P!^H_\ "C^P=6_Z&.Z_[]1_X4 =#17/?V#JW_0QW7_?J/\ PH_L'5O^ACNO
M^_4?^% '0T5SW]@ZM_T,=U_WZC_PH_L'5O\ H8[K_OU'_A0!T-%<]_8.K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W7_'I+_N&N
M ^#G_(L7G_7Y)_Z$:[^Z_P"/67_<-<!\'/\ D6+O_K\D_P#0C0!Z+1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Q/Q&_X]=+_P"OQ/\ T(5VU<3\1?\ CUTO_K\3_P!"
M% '90?\ 'O'_ +H_E4E1P?\ 'O'_ +@_E4E !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *XGXB_P#'KI?_ %^)_P"A"NVKB?B+_P >NE_]?B?^A"@#LH/^/>/_
M '!_*I*C@_X]X_\ <'\JDH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N)^(O_ !ZZ7_U^)_Z$*[:N)^(O_'KI?_7X
MG_H0H [*#_CWC_W!_*I*C@_X]X_]P?RJ2@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!]&O0+K_CTE_W#7 ?!S_D6+O\ Z_)/_0C0!Z+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Q/Q%_X]=+_Z_$_]"%=M7$_$7_CUTO\ Z_$_]"% '90?\>\?^X/Y5)4<
M'_'O'_N#^524 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0W7_'K+_N&N ^#G_(L7?_7Y)_Z$:[^Z_P"/67_<
M-<!\'/\ D6+O_K\D_P#0C0!Z+1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q%_X]=+
M_P"OQ/\ T(5VU<3\1?\ CUTO_K\3_P!"% '90?\ 'O'_ +@_E4E1P?\ 'O'_
M +@_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+W4
M+;3K1[F[F6*%.69CQ5L]*RO$,:2>'[Y9$5AY1X(H L6&I6NIV*7MK*)+=AE7
M[&JL7B+399UB28_,VQ7(^4GT!KA+6]ET[X(3SVY*R+;L%(_A^6EU*);;X4:?
M<K\LL:K*&'7<3S_.@#T"\UJRL9Q!+(6D*[MB#) ]:=_:UE]@^W?:$^SGHV:\
M]^'%Y)K^NZOJ%Z-SX6,!NPYKCXM5N7\0-H09OLD>JX )X(VDX_.@#W&RUBSO
MY6C@D/F*,E&&#CUQ5^O/O$4QT[XC:&\'R_:%:)U7N.,?SKK]:U8:-ISWAM9K
MG9UCA W'\Z +MU_QZR_[AK@/@Y_R+%W_ -?DG_H1I9_B>CV\B_\ ".:L,J1D
MJO\ C4?P7D\WPE<28*[[IVP>HRQH ](HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XGX
MB_\ 'KI?_7XG_H0KMJXGXB_\>NE_]?B?^A"@#LH/^/>/_<'\JDJ.#_CWC_W!
M_*I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "N)^(O_'KI?\ U^)_Z$*[:N)^(O\
MQZZ7_P!?B?\ H0H [*#_ (]X_P#<'\JDJ.#_ (]X_P#<'\JDH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBC- !1110!#
M=?\ 'K+_ +AK@/@Y_P BQ=_]?DG_ *$:[^Z_X]9?]PUP'P<_Y%B[_P"OR3_T
M(T >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%)10 4444 %%%% "T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Q/Q%_P"/72_^OQ/_ $(5VU<3\1?^
M/72_^OQ/_0A0!V4'_'O'_N#^525'!_Q[Q_[@_E4E !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2($ G]10!<NO^/67_<-<!\'/^18N_P#K\D_]"-/F\7>+# X;PA*!M.<NN/\
MT*H?@NS/X2N&==CM=2%E]#N/% 'I%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AHH 6BF\TN: %HI
M,T4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 44E% "T4E% "T4E% "T4E% !12
MT4 4-2NKFUM]]K;>>_\ =SBN;O?%NIZ>B/<Z.55W"#$F>2<#M795RGCCBRLQ
M_P!/4?\ Z$*SG=*][';A'3E-0E&]R6#6]9EEC#:05C8\MOZ#\JZ1<E02,>U,
M@P8(_P#=%2U44[:LYZLXR?NQM86BBBJ,@HHHH **** "BBB@ HHHH **** "
MBBB@ HHI* %HI** %KB?B+_QZZ7_ -?B?^A"NUKB?B)_QZZ7_P!?B?\ H0H
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M!7,>$%&_4N ?](/\A634N:USOI.E*E*3AJK&SI&H3:A;F2>U>V8'&UQS6C2
M =!2UHCADTWIH+1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4A-+2&@ )&.:3</6LS6=-N
M=1A5+:\>U8'[RXKC-9TS5],DM576YV\Z4(<@<<CV]ZB4W'H=5##PJZ<]F>C;
MAVI>E<K8^'-3@N8II-9GEC4Y*$#G]*Z@#CZ52;9E5A&#]V5QU%'-%,R"BD)
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M%T9Q;O\ 9PIEQ\N[I7*7^I>)K"TDN'AM"J#) W5,I<IO1H.KHFCL:XOXB_\
M'MI?_7XG_H0J>TO?$]U;QS"&T"N ?XJI>/#+_9VD^<!YGVN/=MZ?>%"DF*K1
M=-V;7R.X@_X]X_\ ='\JDJ.W_P"/>/\ W1_*I*HQ"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_YXV_YFCSO$W_/&W_,T>Q\T'UE?RO[CIJ*YGSO$W_/&W_,T>=XF_P">-O\
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M85T%*UU8T;C3DG#4S](TO^S+8QF>29F.6=VR2:T**6J2,Y2<Y79BZGH]Y?7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **.** "BBB@ HHHH **** "BDXI: "BBB@ HHHH
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M[AKS_P"#O_(L7?\ U^2?^A&@#KO$_P#R+=__ -<6_E3O#G_(!M/]RF>)B/\
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M HHHH 2DYI:.] &-K-]J=KL_L^S%QG[V6QC]*Y6^;Q+>ZA:W7]EH/().-_\
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M1_=^6NTU:VO;JP>+3[H6UP?NR$9Q0!9NO^/67_<-><_">.27PA?1Q2&-S=R
M,!T^8UI3Z!XP%O(6\3*0%.1L'_Q-4O@P'7PE<"1MSBZD#-ZG<:!IV=S6N?"V
MKW=O)!-K3-'(,,/+[?G2V_A?6+6!(8M;<(G 'E]OSKL**S]G&]SK^O5N7ETM
MZ(@M(I(;9$ED\QP.6QUJ:EHK0Y&[NXE%+10(2BEHH 2BBDZ4 <1\0M$U'6;#
M9;2*D" N^3UQ6/\ #?P]JFERFY,J&TF'S+GOGK^E=[K$\1TJY'F*3Y9[^U4/
M"<T2Z# #(N>>_N:YW2BZBF>Q#&UHX%T4M+]CH@**:K!AE3D>U.KH/'"BEHH
M2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
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MZ>]JEU);,W22/&1^= %NZYM91_LFN ^#G_(L7G_7Y)_Z$:EG^']TEO(3XDU
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$V#2L=M1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110(*4=1]:2E'4?6A[%+<UAT%% Z"BN8ZQ:*** "BBB@ HHHH **** "BB
MB@ HI.]% "T4G3K24 .HI ??-% $5U_QZR_[AK@/@Y_R+%W_ -?DG_H1KO[K
M_CUE_P!PUP'P<_Y%B[_Z_)/_ $(T >BT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPE+12UD,8\:N,,H8>]1_98/^>2?E4U%4FUU"R(1;0 Y\I,C_ &:FI:2DVWN
MM(:6B@!*:0",$4^DHN!E7WAS2-0!^TV$#D_Q%!FL*Z^']L"'TV_N[%AT"2';
M^6:[*BMH8BI#9Z"L<2++QEI,1^SWD.H(O195VL?QYKQ[XB^-]?O]1;2[M?LB
MPGYHD/4^N:^EJ\I^*O@6PO[;^V8V,-UO5'(_B!->SDV,H+$KV\%KL[=3*I%\
MNAA?#?QIXJU:W?2[6..X:(#$TK?<'ITKO7\)ZYJLF_5=<EC0]8;<;1^8-6?
MG@ZP\*Z0GV<EYIU#R2GJ<BNMKFS#&TY8B3P\4EZ%0BU'4YRS\$:':LKM:^?(
M/XY_G/ZUOQ010($B140= HP*E%%>9.K.?Q.Y=A*6BEK,8E%%% !28'I3J2F
MF!Z5Q7Q$XM=+_P"OQ/\ T(5V]<3\1?\ CUTO_K\3_P!"% '90?\ 'O'_ +H_
ME4E1P?\ 'O'_ +@_E4E !1110 4444 %%%% !5.^_@_&KE4[[^#\:J'Q$3^$
MI_YZ5E>(;W3=/T>2XU6(2VBD;EV;\_A6KWJIJ;+'IES(T?F!(RVTKG.!Z5LS
MF6YX98:WX9'C*\U"\LP-.9?W,*6X(SQ_#V[T_P /ZUX9A\57][J%F#:RO_HT
M0@#!02>W;M71^#;%K7PWKVI36),SNWEJ\7.#Z#%;/PPT80>&VGN[91++*3MD
MCY _&LTC9R5CNX'CDMXWB&(V4%!CMCCBO)OC$66^TPK][YL#'TKUT  8 P!7
ME/Q9M;B?4=+,-O+*%))V(3CI5R6A$7J9T?B#XD-9)%'IDQB,8566TYVXXYK=
M^'?@V_TZ]DUK6 5N95^16^]SUSZ&O0K $:=; @@^4N0?I4SC<A4'&1BA1[@Y
M]CR34Y_#%AXRGO-6OY-3G;A;98 Z*>PZ_P!*YVYG/_"PK":+2FTH&6/;!C;D
M9ZXQWJ_8F]\%^,;R?4-'GO8YL[3&F[C.<BF:U)J^I>,M.UNZTJ>WMI'0Q +D
M[ ?XL=#S4.Y>ATGQ>M+8:)9W0@C^T--M:7:-Q&T\9KI/ >G6<'A:QNHK:%)Y
M(%WRJ@#-QZUG_$O2[G5?"<+VL3R-"PD*J.<8QT_&H_A]XC:XL;?19--NX9((
M<>=(F%; JK:D]#FOAP<>.]6[<-QC_:K-UG6;"Y^)$TNO-+)86LA58T7=G!X&
M*V/AY9W,/CG5));>9$(;#,A /S4_Q!HM]X7\:'Q#;6)O+&1\R*J[B-QY&*5G
M8JZ3.=\6:[X<N;RQO?#<#VMQ"WS@1>6"/P[UV7CR^;4OAG:WK?>F\MSVY-49
MM9UGQ7K%M!H6F3:9!'@SM+ HR,^XK>^)=G+_ ,(4L$*23.DB#Y%R3CO@46=F
M*ZNBI\/?"NE7'A2*[O+.*XEN026E4,1R1QGZ5SOA&(:;\5;NSMF*P!I%VCI@
M'BO0/A]$\7@G3TD1T8(V588(^8UQ&AVERGQ?O)FMYA$9),.4.T\^M/L+>Y7^
M*5C:6_BC3/)MXH_- ,FU -QW=_6NU\3: S^")[71+6.*1U#,D*8WCN..YKGO
MBOI=W)?:;J4%O)-'#A7V+DC!)K677M7\3>%YQH=O<Z??P;<>:H!?KTSQ2Z@W
MHC@='\1:/I5NFD:WX;B+)E)[@@&4?ACZ=Z]%\ _\(OY4Y\.RSC<?WD4[Y88Z
M''85S5MXTD32Y-/U[PU=7=W@I)*D(^<^I/\ A5KX:^&KRWU:XUF6V:SMI 1!
M"?0]L>WO0KW&VK'J-%'YT5H9!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444""E'4?6DI1U'UH>Q2W-8=!10.@HKF.L6BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:**2D M%)FEI@%%%%
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MUNYZ2*.17*7W@2]U*V^SW?B"XDB)!(VXY'XUV]%;4L14I? Q-)Z,Y"#PCJ<
MC4>(;C8F %V=A^-=7%&8XE5F+$#!)[U)14U*LZGQ DD%%%%9C"BBB@ HHHH
M**** "N)^(O_ !ZZ7_U^)_Z$*[:N)^(O_'KI?_7XG_H0H [*#_CWC_W1_*I*
MC@_X]X_]P?RJ2@ HHHH **** "BBB@ JG??P5<JG??P54=R*GPE.BBBMSF"B
MBB@ HHHH **** "BBB@ HHHH /\ /%'\J** #\31110 4444 %%%% !_2BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH"2/YU?U62^)I?,.8[7-5[G4;2R3?<W$<2CJ7;%<A#X+U>X8G4O$5U(#U6+
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M[F.0>F<'\NM7\US2BXNS10M%)FEI %%%% !1110 4444 %%%% !1110 4AP
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MT44 )12T4 )12T4@$I:**8!1110 4444 %%%% !1110 4444 %%%% !1110
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M5CZ1XETS68@UK<+N[QM\K#\#6OG\O6N>4)0=I*Q2=Q:6D_&DSQZ5("T4=Z*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSYMS*S,3W';^= '?LVU23VKAKGXM^&;34);*9KM98I#&Q\GC(]\UW$@_=/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)[A5DN6[K&.>?K@BN[M8([2VCMX@!'&@4#V H FHHHH **** "BBB@ HHHH
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M(-6T9+6V\RS@E$DS;@ .O:N[15C0(HP ,"@ E_U3_P"Z:\!\*6JWWQ3U>V8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!]JP'TGQU>6,L'B74K2'2XXLR&U_UC8[9XK>\:^'=3U'[)J&BW'E7UFVX)G
MD']VN=NX/B'XJM_[*U&RMM+M9/\ 6SHV2P].IZT 7OA'9(GA*Y#+NBFN'.&&
M<C %;$GA#0-)234)!/Y$!:;R9)BT2'.<A#P*W-$TF#1-(M]/MA^[A7:">I]Z
MR?&&GZCK-O;Z7:1G[+/(/M4P8#:G<4 <5+J%Y9:'>^* "M]J<JP6ORY\N,D
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MHM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7$_$7_CUTO_K\3_T(5VU<3\1?^/72_P#K
M\3_T(4 =E!_Q[Q_[@_E4E1P?\>\?^X/Y5)0 4444 %%%% !1110 4444 %%%
M% "8.:,&EHH 3'-+110 E&*6B@ I".?:EHH 3%&*6B@!,48YI:* $HQ2T4 )
MBBEHH 3%&*6B@!,4M%% "48I:* $Q1BEHH 3!HQ2T4 )S1@TM% "8XHYI:*
M$Q1BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D(I:* $Q1B
MEHH 3%&*6B@!,>M&/2EHH 3%&*6B@ H-%% "8I:** $-&..:6B@!,48XI:*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?B+_QZZ7_U^)_Z$*[:
MN)^(O_'KI?\ U^)_Z$* .R@_X]X_]P?RJ2HX/^/>/_<'\JDH **** "BBB@
MHHHH *3I2U3O21LY[TTKL3=D6\T5DY/J:,GU-7[,R]J:V:,UD[C_ 'C1N/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)^(O_'KI?\
MU^)_Z$*[:N)^(O\ QZZ7_P!?B?\ H0H [*#_ (]X_P#<'\JDJ.#_ (]X_P#<
M'\JDH **** "BBB@ HHHH *IWW\'XU<JG??P54=R)[%.BBBMSE"BBB@84444
M %%%% !1110(****!A1110 4444 %%%% !1110 4444""BBB@84444 %%%%
M@HHHH&@HHHH$%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E'4?6DI1U'UI/8:W-8=
M!10.@HKG.M"T444 %%%% !1110 4444 %%%% !29ILLJ0Q-)(P5%&6)["N<L
M_'>@7^I_V?#>8GSM4.I4,?8D8- '34E9M]K=E83BWDDW2XW%%!) ]>*D.KV0
ML/MWGI]G(^]G]* +_:BLZPUBSOY&BB<B10"488./QK1H ANO^/67_<-<!\'/
M^18N_P#K\D_]"-=_=?\ 'I+_ +AK@/@Y_P BQ=_]?DG_ *$: /1:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *[G_P! KVVB+N*:L%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
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M 4444 %%%% !1110 5Q/Q%_X]=+_ .OQ/_0A7;5Q/Q%_X]=+_P"OQ/\ T(4
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M0Z<;_4GO;B?:S[N!&=W0#/2O0O&^E:/JNC6<.I:E'8S 9@=S][ID8_*LB_\
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MHWPVFT+Q1'J=IJ*R0*,,DH)<YZ\CBE8KF6IA_%?_ )&K1_\ <7_T,UZU;?\
M'K'_ +HKC_&/@BY\3:O8WL-Y%"MLH!5U))PV:[*)#'"B$CY0!FJ6Y$FFD>8_
M&8;K+3!ZRD?H:HZ7\(;?4-,MKLZO*IFC5RODCC(^M=EXX\(7'BR&TCM[J. P
M2;CYBDYX]JZ+2[,V&EVMF[!FAC5"PZ' I<NI7/9&)X5\$Z?X65G@+3W+##S/
MQD>P[5YGX^L?[3^),5BKE#.(T#>F:]RKAM5\"W.H^-K77DO(4AB9"8F4[CM]
MZ&M!0E[US%\7?#RVM/"L4FEH?M-FNYR%^9_7^?Z5J?#+Q4-6TK^S[F3-W;#
MS_$E=X\:R1-&X!5AA@?2O.K?X;7VF^*AJVEZE#!#YN\0LISMSRM%K/0.:ZLS
M&^*@\CQ;I-Q)Q$%4D^P<UZM::A:W.GI>0SHT#+N#YXQ69XE\*V7BC3U@O<K(
MG,<J=5/^%>>GX0:L,K'KD2Q]E(>BS3'=-6*F@-'J/Q>EN;<F6(2DJR\C[N*]
MKKE/"'@:R\+(TH<SWCKAY#T'L*ZNG%$S=V%%%%40%%%% PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;:P \J.%&!8CH6S[>E38JYUBDF-2>X':G4@  P!TI:L@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****!!2CJ/K24HZCZTGL4MS6'044
M#H**YSK%HHHH **** "BBB@ HHHH **** $HQ2T4 )1S2T4 )12T4 0W7_'K
M+_N&N ^#G_(L7?\ U^2?^A&N_NO^/67_ '#7 ?!S_D6+O_K\D_\ 0C0!Z+11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Q/Q%_P"/72_^OQ/_ $(5VU<3\1?^/72_^OQ/
M_0A0!V4'_'O'_N#^525'!_Q[Q_[@_E4E !1110 4444 %%%% !5.^_@_&KE4
M[[^#\:J.Y$_A*=%%%;LY0_R:![T44##OUHHHH */PZT44 %%%% !W_PH[Y-%
M% !1U^E%% !_DT>OZ444 '?I1_DT44 ';_ZU)2T4 ':BBB@ H[T44 %'?-%%
M @_$_G1[444##]**** #^7UHHHH"X?6CZT44"#T]J***!A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ?6CU]Z** "C^8HHH
M/7K1^E%% ![X^E'^>M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %*.H^M)2CJ/K0]AK<UAT%% Z45S'6A:*** "BBB@
M HHHH **** "BBB@!,T4A.,DUA:?XJLM2U^ZTB%)!/;+N<LI [=/SH WLT9K
M%OO$<-KJ#6$$+W-RB;Y$0_=6D/BG3O[(741)F,ML"?Q;LXQ0!N45C:=X@AO+
MXV4T36UUMWK&Y^\OM6S0!#=?\>LO^X:X#X.?\BQ=_P#7Y)_Z$:[^Z_X]9?\
M<-<!\'?^18N_^OR3_P!"- 'HM%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_$7_ (]=
M+_Z_$_\ 0A7;5Q/Q%_X]=+_Z_$_]"% '90?\>\?^X/Y5)4<'_'O'_N#^524
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M1110 4444 %%%% !1110 4444 %<3\1?^/72_P#K\3_T(5VU<3\1?^/72_\
MK\3_ -"% '90?\>\?^X/Y5)4<'_'O'_N#^524 %%%% !1110 4444 %%%% !
M1110 4444 %%%)GM0 M%)G-% "T4F3GBE'2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0G% "T4F>*.: %HI**
M%HI*,_I0 M%)FC/- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\Y^(X8Z[X:)SY0N^?KM:O1JRM;T2#6[012G:Z-
MOC?NIH Y#Q67_P"%D>'1"/WGS;L?W?ES7::NVHII[G2TB>Z_A$IP/Y&LW3?#
M;PZJ-4U&Y%U=HFR-@,!170^M '!S7/C_ ,B3=::?C:<_O/\ [&JOP8WGPG<&
M4 2?:I-V.F=QS7H%UQ:2_P"X>E<#\'/^18N_^OR3_P!"- 'HM%%% !1244 +
M1110 4444 %%%)0 M%)2T %%%% !1110 4444 %%)10 M%%% !1110 444E
M"T4E+0 4444 %%%% !1110 44G>B@!:*** "BBB@ HHI* %HI*6@ HHHH **
M** "BBB@ HI** %HHHH **** "BBB@ HHI* %HI*6@ HHHH **** "BDHH 6
MBBB@ HHHH **** "BBDH 6BDI: "BBB@ HHHH **2B@!:*** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX1/Q#_T-<W_@.O\ C7:44 <7_P (GXA_Z&N;_P !U_QH_P"$4\0_]#7-_P"
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MU_QKLQ2T <7_ ,(GXA_Z&N;_ ,!U_P :/^$3\0_]#7-_X#K_ (UVE% '%_\
M")^(?^AKF_\  =?\:/\ A$_$/_0US?\ @.O^-=I10!Q?_"*>(?\ H:YO_ =?
M\:P+BT\30^,+?11XED,<L1D+_9UR/UKU*N2N]+NY/B):Z@L1^S) 4+^AP: (
M?^$4\0_]#7-_X#K_ (T?\(GXA_Z&N;_P'7_&NSI: .+_ .$3\0_]#7-_X#K_
M (T?\(GXA_Z&N;_P'7_&NTHH XO_ (1/Q#_T-<W_ (#K_C1_PB?B'_H:YO\
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M^^S_ (5T]%'M(_RK\0]A4_G?X',?VWX@_P"@(/\ OL_X4?VWX@_Z @_[[/\
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M?B#_ * @_P"^S_A1_;?B#_H"#_OL_P"%=/11[2'\J_$/85/YW^!S']M^(/\
MH"#_ +[/^%']M^(/^@(/^^S_ (5T]%'M(_RK\0]A4_G?X',?VWX@_P"@(/\
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M* 'T5Q&I^+M8TC4;9KK2A_9\\OEB16!9?<C\*TM0\2NOB"+0[*)6NWB\TE^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)2T4 )BBEHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %)BEHH ,4F*6B@ Q1110 4444 )B
MEHHH ,4444 &**** "BBB@ HHHH **** $P*6BB@ Q1110 F*6BB@ HHHH ,
M48HHH **** "BBB@ I,4M% "8I<444 &**** #%%%% !28I:* #%%%% !111
M0 4F!2T4 )BEHHH **** #%%%% !1110 4F!FC-+0 4F!2T4 %%%% !1BBB@
M HHHH *,444 %%%% !1110 8I,4M% !1110 4444 %%%% !28%+10 8I,"EH
MH **** "BBB@ HQ110 48HHH **** "BBB@ HHHH ,48HHH **** "BBB@ H
MQSFBB@!,4N*** "BBB@ HHHH *3 I:* "C HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH+.[@OK=9[:9)8FZ,AR*GH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVSIF//85C2^$6>.[MQJ-Q]ENV)EB8@]>H'''6M_3K"'3-/ALK==L42[5% '
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M?!A?PZ]]:ZC<[[51)Y,TA='QV()JM!KNG>(/ >D7.K0M%*)E6&WA.T2.",#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&6;9G J/2KVPUG3X[ZS5&AD'RDIC- '/?\++T3_GG=?]^_\ Z]'_  LO1/\
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M=U_W[_\ KUUWD0_\\D_[Y%'D0_\ /)/^^10!R/\ PLO1/^>=U_W[_P#KT?\
M"R]$_P">=U_W[_\ KUUWD0_\\D_[Y%'D0_\ /)/^^10!R/\ PLO1/^>=U_W[
M_P#KT?\ "R]$_P">=U_W[_\ KUUWD19_U2?]\BCR(?\ GDG_ 'R* .1_X67H
MG_/.Z_[]_P#UZ/\ A9>B?\\[K_OW_P#7KKO(A_YY)_WR*/(A_P">2?\ ?(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '.^-!=#0A+9VKW,T,RR").K
M8S6 OCS6U0#_ (1'4.F/NC_&O0>M)M'H* .!_P"$]UO_ *%'4/\ OD?XT?\
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M1U#_ +Y'^-'_  GNM_\ 0HZA_P!\C_&N^P/048'H* .!_P"$]UO_ *%'4/\
MOD?XTU_'>MO&R_\ "(ZAR"/NC_&O0,#T%&T>@H XGX:VM_!H]W)?V<EK)/<O
M((Y.H!8G^M=O28Q2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>fixx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1654584+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:fixx="http://www.homologymedicines.com/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.homologymedicines.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.homologymedicines.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fixx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fixx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fixx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fixx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100070 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents" id="Role_DisclosureCashAndCashEquivalents">
        <link:definition>100090 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments" id="Role_DisclosureShortTermInvestments">
        <link:definition>100100 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities" id="Role_DisclosureAccruedExpensesAndOtherLiabilities">
        <link:definition>100130 - Disclosure - Accrued Expenses and Other Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100150 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity" id="Role_DisclosureStockholderSEquity">
        <link:definition>100170 - Disclosure - Stockholder&apos;s Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans" id="Role_DisclosureStockIncentivePlans">
        <link:definition>100180 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100190 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100200 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement" id="Role_DisclosureCollaborationAndLicenseAgreement">
        <link:definition>100210 - Disclosure - Collaboration and License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement" id="Role_DisclosurePfizerStockPurchaseAgreement">
        <link:definition>100220 - Disclosure - Pfizer Stock Purchase Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100230 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" id="Role_DisclosureCashAndCashEquivalentsTables">
        <link:definition>100260 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables" id="Role_DisclosureShortTermInvestmentsTables">
        <link:definition>100270 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100280 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100290 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherLiabilitiesTables">
        <link:definition>100300 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100310 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables" id="Role_DisclosureStockIncentivePlansTables">
        <link:definition>100330 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100340 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails" id="Role_DisclosureSummaryOfCashAndCashEquivalentsDetails">
        <link:definition>100400 - Disclosure - Summary of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails" id="Role_DisclosureShortTermInvestmentsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Short-Term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" id="Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails">
        <link:definition>100420 - Disclosure - Short-Term Investments - Summary of Short Term Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
        <link:definition>100470 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100510 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails">
        <link:definition>100520 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Commitments and Contingencies - Summary of Cash Paid for Company&apos;s Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100560 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails" id="Role_DisclosureStockIncentivePlansAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Stock Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100600 - Disclosure - Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100610 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails" id="Role_DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails">
        <link:definition>100620 - Disclosure - Stock Incentive Plans - Summary of Option Activity under Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails" id="Role_DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails">
        <link:definition>100630 - Disclosure - Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100640 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Collaboration and License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1" id="Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1">
        <link:definition>100670 - Disclosure - Collaboration and License Agreement - Additional Information (Details1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1Default" id="Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1Default">
        <link:definition>100670 - Disclosure - Collaboration and License Agreement - Additional Information (Details1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails" id="Role_DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Pfizer Stock Purchase Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" name="StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" name="StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_AtTheMarketSalesAgreementMember" name="AtTheMarketSalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_FollowOnOfferingMember" name="FollowOnOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_AccretionOfShortTermInvestments" name="AccretionOfShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" name="ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" name="PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" name="OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_MajorAssetClassOfLeasedAssetsAxis" name="MajorAssetClassOfLeasedAssetsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_MajorAssetClassOfLeasedAssetsDomain" name="MajorAssetClassOfLeasedAssetsDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ATMMember" name="ATMMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_InvestmentsDisclosureAbstract" name="InvestmentsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_StockPurchaseAgreementDisclosureTextBlock" name="StockPurchaseAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_PfizerIncMember" name="PfizerIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfLeaseTermAndDiscountRateTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" name="ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" name="SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_UnderwritersOptionMember" name="UnderwritersOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ProceedsFromFutureIssuanceStock" name="ProceedsFromFutureIssuanceStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" name="TwentyEighteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" name="LaboratoryEquipmentAndOfficeFurnitureMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" name="CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" name="ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_InvestmentMaturityTerm" name="InvestmentMaturityTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" name="FairValueAssetsLiabilitiesTransferBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_AssetNotYetInServiceMember" name="AssetNotYetInServiceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" name="AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_LeaseExpirationDateYearAndMonth" name="LeaseExpirationDateYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_LeaseBeginningDateYearAndMonth" name="LeaseBeginningDateYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_SubleaseAggregateBaseRentObligation" name="SubleaseAggregateBaseRentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_BedfordMassachusettsMember" name="BedfordMassachusettsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_PhaseOneMember" name="PhaseOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_PhaseTwoMember" name="PhaseTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" name="LettersOfCreditAndSecuredByRestrictedCashMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_InitialBaseRentPerSquareFeet" name="InitialBaseRentPerSquareFeet" type="srt-types:perUnitItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" name="LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_NumberOfPhases" name="NumberOfPhases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_RentStartDateYearAndMonth" name="RentStartDateYearAndMonth" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_TenantImprovementsAllowance" name="TenantImprovementsAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_AnnualLicenseFeePayable" name="AnnualLicenseFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_DevelopmentAndCommercializationMilestonePayments" name="DevelopmentAndCommercializationMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" name="CollaborativeArrangementPaymentForExecutionOfAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_LicenseAgreementLineItems" name="LicenseAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_LicenseAgreementTable" name="LicenseAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CityOfHopeMember" name="CityOfHopeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_SponsoredResearchAgreementMember" name="SponsoredResearchAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CaliforniaInstituteOfTechnologyMember" name="CaliforniaInstituteOfTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CoExclusiveLicenseAgreementMember" name="CoExclusiveLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_DevelopmentAndRegulatoryMilestonePayment" name="DevelopmentAndRegulatoryMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_FederalAndStateMember" name="FederalAndStateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_OrphanDrugMember" name="OrphanDrugMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_NetOperatingLossCarryforwardsExpirationYear" name="NetOperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_TaxCreditCarryforwardsExpirationYear" name="TaxCreditCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_OperatingLossCarryforwardsIndefinitely" name="OperatingLossCarryforwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_TwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFifteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_TwoThousandEighteenIncentiveAwardPlanMember" name="TwoThousandEighteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" name="TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_AccruedExpensesAndOtherLiabilitiesMember" name="AccruedExpensesAndOtherLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" name="AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_MaximumSharesAllowedToBeIssued" name="MaximumSharesAllowedToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" name="MaximumSharesAllowedToBeIssuedUnderESPP" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_UnvestedCommonSharesSubjectToRepurchaseVested" name="UnvestedCommonSharesSubjectToRepurchaseVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" name="UnvestedCommonSharesSubjectToRepurchaseIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" name="UnvestedCommonSharesSubjectToRepurchaseRepurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" name="UnvestedCommonSharesSubjectToRepurchaseOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" name="UnvestedCommonStockFromEarlyExerciseOfOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" name="CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_PreferredStockEstimatedFairValue" name="PreferredStockEstimatedFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_CollaborativeArrangementAllocatedConsideration" name="CollaborativeArrangementAllocatedConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" name="NovartisInstitutesOfBioMedicalResearchIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_ReimbursableResearchAndDevelopmentCostsMember" name="ReimbursableResearchAndDevelopmentCostsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="fixx_CollaborativeAgreementTargetFee" name="CollaborativeAgreementTargetFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_CollaborativeArrangementTermOfAgreement" name="CollaborativeArrangementTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" name="CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" name="CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" name="CollaborativeArrangementMilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" name="CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" name="CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" name="CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CollaborativeArrangementTransactionPrice" name="CollaborativeArrangementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="fixx_CommonStockPurchaseAgreementCondition" name="CommonStockPurchaseAgreementCondition" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="fixx_CommonStockEstimatedFairValue" name="CommonStockEstimatedFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="fixx_StockPurchaseAgreementRemainingAllocatedValue" name="StockPurchaseAgreementRemainingAllocatedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>fixx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1654584+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="fixx-20201231.xsd#TemplateLink" roleURI="http://www.homologymedicines.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCash" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccretionOfShortTermInvestments" xlink:type="locator" xlink:label="fixx_AccretionOfShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NonCashLeaseExpense" xlink:type="locator" xlink:label="fixx_NonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fixx_NonCashLeaseExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fixx_AccretionOfShortTermInvestments" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" order="10230.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:type="locator" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="fixx_AccruedResearchAndDevelopmentExpensesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="10030.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:type="locator" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxLiabilitiesDepreciation" xlink:type="locator" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="fixx_DeferredTaxLiabilitiesDepreciation" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>fixx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1654584+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="fixx-20201231.xsd#TemplateLink" roleURI="http://www.homologymedicines.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FollowOnOfferingMember" xlink:type="locator" xlink:label="fixx_FollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AtTheMarketSalesAgreementMember" xlink:type="locator" xlink:label="fixx_AtTheMarketSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_AtTheMarketSalesAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_FollowOnOfferingMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" xlink:type="locator" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccretionOfShortTermInvestments" xlink:type="locator" xlink:label="fixx_AccretionOfShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NonCashLeaseExpense" xlink:type="locator" xlink:label="fixx_NonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ATMMember" xlink:type="locator" xlink:label="fixx_ATMMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain_2" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10240.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="fixx_MajorAssetClassOfLeasedAssetsAxis" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:to="fixx_MajorAssetClassOfLeasedAssetsDomain_2" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:to="fixx_MajorAssetClassOfLeasedAssetsDomain" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:to="fixx_ATMMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fixx_NonCashLeaseExpense" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fixx_AccretionOfShortTermInvestments" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" order="12030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement" xlink:href="fixx-20201231.xsd#Role_DisclosurePfizerStockPurchaseAgreement" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PfizerIncMember" xlink:type="locator" xlink:label="fixx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fixx_PfizerIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockPurchaseAgreementDisclosureTextBlock" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ProceedsFromFutureIssuanceStock" xlink:type="locator" xlink:label="fixx_ProceedsFromFutureIssuanceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AtTheMarketSalesAgreementMember" xlink:type="locator" xlink:label="fixx_AtTheMarketSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnderwritersOptionMember" xlink:type="locator" xlink:label="fixx_UnderwritersOptionMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FollowOnOfferingMember" xlink:type="locator" xlink:label="fixx_FollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_FollowOnOfferingMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_UnderwritersOptionMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_AtTheMarketSalesAgreementMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="fixx_ProceedsFromFutureIssuanceStock" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_NewAccountingPronouncementMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:type="locator" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfCashAndCashEquivalentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AssetNotYetInServiceMember" xlink:type="locator" xlink:label="fixx_AssetNotYetInServiceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fixx_AssetNotYetInServiceMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TenantImprovementsAllowance" xlink:type="locator" xlink:label="fixx_TenantImprovementsAllowance" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InitialBaseRentPerSquareFeet" xlink:type="locator" xlink:label="fixx_InitialBaseRentPerSquareFeet" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_RentStartDateYearAndMonth" xlink:type="locator" xlink:label="fixx_RentStartDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NumberOfPhases" xlink:type="locator" xlink:label="fixx_NumberOfPhases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SubleaseAggregateBaseRentObligation" xlink:type="locator" xlink:label="fixx_SubleaseAggregateBaseRentObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseExpirationDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseExpirationDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseBeginningDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseBeginningDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LettersOfCreditAndSecuredByRestrictedCashMember" xlink:type="locator" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseTwoMember" xlink:type="locator" xlink:label="fixx_PhaseTwoMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseOneMember" xlink:type="locator" xlink:label="fixx_PhaseOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_BedfordMassachusettsMember" xlink:type="locator" xlink:label="fixx_BedfordMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesLineItems" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_CommitmentAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fixx_BedfordMassachusettsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fixx_PhaseOneMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fixx_PhaseTwoMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LeaseBeginningDateYearAndMonth" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LeaseExpirationDateYearAndMonth" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_SubleaseAggregateBaseRentObligation" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_NumberOfPhases" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_RentStartDateYearAndMonth" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_InitialBaseRentPerSquareFeet" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_TenantImprovementsAllowance" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndRegulatoryMilestonePayment" xlink:type="locator" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndCommercializationMilestonePayments" xlink:type="locator" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AnnualLicenseFeePayable" xlink:type="locator" xlink:label="fixx_AnnualLicenseFeePayable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CoExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="fixx_CoExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CaliforniaInstituteOfTechnologyMember" xlink:type="locator" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SponsoredResearchAgreementMember" xlink:type="locator" xlink:label="fixx_SponsoredResearchAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CityOfHopeMember" xlink:type="locator" xlink:label="fixx_CityOfHopeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementTable" xlink:type="locator" xlink:label="fixx_LicenseAgreementTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementLineItems" xlink:type="locator" xlink:label="fixx_LicenseAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_LicenseAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_CityOfHopeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_LicenseAgreementTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fixx_SponsoredResearchAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_CaliforniaInstituteOfTechnologyMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fixx_CoExclusiveLicenseAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_AnnualLicenseFeePayable" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_DevelopmentAndCommercializationMilestonePayments" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_DevelopmentAndRegulatoryMilestonePayment" order="10980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NetOperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OperatingLossCarryforwardsIndefinitely" xlink:type="locator" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrphanDrugMember" xlink:type="locator" xlink:label="fixx_OrphanDrugMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FederalAndStateMember" xlink:type="locator" xlink:label="fixx_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="fixx_FederalAndStateMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="fixx_OrphanDrugMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_OperatingLossCarryforwardsIndefinitely" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_TaxCreditCarryforwardsExpirationYear" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_NetOperatingLossCarryforwardsExpirationYear" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:type="locator" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssued" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssued" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesMember" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandEighteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandFifteenStockIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandEighteenIncentiveAwardPlanMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_MaximumSharesAllowedToBeIssued" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" order="11890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="10580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:type="locator" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTransactionPrice" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTransactionPrice" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTermOfAgreement" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTermOfAgreement" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeAgreementTargetFee" xlink:type="locator" xlink:label="fixx_CollaborativeAgreementTargetFee" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementAllocatedConsideration" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PreferredStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_PreferredStockEstimatedFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReimbursableResearchAndDevelopmentCostsMember" xlink:type="locator" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fixx_ReimbursableResearchAndDevelopmentCostsMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_PreferredStockEstimatedFairValue" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementAllocatedConsideration" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeAgreementTargetFee" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementTermOfAgreement" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementTransactionPrice" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="11870.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10270.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1Default" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1Default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1Default">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10110.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementRemainingAllocatedValue" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_CommonStockEstimatedFairValue" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockPurchaseAgreementCondition" xlink:type="locator" xlink:label="fixx_CommonStockPurchaseAgreementCondition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PfizerIncMember" xlink:type="locator" xlink:label="fixx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fixx_PfizerIncMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_CommonStockPurchaseAgreementCondition" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_CommonStockEstimatedFairValue" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockPurchaseAgreementRemainingAllocatedValue" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10510.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>fixx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1664580+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other liabilities current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 50,268,666 and 45,138,408 shares issued as of December 31, 2020 and 2019, respectively; and 50,265,575 and 45,116,742 shares outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Nonoperating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding-basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive gain (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain (loss) on available for sale securities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" />
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares vesting of common stock from option exercise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" xlink:to="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" />
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value vesting of common stock from option exercise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" xlink:to="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AtTheMarketSalesAgreementMember" xlink:type="locator" xlink:label="fixx_AtTheMarketSalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_AtTheMarketSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AtTheMarketSalesAgreementMember" xlink:to="fixx_AtTheMarketSalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_AtTheMarketSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AtTheMarketSalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Sales Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FollowOnOfferingMember" xlink:type="locator" xlink:label="fixx_FollowOnOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_FollowOnOfferingMember" xlink:to="fixx_FollowOnOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow On Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_FollowOnOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of discounts and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of discounts and issuance costs, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to employee stock purchase plan, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of common stock from option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting Of Common Stock From Option Exercise</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of common stock from option exercises, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Vesting Of Common Stock From Option Exercise</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from option exercises, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive gain (loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NonCashLeaseExpense" xlink:type="locator" xlink:label="fixx_NonCashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="fixx_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_NonCashLeaseExpense" xlink:to="fixx_NonCashLeaseExpense_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccretionOfShortTermInvestments" xlink:type="locator" xlink:label="fixx_AccretionOfShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccretionOfShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccretionOfShortTermInvestments" xlink:to="fixx_AccretionOfShortTermInvestments_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="fixx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" xlink:type="locator" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" />
    <link:label xml:lang="en-US" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of liability for common stock vested in noncash transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" xlink:to="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment additions included in accrued expenses and other liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs included in accrued expenses and other liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" xlink:to="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis" />
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Major asset class of leased assets [Axis].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:to="fixx_MajorAssetClassOfLeasedAssetsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Asset Class Of Leased Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Asset Class Of Leased Assets [Axis]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain" />
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Major asset class of leased assets [Domain].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:to="fixx_MajorAssetClassOfLeasedAssetsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Asset Class Of Leased Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Asset Class Of Leased Assets [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ATMMember" xlink:type="locator" xlink:label="fixx_ATMMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ATMMember" xlink:to="fixx_ATMMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccretionOfShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccretionOfShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidRent" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Private Placement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock from option exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock pursuant to employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of liability for common stock vested</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Liability For Common Stock Vested In Noncash Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions included in accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions included in accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Additions Included In Accrued Expenses And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized (loss) gain on available for sale securities, net</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs included in accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Included In Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InvestmentsDisclosureAbstract" xlink:type="locator" xlink:label="fixx_InvestmentsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="fixx_InvestmentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_InvestmentsDisclosureAbstract" xlink:to="fixx_InvestmentsDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_InvestmentsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHORT-TERM INVESTMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementsTextBlock" xlink:type="locator" xlink:label="fixx_LicenseAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LicenseAgreementsTextBlock" xlink:to="fixx_LicenseAgreementsTextBlock_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementAbstract" xlink:type="locator" xlink:label="fixx_LicenseAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LicenseAgreementAbstract" xlink:to="fixx_LicenseAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AGREEMENTS</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&apos; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCK INCENTIVE PLANS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET LOSS PER SHARE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEFINED CONTRIBUTION PLAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COLLABORATION AND LICENSE AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_StockPurchaseAgreementDisclosureTextBlock" xlink:to="fixx_StockPurchaseAgreementDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PfizerIncMember" xlink:type="locator" xlink:label="fixx_PfizerIncMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PfizerIncMember" xlink:to="fixx_PfizerIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PFIZER STOCK PURCHASE AGREEMENT</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Guarantees and Indemnifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Guarantees Indemnifications And Warranties Policies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restricted Cash And Cash Equivalents [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of Adoption of Previously Reported Amounts of Financial Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:to="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prospective Adoption Of New Accounting Pronouncements Table [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" xlink:type="locator" xlink:label="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property, plant and equipment estmated useful life of asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" xlink:to="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Life of Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Life Of Asset Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of lease term and discount rate table text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:to="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Term and Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Lease Term And Discount Rate Table [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease liabilities table text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:to="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity under Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" xlink:type="locator" xlink:label="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of unvested common stock from early exercises subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" xlink:to="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Unvested Common Stock from Early Exercises Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Unvested Common Stock From Early Exercises Subject To Repurchase Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnderwritersOptionMember" xlink:type="locator" xlink:label="fixx_UnderwritersOptionMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnderwritersOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnderwritersOptionMember" xlink:to="fixx_UnderwritersOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnderwritersOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters Option</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnderwritersOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock at a public offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering after underwriting discounts and commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock into common stock upon initial public offering, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts and commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Received On Transaction</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ProceedsFromFutureIssuanceStock" xlink:type="locator" xlink:label="fixx_ProceedsFromFutureIssuanceStock" />
    <link:label xml:lang="en-US" xlink:label="fixx_ProceedsFromFutureIssuanceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from future issuance stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ProceedsFromFutureIssuanceStock" xlink:to="fixx_ProceedsFromFutureIssuanceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ProceedsFromFutureIssuanceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds through future financings</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ProceedsFromFutureIssuanceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Future Issuance Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, capacity terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesSubscriptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Subscriptions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fixx_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Employee Stock Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:to="fixx_TwentyEighteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior to Adoption of New Leasing Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:to="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Principle Early Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment for Adoption of New Leasing Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementMember" xlink:to="us-gaap_NewAccountingPronouncementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding claim</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computer Equipment and Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:type="locator" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment and office furniture.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:to="fixx_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment and Office Furniture</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment And Office Furniture [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of asset, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax positions, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Likelihood Of Unfavorable Settlement</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" />
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment purchase period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock through payroll deductions expressed in percentage of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Through Payroll Deductions Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, discount from market price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment purchase period</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Purchase Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Cash And Cash Equivalents [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash And Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementsMember" xlink:to="us-gaap_RepurchaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash And Cash Equivalents [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total cash and cash equivalents</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents, and available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Available For Sale Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents and available-for-sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Treasury Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents and short-term investments, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and short-term investments, Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents and short-term investments, Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and short-term investments, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InvestmentMaturityTerm" xlink:type="locator" xlink:label="fixx_InvestmentMaturityTerm" />
    <link:label xml:lang="en-US" xlink:label="fixx_InvestmentMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment maturity term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_InvestmentMaturityTerm" xlink:to="fixx_InvestmentMaturityTerm_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains and losses on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gain Loss Net</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_InvestmentMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual maturity date of investments</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_InvestmentMaturityTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Maturity Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices (Unadjusted) in Active Markets for Identical Assets (Level 1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Mutual Funds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash equivalents, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase agreements</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" xlink:type="locator" xlink:label="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" />
    <link:label xml:lang="en-US" xlink:label="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assets (liabilities) transfer between levels.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" xlink:to="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfers between fair value measure levels</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Liabilities Transfer Between Levels</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Purchased Software</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AssetNotYetInServiceMember" xlink:type="locator" xlink:label="fixx_AssetNotYetInServiceMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_AssetNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset not yet in service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AssetNotYetInServiceMember" xlink:to="fixx_AssetNotYetInServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_AssetNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Not Yet in Service</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AssetNotYetInServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Not Yet In Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disposals</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="fixx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:type="locator" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued unvested common stock subject to repurchase current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:to="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued unvested common stock subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Unvested Common Stock Subject To Repurchase Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other liabilities</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseExpirationDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseExpirationDateYearAndMonth" />
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseExpirationDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration date year and month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LeaseExpirationDateYearAndMonth" xlink:to="fixx_LeaseExpirationDateYearAndMonth_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseBeginningDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseBeginningDateYearAndMonth" />
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseBeginningDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease beginning date year and month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LeaseBeginningDateYearAndMonth" xlink:to="fixx_LeaseBeginningDateYearAndMonth_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SubleaseAggregateBaseRentObligation" xlink:type="locator" xlink:label="fixx_SubleaseAggregateBaseRentObligation" />
    <link:label xml:lang="en-US" xlink:label="fixx_SubleaseAggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease aggregate base rent obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_SubleaseAggregateBaseRentObligation" xlink:to="fixx_SubleaseAggregateBaseRentObligation_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesLineItems" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_CommitmentAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="fixx_CommitmentAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_BedfordMassachusettsMember" xlink:type="locator" xlink:label="fixx_BedfordMassachusettsMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_BedfordMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bedford, Massachusetts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_BedfordMassachusettsMember" xlink:to="fixx_BedfordMassachusettsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_BedfordMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bedford, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_BedfordMassachusettsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bedford Massachusetts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseOneMember" xlink:type="locator" xlink:label="fixx_PhaseOneMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PhaseOneMember" xlink:to="fixx_PhaseOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase One</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase One [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseTwoMember" xlink:type="locator" xlink:label="fixx_PhaseTwoMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PhaseTwoMember" xlink:to="fixx_PhaseTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase Two</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PhaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Phase Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LettersOfCreditAndSecuredByRestrictedCashMember" xlink:type="locator" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Letters of credit and secured by restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" xlink:to="fixx_LettersOfCreditAndSecuredByRestrictedCashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of Credit and Secured by Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit And Secured By Restricted Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CommitmentAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitment And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseBeginningDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease beginning year and month</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseBeginningDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Beginning Date Year And Month</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseExpirationDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration year and month</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LeaseExpirationDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date Year And Month</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease agreements additional term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SubleaseAggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease aggregate base rent obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SubleaseAggregateBaseRentObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Aggregate Base Rent Obligation</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InitialBaseRentPerSquareFeet" xlink:type="locator" xlink:label="fixx_InitialBaseRentPerSquareFeet" />
    <link:label xml:lang="en-US" xlink:label="fixx_InitialBaseRentPerSquareFeet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial base rent per square feet.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_InitialBaseRentPerSquareFeet" xlink:to="fixx_InitialBaseRentPerSquareFeet_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" />
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease not yet commenced increase in percentage of base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" xlink:to="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NumberOfPhases" xlink:type="locator" xlink:label="fixx_NumberOfPhases" />
    <link:label xml:lang="en-US" xlink:label="fixx_NumberOfPhases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of phases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_NumberOfPhases" xlink:to="fixx_NumberOfPhases_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_RentStartDateYearAndMonth" xlink:type="locator" xlink:label="fixx_RentStartDateYearAndMonth" />
    <link:label xml:lang="en-US" xlink:label="fixx_RentStartDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent start date year and month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_RentStartDateYearAndMonth" xlink:to="fixx_RentStartDateYearAndMonth_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office space leased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, lease not yet commenced, renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Renewal Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NumberOfPhases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of phases</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NumberOfPhases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Phases</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_RentStartDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent due date</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_RentStartDateYearAndMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Rent Start Date Year And Month</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_InitialBaseRentPerSquareFeet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial annual base rent per square foot</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_InitialBaseRentPerSquareFeet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Base Rent Per Square Feet</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increase in initial annual base rent per square foot.</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Not Yet Commenced Increase In Percentage Of Base Rent</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TenantImprovementsAllowance" xlink:type="locator" xlink:label="fixx_TenantImprovementsAllowance" />
    <link:label xml:lang="en-US" xlink:label="fixx_TenantImprovementsAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TenantImprovementsAllowance" xlink:to="fixx_TenantImprovementsAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_TenantImprovementsAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TenantImprovementsAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years), Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate, Operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Lease Income Lease Payments</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AnnualLicenseFeePayable" xlink:type="locator" xlink:label="fixx_AnnualLicenseFeePayable" />
    <link:label xml:lang="en-US" xlink:label="fixx_AnnualLicenseFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license fee payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AnnualLicenseFeePayable" xlink:to="fixx_AnnualLicenseFeePayable_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndCommercializationMilestonePayments" xlink:type="locator" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and commercialization milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_DevelopmentAndCommercializationMilestonePayments" xlink:to="fixx_DevelopmentAndCommercializationMilestonePayments_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement payment for execution of agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" xlink:to="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementLineItems" xlink:type="locator" xlink:label="fixx_LicenseAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_LicenseAgreementLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementTable" xlink:type="locator" xlink:label="fixx_LicenseAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_LicenseAgreementTable" xlink:to="fixx_LicenseAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CityOfHopeMember" xlink:type="locator" xlink:label="fixx_CityOfHopeMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_CityOfHopeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">City of Hope.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CityOfHopeMember" xlink:to="fixx_CityOfHopeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CityOfHopeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City of Hope</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CityOfHopeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Of Hope [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SponsoredResearchAgreementMember" xlink:type="locator" xlink:label="fixx_SponsoredResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_SponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sonsored research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_SponsoredResearchAgreementMember" xlink:to="fixx_SponsoredResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_SponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_SponsoredResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreement [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CaliforniaInstituteOfTechnologyMember" xlink:type="locator" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute of Technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CaliforniaInstituteOfTechnologyMember" xlink:to="fixx_CaliforniaInstituteOfTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Institute Of Technology</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute Of Technology [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CoExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="fixx_CoExclusiveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_CoExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Co-Exclusive license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CoExclusiveLicenseAgreementMember" xlink:to="fixx_CoExclusiveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CoExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Co Exclusive License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CoExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Co Exclusive License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_LicenseAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AnnualLicenseFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AnnualLicenseFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fee Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and commercialization milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Commercialization Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for execution of agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Payment For Execution Of Agreements</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndRegulatoryMilestonePayment" xlink:type="locator" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and regulatory milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_DevelopmentAndRegulatoryMilestonePayment" xlink:to="fixx_DevelopmentAndRegulatoryMilestonePayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimal royalty fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development And Regulatory Milestone Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:type="locator" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax deferred expense reserves and accruals accrued liabilities and other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxLiabilitiesDepreciation" xlink:type="locator" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation" />
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_DeferredTaxLiabilitiesDepreciation" xlink:to="fixx_DeferredTaxLiabilitiesDepreciation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expense and other</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="fixx_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FederalAndStateMember" xlink:type="locator" xlink:label="fixx_FederalAndStateMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_FederalAndStateMember" xlink:to="fixx_FederalAndStateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_FederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrphanDrugMember" xlink:type="locator" xlink:label="fixx_OrphanDrugMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_OrphanDrugMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan drug.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_OrphanDrugMember" xlink:to="fixx_OrphanDrugMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_OrphanDrugMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OrphanDrugMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NetOperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_NetOperatingLossCarryforwardsExpirationYear" xlink:to="fixx_NetOperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TaxCreditCarryforwardsExpirationYear" xlink:to="fixx_TaxCreditCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OperatingLossCarryforwardsIndefinitely" xlink:type="locator" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely" />
    <link:label xml:lang="en-US" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinitely.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_OperatingLossCarryforwardsIndefinitely" xlink:to="fixx_OperatingLossCarryforwardsIndefinitely_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforwards indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance due to deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense, interest or penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TwoThousandFifteenStockIncentivePlanMember" xlink:to="fixx_TwoThousandFifteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandEighteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Incentive Award Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TwoThousandEighteenIncentiveAwardPlanMember" xlink:to="fixx_TwoThousandEighteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Incentive Award Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2018 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen and two thousand eighteen stock incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" xlink:to="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 and 2018 Stock Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen And Two Thousand Eighteen Stock Incentive Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesMember" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AccruedExpensesAndOtherLiabilitiesMember" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:to="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssued" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssued" />
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares allowed to be issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_MaximumSharesAllowedToBeIssued" xlink:to="fixx_MaximumSharesAllowedToBeIssued_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowed Annual Percentage Increase In Shares Authorized As Percentage Of Outstanding Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares of common stock may be issued</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares Allowed To Be Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares added to the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares allowed to be issued under ESPP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:to="fixx_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award stock offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares allowed to be issued under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares Allowed To Be Issued Under E S P P</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Stock Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued to the plan</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate proceeds from shares issued under the plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Arrangements To Obtain Goods And Services [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying common stock fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense estimated to be recognized over period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding at Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Cancelled/Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding at Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Vested and Expected to vest at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Exercisable at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price per Share, Outstanding at Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Cancelled/Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price per Share, Outstanding at Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price per Share, Vested and Expected to vest at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, Exercisable at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Vested and Expected to vest at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and Expected to vest at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share for options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseVested" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseVested" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common shares subject to repurchase vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnvestedCommonSharesSubjectToRepurchaseVested" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseVested_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common shares subject to repurchase issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common shares subject to repurchase repurchased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common shares subject to repurchase outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested shares, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Shares Subject To Repurchase Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Shares Subject To Repurchase Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Shares Subject To Repurchase Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Shares Subject To Repurchase Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested shares, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining shares subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liability for unvested common shares subject to repurchase included in accrued expenses and other liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:type="locator" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock from early exercise of options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:to="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Common Stock from Early Exercise of Options</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock From Early Exercise Of Options [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options to Purchase Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discretionary match made under the 401(k) Plan by employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement proceeds from nonrefundable upfront payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" xlink:to="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PreferredStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_PreferredStockEstimatedFairValue" />
    <link:label xml:lang="en-US" xlink:label="fixx_PreferredStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock estimated fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_PreferredStockEstimatedFairValue" xlink:to="fixx_PreferredStockEstimatedFairValue_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementAllocatedConsideration" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement allocated consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementAllocatedConsideration" xlink:to="fixx_CollaborativeArrangementAllocatedConsideration_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis Institutes of BioMedical Research, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Novartis Institutes Of Bio Medical Research Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReimbursableResearchAndDevelopmentCostsMember" xlink:type="locator" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursable research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_ReimbursableResearchAndDevelopmentCostsMember" xlink:to="fixx_ReimbursableResearchAndDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursable Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursable Research And Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront, nonrefundable payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Proceeds From Nonrefundable Upfront Payment Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Proceeds from issuance of shares of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PreferredStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_PreferredStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocated to collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Allocated Consideration</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeAgreementTargetFee" xlink:type="locator" xlink:label="fixx_CollaborativeAgreementTargetFee" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeAgreementTargetFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement target fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeAgreementTargetFee" xlink:to="fixx_CollaborativeAgreementTargetFee_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTermOfAgreement" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementTermOfAgreement" xlink:to="fixx_CollaborativeArrangementTermOfAgreement_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, reimbursement of manufacturing activities during research term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" xlink:to="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeAgreementTargetFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative agreement target fee</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeAgreementTargetFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Target Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, research term</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, reimbursement of manufacturing activities during research term</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Reimbursement Of Manufacturing Activities During Research Term</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement number of candidates or products for develop and commercialize.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" xlink:to="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement number of candidates or products for develop and commercialize</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Number Of Candidates Or Products For Develop And Commercialize</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement milestone payments eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" xlink:to="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement development milestone payments eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" xlink:to="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement regulatory milestone payments eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" xlink:to="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement commercial milestone payments eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" xlink:to="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement eligible milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement eligible development milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Development Milestone Payments Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement eligible regulatory milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Regulatory Milestone Payments Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement eligible commercial milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Commercial Milestone Payments Eligible To Receive</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTransactionPrice" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CollaborativeArrangementTransactionPrice" xlink:to="fixx_CollaborativeArrangementTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CollaborativeArrangementTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Transaction Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining performance obligation, unsatisfied portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration agreement revenue recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockPurchaseAgreementCondition" xlink:type="locator" xlink:label="fixx_CommonStockPurchaseAgreementCondition" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockPurchaseAgreementCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase agreement condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CommonStockPurchaseAgreementCondition" xlink:to="fixx_CommonStockPurchaseAgreementCondition_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockPurchaseAgreementCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock purchase agreement condition</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockPurchaseAgreementCondition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Agreement Condition</link:label>
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_CommonStockEstimatedFairValue" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock estimated fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_CommonStockEstimatedFairValue" xlink:to="fixx_CommonStockEstimatedFairValue_lbl" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementRemainingAllocatedValue" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue" />
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement remaining allocated value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fixx_StockPurchaseAgreementRemainingAllocatedValue" xlink:to="fixx_StockPurchaseAgreementRemainingAllocatedValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_CommonStockEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock purchase agreement remaining allocated value</link:label>
    <link:label xml:lang="en-US" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement Remaining Allocated Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allocated Information Committee obligation</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>fixx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-10T21:49:01.1664580+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 1f3bd7484b674524836f9a8eb107c8a9 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/role/TemplateLink" xlink:href="fixx-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fixx-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNonoperating" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNonoperating" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" xlink:type="locator" xlink:label="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FollowOnOfferingMember" xlink:type="locator" xlink:label="fixx_FollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AtTheMarketSalesAgreementMember" xlink:type="locator" xlink:label="fixx_AtTheMarketSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_AtTheMarketSalesAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_FollowOnOfferingMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="fixx-20201231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" xlink:type="locator" xlink:label="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" xlink:type="locator" xlink:label="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="locator" xlink:label="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidRent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccretionOfShortTermInvestments" xlink:type="locator" xlink:label="fixx_AccretionOfShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NonCashLeaseExpense" xlink:type="locator" xlink:label="fixx_NonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ATMMember" xlink:type="locator" xlink:label="fixx_ATMMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsDomain" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:type="locator" xlink:label="fixx_MajorAssetClassOfLeasedAssetsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="fixx_MajorAssetClassOfLeasedAssetsAxis" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_MajorAssetClassOfLeasedAssetsAxis" xlink:to="fixx_MajorAssetClassOfLeasedAssetsDomain" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_MajorAssetClassOfLeasedAssetsDomain" xlink:to="fixx_ATMMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fixx_NonCashLeaseExpense" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="fixx_AccretionOfShortTermInvestments" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidRent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="fixx_IncreaseDecreaseInOperatingLeaseLiabilities" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="fixx-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents" xlink:href="fixx-20201231.xsd#Role_DisclosureCashAndCashEquivalents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InvestmentsDisclosureAbstract" xlink:type="locator" xlink:label="fixx_InvestmentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_InvestmentsDisclosureAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities" xlink:href="fixx-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements" xlink:href="fixx-20201231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementsTextBlock" xlink:type="locator" xlink:label="fixx_LicenseAgreementsTextBlock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementAbstract" xlink:type="locator" xlink:label="fixx_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementAbstract" xlink:to="fixx_LicenseAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity" xlink:href="fixx-20201231.xsd#Role_DisclosureStockholderSEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="fixx-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="fixx-20201231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement" xlink:href="fixx-20201231.xsd#Role_DisclosurePfizerStockPurchaseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PfizerIncMember" xlink:type="locator" xlink:label="fixx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fixx_PfizerIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockPurchaseAgreementDisclosureTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="fixx-20201231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:type="locator" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" xlink:type="locator" xlink:label="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" xlink:href="fixx-20201231.xsd#Role_DisclosureCashAndCashEquivalentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InvestmentsDisclosureAbstract" xlink:type="locator" xlink:label="fixx_InvestmentsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_InvestmentsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" xlink:href="fixx-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" xlink:type="locator" xlink:label="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" xlink:type="locator" xlink:label="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="fixx-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesSubscriptions" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ProceedsFromFutureIssuanceStock" xlink:type="locator" xlink:label="fixx_ProceedsFromFutureIssuanceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AtTheMarketSalesAgreementMember" xlink:type="locator" xlink:label="fixx_AtTheMarketSalesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnderwritersOptionMember" xlink:type="locator" xlink:label="fixx_UnderwritersOptionMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FollowOnOfferingMember" xlink:type="locator" xlink:label="fixx_FollowOnOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_FollowOnOfferingMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_UnderwritersOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="fixx_AtTheMarketSalesAgreementMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="fixx_ProceedsFromFutureIssuanceStock" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:type="locator" xlink:label="us-gaap_RestrictedCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="fixx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="fixx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="fixx_SummaryOfSignificantAccountingPoliciesLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCredit" xlink:type="locator" xlink:label="us-gaap_DeferredRentCredit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementMember" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_NewAccountingPronouncementMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCredit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:type="locator" xlink:label="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fixx_LaboratoryEquipmentAndOfficeFurnitureMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureSummaryOfCashAndCashEquivalentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InvestmentMaturityTerm" xlink:type="locator" xlink:label="fixx_InvestmentMaturityTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="fixx_InvestmentMaturityTerm" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:type="locator" xlink:label="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract" xlink:to="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable" xlink:to="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_RepurchaseAgreementsMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_li0l2" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" xlink:type="locator" xlink:label="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="fixx_FairValueAssetsLiabilitiesTransferBetweenLevels" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AssetNotYetInServiceMember" xlink:type="locator" xlink:label="fixx_AssetNotYetInServiceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="fixx_AssetNotYetInServiceMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:type="locator" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedResearchAndDevelopmentExpensesCurrent" xlink:type="locator" xlink:label="fixx_AccruedResearchAndDevelopmentExpensesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fixx_AccruedResearchAndDevelopmentExpensesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TenantImprovementsAllowance" xlink:type="locator" xlink:label="fixx_TenantImprovementsAllowance" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_InitialBaseRentPerSquareFeet" xlink:type="locator" xlink:label="fixx_InitialBaseRentPerSquareFeet" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_RentStartDateYearAndMonth" xlink:type="locator" xlink:label="fixx_RentStartDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NumberOfPhases" xlink:type="locator" xlink:label="fixx_NumberOfPhases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SubleaseAggregateBaseRentObligation" xlink:type="locator" xlink:label="fixx_SubleaseAggregateBaseRentObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseExpirationDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseExpirationDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LeaseBeginningDateYearAndMonth" xlink:type="locator" xlink:label="fixx_LeaseBeginningDateYearAndMonth" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesLineItems" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LettersOfCreditAndSecuredByRestrictedCashMember" xlink:type="locator" xlink:label="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseTwoMember" xlink:type="locator" xlink:label="fixx_PhaseTwoMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PhaseOneMember" xlink:type="locator" xlink:label="fixx_PhaseOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_BedfordMassachusettsMember" xlink:type="locator" xlink:label="fixx_BedfordMassachusettsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommitmentAndContingenciesTable" xlink:type="locator" xlink:label="fixx_CommitmentAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fixx_CommitmentAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="fixx_BedfordMassachusettsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fixx_PhaseOneMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="fixx_PhaseTwoMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="fixx_LettersOfCreditAndSecuredByRestrictedCashMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesTable" xlink:to="fixx_CommitmentAndContingenciesLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LeaseBeginningDateYearAndMonth" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LeaseExpirationDateYearAndMonth" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_SubleaseAggregateBaseRentObligation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_NumberOfPhases" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_RentStartDateYearAndMonth" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_InitialBaseRentPerSquareFeet" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="fixx_TenantImprovementsAllowance" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome" xlink:type="locator" xlink:label="us-gaap_SubleaseIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SubleaseIncome" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndRegulatoryMilestonePayment" xlink:type="locator" xlink:label="fixx_DevelopmentAndRegulatoryMilestonePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DevelopmentAndCommercializationMilestonePayments" xlink:type="locator" xlink:label="fixx_DevelopmentAndCommercializationMilestonePayments" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AnnualLicenseFeePayable" xlink:type="locator" xlink:label="fixx_AnnualLicenseFeePayable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementLineItems" xlink:type="locator" xlink:label="fixx_LicenseAgreementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember_li0l2" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CoExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="fixx_CoExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CaliforniaInstituteOfTechnologyMember" xlink:type="locator" xlink:label="fixx_CaliforniaInstituteOfTechnologyMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_SponsoredResearchAgreementMember" xlink:type="locator" xlink:label="fixx_SponsoredResearchAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CityOfHopeMember" xlink:type="locator" xlink:label="fixx_CityOfHopeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementTable" xlink:type="locator" xlink:label="fixx_LicenseAgreementTable" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_LicenseAgreementAbstract" xlink:type="locator" xlink:label="fixx_LicenseAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementAbstract" xlink:to="fixx_LicenseAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_CityOfHopeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fixx_SponsoredResearchAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_CaliforniaInstituteOfTechnologyMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="fixx_CoExclusiveLicenseAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_li0l2" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementTable" xlink:to="fixx_LicenseAgreementLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_AnnualLicenseFeePayable" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_DevelopmentAndCommercializationMilestonePayments" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_CollaborativeArrangementPaymentForExecutionOfAgreements" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="us-gaap_RoyaltyExpense" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_LicenseAgreementLineItems" xlink:to="fixx_DevelopmentAndRegulatoryMilestonePayment" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxLiabilitiesDepreciation" xlink:type="locator" xlink:label="fixx_DeferredTaxLiabilitiesDepreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:type="locator" xlink:label="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="fixx_DeferredTaxLiabilitiesDepreciation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NetOperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_NetOperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="fixx_TaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OperatingLossCarryforwardsIndefinitely" xlink:type="locator" xlink:label="fixx_OperatingLossCarryforwardsIndefinitely" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_OrphanDrugMember" xlink:type="locator" xlink:label="fixx_OrphanDrugMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_FederalAndStateMember" xlink:type="locator" xlink:label="fixx_FederalAndStateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="fixx_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="fixx_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="fixx_FederalAndStateMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="fixx_OrphanDrugMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureTable" xlink:to="fixx_IncomeTaxDisclosureLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_OperatingLossCarryforwardsIndefinitely" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_TaxCreditCarryforwardsExpirationYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="fixx_NetOperatingLossCarryforwardsExpirationYear" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fixx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" xlink:type="locator" xlink:label="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssuedUnderESPP" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_MaximumSharesAllowedToBeIssued" xlink:type="locator" xlink:label="fixx_MaximumSharesAllowedToBeIssued" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" xlink:type="locator" xlink:label="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_AccruedExpensesAndOtherLiabilitiesMember" xlink:type="locator" xlink:label="fixx_AccruedExpensesAndOtherLiabilitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwentyEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandEighteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandEighteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="fixx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandFifteenStockIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandEighteenIncentiveAwardPlanMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwentyEighteenEmployeeStockPurchasePlanMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fixx_AccruedExpensesAndOtherLiabilitiesMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_MaximumSharesAllowedToBeIssued" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_MaximumSharesAllowedToBeIssuedUnderESPP" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockPlans" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:type="locator" xlink:label="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails">
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_li0l2" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseVested" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseVested" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" xlink:type="locator" xlink:label="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseVested" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:type="locator" xlink:label="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTransactionPrice" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTransactionPrice" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementTermOfAgreement" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementTermOfAgreement" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeAgreementTargetFee" xlink:type="locator" xlink:label="fixx_CollaborativeAgreementTargetFee" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementAllocatedConsideration" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementAllocatedConsideration" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PreferredStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_PreferredStockEstimatedFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" xlink:type="locator" xlink:label="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_ReimbursableResearchAndDevelopmentCostsMember" xlink:type="locator" xlink:label="fixx_ReimbursableResearchAndDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="fixx_ReimbursableResearchAndDevelopmentCostsMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_PreferredStockEstimatedFairValue" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementAllocatedConsideration" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeAgreementTargetFee" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementTermOfAgreement" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="fixx_CollaborativeArrangementTransactionPrice" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1" xlink:href="fixx-20201231.xsd#Role_DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_NovartisInstitutesOfBioMedicalResearchIncMember" xlink:type="locator" xlink:label="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fixx_NovartisInstitutesOfBioMedicalResearchIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails" xlink:href="fixx-20201231.xsd#Role_DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_StockPurchaseAgreementRemainingAllocatedValue" xlink:type="locator" xlink:label="fixx_StockPurchaseAgreementRemainingAllocatedValue" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockEstimatedFairValue" xlink:type="locator" xlink:label="fixx_CommonStockEstimatedFairValue" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_CommonStockPurchaseAgreementCondition" xlink:type="locator" xlink:label="fixx_CommonStockPurchaseAgreementCondition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="fixx-20201231.xsd#fixx_PfizerIncMember" xlink:type="locator" xlink:label="fixx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="fixx_PfizerIncMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_CommonStockPurchaseAgreementCondition" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_CommonStockEstimatedFairValue" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="fixx_StockPurchaseAgreementRemainingAllocatedValue" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>fixx-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:fixx="http://www.homologymedicines.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fixx-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001661998_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_20210308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="C_0001661998_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001661998_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_fixxMajorAssetClassOfLeasedAssetsAxis_fixxATMMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="fixx:MajorAssetClassOfLeasedAssetsAxis">fixx:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-02</instant>
        </period>
    </context>
    <context id="C_0001661998_20180401_20180402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-02</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:UnderwritersOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-12</startDate>
            <endDate>2019-04-12</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:UnderwritersOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-12</instant>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200311_20200312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-11</startDate>
            <endDate>2020-03-12</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190430_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fixx:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-10</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-09</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:NewAccountingPronouncementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxLaboratoryEquipmentAndOfficeFurnitureMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fixx:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapRepurchaseAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxAssetNotYetInServiceMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fixx:AssetNotYetInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171201_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171201_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">fixx:BedfordMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">fixx:PhaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">fixx:LettersOfCreditAndSecuredByRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">fixx:LettersOfCreditAndSecuredByRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_srtRangeAxis_srtMaximumMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_us-gaapTypeOfArrangementAxis_fixxSponsoredResearchAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CityOfHopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CaliforniaInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:CoExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:CaliforniaInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fixx:CoExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fixx:OrphanDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">fixx:OrphanDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fixx:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">fixx:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandEighteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180301_20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwentyEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fixx:TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:AccruedExpensesAndOtherLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fixx:UnvestedCommonStockFromEarlyExerciseOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fixx:UnvestedCommonStockFromEarlyExerciseOfOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20170701_20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171101_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-11-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:ReimbursableResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fixx:NovartisInstitutesOfBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">fixx:ReimbursableResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-09</instant>
        </period>
    </context>
    <context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661998</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">fixx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_fixxPhase">
        <measure>fixx:Phase</measure>
    </unit>
    <unit id="U_iso4217USD_utrsqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_fixxCandidateorProduct">
        <measure>fixx:CandidateorProduct</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001661998_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001661998_20200101_20201231" id="F_000003">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001661998_20200101_20201231" id="F_000006">0001661998</dei:EntityCentralIndexKey>
    <dei:EntityVoluntaryFilers contextRef="C_0001661998_20200101_20201231" id="F_000007">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001661998_20200101_20201231" id="F_000008">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityCurrentReportingStatus contextRef="C_0001661998_20200101_20201231" id="F_000009">Yes</dei:EntityCurrentReportingStatus>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001661998_20200101_20201231" id="F_000011">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001661998_20200101_20201231" id="F_000020">Yes</dei:EntityInteractiveDataCurrent>
    <fixx:InvestmentMaturityTerm contextRef="C_0001661998_20200101_20201231" id="F_000364">Less than one year</fixx:InvestmentMaturityTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160930"
      id="F_000426">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231"
      id="F_000430">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231"
      id="F_000521">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:PreferredStockValue
      contextRef="C_0001661998_20201231"
      id="F_000065"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001661998_20191231"
      id="F_000066"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231"
      id="F_000332">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000334">Shorter of the lease term
or estimated useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20200101_20201231"
      id="F_000333">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001661998_20201231" id="F_000454">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000544"
      unitRef="U_xbrlipure">0.632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000545"
      unitRef="U_xbrlipure">0.624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000546"
      unitRef="U_xbrlipure">0.663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000547"
      unitRef="U_xbrlipure">0.647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000548"
      unitRef="U_xbrlipure">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000549"
      unitRef="U_xbrlipure">0.0136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000550"
      unitRef="U_xbrlipure">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000551"
      unitRef="U_xbrlipure">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231"
      id="F_000552">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231"
      id="F_000553">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231"
      id="F_000554">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20200101_20201231"
      decimals="2"
      id="F_000555"
      unitRef="U_iso4217USD_xbrlishares">9.82</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_0001661998_srtRangeAxis_srtMinimumMember_20190101_20191231"
      decimals="2"
      id="F_000556"
      unitRef="U_iso4217USD_xbrlishares">12.73</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20200101_20201231"
      decimals="2"
      id="F_000557"
      unitRef="U_iso4217USD_xbrlishares">21.75</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231"
      decimals="2"
      id="F_000558"
      unitRef="U_iso4217USD_xbrlishares">30.34</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001661998_20190101_20191231" id="F_000581">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001661998_20200101_20201231" id="F_000582">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001661998_20200101_20201231" id="F_000583">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001661998_20200101_20201231" id="F_000584">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001661998_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001661998_20200101_20201231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001661998_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001661998_20200101_20201231" id="F_000004">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001661998_20200101_20201231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001661998_20200101_20201231" id="F_000023">001-38433</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001661998_20200101_20201231" id="F_000005">Homology Medicines, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001661998_20200101_20201231" id="F_000024">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001661998_20200101_20201231" id="F_000025">47-3468154</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001661998_20200101_20201231" id="F_000026">One Patriots Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001661998_20200101_20201231" id="F_000027">Bedford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001661998_20200101_20201231" id="F_000028">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001661998_20200101_20201231" id="F_000029">01730</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001661998_20200101_20201231" id="F_000030">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001661998_20200101_20201231" id="F_000031">301-7277</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001661998_20200101_20201231" id="F_000021">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001661998_20200101_20201231" id="F_000010">FIXX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001661998_20200101_20201231" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory contextRef="C_0001661998_20200101_20201231" id="F_000012">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001661998_20200101_20201231" id="F_000013">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001661998_20200101_20201231" id="F_000014">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001661998_20200101_20201231" id="F_000015">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001661998_20200101_20201231" id="F_000016">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001661998_20200101_20201231" id="F_000017">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001661998_20200630"
      decimals="-5"
      id="F_000019"
      unitRef="U_iso4217USD">511600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001661998_20210308"
      decimals="INF"
      id="F_000018"
      unitRef="U_xbrlishares">50487649</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000034">None.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">217431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">53774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">208614000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">2133000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">4189000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">219564000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">266577000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">37002000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">42716000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">5897000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCash
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1274000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">1274000</us-gaap:RestrictedCash>
    <us-gaap:Assets
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">263737000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">310567000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">4722000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2608000</us-gaap:AccountsPayableCurrent>
    <fixx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">9803000</fixx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <fixx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">7644000</fixx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">2501000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">1313000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">5632000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">809000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">22658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">12374000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">12941000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">9544000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">32143000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">30142000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">67742000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">52060000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000078"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000079"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000086"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000087"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">50268666</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">45138408</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">50265575</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">45116742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">524358000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">457994000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">183000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">-328368000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">-199674000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">195995000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">258507000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">263737000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">310567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">2702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">1666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">100392000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">89398000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">32573000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">22211000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">132965000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">111609000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">-130263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-109943000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">1569000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">6027000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">1569000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">6027000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-128694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">-103916000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001661998_20200101_20201231"
      decimals="2"
      id="F_000110"
      unitRef="U_iso4217USD_xbrlishares">-2.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001661998_20190101_20191231"
      decimals="2"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">-2.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001661998_20200101_20201231"
      decimals="0"
      id="F_000112"
      unitRef="U_xbrlishares">45910787</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001661998_20190101_20191231"
      decimals="0"
      id="F_000113"
      unitRef="U_xbrlishares">42117690</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">-128694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-103916000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-183000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">260000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-183000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">260000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-128877000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-103656000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000122"
      unitRef="U_xbrlishares">37358526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">292187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-77000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-95758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_20181231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">196355000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231"
      decimals="INF"
      id="F_000128"
      unitRef="U_xbrlishares">6388889</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">134523000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">134524000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231"
      decimals="INF"
      id="F_000132"
      unitRef="U_xbrlishares">1105000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">22409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190101_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">22409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000135"
      unitRef="U_xbrlishares">55234</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">829000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">829000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">94816</fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise>
    <fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">60000</fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise>
    <fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">60000</fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">114277</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">351000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">351000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">7635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">7635000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">260000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">260000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-103916000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-103916000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">45116742</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">457994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-199674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">258507000</us-gaap:StockholdersEquity>
    <fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">18575</fixx:StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise>
    <fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">24000</fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise>
    <fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">24000</fixx:StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">46410</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">176000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">176000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">83848</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">938000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">938000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">51978000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">51979000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">13248000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">13248000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-183000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-183000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-128694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">-128694000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000175"
      unitRef="U_xbrlishares">50265575</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">524358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-328368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">195995000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-128694000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-103916000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">7965000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">6318000</us-gaap:Depreciation>
    <fixx:NonCashLeaseExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">939000</fixx:NonCashLeaseExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">13248000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">7635000</us-gaap:ShareBasedCompensation>
    <fixx:AccretionOfShortTermInvestments
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">198000</fixx:AccretionOfShortTermInvestments>
    <fixx:AccretionOfShortTermInvestments
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">1871000</fixx:AccretionOfShortTermInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-888000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-13000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">-2056000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-2759000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">2459000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-4452000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">2432000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">2315000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">6824000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-569000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInPrepaidRent
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-410000</us-gaap:IncreaseDecreaseInPrepaidRent>
    <fixx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-2251000</fixx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">-94332000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-91358000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">19991000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">286391000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">228620000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">256425000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">3733000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">21833000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">204896000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-51799000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">51979000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">134524000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001661998_fixxMajorAssetClassOfLeasedAssetsAxis_fixxATMMember_20190101_20191231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">22509000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">176000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">351000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">938000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">829000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">53093000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">158213000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">163657000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">15056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">55048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001661998_20181231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">39992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">218705000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">55048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">24000</fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions>
    <fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">60000</fixx:ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">110000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">455000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <fixx:PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">249000</fixx:PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">-183000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">260000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <fixx:OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">100000</fixx:OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000234">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. NATURE OF BUSINESS AND BASIS OF PRESENTATION &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Nature of Business&lt;span style="font-weight:normal;"&gt;&#x2014;Homology Medicines, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage genetic medicines company dedicated to translating proprietary gene therapy and gene editing technology into novel treatments for patients with rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. The Company was founded in March 2015 as a Delaware corporation. Its principal offices are in Bedford, Massachusetts. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company has devoted substantially all of its resources to recruiting personnel, developing its technology platform and advancing its pipeline of product candidates, developing and implementing manufacturing processes, building out internal manufacturing and research and development space, and maintaining and building its intellectual property portfolio. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependency on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and manufacturing of its product candidates. The Company&#x2019;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, conduct clinical trials, obtain regulatory approval of its products, further expand its manufacturing capacity, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 2, 2018, the Company completed its initial public offering (&#x201c;IPO&#x201d;) with the sale of 10,350,000 shares of its common stock, including shares issued upon the exercise in full of the underwriters&#x2019; over-allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $150.8 million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&#x2019;s outstanding shares of convertible preferred stock automatically converted into 24,168,656 shares of common stock at the applicable conversion ratio then in effect.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 12, 2019, the Company completed a follow-on public offering of its common stock. The Company sold 5,555,556 shares of its common stock at a public offering price of $22.50 per share and received net proceeds of $116.9 million, after deducting underwriting discounts and commissions and offering expenses. In addition, on April 26, 2019 and May 7, 2019, in connection with the exercise in full of the underwriters&#x2019; option to purchase additional shares, the Company issued an aggregate of 833,333 shares of its common stock at a public offering price of $22.50 per share and received net proceeds of $17.6 million, after deducting underwriting discounts and commissions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 12, 2020, the Company filed a Registration Statement on Form S-3 (File No. 333-237131)&lt;span style="color:#000000;"&gt; (the &#x201c;Shelf&#x201d;) with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for a period up to three years from the date of the filing. The Shelf became effective on &lt;/span&gt;March 12, 2020&lt;span style="color:#000000;"&gt;. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC &lt;/span&gt;(&#x201c;Cowen&#x201d;)&lt;span style="color:#000000;"&gt;, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $150.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf (the &#x201c;ATM&#x201d;). &lt;/span&gt;The Company did not sell any shares of common stock pursuant to the ATM during the year ended &lt;span style="color:#000000;"&gt;December&#160;31, 2020&lt;/span&gt;. At December&#160;31, 2020, there remained $150.0 million of common stock available for sale under the ATM. Simultaneous with the filing of the Shelf, the previous Registration Statement on Form S-3 (File No. 333-230664) filed with the SEC on April 1, 2019, and a prior sales agreement with Cowen providing for the offering, issuance and sale by the Company of up to an aggregate $100.0 million of its common stock from time to time in &#x201c;at-the-market&#x201d; offerings, with $76.8 million of remaining capacity, were terminated.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 9, 2020,&lt;span style="color:#000000;"&gt; the Company entered into a common stock purchase agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Pfizer Inc.&lt;/span&gt; &lt;span style="color:#000000;"&gt;(&#x201c;Pfizer&#x201d;), pursuant to which the Company agreed to issue and sell to Pfizer 5,000,000 shares of the Company&#x2019;s common stock through a private placement transaction (the &#x201c;Private Placement&#x201d;) at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million (see Note 16).&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. Through December&#160;31, 2020, the Company has financed its operations primarily through public offerings of its common stock, the issuance of convertible preferred stock, and with proceeds from its collaboration and license agreement with Novartis Institutes of BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) (see Note 15) and its private placement with Pfizer. During the year ended December&#160;31, 2020, the Company incurred a net loss of $128.7&#160;million and as of December&#160;31, 2020, had $328.4&#160;million in accumulated deficit. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on current projections, management believes that existing cash&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cash equivalents&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;will enable the Company to continue its operations into the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;third &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;quarter of 202&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;span style="font-weight:normal;"&gt;&#x2014;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;font-weight:normal;"&gt;and have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402"
      decimals="INF"
      id="F_000290"
      unitRef="U_xbrlishares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180402"
      decimals="INF"
      id="F_000291"
      unitRef="U_iso4217USD_xbrlishares">16.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20180401_20180402"
      decimals="-5"
      id="F_000292"
      unitRef="U_iso4217USD">150800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001661998_20180401_20180402"
      decimals="INF"
      id="F_000293"
      unitRef="U_xbrlishares">24168656</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412"
      decimals="INF"
      id="F_000294"
      unitRef="U_xbrlishares">5555556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412"
      decimals="2"
      id="F_000295"
      unitRef="U_iso4217USD_xbrlishares">22.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxFollowOnOfferingMember_20190412_20190412"
      decimals="-5"
      id="F_000296"
      unitRef="U_iso4217USD">116900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412"
      decimals="INF"
      id="F_000297"
      unitRef="U_xbrlishares">833333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412"
      decimals="2"
      id="F_000298"
      unitRef="U_iso4217USD_xbrlishares">22.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxUnderwritersOptionMember_20190412_20190412"
      decimals="-5"
      id="F_000299"
      unitRef="U_iso4217USD">17600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <fixx:ProceedsFromFutureIssuanceStock
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200311_20200312"
      decimals="-5"
      id="F_000300"
      unitRef="U_iso4217USD">150000000.0</fixx:ProceedsFromFutureIssuanceStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000302"
      unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <fixx:ProceedsFromFutureIssuanceStock
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000301"
      unitRef="U_iso4217USD">150000000.0</fixx:ProceedsFromFutureIssuanceStock>
    <fixx:ProceedsFromFutureIssuanceStock
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_fixxAtTheMarketSalesAgreementMember_20190430_20190430"
      decimals="-5"
      id="F_000303"
      unitRef="U_iso4217USD">100000000.0</fixx:ProceedsFromFutureIssuanceStock>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="C_0001661998_20190430"
      decimals="-5"
      id="F_000304"
      unitRef="U_iso4217USD">76800000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109"
      decimals="INF"
      id="F_000305"
      unitRef="U_xbrlishares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109"
      decimals="2"
      id="F_000306"
      unitRef="U_iso4217USD_xbrlishares">12.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201010_20201109"
      decimals="-5"
      id="F_000307"
      unitRef="U_iso4217USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000308"
      unitRef="U_iso4217USD">-128700000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001661998_20201231"
      decimals="-5"
      id="F_000309"
      unitRef="U_iso4217USD">-328400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000251">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;span style="font-weight:normal;"&gt;&#x2014;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;font-weight:normal;"&gt;and have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000235">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;span style="font-weight:normal;"&gt;&#x2014;The Company&#x2019;s consolidated financial statements include the accounts of the Company and its subsidiary, Homology Medicines Securities Corporation, a wholly owned Massachusetts corporation, for the sole purpose of buying, selling, and holding securities on the Company&#x2019;s behalf. All intercompany balances and transactions have been eliminated in the consolidated financial statements.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;span style="font-weight:normal;"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &#x2014;&lt;span style="font-weight:normal;"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale investments. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;span style="font-weight:normal;"&gt;&#x2014;Cash and cash equivalents consist of standard checking accounts, money market accounts and certain investments. The Company considers all highly liquid investments with original or remaining maturities at the time of purchase of 90 days or less to be cash equivalents. Restricted cash consists of cash serving as collateral for letters of credit issued for security deposits for the Company&#x2019;s facility leases in Bedford, Massachusetts.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-Term Investments&lt;span style="font-weight:normal;"&gt;&#x2014;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#x2019;s investment policy and cash management strategy. Short-term investments have maturities of greater than 90 days at the time of purchase and mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, reported within accumulated other comprehensive income as a separate component of stockholders&#x2019; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying security. Such amortization and accretion, together with interest on securities, are included in interest income in the Company&#x2019;s consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and short-term investments. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. We believe that we are not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. We regularly invest excess cash with major financial institutions in money market funds, U.S. government and corporate debt securities and commercial paper, all of which can be readily purchased and sold using established markets. As of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, the Company&#x2019;s cash and cash equivalents were held with two financial institutions. We believe that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are either government&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;backed or of high credit rating.&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Offering Costs&lt;span style="font-weight:normal;"&gt;&#x2014;The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with equity financings as other current assets until the transactions are completed. After equity financings are complete, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:12pt;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842) (&#x201c;ASU 2016-02&#x201d;), which eliminated the tests for lease classification under prior U.S. GAAP and requires lessees to recognize right-of-use assets and related lease liabilities on the balance sheet. The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-10 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Codification Improvements to Topic &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;842&lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;, Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-11 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;(Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Targeted Improvements&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-20 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;(Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Narrow-Scope Improvements for Lessors&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, and ASU No. 2019-01 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Codification Improvements&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. The Company adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the new leasing standards using the modified retrospective approach, as of January 1, 2020, with no restatement of prior periods or cumulative adjustments to accumulated deficit. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. In addition, the Company elected the practical expedient not to apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company acts as sublessor related to a sublease of the Company's former headquarters. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Right-of-use assets are periodically evaluated for impairment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected lease term for those leases commencing prior to January 1, 2020 did not change with the adoption of the new leasing standards. The expected lease term for leases commencing after the adoption of the new leasing standards includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the adoption of the new leasing standards, on January 1, 2020, the Company recorded non-cash transactions to recognize a right-of-use asset of $6.8 million, operating lease liabilities of $17.7 million and the derecognition of deferred rent of $10.9 million originally accounted for under legacy guidance. The adoption did not have a material impact on the condensed consolidated statement of operations. For additional information on the adoption of the new leasing standards, refer to Note 8.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As Adjusted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets (1)(2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent, net of current portion (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) Represents capitalization of operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) Represents recognition of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Guarantees and Indemnifications&lt;span style="font-weight:normal;"&gt;&#x2014;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;span style="font-weight:normal;"&gt;&#x2014;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000332"&gt;5 - 7 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000334"&gt;Shorter of the lease term&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;span style="font-weight:normal;"&gt;&#x2014;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized for these assets.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;span style="font-weight:normal;"&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expense consists of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical and clinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;span style="font-weight:normal;"&gt;&#x2014;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt; Since inception, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets has not been determined to be more likely than not.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;span style="font-weight:normal;"&gt;&#x2014;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular focus is dedicated to translating proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. All of the Company&#x2019;s tangible assets are held in the United States. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014;&lt;span style="font-size:12pt;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;Revenue is recognized in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (&#x201c;ASC 606&#x201d;). On January 1, 2019, the Company adopted ASC 606 using the full retrospective transition method.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised goods or services in the Company&#x2019;s arrangements would likely consist of a license, rights to the Company&#x2019;s intellectual property or research, development and manufacturing services. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of consideration to which the Company expects to be entitled to. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from the Company&#x2019;s collaboration arrangement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company allocates the transaction price based on the estimated standalone selling price of each performance obligation. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress for its over-time arrangements at each reporting period and, if necessary, updates the measure of progress and revenue recognized.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation&lt;span style="font-weight:normal;"&gt;&#x2014;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#x2019;s estimates of these assumptions are primarily based on the trading price of the Company&#x2019;s stock, historical data, peer company data and judgment regarding future trends and factors. Stock-based awards granted to nonemployees are initially recorded at fair value and are re-measured at each reporting period as the awards vest and expense is recognized over the period the services are provided. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The purchase price of common stock under the Company&#x2019;s employee stock purchase plan (&#x201c;ESPP&#x201d;) is equal to 85% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the look-back provision under the ESPP is calculated using the Black-Scholes option pricing model. The fair value of the look-back provision plus the 15% discount is recognized as compensation expense over the 180-day purchase period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;span style="font-weight:normal;"&gt;&#x2014;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;1&#x2014;Quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;span style="font-weight:normal;"&gt;&#x2014;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and unvested shares of common stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;span style="font-weight:normal;"&gt;&#x2014;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organization related to their leasing activities. For additional information on the adoption of the new leasing standards, please refer to section titled &#x201c;Leases&#x201d; above, and Note 8.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#x2019;s portfolio. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early application permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;span style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt; (&#x201c;ASU 2018-07&#x201d;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the FASB issued ASU 2020-10, &lt;span style="font-style:italic;"&gt;Codification Improvements&lt;/span&gt;, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s regulations. The Company will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000252">Principles of Consolidation&lt;span style="font-weight:normal;"&gt;&#x2014;The Company&#x2019;s consolidated financial statements include the accounts of the Company and its subsidiary, Homology Medicines Securities Corporation, a wholly owned Massachusetts corporation, for the sole purpose of buying, selling, and holding securities on the Company&#x2019;s behalf. All intercompany balances and transactions have been eliminated in the consolidated financial statements.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001661998_20200101_20201231" id="F_000253">Use of Estimates&lt;span style="font-weight:normal;"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000254">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive Income (Loss) &#x2014;&lt;span style="font-weight:normal;"&gt;Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#x2019;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale investments. &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001661998_20200101_20201231" id="F_000255">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents and Restricted Cash&lt;span style="font-weight:normal;"&gt;&#x2014;Cash and cash equivalents consist of standard checking accounts, money market accounts and certain investments. The Company considers all highly liquid investments with original or remaining maturities at the time of purchase of 90 days or less to be cash equivalents. Restricted cash consists of cash serving as collateral for letters of credit issued for security deposits for the Company&#x2019;s facility leases in Bedford, Massachusetts.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000271">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,274&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;218,705&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,048&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">217431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">53774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">1274000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">1274000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">218705000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">55048000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001661998_20200101_20201231" id="F_000256">Short-Term Investments&lt;span style="font-weight:normal;"&gt;&#x2014;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#x2019;s investment policy and cash management strategy. Short-term investments have maturities of greater than 90 days at the time of purchase and mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, reported within accumulated other comprehensive income as a separate component of stockholders&#x2019; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying security. Such amortization and accretion, together with interest on securities, are included in interest income in the Company&#x2019;s consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income.&lt;/span&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001661998_20200101_20201231" id="F_000257">&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and short-term investments. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. We believe that we are not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. We regularly invest excess cash with major financial institutions in money market funds, U.S. government and corporate debt securities and commercial paper, all of which can be readily purchased and sold using established markets. As of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, the Company&#x2019;s cash and cash equivalents were held with two financial institutions. We believe that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are either government&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;-&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;backed or of high credit rating.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000258">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Offering Costs&lt;span style="font-weight:normal;"&gt;&#x2014;The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with equity financings as other current assets until the transactions are completed. After equity financings are complete, these costs are recorded in stockholders&#x2019; equity as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000259">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="font-weight:normal;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-size:12pt;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842) (&#x201c;ASU 2016-02&#x201d;), which eliminated the tests for lease classification under prior U.S. GAAP and requires lessees to recognize right-of-use assets and related lease liabilities on the balance sheet. The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Land Easement Practical Expedient for Transition to Topic 842&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-10 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Codification Improvements to Topic &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;842&lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;, Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-11 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;(Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Targeted Improvements&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, ASU No. 2018-20 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;(Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Narrow-Scope Improvements for Lessors&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;, and ASU No. 2019-01 &#x2013; &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Leases&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (Topic 842): &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Codification Improvements&lt;/span&gt;&lt;span style="font-weight:normal;"&gt;. The Company adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the new leasing standards using the modified retrospective approach, as of January 1, 2020, with no restatement of prior periods or cumulative adjustments to accumulated deficit. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. In addition, the Company elected the practical expedient not to apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determines if an arrangement is a lease at contract inception. The Company&#x2019;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#x2019;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company acts as sublessor related to a sublease of the Company's former headquarters. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Right-of-use assets are periodically evaluated for impairment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected lease term for those leases commencing prior to January 1, 2020 did not change with the adoption of the new leasing standards. The expected lease term for leases commencing after the adoption of the new leasing standards includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the adoption of the new leasing standards, on January 1, 2020, the Company recorded non-cash transactions to recognize a right-of-use asset of $6.8 million, operating lease liabilities of $17.7 million and the derecognition of deferred rent of $10.9 million originally accounted for under legacy guidance. The adoption did not have a material impact on the condensed consolidated statement of operations. For additional information on the adoption of the new leasing standards, refer to Note 8.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As Adjusted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets (1)(2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent, net of current portion (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) Represents capitalization of operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) Represents recognition of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-5"
      id="F_000316"
      unitRef="U_iso4217USD">6800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-5"
      id="F_000317"
      unitRef="U_iso4217USD">17700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200101"
      decimals="-5"
      id="F_000318"
      unitRef="U_iso4217USD">10900000</us-gaap:DeferredRentCredit>
    <us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000272">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;January 1, 2020&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment for&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adoption&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of new leasing&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;standards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As Adjusted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets (1)(2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent, net of current portion (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities, net of current portion (3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,441&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) Represents capitalization of operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) Represents recognition of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">6835000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001661998_20200101"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">6835000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">1313000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCredit
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">1313000</us-gaap:DeferredRentCredit>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAdjustmentsForNewAccountingPrincipleEarlyAdoptionMember_20200101"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">9544000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">-9544000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">2251000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001661998_20200101"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">2251000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001661998_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapNewAccountingPronouncementMember_20200101"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">15441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001661998_20200101"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">15441000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies contextRef="C_0001661998_20200101_20201231" id="F_000260">Guarantees and Indemnifications&lt;span style="font-weight:normal;"&gt;&#x2014;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.&lt;/span&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_0001661998_20201231"
      decimals="-6"
      id="F_000329"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000261">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;span style="font-weight:normal;"&gt;&#x2014;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000332"&gt;5 - 7 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000334"&gt;Shorter of the lease term&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <fixx:PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000273">
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment and office furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000332"&gt;5 - 7 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"&gt;&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000334"&gt;Shorter of the lease term&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;or estimated useful life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</fixx:PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231"
      id="F_000330">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxLaboratoryEquipmentAndOfficeFurnitureMember_20200101_20201231"
      id="F_000331">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000262">Impairment of Long-Lived Assets&lt;span style="font-weight:normal;"&gt;&#x2014;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized for these assets.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000335"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001661998_20200101_20201231" id="F_000263">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;span style="font-weight:normal;"&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expense consists of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical and clinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. &lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000264">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;span style="font-weight:normal;"&gt;&#x2014;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt; Since inception, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets has not been determined to be more likely than not.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="C_0001661998_20200101_20201231" id="F_000336">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized.</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000265">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;span style="font-weight:normal;"&gt;&#x2014;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s singular focus is dedicated to translating proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. All of the Company&#x2019;s tangible assets are held in the United States. &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000266">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014;&lt;span style="font-size:12pt;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;Revenue is recognized in accordance with FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="font-style:italic;font-weight:normal;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; (&#x201c;ASC 606&#x201d;). On January 1, 2019, the Company adopted ASC 606 using the full retrospective transition method.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The promised goods or services in the Company&#x2019;s arrangements would likely consist of a license, rights to the Company&#x2019;s intellectual property or research, development and manufacturing services. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of consideration to which the Company expects to be entitled to. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from the Company&#x2019;s collaboration arrangement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company allocates the transaction price based on the estimated standalone selling price of each performance obligation. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress for its over-time arrangements at each reporting period and, if necessary, updates the measure of progress and revenue recognized.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000267">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation&lt;span style="font-weight:normal;"&gt;&#x2014;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#x2019;s estimates of these assumptions are primarily based on the trading price of the Company&#x2019;s stock, historical data, peer company data and judgment regarding future trends and factors. Stock-based awards granted to nonemployees are initially recorded at fair value and are re-measured at each reporting period as the awards vest and expense is recognized over the period the services are provided. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The purchase price of common stock under the Company&#x2019;s employee stock purchase plan (&#x201c;ESPP&#x201d;) is equal to 85% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the look-back provision under the ESPP is calculated using the Black-Scholes option pricing model. The fair value of the look-back provision plus the 15% discount is recognized as compensation expense over the 180-day purchase period. &lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="2"
      id="F_000337"
      unitRef="U_xbrlipure">0.85</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="2"
      id="F_000338"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_000339">P180D</fixx:ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000268">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;span style="font-weight:normal;"&gt;&#x2014;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: &lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;1&#x2014;Quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.79%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;color:#000000;"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000269">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Loss per Share&lt;span style="font-weight:normal;"&gt;&#x2014;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and unvested shares of common stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000270">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;span style="font-weight:normal;"&gt;&#x2014;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organization related to their leasing activities. For additional information on the adoption of the new leasing standards, please refer to section titled &#x201c;Leases&#x201d; above, and Note 8.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#x2019;s portfolio. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early application permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;span style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt; (&#x201c;ASU 2018-07&#x201d;)&lt;span style="font-style:italic;"&gt;,&lt;/span&gt; which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the FASB issued ASU 2020-10, &lt;span style="font-style:italic;"&gt;Codification Improvements&lt;/span&gt;, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#x2019;s regulations. The Company will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000236">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. CASH AND CASH EQUIVALENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may have cash balances in financial institutions in excess of federal deposit insurance limits. The Company has never experienced any losses related to these balances. The Company considers only those investments that are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash and cash equivalents: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000274">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s cash and cash equivalents: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,774&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">250000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">250000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapRepurchaseAgreementsMember_20191231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">14000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">217181000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">39524000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">217431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">53774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000237">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. SHORT-TERM INVESTMENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may invest its excess cash in fixed income instruments denominated and payable in U.S. dollars including U.S. treasury securities, commercial paper, corporate debt securities and asset-backed securities in accordance with the Company&#x2019;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has designated all investments as available-for-sale and therefore such investments are reported at fair value&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and classified as short-term investments on the Company&#x2019;s consolidated balance sheets&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Unrealized gains or losses on investments are recorded in accumulated other comprehensive income or loss, a component of stockholders&#x2019; equity, on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; short-term investments as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s short-term investments as of December 31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-size:10pt;"&gt;The Company utilizes the specific identification method in computing realized gains and losses. The Company had no realized gains and losses on its short-term investments for the years&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;ended December 31, 2020 and 2019. The contractual maturity dates of all of the Company&#x2019;s investments are less than one year.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000347"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000275">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s short-term investments as of December 31, 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,926&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,380&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,431&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">14866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">14876000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">41259000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">41259000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">59926000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">45000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">59971000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">92380000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">128000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001661998_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">92508000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">208431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">183000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">208614000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000363"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000362"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000238">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. FAIR VALUE MEASUREMENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, short-term investments, restricted cash and accounts payable. The carrying amount of cash, restricted cash and accounts payable are each considered a reasonable estimate of fair value due to the short-term maturity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets measured at fair value on a recurring basis were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices (Unadjusted) in Active&#160;Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices (Unadjusted) in Active&#160;Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;262,138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term securities are valued using models or other valuation methodologies that use Level&#160;2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no transfers between fair value measure levels during the years ended December&#160;31, 2020 and 2019.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000276">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets measured at fair value on a recurring basis were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices (Unadjusted) in Active&#160;Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;217,181&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Description&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quoted&#160;Prices (Unadjusted) in Active&#160;Markets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Identical&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level&#160;1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant Other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Observable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unobservable&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inputs&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Level 3)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchase agreements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term investments:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,876&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Treasury securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,971&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92,508&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;262,138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,524&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,614&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">217181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">217181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">217181000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">217181000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">39524000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20191231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">39524000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">14000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapRepurchaseAgreementsMember_20191231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">14000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">53524000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">39524000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">14000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">14876000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapAssetBackedSecuritiesMember_20191231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">14876000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">41259000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20191231"
      decimals="-3"
      id="F_000379"
      unitRef="U_iso4217USD">41259000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">59971000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapUSTreasurySecuritiesMember_20191231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">59971000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">92508000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCorporateDebtSecuritiesMember_20191231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">92508000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">208614000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">208614000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">262138000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">39524000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001661998_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">222614000</us-gaap:AssetsFairValueDisclosure>
    <fixx:FairValueAssetsLiabilitiesTransferBetweenLevels
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000389"
      unitRef="U_iso4217USD">0</fixx:FairValueAssetsLiabilitiesTransferBetweenLevels>
    <fixx:FairValueAssetsLiabilitiesTransferBetweenLevels
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000390"
      unitRef="U_iso4217USD">0</fixx:FairValueAssetsLiabilitiesTransferBetweenLevels>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000239">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. PROPERTY AND EQUIPMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and purchased software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,596&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not yet in service&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense for the years ended December&#160;31, 2020 and 2019 was approximately $8.0 million and $6.3 million, respectively. The Company disposed of $0.9 million and less than $0.1 million of property and equipment, net during the years ended December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000277">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consists of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,703&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and purchased software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,596&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets not yet in service&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, at cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,377&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,126&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,716&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20201231"
      decimals="-3"
      id="F_000391"
      unitRef="U_iso4217USD">12703000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapOfficeEquipmentMember_20191231"
      decimals="-3"
      id="F_000392"
      unitRef="U_iso4217USD">10837000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000393"
      unitRef="U_iso4217USD">7754000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20191231"
      decimals="-3"
      id="F_000394"
      unitRef="U_iso4217USD">4911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000395"
      unitRef="U_iso4217USD">1596000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20191231"
      decimals="-3"
      id="F_000396"
      unitRef="U_iso4217USD">640000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000397"
      unitRef="U_iso4217USD">1363000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231"
      decimals="-3"
      id="F_000398"
      unitRef="U_iso4217USD">1363000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">29961000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">30862000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_fixxAssetNotYetInServiceMember_20191231"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">2513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">53377000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">51126000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">16375000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">8410000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">37002000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">42716000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000408"
      unitRef="U_iso4217USD">8000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001661998_20190101_20191231"
      decimals="-5"
      id="F_000409"
      unitRef="U_iso4217USD">6300000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000410"
      unitRef="U_iso4217USD">900000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20190101_20191231"
      decimals="-5"
      id="F_000411"
      unitRef="U_iso4217USD">100000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000240">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. ACCRUED EXPENSES AND OTHER LIABILITIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued unvested common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000278">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation and benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued unvested common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">6902000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">4551000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fixx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">2393000</fixx:AccruedResearchAndDevelopmentExpensesCurrent>
    <fixx:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">2258000</fixx:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">291000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">542000</us-gaap:AccruedProfessionalFeesCurrent>
    <fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">13000</fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent>
    <fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">37000</fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">204000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">256000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <fixx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">9803000</fixx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <fixx:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">7644000</fixx:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000241">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. COMMITMENTS AND CONTINGENCIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Leases&lt;span style="font-weight:normal;"&gt;&#x2014;In September 2016, the Company entered into a noncancelable operating lease beginning in November 2016 for office, laboratory and manufacturing space in Bedford, Massachusetts, that expires in October 2021, with an option for an additional &lt;span style="-sec-ix-hidden:F_000426"&gt;three-year&lt;/span&gt; term. In 2018, the Company entered into a sublease agreement for the entire leased premises. The rent commencement date of the sublease was December 2018, and the sublease will terminate on the scheduled termination date of the original lease. Under the terms of the sublease, the subtenant is obligated to pay the Company aggregate base rent of approximately $2.7 million over the term of the sublease, based on the same level of rent the Company is obligated to pay the landlord, in addition to a passthrough of operating expenses and real estate taxes charged by the landlord. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2017, the Company entered into a noncancelable operating lease for approximately 67,000 square feet of research and development, manufacturing and general office space in Bedford, Massachusetts. The lease expires in February 2027 with an option for an additional&lt;span style="-sec-ix-hidden:F_000430"&gt; five-year&lt;/span&gt; term. Rent became due under the lease in two phases; rent on the first 46,000 square feet started in September 2018 and rent on the remaining 21,000 square feet started in March 2019. The initial annual base rent was $39.50 per square foot and increases by three percent annually. The Company is obligated to pay, on a pro-rata &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;basis, real estate taxes and operating costs related to the premises.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The lease agreement entered into in December 2017 allowed for a tenant improvement allowance not to exceed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.9&#160;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million, which the Company received in full, to be applied to the total cost of tenant improvements to the leased premises. The unamortized balance of the tenant improvement allowance was included in deferred rent incentives and has been recorded as a reduction to operating right-of-use asset upon adoption of the new leasing standards.&lt;/span&gt;&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains letters of credit, secured by restricted cash, for security deposits totaling $1.3 million as of December&#160;31, 2020 and 2019, respectively, in conjunction with its current leases.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes operating lease costs and variable lease costs, as well as sublease income for the year ended December&#160;31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense for the year ended December 31, 2019 was $1.4 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturities of our operating lease liabilities as of December&#160;31, 2020 were as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ending December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,442&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the lease term and discount rate as of December&#160;31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the supplemental cash flow information related to the Company's operating leases for the year ended December&#160;31, 2020.&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <fixx:LeaseBeginningDateYearAndMonth
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930"
      id="F_000424">2016-11</fixx:LeaseBeginningDateYearAndMonth>
    <fixx:LeaseExpirationDateYearAndMonth
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20160901_20160930"
      id="F_000425">2021-10</fixx:LeaseExpirationDateYearAndMonth>
    <fixx:SubleaseAggregateBaseRentObligation
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20201231"
      decimals="-5"
      id="F_000427"
      unitRef="U_iso4217USD">2700000</fixx:SubleaseAggregateBaseRentObligation>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171231"
      decimals="0"
      id="F_000428"
      unitRef="U_utrsqft">67000</us-gaap:AreaOfRealEstateProperty>
    <fixx:LeaseExpirationDateYearAndMonth
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231"
      id="F_000429">2027-02</fixx:LeaseExpirationDateYearAndMonth>
    <fixx:NumberOfPhases
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231"
      decimals="INF"
      id="F_000431"
      unitRef="U_fixxPhase">2</fixx:NumberOfPhases>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171231"
      decimals="INF"
      id="F_000432"
      unitRef="U_utrsqft">46000</us-gaap:AreaOfRealEstateProperty>
    <fixx:RentStartDateYearAndMonth
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseOneMember_20171201_20171231"
      id="F_000433">2018-09</fixx:RentStartDateYearAndMonth>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171231"
      decimals="INF"
      id="F_000434"
      unitRef="U_utrsqft">21000</us-gaap:AreaOfRealEstateProperty>
    <fixx:RentStartDateYearAndMonth
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_us-gaapLeaseContractualTermAxis_fixxPhaseTwoMember_20171201_20171231"
      id="F_000435">2019-03</fixx:RentStartDateYearAndMonth>
    <fixx:InitialBaseRentPerSquareFeet
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231"
      decimals="INF"
      id="F_000436"
      unitRef="U_iso4217USD_utrsqft">39.50</fixx:InitialBaseRentPerSquareFeet>
    <fixx:LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent
      contextRef="C_0001661998_srtStatementGeographicalAxis_fixxBedfordMassachusettsMember_20171201_20171231"
      decimals="2"
      id="F_000437"
      unitRef="U_xbrlipure">0.03</fixx:LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent>
    <fixx:TenantImprovementsAllowance
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_20201231"
      decimals="INF"
      id="F_000438"
      unitRef="U_iso4217USD">10900000</fixx:TenantImprovementsAllowance>
    <us-gaap:SecurityDepositLiability
      contextRef="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20201231"
      decimals="-5"
      id="F_000439"
      unitRef="U_iso4217USD">1300000</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability
      contextRef="C_0001661998_us-gaapCreditFacilityAxis_fixxLettersOfCreditAndSecuredByRestrictedCashMember_20191231"
      decimals="-5"
      id="F_000440"
      unitRef="U_iso4217USD">1300000</us-gaap:SecurityDepositLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000279">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes operating lease costs and variable lease costs, as well as sublease income for the year ended December&#160;31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,492&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sublease income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(913&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net lease cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,934&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">2492000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">2355000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">913000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">3934000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_0001661998_20190101_20191231"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">1400000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000280">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturities of our operating lease liabilities as of December&#160;31, 2020 were as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ending December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,169&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,442&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">3834000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">2987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">3077000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">3169000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <fixx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">7197000</fixx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">20264000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">4822000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">15442000</us-gaap:OperatingLeaseLiability>
    <fixx:ScheduleOfLeaseTermAndDiscountRateTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000281">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the lease term and discount rate as of December&#160;31, 2020:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000454"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fixx:ScheduleOfLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001661998_20201231"
      decimals="3"
      id="F_000455"
      unitRef="U_xbrlipure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <fixx:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000282">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the supplemental cash flow information related to the Company's operating leases for the year ended December&#160;31, 2020.&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fixx:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000456"
      unitRef="U_iso4217USD">3804000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <fixx:LicenseAgreementsTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000242">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. LICENSE AGREEMENTS &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;City of Hope &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2016, the Company entered into a license agreement with City of Hope (&#x201c;COH&#x201d;), an academic research and medical center. The license term extends until the last to expire patent, unless terminated earlier by either party under certain provisions. The Company is required to pay an annual license fee of $25,000, reimburse COH for patent costs incurred, pay amounts up to $3.2&#160;million upon the achievement of certain development and commercialization milestones for each product under the license, pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the low double-digits, if any. During the year ended December 31, 2019, the Company paid $50,000 to COH upon dosing the first patient in the pheNIX Phase 1/2 clinical trial. During the year ended December 31, 2020, the Company paid $75,000 plus interest to COH in connection with achievement of a milestone event. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the execution of the Collaboration Agreement with Novartis (see Note 15), the Company paid $4.5 million to COH in December 2017, under the terms of the license agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2015, the Company entered into a sponsored research agreement with COH with a goal to identify potential treatments for diseases in humans. Under this agreement, the Company recorded $0.1 million in research and development expense for the year ended December 31, 2019. The agreement terminated in September 2019 in accordance with its terms. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;California Institute of Technology &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2016, the Company entered into a co-exclusive license agreement with the California Institute of Technology (&#x201c;Caltech&#x201d;), an academic research institute. The license term extends until the expiration, revocation, invalidation or unenforceability of the licensed patent rights. The Company is required to pay an annual minimal royalty fee of $20,000, reimburse for patent costs incurred, pay an amount up to $7.2&#160;million upon the achievement of certain development and regulatory milestones and pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the mid to high single-digits, if any. &lt;/p&gt;</fixx:LicenseAgreementsTextBlock>
    <fixx:AnnualLicenseFeePayable
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20160430"
      decimals="0"
      id="F_000457"
      unitRef="U_iso4217USD">25000</fixx:AnnualLicenseFeePayable>
    <fixx:DevelopmentAndCommercializationMilestonePayments
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_srtRangeAxis_srtMaximumMember_20160401_20160430"
      decimals="INF"
      id="F_000458"
      unitRef="U_iso4217USD">3200000</fixx:DevelopmentAndCommercializationMilestonePayments>
    <fixx:CollaborativeArrangementPaymentForExecutionOfAgreements
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20190101_20191231"
      decimals="0"
      id="F_000459"
      unitRef="U_iso4217USD">50000</fixx:CollaborativeArrangementPaymentForExecutionOfAgreements>
    <fixx:CollaborativeArrangementPaymentForExecutionOfAgreements
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20200101_20201231"
      decimals="0"
      id="F_000460"
      unitRef="U_iso4217USD">75000</fixx:CollaborativeArrangementPaymentForExecutionOfAgreements>
    <fixx:CollaborativeArrangementPaymentForExecutionOfAgreements
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20170101_20171231"
      decimals="-5"
      id="F_000461"
      unitRef="U_iso4217USD">4500000</fixx:CollaborativeArrangementPaymentForExecutionOfAgreements>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_us-gaapTypeOfArrangementAxis_fixxSponsoredResearchAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000462"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930"
      decimals="INF"
      id="F_000463"
      unitRef="U_iso4217USD">20000</us-gaap:RoyaltyExpense>
    <fixx:DevelopmentAndRegulatoryMilestonePayment
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxCaliforniaInstituteOfTechnologyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_fixxCoExclusiveLicenseAgreementMember_20160901_20160930"
      decimals="INF"
      id="F_000464"
      unitRef="U_iso4217USD">7200000</fixx:DevelopmentAndRegulatoryMilestonePayment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000243">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. INCOME TAXES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation between the U.S. federal statutory tax rate and the Company&#x2019;s effective tax rate is summarized as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years&#160;Ended&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized R&amp;amp;D costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expense and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(125,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(77,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has no income tax expense due to the operating loss incurred for the years ended December 31, 2020 and 2019. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December 31, 2020, the Company had $265.1 million and $271.5 million of federal and state net operating loss carryforwards, respectively, that expire at various dates through 2040. Included in the federal net operating loss carryforwards of $265.1 million is $233.6 million that can be carried forward indefinitely. At December 31, 2020, the Company had $34.2 million and $7.2 million of federal and state research and development credit carryforwards, respectively, that expire at various dates through 2040. Included in the $34.2 million of federal research and development credit carryforwards is $29.0 million of orphan drug credit carryforwards. The valuation allowance increased in 2020 and 2019 by $47.2 million and $40.2 million, respectively, due to the increase in the deferred tax assets by the same amounts, primarily due to the net operating loss carryforwards and research and development tax credits not utilized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#x2019;s research and development credit carryforwards. Since a full valuation allowance has been provided against the Company&#x2019;s research and development credits, any reduction in the gross deferred tax asset established for the research and development credit carryforwards would not result in any net impact to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#x2019;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#x2019;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect a change in control would have, if any, on the Company&#x2019;s ability to utilize its net operating loss and research and development credit carryforwards in the future. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files tax returns in the United States and Massachusetts. All tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; uncertain tax positions. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; interest or penalties were recorded for the years ended &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000283">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation between the U.S. federal statutory tax rate and the Company&#x2019;s effective tax rate is summarized as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years&#160;Ended&#160;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000465"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000466"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000467"
      unitRef="U_xbrlipure">0.106</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000468"
      unitRef="U_xbrlipure">0.134</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000469"
      unitRef="U_xbrlipure">0.080</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000470"
      unitRef="U_xbrlipure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000471"
      unitRef="U_xbrlipure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000472"
      unitRef="U_xbrlipure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000473"
      unitRef="U_xbrlipure">-0.378</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000474"
      unitRef="U_xbrlipure">-0.395</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000284">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consist of the following: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;R&amp;amp;D credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,328&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,456&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized R&amp;amp;D costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expense and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,914&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,517&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,537&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,726&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(125,034&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(77,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">72838000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">41589000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">39888000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">25328000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">8251000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">8456000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">4219000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">2966000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">1039000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">1207000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">1368000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">883000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">1914000</fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">108000</fixx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">129517000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">80537000</us-gaap:DeferredTaxAssetsGross>
    <fixx:DeferredTaxLiabilitiesDepreciation
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">3726000</fixx:DeferredTaxLiabilitiesDepreciation>
    <fixx:DeferredTaxLiabilitiesDepreciation
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">2744000</fixx:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">757000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">4483000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">2744000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">125034000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">77793000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000498"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000499"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000500"
      unitRef="U_iso4217USD">265100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000501"
      unitRef="U_iso4217USD">271500000</us-gaap:OperatingLossCarryforwards>
    <fixx:NetOperatingLossCarryforwardsExpirationYear
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_20200101_20201231"
      id="F_000509">2040</fixx:NetOperatingLossCarryforwardsExpirationYear>
    <fixx:OperatingLossCarryforwardsIndefinitely
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20191231"
      decimals="-5"
      id="F_000504"
      unitRef="U_iso4217USD">233600000</fixx:OperatingLossCarryforwardsIndefinitely>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000502"
      unitRef="U_iso4217USD">34200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000503"
      unitRef="U_iso4217USD">7200000</us-gaap:TaxCreditCarryforwardAmount>
    <fixx:TaxCreditCarryforwardsExpirationYear
      contextRef="C_0001661998_us-gaapIncomeTaxAuthorityAxis_fixxFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      id="F_000510">2040</fixx:TaxCreditCarryforwardsExpirationYear>
    <fixx:TaxCreditCarryforwardsExpirationYear
      contextRef="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20200101_20201231"
      id="F_000506">2040</fixx:TaxCreditCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001661998_us-gaapTaxCreditCarryforwardAxis_fixxOrphanDrugMember_20191231"
      decimals="-5"
      id="F_000505"
      unitRef="U_iso4217USD">29000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">47200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001661998_20190101_20191231"
      decimals="-5"
      id="F_000508"
      unitRef="U_iso4217USD">40200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000511"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000512"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000513"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000244">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. STOCKHOLDERS&#x2019; EQUITY &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;span style="font-weight:normal;"&gt;&#x2014;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Voting&lt;span style="font-style:normal;"&gt;&#x2014;Each holder of outstanding shares of common stock are entitled to one vote in respect of each share. The holders of outstanding shares of common stock, voting together as a single class, shall be entitled to elect one director. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividends&lt;span style="font-style:normal;"&gt;&#x2014;Subject to the payment in full of any preferential dividends to which the holders of preferred stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available therefore at such times and in such amounts as the Board of Directors may determine in its sole discretion. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidation Rights&lt;span style="font-style:normal;"&gt;&#x2014;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and any preferential amounts to which the holders of preferred stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were 50,265,575 and 45,116,742 shares of common stock outstanding at December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;span style="font-weight:normal;"&gt;&#x2014;As of December 31, 2020 and 2019, there were no shares of preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="C_0001661998_20200101_20201231" id="F_000514">Each holder of outstanding shares of common stock are entitled to one vote in respect of each share.</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000515"
      unitRef="U_xbrlishares">50265575</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000516"
      unitRef="U_xbrlishares">45116742</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000517"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000518"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000519"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000520"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000245">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. STOCK INCENTIVE PLANS&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2015 Stock Incentive Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2015, the Company&#x2019;s Board of Directors adopted the 2015 Stock Incentive Plan (the &#x201c;2015 Plan&#x201d;), which provided for the grant of qualified incentive and nonqualified stock options or restricted stock awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants. Stock options generally vest over a &lt;span style="-sec-ix-hidden:F_000521"&gt;four-year&lt;/span&gt; period and expire ten years from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2015 Plan. At December&#160;31, 2020, there were no additional shares available for future grant under the 2015 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2018 Incentive Award Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2018, the Company&#x2019;s Board of Directors adopted and the Company&#x2019;s stockholders approved the Homology Medicines, Inc. 2018 Incentive Award Plan (the &#x201c;2018 Plan&#x201d; and, together with the 2015 Plan, the &#x201c;Plans&#x201d;), which became effective on the day prior to the first public trading date of the Company&#x2019;s common stock. Upon effectiveness of the 2018 Plan, the Company ceased granting new awards under the 2015 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2018 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock or cash-based awards to employees and consultants of the Company and certain affiliates and directors of the Company. The number of shares of common stock initially available for issuance under the 2018 Plan was 3,186,205 shares of common stock plus the number of shares subject to awards outstanding under the 2015 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2018 Plan. In addition, the number of shares of common stock available for issuance under the 2018 Plan is subject to an annual increase on the first day of each calendar year beginning on January&#160;1, 2019 and ending on and including January&#160;1, 2028 equal to the lesser of (i) 4% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s Board of Directors, provided that not more than 20,887,347 shares of common stock may be issued under the 2018 Plan upon the exercise of incentive stock options (the &#x201c;Evergreen Provision&#x201d;). As of December&#160;31, 2020, there were 2,397,547 shares available for future grant under the 2018 Plan. On January 1, 2021, pursuant to the Evergreen Provision, an additional 2,010,623 shares were added to the 2018 Plan, representing 4% of total common shares outstanding at December 31, 2020.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2018 Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2018, the Company&#x2019;s Board of Directors adopted, and the Company&#x2019;s stockholders approved, the Homology Medicines, Inc. 2018 Employee Stock Purchase Plan (the &#x201c;2018 ESPP&#x201d;). The 2018 ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The 2018 ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423 of the Internal Revenue Code. The number of shares of common stock initially available for issuance under the 2018 ESPP was 353,980 shares of common stock plus an annual increase on the first day of each calendar year beginning on January 1, 2019 and ending on and including January 1, 2028 equal to the lesser of (i) 1% of the Company&#x2019;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#x2019;s Board of Directors, provided that not more than 4,778,738 shares of common stock may be issued under the 2018 ESPP (the &#x201c;ESPP Evergreen Provision&#x201d;). At December&#160;31, 2020, there were 1,039,650 shares available for future issuance under the 2018 ESPP. On January 1, 2021, pursuant to the ESPP Evergreen Provision, an additional 502,655 shares were added to the 2018 ESPP, representing 1% of total common shares outstanding at December&#160;31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the 2018 ESPP, employees may purchase common stock through after-tax payroll deductions at a price equal to 85% of the lower of the fair market value on the first trading day of an offering period or the last trading day of an offering period. The 2018 ESPP generally provides for offering periods of six months in duration that end on the final trading day of each February and August. In accordance with the Internal Revenue Code, no employee will be permitted to accrue the right to purchase stock under the 2018 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of the Company&#x2019;s common stock as of the first day of the offering period).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December&#160;31, 2020, 83,848 shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $0.9 million. During the year ended December&#160;31, 2019, 55,234 shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $0.8 million. Pursuant to the 2018 ESPP, the Company recorded stock-based compensation of $0.2 million and $0.2 million for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award, which is generally the vesting period. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model, with the assumptions noted in the table below. Expected volatility for the Company&#x2019;s common stock was determined based on an average of the historical volatility of a peer group of publicly traded companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the options was used for the expected term of options granted to non-employees. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods commensurate with the expected term of the award. The Company recognizes forfeitures as they occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used in the Black-Scholes option pricing model are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.2% &#x2014; 66.3%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62.4% &#x2014; 64.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% &#x2014; 1.73%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.36% &#x2014; 2.60%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 - 6.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying common stock fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$9.82 - $21.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$12.73 &#x2014; $30.34&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense related to stock options and shares purchased under the 2018 ESPP as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,858&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,248&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, there was $29.2 million of unrecognized compensation expense related to unvested employee and non-employee share-based compensation arrangements granted under the Plans. The unrecognized compensation expense is estimated to be recognized over a period of 2.4 years at December&#160;31, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of option activity under the Plans during the year ended December&#160;31, 2020 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (in Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000581"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(266,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000582"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000583"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,869,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000584"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total intrinsic value of options exercised during the year ended December&#160;31, 2020 and 2019 was $0.6 million and $1.9 million, respectively. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and 2019 was $10.39 and $12.90, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options granted pursuant to the 2015 Plan permit option holders to elect to exercise unvested options in exchange for unvested common stock. Options granted under the 2015 Plan that are exercised prior to vesting will continue to vest according to the respective option agreement, and such unvested shares are subject to repurchase by the Company at the optionee&#x2019;s original exercise price in the event the optionee&#x2019;s service with the Company voluntarily or involuntarily terminates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s unvested common stock from early exercises that is subject to repurchase by the Company is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares&#x2014;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 and 2019, 3,091 shares and 21,666 shares, respectively, remained subject to a repurchase right by the Company, with a related liability included in accrued expenses and other liabilities in the consolidated balance sheets of less than $0.1 million as of each date. &lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231"
      id="F_000522">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000523"
      unitRef="U_xbrlishares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331"
      decimals="INF"
      id="F_000524"
      unitRef="U_xbrlishares">3186205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180301_20180331"
      decimals="INF"
      id="F_000525"
      unitRef="U_xbrlipure">0.04</fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
    <fixx:MaximumSharesAllowedToBeIssued
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20180331"
      decimals="INF"
      id="F_000526"
      unitRef="U_xbrlishares">20887347</fixx:MaximumSharesAllowedToBeIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_20201231"
      decimals="INF"
      id="F_000529"
      unitRef="U_xbrlishares">2397547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101"
      decimals="INF"
      id="F_000527"
      unitRef="U_xbrlishares">2010623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandEighteenIncentiveAwardPlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101"
      decimals="INF"
      id="F_000528"
      unitRef="U_xbrlipure">0.04</fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331"
      decimals="INF"
      id="F_000530"
      unitRef="U_xbrlishares">353980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180301_20180331"
      decimals="INF"
      id="F_000531"
      unitRef="U_xbrlipure">0.01</fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
    <fixx:MaximumSharesAllowedToBeIssuedUnderESPP
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20180331"
      decimals="INF"
      id="F_000532"
      unitRef="U_xbrlishares">4778738</fixx:MaximumSharesAllowedToBeIssuedUnderESPP>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000537"
      unitRef="U_xbrlishares">1039650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101"
      decimals="INF"
      id="F_000533"
      unitRef="U_xbrlishares">502655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210101"
      decimals="INF"
      id="F_000534"
      unitRef="U_xbrlipure">0.01</fixx:AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331"
      decimals="2"
      id="F_000535"
      unitRef="U_xbrlipure">0.85</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage>
    <fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20200331"
      id="F_000536">P6M</fixx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000538"
      unitRef="U_xbrlishares">83848</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000540"
      unitRef="U_iso4217USD">900000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000539"
      unitRef="U_xbrlishares">55234</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000541"
      unitRef="U_iso4217USD">800000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000543"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwentyEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000542"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000285">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used in the Black-Scholes option pricing model are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.2% &#x2014; 66.3%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;62.4% &#x2014; 64.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31% &#x2014; 1.73%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.36% &#x2014; 2.60%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5 - 6.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.25&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying common stock fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$9.82 - $21.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$12.73 &#x2014; $30.34&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000286">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense related to stock options and shares purchased under the 2018 ESPP as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,858&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,248&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,635&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">6390000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">4164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">6858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">3471000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_20200101_20201231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">13248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001661998_20190101_20191231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">7635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20201231"
      decimals="-5"
      id="F_000565"
      unitRef="U_iso4217USD">29200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001661998_us-gaapPlanNameAxis_fixxTwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember_20200101_20201231"
      id="F_000566">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000287">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of option activity under the Plans during the year ended December&#160;31, 2020 is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (in Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000581"&gt;8.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,311,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.82&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(266,984&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000582"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000583"&gt;7.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,869,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000584"&gt;7.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000567"
      unitRef="U_xbrlishares">4843018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001661998_20191231"
      decimals="2"
      id="F_000574"
      unitRef="U_iso4217USD_xbrlishares">14.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001661998_20191231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">33809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000568"
      unitRef="U_xbrlishares">1311200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001661998_20200101_20201231"
      decimals="2"
      id="F_000575"
      unitRef="U_iso4217USD_xbrlishares">17.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000569"
      unitRef="U_xbrlishares">46410</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001661998_20200101_20201231"
      decimals="2"
      id="F_000576"
      unitRef="U_iso4217USD_xbrlishares">3.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000570"
      unitRef="U_xbrlishares">266984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001661998_20200101_20201231"
      decimals="2"
      id="F_000577"
      unitRef="U_iso4217USD_xbrlishares">22.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000571"
      unitRef="U_xbrlishares">5840824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001661998_20201231"
      decimals="2"
      id="F_000578"
      unitRef="U_iso4217USD_xbrlishares">15.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">12278000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000572"
      unitRef="U_xbrlishares">5840824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001661998_20201231"
      decimals="2"
      id="F_000579"
      unitRef="U_iso4217USD_xbrlishares">15.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">12278000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000573"
      unitRef="U_xbrlishares">2869589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001661998_20201231"
      decimals="2"
      id="F_000580"
      unitRef="U_iso4217USD_xbrlishares">12.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001661998_20201231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">10803000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000589"
      unitRef="U_iso4217USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001661998_20190101_20191231"
      decimals="-5"
      id="F_000590"
      unitRef="U_iso4217USD">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001661998_20200101_20201231"
      decimals="2"
      id="F_000591"
      unitRef="U_iso4217USD_xbrlishares">10.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001661998_20190101_20191231"
      decimals="2"
      id="F_000592"
      unitRef="U_iso4217USD_xbrlishares">12.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <fixx:SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000288">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s unvested common stock from early exercises that is subject to repurchase by the Company is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares&#x2014;January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Repurchased&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested shares&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</fixx:SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock>
    <fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000593"
      unitRef="U_xbrlishares">21666</fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding>
    <fixx:UnvestedCommonSharesSubjectToRepurchaseVested
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000594"
      unitRef="U_xbrlishares">18575</fixx:UnvestedCommonSharesSubjectToRepurchaseVested>
    <fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000595"
      unitRef="U_xbrlishares">3091</fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding>
    <fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding
      contextRef="C_0001661998_20201231"
      decimals="INF"
      id="F_000596"
      unitRef="U_xbrlishares">3091</fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding>
    <fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding
      contextRef="C_0001661998_20191231"
      decimals="INF"
      id="F_000597"
      unitRef="U_xbrlishares">21666</fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding>
    <fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20201231"
      decimals="-5"
      id="F_000598"
      unitRef="U_iso4217USD">100000</fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent>
    <fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent
      contextRef="C_0001661998_srtRangeAxis_srtMaximumMember_us-gaapBalanceSheetLocationAxis_fixxAccruedExpensesAndOtherLiabilitiesMember_20191231"
      decimals="-5"
      id="F_000599"
      unitRef="U_iso4217USD">100000</fixx:AccruedUnvestedCommonStockSubjectToRepurchaseCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000246">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. NET LOSS PER SHARE&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s potential dilutive securities, which include unvested common stock from the early-exercise of stock options and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested common stock from early exercise of options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,843,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,864,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000289">&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/span&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested common stock from early exercise of options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,840,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,843,018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,843,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,864,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20200101_20201231"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlishares">3091</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fixxUnvestedCommonStockFromEarlyExerciseOfOptionsMember_20190101_20191231"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">21666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">5840824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlishares">4843018</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_20200101_20201231"
      decimals="INF"
      id="F_000604"
      unitRef="U_xbrlishares">5843915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001661998_20190101_20191231"
      decimals="INF"
      id="F_000605"
      unitRef="U_xbrlishares">4864684</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000247">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. DEFINED CONTRIBUTION PLAN &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has a 401(k) defined contribution plan (the &#x201c;401(k) Plan&#x201d;) for all of its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits, while the Company contributes to the plan at the discretion of the Board of Directors. The Company&#x2019;s discretionary match made under the 401(k) Plan for the years ended December&#160;31, 2020 and 2019 was $0.7 million and $0.5 million, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001661998_20200101_20201231"
      decimals="-5"
      id="F_000606"
      unitRef="U_iso4217USD">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001661998_20190101_20191231"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000248">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. COLLABORATION AND LICENSE AGREEMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Summary of Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2017, the Company entered into a collaboration and license agreement with Novartis (as amended, the &#x201c;Collaboration Agreement&#x201d;) for the research, development, manufacturing and commercialization of products using the Company&#x2019;s gene-editing technology for the treatment of certain ophthalmic targets and sickle cell disease. In February 2019, Novartis elected to discontinue the sickle cell disease program under the Collaboration Agreement effective in August 2019. In May 2020, Novartis confirmed an ophthalmic target for a therapeutic editing program. Additionally, in accordance with the terms of the Collaboration Agreement, Novartis&#x2019; right to substitute other ophthalmic targets expired. For additional information on the Collaboration Agreement, please refer to Note 17.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Collaboration Agreement, the Company granted Novartis a research license, a development and commercialization license, and a manufacturing license, under certain of its intellectual property rights to research, develop, manufacture and commercialize ophthalmic targets. Upon entering into the Collaboration Agreement in November 2017, the Company received an upfront, nonrefundable payment of $35.0&#160;million and issued additional shares of its Series B preferred stock to Novartis for consideration of $10.0&#160;million, in addition to the $5.0 million of Series B preferred stock Novartis had purchased in July 2017. The Company recorded the November 2017 issuance of Series B preferred stock at its estimated fair value of $11.7 million, including $1.7 million of the upfront payment, and allocated the remaining $33.3 million of the upfront payment to the Collaboration Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Collaboration Agreement consists of a research term, where the Company and Novartis were collaborating to perform research and conduct preclinical development to identify candidates that modulate ophthalmic targets. The Collaboration Agreement also includes exploratory work on the applicability of the gene editing technology with respect to other gene targets. The Company&#x2019;s obligation to perform such exploratory research was extended pursuant an amendment to the Collaboration Agreement was set to conclude in May 2021. The Company was responsible for the manufacturing of proprietary research grade human hematopoietic stem cell derived adeno-associated virus vectors (&#x201c;AAVHSCs&#x201d;) during the research term. Novartis agreed to reimburse research activities performed by the Company at a full-time equivalent rate (&#x201c;FTE&#x201d;) and manufacturing activities at cost, up to a maximum of $17.0 million during the research term, as specified and defined in the Collaboration Agreement. Novartis agreed to pay the Company a target fee of $5.0&#160;million if the target meets certain success criteria during the research term (the &#x201c;target fee trigger date&#x201d;). The research term was to continue for five years from the effective date of the Collaboration Agreement. Pursuant to the Collaboration Agreement, the Company also agreed to participate on a joint steering committee and a joint manufacturing subcommittee, with equal representation from both the Company and Novartis. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Novartis had the exclusive right to develop and commercialize one ophthalmic candidate or product arising from the research activities. Subject to certain limitations pursuant to the terms of the Collaboration Agreement, Novartis agreed to fund all development and commercialization costs. The Company was responsible for manufacturing candidates and products for Novartis during the development and commercialization terms. The Company&#x2019;s manufacturing activities were to be reimbursed at cost during the development term and at cost plus a margin during the commercialization term, as defined in the Collaboration Agreement. If the Company was not able to manufacture candidates or products that met the quality or quantity requirements of Novartis, then Novartis would have had the right to designate a third-party contract manufacturer or manufacture such candidates or products itself. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with the Collaboration Agreement, taking into consideration Novartis&#x2019; election to discontinue the sickle cell disease program, and the expiration of Novartis&#x2019; rights to make substitutions of an ophthalmic target, the Company was also eligible to receive up to a total of $265.0&#160;million in milestone payments, including up to $90.0 million in development milestone payments, up to $85.0 million in regulatory milestone payments and up to $90.0 million in commercial milestone payments, with respect to the licensed products. The Company was also eligible to earn tiered royalties on net sales of licensed products by Novartis, its affiliates or sublicensees, ranging from mid-single-digit, to sub-teen double-digit percentages, and such royalties were potentially subject to various reductions and offsets. If any of the exploratory research efforts were advanced into formal research and development programs, the parties agreed to negotiate the economics including potential milestone payments for such programs at that time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the (1) research, development and commercialization and manufacturing licenses, (2) the research activities performed by the Company (3) service on the joint committees and (4) manufacturing during the research and development terms represented a single performance obligation under the Collaboration Agreement. Since the option for Novartis to obtain manufacturing during the commercialization term from the Company is at a price that would reflect the standalone selling price, the option does not provide Novartis with a material right and is therefore not a performance obligation under the contract.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has concluded that the research, development and commercialization and manufacturing licenses are not distinct from the research activities and manufacturing during the research and development term as Novartis cannot benefit from the licenses without the Company performing the research and manufacturing services. These services are so specialized and rely on the Company&#x2019;s expertise in gene editing technologies not available in the marketplace. As a result, these licenses have been combined with the research activities, service on the joint committees and the manufacturing during the research and development terms as a single performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price consists of the $33.3 million non-refundable upfront payment, net of amounts classified as equity, and projected reimbursable research and manufacturing activities, which have been estimated using the expected value method. None of the target fees or development and regulatory milestone payments have been included in the transaction price, as all are fully constrained. As part of the evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones is outside of the Company&#x2019;s control and is contingent upon the success of the Company&#x2019;s preclinical studies, clinical trials, Novartis&#x2019; efforts and the receipt of regulatory approval. In addition, the Company has determined that the commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominately to the licenses transferred to Novartis, and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified only one performance obligation in the Collaboration Agreement. Therefore, the Company allocated the transaction price at the onset of the contract to the single performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue over time using a cost-to-cost method, which it believes best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded over the performance period as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2020, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $30.2 million, and the Company will recognize this revenue as the research and manufacturing activities are performed, which was expected to occur over a period of time that was estimated to conclude in 2027. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In estimating the total costs to satisfy its single performance obligation pursuant to the Novartis agreement, the Company is required to make significant estimates including the expected time it will take to fulfill the performance obligation, which, as of December 31, 2020, was expected to be approximately ten years from the date the Collaboration Agreement was entered into, and the expected costs associated with manufacturing during the research and development terms for a novel manufacturing process as well as the probability of success of a target to move into the development phase. The Company has made estimates of such costs utilizing its experience with similar product candidates, however not identical to those in the Collaboration Agreement. In making such estimates, significant judgment is required to evaluate those key assumptions related to cost estimates. The cumulative effect of revisions to the total estimated costs to complete the Company&#x2019;s single performance obligation will be recorded in the period in which the changes are identified and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#x2019;s reported cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue under the Collaboration Agreement of $2.3 million and $1.7 million, respectively, of which $0.8 million and $0.6 million was included in deferred revenue at the beginning of each such period. As of December&#160;31, 2020 and 2019, there was approximately $30.2 million and $31.0 million of deferred revenue related to the Collaboration Agreement, respectively. In addition, as of December&#160;31, 2020 and 2019, the Company has recorded accounts receivable of $0.4 million, related to reimbursable research and development costs under the Collaboration Agreement, which are included in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130"
      decimals="-5"
      id="F_000608"
      unitRef="U_iso4217USD">35000000.0</fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130"
      decimals="-5"
      id="F_000609"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20170701_20170731"
      decimals="-5"
      id="F_000610"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <fixx:PreferredStockEstimatedFairValue
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171130"
      decimals="-5"
      id="F_000611"
      unitRef="U_iso4217USD">11700000</fixx:PreferredStockEstimatedFairValue>
    <fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20171101_20171130"
      decimals="-5"
      id="F_000612"
      unitRef="U_iso4217USD">1700000</fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived>
    <fixx:CollaborativeArrangementAllocatedConsideration
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130"
      decimals="INF"
      id="F_000613"
      unitRef="U_iso4217USD">33300000</fixx:CollaborativeArrangementAllocatedConsideration>
    <fixx:CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171101_20171130"
      decimals="INF"
      id="F_000616"
      unitRef="U_iso4217USD">17000000.0</fixx:CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm>
    <fixx:CollaborativeAgreementTargetFee
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130"
      decimals="-5"
      id="F_000614"
      unitRef="U_iso4217USD">5000000.0</fixx:CollaborativeAgreementTargetFee>
    <fixx:CollaborativeArrangementTermOfAgreement
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130"
      id="F_000615">P5Y</fixx:CollaborativeArrangementTermOfAgreement>
    <fixx:CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130"
      decimals="INF"
      id="F_000617"
      unitRef="U_fixxCandidateorProduct">1</fixx:CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize>
    <fixx:CollaborativeArrangementMilestonePaymentsEligibleToReceive
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130"
      decimals="INF"
      id="F_000618"
      unitRef="U_iso4217USD">265000000.0</fixx:CollaborativeArrangementMilestonePaymentsEligibleToReceive>
    <fixx:CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130"
      decimals="INF"
      id="F_000619"
      unitRef="U_iso4217USD">90000000.0</fixx:CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive>
    <fixx:CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130"
      decimals="INF"
      id="F_000620"
      unitRef="U_iso4217USD">85000000.0</fixx:CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive>
    <fixx:CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_srtRangeAxis_srtMaximumMember_20171130"
      decimals="INF"
      id="F_000621"
      unitRef="U_iso4217USD">90000000.0</fixx:CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive>
    <fixx:CollaborativeArrangementTransactionPrice
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200101_20201231"
      decimals="-5"
      id="F_000622"
      unitRef="U_iso4217USD">33300000</fixx:CollaborativeArrangementTransactionPrice>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231"
      decimals="-5"
      id="F_000623"
      unitRef="U_iso4217USD">30200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">30200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2027-04-01_20201231"
      id="F_000625">P10Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231"
      id="F_000626">P10Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      decimals="-5"
      id="F_000628"
      unitRef="U_iso4217USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101"
      decimals="-5"
      id="F_000629"
      unitRef="U_iso4217USD">800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101"
      decimals="-5"
      id="F_000630"
      unitRef="U_iso4217USD">600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_000631"
      unitRef="U_iso4217USD">30200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_000632"
      unitRef="U_iso4217USD">31000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_000634"
      unitRef="U_iso4217USD">400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapBalanceSheetLocationAxis_fixxReimbursableResearchAndDevelopmentCostsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_000633"
      unitRef="U_iso4217USD">400000</us-gaap:AccountsReceivableNetCurrent>
    <fixx:StockPurchaseAgreementDisclosureTextBlock
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231"
      id="F_000249">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. PFIZER STOCK PURCHASE AGREEMENT&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 9, 2020,&lt;span style="color:#000000;"&gt; the Company entered into a common stock purchase agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Pfizer Inc.&lt;/span&gt; &lt;span style="color:#000000;"&gt;(&#x201c;Pfizer&#x201d;), pursuant to which the Company agreed to issue and sell to Pfizer 5,000,000 shares of the Company&#x2019;s common stock through a private placement transaction (the &#x201c;Private Placement&#x201d;) at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million. The shares of common stock sold to Pfizer are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Stock Purchase Agreement, Pfizer was granted an exclusive right of first refusal (the &#x201c;ROFR&#x201d;) &lt;span style="color:#000000;"&gt;for a 30-month period (the &#x201c;ROFR Period&#x201d;) beginning on the date of the closing of the Private Placement (collectively, the &#x201c;ROFR Provision&#x201d;), to negotiate a potential collaboration on the development and commercialization of HMI-102 and HMI-103.&lt;/span&gt; Pfizer may exercise its right of first refusal under the ROFR Provision one time for each of HMI-102 and HMI-103 during the ROFR period. In addition to the ROFR, the Stock Purchase Agreement provides for an information sharing committee (the &#x201c;Information Committee&#x201d;), comprised of representatives of each company which will serve as a forum for sharing information regarding the development of &lt;span style="color:#000000;"&gt;HMI-102 and HMI-103 &lt;/span&gt;during the ROFR Period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded the issuance of common stock at its estimated fair value of $52.0 million, which reflects a discount for the lack of marketability of the shares. The remaining $8.0 million of aggregate purchase price was allocated to the other elements of the Stock Purchase Agreement, which represent a contract with a customer. The Company concluded that the Information Committee represents the only performance obligation under the contract. The ROFR does not provide Pfizer with a material right and is therefore not a performance obligation. As such, the Company allocated the $8.0 million to the Information Committee obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will recognize revenue over time as the measure of progress which it believes best depicts the transfer of control to Pfizer. The Information Committee will meet regularly over the ROFR Period to share information which results in recognition of the transaction price over the 30-month ROFR Period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company recognized collaboration of $0.4 million, and as of December 31, 2020, there was approximately $7.6 million of deferred revenue related to the Company&#x2019;s obligation to Pfizer.&lt;/p&gt;</fixx:StockPurchaseAgreementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109"
      decimals="INF"
      id="F_000635"
      unitRef="U_xbrlishares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109"
      decimals="2"
      id="F_000636"
      unitRef="U_iso4217USD_xbrlishares">12.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109"
      decimals="-5"
      id="F_000637"
      unitRef="U_iso4217USD">60000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <fixx:CommonStockPurchaseAgreementCondition
      contextRef="C_0001661998_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20201109_20201109"
      id="F_000638">The shares of common stock sold to Pfizer are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares.</fixx:CommonStockPurchaseAgreementCondition>
    <fixx:CommonStockEstimatedFairValue
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109"
      decimals="-5"
      id="F_000639"
      unitRef="U_iso4217USD">52000000.0</fixx:CommonStockEstimatedFairValue>
    <fixx:StockPurchaseAgreementRemainingAllocatedValue
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109"
      decimals="-5"
      id="F_000640"
      unitRef="U_iso4217USD">8000000.0</fixx:StockPurchaseAgreementRemainingAllocatedValue>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20201109"
      decimals="-5"
      id="F_000641"
      unitRef="U_iso4217USD">8000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_000642"
      unitRef="U_iso4217USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_000643"
      unitRef="U_iso4217USD">7600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001661998_20200101_20201231" id="F_000250">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. SUBSEQUENT EVENT&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 26, 2021, Homology received notice from Novartis that they had elected to terminate the Collaboration Agreement with the Company, with respect to the remaining ophthalmic target under the Collaboration Agreement. Accordingly, the notice served as notice of Novartis&#x2019; termination of the Collaboration Agreement in its entirety, which will be effective on August 26, 2021. As a result of the termination of the Collaboration Agreement, Homology regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize Homology&#x2019;s proprietary nuclease-free gene editing technology platform for an ophthalmic target (see Note 15). Homology announced its plans to continue to advance the program toward naming a development candidate. The Company and Novartis believe that results of studies conducted &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;under the&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; C&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ollaboration &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Agreement &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;provide early proof-of-principle and support a nuclease-independent approach to editing of relevant cell types in the eye after sub-retinal&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;injection, and are the subject of a planned presentation at an upcoming scientific meeting&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000320"
          xlink:label="F_000320"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000319"
          xlink:label="F_000319"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents capitalization of operating right-of-use assets</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000320"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000319"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000322"
          xlink:label="F_000322"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000323"
          xlink:label="F_000323"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000324"
          xlink:label="F_000324"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000321"
          xlink:label="F_000321"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000320"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000322"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000323"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000319"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000324"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000321"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000327"
          xlink:label="F_000327"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000326"
          xlink:label="F_000326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000325"
          xlink:label="F_000325"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000328"
          xlink:label="F_000328"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents recognition of operating lease liabilities</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000327"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000326"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000325"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000328"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031985523752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Homology Medicines, Inc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FIXX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,487,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 511.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3468154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Patriots Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bedford<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">301-7277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">None.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899490744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 217,431,000<span></span>
</td>
<td class="nump">$ 53,774,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">208,614,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,133,000<span></span>
</td>
<td class="nump">4,189,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">219,564,000<span></span>
</td>
<td class="nump">266,577,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,002,000<span></span>
</td>
<td class="nump">42,716,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">5,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,274,000<span></span>
</td>
<td class="nump">1,274,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">263,737,000<span></span>
</td>
<td class="nump">310,567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,722,000<span></span>
</td>
<td class="nump">2,608,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">9,803,000<span></span>
</td>
<td class="nump">7,644,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">5,632,000<span></span>
</td>
<td class="nump">809,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,658,000<span></span>
</td>
<td class="nump">12,374,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">12,941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">32,143,000<span></span>
</td>
<td class="nump">30,142,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">67,742,000<span></span>
</td>
<td class="nump">52,060,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 50,268,666 and 45,138,408 shares issued as of December 31, 2020 and 2019, respectively; and 50,265,575 and 45,116,742 shares outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">524,358,000<span></span>
</td>
<td class="nump">457,994,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(328,368,000)<span></span>
</td>
<td class="num">(199,674,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">195,995,000<span></span>
</td>
<td class="nump">258,507,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 263,737,000<span></span>
</td>
<td class="nump">$ 310,567,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896594664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">50,268,666<span></span>
</td>
<td class="nump">45,138,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">50,265,575<span></span>
</td>
<td class="nump">45,116,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899880360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 2,702<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">100,392<span></span>
</td>
<td class="nump">89,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">32,573<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">132,965<span></span>
</td>
<td class="nump">111,609<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(130,263)<span></span>
</td>
<td class="num">(109,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">6,027<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">6,027<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128,694)<span></span>
</td>
<td class="num">$ (103,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share-basic and diluted</a></td>
<td class="num">$ (2.80)<span></span>
</td>
<td class="num">$ (2.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding-basic and diluted</a></td>
<td class="nump">45,910,787<span></span>
</td>
<td class="nump">42,117,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896418104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (128,694)<span></span>
</td>
<td class="num">$ (103,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain (loss) on available for sale securities, net</a></td>
<td class="num">(183)<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain (loss)</a></td>
<td class="num">(183)<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (128,877)<span></span>
</td>
<td class="num">$ (103,656)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893943768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM</div></th>
<th class="th"><div>Private Placement</div></th>
<th class="th"><div>Follow On Offering</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Follow On Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private Placement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Follow On Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 196,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (95,758)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,358,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,388,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock pursuant to employee stock purchase plan</a></td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock pursuant to employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise', window );">Vesting of common stock from option exercises</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise', window );">Vesting of common stock from option exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from option exercises</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from option exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">7,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(103,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">258,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="num">(199,674)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,116,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock pursuant to employee stock purchase plan</a></td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock pursuant to employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise', window );">Vesting of common stock from option exercises</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise', window );">Vesting of common stock from option exercises, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from option exercises</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from option exercises, Shares</a></td>
<td class="nump">46,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 13,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(128,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 195,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (328,368)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,265,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of common stock from option exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of common stock from option exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895085288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (128,694)<span></span>
</td>
<td class="num">$ (103,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7,965<span></span>
</td>
<td class="nump">6,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_NonCashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">13,248<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccretionOfShortTermInvestments', window );">Accretion of short-term investments</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(1,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">888<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">2,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,459<span></span>
</td>
<td class="num">(4,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,432<span></span>
</td>
<td class="nump">2,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">6,824<span></span>
</td>
<td class="num">(569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(94,332)<span></span>
</td>
<td class="num">(91,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(19,991)<span></span>
</td>
<td class="num">(286,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Maturities of short-term investments</a></td>
<td class="nump">228,620<span></span>
</td>
<td class="nump">256,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,733)<span></span>
</td>
<td class="num">(21,833)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">204,896<span></span>
</td>
<td class="num">(51,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of common stock in private placement</a></td>
<td class="nump">51,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock from option exercises</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock pursuant to employee stock purchase plan</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">53,093<span></span>
</td>
<td class="nump">158,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">163,657<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">55,048<span></span>
</td>
<td class="nump">39,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">218,705<span></span>
</td>
<td class="nump">55,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions', window );">Reclassification of liability for common stock vested</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment additions included in accounts payable</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities', window );">Property and equipment additions included in accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available for sale securities, net</a></td>
<td class="num">$ (183)<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities', window );">Offering costs included in accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_MajorAssetClassOfLeasedAssetsAxis=fixx_ATMMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccretionOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of short term investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccretionOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs included in accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment additions included in accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of liability for common stock vested in noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_MajorAssetClassOfLeasedAssetsAxis=fixx_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_MajorAssetClassOfLeasedAssetsAxis=fixx_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031892219464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nature of Business<span style="font-weight:normal;">&#8212;Homology Medicines, Inc. (the &#8220;Company&#8221;) is a clinical-stage genetic medicines company dedicated to translating proprietary gene therapy and gene editing technology into novel treatments for patients with rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. The Company was founded in March 2015 as a Delaware corporation. Its principal offices are in Bedford, Massachusetts. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its resources to recruiting personnel, developing its technology platform and advancing its pipeline of product candidates, developing and implementing manufacturing processes, building out internal manufacturing and research and development space, and maintaining and building its intellectual property portfolio. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of product candidates. Principal among these risks are dependency on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and manufacturing of its product candidates. The Company&#8217;s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, conduct clinical trials, obtain regulatory approval of its products, further expand its manufacturing capacity, successfully commercialize its products, generate revenue, meet its obligations, and, ultimately, attain profitable operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) with the sale of 10,350,000 shares of its common stock, including shares issued upon the exercise in full of the underwriters&#8217; over-allotment option, at a public offering price of $16.00 per share, resulting in net proceeds of $150.8 million, after deducting underwriting discounts and commissions and offering expenses. Upon the closing of the IPO, all of the Company&#8217;s outstanding shares of convertible preferred stock automatically converted into 24,168,656 shares of common stock at the applicable conversion ratio then in effect.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 12, 2019, the Company completed a follow-on public offering of its common stock. The Company sold 5,555,556 shares of its common stock at a public offering price of $22.50 per share and received net proceeds of $116.9 million, after deducting underwriting discounts and commissions and offering expenses. In addition, on April 26, 2019 and May 7, 2019, in connection with the exercise in full of the underwriters&#8217; option to purchase additional shares, the Company issued an aggregate of 833,333 shares of its common stock at a public offering price of $22.50 per share and received net proceeds of $17.6 million, after deducting underwriting discounts and commissions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2020, the Company filed a Registration Statement on Form S-3 (File No. 333-237131)<span style="color:#000000;"> (the &#8220;Shelf&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for a period up to three years from the date of the filing. The Shelf became effective on </span>March 12, 2020<span style="color:#000000;">. The Company also simultaneously entered into a sales agreement with Cowen and Company, LLC </span>(&#8220;Cowen&#8221;)<span style="color:#000000;">, as sales agent, providing for the offering, issuance and sale by the Company of up to an aggregate $150.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings under the Shelf (the &#8220;ATM&#8221;). </span>The Company did not sell any shares of common stock pursuant to the ATM during the year ended <span style="color:#000000;">December&#160;31, 2020</span>. At December&#160;31, 2020, there remained $150.0 million of common stock available for sale under the ATM. Simultaneous with the filing of the Shelf, the previous Registration Statement on Form S-3 (File No. 333-230664) filed with the SEC on April 1, 2019, and a prior sales agreement with Cowen providing for the offering, issuance and sale by the Company of up to an aggregate $100.0 million of its common stock from time to time in &#8220;at-the-market&#8221; offerings, with $76.8 million of remaining capacity, were terminated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020,<span style="color:#000000;"> the Company entered into a common stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Pfizer Inc.</span> <span style="color:#000000;">(&#8220;Pfizer&#8221;), pursuant to which the Company agreed to issue and sell to Pfizer 5,000,000 shares of the Company&#8217;s common stock through a private placement transaction (the &#8220;Private Placement&#8221;) at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million (see Note 16).</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has not generated any revenue from product sales and does not expect to generate any revenue from the sale of product in the foreseeable future. Through December&#160;31, 2020, the Company has financed its operations primarily through public offerings of its common stock, the issuance of convertible preferred stock, and with proceeds from its collaboration and license agreement with Novartis Institutes of BioMedical Research, Inc. (&#8220;Novartis&#8221;) (see Note 15) and its private placement with Pfizer. During the year ended December&#160;31, 2020, the Company incurred a net loss of $128.7&#160;million and as of December&#160;31, 2020, had $328.4&#160;million in accumulated deficit. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on current projections, management believes that existing cash</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash equivalents</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will enable the Company to continue its operations into the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarter of 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In the absence of a significant source of recurring revenue, the continued viability of the Company beyond that point is dependent on its ability to continue to raise additional capital to finance its operations. There can be no assurance that the Company will be able to obtain sufficient capital to cover its costs on acceptable terms, if at all.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation<span style="font-weight:normal;">&#8212;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) </span><span style="Background-color:#FFFFFF;font-weight:normal;">and have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business</span><span style="font-weight:normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031892016104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation<span style="font-weight:normal;">&#8212;The Company&#8217;s consolidated financial statements include the accounts of the Company and its subsidiary, Homology Medicines Securities Corporation, a wholly owned Massachusetts corporation, for the sole purpose of buying, selling, and holding securities on the Company&#8217;s behalf. All intercompany balances and transactions have been eliminated in the consolidated financial statements.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<span style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) &#8212;<span style="font-weight:normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale investments. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents and Restricted Cash<span style="font-weight:normal;">&#8212;Cash and cash equivalents consist of standard checking accounts, money market accounts and certain investments. The Company considers all highly liquid investments with original or remaining maturities at the time of purchase of 90 days or less to be cash equivalents. Restricted cash consists of cash serving as collateral for letters of credit issued for security deposits for the Company&#8217;s facility leases in Bedford, Massachusetts.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,774</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,705</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,048</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Short-Term Investments<span style="font-weight:normal;">&#8212;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments have maturities of greater than 90 days at the time of purchase and mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying security. Such amortization and accretion, together with interest on securities, are included in interest income in the Company&#8217;s consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</span><span style="font-weight:normal;">&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and short-term investments. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. We believe that we are not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. We regularly invest excess cash with major financial institutions in money market funds, U.S. government and corporate debt securities and commercial paper, all of which can be readily purchased and sold using established markets. As of </span><span style="font-weight:normal;">December&#160;31, 2020</span><span style="font-weight:normal;">, the Company&#8217;s cash and cash equivalents were held with two financial institutions. We believe that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are either government</span><span style="font-weight:normal;">-</span><span style="font-weight:normal;">backed or of high credit rating.</span><span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering Costs<span style="font-weight:normal;">&#8212;The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with equity financings as other current assets until the transactions are completed. After equity financings are complete, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="font-weight:normal;">&#8212;</span><span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842) (&#8220;ASU 2016-02&#8221;), which eliminated the tests for lease classification under prior U.S. GAAP and requires lessees to recognize right-of-use assets and related lease liabilities on the balance sheet. The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-weight:normal;">, ASU No. 2018-10 &#8211; </span><span style="font-style:italic;font-weight:normal;">Codification Improvements to Topic </span><span style="font-weight:normal;">842</span><span style="font-style:italic;font-weight:normal;">, Leases</span><span style="font-weight:normal;">, ASU No. 2018-11 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Targeted Improvements</span><span style="font-weight:normal;">, ASU No. 2018-20 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Narrow-Scope Improvements for Lessors</span><span style="font-weight:normal;">, and ASU No. 2019-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Codification Improvements</span><span style="font-weight:normal;">. The Company adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the new leasing standards using the modified retrospective approach, as of January 1, 2020, with no restatement of prior periods or cumulative adjustments to accumulated deficit. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. In addition, the Company elected the practical expedient not to apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company acts as sublessor related to a sublease of the Company's former headquarters. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Right-of-use assets are periodically evaluated for impairment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected lease term for those leases commencing prior to January 1, 2020 did not change with the adoption of the new leasing standards. The expected lease term for leases commencing after the adoption of the new leasing standards includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the adoption of the new leasing standards, on January 1, 2020, the Company recorded non-cash transactions to recognize a right-of-use asset of $6.8 million, operating lease liabilities of $17.7 million and the derecognition of deferred rent of $10.9 million originally accounted for under legacy guidance. The adoption did not have a material impact on the condensed consolidated statement of operations. For additional information on the adoption of the new leasing standards, refer to Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets (1)(2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent (2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion (3)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Represents capitalization of operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Represents recognition of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees and Indemnifications<span style="font-weight:normal;">&#8212;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment<span style="font-weight:normal;">&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and office furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000332">5 - 7 years</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000334">Shorter of the lease term</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or estimated useful life</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets<span style="font-weight:normal;">&#8212;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized for these assets.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs<span style="font-weight:normal;">&#8212;Research and development costs are charged to expense as incurred. Research and development expense consists of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical and clinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes<span style="font-weight:normal;">&#8212;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span> Since inception, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets has not been determined to be more likely than not.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information<span style="font-weight:normal;">&#8212;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is dedicated to translating proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. All of the Company&#8217;s tangible assets are held in the United States. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212;<span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">Revenue is recognized in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="font-style:italic;font-weight:normal;">Revenue from Contracts with Customers</span><span style="font-weight:normal;"> (&#8220;ASC 606&#8221;). On January 1, 2019, the Company adopted ASC 606 using the full retrospective transition method.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods or services in the Company&#8217;s arrangements would likely consist of a license, rights to the Company&#8217;s intellectual property or research, development and manufacturing services. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of consideration to which the Company expects to be entitled to. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from the Company&#8217;s collaboration arrangement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocates the transaction price based on the estimated standalone selling price of each performance obligation. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress for its over-time arrangements at each reporting period and, if necessary, updates the measure of progress and revenue recognized.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation<span style="font-weight:normal;">&#8212;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#8217;s estimates of these assumptions are primarily based on the trading price of the Company&#8217;s stock, historical data, peer company data and judgment regarding future trends and factors. Stock-based awards granted to nonemployees are initially recorded at fair value and are re-measured at each reporting period as the awards vest and expense is recognized over the period the services are provided. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price of common stock under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) is equal to 85% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the look-back provision under the ESPP is calculated using the Black-Scholes option pricing model. The fair value of the look-back provision plus the 15% discount is recognized as compensation expense over the 180-day purchase period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements<span style="font-weight:normal;">&#8212;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;1&#8212;Quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share<span style="font-weight:normal;">&#8212;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and unvested shares of common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements<span style="font-weight:normal;">&#8212;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organization related to their leasing activities. For additional information on the adoption of the new leasing standards, please refer to section titled &#8220;Leases&#8221; above, and Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU 2016-13&#8221;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early application permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued ASU No. 2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span> (&#8220;ASU 2018-07&#8221;)<span style="font-style:italic;">,</span> which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued ASU 2020-10, <span style="font-style:italic;">Codification Improvements</span>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031891953672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. CASH AND CASH EQUIVALENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may have cash balances in financial institutions in excess of federal deposit insurance limits. The Company has never experienced any losses related to these balances. The Company considers only those investments that are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash and cash equivalents: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,774</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893412600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_InvestmentsDisclosureAbstract', window );"><strong>Investments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. SHORT-TERM INVESTMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may invest its excess cash in fixed income instruments denominated and payable in U.S. dollars including U.S. treasury securities, commercial paper, corporate debt securities and asset-backed securities in accordance with the Company&#8217;s investment policy that primarily seeks to maintain adequate liquidity and preserve capital. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has designated all investments as available-for-sale and therefore such investments are reported at fair value</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and classified as short-term investments on the Company&#8217;s consolidated balance sheets</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Unrealized gains or losses on investments are recorded in accumulated other comprehensive income or loss, a component of stockholders&#8217; equity, on the Company&#8217;s consolidated balance sheets.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> short-term investments as of December 31, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s short-term investments as of December 31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,866</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">The Company utilizes the specific identification method in computing realized gains and losses. The Company had no realized gains and losses on its short-term investments for the years</span> <span style="font-size:10pt;">ended December 31, 2020 and 2019. The contractual maturity dates of all of the Company&#8217;s investments are less than one year.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_InvestmentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_InvestmentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031898709080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. FAIR VALUE MEASUREMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, short-term investments, restricted cash and accounts payable. The carrying amount of cash, restricted cash and accounts payable are each considered a reasonable estimate of fair value due to the short-term maturity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets measured at fair value on a recurring basis were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,138</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term securities are valued using models or other valuation methodologies that use Level&#160;2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, </p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.04%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers between fair value measure levels during the years ended December&#160;31, 2020 and 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031891954536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. PROPERTY AND EQUIPMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,703</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and purchased software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,596</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,002</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for the years ended December&#160;31, 2020 and 2019 was approximately $8.0 million and $6.3 million, respectively. The Company disposed of $0.9 million and less than $0.1 million of property and equipment, net during the years ended December&#160;31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031990091480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. ACCRUED EXPENSES AND OTHER LIABILITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,258</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued unvested common stock subject to repurchase</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031894170904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. COMMITMENTS AND CONTINGENCIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases<span style="font-weight:normal;">&#8212;In September 2016, the Company entered into a noncancelable operating lease beginning in November 2016 for office, laboratory and manufacturing space in Bedford, Massachusetts, that expires in October 2021, with an option for an additional <span style="-sec-ix-hidden:F_000426">three-year</span> term. In 2018, the Company entered into a sublease agreement for the entire leased premises. The rent commencement date of the sublease was December 2018, and the sublease will terminate on the scheduled termination date of the original lease. Under the terms of the sublease, the subtenant is obligated to pay the Company aggregate base rent of approximately $2.7 million over the term of the sublease, based on the same level of rent the Company is obligated to pay the landlord, in addition to a passthrough of operating expenses and real estate taxes charged by the landlord. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company entered into a noncancelable operating lease for approximately 67,000 square feet of research and development, manufacturing and general office space in Bedford, Massachusetts. The lease expires in February 2027 with an option for an additional<span style="-sec-ix-hidden:F_000430"> five-year</span> term. Rent became due under the lease in two phases; rent on the first 46,000 square feet started in September 2018 and rent on the remaining 21,000 square feet started in March 2019. The initial annual base rent was $39.50 per square foot and increases by three percent annually. The Company is obligated to pay, on a pro-rata </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis, real estate taxes and operating costs related to the premises.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease agreement entered into in December 2017 allowed for a tenant improvement allowance not to exceed $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million, which the Company received in full, to be applied to the total cost of tenant improvements to the leased premises. The unamortized balance of the tenant improvement allowance was included in deferred rent incentives and has been recorded as a reduction to operating right-of-use asset upon adoption of the new leasing standards.</span><span style="font-size:12pt;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains letters of credit, secured by restricted cash, for security deposits totaling $1.3 million as of December&#160;31, 2020 and 2019, respectively, in conjunction with its current leases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes operating lease costs and variable lease costs, as well as sublease income for the year ended December&#160;31, 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(913</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense for the year ended December 31, 2019 was $1.4 million.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of our operating lease liabilities as of December&#160;31, 2020 were as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ending December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,987</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,442</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the lease term and discount rate as of December&#160;31, 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">5.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the supplemental cash flow information related to the Company's operating leases for the year ended December&#160;31, 2020.</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899773832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementsTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9. LICENSE AGREEMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">City of Hope </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company entered into a license agreement with City of Hope (&#8220;COH&#8221;), an academic research and medical center. The license term extends until the last to expire patent, unless terminated earlier by either party under certain provisions. The Company is required to pay an annual license fee of $25,000, reimburse COH for patent costs incurred, pay amounts up to $3.2&#160;million upon the achievement of certain development and commercialization milestones for each product under the license, pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the low double-digits, if any. During the year ended December 31, 2019, the Company paid $50,000 to COH upon dosing the first patient in the pheNIX Phase 1/2 clinical trial. During the year ended December 31, 2020, the Company paid $75,000 plus interest to COH in connection with achievement of a milestone event. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the execution of the Collaboration Agreement with Novartis (see Note 15), the Company paid $4.5 million to COH in December 2017, under the terms of the license agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, the Company entered into a sponsored research agreement with COH with a goal to identify potential treatments for diseases in humans. Under this agreement, the Company recorded $0.1 million in research and development expense for the year ended December 31, 2019. The agreement terminated in September 2019 in accordance with its terms. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">California Institute of Technology </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2016, the Company entered into a co-exclusive license agreement with the California Institute of Technology (&#8220;Caltech&#8221;), an academic research institute. The license term extends until the expiration, revocation, invalidation or unenforceability of the licensed patent rights. The Company is required to pay an annual minimal royalty fee of $20,000, reimburse for patent costs incurred, pay an amount up to $7.2&#160;million upon the achievement of certain development and regulatory milestones and pay royalties on future sales in the low single-digits and royalties on sublicense revenue in the mid to high single-digits, if any. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031988367848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10. INCOME TAXES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation between the U.S. federal statutory tax rate and the Company&#8217;s effective tax rate is summarized as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,838</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,888</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized R&amp;D costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expense and other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77,793</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has no income tax expense due to the operating loss incurred for the years ended December 31, 2020 and 2019. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets is not determined to be more likely than not. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December 31, 2020, the Company had $265.1 million and $271.5 million of federal and state net operating loss carryforwards, respectively, that expire at various dates through 2040. Included in the federal net operating loss carryforwards of $265.1 million is $233.6 million that can be carried forward indefinitely. At December 31, 2020, the Company had $34.2 million and $7.2 million of federal and state research and development credit carryforwards, respectively, that expire at various dates through 2040. Included in the $34.2 million of federal research and development credit carryforwards is $29.0 million of orphan drug credit carryforwards. The valuation allowance increased in 2020 and 2019 by $47.2 million and $40.2 million, respectively, due to the increase in the deferred tax assets by the same amounts, primarily due to the net operating loss carryforwards and research and development tax credits not utilized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all years through December&#160;31, 2020, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards. Since a full valuation allowance has been provided against the Company&#8217;s research and development credits, any reduction in the gross deferred tax asset established for the research and development credit carryforwards would not result in any net impact to the Company&#8217;s consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect a change in control would have, if any, on the Company&#8217;s ability to utilize its net operating loss and research and development credit carryforwards in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files tax returns in the United States and Massachusetts. All tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> uncertain tax positions. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> interest or penalties were recorded for the years ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899727720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. STOCKHOLDERS&#8217; EQUITY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock<span style="font-weight:normal;">&#8212;Voting, dividend and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting<span style="font-style:normal;">&#8212;Each holder of outstanding shares of common stock are entitled to one vote in respect of each share. The holders of outstanding shares of common stock, voting together as a single class, shall be entitled to elect one director. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of a majority of the outstanding shares of common stock and preferred stock voting together as a single class. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends<span style="font-style:normal;">&#8212;Subject to the payment in full of any preferential dividends to which the holders of preferred stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available therefore at such times and in such amounts as the Board of Directors may determine in its sole discretion. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation Rights<span style="font-style:normal;">&#8212;In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and any preferential amounts to which the holders of preferred stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were 50,265,575 and 45,116,742 shares of common stock outstanding at December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock<span style="font-weight:normal;">&#8212;As of December 31, 2020 and 2019, there were no shares of preferred stock issued and outstanding.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895206488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">STOCK INCENTIVE PLANS</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12. STOCK INCENTIVE PLANS</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2015 Stock Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, the Company&#8217;s Board of Directors adopted the 2015 Stock Incentive Plan (the &#8220;2015 Plan&#8221;), which provided for the grant of qualified incentive and nonqualified stock options or restricted stock awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants. Stock options generally vest over a <span style="-sec-ix-hidden:F_000521">four-year</span> period and expire ten years from the date of grant. Certain options provide for accelerated vesting if there is a change in control, as defined in the 2015 Plan. At December&#160;31, 2020, there were no additional shares available for future grant under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2018 Incentive Award Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company&#8217;s Board of Directors adopted and the Company&#8217;s stockholders approved the Homology Medicines, Inc. 2018 Incentive Award Plan (the &#8220;2018 Plan&#8221; and, together with the 2015 Plan, the &#8220;Plans&#8221;), which became effective on the day prior to the first public trading date of the Company&#8217;s common stock. Upon effectiveness of the 2018 Plan, the Company ceased granting new awards under the 2015 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2018 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock or cash-based awards to employees and consultants of the Company and certain affiliates and directors of the Company. The number of shares of common stock initially available for issuance under the 2018 Plan was 3,186,205 shares of common stock plus the number of shares subject to awards outstanding under the 2015 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company on or after the effective date of the 2018 Plan. In addition, the number of shares of common stock available for issuance under the 2018 Plan is subject to an annual increase on the first day of each calendar year beginning on January&#160;1, 2019 and ending on and including January&#160;1, 2028 equal to the lesser of (i) 4% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s Board of Directors, provided that not more than 20,887,347 shares of common stock may be issued under the 2018 Plan upon the exercise of incentive stock options (the &#8220;Evergreen Provision&#8221;). As of December&#160;31, 2020, there were 2,397,547 shares available for future grant under the 2018 Plan. On January 1, 2021, pursuant to the Evergreen Provision, an additional 2,010,623 shares were added to the 2018 Plan, representing 4% of total common shares outstanding at December 31, 2020.</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2018 Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2018, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved, the Homology Medicines, Inc. 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;). The 2018 ESPP allows employees to buy Company stock through after-tax payroll deductions at a discount from market value. The 2018 ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Internal Revenue Code. The number of shares of common stock initially available for issuance under the 2018 ESPP was 353,980 shares of common stock plus an annual increase on the first day of each calendar year beginning on January 1, 2019 and ending on and including January 1, 2028 equal to the lesser of (i) 1% of the Company&#8217;s outstanding shares of common stock on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Company&#8217;s Board of Directors, provided that not more than 4,778,738 shares of common stock may be issued under the 2018 ESPP (the &#8220;ESPP Evergreen Provision&#8221;). At December&#160;31, 2020, there were 1,039,650 shares available for future issuance under the 2018 ESPP. On January 1, 2021, pursuant to the ESPP Evergreen Provision, an additional 502,655 shares were added to the 2018 ESPP, representing 1% of total common shares outstanding at December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2018 ESPP, employees may purchase common stock through after-tax payroll deductions at a price equal to 85% of the lower of the fair market value on the first trading day of an offering period or the last trading day of an offering period. The 2018 ESPP generally provides for offering periods of six months in duration that end on the final trading day of each February and August. In accordance with the Internal Revenue Code, no employee will be permitted to accrue the right to purchase stock under the 2018 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of the Company&#8217;s common stock as of the first day of the offering period).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December&#160;31, 2020, 83,848 shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $0.9 million. During the year ended December&#160;31, 2019, 55,234 shares were issued under the 2018 ESPP for aggregate proceeds to the Company of $0.8 million. Pursuant to the 2018 ESPP, the Company recorded stock-based compensation of $0.2 million and $0.2 million for the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award, which is generally the vesting period. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model, with the assumptions noted in the table below. Expected volatility for the Company&#8217;s common stock was determined based on an average of the historical volatility of a peer group of publicly traded companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the options was used for the expected term of options granted to non-employees. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods commensurate with the expected term of the award. The Company recognizes forfeitures as they occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in the Black-Scholes option pricing model are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.2% &#8212; 66.3%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.4% &#8212; 64.7%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.73%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36% &#8212; 2.60%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underlying common stock fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.82 - $21.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.73 &#8212; $30.34</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense related to stock options and shares purchased under the 2018 ESPP as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,390</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,164</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,858</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,248</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,635</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, there was $29.2 million of unrecognized compensation expense related to unvested employee and non-employee share-based compensation arrangements granted under the Plans. The unrecognized compensation expense is estimated to be recognized over a period of 2.4 years at December&#160;31, 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of option activity under the Plans during the year ended December&#160;31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843,018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.78</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000581">8.5</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,809</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(266,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000582">7.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000583">7.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,278</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,869,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of options exercised during the year ended December&#160;31, 2020 and 2019 was $0.6 million and $1.9 million, respectively. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and 2019 was $10.39 and $12.90, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted pursuant to the 2015 Plan permit option holders to elect to exercise unvested options in exchange for unvested common stock. Options granted under the 2015 Plan that are exercised prior to vesting will continue to vest according to the respective option agreement, and such unvested shares are subject to repurchase by the Company at the optionee&#8217;s original exercise price in the event the optionee&#8217;s service with the Company voluntarily or involuntarily terminates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested common stock from early exercises that is subject to repurchase by the Company is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,666</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 and 2019, 3,091 shares and 21,666 shares, respectively, remained subject to a repurchase right by the Company, with a related liability included in accrued expenses and other liabilities in the consolidated balance sheets of less than $0.1 million as of each date. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031892212056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. NET LOSS PER SHARE</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s potential dilutive securities, which include unvested common stock from the early-exercise of stock options and outstanding common stock options, have been excluded from the computation of diluted net loss per share as the </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested common stock from early exercise of options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,666</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843,018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,843,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,864,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031891928520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">DEFINED CONTRIBUTION PLAN</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. DEFINED CONTRIBUTION PLAN </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for all of its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits, while the Company contributes to the plan at the discretion of the Board of Directors. The Company&#8217;s discretionary match made under the 401(k) Plan for the years ended December&#160;31, 2020 and 2019 was $0.7 million and $0.5 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893718792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AND LICENSE AGREEMENT</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15. COLLABORATION AND LICENSE AGREEMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a collaboration and license agreement with Novartis (as amended, the &#8220;Collaboration Agreement&#8221;) for the research, development, manufacturing and commercialization of products using the Company&#8217;s gene-editing technology for the treatment of certain ophthalmic targets and sickle cell disease. In February 2019, Novartis elected to discontinue the sickle cell disease program under the Collaboration Agreement effective in August 2019. In May 2020, Novartis confirmed an ophthalmic target for a therapeutic editing program. Additionally, in accordance with the terms of the Collaboration Agreement, Novartis&#8217; right to substitute other ophthalmic targets expired. For additional information on the Collaboration Agreement, please refer to Note 17.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Collaboration Agreement, the Company granted Novartis a research license, a development and commercialization license, and a manufacturing license, under certain of its intellectual property rights to research, develop, manufacture and commercialize ophthalmic targets. Upon entering into the Collaboration Agreement in November 2017, the Company received an upfront, nonrefundable payment of $35.0&#160;million and issued additional shares of its Series B preferred stock to Novartis for consideration of $10.0&#160;million, in addition to the $5.0 million of Series B preferred stock Novartis had purchased in July 2017. The Company recorded the November 2017 issuance of Series B preferred stock at its estimated fair value of $11.7 million, including $1.7 million of the upfront payment, and allocated the remaining $33.3 million of the upfront payment to the Collaboration Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Collaboration Agreement consists of a research term, where the Company and Novartis were collaborating to perform research and conduct preclinical development to identify candidates that modulate ophthalmic targets. The Collaboration Agreement also includes exploratory work on the applicability of the gene editing technology with respect to other gene targets. The Company&#8217;s obligation to perform such exploratory research was extended pursuant an amendment to the Collaboration Agreement was set to conclude in May 2021. The Company was responsible for the manufacturing of proprietary research grade human hematopoietic stem cell derived adeno-associated virus vectors (&#8220;AAVHSCs&#8221;) during the research term. Novartis agreed to reimburse research activities performed by the Company at a full-time equivalent rate (&#8220;FTE&#8221;) and manufacturing activities at cost, up to a maximum of $17.0 million during the research term, as specified and defined in the Collaboration Agreement. Novartis agreed to pay the Company a target fee of $5.0&#160;million if the target meets certain success criteria during the research term (the &#8220;target fee trigger date&#8221;). The research term was to continue for five years from the effective date of the Collaboration Agreement. Pursuant to the Collaboration Agreement, the Company also agreed to participate on a joint steering committee and a joint manufacturing subcommittee, with equal representation from both the Company and Novartis. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Novartis had the exclusive right to develop and commercialize one ophthalmic candidate or product arising from the research activities. Subject to certain limitations pursuant to the terms of the Collaboration Agreement, Novartis agreed to fund all development and commercialization costs. The Company was responsible for manufacturing candidates and products for Novartis during the development and commercialization terms. The Company&#8217;s manufacturing activities were to be reimbursed at cost during the development term and at cost plus a margin during the commercialization term, as defined in the Collaboration Agreement. If the Company was not able to manufacture candidates or products that met the quality or quantity requirements of Novartis, then Novartis would have had the right to designate a third-party contract manufacturer or manufacture such candidates or products itself. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Collaboration Agreement, taking into consideration Novartis&#8217; election to discontinue the sickle cell disease program, and the expiration of Novartis&#8217; rights to make substitutions of an ophthalmic target, the Company was also eligible to receive up to a total of $265.0&#160;million in milestone payments, including up to $90.0 million in development milestone payments, up to $85.0 million in regulatory milestone payments and up to $90.0 million in commercial milestone payments, with respect to the licensed products. The Company was also eligible to earn tiered royalties on net sales of licensed products by Novartis, its affiliates or sublicensees, ranging from mid-single-digit, to sub-teen double-digit percentages, and such royalties were potentially subject to various reductions and offsets. If any of the exploratory research efforts were advanced into formal research and development programs, the parties agreed to negotiate the economics including potential milestone payments for such programs at that time.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the (1) research, development and commercialization and manufacturing licenses, (2) the research activities performed by the Company (3) service on the joint committees and (4) manufacturing during the research and development terms represented a single performance obligation under the Collaboration Agreement. Since the option for Novartis to obtain manufacturing during the commercialization term from the Company is at a price that would reflect the standalone selling price, the option does not provide Novartis with a material right and is therefore not a performance obligation under the contract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded that the research, development and commercialization and manufacturing licenses are not distinct from the research activities and manufacturing during the research and development term as Novartis cannot benefit from the licenses without the Company performing the research and manufacturing services. These services are so specialized and rely on the Company&#8217;s expertise in gene editing technologies not available in the marketplace. As a result, these licenses have been combined with the research activities, service on the joint committees and the manufacturing during the research and development terms as a single performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price consists of the $33.3 million non-refundable upfront payment, net of amounts classified as equity, and projected reimbursable research and manufacturing activities, which have been estimated using the expected value method. None of the target fees or development and regulatory milestone payments have been included in the transaction price, as all are fully constrained. As part of the evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones is outside of the Company&#8217;s control and is contingent upon the success of the Company&#8217;s preclinical studies, clinical trials, Novartis&#8217; efforts and the receipt of regulatory approval. In addition, the Company has determined that the commercial milestones and sales-based royalties will be recognized when the related sales occur as they were determined to relate predominately to the licenses transferred to Novartis, and therefore have also been excluded from the transaction price. The Company will re-evaluate the transaction price, including estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified only one performance obligation in the Collaboration Agreement. Therefore, the Company allocated the transaction price at the onset of the contract to the single performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue over time using a cost-to-cost method, which it believes best depicts the transfer of control to the customer. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded over the performance period as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2020, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $30.2 million, and the Company will recognize this revenue as the research and manufacturing activities are performed, which was expected to occur over a period of time that was estimated to conclude in 2027. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In estimating the total costs to satisfy its single performance obligation pursuant to the Novartis agreement, the Company is required to make significant estimates including the expected time it will take to fulfill the performance obligation, which, as of December 31, 2020, was expected to be approximately ten years from the date the Collaboration Agreement was entered into, and the expected costs associated with manufacturing during the research and development terms for a novel manufacturing process as well as the probability of success of a target to move into the development phase. The Company has made estimates of such costs utilizing its experience with similar product candidates, however not identical to those in the Collaboration Agreement. In making such estimates, significant judgment is required to evaluate those key assumptions related to cost estimates. The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s reported cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2020 and 2019, the Company recognized revenue under the Collaboration Agreement of $2.3 million and $1.7 million, respectively, of which $0.8 million and $0.6 million was included in deferred revenue at the beginning of each such period. As of December&#160;31, 2020 and 2019, there was approximately $30.2 million and $31.0 million of deferred revenue related to the Collaboration Agreement, respectively. In addition, as of December&#160;31, 2020 and 2019, the Company has recorded accounts receivable of $0.4 million, related to reimbursable research and development costs under the Collaboration Agreement, which are included in prepaid expenses and other current assets on the consolidated balance sheets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893515288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pfizer Stock Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockPurchaseAgreementDisclosureTextBlock', window );">PFIZER STOCK PURCHASE AGREEMENT</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16. PFIZER STOCK PURCHASE AGREEMENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 9, 2020,<span style="color:#000000;"> the Company entered into a common stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Pfizer Inc.</span> <span style="color:#000000;">(&#8220;Pfizer&#8221;), pursuant to which the Company agreed to issue and sell to Pfizer 5,000,000 shares of the Company&#8217;s common stock through a private placement transaction (the &#8220;Private Placement&#8221;) at a purchase price of $12.00 per share, for an aggregate purchase price of $60.0 million. The shares of common stock sold to Pfizer are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Stock Purchase Agreement, Pfizer was granted an exclusive right of first refusal (the &#8220;ROFR&#8221;) <span style="color:#000000;">for a 30-month period (the &#8220;ROFR Period&#8221;) beginning on the date of the closing of the Private Placement (collectively, the &#8220;ROFR Provision&#8221;), to negotiate a potential collaboration on the development and commercialization of HMI-102 and HMI-103.</span> Pfizer may exercise its right of first refusal under the ROFR Provision one time for each of HMI-102 and HMI-103 during the ROFR period. In addition to the ROFR, the Stock Purchase Agreement provides for an information sharing committee (the &#8220;Information Committee&#8221;), comprised of representatives of each company which will serve as a forum for sharing information regarding the development of <span style="color:#000000;">HMI-102 and HMI-103 </span>during the ROFR Period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded the issuance of common stock at its estimated fair value of $52.0 million, which reflects a discount for the lack of marketability of the shares. The remaining $8.0 million of aggregate purchase price was allocated to the other elements of the Stock Purchase Agreement, which represent a contract with a customer. The Company concluded that the Information Committee represents the only performance obligation under the contract. The ROFR does not provide Pfizer with a material right and is therefore not a performance obligation. As such, the Company allocated the $8.0 million to the Information Committee obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will recognize revenue over time as the measure of progress which it believes best depicts the transfer of control to Pfizer. The Information Committee will meet regularly over the ROFR Period to share information which results in recognition of the transaction price over the 30-month ROFR Period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized collaboration of $0.4 million, and as of December 31, 2020, there was approximately $7.6 million of deferred revenue related to the Company&#8217;s obligation to Pfizer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_StockPurchaseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_StockPurchaseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893693224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17. SUBSEQUENT EVENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.79%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 26, 2021, Homology received notice from Novartis that they had elected to terminate the Collaboration Agreement with the Company, with respect to the remaining ophthalmic target under the Collaboration Agreement. Accordingly, the notice served as notice of Novartis&#8217; termination of the Collaboration Agreement in its entirety, which will be effective on August 26, 2021. As a result of the termination of the Collaboration Agreement, Homology regained worldwide exclusive rights from Novartis to research, develop, manufacture and commercialize Homology&#8217;s proprietary nuclease-free gene editing technology platform for an ophthalmic target (see Note 15). Homology announced its plans to continue to advance the program toward naming a development candidate. The Company and Novartis believe that results of studies conducted </p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> C</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ollaboration </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide early proof-of-principle and support a nuclease-independent approach to editing of relevant cell types in the eye after sub-retinal</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">injection, and are the subject of a planned presentation at an upcoming scientific meeting</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031898733096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation<span style="font-weight:normal;">&#8212;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) </span><span style="Background-color:#FFFFFF;font-weight:normal;">and have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business</span><span style="font-weight:normal;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of Consolidation<span style="font-weight:normal;">&#8212;The Company&#8217;s consolidated financial statements include the accounts of the Company and its subsidiary, Homology Medicines Securities Corporation, a wholly owned Massachusetts corporation, for the sole purpose of buying, selling, and holding securities on the Company&#8217;s behalf. All intercompany balances and transactions have been eliminated in the consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates<span style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive Income (Loss) &#8212;<span style="font-weight:normal;">Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company&#8217;s only element of other comprehensive income (loss) is unrealized gains and losses on available-for-sale investments. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents and Restricted Cash<span style="font-weight:normal;">&#8212;Cash and cash equivalents consist of standard checking accounts, money market accounts and certain investments. The Company considers all highly liquid investments with original or remaining maturities at the time of purchase of 90 days or less to be cash equivalents. Restricted cash consists of cash serving as collateral for letters of credit issued for security deposits for the Company&#8217;s facility leases in Bedford, Massachusetts.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,774</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,705</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,048</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.79%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-Term Investments</a></td>
<td class="text">Short-Term Investments<span style="font-weight:normal;">&#8212;Short-term investments represent holdings of available-for-sale marketable securities in accordance with the Company&#8217;s investment policy and cash management strategy. Short-term investments have maturities of greater than 90 days at the time of purchase and mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses, reported within accumulated other comprehensive income as a separate component of stockholders&#8217; equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the underlying security. Such amortization and accretion, together with interest on securities, are included in interest income in the Company&#8217;s consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</span><span style="font-weight:normal;">&#8212;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and short-term investments. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. We believe that we are not exposed to significant credit risk as our deposits are held at financial institutions that management believes to be of high credit quality and the Company has not experienced any losses on these deposits. We regularly invest excess cash with major financial institutions in money market funds, U.S. government and corporate debt securities and commercial paper, all of which can be readily purchased and sold using established markets. As of </span><span style="font-weight:normal;">December&#160;31, 2020</span><span style="font-weight:normal;">, the Company&#8217;s cash and cash equivalents were held with two financial institutions. We believe that the market risk arising from our holdings of these financial instruments is mitigated based on the fact that many of these securities are either government</span><span style="font-weight:normal;">-</span><span style="font-weight:normal;">backed or of high credit rating.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Offering Costs<span style="font-weight:normal;">&#8212;The Company capitalizes incremental legal, professional accounting and other third-party fees that are directly associated with equity financings as other current assets until the transactions are completed. After equity financings are complete, these costs are recorded in stockholders&#8217; equity as a reduction of additional paid-in capital generated as a result of the offering.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="font-weight:normal;">&#8212;</span><span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842) (&#8220;ASU 2016-02&#8221;), which eliminated the tests for lease classification under prior U.S. GAAP and requires lessees to recognize right-of-use assets and related lease liabilities on the balance sheet. The FASB subsequently issued the following amendments to ASU 2016-02 that have the same effective date and transition date: ASU No. 2018-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Land Easement Practical Expedient for Transition to Topic 842</span><span style="font-weight:normal;">, ASU No. 2018-10 &#8211; </span><span style="font-style:italic;font-weight:normal;">Codification Improvements to Topic </span><span style="font-weight:normal;">842</span><span style="font-style:italic;font-weight:normal;">, Leases</span><span style="font-weight:normal;">, ASU No. 2018-11 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Targeted Improvements</span><span style="font-weight:normal;">, ASU No. 2018-20 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases </span><span style="font-weight:normal;">(Topic 842): </span><span style="font-style:italic;font-weight:normal;">Narrow-Scope Improvements for Lessors</span><span style="font-weight:normal;">, and ASU No. 2019-01 &#8211; </span><span style="font-style:italic;font-weight:normal;">Leases</span><span style="font-weight:normal;"> (Topic 842): </span><span style="font-style:italic;font-weight:normal;">Codification Improvements</span><span style="font-weight:normal;">. The Company adopted these amendments with ASU 2016-02 (collectively, the new leasing standards) effective January 1, 2020.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the new leasing standards using the modified retrospective approach, as of January 1, 2020, with no restatement of prior periods or cumulative adjustments to accumulated deficit. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. In addition, the Company elected the practical expedient not to apply the recognition requirements in the leasing standards to short-term leases (a lease that at commencement date has a lease term of 12 months or less and does not contain a purchase option that it is reasonably certain to exercise) and the practical expedient that permits lessees to make an accounting policy election (by class of underlying asset) to not separate lease components of a contract from non-lease components.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at contract inception. The Company&#8217;s contracts are determined to contain a lease when all of the following criteria based on the specific circumstances of the arrangement are met: (1) there is an identified asset for which there are no substantive substitution rights; (2) the Company has the right to obtain substantially all of the economic benefits from the identified asset; and (3) the Company has the right to direct the use of the identified asset.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the commencement date, operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company&#8217;s lease agreements do not provide an implicit rate. As a result, the Company utilizes an estimated incremental borrowing rate to discount lease payments, which is based on the rate of interest the Company would have to pay to borrow a similar amount on a collateralized basis over a similar term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or lease incentives received. Operating lease cost is recognized over the expected term on a straight-line basis. Variable lease cost is recognized as incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company acts as sublessor related to a sublease of the Company's former headquarters. Fixed sublease payments received are recognized on a straight-line basis over the sublease term. Right-of-use assets are periodically evaluated for impairment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected lease term for those leases commencing prior to January 1, 2020 did not change with the adoption of the new leasing standards. The expected lease term for leases commencing after the adoption of the new leasing standards includes noncancelable lease periods and, when applicable, periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, as well as periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the adoption of the new leasing standards, on January 1, 2020, the Company recorded non-cash transactions to recognize a right-of-use asset of $6.8 million, operating lease liabilities of $17.7 million and the derecognition of deferred rent of $10.9 million originally accounted for under legacy guidance. The adoption did not have a material impact on the condensed consolidated statement of operations. For additional information on the adoption of the new leasing standards, refer to Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets (1)(2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent (2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion (3)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Represents capitalization of operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Represents recognition of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Guarantees and Indemnifications</a></td>
<td class="text">Guarantees and Indemnifications<span style="font-weight:normal;">&#8212;As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through December&#160;31, 2020, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment<span style="font-weight:normal;">&#8212;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are derecognized from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and office furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000332">5 - 7 years</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000334">Shorter of the lease term</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or estimated useful life</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived Assets<span style="font-weight:normal;">&#8212;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have been recognized for these assets.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Costs<span style="font-weight:normal;">&#8212;Research and development costs are charged to expense as incurred. Research and development expense consists of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical and clinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. </p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes<span style="font-weight:normal;">&#8212;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span> Since inception, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the net deferred tax assets has not been determined to be more likely than not.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Segment Information<span style="font-weight:normal;">&#8212;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s singular focus is dedicated to translating proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. All of the Company&#8217;s tangible assets are held in the United States. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212;<span style="font-size:12pt;font-weight:normal;"> </span><span style="font-weight:normal;">Revenue is recognized in accordance with FASB Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="font-style:italic;font-weight:normal;">Revenue from Contracts with Customers</span><span style="font-weight:normal;"> (&#8220;ASC 606&#8221;). On January 1, 2019, the Company adopted ASC 606 using the full retrospective transition method.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promised goods or services in the Company&#8217;s arrangements would likely consist of a license, rights to the Company&#8217;s intellectual property or research, development and manufacturing services. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration and variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of consideration to which the Company expects to be entitled to. The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration that is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s contracts may include development and regulatory milestone payments that are assessed under the most likely amount method and constrained until it is probable that a significant revenue reversal would not occur. Milestone payments that are not within the Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development and regulatory milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenue in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from the Company&#8217;s collaboration arrangement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocates the transaction price based on the estimated standalone selling price of each performance obligation. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress for its over-time arrangements at each reporting period and, if necessary, updates the measure of progress and revenue recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation<span style="font-weight:normal;">&#8212;The Company recognizes compensation expense for awards to employees based on the grant date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company&#8217;s estimates of these assumptions are primarily based on the trading price of the Company&#8217;s stock, historical data, peer company data and judgment regarding future trends and factors. Stock-based awards granted to nonemployees are initially recorded at fair value and are re-measured at each reporting period as the awards vest and expense is recognized over the period the services are provided. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price of common stock under the Company&#8217;s employee stock purchase plan (&#8220;ESPP&#8221;) is equal to 85% of the lesser of (i) the fair market value per share of the common stock on the first business day of an offering period and (ii) the fair market value per share of the common stock on the purchase date. The fair value of the look-back provision under the ESPP is calculated using the Black-Scholes option pricing model. The fair value of the look-back provision plus the 15% discount is recognized as compensation expense over the 180-day purchase period. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements<span style="font-weight:normal;">&#8212;Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;1&#8212;Quoted prices (unadjusted) in active markets for identical assets or liabilities. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.79%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;color:#000000;">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss per Share<span style="font-weight:normal;">&#8212;Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and unvested shares of common stock.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements<span style="font-weight:normal;">&#8212;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an emerging growth company, the Company has elected to take advantage of this extended transition period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued new leasing standards to increase transparency and comparability among organization related to their leasing activities. For additional information on the adoption of the new leasing standards, please refer to section titled &#8220;Leases&#8221; above, and Note 8.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span> (&#8220;ASU 2016-13&#8221;) to improve financial reporting by requiring more timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization&#8217;s portfolio. ASU 2016-13 is effective for the Company beginning January 1, 2023, with early application permitted. The Company is currently evaluating the impact the adoption of this standard will have on its consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued ASU No. 2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</span> (&#8220;ASU 2018-07&#8221;)<span style="font-style:italic;">,</span> which changes certain aspects of the accounting for share-based payments granted to nonemployees. Under ASU 2018-07, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The Company adopted ASU 2018-07 on January 1, 2020. The adoption of ASU 2018-07 did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued ASU 2020-10, <span style="font-style:italic;">Codification Improvements</span>, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC&#8217;s regulations. The Company will adopt ASU 2020-10 as of the reporting period beginning January 1, 2021. The adoption of this update is not expected to have a material effect on the Company&#8217;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899974232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,774</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,274</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:63.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,705</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,048</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock', window );">Impact of Adoption of Previously Reported Amounts of Financial Statement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.28%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">January 1, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.32%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prior to adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Adjustment for</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adoption</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of new leasing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">standards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As Adjusted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets (1)(2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,835</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent (2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,313</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, net of current portion (3)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,441</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.32%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.16%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Represents capitalization of operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="12" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3) Represents recognition of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock', window );">Schedule of Estimated Useful Life of Asset</a></td>
<td class="text">
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment and office furniture</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000332">5 - 7 years</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.42%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.14%;" valign="top"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000334">Shorter of the lease term</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or estimated useful life</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, plant and equipment estmated useful life of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the comparison between amounts disclosed under previous guidance and new guidance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031977312744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s cash and cash equivalents: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,431</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,774</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031898854584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_InvestmentsDisclosureAbstract', window );"><strong>Investments Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Short Term Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s short-term investments as of December 31, 2019:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,866</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,926</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,380</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;Total short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,431</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_InvestmentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_InvestmentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893664936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets measured at fair value on a recurring basis were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,181</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted&#160;Prices (Unadjusted) in Active&#160;Markets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Identical</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level&#160;1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.84%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase agreements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term investments:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,876</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,259</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Treasury securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,971</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,508</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208,614</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,138</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,524</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,614</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031989083096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consists of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,703</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,754</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and purchased software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,596</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,862</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet in service</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,513</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, at cost</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,377</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,126</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,002</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,716</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893683208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and benefits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,258</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued unvested common stock subject to repurchase</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893743496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes operating lease costs and variable lease costs, as well as sublease income for the year ended December&#160;31, 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,492</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.86%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(913</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net lease cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.86%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,934</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturities of our operating lease liabilities as of December&#160;31, 2020 were as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ending December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,834</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,987</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,077</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,169</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,822</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,442</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Lease Term and Discount Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the lease term and discount rate as of December&#160;31, 2020:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000454">5.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock', window );">Schedule of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.07%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the supplemental cash flow information related to the Company's operating leases for the year ended December&#160;31, 2020.</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:83.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:83.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.62%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,804</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease term and discount rate table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease liabilities table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893691576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation between the U.S. federal statutory tax rate and the Company&#8217;s effective tax rate is summarized as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years&#160;Ended&#160;December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal tax benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The principal components of the Company&#8217;s deferred tax assets and liabilities consist of the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,838</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&amp;D credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,888</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,328</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,456</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized R&amp;D costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,207</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,368</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">883</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expense and other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,914</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,517</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,537</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,726</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,744</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,034</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(77,793</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895962776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used in the Black-Scholes option pricing model are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.6%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.2% &#8212; 66.3%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.4% &#8212; 64.7%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31% &#8212; 1.73%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.36% &#8212; 2.60%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5 - 6.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Underlying common stock fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.82 - $21.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$12.73 &#8212; $30.34</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense related to stock options and shares purchased under the 2018 ESPP as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,390</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,164</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,858</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,248</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,635</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity under Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of option activity under the Plans during the year ended December&#160;31, 2020 is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term (in Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843,018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.78</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000581">8.5</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,809</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,311,200</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.82</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(266,984</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000582">7.8</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.18</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000583">7.8</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,278</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,869,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000584">7.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,803</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock', window );">Summary of Unvested Common Stock from Early Exercises Subject to Repurchase</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.79%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested common stock from early exercises that is subject to repurchase by the Company is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;January 1, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,666</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchased</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested shares&#8212;December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of unvested common stock from early exercises subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899898760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company excluded the following potential common shares, presented based on amounts outstanding at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</span>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested common stock from early exercise of options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,666</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,840,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,843,018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,843,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,864,684</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896092296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Mar. 12, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Apr. 12, 2019</div></th>
<th class="th"><div>Apr. 02, 2018</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon initial public offering, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,168,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common Stock, capacity terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,694<span></span>
</td>
<td class="nump">103,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,368<span></span>
</td>
<td class="nump">$ 199,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock at a public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering after underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_FollowOnOfferingMember', window );">Follow On Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,555,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,388,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after deducting underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_UnderwritersOptionMember', window );">Underwriters Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after deducting underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_AtTheMarketSalesAgreementMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ProceedsFromFutureIssuanceStock', window );">Proceeds through future financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_AtTheMarketSalesAgreementMember', window );">ATM | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ProceedsFromFutureIssuanceStock', window );">Proceeds through future financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_AtTheMarketSalesAgreementMember', window );">ATM | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ProceedsFromFutureIssuanceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from future issuance stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ProceedsFromFutureIssuanceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fixx_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_UnderwritersOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fixx_UnderwritersOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fixx_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fixx_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896575400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 217,431<span></span>
</td>
<td class="nump">$ 53,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 218,705<span></span>
</td>
<td class="nump">$ 55,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895090120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,897,000<span></span>
</td>
<td class="nump">$ 6,835,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,442,000<span></span>
</td>
<td class="nump">2,251,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Outstanding claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Tax positions, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage', window );">Purchase of common stock through payroll deductions expressed in percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Share based compensation, discount from market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod', window );">Share based compensation arrangement by share based payment purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents capitalization of operating right-of-use assets</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 15<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877542&amp;loc=d3e27249-109313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899997944">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,897<span></span>
</td>
<td class="nump">$ 6,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,442<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember', window );">Prior to Adoption of New Leasing Standards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,544<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember', window );">Adjustment for Adoption of New Leasing Standards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,544)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents capitalization of operating right-of-use assets</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents reclassification of deferred rent and incentives as a reduction to operating right-of-use assets</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_NewAccountingPronouncementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031894980952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory Equipment and Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of asset</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life of asset, term</a></td>
<td class="text">Shorter of the lease term
or estimated useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031985610728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 217,431<span></span>
</td>
<td class="nump">$ 53,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 217,181<span></span>
</td>
<td class="nump">39,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_RepurchaseAgreementsMember', window );">Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash And Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893676264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract', window );"><strong>Cash Cash Equivalents And Available For Sale Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 208,614,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Realized gains and losses on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_InvestmentMaturityTerm', window );">Contractual maturity date of investments</a></td>
<td class="text">Less than one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents, and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_InvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_InvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031985725848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Short Term Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and short-term investments, Amortized Cost</a></td>
<td class="nump">$ 208,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and short-term investments, Unrealized Gains</a></td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Cash equivalents and short-term investments, Fair Value</a></td>
<td class="nump">208,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and short-term investments, Amortized Cost</a></td>
<td class="nump">41,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Cash equivalents and short-term investments, Fair Value</a></td>
<td class="nump">41,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and short-term investments, Amortized Cost</a></td>
<td class="nump">14,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and short-term investments, Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Cash equivalents and short-term investments, Fair Value</a></td>
<td class="nump">14,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and short-term investments, Amortized Cost</a></td>
<td class="nump">59,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and short-term investments, Unrealized Gains</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Cash equivalents and short-term investments, Fair Value</a></td>
<td class="nump">59,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and short-term investments, Amortized Cost</a></td>
<td class="nump">92,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and short-term investments, Unrealized Gains</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Cash equivalents and short-term investments, Fair Value</a></td>
<td class="nump">$ 92,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents and available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031887624744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 208,614,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,524,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">217,181,000<span></span>
</td>
<td class="nump">262,138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,614,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">217,181,000<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="nump">217,181,000<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,876,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,259,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,259,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,971,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices (Unadjusted) in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="nump">217,181,000<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices (Unadjusted) in Active Markets for Identical Assets (Level 1) | Money Market Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="nump">217,181,000<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="nump">$ 217,181,000<span></span>
</td>
<td class="nump">39,524,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,614,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,614,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,876,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,259,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,259,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,508,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,971,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893688520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_FairValueAssetsLiabilitiesTransferBetweenLevels', window );">Transfers between fair value measure levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_FairValueAssetsLiabilitiesTransferBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets (liabilities) transfer between levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_FairValueAssetsLiabilitiesTransferBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896094072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 53,377<span></span>
</td>
<td class="nump">$ 51,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(16,375)<span></span>
</td>
<td class="num">(8,410)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,002<span></span>
</td>
<td class="nump">42,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">12,703<span></span>
</td>
<td class="nump">10,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">7,754<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and Purchased Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 29,961<span></span>
</td>
<td class="nump">30,862<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_AssetNotYetInServiceMember', window );">Assets Not Yet in Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_AssetNotYetInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fixx_AssetNotYetInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031894701512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 7,965<span></span>
</td>
<td class="nump">$ 6,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property and equipment</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031899444216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">$ 6,902<span></span>
</td>
<td class="nump">$ 4,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">2,393<span></span>
</td>
<td class="nump">2,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent', window );">Accrued unvested common stock subject to repurchase</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other liabilities</a></td>
<td class="nump">$ 9,803<span></span>
</td>
<td class="nump">$ 7,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued unvested common stock subject to repurchase current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895951064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>ft&#178; </div>
<div>Phase </div>
<div>$ / ft&#178;</div>
</th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=fixx_LettersOfCreditAndSecuredByRestrictedCashMember', window );">Letters of Credit and Secured by Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_TenantImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fixx_BedfordMassachusettsMember', window );">Bedford, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LeaseBeginningDateYearAndMonth', window );">Operating lease beginning year and month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LeaseExpirationDateYearAndMonth', window );">Operating lease expiration year and month</a></td>
<td class="text">2027-02<span></span>
</td>
<td class="text">2021-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease agreements additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_SubleaseAggregateBaseRentObligation', window );">Sublease aggregate base rent obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space leased | ft&#178;</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lessee, operating lease, lease not yet commenced, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_NumberOfPhases', window );">Number of phases | Phase</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_InitialBaseRentPerSquareFeet', window );">Initial annual base rent per square foot | $ / ft&#178;</a></td>
<td class="nump">39.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent', window );">Percentage increase in initial annual base rent per square foot.</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fixx_BedfordMassachusettsMember', window );">Bedford, Massachusetts | Phase One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space leased | ft&#178;</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_RentStartDateYearAndMonth', window );">Rent due date</a></td>
<td class="text">2018-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=fixx_BedfordMassachusettsMember', window );">Bedford, Massachusetts | Phase Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space leased | ft&#178;</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_RentStartDateYearAndMonth', window );">Rent due date</a></td>
<td class="text">2019-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_InitialBaseRentPerSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial base rent per square feet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_InitialBaseRentPerSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LeaseBeginningDateYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease beginning date year and month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LeaseBeginningDateYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LeaseExpirationDateYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration date year and month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LeaseExpirationDateYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease not yet commenced increase in percentage of base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_NumberOfPhases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of phases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_NumberOfPhases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_RentStartDateYearAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent start date year and month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_RentStartDateYearAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_SubleaseAggregateBaseRentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease aggregate base rent obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_SubleaseAggregateBaseRentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_TenantImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant improvements allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_TenantImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=fixx_LettersOfCreditAndSecuredByRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=fixx_LettersOfCreditAndSecuredByRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=fixx_BedfordMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=fixx_BedfordMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=fixx_PhaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=fixx_PhaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=fixx_PhaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=fixx_PhaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031891927400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">2,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(913)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 3,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896139736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 3,834<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,987<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,077<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,169<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7,197<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">20,264<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,822)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 15,442<span></span>
</td>
<td colspan="2" class="nump">$ 2,251<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents recognition of operating lease liabilities</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031892285208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years), Operating leases</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">9.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893672040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Cash Paid for Company's Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 3,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031895232936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,392,000<span></span>
</td>
<td class="nump">$ 89,398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_CityOfHopeMember', window );">City of Hope</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AnnualLicenseFeePayable', window );">Annual license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementPaymentForExecutionOfAgreements', window );">Payment for execution of agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_CityOfHopeMember', window );">City of Hope | Sponsored Research Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_CityOfHopeMember', window );">City of Hope | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_DevelopmentAndCommercializationMilestonePayments', window );">Development and commercialization milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_CaliforniaInstituteOfTechnologyMember', window );">California Institute Of Technology | Maximum | Co Exclusive License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_DevelopmentAndRegulatoryMilestonePayment', window );">Development and regulatory milestone payments</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_CaliforniaInstituteOfTechnologyMember', window );">California Institute Of Technology | Minimum | Co Exclusive License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_LicenseAgreementLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual minimal royalty fee</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AnnualLicenseFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AnnualLicenseFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementPaymentForExecutionOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement payment for execution of agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementPaymentForExecutionOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_DevelopmentAndCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and commercialization milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_DevelopmentAndCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_DevelopmentAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development and regulatory milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_DevelopmentAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_LicenseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_LicenseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fixx_CityOfHopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fixx_CityOfHopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fixx_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fixx_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fixx_CaliforniaInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fixx_CaliforniaInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fixx_CoExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fixx_CoExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031985579144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(37.80%)<span></span>
</td>
<td class="num">(39.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031898869096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 72,838<span></span>
</td>
<td class="nump">$ 41,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credits</a></td>
<td class="nump">39,888<span></span>
</td>
<td class="nump">25,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">8,251<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">4,219<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D costs</a></td>
<td class="nump">1,039<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensation</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expense and other</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">129,517<span></span>
</td>
<td class="nump">80,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(3,726)<span></span>
</td>
<td class="num">(2,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,483)<span></span>
</td>
<td class="num">(2,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (125,034)<span></span>
</td>
<td class="num">$ (77,793)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense reserves and accruals accrued liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893952936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance due to deferred tax assets</a></td>
<td class="nump">47,200,000<span></span>
</td>
<td class="nump">40,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax expense, interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=fixx_OrphanDrugMember', window );">Orphan Drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_TaxCreditCarryforwardsExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 265,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_OperatingLossCarryforwardsIndefinitely', window );">Net operating loss carryforwards indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">34,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">271,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=fixx_FederalAndStateMember', window );">Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=fixx_FederalAndStateMember', window );">Federal and State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_TaxCreditCarryforwardsExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_NetOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_NetOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_OperatingLossCarryforwardsIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards indefinitely.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_OperatingLossCarryforwardsIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_TaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_TaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=fixx_OrphanDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=fixx_OrphanDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=fixx_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=fixx_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893486712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">Each holder of outstanding shares of common stock are entitled to one vote in respect of each share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">50,265,575<span></span>
</td>
<td class="nump">45,116,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031890861672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Aggregate proceeds from shares issued under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,248<span></span>
</td>
<td class="nump">7,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share for options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="nump">$ 12.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding', window );">Remaining shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">21,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent', window );">Liability for unvested common shares subject to repurchase included in accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=fixx_AccruedExpensesAndOtherLiabilitiesMember', window );">Accrued Expenses and Other Liabilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent', window );">Liability for unvested common shares subject to repurchase included in accrued expenses and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of additional shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwoThousandEighteenIncentiveAwardPlanMember', window );">2018 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_MaximumSharesAllowedToBeIssued', window );">Maximum shares of common stock may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,887,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares outstanding available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,397,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwoThousandEighteenIncentiveAwardPlanMember', window );">2018 Incentive Award Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares added to the plan</a></td>
<td class="nump">2,010,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares outstanding available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,039,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_MaximumSharesAllowedToBeIssuedUnderESPP', window );">Maximum shares allowed to be issued under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,778,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage', window );">Purchase of common stock through payroll deductions expressed in percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod', window );">Common stock offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued to the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,848<span></span>
</td>
<td class="nump">55,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Aggregate proceeds from shares issued under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock', window );">Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares added to the plan</a></td>
<td class="nump">502,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember', window );">2015 and 2018 Stock Incentive Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense estimated to be recognized over period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued unvested common stock subject to repurchase current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_MaximumSharesAllowedToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares allowed to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_MaximumSharesAllowedToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_MaximumSharesAllowedToBeIssuedUnderESPP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares allowed to be issued under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_MaximumSharesAllowedToBeIssuedUnderESPP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award stock offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested common shares subject to repurchase outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fixx_AccruedExpensesAndOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fixx_AccruedExpensesAndOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fixx_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fixx_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fixx_TwoThousandEighteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fixx_TwoThousandEighteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fixx_TwentyEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031896484328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">63.20%<span></span>
</td>
<td class="nump">62.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">66.30%<span></span>
</td>
<td class="nump">64.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Weighted-average risk-free interest rate, minimum</a></td>
<td class="nump">0.31%<span></span>
</td>
<td class="nump">1.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Weighted-average risk-free interest rate, maximum</a></td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Underlying common stock fair value</a></td>
<td class="nump">$ 9.82<span></span>
</td>
<td class="nump">$ 12.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Underlying common stock fair value</a></td>
<td class="nump">$ 21.75<span></span>
</td>
<td class="nump">$ 30.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031898917736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 13,248<span></span>
</td>
<td class="nump">$ 7,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6,390<span></span>
</td>
<td class="nump">4,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 6,858<span></span>
</td>
<td class="nump">$ 3,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140032101388824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Option Activity under Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at Beginning Balance</a></td>
<td class="nump">4,843,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">1,311,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(46,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Cancelled/Forfeited</a></td>
<td class="num">(266,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at Ending Balance</a></td>
<td class="nump">5,840,824<span></span>
</td>
<td class="nump">4,843,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and Expected to vest at December 31, 2019</a></td>
<td class="nump">5,840,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at December 31, 2019</a></td>
<td class="nump">2,869,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Outstanding at Beginning Balance</a></td>
<td class="nump">$ 14.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Granted</a></td>
<td class="nump">17.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Exercised</a></td>
<td class="nump">3.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Cancelled/Forfeited</a></td>
<td class="nump">22.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Outstanding at Ending Balance</a></td>
<td class="nump">15.18<span></span>
</td>
<td class="nump">$ 14.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price per Share, Vested and Expected to vest at December 31, 2019</a></td>
<td class="nump">15.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable at December 31, 2019</a></td>
<td class="nump">$ 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and Expected to vest at December 31, 2019</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable at December 31, 2019</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding Beginning Balance</a></td>
<td class="nump">$ 12,278<span></span>
</td>
<td class="nump">$ 33,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Expected to vest at December 31, 2019</a></td>
<td class="nump">12,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable at December 31, 2019</a></td>
<td class="nump">$ 10,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031893509608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding', window );">Unvested shares, Beginning Balance</a></td>
<td class="nump">21,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_UnvestedCommonSharesSubjectToRepurchaseVested', window );">Vested</a></td>
<td class="num">(18,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding', window );">Unvested shares, Ending Balance</a></td>
<td class="nump">3,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested common shares subject to repurchase outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_UnvestedCommonSharesSubjectToRepurchaseVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested common shares subject to repurchase vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_UnvestedCommonSharesSubjectToRepurchaseVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031892148920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,843,915<span></span>
</td>
<td class="nump">4,864,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember', window );">Unvested Common Stock from Early Exercise of Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">21,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,840,824<span></span>
</td>
<td class="nump">4,843,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031894289512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Discretionary match made under the 401(k) Plan by employer</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031890772328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>CandidateorProduct</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration agreement revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,702,000<span></span>
</td>
<td class="nump">$ 1,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived', window );">Upfront, nonrefundable payment received</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementAllocatedConsideration', window );">Allocated to collaboration agreement</a></td>
<td class="nump">33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeAgreementTargetFee', window );">Collaborative agreement target fee</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementTermOfAgreement', window );">Collaboration agreement, research term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration agreement revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,200,000<span></span>
</td>
<td class="nump">31,000,000.0<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis | Collaborative Arrangement | Reimbursable Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm', window );">Collaboration agreement, reimbursement of manufacturing activities during research term</a></td>
<td class="nump">$ 17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize', window );">Collaboration agreement number of candidates or products for develop and commercialize | CandidateorProduct</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive', window );">Collaboration agreement eligible milestone payments eligible to receive</a></td>
<td class="nump">$ 265,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive', window );">Collaboration agreement eligible development milestone payments eligible to receive</a></td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive', window );">Collaboration agreement eligible regulatory milestone payments eligible to receive</a></td>
<td class="nump">85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive', window );">Collaboration agreement eligible commercial milestone payments eligible to receive</a></td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Novartis | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived', window );">Upfront, nonrefundable payment received</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of shares of preferred stock</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_PreferredStockEstimatedFairValue', window );">Preferred stock estimated fair value</a></td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeAgreementTargetFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement target fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeAgreementTargetFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementAllocatedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement allocated consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementAllocatedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement commercial milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement development milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement number of candidates or products for develop and commercialize.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement proceeds from nonrefundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement regulatory milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, reimbursement of manufacturing activities during research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_PreferredStockEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_PreferredStockEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=fixx_ReimbursableResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=fixx_ReimbursableResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031985599064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreement - Additional Information (Details1) - Novartis<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2017-11-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, unsatisfied portion</a></td>
<td class="nump">$ 30.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation, unsatisfied portion</a></td>
<td class="nump">$ 30.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fixx_NovartisInstitutesOfBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-11-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-11-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140031890860056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pfizer Stock Purchase Agreement - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration agreement revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,702<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommonStockEstimatedFairValue', window );">Common stock estimated fair value</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_StockPurchaseAgreementRemainingAllocatedValue', window );">Stock purchase agreement remaining allocated value</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Allocated Information Committee obligation</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember', window );">Pfizer Inc. | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration agreement revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts and issuance costs, Shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fixx_CommonStockPurchaseAgreementCondition', window );">Common stock purchase agreement condition</a></td>
<td class="text">The shares of common stock sold to Pfizer are subject to a one-year lock-up from closing, during which time Pfizer is prohibited from selling or otherwise disposing of such shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CommonStockEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CommonStockEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_CommonStockPurchaseAgreementCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase agreement condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_CommonStockPurchaseAgreementCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fixx_StockPurchaseAgreementRemainingAllocatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement remaining allocated value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fixx_StockPurchaseAgreementRemainingAllocatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fixx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fixx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ). :U('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "3@&M2A+!5V>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)VEE#Z';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF
M&YA.1ZE#PN<4(B:RF&\F-_@L==RR(U&4 %D?T:E<EX0OS7U(3E%YI@-$I3_4
M :'A? ,.21E%"F9@%5<BZSNCI4ZH**0SWN@5'S_3L,",!AS0H:<,HA; ^GEB
M/$U#!U? #"-,+G\7T*S$I?HG=ND .R>G;-?4.([UV"ZYLH. MZ?'EV7=ROI,
MRFLLO[*5=(JX99?)K^W=_>Z!]0UO1,7;2HB=V$A^*QO^/KO^\+L*NV#LWOYC
MXXM@W\&ON^B_ %!+ P04    " "3@&M2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ). :U(O5/J7] 4  &89   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9E=<^(V%(:OM[]"P^S%=B: +?&5'<(,@:1+=Y.E(?O53B^$+< 3VZ*R'))_
MWR/;V&Q''+LWB;_.J\>2]9XC,3Y(]93LA-#D)0KCY*JUTWK_OMM-O)V(>-*1
M>Q'#G8U4$==PJK;=9*\$][.@*.Q2QQET(Q[$K<DXN[94D[%,=1C$8JE(DD81
M5Z_7(I2'JY;;.EYX"+8[;2YT)^,]WXJ5T%_V2P5GW5+%#R(1)X&,B1*;J];4
M?3]G(Q.0/?$U$(?DY)B85UE+^61.%OY5RS%$(A2>-A(<_CV+F0A#HP0<_Q2B
MK;)-$WAZ?%2_S5X>7F;-$S&3X;? U[NKUJA%?+'A::@?Y.&#*%ZH;_0\&2;9
M7W+(G^T/6L1+$RVC(A@(HB#.__.7HB-. A@]$T"+ /J? +=W)H 5 :QI0*\(
MZ&4]D[]*U@]SKOEDK.2!*/,TJ)F#K#.S:'C](#;COM(*[@80IR=SZ:4PC)KP
MV"<WL0[T*UG$^?=DQJ5-OJSFY-W;7\E;$L3D+@A#N)R,NQH:-Q)=KVCH.F^(
MGFG(I>1.QGJ70"N^\'\6Z )UB4Z/Z-<459P+KT.8>T&H0QT+T P/O^.J0YQ1
M%NY:PN=X^.]I#*T[MM9_>AM6#@3+]-@9O9E\%HK\-5TG6L%D^!N1[)62O4RR
M5S>VCZ][81LQ/-QUVA\1BGY)T4=EIH#@9QBW(=_:,/#X#0\3@7 ,2HY!L]Y8
M"A5(\['[!*:,M6-JE(H/[Y<W;VH&?UBR#9NQW0:)Q\,CXBU<MDXU7.WV!X(T
M*I%&_POIA^#J/!"N5=-+ER72)2I3V-.#V 9FD@#;/8^LXX?K?)"1#.7VE=P)
M/_#@9G(!GN<AA*Y3V:G3A'$&/:>@UQ;@=2_DHWBU&B8NY3B..QBXEY<CC.S$
MZ-TF9%]EF,8:4CP,;"B4W<EQI7N) =$*B#8!^@8YO_T4RT-,5H(G,A8^621)
M*I05#=?$T2HO=EFC44R5,E/@0>RETD&\)2O-M7T&U"C^$ E&5EFZBYORH^)^
M!O(:K65H!<$%;A??OV,DE:V[N"\?.^?4'S!/K9%KMUW:9BZ&5CF]BQMT,7S9
M!TYFP+.5RCX#<9U[&;>YYT&1JD#$SP4QPLKO7=RB"\)5Q,.07*>),2'[9X7K
M:)5BN=&MW-[%+;H NHF$VIKOZS=0T#LRD]&>Q_:^PP7KR"K3=QNY_LT+@6\?
MUAM969HG2"L6KE973=#*Z2ENSXO9[0.9IGZ@I2)3K46B\Y+Y7)E3HU=+5CD]
M;>3TJQTX*S:"-3*U0)73TT9.#R@1],]*2^_I O"X$@GYG&KHN-B8FK6&SY7[
MF;)9Q#Y/^DYO-!ST+L?=9QM59?*TD<DOTW48>#!JDFOK,B!7&9P2N&YG<*;Y
MRLDI;L3E8DL+E:]^C77R8]*Q#ABNB.<86CD[Q:WX,="A(')#7/IN_2MD92]5
M@&HEJLD1/XWX6Z=C:AJRATSQS$/4'VAE]A0WZ2,>.(2WX_%6G*T*:X3NIZOY
M] ^,J;)WVLC>3;X@]VFTMM<R-2+056TVZC&&(54&3QL9/-2Y4D$UDUG515;/
MP%!#EI10%2HS1WU[W]6L%FXPR,KK:2.O?^0O9.'#) @V@9>;*M*+N&1OV&:]
MP<CM][!%>N7ZK%%]/_5],"]8-Q0'Y!,\1S['UKZKD80HLN0:$II.X$ ]8:!5
M$F"-DD ).C-G,-"/4&A;(7&Y:^%OI,*V;5B5#EBC=%"BE1_A4LGG(/;LG8AK
MWDTQM)--F$8YH41;2DA.(?DSV)^=&36*CCMDZ/Y0E3 8;N_9"$Z5X.=1<('A
M""NO694?&.[JGV2V1[&#I1HR+VM$&+C;D Z'&%&5 UC#O9UI'*? EB_8K%2X
M4$W5RJH,P!KNZ)P4K0@5+E97B;$J"[!FNSK)22* A<W:[*IL!-0=9R8?K@KK
M)-&Q\75/-J;-RB+;X$^(9Y)-OD==7BU_1)AF6^?=ZO'\%X@[;A8F"0G%!D*=
MSA ^+Y5OZN<G6NZS;>ZUU%I&V>%.<%\H\P#<WTBICR>F@?*GE<F_4$L#!!0
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M3KBKG9!ZIIG,$2_V3.E\#.O!3MA#\#/&H03QD@B/@PQ;D*$3Y*UD)>4;Q'X
M22FFZO@*O6,23D)_ VVXPR$J[/O#" _E IRDH]BC%GODQ/Y%:)J= #.RP$S#
M*!@"M4A&41C'HU#C%FK\3)BA"$C]6(?79&YIDF&*"J9MB.,!#A\PD"'@H6!
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M_D4+6#=_6-Q#RW&U3'GC1[6K_\1=_Z\V&VY8#YC%#*HS7L!,4')@&BM42R=
M M]66RVB01BGJ0-TUPX0=SL 76>55QDU$TPS3(L<$GIG[N+V#-U3;B\NEGJ?
MC'=1I*OVQ#W/]0%MV):ON77N),.!;N:3Q(]L\;/(XC2-'-T)Z1H(XFX@#J5$
MC=*T%;RE6TC#-+7EZE"4A$GHC4]<?M=9^*<,AKTJ6)^TOBN_.9QHC!_=6XV,
MC1;1L;%QWKNL-#?%?U)YSPL%W=D6=+VS&"(A#Y>OAQ<MROK^\DYH+?+Z<<<H
M@#<"\/M6"/WT8JY$VROPQ;]02P,$%     @ DX!K4KVS(0S6 @  2PD  !@
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M2*W$JAD/B4?,/D2.Q<\X\P[ )KU*-9%:-94S'M*DK!W)7_5,UQ7^JB?B^%.
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MB?K&GS_3VJ# [!?Q1)9_P7,MZXU 5$C%TWJQ1I"RK/I/?M>.V%L IP,+4+T
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M3]A?LKBED$JK6MTJ(BV= S<771Z 7E-04!+%1D)ILZY;PU%(+VK9="7",+H
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M"B8Y/IAI4G&%,^(==_54U(.W*  \1<4*T^0INSI(^9A,^!F3+8#RG6=:@"&
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MR !VE3)>:&-69 1)<97IED.\1:R4F_1WDM3]+(T WI+, "DLA[,!A]DA:2X
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M*9'_(S1*0;+FO+G6$N3W.:7#I3#AH7]>6'>A)FW@\IP<11O)20V.=-F02WV
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M(CO?;W7O92^%\H7I;D$H6\7=^8<FU:7I>78YS<(6AFR-JR:-T%.)M63HQD9
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M"*$&:R8GM2_*'5F^E6Q'R[5P-0A=0A"NOW9R)Q1J<O.$&-XK)<4!ZK*'RE^
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MSE4GC<:)G((RLQI/!<K9Z2Q5VA[-06?L)E^#L4BX-9.>16RZT8MKG(L*)SJ
M$T;L5N4V->PZ3R!Y#=!#HQK+HIUE%]&'B%<0=UD_[+ HB((/\/J-IWV'US^
MUW*/70D32V5*#>SO\X6Q&I/CGP]T#!H= Z=C<(C-KW_>SX_FU_>W[.;[X_5L
M?GO]?3[;Q^;'.(,NVP_%YBFP2Y45/-]B&FR9<%XQ@4[!2PS&L)B;%+?94KQ
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M,L79$C1=P/.E4G;W0@J::77Z U!+ P04    " "3@&M2&[=%($L%  #_#
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MC&]W^GY,A)"&!,DHJ<R-R8!:@E5:G7L""%&H/V*Y2W[$M7_$&!^GA8,!+1=
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MXU;D&,Q809D47#$1/0W81SAOO6"@8'3O26>.5=J#8>"FN/,,=.B^E)98R;'
M][% D7/12&J,90Q>E"2T'.( 3;R5W()IA1*S\&@]%(>5UJQD$ A7>V]#EPY,
MOU0RA ]O)=_$*+2N0+>EN" *@1^DXWZ2)'U8R&)>6<P@? ;!:^@Q89QW2*.H
M+ #[-5QA$!5"*X.#@\-!BO94*BA-5>(G!,M%+FE5YQJ.6M(9QI0IXW!(HS!%
M059(KN3?/&H5D BMK\E%&@2@$&I6"=\DP&]37?.Q9L.5E[" _:+R%;+K.&#
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MO4+J65((^..$S^ED*>J;_(:";XD'S@0$(PS,LZ_HX@,!?;0+^"E?ZK,[24[
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M=DX7_G,M.+R %F!^J;5K?HA!>Q5^]1]02P,$%     @ DX!K4@TG26B&!
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MJ77%08Q=15C)WW'-1GXTF_IQ.#E$>9M6FM;M\:"KQ3^!9Y2 E04" !R<[&U
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M(J/'C8#B7>$$>+\JBK+^@1NX+TY?_AM02P,$%     @ DX!K4L2.++*, P
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MLAV-9KAD209379*1B]JG:JY$.0B)X9U2F&ZA)@U4L@<J3N":47(+%V6&V6N
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M;,J\C@,PS=!J-J0K/R@6FGCL^&7.<QZ-4^#SI=:TVS@'[9]C] ]02P,$%
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M@5B\Y!:"?K^]CZ+'5SX(5^?U7ID9K.:9@)5HR :G""O)KEO 5YE;9D7V=ZP
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MR[>Z4X-A%0?C'\Q]6^S9J,_0G--5V"5-HT4SA@ILZGZS/4SPQ"O;IOE4>BR
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M/D./WAESU1;N(-@=:UY2C3D2Q>+X%XT]522\XCGB@XT^!O(3+R:*3,.,.0
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M49;HO^U;*%:[W>9+:MT:&9&W3>S&(2CA8"(J',*>I<C2,$SCFI'&S&5&<IH
M,PJ#2]V6=,56R]K)UF2]]7 $R<.X$FCU@,9-APL$VOAHR-.+_[3KYU?%9FH2
MCI<(%P_V+\$Q*3DBR&!-"(C931'Q. &!F"J'INPD2?4VQ:J7.GZU&JZ/*!,V
MS'[I03G&X38E"5$@]9F6+"5!7*2O7#8CV M1TFG#9(.!8OO%5ZI(MZS].FB_
M2>3FSR\NID\87IL-:X&WWF:.:N7)7L;AVDC75F/[X&TK+XE81EGV85U&%9Y/
M)4>U[U0;N'(..  XAA*5&ONQ[7D9?X(;) W0AJ+T;%N8,'R:$\3@'4 !2N.*
M'=_\^N-[7UC)3\.WL=D;4GH* ?GL*RN8+#C+PF>>]:PZ3]3E0- [9CQF4M[P
M!'_Z8K*>2RM^E9AFS(Y2?J]!3Y?]T"-)-"0?4MFX# -SN5S5X,[O'TQ-HT.\
MSD/Z'#G9BTY0DD_#9'TK)V'$VQ10ABQ6F>I5)35MK^F00X&3EL"$V(IF_@**
M,]W3/IEL6\G-%21J*%(@O$)]D5[Q.(U05.%K\AIP&#KI""X2JW!:5&Z3B!/2
M;N;D'',T,;0<[,&.79HR#8_\B</%]%'!CWH,_Z/7MZ/R^-6]V))B^RC.Z8^<
M%N3ZU]%*X:A&TM?^OG'2( 65SRZ>S=QP#&W?N+(F'N$-7Y>$([9!)VAF.SI/
M?AUD11??QD%P6PNI#8.0W;HORT'58U Q*"&\<]I"I ^T]6'"59&DO1N!T]L0
MJ$QGKO5)6K!5EQJ>V15 8YM:BR2]ZU2P@Z.&D>V3POC607A$&X2R'NM *W9W
M"G%LKM?(04/$"*1HP!<>'(PL00(+021XL!=IXSID9ZGM2L>!0^"]#(K25E'M
M9<M5N;A%:(RPJE#:0;7:FJO$.K-O7R2GQ=GP.)QW!8]0-_"#F,E>4B_4S4'@
MU\*O>WK32A"G^J)<@_/6@\[N]%P%8+('KGS=T1<7UHDF1[/3")&-'7;;Z# %
MXGZ9":,#EDL0CY:ZI1M;KQ,Q#_J_.0OMS;'>'<097ZM6S5%?@_1B)!.GX(XV
MKJR3FYN >DQ*?#S>?VRS^!*(5$(;ZJ_<F#EX H7,4/!U4!JITJ@A^Y7@-1N_
M5)%AS*<%V /QDI;\7FGTY.I0F$9$">V8B&LH+B6>U0>RG/MY=&AI(LF2RC5%
ML\&5#2E]ETG 1NHG!S&-X$QW9WC%"#FX:#$G><3%G\51&3;J81S?JXT/1R2
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M@9ZO:V(3_0,#N%]'_N'_ 5!+ P04    " "3@&M2_^,^$W $  "]"@  &0
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M#[%CZ798:E^LJMV LE06QQVW+7"^!$T7\#Q7RFY?R$ WL4Y_ %!+ P04
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M91WPO)#2[!:68/A>%_\ 4$L#!!0    ( ). :U*RP9LL[0(  #@&   9
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MM<,!%,P&)SX8[X#WM=;N>>,3'/\AJ_\ 4$L#!!0    ( ). :U)!C4 RPP(
M   &   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;(U436_;, R]^U<(
MQ@XM$-3?:5(D 9*VPP:L6-!VVV'80;;I6*LL>9+<M/]^E)QX&= $O5BBQ/<>
M29F<;:5ZTC6 (2\-%WKNU\:T5T&@BQH:JB]D"P)O*JD::M!4FT"W"FCI0 T/
MXC <!PUEPE_,W-E:+6:R,YP)6"NBNZ:AZG4%7&[G?N3O#^[9IC;V(%C,6KJ!
M!S#?VK5"*QA82M: T$P*HJ":^\OH:I5:?^?PG<%6'^R)S227\LD:G\NY']J
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M.YI98=G23P*-5R!YHZF3QHUW</CM+/\"4$L#!!0    ( ). :U)=<C1>WP4
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M>/CE.=PW/O9F1KV9D>.+3_ =<^W/;&-\,%_KWS<2Q'V"V"5(3B1P1EISB1W
M?\>/6==231R5O<S[/ HG21QF_GYHT>NP-)Y,DC[JF="D%YJ\*71P^%;J,7DM
M03K(&T:#M*VX=X*>:4M[;>F;VFZ$QLS)&KWRT9DKWQ>?'O'V<A*D+^2_#DO3
M(+E\H=\?7%_;.G]BN:5<(0:EP07CB:&1;3MJ)UKLW(W>"&WZ@QM6IH.#M %F
MOQ1"/TULD^C_"?D_4$L#!!0    ( ). :U*L58K[F04  %$3   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;+U8VV[;.!#]%<+8 BT0VY)\39 $2.,L
M-L46#>KM[D/0!UH:6T0H44M2<;Q?OS.4+-NU0K=]Z$LB43PS9RZ<&?-RK?23
M20$L>\ED;JXZJ;7%1;]OXA0R;GJJ@!R_+)7.N,57O>J;0@-/'"B3_2@(QOV,
MB[QS?>G6'O3UI2JM%#D\:&;*+.-Z\QZD6E]UPLYVX;-8I986^M>7!5_!'.R7
MXD'C6[^1DH@,<B-4SC0LKSHWX<5=%!' [?A;P-KL/3,R9:'4$[W<)U>=@!B!
MA-B2"([_GN$6I"1)R./?6FBGT4G _>>M]-^=\6C,@ANX5?(?D=CTJC/ML 26
MO)3VLUK_ ;5!(Y(7*VG<7[:N]P8=%I?&JJP&(X-,Y-5__E([XGL 40V(OA<P
MJ &#;P#A\!7 L 8,OP4,7@&,:H SO5_9[APWXY9?7VJU9IIVHS1Z<-YW:/27
MR"E1YE;C5X$X>SVO$H2I)9N+52Z6(N:Y93=QK,K<BGS%'I04L0##NNPF202%
METMVGU=)2L%^.P/+A33O<,N7^8R]_>W=9=\B.5+1CVLB[RLBT2M$!NRCRFUJ
MV%V>0-*"O_7CP\@CH(]>:5P3;5WS/O)*_,AUCPW",Q8%4=!&R ^?0>R%S_SP
M#SSOL: 5?F#-H GTP,D;G CTI].!?OP3L>S>0F:^>C0/&\U#IWGXBF97?+IJ
MV2T-,&X,6-/FS4K(Q FA\O9\/9J>3X( C7_>=]OQOO%T,#K:=^<G]1A^/7N,
M?.:-&O-&7DF?"M#<.5 "5BPF!5\(B><$6LVLA(WVZ(>CX3 ZMO-X8Q2-PF,[
M_>P>!SX;QXV-8[^-I366YPE9&4LNLC;+QD>$=U0/M$X:K1.OUONLX$)C5[)4
MGJ3*5UV)727Q)-'D*#E>X3!M.$R]'/[B+ZQ0QI4]<X8MR,1:%/36IOZ$K!38
MK4*C\@T*LJ"QGN-Q6Z=@4]!,6"8,RY2F''H"N6$VY3G+E:4'RSBS>V2P3TC)
M%H M'D.#@A)6%K@,+QS%NL+<8Z210 O(88GRK2*$AEAA!?@/(5C$&=$YD.RT
M9=A1##Z"8]2M&'6)49<8U3+J_1I,JF1"_&,NXU)RZ\+D\)+K%1CDGU&EH5 V
M=$@18E8XXJ [*GM'P9NM_6XKY1Q^EXZO,Q%G (&M!TT':R50@O38_;)V(+'S
M.?%U!Y[A-BQ\J)5H;TER:[58E)8O)) #Z5LC _7MO-GSG+3S)M_.O3EREQ52
M;0#8W*KXB3V4.DZIJCQ(GGO$A\&NWP>_N ^$>[-&Z#6NL09='*LL0P<:9R9F
MD"I7*2OX1BN,"C;PT@V2!O,9!V \[YA<.<-2&V.T<8(E$4NL#C@+Z2><IY^Y
M+*%UZO!3FHYZ0?"F==SX<>"A6Z*=6R*OJ'G*,5UIW$W(+?@;P+CSB^5&&!<6
MMM0JVYI::!&WF7I[0DUXDO%NE@@'/\68<:UYOG)'DBTVS.SMP]BZY6*;!!A,
MH=HG/;_V<!JPA&^,SY3=<!+Z!X&;^1<<L<)Q-XA\\G;30#CZU>=KUZ5#?YO^
MODEK%AYWZO$T"/9'BT,"NX8=^COVC\U"LUK:P3 TF?B8[-IVZ.^U,UB"UIAV
M&G.N5??T:%0(@W.?;BKAAS\D=D4W"DY-FVVUZ03J,U#I0_[450MAJ0=6QPR+
MGVI<K4]%_9#TKEI'_@IW-![7I/VH/=+8&27R<4=@2SO9CPN.'E36J:3C7&=H
M8.#XH:[]U&Q_VLI=\8W\5?%H0*ZM]*,.K6PFH8.XG#@"%=_^WD_W#'!0HCL3
MC#<5BVI2;E:;>YD;=QOQS?HLO+@+V]:CB[NV_3?A.0+.6[Y@6B(D:/U"ET)M
M6M!?V^NB_LZ,ZK()?T>O!'9R"4LT*>A-\+SKZOZF>K&J<!<4"V6MRMQC"CP!
M31OP^U(INWTA!<TMVO7_4$L#!!0    ( ). :U+,V-4T-@0  (X0   9
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M6C\SW%$24J$7@#SB7!T_] ;EOR#F_P-02P,$%     @ DX!K4H=AOL<1 P
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M.4;(,#4.@MC7(YXA8P[)\GAH0(/6IS/<'+^@7_K@;3!W1..99#]I9HII<!A
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MG9.)JFJ/U<#(M>LP"VFH7[G/C/XHJ&P K2^E-+N!W:#Y1\5_ 5!+ P04
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MUEK#L<)49:F$?LNTG9HN4R[4Y1V('-T46Y!*9UQ)=(F659D07R.[!AVL>;\
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MA09T6?:PZ#1,6PW) 0UQ@FZD,)5&5Z(DY5N"$!+R626;K*;)4<8Y*<Y1&G]
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MJATPPZ-J\8#K#6I]SYA\GFB"H6G<_ )02P,$%     @ DX!K4EX#?F4Q @
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M#*XN(S#M;+4;I^O0SVOM:#K"LJ+G"(TWH/N-UNZP\03] Y?_!E!+ P04
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M+#-=_">;<FZGWR+Q2AN95\;(($]%^<M?JD3L&-#N"0-6&;!]@_8)@Z@RB(I
M2V9%6%-N^&B@Y(8H.QO1[$61F\(:HTF%7<9'H_!IBG9F="=BF0/Y@[^ )C^3
MVR1);7IY1NY$620VV9^F8'B:Z<\XY>EQ2C[]]'D0&'1O08*X<C4N7;$3KB@C
MWZ4P"TU^$0DD;P$"Y%V39UOR8^9%G$)\12+ZA;"0A4<(3=YM3OL>.E&=RZC
MBQIS2::ICC.I5PK(W]]P&KDSD.M_/$[:M9-VX:3M=V+0";Q@,VLXMA(E1J_
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M C@NL9V SV=2FNV-=5!_A!G]#U!+ P04    " "3@&M2H8,D,K0"  !&!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6R=5<ENVS 0_15"E[9 :BVV
MI#20!3A.BN80P(C1]E#T0$MCBPA%*B1E)W]?+K)B)['2]B)QF??FS7 XS'9<
MW,L*0*''FC(Y]2JEF@O?ET4%-98CW@#3.VLN:JST5&Q\V0C I075U(^"(/%K
M3)B79W9M(?*,MXH2!@N!9%O76#Q= N6[J1=Z^X4[LJF46?#SK,$;6(+ZWBR$
MGOD]2TEJ8))PA@2LI]XLO)BGQMX:_""PDP=C9")9<7YO)C?EU N,(*!0*,.
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M$J9$WSR!8;)K7%3(G3GB:Z3OME28E8;2':I9+0X\(KV(@"FB*)1(<<09&!&
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M1H$BR@!^7W NG[^H=][UGUV<_PU02P,$%     @ DX!K4F*9:#6A P  ]0P
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULS5??;^(X$/Y71M&=M"MM
M\Q-"60%2H7NZ2E<=VJJ[#Z=[<),!+)R8LPV4__[&)@W0AI1;W<.^0.SX^SS?
MS-@S&6RE6NH%HH'G0I1ZZ"V,67T. ITML&#:ERLLZ<U,JH(9&JIYH%<*6>Y
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MS_4Y]]S$'FZ$?% 9@"9/.2_4R,FT+B]<5\49Y%2=BQ(*7$F%S*G&H5R[JI1
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MBCSLK4R1Z]8)KG!EP+92,K.?H="[291&AXT[OJV=WXB+O&%;O$?WT*P,6?'
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MFH!HO .=;[1V!\,'&&9J\0)02P,$%     @ DX!K4E7) +F*!0  >QD  !D
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M<PLOU5L3.2Y=4:96TRTG.SL@-8+-E&95CF0&MSREG",,<XU(Z;=P!L,LXP[
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M&AUJ?5W-M&IC5>GGR$Q9FDI^N:#? -0.0/=SI>QVXT93_6,Q^ U02P,$%
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MM !G\2O'C=Z[!QO*4LHW^_ 2W_=\RP@SC(QUP>BRQB?,,NN)>/Q1.^TUW[3
M_?NM]Y]<\!3,DFE\DMEO/#;I?>^V!S$FK,S,5[GY&>N ',%(9MK]PZ:V]7L0
ME=K(O 83@YR+ZLJ^UXFX!!#6@/ =(!B< /1K0/]2P* &#"X%#&N "]VK8G>)
MFS'#IA,E-Z"L-7FS-R[[#DWYXL(6RL(H>LL)9Z;SA/^)"A9&1F\P+U644M;A
M8:40J1P,7,-#''.K*<O@1525:17^.$/#>*8_D<GK8@8?/WR"#^"!3IE"#5S
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MBU0/1A9NL[V4AK;N[C:E\QLJ:T#O$RG-]L'NWYL3X?1O4$L#!!0    ( ).
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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MR\XV_5L^&_^:MW@!4$L! A0#%     @ DX!K4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "3@&M2
MA+!5V>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "3@&M2F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ). :U(O5/J7] 4
M &89   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "3@&M21H:DBZX%   .%P  &               @($W
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ DX!K4KVS
M(0S6 @  2PD  !@              ("!&Q0  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( ). :U)6A6Q;TP,  .,+   8
M  " @2<7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "3
M@&M2&@9:;^P"  "X!P  &               @($P&P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ DX!K4NQL3@\Z!@  Q1X  !@
M         ("!4AX  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( ). :U)1XW78&0<  )$=   8              " @<(D  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "3@&M2.D>Z!C$+  #R&P
M&               @($1+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ DX!K4CW?K5ZN(@  VFP  !@              ("!>#<  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ). :U+W&M)*20,
M .X&   9              " @5Q:  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ DX!K4H35]L2=!   N0H  !D              ("!
MW%T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "3@&M2
M&[=%($L%  #_#   &0              @(&P8@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( ). :U(6\S\6A@,  '('   9
M      " @3)H  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ DX!K4BUJG-WA @  %08  !D              ("![VL  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "3@&M2T,#\"OT%  !.#@
M&0              @($';P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( ). :U+H0JT=,@4  -P,   9              " @3MU  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ DX!K4C"*9'3E
M"   %A<  !D              ("!I'H  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "3@&M2#2=):(8$   C"P  &0
M@(' @P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ).
M:U+BWXZXVPT  'TJ   9              " @7V(  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ DX!K4L2.++*, P  _ <  !D
M         ("!CY8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "3@&M2>[1?1O "  !%!@  &0              @(%2F@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ). :U*#]_R/H \  +(O
M   9              " @7F=  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ DX!K4D];!Q^$!0  (0T  !D              ("!4*T
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "3@&M2UK[U
MQ@$$  "O"   &0              @($+LP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( ). :U)1M"W 4"0  "EY   9
M  " @4.W  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MDX!K4O_C/A-P!   O0H  !D              ("!RML  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "3@&M2XD*_D(,"  !J!0  &0
M            @(%QX   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( ). :U*RP9LL[0(  #@&   9              " @2OC  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ DX!K4N<AV!Z: P
M, D  !D              ("!3^8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "3@&M2^TW1(@\#  !/!@  &0              @($@
MZ@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ). :U)!
MC4 RPP(    &   9              " @6;M  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ DX!K4CX]N50)!   \@H  !D
M     ("!8/   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ). :U(GVI)X<0(  !\&   9              "
M@0T( 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ DX!K
M4JQ5BON9!0  41,  !D              ("!M0H! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "3@&M2S-C5-#8$  ".$   &0
M        @(&%$ $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( ). :U*'8;['$0,  /T*   9              " @?(4 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ DX!K4L"05(2= @  I @
M !D              ("!.A@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "3@&M2^OLRSK("  "O!@  &0              @($.&P$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( ). :U($Y(VY
M@@,  &40   9              " @?<= 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ DX!K4D)XLM[+!0  @B<  !D
M ("!L"$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "3
M@&M2(.%S04,"   L!0  &0              @(&R)P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ). :U+S[7Z;K0,  ,@.   9
M          " @2PJ 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#
M%     @ DX!K4L%43G^( @  \08  !D              ("!$"X! 'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " "3@&M2K&(5&.0"   C
M"   &0              @('/, $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM
M;%!+ 0(4 Q0    ( ). :U)@W[:)W@0  (T3   9              " @>HS
M 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ DX!K4FBS
M-W") @  - 8  !D              ("!_S@! 'AL+W=O<FMS:&5E=',O<VAE
M970U,"YX;6Q02P$"% ,4    " "3@&M2MG.8[5D#  ! "@  &0
M    @(&_.P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M ). :U)> WYE,0(  /P$   9              " @4\_ 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ DX!K4@_S/R-; @  [ 0  !D
M             ("!MT$! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " "3@&M2:O$WS-D#  ".#@  &0              @(%)1 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ). :U*6;-TVYP(
M *8(   9              " @5E( 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ DX!K4I0;PA&' P  O L  !D              ("!
M=TL! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "3@&M2
MGASNYQ8$  "0$0  &0              @($U3P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( ). :U*A@R0RM (  $8'   9
M      " @8)3 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ DX!K4LH]5]CD!@  @B$  !D              ("!;58! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "3@&M28IEH-:$#  #U#
M&0              @(&(70$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( ). :U)^^KG[\P(  -L(   9              " @6!A 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ DX!K4N?P!DFH
M!   )Q,  !D              ("!BF0! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " "3@&M2P"]QJX8"  #)!0  &0
M@(%I:0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ).
M:U*I [AG%P,  ,$)   9              " @29L 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ DX!K4HI\[PAK @  7P4  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( ). :U*D7U;:/@4  %4M   /
M  "  8&" 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "3@&M2%MUK%"8"
M  !C*   &@              @ 'LAP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "3@&M2X>Q>$?0!  "B)P  $P
M@ %*B@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3 !, ,L4  !OC $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>391</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities</Role>
      <ShortName>Accrued Expenses and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement</Role>
      <ShortName>Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Pfizer Stock Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement</Role>
      <ShortName>Pfizer Stock Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Expenses and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Summary of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Short-Term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-Term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Short-Term Investments - Summary of Short Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Summary of Short Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Commitments and Contingencies - Summary of Cash Paid for Company's Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Cash Paid for Company's Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock Incentive Plans - Summary of Option Activity under Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Option Activity under Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Collaboration and License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Collaboration and License Agreement - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1</Role>
      <ShortName>Collaboration and License Agreement - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="fixx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Pfizer Stock Purchase Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails</Role>
      <ShortName>Pfizer Stock Purchase Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fixx-10k_20201231.htm">fixx-10k_20201231.htm</File>
    <File>fixx-20201231.xsd</File>
    <File>fixx-20201231_cal.xml</File>
    <File>fixx-20201231_def.xml</File>
    <File>fixx-20201231_lab.xml</File>
    <File>fixx-20201231_pre.xml</File>
    <File>fixx-ex102_943.htm</File>
    <File>fixx-ex231_6.htm</File>
    <File>fixx-ex311_12.htm</File>
    <File>fixx-ex312_10.htm</File>
    <File>fixx-ex321_11.htm</File>
    <File>fixx-ex322_7.htm</File>
    <File>fixx-ex44_13.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gmz2lq4320rk000001.jpg</File>
    <File>gmz2lq4320rk000002.jpg</File>
    <File>gmz2lq4320rk000003.jpg</File>
    <File>gmz2lq4320rk000004.jpg</File>
    <File>gmz2lq4320rk000005.jpg</File>
    <File>gmz2lq4320rk000006.jpg</File>
    <File>gmz2lq4320rk000007.jpg</File>
    <File>gmz2lq4320rk000008.jpg</File>
    <File>gmz2lq4320rk000009.jpg</File>
    <File>gmz2lq4320rk000010.jpg</File>
    <File>gmz2lq4320rk000011.jpg</File>
    <File>gmz2lq4320rk000012.jpg</File>
    <File>gmz2lq4320rk000013.jpg</File>
    <File>gmz2lq4320rk000014.jpg</File>
    <File>gmz2lq4320rk000015.jpg</File>
    <File>gmz2lq4320rk000016.jpg</File>
    <File>gmz2lq4320rk000017.jpg</File>
    <File>gmz2lq4320rk000018.jpg</File>
    <File>gmz2lq4320rk000019.jpg</File>
    <File>gmz2lq4320rk000020.jpg</File>
    <File>gmz2lq4320rk000021.jpg</File>
    <File>gmz2lq4320rk000022.jpg</File>
    <File>gmz2lq4320rk000023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fixx-10k_20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "fixx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fixx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fixx-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fixx-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fixx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fixx-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 519,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 24,
    "http://www.homologymedicines.com/20201231": 5,
    "http://xbrl.sec.gov/dei/2020-01-31": 8,
    "total": 37
   },
   "keyCustom": 63,
   "keyStandard": 328,
   "memberCustom": 25,
   "memberStandard": 37,
   "nsprefix": "fixx",
   "nsuri": "http://www.homologymedicines.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Cash and Cash Equivalents",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents",
     "shortName": "Cash and Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Short-Term Investments",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses and Other Liabilities",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities",
     "shortName": "Accrued Expenses and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - License Agreements",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stockholder's Equity",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity",
     "shortName": "Stockholder's Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stock Incentive Plans",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Net Loss Per Share",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Defined Contribution Plan",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Collaboration and License Agreement",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement",
     "shortName": "Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:StockPurchaseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Pfizer Stock Purchase Agreement",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
     "shortName": "Pfizer Stock Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fixx:StockPurchaseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Subsequent Event",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Cash and Cash Equivalents (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Short-Term Investments (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Expenses and Other Liabilities (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock Incentive Plans (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20180401_20180402",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20180401_20180402",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Impact of Adoption of Previously Reported Amounts of Condensed Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Life of Asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Cash and Cash Equivalents (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails",
     "shortName": "Summary of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Short-Term Investments - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails",
     "shortName": "Short-Term Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Short-Term Investments - Summary of Short Term Investments (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails",
     "shortName": "Short-Term Investments - Summary of Short Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fixx:FairValueAssetsLiabilitiesTransferBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fixx:FairValueAssetsLiabilitiesTransferBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and Equipment - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "fixx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20190101_20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20190101_20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails",
     "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Commitments and Contingencies - Summary of Cash Paid for Company's Operating Lease Liabilities (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Summary of Cash Paid for Company's Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - License Agreements - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fixx:LicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_srtCounterpartyNameAxis_fixxCityOfHopeMember_20160430",
      "decimals": "0",
      "lang": null,
      "name": "fixx:AnnualLicenseFeePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockPlans",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock Incentive Plans - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
     "shortName": "Stock Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock Incentive Plans - Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock Incentive Plans - Schedule of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stock Incentive Plans - Summary of Option Activity under Plans (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails",
     "shortName": "Stock Incentive Plans - Summary of Option Activity under Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "fixx:UnvestedCommonSharesSubjectToRepurchaseOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails",
     "shortName": "Stock Incentive Plans - Summary of Unvested Common Stock from Early Exercises Subject to Repurchase (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "fixx:SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "fixx:UnvestedCommonSharesSubjectToRepurchaseVested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Collaboration and License Agreement - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_20171101_20171130",
      "decimals": "-5",
      "lang": null,
      "name": "fixx:CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRemainingPerformanceObligation",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Collaboration and License Agreement - Additional Information (Details1)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1",
     "shortName": "Collaboration and License Agreement - Additional Information (Details1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRemainingPerformanceObligation",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_srtCounterpartyNameAxis_fixxNovartisInstitutesOfBioMedicalResearchIncMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2017-11-01_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20190101_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Pfizer Stock Purchase Agreement - Additional Information (Details)",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
     "shortName": "Pfizer Stock Purchase Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "fixx:StockPurchaseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_fixxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "fixx-10k_20201231.htm",
      "contextRef": "C_0001661998_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fixx_ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Member",
        "label": "A T M [Member]",
        "terseLabel": "ATM"
       }
      }
     },
     "localname": "ATMMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_AccretionOfShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of short term investments",
        "label": "Accretion Of Short Term Investments",
        "negatedLabel": "Accretion of short-term investments"
       }
      }
     },
     "localname": "AccretionOfShortTermInvestments",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities disclosure.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER LIABILITIES"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other liabilities current.",
        "label": "Accrued Expenses And Other Liabilities Current",
        "terseLabel": "Accrued expenses and other liabilities",
        "totalLabel": "Total accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_AccruedExpensesAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other liabilities.",
        "label": "Accrued Expenses And Other Liabilities [Member]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherLiabilitiesMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "fixx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_AccruedUnvestedCommonStockSubjectToRepurchaseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "fixx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued unvested common stock subject to repurchase current.",
        "label": "Accrued Unvested Common Stock Subject To Repurchase Current",
        "terseLabel": "Accrued unvested common stock subject to repurchase",
        "verboseLabel": "Liability for unvested common shares subject to repurchase included in accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedUnvestedCommonStockSubjectToRepurchaseCurrent",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock.",
        "label": "Allowed Annual Percentage Increase In Shares Authorized As Percentage Of Outstanding Shares Of Common Stock",
        "terseLabel": "Allowed annual percentage increase in shares authorized as percentage of outstanding shares of common stock"
       }
      }
     },
     "localname": "AllowedAnnualPercentageIncreaseInSharesAuthorizedAsPercentageOfOutstandingSharesOfCommonStock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fixx_AnnualLicenseFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license fee payable.",
        "label": "Annual License Fee Payable",
        "terseLabel": "Annual license fee"
       }
      }
     },
     "localname": "AnnualLicenseFeePayable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_AssetNotYetInServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset not yet in service.",
        "label": "Asset Not Yet In Service [Member]",
        "terseLabel": "Assets Not Yet in Service"
       }
      }
     },
     "localname": "AssetNotYetInServiceMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_AtTheMarketSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market sales agreement.",
        "label": "At The Market Sales Agreement [Member]",
        "terseLabel": "ATM"
       }
      }
     },
     "localname": "AtTheMarketSalesAgreementMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_BedfordMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bedford, Massachusetts.",
        "label": "Bedford Massachusetts [Member]",
        "terseLabel": "Bedford, Massachusetts"
       }
      }
     },
     "localname": "BedfordMassachusettsMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_CaliforniaInstituteOfTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Institute of Technology.",
        "label": "California Institute Of Technology [Member]",
        "terseLabel": "California Institute Of Technology"
       }
      }
     },
     "localname": "CaliforniaInstituteOfTechnologyMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents, and available-for-sale securities.",
        "label": "Cash Cash Equivalents And Available For Sale Securities [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableForSaleSecuritiesAbstract",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "xbrltype": "stringItemType"
    },
    "fixx_CityOfHopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "City of Hope.",
        "label": "City Of Hope [Member]",
        "terseLabel": "City of Hope"
       }
      }
     },
     "localname": "CityOfHopeMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_CoExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Exclusive license agreement.",
        "label": "Co Exclusive License Agreement [Member]",
        "terseLabel": "Co Exclusive License Agreement"
       }
      }
     },
     "localname": "CoExclusiveLicenseAgreementMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_CollaborativeAgreementTargetFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement target fee.",
        "label": "Collaborative Agreement Target Fee",
        "terseLabel": "Collaborative agreement target fee"
       }
      }
     },
     "localname": "CollaborativeAgreementTargetFee",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementAllocatedConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement allocated consideration.",
        "label": "Collaborative Arrangement Allocated Consideration",
        "terseLabel": "Allocated to collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementAllocatedConsideration",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement commercial milestone payments eligible to receive.",
        "label": "Collaborative Arrangement Commercial Milestone Payments Eligible To Receive",
        "terseLabel": "Collaboration agreement eligible commercial milestone payments eligible to receive"
       }
      }
     },
     "localname": "CollaborativeArrangementCommercialMilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement development milestone payments eligible to receive.",
        "label": "Collaborative Arrangement Development Milestone Payments Eligible To Receive",
        "terseLabel": "Collaboration agreement eligible development milestone payments eligible to receive"
       }
      }
     },
     "localname": "CollaborativeArrangementDevelopmentMilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementMilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement milestone payments eligible to receive.",
        "label": "Collaborative Arrangement Milestone Payments Eligible To Receive",
        "terseLabel": "Collaboration agreement eligible milestone payments eligible to receive"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement number of candidates or products for develop and commercialize.",
        "label": "Collaborative Arrangement Number Of Candidates Or Products For Develop And Commercialize",
        "terseLabel": "Collaboration agreement number of candidates or products for develop and commercialize"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfCandidatesOrProductsForDevelopAndCommercialize",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fixx_CollaborativeArrangementPaymentForExecutionOfAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement payment for execution of agreements",
        "label": "Collaborative Arrangement Payment For Execution Of Agreements",
        "terseLabel": "Payment for execution of agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementPaymentForExecutionOfAgreements",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement proceeds from nonrefundable upfront payment received.",
        "label": "Collaborative Arrangement Proceeds From Nonrefundable Upfront Payment Received",
        "terseLabel": "Upfront, nonrefundable payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementProceedsFromNonrefundableUpfrontPaymentReceived",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement regulatory milestone payments eligible to receive.",
        "label": "Collaborative Arrangement Regulatory Milestone Payments Eligible To Receive",
        "terseLabel": "Collaboration agreement eligible regulatory milestone payments eligible to receive"
       }
      }
     },
     "localname": "CollaborativeArrangementRegulatoryMilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, reimbursement of manufacturing activities during research term.",
        "label": "Collaborative Arrangement Reimbursement Of Manufacturing Activities During Research Term",
        "terseLabel": "Collaboration agreement, reimbursement of manufacturing activities during research term"
       }
      }
     },
     "localname": "CollaborativeArrangementReimbursementOfManufacturingActivitiesDuringResearchTerm",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CollaborativeArrangementTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement term of agreement.",
        "label": "Collaborative Arrangement Term Of Agreement",
        "terseLabel": "Collaboration agreement, research term"
       }
      }
     },
     "localname": "CollaborativeArrangementTermOfAgreement",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fixx_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CommitmentAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Line Items]",
        "terseLabel": "Commitment And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_CommitmentAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment and contingencies.",
        "label": "Commitment And Contingencies [Table]",
        "terseLabel": "Commitment And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentAndContingenciesTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_CommonStockEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock estimated fair value.",
        "label": "Common Stock Estimated Fair Value",
        "terseLabel": "Common stock estimated fair value"
       }
      }
     },
     "localname": "CommonStockEstimatedFairValue",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_CommonStockPurchaseAgreementCondition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement condition.",
        "label": "Common Stock Purchase Agreement Condition",
        "terseLabel": "Common stock purchase agreement condition"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementCondition",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax deferred expense reserves and accruals accrued liabilities and other.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Other",
        "terseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_DevelopmentAndCommercializationMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and commercialization milestone payments.",
        "label": "Development And Commercialization Milestone Payments",
        "terseLabel": "Development and commercialization milestone payment"
       }
      }
     },
     "localname": "DevelopmentAndCommercializationMilestonePayments",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_DevelopmentAndRegulatoryMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and regulatory milestone payment.",
        "label": "Development And Regulatory Milestone Payment",
        "terseLabel": "Development and regulatory milestone payments"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePayment",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_FairValueAssetsLiabilitiesTransferBetweenLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assets (liabilities) transfer between levels.",
        "label": "Fair Value Assets Liabilities Transfer Between Levels",
        "terseLabel": "Transfers between fair value measure levels"
       }
      }
     },
     "localname": "FairValueAssetsLiabilitiesTransferBetweenLevels",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state.",
        "label": "Federal And State [Member]",
        "terseLabel": "Federal and State"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering .",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow On Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_InitialBaseRentPerSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial base rent per square feet.",
        "label": "Initial Base Rent Per Square Feet",
        "terseLabel": "Initial annual base rent per square foot"
       }
      }
     },
     "localname": "InitialBaseRentPerSquareFeet",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "fixx_InvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment maturity term.",
        "label": "Investment Maturity Term",
        "terseLabel": "Contractual maturity date of investments"
       }
      }
     },
     "localname": "InvestmentMaturityTerm",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_InvestmentsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments disclosure.",
        "label": "Investments Disclosure [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDisclosureAbstract",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "xbrltype": "stringItemType"
    },
    "fixx_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment and office furniture.",
        "label": "Laboratory Equipment And Office Furniture [Member]",
        "terseLabel": "Laboratory Equipment and Office Furniture"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_LeaseBeginningDateYearAndMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease beginning date year and month.",
        "label": "Lease Beginning Date Year And Month",
        "terseLabel": "Operating lease beginning year and month"
       }
      }
     },
     "localname": "LeaseBeginningDateYearAndMonth",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "fixx_LeaseExpirationDateYearAndMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration date year and month.",
        "label": "Lease Expiration Date Year And Month",
        "terseLabel": "Operating lease expiration year and month"
       }
      }
     },
     "localname": "LeaseExpirationDateYearAndMonth",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "fixx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease not yet commenced increase in percentage of base rent.",
        "label": "Lessee Operating Lease Not Yet Commenced Increase In Percentage Of Base Rent",
        "terseLabel": "Percentage increase in initial annual base rent per square foot."
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedIncreaseInPercentageOfBaseRent",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fixx_LettersOfCreditAndSecuredByRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letters of credit and secured by restricted cash.",
        "label": "Letters Of Credit And Secured By Restricted Cash [Member]",
        "terseLabel": "Letters of Credit and Secured by Restricted Cash"
       }
      }
     },
     "localname": "LettersOfCreditAndSecuredByRestrictedCashMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "xbrltype": "stringItemType"
    },
    "fixx_LicenseAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Line Items]",
        "terseLabel": "License Agreement [Line Items]"
       }
      }
     },
     "localname": "LicenseAgreementLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_LicenseAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Table]",
        "terseLabel": "License Agreement [Table]"
       }
      }
     },
     "localname": "LicenseAgreementTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_MajorAssetClassOfLeasedAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major asset class of leased assets [Axis].",
        "label": "Major Asset Class Of Leased Assets [Axis]",
        "terseLabel": "Major Asset Class Of Leased Assets"
       }
      }
     },
     "localname": "MajorAssetClassOfLeasedAssetsAxis",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_MajorAssetClassOfLeasedAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major asset class of leased assets [Domain].",
        "label": "Major Asset Class Of Leased Assets [Domain]",
        "terseLabel": "Major Asset Class Of Leased Assets"
       }
      }
     },
     "localname": "MajorAssetClassOfLeasedAssetsDomain",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_MaximumSharesAllowedToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum shares allowed to be issued.",
        "label": "Maximum Shares Allowed To Be Issued",
        "terseLabel": "Maximum shares of common stock may be issued"
       }
      }
     },
     "localname": "MaximumSharesAllowedToBeIssued",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_MaximumSharesAllowedToBeIssuedUnderESPP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum shares allowed to be issued under ESPP.",
        "label": "Maximum Shares Allowed To Be Issued Under E S P P",
        "terseLabel": "Maximum shares allowed to be issued under ESPP"
       }
      }
     },
     "localname": "MaximumSharesAllowedToBeIssuedUnderESPP",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_NetOperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration year.",
        "label": "Net Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "fixx_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash lease expense.",
        "label": "Non Cash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_NovartisInstitutesOfBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes of BioMedical Research, Inc.",
        "label": "Novartis Institutes Of Bio Medical Research Inc [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisInstitutesOfBioMedicalResearchIncMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_NumberOfPhases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of phases.",
        "label": "Number Of Phases",
        "terseLabel": "Number of phases"
       }
      }
     },
     "localname": "NumberOfPhases",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fixx_OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs included in accrued expenses and other liabilities.",
        "label": "Offering Costs Included In Accrued Expenses And Other Liabilities",
        "terseLabel": "Offering costs included in accrued expenses and other liabilities"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_OperatingLossCarryforwardsIndefinitely": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards indefinitely.",
        "label": "Operating Loss Carryforwards Indefinitely",
        "verboseLabel": "Net operating loss carryforwards indefinitely"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitely",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_OrphanDrugMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan drug.",
        "label": "Orphan Drug [Member]",
        "terseLabel": "Orphan Drug"
       }
      }
     },
     "localname": "OrphanDrugMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer Inc."
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_PhaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase one.",
        "label": "Phase One [Member]",
        "terseLabel": "Phase One"
       }
      }
     },
     "localname": "PhaseOneMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_PhaseTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase two.",
        "label": "Phase Two [Member]",
        "terseLabel": "Phase Two"
       }
      }
     },
     "localname": "PhaseTwoMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_PreferredStockEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock estimated fair value.",
        "label": "Preferred Stock Estimated Fair Value",
        "terseLabel": "Preferred stock estimated fair value"
       }
      }
     },
     "localname": "PreferredStockEstimatedFairValue",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_ProceedsFromFutureIssuanceStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from future issuance stock.",
        "label": "Proceeds From Future Issuance Stock",
        "terseLabel": "Proceeds through future financings"
       }
      }
     },
     "localname": "ProceedsFromFutureIssuanceStock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment additions included in accrued expenses and other liabilities.",
        "label": "Property And Equipment Additions Included In Accrued Expenses And Other Liabilities",
        "terseLabel": "Property and equipment additions included in accrued expenses and other liabilities"
       }
      }
     },
     "localname": "PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, plant and equipment estmated useful life of asset.",
        "label": "Property Plant And Equipment Estimated Useful Life Of Asset Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Life of Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeOfAssetTableTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of liability for common stock vested in noncash transactions.",
        "label": "Reclassification Of Liability For Common Stock Vested In Noncash Transactions",
        "terseLabel": "Reclassification of liability for common stock vested"
       }
      }
     },
     "localname": "ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_ReimbursableResearchAndDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable research and development costs.",
        "label": "Reimbursable Research And Development Costs [Member]",
        "terseLabel": "Reimbursable Research and Development Costs"
       }
      }
     },
     "localname": "ReimbursableResearchAndDevelopmentCostsMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_RentStartDateYearAndMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent start date year and month.",
        "label": "Rent Start Date Year And Month",
        "terseLabel": "Rent due date"
       }
      }
     },
     "localname": "RentStartDateYearAndMonth",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents and available-for-sale securities.",
        "label": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Cash Cash Equivalents And Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_ScheduleOfLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of lease term and discount rate table text block.",
        "label": "Schedule Of Lease Term And Discount Rate Table [Text Block]",
        "terseLabel": "Schedule of Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleOfLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_ScheduleOfOperatingLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease liabilities table text block.",
        "label": "Schedule Of Operating Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock",
        "terseLabel": "Underlying common stock fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase price of common stock through payroll deductions percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Through Payroll Deductions Percentage",
        "terseLabel": "Purchase of common stock through payroll deductions expressed in percentage of fair market value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockThroughPayrollDeductionsPercentage",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fixx_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award stock offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Offering Period",
        "terseLabel": "Common stock offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOfferingPeriod",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fixx_ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Purchase Period",
        "terseLabel": "Share based compensation arrangement by share based payment purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentPurchasePeriod",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fixx_SponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sonsored research agreement.",
        "label": "Sponsored Research Agreement [Member]",
        "terseLabel": "Sponsored Research Agreement"
       }
      }
     },
     "localname": "SponsoredResearchAgreementMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vesting of common stock from option exercise.",
        "label": "Stock Issued During Period Shares Vesting Of Common Stock From Option Exercise",
        "terseLabel": "Vesting of common stock from option exercises, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfCommonStockFromOptionExercise",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value vesting of common stock from option exercise.",
        "label": "Stock Issued During Period Value Vesting Of Common Stock From Option Exercise",
        "terseLabel": "Vesting of common stock from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_StockPurchaseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for stock purchase agreement.",
        "label": "Stock Purchase Agreement Disclosure [Text Block]",
        "terseLabel": "PFIZER STOCK PURCHASE AGREEMENT"
       }
      }
     },
     "localname": "StockPurchaseAgreementDisclosureTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_StockPurchaseAgreementRemainingAllocatedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement remaining allocated value.",
        "label": "Stock Purchase Agreement Remaining Allocated Value",
        "terseLabel": "Stock purchase agreement remaining allocated value"
       }
      }
     },
     "localname": "StockPurchaseAgreementRemainingAllocatedValue",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_SubleaseAggregateBaseRentObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease aggregate base rent obligation.",
        "label": "Sublease Aggregate Base Rent Obligation",
        "terseLabel": "Sublease aggregate base rent obligation"
       }
      }
     },
     "localname": "SubleaseAggregateBaseRentObligation",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fixx_SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of unvested common stock from early exercises subject to repurchase.",
        "label": "Summary Of Unvested Common Stock From Early Exercises Subject To Repurchase Table [Text Block]",
        "terseLabel": "Summary of Unvested Common Stock from Early Exercises Subject to Repurchase"
       }
      }
     },
     "localname": "SummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseTableTextBlock",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fixx_TaxCreditCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards expiration year.",
        "label": "Tax Credit Carryforwards Expiration Year",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationYear",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "fixx_TenantImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvements allowance.",
        "label": "Tenant Improvements Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementsAllowance",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fixx_TwentyEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Employee Stock Purchase Plan.",
        "label": "Twenty Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwentyEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_TwoThousandEighteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Incentive Award Plan.",
        "label": "Two Thousand Eighteen Incentive Award Plan [Member]",
        "terseLabel": "2018 Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenIncentiveAwardPlanMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen and two thousand eighteen stock incentive plans.",
        "label": "Two Thousand Fifteen And Two Thousand Eighteen Stock Incentive Plans [Member]",
        "terseLabel": "2015 and 2018 Stock Incentive Plans"
       }
      }
     },
     "localname": "TwoThousandFifteenAndTwoThousandEighteenStockIncentivePlansMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_TwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock incentive plan.",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_UnderwritersOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters option.",
        "label": "Underwriters Option [Member]",
        "terseLabel": "Underwriters Option"
       }
      }
     },
     "localname": "UnderwritersOptionMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fixx_UnvestedCommonSharesSubjectToRepurchaseIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common shares subject to repurchase issued.",
        "label": "Unvested Common Shares Subject To Repurchase Issued",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "UnvestedCommonSharesSubjectToRepurchaseIssued",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_UnvestedCommonSharesSubjectToRepurchaseOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common shares subject to repurchase outstanding.",
        "label": "Unvested Common Shares Subject To Repurchase Outstanding",
        "periodEndLabel": "Unvested shares, Ending Balance",
        "periodStartLabel": "Unvested shares, Beginning Balance",
        "verboseLabel": "Remaining shares subject to repurchase"
       }
      }
     },
     "localname": "UnvestedCommonSharesSubjectToRepurchaseOutstanding",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_UnvestedCommonSharesSubjectToRepurchaseRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common shares subject to repurchase repurchased.",
        "label": "Unvested Common Shares Subject To Repurchase Repurchased",
        "negatedLabel": "Repurchased"
       }
      }
     },
     "localname": "UnvestedCommonSharesSubjectToRepurchaseRepurchased",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_UnvestedCommonSharesSubjectToRepurchaseVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common shares subject to repurchase vested.",
        "label": "Unvested Common Shares Subject To Repurchase Vested",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "UnvestedCommonSharesSubjectToRepurchaseVested",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfUnvestedCommonStockFromEarlyExercisesSubjectToRepurchaseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fixx_UnvestedCommonStockFromEarlyExerciseOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock from early exercise of options.",
        "label": "Unvested Common Stock From Early Exercise Of Options [Member]",
        "terseLabel": "Unvested Common Stock from Early Exercise of Options"
       }
      }
     },
     "localname": "UnvestedCommonStockFromEarlyExerciseOfOptionsMember",
     "nsuri": "http://www.homologymedicines.com/20201231",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r225",
      "r226",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r225",
      "r226",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r225",
      "r226",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r413",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r148",
      "r149",
      "r199",
      "r201",
      "r414",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r199",
      "r201",
      "r414",
      "r444",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r17",
      "r151",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r33"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "fixx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r176"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r43",
      "r44",
      "r45",
      "r405",
      "r423",
      "r427"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive gain"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r46",
      "r88",
      "r89",
      "r90",
      "r316",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Adjustments For New Accounting Principle Early Adoption [Member]",
        "terseLabel": "Prior to Adoption of New Leasing Standards"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPrincipleEarlyAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r292",
      "r293",
      "r294",
      "r295",
      "r376",
      "r377",
      "r378",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r228",
      "r252",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area Of Real Estate Property",
        "terseLabel": "Office space leased"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r161",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r84",
      "r130",
      "r139",
      "r145",
      "r163",
      "r310",
      "r317",
      "r331",
      "r392",
      "r403"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r39",
      "r84",
      "r163",
      "r310",
      "r317",
      "r331"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Financial assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r159"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents and short-term investments, Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Cash equivalents and short-term investments, Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r157",
      "r170"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Cash equivalents and short-term investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r154",
      "r158",
      "r170",
      "r395"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Cash equivalents and short-term investments, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r156",
      "r170"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.",
        "label": "Available For Sale Securities Gross Realized Gain Loss Net",
        "terseLabel": "Realized gains and losses on available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r87",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment additions included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r72"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash And Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Repurchase agreements",
        "verboseLabel": "Cash equivalents, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash And Cash Equivalents [Line Items]",
        "terseLabel": "Cash And Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r73",
      "r79",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash Cash Equivalents And Short Term Investments [Text Block]",
        "terseLabel": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r332"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r82",
      "r84",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r115",
      "r116",
      "r117",
      "r163",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r304",
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AND LICENSE AGREEMENT"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of additional shares available for future grant"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r16",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock Shares Subscriptions",
        "terseLabel": "Common Stock, capacity terminated"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2020 and 2019, respectively; 50,268,666 and 45,138,408 shares issued as of December 31, 2020 and 2019, respectively; and 50,265,575 and 45,116,742 shares outstanding as of December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r227",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "STOCK INCENTIVE PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r55",
      "r397",
      "r411"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and Purchased Software",
        "verboseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r120",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r194",
      "r195",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r194",
      "r195",
      "r200"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r194",
      "r195",
      "r200"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r221",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges Policy [Text Block]",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r12",
      "r13",
      "r281",
      "r393",
      "r402"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.",
        "label": "Deferred Rent Credit",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r33",
      "r341"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r35",
      "r341"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Capitalized R&amp;D costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r287",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Equity compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Discretionary match made under the 401(k) Plan by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r174"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share-basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r273",
      "r298"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r273",
      "r298"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r273",
      "r298"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r273",
      "r298"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r273",
      "r298"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationBetweenUSFederalStatutoryTaxRateAndEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "fixx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized compensation expense estimated to be recognized over period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Manufacturing Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r101",
      "r114",
      "r167",
      "r190",
      "r192",
      "r260",
      "r261",
      "r262",
      "r294",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r221",
      "r324",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r326",
      "r327",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r208",
      "r213",
      "r221",
      "r324",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Quoted Prices (Unadjusted) in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r208",
      "r213",
      "r221",
      "r324",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r221",
      "r324",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r221",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain Loss On Sale Of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "auth_ref": [
      "r79",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.",
        "label": "Guarantees Indemnifications And Warranties Policies",
        "terseLabel": "Guarantees and Indemnifications"
       }
      }
     },
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r70",
      "r173",
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r171",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r274",
      "r279",
      "r286",
      "r296",
      "r299",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "auth_ref": [
      "r268",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.",
        "label": "Income Tax Examination Likelihood Of Unfavorable Settlement",
        "terseLabel": "Tax positions, description"
       }
      }
     },
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Expense",
        "terseLabel": "Income tax expense, interest or penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r100",
      "r101",
      "r129",
      "r272",
      "r297",
      "r300",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r79",
      "r270",
      "r271",
      "r279",
      "r280",
      "r285",
      "r291",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidRent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for rent that provides economic benefits in future periods.",
        "label": "Increase Decrease In Prepaid Rent",
        "negatedLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Cost and Variable Lease Costs and Sub Lease Income"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Renewal Term1",
        "terseLabel": "Lessee, operating lease, lease not yet commenced, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r356"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease agreements additional term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r84",
      "r140",
      "r163",
      "r311",
      "r317",
      "r318",
      "r331"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r84",
      "r163",
      "r331",
      "r394",
      "r407"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r84",
      "r163",
      "r311",
      "r317",
      "r318",
      "r331"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual At Carrying Value",
        "terseLabel": "Outstanding claim"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Mutual Funds",
        "verboseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r50",
      "r54",
      "r71",
      "r84",
      "r91",
      "r95",
      "r96",
      "r97",
      "r98",
      "r100",
      "r101",
      "r105",
      "r130",
      "r138",
      "r141",
      "r144",
      "r146",
      "r163",
      "r331",
      "r396",
      "r410"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "New Accounting Pronouncement [Member]",
        "terseLabel": "Adjustment for Adoption of New Leasing Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r138",
      "r141",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r350",
      "r357"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r113",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease Lease Income Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCashPaidForCompanySOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseLiabilitiesDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r354",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r353",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term (years), Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r33"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "fixx_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r48",
      "r51",
      "r308",
      "r309",
      "r315"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
        "totalLabel": "Total other comprehensive gain (loss)",
        "verboseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r43"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Change in unrealized gain (loss) on available for sale securities, net",
        "verboseLabel": "Unrealized (loss) gain on available for sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r61",
      "r63",
      "r155"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r207",
      "r213",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "DEFINED CONTRIBUTION PLAN"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r229",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2020 and 2019, respectively; no shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "verboseLabel": "Net proceeds from initial public offering after underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in follow-on public offering, net of discounts and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds From Issuance Of Convertible Preferred Stock",
        "positiveVerboseLabel": "Proceeds from issuance of shares of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds From Issuance Of Private Placement",
        "terseLabel": "Proceeds from issuance of common stock in private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r61",
      "r62",
      "r155"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale Of Available For Sale Securities Debt",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r255"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock from option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock pursuant to employee stock purchase plan",
        "verboseLabel": "Aggregate proceeds from shares issued under the plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r47",
      "r50",
      "r66",
      "r84",
      "r91",
      "r100",
      "r101",
      "r130",
      "r138",
      "r141",
      "r144",
      "r146",
      "r163",
      "r308",
      "r313",
      "r314",
      "r319",
      "r320",
      "r331",
      "r398"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Disposals",
        "terseLabel": "Disposal of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r79",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Estimated useful life of asset, term"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r175"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r177",
      "r408"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r79",
      "r177",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful life of asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r215",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r215",
      "r359",
      "r361",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Repurchase Agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r267",
      "r458"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r79",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r77",
      "r391",
      "r404"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r192",
      "r263",
      "r406",
      "r422",
      "r427"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r101",
      "r167",
      "r260",
      "r261",
      "r262",
      "r294",
      "r295",
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r137",
      "r142",
      "r143",
      "r147",
      "r148",
      "r150",
      "r198",
      "r199",
      "r375"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Collaboration agreement revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Remaining performance obligation, unsatisfied portion",
        "verboseLabel": "Allocated Information Committee obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Annual minimal royalty fee"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Net proceeds after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntiDilutiveEffectExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule Of Cash And Cash Equivalents [Table]",
        "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]",
        "terseLabel": "Summary of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block]",
        "terseLabel": "Summary of Short Term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation between U.S. Federal Statutory Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r228",
      "r251",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLifeOfAssetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the comparison between amounts disclosed under previous guidance and new guidance.",
        "label": "Schedule Of Prospective Adoption Of New Accounting Pronouncements Table [Text Block]",
        "terseLabel": "Impact of Adoption of Previously Reported Amounts of Financial Statement"
       }
      }
     },
     "localname": "ScheduleOfProspectiveAdoptionOfNewAccountingPronouncementsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r77",
      "r391",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Schedule Of Restricted Cash And Cash Equivalents [Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r229",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r234",
      "r240",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity under Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Stock Options Valuation Assumptions Using a Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDepositLiability": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.",
        "label": "Security Deposit Liability",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Arrangements To Obtain Goods And Services [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date",
        "terseLabel": "Share based compensation, discount from market price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Weighted-average risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Weighted-average risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Number of additional shares added to the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares outstanding available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "periodEndLabel": "Number of Options, Exercisable at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Exercisable at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of Options, Cancelled/Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Cancelled/Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share for options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r236",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options, Outstanding at Ending Balance",
        "periodStartLabel": "Number of Options, Outstanding at Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price per Share, Outstanding at Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price per Share, Outstanding at Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and Expected to vest at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "periodEndLabel": "Number of Options, Vested and Expected to vest at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Vested and Expected to vest at December 31, 2019"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock at a public offering price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Stock options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r246",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansScheduleOfStockOptionsValuationAssumptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable at December 31, 2019"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable at December 31, 2019"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and Expected to vest at December 31, 2019"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r82",
      "r84",
      "r102",
      "r103",
      "r104",
      "r106",
      "r108",
      "r115",
      "r116",
      "r117",
      "r163",
      "r190",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r88",
      "r89",
      "r90",
      "r92",
      "r99",
      "r101",
      "r114",
      "r167",
      "r190",
      "r192",
      "r260",
      "r261",
      "r262",
      "r294",
      "r295",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r114",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreement",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "verboseLabel": "Conversion of convertible preferred stock into common stock upon initial public offering, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r15",
      "r16",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock pursuant to employee stock purchase plan, Shares",
        "verboseLabel": "Number of shares issued to the plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, net of discounts and issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r190",
      "r192",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Issuance of common stock from option exercises, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansSummaryOfOptionActivityUnderPlansDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r15",
      "r16",
      "r190",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock pursuant to employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r190",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net of discounts and issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r190",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Issuance of common stock from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r21",
      "r22",
      "r84",
      "r153",
      "r163",
      "r331"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockholderSEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r352",
      "r357"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r339",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r339",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r339",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureStockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "verboseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodStartLabel": "Balance balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r292",
      "r293",
      "r294",
      "r295",
      "r376",
      "r377",
      "r378",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfPreviouslyReportedAmountsOfCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosurePfizerStockPurchaseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r206",
      "r221",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r269",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance due to deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r351",
      "r357"
     ],
     "calculation": {
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseCostAndVariableLeaseCostsAndSubLeaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average common shares outstanding-basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.homologymedicines.com/20201231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65877542&loc=d3e27249-109313"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39896-112707"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r459": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r460": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r461": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r462": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r463": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r464": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r465": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r466": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r467": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r468": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001564590-21-012490-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-012490-xbrl.zip
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M#.; @YW]9X+!P8O"X,J+;D\Y8V02@9QY/FX 0J?Q3" X7$D0/(X$]<;VWO.
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M+H8%6Y^.F2-<#-N-RHQE[10MZY3V]2<\Z12^B1;3 _#3)+5.4N^K*5<OB@I
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M<Y.UKVLO]LD#SVQG8#DXZ6@^8?[6X<9MDC,B-^'=O"K0&X?:N0SW$+*Q!V>
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M_#5.F;-1$6'H%,^0I[1"J9XIK3S;.8K;R\,L.,S[ :.H>O9$/UCO&C\): V
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MV2Z[8WXX(DO(":,X]]+8&WJR%XCOW3+?&X2AB\L K';P_;@BWPL(_C&0$[Z
M/8Q$CV!YM]PO9SZSY28RMUBN'=L"6B/?EO ,NW^)S= [AFG*$=& .(W\$4R<
MD;F5%"8V7#2+=J\' "$3%;S@#H<=6[=!>"\ZJ22!^,R]Z!:>F 2.2!D@[*?E
M$[["@0/*8?2L)^:\(P;'L)LQG",=*!PW_(+H*9<-1\8X5?W",ZT0?QYX<$@F
MLQC"RA!P_MARO5X/& >^@8=#>/4X!X;9SX.C@NLB $](J_6]E ?- -$4+C^G
M0K%T-M\&)A(.&=(2 P"-PP0^!B #875>;SR+Q2)L&!]&@JT#1Y-,#(ZT(IF7
M^NK>\_W\=]$@3'PW_ZT@F/RW2 OY[U*$SO_B%#U8B*#\MS&<#IM\'0__*E@%
MLE,&B%'PRB[P \"DB=U$0/<%EP.FN5[!-L,8P6[[\OL*HJ+Q<B](F+HEY(29
M ;!FXG."LP =B3.!GP7=1<!X?)LK]$8.060]ZV3GE!;$/<( 2$_N1SS\=Q37
ML**NC<0D%C7C93X> 3Q#<GP0G$3# A$,EB8/1?Q-33<E=0/<5;.Z5/+$\!!7
M\IA[6(LX'V(W-K )%#T9\9+>Z61:&A=*.<479^P*Y(]]*X!C1XKMNUCJ0Y_G
M 2Z\'0$<)<3^D=_95I ,NW"H\(PI_)1P7W+4+#?%!P@6:3)-8I7Q((R8./59
MFS*U [I2OMAED<.]+@KF #->E<XDS')JBFJ=BFL5]L)YA/>T15+QU+G"$@Q7
M<ZM6L;;,N[=PXY<VCV5D2HP5@1LBV7"7OMBG^]+,W/]ZOE[66_33UM.;PU:V
M\#BD;N*#JI+=4'M>[!".JC66.V<A9ZCG5Y Z!64QT9L-Z!DT#,0Q%MQY/ SP
M#&NT%%0Q--8)W<-4-I"XX<2!G4BTACT@UN._0E7W8@M@&X0Q:J:1U_4)W4V5
M"BZ7S,P"^GCDC>LN_/\$:2_$,&"E[<[/EXB9A4XB-3')9#DC_<MA<PL0)P1Q
MRF)D__A8:L.'SR8^ HPGD+S&CDWU,*?<XK'/U 3OY?J$2"$!]3<2+*@W>,;(
MVI.9QJ30 B/4DA+D \C53"T9S#8VBI'1<_9WXDGC%>P,'S1[1#+?OB=$=T.!
M?*#.$*8E7;@"%IR,A&C@\  P<)E07N>Q;D'$,P_LJ_L!(W&/AJ6$C-#ZQZ B
MW,.!Z.XYE:S<K%C"Y 2AX7$X482ZPU(%XAZ6,PW/)5X?S.?+60Z._]SEUOM/
M&^8(7"=/X$HX'S]/<_4;:]F;^]27X)7\5*1-Y??]/+M<NEBZ,#1SE->&!@SZ
M+X,-1L+;,"F1LRHJ:K6I<@I""54MJUVQ1+BO55.J:I&*.E.&64(),P2H [IZ
M+T'I \PY\EQRT:',F+)2Y-@!NE/01H35>M+\$3/U(BP@$W;:2&<@3WN2,&B4
M>RZ%'$&"2:7>!X4;+OF@%$?7NU-H(R@%PTHB1$4!&ZL;<MC$+UOU+<MAOA^-
M; ?NUW_+4!?]K>)I= >BGF^/(O9!??AHB2!8HUZ70;"9L6QQ\79MM_FOC_<#
M+V95?#<BTCVW1U.#:+3^F<Q&IW ^AJN2>$#8A_/C+>@QP&FJ$DX?YF,&1%_-
M*9E-:P&?&7SBOW)[_J\? F8N*CP_T\F'CB>Y)&UD69N24>N)O<WY>D0<8%A[
M'W7X>RH";2KE9& WY72G)!$405_>5J?_YCNA_"W*!08L&-U9KA4!G+T>6 -@
MD_A@>L*&@$N3I82F@W(ZI#Y-;52AZU0\QU(N0%<]HB>=@/ O2!I&;%LH]V3D
MH/<(S0WI4B,_7=CSB+T+>_A>>,0", 6T-QPU_RB)J.I/7>_Y7CS^]S]V#R>P
MC*+\$S'^4KBL&(F4PJ44+J5PV1CA0D)!^IHLY)7DE?+!"!D!N_;14NHE&'H%
MJ9&&+:0/M(=LOV=[=%G8)48?, QAHWTI R%!OZ*E XB0+KP&^3;<H7QVP@EH
MQ,SQX6B^,([N=.\_]%+E75/!=P=]>NCLBDB<6*4\64NJ*.5)*4]*>;(Q\H2,
M%=ORO:&'^4%29 1]F5(FHC-!J/_$O"6#T^.5?18P,%ZL(0;/O,!,O *Z=P8D
M2H;V+<,@' 9H/ =C%"!0&!Q[8DN!HE*WA'%CI)O=>:894LJ-]<3^4FZ4<J.4
M&QLC-]##-&#VG8=!=]GJB6(DE-63YL5^/6M7&_5FA1CZ,(S 6'#O,,[L3AH&
MVDJ1-UENR$3.!@<C!3-L..LGOBWDDLSEI9Q-<95\K8K%I%**N95L@$0F#@QL
M#D*K%"MK3!RE6"G%2BE6-D:LR'(AL UT'KI1H%'@2Y*YQC*%. CAN@F#),*T
MJQC!F5HDMS@0-F>.J/0_%&&402C\6A'E4TV\VO2 U:SS4)L](H"3Q!Y*'EJ,
MQ=!/AXD)S!D$L.O^6"9*,Q9(2:9*=9CU/?!$)UG:'XJWP#I).)AF%96"QZ7A
M1EG&XB':A$L3A0<)''R^,D76<5!!2W9Q$SLL!>,:DW<I&$O!6 K&S1",F R6
MJQ84%2J3UM ()_Q2B@!::#X+^O%@7!'B#-/3$EW*Z 4#)I,#DD"*OHG\ )%^
M8,:9L#P2A1*F5'./<KY=YMMC*N&0$2**(<$U(%>I"(J$%+PE'TBJE)&DU>/
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M2U111J6$D<,XZV(S>0^/J.<G:")WN8W#<J5[<,!L'H/R!H!G^&TB>V+=>F[
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M.M[$[B@Y+O8H.'U'/7%\?W:^7>9VY4./Y"@"8/LCK#AB^!8V0G\I%TDO<@0
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M11E)<]5(C>8^"CI3VCJB/S!>7;;;31%%PXFJM"E.(?+UD<2<VS")"<[TA^A
MC"E)6603-;IJL(J1MZ<D?8#.%BY<7C'S@"2$'I=YC^6&\';LSY5.4[&%UZPJ
M'?R:[LC(ER>.>$?E6%HCQX)I@;<B5NP%L]B (#QC3W*12LA'8H55%SD.#59&
M;>!.2M^+.>K?;&](WA49+IJ@QRQ>2J8@W:*Z7DS6 Y+B-FVCL_E==_R#C".M
M8$X]/G*/%57 (%2; 2P3= @*W)+K/A8.A2P/I!I&1!%9Y^;)'!$!!'L"!'@
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M?DDI80Y537%QZJ@AG$<WP>DFT6^]H[G[JQ_-7==&2ZOB\7BD/ W E3A2!K/
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MYM@&R.Q!D^<T&5<:\@V=?6%;KGMYI,+DHF]-+&(C "@=X<!6-R1UL2A(1D>
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MFR>.V>9EU\".!\V+ANEMH_D%[UF3BXIF*W22*YU/"DZ3"C,B [F:90U/&;G
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M6,>EQ47M6#?8Y3?1Z_^L8E<D[*URRQ[?N66WW2U[OV/VCU[<1S[:I$'&2!;
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MVJGJ,.@ZH;%Y^5YX\:W)+X ]0"\T;O-D #T0A(UJ59RQ_,Q7((@LBVZ9TM(
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M=6*S<=L]$N@(IQ4KOO.I):<:9+'I<*-=H,K6%&LI)0U>JGF66.Y4=&&?&7Q
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MAL.&A"P\>3O42 D_OL4<9%0LS$S:<!*4M/MT9J?MM0"[06D5&C^7M)IBF#+
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M$OVJN'!/"8:PC)XB6(-T##KIHZFR9)G/0(V56YXN%UHH!W%"-7QVGCO"U%E
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MP]SI,,M8VL3GCZ/6PR F^1J5-O((BD2(I$G!H.OQ$4VL.(R_&FXM,DKNG<T
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MT)]L8#0QAN?";C<E2839#3E;*&8+4,FR#E;IR,\8[IQMA9_(L6R+@=0Z!K9
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M7R'RG;.@>@;];,38H[]7@!PNM"?C#L+W%8(KLO-/OD"#^^-'<U?+!GG$%]0
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MX(FS2"==:#D.7TIVU%1!P37=61>KVS+E(70A4TEV<.AVXG\'!\A,AT,]?RB
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MR_I!*Q6+J!UF%\><K^P@URL<BK=AE5*Q6S<Y%T6YF%)29A3J(;7\=JQ9)RE
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MV#8 #^=1,5-#/(;OU@-2 G5>.?01F[HTQR4-GH>OC8#5@F"GY(0Q*9!&%&^
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MOU!M&QJZQNT>>D[POCN%FY,FGQ""A@3O"H[4D.3.JF-#_NDO E]](+^</?S
M<IEG@H?Q74!'/TH%-4SM6>EJ_ +IPQ=@-&UK_3!I2Y@ULZL-NF<RQF[LRLR*
MH)R9^=LPL+V4+(4B1V1HE)"Q';(PMA_A9 ']B"G!WX0*Y<0/X,L50"U7W'[T
MR_GP;@,IY8E1XOW+B&/OOYF_=.=>T%8U^V($&>VT^&"O6 ,>V+I\J-993C]\
M.5OU577!.<#"9NU1YO[P)/Y>#N^KR^>7,]1BP0Y[O<9/>0%K KG3E6:A1Y_Z
M^.LOW<,XHE1?DTFIK!I*#LJA;P_W$F)W">\V@(BE13!P%3O2M4'KF'*ZC[X
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M QN^"3\FQ8'E/_%)V*<[DJ";(B=[IPX$"YUA#./N,^-12=>XA%5$7BS#HK$
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MMI^I[6=J^SF/MI]Q>NB,Y/,&_W8%QC$BSTT<"AF@G1&(Z=VIFR?P@!,^MI/
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M4?B8!2:12#,5OLC+LRAW2/GJ.' W^^'E][,_QX/5]70@Z#SJDDI8) VKA?P
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M+2T"Y9+0,@'=V_KDYHK$RKI T)Z[0^1C?4I7,=W3X5,X/F;-=[52;*$*S"K
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M=ADJ4(X+[$C*M/ :6G77O;@]$MDI/SY#Z[=O*R;WDDWLLQNEU%ZD[UK2ZB#
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MC,JW^E]V/U+J;6/G"DIM,QS0(,<IKZ5 P\"WDD:LQQS&B1F7PBY,FW!,C>E
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MO61[,NP16HGV?= 89GIUU$5Z;+%3L./? QXWG^VPMG8.V7'!5>&(XN;=C6%
M8-J?4P@;<G3;!WM%Z3K?_&SS.[^X6OPGC>)TS>/-G[_ZEUA+::.)%O,A/!*
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MFG_QE<2XK: ( 7%L!-]/2HU$OK_LVK!137,/!,@6?:.#%,4=8Y['OD]D*7)
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M:.X.VV/!_-4\^#'L9%(%,V^8'^7%'AK:\W6U8M&6/:DVD<J]IB_+P%BB9%;
MP*GGM7FM2504MZ$1+B!G=\?&7P]G>)84-I3%"2R))^QGU>?[Q( )A^,>,W&T
M;H?R/5<@Z5@?0]GY&=\(?$)'U,9(IZ;IC :;I^J:81<ZX"Z<DF'+K%[:-629
M5UVD13^,!-E#862SBDG$VQJTWGS&[Y0H4#!T>!+QN _\?.4.A.79TY-<E8LF
MX(" *1!#S-D2,PJ-=%WJD)8LQH!A:,9Q.!'32#^8;N(F< 4B\TC6&J_&).Y_
MHPOW:^T%X@%)'HODT6[>\; ^>U"P7:>PS7P )Z ;FE#QY/2' 8H*B.*C$$7&
MM-Z'\-Z#'^G4L4Z=\QD%],@C)_Z&SI$\UT.(M[6I=0062YAR^CW>!Y/"!T48
M,_OQZ%R?/L]?&^!]+=X=^)=";/\0XGC<U/KR]G[Y9P6ST)-&(CBQL'8,I8"_
M >P(/1_# V&7HJSSG>XK4AMX:+JV0J \\'D R-!Y[2?6$Z.J?(YHEP$B8=?3
M!6!Y%L0 8%/M][45?RHL!5P3G)3FX/3)Z<#C8U.O%SX'^K:KH!;LY;.WEGGJ
M. <<ID[WM#Q!:)==6PJ@G T<.]DES3KT!SHD=.)[+M@)**#7@@$0+?""6-X>
M*/)^P5T;,O4]4K@*\-<J&-VAZJ%GG0;5<?G'9^0+1:OSC>1.XF"^^W(C"D7*
M@B3"K%AU&5:EZ$$#<* KX@O%8D^G5YY1YDD+ZT6LND7$S:!SXN"-^+4;2'>.
M5"'&;0QZ1!ZZ@LAT^TZ'\,F0P/6&> -9Y6;QFAQ1=466H28O-%P;S,R_7PO,
M#"_U+[B2SPEGQA^"MAMY*X]8")Q7^O6NPHBW-HCQ=QR$0VX"^F$/5)JS/J58
M_W/>V/?.[#&@A36O*=R&PFFZ5C8ZJB?'NYU&13WSCNHJ[*,>[V"+Z0C'87UH
M)Z&8:)=_4Z )A=@YQ5#SOIEB0=XLOF)'EB-647.T?>KW*L""]XUH!5Y$-UU?
MJLC="#'V_#5GDD>F7]M #')G>130-KK$1V:._M4B*O%!VSVSQ\K:)T4"@332
MC%,#AN-'<K 2O-8&NR HGX:T>BTX0=]NM&6TNPM3( ^)F 7F,QT&.D8-K56Y
MZ'<80V,R&6:+@59!N+09$#5F^#./N!RGR0@.R+J0>UQKT2F:=CCY&KI=X1<Q
MGPU]SL6S$29G#'<EH#B6^\G18*$)@"G+<=VC28D4;9S%3Q)0WU\L%?7L)"\+
MU4-RQ!Y"%R:R&<49*R/&1?)]'PCU8#4VX0$2WLDI5YCGC%?(SCLT1>A)T,TX
MVDVDI:):,7RB^*ILS;9\AD:FJ9?OD]UHG!6%WTY"Q39#+ CM,E;,LIQ 'R;1
M8,N5XJ\3'S^E3-YNX6G_>C(,^)6Q)UG38$(PTH; !'L[ZC,,#8.WL9,_]#$!
MN^Z&.XTO4Y3^?3KBRAH(2W8.B(M>?J5>0;:#$R$5)S+.;=@B(=K0<NV'.MK.
M1F*MBHX 9[!T0Y$5UE#YL9MR^%4JABM;XG5+,@1!J#3 CKWVLC= RW*Y(L9>
M,M ?&[1*RG$:4DK@]L</X^&;>#'O6N;=(I5+QZJUQ+IAV)E..04D5NBF\^[3
MS>7FM[^* *H1@2[W4N]HJ[M&LFQWRF"9\)<V@WAT_18HC'?B=][5[9)6;AO*
M^K#ES I=P99[6S'RML2L#N9[6R&TI9@3ZHNE8%^WQ\7[<&2PU]#UVVKOGBO"
MF1410.H!^'Q6)P$]&BNLM:#61XO, ;& X:MEYHJ'(4T+&)XSGHJA3TL,+P<
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M,AWA5]_^]S=?O?C\]P@]%V_XH'[^&3;NY6?NU#0MZ1DH# Y9C>4#^HA\:>
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M$-YK0'6V@#,&I$?'!11 =*)'#'NL@?607UGKQ6_GUHOK:KV8@-YY8K^"=_I
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M2-BA]%VL01^V@?483T,Q022XH'GU(@1T?&(E6+;OT'^.#K"^7T'.UP:Y7)>
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MA*6:)1%*.5'QGO=5)]#[(W]^Q7E;YO&"/).5I6>C^WR2-,26M""T0>@_+5
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M4Z)J<TUFI4\U?W5Y&A[)X@Z&QI U? ]3W"])#)ZV4YS;OW/;%6WFL<* &GR
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MV_@G86]5UAA)(T@J B[O;F@LQ_1)LD?XVWM]Z((,;@6* $#):WY?IM$^12V
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MCYT1A'O27+X8<*ZXESN^XFD_VV+=R@EP#VT$2L!RE'>W9,(H0:UU[-BCQ:#
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M4\M/2=C&5I9,\5VXY<X&$M&>;Y*A"1<Z/54B*W'K1\XR*?Q&&"YYBR05)Q!
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MN[@[=,D#XF.9OJFM\3"KH<!^ 1TF=:8/M7:\]V0ZO[\KZ7QR(WR7_D#B%'1
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M'U]T6)?=Y.ARHS&A+P=^A"+ZZ?0]5FSDDJ[[SNG&(HVQ[4)_UVSDZGRVK ^
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M3MO(XG=3)WT"P*IC^GVK^%V]DG&J0NBX>@^$J*(?)K AM[Z?D&[_#D5L>@&
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MCY$]? 7^\%>?+"<B9:P"[\P,7[%@O_;URS\ UH>VY87@H>"WK_X@,SKCCW!
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M'CJ-YN.;Y>+.)G5=^R*/PY22\'$Q0@83R'[:P9I[G;.Y"<6F8@]C.?JH$/#
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M\N;E@EY9A;S<Z4T3>G5^?V@^%$@R<.^&M=3M8G@M^<(<NGG+97-:0XG4G^0
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MBBDBU[)CYNIVG,<G75(V%._1W=:!W)LUTD5:&8 ECC4G99!R92=Z"NZLMS7
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M'21ELSH (T\R\U9/-W3[/%TO,(&W-7#!&"N&@62[4N&E@ L9;LOUJ"Z_7/S
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M5$+Y.-R%!#$ A28%5_"EP7B# _=7KV.L>@$C_3$#Y9ANMOB8TMX45^*I #S
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M(KO>Z?X!E]YBSU(8V7.\0;_3O5B_^D??+N#>Q(6:M<CNPJCQ^@&(])"T$5]
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M%^_/WI]?G/WZQ^NSSV=ZS?"HHYUPD,ZW-AGX.BB#32\=^<S%M3RU.L\)\4I
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M>&PX+\7Q>"+^/N_M=_W^D;2H:25W?A1 :P,;6FH$!="VAY<":$\&:-U3__1
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M#.(D+J>M*]&3D'M=5:X[;JU;P09V>';=GSGI]_KMXXVH2#O8(  ATK^S;!"
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M@8>V<D84I!UL6%!B(.H@ZK"C;!"\:"MG1$%V8PM_:QAP'A0CWPOA7T_]5<5
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MF#N_0:Q_RV18K+]8?['^8OWGK3_G"IOKF'UG&1/7-'GYEV,JO5EZ48Z4$$(
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MLWB(SSL9J*L@Y82U,0R+NJ/GP8T]TY<# *VE2XXRF.O3D_)!F4[*K%89?<H
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M[]/E;;_=PI3X/FLA^\X;YW:P@?V;W79?^N"_] _;QQM1D5:P00!"I']WV2
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M+QS+\L*H( "444)VH!!V&;$)PS3L__U9]QE(=X*';(9PO_VL70;Z;)P0=A3
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M"/MB>'G(OM ,?3J;K"C$X,_!UXT/YB]C"LH8.-6$8CB6BD/*"Q'X8FN&'!/
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MEWH ?$XK3L9\\8EXV^T<'SI??D9Z\%<\@,/C3O]O+_4L#0')LGM\G9.'T=7
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M$S!K=(?=]T][#SYC1<!,P$S 3,!L8W@I8+;%8-8_\(^/6U<7+%BV+/O[4QD
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M%TR5V@N5E_>PJM_* ",V+\@TEPV,V"].>D=6[Y +8C;-AKJJ" ,$2W]SV<
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MPU=.0A<("31),[;Q2)477Q:N<^#GZQ4RVXX;V4F$*0PY"&[4&@);)9Z&6X/
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M.@8 BPP&/L*(C_;8X+.';ACA4LPPB;"\' ;S]>+C5S,LT6OOP=2!C#!@-W
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MUR26(&IWN;+%+9:Y??)F6=1="?.;W1GYY?&^U>MM[.B:9?K5*/59.V_#P,+
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M*[!B;W[9(BALU'$Y:[/50LKFG<T[F_?=,.]CZ?HQ_,]*\S;DJX=!G);8XLJ
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M@:C#2I%!U<L5?8EJ+M;G^RAM$*ZJLU::<:4MDD N<)Q<'_@$U@F<[H1BZ$)
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M]Z'8R_[_#OG_S</>_7:].,!2SW;_"99ZI0M_^NEQ .\"B+\X!-X<0S[)&/@
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MD=8Z,8F5#N]4?(OI&<KGZLQK7J)U6"8%5>^@>&$,L%JE7Z&T:*X^>-E6GJ+
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M81^@68TG7C!5\&ZX8NC&8H)B32, IP*\G7&$[DDL;NF16MMPH@%Y+N@Z[<7
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M!Q[$T\A@\P'(;#T'0!G\I&_"WZ=>E8>3(_45H<DN^ 2A":$)H8F&:#(.]R-
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MQF'BAPAM/))H&&*= /$?7"X(#Y-[]D&N#*3Q7<1HZXE89I./;)!4IO@QA 9
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MV%#8B>^B+[E^+.#R&"\*A>LKK8"W\CN4P3B-F'5EU!IX"_M#H(^>@[M!:'
M20QV[,$C01J?'[M"R$Y<!UT1QA 'O$CX1N:TC[,VU.?WXE5UL)SLOP%,AU&^
M#^.VJT:_D>2G3K7+52PU(/YA@I<%23C6B8'&SV>5Q7@\WR<J[$MVR<2[L"^8
M-AZWR?7GF60WB9D3@,#](%;:2M4$#W3]>[AQ@%VU(<Z'@3>CIOEJ,3(E2PE'
MFS=N(#LA,K,EG1.%W#IH--C?^*2O[AW(.@*CYH[!.@E0&F96K088/H01?A<8
M[ Q$Z@=P5[,*N%,9 ;6DS"\@S/EQ@F)4>8ZXKSY:$G]-(I$E)I%6>4GD!02E
M > 1,]N*1$*$[<'30G;FVQ7% I"2/(\_P'18PX#Q-_Z7!J:9 )-_-D0$J]9@
M)QS"2-V"!W?B4(C8D)W[OR#\#K_]'P23JGE 08."AFY!(PL9FK2GIEE[RAM2
MQ^/RI@RIYO+C\EJC;M1;]>=X?./H6\9E(W;VU]1H-??->% '<1S(H1K:Y2Y8
M=IBG2*G9,HTZA.PEFG<<[)])!HQCI9DF3GT[OYE3%RW;U(I\?T;45726#<B-
M?$<T?OQNA*/XB0%X7FCXWJG6P5 BK*B7_1[T?1A8B.]@2P8[\@'\'O $-S"=
M!]Z5-X^N[=A@[W@LPS4(T).Y#AQ'QODQYT "M(+/J5[AP^ .+X#+I!GF.F8L
M&C_F1B;SAX_3N0LAM?JL )XX8>*I\9K/E@7WW&R.+7 HDP\1,DL^&T3T27^;
M9C,E"?TPZ]$0-+[?#07_OL][T*&/W'O@C]$>^_#RY'C)^,NV8XPNN,U[@&HN
MC\54T*L 45<9O(D8 Y%L'.N^A?.C7!;<GLD;:<9@)G,L"U,L+H*WC)]NB+B>
MA"%&VF=S+3A>@D< <L'#1U)/Z<0$PD.4;%1-EA\BJ41+K0'#M0X(ZQ0Z9(-L
M X,='[%VW:SBD&F2?]'(B49.6OC5N_KNC0V0-2)96G*(\#OWY0@!\Z0X0C#8
M[U??@O .]',,-%>P?_Q4:WT"BC6;@<E1MII1A?&"V;:R$(5!5UZ[($53,^IU
MTS@PK47IF<\>M[^'$*V-48JFUJJQ;QP>",T^NA=^(F82-.9!FQ(T%&9T"S.-
MTH>9HV'H>LPT,<B8+8/=B $\YCO[&GAHQ!%[=Q6Z]\ ZWK-S=P F!X/)T\3S
M1(@SEM]P "KD./$*R,8YB X#3/:0<[<'+[)=X=O0]/1!V7/4=.]*<\@U T;F
MAM5>M%C 8'_MCUYW-AK#1J/&K?2VIM7(Y:EGWR5[>MYAGT7,\0T5?$5EM7=8
M1J/=>*)'*OR"CH"[#8$)=Y/(]3$2YR+R2U5F+*>O9X6[0!YR5N\SNPS5.?4X
M"\A^JC;WS1:[D8*P#-G)HSATD\$_?FK6/Z77 G&%_O!A$ IFU5JMMEE9.A%
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M>J/24\UFY4"KTE/+!KZ12>[,UNW4)"H'5M&5V/)1(.U<6LEJK(#6)D/"7$5
M2W &X->]YIX&^^EKU6=K%A99_JL0M>6G-0OVHB66D^V,V#4J&*0IJ.BJ)X(7
M?10Q@A=+!W@Q:_F2H LK2Q+\Y-2*JQ$(=DH<SM9R$XIW%.^V4ZVX7I#B71EI
M]D(W4LR[-!Z@::T]A4JE<0,]9+X$>I0Y5NFA)&LIE%]E)R"%M+=R+_*>HG5
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M8ZY4$V3ST[HURS#K^M09I:(A^D8+ EE]=$$@NP.J(I#=$,A:FP#9%Z0;:E4
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MI]S6C*ZT*_V%43W(0 A#"$-T(H0Y0=J5'F'*D377OR7!%<Y7Y$&H_$R*R.M
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M!,M'P6@:=!J@,,;2,(8QX[X13&"[U1$+;%-,K[1L9QYR2\,,40DII6M6(8O
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M)EM/R*0AA?1!)G(=",&.16H6$(RTFF;T(:U&6HVTVDX=DDIEGXI _006P/U
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M@<,..87F-OU!#NE4[:UTM]5ID"NE&5]JJC$(+8GWRTH%0DMRI70A@Y8"0N!
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MJ]>U[WS]3QZ$L'?#&X/P8?4!;!/DTAC[WA0I<[H[E]PG_]?P9D*-\2?NFW;
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MR$#"H $5""T(+70A@Y8"0FBA!QE(&#2@ J'%#N&Y]J'#<Q14.VJ.HC["Q=.
M:H8S-<,SWWY@H:@1-D7$7[][!50HK,FIGS+8ZTJ&L@.D%E0@8WB70N'.5H7"
ML'3QI\/5!4??GH\"V[*9_WP+MO)P+#Z2_N:-A,2;"!'W45;<J< V\/_I'I]F
MC*VIRB'\U8,,) P:4('P=X=@5'>;8-1QH^_";7G"6,V85U.U0ABK!QE(&#2@
M F'L#AC;*Q)CU]=?'QIO5SN[*2CN-"J#WO[R4*2"3EH%$1[K0082!@VH0'A,
M[3UU(8.6 D)HH0<92!@TH *A!:&%+F304D (+?0@ PF#!E0@M-@AUM<_5*RO
M^ C=@")TFK$G=9<NG@9"$*LC%G +*\5GW T8"H=^MRBH0EJ34S]EQ-25#&4'
M!BVH0!8E72[7A0Q:"@BAA1YD(&'0@ J$%H06NI!!2P$AM-"##"0,&E"!T&*'
M:/5@,5I]9OUG'H08/P[NO!6EH^(FYA<,>)VGXEWIP88_^)]S.P!*W'+_P3:Y
M#'G_X*9W[XHGZM%;>*/0=Z-5:=*H%^UX75,M1)"L!QE(&#2@ D$R.7"ZD$%+
M 2&TT(,,) P:4('0@M!"%S)H*2"$%GJ0@81! RH06FP?[NO5]0OW49"N5+J#
M.AF_-0V&X83[HC+5YQ.07ON!&XX7!/K5;E-]*IUZ64Z][#B@!17(AJ3KL+J0
M04L!H8B#'F0@8=" "H06A!:ZD$%+ 2&TT(,,) P:4('0@M!"%S)H*2"$%GJ0
M@81! RH06GQ^OWTZL[&8SA2YCO-TJN/*-;TI_^8%P34/A^,[]G3C^?CXLS#T
M[=$\9".'WWDWS(<#V=>M!-.<3^<.?-):M:"-QU4(OJQF4IW]%O7AT8QW/^A'
M $)7+<A0+CG0E J$KN2+Z4(&+06$T$(/,I P:$ %0HM=?+'FV_EBY#6=!I=]
M>'UAZ&L+=3-5H,;(\RWN1V<;>(YM&?*#AMC13'#F25>+@F2^JCIT/P21]L@;
MT$-O 2GVZ@610AM2K$.,=:2)SJU,J*(II:15N1=BG;+E6? -V(VD*JWP2+*.
M!XY.6VZTU'J$3\="*<(GPJ>CIPWA$]&&\.DD*47X1/AT]+0A?"+:$#Z=)*4(
MGPB?CIXVA$]$&\*GDZ04X=.A*I]:BY5/USQ,2IWV=*?D!P^9[7+KDODNT#?8
M^@+)9FWTFOU*=]#6IH\>P?4A+IT04I=0_Q-2'PNE"*D/A=3M79&:8)9@ML#V
MM>NJE"UO/G*XT:P=O!0S?; CS[%>1Z%=R?&%.<PUN<%"XX*;P@HV6HV*@9)9
M5$'_&H/H[<BCB[P4>ZN'2*$-*38Q1?%,EYHVZVA'MJHVI,S:JH>EYBD;LVML
MV:>1[]@!SF (,L9L9]&8%7,:@N$\#$+F(KGV%'J"WT[5O(=4U&G1"KZZ_KK.
M^OW<J5>:W4ZET^MH<P]OE=F[$BA(X1",EXX4!.-[).5?M:,B(7A1PYBZ.0!'
MB)V 9\W]0 +RFR*XB&/%,2J"Z:-@.X)I(@7!-,$TP?2A8+KW9C!]9BV=O_@"
M9&^4<>HTVY569W\#$@G33Q9("-.U(05A.F$Z8;KNO4T)R[15H(1EVI""L(RP
MC+#L$%6-_3=S4-=<0GA]462KV:^TNN2B'@6;%C;P@A"=$/T424F(?JJ(OCV@
M#UX%Z*^*$S<&G<I@0+G?G3BK4;CZ5]<3?A&=].&WEOVP2LY,V [WUPM:$W[,
M[/YOZ=WBA].+.,2+Q,E@$L0V%U^]Y4EO<:ZWG,,/(3PQ]%#.A-[#:6[&V':9
M:]K,@7TJ>SFH+>[]10Y;MM.U5R7$GAN['#>^LM&<+5.HZPG[EGS\M=I5&YKX
MT8YF[)Y71SYG/ZML#!OZR)Q']AR\,WXI^JQU(N]VBRA821U@1^G;2-LR\*X;
M^FWX??AM^.N_C>^7%U?G5]>7MQ7CZOH\IP:VW&)CE0XL8(_"&#D?7M\.OUU=
MG-U=7OQQ>P?_^7YY?7?[Q_G9[6]_?/TV_-?MN\_ISQC)9XSA5P,_9HB/G1#M
MW]NN$4Z\><!<*_BP%\VP$DL5=@LH5];//][5P?#CCH/V#5A*\<_*<A(_9Q;S
MD<U#[Y.RG<!N<=@LX!^C?WPRE'U5KZOI7[F+C6]DX76[M=X>F@ELRD\OVWB;
MJNV8W4[&K8\B++VWF8BS_/AS$E[(7=.EA("5P+:!$MUW&GCIK7JM\T(;CNC0
MWD!J]"#;5\\'+<V-?W/F!\8EK,_*W!4NW)E]"R=5#U*L=%$):#2G$T&./H2(
M(:>I ^0T6K7!]H'A<D.2!MTIR@T[1:NSG<2$]!WIN^,D:[/>&)"^*Z.9O5*,
MI.5=&@G0M39#H%)IQ$"/,]\ /<JLJ_0@4G,CE-^FE(54VEN)%TE/T30@6"%8
M(2(1K)P0Y<H-*[MU.CY84_1EWN,!2SD'FQSV'E/^YRR8&&/'>PR,L>]-#6_&
M?1;"21A8@/M@AS8//FK7J?Y J*\+432=#_!&BHFHL &P:W6S@2A#\J$/%0@;
MB/?+2@7"!ETI4W;Y*&: S>'<ND:KUM.:!-<\-!PO"/2+;Q! GVY421<JZ'>M
MG;!YAQXS_?KBE?0;WQO;X7&/S2,A/_)F,(1M>IUZN=B>L$U#HNR ;8T=L:TQ
M4-C6&.P!V^JMRJ#1)6S3C)_V,/U5WYRH]L[SF?6?>1"*-BO8B\7G((ZF[7##
M55XU_A;_;6+^=!YPR[!=2I[J0#H* !(5R% Y/LJ0?.A !<(&XOVR4H&P05?*
ME%T^3BUYVNS56AVM:7#!9^#TV0QC(?J%0@BE*0!55BH02F\?:6XN1IK3ZNTU
M>=2-0LR]RJ"K3V=ODF^]Y9NPC7B_K%0@;-L>VUH[8]L+>=2-L*U;:37T&1U%
M\EV66Z7Z>]#7GBN2HPYG 3?XTXR[ =<OM$3F!@7TRDH%,C>V-S?:D;DQMI^>
M/H*2PQOTWU#'74H5]ZJRY-BN&+0&>[,J2(Q/6XP)PHCWRTH%@K"__Z7?;#0U
M)$W9!822MF]- S&NM#IB6(YK>E,TQT04Z+7>)P6[3RO,6G;-I <5"+JW]SX[
MN0G-$^;S+ZCQSE,*[^ IW4:KTFQ3W%LWAM)5U GFB/?+2@6"N>UAKKL'F-M'
M=K=7Z;:H<DDW?J+L;O$T.#--GPMI]L9&,/%\^"+WIX;M/G!U<5:_B!29(10'
M+"L5R S9H4-'+Y/LC77><'R+&N\.%-Y5HN_VD_AM#/;G5I-,%]QGBJ#LM)1H
MN=A>5RH0E.T 9?V]0=D^'.M&I=]K$,YIQE9[Z#E%Z>O=CQ\;OQD@S)8=S+R
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M#\=600*>[@E))LW_K\M#/";+#DS@Q3 0M_[C S2]@+KI%Z]/]#CULFMU/:A
M9L\KS1X2D-,6$ ('XOVR4H' 8?M0<&[R^/)0\+EP)&[1CSCX1?)&JUWI--O:
MW"0GL:>LM28DV-#3G\U]_$MHA)YQ=O<]*9TND9MO'-"WIY3&:073RZ[']: "
MF6^4TM"$#'H*"($#\7Y9J4#@L+UOGY^B^@K??FP_/7UG__'\LR#@X;G#@F X
M_L99P"WQF^#LR0[$I\#C^,ZG(^[OJ[%<L]*I4U68;OQ(B?_"2;!A.$#\U9L)
MK<&?N&_:P>[-XRAU<5I!\[(K+3VH0.;-]N9-?E!N>A(/:KZAT'G!I=)YUFL*
MV%/YB=[^NJZ17)^V7!.F$>^7E0J$:=MCVOKYJEMCVDM]RY(A*1V:YZX;]U"^
MO7 2[)!OY].9XSUSGOQ)#)?#Z^.N?B$KLD\H4%A6*I!]LKU]LG[Z+6H\'#SS
MJN[GB5$R:/4IZJ\9R^@JS 1DQ/MEI0(!V?9 EI]8NCV0;>Q=]YN4OM:-971)
M7],<M WFH"WK_4VS8C6@EJZQ9YJF<C*DI&DJ!9E(N6&S*X:I?(V4\QM./^NT
M*O4!#9L]"LXK5K$07&M#"H+K$I"2X+H@N-YT6.FV<+V7*_V=?J79(+P^"M8[
M_;H#O<]?1$ FS+WGV+(/8R$5&1'A?\YM.'H>76;W>1#ZMAER2_Q=OX@B)66*
MB>/2M)HC(!--J]F_$=3,#8!%"PC__S+1G3]BM8E_.'.M["]2G[SAONV!R63Z
M>,_Q@LO_PL_.'(EZ^235] \6\LOQF)N'[Y#?Z+8JW4Z/LDF:<:JN2H80F!"8
MR$0(_'8(G)LMHQ$"[R>44:EW]G<!D !8KZ#%D95SZ$V4\XUC%Q5CQ&%3+I9X
M>&-C)L2>4D8:T%#7/,-ZTI"9I0^E,F86)7SV9FGE6C>_RM**;:H+.YAY 7-^
M!?:8P3<NL(&J&]KNG%M#4,Q,W#]]P<[:O; #S*OV_JY]4*+H9!4.H;0VI""4
M/GY*$4H?!J5S31CU0>G^SBC=&E0&@R:A]#&PK"[E'&LB(Y8W'SG<:-9*@]?;
M1$8X_/+5,9']4&^IM54^ZNF:T-B^\#)#NS*:8W_5CXH[5=#N1D@RU=*F6JZA
MI#:FVBLJ1IJ-?J57[VB3L%IEJZU$D3)IHV*!A3!>&U(0QA/&$\8? .-S#3:U
MP7A]DB8$\4<0CM%W;(;>YW\[G\T</H5U,4<,AW2\8.[#*[TQ?,@5(1G;?0")
MQUH4#,@L:S[R4;\ /I7Z%G]SN?2FEJYDRME;9$L="^G*7L>J!Q4(70A=B$R$
M+J=&NK*C2REJ ;2?,_&#FSA0U1[;IH@4H3/JV&QD.W;XC#&@[+P)]$XYE0+H
M0+GC2!,LQ2-*$QQ?FN!PA#QEXV/[-$$\YP('6G]<5,_#\;=(.7_U_-3\['\*
MQ7SE7LM XAVN3KYS3R,QFFV*\A\#QU$BGTA!"$T(30A]*(3NO2U";SSKHULG
MA#X&CM,E#T^AD-S(S1GWPV>1>L>[$3/,U1MX<$)*#5O4W' +FV,RTP1:A($Q
M8\\,SDK#NZAD<.D3ZB6#ZZT,KJ)S+61P[=W@RHT#.6<S.V3.Y=.,NZ"<L8CJ
MRC7GOL^M+_/PV@O_S<,;9J^?4+YQY*/1V)]A=:C[IF18%:[^"8FU(04A,2$Q
M(?$!D#@WZ6,O2+QQA*/=V=]M0D+B(PAQ4+5'L2$.?P[_Y"C< 9<](KQPPOVX
M0N05PU ITZ2-N469)HU(29FF4S6W_OZ7?K/1+#HU3P:+?@J4L$P;4A"6$981
MENT_=-"J9ZHF(D?DS+4N(S?D+/)"KI03<N6>21?D4GD@\.DA^A_?$O=C/X&%
M9GM M1/'P'=4.Z$G77YW?0X'_U]N&>\=+P@^&/?,=@W0#.R!V0Y62(C+) %(
MG!%P<^X+Z:T8+@\I8:,! 2EA<S*DI(3-J5I=[[<WNW)#T80!=>Y-9SZ?@%%E
M/W PM[PI3S3X;YZ#9/P5%/@W4.5#]S;6UV>^'<"?+N!']UY.2+OFX7!\QYY>
M56LA^+.:*;KHZS^SG2PRV-8'@F\-J$#P?3*D)/@^5?C>'KUS@[8*0>_-PRA[
MO()"H'T$812JS]@O78;C,4?A!&D,0JK&.!GITB/W0<889;#(&*-JC".@#55C
M$"D(RPC+",L.$UAH9:HQ(K?C'+V.MZ^^:-2I<\5.?-8H' Q4V."7$#/\\%O+
M?E@E=29LA_OKQ:X)/V9V_[?T;O'#Z44<]8L$"?#NE&TNOGI+DFY!P%O.X8<0
MGAAZ*+IB]@_#@9]JU 1S8)_P"ZS'"FJ+>U^[T\;Z,RV,53<B7KR!_!;7L\E;
M[NEKM:<V-/&C'<W8/:^.?,Y^5MD8-O21.8_L&13S+]LIH66[7+<M>0*-_0G*
MJD6H\QMYCK7UV>]ZT+\-OP^_#7_]M_']\N+J_.KZ\K9B7%V?UXQ7[G&EB!2P
M26$-7 _O+F__N!O^<3Z\OAU^N[HXN[N\^./KU?79]?G5V;<_;N_@%]\OK]]]
M%I\T[H9&^I-&_$DC^N3=[0GQP7O;-<*)-P^8:P45@S^9'- _F #RB_#KC/O1
M3U/1#4@FPZ4I<SV?@E%EIJVNW)C/+_/ =GD07/# ].T96CY@97UA@1T,QS<^
M#W!8$/[V#A;]Q?',G]N56<!CV0QI ':<_*:8"W86)DOZPS+=\(\6[_9[UKA1
M;;9ZS6J[PP959C;'U<ZXWFEU!J-F;]3?PJS1B=$_-VK&]=G=[S\NC>%7X\OO
MMRC/M\;9]87QY>SVZA9_>_/C\A9X]^SN:GB=$_*U.^TN;+1=ZPT*W.LUPSO8
MV,0[8JW_!=/4C;:R!)'B2-AOWA3,S/MGXSNW;!._"TK/-6O&>S#Z#?Q0L_X)
M4X_,?18_-3Y],.S 8(;IV*X-UCRL&M#(N.<N#X'QI]%SL(4X?@L<  N[Y(&Y
M >:'V)##Q+"KF>_-?)N'S'\67S?0SV S>4]5_()C;3A\,N3FQ)7KM%UXBNL]
M< >>Q5DH;!9193J#IXH?'NUP8O@HH-&B+#O@#-,GXD]8>"0Z][DA.$U3'LI%
M@Q7D<FX%QNC9,$6V%!<$GP"'P'D6^1DV#\0QX^_5,VO&'?R@3LAX9+@6_(I(
MWWQGOCDQ0"X[!L,SN^ .>\2%F9X_\^24OIIQA0W%X'VF/8,U>&-8&F9ZX&/P
MB"_<@LU9%7A6$#!S BL(P4@#?D42?WZ=L9;BVV*,FUO8-6Q39KVX4(45<;K1
M@4[@W"S^X"'[!/,1\!IH,^8XP"0.GI7X+JA,;^Z;TL#U.?BODFU 4P>>ZW*G
M@L_@CC?#W^(W4@PU V[$=0JN8]:#FKV&GYK9,PY<+D@.S&K-S1!XP+6$]1QD
M'HI?MJ=JTAO^ DYK/@:W5C(2?!N6%^"71G-;Y.H-;QXB-W/?!:IG/XY/0QP0
M[(,_J#>)>]O"ZZR(7T\9/ #^/_I._&QYHB%W' [/A.?/HCO@P':P7<?VLHP+
M(@W'^Q_X-)XA,]SY= 0X!QOW[> G_-$&?F"^$.&))Z5 YB&EF-M"X%T\(GS_
M!#BDBM\$_&0@/4I)K-S3T@.N&3>Q5 #42GF$5\L5H7Q8'#M0<-=\QJ+SGQS5
M SBCM@5;EKG2I8=0$8L&S2#B)F/?FZJ]J#7(K\8;DV>-7"G81F@*M88@\,!]
M0N84F@4_$\Q-)/5X[L3;K63V*@F7)K=BXV4GD**1T-B]3T'T!J19= "@R&:P
M%7Q*-,5!^GH"^H58,-!7\9U_V($IFWB@CA$Q#_S0>([I9??>PU6M(E8E(G0,
M :")02;AG+P1<B-\\WX.4N6!7F<SV-4#<Q;V")\=SWUQYOQI)@@%?\R>"BR0
MF392*SE2D'N<3,%]=%I!8RT\$_4]:%5DM <.&Z^ 9@?UCA_R1F",RK&H@IX5
M8^Z$]A0^[, ;6"@6#D\:VR*J87CQ%-57.L2=6KU7J(X=NL89P(MC-"L(1?VL
M@D4N=SARL-09-JI78S:'XS(1BV1EPGME"5S=#&,K(.%XO-X!]%T3D'P:^8XM
MC.8@'9$<U!=M8]$T]RH(P%Y-5RS=BJ_"&8D_K8M J@?= E;8E@VFQ2VL;C@6
MSSU[LH/H ["3[QQU'(8J^_6VC%GB/YKIF.75]==U0W$_-^J55J=>J2\)9DHG
M(8@X/SU1I:**//!HU:=LL6<IQGBH_ F9/! V #)^9'8(<^31MP$W J41#+"&
M?'"V'"^4RE3A* -=DZ,D<((IJ/77C>+'*RF7*S$7)+K!IQ^".CFB?&YT:\L.
M/?;.*JC 4,81#EV\<B11&"V\C;>?V7*N+N]&/>\K( @R)I@._$I*T(TX]BC$
M_G;\6NW$,?8NG%&G7LO/:39 [3B20S!XA :Z@NV8N? ''%8KN]TJ-)P"CXI^
M,:((*6*HJ#2I9OP>\2[.N%6XAC_"TBN1N18NP3,PA-"N2TL#?!).#-@ZM%$9
MSWP.;_/1!A0#B=@<-"]H9Y-)1!"?%"8W@-@.:JBUE1HZ%^\+1-OO\V252<GE
M^@3)[LJFV:XTNOU*M]-=IVPRHYM !^"1 PP#.PI@,^/5&P+@\.\N2@@'BIKA
M*K3;,%8J/8J5J8O"L*\AP6^P"OP8G#LHT,<J',NBRERBP+/&<P#._BYLEXL,
M[0W]HF@^7K,.GW&=<$@@RFF-DNI2KS3+B[H(\X9?Q3D-W4BW)5II4&\WFO$_
MMF'L3J73P?]?R]>+-#@LOG66XEL@B2-@#F@C?J<U.=)4:((&:=8ZZT!3>9XF
MMQ] */: F=W<,29[ -T)&U-F]@_UTJ&;FI&@]=$N/>,%_ 4C)=]CX%#X>^7&
M_ET%_6%E]7>EYA/?^LZ>C5ZD"4'GFQ@>D;2,S?FM+$]A:J+K.)N#J\BR+J84
MJZS*578N@[7>WX.CB-[:;KY#[QBUY^^I0QR*P]N'_NRW6I56*W]WLC#MF6O>
MK:GV?)$<1>O/7._5(]*?N_'Z@@;MU988!:]4H'NQ<8NU:F5F05JUS7I6Q8YM
M1UBT/_B]'822/8R8T(@,7S'>?5MM&>^_PF>-:Z]F@/K -&"CU?B021YE3?EW
MGS.)H=L)=\;Y@%#B"8F3OWP"9'#OQ0(5">* TNWE>9)6PLBAPR)$P2?YZ2TL
M^#:51;<0PZRC,--HY)'Y<**2 W[Q?"%P0A25]3^R7?6^"?<Y_!X320SE&8##
MF,_D.GS.C6?._$#&BD7V1^$6_AO.&]A-N@3B1(P1-T%HE4<%4HEGKA(V6<*M
M/>JLDP'"X6$8?NZ K\R]>0">K\BL1WXO$X$XV"K JJ2T(,BY]PC^'=)!/:EB
M?/MV'BWG?9SB@T]%E%B[J@JFLJ(WB7 P1GAMX;WCZ>&)1'A2$7"/81&Q !$H
M'#UGF!7.4!YSQB+86E.VZKE64W%HYNL<TZ-1@$;HJ#6*,?##'\BM0HW!#]_9
M$QSZ=!O%=Q8"X8#0/WF(?P[.(HK$^J\)*VXTHG^\$,%9 CA* 2X%=LFCH(($
M\^)_0; 4F1FHF FO3L7:%+EC:@52?4H1%GR<EO6SN^\1?\39QS1_6O8./G"K
MG@NJ'8,5MQ&!5_6^6#3FJJ"PT*![]'PKX.Z[SZZ7(SAJ-;#$1;!A>: '[&_D
M[S#2G$ NPTJRV*B^#"[RTFNE^P+,"-R"K.YJ-92:DN2N&6>AL?P3%:E!06%C
M3A+>LH,$-_8DP8<GX;8RFC6\\[VQ$KD#LM6,VY263U!5PDP$.D) )>X###[8
M^-$= +_>[;8_*(LAP>_+\\1_;$3NHLB/HX>@5KT":?1 @]8QH0$:P:UZ_(\U
MG%9_0S2H2*KN</BYN&9*S4H]CB<6U;Z]>)]@[9'TNFLR'*)^06BD;$+Y$545
MF$Y3-/^XM5V&=]$=Z-7J[8P[T%Q3'[O5DW5P-*Z]!\&FQD I^O7>05J8%ZS3
M1;A2X:)8AV0<"_&AF^A#L<AD?8V;,9R*+^K5%$*M![?(V)7?BYY5R6#GX\0V
M)YEMB!6*XC41NY*Z"]$8?J-6L(/=DX\OOU7F^\:W'X#K;QQF+@(>X%U=_J-1
M'VP7P(>%O)0%7Y;[RS %>%K>_'XB40;7B,59<I&R<% =;YI3U&Z,>#LQBZ@
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M"WJ%3S*5J; %4"7_9ID8BXPXF3";20A -$]LR&BGR_V25.0S;Q(B RMM'9@
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M%<>)@2JPX>6F\@BJT\?!3/,YCGGZH;X6(P%!=X>34$Q4$<,'<7:IQ\;,\7%
M7X1"T?-JBL[_#HL1PQG3\YJCD^/7*<&LML>Y-B0[6$6R]62%VY1M>;N[FSD+
M^R)62->N=P_JZ#XQ-#Z#33+_Z5+,=MPQ,GQS>YWQ/.M@QZ#W^0SBX#/GS4?'
M7>)L2G7&JY28&(N6'I$@QO*E)YROG#*4"\MGIPQMZ?(<?_*0=%; 'H.'=J&G
M.GA_>!^HDO.(5L8>.\U&<T-5R/(&SP<(Y>1<[E(:0EXLY[RR+UZT/LV5.('^
MZ<V&NH%0E>N/?C'!,:5@FR_J[C/>\Z7K![*%Z:DGO"1WZ*3*296?)MGF<98*
MZ?+?,*)$REPZNI REYD0I,QE)ULEE?D7?BM VEPZPI VER=OCA3Z28K0-=Y%
M_R[NHDF_24:<4QA'MQ#\7YEY7!D224$5@4I5.O,$:M2V#%C3[C6Z59K22./I
MY*&%+#T#-V'&^1K#%\L3?^5KI%(,3$A#!UG[UU2LB:E\\WH&W!.D2K?=4@_[
MFU(/LPF'R24^WFQ_TGW+W]PH:)X<]S";LG2#(*Y3/W&5.G_%@5H?][M=:;H$
MD=:07'D39A+W$V829FZ%F9U<U]L-F#FO+?G-<WU_?N&&*06?>(71@_YR;"!-
MH27-PI..*V55V824Q/V$E-5$RE=.72/I.',E1=A W$_84$ULV-V+VKOH6=J(
M8X\BCM+QI2PMR*M[<7JYT&%)OD0"LEO..'^#R$#&R^&O30=E7IO.->HW5*B'
M,%_::DWK#*1I,4I*0VZE09!)W%]=,A!DOCH63")RWB)" $'<7UTR$$ 00,A#
M!RE%A ""N+^Z9"" V.?&<&.M0A$WAA1LJ["RH"++XU* SVEYR,]ID>\:G<P7
MREZH+!G(?-G'?&F6>6?XXSY6JX?->^H,:@.-\IZD8T])-0?A)G%_=<E N+D/
M;K:E*[?< TQ3WG^'T%(VII147Q!:$O=7EPR$EE1R*0\=I!01 @CB_NJ2@0!B
M'W=J8^E"$;>H188?>RHY5+*QI2QEEUM/,ZW&1(=+UYNZGAXPD+5A<( +5AJX
M(0_.%ID'LLV C8HK."E(-=AZ' J93;N936JY%9^1WLZ^Y! 6U$"KM?J':P!X
MEJ-CI&%;FHY%M""P/A=2$5@7!=8=Z:Z,]T/P5'\IK4\8?1+<2AA-M"",/A=2
M$4:?1+DO09*\LD60) \M")).GU0$206YC=V-%3K%%!@7&=OM-,EO/ UVE:7Z
M>-V5N>F&( R*UJ@:7J__[X,;Z+;BCUT/GLJ\B6(ETEY:Z?(:JZNR5)0Q+2BF
M#1[J4A!?1[Q*FF6R#H X#B7)9,M$^K4"K^5?97MIS7ZMW9(G-7&5\;42#"JE
M4\K%!\)J>6A!6$U835A="%9WCWTKO\6U>K]%"'T2[$8(3;0@A":$)H0^E>)Q
MPC-Y=2CAF3RT(#PC/",\*^1"?V/1UAX7^J^."G?5-OF<.S*<8*J8I]:QWS%N
MY-\%R$+P6]-Z^AC3\C:<,,\R=CN,S-Y_7A2@]!*V?JRV\-AVHS?(/%DKYQB!
M9YQX [E]/HR9<NE.X",S)0PLC/+X2@"_]*<@1"/+ *F&S>"_="[[$Q:,75.Q
M'!#4R12^XCPJ<7A(>=0MQU=TQU1LU_>9WU#2SQ_KIK*[*FEMKTIXM.I[*E;U
M!7Z^9<$&I=)4F^I2[7)S>YU1+W6?&:ABGD%D?>;LHQ@W7IN]<C=:,]H-[&?7
MW3CN$O6X\(O5M%9@_U;@K\C&P!=SOIHQW?-_?8=,^5%9SYL,Y,A4/C.#9V0I
M+;6FX+[X.Y%<@KOP,'!UH6XKL#4\O)EBZ@&N:*3HMHW_$\S9D#MGO0]^9G6@
M8Q6;^<CZL""0*;[.1K1.H8G@)/!=EA/JXFPRZF=.9*V5FY=QK5O>[[H=LL^6
M;\!QA1[S'X""GVS7^&LW>C+ M"D:'%[(Q#=A0<R\".9O_],TG.!/K:TS9@Q8
MO=OJC.KM06=8'ZH#H]Y7AZ->5VL:_9&Y X*H_15:,U)80]<VE]HA:TV6/35;
MIZ%<7]Q\5WZ_^/+C2OEZ=7'_X_O5UZO;AWME)Y7=W:2RM]K% 57VPQ(^'5F.
M[O Q[B!P0';!L4!YW_(#9&Y#]\=<*/@_V-^A!68,?JBV0AAK(,7P),L(F#G_
MMFX88.' HZ?Z#!52)%ZZY\U0R>L3_&O\ONT>P>6*Z<98+!?L'/BTCCK$=QW^
M 7@(J*> X7-'("5H@85,,>'_ U< T7P+L7@W.)57RE\O=]]Q;XR9&=KL;I1(
MX@7HK,"_<,POECX$W!.IG]@IB9EWSG?4PAYLFZ<J/.!2#R&O.XC;1FOBV*PI
M#@SP7YR1H@=I@H'R1[I&IZ8,\=B49Z"WHJ/NMVWWV7^_FW#N;*:A48AF/&<L
M85;_XTT3R,5L&PUG6%CR<V22\Y\SBWFOAX'[(3+*P2"V]:G/WL?_^*!$KF4S
MZOZ7RQ$M+SV]W6QTN]OEIQ_<<\@AP2I7HE\D+'P&8?.L*:)SV34W[3+;7LE!
MC:7!/5@)FE3_> .&</DBHVJ-UEXBDPKW&'#LS#M$O$<.LN7L;:I:D(Y&<M05
MDHXC'7>:9/N?T 6_11#O&S@/\.2W/QS=_'?HP^]_P>C6A1%83TQ\Y*ON_<5$
M14E%#@BC-3<\\&?H=H7V+9R<"FWX[1?VQ&S!YNHO!/72$8B@7F9"$-3+3K9[
MV!2_O7("Y2X8,Z]"ROUNZ#/O"<-A%=KTC3,-*PCABD;H+1]M"+UE)@2AM^QD
M2Z%WA33Z#\<EY*[ AB/D;A%RRT>;[;L"27/CNS+#N3(DDH(JPMZJTIDG=I3:
MEL&0ZG0;_=QTQG.&$<M1@K$;^KIC^J5AR;IJ&H*-8S>3VX09Q1]_ZABM /9L
M[%_/LL/Y7RZD0+Z7KBJI('B0IEA(WIJ^2I7CR4H&E0<YJEU/)RMM2$2D( ,!
M!'%_=<E  "$O;4A$I" # 01Q?W7)0  A+VU(1*0@ P$$<7]UR4  (2]M*B\B
M^UT''2;18XL*\0.E JJM1D]NRGR%O\V4":_L4B8A;Q\S@A/?>V[0621K2D,>
M67,[:%KCX1H_%D<E=>M,VFI;";OW+^LLMM;!"_<+Q\3_N9I?NR]I>+5Y5&/R
MI4^SJ!,/=BNZ]MC?(7.,67IV8_+1U ?]I&E/-,)QXP1(C@&BN/<:57\R^C'?
M/&W[1I-JKZ;V#S=^Z"Q3/*41 *K/(%H0Y!/D$^2OAOQ<-[UB(#_YYS\MYNF>
M,9[QZHBEJ"\J1?C?U2S8DPU!-D2E<(ML"'EH038$V1!5L"%>.=^(X.A\52#!
MD3RT(#@B."(X(CB23 664Q"Y[@:\B,E[6J_1ZLA-F@<WP$OO9+R$GC2_+',R
MXA++@28C2I2_0Y,1CV9:%)TB1Z,12PBG]W(3P+C:E>+&7*JH=55&+%818 CL
MY:$%@3V!/8%],6"?FP1Y&+"7\ZZ<K(?*:#FR'H@69#V0]4#6P]&N*0C0SE>)
M$J#)0PL"- (T C0"M(,11Q @/O\C36M?>>W^CH]'A]]&T])I%GM!G?E[-(I=
MDE'L&DT_.HWI1WV:?K0@1)E1[.J 4MRDHY$DZ=:DXTC'G239:!0[C6)?NF\:
MQ4Y0+Q>!".IE)@1!O>QDHU'L--#UO#=,H]CEI0VAM\R$(/26G6PTBKU"VZXJ
M<M,H=@EI<R*CV'M;))54AD)2$$686U4Z<T.^2>RY233GC"(TB5T:6LC2>&0#
M9- @]M(208M!!XG2,V5-HZY4!K2L9%!YB*/J&<QRTH9$1 HR$$ 0]U>7# 00
M\M*&1$0*,A! $/=7EPP$$/+2AD1$"C(00!#W5Y<,!!#RTJ;R(E+.(/;B;H-H
MY#KA]JGG:U1,*<DY<Z;RD+U[F]=!)::BJX.]N[NV!K6.UI9FH"EI(,F!@/"7
MN)_PE_!W._SM-6E$.0$ZJ32)D84 G;B? +VB@%[R@%82#\FU%($#<3^! X&#
M7,2IF'C(4B^W;0/M W5*D?_:]#N;AIXQUGVFZ(\>$T& TB>5E-G'1AK2R)O<
ML4WKFHJK-SE(I6[=::C:9L+N06'UG"YEYR!PD6# (>*X:KL&NY-^ZF:I77"D
MD0%)AI01])=."X+^,R 50?])SQDC3"I?N B3Y*$%8=(9D(HPJ2AW5),Z1TDK
M.4>)_%NR)<B6(%J0+7$^I");@OS;,R".'(7#1[X6UWJ-5D=NRCRX@6XKQD*?
MV4H/>)&&-O*FO&ULT4_FQ:GDS1V'E&=M>NP>QFB=T*WZJR('G994%4YDI<F+
M-X3]\M""L)^PG["_&.QO2WV%47"9]3F52Y,Q(2^ D3$A#RW(F"!C@HR)8HR)
MCM3&1,'Y$#+E-) Q<;X 1L:$/+0@8X*,"3(F3J E  ':*?0)6"F'YSU7]W[L
M>O!9YDT4*\FFI>FZ$HB!',>^!0!57%W)0:<MC86J&P)R$J_RK8'D( -!#$$,
MT8D@YAR)1Q C!1D(8@ABB$X$,>=(/((8*<A $$,00W0BB#E'XE4>8FC*\+%I
M<.'[+*CCF3)3\3'OR@HL1C.&RY<%.8Z]8BI)VCR9:@/V[OFRW<5\V8LGW;+U
MH<VN7>]>M]E]HNL^LV$P_^DR]#!+1<*FUEQ5?^*:>K[< V7(]GM=:3)D21E)
MC@D$Q<3]!,45A6(:0"4+'>344@0.Q/T$#A4%A]W]M-XQ_30YJQO)\2/M=AH@
M0]A.W$_87E%L)\=/%CJ<>T6A_+>FE^YDPCS#TFUEJD^9)U\J 4$U97!4EPR$
MU_OXXOT3:E:\T6F>J^AOJ*$/X2ZWU9K6&4@S'8FTD.1:B#"8N+^Z9" ,+GU6
M$<F(Y#)""$'<7UTR$$+LXZ4-JMP)EMP^4FNRJS4"=>+^ZI*!0)W</GGH0 6F
M9=/@1^.^H3QXW*:;486I3,(@Q[%77B?)00;"[3V<\7[S_,I,?]S'VOJPR<:=
M06W04RG96#:FEU4A$1P3]U>7# 3'E'$L#QWDE!%"".+^ZI*!$&(?ATVE>E/R
M $G#G82&(WPG[J\N&0C?R0.4APYRU)RF;TV/,*!9_MO52]>;NIX>,+#'AL$!
MKE</0R$:H2UWDLYZVE!#?XE(E6WH_RIRG;6IL'LH0#N_N]L$#K(+/H3S/M!J
MG69?FBQHFCHNKS(C&T >6I -< :D(AO@)/*N"9/D%2[")'EH09AT!J0B3"K*
M+VW1%34YNF14G(!V)*-"'EJ047$&I"*C@AS=,R".'%7'1[XLUWJ-5D=NRCRX
M@6XK_MCUX!O,FRA68F"65H],-L0I)&-M,5*=C(Q3F>-P'%*>M0&R>U2C?7*W
M[:^*(FC-?JVKMJ5)=B>335[8(1- 'EJ0"4 F )D )Y";3X FKQ(E0).'%@1H
M!&@$:,7XM!VZJ2<GN3*ZCVP*H@79%&13D$U!3O*9$$?ZJG;3#<&:5+3& :&M
MK3::)W%1/[(<W>%#EG7?9_M?T1>8YE<$?4Y.:N3('=L=KS+$(]-##C+N9WKL
M1\JS-CUV#V=T<^$,KG:EF/?\NCA#5ZNI+?ES^E>B2:64DK0Y_03VTJ $@3V!
M/8']:\"^5PS8[WE+H4I\2]$:U#K:X2XIR'@X7\ BXT$>6I#Q0,8#&0_%& ]]
MJ8P'J5,<-.V@*0YD/9PO8I'U( \MR'H@ZX&LAQ/N12 ;H D"Q.>_CE3'R'!X
M%V"6*OS6M)X^QL;);3AAGF5L?Q@:_)C>>[O1&_R\R&_I5>QTS.DG]QK-=N[)
MQSS)^WG3@'F3?04X"CD]9*82^L"8RL0UF>TKKJ>XP9AY_(\Z-ZHG+!B[)O#%
M(WXQ&.L!?(4IW( 5!Z0I%K=I&\K#F,&?HF?A.Z8>V)4>[!,^8H9^X,U@([IC
MZIX9?XP_$6QMWS+Y>SW+#7U,G @G4UR 7X/O&G:(\J,$<%IBX35E9C';5&!+
M3_##DVO#<FTKF"DCL%1=#[XFV&<UBZ2TFP&T8EZ:D*HV7:;N,A)3*F&OZVHG
M8LVQ%V]IJC^R^M!C^E]U?00[>J_;S_K,?Z.\VY^%XVUNUM+J@M2@?X9>E.5$
MO)1X8EJK_Z=I.,&?6EMGS!BP>K?5&=7;@\ZP/E0'1KVO#D>]KM8T^B-S1RU7
M(DU^!>WLQ LM<1TF&^FA'2C8: X$P1!9^PH<U%\L4$#^N'.++EVHVRBD!BP'
MG@K"R,"+!D&T9RAN\T0FRP'A#;F;60/A5)Z9C=E-D;;PF,V>8 D*@^>Z$\L
MK<']4M )]^$013Z IX :@/\H[@C? XHB)>1<6[A#GWE/J.#A?7PM8L53&S /
MM@%G.\2!(9[U!(IKY+F3]%=,/=!1@>&3_' Z!;T'GQK.TI^Q46O!RP(%T-08
M"WP5GJU8 GL!)8G?RR^@\>L[)._'P^/!>2 -*'\XP&?\S^Z!F4$<F!E9+R_O
MD_"&",]\L?0AZG8 H >^%.9]8L$S8PY'(7]-K$9K:O!#4^7_6 R&W-Q>9Z(A
M=4!(C(@\@T'F,R<=#MEY1X-F83M2!]&.\N&='7;DN$MB.PN_$/(!B_-!\/CR
M %TM81VP6,9CH3)#CT,T2,V,Z? 5!HQI*I^9P<-1@L5;:DU!4G EA#MH)"B=
M1HKXO"/83@/'8#&$]\USI\P+9M]LX,<+Q[SZ.[2FJ*GFP;P'.,E/MFO\M1NG
M,#BM*1H*7LAV "&UOP)!(V$;NK:YLZ#N*Y7=AO+M^]VWJ^\/?R@7MY^5J__Y
M<?/MZ]7M@Q(C]-)C[N6N65<>\W$/M[N-Z7Y,M1>?"^=H%A]*37%89-;Z@1]!
M'DBF;;O/("7OE5?I^KSEN0 AZ!VA/\M!3_B7_W@#&LD V$8/$I:0_!SYIOSG
MS&+>ZV'@?HB\4_ ,;7WJL_?Q/SXHPH,=-*-9E[GD\R-5"72[1VH4M]QE/ME(
MXZ$*VWI4V+:*%K Z-!G_\:;[1H+JJ%:ST6EOUZ5T91@PZRB_6F[2B+@J]M0O
M$AYCZT0!PZ3T8J=C1/CD.':Y6HW*@" 2DJ1R8"(Q(1(DT61 $K75&!RHS+8R
M2(.>3^D((U,YK1QDD4_M[25.I!=)+YXF63$(2'I1.K+(8J&OE#5AM%?F].7H
MK\*!JDIG+F4$IS+8\);?PKJAKSNF_XM\XD AF^,WG3DV($@38?ZB#W%RH.O-
MYM=,\J6G%H,0TA!!WN1NRLLNEP(:NG[5SJC>/4E&W3K+X#?/]=>EQ40/6/G]
M3[/%4:QWHY%EL.0#2=%4/D]HZZ(I5:OUFBUI:J9(74BNM0DLB?L)+ DLMP-+
M34*P?$6%L=JL]5L] DO9&+.JD5]I"/!5=T(L8A+YU*_V]4\M&BP-'60-PE=>
M'\E!!K)A]K!A6B7:, =U]7NU7D>> 3"D+"17%@25Q/W5)0-!Y1Y0F1L\7BI4
MOL+1;]<&JDI0*1M'TH5^R02X="?3,,#B:BP=G8:>,=9]9BJ^.PJ>=8_)%PDC
M*X8"D-4E UDQ>U@QN5&S1[1B8@5[V#O^6F?0I5L+V3A35J5!D$G<7UTR$&3N
M 9FY<6920.;R , <%[OM)J&B;,Q'=_DE$^ Z]$#>L4L:^O@CL"RQ*Z)\L2\R
M4RCD6%TRD)FRAYFR?8? PYLIB5J%CUU'2O4PSGVK>[C\?=(;9ZXW"#6)^ZM+
M!D+-/5 S-X%,%M1\328_H::,S$D7_"43X O3?39V;5.Q)E//?1)C^N0+BI$9
M0['(ZI*!S)@]S)CMIS <WHQ)U.I-2JL>POO7!K5!]W"9BJ0YSEQS$&X2]U>7
M#(2;.^-FN]F4%C=?X?^WFK5^5R/<E(T]9;G]EV+*@C14$1/@X.= F;$ !PWB
M>$++V#O?_RQF+TA#'EFC[=L-[JFX?I.#5%JZ"_RKJ'76UM,K!["?9?-WB8@C
MVUP,@B39]!Q!TLF0BB"I((>^E ZV.%*:NQ&W;O '"VZ<>^%!',*9UVH=59[+
M? +I:M_PJZU&3VX:K)K_K./X9Y\Z])<O$W(<^Q9SP2JNN^2@D[;5"#<RDW8S
MDP[7N_A5-_R=5JW5HY[#TC&4K,J L)*PDNA$6'E4K#Q<C]Q7!0(Z:DW5J-.-
M= Q%M_HR4N4+\WU%-XQP$MIZP$R0N*D'0J5SH<?8@#YQO<#Z#_\%W:O(0#-9
M@_5TKW(RI*)[E>T&^>YN!>7:'U_,E>OGE&Z%?]L,_P&&T45*Q:XTFHJ*+:C=
M6JO7H9N3DV#(TH9)$P*?@EHG!#X94A$"%X7 N=:]1T'@5T0L^K6V>K@FA 3
M1P/@<K(6U@0P3#<<VDS1&@>$XM--97!8:6D,:\RE(F@DN=#(>@^PQ27 .N)5
MTIZ2=2KS<2AYUK;6[J;6]BV?;UEA 8Q6K]9LRE/&N<I^6JGW*Z4^RH4"@F5Y
M:$&P3+!,L%P(+&_?XG@3++]F?*)6ZZGRY&&<"BP+/HK9:!W''2,WXUV@P^G
M;TWKZ6-,R]MPPCS+V.TP,GO_>5%FTDO8^K':PF/;C=X@]^1C'F,ZNJBPERES
M?(;"H@1CILR8[OD*@Z6:RF=F\)(GL>F66E/0 N;Q"Y0YY5GW%7TZ]=P7D*J
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MG<*&@.O=\'&,CYQKY<S-AL> .YB/)Z0$^@O\UA@#G,%;AMDW-)1(< Z%ASO
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M"-*FV:YLNR^/#AK*EYO+J]O[*^7BM^]75U^O;A_NE<7(Z]KM=+?>#E^C%8!
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M:3^"EPO/A@\YEJ[<.'Y@!6' '9X'9HP=UW8?9R>.2#<+I%SO_QING;T8 .:
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M#;*'#=+;:(/ /RZYPLO8']^9SW3/&!?E>;<&M7Y?G@;1)/R2"S]!'W%_=<E
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M_S&%F(BE/IQF*.YE,53.Q;H>3A>N'6L*#]YF^!,=H_A.E+M"R1]&/-O!9,/
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M"?P+N^1UB*#U>  J6@!WTB)B1ZD-0N:868^_GN69[+>R#8U#G_G+5YA,RK!
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M*E<;L$NA80F2]?.'Y[$5L#JJ:]S>LZ=/JR-!959VEHPILI*$T$4>0B3HHLF
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MOH1?XY5&J-L5VO5#/-KYCU)'.TMY<2P'A<@2(4N$+)$EJ/SXZ+%'/:@2+M\
M1%F.;QG*[Z\9"$S:^HC*9%4Q4WG:1-P;5D91R%KD6CE,E>#,M\B>K;*NDH-(
MS8RQLS^A2*>5(%\D/F73@'"%<(6(1+AR3J0C7"F?!H0KA"M$),*5<R(=X4KY
M-*@<KDA]M[12?55&5]%8/7EH(4MON)WN4LZI4\)=&/@!" )6^^F!\B_=";%$
M,"KMDZ]#1C%@(@TYY.TO4ZG6,+*207@BU-ME1=N'EZ%G6[RE@)_I^Y O(E]:
M.GXQ[SGP:3;_R#=]AK_BU?M115E*:XJZN@U]8!:[+MS<7J_K__*Q7>NW6[6F
M*D^+-E(-DJL& D;B_DKV3"-,W++?V2IX[.5ZGQT0'N-ZDJC&(J[QXX5O.X*F
M]N:CVF[T"!.E8S]9E3-A(G%_=<E P C B('X>*?8K*QNO=3'E@E+?2_0KZ^^
M^=AO='Y]AY\D*"F;8+(*$T$)<3^Y5U5%D5T[S?9SG68/Z%(E16*\1FQ')VK[
M"5NM6K\Y(%]+-EZ49=YX<3>F:JO1DYL&OXE^Q/*E#I"5<L89&T0&,E6*N!WM
M']I6X>K1OW%$$_/?/-=?U^]^[42K31>E:JVEJC5X@#2S0$E+2*XE"".)^R7V
MY D>2_?D5UZ4[N[5^SM!Y=Z7I6L0%&]->XU^?JR+? Q:,14AJZ8F@"3NKRX9
M""7EI0V)B!1D(( @[J\N&0@@Y*5-Y47DW*HGY;\+C)WTO6\#*6>)<I:(#(33
M1=#F[1[7@8-<D)//!O;]D)F?^5A8$:SD<4T_/6XW485%W?:UN[6V>KBK/E(!
M!V*SO9MH$/:=F=*M&.-3OJZ49'G=+5_WX+=\,3 6?=$'SA)E[$K'C;+J:H)(
MXO[JDH%P4E[:D(A(008"".+^ZI*! $)>VE1>1,JI^4M?ZFT[&O"L+_\N=<=@
MMLW,=]>N-V)6B46!:<P^ FU.3F)D25#89L9KQ96;'*1J;CV2M]HVPAYWC+WF
MH4L.(_4;PHLN'//J96IY_ E)Q+6H*TFMVZT-^FUIJBND'-TK#:^6UNV?T%D>
ME4\B(F7AXM:PNQ-ISAIZ7W?/>?"NZ!M!N*!K3TT#QB $/@F6E4+U$PS+0PN2
M$WEI0UA\8@0C89*7-@0Z\M""Y$1>VA#HG!C!2)@*O;1][2WZFDM;TPV'-E.T
M1G7@9V'>Y6=F,)S?IK1*GGBYQDBH()7DS3O9.$9Y'?'H?E<B6C:W&XM]$'J>
MM1&RQ_VO6NY SMVO>3NU?KM9ZVN'N^@]$&!LCQ:D= C,JTL+DI/#WO8>B"Q+
MG?W]25-5G-WBMO?@7=X/,>1S>;O:3D.BP=>D/Z37[82S\M""Y$1>VA#8[@"V
MFP>' E3U&OV2!X>2V$DO=@1/\M""Y(3<P!.GU>[#2'=O:%3(,-*\L[?U,%)5
MJVD]\@E/@T%/H%JY@O#[._,#9BH@M0I[F3(#?PA<Y0E^K>@!4NM<=R[X4?SW
M<!?^!68%5I [92T"SEX0+[W\I0O_$Z%E_L*_.'I6U0)==?N@'=H$%7 FRLPX
MF#VX^*O3RP,H*@F3;-'R=1%AO'2T(#DY; "HR*1_"@ 5D >0'^]0.!++G!Y
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M.'B7[M]P2ZNF0?(_?H;SN(;C>!7C8BRTV6@M(=#V?+KR4 Y>R7S(0UG#OB)
M/&CF#F616W?2_JITZO\^<(V_<D(T#3T_1($+7"Y)<$(=Y9NM.\J4>1,KB+Z@
MC%T;S!(?/\9L.!/^CTBI *,\B28J\=,M!_YHC)'0:([-/V"XDXF+81!82T.Y
M6U@,&%3,6UA&,-8#!;@DA4Q3X <O[M&"*N 9U NGON6$;-Z\Q3# EN(J0NQM
M3LYX5_JCQS@KUK@$^*$QGJ]5\#A_MQ\._QUMVF-P9+ UV/9PQA^+W*T[,\S^
MPA_%HQG[[__J@\1\\!477 ;+ =A-SFN*]QAX2/AY]L2<%=_TF?>$GWRV@G'F
M54^N'3H!D-B>P>/A2>E?!$@X!T3#%SS[:\8NFHNL-K?C1];+R_O[< (,/+L;
M_8A.X)(3B_/-M>=.KG3/GB5 <B^.Y,']GAS( UIC#\"1GVSXRFY*B@&"3-'3
M\D"23UG,+H!9^#DB9*5HEA!UJ2PH(SA@A>$))VSB"]ZW_.W8#SX'R#9R;=M]
M]M_OIJUV-H'1X$87B:<]"I?E'V_ :C&8;:-3 E*7_!RY._SGS&+>ZV'@?H@<
M'G V;'WJL_?Q/SXHPBD:P&+>+$US/5(^<K_94+5])Q2F(@<&_)5YAP@=G&[4
M[3 4D8L:Z1,> DRF*-#?1OD<E!)PSGA]@&:-#*V%NHU^=SVQXO#"&1.*6[F^
M;$45I0XCE$=FRJFA6"DQ$=B<[\W CZQYS<TB[<._="=$FZGDHHF59"F")"<+
MXD660U3JEDQ6,G0X:M.MV&Y%"(-6QIU>\*+YQY<XS:GBSPT1K)U+#-1:MYN/
M3<O';I67^G+:0!=H@ZBM1D\VS!/%U])U7R7+XDC]BBNN8^0@ UD6;SZ^W<.T
M:.]C6@B-M^]EX2;S0NW7.KV.-+TC2/0C]OKEK*,;,EH6-[X?[F]94,SBM)WE
MBJD76<E E@72A@=3Y2-.Y66DS$%/K[J_/GEPGIO#I?G^K[RTKC)L'V. T;I;
MZ8JK+3E(U=DZB8#@_Q7P?Y:)!A(11X[,@W4V006+2)>G(TC6Q;%,2DDE,K)X
M,^DF?TN!B)HVG@@ML[9%L?0\:^-CCTN-3I'Y$KM?:+1JS8$J3;H$501317#A
MM2H^%JEL*)BL*7N(=O<41#NI\(*=[K''WDFD>T6;S!8SXD\3W7+0[IW7%NGI
MZB*.4 LU1C51B8:?LW4TFFU+'UJV%<P4RS'L$,MO+0<+[[R0B7'JCA\=L O/
M\9(O6,R/Z]_@$#CD_O_VGK2Y;>7(OX+*)WN+9'CH3%*IHF5YG[*VI)7DI&J_
MO +!@8AGD& P@&3FUV\?,X,!<?"0+$$4J_(<B0('/=T]?7</+3AR0W?F"0!:
MB(2X,Q22&J%FV_11YQO<A@Q727M;":'.TAC%:@V19)S<8(?C\&<@\9=O[L]@
MFDZ_T6'Z777!?N(-W>)^OD8>M\#B%Q B!="YPM-P-KY"+'W-D*066]V%OCEN
M3G<&-ZM:TL'7+5'KE2W[Q';"]2;4A*YZ*/%QU6'J\@)5794'1\N-T.=N/(/S
M+J]%3'+A.5HD3;OK>)AD;_Y][,V2WT_'(^&/W=-V]\#KM0]\]Z1].C@Z:8\.
MNV.O.^YY_L%&/98G%>JPO']C/2VVK<KJ#3K.Y?F=\_7J]M:Y/K]Q;G\;WIQO
MI(:/FJ:&[TJZ1.=1 K %;NB,@S"EGF4IO#0FS@<Y/ F /Y70K6LII0YC;"MM
MF^YCX&Z9ZP4G\9SII?PJZJ&6,W$!AI$0U-K-LMZ\ ;XQ3Q,Z&+@\@0Q_GXG$
M"2.0WW,0_:2'\'3A%\R9JC#/*ON_3--OD<3U%MM+$O1+N]]7+#F)]9;F[KUH
MCV+A_FB[/NSH+V[XZ"[ I/CSTPW3U2Y?;\EH_=N2/,L)L%\B1HXT$5Z')KGY
MBZ\(A_!]-+<>HS0$<T=P3_<X!9L'ST7QQ-"4E%C NJ)%C^B!*8X>F#*C^PGP
MW.F#RV:M?:13G)L KP*=Z*5HNX%7"9;<R,4A0'C^ZXYLDL3!*.5>;US#$@]Z
M+$3 QUJ"WD.%R1,L*^<.%*?]>!/ 02BN_"&PI)9XMT;@G2N)@V,(SC)9<^6_
ME&H].?T=CT2O.7QD*8U,(",-> ( $CW3(3G&:#ES^%?,V-Y&QD"K9QJELR3/
M-&YB2-F039>[J@T#DOW)9L&$1G+#0&IM93ZL(8M&PG-!WBGK2(V(FBJ)2U;,
MQ 7IB<.YDJ!MS"L6S'\QXW?SQDE3L.;8XX&K=7@FK_8S0)XCJWUTU#DY:-34
MB;>;S'FNZX&/5A2%_/JTJ.T 5X7&7W$$R%$31H ,NIV#!H\ >16RY>/N6&3P
MZC4[KS+THR%GIJH0Y]WJEJ82:J]EFD.(A@V:&G1.-R_C>-]:Z"EU;7N]LP/B
M;*MCLI=W>WGW-LG*,;"]O&N<G?U*S>C*[M[=FMOOZTX:MJ;K-Z]"EU36[A*I
MJ871:VB7?0%[ ^C47\L0V->F;U3<>=0MW,#RQ,3TD/*K-5EI]9XGON;3HGP!
M4U:WSFS_*U]=S&!5'VX])JA95?7[$04-%V=[;;_7]GLZ[;7]RVK[PH5>[UK;
MUUR6M9\Y_#;/1+,F$CTIX[E+9,G?R99$CFF_LD,V3<H9O%]:-74ZSGZ0T9LA
M5<YZV\\Q>D8#KG#YZ X8<.H5Y]-Y&"V$(%W!IMISQ&4.6R<'W=9)_Z Q$YSW
M\Z.:*]/VID!S:+$W!7: 5'M3X%>9 H/W:0H\(6AS *; H-7MG>Q-@3=Q*)I2
M65,7S'F'HR3OHL0-7WE<6)F!]@Y)T=3TS7YRY.[0<KU4W'YPY"\P\0Y>VL1[
M<J1ET#KM/=]=6>]EMN1[%#A[1=X<6NP5^7N@Y5Z1OYHB/WQY1?ZT.,G10>OH
MY/E2)N]%D3=X2/0OFH]3,C!T@Q&BQ\OGXEK,)$Y'55-0KR.9Q"()8C$%4#Z)
MF?"#1'X.I!=&,GV>,6CK8Z91\T$/.L[G\R\7E^>?G;.KR[N;BT_?[RZN+IWK
MK\-+9V?FA#H35SJN<]#M??CQ$4283[.<D=8T'@O%[SQT9\X''*^%0T7[W;^J
MAZ_A<_JD]]>/*.T<-PRQ 0P8R!$JP"P[SCF(L "%B/G,F;H+^.^'P/EQB?LS
M]SJJ7L*766]QTCE^*D%:ITD4+YPPF,);:'II*.S!TME2PBQ$\+L)_3P&SD9^
MY_E@^,FGR(W'-$4%#H$'JTL:E%B8HYI]TXT1^L2;P+\T,Q7D90%BQ =^MA!N
M#.B8X5"]%?/1G4<@Q<:SJ8^ZA3'!GYF*9Q96$285](\_VSNQ'WJ:][H\*OFX
M9C(R['B+C1:$V2_<:(UV7]YHT1W7&\W/2N^4S:JM%MTGR[L]PUEFH)Y=7&X8
MQS@6&Z7V\TKKTGG0)SS(U7/=T6G7<]O'I\>B#>S>:[O".VS# VZO/SH>C?SQ
MFYT'?=@!.?_UZ_#3U<V0!/WP\K/S]>+L_/+VW!G^]\WY^;?SR[OGD_P$9Y"
MA><]41=L4B>:3J<HOT#>#>]C0?SSMG79Q<RYC!YX_A4P]'$KIPYH\@!=)D#7
M$GC9$5)B"+"/8^$=5V.#;R: )=TX":3S =7CE.0WKZQTX%EN)8/+G#[$QW%
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MH0+V#"I%(G4!!MHOZ4@F 9@P0EUB44(&\7,.=LBXXWQ!F U0 !'[D\08LWH
MYB&A.Q8^HCD"@."-O>/.1@>]U[A+9KX;MEF/#K8< "+3F&+#,:XYF5H$M. S
MZXQ6',KL8?BSNW2.S1^9P\UI8YL89!"<!N#K%.@)C#>'/R^8.R1/[UX2%;:8
M$ 5X1 G[=)SO<P"2I!X"1&*O[J %M=(3#&(!AY!.53KWXPC1"B0"SH(=TKC6
MN;O0PF4+BRY_K4J5@7,=1YX08XE1FTO[[=\9IFN&X49!6W^;R!F:?B*> QLL
M+N'=IL5)L\;%3!U2>>5_"J)O("K V+M1Q+F8>5FES'%/V8CPPZ!;;2,.#CO=
M@I'(7H!M$@=2XFTWUJG7 ]B9@6Z!J/#;)W2;X&BC7N-)''3&%6.CK,.;< +@
M0*-'MB!-8;2Z384+@!1%XY4/9O4#\#$Z>-<:*JHJ>B$J*.ANP34D7CD+70E?
M(1#LBB?&W:<\C)M3LM==14E6'HJ$V@7='/^]PMR W<9_]UCAOWM<YVV5'23C
M5@*C5QX1<SYP9+>YR!UI]8\T),/F..?WH^S#2"B/PL_)2#JG9!C4O=!-.! "
M:)S2C52^&\08T$W%=B>RU\L)RSPFS_5KOL!;_HDO>6/T7W'L>C7AA)8UH'T+
MM/;?L YZ:>E7%]11YIBR$[1AH RE,,1KN=1IXBOCMB378"UR#?4+SVQ5V 3+
M@')#EFDPZ PVQ:E3;]2]=3O_KL9>)<M&\H5^E@F/#@%&@\'7SQFPR'M&\C_B
M7ZT( /K+$5X)@1!E:[&=/4._&X6Z%P*K>GA]EN4;P/<"1%;@+QP/+SG!"][H
M=L'$F8++3A?CE)GG=7L#]HCT35SD"(;X#(:['Z/XA_;ZW/D<W Q]6Z)B$ P"
M."5! /)<50P2@6:WDYY> BD?5(A&87#O:@M&HTBF@!X;+H,SC%P#@3G,#=H5
M]6-"-V-@Z&0-GJ45I$CX*@YU&UE@?/U>7C?CP[@K9 9T0G2L(^^-<?QD#I(O
M<6U@P1>$Q2<I/.U,0!3!*8C@&2"3!"FJ0A8@,,GQ 2I';1"J$3A=*+\>@CB5
MS@-G"IP/*AHT'/[SM]LS::(_8X; #@ 1CW8L!Q2W/F:_+YB. &?6LR@''OAR
M2X5\O&)GD>=M0+#CIV'8!M4/U/]W&H!U@;B,D?LT:%_NS@U8R-I+D:?L12Z>
M+@D"FY,MZ-O258M;6BM':\GI&[UW_.7*_V8#-S2P?:;?M:"] T2^D"2OOWUR
M$SD/YF6-Y5K%+RV\Y@Y/;^ 'Y(:/38HNJ T"E3(:J(\\!YGXF-C6)CVHH;*&
MY8Y>\D6\E$FZ@4&SVB\/6, J1$WI,ED=UP%YZ.&ELEX<8+S%K21C+GMJX3R)
M@_M[$,BH/?0A94F7_SK*.Q:,'&!%>5>5.#KJ':YU\O 47?F&2*]'&ZM.IBV%
M]Q= (NB[L12S/_W=QQ PI5"7\V;6I90F5CPFK5L;%>PXUUH[U2ND?"",5+-]
MD&#/7C"G]X&2<_Z( E@1U >'W3!,%R3PFXH2\I_SDE>F(_.8N@X91#C8&;%0
MMZHQ1+3/4:0BT&6&36?W+\$<O.%+,#?)G=8E7_M]KS?R!\?MT^[! !;P3]NN
MVX.?>H.^/SHY[/:[QYA\?<.6?RY(0V<;Z_4DGFV31%%F>$DXO$9[H:@ZTW9Z
M%%]S6BVGR8[7DIJ7=$7FE6\6DU=Z-?DEBC\S<,,9#<HRH#7(6BDQ4I8%\"R=
M&@$,Q"I:+99C8YP?!U22RE8Z0%=*5QH176+7=IS;[+YXK5"IK,?E*J#YDIS>
M+/=F"6L,U%!ITNKD#MJ_<K6KD1?DEO^'JYJ4+3YIP+$L@]5@T%;+';-*ZYV<
M6]CM2&3^Q%C;]%6O)^."5)1Z;@ZGC2Q_%!+VM\J!)/-T78/TPL]I,$3L+ (4
MJ L8[527A=*,K;1[+;B2"W4E>< Q_@A2$W-IZ 1Q*2.QBD8_*?.9%0G(W^!(
M+)K)%PEZ$CD:,\9!/&[3P>3",H#/!C1V<MP@V$.N@#Y(I C]SF8%),V3T1?E
MJ?%J,\K]83*1^;S4<IZ<J@E4R&&#<@*.,+*VF =9SJLT#2^9U7Z(+!E/T@;#
M2265 ZT"RY(E*'1)(WGO%/$U7G."S;M;>E/KI4._!:&0"9!(Q9REKK"\BU3X
MN=GZ)G._^D=K.& S]))YPSH *NV0/R-^"VR?KH7MSYF\W!W$GY:E,1T+Y;:6
M*$/_MDCO=]<,"]UC##6*%[N#\Y/:W"7@/#:;+D$Y";FML=Y;"^N9S;H[6%_)
MZ9EE4\KHRQ%TU >JS">S]8HF8T%-P+Y L054C!A'"S<DJPU P+NI)4!+.JBP
M,@9],RL&$\JN[P=AH*T+T&+J.W@=.U+2&-[38-Q&,SP4[3' @;J,2M#:B0!;
MB!M[^"\88\:X +C4DK4IV3$9F&1<FDO@PP4NHVUWM!"B%(UD!)B4*:X0^;ZD
M],(%:E:3J"C-'@@?K(Y$O<8=/Z!EH4HVR3<)\\D96S8I&X M/([+"-OXGXG[
M*$%L\=N!9R/0[M)2']G=]B6'SB<4PWOU>[B/ /\!,VNS1%OC:H%O (]H7\&)
MCNYG7*_RMFN![5,X%NBAD&?"!(._?>A]+"_(K7#$BOD2==B WS[T/U;YMM4Y
MFP^#CXX4\4/@"9W/X]B@"07RZ?EP\''IQ66AY>7#P"ZRB1^B_^>P!- 0<=5*
MEMQ;68D+;GJ W\%'>+IPWJ_%G.*(?/=*<,M=QRPXH'$32$YIS>. 7@B_L)\6
M"S\D88-^0 *;=D,\I.!-A5S""\^W; C'D6#?$D[M _@;EN.'TAS]6XK7A\KK
MX]H[J@\6L#O!?NEJG&F7<#<2[ED[F$[ 6B?G>4Z-XRKD@@L'OAW0M"Y$5++0
MNJ< XQ)9<;@[PW>.N+DQ>Z6!"KDB2I,<-RKBE[YM*9#/YYF- "G,[[19L (H
M?4=A0$[@Q0(4J"GASH=W0#UB,9^DW'=Y4C]0O.T^N$%(P1,5> $6^R&2>>AZ
MHN,,585S&K(/*ZWM4MQCA$8 T&Y$$M*X\25D:*TEL8KI]_4E%G4@U@JJ73AA
M]*2RV%G&V<4LVU6)]M<K7KO+7GV-;W[9ZK3A^(]44@L*AL@!R4//PU< P:]C
M,,A2H#7]U:Y8RYZY)9$?C^7W.0;5P.8_Z)ZN,[AXJ0:[MM */FQ;5>V%(C:T
MTC%&1(V#(%*PSD[EY"657B2+E@[__L%-,3H,2PO6R _[I#U. G@F.Z!9]6C6
M (0R@E[ M:13 <)KC/G^F4E^9BEF<A*617:]HYF]/=!J0$F8 @=3_!=#ZRCJ
ML!2%PJ02GD.I0E((N<@8_PBQB<\I#<I/+T7:=* 0WCW#?"8Z&(BQ*,Z%?O K
M^#'K*=>;!+!3W8Y $DEO3Z*"!QF/JV9)A+SP)74>A=H<X/CC/:Z6SI7HTQG_
MBA7L<C&9 (Q(4_-)@B:'+/8':?='BU&**,YI#Q:EW#E:,VY(+5"ZOCR/M0E%
MXXMF;YF+JQJ^T/%LCZ@4VG+WX%!P(H$< U1<CQ@_9^!"XD?ELGI>&B,3P)\6
M[+_9 $3J<43,&!PO#*L#C^3=:,E\I8JGK58&$]A55ADQ)CG6?#;4+(],H1?X
M<\DOQVW%HJW84%3Q=,9?V?$CD8X'.1_"7GE"=/6K?2ZT%*%. >&BIRWFP %D
MS()=&K&= %A%R<B9,735$C8I0)1$(=:FP<GF>CYO@H)>4C0CB+UTBE:RI\FS
M"[K3^ A<=(ER-YJ1&57IVJQ*1]UIOEJN]+ KE4OHR4<*J"D22XIQ:D@Q]LZ;
M,G:/! D(]#HYF! ]H'.$!8FLL5Q*+,)>VI1@9&VE%5V 5GF(0EO"#YBG%/.
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M"W$2'WF !F77_3O(''[A/PHGY$#-_7?FP W))[:8U'N,B=%?YJ#*D'3H,G0
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M);3ODE$?INSL878E-.;BLT["NBM?EE4@! F-N4PA,"?4!>*0T,#+%$>N',I
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M>0.]*G\'G"  4#T^DE(?A 1=]8!TT%(PK^#XESRL ^>E)D W 0[I=0 76!4
M^HN[-OFZ<CAO8!&!96P](*VTC)CV*(7\\DFMV-Y2R7Y#_Y1C=^'I=:QYS&)
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MAAU7LKO;\[ ]NWNB]/+HKEJEE:H]Z^.X,4&Q4!+'***&9*E5\^DO'@0)LO@
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M1,AHQ5/]YJ 5I43)W?*=,O%M5=.H?=RM&[\TC4R4;/&"!V^W.'[(</C;PW-
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MY!#%3S\':*]TQZ))T!P;)08.O(3P8VO<D/X 2\Y^^(L>CMA(G;/ #$EP$9:
M_2 Q!8L,"+: \1U[GGD)(L(+P2N</!"9\H<E9!-Q 1^S\E\:&TYCT@,BI!XK
M.]B^P.01E\^?GG&2G1(?W8(H?H%IMO7''4U!Q@,U/#- Q60H> /"'%#NH&0(
M*'_YWR:/7X>[[5T"=T$DS@#$$4!EH:#CJDKDS-%4(&]_BLR9-AT)A94UIA\^
MJH,H-E#M#-!#5>!RAFS>9"Q!=9DZY8[,>"=F;1]@R6%P%J#<85;T9R]]H]<+
MK-J[.\N>U'[O$KR#27:X(QK(B$_15>B.+E)NH>9<T45G2)AII^MB=N#<V*P
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M93B+.F187WG^PX,D9 KGH1Q93E/)4_]<K"6!8Y&MGN''(/D-9I1INGA*(#N
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M/ 5Q]$^V CPG7H]1M&;_(,+=$3V(?M++3;YS"- #^83M1XV><UAB:#Y%6Q'
MKLU($H&*2,Q$9*'H(KT0"Y1R*>_;QEJLV;4K[ 2^;T?PK[,]F8]@FE[ -$RB
M72[H69!&*4U<+^5=P=?L#&EF;9M0-_<<?6X.6L,M5I_N+\'R"IQ]>KB^O7QX
M (O;"W"V>+A^H)_>W5\^7-ZN%JOKY:T?GC#  O!PW<\/[3PH"O9 XL_"(9.
MO[^0XN*O5 K Q!C[A51>O9PN.$DP"DU;"G=0&="EM96J[8YB.1L@^'@W(RG
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MA #V7DR./F!D?ZQ.ULR+]=_W:<82T:YP<@L_2UI)<$Q^#/."E(I/7@P)FR^
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MFW-ES=1'?TE>-&DB?D^VD!GK9YPMXC7-"=_1&*"<#ZM/TT9SJ6X>#AN:+3=
M\&;'C1E+K2_8J^5.CM^$3!'GQM9B*KJ>"Z;(-IRNZJHU:^+L0!.#M#,%5,@-
M*IO51]Z^0][@^.GTACW57Q$)6>6:19I"3TYC=!#$!JJ< 5KBOK?+O<X.@&6Z
M39/'T!IOB$@&R0TJY!S@5I+_'R_K0%#%R^JJG %:*E[&74PWV\):?8/=GIA4
M(8W^>4DKB4%/Y9M(NJGEQUE)>- WN@]XDWWVIJ17'TI8476>(H):H;#55HJ
MC1-JPX>"-O'!Y683A?!JG\01K32BF8&D1=,P846#AY/LHY(_>\5>^@=F(H"-
MD,&'+"03D+&IHN<":&6Y4*)9C7:</R@$&)ZA,OHX4<<0%PU#G.H0=<!$:W&"
M=1+&JWUAXOTF"#->V[1@Y\=TJC"-6IX^74Z; V9+2_<"-+?E&:/U]7:7X!?^
M%E#?O#O)##A7;B?K(,(*9D#FYH?5J\"$-?3F,22H"PT[&:B.^NU4-R<Y U\.
M7FYT"L3H4'.PD;]QE_;;?2)]HYKH._DIS#&<*H<P-YTU7SR$3N4(9L),Y58U
M?$KA9H]NHHW6/9\2.0>@E>0=O)M(LVC+2NCM&1> "!N:P1+,X*RS 485-ZOK
M<P:0J3@:YPDH4U_\K+ NH8\7O<XHFH0= -G$:&PO/&'U7SWWQ4ZH5;RR7=.S
M@E7%4TNX"Y]]&;WG"%FW!U%"Y5ENZ&47N^MB-USI7R!:7^&$"*?CK(H$S=%4
M8F#?.4NVU",1O1=$[%Z0.:<G.U ]-+&14F>!'#H";;D!E"?@E[F<*Z!L6?8U
M83RVX['"SJO@]?(U8%6](QS?1+]!%#UCO%YN/L6;X 4G >N1E&6(;:VU'-&,
MP0!X31C:=U0B -CA-&)EN$_ &A9%N3WQT4' 8ROZGB7(PJ>9!(#"+,D 2B&H
MJTMB@%*.P55^::'WLR"%:WJ3"N.4-P1.$MKMGJ<0E7]R%QS8I<SG(%D7S\-I
M_R3:_ZPH5+_B?27('Y,QH@O>C8<8[ATDVHFSX$FC)NLTTIG6 IU"6C=U8EG[
MV4<J)^V45(P%!.5@P..!=S#+_V['!P0".B*P$^_W>;LSUO)0ZF@H>H_L^,!$
MSR;:C6E7#,V'^^%I_0-/;UEF]9D-Y"U$93T-G8:(.JL1_;W*VCOG+=V6R3=7
M#VRQI2'NU 3<ES=/5*XTA*UH!'?XNB-LJ<5%L13I*8D-V=: ;9#\!C/PTOV
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M/RRXVL=K@^FHC8*YFILI.GET0CF)LQ+&RP^#[D$%J^G*3P10F^JG<H%[* Z
M%D\)-'W2UT5ER-3;1M5^/"]Y@9*9'_Z@ !%65YJ_<* .)*9<OARO[FY,WL?U
MDK*]Y;QQ]S*N8YEYX]NS.%4(>P\';FP]B!L%KOYC F6DAAU\N"CL65W(K' 6
M(!"*/3'[ :KLB=42H^B ZH.*UXN7($+T./(*)P\!33,-]PEKO+%X)!NU(%3*
MDA[(P#"9Q92AD]0G*LC)$6@G#,I B'2ZP<EI2GX%TD(J'Q*=!ML&M@+)+.U
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M+^-[:DNT4"GY@UM,%OOY/]G)IG:M1XM,S1W6FA#V#;U<98LF3/0R21(/"/G
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MX+H8P%0W\'<)WL$D.]P1]60DA!13.GMHKC.M]5$R#Z7=E.U;F>#'9C<HF)V
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M&YR @*VT4IK"B/9KMOH&V3,$6R+$/N$/>_ FG[91OFB+_/3F7MQ;?;A;^_/
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M@_4JXH8U%#E&45[CO3M?TN2O8"4W&>6LJYWY!*<8;<*X7$8VKAVCWE7$+$[
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M:2U1-I>U8HRR+<XW-O)&'1.%1<'<"^OCPM@Q/+X^?,B"),M#8MD0I3&R!<0
MX5,4Q_0?9P$9>.C)L8$[6W,3VF08WYQ=.0UH7-"9A3+6#3.]COFB]:<$IUIG
MIT[83V=V#>*X[*-;A#+&MZLE\YPB5I=)68Q9K5B]0?.Q'K>XI. Z%KM5)JS[
M+FJ\O9QX20B3,$H'MT__@>LH9MW%UNU.5O";68@F:^0-C&A#;=JXXO)U%R6,
M0F%H8P9L!6&F\[]>X4:RM'.Z_$0(KK_-)7HKH5W=%"T&>D54WZ[9N9H$)+E9
M\I<D>3DSV)D3_-P.\&WF9=SARK5-YB7_J7>'Z>5$\C,_D6<FRM_P8_K1I*<9
MZC)-Y]^J,HYFE%P@EF!;5N# @-Y84".]@"%+UP3?O3\!']Z]_^%M3#[:YFMQ
M#M(S@2_%5*W/2+EA+V3#7F'V\?R/6O+]!WV".GZ<;6 ^G94>"3-:Y)0XO^%(
MV6YI%D-B"XAOSJJL!SG9!F<9R*1(+&K++GAI67'$<I=$I9)'OA3K%LF+*XTN
M$5U=H!55@'.FQ7$88&QI2A:WW2_P8DW)BMU<M_6;PA=BL4ZOYH3XH-GX?8N_
MJ=8]PV@QV*98#JW:GI@.:['W1^%YW0DZ,%F=@&L;\R_(/#4";VIXN?C&PJ^0
MWK\(K"G9A%:N)>FD<5CAVGA6D=C,>FT&8P/LORQ+M1^2BT',-RH/O83UY:AB
MH* >7W-[&\*_W'R,L4\V+-C(%VW@T^1XF$\%;_4TJGZ59'YZ^L8S1GR958=*
MZO.5O;?SZO_DH0QPBE&S4WR>=GUP@,DR6=[6)DRZVO9E8E 6R8O$!?]6-G='
M)V%?3O+,V'%<RQ"^$'MUFG[C8?1][,?E47N'= ]I47+R^3F.64>@?8!H.[0/
MVI%X;/$FZ'IG+JZ[Q7AAH 5O(#%GK>TJ.T^/0O%$!FVC,^-02_@"C5<.UX]J
MT?K1-(FGW1<^S"QR:V^!VE <I_^M ZFG<Q5[HY@X_,_X-,8+^%Q,';:-ZW_<
MQ-%$8WQ>T^Z1DU3\&X!P^[;.B]G&2+SI_,5 W(GGCQD=[TQDY18G!F/S^ (M
MVG*H[SP \BR<V[DOOR8CB>(T"EE3\HG>9=6%\.)=2U4H^P%X\?24L&HQH.#$
M.\-7\P3>_A.K%A-T\ZBJ"=4W:VY.'T[5K'9F(;!_SU+XYW0A<H"0/M_9MP@]
M:HB=\8G(I%8_:FI*IZ%\L18^64)*JSO-]S2CBL]4AQ9'4GBQDZM)-6IX_N(.
M'-H,T<VY0B.T;]?H')X2U"QW;B<!1R_86#.;Z5:\:O),GM_4*9_]0,D[#$6%
MJ;U0-K1X%<XM$L[L(:I-J[2?9*> [I=@@:[2ZRHO3;EI>[">' !)9UD&]LL+
MLLBY"J)D]'BJ+9HO%?)[177XNB7(#_R?*%.PI@O4#6&;AUWZR"5EMK[!21&!
MGV95DL6103MKX:!H#5^8\5H/T/W56=A? #H60 >C&:XWT>LK"\+O/^0AF'[R
MMT]Y0T4B_!;'3,ST8?_X=QAF*WP/=T0OST1J?DRA$CU-J.K;CCX7.["O<;BG
MX#&0:<O5O!UER$3@L2D%*1>"'FHFA1B _^DWTX:I :!C<[5_Z] T>4\3VZ8I
MJ+HU3<[E_R_OVGI;MY'P7^%C%_##*5 4Z,L"S@TX0$YL).GNP\$^*#*=$)5%
M@Y*"N+^^)"5*E*T+KQ+E!8HBQXDY'V>^&9+#(3D_-1''L2!JGAE=DYJRVGU2
ML_G).3];3?LEJ21J?J8V/RZ)KEU$T.3LA15\$E?:>7!-W%;3?HDKB9J?N+@!
MLR#B=A%!D[@75EB8T2_O;*[M7AI\I5LG%')OD[,NEO++]4L&*@1LA[+!H'[
M+;1)?>?#867+R^J(A?$F[J[+&:^<0"K;760W3*PV<7?=30$[74YJ?H%=LC#C
M'!WW-$ V5U=<#(^J=VV%WM%/2-YP'7&:DO2A>9]];]=Q3*BOGW6:/=C:T>?;
M@A Z0?71WT<4O:$$Y2>>>R^TT@MIG!0[^L<H!5'9'0"_6+*4?H65 >+\ Q*0
M5!(0''CRUL\N5/P!=T4"-_MUFJ,=2HH<?<(7&!>$P[G_*COP0"?0+,U;E$N
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M$!*UKMF%?5C1Z$#*EOX2$@)W/!5RG^7HP I#M0[L*S9DR/2QAKU0N!9:[25
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M\R%!,+MI)Y[T:P$'F[$(.?W->EBD<F'@!C3IQ8"\0,506$-S 1LE&;;';*6
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M?FQY<HSN?]L DU3">4\+<O,]QLL7%(@R>/Q= \Q=D_,Q(M?D-7:0*&/[WS3
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M,U(GE]5VVGJ0'9C'C;3T 9.7+%N<DI)K-"1"I=WR*F)3+'?55:-OOF2YL]R
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MH,8$*TEIK062*:A2>^D 1'4[5[-A5#5F*$Q2C[V*W!8QD<<V)G*!.>[E9R9
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M!U^(/%@(,U5"08JCQY@Z8\:S)ZH]B1>].?Q,3ZKZ\6;*VU$$(O3-\J8H6%Y
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M@+8-:90-O6U':DZE1K\1-2-KD6B']XV$<:>81NM/@<KIY;854;-\_>LGHO3
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MBU:V]E%>(T?;;/6\%;3EDV/YLIBM\[>R++(9VWUIWMW*HHB4"^ +,)P*Y0L
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M*_9L<* ,?R4) 27@SN* F5W\JAPPB%.3(V9V<CH,L;)J=N?O>V+7*48*&'S
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M9DM51Z?J-CHOETG!W]TJ?,T/15DMDUR>QJGH3VCX!H]F 1_ IX7B7]TD59;
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MPF;0>)^U>!;R%(\1Z[%6;34'?0B^*%F&E2N%8U4?0).!%S<5++T%P<V_'[5
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MC7[EXZ3%;&A]KD%]@ Z2#[PJ(Q=1K?[>*AN$<?5[FX2[T*$>7/_3);(9QF=
M;2%^;;P=%-)9OR2'N0,GS#-V!J"X-FJ1!(XR7^.H'-*DB^SH0GT;X 490I>=
M9YW9''M[TEZX6^<;R JTA.^G@S^?"E'<BY\$4_2?((W0[J[A0VMN4-.[39-M
M2"1\O4DBH7:$&!>(]DZO\VJ8+#B;MSZ[TS?1R0,U-1O1;875B8;?.CX_J?S
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MXQNJ[.@'HP."=VU;MQ!<'F 3%C_PC&"'W>A(9,EJ@R,K*).E)=\37B6WR+S
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M2,??-;=7-^S2'BL,XF(39'(3"_OIP3#QH_]>:RR2&M1.O"YSU,:T)\I,$X=
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M+D[.3B_&K,F\WL0T.$K_:&OR/-2]49>N7^A!18^)&3:.EF7*AD962E&<4UR
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M(4FJ1YOC;6\FSU^.(FF,2G<-!.+EXZL[> *!V&8=7I#8A"_Y4*@Q2*64_ND
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MK]\-"5M73?O0^K"^V+'/O?><XX^X=SJ<#N)/LQ!NX\D89G=7X]$ .A9C]_Z
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M2W(VY%7/)^W!Q!24$"M+ BB7BIC0>$K2V.J4@P+4\@B\,:00)1%<@14E"6D
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M/;P]W"NK($@UTJ6P,5U2:J2,A71\,#1_,.A;2MVSNELKLH2 2?##;DAGB@<
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M6*7-/.1V!=!DD@B8,7Z+TSQ4$-3C>29 /]?(%M 8?%2#/C!\XC51+"'\KUR
M^FZYR-/(;;QO5]LWE7/Z&IW33=J^^2@EP?2@ *3AUBQN\D:" X-"U#S?1IER
M>H%AL$_/N4#8)1;=\Y+%TSCW(EO8\? ;XRL\0,J@HN%S!_!&"H9T)%31N(X
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MN)]*^]I[@?+/3&VS_-?4_U!+ P04    " "3@&M2CF\V*$D%  !5)0  $
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M@U(;E'IA*%5]62C%(S4C47B R!%)@GLCBM0,"0JL&A,N$%@2P5(%(17538(
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M#:[_"N:VX^SSA5=\?-0TBX^<_@-02P,$%     @ DX!K4A .+;;A&   0(0
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MA'+JP$!S$LY7+M-PCMMNU1-8T<40R(<=Z%VT=0=>BLPNREA/_H(\#5,5/@/
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MMUD1#;3UQ AS*S"HRCAST*:84/ GU/"T?E&YB-ZU0>SI#:^1.G1=I)O0,FV
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M .]-A"JJW*SPK([A?K44&[;T>9@O@$D^NF*2<B9U:1OJ_L*G;?K]9^+?!?A
M[\=/[7I,8RZMM1(4^N'C*U8U0Y54=LV>2=V5"&6;3J7&S(U)FQK4]. 7'&A_
M-Z 7"!FN,EJUZPQ!1XN *0.4[M>2,&ZT> ?Z<P?*UAC/M65%)"E0OA&U=%27
MG$A$7N%E\7YL.T_L6IVR3<;H&>/;%6Y?.I<V1B"Y%#XA[ES!8-4!34$$![%^
M+V'HQ:GS4[E#N3_LSV?[W:^[.+$.A]T1[1K4GB- !S[:#$Z7CJSX &P#@Y_
MC/%AE:VC]0]ZW8C;>,,]'#=JS4/X184_WINZ'K=ZBF"4/ >ON7/G@J*(R7V'
M+-<5/SYQBRT9(0?CU;'V=8 AL^@#B*.<?Q/_!$K4@2[PL@=4W[3E7W]@'RX2
MUF[XRTD)=^3ALD)71)BL/LM/X=QNL/@M.JNT"; 9HZ))!UFNF71UVW4H)]6L
MJ#T:*>[?6W3Z$Y=X+>AXM<5#OL2" L>!58+[,LT1K-UU8EH[3; I:>S:3T\1
M(,' :S<_'(E0HZ#.#<K"<)I^"9N@]6&2&T@"TH4G%P<P53(B8'M-=PZK$U/W
MNQ$>O'JCPU/7.C5RHV,B:' O/2)R>7!TG[[>DKY^MC<QV0JSV'OSILCAC_\'
M4$L#!!0    ( ). :U(/ZJ=QD^<  *M_ 0 6    9VUZ,FQQ-#,R,')K,# P
M,# Q+FIP9^R\!51<[;<>?@B0P0()3M $" 0-[@P2/+A[$EPGN#-(<(< "4YP
M#\$]N+N[2W!GL)GRM;V]]_NM]M_;]G;=_ML<UC-K,;//.>^S]WGW?O8Y[PQB
M!K$"/)65E)$$D)"0@/</?P!B'A 'T!X_!CU&10.!0.CH:!A8^$^P,#&Q2'#Q
M</#)GU-2D#\G(Z.B8:&C>LE$349&S_.:Z0T;)R<G)1V?$"^[( L')_M?!T%"
M1T?'PL0B?O*$F/T%V0OV_^$-\0MXAH8TC*:!C/02>/0,"?D9$J(#H 0 )%2D
M_[@!_WE#>H2,@OH8A(:.@?E@4/44>(2$C/P(!1D5%07EX5.OA\\!E&>HN"_8
M1!_C*7\ O;3#9_>-R42C%BMO)5 9/:;A^&COAXY!2$1,\ISV%1W]:P9.+FX>
M7CY^\;<2DE+2,K*J:NH:FEK:.D;&)J9FYA:6#HY.SBZN;N[^GP,"@X)#0F/C
MOL0G)'[]EO0]*SLG-R^_H/!G1655=4UM77U;>T=G5W=/;]_8^,3DU/3,[-SJ
MVOK&YM;VSN_=D].S\XO+*]CUS5^\D !DI'_:_JN\GCWP>H2"@HP"^HL7TB.7
MOPR>H:"^8'N,*ZH,^F"']Y+=%PU?+":SO!6=FD/EF."C_2@&(0WG*NW)7]3^
M([-_'3&__REF_X78/_.: ["0D1Z"A_P,  -7-_3??3#^X _^X _^X+\+P>1N
M,)%CQSB$LP6[GW9P(?\C3WEL3 ?VYL=P-*9V$I46U@%BMBZ<5$\FP%-Q1&2'
M GI/E]#$J@93785@N]+IU 8N>304>0EO29LU)-J)O7@OK(ZDP.^G%NTVC$QA
M=5P#E_4.@-\A@!M%9JQGAY1X9;GC<-(]59'@01I&6W$_R5E](Z-6L@![J6;^
M:3^8U*^;Q(CGYQ;C<V]M4$P5*P587 Z[N O@JV4?8,,YRY;->#^"%'_6-<1S
MX4=W0_"D6ST+)*657'O);D//()@PHNXHBWQ]"],S*89'E?:#M$4+\2@^6>'K
MO/T?[!==>8&]1H+C//WCY7#.>X/3(P4/#Z,73H%2+"Z2?6\PD":#W"^?'T,"
MT_&X)*:MSR,^7A]9LQ*+XX_'CDE0X]5LM9IB=;"0YHJBH%+=#@)N+MV0:SS'
MY5L,.GA(4F/#+PI6* @6*Y#(]Z-N_LE:@C6#+64CDD."@O3*L1:6[:![U-_L
M^>=EFAK&+YA5GD:8Y5UCVB6TLR8-%/YR(=&C0 !OUDFHWGL$=4<][#!\BY'W
ML$,Y' G:W1T"7JR".V@^@ZY!#R@#IIX_&:BK'Z]2>W-H7?'K8S)Q/ZXS61D
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M]WV[DJ(H3B@N9:F"U"LM3RSAE E7NB?JJ0$3\PES2 [/*[5Z%AEJZ.BBL\@
MAS//JF9"6.G>VQ.#=.MAOA\MT;J]-K7QFM&%10$]I/XHJ,%TMOO.&6C"KZ&]
M2M,MR_X(0&:M+,,3#P&\) J"[I/8((#O"<W>L!P$0"MN@ "\<>[I0IM]CQ7O
M@@W($< /DQIXJ [%ZLABV2/8;%G34<C*Z,MT[CE/T<UP6\H6N_1D06X\4S0R
MR(<T:8HSP>.Y^5X[.P8)+&D#&9KWA:&/96B. ?*]39SS%E+8,%PWIZO,ZTA
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MEK/PD"'516E8(R7PT9$EY:P9HO^F8"K7M=%8J(NR"S2V^2DFW:4&EP(Q2).
M'OEP@%=-737ASX8/T@_H3S8AMQ2;MPJ'R8*-V\ZNPXM'J8W343#5KC2N24\C
MU)*T4KAMCC.%M,G]/EL^[<++GEDU]<73HM=4 +9(F2@"""!=3;^&3R* HW/H
MG6T] L!VY1$[+G[AV$^CW6?M42!LD;WJD+"/KB0;SN(&*($2[Q1/% -+N>HJ
M]Q  IM["KK/YY<$GV\X&2>+'8CD\02C<*V2>=;_[,;8$E5=;0+,[XIK'5Z%/
MIM;*NXW8D3FJ3XG3\+\'H-SU^D>VO"ES/*'SX\0A^-E?J'U8)YU$?TAM'TL%
M5B %11,_11>T=^A-]VTFH::$3':W)!,A -(,;,T5_:7O@E+YL]0#CA7FIO'<
M6US)[BA\<$+&EON5ILMPCR8S\WK";ZN+@EH6W"$VMF1UZC0)1A.Q,C3G9&D^
MV#X:$0"^LL0?_&^'7G59*:QT6"UI6?X8<AF19'-ZV%+U,FB@S\];DH28)JJ=
M<PSR@3MF8E1/\8YFB>]!5[LA@/A\<%L43*;Q06:_/4, C$K0 ,T*;T-WNCE6
M<%UJ%4''0U657T^_H4N_UO&_HT< GY.[P>>*X-,J$$QY?SEQR?^/X1_#/X9_
M#/]O,OSHVM !/@Z%&9SIW++.-0]67 F;#LZG:I9B"U^Z.Q<K_CUAVB\_<UHF
M6'+%4:F9:"2]3S6%:WYSNB_ 7S*@%1.6(.&CPNGF4LI=B(4FO7+"#:O9&#;\
M7IO^]T-0'L>Y;L-#MN$:#^T41KKI7?.Y9J4!U$' DC'D[Z-$ .@\D="=-.BF
M)<YQUFP+:Q/HC^$?PS^&?PS_)PTU)3*6+>L#POJ+S9=G>1ZI%('F$KSZ?0,7
M&K%EB"^OLE?&6G8#<Y,1@(^EL@0!+2J^LL@?_%=@!S[3@Q[J(H#YI(.B!Q<G
MK2, ^V7XPF1[62;>[UWG"64)T0\2^$I(_R]!3[$]ZCH9NF_<B !F&:M+Z5:[
M[P9;+MD-H/OQ=C!M7%C,_,-%A1KP[QV\_T-!G,8TS=+(MSH?H3.M !^YY7ZN
M]3:'M']'ZX,N[ZZ#KX^"Z_:#IEFU@W;:/4QWUDNBNW;OUDMH-71<D</[(#V0
M#38]$B=.,( K*BC#Q/Y:*F*"_6>,'YJ0*'G1%A2F,6UX7-FR2C#/,W.W+'!
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MNS<E:(( 7N8<W2$C '&=4_?+T^55L.$H)4<JM)%5<3( 7]D@9./??/4+0Y%
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M2)RL2)-#^F-+2'YA^G8O45P4E&J96ZR:5S%B$@4<TF"2Q$HN/%9P79 RNIZ
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M*RV@W0XNK9)."?)(2.+NIM[J@^MI<!;T<;GIC/'4#-]%[$Z$90VD_:R":R(
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MB?OAC^<??9EGK>^*9ZWW?=9:8'<_'OIHF0<@>I$!LQI?V .#T=>&8'<O9.M
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M$NQXEEUP'[[&%=Q[&[_7K@ ]+0,>^26LMN",F=8C A=WR17+P?FZTS-&C.V
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MUVP1"FX4T9Q^!TJ>PU;%-L':9:[?$^S@ZVT04Y:6?T'Y>#+OKK3PYJ$8C7]
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M5,&=9V-FU.ISGI(I25(A?$VO KX7YW$@DTJY_V(?9].[0V-HKW71Z])9"R+
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M-X)M36AC5";@=LS-ZM1;E# +S+,7\HP2<\AXR6N(\BW 6.T($7_G18=4J%M
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M>XI'PC@3RR8SY@>HYT-]7[DML18VQ*UQT @2A=L7;KQ]Y_B.#\H7!Q@PGF@
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MMD?"QV IWA^_#]#+>W[,E5OW5( Y$^!XSZ*%%G!Y@K&+6:]LW;>B!3+3GG2
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MI(*K>*Y(Y A<5,"9*BU;%^E9Y\?9;Y<GF\M'Q\?;LP^Y@7GF_0;@/I_&6/3
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M<Z^*=1U#GV<$S0==8$5.BD[H'D]OUG'-7LU2!EA<<<C)36I"U4PUAT^+]4K
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M;J;:R^YPO@PNX)]^W,LP%GZKK8T[*)?DT8@QX\!&'.<%*[5WG..DNY \]^N
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M=6TG6^NC;W+Z&;NT%T9F_>)?JC_K65KDM_IKS$D#/+I7MB$\SD1!>9[5GQ1
MNKIV#3$JL-\3:"K:L"E2@G.*]?%\C2/5!UV+]CQ,3[63;)P4_H&M,LY:Z55P
M^CY&&QC.E_-2MX,3H$S &Z \N\\W8VOG'464F]WA!,=.CZ:SKXC5=8*\+S\R
MO<! L(5X:D2 %[?F434/[KI+JAAVK4I^5AK-\1C.ZZIP[N:I,K95S:U\?;)
M<<4&8\K7#)?P?)O.R-7T%U?]@J7)O*,?-,S:DTIS\\G\<.5#V]B:"$CO+R*W
M4CWB? C=)D-PY\\Y6-<P<<*DQM\:-:7BQAVTE4^+T>!+?DSO':NH!!8V;I 3
M+1TH:7-5=VB<LF$NLL_S@[:1"1KDZ4@-V\7T.3![Q^.R 9!@9H<EQN(*2^=;
MTK+_EM@RH5F#1CI]+WKQ?<0ZP2]I3W#/Y5D<O*#@</E7DN@^GPL%,$P@=]X\
M4>/SD7@*8&>[MELH>R:*=0EKQEG>BUZ3\<Y7N;&5V J*:Z%9U!+S;P4RF%WO
M7ZOB02XY/70]O]"7\ O.H0="47&-=%^9S'J*J.;PS3@)+C-2WK&.EL.+-BJU
MY$L99DH3AXX$XG+9'"1RM(MDC8/5NU@O6#NT@7KVW'GP85'U9J*F9X4CY,B]
M9LN22GO?DZTT'RE"0>Y22]*LWR<E-W:#K61(F@H)H^LSJL"FMK:':UMBD"?^
MR=PV;3IAR9<<NXIW3'WIP@/W!18<3,D:!Y>K+A:3+Z.0"W.O',2B#I:$>U"F
M7_0__XIM=A<X7$<6GH&&C36D7O-]M"^8</]#]/X#"69EZ?DHU;H$7>^63U3H
MC-NG\!\7T9GJS<A)K'(W4D%&L](^A=#$)E!)3$ X<H/:D.D*;>NF[W(=77M.
MDQ05!M#>WFM:%,!K&Z,;0A>BI>JLIG?6??$TS7*W,,,^\C:YR[D@<^O02Y[M
MIQ@*-*""D0H.XZ26GQ4XN">*Y+>P<\'?]*MC_%PV[S D9"X;V,.F$W'S1@JZ
M&K,I&;_<GC$QM(W>W;I#2MKLI@!F=%B6#YR^ETCZOPRQ@',$S:T[]YCG%DS(
MDY51)U-=<R0%\$WE&2FXQ<NO>D:ROSEYUT6@'4MLO-08(LL2TW.GS[G_QWJ5
MBC6D84R4J< EO$R$H6!!L5X<%Y",6^3*^7 K)],1#8O&Z7&.'2?4>"57>RD%
M\)-'2!Z%2]'GAU]4S3_9'#\-T6F9%>["RRMB'5VY5&4/Z=R?)%]0U!VN^+[.
MM+]8@1]PX[6JW>=TM15RT?*^8-"=( .OVAJ[O<R0UT.=PDG5GAPPG*VZ7<A(
M0C0<D*OMLF#U5[(>XA*X7_T:<[B4FFJPO9/'3&KX>3!SJ%@[DZLP#:I.AQ5,
M6Q8Q!&-\YK"?)D%]K@9&$'JHGZR-H?-N_E>& ,&8P5@IM@Z+T?*\+5T])Y_)
M"C]K=3DCAQ7;R22R8D_ 7!%FT.=-K#$+]9NZ!L#HY%-Q*WUJBZA')Y+ZWPVR
M)HO!LUWRCXG42=_Y/%)"RR-JGMT4%/PZC8M^,+?<Y#JU$0^E$R3W135<X1FE
MPEV,I38F#G 0/^Z-$,(^:R5;>WBXEOIJW=(-G+.RRI]PM3KOV'A93H"X#O=]
MP=!W+99MJOLI6_3QR9A]J2>,H6O.^YW&HR8V[@8'&-+*')K@:]P4C=>OF[FA
M>+&ENU&ONP^Q%:<VQ^4PUBC'_^59B8K6E<=/?[SC\(]LI !DL"F"5^75F6'?
MDE=R%;,JT?.N244TT[L!9?.^!;CES\(91#0N\([HZK!IOZ-(QOVY-BA;(%U<
M74/AYKJP?RWQ>LKP.]>U,_S)IL8:EAY6'+0=V](]1,:A[&SHF&IUW]?^(\-,
M\+9[PP631S H#1L-'$SSU+.NE6"H^I'099V1.BHKH:SW7E72G-YH!15N/SMU
M=F2)/34E8]DH\.PN<Z!*D.DO7I7.8+8>VZVD-33BJDUHFEH:R4+-[IQ:U,YF
M.PPZ5[$#\HZ%MM:A;E3<W4!/)-5ZN+\(25GCR'9H;SU1?<O2[__)9.C_L8K"
M( I@$V*#V!VF !3 ;]%_JVK+J;21N?1[VPU/4U0>F!QVL_"S7/P_F^W]?[T/
M[;]J)@- V8@;^PYK8?MAM+Q!\E2_AF1NW<LH:+DJA;Y>(3,W9PP=P:%[[7DK
MWR!DKR6G9LP\A*2\'9:4,#-I<Y9-3% <[_1."@OK3F'3]@B[GQ^:KVODJ%FY
M>2*QT7?_%7W^/T?3_[>VOZXME!O]]:"A2'Z2UC8L!LDTVS+$?=(7+NEW(E3_
MV>+0+Z =9 6U*1(-.0@]OX,G7R\N&P1!W.SL>#Y+K(Z64TDY:0I&OJ_:(U^8
M@)%]()OW8$>ZWE=]#1[%:=G8D96Z%P>%!E')?*,8A<5.(6&/__MO/!M!)V)D
M:^:DEZ93 +/YE?A+M9]]ES;)N2%DI3T)^K")OQ4+5OIKE5VY(K7]Q,F E4]1
M\_^H'#SUUR+-.K!ZCD(*H">8K!A% 82E_QNZW!_P/^!_P/^ _P'_ _X'_ _X
M'_ _X/\AN#@%T$#89^JA ,Q^YURN>ZD[<S/V L'"^@G>8XY"]]]]=10S3FGW
M9EFRPQ1>X;K9CIY=]Q71IY-GLLF7K>Z!YZ#RR:RUX; E%@H@[B+L=UL8HN/Q
M:=CF2U&R4'5A@1;9:B^]8Y<5!C]N$59P,]] 'IU,;1X@CCZ%_[Z7OSK[ODS<
M$JVF^9Y_5+@N;22<1P%\<)R=.J"F .8;S7]KZK\Z_]N#@#^8+\"<V_M,]8^$
M89<I@%Y!"N &WXGFSOF[NT'F40?AX:H0!2!\&*D7ME([8TS"D/TA^V)7_D'J
MW]P/FD07S;V87NCOFX^_+='7I0#HIYIJM^DH@+:06E(>Y*_>V%LP\<->;_K:
M=O(</*VBD*1'OD,!?-4D/U&@ )J>_<WY?[^R7[ID_3U.).O07VB+^IOO3IAY
M9\TV=WWA9FW9PNO_D/&H?Q#^]0_??_C^P_<?OO_P_8?O/WS_X?N_*=]_3?7^
M#5;_X32"FA2L3/2-V-E%+!@K+#K"9.XW6SR78M#4$A;:69;14E6S'L1&L.<5
M&(=/N(+]PFX6ILJ]^U<WN_^Q_S^-,O*_ %!+ P04    " "3@&M2 U=B2S2T
M 0#J_@$ %@   &=M>C)L<30S,C!R:S P,# P,BYJ<&?<NW547$^T)MH$:9S@
M#@GN!+?&0AH-[IX@01IW)WC2N(<.[FZA<0ENP5V#:W!)XX_?7>_-FS=O_IA[
MY]U[YTV=]?UQUJZJ55^=O7?M777J:?YI#?!2459!%H"$A 3X\/P GI8 ,@!T
M-#0@&BHZ$ C$P$#'Q";"P<;"PB8G(,0CHJ:@I:&FH*)ZQ<#%_(J.@YZ*BD6(
ME>,-#S\_/RVSB+@P+XB+CY_WGTZ0,# PL+&PR7!PR'A?4[WF_5>7IY\ ?'04
M*: R,A(=X 4^$C(^TE,/@!8 0$)%^I<"^#\+T@MD%%0T(#H&)M9S!?A+P LD
M9.07*,BHJ"@HSU+_9SD !1^5X#6/-!JA^D<@G3,1;U!\#CK]VYI.8HV)4P8^
M,Y=@#$P24C)R"D8F9A96-GX!02%A$5&9=V!9.7D%14TM;1U=/7T#<PO+3U;6
M-K:N;NX>GE[>/B&A8>$17[Y"$Q*3DE-2OZ7!<O/R"PJ+BDM*:W_4P>L;&IN:
MN[I[>OOZ!P:')J>F9V;GYA<6US<VM[9W=O?V#\[.+RZOKO\B;F[_X84$0$;Z
MO\I_EQ?^,Z\7*"C(*,!_>"&]\/RG CX*ZFL>- )I=>!'9T(ZWB!THK?Q.36=
M&/1\&J?$9BX3F"0,_.N,9_]0^Q=F_V/$@O]-S/X+L?^;UR( &QGI^>,AXP,D
M 7]O67(_8_XK00#%(;_.?I&2D/+?$Q$!U)44I%")U+-L 0;_AM[_MX&B@8._
M-=)TTJ>82T"=.AA ]%_A=6X*%,"2/T)MC62=G_N9) '* LB%OA]_,:&0U94*
M!W RDF=32'$2J;]_ 67)_D]!U*2NV,:(95V;I)W<W\G[LJ-#7721X63RF3(*
M-5?+!SF3J;I)B0FG[,PW'3RTGTOCO#KD&]/,E(+)G@#>\K09SC[<X<=7&PZ6
MW_*9)5M!-9**'<5>!$H0V93%M5\'O-JIQ(M[:I%;27!01\5&8=,Z#IY4S+MD
MF;[.I,M76UK)75XT&PCY4R6J:/N%,3 ]W(,T]?KZI7>#1CEDB;G"13M_74*[
M9$^MARWI9CO' ;H]U2^J-%!RMXVRZ?KJYP,D-]SZ^#5!S_I$$S;.^_U16H(:
MMT/-DE.Q1'6]! 2LBUI^7O(;DTF1XY D19GKIC'3JBN^C04](D]-[J*P>-H?
MPZN49U5.":Q9,\T))T.9G01JSBWF3;L;*G/1\AZHM5IP>]QJG0_=UT]/+4K+
MP6XIB'3Y@-%U:;MZ#4HTF]&CC<B'(VXLAQP?Q\,U>-&+1%TC>LJ51<>?!Q!K
M_EGYH_+& ]VJ9]CNASTGN12(4U0)L+'7A=0$!7IPK#]R6.+:^#GDWG:O5/GN
MSQC!(4-;0E/@(Z$QY:-OP\,=?\FF./DR2T:M"O!XQ(FB/J'9H>*:,3G=^0(_
MZE-S9""@]ZXI8/G^Y?QY/V+.6)'H-3'[L?=TC5=I@K.2>4'['(?;7E["SMNR
M5T/K"B-&\&;H^0ISV-?H/JU-\DKV?IX;P5F;]".RVYD5R9X4"I6(3ZFXO4,/
M/>3TB7H@\?T2.<,,)7+;2F)^^3\LY='</08!E;V<*R$Q'L*= GG\9TL]DT/K
M^-X,F<FCZRPM_!Y]Y8PTUFT8Q95FIE0V/(J#:5DV?5M2TK>NAAY"UXO1C;!%
M=;KX^<O;J6367N/<UR;I*[G'PTDZ@B4;E)Q,&\)<[\*R"F=&-+/ZFK4(;KR3
M1T5S=V^GHBD2=.4U>B8C?Z04*8&M3&QG4T@BG5U?@S\F TO*G3?;&*K)TJUF
M@(@)"LW4KF OF)I'4H(HC U>L2P4QW%]#HQN?@GA527</SU0-7\=)]^TW!N@
M'NNCF/Z]%CQ43E>YT 1V)4!L*L1HTEA^P!5BVPH4G1'MS9F*OG2P#,7."&'Z
M7J AEDO_M8#]?-#:1EW?0+;)IKP\&M+J;84BW&^0J#U341<9*+%5O[R&2LY4
ME&"T7#\--_@>(7[);UTJ^JD M\R6ZY4N?F)0FS.L3:$P(\TY(:'YV6'$=?UG
M6?J_,U#$V5/.@#&7&4@PIL ZHZ#'4K[[,6D=D%5%?<3ZPC&=9/O'&N <]+P#
M#0&^U_7FW/Y3R1G_@]XS+G-F[FVH):E&WE_U?I/6I&11WQ\EM&1VPY_=2GXR
M)^[$2"H>N4D2V#3?2UA&K=?\C6_\B- 5=SYMZ:YR.,1VE6.E94_36WO@,^H/
MNZ??H*;L#9?/6[(G//*V8-1Y-^:H"6V2PQ-NP.%X9_DE-"&S03P8.C;C#E$F
MZ3SA9EBBN'67Z&K=V-VXS-WOK4]*D"+[XQ$7+#=%/*(2>@ A<M>J0K=A\FDC
M#EH?(];S2IGS_T&<)G5!+RY=GD6"6#7%/M"Y'K:B*F%!^2&O:STVF5 @Q*5D
M*Z2#"?H[?F1=Q3L3P %VY( 4Z6/E-.Q^,LNFM7.O.$%'["SUE'_PNH^$DY]?
MQ,G5E*70Y)O_F@V5(U31V'Y_N%>>X6E:<_J0NNAH%,:,6<JK<$V\FW7:4 EZ
MY/]VG_';]Y=(?R6/YO, _5A<J]#]WE]!Q71T(C:P\%[J8WTG%\+;T)P)@)?H
M#W&*\<D/*AA3!7Z]]W=<SY"V9ZQ)\;# :S)"&GL"E-9(KCOK/P'&F0+O;B6[
MJA_9/OMI.A3EA+G>P XN3R(DR!JG[ M3,#P'"7X$/#3'X57X8&;2$.6Q%AX[
MB2;O:JB'*/;*2W MC#E3R2BFDSHU7<B12RI>ZOW^%24A&C5'3]H=B"W#JT!%
M<*R#W=%A/G /R>]HAT_R_VUJ](_K:87M5/S)G\Q/FU):[!523Y4(;Y(D\MK!
MPS;N=V1,2DREK*T$7E2:[6Y<5&Q]A13DIZRM&^>_BK_L=7D4.L.I^E)I7UG1
MS8H5(;M64F&]SK![DL<V7UQ\%W5=.!//+WFDR@K]$OJ=;VRRII5U4\]/T]49
M6T?#\(:-+,7)%=;@Z,()(J<Z(GA/7Z^AWBSTHND)@.)52&T&.2.)AUA\C.)Y
ML\DY%_*SO U65S??H+XJ>NQF\NK,Y/OZ-I8KTV$XN7QJPN]U@R> -:VY$-D:
MTWT >566GV[E8 7DW%C!H89L/ENM9XNU+U#Q2A+HU6[Z4M^8H5[A97TD/:[*
ML41R@1$SH_#P"5TF>V9^KE(VXAK'T\2?2XS<S!W;\T<P[N(?R&@KZT:Q@"JQ
M@AF,L^ '6Q-?#]HQWE2;K5=W7P+"Y&"6H2[&\IME6GKE:D!R^M[@B"S+9(9%
M]C:3AY9NVD$6\4;#>4K?+Z-Z21^EEZ7^L3X+IZFQ]JT*K^M37CMZB*#C2M/T
M)55?T=-\@L8PI6>Q65F!+0\-ME-"S!RJ+!9#/@,U_,O&-#<.OX]4%")!6AX^
MN+8X5O+,%A*Q*9O\HV]B?#/%58*MB *R&4[[RSN]X]??'8SS7R<E1N%#+ZV7
M_&SG^V1M5))RSNAR=/@0<A-@XK1L=?!SN/@?A&]5XF>/)_72_4- X&H;9I,I
MA8V&J<TA")D;@R%6W5A8H5A;.5TD3$0E1%V@5:(8QEG\WOP#,PU\!&+"TS8%
MUS\R#R:)X?NL1_4$$!T[W8T,_/'ZCG.13PI7)D;^NM=T&J2<_3Z63N]K)9F[
MU^>Q36/,T#SMIOXTOAB]XM'@K2QVF3H\XI4#T7*/*A3T* Q&).*TC;M-]\I(
M&PMVE'<O)(VF PACE&+Q_7-9Y+]8I..2BK.<668MP)\ @I;FV#T\G4>3#6I%
M5."\^9VD0R4LC]N4$V 8I;+U>A+6YU9AG4$!JY^IDR29(UDNL6G^I=Q_3C"P
MI$4:'=+F&6\ZV!9.9U*@Y7,&YC5QT>7E-Z]\H7WYFW\69VZ_JX5F6(_PU^VY
M&%PR;?:ZO,6@W )LCL/VX8Y8^^/6?* W2/S.6Y(ND*SI)\"6QQ.@OOMFSK<\
M<(#@\+$)QC:=Y \#JQ5@^.HR^H]J_L3M,FR\. ]*]YV5A7O!(KY"5Q4U5H46
M_3\+E*S1.%0![R1G:P4BA2M *OL^5$LMQV:XPLQP>TI_,^5KD?SM*WE#2*K[
MQ_6O_!?7Y"^,JMBT#7<D;BHZ7OQ6<#9G;*G?Q!^0Z/MA-=7*B/U"T^7D<4@I
M\4979KV%DVF5-.M]7'4<SH)=O)Y.NG]B3 =?&8Z*R8J"P+E0\9$2V+N_SCL6
M&K@%D3REW39)!MZ&/@'<=&&(LD?9'T\ I,>W;4R_']X%'D./>IX N#01J4&3
M<%7-*$308^72@:TI#N)3UZ:<PG$NP2#+J-[#[P+P&?*#<<.F,5YXQ+T\9^#R
M8V')J'JW[%@)9I)55*I@,Q5CNNG"*L_+[F1UP8G+$3O$^>T[)5^P2^FFJWG;
M)Z4G /VLY'[CHWO.YI+0$T"V!9",_/'1??S/H?1PS3"-]7C),'P(YG5:NU]"
M/0V=0Y6P8EO0/%)#&%S\R7QU_CJIK36T=/>RY')%LIN4PD?)523&SF_O4^>(
MC;6.!!7LP:(V056"::BL@WD9,VV4C;?9CE4SJ0!(DIJ3L?G[!EWZ<1<QNQ.T
M7@&RJ58&87'\0CYV:)UEC@W<H@?>P9=L:,_1X9*7@X')YCHNT>C%&?PV?5Y-
M36XB8T3[9AL[K,>.N<&SKR1DTC,AR(;?NP\M:FQJ'+X] 8;!*.:',%6"7U9G
M8OT>NP.Z6+'2N@(YV0O6J^ 0.8Y?+F1O/M%&.RH(LYC\V>Y1RAA+9G2X@P4@
M>=@+KBLP<*0':(\>OJ',(AE$D[]@6)0_&G&CQ1L@$3*]&@]DVX5_#X)L[#.#
M0I,(8RO8%.Z\YTLK0 (2#KNF0J'\W85U-NCZ'L[,?G,"ZT+NTUQN.PS];+R;
MU6MSND)0_LZ"NJYMK*0G@ [ESMAD4Q9J)^-L$^>Z9HWTX!53[O>LVN]I%?*3
M[B6EAM&G6['YB%PE$0DM%RWDJ[696(H5RC;%Q2Z^.'0&/,U>H3XG@? &QV)9
MB=-!^FFW8I 8Y6$  V1P[K6$&;L2*^.7/QV$:%O?N[B> $&K^QZ1YD7=+Z+L
MU?!F*Z? HJTE@BL+ER^AH5JZ4KE05B*B_R8E_-\"&?LV+,A!B K*AO#-CT/Y
M64+[<EUI]!(47M,A= .> 0P;S54O]S$JK>=(N/NN;E0;]TT8K?PKO/#TW>8U
M=[KI8U/ U,]Y2PZ8K8Z:_PIT.S)97C@;X7Q&J3-W^: RPU]2F?<U=QA=TVE4
M%>Z\Z!G9JOQ0 T$=+7 -3Y:A+R8GWY]LQI!X\W[BC3&K=OT:3ZJPY'M=R;S%
M0PGN,Y!HR%LR]C(%%N-2@.1H?8%2 HXV5):8S77$5\1H%5'AR^HO.ETS;[[Z
MTU- 5_YL-:)P3WV_'YP@16@7G7PS2,94_\ABK;D\O_B[DU*DP3CA@Q76H;XH
M+?2>$3<:VR<E&;\%O-AKWXWV=X2E<2A*0[?AX[2*@/%*V_LLE ,%8 R=8$MN
M\/H0BGB02"_$3Y_RZCM/9DW0+>SW:7A3#L0GDK$]A+CNK-[<:QV(/)WNK"=)
M?/;08AE[C+=C'7I3@P&W!PJ[C,-/2E:] J6K0[JN9Y\ GZ+*J\/]JC1DE;U3
M@_,$?[]\Q^94^D<2F^(:A_912L?TJE/R$M]$;EWRAI5SS\)Q"T+!:Z_55*"7
MO_[Q"4!496!**&=/3XBM'DSD>U6&W+\(O&:^MKJFRM1-K3[OR-K5D6"U_L%X
M+]JC3AI5N8#+BR9J=94[U?N(8\S%YYP'OJ[^9DGR,S@ WKR=S*)OLA)ED5\Z
M=#S']TAJ2M:JREG*AUXH<Y[U ;((^7(J6Y%W^'[*P+IF8456Q'J##/ $@$./
M#B,()7Q2;?L]*$#5J[M1?KHH"-A+T6^DM&GEWT#$&X/9,7H5G\Y79%@O(F2F
MVB!^.G9>N6B/?S"=$3"XU9FMDA(+YQ.@5KNU3FMEU_UG?X'/&W=M]%+;W0P!
MY=G4.@\VK\#.1Y:Z.<ZB)GCR1]UAPC>@ /?Q>X/F%'&VQ045 KGE[CG:Q^;<
M+#+J%=V[U[+RM(<=MS,UFR.B]H%=3J:&O6GX[PJ #"]XG?6$U'4B2\O=&%7G
MA_@SADWQZMC9';$[G;?RE)T*,KY9=3P!#!HEO\*4V[.J.&8GRB&BV\&W?Y^7
MO),O*3ZR"<T!A0E5B?&4=,=CLTVQY)"1#4XMDWY"QN(;.@Z):[&9R3!MXX::
M#(4I-PW#S :A^R_ QS:Y<^)>/[HG0%Q*P0G%[H7 TO.:P7#_!)@K?GS;6!4J
M>4XXW7$(>P+PZ56M:UT)!/8$I9ZQXH,^O& Q3?9"I@[S.0=3&? 1@8TZ1R>B
MSDPTSS3X\+Y6[+"'>5UD&9FU/.#U4GAT%"R#K2TN7H7LXGX[ ENLL$@$*13H
M0$IV?^-);F4K/_[)^J43T;O^_0CD4W0ED'5Z\:B(_00X'K[OM;XW>AY:>-;C
MR95 RQ11&[9F._5M1FSHI1*9'[,-[<*FA)MT>O(@0PQD!,1-NB#!P"#OE.M!
M1I,^5XEP?01G2#XV<I]7,8UW;!7CW2(<#_4F$@,F=^ :1BG\[1Q&@TP%5I8)
M^+)_/ :? %>ZONLCN'W]4O"P5]$A/>1?C;;B$XUB>^UI;,P:9EZ_?6=E%^IQ
MF2>#R"DRW*ON#$B(+(Y[A9Z&$P/D%QYUHRN)5GQ3P6WM(L$P]7'RWJ/:L%@^
M:F\H+YLRS+>WX_9YU5HAOEC-*5X^:.>$7F^0?!D6Y2WYTQ+FCX$&^O(L)#+7
M5 ]._;@&<TEN2="8U)C+]$$"$ZG]>^,%!0M_6C;J")'&I\\D,"DV:?(Q=941
M*C7.44_-T_",8NJ#0@R,08L3K:-[5'/LH7-5CE+1/*20&UUCL%T-,4&M%:C:
MS7#'^5G-#1?>T35\59<Z>M\QQ>DN[-?R+01I/'/&DTA'4>5^;GIA*C*6LT[X
M-T)WUO#BNNEL/\B8*:M@T2;N1F<B]$H"[@.=="]BM.%C\[+56MDDS&@\S6CK
MJWG(=6#$:Q1<QM:9F:E=,5!P^*5M[)$@"LVZ5>\L=DV$WY*4O!6J7>Z= (G@
M?F6H(CJ7MSALQ95D^U%J7>]39^E 3UD3YCRM$\TI:</,!3G C!; 5;)V'CQ]
M'+1 6?G5+<(FM=/L*X9E+X&/4V?&3QUFD)M^,!I(2 P2%_7I!-KB$.E\ZA<I
M\=+ 4=*Z@XRQ"=&R!<6P9X/G@X ?HZ;.P)K?$W[L66&JA=B[\\#;7G ZFQ.,
M,/B*VO>:5M<:8I$=J4=RF ,R"\LSDS[%> N?_Y;2VB@8FTF_\]) F^VHB^YI
M^7N\$ 1=;()#CY&Q!Z@I@W%4P4(:JCJ]%&^@-IRC;S=_"O+^FF3LF2@!T04%
MW<SV):[?<;Z62V@IZ.<5TC2X3-:HT%#_82&#)<N[$^7^!EZ%W5EAQ% [QF I
M^^9;+V1Q*=+0>DU#L2]'6F)&DB@9U\6&JR^^"'UPD%,_NAQA.Z;W>NN72^RF
M"EQQN-.#)%XQ:H1=] C[0<M75[F7V!8.IF2RXN!D54JK>&],V'UF':Y)="XZ
M>,\9A;EQA:(/LIVH'JK+QD?,%9G3U5B<SH3"LI;&ON\>KW0[PV9CZ%-4- Y<
M-YS23Z->U;T?:3SEC.[9T4K1T[JH<0ZZF9.V,H?D+Q*%O:"+JGF$.Q;0%\>3
M4^9A4_1I6S$D^E"_[-8L*M<IPMDX<E5IG^HA.>>H/3E NH%H=AHX+O!7B<_A
M\:R,%;QOQYK4V1QC91<\ZM4_QW'#[ZMY]4Z-"!=0<: 36WOM=BU2O%YXV#SC
M2=K&2:3[>B^,*/1N(AX*,& 9(0+4:6B,_T>8V+^K^:J#T3YCLN0/7&6C\JO#
MD'8^D_S+-AA;\F.R>4G7A(E!/V]UY\#N1=GTM\+O*GO*3.6C-B#4]:0/AP5R
MC52Q:1U]#6OUX2L>W02R[=!LK?F\?17-] 9/)OYUZK@%? N-*"3-:?PX2%;C
MJ5P$EP.-=]T 3(ZA9AA7M5I@?!>&9V(=M4T;RH@^O,&Z?ZL=DPH('EIX!=XC
M<KV9L5?J-I"MX1TIUL^??-558\9S0S%#5->4<>)\SF[0XRQ#]9*!IW)^XFUI
MS$\=[88P-PBGW-W;U5Z"0Y$+9-JS"IAPCD)%4!^WBPA=C!8K@^V!3S@Y\5C'
MYWO><[[Z5)H=$4F^P&BW)#-8>MYI"T87+R)Y:%9'</8EAV!UOGKQ3VWJTA%D
MJ$'*L88.C[LDEO7BR,_,QUZF.)R<2/S^-=LX1.!ZX"VJW!/ OP$QIPQEFU$H
ML%C 3:)LD=^)^ QZ@TZO&$L??_$LDR;"!SM4TR$1<(VWKR8S68^*%+ .&;;$
MO(GRD$4="[X7]W:;(]ROX:]TD6>P.D7+;SY-"?-&>3-6)#OQDX<B6%:2WC X
M2O,Z\9C;$K=7T]QN5M*,!^_'T<(/9K++4A_5"/X, @6&J0J2E7PR%PR1^Q&(
M.C29^5.E)K39@^]*G%!E-@??EJ2$MV1@)3ZV1TO4*KPNFDJ1PVZ65L"CG2P]
MMF>VFDBMB-U@PRGZIMQ\WLM<=HI[Y"@C >PBC=I-.%?E$U"ROL)NF" TS4G@
M$?51B8?L/MIFZU-*%JC*XPI7WF#0&HS:JE._[XAI!Q58+!7#'([H6N1LS[E&
ME*L[-#A<(%/M7E2D7R@IP92*;\QNJ3HBKY8R<+&\T=(;/!($%\)YM9PG&XG.
M5(/-F^[>(FS7WI/5*^'B3;G[TN<V\U8/57<"V\P:0OTD1O7K(M_V;"6^W&EF
MU0[5SL\:3+^R45$YJ]F:+1.* D&(9RKR9!QJT:C\QW&]CTQV2@'(X]J^G*)C
MRI%#/QIBT"\R:BK1;,>O2ZH,%P7LX[58[L1^>Q#5)<&#QO_)!AB)/B7RHQL8
MO)\<?Y/[+P=<_Y\#"><#(DO'GUOU%\YCW*YM8+0CQ7KK^[[-7A*2GFWMH/XY
M8C@ZJZI)!!=77IBDIX=;O(EXRI<&W4D'2^71^3Y(?&(/Q6,5GV J<KG2@A;M
MKL&CH%7LNW!^81VGBLM>Z[UP=E6<3@Y;S'*Q+]2(BIQA=-?%HQ^P(@'%S#'8
M('W:CS/!'X6_&43+WP_M9@PAJ1]!3Q+ 7BE2 1I\L/7=,WCHCS*E@A_\]N<)
M:VNWEV42C',%QA0S%=^ZKS,Q#K2TM9Z55C"ZDDWXRV14E02$VF6,4' F7N$2
M+7VTF/<7X*_ ML98X4(W==]W7^?K[4ZSGYN_&RK<:%ZW07ZC+QE1A2<F0D?6
M,R;;=^+[N?0%Z\7X0#+E4+XI6( T.1!Z<?*'T'G=LCWS0 <F_/?5V!":J/8(
MMWYC1!?AZ%&S?( 6<P4>7E'S244$E4-9AL'!KH75%\$INI!]F)? -H]2X9C=
MQ:JI$;74=A!@4[Q%UW+M2,->1L4]8[A.N4[DP$:KNQ'<WIT3I<TX-+O35^Z0
MJI*T$#RUN0UP-<*9+=EH06]=RN+E'^4=:*Q2 D*W[]V? *]XG@#&P*NB<-B.
MNHU8)*7R>3-46:^[MN/,LEN&MSP:^<TPRG-LNI4IR>$0[P($S7Z*? +0]8 "
MAPD?(%'CEWEE!T)Q2OR1#E2IV@Y%Z=JC;$5\2TE]Z=O28./!@<MX!DLA-$I_
M5_D?/;M8=(E[.*X^A>$$75@L<&)XG6D[U5K'IE'!E+Z-:"MG@?'0)/W&^_20
MHRS%T0Q4\32XD5%)AS=-[B2=_RZR1"'L4Q1UP33M6TC$65E=W'PU PG@[% -
MXD-OL(]_X.C)GZK4X,KGOI/N-%A<_Y?HK))+)_J/#_XK%U5BVL77S"_>,1\:
M^5_G^3WB0+T66ONZ6K@+7*^=;31[\5(#.=MN1#C6CM"2G.:4ZPG[#119'7Q4
M"GPX.)@:A9D$.)#$(<GCW.YM.ELJ<S45U8$P7K0_OLZZ[BL@(R^[06<GJP3T
MOQ@O3Y=U=$,O$6;5B9K+CW;Z/\>HV=;1V92O^,H,'%IUE4>/"J)Q*<# Y:F0
M%[SH]+.M%=QV[@J[C3/'N[BJQS-(/XG;UJDU]%</!@MMS,"<E$(%[T\KV4YR
M"D NZ17VHV.CD5FKW-3>1>QEV&5H-'VM<W)3*A65)H8*_)%H+NNX?/LF044V
MX_LID8X ^\B!91>(:%VR$.3 /KSR$ *ASS@+K_$O;&M>&/[AO?LY,,/XM+#$
MN7B_W"'+;Z"',,IYL:;5 Z.IEJ9*TZ8!*_^ 5*T!*5L_\/781665%;F:CD&Z
MQ*)3K^*)C)#6&5<)316;X:C.LCRQ[(3Q0WE!^4;\4D)VHLG'XK?#5N9B-)^2
M:NY''!%96BES[VOA4,V7:1(>U!%$!Q-125H8W1N60)&1Y3^SULOKQL]6]>-J
M1-\M6KQ2,,+YI]%<YJ![T3RZ W_94FR=A2,V+OK)8OV],I%/1,3:S+?&^&0G
MI!OOZ_*\"$7GG87OPY2LFJEL,Y3UB_D---2^;9MCBX8QR],T1#,.W.4,*==.
MOZB*&9#T%V6341O""UO?[BB8B06!=!S#ZV3*]%1WEQ6KT<3,98):9DNF(CC:
MWC_ M86]\R:29_JT@VCZ(N+IR3V0#Y[S9/^><5,3/5).;+LE%Y\/T_@,[>RS
MQ_29WJCYS&Q09WV0>/[QI9QBWRIK09G85C(#N0YPS]J;@"?E ["IDH1'*-P/
MC)JN*6:@(H7>GR.^+[!0. M2($EBM/A,)8AGP@>3J/+,&U>EM#Z MT5+DD!(
M!;%L[8HPJ;^8 43V-2"PZ(?HZ(P_!'[?3 7DJ;9T!3:4:>\8%O/Y!D[YJ(MW
MA4&?FD=,\+E#\U$LODC3%D &4<D,#;^Q)3.RI4X.S-4V&K;H[<HDN0^4O6CJ
M0%TFKV/0? )PS!=M0_=17;1C.1;%*0AW"_.)ZM35;/_3MZG^)\'H_02(O3+\
MRGWY0#"DJV#E-&DG+.9ZB- -@ R3^3=LW):EES-\QAN?DZ5F9OK]SG6#85K#
M6'_6*]&(AOAT4O3Q_$.N<#=5@O-L(WL@#J*[%W,QJ6'$?L=_QH;<1?QS16 D
MV_R4<="Y]C?)(CM=2V=_SH[0]KFBXA1PT/L/7'\RQ3!G"=SV2\"VOYAIO!L'
M]V*0I2783^>^TDU9*3BL)=TO'Z-X?E %Z98LFTA;V3EP%>B9JZ=\$F<?Z%@W
M0Q12?DDY&"+SZ_O):UC[!.#3":"W=57VSU]2C.7 (TM>CRUK:-C5%B4L$7"'
M)&*>AAK#:_:N:9@GW!5^"1J$\LF++!;!LC1FZU:HU>%8C4?=Z5SW%R9\I;\2
MV\J;)<.JW&[6_'MG^2[<KBM^?^7FN!6,NT C$.4ZE<65W\D[F-A5O$NIT=AV
M6**^ZH_D9]>?Q8 +$\CVS3!<P&;U\ZQ#@Z9SR'$R>4Q,-TPQ]W5H7L0<4&H;
M%L^H?K^78VXJ70PO<<?K*G-*%-RG'>;,6K\LN/(:6HZM@-[^RGVX&K]D/ OX
M_#?0TE@#6?"HA==G=N!#-YLT,(=XW<0R:I7&T!K$['W=UFI22J P9I*\WPZ
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M ]6UP*%M9Q)O>LB P*!!%L/7=+M^=06PA=1_>\^=Z!-TYWN?CM+&Q/HFRA/
MAO[UJ:#;6*4U<D%N+0A<98APE$_4:(I1H'^+I'>6F%6A-W$E#,]@^ZT69$R?
MYLG6H2Y%NO=?XL60R<_8$UI78HC+-D'?_628L*8KZH%M5GBKC/V&_VMW2OG\
M&":S'(L^KULUM-Y_A='BQ$-[_HA^5O:RG^OE)A>L\K0I6EA:1C>*DK,=E?K;
M6>7\_>%=UG'6MJG0O@1WTVD$] H2Z<O0;&-JH\-@?IZ-FZ>$^+'!KFR&[B=7
M5"XX>?:8D_OQ9$S=9(PH6&_RG8@N.?'%3E$Y))!(P)==KZZ@X;S]@DEE(C,_
M?K+AD4TUL&!Y+V56-U'FE;810YBTR#'0 '#M-P&[6*'LUMS#%_H*5W:Y/@!_
M'F9LX<$OH6=&EIQLBB88-D:D>7H7&QT*"9)4\\3@VSEGWF_2M%DC+]K@0H9;
M\:ML?72AE2#Z,B.!GU&$*&-_OU /_JTT[5:'9#*<2=3DRU48&RZFNM*C<?Q$
MVVL"!1 AG6A]:B4%TS"8DIMZ2>"X!-*[EHT^ <36<)U490Q@J'TEZZI?R];W
M!5A/*CXM8KWOR902OU4#_G"5!NDF>G48S[1*;S*>IB2ZS8X'HYS+.OV,417W
MT:8VX+1:#R^Q\8'!1PN*?BU](@4R[_%E^0 N)<F]FO$P;,Y&&)0Y?M0/3+N-
MM=G9"&F8[).D:FS^@C%Z+$TQZ$;?&TV!.HL.V?W%"C8_OV+>4A&-@5@K.)_^
M75^8_CC-W))YI#E$>$['X$$U#BP+<,.>&S.UCG8+/*K9C'A<H&V](_WF827.
M<WE=N:I*9(0(66>X392?6.$>."&T%XMPCJT ^+B35Q&<,H=?!9+N#7KZ;E#>
M>7U(M%.B3#"RV&46.3290F%W?/&N7.]5G]X6#)"D;E3WFP!$:>_*6+?ZNE9A
MTR4F[$8'B*+]/9#*R^S/XZ9A7:)$K!0UZNO24UN25/9FRF_+/N'$$FNRTF17
MV=AM@=JQ<I/,31[=J*^!';:G[-\CFIL3O"DY_NC-69X1]J#=J3^.A74X S7P
M-(TRD\V9\DJD;5X.R\]7Y0WOL?$;*SB,VB:X),>O^ F.@Q:^:V5(:-V8#YRL
MMLD1:[Z?VICBW[-_3<L!B;J=&3KC$5BQC;%;Y5&7#I)%Y20>54L*>/82_Z_4
M0.'973"2/4N J8@3Z3O.N:4UTY6A #^/9[LV&K1RISJC$J7N:NM7KXY4KTE9
M5,-LWMR#]%PI8?"OR$*LUO)>XA5?5<GA:6:X\%F+[8U9CE_)7]GSLH>*F$E\
MS RO.QP$459F<*N_E ]TYNG<+6KS&?\P'.<ECN,\6S3(3CXJ:#:A-N+I:!>V
MDT:O/EU3Z?$$V. .K9O4V36JTZ76#12(9U8'>_?.]3T!T P)4+<2S1^]621G
M2SK/_G;I"E4O]N-FF]B0"$AH;#*L!1(#?#($OK$,OD*:AAGL^KD',J6MK2CN
M$'XE ;'>QDE6 %S;Z1%M^=:>1U:.CHSW7Q0'S)UR5&LZ1_1.&WJ5Z7M2L\P3
M2&N:S+],RBW3GOTDCCW]WM5LD4GS.-O2$+.SX_GJ9H@*(-%AL%<50+&G&_ Z
M0E?K#;]?G=I]:8\;R.V>!;EVK(UJIS&0!C&KB@VVM_J(GJ76)$:/'7#L!5QM
M:ED)W, +RVZ8<4^%M]2X"/52 '1!YU+9>$:[_+I97G-]GAZ9F'6S=0HS.)TH
M!$&-][99857WWAO2YB7B,P7U,'F"'.FVGP=R5%:'4C3?1X@WQKV6^GPB(KG=
MQ$7U+.R7Z+WIU>CZ182I;@,$QB$FK'/WM.M[>3.?PO\:-KM4?YE&,<D,R6Q/
M0MH'39C(N&\$4B$^VKMS?O)E'\:81R:2>I%&OONB^800L8%#V!5G>SW Z)L-
M"A._> (<9N-V"ZAJ3A_514L8+@VB./7QCIAHNE;>RT[5%;LO?;4OK(D/\<^@
MI[S.E TP29;LB8P.U#A]3UK^U<9VH/!@4?IB%V0>6P#PO#9AB%4_78;-%-35
MRN9 WW5X_[S<;&,.NP<+?:E@RK3GVE7E&:QF>#",R0LR"5Q3 "D5(>AV[E>6
M,D3%/"%NF$+L,;M0_D!21)'V*4U92:]'M*^-!.G+*O:@/IYC:^0Y5UGO2IGN
M /:[P,]/@/KC?!Q^]9JD-:0F.9 .<^B]5<G(^HJAZ6RA;EW06%SNFU:/+35@
M@<4$[.PPD #Q!-"?LIS[8U7;4*VA9_@&%1KCQ?"II0/%J\1/-_>A( _?Z-T2
MDY0/!6"_J5*L-Q#_,A:S(Y[IL*R]_;W5369P<[2L*Z306*7-+&PY   [^QUN
M0)SU%>ZO9#1#.)8@<D$A,K"5.' R^9G_Z%'4IG:93C5_61I?V 8TOA0($*E2
MF8*S&QOTL2^QOHM3;-*AW0TQ,H7FGN+T\.[[1(]FF8L^ 9Q?B-+^U.[ -O)R
ME#I-/\HWC6PQ?,?-5Y8RV,\,++1&_C%"=57U"GXF&>.G3#U;DC=B:?,1*ZY&
M$<D*>8JN.1 #L:B*CW"YUJ=_>4#R9=4L1E9J;1SHF,GJ:L*WWD'F==B38$OB
M@6<W*=M3\:N82!9I__,;U=EZ/^"FLNU=CRX,MZ/F.&>4FH@+_4#XV>T76CQ'
M==NIC[QGM%_\E)P+O'24(-9'+@R93NAFN.A;%!UK)^0'KI +A&L/';T_[3),
M(D$-F#OQ;[BUK:$QJ0:4]'X"T#I>50P'(OZJ%IBM].WL5Q=5V!L^ 8I5"P!*
M_]9]$1.<C25CAY.-] EK0G[='NKR6A3A71#L+VQ=L_,6>J\D\9H;.#\4']T?
M^.JZOPW@'0&M"_RBXT.5"/D[^7_P]I5A<2[;FHTD. 0++L$E0'"G@00/[AX"
M!.D P9U&$@CN$$AP"! L!/?@[M()3N/>#30TU@Q[GS-GSLR]][DS=^[9/^I'
MUU-575_5JK7>JEKK+;77E \-F@RIMFEQ=P)TP5) O!MI.](?"EY=XLI' CY5
M\O"Y$&^H)OYPL;$02+#QE8T8W5XA"EM=\^=<,]U9B#.C9IK1)>[O,07 *U [
M!@S1T;W+'C[$<635<*KPDT'R&=4&1+C,<M$1C'5VZM'[1?V[^)%X!00&C.-[
M:SW)Y_G9Y<#SB<8XXK-2N_AZ/<B[IQW#OP-KWMY//!*3D-#VM>">_P06>X7/
M<X5:I/:#,R_MZ!4>RD6GRT&9LT/1+@FI#MSMF4J>QZ9;'SYI=#]ME'H%<2KW
M>7UUOU6^\:/5?-1L-(GS1M)-XC3*E ]_>2% V@DGFZ_N4P8:OM=&CID6%L[7
MO70O!LPCVU!%$ARI7+F=8D#\O;0(KO(16?@\%J]\NYZV91]=-TCER9Y-5.?D
MX]+)Y[":44M@UH<"\;,Q*=/B,XPU]=Y_C<<^IX>3H'$]:C @V 8J6[Q"&^2!
MEK&FMKN)=*_ZK7H FV]2'CP0@^;':S5^1])\?L-E^Z6O!^R!J+Q:^3FY&X33
M//F65GBT:W,S8=W]ZEK/A"_$. !]F6YV7F!DQ+O'C2S[O1T96JKU*@/AX"H:
M]^\7$!YGLR7K;:RJATUXYEZW001F2ML,2^,;97> [^_XS1EAFG%KWYU("-Y
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M%+&\HN35 8%8V0Z@D3-PG SQS'GY!8FQ^/YV,-9IY;7F[-FM#IIP[*)NGY^
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MTV),_\QS]X'.;VE7MA\*QX7K4EL%.E9\UG%-]Q0 &HDO(CBI.<^UN =D>.\
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M)WY_+2 98GY47/3;\=P)%.A"._F,F3!W7;H_K])%#6F]YL2%<#X\R"BR"'7
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MK+?< 7J@MF>-EK?HP5+7QO"QMJH=KWF# I]ITX5JVW'=Z=+CJ;::5:*(LY9
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M8EY&_1<6N#<]XC1JKGKNS%OB#D \\O(\S?:\:Z.V46P  +^,ZI/0GZMV''4
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M(X9?LQWI<+&.PQ+P=L;-;K>Y^6?9P/;/93_N !^L?.\ P+0[P#T:Q@6N&5F
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MIYP_2\9#A!\L#/K-C55_V?A"^([?G!J)8?$&X* LC>,>8M[_088A5H*S4MA
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MD@5^N5!Z8"^FNG-%HS!K-2?4Z+PJCB].M0.2A<3>2,&?3->A64F^QHFG GI
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M2K%ZB*D5A&9IY^SABI=VH09*)IV>8S"U>'JVKPT/TOV!<6"T6JPC6[P#UQ\
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M?<5$U:'-6=X"Y"YBVC><=.P53$D?;)+Q*:[P9^'&T?L^#)CWEU[R5;!V'4N
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MZESF6R[A90MATU)C>L\5( 7A+$KS6M,?U9U)3:>F_>J-UP1"8^K'SHMJT![
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MIG>BC:/+RDTC7H>!*X8@"5CK]O-79@TI<A\[F5Y?S:E( QX3"/":(7>5G:C
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MW&#3F!\@ZK:^<MCX;DVD7;;7C\7NQ=(^ZDJLL-K@F$>P D6 4'1<-7YD8//
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M>^X[N_N<W7WNZWX_OG^K;-7WC3GFF&/.=3' ")I74K>4>(5TV\6GMO9JNX[
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M;L#"(:5\7D%12 &BYF]D,$"0C66<3DH7)3K!DZS4\YE])FI1=HN[TW(4//7
M<B",+/^/II6Q#Q#]9 _!L(\6[0U;9BCR0G-+@4;G[;7@<(3JR3_(:N+6,+SP
M<XP$:UD=W%&NZU$(88 F]!D[_)/X1^],P(K(%9"<<EWV'6O,I.:S+\_6SP5
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MT5D?V"PQ"8E!.%)U2N)O'J<Y].F&.5=EO+X:KB%D8ULHUM")YL\)SP'+52K
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MYZ)7.EK37TT\DG-EQL,-QY"C(3[X+6.-^/PE6Z>UHUA'8I,D!QXZ0NX+<]]
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MOG!PQ>IE@F]IZ=Y]O!)#?3"C^?;NW+-3VA&D$LZ$9GGD<"5IIX^,RL*EUH8
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M3YM9(T?[706:.FIFTB5:,,ULC4"2S# M%))*0#3I\T@K0=/;([[T@H.RWE#
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ME 5JTN[@S<%,><Y':M)D_Z7Y;/8MX  C$3LU$')2("FT]$?#5N3EN.^SVEL
M3,_^IOVZI-MIOZT#VWMA0F#[/8XZB7WH8;_"6-6-P^9PT*.Z:.XSE5M <=.'
M:GGYG(X!RYY6?JGT.YSVQ!WPP%U0T_]0#FZ,M"-S+5+FZ?FY"RGZ9IAV")O!
M/D0@F@"-G7_T.SBS!4_NG]P?3\O=N-\P^VI35D6A9/D7SGVKR-%VFTVA=W+
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MJD3-VZAH)_,>XGX->=[_TB*;>8G<I3_P0I-$F4BD;I!P*P$T6D/")E/!%M&
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M9JQH<4*7,R SDA-.U]+.\:3K,GNJ5UQB0RIH87'/,;>\_;5KQHD(^KGM_5M
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M\HJ/6W>7Y"RY,MXNXOIMP:!#WD)#(H_CM5=D^C2J._DL3(#21C!_/5OBTQ*
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MUIT0PV%?^!-_94"\$M5@+?H!B=JY3K%HB]P9K;@<'6AZS>VJ_=IX4^GJDI%
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MJ>.F]]_UKRBQ?@_W"AF\G[YLCO3 =U.4ER%:;C"I%&:HYMS)1(;U^;V($'U
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M3<5440%TJHCJ*GLE>P@O/[[)DWZ200[^@XH=[E<20T<,-S<RY9H<LJ[[EQ<
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M$3GX*\KHQSN@?;A>[0[(*+&]6O$YY%[WDC%#5(309P_K>:Q:^I@>^RPR)XM
M[H EBYG7(72CI]06!;\J^YB%M;3<!W_SJPK2[,QL6"MPYO#ENPH]".FX=\FE
M][?3!OM?7#/\^2 Q>.T5>;78W/K]S&$'YF(Z#M*;0$X<OH;V16[[WS!UR,K9
MH$! Z/VKC4GW3PZR'SOQ*=F%;A-<#F,LZX[I+/G,U$:)'"WX7S,X_G$Q<@M^
MV0;_:&%<7ZI3)MI5<X?H4W].F='J88MJ!QLJ6B'8V%XOFM8.!DB>39KC]8(E
M$ 44?1SY#R:/5$21E(G0R@IX+ !@P!UG LN/5ZDN5?)JX9N*<7(1[R1>X:O7
M)Q$BV^U,>9M,][R8O)@62ZQ=^7IMN+MCH#%6'FTC*8/$>[PE/5-NK?&?$P,[
M!TJH%Z86=O]D:3Q:_B=.6,A"[:M5*\"1D870:?BT^KX:([2M0MWO4% S([=N
MMX<E 2,5"J\FN,_6\K*5 E"'E(=05+EYCQ\T.W-[9Z4(=FL)00"EX.IV'#B?
MKPGUF)J'Q*46SD%2A2CQL&=QMP=)?+*=8+WO?%+*_U95'D(V6<3-Z.A,BISS
M7,W^C"^S L77^H1]5LJQJM%@HY;%SP^+9OJC5ZL7\&7@3U(]C2*7\%'"EZ''
MMN_C-^Q&4B4KW7>=R%D:"+7S@8/0D/7MB*QZX5!TA9@8K/F#DN2S&U7.$L,@
MDZ;&(JQ&PA870S+Z06H<L'=*P8A&E!&3![]"[0B*+[!,QFB>63>8\O^68,UF
M!LF2\ZYSL;3LB'D):$_+<62X0&@8]G5X@@^)C9L\Y/1$:$.?1889I0;66;'B
M6_ 'M,UV.26/[<[,;[]N;WI4-IG),1L7N.%0TOAB6U?U"_7>./1;I0F?QUCB
MZV!!5J,E*(4P1Z9U?8S:O@Z=O_T2F'$/\95>K3HL+L;0H2S22!&Z)?SRX*:]
M#LS7]L2S:R]2>W:(:_JTY8R[#^9IG;A*9F:S?(V<- S->YB]5T?*D53 W5V,
MC!C92=TRBY0(*J,_/S_"SFL:O0,F2]9EAM^/OJ3$H^D3=M>/&7>9F'@AX!3X
M:)Q:S!<HJ"W!JIRKFCIA6%Q^>LYA>P*V^B'#$'ZCJL'ND3FO%2,3+S:GX2&E
MRC;3P[YAN6F8I]#7VJ0O7U(DX1Z-YIR]K;NZ]MG"A1,AL9#YG560VY'@G7X#
MF6\)TJW.\9=X9VG">%ZA!EMC@?@S_J1XJ%:F(3D/FO-21@MH*,D,E$-8R-R5
MK],1'E/W<<->_0ZHMB5"-T.7S.\W&5;>%-L+I]8K]B9PPERRP!5E+_B!5,'3
MOPSEHK:_ RR_AX.26T=V;,HN L8VFA<I]2^71/8+PQO>.GY\1!'^?EC:P.*5
MOWO$RU/NU<D\$;O"6Y"\KLR:7OGK44$U&;#4B-\TT2">.K1;W<7H)UV,+V;!
M4F62*5:0G'Y=-8>,LHO,"JDW-XVB-&< A"9-9AHQI+F8)R!Y[C$Q1O!]MH0:
M0G[:JT%(M$FF((X3/Y9:/DSLPD^5CF/'X<'R(0 K0_0'&9"3V3!3::(TG[K[
M1(B?:?A>J,J'7^S\ 5REBG]))QPV+6J,PJ6'3&.&707XTA\W!H@[7+T4OE;]
M-5(XYWWDMG3*A>+=RDY6B$R5T\Y-QTK';OT'*O;/'O8[8+QY:'0SQJ?()R,=
MVYOUXDK_O"B3#)P2>BN<\*>W6.;?6KF'.\8!$GI4[&$;HT4E%/YA0F[F\O76
M3:HO?:&&;)4:K%YQGFY#^G:?"P7;L1^_>]8!5>%_96<>K: 93.YCU430A6ZW
M@/2^1KQ/$&F=-W_@IC,KM\I^272=6^I,7!C36='Q\8($JO6S3]EN>W3!ET5%
MUS7KE51W%_Z6R"#^$+D9;=^9-UU-N>*ONA<!?;)^_#>_^2/ Y4.54Z?<YC3&
MA$JGP,'R56MMKQS\D.3ZV2.V*,G?XS\M8A>FY^<76G]+HL\RL?.V_&Q-,XH<
M:216"8?8U)'KF/ KKVW JJJ+V[)F"&U,;'"%Y-S[S@EG2LH,$P(^N3H8:)Z@
MBK0R@DY]B!18^NRB#K]K*+OI&^BJ9V3HR1:Z>6L:DJNED[M>"8FT9K*'DY&O
MPXDAG1L=_F^JA1EK1V>DP]AS1;%A2Q4:LA;,W-(C6HZ67>9S,,=;T PD6[<T
M]-5^F)O?VQGXA1J4!0O)\EH[8*E-I\C=\W3 ,LZ[>H?/LGB0-XX.RL *FJKP
MRS[=5YNQ&F=ZS#L_NK*MJ[;_V7;'":JY&A2,^EQT]V=A H%#0U4?X1YNTBGC
MI/QKR5Y#.\2J6FT]S_O+R07[4-8UE!@>9>;S8J("!\+2GR-U(,07*^4Y4"O'
M>^\O4\RK$2\^F:S6>4RD3G_;1A>_K">]K&EX=IDS]Y)W3B4DBB=]A,9JC="G
MKDF?KC+G>PK"I!KSZL=E5R6478YL-7O8_RJ=4QP.-N?]G<]32HW+<NK28 4)
M,>(/^X+[;0F!8'FE*_'XJC[>KBHXS-^/(D)$>X>+G>57:':SB9I$J 5R%)'R
M\'96;B(SAEFH[U.GD"2H#4K(&JC] 3;UK@*'F*DL;L!F73Y$!$,LOS@F-#"*
MD7: O4-[G$N3<IQ+UCP[3GT7)7:=GAY4ZKAX=2E(C.X'N8TJ?\B8ZA]276!>
M74U2]5G0?I4EZX'*AKV.]Z3N5>HO]I\Z7J5O)G,#AU>HJ%,V!'P0 B$G.#C;
MAUMG%YZT/3B)7I+YQ1<G5FD7,C9[V:$\1QF*"MZ5W8U518N-"KLLCVE,559Y
M)!X-SG-)2Y17*UISP0CJ2\2SH,;7Y]C"4EW'2(VD.5W]+=A::D) U8)LI6X=
M2O2YY/)$D27A3& M:5+L@PP33$J1ENY+R>-KJXP)0.'9A;0H8/^#8F^\,RF+
M?#<5(BU?O',B=2)@#FE$V#/2,'1::C.4\M57C(24WZMFU'_47*4CQS_!/I;%
MK!+8H<PHP/70<*/$R--'[2UT9*3K'T/PE8G^=S$HCS0!#7,7H(BFP>G._MMK
M;5-)C# ^.?*7C73N6SA7JF?: 2ZD;U8R/LT]_P%CVF""N0C5:$%^O4IDYQ]+
MI<R)IMQGAZ$"*?V>+*O.HMPXEHD0]R.^80K,@*/WV?G\4O,]$@S3"J9?J-\P
M8-U_=\3N'F:T-S)7YNK%,KH:W&6@9I[9R-LA^=;-\5ON/B7\*97MJTL.-T%O
MYS3EV>8$CN9S>8B<U#$D,[\W)MMD:H\AMWUV2?)42;[T 33-B-#9[L\N]O]$
M:\;AE4\U*^6^1ZKTJ_FD0A1@0P#3QPT&%*^MQV+K^A71K2<%M-;1[&=YFQ95
M#]:+2(#FO^*GAV_;?HX1G<44*Q5TU-%&PPIRWRXN*S\%("[)F8/.W%@\JR#G
MP-66?:T-P5IBG%)\%)9_8'YQN_.H(%>M\#:&),%S,HB8$MFP\.DU!!6:ZEIR
M73<_F+L7]P;AO$-F^!OY;>+][TG\)NK-_#O@*?8>>((+?SISEO4*N.$MI2<3
M*]4>FA*._"!YCG$$9]BS6]-8D0C 5]*E#_N_4_V;/]L]1;#^&@62)>G'D[@#
MG .Q&4^[W0;;JY%/XI<&IKI?K#E(@IP6&7N&J;*7B18D)*H/?G%P#\1R4CO/
M=#5/E,$;Y)9$,/LHQPQCK.PG76 >)/.CMPQ0*35;>!+U?$)Z[D5IN[9-96Z+
MF1&-0[^@OZ!#T4(C@P?T2#5\>*U_9'4]#\R9BJ>[G="JCK'[NC2 8D[AZ"FL
M,RY//&?S4+N5[9F#EYQ]*MIH1\?I0.;V58V/,[8/:MK89+J&\*O,M14HM2=(
MQ#7E3RMH3<3OO[*V!WSO0YQGJ<"1]EJ$2$C@P+.BM#K\0^W1.6;&FM,=)@1[
M15F\GN;-\*8&24Q$7X\3X^"2Q&,WDY! +5'Z*J9/=;2MW6K !V>^DO(U3^]=
MG#[8F%0RAF#LV.1;^SC<G\SE_GP\(S91#I]NT$4G7E/?:MYS-L^D7?,BS<U3
M"1S&O.%O4N6U(D>M"E>_QW[FZHI<5QB<:N\PY!Z.;'PT8=L:T.(2R!7,[ZHW
MA$LNG@WHB0J5)?W*K(CGR.()U(+8F-V[E(YQ5PI'C1BN<)?.CY*5_"&M:F8L
MT]/R ?P^6/=_M(+[[[TM,6/K\@0<FMNMZLVMB,/CK->*$%!$265Z >)8X,J+
MR@J!!O.\7<C+T?H>VE.%=FIC_F#^7P4.?]E+ /CAB,O*>>,&_?XH"HIO1??Z
M3;K.;:Y.XQI;V5K@_1JF/K7YKV=P_M*UY<S0"]U'_<)7-/:3T/-#TST)7_0Z
M9-Q7)A<CKU3_=:XLR#)&SC3IJ?C0(3R6@SQQ*2=SEZ?NY^4(:G32_\8M$BB!
MC/?"OJ#/TI"W>4V7DTHU%<WKO***G?RYV4AY5B%ZM?D)O\<0>JC'1P['MHC,
M/$$UXBQC6YY71,X@CGG&:@N1X(=2679\+ZP+EK?/K-.9)>V%:KC;R5[= 5"K
M1H[A'N9S"<B/93]OH]W!;2A'SE[M$N8Z0E*%'EW28,^J<0C!@/#P'K1;OK\_
MY*&1P102TZS\BZ52\&C'2H^@YH@R;8V7^9ZLGY*?#EORWYS 2@.7_.Q7]8P&
MNKS3EG5Y*K+$BK6)LHFBW27O%9ZS?K34R=IRP"/.NJI\'\+'='TF5-"J5%PY
M=U0HD8.1USK01&9ZV6#A_M[D#I",$.JIV>Q0^3YY2HQHA%G0]4(?'D4([VMW
M^NM@+M7#Y7;I<67)AP#B6V?M7E4"I&FUS=FH;</3U=_8E]N#C=",W/D@M=/Q
M<^Y2[OK+:Q0C#V;?0>9DK:#=6,V9]@0>PBJE?4!&C+X,]$3#;UURU D:X+;\
MB3!V;N4."->)?3>T:F+64&/8[.IH1@%W&O+WFSHJ^_I5WK-129K5U/99OZ6.
M^QO!CY<J++9K,0N;B9=A9+FE=X"Q.;E9XEGM>2IGJD\*Y0@7^A/TL64A]VWD
MI"3'SNWRYQG6S41.2U?PXDJ=%D:2<8OPN,T:TGRO>%C'.EK,LO(F?/&8(M[&
M%#Q)O'PY4A6=_CQ[7B%N<U!A(K1D<(\"<7+5O<LM\-7SK:$66T@M$7=9AEO=
MV;+L>'C?91*59VQ$"E/ZL"?W2B)D9^&>69BO7TX\;;>W.)9%_QJ]G )S'82;
M,-D5U?$S&N9!LE-OS0R<EX1D1![,;C'RO$H5S6D4Z] ==^Z]\K)J.X"\HJX/
M(P[D_Z:!0WO:ETH0*<.SIT6#D\K&!K&TA/VH&W<2R(>;SAI_-,8@_>VR5K,:
MB(#;K)>1:G#,;1E,[(LLLC54Q+QG,0C[CE']L*8W=^):R^F#7*_U:[16@(;I
M7MR0WLX";>XE%R%6R9IS[G/X>FTW67K!Z1M*YF?MI$)M1_LW&)5OYQB*X/T%
M=7$F*Y%<8RRG3QEGY>,^8Q-?+,FGL=T!0D49XS+2)6Y:'Y]@LTE>/ZR#^[SY
MK%V)NC?P+>MC]QE2(T7:RBO;BL?:"7X;3K<JWI/J08(_KC:=-1Z>N/U%E6?4
M*W.&KRQ\F;>@:-"R[\]F&5&0@O+8KE.11%V]5QDK<1>WH7O, D:2Q$P01_LD
MH:-[UL4>\0>"Q<QX*A?'\'$X@Z- 8UCAV*HZ]"MR,@"[&KQ-PG(1]VUO!IK4
M5W[HW;R8V-&4A??ST;*5?]I 9GROW@'D((9JWP9'J2=:%_6B%S*!X LX;?"Q
M>ASPAL]H5R\E):::2X$#67W076U]2 [N31D6A933K;.,D>R<;(^/,1O609C*
MG_A:=7.%,\SKM.2)UFN;_GHE$N %GF9)AUJ9+XH%0+# L2#Y;\Q9M>/^!<JN
M#E/Q(0PEU#7_'>[Q>^,G_0,?"'M3(OV#;"N8[D@GE5I_(IBL9&7JVUO^-.TO
MY2V$Z60,*'1?Q"F:#=1PY=^%]Y((6V0?4^09*/]'-IR04&DF=Q-G"#;)[5,H
MZ]2!,I/J5^=NO?3M7HC['9&5X97E?A'B%(LE.]0!I]JI\H:%LY(9D9-)#%P:
M11G'?VHD4&2$#[(SH_1F4@+C6)/??SHE59OI.+BN#5^FG\.:*<7!)=<.0_:1
M7FYTW$,"S92_M,Y*BB4QQE3AS9VD8VB77$Y?8<>YSF14R45%JOPL"-X7!94$
MFTHE7(1;MJ?J6#;Y@Q(MF[R.10YRK/[+-*/2B-%\R'8&Q5K*"+1ZD(--RTN'
MVNPJ(C[# 3G5O=$/H91%OGZ\)_EK8C00K_P'W_D Y,B8$EX/>6;./ZS!PW[<
MH;X@D;.&4[?TO8:JWI9@QKU*]A[^B^38DX$C,BN$0S&$8>8ZN\+CFPO/:_$V
MRDK<Q:L:NOS ^0<NV=8V>O,11MZ6!0(<]F-SF_-.0L]#+*7*Z5;YR,>VMH0]
M_\^U3E+1U((1^2$<6A% GCIKZ!VPHC)V!VS/WP'1Z8_S-$9!2LE*"*P[P"EQ
M<@WIV"\L)]/*&$]L:QTCT3EFH8J7^I6X%+/R(">GJXWQM)9<O3Z4A<!80-&F
M"S6').\S//W"U6A)HJ8F5MGT#5V,*2\Q*:!@"9SX4+@5:1S<= 0T18/J?SI'
M!VL(GJU3E>U[BAW2ORNWVN[GE"?XZ;?ZB)Y";CQQ>:(^=;*UU&9YU_8YOMEF
M/6JLFJ!LP<7,X [2+(B54O9Q:[YI=; 4JA#GQW[ !189L2:"\SG(Z6(9S^91
M+^4<RCJW:XL>FS#]P4D"A[LA$GB;GX7*.V"_.5)[!Q":3R11M$:;F3'&/]M:
M>N=U[>>HN?W"C<VB;K4NVB0?^G4O(5UE &># ;7Z0"2$]5H"&;+ ##ZS<*&/
MS[:/G4RS;#O,:Q>2A4SV1R0\X6A[$%AKIBRS$NG-/T;QV/9ER*Q>PZLGLO2)
M];-)*Q\$5;(0MY2QZA&+ZTUTO#.\_D^SB/9W1<GW<W])%E@,Z;T5TU+DI5[(
M<QN!O!QB$Q+;U_,X^*Q)V$1J]?##3\LI(&UQ]SH<QD*X0Q<[M[Y_39SY:Z4R
M,XMB21X\6'K-/"-<:C=A-R=+TODFY=,=('-& LZ-9[+[I9)4]1S$,]1Q4!G\
M?8@ET^1ES\K*^]-]J*J2IHS.P,[&)U6UJ/]:F2 NN(UE?.2!]>&<ZF6EMP6.
M*!-1!O."<1XS#$<&H [.\>'7RTO/7%KNO=1($/1B2%TVZVYHKA0-CDRL-4(J
M L'5\:OAPG^;./C^#X$3-9L:S<B8LLF**MG& P^NW_7.-G%6C53Y$"P!+,GW
M07T>6$ IY6M"Z6=7M6M5^ ! !A9X%Q9S_/K0"<[T+TW(^&^!_Q/GR5.A^%,<
M S@>^G3-W &-NL\V=:X9EG;=>.<W=8%_$[+]X49J1^ZOI=E(7S_,(8V$:S:$
M#E2;[#V$*%9Z#>\*:80 ,<;'5 87X[S)JTRPD*%"O-(X7MM%+@#YCV)(1KE[
MDD_X2;SN"53#8N?D8M>V7-+S[)]$V^<)$QE. \1N!BHM=A2KWD0NZ1A3CYT^
MT> ROW<690^I5C4)\'>/MEM(K>0B!+/V_&+VS^>:K2%@XH,OUH1E#Q<5;#TJ
M8,C@26D?\4A\NNB%FTPO[Y_:X)Q-3C!T!VR\P&@&E4$T$&D.N@S"GQ\O^:"&
M!D1XD2SP9JO-*,G/7:U,@N^ 1Y+!=\#ZU!WP^\UDN9*N:MFI15<<*:B\#F0V
M,+RL?_#)+8WB<,=G'SG^(AP5BHCJXGJ5[3.JI+>NZOR4A^4-*5O;<F!)B'N*
MO*V/44R5G$+"W-RAR$ZCQE7X'> #H9B&E9Z_N+T-V2TMIBW_FN4G]%2U5-J0
MEM;)S:$M7UB]DD]A!ZY1TGD'-&>63)D?);HNY+Z)_$(PR-T(>5Y$A_5-I3$D
M;3I>%SY*(9.T,-"#B?I"*IDLJ,"\>*:N@EO98IXL-;Q@BBB>:%D3FQ\;!?Y#
MC)A(^&LI^Q-5/^Q'\'"1=D*"&HW+T:')9'T,5[?43D).:8<Q <L0#W,;(_;!
MY]UY92#M7K7*!E0CWSM@GMNC6GOQBPE&P4YKMB6X(_RM5!05 '(#5/)OOTPZ
MAS^N0%?DZW\S'C\#C<@27*8JF+:,3PJ*W8DM3M6::7?A7H/=5L(WR#FAR05:
M\%X#X"I'.(43.I+!6%5E"@)W8MT\[5?I/-LLJ8IS_0#)(HN 1G;6-N.ZR:Q+
M13N'$TAX.+@^_19W791[^,K?:JF?F%O@:;/Y=*W,O8FK-+A@[; V IO7-2,;
M=I5O&L-=1A%&_0K.=;R6NCVCTSO]MD\N>D:A5;<#X^-H/XQ8AXLB&Q&C/E4E
MMA^&0J62'XDT+8Q[M/.SI-S6'9FW%[/[33YG;"TXN[&2;9U!F7BUG"35LWG6
MM4)Q/%RDUBO-'SUR\X1V4%TF=K)OXQHOLQ(>:_G:(K0H+9EB7J_MM*0J"@"P
MV(#?RI-QRC8.UJD=_);?_C)]T]3\/^BXG*OF4,4W+$!9%"W6ERFT^]RV7#"H
M2V5;JN_<>MZ0 OZN@S)R6%(!!@A+4>W@JTF8UGAU!9"A4W/J"*\M8EA&/<%F
M &Y5__)56C.!!62%H#<D"JL:\M@VPQQ%VOAQ*[)>/F3?).M3_6H%0C_7?*F/
MD<.;$VH/F _NA^AUDOOE>DZP$C(=58MFAH"]\_Y$?WXP%.RR&-=]H7JRWJA7
M,_S*8%7B0 "[,KD(;6>ZF$'UBTW\QXS>\I,'WN>]NA#[^)9=F[BOSU1OU:91
MX]!(UQIV/GAM9\WUY%Z2$B&4(':II?E_284:>,X&Z+5^VZV4+F!>;B44TO9E
M<2)5U<!9;55P_%%@KZ;CE;E+18:A#=3G059G ZF?S"752CT$R/]'=[0JH>+E
MQ$[CE>K)%Y18RY4,B:M>=:;&$:^D'2F,GM/WI"% CD.33DN7^,07TC#D>'#6
M\[>JX[R1JD+Y#V3^@:VA;/#5F9'&I7"7!_?9I%M9)5+9^^6!MBJ[W:K?M1"6
ME9*] (5KSNN<V($N:;N1WQ)@E29.UC9&WWPPUXJ4]L")YH.6LHF:IU#&AE[S
M/>MDAK8X.,,K99,3@W$%[=\-U/!0]Z8N 0.*/;RI26O:&J,FSLH?OY&3QK1.
MGFMTH3D\H0@UWKUI(MH?+3L>)%6/J"E7U+XM_:-N;;6GEBVG<B1;/:]5+9:,
MG[3Y2G7H9TWX\B;;HNFT'-S:8K_H?C?P",]:P)UO<R*S^8!L?MW7VI,_X7OQ
MT&Y?CORHGX W:'Y8E%2BXG=HRCMS#]:7"CNK:IX%EP? 4K6@W&*WIW2&=-Z[
M-U7#Y0I[W^'-G2' \=D!3YG(1VC;I'9.0SG&0\:JZL>#&"<E?K9/NIP7T8=*
M$DF#JFQ1PZ=_3XKM0P#WSO"#;>410<X""XL":*(M&]K'%UA\@\<E6:VW1/ZB
M0^]'5S3SHCF;Y-+<8A1@OY#>"'M_45*;T-^S\!>=&LB&UXHW$3LQUJU1DCH>
MKB4]$9=+_].-9<4[!3BL'Z1C8OX8<"MTU"7P>84;NSVE\EC.R2/;IZ! S>@C
M[V_8$*JAK^0Q>V_J*>FD2 L%R]PH3<J:@-&B1]);4?\0X&VD+7V\T.;)/Q?J
M>-1E3C^28IYH]/*:B;"W+OW:$DGY%DM $;40_O/5)M:ID&7OLQ#I7:7-PT13
MBRDO!E0)HG9[)NS6--%_/77R'PL(AF*'E$=I[P#5.V O";#LQ:1\J'-6 $ZM
MO@,B$>L719G_=MLB6G&BQLYD7F3<MEZA?LNZ>)2P\8HBFE?ABZ#K[B R21F6
MG&,JXJLV?Q7%AYXL<5TYTN\2/0O*>=7_=G[W?Q?>.LUW+WZ&>>$#&Z_D763;
M7+AIOF,*FRQ>X:K-HX:1:*Z;>VOQ*6@#J2\RX:L#;/-))4_(4X0LBY@=NP:I
MR_(_)HV=N]T!<8!^9E:(<:)#MI<0D\Q?7WS$13K6N8OB0KNRVF#&'CAL[,2]
MV(3W1=0)57W=AS*:;K4QD%"XDU*[3/(1;YDF@X:VC7L<:,2RB=QXGOL[<Z,,
M4H-WH]ON1\AIP7@XQ,ESU1(O"RQU;PDJV?\\ZR&8U.&W(EPHCS!U375K[U4'
M>:,5=MC5A&,><1&7E7S#ID!'RFE5M9E#<EC&BQJC,-7)^&'+.J?OF!RQC"A#
MD_&6$\?SFN5B+R6V1&]9+;,6FXGT-QP?@Q.$I7A1:F=U*GYX%7XXW5C3&:Y\
M*XRYW_!XR3J&@$W@/9*M5'02T:M Z.8Z4$7=-UO'0]%3=GJ)N .>;]+($_"U
MKO%A*'36EC[ZY1:(5H,H Y^I;7.E.0O96>9@<N4AHA:UF0X7F"M^-S_G^>C.
M$U?P/,K/^]Q(80+1ZX.[U6P;06UB_.VGP.&:%X:V9O')'5"-^-Y&5YI?]O.#
M"<J-57'EP>Y"X<M8J EN1Y]+F5W6]K8*7^?S]:G\-VK4W57LB$;&T_2JJFCN
MIFCBRZF#T:23QU#SXMV11\^H*'\\2"-5:B.*X,8*80.(\)&_B]3Z4\-)L)+^
MC+,^Y?F+_#)B L_E@<(8W00!2F*1A5U1/#F[J AWFQ]JBI%V5ZN+'BS"8#MX
M[<#Z:7;2RLN9-$Y%M!B9*/JC!P4IHSSGF]/FC[2JNQWF"V4  24(]SRU[D"+
M9$%N+.PE3U81F9S[<^ZY'>"\N+[1AN&C9I/I:3&X:+,$^FJ=/&Y<%I/1<E
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MW'E<$SOR9#ES5#0Q-#'94C8@/02A'Z4FY]18VMI=U)4U)@;_,LG1?]MT8]Z
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M5!Y:XS!0RYUQ><VR)%M7VE4K["$@@O%0TBJ"M-9;?;P$FU:B7R+G#O>GM=E
M$ :/EG+=['T%<:VWU&1J48T9W>^W.,NHMMA>T1-4X)1ZQI@OS[59LVI16&-+
ML)[?<HJKV:+B;4#L%;UFOL]A?FX01P@'& ]_5$,M^^V,% ,8H0CS5F+ 5(T*
MWR=J;2BW<U0>ZS6POI6H_#1FD63^?3R=B(U6@3MUQ+L3I*I"E<2G0P-VGF D
M^*%IEHRUSL;DZUQL96U9R^4J^P\F+>'?\*<UV:754F2%=T>7ZH16A>%YBBV\
MS#_HX<>5KVC]MYK][WWHV<W!C0QCDM(!#Z#['M21PA"H&=WWW;UO+@%$TA9W
MP #L;*,'MXP$-^ID:$7Q$A!AVL_;BK@$RH4'5'TV8+36"TR[8,SC^KSF1R/H
M#O/E#]^ZF-<W_7-3QL.T\I=BUOO[5]K)0"RS+!VEPAK$.R\=2UQRCI@W*Q.D
M+<&1LOK"=R&(S/.K"#LX1P^4U0@ZXKNA7KWK=0F(1U]Y==W/CX=FIN1QLT +
M>*7"=\3FM3K."U9MRV[,B+I27@*^7Q81_5'.6?IU"K3O[B_&,6!X74QW2!HK
M5YG(8%4QV$>/7/Q*]2CE:>9*A]^GV@VHW(#VWS)3:-9X(DQ2>9<;7!AF]6U?
M!0V!LH<3"=Z_A\DGWQ5=R]M'VD:\^^DLSC,:\4GVWEMZ+XF:Q87Q]*-W640^
M/P84KA5%R>W"@W76&'W0&JG;9T(!D#5,VJ[Y@KX5-(O^3>3 1[=B9-U"Z3>-
M)J&:*T/O#?K/7#1YD])U/,PI^*?:IQMRGQ;7)E2Q</%D]NF=)^"3$")U[>;B
M>:],;%GR=Z90G8^?U4[*2*/=*"=,?+Y4<[=*'1:9JR*I9(#,:[]4*/X<RO\;
M[6]:-[L$W$;62+@#=("5+6CC%]I)Y[HZ\F$4'GV$?;\7VNJ_I7_S]U!P:SRE
M(X7FI&-#<PV$PW7]Q:N*W99\-#HI,41W("P(@K3CO:XY%&8#F+=B2]3Z[Q:L
MKFQ7$W%(8J;%F98-:%1QW6!6ET#S--V?%/;\4\AZ0C^(-<5/36<YT2"4C+>6
M8>*V;7/@3!"/=3*(16]+-R<[GB&MD:SA0=;6PY@;2"%CO4C6]A5=).3C7AT!
MON#KT857JVB**&G_\U$2*IDJ_5$A6 >$<WNE/*G'-UZ$6!N7C-1T<*SVF_8"
MN&75]N&/1#4[?]4#/BRSP(^AM 5JS8-5BTLJ4$T)7#-&(6A$!!V074QOIHZ^
M5PWR;!=%)<?B_1S\+P5!?\N7%8>S;+D3Y97F067SMT?J>$J$>8W=8_--76>\
MJ 9FCF7VZ"M(RDIRN:4]^7Q&(=9I?-\3C$?WUBHVZEV>1C_I\(6;$*:2R7Y&
M'H:^IC<>TET'I]8IQ7_;>>Y]5)C&V&''>_<H9AFFZ2WP8M.,[9W93SBM, WO
M:7V0*"IG.!9B&I7=+Q/57>>Q:_]Q#9+\\EAF7UCN#?K(Y>&&FT_JUL,Y?9I=
M]Z_>:CE1GV(S#I, /]"1*WX$JBZU"G0FIK/%LNM>T_&65Z"*0Y*)Q'HPVK>H
M8WH,K&:AULLN:SJP$&2MS!H^<<I>I&M(]'6:3/NIC4^E9XS.)X+S:;F: RI^
MG2S3Q%SS^[L<](=)+[:,A/+NR9RS)^>%O'M+NX77!:RE<V2C*A9E6=K@:LMV
M;;LS%8G)/M*/YEI2Q\< '])F9'9AA(UBNEZ[;#C? MIJKS7#E[CGD&I)& U>
ML,4)$N&H_^X8SC@I,[(Y16%*487PT<1EQ4V7-_%FV]>"V:R@GT=D,3&750UU
MS#+@%PEJD:\=YG@]7F!=M<Y^]XS[!,-;;7Q>YU_1_"G#2$2$/8AH3[OQ;8X<
MKB58V:\/"\V)NVB4SIZ#C'KCK,E7).IGL61<)<.1D78*RDWXPIL<5"^4@2W9
ME=W%&G [U9]J#*XOVLT):>?0:EPGLAPOTE33D W6T!NQNS(!"^/_4)7IC4TH
MZ]_3A3:JN@028]TW05AWJKD\NT;>8](@;JCD;7)/GOE /*-7-;O7-",%&I.&
M>21E[QZDQ^#H#+67YL-IL ,)%K0&P1%8*G^@_>1W+37V$D#'G8^HY"I=Y*K\
M4-G+)+JA<GP6]9OVR(H]_D\SPQU-Z3^/X_T5YC.3?%R68=^Q*]EYTBNP4HAZ
M'OUDG,_.W]ZBN[^?R01]ROL <_'969Q\P('MY'/8A;L^?7#IL;$.%='N@ZRA
M, 00BGS)*^-1<V9C\-^;U_6O@=DH,TZ<4!E/Z2F.\JDFLT\R[/7V[73J$I8'
MMI6RV($43\;O8OW%;5E8[*&6H@QM@'MORKVA+AW(>DNK._H=22)*U(FVV-L.
M>OO)U?_ZWR7-)_^(RCEF\HH.\:2QE?DR)?,._H2_<'?O%*3R?ZHI68B%5Y93
M%=M7+1M'OB%.+;@&SZTBWN_XA#9-L# @EA>G[5YD*.:VT4FWHH8.$$\6<,?B
MA-(:Z@"Q2&FC:?3\/S?KAA3QGV_:%;.&7S%)@CY(\BKC8ZG!0?[:A5LW&\9&
M1[I=]@0?6 ?.E<_F?*B,[?[I8XW?=SOFW(8IQT7D4#0T1:^@95;&O]) [I.;
MW0$_)\_+?4HZZ4X_$4+7^F1S2NP)8H]+@-3\O&V:!M]TF^:,X^7:!=7,F5B5
M>5E-K?%>YR7 ?DBO$3^>Q\B?H]B[V30PC 05![?_V\OEEE^C3P8\)9)?E@O9
M1UCRY<?J,;[1J:>7)VN^<,.BIVX6U4U$K_9)/]@@.Q2-!];8M#ZS75!1<LLC
M3K]RT&QM*%=7^(11##0?4>474'D\#P1AE:+:W\&,"/W^6'/6[Q=M1U._CG>_
M@_1CY88_\"$:Q'M*Y]OE%"G^4; (F<680QGWP(@^'7SXAT:7_3TPKR#[Z\K-
M'2$DI,XZ,%4\&&_X$P<:=RK^6QZBECLL3Z(1<*\\Y@^U,N.46&RE#S"A3*_5
MS6/Q%LUMQ=6HB B,HZVPWQBU('7LJ@9H9YA8AV/N$G_Z]N,?GU7^(<@",.F>
MM-*(9,"U\];T<)O#</2>4T.((G&^X=L31X7R2! 6Y34:>D(#GC6Y7BJ7#NR"
M9=V.+V3,^.KB-]A*.$Y4(]*W-+?LJ6=<QP;4E:NK%-V:#[=M/O[W4[#1^:SX
M,6N*TH"%WD093^+7X-&B1QS17SE>EZS::A1,3V1? MRW#4>OR%:(%!%W9T&S
M/&>*V4)DGP8\(12V',C>9=?I*3LR_*8LJFZ:"3&8GU,M+_N,"2I.!H66*6*=
MA"[E/4#._#OE\'\!+HWLNUVCLE.<>%RJOCWG<P8!#WAU2^7GO288I0B/2O:'
M,].[)Q=-YF<%\4\5D_O=1H1 )DO*PH7?$TXB*:G%-B/&&S/F&*0T7N>Q=L)H
M(\2^TQWDNZ6)XLU0Q9-7%[1?T_M&1-I#F< JOY#]N2[J5FUY76D,JN[Y4/S"
MDV^C6*.I.'&K').Y54%S'GV4+@^SB,:T#O0?W9].I.Z>17&S0Z0B1:9@WHU1
M<U,S)M\X9(9T([4GW!G'UJD32[4G.QP)0Y[2 +#N DP(@+7*HZ@C^5C05C-!
M,Q\J327SEV^'9Q'^@X]-K=_[1".0K"N=S&RT5&=;:%$L1(7^.I/$0)&\.  0
MD?#(VMAVYC_JP,8$\T_91]BKZ !NU;@97'>T&PI\=.F9'CMH[4<II,\."[E_
M,Z^/T_!1Q7;[]M=JX3\;5/1?U]FN8H1+ !P;$PB66/7*)$&,7(BQ_))'!Q<D
M<K.&W=C'22[_PVV@?U>>&.Z3\K3&4(:!6/MJ,ZGNLCF]Q_305 ,>S"7+4JQ(
M\:Q>#T<[=DK1JFVA1W8:H7H-&61K'I<PAQY2CHV26E,;Q/,PN#=U9V$\&Y<\
MVF8JT[W%:$R>TT LF37F5^NJ#-L*\2<T)/+/W)29C3[$B=]0LKQQF.OH3<+*
M]%H+.4B:K*P$B)=V":Z$8&):8XBPCD=32? 91U6QH%V/6A]U9"@@=3-2S*1<
M8>-'N-5O!;LNM@ IA@_54;5[I>/9SFQR5'A 7B#PD5[M]_MH_D7@W V_IU^<
MB>Q-'+;5^'I].CVA2!X)]"#GS$Y4NF=#<W^@N>Q,4Y:AE>?2T'L^ZE7BVG[2
M@,X=1H(^C<1!GFYZNF1!"HF]C.8,<=K6KELD3:]%] 2D-.6(N&5D&S1B^W3?
M7*B+$Z.R6+2B^A^)6&O '0Y^OU_W'V#PBNYA_]*@I/N-45#=5LB*;%+ 5GHH
M$9*)SUMPR#?(]N8L"V>\4-8JO,>W3P,/^+@F3K50^72IUJ9T&!DI'\O<-5 )
MR,.7:@D][DQW#"=C1+Z<2#S=5K+2U99VP,/3'0]D;S%GZVMT$;_8LD:!07 ]
M0O?_:6+V/P\U\IC.SBO>!=+3PA.:%Z(K*-RY89<F)UI9#NW!=>7ZK#=XC9\Y
M5 )7;91"N\].4=+S80[Y#$=:X>/J!D!4C@+:^>E7E\3[U)+>RH#(48^C3*+#
M>$;2;AN5\;S864%(!)-.X?A>6W=:CS@)*HMB/Y2&;U=BU?6/?/XA08=\0 4%
MT,5/?>3Z<G04;=7KRKXP',CRB%I(E9K_@4=(H[7*G$8L?X2Q..4. K!!Y3='
M$+JS<D,3GQ3TN0P_[J2,VQ"_V066>=2Q"KZFO7.;D+!C0^/.2-FLV8HKXUCF
M%2/*_TB)97#E,9T_]GCR6_R)*8W?9+#*\/6X<1'J^9E$:Q5S:;L\ZFOPLS4C
M(4NIPZ)DV_8RKG%5:4!5GEHBP<8385?G0')\V_J@8%D[T[Z<670^D).,%)H<
MI*CU-?IQ,N)9U%"HW[JR&"& &E1BXM@GM$R)9'#6X1N7=MX'K+ SW46(.44V
M!_>RD2^G^M-(Y@XS\:%0[\(F;X(S]J<%"/\*K+N4;QE1_SN&G#V-[_S+_5E
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MCS^_:TY.WCH="H96AI0']'"+T0&%;!$'SB<CU3B#2(UAU/TPXX/< '.2$7Y
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MUM2RL(X>0W]B=2WZ5 @K\$>MT*\1M"VT-+TW#$YTW.MS8T3(GHHA:HIV\O/
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MKM=93PY]^&$SE#$T_MB2&G<6Y5FK>13WEF2-"I8MWY8;S,OO8+,K,+(Q9G_
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M[T=JLQ,543\U4<ZE7JZ\[W@\@G"N)YP:'I>Y;PZIR:):UTJ%</0+?[=1%%,
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MMQLS96E$C2U@4BD98IWY7R3;/2-MR77S/YR3_R(O@_]B&ZS@;!OLY^_1%7J
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MO-RT:KJNJJ4M[IUU=21DI?PX/H7+OV"XM;0RKJB$F-%B:&Z(5DQDR/80"<2
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MXD*#@3I]VJ>?I_'+AS0GWHT=WO7#]4O* ADLBBO XL%X2_L'4>-=O!\;;Z8
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MLMHXI_<3)'#G.7T.!X3.%X1PS]+1Z@,#QC ._O#4MR(+4J>$--%M]2?#7@P
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MX20->)G9EF62S=XE7+6[V@XS)E)UC*0JF=JIS_D+[]E16*OM),Y%P;(5C.T
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MU":\#=.KN <T$6_)_EE@>HZIFE@@1NE/R/:BW]WW-N$F&2)L.]J$/Q'CC?>
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M<MH6SLUV71[_= $##P$BSXG(4'9,B8JT7$$0JTV*ZD'<G".>].)@W0.RR3+
M/ V$Y3YH,HX:[@-8C!US+@<(D&VYR:M*SB57NHJ)$M ] %=IN1U4:G4EK%XO
M&+0AA.GW7&N(0]MU$5%07;SFA)*1+ 9..Y&+@'@+K7?0>)7T]^&UDZXC^;>6
M6$\H&GM@V7G7/B.9CHD8ALQ2%+87J_'M,AG]+6YH"TW1-F<JY4\.?42]5:I#
M#VRQ5E03U,5QO=L6>R]*R*#1*<MO4WJ5Q@]=9.M&T\;J,+P"VW.3A-[-C6&(
M84@HKN:>-$Q[,[OX&1N+&'2?]MM"OS"*;A&.(%"[R2* AEE7PC[=759FZ>7)
MK?I!(R/I[G=6FU)]HSIYV/FUP6@AZBD_SML^79$-OF;SEG!A27[HV-@V2"PV
M(D$FRND"I28%OR('9:?C)IO%0@9D9>VYN.6X'*M;KM6O[U@#6A )^*MK-P*R
M#6VP6L&$#?(G;=GE4,F9,E&Y CD?"Y4.^[<7VI1%"]I6$Y9O25U1=T$/QY]]
M8'F&/*Z00/SZDM)>%"Z\)?VJNJ&/B22=9*NY!]3.(SHFE#Y*[CVQ_W;M<UB3
M5CH085ON WBGY3@$N.(S,Q4BN:B@G7)1&E9=$2L;7HB8]&ARN_:7)[34/#$[
MVR$S"CY_@>,CBA';A^W=BDX-% K\?,%-^]*U,<VE/5];AU0#XY*_9Z>5*+#3
M$*_EE?=@P_,7[YKBHC?4;EGI$4#E7L8#K)F,CO#0GEZ'%K?]!0'L;V=*AJ""
M7Z]_4&\1A\J#",Q[0!5K7OV)9_N:8+/8)0]0$B>]C61-C%MEU;I75:'%C7"A
M*40] ^1'=MK'+Z+,N[IX7C?C,-_Y-?*T=3R%_"N#TU1R/'=+P%:!"C.9_.21
M<,1Y?[>'6Y>/E])4Z3GB_$!VR4W/_YWQ9_Q'<OEJB'2"1&(R>NY*3'AG&SR1
M6Q']ZSK>9UDQ4([N?%#,XTOKLW2)+G-Q(E4Z;@$NYCH:*J<TG(F&Z!"BR7>(
M[ISD[]6Z-4EBU343CFBH\]/CT0/?U@(#)Q*:)U?TN%OA@=P2S=3P%BJ0:!)]
M(NGW_,J]L+Q^*R^>BJ7WO+L@+TL)Q>-[ ,&N)Q):O#.C<TP.1G4ML:.F2:."
MPIM&/PEWCR2N?,*?GA.R33=>PGX2P.R$\V5?^[53D OC&)D3EWK">_0B_G6R
MJ(@E=&5&O:KFM.:H$ON(!7&_?!=?MG%^'#Q5*ZRY]IQ"'(>0=N.EC^V]FC6_
M%*2-O@T"#XD")MI7RV0'E>L3MF0BC U&W@I47E2H%J1W30>$,170_#<%2_GM
M>HLFT5N35XV5E))">9EWKS,/,S>,1!!V76[BY"?=P^NI]X#JC!_=(J;/I21&
MRZ2RSQ5B4"%L3=%2&:#9U>;<+M['OIS;T>2QT;817.ZB*7LVMQ8<MQ"7E7:S
MM_,1/Y$63CV>IM=CZ%HIO/II2'Y=43N<X,A0=IK1S$U[P=$W6F).JRP[UTT[
MGH9QXB4NN$,E*#VC8V/H]KJ89Q,Q!OKFNGB[6 Y$XKS5)T9!%]($JG8N#]DW
MOVTQN%\<350AR79KYU3].8Z.\N<Q=;#?A6YE_5!#+U!/.0M"E- \.#7"-I++
M(^J=KW)=*W"(-O+<N; CWDG1"='4Y=SLY*)2A.HP9OVB32J%U] %?/)*:PH"
M@=EA+^Y\770@F'@I=<LE6*:*CS@5>_HV7*EZ$CH%>TSL%H/7WFO;XR]"<28+
MCCFNB\HZ(;R]=NF.:/3-Q6&W8^[O76=)*#JAD2X>AFXW\L,K^-"?>:"C^$E+
M4F[\ZJ)TNN&&3'6)_9$_&C_4#MLQ+DGKG=X#BGW]/HZA*G?1_!C(O!J#LE4V
M_*34HPKA/S.O#3(NVTO);CNA;(W?&#X-;8NF/U_7R4:02U8=PUJ+2F?WCL%X
MO2@,SW\\R$JS?.$OIL1GT;PFC\AU*DL*SEPI:?C2AV\I-] =MW!P:WU9>4(
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MFYV+APU#RL+F"S;92039>+ZY0X,(E>;)*[B[BP^9E1E1[4E ^,N%4LL(AW?
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M9ZA!"0=<*X[?7Z@[WO^ZXH2N#](=@@@&W; 2BI8TPR(!+(Q[S('?42?!;H&
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MQ24,'L1S8+%!O9:ER\8/A9)FN;T4X\617B^HAZE1<R1N.V(DA4A_Q-O*L2&
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MYK?CL8)26+KK/WU!WW?BN#=$-,<>214IW1' ?K$RY&YF"YXGQ<8&#?4J<(V
M1MLNQY;36^=UX8 F'>)B+2[K6R*\TFGY 8I 'YSIO51WCK((O6%N!8)):A3.
M=Z_HMP+F#Q'R&\9@'6[+2O'W]?S#7SV;*JR6A .H,/..)??QL[XK*9X$#2W'
M*)/-;*Z/A0?[J-'LH&L?C'YHJWO#.O=F:U_CO7P3;BZ1?TFL4;K>N+/$:6.%
M$MW(^R.5%TH6VDVN2]F6N6Q#XPI^Y_[3899KUQ!YCU;.022!V%LR^C*ZBMAH
M2UP3/?,>;>=GY,IT#E7*-&98SR8.<JIR^)>;>%S=Z\RO(8GTI5&5BAOKK1,,
MZQ-YR_N$VI\\)$)G?J6M79L]AN8%!N$T]R?H0[P#Y*XEO\>S8LTYJ,,?J4]9
ME*;N%'\LP33L.ZY628CST"=[5JX+#I@Z2K_@&!,O?@DZO+H\0#<?(DV\>9CK
M;8#H-OC3])=*,-6Y/ )4@VN03U66!\#/_0>=^FO[JI4E40.2>%IC)T!>X8/N
MJW# IRKKD_V3P6ARJS$8S$TJ1&3G<NXCP*491!Z>) XD0E2HHP<V,?L%-#8N
M-9MXJ*N5CX:\X.=-D]FX,$(,>1>1L)T5B]2P63DZ#_ZQ.2G=3Y^(XN_-<\?,
M+;)S9T2:<NV=4&QW/C'5N$U<PZ0'U!O(/B"B&)?;9TW4%<R=NJS(Z;Y9CU_V
MQ@R*AP&]!\!7G@Y$OJMP2%]6D136/,+#RS6^,%!\DJMHR+>Z J9LLLS4!8ZR
MO/DD0Q!BL*I\(D"YXU]_:+T$UC^&":;" 39#4>U7/6ZX?9S>0X.<K9B_O,^-
MC;.FW#2NS5#]?N( /0ZB;?:*YJ;S<Q"IE^03;K/&+M9B-_\'5E<*N=)68>(/
M1NG0+)>]GQYLDKB]/;T2X:&NN& WCE\T*TT?(?(BEY=@ =DU.&H16&QYN*G:
MD:F?36#+VX;3W7FJX68DE-*<R1V:]!%MD+$?:E,4UE3&X="-I;-^ZS)5Q]?8
M5-=(I/E9)?8;UD,[&YKR,,'PCV/HW"M]D$S(AUR=>@-7. !6B;TNEE#1,T;$
M?3XN)'[@)D!;;BXQ<+\>J&\^>)=L F0),<(I=R2SLIZ,.:I/>M1Z0>]T@16X
MD[)K=O'&ONZX=3^C2HJ;BUO/:F]H0WM$\W0/*?QN0V!+=*+S2SUYT":;H68N
M-;H Z9V"$G PKV]RZ4 >76FQ*ND#7!0;OKFDG<+Q/)\\U-I9BI81HIC@==G8
M?8PE;T12,W^N# >X0[2= B#S+<,PQ&34B[?^RV==,R##HI<@=SLX@(*G[G#X
M@JED@?*!AXI!M 2TGOJ%*6[BPJWN6<4ZJ'7.W0^(*8C\S?'/SR6Z%/8S:V^C
M;+JR21YSJISTY\8CAB!Q>OH);OJ!W,<&!%HMEM0NFJ:F+,^ -\*@=QVL3QX1
MAP]JS]Q&QKU 6A\J=@">DA?O;@!3Q%D_\P@+@7)-<"0>4W%B:VL,VUKHOUGB
MG+]U2ZN%;N_T'7NWPJ.YD/TFUZ#RV*?VB\ZW9Y/?;W3WTZ@YCPL+.LI#[*5:
MGU\W23XZ+C(@U]^S92JZ.H,E(OP^I:NOA\VJM,8NP_D9.%K':)EQ],[6>=*
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MS<D)23M;,%:1^#'Y ('!AV1^O5<&F$M%GI-YTJ77IV-U$^->,=%%&)%O1&2
M,":E>*KKT>:$.EE3HTT-^[A3LA6);^BV)%@)'UI 12BUDSR25BLC53R,4=O(
ML'GNV6JDIZ+JD/-TR/FUFH*O5][ZY"^"#Y[>3X1R(<>XJKWFS7,ACV&TG]D*
M4T2SSD@I[MM@H0V1E>4S='E^+O%"UL/#8A+/'%5/II/[.L_<X)DL*?V<N-WS
M:_U;.0?7#F+5V\+Y3$U$F7;OF,2<0]?3DZ\0A*L/$<Q-]5V=>?T,AQ YDB#2
M^/KZ5#,(8Z+M.%4-*7#@.$M5!478 U.FHOI<=\RC..)^=U3ORPFW_LUB?_XN
MZ;BQ]JM11KX85*BU)8Y0;23U;KG"?$E9 <T$K1NZ$@DF?=J@<)[KC,7%;U X
MK8(2D:K/HLK$A0 ?P(FKX1IR=F C:ZS-F$\^2!>K$104O5NYPKVVJ=H=/*+[
M%%0*R]JJRCT8^R-C$V.D6IOS(1-^+D\KE(7#:&NJ>?)9>':S;1D:,K&0E)4>
MH:37+Z@;7%"[TH\][[^, "V;"9N]XWWND"$.L(,QUPT^M>^)D@@_+GQ$?*,>
MEA=P0V (XBG(R^.=VL&]8&2U%5,5N'6N823.C*2\+5=0YSRUU4<<1?T.=)/=
M((5U*=HX/3%E,5L#(XV)1E%$N,0":JA1E5]<5WHN-%BL\@#R4NS*<S559XBD
MTE42T_R;Y+W/-]R]!]3#$'80[]N@K@4O%'M9C6\_^O)!?@4N]FY,<2;FE@F.
M_$_6%B$(JWH%^*:L%G*%\WO45.77F_<P<K-4FOH=^[JP)M^UHYQ\E\!2YZ^=
M&(1/W\]B9954&=='S$9]'L*/W'' I;L:SEO4+-29S=%!>%;F<"6OYRC+7@6Y
M9M$K]0-VF(LEWB[DF=@5%1;[JNOL&)JCC59IZ?[(2SF]$IZVBJN\4=Y-H!*!
M+!!U2;$?#<O$-6Q!Z%JN?19FU?LMJZ>SX<ZPA0#/L#.2,G$J'$_3VV_4WEP5
M#M-&F+<_K#DV6WU.8F)*V_,:PCN0DU;#.:9I#\*#N?O\6)J1C$YZHDS]-+K=
MR).OV<,!KHI)ME^,3H(D/R[=O[$0+@MFN.WRAH;!D^"LW[B7JSPGK2R@8?+V
M^ZT0;C^C[O*L 65D3!T!,*E#6<F+VUX*'2182$K3H'#M&##Y838O1MIM4\41
M1#-1"&$XE#?@@!Z"5M@%M"^NH6^I1[O3&B_\I/5=1QC*JCI#,J(C<;3*^2<5
M%+^9O-:F&82D-+4R]B1Y;7CHGB[' 4?"8Z9#//,K-O77JS&QV)-MTS^JD3%D
M,"2^_ZLON!,<_+12*2PB#0[(!<H,9*>5OR=)@:2,K.7[Y&W>K@@L;'_AO:YA
MGH$3F[82I1]:=<[?,#7LQ+HH00@,TZXL+JMYD5#I1>=5F90K>L'DRH#"J=##
MY4\[>G#)/S88G0&]5W&1J64?*^SQ0.#T:8+;)^\V 2JVNH<:Z0D8O"3J\4XN
MUR<[W^%./+##R_4LI#26^)"\>I;]0.A!.V8R^FU3D8]J:PS(L6\BC%*:%S6U
M'UH2KQ50*6DP)'HRZJ_R/T^BL78SN[*)\]GR#K+JN6I$.$^E5Y:.ODZK(':C
MY)U%A5EU\V: *K]IX!%D1+B-<!1Y\^8&*?LJ5 >,*2O+;F9MB:?^T5 ,BOSB
M($M5$4V\[(V] '-=\=@JCTUWS*GOS>OQ.5K5?5SGI[-1>^W7%EZ'DDIYOCMS
M_2(2<<YLY8L/4=PA/$0F1D&2*4_RO(KQ2]S4^EB:JTJ7_![PA*Z)/U42H0#/
M;6/K3SBOB\2URCL5E 4:%X/VJ-IF8/@36BO:\O'/A@E<'8IO"3M)DQG>BNI+
M]!2<GF,^"=28GKWD% N1E2[=KH91VO9#-P39$UMGX0#L,= GM,>BU8%S5DNE
M_[WG5"@UILZ!,!%"@ZW )6;UHL-HD+5]QN8LH,H335X :N,80B+8%1RF)U/X
M1J7^B@W8"88CIP@'=/#! =LS23 <(97S8#A@^G$--OC&XB19_!%!&!P@<FZW
M?EZ@;IF=\[0W9&R*+RQ 2JT%G(3("!748 N0XY$OA!H_$48(<1=A)KW7XVBY
M_WD5A-$1$W&54]8N=50?&&D'PLKF0Q-'J[0^$3LTV$+,7CV@P-E;@Y *RLLC
MAN6TDH:51>->^T_)6M3Y91HJ06+&=W+:\.S$>C]!/S6B:MJ(6R-R#'I$HO$,
M>+ZAA!CCX[(N/R'D+I!33:WTZNVNM\8OOL- K3E/CH\&2!4W!5MS=N#A) <>
M1VJ$'N8&_B9CX&_\A5*$9^WM^L<;[0@C!*5I/&3R/Z5)DHB3M)*\%I]!74']
M.Y89/[&4+/:VJ;Q_^@&ZQ!-@(GWS$(LQ<6A"YS)&G,B;:(00NE+W:[N^T=)8
M_Q:A)!"UFJ?@:H+O8S][-2+DN'9BF?PK%%>I<ZR^<H+\':.2+XS*LUD-7R1
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MW\=RB^8-W=BLO&.\#" *RG"VO)> # 4RI=EE@8Z<;+4G)IOQ]F(D27DP*64
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M4$F7:J;8,D81H3P>.,"@S[[BBM.85TU5W(MIXJS2X7OZ#XIT9$):IAW>+9
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MS@%77--7T<^VP:T%M"FCP@7JM\X!WT"-D!N4>L4]#P1<<%X-5_Y3T@ACP#D
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M'-]-Z0H]V3@:C(P(&9E@OVDZ4?O2DAXK,W5<IC-CYZ,VUJX^XL35^B?/AL-
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M>&A OMK2SI#?3IYV)T]MI+-\8%@:]E@^24#]5B2_ITZQ($Q%U_"DOK_X24W
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MK576(%)")"F&[TC]FK-@R<NS;@7?M7/ S^XDOA$0R/Z<.N10\6=^3]L8_D'
M6=_\L?P^X+#O M;]/?8_$O,7;."W9FNER/0' H\"57S7ZK]J^$=2J_Z)U)"_
M1>K?4CX'L+;W::M^)9,)_HU?J[#DJOJO[A3^$O0_4*/R3_W^N^+]-:G[]O0R
M5I;?ZNH<\&YA)2__B\F"JU+"7T_@C_N*57AR5?ZW./Y:1?]9N."EOR!SQN\[
MVG<12?V>U3^=A)0&!<.8X%_W$\,&A66_X"#(OS*JG -^=AOZ/ZBJ/P_W'_1
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M;XBP1J>*=;PV9(X)]V0'XX\91Q#O1=<EV#Z\2<L;'E2):^G-.M4RU^'@K(4
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MAV. 5D(:X0'S)L2JB:[:G[.]_/\,H6 61%I^BEKQ(_BV#IPX9-ZQ*+,G>C7
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MZU]=>TV3$_%$TNB9G1\8\_'_ 5!+ P04    " "3@&M2FY5KK^3S  #",P$
M%@   &=M>C)L<30S,C!R:S P,# P-"YJ<&?,O D\55W_-[Q/DDBD%)E.I2*N
MJ)",1P.*9,H\5<J8A,B\E:2$<T42TI$A9"I#AG 2TF2>RIAY'H_A<*9G[8/J
MNN[K?I_[>=_W<_\?M<_9>ZW?^J[O;UAK_=8Y>Q_:-]H/:(N:RAD5"(5"01?
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M??A7G\_S:!!^69O^^M=R_-^*[?Y!/(DZO[L0*4_XO?PF4KX"DX#TJHV\@%*
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MAM[IYSKO#OT4G"Y?;-[?/DGD-5E/D6SMAZ]\0@XF+_^"X-RKX[^NQ?7DEL\
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MN69EV&IK&:C Q2]&AD94]*?^*@JXBV>]?GH;^$%AB XN8[,>O- BG'YQ\7;
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MAH7K11DF]D*QNE,%X"2-O2]]QIJS2E^T-R[_3L0W03\%GZ7;LF*;7:V'#RH
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M=H@_;%=$NV,NW6U@*6SJ5SOD7Y9SANND$M)Z/F258[G_@\6E,W4V]+*O[Y
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MXY.LZ6@<&"F3T_$*$Y)W4M=:;>B(A,TJA<VJN;IM77851\Q3:6P#Y]I^QD.
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MHW9#U<G/;\'<@G %1C3=1#K^B4L"7,"]J=KA@-O=JGRNS:QP.RZ,^Y,X]GO
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M%K^5M]WC)#K56/PY)\_(D0K=<D?H]>I?0Y0M35)Y=8BU-MF*I(]91]#%GMU
M7_N+@=I:2 J97 TZPX'+#M"LN*XF_E=@D=AN"#;.U&C3!UL*@C;\QZ#./LXX
MZ]Q?&<[%)RZ8>6QVKW2Q*MP;>WC(8+WG6(3FIP-7T2\6'^<[FAO8/T#K'Q)(
M3NLE^F7D%3OD2NSN45&]615\,- F\[OMV(T8&<DU14]0[SF\ZP\Y"TK^[*QM
MDE2'%I/F8<G=?UL0S]+>)Y[T/=*,&*TU0*Q [K7!Z[*+*Q_+!"8J#6@ >#,Y
M_9[EA]);!ND9&3UWR7O-.T%_06<B^&^_Z7*A7CJ@EUUJZ*2GIB34ID728\AQ
M0[7=!\WO#_U:I?0HK-KVZ[_7T.[YIOF903_J'#T48JH9IK]C84=T$EBB 3S
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MVF*P0O.)<!>GOJX3BZ[5KFU6-\_D<QN>U[I0UQ;,^>WX*,AKKY)B<Y:"EE#
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M7\(>^VA/X-UT #MLR'1,2=>E1I6R^9 >(*0\3@8!530HB**QOP_$E$I[[!-
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M];P#E&;[X-1;>9?AVXNF^[@[2V:#/6M.X.[QG:8R5V:&E^:GAK6ZV?)5R#C
MTUJ[#4YO"&DVI'5P*2, RE<H84)KP>"R@9Q-8J:+6YKMJ_I.U_LK >G+S-Y
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MFU_HO[Y/<T.-!Q'XX>PS)@T?L %^_=OED]#HXQ>GWDOBN/U1&!=>&N8>_(@
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MZMIN=,,W[=<+G.O](DDU"JVZW%BROB?&7RRC-(+FD"(#W",) -^F'0% "!*
M3(LBE7:)FHGT*R=2("*HV=Y458(D,3E>>K($JJ5DMPY34=T9I]AT$2UWM.)Z
M[>;C'BO<H\H?S%XU)OW5=W%3\_G&+)7HHL-A85.@ NH-?N>6E^+V/5=#6R/R
MWF9:;%L)5NRBC]OMT3EEK_#O9=_5/*-_;8)I7?""Z)"YW*([E9UN[U3G%]TB
MN3]":[\P<T1)VQ2SCRL%L#)1#G'.OKX<G'12F)?7YU\T.3_ 5G][O<(&"-/)
MH?[03 7K?G9E ->HA^OP+U+HAUW"PK0QYE5Y,U_&TY*//74;;S)N.QX@C A
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M@./,);?Z#HQJGRC7*Z94[H_T@&7B!*:\U@3MU'[92U0A8UHK<BN^2FN(^[H
M*5.'%P?#H;#2;K1B2%_9J.G-9@,[%LY[L1.#];!7!PINV^\3[B(E)87":2F3
MHX%5Z0&L5<N4'P&8<IB$.\Z?[HJ[;S>/34#JE15W$E6SE"N[Z-LHAR3,.6X*
M:\,Q>:Q&Y"FV.'+T['!:T@;>Y>;K0JO)BN,,3,NU8+X)96':V?Y!%I?R<Q+W
MOX*E[CGM7ST<"RCJ1!Q?JYX_O=!& '++ (%6>$0%5G7D].;RJ]&B.[K(RH;
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M3   U<*FR$VL,9& O\-*M=7'=19/'94SB4D&U_UD?9\]MK;P(*'SV7 8U>$
M=F4\:/[<QOCX4'6R+NBNYD87=SW56 +J[>XRNCF7_:W#=A_-E3>;#2K%I,OP
M</.JR6#S$5%W1^?">+?RN%'FDUJKH5*9,YDM&6%/E:K75BQ-P4CTBM):LZ05
M?['#=J\J__R$/QMD2L8C,ILK-:BA.]@%1DL[+'*;X9+B4@$ )0 =X,LNBN3M
M$#8Y_6I+4=Z]6JTF*IV^H/(T=.W7H\[Q/39VOG22^KJM'P@X3B+'(5@#\W.<
M.14!SG)K</L*U'8;* 59#.*OH/T^+/;V\#=AKH[GT7%J1AO=:,9= K;6WD<#
M&O9.& 1>LTP.WWJ# *Q![&I?^6260;23O@T8I[8^YGR%ZM1>M?<HQK&-'3HG
M">\RV0\PW_"U,/MR?Y"H2RRJ.-:>PB9D\&8/&@<,L&Z(20>;;WB9E@S!MW1T
MY]M TP5$OO^'Z-*S( "O10G 65 /,4-E--Q%PHY)YHFDH1%^<I$(X@OSN&1L
MR^:*PXIP2SGI7Y[].0@:JXCJ*>D7D89-O('UE8QN]DJ#C\4#=\\"M'%382H&
M_T'P4$MBU0F E/C92\-#A#[B#V=_*$B6<&??W@[=AM<V9")^Q\)OCEEO9X,R
M#/?1U[*A.#.1=W\@[Z.B&5 4ULP)==+%@*/%=GT%41%[:\HBL*A[L' @Z$M!
M:0(U-E,7HU*:IJ@Y-:/)XO;8OA.Y]J]4\P]6>%1D&G@F" P$[LUZ$*6?CQBQ
M&;Q@,@B3+WT![I^)\GCU9A?'[T]RJ$W UL:[VO3^.>=_UT1($B7S,XXC*@(P
M"1F!?&]96= ^>]%R9 T<3/V#2^OI2%*)-^SXG3V(E#B'I*+1#!(4M!AR<]J
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M\ANYA4?^/.' O?,F !/K^)M-3DN1N&26^9,U^'B8) %PVN*(W"5J05%<7^!
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M;Q[D8DN6SO2^C(]+KH^[>*Y64+> !;N&PY3A&@0@.1[VI^V/I;BG1$AQ#"(
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M',9M$@'5H4F,4_&3KVYD)2ZXEI58-SW&5G_/1N?G<>71]EB]3^"[^NE1'")
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M#N@(MF<"Q0SW^F.T;1US. TN2X\8%[(:5.(<?O&OL5C-SAD-+"Y)/RYL ]7
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M\/M&"5GZMBHO)_M4<<-=&H57;H^&KBP%L"FSK?RB<?>>)'1</NJF%CE9.A?
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M,8.\@9.J(:J;+H<&"O(7)A]$D-[[[4LB%%L=O"<V7=YX!PC$ %OC/2M;$=_
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M=%1^"F&__GYTV;.4G"9=RW9L*P* 73=$.)0U\ZTQNP?(I.8XZP-"[6^S\:\
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MDU[(#TYX?0T6^HVVN7]>FGL3P.T_%G='V5,")QH--__^&R_P; #C\0;9SWD
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MAK 1H_]^7##(S8-!YMO\C62FI<8)932_Y_C8GA_X:)^7^W#0(OVERW<*US,
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M]^VXB' W)[O6LEHF%8XGIJR>+8O/F7+H$VZ%, 4;"N4<_+96<]Z>(\+BN^Z
M7I'_=9L*K%.&=&'T,3?#VV;?(P/'&GRP^/18(K[Y+B/O!'V,# 7J1=UE\ASC
M"PJ?G[$N[V11&GST%FNOJ4\\&:8 3KQ1HPZM >59>9J;1;8R]VUFEL"RVV0Z
ME5.4 D@/Q=9UVE]VEK>_U5$Y%_$5OT@YZX(L.D.H.HN;Y!& '7,:V^YY4_<9
M+03I.#3']>6DBO,'(AK0O;U(P\9(S_E^94)@\ ,$3C9WI8T9&J4_L]>KGZG[
MRU<#LM.DV]=9GCG?=KB7]/)X!\_^/&S&L1+2 841.WAM@S@#Y'0+$=J3:HUF
M8;K"GOGJY)X!K&P,XJ;O;Y:&Q7@;^!2M2.E79-F*ZYB\BZ*8SU,H\-151%C1
M0HZ>,&Q31@4L!=P68O!TWQ<B'Y.YU#BDB&D(9@VXJ6$[X:LVJ!5*E>I%Y_&)
M+/+QC/ 5 ]^5"I7/;7PJY_?H WTI4*&9&Q39X\DNZ5C)_F5YULP U_5T1:BJ
M?GVMC?(:Q;N3#R4;5'KL%!CWMY0E(=.C:W[=,FD\C*S(DD]$[H,WA*^H(3>?
M/W23);\WZEZ69TG?27+9,XM*'&/50A4EQB.:SNA71M(F@V%]]]+;H @R<)*J
M%2@^6V);L/TNQ3JD"LJXK#F$JN%.ZZ2PI9'>S2)F@T :$S9^KZ2<4Q>=5QLO
M"BWI"?#CN\=#V/,4ZS%7Z!99O"'1<6UB@W1).Q3'_P)#&HK3(XW:;;"+I?8Z
MT-1Z+3>T;3#HIZG\(%5M:+DA9M-.;7H.5+?@7$70BJU5',Y#.Y/&P>WGOWGP
M+,R7JN?B5 83%+:W[+-K&\)ER@EK>]48X0K;P_FM.1#&#@OU68>+_:!TP=AG
MVYM3=4%IIZX$2^/VT5YSO-6RD-)THH'$Z/,+<9F84GS$WMDFCU!)*--,$C$6
M%!8^[FR2FAXE5[NCC[GA%!,AI:^'#[ED9-]I6C<CH,NOTI(<7>1925)EFF]@
M%J1>B']_5K+0VC-BPC[7!%&A(WCX7;1'@(^:/KI"@4%NC9)O]L\J.P142'HE
M??7\(:MCUA#)P/A<[SEXBJ9:%I4TNC_FVM &N+]#*D7!.^JN""N-M+Y'V%8V
M!A:V&Y=3UU!;F^D:K_J9D#1E<P]XWA.F5R=Q^4BO<8>];'9A)%U$'K'[E$.S
M/.+;S4_;'0 O9&2IH*]L&22E47_K!L-L5;"/"QB\U:YQ#4;U8FC3LK[Y)0 Z
M#[K9#]XJ^[ZQE64CF&WT^%%@Z<"H;$N@KYB=L^"5P=)X'9P%ZQE "K#D*X3J
MGD.;#HMTZD.2%[550>)JP%(K+'>'>P9S=8(JDM.8.SPYZ(M3 U>3(8_>^1PR
M$F++-3FZ@6JCQHF36Q<60.VS2P$RF\:UF(+HC<7RJ*;$5Q/MZU_J%IP.D:59
MXZE^?$GI.9"C.V9FF79L]9:,"@:5WUSD*>D>D/WK@L7_=)CE_%Q2!.#^_^SK
M]%P\773_G'Q][HE.-RO"ZO5T *74 Q\=53,> I\'<RDBB-\^M'TA OS[(21N
M.JN7,2[R7QUM"'P0[%5NHNSX.W7&$UA=[HE,!US\\51NL"856#CF59;EF@V@
MB^[Q<_6_[/O].=;/\?XIG_X',98I8)[?-W!IZ2S3$(/_QPM&4+#J<X?A%'UE
MK:R/B3MFF,;.=Y>.\Q!^V?07,S;J:EYN\TY37VL#(@IJL1]?:S#&MC$7&5PA
MF>B2/7HX<QFV8+K:_R;S:WW_1>M3ZF.7F2_FB_*7(*>\Q_ZYH["QUSI0[6G+
MV%?+U:YZ2QALZ$,'X,SJTD9S#RM?-_#MTH>A.1CMFIG8<)6Q].$U^4^6_H/'
M Z35.F8L7F78GE:S:]5#U13ZIG=,,E\^CR$V'5W$%(1"A\!U&/(^F^\%W[$@
M'ME"PC&;$F-3>PGT]AH-Z^,K7=Q%$RFS6?48@QA!SOK!O5#$!L%5!2:BV#R
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M6>7NP\W]CX(J!]V ZS5P<R='@NB(;>!J7^A*B[X4#U\_H@W?.B5<=K^\&:^
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MQV@!D\'8-TPGGRIHE]:2NX\N/W%Q&-R(A/B[&!HU5&ZB*J&@7F2!4'5D0 J
M4"'QZ[<!'_5S++RX!C3 %[EGVD-U\[?&CQPBK+VMV3QU2:486VTWJ9Z^B/G%
MQQ1_OCA%O2>J&(+.5#O?0FS@%A,_1-=GG)>D*L:N@2O1^>;,[I.8%[ESRC<7
ML/S)-!%3R?;7@,4$/_!PJ>0X$<[J,*)0,+=KE,GET^[G(38T&\,7V54EFI$X
M[HFOTU@]34KYR)215@'N+YXUZL:1S'W<SRBRW.)F&INF3;BT-N=:6*5JVTB/
MB2IH:I*8_Y[=IEM+"@<"OU-"$[4CLWM7C4E/*\9VA[NT(]S+RL8?<OL^,'9Z
M;HK=XM3*<FJ;ZYEC++#HQ1-I3JZ*W9?"W#Q-TYW3\2;UB_1Y^(6'3+0\M-0U
M(;W]9N58@Q^A#^<(DE\BG=*>RI7W%KS)-Q<@ K(P%P]S*\F=TIYI/RBO@<8+
M. :QA /[/)%&S+4UF2KC&8X?!E:YB4_D^(=.2[L9;J2VU[ZUAN4Y>)L3?4V4
M$UZK:Y8HY(D4]2LU,)HY2ZK=QXJ4;Z8YC!C&W+@I$/>XT;"$DFJV*C(<R-\[
MT5<V[:CU?#XF1T)\5/D T19^V%09.G7?>(Y3@"27,^_PBXQ$)\W$%6'K-)=Y
M&+)-XH31FI&JO#)XGJIFTEA]XLCV<7)>_1Q5HDM[%I%<]]6]O6W/")4)Z,/#
M)!TU$S0QH4IM!$,F.+R9@LHXC5-)$'Z3+X-M3S;>(^=)$L2\6;URD)H,.[SO
M5*.XWW=INXDV"_XL1=[_^:L-)E5,/^ T##N@DG)7N;K#'(_8Z$%X\5ZA2KS:
MI'VS J_9%X+GF29^/?4HCEMTZMUC_.TX5K@ZS=^16$OT&A Y 6-M@A[O?:=,
M=4(:IP->X"Y:[^U,!KNJV.7402JVJ5KLD&9W.9&H73_BO4+/0#;BKJ[GD=I#
M1DY'E28HE#A#/TY^OV*VQB]5YHRC/N75+O1<;E<]35FCC7C8 VWU)XFA6N<?
M\@P7IH4G17^FI;A)E^8HQ._2XP=KI4/(9%3CRQ_C* TVL(#? &HDGA>=X:+U
M%6Y4R[OKU!5!':_$(PSC]/%G'D,G'GT@#8IS%,XWCC2ZF33+V#*<)L>Q0F?1
M< U@;;[36X@B:J[MH'T\[Q\0&;2 NI?@TFMCQ+/YYLV+'R+*>4<]RMX2FT8\
M<$)!M3V>R)L&'R*'3#Y?#!ZS5%(TO^*U(C2O(6QOXO!O5>CY<0T8 AY1'J;'
M!PX-K\:PY'^$Y\+%N'O6Y9M3],UBNQX'RCBUXHP?V6EW:7C&J,[1.1=T1S((
M?9%(]VA<N@;"Z!=!5[IT)OZBRTMW.#W>!3QC_2I$48@0[(14-+GDU[ZO\'G'
M_$TBI%SM5(,\=L$(&CJ 1V"F%1)]9(B2QX<7G^5/OI7&._4O>>U(TDU> Z^1
MQEG6UP#,R?:DCD%O5Z"0BF&.(V_O1Q<QU%-]]WSIYE!5QP#N#]W&:Z#;D/U"
M.FZJ2YGYL-@_BA0DH3=R:KD4QGF8VN^&0Y%T^3I88$45=)@9]L'F9-OB;98E
M-@;-HAV?5"5212?_[1FFSL?EZ)J=S1QK1S(F@7NRBW2\!81>?L%+3@A5B:2!
M  -+.K<L N/0*[+:T1H.R]$1O0=0JRO5+5Q@6@;.@VXUQ4 :O&J7>Z$7P)(9
M\SX-I.&C(F<G.U%RG^&E+Y9W^ ;2JLR'+N!9YAP1< V8J6*SO?!BO@;:UU(L
MN+_&.OOZE_&$U&;<?==>&V,RCF_OOB.JU1-%=@UTI)I_;:_F^1P-P=ML)<YE
MZ?05-E3,\&1D2  :"0O#;ISIG:WM5R/EPN'BC$K,ZQ$O348>7&:3OQ:**1:=
MKD<8@<LB,K%.CPV-CM&//<@<B-!,<F'^]T65L".XNFN^M-$M?!NM_('LW%^>
M;Y%"OK#+]G3OD%^6B\K&]-K@>(LHC(%> U0;ZAN-3,XJ3LY-?EZD!N!R"/8;
M%#]AH(6&J :8.Y%@&E@ZU #/1IK=;H;=L#*->O;=7NJX0FE)?&''&RF@ C._
M!D:B(#''AF_2FX?L;,GE3'V[>VWVC'%/!V8Z(-U[S>'/E;M>F]R!5&41YS1F
MR'A.%6:>&@K2.:VR')5;O7I@S3M,)V7Y^8/:1?S\!U%3YW.5B&7$O2C8O%VH
M8]ZBKP0-L-MZ>P>%%0^F/:G>50/F^7(7\[UMR:HZ$\+-^W'$3]E5:$_GP3<V
M1J1SY#C?/#5;H#; J[D,X__1:<B^RBAN%Y<,W/$7/*P,$6$>?@/7_7Y;< <L
MR/SJY?G40E"SF,?287VP=_'=T-A5++"KMS9U 5(=&M'9T9>W +-ZC[M*9W\^
M;;W8.V'/F;&+I#CX9&ZP3HXV\3?,GR$!&NQ/XMI78=J[+DXTT;8=I*TV9'J:
MJIBJ-V)?=MM-X6YDE@4='M!^^M0//F,M<3300(^#KQ)V_B[%_>P$S+W[X-.F
M4=AB"[H#H:?Z9\7Z6+,D#-A@"Z'+%=^>S&ZAMT/Q1G6O@Q<:5T./%!_P(Y),
MMHW(3<B#F%?^2G/X;N6IG*("DMC<0?R1 EZ\ 50<#V'4XF?OHU"D/VQYDYCF
MMGKG0:4JM%9)2;X\ARJ:&88)\'9TT(N0$8!6642G.1 <CX+T][IB#?C\L68%
MZ%PKIF%5/FH.S#T13$X&W2#P<GP^X).;I1.A0BN-Y]#1U^9=J7>!-X.%T[C^
M_$IS/S\_:JBMZW6XX2/8T@EH3>;$*2-3[_SC0H15=?]7E(!3EB%714,9IIWT
ME>C"IK$(4AZ1H@M-<;WUH$TT,OR<1?4:B&$33]R_V94N I_IXF$*[::*3W-D
M!45X'#!;VI>YJ'^;4[ 4&2)MUT@Q4U-Z^#U<P.,[N6;>: TULTYWVLS[F*4L
MXNQ6LM-H96<,W:JUHG70ATI+"G@;#E*".\8^2N)\>7K3:(KU/S4#\?3P-99A
M&1IV$5_>V/,1#"=]*=#]8*IEKHD<0%DA&@IUS<+;>6%YF[G\N0DDGFHM+YHJ
MQ[!*-C9&1I5M64P9PX,/((V-QBG*J0M$?WQ/AIJ%Q00M<Z" (<$]"X?Y(S1#
MBJEVI"DZ<C30YD7 ?D"D^B(\$C*"<1>&%3]H=8?K$A[$+Z@FR]H-/+(K'PQ?
MPQD,RB6G!D=Q?I!V%!BZ(=_26<1X5"P\3,_Z\HI^ W3?1R*_[,KA*U>=WS0J
MW^"-A.-DTYJ$"_7FL%*PH&Z#+GPKW&V&3ZVO-3IK\G[V9J##/1V]:V A\>=G
M\]I[, %^1OEW+^5+<C]&JN]H]S'>.L)P>@H:B[$!PA]ZFIB@;C5\P8[)^:'[
MW@RGPJU#<ZR\7KK1\0!):L1&BAEO=7E4[9KP-?"L^56BEYJ:>\D;M:\$&D5K
M_F2!]]4B;%WC(>TT_9>+01+I2D-4_<,0(%S)T[P]B6HV.C6!QEN&+JQF5->7
MRDRC2@9XQ+4S)<$D115S$8"U,)!)IR9%$LTZQ4=/00Y(L/NR",']R8G86X82
MR^'D]8'":%?G(.16-SE:LG769M+38<(TM+ O/E6Q>M(!_@!YB]6.)([<Y^UG
M7Q(+*9G+N'1CF-X_NP84FT946='?'<N^SR,MA*U7D52>/JNTM&4_<]:7N1,=
ML(SQJL8D2))"0[E*ZLW'6N,\18G\)[?>F.PG,9%> ZZLO:OJKCG^['[FFS-U
M^+1V\ZV*ZV>:>9HRL!(*.4DL-F_5_QA>'/C=;V$JV0/OHDM)M_3S[:?D0K.@
M]6-YT4<=TM$Z(]B#E.XIAG5=9M$]5O,+D/3/X\*59;? &Z-V$C\GX6HHDF*P
MN[HC5-+-:C&?+DI$\!_QMR&]>Z-3L?>S<'__[7*_:X#!P<BX; /RZN/NNSW.
M7"'J2M4VU @3K$"WM_ Y'\%^4'C*^'A\Y6#QHTP" \YA^9OQ'2W);1)M$'4I
MH]A,BE%N[.D(5L:; -^ 3<-/&QPA(XAC5*EJBN[PI_S5BOG?,8PA:K[D2ZM>
M/4 /;>C^BOPT]];[W5X*PQIE,2'O"TWQ ]8K*)H#GV6T3:/QMP8T[IT9\3B0
M1O!P-CG0D$\>,J**]5>\WG*;QE4O(^/X0-[TD? =* =MUY1@2G L$R4WI8D0
M$XK]>=?O'16\0^B^W%FWC,3TG3^K++C5,=,C\0T\T*H9]&C*=3A,P;KH2:5+
M@\$''V3#465)UIE=#G9%^^^M991Q&%\#O:G3F4-7#5<U&S>O <3:T?J!7X5?
M.?"@!A2 \HM0C/A* C4>=['G*#HW_!"7I]J.XCM_7X+\#QCN48E>^N;X=^9Z
MDN;\FP_)BDM;K+#K(,"!4KI@]RM6!S[#7@>3V3/NUT(,R4,R+!WXM#7$;ISE
MW")E>7C?D1J5E2&NUC]$JQES5E49]!J4?C#,Z7@^LM/SMJ:T4!WI4F'R5L74
M%:=:T/6'&6Y$3>^^,_$K?^GIK3X-W9X<=TNP36+DX%-X QIKL,/N-;I=-Y%E
M9P1;A!D0;@U'LHIAZQWC,)-)T>7F%KV0Q,.%X?YX2J<^^D<7--N:PWN^%:0'
M9M$KE&I*:XW?FGQI!%N2EI6[-8(]W)A19>F'\++/B37B#?<O_I%RSDM\1)JI
MB8JJ=</>9'0,PO!E.5PS%#,>-,U_"*63 HO:_<7: ?2::P#IU>)(]C.('B>_
M153[A!165CVPI*;0SP=L<?375(9'T<_(6)-A2@=^.NIV%2<Y#<!JNU>;0D97
M_V6-#VTS!8ST>T4Q$]-D(!OHXKT3OA,R1_7WF___$Y9.K/=(:#G0>VR=,3R[
M%#;D4?B9G*B?D1M-(U(5^P&"[&ECTRB#K>=@^0V_TJLCK^GT(L_/ZF/0R>IO
MM@[@=\(:;PL:IXWI-OT: SOPFU[M\(4PO7JV#:;1W1@C*[/>M&83-L4P+P(Q
M&J4L:T^6N=)2\5853,5"(DU:['ON!G;,W[WHI](XTQ;+.XWIA*1_2NF73+@&
MR.2@TZHXYABN? !4308@_]W4R0)2'IRIHH_K[V;F<]NR=&E->T">Q.K>)R/M
M(6(%=?M(70/,>7;K)PI&%\3G[WLD7ONQGYGS[1B-PYVE?0;MT;28:E\93$_4
MHJ+WX^9%T)DJQN_WU_J5*BN9$'EDAE;OU/2#ZM,0I]/E"[\-8X,BCU@=,[*^
M+.($^]&XW6<O#K"$*]Y]TAJ?/0T0C8PD2-,NMY$@/BR771SLZE%1+=5+80E^
MR2>$L ](O5AQD:0W#KG2SY>>8*U8<:T /X)?[%4LNI+_T;?_86.Q>4J3%(T:
MD?2FSVI'#[\Y< _OYE(_%YE.&5JNFS!<K1[34G(3,X/V2SSEL(7G+'>ZR.]<
MO)%N05MM333M,&+:VSZ%#-QVLR5CDJ1PIT:)?[E)*)>'MKYM$??WW;!E'!/C
M3:-.^Y(D1,X-S6> 0B4#8KXZQ\ SZ0NM4M$-YV0R#J"T;]LH,<\S2*&^MJXV
M1*,VR8D*4VU?A1RM3H:Z;^@G.'D5;C#Q,&*J\BKL2!+GY 9;5=S1?>'F.9/+
MMCC*.?HH/]]-AKX_"SLC 19(+SNP>BSM0EN74V-VFFM,PYWV@R8I\U03D@(L
M%+2ZI[EU>QVU5L-M6:*W$&\FH>_O",6O >?3?G09YA_[I##?WB!6ZP8\64(?
M7 /X1:XH:I/XPW&QFQHEZK0#/?U1.G2+UF\];KJE\ZI XD0&4/J=VMI> Z<'
MD(.SMFF)J1;TWWI55PY'PT=96*C!A5:8C<+/R9+AIXN:/^?XC?_5965H(I.V
MVWW?[<SJ$_Q#42]6R]M)S4!?Q@-?6@0[*IA:15J2;F=DU,>\L*:^/MQ1EEK.
MYE/,XH\0D_A!)?D@#Z%BM\J0>-%@7S*U=T\9T]^B';QR>^W*0P=+#_/VXKT&
M/)>1K"!%OZ!6:N$D6QU)>@4*HJ E":R-\W.!-+L4A!2:1N5^294G;7=C6=:<
M9_@Y[,&D)-65YIR5.,GXH:8N-:4WZH5Q??690!OAP6M&1">T8#U0"HA.2(>,
M@)CC!\+F&EF'/->[P#2V'N[321#S-UV.CUZW=,36A*P;#2SI*G[H$R4U>!?]
M<F>G&5Q,ZZF)&U =#EAV;.9E+JTE<I8WI(@KN[QBFG0#DYP6T--T6 3BK'P3
MWJ)I!+]>V%>&9IZO&L0$IT@C)'2(Y-5<]J\>^5/#?8G5]_B4*O2,+6B=&I^I
M11UZ-JFV3#*/VG.NWV^>6DH.,36T[%ZZ!BC'M<3\/'3/>8*_-"SJ\]^@LO=)
MW%\%O65%+T<5#B9QBO'R(X4:4[%B& W)_?Y*Q=K8"KX-B[D#!1*'06TL4992
MF^I.K&PWP:]P@.JKXXHKOPN<\V;M%1F^:9&2F2E,]"LB#0\XR"1Q0N0!$JMQ
MVJV=5SF_9KK?'GI_JQ#U(/AH\]&PO^'9X-?^]7Q?-X>K'&Z7?>)52;(_)7HT
MO;] 9Z7D;^E.(O72Y=(*+0&5$*S_C,\*L#3JXH^.IH"3_]W%6T_4HN\KR0#\
MH2!,_R'6S6V#DP@[?H7#M7@%\YNL;7</ E+@K@L1]S;5Q I#*9*V&.M6GA("
MD&)SC<]H1WS?T5V,5 ILQ6\A:DON0K\Q)(00QM;$Y$/*<$P#^4SC2M"R<-G8
MK+(PEOF'/'?OIG;HO;;"=7_MCPW9%,&3DW'K9'T."?Z9UY9\FVL7B/F*+ PK
MJA:###+#.;F1]Y?Q?6UP/L,^W_8.FB7.APSDR):$!I"[XMW#9/K0S0O7B9-!
M:29_T?BNE&4?J0 ^0RZZ=I&=]&3%Q>G"#7?0D]%RSJ9N*HU3S?=E.R\>9M<&
M/]BJ"M! 583Z]?!UI$F[*VZ$+!V$5/\2T^2TA"/L4->T]ML::<]5 MK^[KL[
M=3$C9>Q!@V!6\([VM "JE.W\+&7:_<=:*:_!I'$/*QF_S!+W1YKR'[UIHT18
M_F=Y*>_OI+3M/^2D=ZT*FB.HF+^B[5JA35A&VXJ,ZT!;FC+&[EZN2/CQ9]T/
M"(J5Q&],2DW+$/$H_)4H_\)FGZ^W '(N+A1YA'Q#-3>+*Q0O>DEAI[TJ8^1=
M=KNFW&/VJ"(9H@\-O@844N87^QB=AI.\*M/MD<1^8JM3Q;1SERDPPR#.&<3.
MO+]X0DU+\!'^IZ7$I[C%[6+;Z7ONJ0X%&VIY6"[U6 Y\<2XQD(V ?VF^!:4B
MHG.+=#8=+E-I^3MY!AZM8S4?#R\9]H:^7?",&M/-.\O%$;!C.-IHY: I_B#Q
M35U$N2XPM\5K]]5ME$,QG^/$$] $8L&AR)OEO85]F#TIR,I$\!S]1]NI;#]>
M<F><V:S%Z7!KV#40 4<P"8AT3XQ*GCW,H].&SJ3-R'K8#T3[6J'K_9QDNBO&
M2CW,!U5%5S=-<2,'0F+E['_"F3\>3HL_)*<4AR^L):PB^Z+;=DHE-.D26HR5
MSA;MX]CA+_Z2AK*T$*FBI'11M%J/:0PA(&S8-%;71^&B67H4>[\R:92_'2$L
M6^B\/V?^RIUN9UCQ/([@,H,S<_%OV; 7<F$[<]LHX#?QZ2=XOGX^ OHY=,='
MKH'EGS3'=]1 /.0: "^\\0#MA@-Z?S5?1N,":P"#NXMK(UG&=I?KXNB:;E+/
M&;XBLJG9S;0K^O2B(5*$H<=?W'6O(A?>W_QHO^90ZQIX^3Q_13I,/&UZ5,]5
M0^H%@0<1@R;X 8^T;LP2(>G8D%$_3K7=B-]'6SO9R477#5:T;_EYPXIZ?UP(
M)U9L+<PRCJ*_LO?/QGW>^_<F-1]159CV, A_V'N3';=N.R"KQ;E8XPB3Z-T1
M5)O0@GE3ULH*'=#WL(*^UBXY9A%W1/MZ%7%6WFFM45A\*R*$0:J!J@$2>H#;
MOTR0)9>(#%U8I\@,P;G7P@31HJ%HVEWB=ZKW=N(-C>2+PA_$&Q@CN=L(B,]>
M11R4-56&/;J2X-Y6BC9GQ#3BE=LO6SA5X@OTW)LK!!]V7@/EDL232 UPM-N,
M%51^ZCD60:B74>(.)<ZHCG[/->!E"EPZ&6FBRAB5;I2B4#G4BNO$[\9C&<@$
MS]JCF,M5+'_P'P>Q*IJNT:T)EG&^!FZNQ8-9/RS(5+F,8Q64DQE/&]PM";XG
M&%K)[Q?.YB6>P;5RIO$9NQ8R/7Z\+C!ZXSZJ*!F+;SOIRR&2M>X%B-9<M#PP
MEOI5S&1^+9W]U_$J-.)\^A*.9"U\Z[OVZ&RFQGP^LJ>EQ4J52I:%?:9UH<B*
M\D KT&9['*\U-G:\,8<G#[RGVK)"BG#\[,.3)8,F,JBW]H3 3:>%;S)NI /R
MO(2 CJAWBN.FPE32'S!,<EBT&FL2VK?SAEY921<V!*W34^ZZYU?FUG$@"69#
MZB"HIT65F=BX5^M,@E(65:\03Q].]49P5KQ$*OC$YV+=2(MCKWAC1S]?3J!>
M2Y*A#/@:[B57I';8'B>9. NLCS5M]>Z-P62R]?*KU'/XL1TJ. S<N@&1?U%[
M!0O^ 6E:/)3GJ:0V<>NQUZT(Y[*(MZ]RZH!;1_ &A]!K8%^E)O-\T2\=8"#*
MH/?HU(*\&4HL2K'J%/CZC.!*DRBDPEKD2[&7.44DVD[^_LR]HO7]LFL@1&_M
MG<-BBP";0Y8<B;^TQ%/;=WM$I87M\!WKU:8PBMTP+:YV<K3M;5.+\@:[6^H/
M0S]=)5H])R!*3*5LRA^\8&RK<Q<#(*,8)#C"6'_;?:KR43/U+MH8DWJ^9"F&
M*U1>8GLY?HB29MFC_.D/X8IZ6S=*Y["TF<114F]2U0^5UEK;,P>:R;J8KH&.
MS9_STO,H^&B"*T;_>7*TXWC^2\'/$C?^;=^ON$CF. (_U"40$9LQB7@7XWI0
MX-FX/PUI'9_4O],Z.*FYH-BH<W46^>8<WLJ)2+@I<,7<H/2A0]5K"-#:ZZZ#
M-2N\P+WED$ 0'WZA_:CF@B'"#GCNSLU+9 L7HT:V6$PISSB>#>?[%BZQB:)D
MRM?6O;.8HA^2M'YZ>D_?_]4"; U(6L;$EHH-@ !'0V0"K8-W3#0S7PAK@B3T
MSOH><F!IL<LY.ADM(6:Z&=RZ]%[>>@/3/)AO%G*6/,HBAIR2PFF_W15Y6;'_
M>%"?6Z';%Q0GS+^\ /)Y2%@1?/)=6J5ME?$#__=G_S(!>ZOLTD%)V5:N<7SE
MD\*X]9"5=XI97)F\830%2K_M;UP1ZG92R:2($@79W1?'UWT\N,DG6=5_9COF
M5\OIMUZ?>V'T66*[EP^MRSH3G^OPHJM!-W>V-;"%B&D_6_X:: 1*8K>2HF>T
MG@]"\!J)),6A?_/<%#%P945##OFX-2H];7!'BZU)=GVP\+)YHG2%^&86<=)X
MEP>DLFNB)6-*?H59PY;!*>4\:2'5,Z;D5RK3^J#O8Z:S'* NP?5T=#OEG(CA
M5@SH5&X_"_=W8)3_17V<SOH+"@8%!E )A.]0XO0*R5$/=M4F_G-B^]NGO)?1
M^KXR]M7]$ E2-\+>E65PN:\,/%T*.H2^ZRHA%%9[0:?=G?*EW*W,AG?.<&!,
MOC>NQY]-EG9(-2T-$7Y!O/2B01SO UDP\%A@K=5HCY/$T+/I:5U]E)'@>W1B
MR(7LV!@MA\Y.^3+N#0+V2BE)LBLH-/U\;.0/25]-2=3)K\RQL-9&>JQ!@E3Y
MCH&L()U[%O'-T]4<?>9#P0\&MSGSD^4@B,\ZKZ?9J.T:&%-VKUB-9X=+RIP?
MOC3PY_!_I#:9<) !13N6Z/Q,JTS<>:^KCG7>IC0- F^Z)>W3_K&@67KIZ'*H
M)[# FFKG.98OQ]?#.LMJPSDK],M_59<S/+]TL[346IN2\$''7<."QQ>?#TLG
M5+$3)=I3=1*J3U,U-.D5'*Y:+"0ZHPB96'T,BW;!.\2(BFKXF[DN"!E,<I6@
M3W;/*::G&7;QB3+%1\]\>V$^,87K  R]3WV\YB_BR]-.PYU9U"MRFG-E:10Z
MB"-1#IFLQW>@*:5$D\7]840S3U"W5]M6N#4R;]!O,;KK%F<RF^9^MZ5U:$I)
MR/#5]BU&%'0V<H(D<5,>R#M%QOMSO$9,=^D;$^CVU:X/-@)O\ 0!WPU0\Q#U
ML.*Z#W'Y[&E$!R5-_J*4Z&;#<21>+\(O<M?U\[:OH(*F][=^S=D&X&($VY4*
MW%%D*S*9$5307V3<H.1YA5"+-W+/N(\P"BKZN0-(F?X#-#5]Y-:B=\H8XO#C
MUA6]S@Y)/]T6W0L729KC3%(^_&\WA,S2J@\'91M]EY:(6JB=.08/=UX9$G'H
M'-GBNX6RJFX"2%XGHT2Z"*Z/BFUN(_?.2249<.%HU\#-?)=K0#2N99_N[/ZY
M'7B@F;@+)$$3[+?^4\8.DJ+&*.MOBX#^)0J%,8T1+*6D''^I[TL(>&EW*44T
M'&XG1$6CTT4>5R:E^7P7VUZX8O<L/TR*@WUEBVW5FN6]9_MI+6'X@?PG=,BB
M*M:[8.ZQSUT"VKSW-:,EN\+/(Z2G_:#FP?+<NJ/#=--]R-VSIV(<$Z](MNH4
MRO%-OF\,8C.EJ6)/DJ2/<D.64^)R@BX?$=O\D2/@+3?+9$*)R]WYNST+K!8=
M1+3PBF=17TH_K6M/FK\=,8A1-G#OGL@T1:$/>W+E?==N4^Q (L]R!W(?Y? )
M41J'!T2\GV-35E^VLFS?GV-[-_ 5@H2B[:38O18Q+W-' !22V-$U&S 5 449
M+\'@9C7+2LD8 G_%>]0ZRYGYD"_QW7$C6&_^9<0TD6+X_7,_UB4$B@R#>F"/
M];X$B54EWTZ.Q]GUI.BK"^8O5VD7I/$YN=_2I7@#)MEL4H5T8 E/GM,8CKN?
M!G!(/VE&A&\F+6DM D$@<K2WC0ZA1[2?#26>-85Q9:MF\BX+(6UAWW/W7SX/
M)7&_14U_6LEVU8N0;2F7=+!(HB+WF>FEV*8<I;(S"4U+4&TXRL*U)O)6'Y4D
M50:G@GK'';N]*B-]B/-@GGX:$S2"M@6OX[KW.<;K_VHO))+E&HBSR_.;9E_A
M4Z \@+_*J2;LP8^)%ZNGF/;Y[=K!-<!9&NU%U@F^H6?;OMKM*[[$Z(K"L2JV
M!@)"?@V\\2A6AN+>D$ALX7B@,N$6ZL-8.*_+&D>5I8KX/COH6_R*]32P5V.O
MIB?*5,3 8*Z 5/7 \-UK3N688,[;YC XQ:S8!NCUM)M2)I5^9TY!O)O]%TV8
MY1/6.XTQY*?!*CB>>KA)\[KS?/)]D=XF342STX++H5K&1 ,T+VY>R-4 /B?@
M\!G#TW>4.2,*U,^+:T+$;+>47%(]AW\6I=O6K&2]L94S<<LG02=!A?.;QD;Z
M,8>>'_S\_=B!E#_Q*+SIOQA<$,R_$'22!#^5KLJ?VT R?X_UL'WT*W7(+M0P
MNP:T%J0EP4)(DQ%N>WN:8PKN!WUJ?13PE_GZUE2]-N<+NF\L,ZPR$YV"C*B7
MP2$GL3;$3@4=8SWKH2.N6<2BCWE%>EH4/E5ZG>HO:8Z;!A\_H;[;SC"Y?G5S
MCRC?I;B;>848P^K3V^5R[YY8^]HX*0>J,Y)%$W^Q&VA7T<F'Q4W/5(EG60K8
M_ZCQ.'K%^0R&L>+O=,EK:=2''XN@ DIOK;JUQU_VB60QVEL5N\\\.95384BP
MQ8.!;8_12HFK8XZ#YUDDT607B;0IW0BVU.+VMQU1*="CH6DJI.WW=(RDL6S3
MB9SX7QO$"'VXN'JR&;)=2/<3EC'<*HL.S?%-PA\"F(#5WZP45[;X="2>X!(#
M0<G#D/ G!]N21#GQ+5S_%$FZZYD[J^Y]7%11L?01ZIV<^E(MLNHPB\BOIW&N
M-BA;Q8N3C;.D06?FM/1+69FH+5PHZ8JVM)36@S97OJ]'@GU;_+9^;=V27.MX
M;WJM:$E&U+-F8<0#*>C(S@[WO$YAG60<:X2_%7IT#%R"Q-/%($1Y.B=V,3Y3
M7,.HBCR"C^W.?AD:Q3+-<-@=Q'28W4NH%4S>Z6!@XUD@3J7IQ]!V4PSEDUCT
MS %_EIQ_L)O55>P.H0B!EQ,W%N:SZ6:>%Y4];39A!$42[BO.;8ISW7=906_'
MFC$+-D\XG.YP#59EQKYWKIEFQ<F6_$2/R<T*(@>T)9;)J$:8>6_%.ITHN_)'
MP?6K+?,4V#]5DR()A% \S347Y'E&H+5-XQ6T2B]^Y.OF@.)="+]ZB42?2JRR
MZ06R&\O?U3XYEZX6?=J>:BVJ6YOG.?EW)M'_0Y[F7N_[>Q7ZJUF<;Q*3=2/C
MQ;^&11812*-W)FW2J$2HMT5W,IVQ*3%MZ9E%LU_WP@W+Z@F&L6[21!5U)TF&
MTOU%[A\]9=_\>E>D(*#^RIM[PUV?DWF6:UNCT!^:NCO;?G/MU_):2F%\/[NB
MBITM%83NRZX73GR$>UAL]8?^5 5MSTVPN6PFV"5-V\5 )7SQ)O: 7_VE%6@U
MALSV!!9<ZOS10#A2&*]A$:]TZ=MM97O*QC<6,8UUTH;$X3Z$Q3-;U4H8#W-B
M(]B&;:J6B-%M-+:JAMPHOS[;=Y%D&,[K="!,N#O/'RV@ZEZI>&C'>"6:5$]K
M-<6:^]I5$M/C7 7IA2K/?UP,/984#EAO_]!I99[*'X$N0+N!Y+KG@1!BO9FR
M.8NARL/-6\^T.7'6:P OAG>(.Q:(H<^T\9R$./CV*@.T*4>7#,?*<D^5BDWV
MD]M>:Z=*[Y7I]#JXD%HTDNTZ^C6E'#WT[%)EQ\0/B,0#WHFGC8U!U$?0_KI-
M\0\,W0(E<,NTEZX^#"C&HK5CTV\7\7]&RH*N**X^J"#W)+[X"_\(N;H[9K+W
M*A-S:,(<^99.?O$:$*GV:25J2TQ?J3/R^CKPP& AX(K2TU)[KR5J9U:0D+,*
MRZ2:Y($A"Y(M!ONXKO$::%M'LH*T9=OVAG(YM;A>@JMH/;1URJBEB5Z;:9.^
MV,OL@-G!9F>D')F?OBE@TK:CX50KLSUY]EP55/37RTC 72D!XZ[)W)1@OIBE
M;TV'Y>'%18;Z,#UH'?/CYRZ-_N+&RKY'QF%AGE,6E,P:EO%U;08FK?EUPG41
ME^W(TG4QN6<?6DX;JV>HD.DE;=SWTZ9'/QPX4(/G_DM]/=C2GU6+ZA^VQORI
M&#PMZ+\J;PWV%]TVEGVW0\JC]0C3YS,\BA?^63]#F'2?>/[6XA7_$59^]\&T
M1(FGQ],IXG.SAZTH2O2ED3ZJ>[[2/E:VEV<"U.W+O]3D41LX-B]]4$EORZ.T
M5QN;)["MY%R^]=0V^R.J0O6U1 $>(^8O9,2<-)[=L^Q_<OYLX@_95YL>+NJ;
MS5$E)E3QL$O2-UO,>P2+3#92*I&B:CQRI*J$;7]2>^/^TV'LZ1HZM/C^+$SZ
MJFG^N4VABQNQ!G=6[AT.>4#DD)Z1JG]D4%CATF/^9(Q"N=MCR7S%#OCR*YBJ
M"G>;;;O!=&6'%VLUU>&/U#[HT*%2_K%/U/SA4M]:\_"G:X 2>@V0S_K&3N:\
M)U@=QFKAI#OX.H)^DI^''<=F]<\THM'$"\LU)_@N[)YVV'+4=R4=<$]+SVK&
MCP6,5UBAUZ86P*RUU&"Z77>"^6%%#_'J%)3^?3*G.L77QV^+75LON=&977J4
M6+GU8!-B]DY@SVL7&S<%.%O;[A30D^MVJZJ+TKI'^8388'ILQ+0_DJ@/E5/;
MK@%<BN-2A!@/-R>&>GKQZGHM9'J"Q*\H<ADCZ^H9VN^LG*(2!9JA[>&U:\#@
M&M [Q/^+YIX_-6HD8F7\6XOXS[!R_V/C)Y7EO/:<QDU Y<CND _MDXT? GFD
M7K[UZ^2/5V6*ND&5KTV+3A4*$E];H6@;J.=0R5=0:[_*%D]D_J/<[SV-N1+'
MGFK"6T;*H;X'VI:D<B6"JHJ,H%?.@_5^\,6<[NLM3O\@+O=(D4-Z<0'&?ST)
M@-\=.\P=X)BT\@,&@9BTLDV8>M9P),8^_7&_\=+V![:,F[G;0&R0L;"/U9B/
M1/[@D-4=I=I;[Q,@)RBN<^J+.7'%6G?!6TVRI<^07%D-Q^Y_<H3WP!AW,Z5\
M+1["_;+0TX!!,2.G-?M4;1GUJA0.5ZOKGT\[<:\S'4@RI/]04E@(U_LG)]+"
M]?X'M];^2U3<;X'>>IFY-;-A!?*?0$'H;"M?_T]G@,*D]TK"Y'P2\J?(6X%&
M;ET#JIF*<;DH^>7+KOC'U!F# "-14MG]]]#[W]N@M\IRR\(T;A:OF;<&(U9J
MVO\M]D#;'TL%#="+X,Z!642(=1!\>(2]:GS3]KQFOKQD5LF-XZ%7)-9RQ@-C
M^X5O<D6ZGS&";D_$C+5:((S;TRV&->+T[T5A1,N??716!KSX[3Q-]9M&W4)9
M:A+CUVD#T\RTI24Z,DEFNEOB>/T:B516]1A(3]7*;43R>%6HY-7:[6;I5+''
MQ2DGC?5&N"IG 3-J>&U)<&RA3)[UJ.XC"0^J3Z6'_XW%/UC^>&SWNQF^9F'F
MO+VT9D6;4'>1F_*G+-J"&=96FAS7V0R1TOD[::2^UW("*;;:$KSYH4[W6E@8
M[B]NT[SW)3/?1T>?]IF;/WL?VLNTM=;XH%!&T,>852-<./$9E_15 [/W=XDM
M5'1<49K#][^5"OYQA1$B5+F2R"C1;/EU4D73XO1;/N8IURZEE$!<W)SR%T/_
M1978A20F6,;R_MA*KK\&2%%(_70^_<+ +Q3U;(LH)!$%3(5CZP&:%YW;AFNQ
MJ!*H9$!SN714<2"/RBW,6?B'?\GX&*SRQ%C1DW*+Y KUD\TP C:-W"J09J/0
M$*OYN^DA)_+\(S[2]2G$1%_V@IJHEC>-&8SD]^<&OSA[U!UD$5N!Z5Z(S!A<
M)B.# ;M;VD4;8!+HCLV096TD&V/"\IU6\?8O''Z=#'>:1]VH8+B*/5U8H/HL
M8BCT8K4E5"202'C(L$+CTW2G^BB\2;.CKX6C]+\^%_!V;(P&$ D?G*II4B8:
MT"]-1B_A=K1!7CT/E";!DFQC%:]99A#:ZZDK^6HC>)XVIM]-;C[*Z!.T(\E0
MG;6UMPWC;\W'(M#@EJ+0[V)@&VOFIQ'(=?Z0C-U'VV+Z2T_;_M+:AF1=F:3S
MM+EKO>;BHK4K?AE6H(IQ<:8-O42DN].\W-K *TEBO<T:KJ<+RN-ZQQ[X-V*:
M;8=?L6T(Z#F\J>"/P/?<V>4B8S<UT.2 (F1;\JUV\F=DG&SL0M+7Q,4=!OPY
MK&F2RKT0[L,[RG?T1;G[7N]][B'TYO#M/*S$B?.C:$<\5"(NT.>"Z2<^)MY/
M7&;)]\8JA^.+82OJMV@BLR0)H98$,H!G;ZC$2@WQ^4KBCP_70/'//6JE:S,_
M2*S/Z[JA+="$9L[0K-@%_L-(EGN]5QNH.L?\7P#W]+]U>G/^]85.72U6$E^&
MA<_"G_+?$&Z<LB+ZSY>[/#$VJRPBCV['LG.7W,A2)V/Q[6L _V1.K+NL'+K_
MC"CQ4#!,&(J4\;3LVG&&]W1^/_ZNF@2^)\2'MJI7&W8WT_6%+"\:4M/T\=Z7
M[&*CCCMUI@Q+#2$O=,8,#>17YV5-?)4A)QTM\@8SJ7)A'K(-"]'*@+>E_W?9
M=]F=UO7I$9'3^CH,M. &"<6%_P:V#_/S^("@ AD7!@GA/?=\5'QH&J-MP5VP
M9["I(+<7^"4*?.:@>XNJ6#<[@F*"8;(2ZXG.-%3Z*N$T;]^QCQOX--4/@_(A
M/(&';$C^I8?T['"9.'W77QLUYN_O:>YF%\W8P!Z/MKO9*YD'.UO]['BN2>W]
M4*_K.V"*6378MU5:6B$F?L/9B?[@QE&%$0_V:6K7S1&)4)X726/B#/SJ^2'K
M1LG6=O3I>>X([AO\,$Q +?41])U1A*[C@G48'K?(\VO@O#3S]%VV_K8151P;
M3!)D?X9+SU%39DPNQ=43P2[G0DYX>2:BBCT@@AD*14#O%2 Y(TX:CRH_E']X
M'E'A3KQJS*ZG,SN#E)?/G["K #N*FQE[4&\>599RG=9&B*;_7 DY\<>5D+]F
MOVQ'>/X :< <!7,:R)^:04U_?VK_5]FVGO@EAT>PT8I1"#R85*S[TQE@[XY!
MONH^*CGZK8J/8&=)_4*O'/;YZ_-G";\VUKPV4P4YXPSS[4)=*U2Z7MV+D(O_
M/B+%//1MV<P@<=B9%526MTXWG=R[K&S_13/IN&=IY^OALYZ%<@_8TW*'TF_Y
M0TT$][[,[K.B[ZW'&\3\EMMM*ZF'G!D840X&'&41B&#KL=);H6G_&?F.MB<A
M4TU#/Y6M/\\?FSC,P O/=Q$J7=IQGLN=X)ES)])$7>VU?B$Z[1+/GLV7A\5W
M3="+AGRZX<2AL/+NV5@]Q1NS-YKDU_R%">6>OE-NMO4*3S+>39LVW[L&NBDA
M7&.=]UY^?HW!Y733H]IHEGKM9<.6]10NY_2'LEO)^ 0F_N+C>]!^L?>NMXKI
M2 T)G8P);Z<0$^C+.67R\0RE[/Q32N$?6AD/9:>M>,@=(_EB8N<Y#O=J_I6J
M^">Q;H2MLL)S8_[BAM#JL?*K.SFZ2K0SN^K4$/LA7V-[[&_P]:@@<*)/E\DH
M&3R\(&,T524A*C?J6V5A5N\W>.]_J:GR#R:__KJK@HK?>DFBPV_G!$ S GQZ
M&;&MN?4;JK*()7^C@-&_ZOY//PD!F8>D&*F0UT+(TLZV6GX.,+V1@90IU]!(
MQ-JWR)VUEA%_&<=7[/^ON>\.:VK;]EVA2"<@72$@(!V4JM("(B @4E1 J@+2
M M([& 3I2 0$% 5"!RD1I?>.B/2F03HB12!!2H 07G#O<\X^][OOW7W.W>_=
M]\?\DLRLS&]FK#''^/W&'',LS/-A/;G2?'.EQM8;%^."9Q7T*<X3C=U9L]'Q
MU=Y#UN5PM27:>(KOIE9491L%HZCAZY:B#U2_Y?B4W6J7@_",!:GZ.BE.!N7S
M>Z]JRJXK0S!X9>Z1G.I;2Q]/00RO. 'H,K4..!:C7#F!>)C\P>]/ U$M':T=
M)$E8MY-S?'G9TF62M[G8E'"N[U_2CLB0LZ6 *[CT@NIP3ORU1-ED>H,(U8*?
M$S*@#WB5][ C$@?FV83,X2:5,3'!MTUI"E%?E#WCCF#KW*>)DGZYH"0ZL(%7
MRK."OG0O:)?V%1,B;0D2GWOU-&!;,.6:A:]-S"X=V]QN:MY-0;^$7.#>0E99
MXHC.R/:WSO0*-\2NNOF XD\5+M^("/'R=;.QL+EFW-YNI^N?CK_\E^TNNC^3
MM>C>[LAU&T/YF*$2!.-G<R?3&\_,E'O :O7,H)]]$Y$N7IDQO0_(EJZW&'_5
M"YH883U)[8;(NW!_;#*S .N/$ 3/EX[FY9-;*?SL@JWJ!.TSQD_^1=J9ON*8
M:QNVHD*31M5Y;HU(R:0"1VRA=:Y9>=VELO'6SEZM2'J:?UU7A4!TJH&(<EW"
M7%$_F,7T:$S,3F*U^.W632'2 47P,< 7GX787X*^1-T@W/G61'%2YO!)VS&P
MA_5D[^Y7T@UX=H6K$&#Y7;WJL*,3Y^:A.!RW*=".],Y^/!["\@AS,.&?"^].
MG#C5[!<,:QB&+O3\OKUZGLS@9"<4KSWN_:K^A0P<S-NP=1J1,AEFZ56.&Y*X
MI>4B,(3B7*>W_0XU-R["U>ME:D\X[Q0R-##6!H:<NJD4[L&->?F9FP,]0[FT
MU;XAHK^!+R0U;CF#BJH(]E "6SZ]EBK^_.S>/>I=^LHE2^ZJI(X,,82%9(/[
MI.2=Z3P/N@ ').V%$]TLF!=-Z&&9\$LE*(%'C7D"?A$ T(2?*T&IF7JZA)N.
M>$WSG-GH?X/]_(=J<6:''TI<TAQ?B(!&TRIOR[I(T1EUKI<QR]AZT %!1T5K
MK*E$KYZRQ,&2(U3\+'"I*2[RU/0O.IPF$21KDX,W-A/U2[;^O8X<96?#/>Y9
M]A-"+(QT#^MA,?Q^I_R]2_4E*L8?[(/D:!&:P!J)U*#38K&K(I;Y(3RCT#\X
MV<T3&#ETB#6G_5-[,6K#+[;X'>Y^%HG/'4V.G*_(T*.?$G^K_' FE1GT<559
M9%RVOD<\2)[VE(#0\/7Z5%G+&4OLI<C\NXI7YU>_OF:B=NF"RR]NZ[$[F8J7
M;G[>7LF[G73Z'6,K?M7"N!M=592M8.%XB<:E0=B.CV-].D2I:GCC;*]M!BMM
M"1(3</O$).=Y<-/;U"':7Y4E/Z_?T)^.S//>.ND&W.0S\7"EV\4!OUZ0)"4F
MQ+OVP\H4]3M# P+(N%>95@QON_U"L$0,3?3[(,NE#?08C:X(DA0JV>G_J'&>
MJD&G].N*7.J0&HPYL,=F8M0>4V(5ZWN0FR& N%'1<%&31W5_OI8##RYV."CN
M]"XMK=!EN.^VZE/.EP<X^P6J546:-J4,[_"E">V)2B\R]04@PA2M6'::/[MN
MZ,]<@_KMM[@B490CVU2FN^NW.C#=O)K)EZ$-RF$Q01FL$]O!_$2\B[:[E.![
M#R7(#-K1EGH7840&F:^]\!NL'GG$X71)OB"TXC"V]D:2C+^=TLKTGP<89VYF
MASHL>LN .-_R+QO>H2TH9UG8/#D<CREW&>SP:2C@D_WQ:!]U ;XOS/IR8:^
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M95$,76L>R#>=@I>90>6P63B]12^D0.)YM$>+G)Y^P(110HG[&Y$Y3>!650C
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M+WYH18+3%&_-OUJ;.CW07O>.'66XZ"'E]P%8JDN_U'(&+^_L^=FIVF/1K52
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MKP()<\$:A.EI;BEVG4+).*9-\[S,>(G[.&_Z]V+NXKVMC5=YJ,'#=5:0L&.
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M+%14++>X.;AO_1\?N&\ W27"*M)*(@(>@)".@(B. -<%@ " @(3@SP'\RT%
M2$1,0DIVZ3(Y!3Y!#2U 2$!$1$A,1$)"3(R/#<#' \1T)/3<XBJD5PR>DO&X
M,MP*3OQXB?=.93NCX0B2[_8SM]>7R9F865C9^ 4$A82O24A*2<O(RJG>55/7
MT-32?F#TT-CDD:F9]?,7-K9V]@[N'IY>WA ?WY#0L/"(R*CHI.24U+3TM^\R
M<O/R"SX5%A5__EI575-;5]_0V-'9U=T#Z^W[/CHV/C$Y]7-Z!HY87EE=6]_8
MW$+M'QP>_3Y&GYQ>U(L ("+XZ_%WZT6'KQ<A,3$1,=E%O0@(O2\2T!&3<(N3
MTJL8D#UUO<)S*_@2PYW$CY7MEWEO&R(9G[F-D#/Q2<#Y41=5^U.S_[V*O?YO
MU>Q?*_9O]9H!*(D(\ ^/B X  \>G0KE!Y/^IY \ H@SO\B2 :D.;M/\B[?_(
M/T;R_SR=HCB;;XOOZ=S"5SP36@"KW&2):?[X2S^2ZA]R).D"2DD-ZZBI\.64
MGIE\[O8>Q6WGA5WVWC1''R;-H3LT9D!*<CRU\.5V(MX-QVR4291>Q YC7JU?
M5#Y"PLIL/X#L,8HT#Z4(KKGW1D2$,40&IG=?B&CAEMQZN?9E(N(W2C4?RAPV
M<S>'O/EL+%H8?3-05"[=7#P3"E:?%+O<IA\UYSWW:7^*UB<;)BJ<S+Q&\>"]
MIM[Y;:O5!]& F1"^;1FH,?R/_!.)H?3\4($H]Z8RE_VR7F35]..^/+NTI,=6
M=<0[5P67+3V1!V=&_@8ICK?$F[ACJ.8\& ]I?END/.CSJ.T5=.U?SD Y,2?$
M2P=QD>* %2&B^9-M2VZ4?)?WZ5"4D[]HP8^1*);+VF<HRP5U4K^I(-,<:+R;
M3V&>:_9Q$=&7D*6LUS-F4;&?=MY<$7P[)^FV0#,A*48$V6R6A;[:G]%VO>P\
MO[W0_@U6J(V$1BD+=NL*OW%RZN0+P)?#)E1&*-]3WJ,.'VWV^D6 :E#6!TPV
MT2:5LS@ 5BVK\ OTO7EAO:/Q2S:#>@6/7B70Z87U@3D A^]XM,*G:6^2R?!*
MKEA=H16,K994_IS[<(G&VK(]NZ=Y&1;(/'Z4P&#OG>;*JTI4[&;.00X<LNNA
M#T-QP)@D]B'8+'K>5#17'?X:<#TLYT57+<][=Y@@R[)BKSJ7#\KAK^UG0!CG
M@95()ZJ_:T_!SHK[+=&!W[G()IC*LK\8XM:S#SU*ZFYHK28HT='2429A,/@?
M^6<1[H)\"0)V'%#BW$(%,8YV17U'>IYAL(0M<V6JU%TFW/;(TXZQ[J_H8)OT
M'7I;D2S9'.I.A?4,) V[*CBT5=!L.^FC5%+%W)+'NN3>R?+"UZ,A&OL%GDI'
M<S2]&N]K#9Z@:V;HIKO9.CI#.Q0!341/>F^)]&!'!!,"1;K='2C3TKXH.2^D
MCK=]B^./N>9@4LSZS(N,Y=3$#SYT:=.2I8;VI_+GGVOWW.R('"2GZ85@WX%B
M&851ZZR4''V":&&['&*,8Q]604B)AB_X#41RFZ7\.GK527$HU+^>VYXE&\Y
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M/-VYN>7K^FAJD1 C[RX_0'PP&[ZBP<*N9H9RZ?AYY+@VX>$7_G4\J/>%C&$
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M]RPE7\^/^NO>I!PD#DG?58,J.^MNG3+ HY(/]5U6V/K*A8Y'S-'-!\I9C*Y
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MO89A85L1W39MO#;RU%Y7QX46=*TOQ&V8*\2+/>PX7$ EAQ(\X ZZ)F_JOC1
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M5NV1^"5A# \!6=+Q[VQA'\L9+4L[F*E>Y'M+,."U0.JI?4:MGL6\;B+#N$=
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MY8HX([[&=L:Q51^]_G<QMGG_[.CKMD/CQRL*//BD_:>FE[M>@ZG:PA?%XVA
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MM!RS/-F>GAA5CG-"R!8:9G8^C[Z-B-K?,I^CP?N1Q5$U'J"P+*='>[.RWUG
M@79%<K&11U]KFI@[V1"C6CJ'N7/5ON%1=J"STT_%T9NS@G3$%F*3^7ZXWW:C
MDXW&FFX4;" =9(V:+I6Z -:U+ZX@/LG[%C@^+W:PX!U]+'SS_2^/._6SAF_H
MVC:AM!NX[GNUA16N0T5FGSW/=3 )%YW-_/39RV7X0_'BGN/@<WEJ'^)0SS[/
M\4?-(WVOR,Z."&@WJO2)7^NAKB'6;C-Y9246QYOG4H7=+!$P/<7,9_H6.[>
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MJK9HX1(>/]J/_KF36K':H$HR>/,\F&H)SXUAH=I@6?SQJC18P#E_JOS,B"P
M_2*=ES>&WV\=-5HR=TVU+S0/MV5I1UF<)?]L.UZCQ#6[5/D,V3C"MRDM/*O>
M]:C2!]B_%R)XP+T;R%D\>75W\3#';/HBCTT4"!S+WQ[ES/^=[@@X622RQ7@&
M?XF 4U*V=2X<FY3Y:A$5)]ZS1S.([7J\+8OC;#R/.ZG1=,M$\%3;VVMM\8QH
M%:Y[#4< -\?Z'F:F^[W-$_B&Z"0<U7.CB:4?\^.TF4.=:/)(95FRX[VZL>8L
MIQ:L\O/80&AYYZ;:NWV^"K<4[_H>;LBC!L!?8_B$IS/?);J<4FJ$))9E_!MM
MR3<41;'YF6=GUI&)PL.J"\BYSNF3HU7T]Q1[F>12[;FM7.,%NA6"',@:CP^N
MN6V5V-Y,$O(L6AL/B#Y6%9H[HSO[(BP)4W(R*&8X;I7N!%N]#QO+<O6>\Q<'
M[;L.TSH1(&;$O2X\BK%0 T>YKQL$<F%O=4CW<_%'J?D9CU3/(:3(IKX9C?6^
M'F],VW_[R;:;;_%K"7C)DA?F9CV@1$69C%[)PK]0?Q78>:NAN'C :$\9-"(M
M0^]?%B?W*+U:?B%$CO:#:5O6&332P(C^!A/C_4*^X2(.6#@F8#)HWT5([=QW
M;0;G;-SH([^2I0OC=UX-BWZ$R<H,U.)&7\ZZ4&YJ#FH-)YS9,PK\7%(;X*D"
M"F H>3MY<&64'779RN+[&@N3UN7'QX/H71S,32/L<!M.FP[:N5\J]<ZKO[AX
M3ZZEN7@\*TQZE;4C<87 %L91X9VD7+GQ%"77O% C!<5KBU>=KQ]%A^N%20GM
M6/@]CCH';=>_(TB>,%#YDNC;1"E$/Y=P$XQ6$8AM3)9!.#*\Q-EK!TB=W)U@
M4DFGY-QA:7@-<S,JPXT0BA6RJU)OGF-,^KB5.XJ4+9S&K^N.O%+?%Z'+OVQ#
M%;V331?C3+BVDQ[T'/SCXYMQ%?;%CAB=F3M7O[?Z&=9^8./$65'FH1LT%S%<
M*67LFO=?3S1$;0YQ78BM00=YZN+,<(QAF,@%LS#^FC15]G0Z!@?RMW4#;UWF
MZI!AQR-MSG=]D'F4K/S$KR9,_/P[K'B$??CAG?<M7(W7ODL]P_GDG?\T/GGQ
M9L&SCUQO3Y\X<_F*4<"M$7T:/&2M7W6D<M70$$+TIL0ZISHG#:A8T=HEP8NM
MV1JS'Q")2[[*;9-BEID'&\(U>,>\%06]."7SAIHOJ8N^L:+[U45*=*-Z";?G
MLDZH\J?F+9F8QZ0UK>5EKO3<M6YCF< 'SURO&3H","[N=]\G]"1_X"%.'M2\
MA<QD9?_LC*M7_0<'V0'Y#IA^' -$Q%$.W-[T"55OF@AK:O6OSL&=UALN>3WE
M<EILH2L/\'\+QBV!]Q_MFH9^>Y ?@WN-%I-D_Z0Y-6E?$K"EDDM=,BSX 2&+
MC\$NZY_4!A7G7;TU?'O^XIP4V9+B$>#;](X- 0SGZ3K/1</M=E.8)C[L%17W
M0CM8RPA]&R>%.)0^<_@H>)<BT/UM*=@)K:)EH\,<PZR4.YZQ%QW(!ZET_&\$
M]'!8X)5>UIHX]&/?%>VNZV=3<]=$CK.$G6WEV:(=?P]G#E0:0%H\2'*ZH!/U
M>96R;L^15.4KT! ;EH7..C7^9>S<1CJZT=*79;F1 R^/+KG25BV;I+'_T79R
MAGO%^GDAS$USQ-YLO7(_(((UY^I[GDJ7V<AQZMG08YJ/:'*RLQEEB<LX!]HZ
M#'K@3CK1)MO:M/F)E%NV0<KH,U62DPT%4IHR0^E=JT[D>X.3W@A^+&/;DK3;
M60YE8_W:V$^*]/VGR#GG2H+N:&H*1=$Y3"0# K7,9 M9V!SD!=A&_R%6"([6
MA)D2_++V9TWS?^1E,Y*BF&QHF]T%^'JHY8^81D:'.ILGXFM;/;Z):W(1,280
M+81;?GDXQTT[ ZI/3300MC;,"?&P!ELE'BE*Z"41N\7I!D4"L]L3^&+J$=!X
MW-]</6'QSO$]XV_DGQB;9VCF#LU(C\'8G$#AK&U[ IYE:<N JMOF=#!7QNEV
MDYUQ_BP/T0I-6BD/)LDLIZU#UMF:<#$I"Z&UV[>5$H3<#>QDY!'F,%O/YRKZ
M104 T'R6.!JUV;]V)WX@V$]#=$.)<)D6&*J ;O_$;&;S4QP>0#"/!AY7KFDW
M&7+96DD9"AX^*?=T[IY&D*?.1?5^9/;42B2P*4B@@IF]-I%(3SALT?\%">L,
M#< O[D!PG=;^MP%X@J!X??0A52NK^9-<.UVVLZT,VVO))AN=$X;5SLZUB0X6
MZ[S1CU3 DH%@+'\R9KY1(9'I=OR%KY[C#:8D>#P);TEJK&\05QG<LI'<5^CF
MN+4H^K54TEPM#_#+^GT8DK]E%/ZKAHA# BL$ZN--;5\Y7M1];=8CE9O1*K<!
MOU:#G4.+I9; 'BAFW!N]6:I_ X:%F_] Q5C>'F:_KJ'ZQ("JZB?7F5^YXO_@
M^A,HQ5:B:VAZ!,32X'35FHW;<&12>*^)I(+4BY;J/G-I>PLY%]5M?%JR+ VH
M4M6P:FV,%/<'3EY[J-FR9 1OC<$B#C:A/YH1NK\;$<?OT-U -%+C[PFSS4?R
MV%T_KZ(ZVF =OSD: M'&/F_;]6;DE(XA9#Q(X;%Z-<X;?:_A)8'9_@_;:6.7
M^:K"6'KA&K#)B#?,9"$ZK$2386XB6<\1H$2T7^&APFS&#(A@H$C99R^'A0%1
M_K0[LZ<X_>3ZJRSQ'MB7.J-(!5?I*#.>VID8!(A!8MT:C\N)2U4+<E"_?O9&
M!^!70%*J;]01P,G\ZR!R!5940'=__>*0OIB91U+K)U9,SHP[<24)B6[,-039
MH/+N.EES#$JG&EE=;J6-X$6;H>2R&<6PSUO6&9RF3P^YK>5  K'A\'CO$@3>
ML/'W$;!\VQG]_&7BBHL;>Q>S+4VDW+&\/@D5D/VO_677X7G13U?OVCU]?H,O
M\&&#3GI6GIA<ESFP*] "9EP847(7\5966%#DZJ-5NG*62W@<3M(H>)D$RF#*
MV8&:"\!T;9$@^:<_OG"BFJ+_,D+]UR%*-AU-E%Y<BJUU,5./&7YXJ)N?O]FI
M]:'T--J^S0ZU38O?GN!XRAMS)<4NBDU^L21(O?EB"QMS>Z3<KOHQHIO]RU<N
M_JN];BW_J5/3I$ C_ ,I+FMJ+T7:B%<.+;:<9HM81-&R3*0\@Q6Y[; !53S,
M=[8I'.$E;+;.?3=C[GB;YB6&XT[$_<H?^@ $F\_^&\/2^M-\"(DD M,>#*3T
M=!47?%E"B=Y>7)TNXW3I#:!'M##2:3ES**DK"@K,<SD/ZYR2=!64]<=DQ<IA
M0I2Z_CR./[Z0K7&]@,]4$?@A-&NXEQOME(V%9N#87N##,JC]$^$B&V]R@2-
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M]J/T.YDNV\>M H9G0.U_]U;K7_0/T[]*N?P#!#WZ\K\ 4$L#!!0    ( ).
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M]GE"=)Z6?]%LUER1-SY'W&^2LNXC8T6Y4NOM5@K8WE7U;U=[2[B"]AY(;00
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MFKNEX9^#@3\IID'4&-'J6$59</D<M6)?;W2.0:2!9>0 1=#&8S1O'_A.@L7
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MV3$S;RQ;U0.R_/>,#!--:E)/?[ J%2E%")5$3</O8IR7K.'&,DQ*KP=NNW\
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M6_EPH'=8U(.MZ_$;0&EG5%D8DOYLQIM#3%0"Y6K7],KZ^9I'[TL"K/%!7Z#
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MBBUR)A0I+TUJ_? UP??DRCFQ!_9L6 W3V)R9/65<_ 298V=W]V[)AK$W4!L
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MYB01:Q;$>0/D1MX '=#SDU5.SG%^#'%Y(_6/TMW"#XO3OZ'=!5.=&_M4/V^
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M83&C@XHLM>8IA_F&X*L60"82>+>EB+@*T"763)_7AP,6H&5;/2M;[,N-J8]
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MXQ4;[N.VRN5M^%X?)#&$J_1$$>^1U?%.YWJ]CP<"?X2O"YK6'RG(_&XHQ)R
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MADB2,[20UR2G<.9K/BC0B3J^T$X",5#4'JXGW%2LW@$H0M0Q<>2NS!WL2F]
MU<D&5\;=Z: *TJV&%U5_7KT,Q>MT]UM>&W_T#*Y&GT$CY4ROJ-(24/Q][E7
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MBP%!T[F:BX2W4$G6'- NK>9D;NH TKS4SPRKOCB;8(2Y!_8NF"16M3IB@:%
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M'SI^B<!HN[R%UW#<4XIVCQ!YV%/FX():""_/Z5"&[$&FTE\#;A;'5F@?6<!
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M?+\UCAV70M/D2;CM>KOUFN]L,E6_U:0P*)*>0I\:K;T&_*1HCPO^&2%XS_Q
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M6]L6SL^EQDB]>9\OIH2[IB[JD;^3_?-C2TD#E_L]/\>1W#2%QS$[BL#SGKG
M_?9!'^+DHAE;0=)%/?4J:?C#L..C<KYJE-1[/U > ^_6&(.@M?SH9YG$4^+;
M4GS&R4$8CG<K_I)Z;I?RUQK_E[ EN_0YY?G$1+36;+=V6LYIP_BH'&5@_9^L
M)LXC+*#P?^ESS#80,<&(0JM@OC%WZ<0^(P*_Z,^7C5<OP_%F&P]'+CDZF_&Q
M@,=@'2R@K J\(5^33_FTC9D]WCG^4*(GDF,PX)E7MAYRU<=YS)&H(?&S)*FA
MU&<!TJB$2M=D]H9-'9! B4UR4AO)GL#3O#F/I% Y/V(Z!N>Q2DE:KZA7T\T"
MWIZ%"S2(6/F[<Q2OS4?NEEOLNOAGM4"DLYJ99%&G,36VJ:6\W2&[\+2>G:*L
MQPR^.//NI4 "K].N6I/G:C>[<I0/)#N4 1K'<$=<9YT-);+B[O0^.>_A+D?&
MA0VJ>]:T+\WV$32<T3O#TGCERNOE&! *K]. N:]4#@M@ G@+/7C(D["%=Q-%
MD2VO9G(1^RKK*\0VJX$D]'SPJFE%<5^ YN?TK5[N:I(U8_^7"5%5_-&?$D<T
MY2B9_[><L:+9D ']S3J0<F8*=8HTB6Q@2I7^.0+S7H#I_"0!"WC!/]94D0Z-
M;T<E=U'9P:8[/PY7+Y_)R$/7M/-[C V&=$3;PF@7[POW$N=<"KUI  *\]J;;
M\XX=GN75'\XQ#[SF.9O*C\*X+$I50%3&W,02'GSD<6GJ/YQCN.7A*^#KDF:3
M7;/GZY%<:+AU_I;JI+21)MDEI<&(LJ4;VKD?,MKG5C2MH1 B+^XH@5-&KHS$
M F+$S<Q8PZ7J'@>S?(8O@@(D ,MWV[6 VIZO2FGV&43*U >@NC[)4:LC=C!+
M*UGO[^F !_ ;#6 <KU1MU.TOA5Z^FI_+LG'?LD"#8\.$CV#-B!?(GOP"]-BV
M4NTDH9 3GV/]?*<''5Z^^&1/)&C]R:O4&H@7BC@7IL(QIS/*;U7^#7P\)IZI
M['I, ZN#<8UD*S89O=?S83R&2Y$C)OA+M3N3"OU%$T/(9.E+LF3NX*9[8VR!
ML+7=A?P0?F_.O;R0F9[U6)D<3/!8_LQB;\#8M&6QI@F^9[;7L!8R"QUO_$9Q
M)9)S\X9B_QQ>@.37[2:T&4Q-UA"9-NA"U#U9]4E&\?:+P/= A#8[&\=\P93]
M+/2;IHE6*PGJ29VK-QAF;P-7H;GL\IB^2T'BY[RITTKC!=&&='L&,-2W"M7&
MA;%Q"!X>?.2EJQ?)WZFVY_$UUI*(C90H*%'[.W?J&O ?8 'ZZ%<II7CGPQTE
M_UI4-0>ORE&%[")MDU?\. ;_H/*-BM]OY#X*+<8"3(:Q@&\I\R40BKE!]Q5_
M90*O6:6<P$E->25A?CCJKBG^LL_]Q!,L('1VHI?DBZ-H+\DW +FA@CX6\&%<
M$YF4V*RT!A@OV'$-(EF^Y;9$B.$#.ZYPFG3J5*1/[GWY]*Q YZ,.X:&^%*$X
M0Y%U.G=]TP3_YNY*B-[+@TR<[T#9Q2:CJ1*8A@\'S2)C>">JT0L54U5Q\Z#8
MY'IV\=N64%3^@0!8';E>B=>C=$PU7B87]^6S$?50A_"^"HJI0_04\]@)'25;
MYQNJT: WD:3+N'"H\L75<<2O5,$A]YH;=_!"[7KDU7KWI]=LHG21"Z?A5^2;
MSW\1C4M'L2:G.=+Y@ 1@QGPPO"C^WK(:3H%),V$5JS</^XXY^C"V;?=-GM:A
M_?/;L^XLM\52DBGP?EP0<VTO\(C6:E ^2/ 0%N,.3TD*SH=F>25('W)JBK>4
MA J:H5$F@=E>$+E6I$FF\PI:=Z%TV<.*TJF_W>O\TO:V&KB;;Z,\;TOR;F-C
MRUL>NM*,ARSF$E*EUG["2(&AX#R3V@(*%;^[U1RCH+&(^AH/838V??JE]D&N
M88WZ2>[]!['>G>]Q@YV-$.*T1P3@L'/*\G#U&LHFSI[=_B*G(G]IRG5X9SH?
MDKC)U77E0M;?WDD1QYSKSFXB7K1%C1]'KA?B%4K+5K0Y?O/D[+:B(D<]R<I=
MJ_36 S,BB:GH<D8LH,]L_,*9ZKAHB9PK'0Y[UTQN,.!.>#?5'KYU1O- =SJZ
MFLCD%!83<UG[U54@Z\ZI:EQ\-H/+M00!@VHX@1HUTVY2*2=+H2\F*T<@R--B
M+95/8??/8DU[R($PB2<<MMPX6Q[:'0K)[#^\&)X[U6PQWA!:0H;^>I)-6#&?
M1?DV4;D"\)&7I)9C6%L/75@X;V@8([(K7@OHMY]YA04LLDR7ZW'._NJH&X*X
MW?..C@I,Z2\^M;-5\IU^=JU=A]S^SH/YO1>35:A]J3V"J_/'CZ;^'KR%H-3S
MFREVF7H]WY^;_R*/W,7@/]/V8E:RDK[+.7*/1#:R$I9!/(?.D$U5JQ?S=($L
MZ+D)K.G>7R)MOA.O9WUB.GL_)':PDH;"-YHT<B,FGUAGR-N$?-WJV!_4=2X?
MY>MH6[!00C9/F+>'@[']@)[=9@TY0L@3ECK7DX[$Y%/&Y:*9NA8Y4?0&PY$W
M#3NBZ?K?M3]PTR!Y8<S:W7(?"]!!KL6T)IL+#"A(*LN$A&OD:%)2#[)TJ&L%
M-XJ"<:^]VR_73#[-M&4[T,K#.P"[Y+K3RW=G^H'[6BS;K&5XP!-K [O[]Z]H
M'=DI?^66S*?Y'H+\!);]P8:HEP&/4%IG9M2\'9UX3AL\ORS*V.35U3ZNKE%2
M0("TN2$A-<V@Y%JDHKEIDM*-!&B+-TDLAKEPHS$ZG2UEG4'F%[#9L)_N#@E\
M/'9R$J.&?+7>1M2:F1-W,N! *WZYM@MQ'G0^_8B11[U+H^4\^?*XY?M'6E!(
M@H=4,] @11?XA;=HH4PW-M44'0Y::::-B391ZU[:DS:)2W.-/#R:Q(A8(\\/
M.CB^L$XY/A^KDEEP37,HMQCW(\B172GF9-:LB479GPT@Z"[B(A$8>^2I I#
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MNKAV.#(GVLB;13@_&8 CW;K9^%68TD"5U)U@[O[&)5JOVZ;W;06I-@L>5]0
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MHY8]]0_)UN.TPA:#7V-\!ESYYG+>,4L0@<\!K-TKJQ="OPS>R7X>PC#Y3:O
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M3/&H6P-94H8O(0AQ?9%SI1N@UAQY[M.6TAOX<J*\VH6@S[X0T=*,A%@RG'6
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M,:M^G$'A(]H*XJ=LB?)>5)+.(^\.H*&8NEL &^,MX&P:5NK)3#GM#%IY-.<
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MB;GM,N'Y HI*<'S>L-O+GJZW)9R%C]W5;:?CY(FRO'C9(&UL.V\GZ!Y 0&.
M"*IK$>0E"E98_GWBDIY+:RTY,XXLZ29?XIPP4&UT87@6VW&3ZU$VR+Z=%/W+
M65YKX?0>@'DKF-R5DF-45PYC?Y_=NTF&#@PM$N>"'[8(KX$B#?=DP"*ZV#T&
M3O'[*<?L^7L#9*]SHA"P+P9],N-X"-"%LW=ONSN8>-=(*-GR+C5/_X_C\L;;
MRJ,^_B\1:V43'X8/!R6U_,V"*W+^@)I<DX3AH<^<Q@HOR;:233!R;A1O")H%
M6RMWG\KIKN]AH[3V-3]$*O($L<L9I(T%B1/F>:H*"7TW7I,^';Z-/[LH;:?R
M%7<DVQ>"K6N0+RD%S9HNIM&>#Y3OA8EL^G_<B&Q\=Z>FC)H8+YCR'<GX9&Q\
MU]C?QH75D8$KB5_;'%01!)NC,V#B^='G-U;F-JVQE=@H_YO\Z#,]%U*G8/^R
M FS]^8(BRH69Z>C#<43TMJ: 6F!=DO!OMR([%Q,!"S+ IPW7,;:PLSW.UMPR
M,[\$QV&F0EG<'-P<@,;$O]G/XE_T(]^X!U"Z7M8V3/J^04L4.OGFW.HG?]+K
MW6NU/_>6^BC2I6"!W3+Q%?_LA:#K1@X3IWP*ZR*A9KC>A+T@MB'?"'5EOYD\
M4PVHUY\2^>7V99D14EXWI@^CX.!@D3\#\N9WA2V6!'L1O1YN6F/L"DH":>GI
MJT>W!:$"T>Q.6'#R;U03X4@N[M/TTC\W(1AS6BW#G%S"L]$93'%7&>,B_CUF
M=_WV%-IFAORYJO)&&H$!@XD]J3TH':^BO;9@>&-$:CUZR)Q1(T(VH=/KG0$I
MW[G6SJ)%3N>$'UP2060W& J>0[R\Z(+;5\,;Y<S#U>JLZ!=@S-0"5=PV>/Q"
M +K]"4EF3]53I8DSKFZ\3U$3/%N.1WQ1_->P-YL1<:\,1X0L/>O?-T[<>H +
M;45_ NW,196)4>0B\P;6\JW(V-5]FAN0JVB-#H-U0P(^YKNGC:U(LFURN,3,
M\&<YG#@Y[)P%V+0)H2_]$N$$-=0@6M3VA\(]X 4:1%IO)JZ S'XHCT)$[, 8
M[A'\$9[_A0!",;SBD'@/:.DO<Q5(U+]&+:M4)1WM2=,2<UB9>3\RY&D42]]E
MSQE%"8!*+%>_33&Y7*3"T.W.YT11;N.>S JH'GADT$^CJD_+;#=]+?-242;?
MEXGSH>4)Z4*_0Q)*7W?L2%QM(RKL .P _$=39*5WLX4YG* 4U7</;DG/[#_Y
M)]@8M&?B&A-2]/PYHVU/D&-N((Z3PY?A&&.XPK31F]>P L]S\67TO4&Q[CM9
M9Q-R\5=S&5$IK=F0.MWT9?:-BGM *>XX/.3[&J+_2T%5TKOEO,8P"[8XI\X'
MS:R\I&0M>FGP)0?>IB[<?2B8G(D/?,Y4L0>>3>&9Z2OR\R&K[=FOM$Q'JKZ>
M$_.&)2 =^YJ2 WTE7H90*#2D:GRU5FC[4!VGZJ*GX<G0[R\T+3E?E"/;'.-
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M-1]"0&=V:1O=#.6>.I'4W?$QD/>+3&9I.4%S6\@$G3R&NB&X6\7!WJ43>K(
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M?JV0T.)!PPQXD^HR>?R*@+HC>)($8\U1Y4 '?![586A:.V2^:"?(0_YE-T#
MOE"-*2G]A+^HAKGN$K$?B0ZX0%7WQ$_"(0-:G.]0J.@M\EI,3:DW-!'1B>1[
ML?+1)!M4RKK%W08&8/J:^9561;&O$"Z_;%#7G&B9/]1M^Z!Y-8[-6%96?]K^
MW!8@8 2E]3/RJ#N[T8ZG[\?XU/");"7VG]D;8*EB^F&H_XM!_H:<S5[+:/W
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MZ@NI0[W_+%0Y4-L9\G7(D8E?HW<XCWKTJA*CI>Q'+$<I=4M9NZV[''[ELRA
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M>"_L6IR*TJMA')R5%:7TLC.4;.[,FV6VA_X]D #-D[?2F:]X86^U(WUDBJ'
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MD/E*W(]#6MK-@NHV#*3\Y^=&'KZ56D66M2]%)E]C#,3<Y/Z55U:SCN[-HI"
M,<&J?AN\D^Q?9[XX,3[ Y].U;%]:M<Z9.%X8#<F.X%3;E87,?19+F71KS2G/
M[^$;HB>]4/#/B6X:YDT_49&:3/[ICU^E:&@:B#J,(D0!I 4)]Q5K4_#]A97C
MZWL;]T-YB7N:VNB"_K&F0ZF$AEF:-5PPP?O58L;.WTN"39^[B R7<UQ&FZW>
MZ[KB7$NZ.)7Q'$.U;7CC58=/TR:&6=5FG&$0=<4<C5HA<T]+U^SU.^GM+3#&
M/[S#G-:K(OE,I7>O<5QGPWL+6UTI[B.Y2:XG//JGL:Z:[U6UL)8X+E]LT[[4
M -3-6E9 F33Z?:W,MO)+'N>W^:,=E/TK/O4U6*Y::U8-$W)7'2M:6:.WC>5\
MA N6:L_2M274H))-NQ%;KGJ*2NM1%FVMU3;<.J"1Q\V!WKA/&%A<VEX9X%8I
M*.67L?2O0]I*YP /0^E<UXJ@NYUC^S_-C@CL/>JIRM*X['G^BWTUG)(ID8Q@
M<UH+J3V9'F1>9;N<@CK^%/O(Q&IACC"[_P#6/CO264WE6ZVE[&LL0/R2KVKH
MW5Q&U9Z[;R,$7YHVX*-5ZXLK&.19X1B1AGZ5SHTV.*Y6:%MRJ<UNP7$=P WS
M KP<CO6,]-BXD\#!VW$\#BMG3Y%D8+D(W4 GEJJ6NEM,P?>(P!^=;5M:K @W
M8:0?Q8Z5SE-JQ/Q2@4#GFBF9CA]X?6K=4U^\/K5SO0 4444 !Z5F[@J%B< <
MUHGH:YK3;Z\NKB\CO[<0QH<(3W% &G&ZRH'0Y4]#3NU-151 JC"CIBG4P"BB
MD/3% #2 6Z].U/%1A #GG/?WIX]Z  U$+:(+( #B3EAFI:6@"*WB,,00L6P>
M"?2INM &:9/*L$#2-EMH^Z.IH =2'\J;$YDB5RI7<,[3U%-?SO.CV8V?Q9H
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M\I6N+A8V/K7/0?#FPM=4;4()F\S.X*W0&M*7PK!>V6RZ=EE!R&0XJI>S8M3
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M^E0".-Y2S*1(P.#VI(!;B^+Q'$;!<[-O<GVH-O)%;DM*^UA@ ]JGB. L38)
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ME)I]V>_I1$\5L8T8X'7?VILJQSAXHV^[R2.AJTEK ]JL4Q)Q38B*>Y@M]B!
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MA-)'&>"N.35J6V$/S[4) "KGO4+ZG=(H\JQ<\84&G1R:D^TW%J@!YP#RM&K
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MMY+;H1\FXG"@GM6E6>RQ&65[E0 I^5F/:JB!2FE@M%W"(.7P6QW%.N!MV2C
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M5L0,#T^\,]:49Z)+<+&GHW@VPT_P[-:VY$WG?,LC#OZBO,?&&C31:@MG,^!
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MW..>U.CO)[:&1GP6)PH)ZT6 @&8KF,-(4C7HM7IH+>[NX6+(>-I5OXA4$O\
MI$22856'WEZFG6"IYH7&YL%E9A]VA[ ,N)I)%*PC:8VV_A7BWBW?#XFU*;<,
M^<<'.<U[3<W$=N2)"S*QYV]J\AUBP@U'Q7JL1G6&.-V=&?\ B]JY,7\*.O"?
M&SG[#5F$RQPM+%([#&PY!-;&K_:FB+?:G\U!UW8W5S?AW6+'3]?#W<!95RJG
MT/K767R6FI6\T$M^J32MF.0#@#WKB=['9I?8X^_O[Z6P\B2Y>6,G*AFSBLN
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MK-_&M1AE2/6LQQM8@]JWB<S =#]*3.<<4BD GU%';VIB'=J.] )Z8H].:
M?CUI, @@]Z7OC]:..01F@#+?=N8$9'0"H8_W,C-QSU%6[B/9)D G)SD]JJRR
M#85D0@D_I6;0T2-'O8@J-C"I[6W6$'( )Z8["DAC$TFP$<+NS4%CJ%I>RR&T
ME$@B<QLPSU';FA16X-LT(VY(["I'C$B^GUIH4;RP ^;K[5(.^.M:$E4A]PBS
M@>M/CPJ_.!N7C([T7+,&"C&/I4;N91CRST]>AJ1LL>8 /K50H/+>-FP0<K4L
M"L8F#XW>E4W9MY0 ,1Z]J3 FCB5V5<<^HI]S:A@J\X'4BL^WU6"74)K2VD!N
M(@/,4?PYK4>ZB6-5=AO/&!ZT:#2%9@B>6#\RKWJE&=Q6-L'W-6;E P+[LY&!
MBH615; ' &<TF"+J+A2 3@=,TV3)!^7MUI(>4SDX_E22$KGG@_I5"(UVN,'A
MP.M1E!MQYF&/<]Z4J.6.&/;FJLBN\O+<#BH;*2)85E#L95RN/E(J9&.2,8R.
MN:A*S;EYPJC\Z%#[S_=/\-"8,EAW.2[KL8<8SUJ<')SP,U7RS*0&SG@<]*0-
MA@H.1CBJ3)L7,_6D(YSSGM2VVTN0W"XX-(6 +9(]CZBJ$6+7_6<]<5>%4;;A
MU_3%7>U#*B+1112*"BBB@ S1FBB@ '6I:B'6I:0!VK*\O[/G:ORALYK5JDRA
MCSTSTH \VEM9="^)8OYW5;.[).3V)KT.>3_09IHF#_NR4([\5R_C06FHP)92
M*N\.-CCJIJWX3%]!926%^I8Q<(_8BMY7<5(E;D7@>*>/3KF2Z#>;+,S<_6N@
MO+:"Z$8G0-M.1QTJ556,;4"A0.U*Q^8'U'%92E=W*&@MP H4#@57N)&C60\$
M!>*GDC$@QD@FL276[.TN393,=Q/S,:<4V!DWVNZ=X>NXX'M3YDO^LV] *SKN
M^EM=87R"'M9OF7C@BH/&OA^[N+Y-2M&$D3+M8$_=]ZKV>L6B:7#I[1EIX1\E
MQCBNI15M"2;642XGC-N[1\<H#P36>[7]NIB.\PN,,#TJTDT,ERCW+#"G)P,&
MMS[?92VK6ZJYW=&=>*K86YS_ (>TE=3N#&Z%$3H>U;5]X'-K#+=VUX6DC7>B
M'KD5?\-361OY+421I.O(3IFNJ>-92ZLH#$=364ZDE(:2L>):?=W.I226\X#>
M62Q+=J[G1-6E<_8Q^ZD ^4KT(JA9>%9;/5+VX4>9#/D!16KI^EVEE,9PQ:51
MC:>U7.2D@L7IF=C^_=G]/2GVT89E*' /44QLS8V<GIS5ZRM/G!E;:0.!6#T0
MT7X$V/MQVJU3(XPGJ34@K)L84444@#O1J+JEM\V<$XXI1UINI1M);84X8,"*
M3V!;F&6R<LI'IGO5?:LPG",P8@@U+<;_ #TY^4'!/O4NU8@Q!&[KD=ZA;FNE
MC!^RRVMB+A1FXB)P3W%;$<ZO;Q2#@N,N/2H);F!+N..4G,HR!BH=1/V&SEW8
M ;@52NQ:%RYBS;'&6"MNS5NT0F1&/.>/I6=9>=+I$4^2588(]/>KVA7T%X9U
M23,L;8*GTH47<3>AJ7"[AL'1N#7-6&BQC7;B\D!S"-B ]%-=.R_O%8=#P13'
M S@J '/)]ZTC*Q!7OX)Y]-FCB?9*Z$ ^]8?A+PV/#UM</,XDN+ABS,:Z+?*N
M R\#AC[4,IVG&"I'RY[BA28%>SO8+XR>3N/EMM+$=3[5B>,&N;?2_.@(5D/W
MAUKH(X8[>$*BJ%SU7U-87B&[MS'':W",T,AP[=,4X*\A]#G)]1EU#3;=Y7Q(
MZY?;Z^]9.HD7!@NXO,PJA&/H15:SNC9Z]) YW1%MH4]-O:KDM^TFHO;I$$B+
M8"CO70ERBW+%P$9=Q16\Q 2P'0UK:'KEQ)&T$P4A%VJY_B':LN:S:WNW21BC
M#D9Z,/2K=DHFAWP)Y9SM*]L^M*=F@15$<\6I[W4C>_)'<5UVDQN9]FX[/[WM
M5%4VH@G'S*<'CK72:? J+YBXVN. 17-*5R]D7^U':BBD0%+244 .'4?6K=4Q
M]X?6KE !1110 =JSCUK1/2L[O0 E+B@TE,!-P#8SSZ4[-,:,.0W1AT-+@]30
M A=2^S/S=<4')4@$CWH\M=^_;\WK3J (K:%X8L/(7).<FIJ.U(VX %1WYH 5
MOE6EC.5S3'RP-/C&V/DT )WS10?O<=*:S!06;@#K]*0!GFH8Y@UW)&%Y0#YO
MK4B.DJAT;*GH:A@C9;B8X^4G.:8%F@=*,&B@!:CEC,D3(IP2,9IJ7"2321+G
M='U-.6=6=XUY9?O&@!T:[$5>N!3J0L .N/>F/+L9%QG>>,4F!X]XD<CQ1?XZ
M^<<4UBCHIR=V!D8J;Q!%YGBB_'K.<5#,Q$A48PO%>3/XF>Q#X4/@$*S?O =W
M8GM5[/3^=9+-G ZFN@\,Z:=6DD60L((N2P[^U$(N3LA5'RJ['65D9RTTA*V\
M?+'U]A5ZZU"XG0!#Y4(&%C%2:G.ID%M"H6&+@*._UK/)R.1@>M:WY=$8_$[L
MDA;'RL<@]156]L)+20,J,8W^X0*G$FT?+SCO5VTOW/\ H[G<DBD#/8TM'N/5
M/0Y2;44MV/E!6D!X'85/:^,+F) LT2R*.XKG9X6@NY8W&&5B#30H' '6LN=I
MZ&_(FKLZ^6\.H'SP<*PX'I4"\-TS5#1Y&>&2/.5C^;.>E:MJBSS*NX9)]::=
MR6K%Z!-D !')YI&;RT9A\N!P:ED;@XZCBJ.IR[($0GDU6Q"U**7UQ"V5E;(/
M>KL&MR!PDR @_P 0K(^\>O2GQ<$DU'.[E\BL/DE:1W<]R320N1*C'D!@:C(*
M]6I5'( ]:+N]QM*UCT*-@88SU4J*4OMB9B,A03BF6<3O9Q*.<**T+:WV!C*!
MTY%=RBVC@;29YE;Z1J.L7TLD$)5"Y.YN!6Z-!M-&B#W["68_,@QQFM>]U=HW
M,5HH2->.!BLB[$^H2#S)SMQR*RY()NYMSS<4NA@ZA=/=G?*Q(/1>RBLX H20
MO%7KI<2-$PP5/>HE&T8)S7*]SKCMH-A+L",8SZUW6AW*3^&)A>."B KSVKBA
MC< .O\JDO)+BUTLVT;$),V6JZ<N7<BI'F&R1JLI"$E"?E-::8555>"!WK-T:
M/[8AA=_WT8W+GN!6LH]1UI*^X/00>A-;?A _\50J_P#3N_\ ,5BA,M@?A6QX
M/5AXM&?^?=_YBM*7QHRJ_ STBJE^0(XSWW<?E5NH+I59%R <'(S7I(\TST=)
MMR '<..:5LJIW)T[^M3! '+C[QI2-PYJK@4]C,FY1E.^:3?'YHC&>:M[!L*@
M<&E2)$QA1D=Z.8"L%?.-F1ZU"=/MQ))(L:AR<D@5HTTQKG=WHYF*Q501DY8#
MBC[.A_>* /2K,D:RH 1CFC:JH(QP*+L96#,  H+J3TIY7YB5&3CI4T48BR >
MM.  8D=Z5P*GS _-D$]!4D>6)0J5]*DV!I5=QRM2=#GH:+@<UJ'A;3KS4OMT
MT*F=3DG^]6Y$XP(P#\HP :L%%8<@'G-->,.V>E4Y-Z,"-P[ !E[5"8PHPXWJ
M:ML'\HA?O5&$(D4=@,FE<"+S%APF.#T %9^MV,FI1Q0H@)4DECV%;153U XI
M#]X5,M58<79W.=EL-D36<=O"25 WE/SH_P"$=M$TC[/#$AD! ) Q70E!NW%1
MGUQ2+&J$E>-W6L_9HOG9S5II5K8,8985>+D1Y'.:GL]&>S#^5Y<:3,21MZ9K
M;>$,0=JG'K2ONR@(P.^*.1(;J-G/)H$,=QNB3%SD[I,?>J:[L+JX>W8Y?RVP
M0>N*WB"2,<4N,4U30N=F7+HT?FI<1$B7C</[U3W-E#/#DQD>JCUJ[B@@@<4<
MB%SLP!I3/.F(<1]R:TY=/@GB\B:-?+4_*!5P$GOFFAB7P<#VH44#DRD-.CV;
M06 7M3$M8H75BI*YP"16BV<[@*, KG&*?**[*LT2"6/"*5SSQTIKV:-(^]<I
MC@"KI48[4$>E'*%V53!"[1XQD'DXI_V6-2,C=SDU+Y:\<#CO3Z+!=C5'[[..
M",<5I5G!P)1'GGKS6C5$B5BW:(DS2$J&+$9K:K%N(XY9'5^FX]Z<0*=Q"RR^
M;&RE=N23V-(ES$+,2$KDGE@.M2R219$8/'3VJ$VZ.=L8 "GG'2M1$/VV81K(
MRDH9,8"\@58M;>%9GDW M(*?#(+F-P$QM.,$=:DM46)W:1.>M)L#/N2B7,>3
M("3T!J62>43!X&9DZ%<58<;[F.2(J5!.[<,FJ\LT@#*WRLQQ&5'2FM@-:.3;
M;>8>O>J1D<,68<GMZ5+;[A9E9&W28YJJ\#M=)+YIV#JOK4I*XQ\=P/.:$@B0
M<Y[4MU)).(D3<"K98CH127$R1 S)&'4<'')J:.-R@E7A&Y(H$5H82DTQCD+\
M?=)X!I#%$[QO= )< < -FI1)\S", -GDBJ;0F29F"NK=2Q'7Z4T!8D<I&"(5
MGC9OF4C]:CO7!N(HH%,2R$;W4=O3VJQ'>1QK&L@5-QP!WJ0K^^*0[3N'()[4
M=0*47VA[N9?M$9M$(*,1DCVI7D:YF>.UECW'[YVXR,>M,%FZ7NR)"(P"7!Z-
MWJY'-$;;+VYB#DK@+R/>G<#)MK-85C 4M(2=NYB<<UHM%(T1*$+.<;CGK4$,
M@#YB&+=00&;KFD:XCS((9"9&'U I@.E0S7+;H\E%P&]:EL8V@BPH(W'E<]*?
M"K?9HS(?F[^]21QNTI97PI&=A'-)@0-&TMP_RHJCN>YI/,M9VV.K/(G0XXI]
MQ'YB.@R.X^M(;@Q0HJQ*6/#E:+@0+92LCR/&83NSNW=1]*M6329)<*%/W<=3
M3V*&*..63&3P<]?:H+F6.&4*",IS@'I1JT Z[MTC<,T6Y7^\?2O&/&%K+8Z^
M]PY06TY+H<\_0U[5->&6)4CV[R/NMZ5XIK-O_:_BK6+&Z<E!,3#\V GTKDQ5
M^5'7A/B9@PZ%;ZKYU[;<M;C>ZJ>HJK-JL4V]EB;<JX&#TKKO".F'P_?WDFHS
M(EF\)0>C?6LQ--\.2:BKV=YO9VR8N<9KDY5:YUJ6MCEO#^HVUAJT$UTA9 6$
M@8<'(-).WF7LS1*!&79E ].U3Z]8M)JLQ6-8U#[ J]C]*Z59],L-+M_]$B:\
MA 5Y#SGZBDVBDCBH[*-B99PP&<;14$JR_,J,[KU SGBMUW@N[J27S@IR?DQ@
M&NH\%:/:00W>LW0B8Q#;%;N1\_OBG%W>HI:+0X'3TB,>)B#'G..]:UBJS:K
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M(QRS"DD.VAZIX \07NK_ !&M!<.K+Y$N,=OEKW&OGCX26JI\0H9(I@\:PR@
MGD_+7T/790^ X,3\8C?=JG/&2-P[=:N-]VH2,]ZW3.9F<:4'CI4DT91LCH:B
M[59 _)S1D ^M(,YP>])D<\<^E QS<$&L;Q%-K<=M%'HMO&TTK8::0C;$/4@]
M:V#\R^E<'\2+V>$Z:DTUU;Z4SG[3-;@[E'&.1^-)@4+W6O%'AV_M$U75-/U&
M&XD$9CA4*R^_ !IVOZYJUSXD.C6%_:Z>8XM[2W(&'SC@9'O7(ZI<>'I+W3CH
ML5Y,%G7S+V??C_=^;_/%=5XTN_#S:F;;7]/GB*KNBO%4D-GL-O\ 6I8=39T&
M7Q$-/NH+QH%N$4K!=+AED&.N![^U<[X$_MBWM]4GENX9($EDW1A.?,YRW3I[
M4O@21O[0ODL;B[N=)V8A>X!!+>V>W6E\(ZE%&-8TE@RW@FEDVLI&5YYS2N,T
M_#NH^+/$$=O>"\M[:RBE*3!HU+3 'J..../PIT>J^+/$]U<R:!/;V-A YB$D
MT88RD=>QK1^'J%O"8#8P99!_X\:PM!\4VG@L7FCZY'/ R3M)%((F99 <="!5
M"-;2_%TWV'45UJ$)?Z6/WH7H_H1^59B:MXV%E%K[B"2QE(;[!''EPA[Y S^M
M5K/3[KQ/;^(]42WD@COE"6RR J6 SS@_6K&F_$2"S\/V^FV]K.^M1HL0M&A;
MJ.,G Z4 S;U+5[W3M:TB8.5TV[;RY591E6(R#GJ.F*EU^]NV\3:?IFGN$=U:
M2X.T'Y #CZ<XJ3Q%I\VI>''\U5CNU19?EZ(XY./UK+\!32Z[<7FO7 (=U6WC
MSVV@!OU!I <YH=OKD?CC5R]W%MC.;@!.77 V@<=>E/D\0:QKE]-_9^I:?IMO
M ^P-<E2SXZ\'.*T[&_@TWXC:S9W9:.6\51 60X;Y1GFN;M;/PMHVH7]GXNTV
M02^>7BN )"KH>>-OXU+B4F=?I/C2;^Q]2%X(9;S3E+$PD,LHQP1C\:QM-UGQ
M;J-NNHVFHZ==*QS]@ 42 ?7']:L:$VB00:A?:/H%PMNJX +'-P!Z*QKD]2N/
M#4Q,^C?;K'5#_P NT2/DMZ'BE?H.Q[;8NSV_[Q"C$9VYZ4MR2H.!NQ6?X?%V
M-*LVO6/VH1 2@^N*TYUW)QQ]:JVA!Y_JFL>(I_%DVCZ4T"J(%<-(HQ%P.>G/
MI^-)X?UW5(]0U*UUMDDEL8S(\T8P&&,]!5FU0K\3;X)_SYKG_P =JC'9R7GB
M[Q/:@?O);4*/^^1BI+3(5USQ'JRF_M=7TFRMB3Y=K*Z;F ]3VS5V]\67<G@6
M35;-EAO8I/+D((8!AZ5R.G#P;96OV37M+FBU*(E7!$I\PYX(Q70:C86\GPZN
M_P"R=)FLH7;S1 Q+,P'?!Y[=*H1N>)]4N]-\.6]Y9R;)GE0,VT$'/7BJ>N:S
MKD?B.STW36C5KF%B"R#"GCYC_GO6%KWBNTUSP];6EE%*QBEC,K%"%3';)KH9
M\CXDZ221_P >C\=NJTEJ+82_U?7]'MK+2C-%>:W>.=DBH%15]<8'ZU VK>)O
M#=_:G79X+VSN9!&7A0*8V/3L*M>-S/IOB'2]>6W>6VM]R3",9*@]^/I61K?B
M2S\72Z?IFB)-/^_62:4QL @'/4BJV$M38NM8\3W7C*YT719K>-!$KB25 1%P
M.>G.?ZU?T#Q5K, URQUL17%YI49D\R)<"3Y<C@56\/$CXH:D">EH@R._2GZ7
M,;?QYXOE%LUSLB1O)7&7^4<"CH-%#3-<\;:K;+JEAJNEW*L25TP;1)C/0DC(
M_.O3[=Y)+>-YH_+D*@LF<X->&:O=>#;I);G2SJ6EZV02+6"-P2_H>,?E7L7A
MK[;_ ,(Y8_V@3]K\H>9GKF@HU:*** "BBB@!1UJ6HAUJ6D 5F74_E0R%?OA<
MUIUE2X^U .,@KFFMP//6E>_N3,58L9, 8KT:$,EO$I W; #^ %] H+]5SUJM
MM<>(9$MXAY,'WB.FZNDR"WMC(K6I*^@D-8$IQCWIRNA^7'3UI&;+*JCCJ:#C
MKC(/&*Q&(@.T9^]FN)\8:<[W0N(D^4_>P.]=IMD ^3IG^*LW7;V*TL@)%#[C
MRM:4V[Z >9P:]?6MT]M=;Y+8C9)$3R%]:2;318P?;XV$UATC.>OH*COI8=0U
MCSB-A9MA"]<?2MC5_+L9!H<0S;HHY?N:[;V(*EF]KJ%HY9MDB]8\<_6A(KO:
MR+(KJ.5'?%/T31=E^;HO^[C'W">M;FJ>&;VX@,^ERB.9AG8?Y4I2286.;-A<
MW%]'<6$FV[7&<<5M:EXIU>SLULY-OVG9AY,50\/ZT8]2;3]1MA#=QC <C&:U
M]0$&I7"1O;;PQQO7BH=F[L:V-_PC?RZCH4<LBCS%)4G'6H]3M/LMYYRG[_4"
MJ=O+/ID"6UD D2U96263'F'>2>2:Q:L[C1);PM*X9>!WK72 %AWQS4-N-B@[
M>OI6B.,8'%9R8Q<T445 !1110 #K3K[<+<LIZ'GZ4T=:=?$BU;!&<]^])C1C
MJHRPD'WNE8M[*;77;5(P?*D!&,]ZVG8Y1B. .E9UW"ETT<Q!5HCD'UH3U*L9
MNI;1K]E&QQL8?J:F\41O)ITCDX1!\I-1ZS:M//97*'YE8 X^M;5_:?;K-[9L
M9=>]:<RT AT>0KX<LQUW#!]ZQ?#EK<6/BZZ:0'9*./I6Y"/LVGQV0(S&O!':
MKNG+^]7.&91\Q(I*=F_,36AIL."!4+2?.JG.[J.*G%1[\INXZD9J21CE@5D^
M\,?,/:LC3]:_M*^O+>&/BW.U2>]:%V9$LKB5.6"$*/2N)\,66HW&L27.UH;>
M,G/;<36D(IJ[!G<F*5H&5F W#C Z5R?B^VGO=.AB.5:)CAU';WKJFW^2=QPP
MYX/:N9U>X>VL4O+>82H9-CHQSBB%[Z <[_8]L\5I=M*$FAX?)Y>M2STO3QJT
M=^[DQX^Z.@-9DTZ78\]$ 4C8?16]:LZ7*\=P;24Y_N^AK:2=@1U<VE6^J6\G
MG*/*S\KC[U9]MI":>GE O+&K9)[XK1MKQH8C VTH!D%>M6;*5)I7#-AP,!?:
MN9M[%(J+8JDZ@/YL;\K[5O1H(XU11@ =*JV=L%#.1@9X![5<YS4I";"BBBF(
M,4M)10 X?>'UJW50=1]:MT %%%% "'I6;$&$2B0Y;'-:1K/[F@ ) 4D] .:H
M?VB/,1!&Q+M@8';UJ_VP>G>H0B;]P0 KP*: FHI :6@!:0TM)WH 1#D'(QBG
M=JCCE6525S@''(J3VH 3 SBE)XJ)/,$DF_&W/RU)0 G(/M0P61&5QD$8-*>E
M%("M:6RV=LL&_/)Q5FD*@D>U+3 1C@$^@S45O,+B$2*" ?6I6Y%0V\)B9^?E
M)RH]* '10+$SL.KG)-.6-4+%1RQR:?11<""X8(F2I92P&*5&)GV[/E1?E)J4
M@9H%%] /-=3TJ<ZSJFH?+Y4<I.,\USAD#9=G4<\Y-=S:PO=>+=1B?FWWL'0]
M#7.^*!IFA3^7!IZ&Y?F,%RV!ZGFO-G3NN8]*G5L^4S([*2:$W$CBWM1R97XR
M/8=35\>-X]/LDLM*@Q".'E8<GWKD;NZO;LA[F9F7L@X ^@J%>NT8P:R4N5^Z
M=#I\WQ'HP_>01SJ^\.H8M3';<-N>G:H[?4X1I5I:B/#1IAF]:7=$YW*X'UJV
MTS&*:%#[>%J.:X\F!F[@<'WI?,BY*2#WJCJSQK;Q[),EB<CTJ64M69,P,P)D
M.9"<[N]5,%#TJSGD<?C4L%M]KNHX-VS><9-9=38KPEHXV()&[K@]13A*ZN&5
MF4]L&G7$?D2O#NSL8KGZ5"2.*>J8:-'2:5J3716V?_6_PD]ZJWUSYMRP&3MX
MJMHEO-=ZB#""3&I;BFF"?S64PR%L_P!TU>MC.RN2!@RYQCCFI3E;<,>CGBKN
MG^'-0OI%_=&&,GDM79GPU826]O$\;'R>GO5PHRDC.I6C%G 0037<FR*,L?4"
MNGTWPPD,B37\R@#G9FNH@TR"T3;"JQKWPO)IOV:RM TLG+,<DNV?R%=-.A&.
MLCGGB'+1&?<:F+&WDE@BV0QCDL.OTKG[+QX9[SR;J()$_P H([4>-]0>X@MX
M+<[8&Y8XQFN*$2@KD]/2HK5FI66QI1HIQO+<[UV1G.W[I.<4B$9X'6H;)D>R
MBDZ\8S4V_/&.]9%/30S]4TJ:?=>0+N_O+WK"8D?*P((KT#3MWEMW%9NM: +G
M,]LH60#)4=Z)4KJZ"%6SLSE858N".E2:E,#&B?W1S20[H965@1L^]GM6;=S*
M\C.&SN/2L7=:,Z%9NZ'Z?/)%?H\1P0#S[5U*X=!(!PW\ZY?38B9';L!U-:46
MH/;#8J[@WZ547T)G$T]OSY)X[UM>$L?\)6 .UNW\Q6*/GC5B1R,UH>"9?-\7
M.W;R' _,5I3^-&-3^&ST^H;C[@^M2YJ&X(V#) Y[FO2/-*_3GO15>\N1;6%Q
M=)B7RHRV%.<X'2O-+;XJWGV*\FFL%=HV_=[00!ST-:1IREL*YZG@48KD_"WB
MV;Q$JR26XAC*DMZ+6Q<>(=.MK;[1]H62,-M)0YP?PH<))A<U:/Y56DU"WCT\
MW[OB!4WEO:JFA^(=.\0V\DVGS;PAPRD8(_"IY7:XS3HVYQ1D [<C)Z#-+2 .
M])2.ZQJ6<@*.I--:9%A:8'* 9R*+,!_UH8@8R0,],FJ]I>17L;/%G ..:YOQ
M<+J*:&YCF:.&/DD'C-5&%W8#K:3OGTK)TW7K2_TJ6ZB=G^SIF3C!)JGX:\7V
MGB6WNFAB:*6WR6C;N.QHY&*YT7?G/-'.:\F@^*-Q9Z_>07H$D08A$ QMP:])
MT75[;7--CO;9U*M]X YVFJG2E!7'<T:0]L4Q)X979$E1F7J%8$BJ&JZM'IEQ
M9I*0$G9@S$] ,?XUGRMNP&B3S63JGB33-&O;>UOK@1//]T&N0USQEJ$FLV/]
M@_Z59,^URBYR?0^E:'C/PM8Z\UGJMW<&U^S,!)N_B'I^E:*G9V8F=F718_,W
M#:1D'UK%TSQ1I^JWD]O&X5H2<[B #CBK;7UI%8).K*]B(L!@>W2O'O%V@RVE
MX=5T6:1+ _-(V[H2?_KTX4XRT8VSVB\U"WL;4W,KCRQQD&N5LOB%:WGB;^R#
M 55CM27/4U3T%K'Q!X&^S27DC%6^9NX(YQ6CH>F>'C=V]T+=%O+?Y$=SC?[_
M %IJ$4FK =!9ZS9WUQ-;P2@R0_>!J#Q#X@M?#NF?;KD,ZYPJKU-<+K LM"UN
M]@ANY%N;H9&>B#TKD;SQ!/XCLY---P!#"/O2,.M5&BG9BN>JS>-+4^%3KMG&
MSQA@K*PZ5?\ #_B"T\0:8E\F(F+;=KG'/MZUPGPZF \,W6E:RB&S8_*S#@_C
M4/B725N-4TG3O#ET(X[=@&C63'/K[T.EN@N>L2R+!!)*_P!V-2Q_"N%O?BKI
M4$,<EO!)-^\V2)CE1ZUW0CQ:"*8AOW>R0GOQ@UXUXF^']Q:?Z3HF;U)IBS)'
MSLYZ5%*,&[,;/5K/7M.U%(_LUS&TSQ^:(,_-BN/\,^/KO4O$EUI>I0)#&A8K
M(WR[0/6N&TB:'0O$*:M>RR*T. T2C!STQ6G-H,WBOQ!?ZMI]P!;M%N1<[3G'
M0BM?8QC?L3J>GZOXFTO1[6.YN+E6BD.%:,[LX^E.'BC1#8"\.H0^5@$_-R,^
MW6O/1X*,/@F2VU:Z_P!*23S(T1\E!7/:/X<TAKE].OM3DAN[K @7!Q^/%2J4
M&AW.PO\ Q=JS>-K2/2U^TZ9+C:RQY!!Z\XXKUH=*\VTZXM_!;VVCE1(B, \S
M+U)]/QKTGM6=7H"$K(86Z73L2WWCGTK7KFII8X[]X#+^\:0G'XU$5<97N)Q%
M=%8X_DSRV,U.YM5@;R7"&0Y8Y[U8,>,B0 5GO9%;@A8MT3<LU:(1-8V#C=FX
M; ;.1WJP91YS1A#QSGUIUK,J)L0 H.,TDT+O S1#?D=!2 ?;^3#$^>#G)!JN
M9))@KQ;=N[D$4ZW:/88Y6!D'4#K3I8O+@;R3\X;@4NH#-H=F"NP8'GVI?M$1
M)B)_>+U]Z<-Q?=D<CD"J9^U2,S0[(V)QEA[T[ 6H]@@9PA&<XC/4TZ.XVJT>
MXG/8]JJQ;([IHB[/,!RQJ>* +*\I;EN,&A@/CBD%WPH\LC)--GC$0F22=@C<
MAO2I%25 [.Q7(P*SYE\N)Q=R%T<_*!UH0R26W@2V1FW2L" "*LV=G+!=!W $
M2KPQ/.:CMI)(("\J#:#\H'IVI=0>2Y6+RW\LYR1ZT7Z :H"GD <]ZR]5D8GR
M4!0''STZTDG,KHPPN/E-5R7BN',S9#'"BDE9B&0V\4\+)++AL\!>E(EM);0R
M;(DDD<_NOI[TA_T&1I)(SL)^7W-:%O!*S^>[?*1PO853 2%58 D%2O;-5?(E
MA 59R27R6_I4BS,M^S.0(AWJ6]BBNH59#M*MD<XS2L 3W,2*HDXD;L.]9\'V
MJ6ZD6.+RD4[CO'WA[5-':QJ&+$NP.<YZ5:B,CJ=IXQZ=*>@%>.2-D??&R[6Z
MM1%:XA<[E+.2=S=0/2GA"B/YQ##/ 'K3X)8I,HZ%)%'"D]J0RO;JIB9Y%&4!
M&X]Q7C/B6&<>)[Q;:&1)&E)R?[M>RM.LT>Q(]R[N5KBO$J0:QJ\WE*89[?,1
M]6Q7-BM8G3A7:3N<Z\%SKN@7%DK#[?;*&7'_ "T'<5PEM:RVLF0IB99 W/W@
M1VK876-4T?5&,/[MD.&)')KGM1UNXO+^2\>1=K/\RBN-:H[=GJ=YX@\,27[:
M?KUN_EP3HIE&.D@'7\:@G\,75^XAMHC)(R[WV^E5=!\1S?V>]E-<EK;(95/:
MNT\+ZQ;I9ZD8V"2(F48GVH5F]2&W%'D^NZ/+HURD,K@.W.P'D?6I])U28RI;
M2$G=PN.M3>-8HYM3BGAE#O,/F(.<&MO3-%EL-%@FA@C>\!W&0]J&E8I2*IEO
MK+5HUFM)$Y&9'4C-3>+FN?$[1744(40*5VYY/TKO[1HM>L#!J@'F1*,D#&16
M%=P6-K(X@E1D3@*.<4FN5: I*3U.*\/W%SI0N(?)$1G7;N;J*V-"M;F\\106
MT0RY;<=O/'>LR2RU.\O)9HXO,@W;MP'W179>'-3M;"\BM;2)X[N90-T@Z'O3
MCJ]0F[+0VKW3EM[B1(P3*5X&W@4EMOTZ,FZD9\+G:>*UKH3,Z)*!SSO]#5:X
MTZ.^@*3D&X0'!ST]*ZK65TSCO=ZF9;:\;L,J_NPA^7><U$]W>6D7GQRA@#DL
MV,US5]H^I8DCT]#/)D@B,UA6]IKMI.?MRS*@R C^M8NI)ZFZIQZ'INE:H);>
M6><()4.=^.HJJ^C)>ZJ+S[8AD<9ZX)'TKG_#>NVVF13)K!18FZ%O3T%<W<:P
M'\1M-#<L\+2_N3G&!G@8JE4NA>RU/>/#<7V-'MF<F0_,23UK>->?:%JB7,\!
M:8K- ^'!/W@>*]!!! (.0>AK>+36AR333*MU9+,5DC/ES)R&'&?K5*"\;=)#
MJ9C20'Y&Z9%:]9.KP0+)%<R#)!P:8D4=0@>R=3!'')&Y&[/85Y?X@UW3)M:F
MMXIVCF1]N6'RYKTS[)+=PLER0+;/[LAL&O _%=E]D\2WL(R"K\>M95M4KF]#
MXF;6LVEAH[VXU!UEF90RQQ'M[FL_[?;EVDC0K&>BDY"BLC4?M,KPFX4^9Y2@
M9],5;TC1K_69?L=A"TDNSYE[ 5S..MCM4M+C7U>U.W$0DB5LLIXS7;7?@_3_
M !!X.75/#2-]HCYEA9L_45YU/I%Q;7,MO+A;B,E2@]15O0_$FH^'Y9DMY72.
M7Y9(\\5:2L0[NUCOO@Y;2V/C98+F$K,8I/O=5XKZ%KYT^$U]/>?$V.21BV^&
M4DG_ ':^BZWH_"<>)^,0_=-15*1D4W9[UL<Y&0&&"*KO:\Y0_@:N;/>C9[T[
MA8SGB,1!;GWI".=W>M$QA@0>]0?8^P;C/I57):*F,'Z]*;+%%.A21%D3T=00
M?PJX;(X^_P!_2E^QG^_^E%T*S,S[!9JNQ;6 +G<0(QCZTV\LH+E 98(Y2O3>
MH-:GV,Y^^/RH^Q''W_TI7069C-IJ6JHT2HN1G:B@ 56%K"LK2"%!(?O,$ )^
MIK>;3G/28#\*B;2&8G]\.?\ 9J6.S*5DD<0\N-55>N%&!4\MI;7!S-;Q2D#^
M- Q_6IXM*>)L^<#_ ,!JQ]D_VQD]>*:8K%)8EC'RJ  , *.E-CL[82"7[/$)
MNOF;!N_.K_V0YSO'Y4?8S_?'Y4[A9G*^*HO$%S:K:Z+%;&.8%)I)6PR#U'-6
M-%TE=!TF"QB.3&OS8_B)Y)_.NC^QGCY^GM36LBP^^/RHN%F9WDV]R?.:&-I%
MZ.4&Y?QIMU9V\N/.@CEXP"Z!JT5T\H3B3@]L5)]C.<[_ -*+H+,P);..(?(@
M1.VT<54AM+99%<6T ;.?,V#</QKIWL-Z;2X_*J@T,B57\X$ ]-M0T5J1Q1@$
M/ZU+(!Y;<\=JN?8O1@/PI&L2P(W]1Z52):9BF*-9_.$:>81M+8Y(^M&R..0R
M;45W/+!>3]36H-,=3_KEQZ;:9)H[2IM:88Z_=I,:1E26MG*[,]O"[Y^\T8)J
M18U$9C/*^XX^E:/]DDIM$PXZ_+1_9#C[LR_]\_\ UZ6H[&$+.!Y5,<,*Q<^8
MGE#K5I8(7=)?+0RID*V.0*T!HK@G]^O_ 'S_ /7J0:0ZC"S*/^ T1!HS)(_-
M;D@\8*MT-5EMH[<A+>VBC)ZE4"Y_*MJ31W<J?/4$'/W:1M(E;_EY7K_=H8DB
M.PAC6X$OEH)F&&8+R?QK36&))&D6)!(WWF"@%OJ:B@L6A<$R X]!5O9[U0)%
M/^S[+S/-^R0>9UW^4,Y^N*LT_9[T;/>@H913_+]Z/+]Z &44_P OWH\OWH :
M.M2TP)SUI]( KE_%%Z;'0[R[4[71=L==17-:SI_]JZ?-98)W,&R:J&^H=#,\
M%6\J:!]JF5O,N"#ENN*ZACC.!]T<5'!$MM:Q6Z+A8U X^E3!0".?K3D[M@,C
MR/F<_.1D^U"D<,><YIS LP8#M@T?*P Z$=J@"&9I(T:3< !SS7F][/?7.I2G
M+39?Y0IR*]&OIH[:V9Y<&,##'TKR47;Z?KS2Q/YD3297'0BNFA&ZN2V="-*T
MV%5O.MW&I(],US_]H37L^^[MGG=FY<#&*TKN^22*[#1,HVY4J:R-.O)OLY"Y
M5."1CG-;I/<1M2I/'J5I!;!H[64CCJ37HBJT/E1QH?E')_"O,KK7)H([=[8C
M="<D,*[_ ,/ZQ'KFG)<(V)1_K$':L*R>Y2(]4\/6VJ2"ZE1$N8QE77^M98A$
M$813AD/S'UKI+R400,>?FZ"LFSMA<2R/+\H]^]1&3MJ%BA%(7G*-R".H]:U+
M.)E;#*3]144NF_9;I9(F!#=JTK4NS?,<YI2D,G*AWPG"BK(]*A@!7.:F K)@
M+1110 4444 '>FZG_P >HXS\U.[BFZH";90IP=X_D:3&MS"C+2*2S$;<@"G*
MJR0X/8YHC=87$+'+GKFI%:!(\NX3=P@)ZG-3RMEMV&R)&[^6!\QZ#'ZTK+Y4
MT9=^HP*1Y/*D$:H=X'6DV"24&;Y=OS*11Y 0$AVD.X#=D BM?3D'D^9D9/&?
M6L"TO%N+J>(*,Q/S[BNAL@$M\=,'%-*S%)Z%DG@]JKRJ1:%6/([COS4LGS$(
M>C4,OF1F,CIP<51!&5./++?(1R2.U-51$OEP  =,&I =GR;26Z9J(#<"-X !
MR0>N:$QE/4EN9K1X[0$2%=N:\ZAL=3Q<6*%II"^XJ.:[KQ/-<QZ'=/:9281D
M!AZ5PGA2_N;5;B[>4LZH?F;UKHI7LV)DVCAY-6:SV 1.N)(V['UK6BL[.VU!
M"DX+1\88YK-TFZN)[NYNEB4KM(:0+WJG<7.RX9E;#KP0:;BY,=['>A8E7!(.
M22&]!4]O;P,XDBF._.,XK#TQ_M-K;LY)!."1TKL(4B1 L:C;TKG:LQO8?&I1
M<%BQ]33Z08]*6D2%%%% !111S0 X?>'UJW5-?O#ZU<H **** $/2LM0PD<LV
M03P*U:SJ "D('6E%% "4N:;WH7=O.1\O:F ZDVXSSUI0<DYHI ,B $8'2GTE
M+D#DT %+03Q0"" >M "&BH;D2-Y8CZAP3]*EYI@+2,X52S$ #DYID;J691G*
MGFG.@DC*,,@C% #AR,@Y!Z&BFQH(T5!]T# IQZT@#FBBC/- !UH^E%% &=#9
MP6D]S(H.^:0R,QKQ_P 1WPO]>O)V'W6V(/0"O8[V=+2)YF5F7."!7C_B+0+Z
MQU">X$+M;2,660#@ UR8A.UHG;AI+FO(QI!N^E)91>9=*N,X.35VPTF_U.41
MV]LY)XSC KM;7P6+73&6-UDOP=S 'H/2N6-*35['7*K&.ES!0$<D 8I<C/6M
ME/"^I2?>55/N:63PKJ,8!15;'7!HY)$^TB8Z@\*HQZU7U"-C;[U4D+UK?C\/
M:BTHS%L4]6/2G'Q!I>E1M:0VWVIL_O')X)H4>XN?7W3CD#D8"L?;%:^B:7=W
M>H0R&,I#&=S.PXQ4L7B?[++(Z6$/SG.&[5J6_C:UN;2>"[M/+8)E2G 8^E5"
M,+W;'.52UDB6\\(0:O>R75A<[(BWS CO5JW^']@A!N+AW Z\X%<,_C35XT,-
MIY=M$,\*IS61<:WJ]RVZ6^E.3]T'%:.5).Z(5.JUJSV^RTFQT]1'9[(L]2#D
MFK<L5I OF2"-0.Y KP&'5=2@<-%>S!@>FZNVUGQ%>W.EVEBQ"R^6&F?'4^E4
MJT+;&4\/)2W.UG\5Z/9_*9PS>BU!9^,+:^NFCAC(55W9;J:\Q2,;@6ZUKZ%C
M^T?^ FH6(=]#1X9)'>OKTC/\D0"_[50LS7,IEDY'IZ52P*LV[#:0.U:*39BX
MI(R?%L&[25E11^[;/ [5PR./SKTG6(Q+H]TI_N$UY8CXSFN>LM3KH.\3M=#G
M5]- Z[6QBK\DJ1+YCG K)\-1E=,DGD/REB0/455N;QKB0DG" X %%[(FUY'1
MZ3KL1NOLS#"M]UO>NDS@_P!:\PW$<IP1T-=?I&N+-:A;LE6CX+ <&M:53HS*
MK2MJC/\ &EQ!!:K;0JJS3-EMHYQ7$!5VC'4=:V?$4AN];FD#DIP$^E921;I5
M7KN."*PJ.\M#II+ECJ6[595MAN;"N:T(T4+GTJ*6,>6J@?='%,CDD7J>*A#9
MK66Z=S9CK*N ?0UL>![2>T\5,DT;*1 XR>AY%9&BQS7%['*OW(VRS5Z#HC!]
M1!X)\L\_E751AJFSDK3LG%'25ROCN1(]'B#7@M9'D*QN3C+%3Q755Q7Q(TFX
MUC2K&"V7<ZW08CU&UJ]*DO?1Y[.+\#:O/X>O'T36&>;[6V Q;<%S_0_UKH];
MM= T_P .WMM;6R2L[_.!U!SUKDM!ABUCQE%:7"F.6V&T%3RQ4=_RK6U[1[AK
M+4HH;I5NA\^P]TKL:7,3T-7P[G4?"EU;V5LEK*D90%3][CUKSW0]0>WFDLE/
MG;IL21'GI6WH.N7/A;P9/)')%/+++@ G(3IUKC+K[5I;IK<?RI<DE,#^+O50
M5F[@>N:OXBT>Y@7PP)&AFGCVACT0^]<O9ZD?AZ&CA6.[EN&P[9X('I58Z4?$
M<L&JVH87#Q@R1=RWJ*@N#IZ:!>13L9M3M) P4?PCFA0BE8&>E7FI07-E9Z@D
MK1R21"1(P>^,U'IWB>X;3C-=VY,GF;>.F*PO#<D6IZ)87^H3+&5/E@8P,"NY
M^R6%Q9?NA&\*Y8%.02*YY<L=+#.7U+Q+*?$T&F.N+.91GCGD=:W=.U:UFD>R
M;;&$.U Q^_7G_AJYN=1\<WMU?*&MH P0-QMQG %+J.H0:AXGM6BE6U<,/D)X
M&#UJW23T0DST6U+V<EP)E$</52!TK*U37](O;A-'G)Q<<+(.F:V[R-;W3V@C
MD#.Z?+@]:XT:%837@(ND>_M4R8 >0:SII-W'<S+:[FT3Q5/I181V4F497XW^
M]4+/58_ FN-;1P"8W3?O"3T4G@"H?$T%U<36=Q<2KE2><\GI5SQ@UM=^'[#5
M=/BS.A$9D(Y! _\ K5T\JZ]1%?6/A_%>ZK>3V\S![G$T2D8P#R<UI:3!)X)T
M18?M'-XY#%N@/3BKEIJ^L7*:6S(JN8P'^7EQBL[X@J^KG3].CFCBO1)Q">,@
MFINV[,"]I;W/ARVU'6;POY;#$>3]\GTJQJ7B33]=TS33);<7I>%LGYHN!R/S
M_2GZPB#PY%HFKOY;%%6)E&2&_P *S-!T:34],U315=$F@B AG[C=G/\ (5+L
M_>8S#T1;OPAXH2WM;E;G3W<%YP 4Q[GL:ZSQW>6MZZ:7_:"1/,H>$ \'ZFLN
M7P)J=EX"N-+%U%)>M.'X../05G:'X4DUS688=2EDCEL$V/[XXQ1>+]X"A'IV
MH^)$@TO2+UP]EGSAN^5O7%=M936T?A6^T^^@5Q!&58-P9"/3\:P$NX_ 7B"[
MM;:%I/,R2SCG/^%.UR;4/%&A0WFG(B3,2LD0."QYYIM7] )?!-_;7'AJ^M-,
MM@MQ&[$#.>3TJ/2M&\1:K$MPZF(13[>>#UY-9/PQCO\ 0]<U1+NVD$(B9I<K
MT(&:]$\,:I;.+B4W"^2TF%4GD$U,FUL,S?&^E6MM<6&K.H:="$8$\.16/XJ\
M,Z#]@6Y>2/36*AY%3DL3[5A^)+G6?%OBJ31IY4MU@DS#OX&*H:[J=EJ4<L<T
MTBF#$03.2Q'>JA&5M1,6SL]4-ZMFEX&T_&Z-G(56'^-*E^#)=SV*3)J%H,#!
MR&P<%JJVT=KK4%O8VMT\4UNPVL_0CO5K6=*-AJ,-YI=RKIN'G,O7<.OX5JP.
MST_Q)KUYI]K%=HT3W$)42%,=NIK,\)3:UX0?4M4UF5GL&?8B[L[CGJ*[R'4;
M"^M+.UDVB:6!=K =#BJNJ66E_P#")ZA:7*//' I=E!P=W;%<KDKVL.QR^M_\
M(OXDU"WM_M2VSW@$@9>[=,?I6K:60\':I;6=J/,28#S)&X&VO--D-QHB:S:6
MSQ2V<WEC'(QP0?KS7I>OZHM[X2TTSYCO9HPV3QGVK22MHA%7Q!;W]AKQU69A
M+IY(VX.0P]*XOQ7K%CJ?B.(VUD]I<6X&R1._X5T%KK%]#K5EX:U"'S;61<LI
M&3SW!K*:"_\ %,^HP6\$$4ML^$D;Y3M':KCIHP9IZWXB6^MM/MM25EE:2(JZ
MC#,<CK7MXZ5Y=IWARPU/PE:PB:"\U&V="9$/0@C(KU$=*Y:S3=D-"5SES!'<
M7\DD: 2AB-WTKI*PV_=7$SJ."YX/K6<=QE>YA=W"B8!QR1FHD-Q);R(ZX)..
M#VH1%N/->XB,;L=N0:LH,*L:D87KDU8B!D5P]K%+LD"YJ2SN&C&U\G;P2>AI
M$\N5I=GRS+W]14DSI+B$D9V\ =: (_*C-RTZ##-3H&!5UD8;QTVTSY;.U"C=
M(<[<=ZJ;EM)UCCA8LQ^]0EJ,GEB8N)HR5<#!4U(RR;X25X )>0'I2&Z,EYY9
M7;ZD]ZENX92FQ& "G((H$0K*DC%@%"?WSU-6'\F0HYY*=LU6-NLL?DA0<]1T
MJU'9,FXY XPJ^E#&12 6XW%V82'=\Q^[3-K23K*61K4#YLBK,D:S1+'(WRXP
M352Z"H(X(740KU_VJ2 M3R6S+%*LO Z*.AJJ&:9F,J["#Q4$;VFT*"0N[ P*
ME,ZR1RDJP2+DD=:JUA"66S[:4,Q)[*>U:%ZL8B$FS>RD51MG@N%CNH%X88)8
M?-4KMF<99@@'/I2:U CGEG=DV("!C(-3R7221-"9"O&#CK423QNID5AM!QCU
MQ4#Q,S^?%@NPP!0!,UJ9;?RMN8QU;UJNI@34%+R, /E"YZUH)>K;!().7/4C
MGFJEP(?M28C!8'*^U- :D40RP,04 \>]0-/!<B6W;="JG&[IGZ56_M%EE-LH
M+,!G/:H1 ]Q$2[8)/(STJ>4"W,L4(WRDF-!G- CM=1*,$8 $.KCO4-TSBV2W
M2$R\<D]*6.1A;*B'RFZ!#3&3RVT<)<IP&[^E<?/HUKJ.H27EC=I-- Y$J$_=
M:NGD,WEHN_+9^;Z5YUX>+Q?$36&B/EPR;F=<X&:YZ^RN;45>Y6F\*076H7)N
MM3@$S_<3/6O-_$?ABZTB]8RPL(RWRD=&KJ-?TDW=W<36LK-=*274]S[56CN-
M8N=%%GJ$C@P?ZOS.HKB3ML=R5]RIX:\/BXT>XO9)=DF[;%$PQNKHM"U+3-(@
MG%_$XG"E=@'!JKH[((%CO-[PQ?,& ^Z:TY=$@UD_:HB?+)&X^U2G?5!+31['
M$75O)J&JEK.#>S'*QCTKIC9:U%H(CWF)8FR$;AL5UL.D:?IZ!M,189>-TC#F
MLSQK<!-!*P#?<YR6 [5;2MJ3SIO0Q_#NMVZ7AT^=I-TI $C'OZ4^[T"_T#59
M/.(^S29/7@UB>%8%EUZU-Y#N1F^4>]>AZS96^I).P=DDB&,MT-"BW <I*,['
M)VL-U=W(MK+<%(X1?XJI7$TFC:Y'+>3AYH6R5STJU,E[9 -:SM&JJ?G0X(KE
M+?3)M;UQ 9/O-N=I&YQ]:B*UU+;T/4-,\9_VA*2]D7@W !L\BMO7=2BL[!YH
M%'G. -_MZ5F7>FZ+H'A^%XY_)^3[I/?U!KC7U^VEMVL[-VD)?>=YZFMY-Q6I
MSQ@I/1$UWXHGTY&>PB,=SD$R=JP;CQ'JNI7?EW-ZTZ-U[8IVLQ745S#]GB>6
M.;&<#//I6W+H]OIULLC0>4SIDEA6%Y-'3[L68]KIEKJ5]]FN)"\8&XE>HK.U
MG1K72KU#;76Z!&R#CYJV'\2Z:;>""RA6*X@X:;&-].O@FI:$\:VP:\C;S"X/
M\/M0KK0'W-_P_>0ZY8O#&6+*F&[-7>Z'JWV&U2UFG$B1D+ES\PKP+3M4FL+Q
M)K7<&48D4?Q#N*[F/5[2]=+F(-"L@ *OU5QWK>$U!'/4@Y'M8O+=E!$R_G6'
MJ%\EW>8B/RQC&X],UR>CWQN[J&WO J3$<./XES71W+_(D%I&F-VU5/?W-;)N
M6QSN"CN4XC<R7!D*>85? YP%%</XMT^WGUTW31EI/, 8CH17H\;M"_E7Q$3!
MLDJ."*XG583=WS7EK*6C9L8'M4U[LNANS%\?0V\NKVT8A6)8[<<IQNZ5FZ%K
M\?AJRU&XA#-<O'Y<;>@..:Z7Q]I(N['3]1A?]XL(63'3'%<9I-PME=?OH5FA
M(Q*A[CVKG;U.N/O1,=1<7;FYW%I';=D]2:2ZL0$\YY</GYEQSFN@L=2TRV\0
MF=("MH2?+W#E:=XFT_9J<5\"LMK<#.U.M3?4HU/@Z''Q&M,D[3!+MS_NU])U
M\X?"4$?$ZV_=M&I@EV ^FVOH^NRC\)P8GXPHHHK4YQ#P*,CU%4]20R11@,5^
M?G'?BLF2Y6S3DLP!^8 =*:5Q-V.BR/6C(]:R(+F&X3,9+8Z\4><J,YQ@ <>]
M%@YD:^0#U%&?>L&9F<"5(^1V/6I%9]O*X)'%2,VMP]11D>M8$322H7<;".,=
MC4@!V<_>%#W!:HV\CU%)N'K7.O(R-MED51VQ1'<(6=,D%!D$]Z;T$G<WY9T@
MA:65U2- 69B> !6#X<DN-0FN]9N)&6*Y(2WA)X6->A^I)/Z5RFJ7TNIZA'HB
M2N8Y3NN>.D?]W_@7(KJ_LJ&!;<86-<;0!TIO1$J5V=#N7U'YT;AZC\ZXC4VE
M!VQ*59&Y8=?PJU86D[Q*\ER[;3D$]_K4*29HU8ZW</44;AZC\ZP04C=G$@7/
MWA4H<%PL@4Y^Z?6G="U1L;U!^\/SI0ZGHP_.L*XTZUGD\PI^\Q@-Z4Q+8VZB
M-1PO0CK0@=TCH<CUHW =Q60BL54%BWK45Q#O4<[0IIZ"Z&WN7.,C\Z-P]17.
MF%4<RQ@-(X.UCVJO:><+T/,=N1@CL33M<GF.KR/6JFI:A#INGS7<S#;&I(&?
MO'L![D\57'7&>2*Y;4436/$$>GAA]DM&66X/9GZJGX<&G&-QR=D='X<AN4TT
MW%[(S7%TYF<$\)GH!Z< ?CFM?>O0L/SK.6/ 7:VU1SBJLULAF2<9.3@[:+:B
MN[&YN&<9%!8#J1^=80G'G/\ NRLB\*QIS0R7#IYK*8Q]X#O1RH?,S;W#U'YT
MN1ZBL6XM08U"/LV]#4B *0AZX^]ZTK#N:V1GJ*-P]168VY7SMW+3)4B\OGC)
MI6&:VX8ZBDW#N16<B)&O %5VA$SK)*F'C;*XH VLBBLO)+APY /;UJQ;9^T'
MG^'I3L*Y=HHHI#"BBB@ /2LI$945B<,#D^XK5[5G##OG;PO- #@A\UBW([4K
M'!P...:4 G)/4FL7Q-J TW0KFY+8=OD0Y]:J*N[ :27,,N_RY Q3@XZ T9<_
M,715_O5@^"K:>/0_,N>6G<N/<5:UG4[;3K1I;B [!PN.YIN/O6 H^,I;E?#L
MRV@+X/SMWQ7"^'8(&:XDO@PMD ;=[UI:CXEGO8Q]EF>./[KIC!%4&-[>6C0%
M@P89"@=3773BXHA[BS7V^ZN$6)1;2@JGKCUK5TJSMK3PI/<7A(=&V=*PKM4%
MQ#%$C17& 3&3P35EX=36U>VN$D\F8@N&[>]7+9!<SH0;^^$$9 D8X7=70Z*U
MQIFJ-9R!H9CQO4\&J=AX2OUU%)8?FA4@JU=7+9))JL6_B0 !LU%2:V&D6)QJ
M1"LZ-.?]D=14VG:I&S26TL31R?W6'-:\@>)(EB)P"!^%5-5@A<I<! )U;&['
M45S<RV&7=D>R/>.13H40#<IJK:*S0_,22#5^)=J5#&.QFEHHJ0"BBB@ HHHH
M /2J^MRB*W@)/WI@/T-6!6?XFA>6TM0BY*W*M^AH YZYCDDU]9-_R!<,OO65
MXJ-Q%?6**C!>-K>AK420#Q1+#NSY@X/I717=A#>1HLJABA#*3U!%5'W7<ILS
M&CDB>WDD.2$ ;\14JR@7(5021R,U-<*95V.O^]4<4 90C<LIQG-9=;E=#&%K
M):^,-Q7]Q.O)'3-=FJ!$ %9MLB-\K)N82?+[#BM, A ,]JT;NB&(1D9[BD()
M!*CDBG4T#"X_R*0B".Y4W1M]I#!<D^].E.PHQQC.#3I,E5;&6!Y-*X&S:1P>
M<^E,9FZE*Z6<K10B23:=J^M>9QZA?07ZMY.W<^'CQD,/2O3K_P P6%R%V@;"
MI(/.,5Y#:37$&LQ7%H9)&6;:!V'/>MZ*T8F:FHZA?6^J;(R4A#8$8&%(J[=:
M#"TV9KO[/&_)#=:9-;R76L2S7$BHH;<0WK2:ZSWKB1)%;. ".U:-M["1T-E%
M:6UFL%O<"6.,Y+>];%G?.KLI1FB(&,#O7#Z)&\-XH7+1JGSY[UZ+:3Q3O&8L
M!1'G ]:YIQLR^A>&=HSZ4M-&3U&*=4$A110: "BBB@!1]X?6KE4U^\/K5R@
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MQ9NWI4VG0F*=R6+9'6@+ZFG1114E!1110 =JSXBQC)8<@\#UK0JGP%&.F.U
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M+Q[0NG!FL2"AI0Z][63Y2];F"N8_D,^S507P*2^6C]*<HX#XEB&PHP^ERF9
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M#G&.RMG;"0JCCGPFSV3SA+<F-KIOAE!$U6O)Q+#R9CUP1YAFILP!B[NR'81
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MUELN83B]>NH<9,1T9HMI6C !\AC'9&:&GS <'L "S7A=AY4?!)%MZ&::09\
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M%JT4$X4W-6T*/%3>&VM<_)$K&;*A<P)N<DUNNOO>B=;D1 YVB>1_(%(C(#/
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M6S?"QQ+$DIMK@I$SKDJ,C@>E(#T%?$VC&TM[AM0A$<ZEHVR<-CK4%SXGT_\
MLR'4K6]A>R,FUY<D#WKF?$NDV$NO^&=.%O&EFS-F)% 4C'3%2:[I6FR^+]%T
MF:&*+3UC>5;95"H[_3IT)I@==IFO:7K2,VG7T5P%Z[#TK+\+:[<ZK/J45V5)
M@N6CC*K@;1_6L74-,T_0O&^BMI,<=K)<;DFAA&T,NTG) ]P*O> U#/K1(&1?
MM@_@* .R Y&:8B;5Y.3UYI](S #<3@"@#&(<:JUT9P(D)0J?6L+QSO\ ]#DW
M'R22& Z9K<U18U3S,[59P<@57U.P75]$D@WAID^92/6LJRO#0VHM*>IP+2;2
M-K8QZ&K%C<W"W".ASM;)!-9;"2-_*D&'4X(QS6S:QK$H X;&37FJ]ST7:QD^
M)85.KM>+'M28 D>AQ6,&!)YKK=0M&O+)US\PY%<Q;:?+-+MP57/+&E)-LN#1
MTOA"ZGMH;J?&8$&(P>@?V_2M+<9-S/\ ,6ZTW3<G3'LD14BC(;CJ:E,85<+6
MO0Y[KF9S>MZ5 B_:8V\MB<%165';Q*RL<L0<X[5N^(9 #%$!G R:PQTZ\"L9
M;G3#8N.5=_-4!0W\-:VCZ+)>RB68%8E.>1UJ#PUY,EPZW$2NA.%+=C7=)M5%
M X7L!6L*:EJ85*KCH5#I5ID-]G3CD<5P_B6_:[UI_+8F.,!%KO[FX6*$EFP2
M#BO+IPWVB0GJ6-.JTEH*@FWJ-^US1<JQS71^&/$3"3[%=8(<Y5_3VKEVR/>G
M6,$UWJ$5O"I,CL,$=JQBW<Z)Q36IZK*(H8FN9SA(QDY/4^E<9>:K=:C>&225
MEB'"Q _*!VK8\1I=NT.GI%(R0J-[ <,U8_V"Z!XMI<#_ &:WJ.5]#FI*-KLH
MS)M;&<J>AJ.'Y+F-AC(;.3TK4_L^XF(C-M(-QP#MZ51U+1M1M6\IK=WW#.5%
M9<DD[V-N>-K7.VM;J&ZB5DD1CCY@#3[A_(MY)#@ +7G$%GJ=LX>&WN$(]!72
M6=]J%U:36M_;2Y9<(^WO6RDWT,902=[F:\OF.6;N>::%/..G:K']GW:?\NTG
M'^S4@LKORV;[-)D#CBL7&5]C:,EW.-GRU[*V>YJ1&*X(X(YS4QTW4&D<_8I^
M23]VECTK499%B6SF!8XR5I<LK[&G-&VIT^G2-J=HLB EE^5_?%:Z8"*O3%-L
M--FL;:.)(6!48.!UJ\]O*0&$#>_%:J+L<LIJY4"EOK5WPG?,_C$VD;_NUMW+
M@>N1C^M4;HRVEK+,87PJYZ56^&[F7Q=)(QR7@<G\Q50NIHF:3IMGKPJ.?[H^
MM25!=-MBS[\5Z"//,_S&:8]".U<UI7C:'4?%%[HLT AD@.(FW9$G'/T-=-:M
MEG4CGD]*\S@T7^TF\0RVK"/4K._\^W8<$D(IQ]#TI@=]JNM-INHZ9:+"'%[(
M8RQ;&S&.??K5N6=88V>21(R3@;FP*X*778_$=YX:;!CGCN'CN$/56 &:YW7M
M4T_5/$^HQ:[::M=V]LXC@AM =B>YY')_I0![%]J46Z%#O#'EASBH?M< N)$$
MT?R]]XS7EVD>(+FQ\,ZY%91WT5O%M^R-=J0\>[.1^'%2:SX LM,\+'4H;N<Z
MD4#2S^:<29Z@T >L6S;[=6]:YC7_ !B-/U'^S=-L)=2U%5W-#&<*OU/:MO05
MV^'=/7_IW3_T$5RG@@*U[XA9V_TK[>5)8_-M!X'TQBD!<T7QI<W&I1Z=KFD2
M:5=3#,(=]RO[9KH[^:""+]Z57=_>(&14.IMI >U?4Q!N24" RKDA^VWWKAIM
M(C\;>,=1M]4EE>RLW$<4,<A4+P"6X^OZ4 >@1/#+"LFY3$O\6>*>9K4KM,T)
M9N@WCGZ5YM#!+HJ^)?#R7#364%J)8-YR4#;AC]*IQ^![1O 4>MM<W+:I'")8
MY?-.$] !Z4P.\U+64T?4;"W8*TEU+Y9W-@#@G/Z5IW,\"CF1$?(ZL.G^%>=:
MYH=EK=QX6O;Y7>>\*).P<C(VD_TJ?4_#EKK'CVXT^=I/L<-BA\I'(W8V@ F@
M#T!+R 0$O*BCH"6&#4<]W%964MS&5E98F90&X( )ZUP</AFT\2^);K3+YY!I
MNG0QQQ6R2%<G:.3BGZ=8MH&KZWH<,[RV"V#S0I(VXQ94C% '8Z#JO]M:;#>O
M&(FF!/E@Y P2.OX5=N04D20 EAWK"\$1J_A?3V7[ZJV?^^C6_>3(CQ0LX5I<
M[2?:@".Z<-"QZ>H_K3[:0D@C)4CKZU6\P>2T;\OC''<U-:$?O8U.4(SM'4&D
M,:$*231OC;G<#Z4MS_JT'.!T(IK2;I K(2",$^E.F#H6V'/E@$ _Y]*8#2%F
MMN.2/6FP(KW&X@@XP1_6G%QY#2H -U21$&19%'. &'M2 ;(/*ORX.=X&?I4;
MCRKANA0GY>*EDQ]JCR>.AHE0I!P"2#NQ[4 ))\B&/&X!@5.>@HB8*9E&.#G'
MI45Q&9HRZG:2 1G@4\'9MD<* 1@MF@!TW[T(^X*Q7K1&1)$Z8.\*.?[PIR0@
M!LD,N/7IFDM4P%W'[I(!]O2F! JIY21J2Q5N!]>U/=VM_+AD7<IZY]#1>;;*
M-IW=5^;.X]A37U.UEMG>5T" ?>SP??-*X;DD:1)'M7)13R#U%,C1HF,?5&^9
M*B@GAOU8VKYFC'+#H:N!UGA"@A9$[>E,":,!U!8?O 1FM/M6'$#)/AB4=2._
M!K<I"$K%>XGB:1)0I+2-M(Z 9.*VJQ+D;Y77K\QJH@4425DE,A^0<C%2FXC@
MLXX@2KS?=R.AJ2W;]VP<;7!.5SFJL]PTLZ$P<=SCI5[B','FC6/)$L?S9'1J
MJ+-<>3)^Z>-]X/RG&:MP7\4DC*N058+R,59D1N&()(Z4[@8M[8+KMC-8W$;6
MX?&9% )X^M6[R.W-DUM(%>*1=AWCJ*GN)I(VC,49*L?F]J2\@ADV&<@?W 3W
MHZ@9.A^%[+1]'NM*4/<6MT26#C[H/:L.+X?:>+[8^KW\L"=+5I#L [#KTKMD
M,MM:,\IW >E5V1 HFQL\P=0,FE9 <;XV.CBXL;>]:ZTWR4Q#J$&<1@?P\<__
M *ZS?!UK:?\ "6?:]/N;J]MTAVO=SAOWCG/KSTQ7HB"WEB9)[..>,'I*@8?7
M!IDB10*6AB2.U'.($ P?H*5M0":VB$<Z2@S1N/FC89!'IBN0_P"$"B$L*VFL
M:I:6TQS]GBE(1?UKM;N:$Q1^6QC9\8R.:L;F:ZA@BB#A1F5S_3WIL9CV/AG2
M=.L)+&&)61AAMYR6'<DUA/\ #G389@SZK?2VJG<EBTA*8'8<UV<U@LEPR99<
M\[@>U']G*L\<@=CL^[F@5S"DT..?4-/U*V=H?L:'$. ,C!JU>P03:A;:VXE+
M0(8O* ZYR,_K6X\"-+YAR&QCBFK;_O"=^5QT(%&@KHY5? \,-Q?W]K=W"K?1
ME7MCC:"1C/UK4T?3AI^BQZ;. ]NJE'#@?,#6VD;++O\ ,+#'W:;+!&5=Y7^7
MKGL!2\AW.(G^&-FLX*ZK?C3RVXV?F$QX].M:FIZ$MQJ.EW-GA([+(2-5&/H:
MU-/\0:=JMI(R2"-%D,8,G&XCTJW:I#)%YMO,'C;D,IX-"5M1*29#%_HL"?:"
MOF]"%[U!*2H$D,996;#^U:4UG%-('?DKTQ0+<< GY<]*+CN5H;6)"98APXY'
M>F6B)!,\9D+%OFP:O"!5F,H)R1C&>*;Y$1E,FTAL8S0%T5GW,[)G"@9KRB2U
MO;GQ9KB(0T F(^8UZCJ$+"-8_,8!VX<=J\RF\66.E^)-5M)K'[DQW2@GYS7/
MB5[JN=.';N['1>%;N2UC^RW@$84_*Y["NWCGBE_U<B,<9P#7E.IZO%J,1%L&
MCA=?E..0346GW=WI!CE2:1G4?QG[U81K):(UG1<M3U^L_6)?+LBOF;'?[I%0
M66O0/I45W?.ENS#!R>OTK-U/Q#:7492 I)$!]X>M;.<;&"IRN>:ZSJU[#>RQ
MM,8V;.P],BGZ+IMYJL1D,&^,G!ES@"MO_A%U\2745O+,PZL)E7[H]*Q9KS4/
M"5_+H_FG[&).?<>M<LHN]Y;'9&2:M'<[>>VCT/1XHWOA$J=-CTR.]CU2T<1,
MLD03(D[@UQ^H^9JEA<NV1Y8RA+<&N>T;6[K1KPM"_P"[==K(>0?PJU6M[K)]
MBWKU-/4]"@UF].Z63ST_UAV\$5TEAJ;>']'CLXEWJ@*JV>>:YVWO;MI6*R8W
MC@\9(K;TG2H-6L7;4;U;,(V(W=@"Q^E9QN_A+E_>.+B\)7'B#7G,-Y%%YDFX
MM(W*\YKU'3Y] \-MY-U*+BY0!&(&ZN2US1H?#I62*^CG,YX,;C(]^*Y73+'4
MYM>18(Y)6E;.2<Y%/GLK,.52.]EM-.U?7GNX[.W\@G(^4!A5#4?!]Y<O<7%B
MTDB,/]6#4^EZ%J9US?=2"UM5/S;CR1WKMM+C$4MT]M.9+=F 7GI5P7._>,IS
MY%H>26G@[68-0BDGTYY(D8%E)'(K=U/0-8O+YGLM/=87; 4D?*/SKTW<6'4Y
M%2VHD:X!W84=36OU>+,_K4NQXY=^ _$6FSF>.%F8KE2C=":R[3PYXPDDVS6,
MS<YW,X/]:^A;I5CBVEB6-58$9QL5L'J>:;P\06*D]SQJ#PWXBMY _P!BD.?O
M+N'^-:-EH.HPN&ETPRL#N(<C)'YUZK(?*C9B&;:">.^*\YT_6+FZ\7332RW%
ML\L#K&LBD+'C.#S_ #I1PD6*6,?8Y1/A]KLFOM.UDQM7;<5!' ]*TG\(ZE+(
M\8TR6)%^Z=PY_6NW\'ZY>ZO+=&\G :$A%0<;NOS?3_"NO.98]O.[-.6&5Q+%
M2.+T;1IGLE6ZL!MC3:5)^8GUIMYIFJ6KR6UE;NMNZ\A3C-=5'(Z3\G!JSY[,
M,,#N)_.J=)6L3[5WNSRAO"VKJDGD6SY8],C(J7P_X/U26Y>"^7R8VR0[8_*O
M5),1 9RI/-02.L[J$8Y'K6?U>-[LT^LR./\  UE'IOC-;,9#*LG4^U>MUY9X
M4L;T?$>YN9D/DJ' 8]\K7J=515E8SKN\KA1116QB5KW!B&3WK&DM1*Q>3!';
MBM>_C\R)1DC#9K'$+QEE>8MN;(%%[":N0(YC=(T<RG?SM/05=GV,1'SOQD&J
M"V(25GB)48)P/6IT\PB,2$[@?Q-%[BM9V"22.$1QW!#-GBJFI:5::UY0U&!)
M(H'WQJ>A/N.]2-:.+@.X,@W<$_PFIY,F6-<<GN.@I1;N-I-#-/NX9X'6S3;%
M$=A39M ^E*T$L)>2.4X;D"KP5$4!%_(5GS)<8<"3[IX'J*=]1->Z:D8 @4J,
M$C-4I;F9#D >6/O4D5S+',JN<PLH"GWI$:6YEE1E7R_X<TUYBD]"N56]D*#<
MC+SN'>J5TYL'>>)=S*.<\9K2\MXV*QN-@Y..M4=0N]EB]Q%")F3JA_G2DK+0
M<6F]1^GZRM] ))H2N>/I6G&8BHV@&/'%<[#=175JCI'Y1)PP XK3MYC$K+(N
M%'0@YXJ$W;4II7NBY(\*';\@4KP,<UR6EW.KKXK?S(V^Q-D#T KH72WE3S?,
M^=1^=1+YBP[X=S;CG'9:)PTN5">MBMJ7B6Q^VMI4KO'))PL@X --TN*X?-OJ
M!WJK?(Q_B':J]WX>AU#5(KRYRA3!;T)KAOB/XCU#0/&5HUA.55+5<H>5;YCV
MIT(2J3L37E&$#M[PPZAKT.DA?]%MV$US@<-S\J_H<BNC5DCN&+HY)& O8BO/
M?AOXQMM3#V,MM(=0D<RR2[-P)^HZ#CO7H]Y+%%%')))LYX85M.+BN4RA)2U.
M?TOQM8/K$^CW.894?;&[# :M[496MH 84#,3@ ]*YO6?!UAJVKPZGN<,3DM&
M, UT2@OB.7A5&!STKGBI+<Z)N#^$9'(;C_6924CEE-$\5];VI-H^]L\[O2F?
M89%NHVC8XZYSQ5I9I(Y=TF=@.">U7S&=NI1C-W*B&3(8'G!Z5H/<.%&6 CZ$
MU*NQV8J,$U#)8L\;(&#*W4&K6Q+O?0G@=<;%4[ .#ZU+SCIP.M0QQM"D<8P<
M?>IQ#2(6C?YL\#%(:;MJ3#&W@5%-(5CXXR:BA:>,,TY0YX^7M3;J+S2%Y]00
M:+ WH60OF1J& /?D5"]FA?< !DY(J.W6[CD82N&C_A/>K>-Z8/7ZT7L"5UJ$
M:@#!QD'MZ4%XQ\NX9[#-1)&(YF<R AAC!-,S;B0 (7;/7%&@_>)F7>%]1^M%
M@VR^>#R2H"DA^QYJ /(=Z.V/FRN.PJ]:C]^"#D!,4K#+U%%% !1110 =JQI;
MHK,J*AZ_E6R>E<=?>9;W@=69RIY4GJ*J"NP//?&$TY\1S[K@OSA=K<+^%07C
M_9M(*)'FXE@)W*,Y^E:&IZ?I^L:O/)97PBEF;+13# S[&K.K(=!M[2S6)2\:
M;C(5SN)["NY-6L1U.7^P"YT2.*='2;RU*%@1@@<56T3PW?:W+?"?= P7;N((
M#G&!]:Z3^WI+Z$1R0@M%SG8.E6=*U"=KV-ED!C)QCL*3AH%SCTTW2[9?L=UX
M7U"2_4E2R2-Y;'L<YXKH&TN^TBWL-1@T]I!:*5FMD;<0C8Z9Z]*[Q,.^<@H>
MI%9NLZ->Z@\)TZ_>RNH6RC\E#G^\.]<S5BCD]-U.XU3QCH[&QN+:U#L$$ZX8
MGC->JWNE)JFBW5I)QYZ;<^GI7/:'X-U2#5$U36]46^N(T*PB--JKGJ<8'H*[
M9%*H%]*R;&>;6/B_5?"UK'I&KZ#?74EN/+BGM5WJZC@$\UIZ3!KGB*/5+[4%
MDL[>Z@:&VM&/W>,;C7;T4@/,+;Q;K&C:4/#\OA^]EU&-3#'*B@Q-G(4DY],5
M9FT6\T[3_"UM+&TDL=YYDVQ20N6![5Z(<YI/SJK"N<WXEAEDU[PZR1NZI<G>
M5!PH^7KZ5E1W4^G?$'5()K&Y:/4(D\N=%R@QNZG\:[G^=&?>CE%S'(^"K.8^
M#9K66-XGDDE #J0>>_-8%CXGU7POIA\/W&@WMQ=Q QP30H#&R_PDG\JZ[Q#J
M%S9S6J6MVJ32-A("!E_7.>@K,A\27\=U=2R/'-&J2/Y1P/+"L!_*J5-LES29
MBW.AW]AX:T6*>)GNGU$3S+&N=FYBQZ>F:].'2LS1-3;6-+COO+6,2\JH.2![
M^]:/-3RM%*5Q]+48SVH.118=R0=:AUA@MHF21F0 $?0U(E5/$>[^R]R EE<-
MQ4C1BZY;)<Z=D!BP&[ [5!H]PIL+<2 M@E0!U'UJ_#<I/:H[\*X^;/:JVF0)
M9F0,I*;CM)]#0WI8LU(3M=0WRC) Q6-XB:?3;JWU>W4YA8+,@_B3/-:TK ,&
MCQR.]2S>7=6!,F&4KM8$41:3L*2+$,D.I6<<\3[HY!N#"L=EE266,X*@]^]/
M\.64^EO<61?=;[M\63]T'M4]_#B21QG<1N HFM0@R72I6.^)@<=C6B>G7BLS
M3FPV_P#O<'!K4[TEL)K49&<K^.!3>22IY(Y%*O$K(/3.*4C!# ?-3$"].O3M
M2L,BFY*9)ZDT\D!230!7>,$9VAE P0:X?5O!=J+]]0$QCA7YC&?6NZD<J"<$
M9( Q6?K5M#>6WD3;BCGG!(S5P;3$SRZ^,D\C)<-M?I$>Q^E2Q:%XC@F@D 81
M*<@AL_IUKN!X=TSR(W>$LT9_=EF)Q5_3].A@N'F1Y2<<[G)'Y5T.IH*]S*OO
M$":9I$<%TCK+(I4D]L]ZPM.LI8KF"0!9;1\Y;.<@^M=7K6B6>H1O/+#YDJK\
MH+D#\>:Y>WU.#3;:!([%M@;+Y<X W;<CGGI4QVNA.26YHVMI96<<AA )E)W)
MZ"JMKI-G)J37<-R-J'.RM?3+_2M6FNK6VAD$J#][N4C;GM2VV@65K(Q2-P6X
M.6-2K]2N9$-S,EM UTSH(P,L,\USEIK<FI:BELH,4<S?+747/A^QF'E2(Y7T
MWG!I+?PMIL4Z3I$P*?=^<\4K12'S:FI:P*D&QT$6UPH]3@]:Z45RM\[B:TC#
M?*T@R:ZJL+6&W<6BBBF(0UFJZN6QC@XK2/2LU8PF[:.IR:: =3)2PB<I@-CC
M/2G4R3;Y;!N01@T 8^FZ+Y>JMJ\LV9Y8?*9%'RXSG-5M=\%V&O>0TTCQRPRB
M1'49/7I]*Z&&-(X55,[0.,TYV"*6/0#-,# U_P (VFO10$W$]K=6Z[8KF!BK
M@>G%1Z'X,M= EDOI;NZU*\V;1-<ON;'H,FNDB99/F7E:>W/%2!XC>CPM)-=-
M_:FJZ:[LV_25# .WX<<UZ-X"L9=/\'V4,T;1NR[RC=5SV-;DFFV$LYGDLK9Y
MLY\QHE+?GBK(I@<_XK\/6.MV*-<I(LT+9CFB;#Q_0UC:9\.K9+J.ZU#5K[4X
MT(:..XD)4'MWKN'561@W*D<BDA*>4OE@;.@QVII 8GB+PI:>((X2TLMK<0?Z
MF>!MK)[#':J_AWP;:Z#<27;W=S?WKC;]HN6+,!Z"NGI,4<HKF7HNB1Z+9S6T
M4SR"69I26 R"<<?I5'_A$;5O#4^B/<2F*5B_F=&4FNBZ4V61((GED;:B#+$]
MJ.45SF[;P<D#Z4\VI7-P^G$E'DP2^?4U<\1>&;3Q'!&L[R0SQ'=%/$V'C/M5
M*T\9VSVUS=W,9CMXYA'&4YX.<$_E7203"XMXY@I4.NX!A@TW%@I)G,^'_!-M
MH=XU[->W6H7A&U9[IRS*/0<U?T?28-"EN(TFDD:\G,WS#H?3Z5M$9&*:$&!D
M D=#2L.XZFR<1M\NXXX'K3B,=0:"?3\Z+!<HND=S%AU!VGE?0UF.SZ??I&)5
MV2/NQCM43>(+>RU.ZMID*KYIRXK1GMK?4X8G6094Y1E[BLHS3=C64&M3.UG0
M;&6.;4!%B=1D8Z&N7C3;@G&XBN_E59+9[?/+)@"N'=#',R2#[AP?:N6O&ST.
MFC-M68B?O'0 C;_$/:L^YN?M%XQ10D:G  '%:<Z?9-->X'!E.Q/IZUC;65?3
MWK">BL=$-7<U=.N%#2(0.5ZU,^ V2??-9-K*L):1UR,8Q[U+=7?FV#^3Q)T(
M/I1?03CJ8FI3FXOG89VYP*J>6&;:I/O4K\MM'8U+#'L4OZUD]6;K1 @\M0$)
M ')Y[UT^E:H[Z4YD<F2-MJ5S;)QUX/-:FG*JV1+=S51;1$XIEF6XDF;,C$FN
M9U,^5=M[\BND9T4<#-<[JT!-S',<A2,43'3LBAOD8$!:V],N6T:)$0)]MN&&
M7(Y1:J6^R"W-W*!C/[M3_$:IBY/GK<2'<0=S'^E$='<J2NK'J.GZM<7.J26D
MF/+0'![G!K:K@--U^/[2=1M]*U*6.8$J5B)!S^%;P\52$9_L+4^?^F1_PKU^
M1'B\QT:<R"I;A=T>>XKFX_%#YW?V'J>?^N1_PJ4^+'((_L+4_P#OT?\ "FH:
M"<]32YK+US6!I-FK!U6>4[8BW0'U-46\52*Y']@ZIG_KB?\ "E;7(KR(K=>&
M=0E&. \&<?I1&.HY3T*L/BNYL_#%GJ4^R[#L4F9< ANW]:ZS3?M%W81S7"+'
M(Z!BJG@9KCA_9@MXK8^&]4\B+.(_+."3W/O6MI_B%;"R2TBT/5C&@P-\9)Q5
MN*>QFI-;FZ89%&2,T^!#DD]JQ_\ A+7'_,"U/_OT?\*C_P"$J=3G^P]3Y_Z9
M'_"HY+%<]SH^3TJ-I&C/U[5QZ:AJ7B_79-*LII]'AMXP\A=<2N3Z9'2J\/B#
M4-%U>[T2_BGU62W =+BW3)VGLV._%/DL)339H>(-4F=KJP4+Y1B/-8_PSROB
MHJ?^?=_YBJ^JZ[$MPUU/IU_;^=^[0RQD+N/X5>^'2 ^*C(IX^SOQ^(KDK*U6
M)VT7^ZD>MU!=('5<]F_I4XJ*?[@^M=)R%*#&6.TK@XYK!T;P[-IFH:M=R21O
M]LE,B!<\#:!@^_%= \0>+82<9SD&I , #TH XJ;P-N\6V>N6DRPQKS/ Q/S-
MZCMG&*;J7AG68-3FU+P[J\=FUP<3Q3IO3(_B P>?\*[.698MI;/)QP*DP,=!
M@]J .)?1C8Z!J)\2ZK+=&Z'[^09V1CU11T_ 5Q>K65^OAP1/XML[O34"K:P1
M\S2<C ;C/3UKUVXTU+JVF@GD,B2GD$=!Z5CV7@+PUI]ZMW;Z8@G4YW,S,,_0
MG% &IID4D.D6,#@[E@0-ST(6N7U7P=J;ZU)J>A:@MC<NO[SS!F-SZD<\_A7:
MI-&[LBY#+QR*=(7"?(H)]#0!QFG>$=5NM3M]0\3:I'?-;'=##"FU WJ1@<T[
M5O">JQ:S-J_AS4X;&XG&)UG3<C>_0\UV2@@ 'K3)4\P;"?E(P1ZT <CIW@V>
M#2M2-Q?"ZU348RLEP<[1QP![=:TTT&=?!@T3S8O/$'E;^=N?YUK-;_N5CBD9
M O0@TY1, F7SM^\".M.PKG+ZIX5U"YT?2(;&]BAOM.*E9'7*' P>U6[31;V#
MQ0^J7$\3&:T$)" CYAC)Z=.#6KJ6JPZ8$::.1D8XW(,A:J1^(+&Z9B)C!Y;;
M09!C=GIBFHL7,C*UGPIJAU?^U_#VI1V5[(@CF$R;D<#VP>>*BT3PI=VO]HS:
MC>K<ZI?PM&TV,(O&  /2NOBW@99MV[D>U)*KN4*OM*G)..HI6'<RO#FE3:-I
MD%E)(CM$I#,O1N2>,_6KM^51X9GB#Q1[B^1DCIS4I$P+$OU^[@=*;/:-<VWE
MS3,058';QN!H8UJ1VDUK?VINK*4/$P(&!CFO.M(\1ZO8^+M2&HV<P$N?*C4<
M':>WYUZ!H-FUII,<,D A?)R@/ZU>>U@DGCF>)6DC^ZQ'(J=2C+L+^#5KU?+=
MX98T#R0,/7UJW-<QQ>9))A58[1D_A6>F@/:^(IM5MI K3C;(I/&WO^N*DU'1
MI=3MUM9I-B(X970X/6FFQ%I5_P!':,D<]/QJS$-MOC'.W&:I_P!DQJ8E-Q(3
M",)D\9]_6LV&'6;EYY;K<IA8K&L9 #T :GEF8D'@>OH:DCF\Q0DGWU.*IQZM
M';QE7AD\X+S#U)/K3HKA=0?SK<#V&[!![YH T0%,7EN0RLO# 5G:EICW6C'3
M8YGC9S@2=P*TXHRD"H0,]P.U/PWH:=KBN<]I&BW^CY,]TUTJIM SUJ7^S;VY
MU**\2\>.&,\P#[K_ %K<PWH:@O7:&PGD!==J$@HN3^ ]:.47,1:G#+,BQB!9
MX6XDC)]>]<38>%=8AOYHQ&%TQW_U4K[N.^!S@5H6^J:V'M6/G.A0MAH2-W)^
M]QP<5T>CWES?Z>MQ<P-#*6(,9!&/SINFPC5,O1[2\TF:2VM[4"VSA23D"G7&
MJVKZU+8-%+%/&-P?!VN/8UT)!"G.0!US5&"[T[47D2VGMYY$X;80Q%)18W-#
M8[B(K$05?!ZBM_M62EDD6-BA>?3K6M2Z@)6"3(+J<O\ <#G;Q[UO5SMY:R/(
M^R;"B0LWOSTJH@2)$'+2J.2<9J-3))>M J84#DD=:DLT'F.WF'##&TFG/(T%
M^@QF(CKZ55Q$,UJD>SY!OW;@139'N"^=P"8Z5-=W*NXA5@LAZ5#=@BW*G/S#
M!([4UY@6GC564*,[A^M/N(H&B_>H'*]O0UEP>9'<*WFDJHZ'K4IN&ENRA3 (
MZCUI-:@2/-)#&Q95DA(^Z*E"BYMUE4!5'\![4V/'RQ \ \\5"UZB?NF)7+$
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M[[6+:VCA70IF5!M!:89Q4NCI>V/A:Z">:UQ'(^PR#+'FLM]:UR[9!:B2-6"
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MIM3N+2STQ[@VY =Q(%&2/>MNLK28)H==U::2-DCE=2C$<-P*J)+1'_:&K?\
M0"D_[_K0=1U8#)T.0#_KNM=!O7^\*CGQ+ Z!AEEP*?,+E.,OIY]5>V9K%P(W
M.Q8[N/#GT]ZA;19G4JVB7!'F"0 W"\$=,58A\*WL;6X^T1+&C'"9_P!6,]CG
MVK1U+2M4NKZ0P7BI;NP8#/(XP15\RZ$<H\:AJP4#^PY#QC)G6LW6]>U>QL X
MTLVH>18S<22!EB#$#<0.PS6KH>D76F73R3W?FQLA&"<\[LC]*W)!#-&8Y KH
MPP589!J7-7V*Y78XG1M>U6>>[M4B35D@8!;R!PJMD X]"1[5T6DZC_:=B+GR
M3"0Y0H3G!'O6C;P6UI&([>..)/11BLCPY:SPZ=*DL91S.[8;N#CFDVF4DTS4
MHJ3R7]J/)?V_.H*(Z*D\E_;\Z/)?V_.@"$KGKVIU2>2_M^='DO[?G0!!Y,1?
MS#&N[&-V.<5%#96\$S2Q1!7?AL5<\E_0?G1Y+T6"YA>)]_\ 9"JDKQ^9<*I9
M#@X.:?\ \(E:_P#/Y>?]_:T;W3%OX%BFR%5Q(-I[C_\ 75W$OH*KFML3RZF!
M_P (E:_\_E[_ -_:P-3M[?3-0:V=[MDV?*[3?>;T]J[[$OH/SJK+IT$\IEEM
MXW<KM)/I34WU$X(Y"*VTW^S;>[N+F\C\T/P),CY<YJ& Z1/=1PK/J7SL%#[S
MC)_"NT?3+>2W2W>VB,4?W4["E73;="-MK$-I!'MBGSBY#%NO!MO/:2PI?WJ%
MUP&\WI678>#+V2[MGOVAM8[2(Q*;/*M-G'+<GT_6NWQ)Z+1B3T%2IL;@CG-&
MMC8ZYJ5FL\LL2+&5\ULD$CFNIK/CTY8]0GO!GS)PH;GCCIBM"DW<I*PE81\V
M6\G/E;8@2 Q/4@UNU ]I%(I!S@G/!H3&8TFW:P#A9".*9;12B B9M^#Q6P--
MM@N-I/U-.^PP^28AN"GT/-5S 8$BC?Y[1_O%X&*E59C<K%PR-RY/8>U:\6F6
M\2;1O;W9LT];&)6#?,<>IHY@,*2.2,-M53(#@?2I;&&%)I)N1(W52>*V&L(6
M?>=V?]ZHQI=N)-XWY_WJ.<#&N4ND1I(RK2%L].@IQMTN#'+(H+*.:VCI\+9)
MW\C'WJ:--MU38-^/]ZCF S3&DJ,H'08QFD,(6V\MLJH'45J-I\)Q@NN/[K8I
M6T^%FRQ<Y&,%N*.8#F&@#70C$1:/KO)[U9D9;2:*,*?FZ8Z5N+IELK$@-R,=
M:8^D6K[ P;Y.GS4^9 <CXP4?8K$*"TGVM&8 =!@\UVWFHPRL@Q]:B;3;9A\R
MD\8R32?V5;>7Y8#JOH&I.2:)2LR5GC&!D8]<T+(A?;D?G4?]FV_R_?PO;=3Q
MI\ D$@#;A[U.A1RITG6&\4RWUQ+:O;LI2%6/,:X]*J2>%KV43S226T4R[?)$
M7"L02<M^==E)IEO+.LK[RR]/FXI!I5L)#)^\R>V[BK4[$<B,33-"FM_#]Y;7
M,\9N+HL[LOW5)K$C\):K) 1=3VV1'&B;3U"UW$FGP21LA#;6&" :5;"%8U0!
MMJC:.>U)3:'R(Y=/#DJWZ7"R0+B[,W'7;@\?K76;E(R7!]Q5<Z3;&3?\^[']
MZI!80@8&_D?WJ'*XTK$C-'C)8>U(C#:OS8^M11Z9;Q\C>>?XFS4ALH=V[YL_
M6IN,X_PI;E%U9Y4*J;US\PZ\+7FGC0WDNHW\4+3F-)B8T4<8]*]\-K$RA<''
MUIZQHH"[1QZBHK)U%N:49^R>USY-C\/ZOJ"+,D;+EL_,"#BO1OLUMK6@/_9\
MC"]LX0LZNO#8ZXKVW8O]T?E2A%'10/PK'V'F;/$MV=CY>M]7U#PY;7#QQ/,9
ME,>&4\ UF66W5(MDT3J[,%/RGC)KZT\M#_ OY4GEIG[B_E2^KJVY7UMWND?,
MY\)7-A:,EQ'($+;HR%ZBM^PU*]TK29K>8-<6;IC8Z\BO>MH/511L7'W1^5'L
M'T8OK5]T?+LEU>0QL;>-@A;.W8>*L6&HZC>B=)ED8<!2%(YKZ:\M/[B_E0$3
M^XOY4EA_,;Q;?0\&&B3:?9RZ@T^^Y"AG@V]*GTOQA.NM6LFHP;(D&TO&A!;C
M S7N11?[H_*D\M/[B_E6BI./PLS==2W1\W_$B*>37_MT2M+!,H*LJG ]JK^"
M;.>6:XFG@9K8KL92.37TSL4_PC\J-BC^$?E4N@KWN4L3[O+8\ .H66EG[#':
MR&-7W$J.WY5 _P 0;&P\86E_I^D2BUMXC$21AFSWZ5]"F-/[B_E2>4G]Q?RJ
MH4W#9D3K*:2:.&O?%*D0,EFS1RH&4D\C/X5F2^+YK:XC*:<SC=@_-T_2O3MJ
M_P!T?E1L7^Z/RIN$NY*J1['G-]X\@_MB&TM[?>73+.3]T^G2J,VK6]Q=2WAT
M6":ZA(8DM\Q'8]*]3\M>NU?RI=B@_='Y4*$EU&ZD7]D\YC\2V\?^FMHT<<\@
MY/?^55=)\8:/;7%S(VDBT+<^8@SO/Y5ZCM']T?E3=B?W%_*FXR[B4H?RGC.J
M>/K2#4UG/AH7&<?OG/./RJY!\0=,U%T%KHWS[M[[AC#^O2O6_+3^XOY4>6@_
M@7\J.65K7#GA?X3RV;QZFF:?<20Z/L89=E!^\?RK*T_XFWFH1/(FCNVT;F <
MY'Z5[/L7^Z/RH$:#HBC\*7)+N-5(_P IXW%\3I!?QK=:/(ML3S(K9(_#%=!_
MPFL&I6\]I':2!+F-HU<]LC&>E>A^6G]Q?RI=BC^$#\*%"2ZB=2+V1Y!X%\+M
MH_C>UE9B=L4F#C@Y%>Q4T 9SBG5<58B<N9A1115$F9K*R-!%Y>.).0>XP:R]
MVTJ0&W'@>U;>H%A&FT*?FYR>G%9%Q.L3#^+\:7*VP;26I(GDQ@OMVLW4^M2%
M@TGE^4<%<[JB62/*OT5^F>E/B:4@@D 9ZU=K$73V$BW,64C@'Y6IEQ&2&V)E
MEZ'UI?,.,Q MAL'-3[CSR,'UH6CN.ZM8S;1I5#L6S@<HW+US=";=MR[ZQNB@
M8]MXT['5'=MZ8]M6)YUT;*MCVU;'MFW;3DZ^W]E[CXMQQKEWC#O./G?_\535
M*BQ4S?7,.5?-JH6L!&+D2OANI,=C4G6'QW/?&31$3&)5"S&I.JJFX4-EH^YZ
MEP,Z_O)]S!Z[&?-IA'$_CY(SV0@I74:,GJ9UC)8E ^Y$Q99=@I2,!7I<)4A2
M\Q3YQU4&,<=-X\)\B9P+9$S EOH.ZP43<)..SBZ7JT^^_IIA#XE\+2J-,#!)
MOM52\6G1JQ\EW)7_#EU'^= A6^X*J;]HS!$8%KOUA^M(PHF\L?K%.,O$P4&4
M6X&\&^C"E2X[H1"E"[ZTJ^EB51(9--^JH@0Q,/5+$/YE.W?Z7.:N,8W66K\'
M93T/B"=3AT#\L%_PM7;6,7T^N'O^%/1L9GR#823V%-3@J=)ZP;P]CMD(UE8=
M.,9%=F/B1'SM *,O6Z=(*)X'#!*@.:49APO@XANRKB^F .>H7P5T$<].KJ>$
MH4%0*RWG!,DQK9(-#JMX&+:;%3YS,ZK[8D^,B)3G&-H\UPDAOBJNLOZ@DK;#
M"0+)*$!&TRM<[G72.KTTP+G8&.]"+/^9V%\4']S*HXOF>Z.-W5.C:+@EBUS;
MJ8^!/S=HPK\KX^$I[JSG'ZZ*[O$?D\JQ>%A0@YX^!X8'D01)J^:=(&#]=,A"
M[1QI"=O0YSPI#BNJW\7Z2Q^QP#_7"C5JL,PEZ7O*Z/CC;ZA+]0;9@^%T[07K
M253]2G^%-/GFBW*]M6C:XM+-W@ *-.(,= [C<EVRT7>.>B&,:@V7_FOP/V@9
MM!<):0'1 08PE$6>85_H>NK"H79B5"ISTG-&U8F=0$[K]JV+WU$RDMDP'C+C
M%_-VLD&6#CJC*2:,B^ ]#[Y&H8D(HUZKUH,E]U)V1^^Q,(WXLPNB3OY?OY;!
M[C[+PYD[V)5@)Q \/11(%M-+Q]+0]N1S$E3[R7&.'_L11*J+CHZ%3YGPE&)<
M5>^$KI/\ZN)/J+3(U\UH*OETSD[MZUN^6FBS/80?\#IGKZ**3^6$TDK"4^?X
M?@WWX[.,;;L$MD^&PR6 W_7Z>-Y5M(3F4Q'X;MN^$Y4O!1AV7.=&V->.C,M5
M@F*_@>4<78-&7(@$G'^[K3PO&(NHU6?:J^_458*+% [M2[D>5+T4FC ]SZ<^
MND\_:N5/8K^C9KYYK.?DC\L5C1ZR)F?%I,N-NO.J=)*]54X7Y.0W_ T:_ !8
MWN;^:UE<E 7K%77?*2E'_ 'PO"T^S((?,L65OJ$M^3SL[KO[9B$'[.RP %&#
M?Z/I[#"[CGH8DQ(!B.RQ_[S*';;A=QPH_U>2XV&,4,G':[9.'E+G<SVU1W21
MFA@**&NP+ZND5D'EYVC";^!6JK V; T:3J)PS.#\+ AAZ!:/)\SX5\\I :R-
M!1PODSZP17#?.MCMJ9DHWUI!]AZ"?4.HKJ'Q:W9T%A=>&KE2IGAC-  D#9&!
M6T==K&=(%5B6VXI%;8(*D=GY 9@OER-QV8F[8P.B_ZVXMQ=OLI.AU21EF&J%
MF)V]E8?\*?GR[A0(R5\/1 <CBLZX_=SL3/^LNNE(SJ*L$?-*:0HT'EDYW^VN
MD;!$08B\OK!UI !MJPA/%;&F7DGN:/1.LXV,B&/A@#/A0*P*8=$BFT.H&@2A
M+K((D]#]RAPL(_@PX%V%KR,Z\=V$X3S3K6N#F//9'L2JU K^:SJ7"?OUZ-+S
M_.!)6?$P1LH67\"\121\EUG"[V>;:CZZ(R,+^91!0D+$W"0M4V_FFX7YY XC
MKZYE6\\=O]ZG:Z,:RO#W *W+0V\V2=ZU.75+$"P_FA!F2QN3QBQO1>^?;RM(
M2CX )O\\S5)6>2C;F@] X[/"O>[]!T"R5@2@^O+MQ2>?R/@#8/NOXSZU^(8^
M1Q+W2F\?@.FR*4&,CI'WC2.Q)9^5-]HQ=##-T\*7#T#^CV4+(L9<2'/^%^K=
MN6?J)HS$);]?^W&_0G5K&U]O!1+4<WSIO),S*C.+\E]XD**>54(_SWD-G-AX
MHZ6JB7F6:T3,P+HMK5.PHWM+[SPH/)*T7HRZ"RS,\:7-+\WQ-:9:C]7$2*Y,
M"UIV:"9 U,SQ)<:<\D$W&UM-0+^H[?D \!I^ #I$I"0DN^QSV"#@2_C](K+"
MK;&?E8H*( W6B9YV,Q\&<T\O/QTF[ _ 18RBXG0-P1)1'-;KC=R@PF[?9P8S
MUQ@4Z.K")K!RZM$?@+\B5$M;'X ,B0^ 5VAB;!C4X/L$\NNUW,NN4EO1!^#3
M0N(/I<?"V1-;0O^)/E$K].\UD)$0B48I0Z$9[O=]H2YTM_Q'X1_F_&49D3NO
M_+3>Q-X^B^JPD*2N0KB.=A)Y+>9-_@ <I+XK/_^SQ^"S0/,G1>\,HJ<]HK=K
M6A#U9R6_^I%,DQ-=HDCMB<H]U[^6?%X;_)K<>9#Z4]F=R6>"[=_R.Q?[[ZUX
M?\I'R3H,Y??+%,'\0<+X0U9:7*Y804Y9&5L%G@]0:)#HBQJN."4-^3<7_+._
M2<,STIAE_7M"(11$#<9(/3#]'PGVJ7^63*+_G-2'G9_CBX9>IR (A?YOP,X)
M!5#_KT3>A0@ B)Z T&@GV&6<H!)%C#8&D%E/;%M&1K>0*5OEFU4DIQ[ PRLZ
M!92/D?6Z)CUW:[2A"O_&'"G:17 E @%.S$JX,_()TXS)S[\;$]&:)O+/J4DO
MY'8NQI*$JN' >TY"]_U[V]!3\K-@;:S[1C6_H)S3_IHR,#)RI4<N*@=)*\EV
M6^RAY?<:J \]*7NU.?'7S4W?Z]&/0KL_><P'TIBU(BDKX#H@^.Y"K*"7%_0;
M+K5>]6GG)'0/YC5@"Q8H"F*/TY#.&$8T0@LDZ.1ET:O$CC8-I J>LT]_P8"
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M75241FG^WG66&MN<B6@Q\9:1^.P/U:14A[ ;LW);$<FEJ+P>CN-AA OPIK3
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M2V^OR-6W-CCA@10B5DV)74J6*R+<C"*LMZ*'</7UXO81<M\J-M+YOZ%1+ ^
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MB6U$"@.'&&WR7\OBR5_%O)#:Z4 ;BC-L*_F-GI^B)!QYVH/@X<OWK+J]E!:
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M#94*X?LL6(AAJU*U$CZEQC3PFLLZM_%$F4%G_7AY_QC'!$UX^,QJ#6YP:.)
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MK[0<X.^DIEYLM_WXJWO40K%WE@IV,)$>AL)7ZY\ZU*ZBZSOD"ZTG]+BK]"H
M+W;)OF/V,K@7]8KDRV-)A+)X\OXU4RT4C:+93X@<R4X6;#ASN+H#[X1;MKA
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M$#SW!)[OIKWH%U"/;Q1F"J>!IY4[4/EN9"NM,) H)W&"!$2!KVX=)%?LN;G
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M\G__XQ6G(4;B1V4-!A_OXK3]>]7D-!C#P:&"F.%Z_+KZ8S$DGII[^#8Q*VG
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M61R-&*63<Y6/ A,:==Z"3;BZI-\JL7?VM2"/J#W2,T83"H',*8$[,OQ7]&"
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M9(T(Y7K&N&BJHKVN>&"'MLUGZLZX L$,^T-6;%ARPLH_V+6J17#_+J\M&C>
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MM,M[QF,)@WN+[/;^>47/J;"E$9<Q:Q_SZ<M["LS%(1LSD,/N]JO)[C(5M.A
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M-.?QM9HX]"4(+R0=^":> 14!'%<$]CY1B-1/"V%CJNW8[<[H=<,;#5P_#>@
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M9?/#T.;&2?%BV?>&9N?K2T;D=D@3\$NMP>NK.NM?FAD5VN,?Z  Y*LYN$G-
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MO&= #73B\7P61'$NT?P,R/WLGS%?.(3QH_HOCH$7VQ@JX:B?GM27:/L!BA2
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M,OS[+>EE1N[WVQ.;9LCT)WN7&8^RY4[9C%4D)2GLK^2L3.1TP%5!PC-\9FW
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M4/CH/:*_J]@Z$V75=+N#[=;-PQ3^3,(2(/GN*A_AU&4 9AFOWDFFH#;O6=\
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M8FB'QHR\"I*45Y1GX#4D^ (=\IH$IHKTDT-?-G'(\\CRR-M<AVH=J:L-4K5
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M&/WRF<RBNQDGR/!0!.<+$Z/OQ$ZF1&C5U>@5_LM\%82(]K3R6H;REW;?I*G
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MFB:Y*B*R/\[S]"8;DSM>0<PZX'.!INR)R+&?,/'C][TIJ!)T;=6!0-B#;,'
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MK^&&R'DX$,/51'[P;.@9.EKE@?;(65,>47OTX)2D?-%VO3\P( [1VU5M(;I
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MY/?KPK=\O)T:@%B$PQ%UNOAB:+"4IVKUNVUTP+?^(+=GY/4D]= _ *Y7)80
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ML["X$(\8)R\?SQ\7P;AW[QX^'C[%_?L4/(]I'O/\CP_T3X#H[IU"#&%,C"?
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M57U.L/T>P;NZ:H<RU!K5CC47"V;DN _5EH%<CGO!2[N<2<XP#A=VOX:XR0A
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M!,O2%,>K]"6 BP_FM-U>$[?X)K1))D]5=H#5J&3R@S^D/0%$>5I:^)QDBW@
M2V-7@) 1Q97YZ]GSN"CAS63$?6RB%@ 2R$(PO]DMKTI>P:_PI +ENQQ>Y'*X
MSUCWWAIDM.:609C/?U]7=?RM?C7UKJ?"S++8(1;6M8IEUTHKP9("1XG+M?AF
MW+HL=!W/_ +_I(P;N9&23T@)L=2O@]H.,0FM+MG?/:)W$&8>H&3GDH/DH? Z
M='4E24ZB2>1S^RRS&L'!G&\.%Z+&>N6 *,]1[/00NB?3+O1TJ#CER1/] X[B
MGX<ZZJW/)7[JYII  N4G2L?'S[0J:^KBJ)\D6.A\0'#=.RFC1('9.I />WBZ
M[SD'56#\BH"I^?M672GFHKZ3O*0J_>[(%Q->8!=#12"ACNG4M@D%+OBXWMP5
MQC*G:D.&0L%BC^';)X:5GP/O)JW/'),9_N2RJ4E[4%D%:ZKT!KCK%5^FWNMA
MF"?KO!G5>2B8AE>3ANT:-;?J]5W^'9>D 5"[O(;4C?H0U9IO>^:AG3KL,V3]
MCLS5SS%63S#'V4"LY7$5\DNR28X3[7!:C8\Y"59'_4+TM^.145S[]L:9YS>T
MVYI2<N0\01X/%$KV7'=_-\A>U?QN_0"=6I,2?NOGWF/TW@\OFGA+QVWI73V,
M_6U#+]VKN,(6-=5[0VKYNR(F,52*!3;D-9\V[T[T/^ ^'8+(!X%+3IX'F3!/
M5I/IESV-SW;_:C'EOYJ6E:Y4DK]H;(,&*IL>4D&3F$*,R_NO%?"E).,!SWY(
MRHN$?5&]DW#RNB^8-"_@REP,C_S3(!O9U=-5X;OU8#"_J.+^8ZP^4B<VGC?+
M:Y@]_$>F4+Y+0V.VGW*+SSER7AY1ZH6 AT;$/:=U+:GT?,:4P3:9+"H-CV6W
MY!.$;L7,6S00U-CAG_.Z='O^.QK0DQA/9Q;:3!,NH5;>5;ZTJ*^LAZ[@7%:\
MA'^Y>=)$V"Y GFA*V:1-@Y!#%I-\+A8".>QI7=$6VQA8^C4YT@:5K<\IAWO=
M<;VC()1!Z*E&8J6Y0_\F6J_<=FA=S-\AYXP@R\XI.?9VZCW.5Y 5JCZYQV$>
MM\\XP4I^<<>V;?]#"1@-6%X:RVK[+#(?Q<(E;@[5='9WU;T4ZM,U$?(!^P=Q
M@CR%]N]I:J1NG#&.L4OKLY=,%"VM"PS4G.C<.FCZ!^MV/Q/8J,CH3%1]?3D7
M>=*<_7*/4,P?0R*)'ZZ#9$J_E-I.@(6O=8*S-,-_F;66J!3LZ-:VTFU4):J!
M544A=VLK8RTBG6*.O'Y1 :<'>Y&"EX*7RGNG2V^[#ZK<LP9Z2O?C7T$:.T*$
MUJCVOVF^T*;>>Q;"D$]S9 +.LZ;:C\^$M-/J]%/;XL5;[X&#VY7>@80I:$%*
MA[W@-VH!SR'E^74B&7267OC(/2EZ!51'=[)N8%5(<VNJ5_<*A?1YMD3'Q&)E
MBD$3DC#D\=25<,&\^/&S#?$&+L@O-.#B)PR*-CA*AS*,H 3AETE2[F'A/'1J
M#+!FIW8!1 ><5K0/*G1F6 "&XD .I.[!"4GG(;52T1K^7C5]BN^8O_YR(1O5
MC;BBC56X,EW9?=E7K3@5-TILR/\[TX_\+]:2<,]JRDWUAVP=&C.3E'C2EJ?3
M(+B+]MC&"Q U#<T??=S)W6O7?3*.E>*"#D*[0QXZS\KP-<EXY*+4UY4Y';QE
M 4>DEWCUQ K1ED?-]VQBQ:02?<-AYGH""L(.,AM"S.W3%MK&<7!>VL,F34Y[
MTD"^;(1>+'=Z>T.$!A0X\C0-G'-)#"GCHZAN5M<WKHN5>N4^XN75O$.='M!@
M 8M_FZ=<NM,]UYE0:]1S2((&@#+5+HH,0D)4"AQ>"$E1G)!K%?B",'AK7[ID
M_CP"<;=G9'<DYSU$K;UA/WB55L@ZC3M:+^KC@-.I/GXX,<94&".AS=E\"IOR
M3^RI*M[@K:<1 I(BX)9TR_=Z<W/2&'8M6F^=;N<3]/#T$%>ZAT@R6"6X<&F(
M'^:U]C6W9V1,_M6$+UQWQL"V5J0FLG!'Y%6MY*Y9E?G,8A-/\GZY',N=YM1B
M5YWR-CJEC.[5J>B/WGUYQH8R[N"GU9W*[#S/=.4HL;1F;@5"N\$53^VXW3[3
M:/6>KD*(4QSXPUB5[3%!L6W>>!6;,<\]+;Y$$E5)7[&]Q,0(IQEO@*S@5E<>
MG=^0;I?:OZV:XL?C$+G0X.@*PD][_5E:7.O'L"A5ZXIDJ(?I)S%A<$9)UU!(
MNITTT5P\=7/4LNV//UJ,MQ'%F[<DD]OE6&8SG.PJ,7PO>KVM]P:W]6'[)8N8
M*3V4WG R[4+,O#[:&C #K1^77GSVDR/DPSB*#BDI<?&-6'Q2(U*IEY2@!;5B
M5!]TB_!O?/3-,D*W"N+T\T(RY/A>53AD#L+<E[KQJ"H;#7B2U22KIM+<>.@9
M%-</GP3+6$X+%4$R""74@AH,9&GC;#S"MY!&U$$3E'%]H#3>6E?ADZ(T3A0X
M%]6DE]-ULI M('.F8?@!5\0L7R)^;B5"'93>A2@<$M.U7Q&<YA>VS\ EK8_&
M(NC!,Y!XBG++047KU$S=C#GE[:A[SQ?)88QDB/K3Y[B@;IMZ6#*H<PY[,<FQ
M<'&(?_QW[,FI>[8K#>?2>/U3U-,<WW8)9[6](=W?./:B X.^GM/[NOGO(ARE
M:"+10,>>H!9"2X*RN;X^>1' <HIM>;?Z?=GL.#_]=SK!%>?CAX(-D6UTV@TB
M!PFOG-4+10B-W#8:Q5X;4*1.+?*]5VOHDF8[/LX@8(;G!>4A8.'\W1E9EYHW
M,OP]PO-IX2@GXY]9I%7_96;L_P<T-134*(> YQ[/POGL%.1U&/)!?!?\Q-;!
M'$])\0W^-07X/T5V!G9F;)P0909(DUC<EED#B1WU+9LO0%'TB4NITE$G54(9
M<YQ-U"?5.WFFG=.R8F*;I;WK1>%Y:K)%AR(+RIWD(AZ?QT%Q%<^&/KKY/)X\
M<1=+T3+7$;K#/;+BJ=TLVC8^^++VD R4ZK>67E!:,:):\R/:G(C5<S4.!6N:
MM+H2J4R5:V%8.=/X61U2G1U??T<C3:_(\HBL+!?52UQN^OWU]<E-9N,=_Y"[
M0^]L?"@J6@>>G&O2KZBRG![O6&L8CM*1EW!8*]WD5E>O/70,#=!V$6\K(MLD
MV3:H"7Z>@BGZZ(91S.=)M?,2Y>&3UHC "8_HS==B;+7\@L[6:A1Q:X7%PSU\
MU0:+^WA5Q-*LO7FC4_Y&4=NSJ86*1=^MLC/]PV6?D@)5_T'U_B4T-9(!@V>\
M<@Z\4G@*"L6I\IT"(AZIXZ#/OG<^VL8U(0GRBOK6YK*>T''3FPXW/(/GB;O*
M<Q@9BWAPZ,-L3!Y53"3>?Q2KML_,5"\Z\L#&H_)<(+^WV+%&(@]9Y&$?N/XM
MS'ZMVWV.D'G7&)R6:ON60AD2[R#RCT9,3R3ZA$IG5Y5713A7$G%^?VQTJ$ZG
M-CEM;)%G,---?%?;<8DFO;OD7<*/ A,709&"MP7C*/4OFF-ZJ7<TE&4!?C^+
M-N#:EE 3T1Q_8ZS;EW@Y\/.JR(WT72')%]J5P1W-8%EKAF$[OA)#Z90A_]0L
MT($<Y$K69GN1=_U=:[3UEK'\4>G/_$<!//?_Z*3RVT[Z9"&.BT_8WP![0L97
MV&))^F/*6G3,PY4??,"QOTJ(5;CC?5_-Q$DBL<CJM?L/7AX"M\>K2+*"7-3
M!I%I3]4Q#\95UZL?I;\F%\:<D0V'DSJ6%LK:>V6/&B+$B(L*CODE;.-SJRQM
MK/_HIB&.Q\&D&E+8_P7N*:B*PNP*2@RV%2\WV#<S"7+K\5IOF[DJ3:60Y[$0
M;JJOR&("G0O9!4UUN7KNN9MW5*7FW\:!_]K-RN'?.[ UQB8"^@L[NN#*9C%U
M>?N]O<!U?^#PSX]JL(8!<9&Y=JX$Y!^.;>BDD86X'-Q<[]1%-<]\2TM9/G__
MQ/ <-W!XU/W*UN!(&[$4]#;2GG.Y>M$U_U%E^06@8K,SW3K;(+YWNK#TWG]]
M?K=:\28>C@9 GR$]W50]8?P11B,D[S >C22.4%S==YHL$TE)U?HQN?VA6CQ@
MHIN.OB6BB>J+ITS0^=CG!#$ $U SF:H3IG$K=>I*(ZU!LI,7CW5REM@]21;^
M^O&[$3=PZ><KT@>[<G($A7-X<63,&2[:J ;G"A*31CW"$/M\;X0N=9<A8S^_
ME+I#0@+L(Z[9;\A7 ZN:\A6XL];M.!HX#8J:ZMLVI>0OT>S0@8CQQ1G-*%9E
M\R08V0&Q"B/K4G0#LNX"14@SK?$FM9QMGJW//*;ML07ZAAX)ZHX19L(K-7QH
MX--X;FB)C<^C\255%1%[#G7B5X&U)L<86WRZ*097"I-O1+0W:G.DK7-V*MQ=
M*WJ>63\49C4B\O\L2@*K:M)?[1YS61#MN-#.--F9SF.)%=:;<DQ3^&/AO3;W
M/.S(JV/]\M=QF?B$EWOQC@=.TT%63FY13N5CW?>'*91KW)0,T4J;/B2HP,Z+
MC;#"'3<B?:,>ADK1 38V\LUUW(> RX$474X.)%1QFK%!1>!"-*$Z;N KDX_<
M\>:V@0L\#0M)UBDB".47Q^P@+_"V_TBU@NG\F_%R=LZQ6YRM$)'8J:+;)4$T
MZ?)EXO?CM-F:'DPC2>;KLL3H#^J@;#)\+BG^L'S4NWXTP%FT-G"]1C]>P6]/
MW1KBQ6!?! D8>]SR+4A9@:9VT /_FP^_K@H2ED/0G+<MP3@!_FTQF;GT ;S!
MR=NM78%#*%ZIC1L;V*3_;5LNLRK&P)M-9_3]T1M+[N@5F9X5MMMW?F:4]:4C
MO#K6N.IRN92F$(OVZ)ILXC;S3M ^M+@YQ-W5@[K\,3!)VB>S#V2W9Z9J&@-V
MN!!*I7EU_.+N@Q<Z)1D#&S^'U7V)Z22)#!HL(UI^ZR*7-ZFG+Z!A;XWK"QHS
M"U:USVU*=5RUM!Q>Q;57=+?%A$C3[BBMBTZTY+-D0H%_AJ,E*C30:RU_S6TB
M26*<EF0&MK:FC\/]SGKOT4?;"&3>5<CT35WTAFU3#1J(UFO]1=_?:%N3WT9G
M1\G\*7^6@^,IAR-=C,'%V//?G.SK:$!73(7:F^+-= A*!'8&9XYXON>2XAX5
MZ343L,_(GG&R21,E5.9QJZH(7.>[:I*K!QVLK,YF[1<''V0[$ER& 9NT7(0V
M1XV-S(CH[FDD3@[U?<X;'O*MQV^IL;H)A/<NIBO?W2H:*(1$N;X>J0OU,A51
M)$\5L_O,6T#WAL:2UK%+!L&DL#+5)$-3B!P0[U"D@/3^2MJY1[8OE$6C#@I
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MO?WRP-M':6L=.5R]0D]A(\(<O%X1P"' ;+W1&#2P(?0(K$[IN)1F^PW)F5Y
M'^DAD66?N:.Y#9,V<Q]?@%X/U0^S+J9F[TA@(3>:W9B2O#W-"N49/P]98RK)
MQ*46/\PS .;&6EASI@/YP9JGHYS?L^\G<F4Y'$PPC%I6?YP+[4RGF8.P3G2Q
M7JC7--8=QN)4?>S-$WI:>S0Q7HJ2:4],!@5<*1?MBAC^4LD/%)RA(.[ZJ'KW
M9%,RV#TR/4J,GZPZ-?=[MLT9><WX>>L[VTER^"7<U9)N-H-0 VD9<>4.;R78
M;OC-N_U01U"IQ>PZ9K);S]RQ==?88%?B\>2>F"1G3/YV!75O4"+^:4F("4^_
M('(Z3]QF5$2M4S*TF".K*_[74VVEPR#";3U3D)BH;Q;$PW1/WC)!V("%K-4?
ME%>^>IA!^(KR9]]&PF?G3#_<52\W-,!IBI#<-HYW;!%% XG/40^/2[_1(S/_
M-_AWQ>MMKK$RI#9&SH3+7W7LFYGDJG(.I&= .^1"#..G2VEO_MO WN-BL%J'
MCNYR15[\LQO&TEZ=H,R"20.&@%RZ[/<[FA[)KK4U9S'NGY4JGAV+LWH<-:;2
MZXR9'[VQ-*>EDD24< AVRSK27CBO_FUQV>9X810>H7@XI6-I*6]09NMI[TZ'
M>JI+UY.C-^3$-S&Y%ZYBC"?WC%=9X>WMHW[R]"?G)<(NK.0O*V1I&OA>EDYT
M 7[\+%V/WOPDZA6_3SD$<) FD;[_XVL]8\G T/1Q_#2?<@E_7BR&"/B(08AM
MV#:V%I$8!B^/ZCIHDAAE?R?@F"?X59=BV.WDK,OMVBJ#4*0.9>UH[9NIDK&S
M9TF02@15R-&\L1+J6\44T_6VM"6+S]89W1R(?%'J,3EI;C;N1_ZYAHU!$TD;
ME8:;A!5+N/S:*'6QN6"7F *L$4^(Z.;Q)3$F14PDM_2N%84'\1E4%D\VR9OE
MW<GIO*VK:ALYZ4(]\F#A23;E71]MC5C>78,&^\#LF*#:0Z*;]F_IG=/ZUGGS
M^G+$BV12XB#^BE0J>ISB3>?=%1_Q)_)9\WW6V8;2+!V9@,T)J2Z)FYLX14_"
MLUMJ5LC(A+( ?P$,%KZJ+P!,O0-+1R 'GL(A17YO7<DWS-8.FJ^J[A;.F\JB
M8J!P5)1*K3W&> 2>G04A>V[(<G)1O05$2SU[S?)'MQX@1I1>8F9C0E4^B6&A
MQFIZD./"_I*53=N4%ZIG\"6=G](KDLUPWK.WHXVU3B(T1Z],I'ZL&DRL)K*0
M])F^F5[RZS\\8-!TYYD:7LYV8R8\HG*]L'BXOTEY5:7DX!,[9VFQN3W#"V<>
M%GH/N;;>"YQKM@F7,C*#[61>4^G[0[LQ05$P\OA:UUYU1]0TD46&0"4\_+(6
M"?JT!T]W,C+@CRWHV\0P$!\$J;+%YZ8FS64G-UCJ(E8[GZV88EF?6<W&,! I
MIGU/C/*I*Q60#/-A]J6[-2A:K;S>T^5]Z(".YB]S\X0>I<V6!S8&T4$GRM=,
M9THPR4KF+RG6R=VO,+_=D5OD89T.@6W01QDD9'$FY>?D=+^#OJ_\S 0_B *!
MDF4X;9=(Q2PRMJGXUV%Q9J33E7P\\P/417<H_.0,_:0.=G75.D=(]%$K2QV)
M'A819>ZX372*K!I);EZ=Y2!,X1Z#'.0XWOSE$"X>A\#%5IM0LES [)JVNK?4
M[M"[G?LNCLAP65C6N,OKMUAW*Q1/*2$2.B+@DPR"W9^M1/SW/;6GJQ8,YGZI
MY3YDA?7_%'H=V,:<_!V>'M8P$L;<ZFGH"5*P/(0-6MB1"9JY8UW]),@@. E%
M=+/M/O]$Q]20HM0"%2T37K8N,=:^\?*/%86IA7F).SJNI'*B@8X&B9S<7:=7
M):[EG2L8:<KV#/8222O!^9*\6PV$KV"T2Y_ SKUD3%]4'!YN$)U)CM=[-GMJ
MP2P.P=HQMT-!,JED^\],SM,/%G_/Y#PIGVC3<60,1*EOU"LWN_VM;OR?=8L:
MW *S/X?9KS&(_0:E#S<,J$C,]?^1,\#88K.SX?.AU0]]ZB7?M=^YSG> ,_"8
M>*E7SIV%0&W%MJAJ8N]#UCTL5C\/W&I9I\DRX?WA!CT;9]BG5YICLN9V'/]-
M]N-?\92#=@LC&P>+*$:O(3VDN*SM39I6^J+2?!:9QK>, W)+$?7\$D;WJ>'H
MPJU8=]C^;[_KK?.K+FOK%E[6E[K(0Z'%K'/H;Z4 +CE9,QL?JHI6['BQ M^6
M^,FB]LQJ[2.A-/(<9H_G:]9SB_.+<G3WM-O^SI;4.G\;>QB]5F@@_X_18N%(
M=N5U?'NY\32R^>24!E:*R70.B_>NSD&PIYM0YTLKF>(T6Z[^PNGG[F4V'IUI
M*A4BCU<_F)5-3K[N4#5H)LHQLA"RJK;4+X!$]:ABOPI0E&SX-LWL5KKC,=BB
M4OAGW?/DYCR(@**>LN\SRLTWPI)AI373:M45T19-K($S3@9'&CF(G4%2;K*3
MQ(8H956$<P57PLT+WCY9L?2"TIKQ=MAMSR *,;98A\A&-)MV[(8+A6R<$\+5
M<[J><I@[_YE3@AK\]3+-?P6LC/$QJ?L,#%CF.@)Y\*)_H2NA:[:_$]839[B&
M@=(F%&*I40V[<G>'3Y"&GXK/_XHY G_0_6%@?0K3" JXI4YLB%I'^CGGS6,T
M4--ZP:4[RN_"IIK7.;C]MF#BS\R>/G68+ <I\*7J_](W_@O02UX)G;>(H#Y%
M.6ZL15]LL6WAGJ,!N.Y5PA(I&IBWOZ:Y?>6?KO?_O^#\\M]?G>J/^ST\N.&#
M5%]\.$+=VKRL._J_FEW'.$(#;67G[&E<:* V^IJ%[!C;"PT@;&^4Z2,(K[U\
MMZ7*,OXR /T/H 08/+N'6= #*^KSM+]WOJ[NS7)GB"QYKO,1W"RF^2=%OJ%>
MHB0C7O1ILI_ L^B;DI:0\J@"9P]67//D2+C<^:B#;XB?F.]RF229EY&:T>V\
M/:O+\]IK'1&R8M7R%/)]]0UEQ.SJ30KN&?V>:/EUAQ3U%QW6G6G,8I8E!&L\
M?S :2/A<AP;<DH&IS +Y@KE6')6\L6 #?:*>_AV?$#]ZV:<<_WV>^U^1_&KT
MSOC[0J,=KK9XD"<:<-;1FG9[2.]]^OQ,:Q2GZ2*XB89WWWZ_C*ER?<K2AT&:
MXD0L.9N4Y>?JMI+(Z)W>PZ&;&KD/IR.DH]!69XSCG&Q&@MQ;C6.'_(:?GE&
MQ=NZ4/LYVD@=T[J"YF5/*6ER!;L]A66_Q@G?;-7N066_:SO.Q-1(WKB?F"3\
MP0(2U#E.$-0O><C"O^=MV]U"8*@F&'7U*@:+O83)30!T,68R>YT.D5Q/IL_R
M/<F_@\LJ W9N!O]" XT: NKPL<0=%@P%4,F3TNY^XM I519\0IED Z"<]GK2
MR)Z8Y??2JN[;J:P/][YT+S87L4*!K7%9E_X?##,31<D13<S<PC)[$X<EU-Y:
MT0EK9M?EUU:8.E ;A:C&>'_0>&KR?^/J!0N+.3]^BF:+D_H: &G6J_Z""C]Q
M>^I;$[P*B6.NW?E-Y-W3O4H2KD'CL7Y$4B8 YK:RO-TDZFTRO!S7W,UL5!U3
MQ&D\GEBQ#BK@VP&=#%4*<W@O8>9!EQYOQ1JL7@A@9I!B1)/'W\KJTIC7L^Y#
M1M'*U6I-*2.77E-S+!AAQ')<GT@]7V]E^A%GI=^(YZ !!S3 FI#1N#+LY?AI
M_EP=%.Q%@ 9B@U=&SM;1P%AF\W[3PV5U4'?+,Z<!]UCSV_&I=-8 /",4TQR3
M(C/_4?,E=K3T0%VXL,)J-Z*#[7FED\$7=9#DTYQ)X26Z]1.99#\NA@M=M;G"
M$0OLMJ>CH!O$KA2%LW9*I(@5@=GUCD]F80 A76KY$"!!R5@+'A-87'/E+['-
MEY<@NKFE>,]K-KK/?I[.VWM2M$+;LN8&-DQB\L+]QX0W_,797+W".'^Y9>Y.
MG-CX1K[IHCO#0$0T?^BZ%/8)XI.[AM.S:S:&V*ZP ;H\6/1I6)_8M[$Y/UR
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MO)BK*G),SC:5?9Q78<D]2@4@#5I^GU!B#;OQ[OG:L1:=5Y^!-^>=$?*<N^>
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M#3E+H;W<Q<,'$Q(IOA3]UL&L\#<0( 4TD('X_LN[FV3AR.]02P,$%     @
MDX!K4IG%>R=38P  M&T  !8   !G;7HR;'$T,S(P<FLP,# P,3 N:G!GY+MU
M6%M=TS<:2BE%6@K%O87B4BCNE&(%BA.<MC@4=Z?%BA<O4%R"AB+!I;A[<'<K
M$C1 ""?T?N1^O_-^Y[S?<YW_SN9:5W;(WBN9F=_\9M::V;?3M\N )V]EY&4
M:&AH@/>H/\#M'$ *\/#! \P'& \Q,3&QL!YBXQ(^PL7!P24C>(I'2$5.0TU%
M3DE)2\_!2/N<C8Z2DHF?F>TE%P\/#PVCH*@ MPC'*Q[NNTG0L+"P<'%P21\]
M(N5^1OF,^__XN/T%P']XKPCM)SK:<\ ]?#1T?+3;#@ - ("&@?;G /SC0+N'
M?A_C >9#+&P<U 60)X![:.CH]^ZC8V#<OX_ZU ?U.> ^/@;!,R[)!T]5/V ^
M=R#D_AR3]9#N=7DKD=KH$?VKCXY?L+")24C)R%\P,#(QL_#P\O$+" I)O9&6
MD963?ZNNH:D%U-;1-38Q-3.WL+1R<G9Q=7/W\ P(# H.^1H:%AL7GY"8]#TY
M)3LG-R\?5%!85%%9!:FNJ:VK;VOOZ.SJ[NGM&QN'3DQ.3<_,KJRNK6]L;FWO
M[,*.3T[/SB_@EU=W<J$!T-'^>?RW<N&CY+IW_S[Z?<P[N=#NN=U=@'\?XQG7
M P))5<P/#D^?<W]^2/@Z)JN\%8ONE=H1T4?'46QB>IZ5%[ [T?Y(]C\3[,M_
M)-F_!/NW7+, 7'0TE/'0\0'B@(LKIFQ_[/_M$&5^)8$CS6 Q"& G3-NQ &3'
M\21G8JK*/6('$*I*_WNHF46D '3_>1OSJR&FNSN2\S+OA3']1^.^*$O3&6CN
MTWK-]9LC.](36I\HL1"(3J[H(X#W]N)+F)^_B!'54)F?1P'<=]4\4N12844*
M?ZH2US=AUS/7NFS1PC,J>?71.PJ%F8<FD+K9B :L+F'**"N9H\&0<!$RAWPC
M6E./_.,ERAR[3^3'AR%'>\T$\%";Y7UE)UWZ81Y<3_SR.J,R4"G 2Q!F'E)R
M]F)T8]*F\XH#EUL^^3&)H'@(K[$\[%U(F3(/N1;(SHU-?(^ H=?08=#],/P7
M315'=+?&%O(F)7KE331)1*,#/=W%5T;F:!6$"N9/*S&NH\TXKW-V*9VJFKJU
M"UNXR&F9(+P);%4O4[QR'4FGTU 3O*LI&T4F)ZLF*U#B%WBEE;'VB+7357?$
MO+:N8:"#CQ)W*V NQ:U+5&A)3OGASGE0Q!/%KZESC("U. GJ*9^BZ1WB!R>J
M#5&+]P%5L7R _!W=S22P7FHDQSE%0?P^^U,3=$-.F!CRR%OM:*+L6^5LP0+E
M4X4*00JJH<=<I^",-V,BLI8P[ L@]-G/\1+.TJ]>[K:-[;7&F]<YB_["2@I=
MOI2CAV*]!7M\B5.4O@>RK5MYEOJ[B7R>UE;\)*JR9L5-^6:7KZ\VFYU@]\N[
M5VB>SED"&8&5UT:IHO,Y_4^XV-M<EM(]UO)<7:_HD0SP1WD[1PM?;=/H7EY&
M?J;#6,&Z!8@RH4.=A_$MR?MR+.L#29ZU$QW/":*3(2I8V(&=NL0A(O:[GGF0
MD@K<[)YI1L1F8\9*V5<&92(JG YRHQF$I*75*/U.=S)I%SJ>X8])V8"#LTCE
MKD5VC;%2",Z."9/OE,L&:1(C[2,0'6A#@D:R703X,G>DIT)FC:7/\6'1;!YH
MKNKR_;728+.,=[\'G\ 5^3("SW1U"1<N>\U;\ML%IX>15O9\H9C<E:(Z/3UA
MTC(IG;:6&UR:,SOSYLF^A9W(F'(^7X0*9B1"H&%*!+AJ8/VN!293];R*IHYK
MX9NL87,3J]Z*7X2()&.4"R?V+G#,*G'R]P;'^D:PJ'*>DQ_6J<!9"S$\EK^E
MI>KA+[,A/T[[%_5'3KHMCWD_9WJK0+WI;*QM7F2:J3J'7D_.C7NY[4E0-Q7!
MN]OKB89G(*(?)R=M&JKEX *E)!-LQN,4:EX%0;&@[^;LQT%G@]X7J\P?PI5@
M"<T)[K,=:OS)3O0!'_6H[35.&G]X.1.-P_UDXSHR .RG$XU/E+CW0]-^DC4P
MBP6.8!99IM./0O*TQETHO#([BBYM?GSC]DOC!\+X0C._=Q47ZLV2O?KY=GJ(
MM4>,8L^-CYH;<K04ZEQ.7&Z-(VOG_,,N>N0JJE;L+&.E?]_P8G4X],O.-RN2
M[\=CP@T93#*U@MU]3IT KW6WZDJ=\.FMR-*P0X* X[7)1N-54*2$D.9A4*.J
MF.%63VW8I%,E.I5L&6\J6-L]NIWFX5D_Q66FUO7'> 6/FDN+#E/Y7Q<EAU2Z
M,YU'P[_&]#J*%&L7YD^0@IEXV<[G'CQ[.E3AK]X$QLTO:Q85YBWO\+G? M)1
M>,L,JY' (%3]SX964_6U:<DWCQ/)1N.!H.J?5^25TH /[E[MQ$B**.W]LC.<
MK_.),RYB1[D_8@4HXX <5=84@V_'55(H%W0)/GYS(;N/?[I9Q27#A)XXA<#(
M<0_7ADR =7=Q]MYK"9;F/7083W\DM5(6HLL9Q&N=)JN4>#U4WY-@^IV[^ITR
MZ1FX^=O5"";E+> 1C_04V"6<N>ST.C4F-.C'*H_WL>-+S_2J=%JX:28\YG?*
MV>$WG8C7WP:(9%ND!EV=J] &K)'W1T440+.SN_(\D5: L!4C K#X;*?^&(+?
M)O_-MNVAG0(HD?K8B"O!!^W7K])Z115,=,PV/)PY2;]/7TYGERC[T17Y'OS6
M,/XBV#T)*6G$RIUQ]Z1ZHN#!_H, ZSG!8-TW?PG &H@7^C$J'JU_.QUCS%G)
MUL>4OJ$!FF\0Z>3!%//K%!.=Z$'6T=:;9AC6U(?8\W;5]V[]IB\CFCVW @S<
M)B.0SFBZ;5WL0J,VJ^;>+AX4'%O0],TXU7+D:(67'41_[L$M(+%ZN+Q[9'FB
M.1[U\_*]Z4=YK),/G!?4]2 I?F=E5-,8R!9V*W?CE8L0!"-;#;E/0Q,T-ZFN
MUN>8\GP(DVC"+ RPO J77G%GA%(1G_1!T9[^,J/6V?OR0"CBAU9BVC(5C=+1
M+>#\N;P'N_\WN?)!OOU<5TIG<'$30 63-1>.(S?6*'&UG'A\J&IR/&E=)Q5O
M)+UL7,JO!7?+MJH_WOL _NWR;'*U3Y6"?RH@98]+08)TJSW%NYY^5JFO:>!I
M(4'5?MWZL*./]7?QA][\+R!II=#ZH(F\U,,OB];^/3^V2+O?'NYP23R9G6TU
MM:&"5"D0XD<6A(]@I\<15@%4I0G_XZ%.]855^ F1C/PIX55QH<2%D"D4/Y9:
MSH P6NUA)AZ3$86UF!BL$4ESM#$Z?MH@<E,$ UZ4!@14G5+"1J:42[?%Z$9/
M&\*7\-R#CW=W!7HM7)XS:!F=NP:U>YT8VAR)ZLG #EIREP*H%KL XA@_UR[/
MP VK91&-ZLON62WEJ4J)0ZNJ!%+LE23J5;$*=JT[.Q+4 2O7J>$9CRVG^$-N
MGNW'; S3<*DH[RE6P-X%%.SB@6:LSMU(8F*I'V[B[@4$Q!A:KE%9=Q@OM^\"
MDX@WO:;7[#^M<GV-\1<09)PV*]^O\O'2.G(+!CLKD8_UZ(@X04Z,.$Q(VTV,
MZ>@O>-!^\XNQ'YVEYSKOI9GUL8Y.8G['W$G/>%N>9SW[KHXRUE(W$K(J8[]_
M__.7#&]@"/Q@4;@E$DFM\#4FL" /ZH@UD]%5BN"(68%GK,)SZ)\W#N![FHA3
MHH+[;CK#R*G\6H#&1"G;1KPI@<?KQ"OS/5VY/1;6KM:88$G, ",Q=XX]]4F$
M_.KH321UH0]])"D_B0)9D*,[(&!_?*Q)=L4WM61[D9#<K'J4M[,Q2$.6*<[J
M_/X(YE-8CN8D@LL--+\C=)Z'.4<9\E6.CY/N(,)ALN;@U$#-YCGIZ3")=0 P
M%DTHMZ(X"YV,%%O4QSKQ)CO8>"18;B"RYRKLMPC=2G$38X?#KJ.1P:*>OC;3
MDKT;:=]Y#\ X8\Q?^#[TV3@/*?C,*[=:>XW:N;)Z!-0L7\:0U)DT" ,I58PA
M9$4W0UT)7H<SN5^*^$OL*,$'"]EO;@%!'W623QL*=7YP+GPS=3C;TSQ+U6;W
MLXC$?Q]JK([[)HB42@G@,DG>E>,&LUH50"A\X(NAO$]!6*NVVPY6+^@NU8'
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M?O< \VWB_T-6_C\<4@JHH)($P_0_-7JRT.W#HF!=(".IUZ\U0]O]:3EZK-
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MK#2J\L'7R2Q$Q7N:,ZZR_/GN8K-+GY*4-GL$YQ#/Z^76Y.+IK8IR?I*"5B.
M/+M]ML?F-BPO<TL)"57#= >@;YDM,A]RL&?5172C-'B'Y:ND +H[+'?ME=<#
M#<)8W[J E*Y+NL#4:9J'=$//6B9YL+SK-!'E$T8Q</)=GF$BG:4/+\3^,$"E
M: G)G4^XB'XWJ_-1;BVO-BGW"0%W[1B(C248,)1<__#M:\+T1%EB$A.H7WC?
M2SW(HX/_J@ME"28?_YNI=9JL?0.9I-5BX1$"]?7^\4<CDYHO*Z.;J%0A;)]>
M'/3+V(V-:TXDH<BHEJ<.[%2.BO)NF??W%1,U0G%Z=HN$8JU3)T2,, HM2DD&
MOSFDM]4AK,6>)S%Z1(O"4:INZRWN?^.@T=4IILU:Z:<.\X'<L>N.,/\'?>2"
M>8>Z4VV7C[NJ 7'J"HZ>39GS'91'@+*4\@3W(U\7; -*14M9=-5T+[@U6+4F
M*U&8KT=AWL:U]^Y"V[9Z)A0'LS"I" &83X%L?ZE9Z&5^*2%I=G176(#J_[H6
M??N(L H-H[.$1#4^A?Z/OFR46\/<%-Y?ZY4E+K"695>!=.W=PE_^VP-0Q-&7
M@/( DK^TE+R:RKI,('-L*IJ:5>H5KFV;PS5(7I_> >0LA'.1DK&9S"Z=#-;[
MNHSO,TW )Y)[=H!9I?PNTWL)"<$:7_#RV#T&A!++,_N>)QN]1TUI/'T.+I:'
MO<C/UZ+[#A)O\\JPZLLG5P'JYG@*U"H=]\O8CLH)J4T)3OZ%=[EN=!Z .GVB
M@$95%.'C]2G!(GC]XF@*J^:)"=4M(! HXE?M+<WW>(U,5(@)G.*NPSO(:.*@
M>1?76"NSH @C&[MZ8<DM^9O#%:)AOXZM#G4_FD3/<U6#!W?L[/.'G1'B;:RY
M4?1!]V0^HQC'0==+5Z,E& 5T+^R)LY+?#72IXR(T-G:A'-&IM$CJMGHYE/KI
M+>Y"H%C81IK.X*+B?M[K-%Z+S$R7[  5*W:BK27BE92EUAK=TOPL'TL7JR(Z
MOBEV\A_IR]2>4S3+^R2:,,YV\?U &$,E=4E6KBQ_5$^GO #KC_=KA&@'/, X
M;QX89#B:9T%*<G(C451F/#AE9D!Q]S'WPW5*F+XP*D_*>.RM0X3,\O(HL"#A
M;K1B3,Y%D\)?RL$U7_07B\FNI7HW.=PQ-4M=^*%D5W7.4,XM#[*6S1U(CXO>
MVK/9()@7K3R>+FO&U4HM;QQK+YR^Z<\^9M;HMF(>S7E61KI7;UC,&GM@!@&*
MNSCY9_H(EGW,O!>!LH24@_6C 3/!'*#Z3+!U$K21C,),@61Z:=XV(\T%JA6_
M]RZC;<!J96=B3.[D^Y_0TQ\OGB@>=(FY[054RG<O&KK&8OZ#H"ORV?19BH(!
MIRXPJ.!#RL:9^(.N2R^2Z6XX19[S]5O>A/R2(7%3PX"F.P@1H5SP5[2*95OC
M)L7-W:0)?S!$D^>B*QM:ZL*HK<?U;H'P5/SM4#ZY*@I"5@(]@R@(.1H25P5?
MZ!P?T#W.PGE_!3.,IK0D")+&SLE$S_.X"!!?%_+;B_/C,@QF5?3RG>S2L3+L
M6E&05]"7S28,3JPKHYP>=%M)[;4I._QT8+/B%KH/XD),K[D*A0%VA%0-,9;M
M:/::"6&?TLEA$.A8]RL\EDTW-HWT$(==T&FGIW1Z3&57$C^FWH1)5=3#+6U#
M6(IH9ZJ(&REZ&&"_ &S%^96:,)DC7=1V(G&*VN,^\G"ON[Q4B=5@[*P?K\8R
MJ5Q_]HMD EY_C 0YS_PD1DN4R"NW G#&@\I/%Y\ZM5Z^DZ<*(2T3KIYPT?.;
MQ;QFO-:]4A)<=;OFB2.6<*4.R -XL1/%%,,SI$=T>2=X26U2E.LI8Y6766X@
M9Z4;*09S0[%Z]0<Z:"BH?0S;RH)-!3-"@<K1.M7\MIU:;-]0DQ-Y:<.(XS*E
M"5-*3[6*66U>KR.ZYPC10-(:E="2LX<S^QQTR>H48>G)9#19)>UKXH_!A3<I
M+M9^U;8S&R9;H@X_/OKS%^1BTNTI_-F-?:(_V^J"'^6>*(TBGL8+Y= /L+ W
MX4$*P:JG9&5RHJQ#I>+KKK> FD0D9"[(+M&ZYZ2\UTG=USQ'59JHP_/9W=I*
M,>E&SX?YM-=O@G\L93[YTS#_T485?\I%DOV7-^U\>&5-GB(.L@08?YBS3.SH
MVRT@++QFWO/T[6X7_[!Q"!I1S])W5 QUI/:_R[G5R'69T /A+;< ^G&-*TYD
M("O%"M& EM_#H(XA H&UA.30[0?6$!AGX"<135MV"$7X1$T7.1,'KM4M0$5H
MDIX&"R%N!^+XD214-HW^@"__+$)IR,,P4 4S%8$YSL$AH@G>LXIBFTG&O^9B
MSUBW'N\.X;D%$,$Y;/BN>-W7$VU*H3EVG_ -[NMB!(&C;Q*,*;1G/P<1A_2Q
MGM)E%:%6%I",X+588>'B'3I'>874Q&_WWLD#3NE',,/A]X8-COPZPOVPK##2
M.TT]2J?3'TY[&.V*6D]X.Q2\39R<=2DM78 F$10F"O,^>IZ=-M-*]T5&Z (<
MMB5?T= ":4YY,L67^SWW@/NA^, DTY&H_U2JCMZ-AD'Y9;G[W-LM88>[!3+C
M&NM,HRA,7 &F2"Z6E3?;MT?Y99-7J9OB'5_Y?IR1S.R\M >*!]C(F56$8K9E
MI)W268X>1*[1D4ZL-[FO"6KGU++X7^WOI(P=7838B/!^.&=E/ECW-[::?V<R
M+?K $QLPE1W&!/C'N(>3:F%K?!=+J =>&?I98DNN":Q&NF;K[Z./ '.H@QN/
M.2^I0VY\R/?;^"TY&3RFM\$6XCS4N+> ;X<WY7:;K"-[P]XDMX!GA]<?EP:
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MQ22N&_L@IBW:LR]#/5']ZX-.)&S7*K2_^L+,[,PX!3">!"3KP">Y, X#O=B
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MP 4U.3['HLEJ@;,G_J72,KH!?:9S53D\E21OB\.]&\9X,HY/9F3D1UI?JV&
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M_G<@[03H_@YCF\SD9,9#!K0HL&((L (EDQ1J>LUL5%,=]>!9@"RN+[\ZNK"
MSR&'<@U8WL?F %%;CC3S<*Z^ 6Y U<B"%Q?NRX2VTF(*OM4X,V*4]AST\ $!
MK2L?>6ZQC0B"H33YZ7Z,Y+3!359:AX"=)GFLQZ&RQROO]+A7O+*%-(>8X9PW
MTIU1 @)T/>:2[7K+UXQ5<83KXE&ISD(2&.@R "E +J<#?*T=<CH$T^,K'^2<
MW[%/N?N9C* >,$+M8H,!7D3'J"7GQ^]N6O20FOLO\%EN)\$WI1OD :3TP=_?
MC?]?)TV<0P*HD%/3Y?7M&&A:_W9AB)+&D!_NDU_Y7:C%DORI%/.[\_QO2#_
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M%XM7Q]Q':J(E+/*4]Z^O#%A4RXV4,#IYD'IOXR>C*<1X&X<37'OX^:38N4%
MN"B_&5*(RVCCB(;:B30"=1Y6'4"B9PTL<;IQV7\VA.9>KTPES0N$'EV.8AU
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MFX*2Z"-5@X1%^'M4=ON8A\+\)H+JJ/J:XN[8J+/L L1Q,"!.]0N&R((HUN7
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MZ;/DGPYNNBJY1Y0C3W]%NJI9:W!IMCTF3I1/S(K:;N'!B4:T@&I%)RM509(
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M#*ANDE!3'7)-K^"[DQX5]R<3YM9:B JY==;I+8$?"P(JMQLE9T)6WI;RIDO
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M_5]A..R7^G=_M:]__>!$_]4'\4_*1?^7V&'Z_YR=?\G4R?Q+_93_WSQQI;_
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MMIQKZK6QE4QK2ZB..WI@U":U#(:1D'*.V-U=#R__ N/"5\9E=>&NW[Z9S5)
M5)E%WI6/?3@JSI#.HN75BW/@6N]EO,K]-"*3S"']Z$^I8NY]11DCQQL_.EYM
M6;>4'1@?#?)D'EH*DP5CRC.5=6;K"W1\W'X>!PE<MNC5?>% V9)9YHCFN1/9
M2SN=5S5M%Q1 4^V@\8:%I=]@1$;2_-[Q\J[!-QPRHKCK+55^U3*"%NUE%K9G
M<0GZE=VW "\UFJ;E^<?Z/,KC"43J+.L]^/"=7D<Y]38>;XZ&FL0>IO6V5LU9
M,ZZM#Z4,37SO>,Y=A@.X*X6VB?)9GF#V183W.2BKH2?D_$S&KHPOE\*T^UK9
M!.10RX'B1=F(N $!E[Q<'5O"EF+<2NZ$E>H\/.&.=+Z=/^P%J*R D<6]PI2S
M\8S6.8OO/+ ( #=.LBBJUY'U N[B.J^]6:?V9_$6B%+%?AHYD4WFQ*]VU8B?
MJU4[+^S*B&04769/=8Q>!+P48*'K@6!5DA'H82SNC'S;PP8&%F0<"LV%W*2N
MH&S)>^6(WJ@TA7%!Y4]Q?XQ8N@]4A^3HZ TN,<E^-06[/A3!LUF%AFQWC0CF
M/:!(VK1Q/SDOT6F"66;/3W]'Z17HV?'97UN:"I<XS%.,Z0S+=H/NBE*]!%:
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M3/[_^>W_ ]/E#P-BI/AKMB.$2]%$F#P%#[C3/\_!32K]O306+[*[^#' _,$
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M/<:UN%OR+,_TS4N_\OL>TU_UGI(4#2S!1(#4'4";22593_AV2HWA+-<6/TV
M<;IYD*%1BJ(4DWO9J?")!1J5&[ ]7-"C$&1R-^2%DQDKS.J*T/YZEP"F7?+Z
MP/*DC2!98?[CT."?GJQ+EJF('>K)7VLB!XB7EK&D*6FYE#5A#DZL@40:PZ?L
MA@+1_1K//GDQ6/75UW6X3KUI&H6+YQ%=RQS8T,X,-?@2S ^CGI2\@C;'96W7
M<WWEC\\A"6TU07(XKS<R/"J^DV#]:LX/'JW-+*;F^Z-Q1H<6=*>3"*@KKF @
MB:W($1)IUW'/OTJ4B?$A:M$;IVI34N?%'6WT6K9T::EI?/[Q4:L^V\"77>>T
M1TYISZ!*KB7M+@5%#T/Z(JP[_D][[QT55;(M#A\$ 9$@$B2#1 &1V&1H!$DB
M-DERD)Q!)#6Q400D)P$!"9*5T"))LI(1D-SDC" 9)#70='_@G?ONS+QY-[S?
MO'OO>]_\L5>OU6>GJMJ[:E>=?6JGD;_!XQ@O:W_B:W1PV\Q7J]&\K9?7]*0A
MC;N@7Y(QWV:</$6?,U'LR=7$U:.\>+(XR6E&7+MIWS(HV#C*A^DDU>*KM-.'
MCVOZ#?0[B$:\T(5^R=L$B3'/-,A,-4]O%]INK^D/."T[$R,#USV^TR58=J(?
MY,]M84D%%[G[F2%G5JGG II.;5DWB0KIJEIA1S1"SH=XZ&"[D=;78OU"3=7?
M;TOLK+5Q9^XD/;WEJUHX.OW)BY#;">!:508+V\-T^F[N]S">B.\YR683UFL=
MAWEXAPCT68=,3]7Q6"U;QRZZQL=&[<N#8(03MMY!7U[<M+K2IF^S,>P%,!!S
M)YN$-+!75OA)#[9T,:3?EXP+R1^A&+3QQQ\L]\-U%$PF^APKF5]H%2Y!L+I,
M-E?;2XK,+6E+="COX<_AYI:[6@BGG@T0\-:V#N31[YI_AMAX/,(NR)R<43B[
M7Q(V.%=9G6LX2<31<F'\B]51#.>D3J-=5;:O<*KLSAWOM+RL]S+9A'%/#9?A
M+&':W,EVIBB=LRBC4!$#N,#V!(TKSF(@AE(,4,,=O1/]4\.;O<BY'3(IW%E?
M"=N_#R5\E'556@W7+G%1.2]V"4P=O,;#Y_U9\9M=5-)V\(S:($_)%SA7<K8.
M]V*4@'3%&'2AZ1K#S> !"9^"63[E#T=A]Z$')>$J9<(T1L6I[ZR"0;+-KS_F
M=KTQ/%#@"/(ERT?JZ<WR2'412O:V*;[;,+9>6&/< (?RZQ:^$'S>)Y)G/UD8
M/.Q[V;4 .3YBK-*A095\*?3%IH3?-_O;LL;[W2;7?"4KR[>+-&QM_ >M:E\%
M'66,'*$3WFQWM<II#S26;5KT3+W[V+O#YAE-TTFF,$MA&HPW4+<Z,U=QD#K_
MNM#6^P6?W-+6E?>O-GJYY8OVB.T+!6GG,[]+&N1,*K?<UHI?IQLIU+>CK!+W
M-I83%R*L#5R.T+8.]>6VG(^4>EC_N>-5.Y>[)IIB.7\.MTB@="WVIM^+D*P>
M_BF065Y _RKX6FYU%;ONLYQ"7I;-^?J2:@@^E*:KJ6,@1'!:?&Y1"N]=2<DK
M=4%/4WGR!U=^]Z.)L"6P,$)IY_!%%)?^#=.A79.@2N&8AOQJ%I'^+[<7V'3"
MJG<$6"G'_;JY&IT,@DCYP"*^L\/U]I^N75UU?&LC'F];]=Z%L^U!_<Z:^@H#
M?@-Z,%I]A[+(G3,3_ $PU9F,<"^HDE/9YP>=7/:29OGVW8X@_<X[PI!%2NKV
MM; ]U?O3XT8,4.L[)^#$V]IT6%IURG.I$-(Q5DU!>2%%-TV.:;GQ:M?9:/(I
M+/L"9$Y/?CIKJ ZAYJ!H5E-]5R/AO?9FC9O)WQ$>I*X925$)M06M.=\2JVC*
M] P46>UT.TH#%D_M#E+S)FR%KXR-YXUF46$CRO9/KSHZ%E\7S-++25V*QA/P
M>:";NOKH^*G1*%3:44'!HG[8V@04^#"+$INZ,&7C%0,#A&25QLV>\%,<)Z$<
M@PW+JP7X_?VQ-6]6FB\1Q[XA9C'"?.BK8A3AUX(JN OKI2I\)KP<BX#OV4%4
ME"RO'4Z\M48+T\SBS#5\GHRG*0'8@%MN(=/?^6X+YV>7"VG\Y:RG]3=>-6#=
M:.4A!UZX_E0^_J?RKO]';^?]-_GP@.)'&%/](Z9Y&[4(F>/LEZ>H%9-#I>#5
MDZOQ;2'.#R>CFXM_BGUF4#>VXL]/(T=6SF^[BE>$G_]ZKB@>":G+X#FC*]C.
M1M#C?#RSS\BQ%'W[Y2^0M*#=?,X\GF3@C!?VD=]9M'YA;C][39X<7TJJX+>/
M-'\78-27\OMV-CN 7YZ9HI1W__'9?PS(8W6T=_\_R.S/)BPW:N^JZT:N)JYN
MV*[_6\?=.#WDSQ98$909\X4\*B8U ]>5<0ZZJKLXL:L@7P)$RA3L*4]:'HVO
M$IGB\+H^#FVX(W>H'8/,OX_N,+JC_+++X1+*H"Q"#?<K160^]"EMUX*ED*JC
M>Y5WV_(6;X5#W]]V",\_'.+_V2&T-Z@/-C0>V0VS":VSET3T,IMLTDB&PC[8
M0\@?^"A8K\<F+ZJ<-BO&\AX2V<Y'J']I'F,1[$@Z"8X^1QQLI<I."WFO8'W^
MF.%.XR0H/XQ?48+$XA=\S*(\&#JIT\\>"WE=/1LY1/J-5KIUJ3C!\^<VW]G0
M<\62ZF%BHSZL5C^>]Y]+U(=FD[N^.U#J/G^>?2ZQ?$?AQK+I'PK]H= ?"OT.
M"O5=CV=9!+U1/O]+Z/) F#X7D>QO3?$E9)"%^?0"F>7U[%<^Q9[6H Z];_IU
M#**U"/J-R/*=YTT!GECMC16 )9*UHCT"I7P3U<$^+OCMLDZZG.LC-*\/<S?/
M->U9CY-G(\4]<R<31-Y;#P;T>4;L<$H[1 D%.U"K,=LX*KD7KV(77$+W6;:?
M[6$(U2Z:D%=7(:/GEL.OSSP6EH!W&266>GI9/MS5'3LM<1E@<DEIJ]@^G9IY
MGH5PUX[N>2H5RVH> -%$%;[))": D2/??9Q%*@>,NYX@, !!X;91,HKMT6:M
M7DG.S>IOG@S<?27_IVL4_[-/B'X)R1LRE^797<]K3R2+S;]P^]>_L_X/X+S4
M>J[5?)0-ELV/<M9W!8_5+IQ?6M@#_/5JSO\ L/\LM\[LCZR"?V96P3F\M=./
MH-'. &UTFA)RZ1U$O"(HMZO_^HHF*">Q2CWT>NS=&H9G-$!QCOVQ<2U6JFI]
MV)P"MH-#@M0COS5%T*)W8Y-7>1*Z?QOQ]@!.:6)1@B?='H"'R-J&MQ@YC1A7
M]8&&PE:FGA[U*U&_AU(SS:+)L5:.$?7Y4/^6*3L13@(WM?9$Z:=U$TV-5]TA
M5Z';H]G,MDYT.5;\M=AY$/W5.M59;F<*>X_#I$-BGM?1%\A%)\=ZI4?AHML5
M:?4A;>&I*KK/U%J^OV7ZEJF&]PX9;Q387$/?EBW2\[7D@>MA="YT&QFZ@ZU6
ME:'YKAP;HJ%L6:6MA5WJX %7WSF( /5>,IH(U1!Y,!FQ3FX]F?)=ZMJ\ -2G
MR5.:(>/^KA/NWE66IZ\B7-=D& IG>:GAX7M)B4HM(FKT[PLDR5:YX7 AI'QF
M5[YME7[$8,L6=.*IPEPEB:\G_"[]WW/9]C\'.*5L;?.C;+"_^*K,,Y*K+H#Z
MZOBEWB:$^*8_OH"UW$"2JS?P$)E84UPZS"M454HL.4<3V>K7H+^TL;=%MCHM
M-I([D'$B*@'<^AJQB#5FKT\OU\IP:6C#?&2?8MB!EQ7?>B+PT@;2/9,XI)44
MVK]I)DWSH32*OK'N&F M/4FSL%^L,N_T)*\3!BNPY2;P>' Q= _;67\_]^$J
ME1L+:$E_QYG*]TY%OU:9+0*[^\.XOXZ3*+@8<(!ZFB RM^\=SSQ'52;9QK'=
MN9S03MU>;ZT\3T*FB_0@N3HYV<Q6%$6]_NRZ1YL7(UC#)6RM3CY7.'^NL%A\
M!BO])M-&;)].QI21D3T#8=5VG;".\AMN? OMT 1R7IQ-%AQ_(:R9U?'3AHRY
MP3>;[2\#/VM.]1* )1^D78(O]F]\'4K67Y*?GM#!<NU@#'(AHZJ@]QYOFE<3
MZB'F9VN.#Q+P8 RA&%YIN-7OKC)<7OG!1?"6ND5H-B%X["8NC "8_HV#B_\V
MY.061?H8ALB5*[K4Z!E8*)\N91+9Z2\+80!2U=-W-=KY!,WNS%ZQ&Y)\>R51
M?Z[ ./E_NP+COSA=]0RPN$6,ARP&W%0*OYE>K>-/U.*@9M).+IIRUAO<HQ>#
M5RA+UC[\=-F!IW/E8R8)ARIM^[1D NLPAZ,(Y M!Q.L;7E3JS?Z@2:CY7$/(
M7)[R?,3D](TE6S\_F67&H+.]Z66#3Q\?VCEB ']&U T,$ 2?W3J^5'6*A&UG
M$H^4PHG[&A>K9]PP@ $OS/L F:,\%Z7[14.>,)_^>8\K93K6X$V4'N_S[/3%
M*:7NULM$&2+&8YF$)A$0:/H5DS)!_.X/J8Q3[;!VBB](>_5M.F.L[\Z1,77?
M4WN4R:G#S=/RX0/U3U>_3!\C5.Q?)NI:4%F8?J)8'@%?]!5Q<6?M BUR]<22
M.]3JC%JHX9)\4GPY8U=("GL7\8)H4(SJE'NL5MLJ---VFO$]98U[35.:;E21
MGZIMW[\\8OLSJ(H!L2/DJ_?4\+CG&JDBK;6&A"8^L)375<0[)S6R)2%*I3E4
M&+*$Z@FFJJ8F#0O?OOF6+08N*&Z\Z@ON1RF+3]YCJZS&6TJ9JBR+EH-LSP3L
M11-V6U==G32,?0)J=K)D>!H@_-75,D?Y.@9(Y*-</.9Q821PK%NCA^CXZQ]L
MC"GO$0Y/S>CEGD8@HM;#N<AOULNP4&@V'U,TAKB]W%O38X7&Q-'(7A(3VY"A
M28B<=S1UDR+P:1)DHC6#;/%_X[9Z[VYT84:WNBQQ2=G#0'D)_PFM[DD?7MK:
ML=8QI+F@NR5YZY9YW,Y.[\W&@7))J]"+24%?R]0/GB6R/2]8=IK!  \\QZ.2
M[=_J*ENZ7X&R&N5"G.5T$QDNE94W5M:F'VSN%^LXUACR<5]9R /V,HGC!'QS
M.=ZHI_B=Q6>_F_?!Q9!15&L--!S2:K7+:Q6%_87<!OU,B T<C;22R :1S;P
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M1($*U*3G*U4_0+BS(LV4/CZN1YBN$T>+\]V+O7;U+K  FR/?(3DE<H7-"F"
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MZFND*HM4KIW^L*8BN7FQC7T#>R*-BT$E2?P"Z8)G%ORG[#5-^@,6X4L?O]W
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MS86=%YT_9I_GZ[<F;SJGZXA^ J<!'N0:W'@RGQ_G6-#H_]<Y1^?Y?%F)\>2
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M@ !8W$\&\5XR,9F<M-U9]:>O-K-TI[;QJW%;FZX7E/M07M/O:%7*.B%N)7E
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MR9?:GV-F%9VU6*KN1>IY<Z!V:PY.9S" <3G*&&M@XPDU[J8T6'PL"K\NYW3
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M@O_\"-:C1X^("(FH'C^F$F2D8Q3\#X^['P!2?&P$O@HV%A/@ 2D6-BG671\
M" !@X6#]RP#\UX'U /LA#BX>_B,"POL)#4\ #["PL1\\Q,;!>?CP_FGP_7/
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M, GC._VV(0%GPB6ACX!J:"E2FOO+%.-,)R-D3[*,43RY5V6HF?3;O:-?FI
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MMX_Z0O,0@B,CS?)%2N\QCR;@9.IE6?$E7?!<?:-85T3NB9YKZ.+7J]AKRLY
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MX,1RJ'1]&S.O5_N/EK%J#V-9 +\8N2[T:RN!NX>^Y80"Q9?2_[GC-0M[CHY
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M7]!BCU!(OC:5E(.='451A>-]UI+M9]M0RXE:Z2/D6UE<=F1Z[G_Z;;[K^G'
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M@(BQ=<%LBHTS,8YW)6HM5!)-95SR(W!7SU/_M.!P7^$?%AP,=+G[-"!I\:%
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MSVN;&:OP;U4Q_"M"/ BEQP-6OLY ZV CS81+2=AX7M%-^D/:=3S@]P??C/&
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M^S_XUYB0HU/N[F@3^,7#:C&/(/%%ZI]IETIJ7S?HY)A'Z<&CL1-SAM\I5Z/
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M'>N(H6O#AH1=MV ,5)27R=@%[OY##W++#&&,_B6 !J'WCF>+4;7M^EL[5R6
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M7?X2G<&Z?KN;5G/3OGOVF2-M=X/FZX:K45K7V%\CL\-,!Z"W!LNK-2U/PN]
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M2ZRK_CT=\Q)S(T0(L*=_5V]P__WGM;'^Z9RO1E9PZ')]?IL09Y5OO7SF.H4
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M@;JL'HP30*S%< XP+CJY/YP]LE>]S67%5/*NZ\N-,]CQ-<#P'^TJJ"BJZ1Q
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ME<+)AJD\CL?<U#[C.;0-* 2OMG[+24L!BH]Y,YEI"3&.'NL5>K@)N5E>DIG
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M]0NM.H?^.KLG'FWNTUH4&=FL-QG>^;ACA)HT6)P#'I8,PPD-=*0<R 1QV:X
MT" I-"&0 -(/_.5V)0#4'+H*YJZH+1X"$;+RPKY82*JM?RI2YO8CT5RKI+UN
M40+5S_F*O<K>5#)PKX=SHN#>B:7)LP">#J)(E,8Q #&'CZ)@CZ"QB&'6;-(H
M?NX4J6<3O?6!'ZIS>(LGQ5W#K/Q$@"NS-F"4L3KV['F>SUTO)9WOFB\X2^>
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M<P\G%X[UY=Q$WUOSGNE3P9M;&YS<<$+]J4Z1IUNX]"_OKC_ROY;Z^"F&#Q;
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M^4PQF7*MN+I;+E59.&R$.^14!(TWO'$JF295.DM/\D#% %+(SJ-I+ZNX</8
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M^?BBXX[J/K=YE'CNI&B;@#![5F98T2I?D,-+X;+[G56<H1CK^WDS^.4C!VB
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M]!#O7)_C>^GRQ] 0FJD;T/YWLUG(L4I"&REN5YQS];==J(DHE%OFF6A'V&:
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M/7?9U[/IO% ]ILF2P2.G0E\]C!6;G_W3\078N!B189JXMDKI=W#(@N#V"*;
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MU-^_"*39LE"]#M8/N^ZQ(!;A2/+JXK]6QE\$'N2OK+CW>+4Q'!F+@\B!#V9
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M-CNPK";8U-D=_G _BU_7OD;4E(+KQ@MEOH!M(W^)R:;4=/RM,$*_1![P[ K
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MM+V?;Q+CSJ?TQ.,#R,Y@1,WU77'@8'\7;BFD1HA\ST5FZF&=,9?LM3$70/#
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M&6""]+I&YTS[P;0T[LL !19D*%8NO5&.8/)F4(FCQ]9C.H_H**9 ^C4;AF,
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M6T]S#Y0ZD=:T0T]%B.\:;?F>C+:,L.T9IZNP2)'-(I$6E)NSD[$728%,+45
M@8:W?5I*CJ.Z:T%]OYOHS9EPX?%HU;5XM7#5U+=I2^S02Z^EAWZ2RGB+I(O2
M6XG^TC-5BE]1HXWWKE52[U%JU(L<<X$*H@?>C;%9WR][O<DD;?5!-":[P/]6
MJS .%HTT0N-9$T[4R&G\$WZ'G24,!E::KK"&U[/XHH$1R&^U37J)DP;2EN2
MLB!W^&AF;BNG3$(200O<^SCKS@@4Z%FX\;"#>[Q'F;I.07Y@K8)X=VP]0G-<
MR$P]OYQ61 8GC2 'AYS=TBV=GS?3#/W>U$XVC3>/+=J<;#1+-O!YDR^!IQ#@
M6]8?RO>7-LA7S&PX3;?W6GEK$\NMK/*FO^L6=0?-%BAS4^X*\(;P AVX/=EP
M8!O9Y&JCP@:<@H\DH;/#"D8YQYBT>YI=ZD4:*+6;O.5!%3TL)1?Y30D[V.G^
M$:AX(0&FX2*K'?>JUGG57'$AX, )I'Y=V%H>&YKI_I[4:S1%_^\0-3GR]N_O
M53,XI#S-">%0-6V>)]^<1TD+3R+ ?^/6/WEIWY.KR._@<A%:6@))P&0V['/W
M)LE!BWVB&-A-^RR0;=*;L.85>F/J2+9@FJ7[!/)7N+;,2>K?K#8S[ YW^\\,
M=099B@^;C$P36ONX"ZZM;3*^M+S(SDE@@9]+.#UR?3H#B0&3;)@+-(1C]>L2
MU=C-?NH:F%*L([V\:CS_!$9<=UU]CE> ^U#)LKFY/OD\D$DO9^Q(I!0)B4);
MK#:Z+>*,+&Q5U&AVS4-X3;VG_\RNP%MJ+>;-.@B".7%OV>'D:$RQI2CZR8GX
M<(;JS*9P>JSM<8*X53%P\+7D\B5\S[Z'.CGOURJMX)#*<X(;NHU*ZZF@\[\A
M4LF_/5< M@!#,V6^_)5%K(Z&C7LK&\$.C7JP\*WIFS7S^K[8:T/?\7N)?] 5
MX<Y>WV)E0!Q6]:;J/0.>1ZZYC5L0Z,&>=G6\-7E7%O6H'(BFTN'- &._1\>*
M$'%;/)B18.M=61IMW#K-)>)Z.,?4FM[C?:2[EN9^T%=Y>R'S\23*S?.AQJ,8
MD5_]XAUF1$9<0?>EXPLQ8^EWW%94VST!W#S\Q6K.'1WR(Q'H_;OVEPP?^PIG
M/_/NJRZ) KL/(8Q9*;:E,TC$<:,FN8]E9I# &E\/S\*>.$U*O-2WY;JP_.3&
M_(W\E9\IE<3M@O]B#"9?V9P,L>4D5?D?1/'2L_I6S%,V(Y#YMO$%G-]!>E#-
M+IKH.L)E_,3[W(NK&]IP9S?T"TS4/&GY0E?>J1,2]%O*N?,GX1)'#T;8;S->
M^WB!J9$9FWVA6='<\*1**)1'CK/PCS7+&(I<X>@^4=X3TK!(MV/S8WQ__M,?
M-"K\Z,+>\>2D*GJPIX[A:TRV\Y1QS'%NC(%+7:F8FB!UOQ.0HEFH?$O7\?&D
M!U.4PJE:^HU_[>59D[V+HYVR?$G_[GR[68FBM8(SY_][&&/01U(,9<?UY@3\
MXV'@>#J7SNE!<T'J5[J+0W4.YC_]ZG4%F >YSC-'\%[L(:<2E 5:\INB9_HJ
MXW/\K%_CUC)/&+T\N)L2U9O#&B^"D2D%1 G<4$+PO]1:[;7&JKITD,P7/SE6
M4'E^L6[BEN2=UHAL;9QGIZ<YPR5*Y*8O_?^X_ZQ#AEE6@C7+]YB[%,(QMTE.
MSR9FA;5T78P_P;4VUJ%*R]^INK$RL3]$?!(H)XD]GCK7L%SCZ>:5I80B7_MU
MB=PXLLHHYD*XR[B[GO!O-IJE)KQ/3978I "-Z%F#(?BE6,/]GXYGYF&NOI6R
M,RIO%L@VG.8J!]U3KP!4B#:T"(QZ<5Z\^_0W^T;1CPO^L42M YY\$X,H)%J3
MWEZ!L7*L\O#E TH5GSZ>VF)^1Z:FAEP#@WM\N5\Z_U_P:>O_?_Q_=?#?!URS
M_9.1H\#5JN8&[WK;>4Y5LR'YX#<.UPE)NW'V?6G&I=QDB).=.PJ+&OO 4*YB
MV'*)(E2[22$;&Z\ BI:K<RHM#7-S'+&>>A$&>.7/:0:2LXY<97_D_[*32TB]
M\5PZ&R;+6XLY-&U%P$I;"\3<3<M3BN94&O;6/DMY]CT/-%!.PD;9(*<X'PL[
M:A<IK?5Y/@PSOC%$2J:5C0#XGN:)=SM(9G&,(YR1($'7WR?\0%$3^I2;%7)D
M#-) ]3I8V9;D);?+(_7ZN.'G(7M/S9^=>P[?!L<"O!\_IH;,#<@-UDJ-5P.?
M"V1"5C]O.N+5A^HLMM*MK:@V^["FI=N2G?).+R=LXQQRD?Z6]4KD:SQWSO-R
MAAS+X\O,C8S\#$9)=>XOTCW78XX)3KZQD9XGWF.RE7%9@0DRT:AMAH^2*]_F
M.2#)"GQW(3/V1,[2DS2DQ-31DKM^;$W8]44(CS892],;,O<,45/!W@*,B^0K
M38^MD[M?;G"=<- R/2J^<9:HD#(SL\"]FRDI?#'PYAG1_B9T)./W).\4NWU;
MU1.7IR&H])/H4-:EUY9:3C+D2_0U(U$U9H*<3R2KEH39?-F<US[*6+7S6P]3
M9*RAXJ'R:S*"XT/6+F6ZL\J "\5)8L.Y[!6@$9;BCPJ!:N8Z, 8=M^84F\QI
MGLPPV<2&QO&1-(XB+R0A#X/"L?XQZ(GD/*KVCTXJXNL9WCN/LT3'D;MR=IKA
M4S;5/T_?OWNQ_ ][JO]-4Z.[L3?A*=(NZ!9U)K(E2;$HX.2/-\/9&S+OZV6R
M(K!,:[C>;S\W+1]BMBQI(KMDM3XXE8PBO*6HO^F,&^QFWQ)HYYS9DI(;)DVU
M'_3($IHX=I'95ZL=5600XK9?\KL..SC<4X?EK=&P]QRYO,&>[';@8:6MT:OW
MDAU2[5O/J,1N3+^/F:)V^TF(,,0;E!;.62C9.=EW.6?;&?)RX4./BCDFO!&>
M)LUC-=O=->%=U'\\ALE$%&ZTOVW?DATFLW!WIRVCDMM[R,7P7AZ0N[@&*O7*
MHEM@BBFE/%Z762PM,2=86XRZN=*!YO@.]BIO\L:L,\/N*DQ8S1E,>&53;LP&
MU6QZ!P7[=/]O[9U74--=%^[_2!-I(B@@!) N51$0!*G21'J+1$"DA!!#+P&D
M" (2!"D" M)[55X2>D!ZKZ$F]- Q("VB*!R_,^?VS)PS9^9\-^_%[V[OF35[
M/6O/>O;LV7N80_T*4PO#)G<&</S@R0Q(JJP2Z6]5$V'9K'^FWW/857'Y7<_Y
M1Y .38)KQ@:VRM6RR6("3 #7IVW(\FN*'R6.JN..<ID&9:&H]<(#T%[6RFU?
MQL?]J]BW/T,@#+2(6:H@'D;HPM)ICLZXE4U+"PII3B<ED0K(BYA%[W@>YS+5
MGUF.GIF=W1^Y /3G-@*0JO[%WJ<6^!6$E.G1ZJ._:IJ37;>_ (+E_,T!BX>:
MYK43>4_=A0['/_(IB C^$5?MMMYU>6"4<TU\_O$NFU@O4,O-/#G#M;KK?K4X
MS4F2=&SET=(WP=\A<)=U2V?QF*3&DYDM(SKL_0!+KO9E12#NX%[FQ0ZE_@)'
MA <#<LGYR/PCTZ8I=(.<>-#/Y>CA\#V%C@@"M0[(A;)EF+,:HGV@WO#]#3YK
M5QHO22GTE9+#=_G@I(J9?M[U?@8;NW7F[8;,37PIN\LW44JHK'-#F:\TBRN/
M3-N$A%L^!EUO'JK<P5UM_JKAH?>G27SH6^D) X<GK8Y!9Y=;NK+,*?@_+1-K
MB$6 [U"[><T6C8$F-(CQF,>'&N4F?G3;+/$;/.G[PM+;D^!;<D%5VJ+YM_KJ
M(4Y*87V<;@MB:)4[DZP=+TX2I>3HJO%XZIXQ0X][*&#?6QN.:IW$_.UNBXK(
M>4&@D\+J,EDX\*Z[8?FJCJT1AOU7:[T_46L<3?A((N'GGSBY1*1LSY[LJH&J
M7;'%>?#@C> ,$Y%4 B\H3COU1VQ)@(QM=--E';QRKN()8:*%V)'V(X3W.[FF
MS  I): ?;1'13]\X2%0\_T"Q$U @UVEC=UKP>-S,IKD9Y3)))U(#!F:S#'G+
M!+9M4K(&;.<TO3E^"AEWA$DXE^F5SW67:96TS#:EZ/,_/Z2] ,IKY/YX'<@U
M2]+K(XG-C=2+4)M%:P9'8N.:Y4W-<OQO'=P%@-XS7:>ZQM8 [F ]S):/S\D"
M GE<ACVM0TI6F5GEUJ=S D"1A==D36Z'Z3J)>>B-&FI9-!Q@YVTY ]; I/W5
MQAMI3/.%4 7I8S:*+<[RNE^1V"&<)JLBTI";C8\Y3R"GX\OQ9])*D+OX3FI&
M=I9L )3E;3IS*:52V^/<5OY)O].//V,R*<[>)[S"!O[ZJV6<+&:SJN(T\YQ%
MH>61>ZYZI#/ZD"V*ZTM(2,%[U_&V ]#) CFM:!O!S7[_2VR,D._"NC"M6F"V
M%N#'650M-FHQ4Z6,H(D)];S>7=LQ03?-%WFJ_-RGYV'0#/S_X^]T__)_S:VB
M0EF*S<#A);)1UUGPXU4\B42=J6U+[Y^\H>3Y0_VX:$::O:?>VC<U'1Z83Q^9
M\11:C]0(4R=Z<&[CL9<3"@3#'AKPZR9)F4Q%EW\:H\UP]9OV:Y5I3NL*]%T@
MH1/+T"XK 18>-.J7%11/RI3ORRT?&+:5@O@=HR".<"0*L9A;SRD G%D5CJOQ
M&)7K%.P(4^;!;D:FUCDS@!!K<>87P UP7$./ZV)5'F1[4338"(+C^=6S<=TR
M21#&R1WZ3\M1QC'>:%N-Q[MDFSS#LLL>:!M5Y_=B*A^E$S,-@_#$]7'_,K=,
MM7J.5.:"1:=V#@U!UXAM18&:PVR/:!.O9F=^9,"U]XWNJG%'1TMNO.\)N96R
MDNC@9U,YH.86Q',2R1N]=V+#VS6=K2F1-!\=.V2:=[ %GYA+H7D:QE.X;!K.
MZ75'/9=9Y(Z+-ZQF#H*TU*RL$W#9"+>[#6F4_J'[&SXIP2<_?57-Y&H^8$([
MH)("?8>S2&G'?_W#"$!=,\R;$M_UEML]?3FB5?NZ>3?!]8T*9R/*W'O5P*GC
MBQ*/>6<0;]I?OVE,Y16QIL#]N^1@M6$_>EH8)'QJ8RVCB$UX+8$4].SKV[:I
M%I6ET#>NT<>*[4S(6APYB-VY<P]U>$8/8M6>B,\J/W4+.'&A&5]O%R@LJ5E4
M,<DXP</$"B34> K':+-V\ 93;5$^NE9&NH600O^H.3ISKN@93*#H&;HEA,V8
MEI%(V,!A[)@7)*2E^M?F8V8X.+_NF\P/G<L<T'P@^Z7=G9O5WS20[#)@$:%Z
M3@-D8^$%4^A,&RM3W$;2_D#J@"9_SV6EVGCF=>L.Y%.R1*E=4Q1G+I-99X(!
M>^QO=<%$W=*]9LZ$L/EZS<52R+!TQ&_]\N$@N*=D:AY?ZFU$'DQ72:W]"AU(
M'*M0N/BZ+I4B,U<D SCRFSAA?-'9U50_5_B>-/;3KT:A\P[P+G'2;WDBM'"T
M:"L0FU+4%:WO .J2T>@[%: *TS:BQ01:BCI?D=&E_)MNZC]#V3+3/@W'9_!2
M$D*8]9F^-[U6_.6O##2!Y!*(K=X*8Y E9!>2+NDN=(_0[TZIW[_#-.:);Q[O
M&Y8$/#/BLFM7C6CF8S\ZH-;G]:@TWW^XPR=O9$KM[/IK_ISO.V[K1H;OSHY9
M23)_/Z68"(=( )<NK_6QM>TQ12<,[T/F4:QGY(X2]5G7%.Y$)T $'MZSL<TL
M)[C6])&+-6KZ'#SYK_-%Q$=O6W'E;7* 7.-38 @GMIIV#V%H8A;!0T1P\W@8
M<#Q=TFN<\D%FC_N/PF2>203T+!=>4VFQNK_*RZ+27$1X.@=+VW!*9#AWJBU5
M8U80?#7_RZJPQN)9#<!4^,D<YDGUODZQP'NKDA$(F,8B$.QQC@T'C)$+>YF"
M?.KKCP[?V']:XQLM G]OS X%+=I< %!]N(-0?E6CR\"ZIO_Q0Z3<EFR2N.S+
MTFZ.<$J*3[S6P!&CG6'#^QZC7(W,2HP5)/WN;[$6U8UG5B6]-[NO]11<*0 L
MY5-R8PTT;#3V?G[>?^I'9W/=3SJ7\KW10-T6Y=\FJIXXKG)K5R6X:NC+ YVT
M<.&$,KP"/C>GIQCWK1K#->S?Q8P0O&L#"; \:$I88YQ/V;F7G8*SWDJP/HT_
MLF 7*FK2HN&G!8![NWB,8Y)"U#;(V&>0VYA6<47!*;J=14O0,.GR&A>G[D,(
MQJNN2;Y .GPE:7%N>"H[=^82'<W$,F_@\9I/HK] E&VWH982V]]=<;%$.I8D
M<1PG/W @=$]@Y.CK>#DU7S88"/2K4H+KY9\FV TD]T.N9COCT(GU6#]E"A/)
M(0:"I<L@--?# -#5N;Y>9XT8WHBL=N%?]&D]&MIN%6;YLI08K<P[@M5:BY=;
M$"B7KN V%4P<N*^]0YPRU ("]BJJG\&S;P;3$ Q;#$Q]#AVM7J?*$JGV!6"\
M<?X/;"K VY9UE5[CVFPY@5G5S[7Q.&V.4+KGC*I\4N PK'>V*&7<@1"F)VVU
M@O>:#E7]C?&N,</$VU!CW36*_C-L>:%U\N[Y_2_9BSU[2H*H1T?%D04_4=E#
M-$I6_MS?!V;CS;U4F[Y.1DR$*?_0GBS\[F.585L$]5LO#D"LU=<'6'3>54ZA
M!05-9AA@1U)6SDB:YA.+RW;SLO\0I(?ZN0+C3S=?#_O/%K!1K)/KZOQM17#.
MWXOB2$D]>BU'MY#&Q<P_>D44MJUN3&Q"WT7/%?W9^C,[&Q**Q4UC6=E>A"G
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M? +^X?#)-?9M14-*HKCMR22U+C/J:+ M"[$ON#/ ]DBZ%YUW/L8::* ;B^%
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M4S]K<>1>9,.(@>Y4ZO+XYPAP(19TPV@RB.4QD',HMW-;G?S 2H>P9Y5Y.M/
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MO^+B"U(RYOQTGX_?9WSOOVX*\I-K O@J9'-@=H5FC6OYGI][.W]>W 0L/$E
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M:PYS9@Z4[2)RZ^L]?VW(<U3:H)0'IY^?')9+)7O00KCD%_60<WO]]Y31P_W
M<BA,W$IY,$1,*R(NFB'H* H:YG5T9*4X]";AH7/WQ4!W,=G:/%[7>$XY8H\-
M$;I_![@XR1TV+BF&Q]&I@]/:4AIT9/,__P/4[PB750U$4\]CHIB2!CT&M] -
MDQSG=7P?T*TQ'$JU+O[N=7,V<X59)G("U\MS8*15K#!#4V"HQADC@L"4"J>
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MSXS^I"!55#%9)B&O]FSF59BWG+_,38[@G+"\V>8QY8O:7+VFJ"D<BD_X[GG
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MAH2<B9%DP!98\%FCE?OFN9CS*>Z<V^_ICTUX]*$:&!^QDH)D755#@58KB?+
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MO0^RU3\"7:4TC_1R/[NK*?>.U)LMO%!@\P([+.T'>RT=/-6QN/)EU)74L=5
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M;/PJ!CRCK*Q%M7'BMK[FP5B5Z9\)R^DWL<411=X"5P*=2+!,@"TEX*/ZRKS
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M%HA4[[9PPO:KTY]:$GM%%^O*8[]!\GF\,EDGZM^"..7)7#([NQTI0:I(/L%
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M*GR8>0M2$ZPL.\D&SS)!X\AKP-2^"/F=VZI&6O*2Z^D![K8[?$ZP^;B '0]
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ML>Z$=MVM'"%FI\E"H\4\+T6D3D29-;8.6>_GSQ0+?C'[G'!'6]B264YNUIU
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M8+E&W&\ TSIYP66H_T4@=^H'N'0\W.M;;:@9K:%=+7DBM49M^"F&3B>(R5E
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M\.EU#%7GC)\J+^?5WTIR9A]U)"4UQ ]"0% K=QO7)Y%(:B-G"/GCEL;I!:'
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M)M0FGC?798IJ^&B>LP 3@>/DAI'_@/S5"-HVY0V6T=4Q>;-WW:VG^>GG[#L
MN'2(25\T+'#^:BZS:DFM;/MS:8@.9X-+7+59*P'=;/#2%]5HG]CJH>*B?O=[
M)N^O?'@)%_&DY>[.VW=-E-OA9X^.H?RA+[BCWDFMX>)B6T@:I@RYA9)RR*IR
MUHE=B4Y4R44RXCKTSSZ#0=Y&1E;C1 65X/UPB/Y7]=Y D[H,X9(,:5/2Y5/+
M#F%+1%1&^?#C% RDZC#9TK'E(86@VI=,@WB:5$'10$)J^ZTF&&C_0^S0N6&W
MENR&38I#=S_;Q;1P_<GR+=U@06D(<'%-X4#X,\*7N'[&H/>Q_F X8\<UG_D8
MMRR?XQHYRN98[G)UPTW2S]<G&Q36LAA0@ -<AJ2M+5H^VA_9!P"JJ54PDNGU
M*!<G:8^7E%"_&B1-M8/:4(BGG;LB0F]!CH&[V3APW%;VX1H[HS&J\J0YMUNT
MA!;CI[5@$KR08HX-76+FX+$YA/$R,RM\^<)1%OU#**5-%?HQ<>"VAC?_W'ZI
M7/KY?"NW%QF$#6M#21:'\4QP-L?W? !1[Z<7!.RG%T26QU^5(D<8!)OSV&O[
M&==N]3%O2#\JS%7#A7/H)O_*XYG!%?SQ@<&!W95>1XJ+4X<"]L3,.*4\<8.R
MSI/E1F"K)15Q[!)O[0?K8TH2 OO8QUB61=--8/BV8#"]><^O3L*/K:_[BV57
M4+M*=RX7J\R.B2\\N$BL5QP?17]+KQ#5XNT?6"R_?NDL%!O&.9;&\4;4-BD=
MN<;<F#L\7F&/&VU>VUZCFRTZ_QLM09^39X#61;)I6&]'?*EU!\PMH; T>H2Y
M3&O=VKG+LG=5C)(L?K.LDE^M:99()6:1&4?9*8]IV4/I^[EC%YZ%LY3U>^)0
MCDK5?1=*F=!N.B?^;M]XQ86/EZ,US,(['N*NWG;?V[LI_5ZNU[E>VVO%]!+A
MS'RY<#0E>5Z:0<M#JAGC;I4MED4%TNZDEN=X/ENIHJ)873A$53.Z],KE/?,*
MZ>3#LEYQ3GI!.1P($3?!TS/<-%]0FK,<U+"?(VJ1J^/T>\R]D&4:BNQ,.58'
MIS"6ST4W"-W%G/1W\NVU/;SF"RD;9!#F/#K"V<7(&JKN$<$ QZJD[X->1:8T
MZO,5O.:T95"8LGRKOQ04G+&C,]HKPO:@R2 92J_/'Z%Q5D\TO&<COASTK+?C
M6P@D3GD([5(BQ]76VJ@/52[XQJ(D0>:2+(!+SH&+0_Q-EX%3M51I1;TM+\'1
MC+5(")%C>8:5U;,Y7>;6@-WG8=8B*@KQ._IKSF4A,@)C9/%W *2'LQ'9-Y^F
MOR^D":Y^/&$V9%;HTGDN;57S4(F6]](P,L?174-W%+3#80?I&N5RY;PP4BNJ
MJ@1V,6.M64G;YC>!,SO<!>WRK1%[*E8)3W!NTB5W]#_+;8.5OHQYAA:!LS7K
M1K#(Z84/#(*5#/(GS.5[P':1Q<'AF:$N]6DJ065)JWZXCZO\OJ1$\(2R)8&_
M;>8_T$?*K698CX18+P0/^6Z\=A;+H4NY9\;9XI7L-!YL@NT>=_+AU/J^'$'.
M\<P&;8S=>L[DD7BRF^>[?=X$:<V +:HND%:O4Q+DP69B.3@[(R.T<%"5(+7B
MI!TH157(FE(DQ!572Z9LY -[(G"!&HPX(]ZHM+&G,K'!S>^T5ZR5+EY%+4F3
MP;UCJ)K!R EY/K-EOYGB&<O+%!%HXM3#>TJ:PZ6 #+XL'9*S7Q4HWB&TQM_0
M*BU-I.L"@3X.!*<N"<D+M'@A^DI6N7_VQWY-?&9*0G<'(-IJ/,Y2DH^A4P;Z
M%*X/^A$<-FG<2X^E7/_3C/NO!7M#EWFIET,Z0'/$$44/1R&SEEV2>;16R34^
MR@Q9?96<&\U=SB4@J+2.I:=#N6[OHR4S]'7S\50W^AV 4T+-_K9/W@QNT(NT
M+:-C@=AIR#J]QE_=E2I)*< 5!6LEP*@R87,K]!P,7RJ,@Z6EU^9Y&O31)-),
MXDF- !9B(15DVPPN_J"M+^#-0I<-UWFLEA2!5%&2,R^EV?6!KI@[LHX+J][X
MJW D1^+/II%#,\MB  >2J^_V)S#GD=(0 8WR*^&,-V@S3Y>I.@E,<C7.U46'
MGR4QDM+TS0GX3;-W/'GX<MT,KM>#!FJ[Q(IU!VCF/4BQ8L<-?2'B1#/%=L.8
M?# 7?\".\5BW![KIA+7Q'8/K&:WM6K"M[E*&F9M) )Q8QL3TE,1.52P.,E*!
MUN*I]P+H-VL=]!>^_Y5%XJ^*22$S.-8K896"F[)/KK)XHV378QEO-A:W-YU[
MN>\ M&\Q?5PZRLR!G%8]#M4)JG5#EG0_- K]HR=F#I\E8L5B16S=HS3=$"'X
MRN%-]A\^)<<-9A]8Y>-S1^3(C;^>-NC(R7?'0#7'H[ I;Q_'_!(89GMR B.K
MLU1NHY;39;0?29-%W>_MG5(PJNVEX'TT]O2 *Q54&T><&BE,1D.R-I5:.5X_
M$=&2P1HOF$8=]I!M3V</7];XA#>6J&#'S,YM+.UM0F^G7_I'YUW&I'33A(UK
M"J8X[C-\#OHC:B_M4(RA*ATO 1=3J4A@PHJ=:?B9^<XUAR/I6 C"-X00T4+2
M0!@V8/F@6#EV%D./*+70UC;T1BZAY8#$+\5GT)4'RZ]CZX;1KM"Z8:A6R89@
MQ6J)Q2LKZPAFCW73PU)-)@2_IW/,O?221,8WA0#7;S'DF97\-TYTYXZ^;_NC
M#;)JH _FPZ=V$PEJ;V12<T@'5]V R>[&6SF"\N'-Y[8SH1_&TYK8M46+VR>!
MA A?#G[H9>$U],- 345.@XZ46=T=VT.1^D83)XS76V$8 :$HLPJ2%XD:D#V\
MBX11+TDQ<6IF-\G'BO+PN&$%NCTD8%.KWMZFJ<I;S)DQ1YJO9"8ZO'P],;BN
MXUQ)$I8[Q/O.=X M6QUT ,&.FL,63E%QZ"-R!SM/!;=R<[KAXM78[=R2FE(G
M">Z,#-[/.U.VF#KO.W>>'G-QQ^<Q[[/Q'NX:+4I-9T,%;35!29$LG[2U*J)<
M?)?#O2EW5.CD,1*2>W$)<PHT;U8+S/(].8 <TJ<"HX?6X]E"Q#/ =@L-U>#1
M15->7H%[AI%1]&'P\.M <@.#RF/"+.5*>&;.0E(YB;/G[>Q#3R\3M+NL.3]/
M)$26T(P?K\L3+4@?ZYI7'9!8LUF![=EV/BQ=C"E@2PMPFV6KNJ5;K6;K6> E
MV+=78%FQDSS0O /8C+-P+(,/6@4(C9MNU3HMQHB^.#?MB;@,?6&DI=S0=JEU
MV!A>S<+KJZ5!YZ(UCY3:L7%L4\<[E;)FT4J%O=R58Q\7=UW1@BHK\!MT9^UG
M#<4O6+%8B<C? :202?NV'W22@^:AV<UJJ;EJ5\'FW9SI"[)[3^B4WCVGMQ5G
M=H*B*_YABJ O?M89'/H 2/!T./M9U%235QN*;)"4*;_ET[Q7*7X=!'P;%VJ7
M7QUMP(^V<N2=.!GLYD;M^/!>H6<Q2+S,_S[ED5^EN1DPZCY-9P--0!I@?YZ'
MH];-(//M4U?;+ %W$L[PSDX2/78ODYU.P+.$*:>,S.LISZY8BCL D\G:(=>
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MT4A.R+1;?/-.30EV:YQS+!Z2LUGW(WG47,DY[>^C(>3:Q6-6USW2SD9[<"-
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MM8.9F<NE%ZS<3&GM:\3FIQ/*[M%O"[CN^IT:(W15PJ9G.%.A07M"MKB*\(H
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M4%;_]<VB%9VH(V[H(I+N#HLL+AW!A=61 Y75]=;,U<#/AW;^N5?G_DWB;6K
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MGBV/O'),A"7<47M_3&IJ;?[MFR]Z)A0P@G)'5$JOL<YE*Z-B1[67X9\2_$>
M^/U*_SP9M__<XE=%6)M&"J8@)>C"R%JM=9^D3I-VD3H4 )0!U5?3A%?0"4AN
MG0_QM@TKSJ#/A[+V\&#X_%34K,4-36U%"QQ8WB'XK#KI75V]KEU,:%H2%-H)
M\'S>GJ)E?45SWW[:0-M[7T=PZ20O#$>[CDQ16'!*5\O@L>[R\IS;.+<61";C
M!4NV?O&.@A2%[#P-990.H!M.EU5D>6$4)_/ETG2U(9M*E+X7^?FT)DX&S@D)
M)J^^OD;;@W&N7II@GZ2H3WMTPSG\PN@81QJ0#'10 UU&T;R[U<7AI5++]P\-
M22]?HK^-_^$4_EXKX09SBE4(W2VG)88L8BM6,$9P_A%F?_%RY.H<7R? >1$?
M#EG?.RTH0 2B>PF6$&HLKX544"1\)3U4?'UQ6LH:*L(!VRB W0)4(%63U@5I
M;7N1_)_BAC*YLY9%T7;<=+JJBMTCO_/1M$+DV*UH%SXI(=%&J29_1<3!EMH\
M6=]SHU^+2H6B?_;?C9%[Z[1O@3S<A'P+H":/N@48K)XG;S.E_(;1,?>?J''_
M/\"JN*^-G)D9Y39KTI>55OO>H_-?(.FX]'I+38*/65'G]::7;<D2:&,"7YE&
M+69BTU35#X,APBI00UA^O1?7&>L+%2Z5<"K:CU^1"4DU:Q"O9RBP=-)$!D&"
M^JVTN \P6O7G)UD*\G:V8><J9#:X*OY/: QV]63>QR&(1V $];S!320%.YI/
M/B2_:O_Q!H>/UL<".=OQE?7W^C<<J&4>0\%"2C47Z@M3X<X/?T @/I-&&YB;
M,JDL@---6+E,L6=@DFEQVY<EG6X'XIH?8(X[.(N9IG+P=7:PFM4ZOZZUP5\W
MQ8M70XL:Z[,*$O0=I^[-4]%9 WXX;3I978B1#0O]:C(IX:1^462J63/'5/L%
M,%RETZ;@&YX3AG1Q$]M9D?,>7;M,<*>1)7Z3M>,K$R(NI!5R#MAF1XH=FN%0
M,2)=,.S9Z[['$9++R<>W@)^D#,Z_JD_+(S)^PB7-7^"2:LMOI24!+@LEB?#0
M7?\NZ(W[@J0?#V!*6<N J?92*LBVB_\5!W;QT343X\[Q3""501P;A$3XY?[I
M_MS0',I8-RTP@]2A#ONK)LB.(A'M^9D:&JQ,0F/<UG8Y>44;1_KKX;M56V$4
MSUO 1_#! 9>6Z3C5X3I-*QQ;9^6;L8F*+0.YKV'81YW8T-=SV:%,H\+V/W.(
M/4,!;[=F.X1,V=YJ*%]/ ":UZ "E\&=79%(?T%;.:!-T1;/=0DC?PL[Z791Z
MB*_D\Q#4K'(IIG*%0#K.H@I<^3(LU!^&(78T$V;#-1V3E<@LVN_>^#1[3@T;
M-TTM)[;S-3%8LYX *JU&L:2%7MU].*4<KC+9&CK5O"_B7!""4/IROB^_UMCO
M%EWD!,91MQVN'!,*D(CV0IV92;]B\LGBH-(R81%9IURJ:I5G] Y0+KY97H >
M3YW@;])V?,:,AT22::_^B2/&_^%*/:;Y\DG$VL:93+(^DS*J??+T#_9;@*6"
M./Z,"G&=>CRO^Y>*HX*(&UI$CCRGNY7VJER*.=(!M4H9Y8](3.<,U!.+*^42
M ROBDCZGDI=9)N:&L7PP5/*US2-P:_<2U@MO2^M(M-FE+LF9KX.:0@%0W71\
M6$W:LCR=( GANS>B'L_A@I[))\6K;$./>A_.VCEQ/QT =ZT[M#XYGLD?SIFP
MGN)MT,O>$7*ALM?RI=0TUS/L.)V::GN*+"XV*([[QM3?;0YAUC3/:%NMXB/G
M14APL5<>Z>V6U6T%Y6[)0&KX7 [K\40^9C(H,*2]XHOK8$=T4>P^H_M1\QQ#
M1+]^TPUJJ-VEVR>/6'K?2,:I/P,F,BJF!RYH?18LB=5 #1-B,%I9()<CV>JR
M?^WX_DAR,;NV"-3_85U!5GF!P(/WG0AVY_*"K+R4YMOZN@BX;<Y^X0W\K%P+
MKSH^G^:)ZA,1S\A=F6=?JI6!QO\-.O+_;8:< <_[N%CT8T_E>T>,TPN^*#*8
M.,WA?<TT+6\@+#]EF?"*WR-/O].#K,Y?#MEZ2>CSMZLA[EV7L'*K!NR@LLE+
M#1Y8H$UQ?X 3KQZV#J +H9MOL&V 'D@R;?# XVT"'T6IQ:!L^1K0%9*6#=7Q
M;2YX=IID'S=70<F1_H'TB0[7KX*V?]-&A(S>TN\W(O[EAVK_B88OIS&ZQYW&
MX2-R0?6L"0H9GY@=G(0\.AX0!F=^23@N(LD..S 9QW 2(WUZQ3!GW(8Z=:(Y
M)GX+B#*A_T:>U"U[+(=.8L/11L(D_4$#1OE*>1KM2!'7'7QI %*#30S (H67
MK&NK#(\+E[XP^(N=K#0J/J@!+Q+7"FP9>24,P@/G,A+=+K6@8F28> %YOW(Y
M.5+\9;8=F;]"T(,TI0Y"O+KPZ1!=BD@\PC?[O,H4JJ*I02<+MUB]$LW9G@4G
MF@KW,]&>]O=EY)":-:(H%>.+H0EHLB^SK^E;);R]!137TV(;(X%S\",>=DIN
M$QJ9X*/G%5:;A;Z^U.B6KC;+N4OTBK_0DE)8Q29;[M(>?+E[O##6G>5L-/JZ
M=%;FDVC']M'D;'?=)8Y,I;;UE<":';-=.;G0B\?O&,;VS=GFK^HI,QJ<$,0[
M0;*390NY%W<9Y"-T()Z&!$DZI%<.3M$.<R_R%CD#G09\BQ.E]-N/@^I>3*3.
M!L:X6-HY3H[)$:G%>Q:5QQ? L$-HX,$CKSF$5UO64Y']ZR_/C\L56;Z-=#AY
M:<_VA,CD^]BECDYJ!G%!TVC$JRN;&D%%*^%,WQ=^=A6/#WA4R@@^]WHZO"I"
M-6<@E^OQ1<_:7_2D:,R-NP=!T*Y<-]%Q&GNNU.7 L.M3H5^3D_'8/9)9&,OF
MQ5"2:*.KX3@Q%T)3#AX_T/ N1O\5+9 \!_E",UXE2H1*O24H0A-[CUT6<CR]
MT\E,F5>N=.I*\+>BH)\\C70,#C]%8#D"[S^)]E(9$2/R- ^J+J/;6%GI^DYO
M6F<SRA$I4_9:&<@OT[NHL/PF.Y3A7YXY_ 5#2BI/L=MEJO)P/4U8$6K:^B;K
MR"9^L=(4O*3G'LD58F<^2?G%CT<P3/UP_P=AUTJ!*SQ@&@NRJP-.L2NU="/V
M&:8C2L2L/IH2\J6NN.+_,:>(M3#@6NNFZ88CM>Z1B$5BA>&= _!$ X1]?6P!
MVV*^CG(0VAJM>GU&>"34G[J/G#7H#@8GD5J2NS*"/?@("WZMJ/V1F>>GI)(;
M]V^*AL,/RG_G^)Q\D6X!,=A2MX!RAZL!YT__ZKOY3S5-P563,FS,U\Z4&P<T
M(EI]>P>UBPV,],C?K[B7!9L][-Y.&8U3LU=>A^ZL>;C)VKNY=G'N&01E3R]L
MSUKI&A@T[P8KT#D</4GG/-#A4OI3E6;M/U)Z^RMTO+EY^9SW5?KM ;U<;/QI
M?.B&)#M/XFY:GD5C^TH=@[.;JG3@WFR(2L$^?!Q:IO4>IW:,U-6C\E>C+G(V
M!KTL9:GX1CW[V'D.RR4O%904B[Y]Z%#]E*? JM9W$K+B\_)(?B2OKNI='R7%
MV5"SS:1HB OV[C6!!YYM?&#/%%$?N7\#DS?68+>\WW*SM8?">_!.PNQ6,LX9
MCL)7&7+?:R^U%P;/S/1+):6/RT7'CM5@^U5Y\^QFEP8F<<*?5RD&FS&<P4+W
MGS^$\!:U)Z@6/83PW$%%@_<[1+Y4XX%16?H[DG-[=#-"WRB<CHN.?629#:4A
MXW>>7-,)IZ?IE+I4[QM^/XZ$ &K$-XR"NM)6+ -+E9E>D]QWT=N')&;A&-9,
M74ROX@IJ2@Z?JEJ%RC*Q)QG01"FEB#6%R3XZG<&UUAT$]'Z[YM3[."\0%+#;
MQ&YGJV,]_X(WJM;!.@=W*!]HH]->MH#8V=E9S@V0J?D@A:&]8L[WK!6#8K!:
M2+74[XT%IY6?.>[Y,\>D+HZOYB?@S[P$F9"Z9OGD_BD7VM'C7KJA ^P^XK,7
M[OBND\NVI2MUBHV,J*2G--P#CX4D5NQ]3R+3_1[$%6S'Z7&G1#74FJGGCZ[K
M5LFU>YI8SKINMX"2AE*8W.8]NI='"]T3K[&U1EU(25^TJ%*8W;];?=(_WFA0
MA-DDKXI]SCQ?H;X+;>^B_?+DI>E'*[> .E9<U@U6-D4]]]WRBCWU>QK&F/-1
M!5=5?.LVP!H5;IJ\84VJ/P5_Z']][J)_)6ACQOND=/>+W)_KI"O=&WVK+.TY
MC/R\P7^6DW:TU(+O622*L+Z^! .*= ]U4V+W;-[Q;%%E]&Z-@AK#Y>)& VM0
MXFS:1$JW<UZ9:G"NL&]\NR)Q@?ZH])'E!GM1L#..8#$#/7AUE"#T/^&!^E<:
M^Y]V!+A3J:O8D7Y*ORX41#FC#W"JC)LT=N:G,01Z$+ZQ)0LJUU-"E?^MU[1!
M.'5>*(:JF!1(7RY3RI"60 +MQ;L+J+_<L#[V);9J_7.5BO_5B/)/%NC_]9ZB
M^&3]@E.7@$%\[KQ>MPO>44$O*?W7A.A4I/-DP%9A;SGNZ)7="BU,I-G%R^D6
M@"M>R-RD+?B!Y/,]U#'NUF6_)U8Z(O5EVP(35PT?>'AD/*LXKA!4,H1#15Q(
MS7]-H*F5Q-L8MEB_C"DA7QUX)2]@HTI+:- \"!H1^7U!8+Q+F3K>*)[FONHV
MNPPTDW/ 6PIVH]$,BF"UB#@<(-KU*2F&!6ACXM-4ATOVR'Y/:W<;L-L[ :ML
M^RV3P7$,P,"([4=LNU'#%-U1W^LFR?$8O:3+SH1. @N"BO;>5'NE&8 2FIU*
M$)6SO9)O*LB=/]_ MT1EMUA9C:N_)&SW'(Z@Q^UIW>!"_"ID"H=N6N#]$3NH
M1KIJ9VM99RD39VM%5],'3W6%&C#B7K$SUQ[$D3E"2O+FRS;24-I22X,?<@N-
MA&19S,4;!21O-M$P 6V<\J6=GJ5VHEXVMY9A.HZW.K2Z5OH0C8Z.*NNF(6D)
M:,07;,WNY]'R4FP3QX4L$MA^,*?%1N#;:<9?24^]:&)?:<;5O91-"9;H9*[,
M2%JUQO'#P!YL8!M?UU!(]0Q5F$W/W:\H$4QE#(\%M0MYP+-7EC0NL8-HHWJ#
M5[1GG.IN 54&671U-U2P$@.$_H^&!-,VC[)W]=#&I=FF G7$TT)%+TLAS1'V
MM#,#(]</S^.J/35M]3&X&'E#1Q<>I=B93'H_74'W>X(P'MTGR7*@C- PH[DO
MPC^TJI/<I.&TS<M0^.I9]4R#&@T_<L:VNC?O<K-HV\4K'=^,QUKCW@,+0T5E
M)'6Q7C)9T<NTDI(B'<9-%Y5!$%L2/7!RZMY0L'7K,GY-A@R_7*Y6F1J&"RGV
M5S_&B>'JSM'CGN7!MW;I&L)RY(I0O8(/7/0$>\;^4@GMK\TBYUM5U@[]L(!N
MEZ#X9XR1(-L@8:;QQ&K?8$:20F!GZ9=:J9<%<'QNU#R+B<D""4T-_M8'<FF,
M<BH*4.UTSHRS2-'7FC)Z-7$-W9VS\6"VN/<<-V(4Z_KRIN*7";LF@6X?,\0M
MLD.GY_^P"TH/R$\ O$U%4]7+B 1#!&UH>.A=>5Z!L1F%2P0@PJFDX27JITI.
MB]WR* O-LPG^ZM$,WQ@]B5.=RXEA\AL%!#45VLBTMGZ>N? HG5/Q,;J*MA6?
M)OXR$PP"!F/+H]FVT5&5*>7I/ZU.%;-0@([LHWP9QDX2P>CB!S)<'@&N>%^4
M8QWT!O/ >DMZ-2G9[X[,<8:NV+'AA;:L!T(R]I.>1NS:#'/<4TX[3Z] 66/.
MC38L$V]JQ3)=A'M/N /BBG)=^?7RM&<%6#;4#!Z/R0>(.Q&ERSRTI+5K&E K
M57,WU".06A_;/P\0?G)9OGTQ91C:/^6<.U$]]2%56L1BVD6#-.!\-.UAW@!*
M\:/E5?P!>>V<5Z3A <EN5FVPQ?RI&K-'A[4:FWWQBH4'Y\:U( L9!5[>#^.K
M#A:Y><4O_KK_C_VCW.P?&(/_JJDH)_]4V9:T0++('?@;WO^W6A ?'U0."/"P
M"\E#1+B8N)DEJ^?HRK-\G1S+8.ML3+UJ,G6_ @TYS]F(N=-T$BAOC<[IZNXH
MO>Y-ZWQ9[958((2QT1)7.$D8S:8U;K?^16 8-18!U.T0>0'GWH@2;+?A2<.O
M=K-BK]'/*:B[B1]R/_OJRS#:1.;EX;<JUW?I_G7!CE+0,*/,:_XQT#:%*D+9
M*97^*YCU-^>&N+W_79G_O3UH0-70(-+X*477M73%"(LXGY_5Z=A0Y&I"-6*&
M)N_19V*SC/EBSTU;7"Q$M_B<C3UZ$QU^[J7% 9]?PP*YM8E@-8]"F/9TM9ON
M9J!N\@$#^836.. !YQ)@RA((L%_"Y8+2^Y+O#)&5RK:Q/#1(#:W]F0P,1OQ-
M.M$X52<ENJ !1G?P]^!0THH;"L^1XJE)^Z59&1N!P$CQ0'Q.S;!7:IIA4G%]
M*TFL.)CD.^*GS^QC%;!?9-X"/GIVIKR:C"%\R&Y#<H?F.>]><7.Y;ET+[,HX
M:QJ9(H_?UN!QL#Q5GOW::!)AGUW'QEZ:QVH1Q<L2226K4'G\8HHY<,S;%AL=
M\TKKHO(6<*D^X0JVZWI2K:%Q$0Y*>K&.X_?5:TK?=/^()<B5RJM8/S):66EV
ML)9@F_'+FW;^!P5EJO(6UKFYX,"5%D]$(^Q2DW@^>3TKX71Q'?;=PR+JC7#)
MEJ=)9>%Y,/)B \R]=_DNLH;*<!=M&CYJPO59EB=:'W\>K>@2R#-S;G('LZ9R
M5-1P#73G>HGE.'*D[3/3\RL[-%VL!.(6 F-TXP1++;2#U9'C]+ :5PO7ZN/D
M*P$E5X$^\_<41?-!;AV>S8VZ+4EHW /CJU:=%':.7FA'B*9')60*3-HTZ+B8
M _3\ #<*G4-VE^)M-)TSH29?ZD8K//S+M/+W7.C-]Q9O^,$J7AZ;1S8S"@IC
MZ:UIKOB=%CS)Z8FKH&917NR<,"X+]-1"AVI2KW1Y5\B.##?H5)A1II#I(U5>
M+C==$"OXB>F*#^,EGV8_-L)?"JK/QX\_A.A:ZA_!V.%\UA3">(/QZ)K)K,O(
MP>1^.V*8=X/IH:5R]X;3V)G5=^&3%R- _/KA7^%60NP[M$UO0_N^G!2MUBE]
MMH^HDPTTH_4RV*>U$291!^)&Y"M^<W:P3A/MRZ;F8WXX]ORZOC-]7QYPF2F,
M^>6(ZUS<^H)7P!)LH_'M&W@)<K2D54N6*=E-!G=I#@-U-(BBK3;6)UF>9[W*
MR6Q1U[QNUR_M%7618KQU3P&^I'>8F;//MB4*LW.:T1]P]CTT3J#R^(F<#<M,
M?ETTMIA Q3%>BHQ^J(JRYMLS37OMN::QGB=X=R#\R].6%QD;2S:Y##^<+6\!
M7U7+JJ%#3_28]XL#F8#\@5/"/D0E):^T1I3%T!X R$K0!5*V(D&R-1=21S00
M2. @2N#]1\08 !0MO$^0!ADFFCS:^&@E3V7Q[=?FS\M>7="5$-0"KL>,!2%D
M4Z)>L*%M?2%.6EANH6,X!R;/QJ)@B25EO 1MJ/K[?4RG%HKZN->M*2\;GI_Y
M"5=EK$C,[6"!4"[KSSF3?'<*XJX&LQ.B528WI?]:'2$PRE-'8O0=L33>;KAF
M"F*NLY9M@2?%>/1ECU02G;T?VC1,,R1WLFQV=AE[EHJTU8QB5:^B<RS>T'1\
M.5#@4\DE2OVTV4\]WKJ_*GS/P,BP3U4K/]I3V+I'+)]7=W=C8S<BF=+JX3:Q
M/485,JQT-[M,,><3IN3/)E+. H5Y'MP<#-X"QO#CRDAFK(Q>O+*S**FL#1=Z
MRU4Z,UW9O G''6$\^'"71#;:K,L<ZG>)N)R<W;W76T0W12-A<46&-:1/AM/G
M%@ K:\5P-UX2KQE$UN>[7OM\+1+?AUUZZ=6WS%=T[;!2SOIAJRXO-Z]<[.3E
M?[<WKK,+NP4<RG,KWJ%\@7U0(*+U%D [IG;!>I2):?C[_K:-J]_%L7_Y7LB_
M=!\F^J_UCRF&4APJN$1=K%\#6=NQSY\3LUX[B%X\R<1J^,-M1\8S#J5'@O0@
M+M7KOHQBL'W5-D<A?LFGK.^CV5SE?S.QMT^#31+^&&BJ@V7O$%;%UJ$:+ZO
M[FI]N(0,FIJ<#??T+)&WH[ILG3\KUR;CU%,,.MX2$EY)B1#6=%0DC*4SZNER
M%%76ASC]R.)3K5Z8&4A4+5)(9)9R#4@^+"=S#U#RD=F]UVMWWR9FSJ]UM%DS
M>:5)QNA!ZPI(F)/P2=>H[ _'!Y*HJXID1-_3,G>[/[<YY?7)S\P7+"_A01-U
M;#O&DN%QZT=A;RC*'&YHFB; W/DVXCH,T3=[2,NH$"]@_ =BGTI=74KIZ#<
M1O0%G':E^D"OSP0R5/PJ0!-5%!7G<;T3_IWUDV+E<#)YY: ?H$?9HP,3ZRUS
M20JK-*2-49Y0AGOOO^)!%A22"U!P1W-D5/S?]X-$J!O'O,VS+4%HD#R$B]M^
M*1+-,?ZXINB*OHG\\,>(]>N*3Y"OH<\?/HI(H1%9NO9<0J5N>&ZKU4CL0A!*
M7]JE/FYS,U$PA'IU'%Z^P?2\[>D#&TP:L_YHSE>+T\:B\79Q,7HU[WP[5\AT
MVFWQ4U]GO'S@IS?).9IM+JSH6FJZ)%&2'<IDDOG'G.(>>N/G/6;:=(TY8@8S
MD?B/R^B.UL_&GREO&DB;/I_[D@O_D ^B=ZX;I&V.EKH%(!U<07TG46IK(FD!
MC(4 M/;5HBTG;_7F1W5@51W)$<B<C1&?O\3:O(\@17O&8$.5VHD@X0FS"$A;
M4@/8J:]UQ,S+58;EOMW 3(61&? -;V>SB<F+-D'1Q'FFH=J.^=!#) @.#DSC
M=P*RCV4(J44K _'-WDO)OIXDJ"HGL42)S""J:XW["-QJ6;M04[!BW T9$#<
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MPIZ)2%60R+4QK8SM"Z-;]-L7IV!"D+]]3;V[*Q-]LW_;R/Y[DZK22R]1ZMB
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MM6@!^QKW(#YKZ0I]JF,SWOG- OZBT40.9%HT$<XJ>%*D2B3+0/.E]VTRQ1U
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M"^9D>U\=K,RMV=BSS/F9Z8%E#BTB$UGF>9F(8ZGRL1*>57I!L[;(1/D8H1"
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M@NP88[I&4]<2\S?&7<?JVEQ(A<D_V#.W9;CF[9@!H6.?;-VEAOIR9YZ5U0W
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M)/S[?T%.]'_\'__+ /T]_F]02P,$%     @ DX!K4M2&(]T,! $ Z>P! !8
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MQE&'QG)&6 HD6,HEST)90M/*6+PI1&EAPBR6J2)L=L3X7*20NCK;=%,:E2B
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M_](URQTJ\-D9''^>]Q:4.4#D=(_&P!@,\/+8D/2*.+4JZ'X=Y9E.%S\W-J:
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MZ'8A\"L_^59X7HG=@7T=P_$GO=#LFN L"+CU2:<]-J?D6;7<3@[\!O%%LY?
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M:T,Z/9,\6%4[.NHS$L:8P<4&%#Q\'QP0[D:G-P$DJ'D9X.$6$SX0M#84;GD
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M\&LFTXNSC8VMI;PRFP\8D.')@V:#_>_S.,R?#Q>$53ZD) =0GCFWH\$,)03
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M'*^24,7]  ^A'U=&" 05]6\.XO@=/>P(8T+=1WA).FPY$5&85ZU.U*A-2F$
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M^Y J[9!Z]]R%!"H(@>*[M-AEW!-EPW'Z+&N6HK#K"*'PN\]=Q%7[5F<F)#0
ME&A]W92WF-+/ZOK3A0#G/UT(\&E!*V<D#0-<PP"KL8A:/XH+;_=ED<%=KW+(
M>%^]>MT*$!:+I&_C0JX@Y0I2]_4J>@4#TZ/A\Y#D!R(:01C@BG:N1=6:/!+R
M4$)_BHWI6I"Q;@1#M#K>^U7I_:5:ORF:1P]?M!7*00)499U,IOJT0SE*4M.5
M(^7 04->S//4>*5V::.CMZ/EFGQ%20_ ^25ET,7#L53DT_91YJ*'M4ZE:))J
M1A2:5C"GI2:_I/SC>]1B_^!FB'QPJUOQ;,"D<LX2U>6[K<&YU^B-]3:.@T[L
M:]<6A:P.'F-^(%W.I,-83X:S^B"Z:F.R-5B0RTN_&J03Q/4^2_PI<*Q^[JR]
M(??S:35B:V=;L'O.2*/8EMQK^1E67#=H'MYSR[MF/.?*@E>@JQLXT^2A)"$>
MO/8N)>%@H2YQH9X820@[,&^5F5[^8'RT6R SG+7]GH1)P;*'Y>28TL9RM%MQ
MU4L,<.<DR2(K[KU(P48/)21=QN02!YOCV\'ST8;Y2GAMTX.I2+R"S!$CJQR[
M/-VWG).$!:HQUG?[21[WX(-C]3HJD*=#;V;*WW3.E"'O"\JU"U/(+,( I^?%
MTB9?%@R<37CG%*S8!=AJZ.ZFEZ=;O0APXGB3%[;);5VA59L&#B^*-=_49L_
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M:!E(S]O:^GV(RSJWP+'0,X7RYQ [_-1[(R3+V\T68W<;1IM[TXR/D"-"X4<
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M6"\FP_CW]5%&.9:Q&S@QZ2,,'@Y^LIMOU7K?;GF>[#VX,R67$LY*"^-2KSM
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MUFVO$V3[DF/WP$^$[W.8V;/*%;^;19RRAE=>R;",SX@4U($5*%F]T?=W:?%
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M48I&B:H-];E+8/>U(+EBF-!B6CH4K^^/GPVC?/_?^8?^,S.]* ^<+TJ2?VD
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M->>X?O6F\]?'"KRNO=9#Q2G$-J,_M'?7P4<2V#W/Z:N3*[]\S<*^V$5'^?"
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MH_@OSTK>@' NU:N$66Y(PGO[7HA;>;*P=W M>+O.!*:@&0-M.2XO=3'<NR_
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MZ!$@C=E05=?L;7E_@^.X@I?42,X1T"4)7H>BJT"VF"$O,B3M#AX!!E^*>/W
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M_M0,RH1:->9N#DOGSBV\*0./GH->:0?40'0P5N6VR3$%_Z['([A;F1 ,CXZ
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M&B=-NF;T9ZA]0Z<>O5!6OOCF%VL'!7B9\R-MZ]X*?%@#N;M*'#"&+@;')=P
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M[W$,;:(J[=P16=)=,%.L59HH-9T%.QP"U[#32B5;@B)#6Z4.^OSFB%XA+:,
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M4%!O@Y;]2K($?5* )XKZ8^-!>C'(3Q96\3ESGU[4V[7/7++'SRQ@%SY;[I%
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M8,Q%PNFK/.O#+8ZO%:T/?#I%+*=).L<\FJ*$Y.Z[,\6>V\U7L*'/NJL:96B
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MT[WC/3C&)O)WDI.J<[6"V:OE 3)T1<W\R@*O>K\H_UA@PVS]5'PK_DI/:U#
MYSI]I,9G-XQ(2L+AW+I;]1D]K7(XJ^X7XWN:F]!;.08DI9 ?'S]:K,AYR:T\
MDL%H-G<^=7[;%$J$8CX)+L/F-6N% 9M#O/C+61;Y(6SJ^0[>))":[>DO2LN^
MV2S,URG/I[].]_*EUB*!;]?*[4F#4B1) 7HF0T*#6L"TU'<+;%LLP/8@3\=H
M0*BXN#VX=8BN616+=_TSH/ZD1]ZNR-!A/2[E(_EZZX\42M-K/;=HP&->57F
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M*2 V[[4^X,TDL=:\T?Q<SSJLBY9W4_SVX=*MW+O%=>$;Y.$^24JS5HDS#Z9
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M,$)(BG<>?3:E8JY/.Y"[.V@] VO^H30:WSCA&$2,%#C[@3FHZO+*[>?)?@_
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MNZ1@4M0;S7I5W'I.CZ,)<=-.:\YN2\QG,U#KOB!/NB#0#8!H.Z-)T>4Q>>K
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M@<PR#]TZ3D\00Y?!P8K)0%P(V%ZDA#3>EVQ46?Y^U%^&T!I!^[6@*QK1K%R
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M5'5)9)7D%T7*$3\;V8(W^IA)9@,7+6+E41U+J.1>\:26>SSVP&N(?4;*,FN
M6+%A7=@1)+R5OBE9Q2!W@K?W)\R;G@JS?AE<(!-1<<D$S$/9R%6#_75ADC]I
M-9H2XEW'H3\O;@"XX%-IEFG%J:3ZX?!KP=3N1PG=OGC=@6^<^<T: Q)_3DLF
M5MNH>.J)\46TW@\D0JFO>1E1D1+&^?M>IU1(H]P1\%ZSL1M ;0W\5,U)O<M&
M2DIY>Z&1+R;I0 U&G4X![GVTUOM$(!9D ;.?$)7&J"3Y_$"@,DCR+: L8;7
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M.565"Q4])H!%GN:DTSB%P6#AB#O^/M-9<KZ.SI9USBIEZ+R()23XD#BF]M$
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M EFW8%;F,/W.CX91+]K=]OW[8('@ZV/?;GFEPH&GF\K]=EX@MN9%"A%D,89
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M>'WKPF)UO.8<;(S:/4?I>KW75..!E8$PNGA4%C?%-\MBR !T N6[9*_0J=>
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MBG/)VT6;D$ 2/+@G>"! <.^.X<'=0]"F P1W",&".P1WMQ#<78.[0^-.-]I
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ME,"_J"=W4W"NUO@H1D51;NDE(>5D2_.%3W*:9:$$.XT5W<A MAR'YX S7+=
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MB/8VS!!.'.@+*LD; ,;1VZTK?X<;@(=J*$(OWN0*A>W\!I!=H ,*=N5*FT&
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M1G'V8%L3*<B_D+&FJ?JS0+RQ.G0!!:.3O]]^=&YVEN%\(X#^^CB$P+UB^0:
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MIYJIJS1X)6O;W!+ORUVB^G3KILXT#A!!I@Z"NP9#LU4L\CYPDT?86^+A5QH
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MW9?* B8119^^-8J!WWA#Q-XA4*Y^GL%DU+"7>1U^F3A63MOIV2T0\&/-]>V
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MCG [/=4_V;**--P@8C25/IA +Z\J#G39FYAV">HR2XOJ>!B\C%PLC[IQLO3
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M0?Q@[1;"W9/&0/O#IZ->F;+VJO<47KR2@&T(J/=S&,JD("H#-WWX;'4 )NY
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MWLB(S&^T0'>GFL0=L:FYNH8A-XE1!^;8 473;XCYQC4_'\,=9S"AD]I(F&T
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M$T[RQL^6Y!('N%\*C6%3.ABE[FI?,02?#N'PK*DA*5M]Z>3XG.1ZGH:IO:)
MH)4FZKYO=;:O +T?^*D;'ROT6\=0%ANRYW.T1Q#LT%_-JHV44O;+&+[:8[@!
MLY\%B]!"_12J1O>S8=TUD7)")_3SD6Z>]Z9<OOD,;+!Z2)_).U8S1S*=1I4<
M#^[OY'&.'!T1(V,(YA$E;\W3D<@R.X^9!IQZ]IY*BB[BMT(%E8^;&G9$IZ_D
MBZYSZ;V?E%=5]%!RECK$RK7M",12J3,LEV+I;RGD)TV$H@7/2I^+N# T 59F
MN!8U D+*(*<1[<5JYT[BOG"7 W=UKF.E%RX\OCZ$@Q$^HK/X"^H8Q]JPEQMW
M0,G(';#UPD<@&1<FQDMY=I!ZA9+OR&AMS3T#J4C=^U&_0M>](%)% /:&B-^;
M8'K;=T :^$?75)4H'#3E=-?;HGZ4_?66"4)+_%BHEX<BDA4LOLB%0]>O@V3^
M>)>S(FA6#=F!_QF"E^/ND0S^>I8]7#V_XC,$)QJ>=0JJ8RX/"8)9OL!B^NB9
M;/44R$MFO =8IZ5J7_WVJGG/+X=B27(\;9^(4;@>LQIJ'"W#P^][#T]EJR=Y
MO+H#(KL#17</KTA. ]X6R&SQIR'FY4@\ZIF3A.328KJIJ?E#DODZE'7I_&2U
M)A78Y;=K4BTF4V]?IAZDKHM1>!Z5'N[> 6=72U>XZIGJ7VY8KN]GW%NO&MC'
MB:WQO[N>>8.AK?YUA)6VJ26IKT:A\5JF>UU]!ZU0$+1%@E9+DT*_$\WXUAM>
MC*R2$K>1SD[(5B+_(%H2-;//2V9[MDS(M"0WR+'6@P7D2$:P']B0,,\XMSTT
MKFZ;0C!,$V4D3]*I^UH<A9 *]L8_WX/MJ*O8FVU]G!!)4^1\)H@R%K 7X1<P
M3G(QF>R"S+<C]A"%B[T(YW]6<@?H?+T#/H:T.ZOQ\ME&5#X.E<5<W][74UFU
M";S"#'3/[#;$6[$N07A_^*E:?6ZTZ<$=T.8]DX)2.^HAR'I^PFX4%/QZ?S$A
M#=6-HVT J5M&VU-R5G#WB\<8KXO(1,Q*4%);"TZ)AR#Z5]Y4(3T'Z>['6*++
MC*/-3+/;)&9EQQA-\UI?X,U5B 5O,2V6?/<YS@[Q%ER^PB:*,QU.BC,-!A==
M;\W@1RJNU#$@6(%+1U'0KQC*Y]L87\PKO\'-NZ6TA-GD@D][A62O'E2V6*LN
M2@[%DSG?@**.>6 5*PJ$.65>$XZ9KVH3>6B+] /7Q=!6*8'[=2#>;$"4936A
M$]A8_6/4%_M;EOPCM4+ZBA5MEE[[C:=6[]Q7([9U))N.D40)IGE#5I*TDX)+
M6IQI&HV=F)833SDPS>4RMGCCT(8^^8FJ]-[+I_9/QEQ =4O)-<^<EG%WYXBW
M(?I>_;![7:??&T_H,7<^B46"Z6-55X5Q&/ZDSNS<XK=AG;:8E^WHX77(1T43
M1[F!(W[L(6^)R'RI]$1E@34A4(Z%T^Q$? BW=/\ASG[<XXF8B*.""NBNYC%!
M@IUISA:?FKVEB.4%$8H?691V"N>48PO&XLR"EO;#2KO.OBQ7X^VA&K?-L])@
M;)>(UYX<[6KQZH3.\(;EH1&LSB*G<(5'/M)">'Q1 ^VKE,^U*1]=8#W8:0 8
M>GD8 BNG&RE74%:2O[*M/GW5)_AA4)19P^;T#B"#:JW-$/)>H(Z8O)Q]OCWJ
M(W3?4?0P&HYM HKI)ZKX(5]5.QMY-ZWY=^RA$X6,55B!BT\JQN3W:@0D?EB&
M&5G&VIR8-U,>Q[C@S%0JX&@IX-D^>21/9NQ7JL=T?H%[(WZ<'9YN8\YL=H[L
M)D<UUU2[#U5$+CR'Q/EP/OG;6T6*D\;CCT<W8N3\Z1OA+^SJEJ="?\;K:NIL
M^CSID*3MH#G>86AY8'F$U0]:N.\T0X&'9]?:C'LOC=.3C:P.P^'2T%NP=E)$
M$V%];%(2%8$*SW!D0_D0N_6;="\E#*/3HN;!5O5$^Q#)ZSX?RKZL+4;X@=/7
M(IP[F9/S]E#4+2$;R.=&KLRXY04=2G9\AKI#'5B0-^1HI^7L0#2RI+##"VM4
M2*TL3)E?X\7[%!U_,_BPLK*R40_D?'G[/&WY CVQ0R[7/FTZ!7*0Z4K31(,+
MQ21B"@VG>A\R:2!#E2'H#D 58LO=XJNQ%7]/!R9P8..GH2))73'U=_AN18!A
M31NI]SJ,%/<Q#?'I#>,#!7_3"[=O/V>I5#W?'&A=*E2"!BVL:T.X1:M3X-,2
MIH=NGIP[B,5LJKC).,R^[ Z(DO$LECEFT!G;.TTR;_E:O(8S)!1<\XPFPOH4
M;H?$S&:O4'YZ*#KAQO\==*K=F8)I.#P)L4_[P-'$%&'M 99%13$T0OZH.+M0
M/^&%=!OMR9CSL_O)74T_O/A,^Q!+PCE]2$#G!40QJER%JJ?GV94B N_]9'W#
M0_$IKF*&M>)CNTZT\^:XFGI[2$B8J,ZD!P_KJ!Q^C'50W2#>ZH?+L<?0EESQ
M7%9"WGA#-8E9JYN*[Y@"UY,1[0O4E\;C//O*N!B3&=<?+?E55XEO\N";_MKP
M+K+!F;\W;:QOD499DIJ6WHM_B.A7&V H!EQ$@WDH208@PLSR4C)5X&.RVV3L
M6OO#'^H9+J;*QYV31313E2':(.&/"326R0N!B]QW *Z+O>*$AWR6_ARK"9HZ
MO?R07X2!KM_3--9NP)$;3N_J:NYU9?3.P1LP+3%K5R,$KP$: M%V_X$=(5;N
M.5R!3JSAW)W[H"[,M)M$/TA(>637F1![ZSSBNO;>;DZ4NJB[@KV9F;G1/++$
M[C0W8W\7:J!$, >X.Z:AM6 ?[BT/KX[1?B5T)K3$6>20W/-&7=/^YL6GCVEI
MY>Y8GW-8]N.+XUSBM@C5M-Y">_;NE6Y=K3LO3E!YK\J0;)$7I]G^6X/PV:T=
M8Z<0;\95[QPS>/%O\6HD0Q\W1@TK>2, SB%"6P4$V+,2D-QD56F@_;RY<[W$
MP&W$9ZV%96(JW-1=7<+V 4J5JK$S<N5S4>H?BI$]U 9A3=)#FZIL7G1#Z3KS
M,]#F1;,<3:P86L6CW5D?_D/<':U[5F9\4VH!@R,'G[1;'W\_(V; W_<3E'"U
M3K01<E]E=#1G,ZH990UXR]ZRBR44,=H0IMZI91U2H&D^9:)DYS)G@)* <)VR
M8 8??9Q[\\D;?3-'02^9I(E _TPA)4G>=@G[-&DN!(1A*!_4:V_ D5")J>FZ
M2AEFO."A\[5A='&RKV^[RA6OB^ID$#^"W'T8L=1?L 7B/=1[OM&] 1K9C8%Z
MINN8>9$_.'ZQ,%^7J+0EPW UI?G?#60Z-GI&^*1)(>>5!=2;&0L^F/PWQ4ZA
M:B'*M$(!RA!N&QSNPNP%UPW1EA/\[@WFA:7 4_?+F^NFIZ.NTEV7U.AV9SQT
MX5$YV_YA86%-Y39-ZY*$HK' ^U1<'N>RHZOIN0JTD$L$1O4:&M%L&ZBAI#QR
M^WD<2MI3JD4IIV[ZVB4"JW$8_9: />^[L%?9]O>6MVP:)F4G!9P-GDO<(&QC
M7^(36L!'^+H6DGQ(:J ;F1O9E(!QQHRN-E.L4=!R-/_F28Y+\Z'6T1*X^*Q6
M9,P^*[;C*)U.90E?2@L:@QRTIRU[M) ]T+G><[+D8&2)[.N=##BV8)T%.[:@
M:.D,:O1QD7(Y"KH,J$,_#S8CCLL"7L]3^]\4DRPNM7JAA>I6N#J-N,;@$_-W
MO68:^VZZZHVL<$[=19K7(TZ]O$:IT.;S3 '#A7JU,X7D:_VDHW;>_DTVP9%V
M]7#A8:?6B'>E!]8JR H)U%TW9B-UP%?#['('D(2T-POH(VZ/;'G15Z4\9).*
M)RM/?[LC\"Y[-'&S6T^P>DIM #*ZIQJD]]QWD^:+U_V22-$Q.PNO\C_;7G\<
M0__CR,/_K^!?.Y@ \M9]B<\ORVF37DN>(2-E_8RK7?FO'[H\_"UD=][H(E%"
MXK,HXG"- A^%R>P,GT>AH88_"MI??\5Q]1U<\KYHS![:!%=) /2+3SY$R()9
M7-ZR&@0\NR"K[H07U4H$ P$@,VNDF97P-Z>.&#=; 9-HCBP(3SJPC,1:^G+^
M/)WS?X&L;NZ?<;\3:)^\3J(+H]674I20D0"X&14?^ !$ &8L6?7P8))) #^>
MTSW['0O&!RA6;/NUOB@9=X#=O57)G!@'!L!R+B;,QOYD^7UQBG:G^4\ZV?#@
MT-6&OVFTH]L=\ OBH=]:Z+C=KWJP)1 4"4XRI'\3GH?MG]R>5=9NYV**PWO?
MF&^,C#S[,U4UBXR!.5=\W"BR]R'WV]3)'%64=$5$I6$X'Z93103J66S1+X\C
M!KK0DY .!U-I99[B1>&/GZD1(Z5* .H!?9,+%^)6Z);N66^]F;\HC_Q+[PS=
M05.Q,.-K2GJ A 1^;!%&/:F&H8UJ*/S5&S C7-&'\4)&9A>J\,J>-##"#+H,
MR1W@B =WI5JIB("K.3?_R+0&K..P^*$E68"1YH-3.XYD<U ::MS?W[-@^BW>
M>F#VO48?U?@;/RUBI!4B1.6C[/J9"1V448_OB)[KB]+#/0T)IYTALP@28/8!
M\AG34')J E:<!M#?<V3F&5R-8%02+ <]#J=RE_S@'7O/4(*MD0]XF"$#K"$K
MVIHOOS6$I_!-E@#>"#A&Q;A6U'!\.7C"[BWTYHMA6O:?!%B0_1EP?M",BN)G
M[/@<A\('[RVM['?72J%*M[&Y?IW^>7= -0L,_ST8,%/$8X0'#(D@A6&\'2)W
M0+GVP:"SJUSJNEI>&E*XH)V2O*F5;6M.=< +P7HDF*,P'M #D8XQLBM@W,)[
MJT(Q^=!(DS: SV%=\Q..2"P/'O#1Z*V/5+::KL@ [0^"4>!R<(5HZ*105?$!
MZM_),X\25LG&^;F=,E% 9*36BQMF/JZ(8$72DVTDMN/"W$Z= >Z:1%["*,*N
MN8CFQ-I6,TM#$@)1XT6]^:W/1#,:^O-*D$AF9F0LHT:#@5*>Y*K6_O/A/D\]
M3N]D&3(F5$LPC\2I!*#Z2?$!^L9??6W_CIM:O^#?#Y"$\9("\S)MS_#'#,%;
M6DQ\6$J2*SN,9;IH$O3W>%Y8@@ MW2SK'I,&YF6T.K#]\3B>!KM_1LP]MJ;(
M"$$<KE2^QV'MXTIOZPG \O>XU@W,2OAB1.8>W[.4\/V?QCIB,.S[#F-%F<[X
M'S=+TCZ,OTCEW-Y5=@V^7;F<$I32LFC?ROGMQ\@&PT7@ID2@@PC8]'/J(F4R
MQ3MO%R\'#?; D5<_<*_;?V3V*QQB#=Y7>,64\EO1[W][6T\IP?5;4<03T491
M 59"\?_*T7?+$V_HMR*A#MC1S5:9+E9&PF]%4K_5<]_(4Y7?BWZKY[ZEOT3X
M)<(O$7Z)\$N$7R+\B0BK_R'"TF\B>'@Y%/WD&*AL2T3"2#QP!Q@_W[D#DBEG
M%-U:-M7S2II=*;R_1KR+.%>E*+T<N8U%+H0YNH'YURCZA,&BOSTD]5O1Q [C
M9J0[XSGC7W/(3'F^ESF=^=L_';Q_+]/+"'=%_L7U?P+7I3^8AE7CL*%.9"AK
M7KF-W0%E;-Z-]_\R^R.,M89 ](%C 6=UE\(Y8NE%ZH_,ZP=3UT.7DU5X3477
M@>6!A@R_$T9N/X!N-V]VM<#"O^B_Z+_HO^B_Z+_HO^B_Z+_H_Q/H=P#*;>E%
MUN\E#?<E[_QS8A&S,J2_XR#;2^AG9/<V:=J!P5]_9C;<XO^_D,WP/T-FVK]T
M=O8+_NW@W_.00H+U6"QI(Y9&9]6^#/XL3[3*X0ZXO .J[H"6[S!NN/?@=])?
MJ1R,'84"5"+-_W5/K]_@E2L.-P=- =5.ORTB<WT]DB1Z;N3S03.X<=7W V2,
M>IHX/)0= Q]>!9PL;HI(="BOYDEAW.0]</MY!L9<N$-@)[/>ZVQ=(I ?"7]I
M4L2"#/?)-S<=R8=<@NH?)?5AXA)#DZ W2T/,*)3Q-(>W2MQ!F1M9 \9[F673
M1R;&3YG?,\*=_A0"K5Y3F>?,"?"J(E.OKD%^--_^^%0*^5(1$<R$9#<9=R]'
M8\UD&>],25I8$X48A@Q9/O-AV,3XA4J4&(Z2S#^30%B%0B+,67H'+!#W# ^X
M8JYT/H_AG;9.BVK"$9/7& #8\)6J!!'IY,_*#%J1C.\ DFC2[Z X:K2@[&[=
M<%+*6$!!@HX-P%-5UI$@+1#*"]U$)?9AV%9&_<>Y:/X"3(P_:R%,)4[J^Z'2
M#T_'A[$4*_.3I"7_8I"0B6X>I;V@TH<D05<7GB9 9=@OT@SN5-DD@?9_L?>6
M87%M2:/P)@1(T$ @N 0)%B 0W G!@[L'MP#!W4)P]^ $)TB'0./N$H)#@KM+
MXPTTW9?,F7GNF7GGG)'[WO>;YW[G1R%[5:U=JU:M6E:[:K0C?2..QE#C#3H0
M'_Z.M-$KWCOB+UPI_A,-3^7LVPQ__4J%UI\,+Q(+D)'@K)F+%U7B3ZMHB$IH
MZ6ZJ9;L991@^R<%04[$(?QX.Z##=![&4]SV<D\ 50JXCAFT?R9/UMS 2C)R:
MO9;:OA6W-*/E;P^S^+@/U,GFZ$ _+80!:4*5)HY._JBA(2NRB#IN73JQ*9Z)
M84=KZ6=+0%AG!9VVP3O$1*XR2%R\PA- M8JZ:HE6'H'7K-EM'ZC?]:U&LKMM
M\*Q-,C/*5XY8CA>\;WS5A7['OT'*&F#X=+PPJYLA[X1I<:MG<#"MJA2'?;A$
MG(]Z &7!;=N?6&4Y&]@GFHD])KY?9W>KY+(,Y#\5%<2U#J[OFF:75+1XV_HM
M/UHMU4V"FC]KQY'ACBRCP%^GTOXE5/6_DXKK_V+:+E[HIXV#6?E1S_3!(/JL
MMM6K25+%$$J<"EHYTQ8._==V46QB;RY6:KS-EB(6"6QFG%>VC;[4]B78/-CD
MW;Y4%W);#HZRSQ]T*0@KM\^1W^7HZZJDJ.=$6K!*<VE)*&PWLB;M"[CS9#4A
M8,=ZW=$0^ZP>O'AO5F^NTN:]L&[E@2CEJK[MO^B,(I/U/ W0B?:(7T!+[9\)
MI+_SV<[;93F"N82EPB7=LBBJIH&=3_52(SF]=+MAO21;L2%Z W/_:48X<&Q/
M"@5I'%$DB9R;Y<=:/7CV4)Z*R723S)=KA^+1,(QZQN+&"W1<)A+&+H43 'K$
M,$H8C2M*Z:YQ&'0)J4A%  :[L&+DP,F\NJ/-:+/1J*\CV]Q6UZ.DN!L\9)2^
M8$T]2#W4C:NP*D?O57(I@VZHJ4];8(_/U51MY_ E,4PF2[IN5<AK"M1U:Z5Q
M#_D?)O7>G#(@EU?7R35*VST\Z L(6=6F8)\T'VUB\?$";O8<8$4C$RT$\[=K
MF9K4UD.?U.>7:L+L+>-E@L]=KS)\;:N>C!/MP#O\>=EP8!R?IT\97'PTCE=L
M7VP+MC,-7BC:EUM[/Y^PU]A4&V4]H%A_4SB+7^;HD-#CA[[)*8+C?KKUA9SI
M7(#TON/HK/Q@4*\=SDE%X++/$+BD><RBUIWKO>,TRE7_=!S<:P0M/UQ';.(?
M)(7_4Q+=,P2 ;^7YKCL7ZG0M>:>>PXX&;<R?U7*!B:0UE OKJ0[14.KU]4EC
M$5C_B.ML(3M'7T^KG?;BL0.)9'Y&UO-N]XN0)K&54D-\Z]I'OJ37$G/Y'B-V
M(HU+FN507;4I+GF^C:G3UKW=F&>?NC/6W_+E8#^7@1K:EF]7+D*35XY]7A@U
MP2$57T\BO52]'[-<!#<YN"V'V66M=%7L^FS2>?IFVC0<X80]%>0I @_-!;H*
M2_<N.&TQIT"$HWQ<2A>@>9HA@W6-*T0Q:@K/_&2!HI*MJZ(H;PL/,U^[<F>Y
M9P! \) L2PR&8@8M:J^$8@\(N76Z:3[@Y$"B=936XD4 - 6>)WUQDM_V"/!-
M$T;03R@?&,H?H6E&B(\EMB3=#:@X"'D5LTP)6A>E",M?(+UY,K4726R"*:%T
M9%<G*+0\6XH 5M6[O"TVA)AU9N99;'/?<2'AO@C0H^PAIA!!7=>D4G@/=T9*
MR?7F4<33PM+MNB!\;J#GO57*2*&3%;@(MH-*=7IN!G-%1*B^9766-)PG3-B(
MO#(Y+A/ N;LKS#!6#G(1<MT9OK!9ZWSS]LYJY&FI+_8$V/9A-P=44S-CKF+H
M?)PBWVGZ. ='YF\]S/X.J$ZX, L]F:P '>!AN%R/B8B)/AJ6/0$]U-JE8#SR
M]F3@T6@05#Y(4[O[M)EW>/5*4YPP!L8H6(*OLUXJD/DI)TL&QIP[UV)PTVGW
M_&<^,C\\F$ UI";QJC>DPL[VH+S/F$1%''/:J@ :=.!]KV$">H*WZ'7>CYRV
MT:1?-K@RVPJ5Y'R\R>APWC]]T)-S.@PB&-\Q($^$,LEC*%B.?J50LEBB8$\#
M3D2PW,4[TK(^S*2$'J(T7:A4]6#UQ41F]333=_ABCWCSFC6,ZDCI)@&-<DT/
M^$U.RLA)EUGC'L7'V2 =LK9=PTU0%%\_5Q>DWX0:]EX($_)PR)L]]7V#],WU
M;/44'VF'?(>TM/C-OFE]9H<42;*YB3^3O>>)X:,=T(K? XEE?>'7L3WMH()O
M .4\7 VI?]'&K84:&IB_@WEOW'?RR[30^>=^N/I!9X&'883M7C4"> !5&1OI
M^=S)#:CPKGM.ET@.[* _,SM#]:?\IUPD"*34)O<X;0RK=WAD[+$=FJ^44&8V
M8.HK8,BQ%*;KE[D%Q2[EW/CGAPHU1XM!AZPTM;53Y?EIXF!<F7Z1)'O.9P.#
M-)*1@Z/A[R0 #[: PLDB:*K'D^H[\\TM^_XWDS0!^KW13:(+%)"]A Z_,3-A
M-<I#DDWG[,NG,_X(H$@9]@DG,D'N478!IR511(ZHT// <$">;5F]HK2([B*T
M@K5PDD[_:X?J,:6BM\;%NU-YM\YQ?:V%KZS.^S]JDO('&4Z[C6* 7>''-?+B
MJD=8\\VK%>O!R.\-13W5A^_8\&>0@&]5.X5C3A=K5.9F[0+6#7AB>0B78R&
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M=&QEYV<T^FT5;Z6J^DE!>AO/S_R<+,TK@G$9GJIVU_<EBDHR\]UU#8XDTV]
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M6OWCZSLJ-W...MCN .RY"TIVM\#E 9W6BBK[TTWR79,E2'=+_O.1E?I]0ME
M36B>B[UCT,I#Z76G:;2/^=]7RIW&/T)#EALCVJW30@Z=JO'>XPP7.#OJ21"4
MSE7%T.'7FZV]QCPR,#O2E1@O<V;6C=#EM5U[B#*/A]+7?EH!:H\X1P!WOO>^
MU9Z2\XF467O'KN[S1DYVFLTRBWZL27S3S_RKV7$T)8/FY=20\98PP5@3KSE\
M*/SE<[*62PP__IG"4(MLZ&#73-^DWV=G.<GG_._&5ZF08:714#.R4?<=YSK:
M;Y^6OWG0OQWRLD_ ZQL+'9'N1.DXEIIJLF_S.U8YA'_QVU)G<Y*N'OWAK;K9
M[H8\F7(9OMY$"MF5G(8)$=S,I;PP-[\KN80M@K[3PH@ ^E)$R(G]/H!X(1?O
M8?HEV^QSVSH!X9-AZ*W6INV';?D79*Y"Z-/+D@%63@1=3@;V4;68?>RP3P@@
MREO.(V=&[%&FY?B\7J7:ZF.'N0"]UA!ORE4!+,]ONTH3WH/2BQST,S^^//.B
M ._@8"I2N4413Q_$\^E=3[(H8^W.7<+O@:7AU%KDKZOT99BD';TH1&%1/G>S
MG2DR7$%D1Y)^RV]_((!6PF."[2SJJ;P1Y_N'&1F?C% %TI29K+>U5H6?N*>)
M49ZC9LC4Q;G)5WVY\A.<I P4+;46W7SL+SAE$6S'F5PU<59NJ ;F3QK@C::/
MM=,+G#TJ%4%WT<5@;H0>@*C#"A,NK/??+<JF[Z@:[,>8< 5[Z^9AO;'<?SOH
MKB!8&QD)%V)^ZTS$!V* %A3U%^W44%"!Q>N)T(172?W*+7\DJI\*/5>>L'5.
MOV]O3WN\%&J63MRM.0J^$3&HMBD7UG!7#WW:IWDYG0E[>80S>TK.U#%9R[6E
MX>U&SGX9_GW"R.\^C/78>$"!1CTN1'^HO63#C#==,TL$LAZU79V% / " RLQ
MD*#13(I0^5.<?:*R1R?.QS=MQ=*P*\W'D-;.!I^%0*Z;_28WCJ]K#YF">^Z3
M[Z:WC"V-^3)TVKZY%S*$HI;=((1"]FV:)+PY^F0E:55LV<3NO7U=G!KRG";;
MZK7(9W>:E_X.X$3XZ[2IHY/;'3VT57QLQ&Z6RLW06$+BR.>E)\$[I LZ ">'
M,_."S*URPI(_,RMNR59XYUP]G-;?NQ<F,!4=MB+/T\4NF.8<WQ?6;AZ5Z$M,
ML-0Z.V83;Y5F!BLD%[Y3N:\ .^,ZT,35@7IU/*S)"(\3L]-'OU@MY^QF^)@&
MBCK%(MG=FTZ9-3^58(DQ"3>%"T'VZVLU6H9GV#]3/]K=C4YJA[&-[G.5-LNI
M3M#H)N/4XD5U"I*=:"^(C)9S9A/^2.<\7DT:C;1I0Q,JX;Y (:C<HL1U7I_T
MIJ3[:L("/,QSZQ&Y.N/IW'^[:T 4VGB0AC,OT\.' )Z 0<8/H48K5 ^FVE[?
MH'ALME\.S[@(^/1:9W[?G\8_+(X?.0MGR"WS_YN[ZBU:J_:?;FYT4G_V=A/Z
MUOWY9S[0OSVWO?LSYJ/LS\BE?_GCKTX0XW^W]+_2Z_PKI?^@]O]2>K?@;RYP
M&'^W]*]I<_].8,[_@Y;]#7?_L&6_S]T_>/=/C/A?H?YRJ$LS"&?3>18AWZ).
M*\5*=(5^<*K=/1V\_\1 ?+9D=5L96B2A[R5:7T6S:3;@(\45 UE:%,_A"OYX
MMU+>YK&2OO1=UUZ0;%9ABCQ92*>7Q^K15.&Q.'6)9B='+,XWYC&8=-D">8OZ
MW6PZ?\!+ W2<^[Z:KEF1!<IW=Z2]),S8_7@[:D?*1#LE>1P!=*SCA9JR7R(
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M&Q3R:P9"L]ONY^]>"7V8LM\D='RSR.Q$21-W.?T%ZB5%@AV#G<5:6(^[>9%
M5MD_!%C_D[[!2%_=J[H\L]Z]A@^/%$W VN0\7L):8[G6*]UKM0U#\:Q-.C59
M7(UGSU]EMCD-RUX$ZCWE%\[)QC>;F!D3,WT]\V25>,.?TYMKQ59<N[8Q06/T
MR5B>/[8Y/2;?L!+SM]/BL\LFL>(Y*!X[043]@MUPW_Y<Y)%!>^E,\T&<FRWE
M0C)UWHZ$1VT S*C0W;''EE!/Y,?);%^G=U[(IE!+-9)N)\>PR=']V>XM21#U
M?FTL67>T.WGI=^9^+GD--C+HHESMZ/C7FLJ$H?@M;)P:/_33]'FG5^.@\CV[
M0Y/PC=50DS?K6\CQT((G:5?JS>5=CH/%@JE56BT0/\,"1\^HVBX05-+5\(-.
MY^L3#9KKE;HUBK,1;TF9TQLOR2.@UF/?5A<OB'B&;_.LG/DP#$Y"\C)!S#UA
MCL.[9@![17KK9XH_37[UWJ#]:1D-K=Q+?<-#U,/L7JX)]&7A1]O3W WDD^M=
MYFPUW\RE^Z[SGC0._.8&EK$(=J*0ZR_8VI7%,YV\ .]SE]QK?Y=MV=\CY+MO
MY,[6X[F1M/S=ED60T<T+/2$L-H-RK-E-[YU<YJ-C(J6F&&+TO!*N,,B%?--8
M$YV]E9\=1"'_0+)'2A8 K603]A>X>R+A/TUK/GTM9CN9%'IXRO5MIX58'WDY
M"9;@?7'QV&!%?"*^,Z9(=LM;%W(^W=T0R?-E1U-C[$6CV@LT<B'?I&[WQN5\
M3[;@ U"*P42%8(Z("[-W>1\^TK8O(<[MS&F>07.]:*94S[M)T+G5BIY?EP97
MQ!VF3Q+\NHW2M(8<[\%;[@= #>1I.H./%U7JD[UFS9B^9)1)H1'!=F*"X50(
MP&+(K="]8:_=!;/(=*R08%K0F5(6&,[J4 QN81COCIHKDFE.&+ T-7Z1?1)^
MUO*#G'D 3*[ %BK\;+R<LXM#2ZM_4\8A^OY^S%CS(P2@.\[9F.ZE.]NWG+:T
M'T3*9[(O2C;=)8*YDT5?4UDS_@./=P.'N6J?ZG4T,_?)\I.D<^XLYM+*3TQV
MA"R,?$;[.A3"D^!RS._6.L[14PS0^C!\LF@/N%I*-GX3;YJ HKTK?8/II6TL
M^5*V#N#6*>]XJ#9F5W:X?F)7]N195589$I4?TP%S,-2L0$_;\D+SPN'#Q@2]
MU0!NW]UX$7']H;\[44J\W2=OBJ<F-%5IE]*@<@91'&5'<0V)=T[7: KC-X(#
M E3?=BUA>VP;#-BD'ZT'+10M8\S*,9#8A!%BD)P)D@ K,+[5<E\LUHXQ$;3Y
MP7M*N0Z-=RU \^6'9-#PMY^A7K*T.REU&AC#R2$EL*I+39GE4JLRF(")O0-Q
MM-9J)^,.EI/P8ZB1S0J6J[PVV&;6*M-UY:G#J9#7""I.%">&'S:46;XJ2/+$
M.8IY->4-V>812+6&^$LHV0,3(*:C2:J7$B>A\\JV:;?<<-XCX9-MZA=4I^&I
M9L5V.)DAUK;PBT4]_;#0!.=-6E-L-#"@>919T%ST#JQL?]<!-6CP[JW:<-'[
MBZS)C/O-B7P=;W)# -0:)0A C_22Q/Y/SQUN.F%#@//DAM_#A:F5@XZQ;WSY
M1X! N7<9+#!:003]8'VZNH_+=&RM.<H^T^TI/1_-]&D%<O=X__)P:++PX[K:
M>%W4B$$WL<R0&$@.IN*#]E4$L.?>NDR%*U/P&-44+,)G>%YI4+!LD\F]VUGC
M:"6H'=J1(R2))GZHUQOJ2^ON<<JW^KE!;C=UW'BVYSZ?,+@(LBA7/]9$:H,U
MEA37GV $)UL-!W8E?B-OWAV2$T-<]T7#D/T:9:CL@33 >.ZO>]?S9N:TH>A3
MU\FVIK)D0>8J%=*"OZ!]NP''-&<FSMZ4+T%#2X2'L/7#VU%Y+L1Q8#//O;#C
M95Z3IH8)J56CKZQP6UY(]<J'VN]-GQ_>73 2(*U@.#K;J"_<=C#<^O8]H%.1
MA($NH=6PQY_!?6&X9[K%6T<PEB[ 0-3V"Z4>!9BGTU9<,4'2AW_FQ[Y=N2[A
M@S[']F:90SFT+@2 U1)?B[?X:>[2>_:!V\%I&0((/K_@\8P&K1"7#S7Q''Z(
M"^$EV_ 7PL_ 3 @P,/-B]GYQ9&QU_M6OLGISJ-,UZ49$^5+3"154L)M[T#-P
M29O\M/=9#%\DG*L3)Y [KI^F<P5+EHT]XED,<CD@S& 2N*KF\#( ]^G;3WD
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M)^5<(N0\9P+>3SC[;N_D'/;]='A5\^]G0/R/"Q[[!_SGP2_GFE3_SE3VSX.
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M0C[R&_"PS$<@("$+-IG[%V# ?E9P8N3K8U)?B?)UTQ07)"9_L'R#0N53.P!
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M2"-%;1/L[,2 2P)??MZ(8=_AB$![*7OB]^V'.:RQ%F(G&=!ZOCKYYEZ3N88
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M]GT"B(:35JYNG^_K8622;[%?R;4\V9-I2Y:5P1ZI.[UE%Z9(]\*V5QB &L*
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MR_0:33783./^)^E=J17:!>P-VC6T+-+(>VYCTBM:GRE_7?U+Z,9$(*P0&\*
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M)3<59E@G82.$<;4=SEXH16>[A]:O)+J#]C=<=F%5?UE -&)/8,7TL'DOHI#
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M1[IJ'_'_]+GZ^'2+R46_M#K\K#2 -T]*Z41E)D9/W\B># /<2F]O/6G?06.
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M*;Q.MZJ#N5B:4+?CK#@\)MG#^(FA@9L3^<"* MS>T?IDP_]2$#F* 4AD-#%
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MOA?US)([_\28.)Y\PM@L!@W/?C\[Z7C1> EXZQ<""6U^X_GL0\0BB!JTT(_
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M5H+]CVNW*F3)M7PO :3NMS8:!W;*WTHE\+.Y9L-3YFXT@Z#;C#'V+@Z'R;\
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M("9H7Z[33-+4RJ^I2T"*ZZ\$6ZSS[/90""=:P-E0J\1$56'.K<&'Y;DN5B7
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M!+T]!A 51@G"L*;WJFH@:.WR"PS@2X%BLS&ZMD:N=<_1)E.G]3Y-02;##>3
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MR2V]U\'K0<I*Q_RVH:98XW!XJM,SE.A"PQUB BG:[2W!*L%@X_@9BTD&L\4
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MDE5E);GK[8"L3/+YVF"3:ZD]A7_YI<F9WW[)H[_["0\J@KDHN>B]N:B2I=U
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M%^FF5]L86X^Y)16[/,U023Q6^\]5*IY;_ZU4(06$WWAGF?[Z'@8P76\Z(*[
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MHO('ZD-[VM;HVMS5G6 V(?%SU8N6M-R+/>WWJJ(M>2W.WS5OQ!;IG_."#EK
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MT;S]R8WN*Z1*RAH_%S?]WQ_=];(,@K<^0/HL?M-X7:9[$>;HOA>8[REE0RJ
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M/5?><^-/VK3Y'W/N+CLVI1-]@K%*QD7*?&> +I,B8E+V/,X2Q6,0(DW>'AC
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M+C6.<Z84+LD-';9F:-X9*;C.Q>1P&0,X>KS$H_^_Z52/JW?H<@^SVMST2N[
M92]H ?4&W2HDQ,/)='?Y!YG%OXYTFGK"(^PDB_/OB%DI[I!'+?6I!ET1Y>!I
M_W]F^%=&V$&+\Q'#VA14I%'SO6I!9#3\=O_/#%__:EFOK%6=ZG$(!4UA)9<B
M]UW;*II;X3$;\_\PKN4? MM=GDK#^?1(XR+1.W=Z'U2<:MY[*=,G_/KEE?\@
M+%:PAV=.Y>#*_,2<=TMY3?%=B9DZPZE1$5GEW^]LYFN@3.$<J5Y7$JF:B?M@
MMWMM[G,HYG$!A ZZ$;\981M$[8O20!C<0YN"/GIGT'/HZ:4.Q9040M6T!-!9
M!E:_J^3\I:[E)2Z>Q%MGPT._)%WZ7>:2H)^+_3V5^>$__^ZWQ;-K$O2X.$>9
M?\AZ?G%K#8>YGOV76H-G$F(28"VMWS^>T83[\:KB'^Y>NH:7@[?UQ^S,=X L
MX# >^^O#=^E2:)3_<*[97< 4N(7MSF^IK[??V7TD$%8>^CVK]"[@")C$_A<\
M\;^R70* U[=N:/U2A_#^$@7]?>P_U[E^(_<UW/<2@AMR?\B'_4S9?]7+W.SW
M2H:/@## ,_['^<)^"!#_5/9;T<?EV]>:@0AWK=]+(7"QM 05L/]>'W+Y-?%U
M'/K,?W7W\C,<YG_U6P!/ F_X5VJFO).^UH7MA3#!'P;U^IUW6=E_H5A%CV&,
M( 36NR,EP8XK-0K2&LM7)#?_9C%'.IIO2!FE\>SQG@2%VAS>M_K!V-V+U3BM
M6,Y'14_[*-]TV%^U"SU7ZWQ_I'ED@R_)/K)7]6'YO3H:(?,0VDGY-=XTY# .
MGJ&NK-M.VGV5;G*:F-7GQ/FHWW5#&4G08DEX2^8XJ,]^1IZ]67(4S]G@C$B"
MEN]?N,T!S3):R+YC..*X#RDKO[J?2H_6C%ATV$Z'MM3<6,P:1FGC!>\Y69HY
MAN0LJX9/[Y!STTM1T(3BTD='(P=Q(;?8IP:>CQ50F9OL\SU\R1M6=:BU:]G?
M0-5=2!UFICO]@S%WU)B;5T5$,/IFTQ4)UKW$<_6TP7\AR!5VS<+H9[66]Q(B
M22C0546\X2.M<70WA=-G7O#!$[1LA.I@+A>SU1TNB%#U5&3L_GYK:]R$&A$E
M1WK$@Q331F8X)5\G8YQ_UA#Y*RLKZ9+E4^@4R*R]ZZVIS4E),K^[G01M1ZAU
M?XB)S<%QT4//F5#:'WM[ZGGTK>3J<0TTWZH:<75J:-M"2;J!I9G7:+ZB?R+(
MRS&VW;W49U9%\FEW+K;25GK.'JX3-N#KYUC;L+\=%!OKX[HGB,_JCW>00B '
MZ_-6@.9)T,EHE%.2R948A>5JU<3Y\2;I'<O5RS+5& )2;L'YDA<?J[;VXEN1
M7KD:PENW"W9*99FR[STE+M2P4O 5'9UC1(C:;P:VJI&/'T]P)!06&L>\DDCV
M98X%+TD0(R\ONK&5LYHDR^ZPV]!1:S((B>"]/6GN0K$6Y1=<9N<8>1'>^[SZ
MO=EK"J:'.%&*#(DN#&N( JT_\:ET_TC9NQ\+D7HN7S5T-5WW6GEF-XEG9@9$
M?1#['7BQ:S?J R0V%9\?*DM0BE[2\UH,TW]A0XW4C%,J8Z5M2^A*LFVL]:Y#
M2% W\(RM#!_FI+VWL^&;R;N6"#UZ_NP6!GA)8'E3*@1V.!56HZ7?[/85)Y)>
M1\C%1N?-+329Y>)E[9D-=[VLH4X7 W,WFE(K.L-3CP#M\"H@/K#C+" N#^E,
M+29LQK&7%2/>5<QE$M98WSG;M.MEAE.?%OGXVB6AN_;F9G_:D8!58Y"M?.3&
M_)?D:]U,5SY^%3IZZ] Y7EU_Y\J0^%V=]3.C9[P#WZYGOJLV#GZ!>.^V;+I?
M "%#9A$23+<2E\GGZ%;&69%&X2I[:20'B\2'M(R?>:7))VF-G[^J$S?N^\!=
M^N@0 -5PVQVEW*IG5:A %!QG0_)9=;0?VQ^/%U^G5+W\2-GU[O)'B' YS)<I
M8M%+L=7;H]><U-S!@L&J@]?P\8NSRQEH/OT6EXKX*[LEZ9L\[98L<[)VE%]:
MKA-+LUUC]@W[D7MXF<^&9K-F%$C@?2_R+'/GGG+?LR,0/\^.!&W,3XZ3$=7S
M))9:%?48#5NW;9UY%4/6WJ86.ZRCL"B8KMS?YPJ\Q+NT6(1O[DT]2*TZHN7A
MI4Q)TEM]\"59G>TJ!1W!]L("0?FDCD7D1@W><1ABBMY/-+FZ\_E2?KF72 ?5
M)ZW,XW3SJ]&6]RSE-#EN\^83$@L.T.SC#2*TQ5E&G)(,=;GEZ<_%/9XQ\,B2
M]?6%/*28[LE[0P 1!E9%1>ZDB#^0],CIYA[(,?_6-[[=^9;>TT.=+H681R]=
M3\L$H8]BUR;ABPVO!$T.7\YUN*?/Z>DF-)DTR_4(.9'KO/I/UJM[#"5B5-A-
M>.P3_^S^P)G@QZ^/Q/J%NLY."BQ64>J+.;S7%LK"GREDNC[7[F3S(74O)1F\
M%0STP[=O9B"7E(<.CZ//N46,/[7T:TC>HW^G*/I>WE3**MMBCG6<':4A)W\S
MH#18EO+VXS+[*GK1W>^.>F25(_GW8DC4*D;Y6&,/K$UD5>.ESW":*!><"^W;
M-L3OUXXJAI@&[MR>X;73G*UZY2\S:XS?S/!ZEZYJ1X):#^? WW\_XUMO%GOO
M3;RXW!"<U%V>1*HMRRBXT^B.UU=-*3?VXSCK379K8\-.9I%HN_.FUPY[NE9_
M,FQ2#H135L:!WZ/8-]4]36]5[U[?TW-9]"*7@>\FD(T']<7#8M0F8YU=XE\<
MT@L*B;F2K0M,.(_S*\_,-O0Z@D2LV'T.:2:2D<&MS>/"M*NY*5X!$QK[DSM9
M(\\_S#WAQNOM[MXD7)*@K4A/;R_4D+3Q/+BV3Z61[I6F(+[ETCD8O'I_9 &^
M%E$VC4_NJ39A6SNK;<.6 MBBEGT3"3O*RSE)L@,]V2V]OL:01WU-:Z^ZO$\T
MD@S5*H YE6E7.U%?Z/5L:=93& <[&1 ?$66+X8%T3-X);_[+@2=.180;-6U#
MLE]E69LI[EGU3=,S8 "B#@*9B>I\SNM!5I[J>>9G3T//>!\T<NQOT<P8OX*V
MC3?4S=T9M2:7FQCO4%-:S5</XC][<V=)]&R<Z7U%K#B_,"20!F)T4_F@]?KW
M.F73L,\+)!UVFV8XPEOJ\..2/#WY12_5^]\"5*X41/<H:0,D]SJ%NCOUQJ9<
M+=@)Q-@$ J>8OCE\'.K2(3EBB%\5O6>7928<7IVM7UZ>M#?5E[G2XC943*V@
MJ"=)V%*(Y)7AKU]DW6*8S!H0=F.X?$>&NK*8;HWF)(6@YR> B/Q\/];PLD^4
MHH56"\(9^G6S 13?^RP*-UF9K&^W*Y/GX%8.PYLW+_&NYP^XY"/C)"?\#J0,
M^7@KRH(>79I(ZO=R:,+B[0F514VF491LEJL3DUF!B4Q5[0_;_I".F>-N^OU"
M_?:;_U][;QT49[?TBSX$#0[!/7AP#^Y.L 1W@D.P &%P"Q \0" !@KL,) $&
M'0B>A. ^N#L,/L  AW?K^WWGG+IUJ\[9NV[=_4?7_#$UZUFSVG[=JY_NE19+
MA/+^^MBIZBBW/$NHDL\3]%!1O$^]F%"WW4?:1: :N<DSU=4$YC PCP6CB6CV
ME^]KH6_6/5,P30#[FF(3$,_UL_%3C_-A#1_:^G$Z&P'5Z@ZYRYBU1YF'*#_0
M?*LY>WS?-".OM))+M4GG$OQ(CBG,^!*((HA5E[R%86&1J,,Z#T;N8:@!>:RP
M[UC5<]@P^3BOZ0^(_L[#G459@1#L^6J1.T#C2!W1[&KR"X]U X4P=MZMVE;Y
MG6=+Z%O;9%D2:0J3?FNV&*[BQG0OC,+P8W[F5!+;6TK6XJ.)WU>=9EL&S]5H
M=&3=>!WB5QW[?F6<2>8B\!R04JF6T@Q'HCFS6D8#EX(?LG\:2Y;!24C7/1.U
M)([4K]SCZT+PG2NY(3$26LSI 1&^/!<_3H^/$/?"-X3:HK;DBC<?)VC4J?$H
M)5C.].QGX%-7M5:B8AP$V";>1&F-@MF>*PN3^SU?4)0+^"\X$*.ERK.V!5V?
MDOF\AGV<K6D":;E\2$A9FCAJKO"C+MH3I6!ZK8GVPBI8?Q[4]VQ". %]S[NT
MP9C%@^71CQ]4,BMF9<SVC2&/[H!.0_S295#Q/;>0+4O<DYSEJMSK[??<PA <
M$T(906R8-V0J&AZKT45R];A3/@0^TX8EV7%#*HRGIYW:GGZ-Z,+??1B3I1/)
MS$MA(4*L)BH30&K3;5C;5E_LE GMF_:>6>;U8A8@3%&76<\(EK:L%A ]U.]T
M:N9I+^Y9-JWCG].$;'3"9.%O5WG#.I-W%^%Y^+?_RA>+FP@>:8B4KF@*=I4+
M*KF(2_5,=D5Y6XAL0M3HTWS.>A")BB-(UT(70R#N:<S>^D=,HO2N!T&8_?'7
MP^BNENIU<//SC/*MY?V\] T)ES+)7MMD\_"(DT<_V(074-]C'9IIQ_'LUU^>
M9C-IYG V41T_6>-KM*9BPF!._K[E D'%QLSK ;C_ 5&EN<=9'5>&3R_LVMO1
MW"TO;2BNAZ["$%.:9D_/+>.JSN9?/(]:5&ZZ5IM]-.3#\4U1,/*[O$3.Z7UX
M'9G\29*-NSV#.0[O[+?SJ,A&YZ_O7N;U?IN='R=FU:'D[XU9:F:K51V+[4,$
M!U[%DZ*ZF]%LPJ#X_XR]3@)<7#D-CO!KR>,H,X\?^M[[J*IW7UPIGH0+#NZ<
M)DYL4CF.(!6GOB&^;=!#E"083<Q5B5R_;^D\]9KRN/V TK3$)'.N^>/$[J,V
M.0\7G7NK]2U=0)*"N?GK'+SF'#4?#=U[?Y+KRFYJFJ%F;^65-A=\SB=67?W/
M*6L7?;"@49.>$,\R]6OWEX0*]#_>X>!#^VWB-VE.JW<.9O?3GYM>CG9M/+84
M8$2M5M%1E9RB/F)Z\85*B(]ZUUK 0J%9D.. PGK<OKE).%L$C\=5J<;*196P
M+J4H+$V64HH=-?9()OKT#L"9-MD1Y^AW+\=YFT"A_MM^2-]*C6:UWI_%@\J@
MT&[%_#EMP(OQO>7ZM[E?C(4[;4/&5"BO%R(:5LWA5K\H51E.F:#_8!A=0(W3
MA4'.$_CZ_$(^=T]W0XM'.[-CXU;E+?-I=5PO5?\6[#'(3$7RF(N_2<:++1V)
MH;UL9,$W<3JV0H!GHU,G;7YN^8BWOR\85$E/R!C]'#X!W=,@W0>#Q[U^E,>0
MON?#!>V&>B%TT/%8>:/'+&=[FS^0PR#PP*G&H&.UG$8T_+:)K8BPL-%& NH=
M$V7P4D/MF%U#<VNCOBE[OM5@"GVSAY@9S6M_0R_'ZG2/JF@>0HRKE5#6/P*^
M"I.2+#KPR\F4 4E=,6KD1YB10QH;+8&"H8N@Q117JT310-GB#V+V/E3)6KH'
M2:\]96F*;Y,=ED,>.<I,:["T+&B]S$%A$OA)T:LVI_UL BK/BU!K=1))\F&B
MY>E%3S$BBKVLO@-\F;U"4;W/2D!O3#7FM:\#]"=>9>EDOS$U ?]*=HM&J,B
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M6V?RF].&596QCRM &$V<,8&&]Z[)4.VDJLZGB>Q1I%[3^Y*!D0.QF<^GWWN
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M ;N;CLWJ.MC;QC>B&.4&%U*N%!W5Q'GG$JNY2&<4THIL/#H1YT.)=@-H-J&
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MEG9W*%C\#NB[3;X#S!8O8[<"W>\ YI<$5\OWG]^&T5./HKLJ"ZKS?GJP.'!
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M/E&8RKK%IHN#JPT0/KK _M@BN3M,+_A!P5\69&__ZS7Z5L3J=B:P%(RW_9(
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M-PJC)V98ES"Q1*9!*YKZL6RP'E[T *;5OKU7J(C4SBD#(D)6ID#C6WAU;"P
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M2/[;L^F!IG>DY9'6'XUU_O@#!,M>0$-I_XM%VGK'5O+ND/Y5 ]!O[7:SOUE
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M![L<0-U%5#:*L;MLV# N+2I68!]ZW(>-L4.AWB7+G? *[C=;2Q%-6E#_?A0
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M/LR/JPO]H=!<IX=Q5O&QMXT[P0C>(T9CX<>7$?_UA*X'6]_,+WQY]F)W%?N
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MSDMIG!V!$UA87T=;P?*&F?.&U[42/"'+:@KQ[%Z=/_XYQ^>-RT4;>/EQ202
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M'E6?>*\\?539"P8I?8WVEBI?FQ%R-/)8):'W22(N-_N<S('!XE/FCB4"%]H
MF/MN[>@O]8R)M1=3(V$ZUR^5Y5M]V% _YK.=4FY 35T!D*M+VA5(34+PAI1B
M4J-^)LW>FQ?YJL1$CY\M_N5G-G;0XD-LG.RB_\9/Y?\)_X1_PG\&-0ZZ5,"%
M0E'-H(_KJ;H;P[%CO?3,UP6C@%Y -GPL^=54=MI@TC%%PN^"DKT&%X)\"FE_
M3K13+?J9^\T/\7!8,Q-5Z,W4&],&@X\I$\#.HH"5QC-)S?\[">^9M34MVP<B
MXG+@L:.+@RW#Y?:SN9EH[J<NSKI:B6]BE3S@E5$T[[8"%XTW;.:T>.>8#!Z\
MO>]&17U>:3N)@U+^=0OLA]\"W$#="XD1R[K6@O+5!344NM>&Q:%M&+)J S\*
M7ZU^2F2'J]BT(4J?0<,S[D@O&^F8U[MN6J5L7^FY]:YBW@<^&-.:68/VXPNF
M.0-7]1"=8 JKRU/Z5]% I2A2 S84I<AS1+SGE-P^E?7:5;K)XR:KW )2:IC5
MVTY2+DV-.9KJX7-\\J;S [$*<(9O[/"\[5.OK2=!-?&Z[G;E6:4(XB+H_2F4
M4*PRV[ @\<QW)0;O8( ^FB<7[A#!C* ,8)S5/V#"_0QU\=WVE:0=^FV(V[)4
M&KJNKB=>N+ GYA%H\JY@^*- "=U< D2YOR>&>L^@L%CZ6JBWI=G0=4MX5)FA
ME5N=5@@EAB#*JM@-V[2^(-XR7BK"4ZJ0<<\F-BUYY#&:5M2@6CJ08_&3NK$,
M2HXLH<?IG+*UD??9=Y;_W1/-DXST7!^R@SZ6/&]'7UE9C5_X;#_?ZCNF IPV
M6(1#>N*>502:4TA@%U2"QD7=O4 ((0=\529)N_%5&ZI;H)3CZWFE";8O_?^%
MN8.A^EHO"1+3>Q42VJ(IS;&>XE5GBD0U@8Y'//V.P@^\K$MO@3<0)<UIM.Y^
M#$SPP7W'J[DH%/,42L&QR'1OT>M#_IPFJ;V%A C:_I5 @$@4,YL#QUCCWLG(
MB3#(8!B9!MM8!^&+Q+XV,:I/ $XYVM<D*@Q68>RMZUF4O3G(.BI4RL#]'TH=
M$AN7LQS]7T;Z&M=+/WS$3XSUW J]T49;AMAV++KL!.6EZ40<4,[%7<8/H[YR
MY. LA7]'.L!4FTU);3*)IPNM&4;&%I:CE5]D^RBV\CR72]5)C?8G!R%_5A*F
MRMO^5FQ/[$^I$0/_($>;]'J*X!NYJWA.5[&MOU&AS@E=O[OCSSEL&:QPPT6C
MLH(*&R?>_N;/>P=*(Y^ ]U1RR#925\J,I]02+PJM;TMP'L1TXE:ZS_C:T5RJ
MRSMPW/A;8:0B[6 GL".\;C=^K&G3YK3K]95FWKG@F[')^I0*PUM@2.13W.7,
M$8V7>1N\/MR^YG/--Z$GE,1C$L#52YQJB\BYL2SX>&K,-9KZ_@V%Y7/DI:=W
MZ>*"<@$N:A>=U+ 0B@=<-''A,/ZWAY9 F*^TV\8<"F*5=89LGVTU?'8+Q,ID
M73N:;IEH(';2""EOVBFOYDJM<6Y8SZ%GO=!$ *+7,VAPM"$;\'Y'L#02[^(8
M[*I4"S'M'6*?:F-"0HVYGZ++E2W[P5H'\TV_I:#1NNZ(H)WL!!39JB_BZ(4+
M![I\O@]>H;!<[Z8=BS)8[DFO/M+(*E>&]ZMYF\%&VRN"1EK8IMQ^/X?<Z' $
M,4H2]Y<KSKZI,69I<3\: 3Q6(\WTX,$EY>-+]<>5)$B[8C6<KBRRODBYP&\"
M=8]O ;QS]5#*",LU.UU=\6&"1EE8R\ZZ6S!;\CI[T383J0W;]T@7(T?4"&!\
MG96#T?5("TKVHTY]2\O+1\$!HT]=0P!4H(?$%PQ0FJYIA*2N;!Z:/K\%KKZL
M@@J%(!9]78P&[CM=V4>3OA(.(!LR5;A =XK9[QGC_CGLUN2.KV4F^)/C!,2L
M>NE>2O"6*A3EU$'>$U/U*'U?2:+"5HSU&9@)DE(UD4@N H=A&FT+2I$O!GW@
M)25M!$YC>'9T,E<,V>A-0*IVXW_IM#U/'J 5CFZH%$64E]K> K2GMIS!M\ W
M(65V*6"ATC%I$O_S4^&>>$6<Y3=Q<@PXMP A?LDM, Y 5RU17,0'A"6<O(MX
MOI+Q.RB>9?!7D:PK'$/H:I51<D\YK5H]'+N45^PA2^@+ZI?HG.C0X!N)M'Z:
MYW/5B^6-4><'A.EPGCJ*#=-O_:CP^JRSU2N\<YM_Z!>K_QDV9=FM)_>RB,\,
M(8^%<"/\]NNS=HUN@8[]SUMPYB=%I I<>O2]'D:AU8H#&]S=F!YS&09(80-X
M4O-'[_5@?UNINF6^]*.O7&<X65MR=+= ?P1;!DH6P6^O-EFR\86Z!$SM'!$X
MCA(NI>"U(W <AC9)W@+"QJ<,9-.BY1Z$ECWE]\3:$0?6E,/%WLJ'4+S=VG*:
M*>-)CBD'%D*"TAK$U/@X1HW4I^;Q,LLG>"VX2ELF KD&=:V("\W62'O_\;7Z
MUT_\C!.#(S;L\-7M*%\D?;<53 S>TV.":=V,>7G;0CMOB.K@Y?G-1F/N3GVJ
M*?-.O]S!08"[=E+,>OLB U<![>O6RSRS\2U!U/X"2LF%/BO8A2<,%Z]NTLG;
M->X5@S#<7)8S? 62_KAX43Q^T<N9I>J\S$Y>#A$3]DOOV<Q63<W4*.9QQ^^5
MUU)FD98,IVA^< S5)'JB6T K3B7BRXL?%]25!@GJ-9GRK'434@QE0_$V,ARJ
MM1/. [R\>22=>$$:>D& ULWWK[= ECCTR,]4!J7ASP.-I)&4I^EK3@BBHB_=
MI;D<@K6CDF1H][(F?64C39MD/]5$7"A-)OGB<>;^]X'BJ/A=/2I=#Q,(0*EN
M/*H-7N9[75^;/*PY2:H?G5':"#^VB=VM,MS[T!/?4Y*3Y]WY539=]Z[F\X.M
MXAM OCU->-%$JRR5%TND$2)OU"-F(AGQU!@K?J:NZ),H!M/@BY2EZ/8HC[M2
M>A0IWU771CJ1U+?*_\MMB(NNV8V]&O5N+<4EXK>:@W*BW5D:^S+9UTO3A=*Z
M.WEVM,=1ZAOB;Z=J0U]_G?+#=B0/2C5]T]%1<=C512C61<MCU25/BJE#'V1X
MAWR\TWF5%8+2 8=*BU0]JS>CU+5W#9;-/MGSU,J&!Q?!0&2&^YEL),P&)W86
M(1^T]M1O 8-6['"@U-V,\/I373(NS3WR4H':#Y(O F!0K/*^K+Q.K/,TEN2
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M8H>0T(0Q2G-*"2UG>LHBS6VK0;,ZS\[=[>RKYE/V1R ?*4WGQCGNB9SJSGH
MGV(C T1;[ K$2QV-'4Z+]XX)JBQ4,J=Z_>QSVDP)<"OR(QF@.ZDCX.E93/=F
M!*2%#*93F4WG#>V*G8Y;7(\QCHIZ=A#>U#UA_V[U+.*.?,!MR)?>Q<N,-*YW
M'!P_,Z2'&V<M/8\'2GXC1M$435X*N!=NDG4/3;A85M5?[)=N7C%>J1,X2:U*
M-RYT;%A!L"2+M/YJR#Y<_0JPOF <V9C*E3,Q?$)1L.548FK/>!6U!MXH;<2&
MYG#Y!S&^),YIRT^P!, U9+YS1?%H^9A?/([:LP]GUE3(FNF='Q]F+M]Q@:-$
M$B,6XL+O<&Q>AJ;7TGWD@/G1B(>*(X>("AKXNX?P+4CW)*]+$S!#8 ,2;'C7
MUF=_C\;C#U>^!'D^X4_ 6TU0H?!FYX9[_#.[ZQ0;/CQ+]3,I"_V,?"JJY>']
M"AWCIE^7_I+ C[MU8TE\<*,FF18YED^TW#7"L?6W/Y :9'C](MDJ<T;;R^&6
M2(Z=4/UE*XOA7,*%>256G21@'^C,&64DB.E%.]HDV 7V@[*>+0V X=['JTS[
M,=<\THN68C=/9REI/@_YBK^5D9$T)LD.<[^PQGG_8?T6DALW?T/F@-MM&4=Z
M>\+"(.I$)%[>N;5*ZKDL^YT<T[*G)'%#*6Z+THR3XAJ.ASE]X8/R1RGCL=#0
M>V4-ZK3G$8BV4"8RX%,E-GX@H"K+3?,V=O>#*2&39_?FE159MEC</$QB4H;[
M.4C]UO0G$=G2"TTP#"T>5 LP?3,\*)S[<]''W,S&[3("763R'CCV77\5+;*]
MW_N2+'O@/R?,47"J1L0JU_SHQB(9^!Q=RC*T!@7EQ*=TD."4(]8YC%R"]SAO
M\1[G)3W]YX2YJ-L_(\S31(H#?*4&)[C>(NY@%J %)BUPSC*5,%PI[6&&F=IV
MTS/JA',L@3>(:R;]C:/;C.OM.T3U:?Y79N7HY9!U1Y$S6H1/N+4;:BI2J+ O
MN^Q@5<DKO@5)&@W4O!\]:]T#6\'DJ?!W[B0(-CTGI@<M6Q C3<G VU30 :$#
M(@L71M=%YJ%;V+X\>F^5.%"LV=R5?&7VUZQ9^78;>#NNEVZI&EPBYZE>>A[M
MZ]7K@4V> D',V&B;)7ALCJ?L[IPEPY3(:VE^C-U&7_H8C<S\ZJ-$U]&*H<DW
MP@S?^JFQ?B3E_-<;46#11(?UGVQ9]7(["]!K7O^;P^:F"-S#S_!V*LFKZ:C,
MD8\>^LFZ;#?ADIZ'T] \ D\2=G?H9%EA3ZLYW!Q(= O6]LCC;=;ZYHKSGJY,
M#)]'Y[%N[>,1T0-73T;T*5A%'[W'VRSZZMTMPA44VOU.CV!>]$:$R*=VI.$\
MBC$/SZA0$="NZNK9$D@7;.)CR3GF?0#P*%_/U-9+^'W$^P%GS13[V\P80*%4
M.#NJ0XJF6+]+[%Q/3_N^Z.]?_2T1BL<35TZ78Q/?,M2W'+6$50]3I;O/U(&X
MZ7:YI:ZV6WN7TU53\J#[V^'IAXYR-7O?]IK3A'LH-"9<BE8.H*9X(=D?;>9U
M 1N0P!.Q5J]^XGE"&F1.ENT%/A.S??ODQ(VAFU0[(/":FSR%T,?B4)Q,K^1N
MT H/H"+5\+H8.X6GL1*+48OV(51F;56V7<-V F?*M%3J'U-(8X5E3_Y52/-:
M)T-.XCM3C8WF/ZB'G Y"/7I!(4@EM["CGVLSD)>1F2:?-?@ES^&\9]U,V-W<
MX6\UWO!S>5^4SU\\*G'EDVBS/+;[1HG^D[Y-$C6C^.5LQQH9O\0#P .??9U&
MNG@DTBU1M"'D4L,)\\#S'I$M&UGWWCM0>3T,V=%\WZ1S8'_@<@"GB^BBQZ-7
M-FG?E&PLCM0=-3_RCJ^T$K,D6:]'8Y7U\5S8FQQG"YGD#:HY6=:5!AH]:=C'
MK7>LS/F,+>%4>MQ=1216_)4Y! VBR+[[_M;CM&CVP4"5KX5X]PS#$7D7EP>N
M65+0>?^AUM/JR9S]AL=HJ>@I)I*HRMP\#?N\A-QW*U+CO@0;X7MFGF]KDRX=
MEI)W2L/?_;12'F_7QI@0VL15272MB;>L=&%;3+0K6?<ZUUH9[2A]4?BYZEN\
MV(V.9=-5X7,-BWXT3HY3HUCN*\FTKDV)M*0NO 4QRK8BMN]T9Q;;=08'C&EN
M'.E02?CK$P/3O!H;6M+PLL'$DF93@E37LE!&97%Y90$(B/T"N5]"R(#&(>:M
M9-I]1I03T/!FIV.C%NE+ J?G4,=ED7#*Y-PEQKH=G\=6FW8R%"PSYYMB0;JB
M!5>G!TI^H:JN.4D[=^$%/RSC <9_G"TL^6E5M"$@WU6 L@)9J'T>&3!M)^0X
MK^=&GAA00V 2KO8=&#Y?<#%K@U/+<Y]4SM[@YU_G!9Q8])(FU(14R@I9]J%?
M'!I&(T6=V"^#:.6.6)GRLN?FJ6_+38O3'LP,RTB.NCP'/T'B=]AAC"*1-$&2
M4$:D;@9QCQ^Z>$/_+JE2M:),X:YYX^BZ$#>1D-84CIXU-=O=5MH4Y"_P?A3G
MY.CR"]]E!_EN_L1.GZ64'1FX.H\8_3R*-TN!LSQ*SS.U[4NRA%<P=#HE&6Y>
M##MP7U2)+VBB\>X9+=YKZS6JUWGAL^HB?V.!V;F]J39& X)XIN0;OI$SW-W/
MC;7P?M<'T',X9W8TQ@39M/^6E'A&JN]GAV/'/%?YPTP@JE_1L\><H1_YNS\Z
M+7QV^Y;YOGO@,$AV#X+>$(;S06.4?_RA3JKK(@,SC9#=,4UB8#H9:'\*W?J(
M5-UJBO02>]F.ORX2N4T&0C= 3VJ&O^[\UQ^NF^QQH"8^MC<UNB@M1/(Z_7UV
MM1JRZ2"<A'UF UT_]CW=DUVS+B/U"EUT4-&UC[3N5W9TD8O2_+\FUZ_N=&[H
MSK]U__;^:_5L?A$T"NKPS\LF0CE..<8;0D^AJVK%[4[<I #XAWQ&#!4ARD2,
M'10^;^.7<V;2*S8*O_W=^09]2IPE=3;A=.WHHX[M*.AP_DZY0XAA7MLKC+C,
MEU3GUJD7BHXTP-W9I*-2I[S3C(S%W4TZ3CYPU.>>BP?-TQPC($,:61T0E\+?
M@[#;'YYDC;ADZI)!$,6]V:13<\A2<J#W>]@T4]XT=N#^+)J68&&1]\W$Q#8(
MJW 1%2+(.B4WZ9P,L6"SZ>D<^,,>X!PHA?YUQ)LID;^'JXL@ZNT.?"EL?#11
MZH8\@VVJ4XUDGB,#@Q+Y.9RFGL)JJ>Y2:V_6D8:XZ"XCO+;&"YZGR*FQ,\8S
MW&S\M<604_C,NM(\.!S.+VL0H_3T687X1 C0WX]B0V"G-YNTNT7%N1YG')+;
M-H+)-?(/+7+!$V1&7)ELSNIS=#R/WZXSQ+D&NPRVN*_8G;M7=GONV-.E]FRF
M_.[:)#HOM6Q\0-/-#^]7E^[9Y5Z[\A'8]=2@>M^I_ \(DA\G7/KO_#:F*4+1
MX/-WERLP_?#9E1A?%5[KC'U:3C?!:[%_8W[C%^K5-*%SJ073<O#)82[AX9R+
MC1<=#R%ES(XEI)+.&4;*PGK <BS,]BD\"-!0*L_8ID.TBX V $^)..L<]^'A
M^(7HA<&DMVN9!$YNTF.)2.(.&5@ +;,6U*D:"4HD(@+,C#PKM#V=%,-^S6RM
M%<8WN+!QTV'Q'54;&ON,#/1P@^"%-B-ZJ..O(^9/9)&!422IRIMQ4H$,2'6O
MIGX*);EG3BGUSP=NZE+._)1(WB6_N$^[_H/>VXH)"^B'9:6^ZN>K9\E HLVV
MYJ_9TW"]+(6:+3P*&1%B&)$31EZ2W2F)7!$*HS%WGLB8FY2(ZO#4^E(E9V[F
M<V?/IM_^NTNTJ<<;ZNHP7#JE:X2F05]:_:&[E0-MO1NG!(348Y>),7?"[DUJ
M4 7-(1A0RAES.$,VL;;5QH[%-%8?W9(4@EY_B8#]Y\]VY[3$IPV^%;CMG^@J
M5F]4/YKS3&0WRB\L*"ZI+W<NZ:24=+9M;*F&@7%NT>?"5!&XK_+'%5GV%Q 5
M%Q'VZ/G?7\C\TU3&Y1^7!B=#4K_/S)[=,\OD_2*ODOM?NLTTRG!V2]VR2YV]
M.[A5\.KP2ZL,Z:IYJRL-IO+*9?<\O 7<^@F<9."XMW/[[@P9R%,%85>I/LGD
M$@G$T 5][LV 4]N=9;WO'DE'X5)QR%-DX&GJN'K^J[\N O[I)ZFC#B$!R>E=
M]#QW!LGZ\\UL2#")<V<._<M"X*6C8FO).R6F3>\M8U&Z*)>)!$FM[HD>A<=E
MY0EW90S7FG?TBQH;4K4\?>$9"==U(D78.J.3QQ>;P3KH^),^K:P"&-[<B,O&
MAZIT<5A5586<3N4\T>J^68%+^?P592B=.OR!#+0H;FO/2W10O1.F4.9F6K:A
M?W*15F[%E,(A![_65.1>^OY3:= NVQU)1N:5B)+E 6<ANTS#FC,')H)U"^</
M\NR;^D?0[;^) /_J;_CI'\89UD[OU@IMNIPOO+R];X/?9-@QB4%HY;X7Y^A=
M2\7GM9)"=V3I4=(8!THSZ]CN(+M[=Y,N"3,/CXKGO58_["8SL,J<9W>_?A:3
MRJ=_YO$XJJ]NK(%(C-97SVK,XUOA8&[T7C!2PHN[IB_HZ2]E*2XX7/RD(V3,
MVD%5$%'=,V\]0?]'+4!T@@2"UXL\4.>9YA'ZJGS[(_'=))620*)'V9KA9!.B
MLJ5C$$*X9JVIP+#=/;1S(26$=^^O+U.)CB?A"9VPA6W82^2#ISY3L&$&S @?
M&8AL/4%"1VV';/$@>C)W4ZIGSI$!%R7_"!+O.7I-TXK&WY]D5XX'#'EYD@^D
MO @!3_9F&9^]83GP]]VE$M<->RIC5IWH:(HU:-!ZGE9+/2,CR\AK5X&BZ]/2
M7Q3UN9DX1'MM!E9\R0"&]<.3D2^W1E][5R10?1GQW>"J*K6^6QZ<$B_ZXC(3
M7]WI?N8\@@!V.=]DPM?PQFC#L8]0?\""P.0,&JCEV$'H0CLS4F7%E-%]3)T.
M?]FAV(8E^60-JIGQ"^\SR(.1JAS55\LB.>)IXNYG%,WGKQ_T%>S\1[K/?W\(
M^%\]B'? <90^?,U-]VUA"2,-A]T]WLI(VV6;I_?69*&PN6I!?&"&09,-3:K4
M@S#>6)JFM58[ZVI1''&DPMS!TSK'CG/^?5*1^1%UJ>FJ-Q2S/*<]C@!4YC>_
M#Z;^*=T5^4-W=6LGJ53]I^[:J3P2BY:TWCD-]E?:6? E^V:G4;ID !K/341P
MKS$L@W6=K;ZEX.80@IA8NT8&D#VDNU6?A39X2;/(BF;$L";&'!VBK$"OG__
M_W?JY[!."3RSL"M_N6-?1WU;\M9IW8$6')00:AA'](2MBIRV>O;-2Q<73GP_
M))<^P/05!U+L!=U(_*T]\9*LFT0DP##&_?ZP29,R B+!3K](E>*FAI956W\K
M_]74$ &0+7S"E1'WY9*!%0S(O6&8>VZ#I,=ZB*V]!9PZZ7FPHKF79 #>+X#X
M>PEUTPC6I/8,V))' WKOU4V$)[\F'(<7X)TF:%0;-,UH5$9X+$JC+#G$V8A5
M.4^7C,@ %6)BPA2LDB1<_GG3D_0QXQ[B/I<SSJI=W_#@Y86W2_]-5I#&2=$J
MH#A_B]E;D8<RMM_G#!XA/_1^^+"EV;85E NUI8>OS#-[%7>U&U6N8=7F,O2(
M*.GC$HIT@]1[*")=LB^_HMFH_+1ZVP<GR[G!E,?O$+1)9RUF:+(<O,D<QFZ(
MXA"'W;S 0RDIAYT)]CFK3$QUS8H+8;X\;<5-*7Y&P9,84_9U,;F42D;']M7&
MQP;WS)J<784.P3.>3V]YC3^*\FOU>'G6]^2/DQ4IY14!?2?CW4]>Z;%X%0%D
MT_(W^@C!^P=B7R,RYB"AJJ*MBV.XQ$\PL\^^TD_ZEJD'7<I+8^[Y-^KV8&U6
MVUGI7IUS#!'G3(QI].*>P91&*+<O*W'/\L?@+I>)A9"X#-TD#M\2P:/=70M6
M\=(\E#UV+JT7=\SX^C9YC1%'RD01HM,C,MB&TN>8P%[G*[%=.W4S2F'FIUT.
MEJ$8QS^A%,9RO&VO,CRAN\+VDM::,@75(W#^[)K@,H>_M$'7K7D]CR<.Q141
M%FPJ>U$<9.1QIQIV8K.S2%LWBQP$^R@_6R6JHU40$:Q>XOW%2YXWM!G"5MU=
M-9!'ZB)\4*#_L,PR6?"P>_I$,N=3BA/A_%"?4 A*G]9_K+FD^/2T0*?GBROY
M5IC^@*4-)(0,V"\\#ZT<EHWENOD(>9N'L@M3'C)]AO/B^2"E S?ELB^9PM[:
M=N$EQ[U&&%\H2MA]';V?B^A-DC.MYJ'H_4-+I_[5Z_@,$KG[,=CI4%%"W:.:
M5>16N%T_#4Y5N:+7BVO\&S5*8-J.,I^'TC^PR><"JG?1/LU_J;@E^^I;WM6"
M]CR7/M+EJA+<RN;EU,.J1F&'V +$842/,5'U(+VR <MPN$!J@VC8VS3*MY1L
M,+Z>TMYI_..)83ZXJGY$5T/,MT_KXLD0!_KB7J;,/[;$4&0#>0S_+#Z4H%;
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M( !;&4LE'6<#D3,V:0NK_U%*%$XXOP.QH9V.87A-!@[3AH,=RTA]%\\#ZK=
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MJ2O07&C1(^&+(3_\YUN1>!V62.)1T+V.@CP&5OSV*ZQPWE58^+L@<$_Z10^
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M U.@ZW2/LLO1ZV(:'4(*K!7;_MNA[,QP\-?[7/O\C]UK-L[RM0P4JQLZW*\
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MTMV//^,)%O^T'UKYB23)P=M"3[3LYD ?-"45HF!VLW"UOJ%U/5B*]E2@[F(
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M*!^O7N@&KG'P7)QA0CP2O>?I+M)_:$B>@&%1W^Z<YVZX',E6)$$E_NY'RY:
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M4%NVZ&^*729H0BBJCAT;3P@A..H-'@%[H'H_IM&;)]L0%SQ%JJ/G]'BO9*X
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M<RF$1\Z5EK;9\-6*YM5(_<,(XC4<.;\Y?9=D\1]#TF=#\%U,.;JT2E^"GD3
MK<G-SH+%-ZAAOBK9ISO)F\.RWSW7:-<03"2*,)0C_N\G%1,IS*'7$W:+*V#L
M#;T[9H W.T,&EX[XTVFJ+)@^VXIJB]"@'C\H?JJ?/3Z9\C#X4R/"<7[KZU<_
M+PU>RP/'7Z&20RT/OS2*92C'K5K0!I2^[W\$"KN&>P\UQH'%S.?>7[.>K_@?
M@(NP++5JF$KR6MVRNA,=A9UN;T[5S[?NXTW*W[/Z1A(/\A\?_3$S)*:O05R;
MQ-S36W9QO6*U61#ED>](A_)^9B,WT;I^948%?SM9,-_@IYCV,[?91-1T7JL
M7\Z2I=14J?E&AL/.J(7Y#\7[FZ<6Z4EZ=S\XL&2:"M3:SM6\QW8, CRDZFKR
MM]&[49!/:K03W_2)6!8[*'-[7BK9;4N<4N-"S \L$E7\&94-YMZR:$E/E6R>
ML:872K?$Q3X0O<#$3,)5;, WWZG@\;Y;[9'#7AN83#'>JSTYU+!)]"E5J49
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M.[EK,I;2E&]>)'VT_63>C4G_,",AKH0LY17+!0]<!< I'<FB0 I=(^NK7N5
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MR5NS8/<X9EK*1HM;F]M-L,9A[2PP_'7HL0^.C9!3U_:*AP@25,N=)BMYB\D
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MPR<(A.2*GC$'/-OUNPG/*:WFU;18'9 U#^,:LL)5'"$I&F_EP[!Z&Y%S1EV
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M9O_-R($3#,PW,*;\>F<#DSN5<!5_<>R_O^C; =[_4_<* N-WELR_GU$^>9)
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MD^R](YGT+**D/>2W3">A*1$6*HD'SBJ3$1["XYH[=T3&T@:BI4I%P\O/]^-
MN$5V<4MB\KSTV*Q.LP5:;FD@\U'18LU;\WI[)@E$'/K>HHR#>,@+6D^ADF@
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MK66(4GQ2[Q+>YLJZCF#/3:/'/=XREXHE8F27FH*%U1]9B4D8+K[)31,^>(-
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M6K8FX1.'\:CJ_?0]]?R@\(^&U7[.&E9/6$Q9S /F?S.0\\BS@3(AB!GCRER
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MDS2J!PBF^80TPL0(: 0"[(.'I=Z&1"VT&=?-."Z,;T*QDT\@1KO1/O3L#^2
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MM7SURXL&NE_=UG+#U).F-3OM%]8_SX"T8,_R=U):WR*+F7=M%;DN!:#31#Y
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M]G)!:]2@V6"BW4J]RV:,1$M[LB-4_>/&>QHK8PG!Q=SO7?E-YQJ>^N=D]N!
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M-O+DI^.G&5EZN) 3-)ZX$V$1G#=4GEPC4Q=TA1M36L2/DP:QFA]+>&HKTFV
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M?^XF"4]Y=JA%;!IRYMTZ&=BU-NX=)Q4.?#4-E^3H$OU(O&A6/14SD&=WO"7
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M:)_P3@)L#W.C8DQ8X[7K>F@UZ3LR@H%Q[6.5SK)5\"K <H)[O)Z2"*27<YT
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M1<J8=LW;>Z4G ,NOD_1..^U$]!*KH7R-TJCSY&8(Y8WTT&N:^K;S(6GN8B<
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M5^T@C--O5;#_Y@:-GPU=_@R%P<(5870\O[E)C0+6!Q#2HP;AJM(2#-AVP2$
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M :;IH 4+]91%45THY%%";Q<<29=.K62P-<0>*R? /T0UU.&Y@B3]6(I,5PY
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M G9A'135*Y<Q0FH.D15.]!^B_46R_W>"!?ZG)/M_!/LWN68!(ARLF\[#(0-
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MJ0S76&(GL_"8@$CSIW?\@_?36T+@&?.;W\^T\!O=*]20FH4^GZ%".X?@!J@
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MD+SM;I2,?CPXPU(PWWN3#J^F16X[U8J;I^V1?8OW/FA]8I"YM'W&.0U_Y4O
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MNLDZVO+-]];:21&@]^4,,7+C,V#(]L;SNN>'1&$%\S:BR\Q2@9L(?Z$9;OB
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M!3AV]\EWX0 ?/G*E+4@6!EZX>_99C+I)+_C48R7J:WS.O<P?E1IZA#FR'8S
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MU#7>@Q2=/F88J5U0N/.4X#FA6 *)R51#-DG:?V(F]._B?8#B[7[I8CL2YQ[
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M\QZG"09HI$9'*G__V07ZGU\ IJJ^5+Q*/5EI[FT8.GR&$ D7(K+G11ENA#N
M-:Q9>>@ZR;ZM1B]*>J'BYXQKT:U6<>9J/+5ZL:D.1U-?^IQFZ9".UOCQQ*=9
M//A9CT*E!Y[/<_;<<$F%C/MS(\&:QA0F-?#(@_6CM( 5(.S>E>FR$D8<5KSA
M$I0LEA_&D/.@0LA!.A?%%W%5ZB?HB?ZZ"*>REN=[Y>][:+I[A+J044<; IE(
M%?"X*K2/X\/1:#CA"-Y[JGJ\^J>^5GA0+EM0VV3J454T51M).=_.BMR8D1O!
M@4RD#?;SLUM; 5E2/X3>H !BS;/\]O-=3Z&/4;?+6RG+O"._1'\#7RQ8%T>G
M%EA?BT5.Z5LTUO!+".J>:%9&,]=M=@!>_)*#('KY(;Z*GJPWN^WBP3G%-9==
M2X$FV!.NHD__A52F-_[7PKK'0E[3Z6& TM415E7&Q3U:AKCMRB"7.K]LF*_<
MPU'[:XYDF?H/\K[9YTB4"73M<N+59A3HG7_65Q#"?[G3O)Q>K96G[HVKM+ZK
M:_6[<#%+BLLJC=3VT:BDAO7-]H0ZWU=5I<&6S^(#KX@M/?ED33<75FFH8MN2
M8]WC*'Q9VL6">'^RSE@5TIZSCZZ1P>)X@9;F/:YU#' X<)H(S!AMT]?!$@U^
MFLY<EZ^[IEW,J.51[(Q;?P&E%A&_B*SVO^;)WTG@%^_0U0YUK[[2Z4J_9AZ#
M 8J<]J+]WN(,:?[B=) _B#S.#Z.2%YE?G[:+'^3:5\@:M&X'.=26/.YF5/-<
M?>TCLC# :"NBV[J0-KKEKV]QMY_4:<M[D "/*B'1CU[1QR'"("C[JV^\YLD3
M/:>P8T9"_6>#=C=3I6V_!.UO5H 3%>'-]^!EC*:/FA(VB)XP=%7@?(3;CG'G
MAJWTTLYC !T6?%4O\@Y X[]#/L(G\?;CJCJIZ5/[O/K&*':KZT\GV7R>UVXG
M HWRGL]0-S$ E<Q:RA1DWAF"> 1I-45HHT.WJ]$$6$U*)<N4+#@TU;JOO& N
MJ\(OB6-B-N\8VM;N=V>THCZ8"*]JDSOB,5ZW=-:2GTZWQ]DB1P1L:&E8J(3,
MT)H=(;QC&,M*N:: (V7;<U"D#E,8LS^D5V@?%'43.J!]\:A@(5?+NS$B5ZN_
M:^I>0D.(*C((0:_W.>I8'2Z4W5<1N!3K^!;O)+$: UR&=&B<<E3-(1F:43H>
M N$1M:9RAM.'XJ !08VKJ/L-XT7VAZ87[UJ:L2[:!M7K\D>X=7J6R.7_ ^(V
M#H?<#V]/BT?L<>)U: 0T+_ B<NI..W/&]^\*LT1$J4):%:7XP\9, TZM'L]-
M::><RYP>V)H25AH;&M>.-E>_H&5[JEIN29E"+?VV'6FX*#A)$+8"O-@W\9<R
MH"2_'QN8_ G?UT8Y[/J-8$'W"_[4;(="/+])FJ+ZA443*OJ5Q9-E@LR;SB"/
M$#+-N:US!>"<)- ]Y_'!."@[?YR)Y8+,#$KM/AH=3>_K][1$IWCZ15G@+J6J
MUT<+83\F^&Y4KZ+]G0VZWI.DL,"K;VF^H-=/;,MW]4QNH<?#5:C%J;+ XF^U
MN"+9NF8&^@*\G/0F.[K"7?NNK6I3']U\$@UYM[Q_T ]ZG5G=YYPBMK][,'%
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M6%;AX_G2@V+UXTZ#JA0>]-!"+72;HI <?5Q0?7>X[JM*7HG=0MW+<+D[EZ_
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M,0"*<^['VB/8%.N6[*([HY&:3?38R5+<C %>SIU'"DZZW[.6ZE]%DY^1G:Q
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MT>+15%(Q\;S[AUO;?VRD'VCZ,65>_&G*^ B<-8<VL4>/L4*6C<$A,DO&GS%
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MXC_O7OIUUA18;'&.0,^C<YS>_IY^@JBIA]X4K6B7T-"PSCWGW)N<]8($[S!
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M:5M4<&V"?:*5 HVYFV':I']/<N<2Y0C&ZR+IIPMXD%=U?!B?/_*ZNCKB$5:
MYJM1CETI&E>)*4+$8QN+=*$$MOE7LN;)DB :63N(IV4!0L&@7D[A^<Q#KH(/
M@9JQ;;QW#>3.L7J#PM <[3879-SP,XG/?+32L+[$AD*WUJX!&IVDA_]D21<]
MML=5BDH=^J;^"26(5%33@#Y6Q:TIG>&$#Q8C?W_J2N)S(X+]4>* :HV1VBAD
M6<1!O=V#A (G-7].(CDZ2<.HB3[>=<3G="8_4JDF3 4Y'+.D^ZU8G94PBB;W
MG!_E61<##>$DX!:0<:]AC\/(YLU!;F-CE#R6I1WK#W;#/XQDMR7IP/WQ)0#O
M$_63BH#)Y_ 0Y\*NL)X93 ?8VY &RJ"-ZH69UFA+I6##B4/^ZU#W"'=H[T-T
MVFC#4.*@AVM:2CDAY/MOI6C\US^C\0/#9JY,\KX9&\M?;V]%II!;'F78M>EJ
M^XG-6$Q9?S@\NWEF9VJL."1/OS._WYCOV=(7[5@^7UX_U%]4PQG8)R6B'8\H
M\3V07-&L2AG<XV'DS9;3$M- Y]HP2LM-[+[\MG_AUB''2QB(<I2^/'O$== F
MXN_,653M_[EJ?G7366?C."-#7.0FS&G2!(K;^KV*,[?A(6J^N?1QJ6S$UJN4
M2ZWF]U21WA5\M%L1 .BQ5O*QQX<F/!4ZI'OB1CA:2N7:DM(&T**AY?'K'ZW5
M06 &DT\:D/N*1$H$_)0Z\N8:RW-&=H()ALLRM=)TW0PXV !+^%N!U@4RJ^/#
M2FL;]&\GWX)DK2"601Q1JF8OICMHO*+=C>8JMAL\WRECH&D!#MX:<1T7R@E1
M3MP"7L10P1Q2@:VHDV0C0(H=RJX6_6,$E*N-&3JAP[ZL^;/Y*#'#!C6V&F[K
M+!#2%MQ'L8<>;60W(D5.C2ZP8BN(76 ;9U#_;9:+ .VT0,03XN(/BJ1]Q-\+
MX&ZL (BBN 'AZ?O\V#BTN+9!?90?/[[#,O(?.@SPWT'5_0?K,#C:ZY+@M0=3
M'I^H/^GR&Y+V4'[4B3 CG,.T)02]/PBTS_,0\YFU+=O% Z4;0_V'^JN5GO;Q
MHMS8_7!^O_&"FNCEZT#Q_5XHQ0[RX61=*;D2[U)7*9_[LK%5;(>:G9B12  U
M*-Q5?-@U?T],=WM;S53$7W$_XK ^FF#%,(C,P516OT Q*1NPI<#0J,9NKZQ2
M/UVW^\:1@4":_> E>-00L(6P=B:BR Q[0CTEU9A[U_2\Y3$@4"]IPT4&R91U
M^@M]Z/RTHCC!B[>Q([EW@%_ICLQ>XI_U*)'4_?S6_>PKP*U,S#'$AU.(@W$V
M/7G1;N$=*>%A;,PGBT!1W$>E3T+XQ[JQ-V.P7\+'>V/#$2(EQJ_TOW) .#+>
M?WLP 688]ACOBY>K[LO6E"/"Z<KJG#QP%Q/A>D)OD!5G'A]F".B#$?D<+)7Q
M>?GJU=9(GRHRCH?IFED&&[^XZL@O\^.>_?BB-6+/B\GK>36=#AW*)"KUOA."
M;;QCO,UL+Q('O+%HC#RB28.H]S4>BK/D#Z_-NPGG",ZXL&G1"XM?#HSRHPPL
M^/$V^=ID(@FIO9^Q"A-F  V/W/:?F1=*VTP..5E(A1JH&1R+)NX;*\ 5"P"
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M>*Y)EPP(ZN/":;?DZ?3YUVEE> /;_-*NV_B3+!-U._]E<Y?_T?G+OZS:CD:
M,M%;;P&C(NMOKOSV36C_[565)&M% .T>UQ*6"O!H?58.']I&FY9?/;4[W*I:
M[ZB?A PJU\$F;[1)X=IW)+\%0&1-ARV!X5&&;'GCZ7'4LDSW85*8LLRJ]"]S
M.:5H"@)_/5D/)(E08D6QR<OE!]1IO8X &++F_>KR21KWQA739:8 >VQ\<C9W
M[X?U0/MN;3'C!=+.=)SQWQ/0M569+^X-$R5I_36QYIUP)O(LM)Q$_M\2\]WQ
M/)\>IS"^Q$HT3@U%^)JOT^+9M1BKE+Q9P4\ SZ!\!7X&80BPD*NQ[SHP3XAA
ML 7),M"_O:+P6-LWP#)D$\(UY/U5LF'R[;M"@H1U&#^A3&5,)V?#0[M[!&L6
M;4]^AE.5$_K+:KW[9)PPCC9>*<ML,ZR ^>OWUP76OPJE3:,3(^A)KR/-J?[F
MA<>LQM)"V<4$9S5PR4J<PL.CB7!<=9C;]NXS3RURXH!3UJMT@#^Q2:6]]I%Q
MEV0%>UO+\@? M_20FEO @N:+;)::>S_%-3B&D?0(N>J)-@'6"<>-%*1VM7C#
M@+JV80 1/"QWGP(M?W@)@;=4@\+_9J[[LJ(P=9T8S: 7>L'RP11B+VL-J;!U
MO6<YQ14C? LP9'?VMUOQV"8\<S:N(##*J3#(R36([]@O_NTOT'Y)_7M-B+5N
M 5KUD^8&#MOZN=;Z7RVGTP+1M^WZWP3*/U,;F469TM*:N,.8$L"0C4_V[G-3
MT)"O]^,8VW@:W7DREA3)H,)A7-4O=R]-00\*8;@&S>VI"A_EC10<*(@)B[$A
M8Q2 LQ:.R./+]_4-[5/\_@$/"37K@T<5Z40427?AT]' 7ECW&IF[O:'LZ>?/
MNL*IVW%A=&@T;1B ?=8*)8@6C/0"^Z*\^"'7@,S%3#:OI>E"K.N!D2E-QT>M
MX\-,7^?&D8PE1O]<5"9IX2QL48Z,\?K(UB-"D <AT0GGIFPD9G!0B9IZ0'VK
ML[C'S(DZAWV, "<$&LB8T[;K?D3IE40YBKV@;[B[\#Y&>4)924(*-6+N>*:S
M;*A8.1<>VDO?$2V4=[P)X;V*$?YM24W?'?C>L'?I+/WYE<Q\M]-8)10O=(,F
M\&I6>2T$YC,JA&"LV1VE65G"E'+!\=W$]0'L_E>?MV0/K2V&Y.Z2&KY;S,-/
MA52PW[B8X7?? KK(W5ZL/M""W&2<H>1FUS5 '[9/%3B*:EA_]*5B]L65/C!.
M#FTML>O$Y]\UR M3SB#';A/A:)=S^M$![R^/)=,'I5>\M7X06J68HIO\RK]D
M#UT]W_E(*)H4TL+:.NG65*%%4 TA_)RA!Z-IEQIA12V#L82=2VA=*$=V$G8D
M%\BA)W%E#KVY7(30CI1Y/;BZ.E5L4AX*;55@X?GJID=CAQ.VLJ]S;D:P(R0:
MO1*&4,72K98CGJZP@B;ZXU)CZ\%]&6G?S#R>,,A\IOC",,$ENWF1Z)*:%;6H
M<]9\LAZ$^2@[[J8N65%.L!CPB7:PI'=]B-S/B"5,A_9 $[)-VK]P=CZL!=MJ
M1O:&:481,F<Z)0:)!C[$O@7$)!KKM\8,0E<@:FVJ?M\@M"?#005 V*04-7H$
M0F'6PXJ38AW5OKC7X:34'K?[%99'12:2@,-;X!;PXZ--7E,\4=T))#KN%M#F
M[Q_B?5%?J$[;;<+/EU9Q>+21O FA3Q,2:%Q[X8@):@R@[HPO 'U:-%JL^EEP
M^.4JHS,9H R&/5.K[4RY/^E.&6EC]*8QKDM%,:99<KIT'7, 6/UREG]WKKR9
MD%C+8XA\[V&E<+N@KA#IY([IT]"O6!6O)RN378877UX(K!C8X18A!*_M?[#A
M^VH9:)@'9/EHH*O;NA,??!+2$-S)E]I9SHJ:.A^!$RET/)IXWNG[HQ^,A:4G
M^X]VP>8$$E)M_]T%G8"\OT;1_4?T6V3=/P-016O\OW*V1C^ :[9SC?+X[.I]
M[+=X!86Q6P A31)*8_K@'PQ@MXFCYKBX;)XMM*[XZ31^JDN4MS8:I]0MP!IP
M?;;=*/Z_F&LK>Q+!"R'M'C;R14DR?G4N-M,H+BR/8$BA/>_1BT:XPX33]U:Z
M+TZ<\0E&@U>H<&?:J4H?<>IRXYEV.A,FY_A<ACC2M1U7I/+SHC][$TQWB8%R
M(UVV0@WOP\6 >X":-J,KPA\1^;YEZLA(7@=CEJW"F#;3!2XJBQ;NFQS+.C[5
M,9^*R33,W6C'\4+(<Z4DVX(ERIOFMY4,+AM=,])V3=O%4Q*^46/4CH-.SOG<
M:;G&CZ"D,6X21L_J.U.U:X,4&;!@BJ*E]!"&^[-B,/1UG=#4M69@M?M#YHZT
MGS863@L2ZC33W\$8;B #]V+^&[",-XG5$E9"+G:96(!!$<)UM=Q3&R;0O2M)
MF4[Y$*GPSAF/#*?P=-A$O!(-JWM>+6!OULAHTNE[*M>HUAB2 ^ZR\:PV4V.*
M +- 19%<2\%\-JOL"2W"8#)1&@_N U?VYHQ,T6&P"/YT>@;9,*#%:!,HV[EJ
M[VVH7]L6="W055Q%M\1U$?M^5G9$@1"#J;6O^Y:V2C _M$=]$Z)1$IV;_85:
M5963Q SK:Y_+)4EC2^T).MO)Y\-8F*],TP27Z=HAQ='0O5<Q2PL@G+:W$9L!
M# B]T(L^2FR\Q5Z6-!I%<@PJG.!/--[EZB$!!##<T*.*K.FS.=5/^\W&<;WZ
MX.B7\,@U8*3 @<>^IKE-D/5@5AR@=$['?&<K"39Q$;MH6.A/)B1$V#@N^73'
MTT>GK;%KG>T"5^P5SE[Y2ARVN=?E^GE:=7UD=ZHZ(]*G+3_G55<Q.NU3:N>(
M<;C]JK]C5Z4W3CE:V85+P9;&,[P-1/KI$9$78>_5T?NC)[-R/+V,[^2*FE#D
M4:-\M+K67.8W\H]\(W4J8ONI"G)\:5)A0MVD+6Y\ R6R1%&Y/I+2Z.TVSS8Z
ML=0_IP]7TM2@(/9'D21PR5N VK5J[/LZUBC&L% #/ )<)_4MTTB6((0(AX,_
MS53F)8^I+F\,1K2W#%?]>"F?0C._(FDD0HS#WN0U!'B@EOLS?=//%28YU'UB
M.U"PN+#,7XL*3*1SJH[)92APO=*3]EQUQ$@SV!RWGZ,;(:)"AG:XS+8)E9GN
MI[K.>WF<8.K&O5]7,$(!-;)^6:W6R11/5VY/W5/98LW=[1?7RU*]IR3P6?P!
M.6"1#IABQ[?Q!.>>_,5P*NW9/+BO#;)F%L)_?<#MJXX'=T[8(QE4%N4]TH9?
M5"J8W8.;$['OS,RAQN#"9W$X<-]USR0+L8GY@#\H#I2&/XEMX\$\L'\]6^#E
M]VMC_2V PL\H:+2'PEA48F+8EBK#:I)%#CTJH!G!,<8MSI %-1P6Z AS9"P)
ML[L_8+EK!C1#",*B#Q"7\G)LV\WV14\?^*-Y;I&]Z:B79Z^I42ZO?YQ7T" Q
M(,D&EXY7OVBY)^>DV=F5A- ^=JE0JTK;1Y9W=M5(DL%]]D:[#\S7L0G0TDDE
MC1-D\EHRO(4O*S:N,7^I'JO,&[C9<>430G5,I;*LB@G?)7!\SK;-MGQO)GK-
MEONO\U[UJ;17V$X93/!N#/B0:JK2A\V)@]$K^4&] "]Q&B_T4^)]BHK4^Z*R
M U43!Z:;<L\5MU@'$*7?O9&$\(GU=8/-JEB_&)-JNC[%@4IMEMS4J:1\DWE#
M:/WLIK7F\!M?6@17-/VD>T-F\>(]WCL3YGHP\>$6@"F[N([[:#_!-TWP%B"N
MLQ)ZY5!9X&7%*=#Z/,+7DX,R"&?KX 94^Z52M*VJKD18CE2YDH^+3?]T%G;Y
MGIQ\_3ADO83M-6\+*RKRJI)J*H!ASY-&(JQ'3+SVC5]]H! ERF: P%E&9X%R
MF4VCJ)\0\WRA:J@L.1U-9[ZW'H(54WM@AGGT.J==I9 T9?)[RF/!CL]FQ<0,
M0M5CAGZ:;;["%:^/"PI@"MDIRB\K\GR.[3;!Q&=1X/RY/8^T_6THD#:N?.6A
MES/B279!RJR].]4;E3<;R33)]4SE;2O[]-&W@&4-T$"YWJ.1*?-">0]#K>HA
M(X3J<?(DFJH!<3NCG/HV1SHM25ELS[,"_YPG/V*?O,QL_+"?J58_ 9]4:6@\
M7EJ<H;BOEYJ/T4VEN_;1><>+O-=O4QQW?9PU$8G?KK!6&ULK"$SVF5=#1PU_
MMZ5KW$X,O>[_E$^:??89TF.&863];89.&-B=@M21O=.+1DC]Q44UWY\>-;0W
M*87' 9'FSFL+(D=^0.+\[RDD^M\;41IQ'GVEOII52+=Z!W897 J(9T4F;ZB:
M%P_W#2\,WZ&E59[L%D#\YA09FPWBNTJJ<P#RJ-P"0B)+%N^<L,+@>C/UY1!3
ML.C1#&.4.;[>#H_ZEXO<A;69J4X2$O]1B5O NTR()]6"EXP >M2P2RYMHG;(
M2L_'RI].$P=\^\P_P*)G.&SLDK5$9P6=E6DN'=_1;C[ F%T3*W8]5B_TA?!_
MEJ-WF?(TWP)B*TEK+B55V#LG6O> %)45HWD6'0HBFNM /#?*(TRX?T4>3+?6
MW9WC30QQ4I'(GMKD) +4SU_87#=-G]PQ2V3U)3F'L[PNPYOX0ORBX5+JT5J,
M2;M0T9L =]P+M<^W $G!E<M=<%?[&QS_<SO>?%97H5G'L9$7S9]'<!;6VCP]
MXA8-O3*-(\@U1$-: S;VM<%=U<VFEK#0EO(]!_).&= 8/HG PPABJ5640+;I
MC38KW2-P_V0RC>\M &/CQ2T@>]8 T2N&Q'/$KQSLX&F'BEK)@<98$;:<5CH+
MA]*#,?>]@+UW@X<BF%^8A-]<TBU ";A&!AOT&UB?&\)Y6SX5>_.@]:@OMJ]R
M?UKL23,ZN[CV^H/\#3-,&^L#)%-]FLEK>B+=P3+I/=?&&+'93#]Q&$UC(>B9
MVL3Y0ZZ Q35E8^[-I85JB.$51X\DYKB?)K_+7D.?1[A'X8@<D'T@<DWHG7DR
M4ZP:=&<A*9R2#NE^:,[WANII0KY69MLUDR,7UI::FI[*.]M, M@M@'Z)ZLYC
M1+T%](QO^2F92D[F-8@=B".3E]D/-/C&M$N[KS;V']X"5EDGDU8]$(IJ?DM,
MU0AA!F ^"Q3)"!X-3;T%@+$];P')5%I>K3?O;[X.>O^<DF1\+@2VVDVX!50Q
M]=D"&SH8-I"RY;]N, )?G>]([(II>:5U_O3HI#W%T>Y!>&Z,DNZ*<LS;^9@D
M)YK21].0-PJ?;TA^"A"(/H;T23*#U.'R=6GV+#:GCP5ZWA%3*]"T[X_YV1ZW
M>4$,2&<I\N(?TRFLZY!IKIR6'>$B*&FH9P[JQ4PL''E)[U>,AU)_O8JXW+6H
MV0IT2S<^,OE<.3;0Y[<L!XF'L7_/7TZTS?"6F;O8E1H+H!OM0;+51ONL4YI#
MD&(3K>/*IJ2SKQJBP,=$H,%8H"0J#'L4X>\U>.,Z</+B"7_D<=,=CA5A<HW
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M'Q[04.;IO5NM<OAT-U3B4<"QPT6#MK>IN:L:<69EGE4ZYO^*,:Z:>7/_'(S
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M/).+P-;3P71WLTP5$AG\P3(YI7OT6ZY$?\W52'CR7&0Z^)DSUZ?,KJ]MC7U
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MKK'[%_V+_D7_HK^GV_G_!U!+ P04    " "3@&M2/N@TTT\B @!YGP( %@
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MX\_KC]3#N(5)J(BX"5!)SQH2&NSG?@2:JE5AALS&;$TQ!X633Y:BKWJDX2D
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M.-DG,I<BZ'O\@MX_(SKH\CR";4W):4@HTY)>+'C*HR[H%4^MKFKI*)/FQ?N
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MQ7WTX3W*V!4\?0=8,E6R**!$Y]F-D+*4NV[UV#.7)\!C=S\)P[,>P=P$H(:
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M5C.+[$3!$>7^@.-PG-XBE8MQ)A6X _*CMH]K.</W^8\UJQ=_%]M>9Y_3<0:
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MZN[R^:8G!W^[T.U'<7P <\"WCUZTNE8=#YW_/A>_(R^-BS2HW?4-=UA^ZWU
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MVS1%!W*NGE3CT!%WRT'F:%4$_U#-I'F?]*L1UZ)/5>R:^\\+[4/O5WO("?M
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MRE**0,)"Y9Q2'*LX0'2/<**J#.382.D&P=$PL^6QTA(;P5G'2EZ8!.J%E(F
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M(\3)BO$_\OW=#D!,@.EY%D6N.@ 9HJY/[YTP 'Z_*]F54 '&TPQL+/VH!)B
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M -Y/9K9N)BW8S[CF^4])OO] V3;P4;LA*SZF0J15PH_<WS].\09E /O#U7(
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MQR_LD(B.IQ*<)<!5%)^8>$&SJMMP=S@(!WYI.2)CA!ITSI'9/75T]&V;R(F
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MY\M!=?"(@&GAI\N 3+;Y;*V4,%49^H-QX\MFI<QB,!9*A4>BZ=4?YJ,1[^M
MA_0NDUQ%V*"/!ITY*UJ&Y^HZWC[T.@'4YBQY3?O>NH"3JV1?Q341*"J1-OAZ
M*4524R]C[5DY>S1&=*9HX&GR%SY^[Q[I\$ \J38T@F"6TL%T2&ZN7+*=>6S?
M,5_*.@N<W$<:H@/EJ'MK5D= ,?:#;Q]FX<B;NHI4.^+!.@O1Z)"6-(NVHE,M
MA1VRSC# &?<6+CVUS]WIYJ4?K4B@/>7K_._&&I\7,=+1O%%QC1N><K^*"7R*
M8$>&?)XP_P6;DZ?,;&:\7*OD+"8!/!+UUJ4/_9CV^?O;Z4QVPZ>P8\(&<[G1
M\6#F=%DNGW+'D;=0B'LQQ1.VZKBY3^LDI5V@S4][O+Q7E2YA]>9T4C2BJT0M
M%CJ=0>Q+E_?$2O(-@QPMQQ@&26B[J]RD',(PQFHQ:<4E?<ZS9"ZA!'63CC$&
MH6.A8.#V]O%%K])E'591QH[X6_WKL;R?9SNX4K;Q-=.@(#/.&N..)7Y8DVDR
M9S 9WM^P!\>-V:%M$6Z E(M=*(MQBL0.]3[0?XS4$GRP(Z)K%9/G*0-$E\S>
M2BGI?2%(=! (/EJI4OHVSB+AVT]G\I3=8?)#?A<O3'M0Z='_<$;XC\IB[$4S
M<OSJO+,M^PTJF-O5P$&*IZ7"5ZD[7GB2,>YNFJU/5D):#A<^Y$#TC>CC7ITV
MXI1F-WT. &U2VA!G8.'3[PK50L(>KQHP-Z<[5QC-W>0K>=DR;_;<7&K9%T"0
M_D#7L5R[/LTCIM>>08^?6#/NU#$B[=&^2+<\J%Z#9E5(>UG\%4L3BP07>98_
MNT \A5K.& E1&B-VA:>(KLB>:]_]7$-_S0#V"*UCQ!V65M) PCC1H)\"/:I;
MG66[:*\-O[9RF>:.T+X!_-#?)8D)"\]%T(U!\'PU 0NH=I#@P%56HCZNYV.W
MB3JQB"9S.@&8LO?%@/B+:<XQ_K'""H)0&>;M319L7\ME(_,]_=?KC3>[6\\*
MGZ_;/]0?C.G$MM3%6X?NI#[QK3" Y[Q7_A8XZB=GUB/'AXUK\/K%Z\FK?(%*
MRY@+F3)XT:^^DMA,ZX[;WOD3&J!$[_!H](?Z<JL/]#G#USN2%PS)^'WL]G%\
MYN?A/>Q4[<7IAGW@7S9NY,$VQ9L).U\WA=+VG:( 2L(N$>:"0']8F=K^[KF'
M_'0"F#'"JN']T+X/X/5%Z%CX'!79O,E6<.S29.RU7.!,>TNG$;@)0;/TI5(O
MZBY]E\8\:-:@!"\\(,JRC!1DN_^U>.&*!S+G]#;0'[?1G4>PPK@^VL@Q%R+4
MOX2?-WO,%-<7K)%@5!1JAS^8S,B,M:FY))I[%CTQHO+B;H7&M)?N$4$DV3G[
M,VC&U:@?WJJ//(9,PEBFJ2Y,0174RTI[4SPM7S%8C _^,;GH5#)VO4(VKC7S
MC1VY1X$HAQJ2#GYGY3)*)8+9S&P=5,T)F>0O"!_2B1)A%IL?3G,Y&.H'H7-E
MKI\ Y*$@7M!O4]9]\(B<<F<@)%O;S71A P;9RR8BD^6K*< .H<;X).P?QP-Y
MZ:CS-!<!#SV0'_^V4G''1#.X'+N83!V4A_!7Y6XXNNHTSTLVF6!J@+$#TMTA
M25P#6A^K*L#76[@O!Q\JX.F1KVJ6"*NK_/L\@D5-);/3OXBZPL9L,=:-AP^<
MZBR\/M*QWICD93-&9;XN^ACFR?E+R[Y[-F%:AQ8_[T#U^QV [<&[LH4):26"
M;^=5MQ5'$+R9X470"393YTR.X($!.0'H!\.^L+#^-P=<3*.9,KZB.\C??QF!
MU:NF.0$DRP!C'J;0IX?D&KD-?))&\,J5N?-;.%USE!PG6F3+L>N>)0OFO]W?
M-Q,++/BXQJ23X.O6@S5N&-6=:A%04(W_SMXL]HY?.;G!R6Q:COG'\N ?I-Z[
M5179J?'6MB(-5G<"H. R:18_39%#8')&X<U4=+:OV^SY)2RBR\ $[46@"^PZ
MXH"X[D#K!$#>5V^^0Q:XE1W _A9XV\+*#4RM!XD%*\Q)3SAL:E?';ZSH"=]O
M&B.9O9$'A3=+(0-$P27+?4!Q6_-)&J6+/H\(=QCZ]0ZIOR^W*9)66W/.F]$0
M*'L"J-_%Q.'V2@@THL(.J(-G+P<3]FL(2_;#F_?364EE7F*'OI\ _HE3WEK-
M<O:LP8)+6EK;WI'M-#E"O5$>KV&W'@]ZN4:>,PRYU X&)?I($EY@[*\O0#5O
M.ORYO?@:.>T(]3GN"@2?ZFRNF2K3MY"R<#!]2AKN 88]V!(B^?CL?8?Q3!QD
M&?$'78"G2W/Z(G#>;7J)3-?PMED^#9FOL8'?:+ 5#S"4G_<]^AKS</E+H$2Q
MJ69F9."N6\77^!N1YT>]0O6_X!ZC'0-WP$3J'IG+W^ND6OVDPCT?\N[73Y%
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MQ3@5'/&:M##[DW\.OD.\_<D"999?Y<!L)?[(:6&_.]?GUF]S?[F%I*I$[\4
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M9+<4#^+@D9<D5SET[?;:F2!NB+<.^$R:%/?T2U-"-.Z^C^JFT3N)N0M]@?<
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MRU<:N_LQTS<O&79=ZX=#6D/;_^-.DNBQ(N"-AP=M':67WD>.OSII$O(._5/
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MPYIWH5\)J]$R23"N54%BRU;E\19PQX7Z?L+RI1JSTM%>&H7@A#"SU\IQ\;$
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MFZO/KZN9EFX V2>;-:%:P*%K6K182LZ6=_'T+F<S^D/9N\,-]2$V:=*6P!L
MT5]7R?Z4#:/2$NSVSE_GS%0W:EN?5-E\E&U&J(N'@J02*)0KU"P9VF(MWO_$
M7M?"HP$ Y-_#/OE6) 4J?>R$J=$ 5&54 /F)P-V*D]O_5)=^/)QO9M01$-'
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M"?P)1=XUKV.&QMV::9Q5^I%K^\M6AQLML\.-#)O=69"8J.%SK7_Q\TG" 4M
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MJDM;T"JQNJ[JZJNGQ\AJ7[\; &> VD4G=J<\9%DVRZ;,KW7B31M<A_OSV]C
MB-GIFI.VB%.CQ6B'DS\01_9TTL]Q@!F/42 E.OZNY62-U"EP=["6_K2/XP;
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M?KVU M9JHQ)"RYO9"@>M'%Q!6QSAS\8#[RR1.!_GD NC-;%I]YD"O(6N\-_
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MR_LL*6J@2N^JZ9]^@NS_7'D-EQG"'58CY&3_\8^!Y_YC(1[6XN+ME<(K*%&
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M@O^D@\[TK0PH[$9)LG8=V,]J1S?]^Q7FRV=&&49O LDQ0-P@(P:8M&CYH$.
M[=DKPJ\PP+I: P;X@H1TQ2'5 [4QP&UE&)J@'2TQ,:S(G(SB:N;! !D<V"&
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M/!0[#:S508?72PU*^9%\&(!U#JL%RK+3SJB,/@_]E<.J:ZHKLAK/[S\5Q3Y
M! .@;S3=AU9'H.PNJ1*P35VX=2-@!3JX!P82HAB LK'E; E+1<8;"CY#>F[L
MH>M:]L5QUK#J0AKI&9&&/$O  (]*-4O%D?2B\(V;(L'C/.@^R^0_G?_A^^W%
M56$ .JOOU"/6HURC]WQ?6^)@[7;RI::KE4<M6-5C8WE1)%V[;_;MREB)="?@
MV]34$KW#KL:>W/:FF[XM/U$**]RM*4^R*A;2T1U[/-#;QF\$?!\]HJDZ _>*
M0.V#Y>911$+@G0@%2X;!_K23PCD4=1Q;J'A8_/57S7VLJS;NI,.*++^:PI )
M;5DJ?0E5SYEY,6)-;I*A+S&UZ:[Z%00:"9&_(VZ$M\1R'QUDUC[-4CUJEK/?
MV,_QK/$J#MZ1Q""D[7$QSPN[VG.U<_=--ALZ617OE8_+N6Z=@/\%0PE36TK,
M(:O01*"\ER=,9)K+_0YG"-./V=>0:X9<R)P%WT>^*PB6S ;*(M)=PJWI$%E&
M 28EQ/V(I4>?JBQ4F,9#GEV+ _')B[W9!MO_O>ZYR?=LN _?RZ9)49[W\=W;
M ZU&]3S4P!G?9_>;I*K%,ECE)/R<#7&Z;'5.5'O@=#3]=U7@:/KG,_A(Q&7V
MIII\;&4]^@&%?W;,"&_9"!5?;+O!AHXVW?BY1\]Q/P(#6&(!=1VWOB7&:E^C
M.BX;<B8*SH;[H%[)L%WXWL%J_JO S/]=M?M5+(40&L<#9$S&K<5.R>4;VJX)
M^ DLBQ7!-I>#"J?!7X/9-U(2:Z-VO,YQ<C^KNJY*0Z5)>I?9XIR K 45N+YO
M)MMVU(4+N#_/:7;-FMD_\ECF(.[*K&_DLEG43HVIH'>G)&TUFP*I*-(H:X@@
M%GG2(8,*EKY%6VN:D_K!]?(&=]6S>3<I^>;J45^?KI1;:8L"FK-W.J[O2V<_
M,GN%-N3">:TDKP(Q3; <#K2<_GYBJI!A=^Q#<6H_MP$:_^AUB3BM8S10%#ZJ
M-8(28TTNY/)_\=SP_;MH7N\NM]%87CS.;A Y2K3 E\>PLGK<.M[/NHW=.M[G
MZBA27 D)SELX 8U\]CWX@F8J@]\J]G+.46(>;D_T&E#ZSC_?6D;0;@%BZ>4Y
M3"=%_S[<4MR5&+J4_=8Z(>1;C$+-KYRSS*,<JXE:\30>L$!+9$*W=.*NH)39
MV9#WEM;2C@2PU%P'SXLLM,$R8ZES(J>ACBM^+^GT!$NH"&I(_.^*OGP8R][Y
MG-<\H;?3;Q#%844!6?>,0Z-*,0"%ZL\J:-TCZB]51=:W? $_H*.+78VEWY')
M5D-'?:M-SM+C>CH9'O%S(?Y&.4.XNEAU3*2NXM#/&,*:N&A%L_I*3HTXY<4]
M7)P5.IR$4J>3>PCSQY%><<2.DEGG&@-7=K][O&M]$O"CHIB^[GR@.R?1L%"3
M/$=#;K!\\:9YY4RFNJA(WNPEN$+B=MH50AGQ55?.=ZZ#;Z/)DLWI7J4SKB*:
MAXL8BMSB9O.[@A/7(43BA;-B*LD[ADL4G(\>Y),@8==9;Q44'-:O/M+'K8G:
M;$A]IN*0);'.1DZMJZF(?RTGNQ/PD'%]<:T,D9NU)/$I1;.#4">6#FM$QG@>
M_I9OQ%#UI9RR[6*QW-Q\99%YB(&[6.Q:-=B^/%!K\8,P]49NU[E;5#S Y8'M
M:%";I=P(RIKBG.P=M_F>WDVZ37"^=1-#D(K &[A5^XYLZTO3X:G<P(@G\+E$
MV!"!Y"(98?NBU-&E</N$G60AV<?E7!^#JT?U]/ZV@<7'!_Z$B*UTRW00FYWN
ML+3^LIS7Q"<KD**7QU^I$[L]@1ZLQ**VZZWA#V6-<CLMM^;OH26<H &MJ;(3
MI2@EEIRI@Z6W'Q>#UVBV.:N592*=UM>[%IP>;@9(H_$*& S&"H$'T>0!(\.F
MS(_ 3$1:M^:WCPT1K8324_1?^DU^:X*&F+*U;V4'"!Z][N'$9A^_D/_E+L/:
M_/3GC]QZ&J*SH4.S!!-)4-CB8$= &LVLUF,_FUZ.^+8';.P,ZT%;(X7F*JRY
MK'F5^=64/D:4[]=4N"GHK$2BPP:E\I;JM)D$&XQ>04$E=[^1FP<EN=7M=(0]
ML OP,";>Z>_0Y.\8X7W3O)G0B^*[WO!\TMXO7FY?LD:@N[K^QI%0@ ["JVC_
M5$9HY,Y5 9:2%T W"YD@.".6%VJ-H%R<G7:^T36LP^M.,ZWH,3KJ#/B IL^\
MQ8ZW(.=(_F]BJF[T\0PT0X>/I"]#*P[:SFX'ZI>/)DUU9DTR,(*DX68!Q$>E
M]RHKJD>>=-!NK'[YN,RU?)!.Y,60 I+M/:#[UN6]]M$P*.YEU2>-E9FIN6[Q
MK,_YH$7ST@["W!'7PT&:F:H/3^RF/!A3&:G&WASAALCF)=K<WA<Q8-%DONI>
M]H@XCSWZ9\)+\&+)W(8_24ZK6G;GSLI+[3[*P 4[_QV.RN)FSEGSR3X_NR<V
MU37VL0*.=\/5<5F:GK$T.>"-!:X<!%9L,L?2R8U HQCIO*]F%<@9)30WYH,M
M;\%WL[)OTVK.T+GR+[XT1ELN^!0+M-#-0Q[[1FF-;Z<'?)*@J*0247]0X;.%
MLLH!_&7*O(B+KKYIO9RRG_W(8,7 7@I(S:W3!%$Y-22B3*^_ KM2*3DRC_;+
MWAK[3DIMRU->5$KNQ B=S@L/+W8^5L\<8Y9,P@!<GSELWPRX':63Z>\H;EG:
M8@ BQOW3O=R*^#9"9WO?K,@%-4N;/(93)9III*UE7(<_24WV&W'+AZ=9UL^S
M&8'I_Q>/FO]/I12$D'PI\5[.+\_70UVD^W*[_,%7F2[1+]*'_?[X3]$2R""L
M_E,^E G++5#X%,#L3"5G?#JT''JJ0_ AC=:WUNR#"4Q<HCQ*?<1^DM,7;D4_
M<-]_'SP-E?[\R;5]@O&-18P;;L]764H<B:X^>,H,FD) F&QFTZ/UDH=?K3L[
M3DE0W(;%;IKMY?=Y9I,S-R:=EXV'@P!Z:AR7G_J[/HX9Z;W<@68.DIE6CE7Q
MDOV0=[G!_YX. 6<)TG)_UYE39_1'K.R%E(C.5N+3+[@RYX9J2#<Q7SW-Z\U6
M.[<:SJW2*E?)/BXS;,3*P#)MHG4(!!9+2>:,MV22:@OZF9-K6ZFSP6'*Y@M>
M)WF@=LAE34YUGO"J"6_N]]&<7"F;HIJ*K$IPRVDB$*7OYO0T=R2A%_F;KBR<
M!W3 U:.S?:L7;/NWL-02W08Y%X,5_P[0[].!";)H5YYR^&IG9_58TB@?DYU:
M=(3"!]7KM0VCIN)N$0;6Z^WB. ?S(5#U)76H8P#+2OQTIWR/8^24]-R,(O 1
M!07\2N*6;Y073K6[.>8-<I7U7;Y><RYV\_-RTAPI3JE^Y=#A%M&'#U'@1^HN
M5M\2&W:?X*3Z/R702- =>5(-EBYV=9XPMK>(E:&4ORF=3LJS:%C\V2GESJU"
MN7 [';FD&H<7MK'OY6 98[>.RZ:["HB=(K,<ONSHZ^ :)0>RC.P=SK30,<U(
M[W2<9<FI/!!H<O\>?42S*;^>CI^9(%Z%HZ_OP?K>?8OO9=&3N\_<C6+K2E.-
M.H.QV/D"P=S'^[)S]:)TF]2XLZ7D^XI'%WCCLLZF00C[4;\.NF,4 U2U5"E\
M2W/<1Q7/UJQ)==^OPI%/J)QJ^[;:Q\[=T^5[N&.(TY,.7 :^'.;\M O%_B['
M!P$.HA"M;EA^&(<!5(0\4TDQP!L>+#<L)80<XIC/=Y7^7%T8 5W05X_XRF*M
M4C(T]!H&&,('G(?_L$BZVE)%@$J@P_ZL!U+LKY", =BCA,\6TLX(2Z7^U;(Y
M8/:/LR8[)QO;P%.FI?LY!<*=+/Z$U4QUF68?^;._ :>J2BEKP;,%::=15AA@
MX0XDQM_X7B%%9(3\36X)JIT&@<73(R$]J2@2TW-.="H;"KR- <@J0>%5N?:"
M_8\IN%+5)P72&$(+7A1L;[H\L'MW8680JC(Z=[PB^HJ0I,HNSC^KQ+?T/AR=
MYAC@.[@ZVY!]C8[[%</&8:$E^VA7P>+6.>O!EW6R#/;(@W/5N,XLC0J^IB=/
M[-Y)KU=PBM]![)EGR1;;=GC[RS<55;SB/G]0R*Q)F22H?3\Q#-01Q12DQR*C
M):9/I_]\.&\J[;78SHXQFE52IJ9XL2\@X@!449RM"3UYAS\-$7%"-V$ ;G#[
M_-$N!CB7![Q3O/:.PU+,"1]%^, U<HR#+Q?_3TH*]4^9M"A"^WXJA$K5X\;'
MZ:;2R6GQJIA:\9ODDT%U"EEI3L=8:_PE8]"VI7CE^.&LJ_9H"4?MI.%BK+G=
M\4:L Q[3(OI]D14R2WW,2*U^9+&B>O]&]CN: _0N0,\2%N#EU_VB.B9XRRR2
M:=9#M2$DUJ9F%GHA, )B!'XF ?A/[@WT_OH"]FMO $MK?_.4D"M<ED0%^X+0
M;5$8((/;__-%YYE1(LI.-:"%\(G*$Z>H3UE23/%-ZL&;%[PXAWJZBJQ&"V2G
M_,VWL(90+VJNR1!:^T6W#IFSK"I:4?!>I,-K=6LL'X<W)UN>SPN/KJ.9JQS>
M_/;D9/ %,W]L41"^K:_ $FG:,HUOEC[^2F"5H$=WL8OO\WF-IM&404,#!^YE
MXBM%$ *'.::A)1&'54OUF_?JI%V[&M/S@TP.E \.@P@GUBPB%^0>P8^@=PJB
MSLWB^&TRC&^N,$/.MH9X2Q7<] P?6]+1&)'H3^MY/\8R/:*\<,^NV@/B"ED7
M[YTTI_5NZLT[6LK*)A2F55M:8Q\:;:BJU0]+%<:"A1UD+#,D8KX9@<7O/2AX
M>7!8',?JZ!^>LU@?F^PCU/0=Z F7"YS<) TJ;-\)Y"[=-!P")U-6.JEZ=%)_
MOGG;=F:NL>S0L=]#*Y)"RRF(+=>JNV #/G>WI(!_U\#MN4)F"5:F?&-RVL5^
M)PW5HT&1G*O=%(HWVULTCD0GZC?;XYTYN(HZ,R,%1']9^Q*]A&K;?&-3H/':
MD1"YQRJL-Q"Y+:51$*K>O'9;[Z%L1P9.!G8(^6'Q'E))SA$#W!F;/UG   @#
MJT5A5(0<E@M8T_[::= (D8.AR:T8(4-'H LD"&7@@18=A3Y>V"-3+TJCZ_/D
M>$/PUD:@49# 8NYHQV -PH@!5C[,8@"80\NAJ")+29Q<LC]WV+=L!NZ:F.]G
M\>DI4!E#UXB6%9.1EJT!M@O \--?/2!I-'7!=E5NWA\671B\UR2\W[/K98L0
M;*D79F;N< W8JL:UU\"B/6?L8@UE-3EPXIPV!:@4[QZ4PJ,Z6[M9VVKY[MQU
M?I4L?H;"2H$_]NE?/9%RPZ67?'-T>A8*^9@I]'25M[\,C'AJR=X-6QK=L7W&
M$E6FW*5>S,C[^>W'3RN[G79A1:[4Z^ E8;+OCG./DW;%F-^=Q\JP?9GHO)S]
M6#33][:0<&O:Y$VUZ\),5QYQ[HERK1WD(IG:5-L8Q4S5G[J4L-X>%*47E"5K
M:TB1U2&0=UOL_M!U?(8!4G';P2M^QEL'5!_1$D,BI#^3V+B3L.2G7[W5<..]
MK6C*1-L< YEAK B)9OYD>\'&P91YOJ_][1(R-\-*9< ME0(N/42+*-UC/%OR
MW,<KZYI4>=ITH;UFHHM2&#L<2^G6A%::,=@]-DKY+O[&19J=^6"BB5UOB(#[
M\2)!)8(VN2"H])N9@&'(<V@])\. 4TW.@J/P7O566".AA-H;@._3!XTTJV-P
MM;@. 0D&('0I^#G\'%)>N%DPV=76F=A^K\!G9H6R:EV#2UQ\F_;J1Q=S]W<V
MS9AK0@.SJ?FJ57R981[]PLN*K-Z!>/D;HQ;=6;,FQ<7?BGFI9B(<HI@_,L,<
M,S?R-$;2*QWO#3(N9G,RQ3CHHM:Q^F-#&1"B?EOU;TWP82"OL5'D.?,AY^77
M815S%9D:68.O>9_-A.;>>ST9I;];GGCS\>Z*5SJ98 4"BY:64ZY%XL6@[?AX
M&]))J4NQOL>E.B.L:"W^V6IQM;VK9!(Z<";F)2BSKT];DA 7!4JE^:7 Q\Q4
MG,'SZET%)C4;^$6\DB_L#>%;H?:CU[;% %A7?2X2,.7C<_B;TUPP.:1G9AF+
M3%<PP/:@9;6E)CP4K3+/A@$FM3& O?_1Y[^X/7[S&J3R3;**>HU456^IKJR)
M[]YAM:N9<R26?%QW2+,QOF($VO>82#LF!/6NXY6@NQ&#%R3>;$@LW]E>_UN-
M#67A=:A#<.TB;CGMC'$;!#<$(1M Y2@/[#RWB$!?[<8 =!9!U#@]$%OD&CJ\
MD0Q%$X>^$;<-8<9.>9@U!GA>C@$Z85;*@)]D%.K.LO9E)P4V]:,/3)/5 JLU
M7F9D@I]7/0:6MRQ@T4>:371MC$E9-CVU.BK$3[;JE00).%M,%YO%3+^;;RH0
MB2@)9LH;F'QS,'/XZNXVTDCVT@TZASN^'"GIXY!\-8L+M34=(G C83G"P!6I
M4856@:S08MOJ<PR*A:R#RS! JS$&6-HJC'N97(N;G4YZYYRM&W0H,0E9*((@
M//^N^0UGO'BO_TX&;)-H:2PBE;1C 'RL0HLJ:8X$EM,T$%\Y)5'<A@0./&Q3
M/R]_AER5,_CLV]ANY--0V79"/B?';Q/W<!K80:;LYF( 79[SO%.L[L7!\CM)
M/0Q0]K&EUP%O/$+#]'_L*N);G.5@/B3U'"?",*.XI.484MWWPP_R>+8V1/33
MW'@B!B#>$KX@(<  .)!S_I,4 2??R+'QC.NOBU+7GDMN+W-&2[[J93O:P@!3
M1O6.$VD/1X4$3_;.Y?AHMVV]Q_% .2:9N3GJ8SX?ZD9JOOB[F9]$0/D((G;W
M\B*QXG%\75% /TG&%1P(NS.7D/*-V)FMO<SA+#S+ARH)/'6OB/ \CPO[[YSW
M(FRA".7PFE&: +6OEV9.*M,0Q0.'.@"?HXPNEF=SLZS_RDWZ9SLB_U/GY/Y@
M=O6LW'*RXX@P%R\3N3>OLB)\\7BB83E&";X_)\X9032N_*C9E*K-(+7-S3:_
M^PN7W69"%1D4*$:B6RB>' FQM8UN>%.T]3T]Z Y1YZ1?#FTM==FP9%EPOM-A
MF"HR4EQ2S;<[H_.L1%AHUC>$,D?[OI3$+L<OEU12LR555$(3&%T'V6ZK",8J
MZU[QT1:V%8%_<9T7K[F?X7,M;&+:JRA9TH-+)W/U?:P 4WNPQ##T_B,SHM=V
M,2]YOU/**TJX9>GI>FC>%<C*2D\1T]6Z>8=(G1-?F8$K-9$8;&1]O::VGM<^
M7/H62V^]TG20LJ9Y-!OY(=\1J)R[E=3,P2;OT@6XR(@XX^T*:^J1:$H XWB&
M84Q3MK/;H4VDV ,[999BJ)BZ^--,=9[Y1^:T9V-CNHI7E'+V[KT64VF]3Q\:
MNNZ QZ8_(>Y0:COJ>H.=3J] M&/%[H*?C'!&,86FZA6QTZ3<YV=ST(2.%F*)
MU@(+IY/IU88LV=XU4<X^A@6OP[QU!5Z8T+;X.9$KU88#LY_;*YO :(COCZ;(
M=Q)'GO!]]V:TBH;V!_TY?"&=X;#UD47&%_!!C[A4-:7I>8T62]EM)VJ]$4:@
M'<'V,@N.TJE*HDNV,9R)<JA]<U3">M ]T5_B>' CHI#C;LE5IB=4'ST9CDOU
M[ S9;H8>T2S.B30BPN(ZB)P5!G3:O$%V01^!#CNV/)IJ0NE&\_RL(93TTHS
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M>$F<.UH,/3'J6>\9PW6GPI@K\'1P4&IG+-B@'L%SKVD\4-85_^UU$_QI:9T
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M2D?F'\UJ=0A^\KUO&_%@3Y3B/O0J]N@6^/C]%D@<,X#.;I[8M$^*IU(NQ;:
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MDM10GX/#T= >JGGF:_=CZLQ<[.!^8=PKQ4</V_V^4[6J19WI6_M5.WVU%.X
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M&?E9">,'L,"VTIY^%T9&00K57@2."]@![,&4@-FD\^/5CM+4K!=?D101^2V
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MUS_Y2)J14RI[(C")8&[H3K2^\4VG98,!7@6YWN7T:DV!-4[PW=QNW0)FQN#
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MM/AN'C6ZHF%)WKR>H;;\ />'$69(&WJ*E9*7IP7[VF$:;GO8:-L97ML8_TV
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MZGWY9I-A63G!5OKE7P-#5JHZT>M@M:D=%WXSMT#H=BW?BWS[4'Y)042EPI&
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MVQDC]F:0^O"#WDW#LYOR]0N]*Q^6ABT?R#I-[=+)'1Z,TK\%CL_QCJ$2P[?
M\F.CW^7V;H'7_T6R_C=14K%!P-G1XMO&5"*')1M.ZDG9.]1NJ,I4/6Q[JG9S
MSGW\ KH?W32Y6V27MTEF'Z4S77^NK<V_?(V2K[>?47O_[L7R(/L,<@?%0<X!
M,AIT?7D(&TTZ]SH/X21$[]/7JX8?_6CJX?M[5\%D<M<N+;^!T!)D0<(9[\9;
M\1:8_Y"ZI'-=5.;H^'/JS:NVARRFG$E,)(3)[\,RZ@K?K:[N]EJ3WRV+X.);
M8"QD[@(%RIY@AC0JA5L^*C@+&J;\Q=1YI&;Z]!9H?#16-H"F]E(*K9.*F: @
MCQ2-*CV-WRB:NX:[[-T4)(\>HZN=%UG8*0AN/1G2<'9JCQTL'E^4'!5=!_!T
MZE)]J16'D0=Y8)ZQ5P44G\F-;4M^H@ '@Q2>*@CI3'79TD)8"?_ 31D':L/6
MENHHX2,:+T)Q@-(/L*GNU25"N+^E#RL@&]\D"JR7Z9&D9<F$H A2?'0=FB\H
M:#L@RLM^D?4B)^LU61F/XD]]BA3YE_->?$N(ZLL^6MF1A^4KWYYP7(\Y-WU"
M"IF#M4!:)+4%6LX_9&M^9].FX:)JW$UEUQW.&^> 7&,^GVN&GA-9-6P=RBV#
M?KEA:; 1[<R_M<E7,'S. [B&W!# 8*H(=I*B'Y(1L,5<]C[ I<8TEFR@[5K!
M^M/1/8UBO@ZC_+%)[MCPQ6MS$!,,9+J<8I<:LS6BVC[Q8G+CTVN;); D\2KM
MEA1#*IAE@"M"?)C?PO@YAQI\0Y2*V];#=N&2_+$9J?5.@8)5C81&15C#_GVN
M&=UFUA?P#L='(1+H,=9DWNM$[T_$A[=U+$>+]&EF*MX]Q(M =B*WWB6HA,R9
M'K'J0\J8-'YY[:&F"=?) ';5IF.W0$E9ZO8$"V)J>Z-6AI1USS=2@^HI8JSU
MM(**%-8 @Y6&?!FQTC52\ATE>#(&%5PB7%=HC6@O:?^A($XH.O^P!X)M^DN&
MKB]'*YY.OW]6O>?)]" &LSV"C#$$"?*+XH+KCA8M?7]Y.))KT&._FKS JCH\
MR6JG465'&-JV\2XR@)KYHY9PRC6H-%H2OO)+FL_R6=2,\+:%ES>2\"E\^Z;C
M1.17LV5).%W[*X.-82]>+#IXD3"3)B6Z8:Q IZ''VVZ;C>:H+Y&#JS4RVN#[
MM#==;D;6BT>#D6<?@U)Z).'(Q?;^_@>DU66V7C+:;8!QGZ63R\*YI56\\!@7
M=MA0R(M%]K;/-_<1R&N!%E".WHR8F9/Q(4ND-J]X^Y$/2OMKDJNMZ@[N-UMO
MAJ$F1[OVEV9&-Y?O,$64PDSOX>&!#71+8W=84TC>]49RW@(]*I04;F1CV1($
M-NTEK4&!&0_S7P(G!!?_01Y/WSL)#FG56G<0^CS5\G4A<[1XDHV7JY" YI"7
MSF&QCE@!%G4D5PD+<O21>I3?72>?LEC[MBV%%+:_^\/:+M\9KFCYUGI7D62D
M?M8#0[8,9<092V($J:/U<3^F.-&:9E'Z2[S&0,6].HG96LC"RDSY7B!!.)$Y
M,6=Z] FHTL>*PFZXSO<WI>?J,93B#"):1^1TNAE',JV@\CWWF)="M3T^;V+S
MA'UV7)ONY!"[(.>M*(D>OLAR\M:?J6.L;Z2R_T =H]GP/R\D_K$X^/%_FL[G
MW]E4Z\O";KK=I$I7>OW(S=;0"T=9-6?=BAAVL<P$JY:_QO+<;'2@>PDJ6N/.
M-7V>I0Q>5,E4Q;X4[E6W5F&D%S[5:ZES10^?E]N>(Y@T3[7DT!@?+RK*I/M<
MB],K5Z6@^_8ZFD 5WXQ8&+W>PV7:UV4UB7@ +WGV.Q2R/YH\$^!O/R4]QF:'
M4TWW)>F0 +4/^"Q,=V;&N@H5+EWHL[+$4ZBD;H@55KGN)"G$H7TW9*^'/ZE[
M5M#6HH-(]X U5@IKB&PO)R&H0XP/% XHAYWCRYUKA5;QGB&/926J,!R?K[7P
MNM/<<(Q^P([ZV':B6D57[W@UYU9OBCH=\/0QO)P_PIXDZR]:^?]TFKJP_:V-
M(_>/Q57^)@9/MT97S.X68!2Z4ZH_^EZE> DY_AXPNHZ5T14X^EU2\._[2V>%
MN2%=+']C\FCZH\E#X.69PHDV]95Y2F!"$!.4Z7+_+]8,M4W_C)OJEIOZZ/,Q
M<>*SW(.CO5/,U$^*BL-JM9X?6 E4P%M9O\JB%B*3GG:I4"0 /T6?^G#@*2C;
M%Q'+#!:ES$G_\A\FMJ.ED_92/^8>N 6:/<#AY^AZ?Z@_;PZR#KSPF-8U).+Y
M]8RW\[4H919A>/K6 5C7),Y24(#_O"#D=S[5?V-I.QGX.RY2]5N  )EX;;<P
MFY.S >NS=7K1%_F,U(*7L<CJ3'<2S/;0[%4%^_<U_V&FY;>CZDQH\NCE?[4F
M_V6E0K.3!E%SBP6W)BNNZ-E,8'B_/@>-6UBATIE0NU'[*0_.CSEL20>W+((+
M/K[("M4/>]")HNT]8I*6AKL;M";(DSO3S5;$MB:5TJU$/<EOC4J1TCA:)?C6
MX.3X%XS5R38U^1GI R$I08-U4U3]H 6V8R'S]4W7Y)C32+/LSJYE-$6&B1[#
MR,C(#9W0F,X:^'S5QJHXQ:6A_/U\D$_]:'D\7!'!RE:;*/-*5:_4 NW]D[V[
MFU/-)T:(E4:*=G:+RAW@+%<_:/F?EQ()A2V$>):A#"MH&X7E%&]Z4JGOA&U%
MVUOVS:,&-M'V=GQ "CWWH%E3+#G@7#^M]AYYG/:$I3BH,(?.8 4P" *VF-+L
M_R\H@OKW&O^0&,  ZKP"4V7AM6%AS3SL1^P>L[X\D&;"5F,=-#B&ZD#ISC)R
MR'4\!_2"6R/6CSJ(8U.?.7G*?<P),T5E6!WKJ-!E+S_ 3B$OQ]=Z9_"52-NA
M@VXI)69KDK#]AT-FTZL\"]AI2%44O86?B.81-&#2'UH IM$0-"/*0I.^['F+
M*7%QZ%.G50>X\(2YB_U8GT1>>$:#C6]H1I[T))A)8I$M%5!G\^9QN>$X-=??
M@Q?64IRX)F5+@..Q?+P#=?UKM/;NG8$5:J-V]Z2"M+[B:K[IB[Y 9,=GJJ_#
M].&R%>JL+58/,&E%0@$7ABK&-AT[L6KX"ZX"%,)F"_VB?L[4#95:3HPV-FQ3
M>3-55Y7@M[@V.H?@:=N.WY2#H*E;( C6_ 0G)5$8V>/M_?-"16XG-3@5^0#>
MP'\<=!]P$3D9:!NX0#.;2T;5.+L32:*A C<74,W,-#PLV-G7 ZJU5KCIXXT3
M]!O"'@9>ZO %+<B4"/$=BGCZ^[X",@G_<C D-"&V@C7C12J+(=T$"1_& 50A
M#8_A9N*_ACO*N#197+N^Q[777V<>!!SJ_?D%1&">+R"#M+)7=T+Q3G+^W2>,
M[YZP_L,3F/!;@+]"Z!9HDRS\F"(@Q"]E>'F -W\%AH?2__$[>N]T $;96Z ^
M]T]#B1Q!U2F935&;RQH"4_&Y+3\?29;#"W5W!XV5:4DVY@Z*!NZ&_GZW_\63
M;P$/E7 T9VLUN">C<X!239GIS@N#5@[\EQV@LY/_XR_*TC%87'JIMYW,:[A$
MAX2JIPUB?-?;I"8LLOK@>,)OV>J,QKMXIY9:7-VIUVGBR>=CA4&\?_.3:5LB
MQ,# B7CJ^5B1DM[N2TI;42KB#/=W9Y'%FVHG1/P.(='C#7'\D:%% V>J:W^>
M5+G]I1;-^O E.0+=N4FN5Z=.] N?7\]R3-^4;]JC+#?<S:7(^N,<3WO(7WZY
MZ$YV2E^7'MC=>),YK4G\>2C748+_LR<HP8OS:,FTLAM;NN4?;-Z_I&Q*P\/>
MOP5:1;X*TX-CX&67F#BEV]&T)-Q5UR4'3K\'NSY6K<<_LU,=M.+.'MG11!%<
MR>C"L%D:KA/V$DS\\R2$_V5)YS.A=D'^/ G6S9-QK>2AGPP.T%--<"(I:B62
MQB!208#F?UID_2C4EC/+F-76VCG*^!K/8]])80P=8R[>K A0K!X6*5FI^N7&
M$]&+BTKAT5^WCMK+U54K43C!>G0E45[F0AJLM;<J+-DQ"S4=1"@/L1*YM=5%
MB/-HXT;9(NK=W(2XZ1UN 3_(2X'PJ]JE6\ $ZK%?^7HA$86RI%R/WA;3XMM2
M]F=3U%3J1T1'6@CDE@R_AF59CY.+E=0Y5GYT10[\"/IJZ$HLT]FW55-LM6"^
M[*=T%ZPEEP%=V[YKZKCH,G5GX']1]]91<3Y;NG 3$DB")037)+@'=TEP"![<
M@DNG<;=&@EOP! _NVHU;< G60./N3@>'!B[)[\R<F?EFUOJ^.^>;<^\?>RU>
M6-1;[ZZJO9^G]JY=P3-GD,4II6++Y.QOO&)2I\P/$OBIQDX+N*Y!)MT>>=%
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MX30542OCC8$ _Q_10M%O]8+/ACM%K\CR[JDH^AW@A99Z)RQGG]<DN88UDG!
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MUD;EA,%YBD;ZW'VVDG 1"<=IG7E,/5U)^GL2CW+KM.'V:7^ 9VHYTL$3\$A
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M4<>JEBQM2]_#>/S]S.P_0W$8)578*#+:#WH<)#6BE0(17"AUS'N^R/YZ4I'
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M/XZITT F>61D9:%23'),=;3CQ_:A<9_]P_I+1R6-E/[-1XG+;SF'E>RA2O;
MD9@T_J\_,0\:(SV4!>&2\V64=,S9/JTV:.;/UV1FQ$)5%X F,#Z:<&6PF[Y=
MLBO+_+(3U_$+MYXTYZQ-M>Y@G:<$L"=]ZI.5^<ZQT Y^1FVWL= 5S&8F^W26
MZ5B6\9:RD>UO8:ZDN46.(O-HJ:_U$9 !0[/[$-P5,XQG,I*F,X5.\)RT^@<N
MF';'U[VR/XD*IQ<RL):2AMQMJNJ;[<\LZ6W5W9F/G[\:V-*"J*Y99ZSYJT%5
MORQ4&&FSV2\N);Z*R^7(]CFTE5F? #$5W,I5P<!SD9\[4U2<599P9'&WI,A0
MJLA#P C;JCO-M]F9LE3.\#&/Q?SJ_*2R(Q4/DT.JU']]IQ'S0[_\? KQ-U'C
M&97L0HOK^%0FB@RO&_F7=/IU^IF158/5NX<L[UWXEUM:9)[>SK\6&J:.D4XN
M6ACR=G7T*.YG^W3 2PN /ES>ZXM;#8TRW3Z_ 180GU//:D$.D9T02V"=F++K
M0N^']FTO ]'71#< TSRV\'##H$(6EYP6,4^[:Q*)C.N/U@0QK74""UBO/OJL
MU@<G24,!SR:? Y3Q$*D+'6]IAMYEX5:,I&$YQE@#[P6;?C^E5/>XX8'O)")(
M]!#W2@:*%C?](Y)HJN;U)&$C 3=A.O:)G\<JD0:3G'V=J:J-4-V!2KZL,G/R
MO)8LHS 4C61R?CM9=2"D\KG%>I&,&RQB-RZ),0%'M,E8(1U)_9_^<:,:B9G?
MT"@YKS T>P4@Z_G"==/-/A>A9_^>M&1EK>\;Q#_1R'W0NQ@P)L[=Z,AN.+O(
M3YEP/T(85*0RZFMF*'_;+>5KZNV4 *)F]'*:A]!W+WE*8\[%PSDIC79GB'S/
M6<=]] F]6GF83MSAJY%/6S-1R_FW"\#A!B#E.>VDF\>F2RDZ2)096UE$DS_F
MCS[>-ZE>Q9F+,A2_'47?52+?<; AMJ:JT*"B_TZ37#TF%GH;]._5'U+L9"/@
MB%!X4DDU;-&0_T[X],-6C%P.*;@[F_CDD'!%K41HH[^PY&>KX<YN"A[F=OVT
MHSKQ?F%W%=6D-]<JHEXQ6;\DAM&AL@UW2G*(G8DA/G,]B#N5";8&J%#7MFAJ
MZ:)F#2H_]NG3)1.H$9/ZL5)[TM\/*98Q-T#0PW;*=BJ<?@C76G_&ZJ^M5M7(
M0RA1$'ZC'@?W2NF H5,H>F=: 4-=4>;?H)I4RJK"Z@YPBAYB]>Q499DUO-#"
MHY6%XF814#7AL3<I]:%CL!L@3L]M#4RXO4PRI9Y=3/!TM$/)+7%_Q\%W.25(
M\KQOY=X'/ZW*2BA!J5?ABB/AT0*S/EGO^[3;Q.=SBC0#YJWX?FR9IY7^\'#B
MU;4=RZ>^R'&?$^-C)90LHV?(*I$_J.\B/,*B,\6.3XZ 6A9W/60.7: 1?H:Y
M4G"F]>]XPQ\]<.8?XBQV.-?N*=4R=9MR"<U=DVXC&EHN&K)_+&]3CEZW[I7+
M)IW2EOKQH.,TT,5?9!HKA!C2C/L'WW^U83]]W[O93D/U/@BPL^-7E;WSKXWK
M_]W0=C)&N8P7V>+8YL57X[&C=F6)% 2?L;&L^VK343%2:_K?S0%-JE$\$26^
M>S%U $X&>*@F=@9P@B_HC2=P)]5(BX/D^GC^?9/]OR*M\#9*OY#=E;5ZEVP>
M$!9$_=\/XZ, E9;*/SORA3.,U$!6[]3FO[?\U]&!H'BB+$N"ZNVW_[@C3)<O
M"&@IZ_.Q!TG]QF<.%P3JM=)?WW9$@0K0^H]0M/U'3NN<Z*+ =CK@064=!7#F
MW2)?,"WG3EX4)_"_'8DI_VM')_*J*K+,.JLF\FK.8$BTO/^/(6Y.P[>M[]9S
M\&V<2.TNP@<TR Q6U(B%Z4/7^87AS9^>65RLIV])@PLHKA0P!5X4A&NV^A))
M0?E<HS;S6#<S]'[H20?YK&"%%ZRJN?)]<@BO1.5S6[PEP=N\ME?\K7ALYK.4
M9:UX)6<+C=G3+TQD:AF:,QSZ/'ET-O;K'0\@(:_GKH2XMEO>BMLD\<?:L@*\
M5\0)05P,J*V,&X"0T5>$ZE+;&:_HV9(M'E<OF$[0T0'FDUE13W/V>I*<Y.<7
MJ*4DRLXPM3M /+PGF_ D4T/7J PF!>NYU[ Y9-VO"K9O1 KDW  ]T7'?I =Y
MY@;[^3L;9!CULLQ*9>K./BFQ>N"JG&S\QEOVJ*(U^)U%P<R:M>S-$U7F;1>S
M^%>="_P&6URP;4HQ+:D@E?D+VND?$47ST6/]>!_1/!XA B]>]>AP8OM9TT^Y
M>3F :.JD9@G\E$6JN*$&)[PR#))Z(X>M*,"&Z/BJ^C+\SE&.+CIXB\N3OR)6
M[IL=1W^G?3&A**UTU"FN>DF)]FA<RBTK><)>A-H4C-5THN_G^@(1Q%S'HC9<
M&W.K&&8>8DA+T2TFAHZ*L->3&01<#*(]H#\U(2'P((G#:/H+4S_!NEG!C%_4
M3RKS'RI_*^UG8(NRSL!4O9AVWY>>0BY?NY,_'?(IO:SV']IL&K4S#AA#:*1_
ME%X:#Y"V/SSHK)994R!9L;D$SU^_1C%;2YL-B.: _(S@NKMK;3ZQJ1"DF*6N
MRKN/;?X*CMNF3ZK16S 3CC>S!Q%O[+_7C(BQG0JM:_/T7(_K=MBRJG4?'6\W
M3?G)BP2B(R'W7Y1N_.$*$;EHGS=V.LLA4YF\%OI-7U3(5-B7>?V=7<(B?><9
M^;@YOVDBH=4BJ=SZ^PYWC%,F!N_MQ%[NW(&?D+,UW6T8LHH.6;"K@J!_NL'6
M8IY+I%&HI"">C<4TZ^\SABQJ@O PU(<:(?T=8-6R)5VZK+?DA?F<,1W.J"%&
MW;E(:4[;#AH,NSAO[H,N;RJ1[SD/& ,""UT#J6^ ]7RL'L+V!CAY^J6OH7KI
M>H*>T2W'O2>SN'B)"@=N:T;GSN1L:L):X<Q=Y!:!V, -EZJ)]:Y2V#=EPKQ?
MIKU^A%6WC*16:HXQZ%H/@@%S37R+8#E99B(,)=)J(ZZ727J,\#"_MJ:) **E
M:--]#38TBY3FMCL%W[7'J'I9.(@9,'.\+P &)((N=&Z 2+,C?3_6[#]8LTTH
MN/];(JJ?^4&45C/]6WR?J_X@<0>-&&EPTUSN% )^097<H.3UU#&F?2!PJL7Y
M 79%"1WZU6UEV&#C!M#!M^#CF-#[?N7S2510C2DO1K-/_,<#L+NOG@B&">J)
MS<CSCS#RO@&LXO8V]ZY_-VA4^0 GA\1^1A-M*B45(49+VW.\KE1>D?5#)WU>
M?ZJ^7VD50G:UYP13,0^VPATKU^*%FHU"8Q6-CT 5_E09GV5%E@<$<3:G_!S1
M5WJI9\XV_F=?%+DV?A \CP\,!_V9^G7[8'8YV<UKPZ3/[2Z".U. *\L'9\!^
M4YK<4(ZO-Y#*6(6BOJ8._[VX7T\^6B>T[,I[CMU6LUY145V<\?1B I0#$4$Z
MQ:!42_=Y<IOJ6[\DW1D.ZO7!Z/J)H/9E>A%G^04+AHM]/)^C$R4S/&M C.9S
M67:N!8'UC@>]1,VTW[TD2#AZTBC D<M/HG3OLFFPZG#@Q_0'2=V;0Q)D>Z&:
MKSA34KF\"-];27@RXD*VI,J^9Z.R0DAF-TJF/>B<> KY:?,5'J%=$\9?;;;)
M2(K(U#OEH95K'P\1O-W*+,I&.\%I,%M1O*9"S\NGGM8P$5P 4W"/OR)O,..A
M!QNIAG7I>TKLNH-OE89H206NRHKF KALLY@P_)-\J\T&+YR.=>3>]+ON9O<T
M'8*#.NFN>'/,0;+\TR4E0ES*O)VV94)9SW;*6DFF)=0 3U-Z;&<N-L[$A-6Q
M<J_2&"E37V*R-7&[;FBN7DU*LHHOJ"<MFY*W[L%'FC&[V\9D<?O(.%1JZ*-8
M(;U$G<6NC_/] L8SQ7U@=,MI4BY/Q(Q7P.%^KX633+A,#. K$G+-9KO,G[#:
M:%#!=]\2L5CYBW_7)!1"D%J K77^DNZ96[G\6\LL'T=0N/%>K;C%9;N&_;GO
M0M/>!U[>#:2HA1WM)4Z2+#,8DZHW*Y1-^0OK)9?ND?*+>)K6\JG;)U_F;T++
M?NP8-DA(%WQ4HL[$\'K39(MC _6XC4,=WN;HA6PWZO4A2'J$:;8.+:3NUR'*
MD@X']%30(?JS?E*HRQ@&H_J4(2CYIK<V:QS)PCU?Q@D<#.FT[EP CW3<NPJI
M(/>U@B;+:->LV:0*B$5?%BY4[0.D?_EW[RKA6HOW71E%%-0><M@ST"]#KYYP
M5E7[IV9K]%<K+?[)X$EE0"#P"\(V0)UBRJ7",67MO+38OP!RTC ;#I*2'P@0
MG]V7IMKV*<Q@\&V7Q6$/\A]3#!1?XY$D0P56#U3:23\-N_;4>KJ@X+XQ)(ER
M<#5M1E7H=2/TPLI/5N[+L=EY093]OC7>Z2<S73'$_'W3$T WF9]D@*Z*<]S?
M>+G$U/35^[./C9=93Y!T,#H47N.QEF$@=*D(G4GV_!FMJ,*$1;:!!@)8X:>=
M]#OB14E2P]LM_";7QJ%O@_0D\<8?MW:27LEURMQQ.JUX]<*9=<69:DP&+DPP
MY:^NYBW]Z5HF7'Z&=5I21JHOMKQ?Q5+8ZOSX5^<]X"(.)OXS@ 6]'UM,=\MA
M(Y('3T37==LAQ5UJGFL\SFW\)5Q];C:L5K'JM#8281(6N.V509)F?2W19RM,
M]<JCZS6&^]K;F_<S05K?=<@HL:EZV#1D%5:AC4<PW@X^1C*Z]T'/95Q32105
M]1/;7F#BT$E=O_1\3(MQCOP' 0?MJC9/\ERW#(/!<&T;XM%%Q(9;UWC@B%@.
MF1)&L0S<<P.$#S=4L)^+DK^8:OYXQ*S"GEWA'9:-/D>*1._-&3?-Q>0;DXPP
M)HE32-RG##9I[/^=H8,6BBVUE-R%<*B&65UODLF45'3>O=)"%YZ'[3.C=*%U
M:6SWT.,LNOBDKEGU.(-^HACGB'H96C !I!"AY,2S'M!&?'KPC,SP['A :)7?
MX3[D$-60[5W I6)C7FAJVFM^?#+4YWOL#[NEV/PRC)+2M<O=9PS'4G6._$\)
M;"[,;P#QE&F4<UCEB5U5BD1]4^29?T21M<6XK.C^KG%GMX,RN)_Y<1/DZ\\J
MJ'ZL[*@">JIGXNH=AK@(GX=261.5RP,/DJ+I#J00#*0?D:1.&'?P(EMI; *D
MI2 _.IYBJW(A9EK7X_S&.S1?KFL9%!:'3D== QAB+/[F0FLH[CP6D?19*^TD
ME!Z] >ZN1';6"P?:_1FO^WFY(( (DF+K89:9O+*,Y394KGP/;FOX]E[A BX2
M(?WL-SUU+<)0WJM$/9R2X>7BPXNM"STZYXU F/QBH(7CKS/K2Z7D:2^,#=/V
M#8!/DGW%SOSH4G=\GTRLKO/0VQM<" AT2[/3'PYP#54XVR3V[3.E"'LB2/6P
M&O(FJ1$=SVS%"8K.R(U,[=_T>PYS3WNE^!^;!JY9V-T 1"N&U\/S;_;JS)6F
M/14##6%83S^WLR6C:_+@0N]KM]NHY#B0=G%+$OS1A]&"532VQR;;M9F#!2J4
M+ICO[D);-P!!%6]EFP+2JJDYW4I%5HX]]-.1CW6)']^4AZ\&G8->ZER+?)IY
MH#31W=F&H80AK>EV?>RC&X -'*7T5PC\<P($_?^P]_^-H#^*,3-KFK[FA#&>
M6TNPI%F.@PI]:JH8X.4\IWS1PA-++)"HHP)_3KS)^D :._JED06$.O'0+!D^
MG*SWK].NQF3B5,^+1B\046.%&XVNYX5-WZ[M7OY]-LY!N2"?63)&2)YH *N1
M1,\Y]9G?5[FL?YT'DL+6G)J]?8M4BG?4#8_FUQH];@!)/0ZDG="HWL#4=GI
M'GP'1/?A7DA/%G=48*2S*U,KHMN[?P#U_08XW>Y@FSP4ZHQ,1&R?6R,<FX]Q
M<O [-:BP#W?@%UNZ-/PT./E+W^?4,'A]B&CQ@ P'\Q6;1"SQ<&"XT, OVT,'
ME+)[-O7RZ/.PG]RC1XU;IL$HVRL^'WBZ<!E' AO.NG)[G#V NAY :1 ;&YI5
MH.R?#2J>R'_',VWV^/$W&U95,MQA0.[T="F6:_"41\8,S=-YEMS0Q.LH#]0(
M;'$MM#M"COO47-%'PQ\<4TY(!L7/;@!Z8!!M$^4!\3-E>),\FGR<P'P0,OU'
MKS$D(?U/XQN,?SL\NT#>N7B4..7UW?A*@6LW,UE;^J"9$U6C:K=-%O9K*IR<
M@YK^L8%[^>QS?!R]/+BB&Q8>292.5GCIOZ%D?T#&MT,J?*VS#B8^4>/2:H%;
MMD6)65,^N]?E<IO>S.Q=R1>;V<64&*G7O@CA5M(R4,6 Y!(2+)IX?R[(:F4Y
MC+4][[28:=.PLE6I59X/9<+IKM#X?$&:_3C5RUNH5N596E0*W<#C((E]H[YT
M]:B(.2] X.C^1WNU6UIC7?KNT5)%ET?,QY%%O72L#WS!!)OQ@T0'/XSB)7_G
M:S=M@X7N0C^]1)BZUIE!_F-]I25&S3LQ#$C.3DSOV7$K3XG$.TWQ;)_]TT!:
MVPO!2*;1KN7%?5/E*@ET2J;E#4 !_2R,^1KG*O?;35_W[H\=:;[9&&B!2"+7
M@UZ8A!(4\)5L*8PMR]%P<X904WP?;->ND90ILVM1"EO&G"JU-I*Z<7E6&L$0
MU#5YOUM6.^?C7X6F"/XN@)/\B,.^I9%GI(N[]9;:24BR<-2SS;WWII])N0K#
M; \>&KPW_PUCB46V?;P!8(@/,G=S6HPLCX<)5F)]Y@+1I[^N'IB;-#*%))U0
MX327['BFZY09F]RF5A)9IVGY6)@R?/,98C$ [:ZXFEWH(D-3W"(>F^I(,\H@
M^H=,44Q(05( *08=%?_#PU-^E2<SZV( N>V$-,>TWJW3\?8T1K&(T!6$]-$[
MCI7Q9A.W;D9882;T<#!." 9][E,&.V'[D:!@'Z@1UL+1>AG<VKG2J?U5)$M#
M\]8\BY*0!,'@=!*X(5N8IEB%E$RON&=QL=1I^0Z&9<2BI(H'ZY:W[9/27MZ^
MQS_"$A]4*3 @]4.&)*<& X[\4!YW\3"?*3_O=D3D;H#0D)P&7&.:]PN>)5M"
M#F\Q*0D%A-?3,J,L@SKK4:O7E+:Z--3G<TD+!;61L5,HT?4Y,=N6HGR4FKZ1
M <SS=]^+UP+UOIJ@)KN+T=ABJ[-6N]DUO*2L;$-8-A(<OMHJO.^1R&!G+CKZ
M,8 </0:UH:YX@&)_9ES:D[NF]I&H>"> H3Z=(>8ADY+&L8B*"PT[624GWC('
MG-OQY+!QR.73"AU9%HF%W;74A <#M"%JBT)F:9$_?=V#RR&0^DKBLQW9F2U*
M4G&+,79V9&&Y(]+5 APA2#NU_!B7Z]O<G;@-6>8D)*C^!OB<!?LYF[7\XF-U
ME=*N4?IXI/LH@9!((XY!"^>NJ2-R,S80# FPO49Q6EZ83[YS)FC%6)_QO.7^
M@GN](R8.[@F2XE/$/$ZK?#%E8$S -:NA]=82TQ].-7>_?8)"[CRUW251CCH2
MH\,RU:6\&?VGAD.N^\<RQ10WE"]"?&2IJS:4 R><Z=8XZS7(MSM8(K-Z7"Y]
M8I%0, /#=U=XVY<NS<+L7A/#Y45OEY >4I#/Z5#@S-#U=@ZI@&QS;8C!K+6)
MH6HVWR.D4R2\4J873%98IW%6K6/D (@]V+JF QRD>63V1*Y'E8(%F<2W>GSZ
M1D=K55AYY=XE<N+-U2]I3^O6&96)Z2I_LR1_LVBLY.!T/.P2(4)IZHIV3YZL
M1!%[<O=R2C4++6+#KQ4N5R[65X:#GC,@:<+AOXHO]9]6U >)/6@MMC\S+(QH
M@Z:94@BT2G$-7H.Q@>IMZ-@J#[</B4.;TK31"4,_KNE;FZJQSN49[Q7GK/ F
MW@=)/48-($B@Y[_H]ZC'B'"Z*ASV/7M@KZ\G4JR$Y\<P4VV[,&GF2:< 1@TW
M2:TA@7R)X2X*4G^'S*A-W[C/J1.O?DXJL;Y][Y8@RYS+<:OWP'J2Y[V1B=A/
M+?H<L4BJ],?$L<\+O*H8.M!G&60]MDZA/[PO\;R_;55\T-\U7$Y&'VID*]>+
MN"7CV='ED-PFLWJIU*:4*0X&AF)X9-_\%3316[$G(R:D_5(OCMT/<JC/*VV,
MYSS^VG2+V!A57[)QO5/DS_J:ZD.: >K1:3:RO%2<6+86&P5\4@J13!*O:F./
M-LU9XM>,W07-(%\TINM_5U4^6L#_AEANKGH\MU2(U<I/(T5M$B<&))>A:K/1
ME2=0[N<OS'TF0+Y>R*7'O49"?5T*30SY'$T_&I8E)WB=+(.='YB ))I&O>.^
M.**:S>["6(:?<[)=_RGUL\K=GL".O&P,6V*+/#N\)WU^2]#D7V'"$LI-I0JA
M@\=?47:'BG4H)K#\-WDO%\FQW_GL>ID.PL((C3Z>)Q\>ZE/E+%*9,R>[Z<[4
MC]P Y&:&V^G/VF=T2/]\M]*K@@(^S)E('A&=:M\1@UFD7,J _8ASA#38R"9[
MW_SSAV=X":;>Z,7!,B2GU;UONL-\LOZE-P#I"8GXY0LXK]/^E('(LSOAMQUR
M5ITM/_TBU%R;;!G3&M6^(+2Q JJ-WTG ]:O_%FJFGKS#5(*7GC'@P]0VW7/.
M]C-H+;7=;,I/M<A!M\K52M1#HZT=WM;8C5#/+/63AP<L4*A"8V<#PM&E@DV4
MJMBD4H/M-B/)ERT<LI!]62;4E>R$3IK"V);>_%M2-P-X:HH MG'_2=FP_D#K
M7H%KU$8 G:TG3<MFA9L'[JN1)PM--E1A@G%(*"('(/H(@.5DF?:692988Q5%
MS+_-EW$R1KG?.AB6NMC?RUP%F:F)TM#-:]#D'I]9[QOCKL1JZ]OWF>SY<'^G
M^X^'"_TI;E0Q(=I;%&C<EF4>(JA[YUIT ]@JN80MT/$AJE>QX3G&IE]T6F "
MCL2P3PZ?T6&%[XJO1-H=WPJFE#W!E3S=[3.'5$0C>&*6LA*88N+2.XP_OYM?
MO_6@N7Z*F%;;9W+.UC= 1W(PM[AC9;@"1CK;;6W^]"ZO<'_IL00FR=0+A65-
MZD%0'=+7EVO22&DP/>F\'_\+&Z@ K8O1%E/FCGI&B[F=#? K3%%,N7&&K^]W
M97$"E-=4,;SM3>%O?:.A+L_?(4FFVLMT&*:-Y30/IF3HM\^E)+3=[PR9!=%G
M9;>L7:JCPKIF^55-#'Q\7.85<!)#<QO\VZ(_V!"/S))I&3U8[\"%EW>N/4R<
MVGUU25"$BL\'KI-WWP+U6@H U?_?2-NB@B+-J*ZY=TUIYAB4IO;SXM9!^WSC
MIN*W_B5]\PP^+/!HM%<SA^ZQTCT9P^,5\BM[=$>$(8.=F68SB-D8KW,&[3!V
M);9Z>1A)Z.PQ3L<]O BMJ"_LER(<['N+M5MK?TX6[1.;Q-/F)0P/A0NEX9'B
M=&^U [[AP6U:KLA1HLM7OH_K%]>Y/Q"*5N;E1W&N1BM1/&7Y_>,9:$W[?^TJ
MMXJJ O"1'@Q;DI"?@ZKI2D1N)6EIUP[P"@<I;P?O&Q_DH@7DVCH2?1V5M*K#
MY),<'5G(KQ7;%:. ?O1<F.#*O6W5XNWXO6BFGP-EC:7G988="5:5=K7;%Y^)
MI.KSB6/T?N>0/8U;%0E/YHA2D]=*N8MSEW)0N.\@'SS6PN4<UB(H#3*[]_/8
MV*#T?:U*S&JB.@35[NFN"4HJ[I("[(X,U7[8NX7U]R=T'UV'T%:,*JU9IY5"
M]%0GV#M:]06W)0?735J_'<]%>U4>10%C20KU31,W0"WOFW'HLS_<55>JT6Y1
MQ[N!P=*,$8O<C:G'W4_CXU58?I%+S9!I^)P^Y<0;+\*J%6FL1OAQ\1;[P>-'
MM[B+G:ZOW/O%RG\%X&,]#=[UG>4T3 9GO&,Y6F$:O 'NG8ISXJ7,7=TM<NB@
M_2*[\JBPX*7C$7]"7*7=>0#!E!#9W06LSX6 JZ,S?<%'F15:1F:)N5?*3.I/
M;/%&3E:"$0]B\Q_,CN67F!6H-;,TQU.]6<BI4G_Y5C8*T'P&_'ZR)#XY5PA\
M-'V$)@F/A(Y*Z#2W-D49T9#1*S4ZF&]]C^)KPWL7B/+5H!KR<FG4[;H3Z;DG
M:9$E8.)(A3,$2>T29N:8$QS5W3Q TKG_P4\H\'7IO>\]>%9934RLJ8S''B2U
MW?$A<,5L+$@,S. G-G7E J\U631&C']0'ZH8)!F3"DA6/UXSS?!+Y\S0[N!0
M&4CI+7UNGG1LZ3L'T><<8O%7PTGNV,4[$<09@4QWI9@*US<VMK<T!9N[K,*B
MO_O+%4,RNGQDHNKG'?D2/L<3*[C2]48><)7D!4GNPK)![FIX.G%:*0?'VDV?
M-]D@:VUU^U$GK[4G91E3PR3Q+-8<';1G]IT.'B5>;;Y,<II=9WXF53(EB?,N
M']MSWAN_M-C>M[R/D5X*X6BDJVR( M9ST'>BF<63^AR\/CH5X-.J+X6P,:>5
M.]_W8Y@X7?*&>K2UUZ3= '">NB#&RZWT$_L7W8KZP:>".-T0KS7I+VO9E)D?
M^S=W?W+J#7V\=\2?E?;70:FG ZA&9Y65[% W>E&J^&TL62V$LF]%W]OU.<D+
M$N-QZ!(67XDZN0'NJWFY,O4EX284+56$K$1/<@1QLV-F KA$O'!W^(/)1JHQ
M<:_GC&[MRG EZ(/0./5VUL.L Z1$C%2($H7C_)+XN@U4#GD#A/F(?-E2+2W(
M&CM5E)ZV7S".>[4'PU7&9_3H+LPAY>J^ 8CK PE-I-:?+YHN5P\@G#+<@K>-
MKA].3/<:/NI/??03/CDF7!^/\I2(=3", KK1<:'<5^!<A4(#%?::7/8A7A%^
M#DEDG:0J>E<=PQ%1_]=)M37#:.3Q'4.23F'^Z'7PJSW;'%)9/YGJ6RJZ+$.5
M,9+2^A+!)N')S+^=WG[;0=#VLL#D@OJ,R,-$ND=Q#!,7T7.R=$8'\0%A*4%B
M"FC2-+[/>>B#0O:6F'IY\B'7F%ULM!XE>&]_K:"5DDE)TY(DFW-O(4X]K>I=
M?K$A@!2Z55E<NG&MS 3W2:7@7^FE1L+]FF-F\0/05,NHB$:XZK3CGF/_PV!<
MOC5=^3)&KMN5M@.@6+%NQ0N0_38]9U^/!R/1DD2-(\[&F"R'NKSX>/'OFB".
M4@C!P!L,-#N*O;5)M4P3M[?5D]&BBFY?K\UDC4FFWY!MVR?8\D5WBC*F6?ED
MU/EVP1V&M[$ZYD+<+DE52T^)7I-_*:? V>]Z +,/K-L*/3S,0A*U+K!;]#Y[
M@.A\_<D!ODWT-+H&;\<6[SLZ-?C$C.#7-_<1%_9WET,9*8$5[I:6Y/^XT  J
M](.XSU"2%T=3.TB;#L>QVOV>XP7<C!P(+@QV_6A&:)#WP"KK7 )UN[:'QFGI
M*AM=QIX+;*<; NOEDGCOWJ&^5#UX- LS,<:E?[Q0;2/]Z]#@^BE6(Q>;KR4>
MGNE6;"IS,52^8)>TFWYX.VE&/<RX4Y(,>!6);7,4-T!%R[=-I8OT7@RH>PED
M I>I1S6U3F^YI04,7K[LO$W-7YV\XL3[A)[KB:'I6>9P_-B#W/II^UJ1AJ58
M=&C[.V97YTH)[77K_\6$")T.W8<VQ+[^:C)[=KG93AT%;/H]677DZ*'W:VBX
MMW<<6)$EG^JVHR:_IH&CCU6\U&JM;VE*J_HF$.FYIB'U3&JW_#_[)[7_23PM
MW,RW,\^M+%8.WFZ:T=HU=*]]^&CQP_BYK)0MWHNH5X;_=J1\"Z[X[&Y3YY@\
M#!EB\*A?LEQ/_XC;UF3!/CA1PSX,?H8X55UX7<LI^D@-^(@(_T1_WC>Y6P;1
MS%M5BI*4655VS]2]U&Q-=EIO_A"TFPF=1T5QXL5BP$'[IV6[$B,&U&,.-B1?
MC:T3Y[I&05%SQKZC>Y1VKSTJAV\]4YO-;4#1CV\9<ZS,%5-Y^_$IDTV7\,5!
MJ+.-KYA#$\W=C^)S-@J MU!V=[%1">(&,,[:62+U*Y(,?+HM9 8HE=J?T8#M
M%FRL 2,_%U>LGJ.2/= S>\57O-/RLD'&)DIJMUY4*_F\"*($F\(Z*)I(J^:[
MW+\J]^?R*2-1G*PBR6G2D/2(9K;%\2#[ UK\MWT9I"DA>@G>*%S!DY7[Z&N/
MIW'PC.6E7DMMN';Y\P+SD.4?^MN>AJY)>RG;Y/$;#=&6$R"17"PU$\/+UGK*
M-*?*KY$<4NH*QFBOT,"U!],%T$NE[/:1 S9XRVLM64:E6UH>HZIS/3-UF-Z#
M_GMNABP+H$6_-B3I;6P4(3BX,&L7T+MUABZ4?I)-&M3"T'>ET*:OF\I=ERN%
M] .P4EXA@1([\21]C8=(D_S#@.05&[RDJ-R_T&*&[#JBII^_^G\>R](:ZH7(
MU-4354BK;MNDKS,=-8\_KGN/==V 2*L1[?<>^B];B[N?51[+O'+.I+/61'&-
M$)_DD+X_[%ZQ1UOZ@!!1>R8=-A7V6#>EZ^Z)_9,UOHP-8J?3LH:YL\8/(_@C
M;*PP\Y,R09QQ2%E/RC)'G?ZZ&R/F^P#G3E&-H#-@9F ?OVPOOCCWB?QSG"@X
M[L$R,HD*IW]TU;,#8[A+,U=DJ^7*U,S(MZUE@&6M5[,_?U/7_L11//%LJ<[$
M_?RL8:K@S>N:UN^<%O!BEN?QWOANLLPT:V2DB[N&#36/,J]2!,H+G$U11U6*
MZ!L@^/VDX,B@X?JHAR=AXD<QL8HR_7K_YW^0P>_"-BU2=/K5'#1! JN'=V^
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M_@T0(^^!&>[C73<B([/W.G,5GFL+)>T;>'/N^U;853*[KG=ROO+<X?$:F=B
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MB5C=@V@-V+Q^7_,KL(P!YQN$X9D"9KRID'<QHX"MX<&"I3.3$Z KGY)O*_6
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MTC7R5<8R!:XL;.79[Q_[VZ3$GG!SX@B8A40'TV)#!JZ9F^"PNZT7^ETK82\
MNHT;MC9YP+JBT!>RE(%24X%69VY5;!<0/-;G+1;2I/BQ:R[<(YH\%X(J5.JR
MST8%GG_EF:7TN;U%!;10[[L;P+Z%X@^Z9K\G;S>O1%&EOIJ%.Y-%-P ;6(Z]
MUM%E,0X3_[(-9;$BP*\"^WB]-^BL]LFOA*6.M.='U]GN,VT)(;W^RM$G!,*F
M QF2G(]-A#\TV3CT,)#20&-C 5NG^7<=SG]'%DVYZ=C84ZW$UT;1_(1R-]6A
M]^3FO8 N8F\BC5,7[BB\<-\J2ERJ^YL T0?R1'!$! I5/#W-[3@V4_)(\F0.
M*E_Z8,X1(PR#!TH&68V0YA(""":ENTWFBT*ENM=A$X%<OH5F\<L[\\\HJH*^
M#3-%&,_)$& EM;N!3<UM'SYO#+MQOI*-Y)EZ FO^L(((XUR8,$\!\ 9AX&44
M.'$N"'/NT7ZW@D73/U0D$6I#[_UV@V%,41VL92![>1<FK>/KD<&88R;/P'[\
MG "#J[_BY]D#?A;)]VS?6<>1I2OYF\0$XDBK'#?VYV3O,SP&)?7)>JWCM(ND
MYWX*VRVU2K=<F;P/>J:*-L\Y \OE*$IU >];^I  4!^&*6$!=BX5"Z/V?G<T
MW00_I8H])I(F-KZ]J>\R>%@^$1S?,V 93K,?'Z? 7\;XT$Y&"J^X]1\6+BMA
M?K01G+WT22XN8$R_E>]WVR9\M5&- 2[\HV,7TFUWD\9<QI,\->8[),M V:^!
M# ;?[3_FQ"?JG2<IF#1JX^<XYM\-I"M=>[HH[_O^J\<CI-7>'^LV)DHLM2(F
M_1-56XV@<^B6:$13_14)L=><-CZE;-\DL3G(FO@.R#[ B*;1XS$^N.3T3]T5
M#\<UA7VXS$@R@>M14H?Z3^*?2^([%IFW.GT^'RYL^= A><<DH3G[+N<C48Z?
M&D1W2"$>ENBB0.JS9PU^8E%;*UM9D9C]'*]:S1)AG"U+"BG#(JQ-/S%B8<88
MZNH29MKW,+F'GBC?@A/+@5!&'X9?SWJ2*_L&]BD3/7^9U'Y.>Z)Z<B'9;-C:
M&&9OV68;+\#TN;(O0KL*@%MP:];6: CW_+NC.IXYBVE*]X#U]R[JYJXC.PU&
M5IQ_%31IM1,YA6_C<0)-?5J,%PG =C3&#XA[@OSG^OY'%6G^TXC E0_9%H'(
MPAU"W64\_4H:<4UW89EGE1RZU%&_]FPS=M^A@*C]"E=SSJNW?'F)Q[2B#RIS
M.%,OG!^U2)+DPV\5L:HHRY72D%1.^7U:CL9PE7)6A/@=L0%2T+7@(DJ:<ZZ#
MJ\RI#0(M]GX,C+/Y/.%OL$^!$^&',!?];1YN#!9T1= 8C%,'4\P^\Z[P=BRV
M\7[8EPR\M09]#6AHEAU4L[J?CK!5Z7'#X--;"RS<J6X8I=L2G5WQ6K_!]-;2
M4<Y'"+>/>S!8&_U8&7A>0ZK&U-=F@_T(C!0ZFQ)HE_J[UBA0!F<*-CH)6^[9
M$;@8$ATZK*6L+'6@]8E[>\;#>>=E,/KZU&E:CMXKGUA*\NG&/-_=T-'?Z4;W
M;C741AZ]E8\8-6R>+>:BHT\!+Q2%TGR%UM045!/1SS/YHD?[FS-K/= JI1/&
M;[Z4HP?_9L#(!JWO,]X U*(T4M=<:M@H%,4A 4 CB#,*EA#B%=>(NV/@4$ B
M\1O1'%5;FS#;LSWF,9(0&EQ,V7D5478#L MY=Y4N,YK0+F!R.Q<E?C\IB;Q'
M?8U.,MW[^):E/]9-L"1"1XD5\)*%Z9WHY]D@GA-(&R=N^O0E3I%#<]@!0>XF
MD]?7A>$=0^H^?Q/@)(0@>S_QN:ETM7\LH'\FD*_,85Y,=V%H].GTV,<\&$-2
M1./5(^31>1_5Q:OUS&\70VT/-/[FX7F+?#3I/,GLHF]+W-[@R""9E^GDJ<<:
M%ZXX^GN/#\[):"W2U[,PW/,==R/,:12H.^7F6@<\!P!\[H3>$>^E-^2J"I1$
M7U?[NVY^2'WIL6IJ)38?NW<K1:.:#_J&U5TD5G$8VHD>2LY)4$>>W !(!GD-
MR#X9TWG:_H: .7$^XNO4"!(,>IRMD9Y(:AIHOB384+6]Z!'#/X%";V]B^O)9
MV;:F%_P-I1A;EJ#_5IHJNBRK:-E<$TA%NY'&'@"_Y?C0\J40>G/\V%RZ/6R\
M-<7H'L=.[*X+[WI=DWJ PX![05\%O3Z8$Q?7%)V8CB3\;#_'(BAE!B76F[UF
MVC;Q*;\JI"":3=2K^\I4ZJVGC4<\_/%D--=?^IU*TB**AA@<9XXV2$ ^-C#]
M2J/6/?QX$5A<%"K0*$N\T\48.FQ#,N/?3E]W"90U1I-$0%:"RI!XJDFK#DMT
M71V&NK>>?T>"*K_()"AC!)"2UU6^9Y0I2Q(H[5G1>6S:]O4&$,ACQ333=LZ)
M2]I_334K)9S&GTNG5)\[GF;2_%#9VXWM47QQ0EEY4:AX$]8&,?2AZ$*RPF=Y
MT(CH.KT9/[)Q-(BL,;I@R6$4]HE1TWE:[K&):(1=P<[:V_JDAQLY3/Z#+5AW
MQ$6"ZF$\"?0G?]4/7:SUW[7 C6B9!!L[7_N[O%_,B53:N\_G$M9=*!OU9DRH
M1*N6PGX60L&W.S\GQ5?F9,)KHC_@#*\#4.#NF(B*:M_"VD53Z).$]\6+D-L%
M)0ZC?@4JVI]IRA,.YJP;<%SR6))<53V^GO@YLOGPR_ 1=.A6L>$=7*7 LY2E
MU1ZU5\^S7Q/4_)"A!P6O[&\8T7_#=37DFPCAWMLN(,)'YV6QMX#;E8;V\7#M
M8>I0K/UKS*.^9ZAGFZ(;O<,BMW[&WF+[K/G\S:R]CLO(+U;IJAP9\IFW4]UU
M'0GPD!77OU9DPZL[2H9IIM;@@(:A1*M]2_3EE3B$;O+^CN_B,FW'-+DW0=\7
MD79% /,$-UV[BIN+;7,N[C!S/Z[NK4'0LR22$GN8'CS)HBJ4SM=SQ?/2[>[V
M;UIA$[V4%["89NZ#0W,^"IR82I"EYG<OT$G[YSA3Y83J?#7O^<C&I14RX2S$
MBE,<3-G=5%@;_U$WX:5H71$-FTM"JZHSZ@3:MWJWZ0-+_%OMMTY.G+CD%NBN
M+*06QX42*T>J1XM(MAOZN/^L#6P):6],.2I,E+OB@12%/O<FO;_CGU?I5F&F
MI'%V W@?/I-FCHY,03[,=_V8^3JQ'/\8<LM/PI?HLG3$=[<O+Q6:#6TR9!,,
MYP-)B_:.8PX*[#Z'T-*3_[WLE$*LIR;ZJCO-!B#G7[<+Y-'&!A3L2F0NE7Z
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MR0D#56J6*)FASDQU]'56434AH5Z<M H%N#SJ9-S>;0FBH]/Y]58"VOO.WZO
M]C8Z+U2>)X]1A&HQB$/6(@UV5TE:CY!W#-X!4#GS[L B1[B!IKV;<TI?/U&5
M #BC7Q,VRWSD\H1L.&?] 0!MSDU7K=[Y^O&IWA?KGQY?/QXRI4"R@\2- T7A
M3U4701O6_HS^)[6Z<X$\Q4X-,0>_BE/EU^Y 9)+*NW+/<)W#EFB.>GH*2+G#
M!R1HL!9-3PWWM1XKQKU=::=,@.Z /S'23FV^WZ%M4K>1Q)<&_I!%D$QU;)=>
MW THNNCF1,+X>5U<]TW@H#<(5CH59*B4@21Y)7#1RL6%OT39X TM6>,="8SI
MD6V@WM(.OEF H5\YR%1YYIV0\<)0*A.R9]Q80CK<"0_;T^TP)';[[VR-A)\-
M&*<G5$]_H)@.=:TP_%E,?0N-*(YS;?,RZ7)6\&F[.6W?A&H> :6)JRWJT"#D
MD@6,G\V6OX!Q33L,+ J5JL+B83V+(C7"Q5%,)LN8JXXG_?V8/SQ) LJ$!SQ3
M:_V+I@O##O#J#26/ZL3(TO;I&K>,IRT?S%YY9.W+,;JA?A0GZ:&'OO8==7L%
M 0NPG^N9[JGILI%VGD"+#I7J.D&,R'L^X5?&TI7@ W ;-,[36NX*^9 3-Q(N
MO"!B&7$68FT^^0!_47)]JW(GG\IKCP&'[X YQ>VM9J1@>:HXM+T'WMSD3V=L
MJ=@XL&DH/6B:WPN^]QW1EODZ>N2UZB(G;DK;_,&E(GKU_&AW:BD?<=>;,LZ]
M>/P&0$ 9V5I>26VP[1OZ@L>BE3_;423SQRKEA8S %Q*NM[,0EU_!P_1J?)B$
MSR@*G$TFDE/E\#[:C")XP@M>8\0PG]E!:<!ZIZ(%AFI/JQN00FO[MGJ%5QA(
M+,@1.[-BH_S"#C?<>!;+T3]/K;1E+DK.]8+#H8!$M^?W?+,%3E?0F]P4!8)%
M^6\F,'0NO8,8D>JBG4M1LY2QO2#6!,C'C],Y-*B/N@/!ZBI?#TY9P=[&"&2>
M3^&%).Q[+^4*4+_,',WWY5@L0>LW-;N4.L\_/>87ZH6",T(?>I7^FZ<S:<+_
M7.GM_[S3^#\U/Q?Z=R/.?^I$_K<3NLZ_@&?VOSU8TOY;!_-_^EXRSO</ZS@Z
M &X'V9_\JRXF."5V6C,= :;HI#A6C#Z\N'B$554S@.%VURUHT:*MOA#%:E#J
MX3A(]GOACN%I-^&>A%MTOBGZN-#1\-&K%9YIAT& WVK"^I5J_IOO,&/<73%W
M88?PH@TF#$0+UX&ZC3W.'>CU(V7#FF#_&[2?0AO_TQXC'49H>=F4P 6ZGL^L
MMC<2KK,:^*(]J1?>)'I\V/;A<J;DLN3<L/*-'*-*%SF&;ZNVU,DP[@&D$# 0
M3N]^33EE@G7](\.L6OV%R=X6$ 1L+QD$R >0:]H)J_[.5:$<!@GU-3C"Q<X6
M/P&?3+*PLM9!MU)#I7XKH)O*_WIM\U[R/V#I*5D665\1^4L1I!OQZ@I[^!/I
MTE&J_A!B_Y@=I=N(%K?T4H8,ZW0$/S*?SXP*3-I>VS!@0:_%/_W"R)"J=STY
M,?LL"+8GY3]]&Y_F8HM[J05![_I&U:WL&JQ0L@/R>&UK)#< AQN [:LV<$2+
M_@.Y,TBP+#<G;A)F.&PX!H("+UH^.<=M>W'O/7 ]GV;7D]!<#;2*<Y1%<\?=
M8D')4X[1O390YA/(8&)8(UFX*9Z)>'K<GO3!+1],9TXE!R,,EB..DFWN=-I0
M6(>* TF)UQ10%PG&F#-?#=*9ZGX$\/.E9;43M3/5")+=[)R(]H1>US;!+J'8
M/?UMF+0B #3X42(O_VWE#\?%TH:=&J/#=_W/8,\B3]0[+1&P\=PO[$K9+$G^
MO_AEJ!W25J1&9I48F@59WVHAS-]EERTYB@HLFB@]8J,!:.,35F/5W[0UH<\'
MXQ=2MJX;KT+Z%F'0-O#UQ[VSL&S;A#;:$RF=*?P\;$ ?.&>Q=*(=JD*\D?+I
ME47<H":"E-ARAZN:,">D1&50]A&P?9 /X&Z!@SX]^"A""D/]GJ6R+/5I_%SZ
M;SNYU(Q;UE(/_6V0ZUF-G="T'MK7$9_@RQ_3YY25_:EW T!08EOP+Z,F!&X
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M;VKWHF^_!5> (X$LB"5-M\'SQN9QMK 7,GJK[U\(7_#QKPUTR7;6SY6&-"Q
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M__%2KHMEIFM*SC@E]FO71]JM#GRD H18X75K8R1=BUY-PJ-0NB2G:O1W,'&
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MT^KTF][',E1/B$YT5D+#'(_,[ C@51PZSKJSUR5DT4R[&NDLB?45+W$6&I@
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MFD 6E?%Z5^T!Z-Q3$T%>+EU"(/:^N],-E>'?B ZG7J0YZQVRA&L[1A;=T8[
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M!MAQL#N.SQPU27O%K4E^@*:R#:TJ=. H2"AX%'-ANM [D81B7+2/AE! \Y_
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M#9;YJNZ'/(4_'*'.'-+19&.^=RES9(]DJ$W^91ZTTP6K8I>Z+7[#N=<D\C<
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MP3'>\4:>E,A_)3=#(BD!X)0VQ0H\-;1YOIH4S+H0=%6:%KKKE?L'C%X296S
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M+?AE6J#24CG0EC:7]'!5*X%^M9T'.49EG?3MK-V&'5C1+4D\2KZ^SL*/E/E
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MQWR:[+=F'DLZ8SU:F'QXYUZO@HA R*:_5!:KJ6*<W8J=DYU?F$>8=SO]@:9
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M,L#%;[V.F,FOVC[>URPJ2.4L-PSL.BG9MQ38[K*.<G(&O[LN>,@'CKGWD&-
MR:L9JEI ?XNHI9/KS]!N+!6IZ_/]KE<5$*UC]E-4I5/UZE!RQIYU@UXR7MVQ
MU9+5A.2X Y[Y 7ON12&OR^17[@VEB_&T4#5")#Q.4.S4%)=80TT7]G=3KI^+
M$._;:9@M/^B*1@#W0V/2<LV0S?1LTE+USTDDJAV-L3:T-3/(*ZEFUGZ^]8VS
M@P@UI;$+F!!XK1Q+Q[E'=+P9+F(_5GXQ*URVB&DWM>,E;S9[\E!\X+=BG,JM
MU)XC<&5-2C]Q=2PY.U@_U[9I1)F=Y,YN'OT])]X.AD).*LLLHF',2LWE=9U8
MAFJ&HD  %O)FL$I>E:S+CHF+NUI1=Y]=@JJ63#=;G.LB(0(:JL6Y'/=H^RDF
M<QD-!(F\><[8A;D6J81EZT!([5>6E((;/IG)8^&%+>%HE-R9$E%4ZJX]3UEQ
M$]-%<WS/HOI!R@E=16^WFF/4@?<)Q<UD,: /MZ['G::=)T\ 236L)?$LN7OZ
M#7\-9W66HJ'O;YQ<;8)MOBN#'%8*DXZ0V6K;3'F)ITKN#Z6795G75K]"$373
M6& [-V&<?L!1B2.VTR(J?'P";$QGSLV+FEJ%OV?$1X)08K'$'E<+(*_5_#)O
M%S&!GP6RDDDTHD+)W?2P1E*IOOL@'S(J3D7.VU4%Y^? "U]!Z%WAW56BM<,:
M%V)FN"!5"L-1),M>F*5TEH4MK_X-O[-"N8FH%@0_B:;/#EG> #4<N/X$\'@"
M<.X4'T8>34FZ,I5VH= @TW[P%R_'KEKYTDJ5D&+ZLQIG@2[/+38RMI0:[*1\
M_*?^R7]CPB*,H,A )ZNYT(V0EW=*166:RCC1:5]^.;@F>>NTM-BE__(0.:)U
M!XZ()CGNM*35+6!-8]#Z2NH 2UNL%8]/H-/.V4F9^-7-$\#>?,V8#'Y- 5IZ
M1ODC+-P:1W'W&IL_-QZJ/T..N[F&N&YP!<-+!,GU34+'WDZ FV4Y_PE%[#S2
M!S;@AX^/2CRNW:U<B?4IGUF]S>CG\6)9[<3);4M$_S.S]_FR,+Q_V7OX 'H.
MFA(\ O%<YM\*D_[_YL3X[+A_!#O2L-2=F+*0'\&>IQ _%OW%O.1HT!>LQ_0D
M<WU+HT32KW*> 6H9A./U)$R5 9V8<F("H#^5?'91$=1_YT\4Y+,'BZ I]_R3
MP/;Y9\/?.!?\_["T_R5%5\C"?;\7NI'37S>=E@W<+*P4UDK7[?MQ322^/E43
M)..#7S0X(:1^BI-DDJ0?(J9_P<%>XI'N0[V+KU0<E#6_.V5[4.W+FOM8Z149
M^T^A?3G-L\Z K>["UGYF5FU;4:]*]CXG3G]$1=!-)>;>4908H[)F1IW:*B*S
M90A6&$ ?<JI]LE^E[M2<UI^3=3/8T-FD[68,NF341CQ%5/IQRK/M#YX_-NGI
MIU0SK1GX:'R'O&DNFO%-FYB:(P=N9%0KQD>A7-<<%AM.@SUREGPX_GK;NHO#
M$P#YD4KS)G*^ _TF3I(SJ<*(.GO&2XECG8!Q8:KYGCP%CV_':JSY&.S:KU%#
M39FC=BR]&;NGRGDH5TS42T8#]'-<0-8PW(AZ,8)-PL4L[^6()T"'2I*'T%B#
M8\Y^'4OW5Y9$21^45W5H7EL8PTM:#8\B/CR,O.P[MNR<H4FY,RWM&PEBJH%W
M'A54W70O.7OML\W>JI;>6LUASWF?SIT>?Z5=8SB8AYN\?&!2K*:X-3?P=7+8
M/P,%:89UD*]V^FN9)WC<6?$Y&^.'L7 <.3T!U %71C>;Z5:F*I(3VBWHR#-?
MJVR? !!ICQPF8>0\L8FYBW.O;H_0L>>:=6*;W,M.4>H>"6I.+IQ+7R>$-QP2
MB-3J+L!VV0]:NPCRO4R!-OLL/>WPDXNP.=&<TY\BA7IH.?J2^ +BX/BT6S#F
M\Y512JY.;G?\J. R%=%-<7=;\KLQ;AV#:7R+;CM"<8Q@3A(;UY($7GR&+TC.
MW2+3#H=T L36\R]9'[D,I<QOV#Z<5F6M6RI;HYHKBX.]&!VW"#VX_1'+QVB(
M2V2LC>:3T.=KM]/J)9X S7P/ 20GH1X&?WLF?P)\24553V^(>T0;#DZY8#/5
MN=[P/L7T;N,XC7H,/*1]O ][)//A,0.=Z=R(\K[S_CMK.$R]3]7/NW&6L&0P
M9A'[V:&/@;Y.+VW'-X:\=.=\>*Y^E?@+-^6> /#;73)W!!4E/\_X;D" RWS:
M7N]5PIO>)X"04\P3P$OT"8 F^A]D);>$$NRXV:]3/2#/J3S<DMP+_XM]X#H-
M^TL?3HAHY6X*"ERZE4\&>%^7218Q*F5%I&H%HW!Z?#O68@ WC/O3Y4]UJOT;
MN/S[G:3P1KW7?V_$2S]V@[>&]@PQW\K^,6B)>6QKXHV'C#Z2K?0(5@),KVYP
M\LO308#[XB_>_A6'C+^2"[&OJ!+Y!/@+T6%_I5<6KDA.6_(?B.;[1WKYB2N%
M71G^2C0-QP5?L/+5V< 2W3A"5T#/R]!VOH545.WT!IS6:F^L>\O4$.WVCJNW
M;88F55*01WWKHZA%#O^;I.]?0_FY6\==?'_*E4#;77SA'8RMS(8CLS;(&(D[
M)X((WPLP#HN:*_-X97NJTZ5-'*9:=BH<_+;GP/>UK[.A-.I[9HBC"Y6HOXI3
MU'\GT%4961X?QYG["VX]U+*9G48:!@K@>Q%>L-_RY$+-[)0@GA1XJ)U:?[:\
M3.3#G!&&WJS*_!'2#AUJDSQ9^0N!_\8A]X^,.['&7?10.5'VF>N\_GI@%&"@
M>M4.>=3O*:L\6?7Y-'!K"F^\L^ZCFBP[+%HX_/ U-=3TSO^NIO\]F=&\#K;F
MI75A$ V3;SKE"1[EW@>H?M3<+-_S#Z6&6MHI(0_CO^FD,-M?6WP#"PAN ]?C
M_'\.O1*].,;=JUY7LEZ'4NIO$S;#OC5A>8.J_Q?\&OX]TD?6?Q$L\/_F!&2#
M^FX/4E_Q4%A)TCY7MC07.,6\\]P:09+QQ_AXC<L,,;^X*&IL2C?0;6$+-.*=
MW"R]5SQ%R6O:%CZQ7!Q*QKVUMR(?($ZUS-9RF>Z8HW@W<U/?WK77V1UWU4^2
MZ%R+-[RK>?W9@=P30\-%9@U1??8S1\4WP3KB]2UUP*4,C,O8?!<K1E_LF?K"
MO/BFI@"5HMF>>?2)J%^1!U[.())"K[VM/54B]YD^_7* H\,_/4&H9#Z/J"4Q
M)"G9(^_N"DO,A@>ME$ -E3#J ;5:@KKL62XUMA*X?J-)W?= F]G=^,=:CQ*1
MBLCX93U.^82E?HWO74:QL$ZZ#[NYS"=BA/*D+'QN^>T;(XBXLTY6$O]'!+_S
M0W+QD%#[TA-9+]SBH_3D-0*3X/*^")&&6"< ZI /.].)?JM4 6NJPWIM\V;@
MZJ;W,GO>4=-+%YJ] TW6"'RT>[15Q4?<XK9AN;)F^:DXV2$X';IV_;,"18AV
M;0^R$ZV-B'I3M/<*A(*0_K[+H#UF+42IDP>_65.GB/D6CKF@X!0%=6992+W8
M7VM8YG5= 8M^N7AOI &I,(.Z<S>2DA6GCLM?US"\31;;7H7'W;(&@Z<8-)5B
M1W=$2WHI"<G<QUY\'%,A@X^*4S@_]EC?+LY_;W_W66@/58@?V_8O/\*D$E17
MOF;&3))K2S*V8"7E[]<YA65(YB]JDI:'.+OZEJ&.3_G0F"ZAC5TT8YIIDU5C
M(#X("PZIG=7@[G Y8#7+";R3L2;L[1/SG=X1,?MS&,U?F#7,;HJ%$ZO-0-PF
M -QS#6G<T$ =)\T!S,/PIF,SNX*Z2.7,AUM-ZS7K?'U%>W.+@2$Y0?.UD[IZ
M6/ <"S+\-'=O'9'@H"&I(2[^<#%$S0 2H2Z1+@8!YU7"-#:NK6N1:UN(BJC<
MHQV9 3 SU%2G^>K9M;J9B-Z5TOG3].0!;G%4R=20S0$>=/^CO>\,BFI;MUT$
M0;(@.8JP 84FY]@&0 0DIR:)B&20W&00"2(9:10DTY)I4I-S:E%)35*:V"#1
MAFXEM,#&ZSY[[W//N56OZMVJ6V]7O;M_C'^K5JU9-><8WYA?6&^(&EJ<YB]^
M8>W72@M&M*X?;N)KVF^@_\5FW-(U' _P]JPSD/7)5K$()6D]H09TJZ![.*'F
M%WSB#UV67?OZV.5R5U-I79>8)AW1_GTB2&UG4HL%7Y1P3K;A7+4L9E=4]%E4
M:^>#NL*=0=H?P-WI?V>.?4-[JZ'R[6-YF<V1UF?%X664[K3<$?[;7C6K65=A
M4+2..K81L-[>-=V8$P,=OK?EV;1O7BA1]0GJ3\H$,Q+]!IIY62>OH&4GKR#C
M _L$O+QTA LJ:MS^E9^N4[2WZ,9&;R8_<LA*:J6->!(E?6:R&JXP="*%1MZX
MUBPM]O3VJ;5 F5P-^35O;V:JO/1RS9&17O9*89MZSITM[/VY.!G^I !#T;M1
MK/]*?'5G1JNV/]\"<3TI?-F;43WP+KSL\9C2F?MCO+1;7G>%0]#CHZ/CQ^^O
MAZ]KDR<"2$XQGTJ)14.@[*^VI/\?@@5KSXAT?]89S)I9N7L,X4VKVT^Q]%4=
MWJQX>X#PK.1,>?YFAY!P2*-8R^S/).Y"-N#/8]:TS[NM[!U_INN'I1'MUUSP
M8]IYOINA'_*H S\P$++0X\+:\Z#3)%VMZ"M&O8S'O7A*5:5D:S!/Q>#)0CZ<
M+0<]!/B>,^"/*E;?AS[7_?6!YSVF[]$;ISMJ5".C ;(/_B_$I[Q6_"HR>C-?
M,T60XY%?U 7SMAE/SX-7 ?Q71SS27RD,!Y&JU8.Y"Y([/2-7?KT[;"7;G*OE
MJSGZCM=Q&W>X;^,]9, (L;<FAAI_*VW#=WZ 1#:VG SW]2KNR"0N3\K9,T%7
M84?8=_T2-(L4'_QHVPS&*RC1;8IG:O(QE8RK![9!_7/?O@?)>P0%ZR^DZOF
M60ZXGMO3V6%VVTW=?IG9M/3T?UM+SRI3D!>GI*:(XD!$:#ER-M(R26O#_3CY
M!GX:?1>+)T<HO125-/IAP8R8"0N3:##-[SSZJA XK%[T:=K_DIL0H(/FLC(L
M:91?8NBR:N]IK#=3"'IL':=(847J_ W!0,RJ'/(F<%(A.PQP/%1?WGVZW?!
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M+ME T]1EPP6;;E.195$BQ>.W+%?BL.)-1>Q_-_Y3[C2RU?JI!&T[%)J5W@K
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MUYBEDJY>C0).J,/^H;?EID:Q1A/4X;_;9F/.AQF"=] JE5>3&J5ZF8&3KS^
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MN.?R,&=\T_X(#M?YYER$"@33;6/C)[20^H+;5W'/'8&G[ZG>A=BD[[;;S%K
M$)]E[I12^9S=;#\S))<_JK..DQQ@]M@4-R+=4R]C4?\SYME4=<+NVE-N8;^N
M<EHY^;!TBLYJJUWP=X;[+5W#QQ5@/WH43]-&>PI?1M77!5$#Z_X2ST+>0]_,
MW29HQ_<T/.Q6;+K_:7DJ9N2090Z:VM<ND7B5S!!)X<2NDY85<*89O#ST_J.L
M-P^1R[C#F166V?CAU\=DH "["P2M#FR7ULE)N*JU2V3@Y&N'A9/31*!W\OSR
M3@Y?BB<RU#-XHT$3<_6#]%YG6%D2(VK;KHJNB77'_*+C,YV1BT4W-&)U$B&
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MM[$"*:XN_\E@3%7VKD<Y>260I=[,WA] ,%]1E:GA!3H9S2E_2]5D^3$NEQ]
M!R<6\5MK._B:RU]$LW_C;_POA<:/3_\!4$L#!!0    ( ). :U*!FR'+*=T
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M5 0>D,S,KQ  E3LPS+U!W*4*C/)4>3$TM$4V_C[[7(#()*NXYFW&:K(<30)
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MXL4A5:G,M>C8 !F'IXN=OBN2TQUVB*%/*F:H/DV['036YB,!.*+/)@!?D@C
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M#C;([CRX0<U$:J6\TV,"E,]H2U^NNVS/'_I0?&5I,TN4QGO>:T1'\(K(^_*
MAX$R,3++'\1/Z?YC29GG4N,DCT%?';>'0_Y8AX.4G916/BH^SQ&\8A%DDT'E
MBFY[RQW^% .*0]Y*N@!.65*\:QV\NZ:1-ILFI3,LMJ=XA<J(>5YZ5O_;=ZEN
M9<\U4VD#D"+JHV[D%KG=<$6)].=.FD'UU?:+L2#C+H<9<]&V[4LQ]SYKS6NL
MTO2>+@Z) #"=VDK6Z%5?39T!G-)8&URZ1^9=2<.T<#6_+?=M^V*LTVSG";UV
M3=U0FXSR31<7!6L5"R@E_,$I][(RX+7+U+]5R/][JNIOR"IZU4LZX#TB-$<
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MK,I]M\]2"-94CT6>;-PA !0O"4!D%IYQJY4 ;-G!L=+<.'/ ]XZZ3Q$!.'M
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M79EA'_/RP.E9S="<$-X8+:60\-<O\CK73&"TK<@6L9"250L.HRI=R@!)C8+
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M*\UX!>FH7^'0<U07 70.^'BBU^X-+926H7<=. PZ)-XU!Y0SE*!8EX7ZE"Y
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M"*Y(?VXVA_#EN-T+(KJM7_X["T\;&P/?Y>+&,L!Q>MY[1*((04?YN!+Q/IH
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MPDUAQA<M@$*"*DUF9HQ-3D^BH JDYLO@:Z#\?RT _KNK+.C_3G3;O.=O^T;
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M:X#'<0A*L!>UV0T6-S?1S;G>96()!!WQ9Q58EFR>*O>ELL?*4VV4I FTH/T
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M.#E.D3!O.0:<=X(*+OO]CN02LNJ>3.K62!4=&-D^*1[.I-5'HPN=&:^XTU=
MW69S^% TSKN#)YNA[8(:L^:%%QB&[X8_F /_375V'5U-0, .%4*4;2HY4$O>
MT*ZT'\9YJ[1_T#1(2'D;YOY,:KRI89]UA(;:/R]H9>LZNPI^\*BZ_"0$J/P7
M-6E),R"K=_0:PZ6N*X]3&^4P0@FB*O>'? \:S U)2#9:L2G-V#\?>3\CLU:1
M;>M>.<[@F2+SII,1*41YG@VXU$LQK1*I$C:2#9-BF-L? ]O+KRY;Y]6&!NA
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M@X_C?8V<U1=W?MYK4GE)6=C SAK^DS3S%W_Q%W_Q%W_Q[W(\]A]02P,$%
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M1SNH G,G.'6801.#BPPFG5PMMA%V-78YC),#G\F:7<;+,K"7J\JCG/W"5F#
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MR&OD-?(:>8W\AY",NF>.3#4^,[S(;?/W<PKG,H"R#).[P9\U\]^O8%-;6Z6
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ME[P)B]!DIJW1EM#4Z%?#M!M)WN^6.%L/__TWO[\7T_C?X K4)4E<3'QZ!%'
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M8XJY>MJ6,T^*(,VS9H1^-)<OF'Q6;[(8D0(]J"*P> 3W&SS$>)$(J/OYBN
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MC[R[^I:<#<#3:K8A/.G\D#@LZ#WB(/NPZQ6[6CN1_8>P5^.5O27K EYCH[V
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MJ<K]^E*!5: .T8J! >-R2J5E^IDQ8[*=K9GHYSWP0-R>F(EM:3-XH+;_Z"6
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M7?G, ?'>/6-\U9O\2>8N F*9C2U66<NL.N0N6M+/W=W*1)^+\.WJ>3QYXCG
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M>EZ&S"/:^9N"YAO0O0,8*9V4T'MX198>4.AN$@2]_RA4.:W*@[V5CE;S:]O
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MS?)0"G>96R,JN]^", J+677.EUXE&$U(^USTP2:5]V%:<W0]<$DY1EV0%Z9
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M?/BR5&6B)I7X5=GB](,M.]$NNZR6#3+E#+LC#>@ O@DO ;",<"=CCRU'AEV
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MWAY\8TIB\,XE .>(U%(P#MXHVSAB>D&X7ZMB)&Y$[GW_@**:%DXE/=EMG_[
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M7EO4;^U2('M;QA-/L1!P2%T7(H=!=QVK+OOD,?W=N7<WVB.M+P'N&)# C,,
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M[HWG/UH&L-N[YS!3DW=O\4$WSQ*2&G7G)I+F,#]!MW^7XKOUI$2EXGFRW+6
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M<)B%S\7Y%S=YV?XT #J@4YC[I^@%)\4,HT6#GD<ERNE_NQH<15JJ;<>063=
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MKP%<;F(T-_.[]MT3JGA?UZAI_1MC+%DX),#PN73]R.NEB\+H2-WSS_A1<R
MEOU'&5C7?;:$M1H/Q:@C/E(#]R%Y^?3[HVR?BG]K'$C3!9.A;6[!DK+K6*8Z
M-41EG$Y?_%ESKRWE>M'BI1\[MWG%&K@X4).^O,C-'AJA]>SB\?([GW5TA.P-
MXJ'[KW@0X*G]PHW!;7+NU\+S^M]RS@,>YNX]/5JG7=7HYGF__>\)>X3L,&1&
M I[UDANVM'XB4]WV=T)K(Q<\K?*S[J3&GVK7NJ:Y;)OH")4L<EP]G)HT^5ED
MMJ<T(D^Z_ CC70?<7]+PMS;L/_3R^[>0%-@6MTH,V6?W]/-Q)H_HDF25#"D-
M]X_R*Z;3G/8KIII*%&O0IYHT"^4WJG9K=(BLV;E98QMINV'OT!7'1FG!5FVI
M:K2*79E+[H][^65+^*J:+N/;SNMEY@L1!*K6-:Y+-R>;:<B^NCHD#Z ;%H/;
M-Y]%>$IV@"&DQAB7$PGSUK/U<Q]2DO**UMVT;9/Q!=MG5 IXTUXW$MH"AW\_
MS[FB70 OFVW^%S^'_)?*+B[WE<RU.^,1]*TUWT&G35VS;-8->]WIX&-,$?T6
M5NH0,PYT6"... +3<DD2A.\ZJCA^>)G\L& @CIQ-(EK.>#%&AKD%$/L7BX,A
M2N8T&PU:E9#+@R0W=D6<V<TEVE%)O:/L7LK<RR)(S7NH[E%ZO@U"J-F8U?O-
M*I_H-Y1\#];T(DX!7+#+X5%'^#U(J9^KTTRIC!SF78!:!J>8K^ *YQ(?_<WA
ML68/0?:HDBA0/&V7.Z$5N8",S1_@<5@!RM4./<]/LNZ!GR"CQB*;'/K_L$<I
M^X5'#L1\7;&6/H_S/@=%:"E<$&?<8ZC9_)2%_;\U5>5_;<C(_PI1(\>7:\6,
M$$3Y:UK?R^D:4%8UO!U?6S,>^JY+X)Q0,RL3E11R>8;U^.'8/&ZP'KUO):F,
MU6BC^T&*U8DF887W\S+C7@+$[Y"T_H\&'3<^18[A-9"5WG-Y9-(LP9S%^#NH
M[3>-Z>DS">EK0*;)KQ=ABK#Q8PH9WW23"+PBB72X"G!C/!G_8XW,OZ]1@K@&
M%HB&I=<IL9=M;M:3D[E9SX@Q-F>K6CI&,DA]+<:O70?J-ZR^='66<T62[O3W
M%3Q/+A[08%_>F;^(9-S[:,-XB!NX+^#S+F0?>WS3CW]9^I\>H"^+LB]GR*'3
MT>#MJP+<Z!"Y-]O+O' -G&'>\)HTU>$IF=;/VYJ)HR3VB)Z+RVR]3TB32X"+
MO41D-US-\1JX^XMM4BO_P)P+^O;>C"K6%Y3TKY&@$8&G30J$R"&-ODI?'O>4
M&7,U(5S52?O7GW'?U)K5X\<'<#>.7&A8^BRLC#&';;Q^1ILXSW4-G R!#J)R
M2QT9[B;KQR\^K$;.M#13?E+[87^>X+@%\NS.\5KT(Q]8V!;7SM0PU*1Y6=8[
M+><#^3S<;'V#I7 I7S3'#6D;>F67$)_3'D01^'"MEAZX<R]B'Y\C!]A2"X/T
M;)@?;@)#,V1X\1H(;\6%2T/-O8[G+KC5H2;PQ94]XT^'9B+HY,D+Z$N,E."Z
M$J]2#4LRTA^5$ ^T=VU?7P1>,->\0<Y R\LVI?@@JD&C3.^]6X:_)GY6)_R!
M:+&^$$+1UT3%EK(<UZVC^GF6:?567I[V%!UG89V"-,A/\]N/N^U,O"!>HNG:
MQYS8Z4S85/=185N^=)"ZY$:7H]8<\0'6O(YGK$YQW]T$?UR(H.C+TC.JZR@:
M X1362Z0=5R&$5[GNN5!H#1]?61+_)1Q]X'Z?E$2EBZ7!EW&(9K'VKB$6XDI
M6V;I#/CK9-,SJ4'%GQT(P2_SC,2ST]-S-J"<ZF2]QU1P\Q\Q:&.9H-4W@O>D
MZ-SKM**UJQN\N+O!2Q ;D(F&C".L40,3I'Q<IM.93"2@922NBI,H'D8\[8*-
M].=P9]D^#5U\Y^E3%GTEQF78/R#7W<K:"CN\U%M3"]$PIU6V5S!88A8M]4.'
M$/6C*(WU:EODFS\O1V;,)#I6$^2GG3SQ%D==7LYLUW0VNN9N/ZYI5F.BHJ)&
MSP,@[AJ=9U&9/L6G?KI)JB7A1,]TZMB>/WP'P1&Y,9QE- <FX9UNM03WIB"X
MD>&!NP/.4E0U\;KC-0ZDDE6LI?,UC;UY+Y,=1+%CC7!G-R*=1.T,.VEL5:Z!
MELK*KX_EVGY-K/J+7P/H&\C\+_.3!9F=-!\0I#NZ;MWF]X^+KP$"BW'>(UYM
MA"%\Q_YAC"/9ST<Y$L2[89L7M"4V)V=BBCFY(QU$*ZP?NR>/[B,XEW8)3&X.
MB)QEX?K^;V%*C<J%]T B>G098._.U:%I6#+S=,V@N2E T2**$_6APQ4:#[H&
M8@3G+IT$V5)M>7F8/A+.8[9,T:7TH:*J['+6GTAVNA&N<NH2/3-:6^= 'Q L
MT=\[KLESCYK$Z>(IP6]#SXY2%EQOA.?R.6\I;1N(--VG8UP0_+G1&!D=)<'D
MD\=:@]18$9J3FHDA?*NFOT?GAG3-='(KR^V6E'[4_5Z5I&3XO0S^'AZN^1*O
M-CDCCWR7^6E\#\EFQOV6"N&4\0^N<50=X-I5M8FC G>Y+B'3O=0Y559H;J@;
M\]U^D C=X5">4?#5R<)NQ-$]%^Z7JS"'97!GC +L<8:_'1D:WWMO<&$>M# E
MP'3 SBX>LVOY.73^H8(BO%@Y_S2PFX&F$46%PCQ*T[]K$083HA6:7W8:LMVR
M&F=##8:[,:3;\>@%T9*H!PO/!+ZO1E!GN7=5\^%.NQN"OK88]AO\5-J;:@Z[
M8%SL%A_&$LS_LFC,ON"3T&B8^Y;[/<_B<Y'?33C'/LS:[A><Y-MC0=.*#9^;
MTO2#HTFF^#KDLFJB"HX7'M3.5;1.8PT9Z7]U!R^@L-_GO#?_+-RM_Z8BX?XE
M/N!T#*=9B[)C&=^N.9\15'W<@]^$7X!-M]HPM37'N Z"AEB6S#R84G;N7^V2
M6DLPS\$9W>L)&_+/295!82:NKANGB/*^ @=BB6Z*E);3N0_26^L.[]P?/4+'
M+&MS=:AL?:L@9N8O*,6\Y<L_6B-)>2Z8'06SUE4@F>^;>B='T)Y9&$UTZJ U
M7$,;:;]JV9JN;6CEN%).+5(HQ;(UK')%JU16GOEK/S1O\DTG)N?%1B9QLR)$
MP)<QF-OPQ,N#PD,(68%V(^#2ML O";_%D[V=$#L>E96=:<5/"4E&45D$1ZLQ
MI^4Z56-E[*.[%\K>^TH87XV1C[MS6@FX:U&)0:MU"VI/7L"879-^)/D]E/V:
M1JA>8ZYPFHQYU-(29V#J!T[$V>"M*GW];38+;X@",CH#H?$I@Q<5VL /.FD'
MZ]31K?V5Y_6-Y[>%5MMG5ZP0N? '8+0HZUB#PAYU;M*NJ_O#8QWYI^7R*2OT
MPK'X33^+Y[1T6VDF?HM%;G?'V3\887FG?2]G_YCN[9V,&V1[574-W%>].#R7
MR#R[5_YP[P6R4QIOU8>"PV1%AWG )XO@G=.6\5J$R[DQJ5R#,/_TC[5GO=EW
MGX>P$(GII[IC=[GJ,1 TC.[P"I)]>M:'/<E(?7\87>)^*Q]*(X0MY<2POL8
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MHY?J!8W9% VYZP9^WI72BDJL6.*C!1^_22&#"U?=([LWR6N<@.?*'*AK]GS
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M3\;@OH%"A]XJ0<O45"3F*Q!I.WE/0 QOAV4,6B.0.H"%0#OL2"?FR[8#I#K
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M547>A[+&C.C,__8BF%Y1L*TFB\DY)?,X^?Q:8=GXW&W,EOC+-7866V5&;?2
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M+Z!?0+^ _O\#G>94G>M2Y17+!@Z!1;CM)+ST6:DZ4>CPR]\ 4$L! A0#%
M  @ DX!K4G#*2N3 E00 U, [ !4              ( !     &9I>'@M,3!K
M7S(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( ). :U)@TR!2!Q@  ,X4 0 1
M          "  ?.5! !F:7AX+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( ).
M:U*!RI[560\  .'F   5              "  2FN! !F:7AX+3(P,C Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    " "3@&M2AZ-4QL,O  ":4P, %0
M    @ &UO00 9FEX>"TR,#(P,3(S,5]D968N>&UL4$L! A0#%     @ DX!K
M4@OYCV]O@0  K;8' !4              ( !J^T$ &9I>'@M,C R,#$R,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( ). :U+V5+7YE4X  /\!!@ 5
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M>#,Q,E\Q,"YH=&U02P$"% ,4    " "3@&M2A]4]I5@%  "F)0  $0
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M;7HR;'$T,S(P<FLP,# P,#8N:G!G4$L! A0#%     @ DX!K4JM#5Q QJP
M >@  !8              ( !^T0, &=M>C)L<30S,C!R:S P,# P-RYJ<&=0
M2P$"% ,4    " "3@&M2#0#(9*:R P"BZ0, %@              @ %@\ P
M9VUZ,FQQ-#,R,')K,# P,# X+FIP9U!+ 0(4 Q0    ( ). :U(L'33R TD
M *%0   6              "  3JC$ !G;7HR;'$T,S(P<FLP,# P,#DN:G!G
M4$L! A0#%     @ DX!K4IG%>R=38P  M&T  !8              ( !<>P0
M &=M>C)L<30S,C!R:S P,# Q,"YJ<&=02P$"% ,4    " "3@&M2- ,1./O
M  !.0@$ %@              @ 'X3Q$ 9VUZ,FQQ-#,R,')K,# P,#$Q+FIP
M9U!+ 0(4 Q0    ( ). :U*0O+O[?&$! * D @ 6              "  2<1
M$@!G;7HR;'$T,S(P<FLP,# P,3(N:G!G4$L! A0#%     @ DX!K4EG&BFV!
M5P$ YLL! !8              ( !UW(3 &=M>C)L<30S,C!R:S P,# Q,RYJ
M<&=02P$"% ,4    " "3@&M2U(8CW0P$ 0#I[ $ %@              @ &,
MRA0 9VUZ,FQQ-#,R,')K,# P,#$T+FIP9U!+ 0(4 Q0    ( ). :U+'^A7>
M/VX! #)% @ 6              "  <S.%0!G;7HR;'$T,S(P<FLP,# P,34N
M:G!G4$L! A0#%     @ DX!K4OW)77IJ/ $ L; ! !8              ( !
M/ST7 &=M>C)L<30S,C!R:S P,# Q-BYJ<&=02P$"% ,4    " "3@&M2_B?[
M]2RM  ":Y@  %@              @ '=>1@ 9VUZ,FQQ-#,R,')K,# P,#$W
M+FIP9U!+ 0(4 Q0    ( ). :U(N R+FDJ4  #_[   6              "
M 3TG&0!G;7HR;'$T,S(P<FLP,# P,3@N:G!G4$L! A0#%     @ DX!K4O!,
M1QRFPP  JAH! !8              ( ! \T9 &=M>C)L<30S,C!R:S P,# Q
M.2YJ<&=02P$"% ,4    " "3@&M2/N@TTT\B @!YGP( %@
M@ '=D!H 9VUZ,FQQ-#,R,')K,# P,#(P+FIP9U!+ 0(4 Q0    ( ). :U*N
MWDVW F4! &6: 0 6              "  6"S' !G;7HR;'$T,S(P<FLP,# P
M,C$N:G!G4$L! A0#%     @ DX!K4H&;(<LIW0  X3 ! !8
M ( !EA@> &=M>C)L<30S,C!R:S P,# R,BYJ<&=02P$"% ,4    " "3@&M2
M>6COC@O<  !.;P$ %@              @ 'S]1X 9VUZ,FQQ-#,R,')K,# P
=,#(S+FIP9U!+!08     )  D &$)   RTA\    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
